ID   FA8_HUMAN               Reviewed;        2351 AA.
AC   P00451; Q14286; Q5HY69;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 215.
DE   RecName: Full=Coagulation factor VIII;
DE   AltName: Full=Antihemophilic factor;
DE            Short=AHF;
DE   AltName: Full=Procoagulant component;
DE   Contains:
DE     RecName: Full=Factor VIIIa heavy chain, 200 kDa isoform;
DE   Contains:
DE     RecName: Full=Factor VIIIa heavy chain, 92 kDa isoform;
DE   Contains:
DE     RecName: Full=Factor VIII B chain;
DE   Contains:
DE     RecName: Full=Factor VIIIa light chain;
DE   Flags: Precursor;
GN   Name=F8; Synonyms=F8C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3935400; DOI=10.1089/dna.1985.4.333;
RA   Truett M.A., Blacher R., Burke R.L., Caput D., Chu C., Dina D.,
RA   Hartog K., Kuo C.H., Masiarz F.R., Merryweather J.P., Najarian R.,
RA   Pachl C., Potter S.J., Puma J., Quiroga M., Rall L.B., Randolph A.,
RA   Urdea M.S., Valenzuela P., Dahl H.-H.M., Favalaro J., Hansen J.,
RA   Nordfang O., Ezban M.;
RT   "Characterization of the polypeptide composition of human factor
RT   VIII:C and the nucleotide sequence and expression of the human kidney
RT   cDNA.";
RL   DNA 4:333-349(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6438526; DOI=10.1038/312330a0;
RA   Wood W.I., Capon D.J., Simonsen C.C., Eaton D.L., Gitschier J.,
RA   Keyt B., Seeburg P.H., Smith D.H., Hollingshead P., Wion K.L.,
RA   Delwart E., Tuddenham E.G.D., Vehar G.A., Lawn R.M.;
RT   "Expression of active human factor VIII from recombinant DNA clones.";
RL   Nature 312:330-337(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=1427887; DOI=10.1016/S0888-7543(05)80155-7;
RA   Levinson B., Kenwrick S., Gamel P., Fisher K., Gitschier J.;
RT   "Evidence for a third transcript from the human factor VIII gene.";
RL   Genomics 14:585-589(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6438528; DOI=10.1038/312342a0;
RA   Toole J.J., Knopf J.L., Wozney J.M., Sultzman L.A., Buecker J.L.,
RA   Pittman D.D., Kaufman R.J., Brown E., Shoemaker C., Orr E.C.,
RA   Amphlett G.W., Foster W.B., Coe M.L., Knutson G.J., Fass D.N.,
RA   Hewick R.M.;
RT   "Molecular cloning of a cDNA encoding human antihaemophilic factor.";
RL   Nature 312:342-347(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1303178; DOI=10.1093/hmg/1.3.199;
RA   Gitschier J., Wood W.I.;
RT   "Sequence of the exon-containing regions of the human factor VIII
RT   gene.";
RL   Hum. Mol. Genet. 1:199-200(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-1260 AND VAL-2257.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus, and Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2064-2070.
RA   de Water N.S., Williams R., Browett P.J.;
RT   "Factor VIII gene normal intron 20 sequence.";
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   PROTEIN SEQUENCE OF 356-378; 727-752 AND 1672-1708, MASS SPECTROMETRY,
RP   AND SULFATION AT TYR-365; TYR-737; TYR-738; TYR-742; TYR-1683 AND
RP   TYR-1699.
RX   PubMed=10368977;
RX   DOI=10.1002/(SICI)1097-0231(19990615)13:11<1016::AID-RCM599>3.0.CO;2-5;
RA   Severs J.C., Carnine M., Eguizabal H., Mock K.K.;
RT   "Characterization of tyrosine sulfate residues in antihemophilic
RT   recombinant factor VIII by liquid chromatography electrospray
RT   ionization tandem mass spectrometry and amino acid analysis.";
RL   Rapid Commun. Mass Spectrom. 13:1016-1023(1999).
RN   [13]
RP   SULFATION AT TYR-1699.
RX   PubMed=1898735;
RA   Leyte A., van Schijndel H.B., Niehrs C., Huttner W.B., Verbeet M.P.,
RA   Mertens K., van Mourik J.A.;
RT   "Sulfation of Tyr1680 of human blood coagulation factor VIII is
RT   essential for the interaction of factor VIII with von Willebrand
RT   factor.";
RL   J. Biol. Chem. 266:740-746(1991).
RN   [14]
RP   SULFATION AT TYR-365; TYR-1683 AND TYR-1699, AND INTERACTION WITH VWF.
RX   PubMed=1554716; DOI=10.1021/bi00128a003;
RA   Pittman D.D., Wang J.H., Kaufman R.J.;
RT   "Identification and functional importance of tyrosine sulfate residues
RT   within recombinant factor VIII.";
RL   Biochemistry 31:3315-3325(1992).
RN   [15]
RP   INTERACTION WITH VWF.
RX   PubMed=9218428; DOI=10.1074/jbc.272.29.18007;
RA   Saenko E.L., Scandella D.;
RT   "The acidic region of the factor VIII light chain and the C2 domain
RT   together form the high affinity binding site for von Willebrand
RT   factor.";
RL   J. Biol. Chem. 272:18007-18014(1997).
RN   [16]
RP   DISULFIDE BONDS.
RX   PubMed=7613471; DOI=10.1002/pro.5560040413;
RA   McMullen B.A., Fujikawa K., Davie E.W., Hedner U., Ezban M.;
RT   "Locations of disulfide bonds and free cysteines in the heavy and
RT   light chains of recombinant human factor VIII (antihemophilic factor
RT   A).";
RL   Protein Sci. 4:740-746(1995).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-601.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [18]
RP   STRUCTURE BY NMR OF 2322-2343.
RX   PubMed=7893714; DOI=10.1021/bi00009a033;
RA   Gilbert G.E., Baleja J.D.;
RT   "Membrane-binding peptide from the C2 domain of factor VIII forms an
RT   amphipathic structure as determined by NMR spectroscopy.";
RL   Biochemistry 34:3022-3031(1995).
RN   [19]
RP   REVIEW ON MOLECULAR BASIS OF HEMA.
RX   PubMed=1902642; DOI=10.1111/j.1749-6632.1991.tb43694.x;
RA   Gitschier J.;
RT   "The molecular basis of hemophilia A.";
RL   Ann. N. Y. Acad. Sci. 614:89-96(1991).
RN   [20]
RP   REVIEW ON MOLECULAR BASIS OF HEMA.
RX   PubMed=2491949;
RA   White G.C. II, Shoemaker C.B.;
RT   "Factor VIII gene and hemophilia A.";
RL   Blood 73:1-12(1989).
RN   [21]
RP   REVIEW ON MOLECULAR BASIS OF HEMA.
RX   PubMed=7728145; DOI=10.1002/humu.1380050102;
RA   Antonarakis S.E., Kazazian H.H. Jr., Tuddenham E.G.D.;
RT   "Molecular etiology of factor VIII deficiency in hemophilia A.";
RL   Hum. Mutat. 5:1-22(1995).
RN   [22]
RP   VARIANT HEMA GLN-2326.
RX   PubMed=3012775; DOI=10.1126/science.3012775;
RA   Gitschier J., Wood W.I., Shuman M.A., Lawn R.M.;
RT   "Identification of a missense mutation in the factor VIII gene of a
RT   mild hemophiliac.";
RL   Science 232:1415-1416(1986).
RN   [23]
RP   VARIANT HEMA PRO-2135.
RX   PubMed=3122181; DOI=10.1093/nar/15.23.9797;
RA   Levinson B., Janco R.L., Phillips J.A. III, Gitschier J.;
RT   "A novel missense mutation in the factor VIII gene identified by
RT   analysis of amplified hemophilia DNA sequences.";
RL   Nucleic Acids Res. 15:9797-9805(1987).
RN   [24]
RP   VARIANT HEMA GLN-2228.
RX   PubMed=2833855;
RA   Youssoufian H., Antonarakis S.E., Bell W., Griffin A.M.,
RA   Kazazian H.H. Jr.;
RT   "Nonsense and missense mutations in hemophilia A: estimate of the
RT   relative mutation rate at CG dinucleotides.";
RL   Am. J. Hum. Genet. 42:718-725(1988).
RN   [25]
RP   VARIANT HEMA GLY-291.
RX   PubMed=2835904;
RA   Youssoufian H., Wong C., Aronis S., Platokoukis H., Kazazian H.H. Jr.,
RA   Antonarakis S.E.;
RT   "Moderately severe hemophilia A resulting from Glu-->Gly substitution
RT   in exon 7 of the factor VIII gene.";
RL   Am. J. Hum. Genet. 42:867-871(1988).
RN   [26]
RP   VARIANT HEMA CYS-1708.
RX   PubMed=2499363;
RA   O'Brien D.P., Tuddenham E.G.;
RT   "Purification and characterization of factor VIII 1,689-Cys: a
RT   nonfunctional cofactor occurring in a patient with severe hemophilia
RT   A.";
RL   Blood 73:2117-2122(1989).
RN   [27]
RP   VARIANT HEMA CYS-391.
RX   PubMed=2506948;
RA   Shima M., Ware J., Yoshioka A., Fukui H., Fulcher C.A.;
RT   "An arginine to cysteine amino acid substitution at a critical
RT   thrombin cleavage site in a dysfunctional factor VIII molecule.";
RL   Blood 74:1612-1617(1989).
RN   [28]
RP   VARIANT HEMA LEU-189.
RX   PubMed=2510835;
RA   Chan V., Chan T.K., Tong T.M., Todd D.;
RT   "A novel missense mutation in exon 4 of the factor VIII:C gene
RT   resulting in moderately severe hemophilia A.";
RL   Blood 74:2688-2691(1989).
RN   [29]
RP   VARIANT HEMA LEU-2326.
RX   PubMed=2495245; DOI=10.1007/BF00283686;
RA   Inaba H., Fujimaki M., Kazazian H.H. Jr., Antonarakis S.E.;
RT   "Mild hemophilia A resulting from Arg-to-Leu substitution in exon 26
RT   of the factor VIII gene.";
RL   Hum. Genet. 81:335-338(1989).
RN   [30]
RP   VARIANT HEMA HIS-391.
RX   PubMed=2498882; DOI=10.1073/pnas.86.11.4277;
RA   Arai M., Inaba H., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr.,
RA   Fujimaki M., Hoyer L.W.;
RT   "Direct characterization of factor VIII in plasma: detection of a
RT   mutation altering a thrombin cleavage site (arginine-
RT   372-->histidine).";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4277-4281(1989).
RN   [31]
RP   VARIANT HEMA CYS-1708.
RX   PubMed=2104766;
RA   Arai M., Higuchi M., Antonarakis S.E., Kazazian H.H. Jr.,
RA   Phillips J.A. III, Janco R.L., Hoyer L.W.;
RT   "Characterization of a thrombin cleavage site mutation (Arg 1689 to
RT   Cys) in the factor VIII gene of two unrelated patients with cross-
RT   reacting material-positive hemophilia A.";
RL   Blood 75:384-389(1990).
RN   [32]
RP   VARIANTS HEMA GLN-2228 AND LEU-2326.
RX   PubMed=2105106;
RA   Casula L., Murru S., Pecorara M., Ristaldi M.S., Restagno G.,
RA   Mancuso G., Morfini M., de Biasi R., Baudo F., Carbonara A.;
RT   "Recurrent mutations and three novel rearrangements in the factor VIII
RT   gene of hemophilia A patients of Italian descent.";
RL   Blood 75:662-670(1990).
RN   [33]
RP   VARIANT HEMA CYS-391.
RX   PubMed=1973901; DOI=10.1111/j.1365-2141.1990.tb02618.x;
RA   Pattinson J.K., McVey J.H., Boon M., Ajani A., Tuddenham E.G.;
RT   "CRM+ haemophilia A due to a missense mutation (372-->Cys) at the
RT   internal heavy chain thrombin cleavage site.";
RL   Br. J. Haematol. 75:73-77(1990).
RN   [34]
RP   VARIANTS HEMA PHE-1699 AND CYS-1708.
RX   PubMed=2105906; DOI=10.1016/0888-7543(90)90448-4;
RA   Higuchi M., Wong C., Kochhan L., Olek K., Aronis S., Kasper C.K.,
RA   Kazazian H.H. Jr., Antonarakis S.E.;
RT   "Characterization of mutations in the factor VIII gene by direct
RT   sequencing of amplified genomic DNA.";
RL   Genomics 6:65-71(1990).
RN   [35]
RP   VARIANTS HEMA CYS-1728 AND ASP-1941.
RX   PubMed=2106480; DOI=10.1016/0888-7543(90)90569-G;
RA   Traystman M.D., Higuchi M., Kasper C.K., Antonarakis S.E.,
RA   Kazazian H.H. Jr.;
RT   "Use of denaturing gradient gel electrophoresis to detect point
RT   mutations in the factor VIII gene.";
RL   Genomics 6:293-301(1990).
RN   [36]
RP   VARIANTS HEMA LEU-345 AND ARG-348.
RX   PubMed=2107542; DOI=10.1073/pnas.87.6.2092;
RA   Kogan S., Gitschier J.;
RT   "Mutations and a polymorphism in the factor VIII gene discovered by
RT   denaturing gradient gel electrophoresis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2092-2096(1990).
RN   [37]
RP   VARIANTS HEMA LYS-1723 AND SER-2319.
RX   PubMed=1908817; DOI=10.1007/BF00197155;
RA   Paynton C., Sarkar G., Sommer S.S.;
RT   "Identification of mutations in two families with sporadic hemophilia
RT   A.";
RL   Hum. Genet. 87:397-400(1991).
RN   [38]
RP   VARIANTS HEMA THR-108; VAL-110; GLY-285; HIS-301; SER-312; ARG-444;
RP   HIS-492; GLY-561; CYS-612; THR-723; PHE-1699; HIS-1800; TYR-1803;
RP   ASP-1941; SER-1941; HIS-2169; GLN-2228 AND CYS-2323.
RX   PubMed=1908096; DOI=10.1073/pnas.88.16.7405;
RA   Higuchi M., Kazazian H.H. Jr., Kasch L., Warren T.C., McGinniss M.J.,
RA   Phillips J.A. III, Kasper C., Janco R., Antonarakis S.E.;
RT   "Molecular characterization of severe hemophilia A suggests that about
RT   half the mutations are not within the coding regions and splice
RT   junctions of the factor VIII gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7405-7409(1991).
RN   [39]
RP   VARIANTS.
RX   PubMed=1924291; DOI=10.1073/pnas.88.19.8307;
RA   Higuchi M., Antonarakis S.E., Kasch L., Oldenburg J.,
RA   Economou-Petersen E., Olek K., Arai M., Inaba H., Kazazian H.H. Jr.;
RT   "Molecular characterization of mild-to-moderate hemophilia A:
RT   detection of the mutation in 25 of 29 patients by denaturing gradient
RT   gel electrophoresis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8307-8311(1991).
RN   [40]
RP   VARIANTS HEMA CYS-1708 AND HIS-1708.
RX   PubMed=1851341; DOI=10.1016/0049-3848(91)90098-H;
RA   Schwaab R., Ludwig M., Kochhan L., Oldenburg J., McVey J.H., Egli H.,
RA   Brackmann H.H., Olek K.;
RT   "Detection and characterisation of two missense mutations at a
RT   cleavage site in the factor VIII light chain.";
RL   Thromb. Res. 61:225-234(1991).
RN   [41]
RP   VARIANTS HEMA LYS-291 AND GLN-1960.
RX   PubMed=1356412; DOI=10.1111/j.1365-2141.1992.tb08264.x;
RA   Krepelova A., Vorlova Z., Acquila M., Mori P.;
RT   "GAA(Glu)272->AAA(Lys) and CGA(Arg)1941->CAA(Gln) in the factor VIII
RT   gene in two haemophilia A patients of Czech origin.";
RL   Br. J. Haematol. 81:458-458(1992).
RN   [42]
RP   VARIANTS HEMA PRO-1845 AND PRO-2224 DEL.
RX   PubMed=1639429; DOI=10.1016/0888-7543(92)90189-Y;
RA   Economou E.P., Kazazian H.H. Jr., Antonarakis S.E.;
RT   "Detection of mutations in the factor VIII gene using single-stranded
RT   conformational polymorphism (SSCP).";
RL   Genomics 13:909-911(1992).
RN   [43]
RP   VARIANT HEMA GLY-1715.
RX   PubMed=1349567; DOI=10.1007/BF00207049;
RA   Reiner A.P., Thompson A.R.;
RT   "Screening for nonsense mutations in patients with severe hemophilia A
RT   can provide rapid, direct carrier detection.";
RL   Hum. Genet. 89:88-94(1992).
RN   [44]
RP   VARIANT HEMA LEU-1960.
RX   PubMed=1301194; DOI=10.1002/humu.1380010114;
RA   Nafa K., Baudis M., Deburgrave N., Bardin J.M., Sultan Y.,
RA   Kaplan J.C., Delpech M.;
RT   "A novel mutation (Arg-->Leu in exon 18) in factor VIII gene
RT   responsible for moderate hemophilia A.";
RL   Hum. Mutat. 1:77-78(1992).
RN   [45]
RP   VARIANTS HEMA VAL-30; VAL-89; VAL-92; ASP-104; VAL-164; MET-181;
RP   CYS-550; GLY-554; CYS-612; TRP-717; PHE-1808; SER-1941; ARG-2065;
RP   HIS-2169; CYS-2178 AND CYS-2248.
RX   PubMed=1301932; DOI=10.1002/humu.1380010312;
RA   Diamond C., Kogan S., Levinson B., Gitschier J.;
RT   "Amino acid substitutions in conserved domains of factor VIII and
RT   related proteins: study of patients with mild and moderately severe
RT   hemophilia A.";
RL   Hum. Mutat. 1:248-257(1992).
RN   [46]
RP   VARIANTS HEMA CYS-1800 AND ILE-2173.
RX   PubMed=1301960; DOI=10.1002/humu.1380010610;
RA   Jonsdottir S., Diamond C., Levinson B., Magnusson S., Jensson O.,
RA   Gitschier J.;
RT   "Missense mutations causing mild hemophilia A in Iceland detected by
RT   denaturing gradient gel electrophoresis.";
RL   Hum. Mutat. 1:506-508(1992).
RN   [47]
RP   VARIANTS HEMA LEU-308; HIS-391; TRP-546; PHE-577; ALA-653; MET-653;
RP   PHE-671 DEL; LYS-1460 AND CYS-2178.
RX   PubMed=8449505; DOI=10.1006/geno.1993.1073;
RA   McGinniss M.J., Kazazian H.H. Jr., Hoyer L.W., Bi L., Inaba H.,
RA   Antonarakis S.E.;
RT   "Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A.";
RL   Genomics 15:392-398(1993).
RN   [48]
RP   VARIANTS HEMA ILE-299 AND ASN-450.
RX   PubMed=8322269;
RA   Pieneman W.C., Reitsma P.H., Briet E.;
RT   "Double strand conformation polymorphism (DSCP) detects two point
RT   mutations at codon 280 (AAC-->ATC) and at codon 431 (TAC-->AAC) of the
RT   blood coagulation factor VIII gene.";
RL   Thromb. Haemost. 69:473-475(1993).
RN   [49]
RP   VARIANTS HEMA ARG-113; ASN-202; LEU-275; GLY-285; CYS-301; ASP-637;
RP   PHE-1808; PRO-1867; GLN-1960; HIS-2169; CYS-2178 AND THR-2281, AND
RP   VARIANT VAL-2257.
RX   PubMed=7579394;
RA   Arruda V.R., Pieneman W.C., Reitsma P.H., Deutz-Terlouw P.P.,
RA   Annichino-Bizzacchi J.M., Brieet E., Costa F.F.;
RT   "Eleven novel mutations in the factor VIII gene from Brazilian
RT   hemophilia A patients.";
RL   Blood 86:3015-3020(1995).
RN   [50]
RP   VARIANTS HEMA HIS-217; ILE-299; ASN-450; TRP-546; CYS-612; VAL-705;
RP   CYS-1708; TRP-2016 AND ARG-2119.
RX   PubMed=7794769;
RA   Pieneman W.C., Deutz-Terlouw P.P., Reitsma P.H., Brieet E.;
RT   "Screening for mutations in haemophilia A patients by multiplex PCR-
RT   SSCP, Southern blotting and RNA analysis: the detection of a genetic
RT   abnormality in the factor VIII gene in 30 out of 35 patients.";
RL   Br. J. Haematol. 90:442-449(1995).
RN   [51]
RP   VARIANTS HEMA GLU-75; MET-181; ASP-720; THR-1853 AND ILE-1888.
RX   PubMed=7759074; DOI=10.1007/BF00223865;
RA   Bidichandani S.I., Lanyon W.G., Shiach C.R., Lowe G.D.O., Connor J.M.;
RT   "Detection of mutations in ectopic factor VIII transcripts from nine
RT   haemophilia A patients and the correlation with phenotype.";
RL   Hum. Genet. 95:531-538(1995).
RN   [52]
RP   VARIANTS HEMA ARG-26; LYS-48; ASP-89; ASP-99; VAL-101; ARG-117;
RP   GLY-135; ASP-219; ARG-278; LEU-301; GLN-302 DEL; PRO-327; PRO-659;
RP   LEU-1012; GLU-1260; CYS-1708; ASN-1865; ARG-1873; THR-1971; TRP-2016;
RP   GLN-2228; LEU-2326 AND SER-2344.
RX   PubMed=8644728;
RA   Becker J., Schwaab R., Moeller-Taube A., Schwaab U., Schmidt W.,
RA   Brackmann H.H., Grimm T., Olek K., Oldenburg J.;
RT   "Characterization of the factor VIII defect in 147 patients with
RT   sporadic hemophilia A: family studies indicate a mutation type-
RT   dependent sex ratio of mutation frequencies.";
RL   Am. J. Hum. Genet. 58:657-670(1996).
RN   [53]
RP   VARIANTS HEMA LEU-189; SER-263; ARG-947; LYS-1057; SER-1610 AND
RP   HIS-2169, AND VARIANT MET-2242.
RX   PubMed=8639447; DOI=10.1046/j.1365-2141.1996.4981042.x;
RA   Chan V., Pang A., Chan T.P.T., Chan V.W.-Y., Chan T.K.;
RT   "Molecular characterization of haemophilia A in southern Chinese.";
RL   Br. J. Haematol. 93:451-456(1996).
RN   [54]
RP   VARIANTS HEMA GLU-303; LEU-308; HIS-550; LEU-717; TRP-717 AND
RP   PHE-1951.
RX   PubMed=8759905; DOI=10.1046/j.1365-2141.1996.d01-1792.x;
RA   Rudzki Z., Duncan E.M., Casey G.J., Neumann M., Favaloro E.J.,
RA   Lloyd J.V.;
RT   "Mutations in a subgroup of patients with mild haemophilia A and a
RT   familial discrepancy between the one-stage and two-stage factor VIII:C
RT   methods.";
RL   Br. J. Haematol. 94:400-406(1996).
RN   [55]
RP   VARIANTS HEMA PRO-303; TRP-546; HIS-550 AND ILE-1966.
RX   PubMed=9029040; DOI=10.1046/j.1365-2141.1997.d01-2008.x;
RA   Mazurier C., Gaucher C., Jorieux S., Parquet-Gernez A.;
RT   "Mutations in the FVIII gene in seven families with mild haemophilia
RT   A.";
RL   Br. J. Haematol. 96:426-427(1997).
RN   [56]
RP   VARIANTS HEMA CYS-274; CYS-492; ARG-498; HIS-550; ARG-686; CYS-1708;
RP   GLN-1960; HIS-2169; CYS-2178; ALA-2264 AND VAL-2304.
RX   PubMed=9326186; DOI=10.1046/j.1365-2141.1997.2963113.x;
RA   Morichika S., Shima M., Kamisue S., Tanaka I., Imanaka Y., Suzuki H.,
RA   Shibata H., Pemberton S., Gale K., McVey J., Tuddenham E.G.D.,
RA   Yoshioka A.;
RT   "Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced
RT   haemophilia A patients by single-strand conformation polymorphism.";
RL   Br. J. Haematol. 98:901-906(1997).
RN   [57]
RP   VARIANTS HEMA GLY-33; CYS-639; HIS-1800; LEU-1908 AND ARG-2106.
RX   PubMed=9341862; DOI=10.1007/s004390050543;
RA   Tavassoli K., Eigel A., Pollmann H., Horst J.;
RT   "Mutational analysis of ectopic factor VIII transcripts from
RT   hemophilia A patients: identification of cryptic splice site, exon
RT   skipping and novel point mutations.";
RL   Hum. Genet. 100:508-511(1997).
RN   [58]
RP   VARIANTS HEMA LYS-98; GLY-101; CYS-133; HIS-145; ALA-159; LYS-163;
RP   ASP-164; PRO-179; MET-181; LYS-291; ALA-297; GLU-303; SER-312;
RP   HIS-391; ILE-427; TRP-437; ASN-450; ILE-454; LEU-470; SER-541;
RP   TRP-546; CYS-550; HIS-550; PRO-553; THR-560; ALA-578; ARG-603;
RP   ILE-633; ASN-683; LEU-721; CYS-742; THR-1698; GLY-1715; ARG-1779;
RP   THR-1791; HIS-1800; ALA-1801; PHE-1901; GLN-1960; GLN-1985; ILE-2007;
RP   TRP-2016; ASP-2022; ASN-2030 AND SER-2038.
RX   PubMed=9886318; DOI=10.1046/j.1365-2141.1998.01122.x;
RA   Liu M., Murphy M.E.P., Thompson A.R.;
RT   "A domain mutations in 65 haemophilia A families and molecular
RT   modelling of dysfunctional factor VIII proteins.";
RL   Br. J. Haematol. 103:1051-1060(1998).
RN   [59]
RP   VARIANTS HEMA VAL-129; LYS-631 AND HIS-1800.
RX   PubMed=9450898;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<18::AID-HUMU3>3.0.CO;2-H;
RA   Maugard C., Tuffery S., Aguilar-Martinez P., Schved J.-F., Gris J.-C.,
RA   Demaille J., Claustres M.;
RT   "Protein truncation test: detection of severe haemophilia a mutation
RT   and analysis of factor VIII transcripts.";
RL   Hum. Mutat. 11:18-22(1998).
RN   [60]
RP   VARIANT HEMA HIS-2182.
RX   PubMed=10215414;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<334::AID-HUMU21>3.0.CO;2-X;
RA   Theophilus B.D.M., Enayat M.S., Higuchi M., Kazazian H.H. Jr.,
RA   Antonarakis S.E., Hill F.G.H.;
RT   "Independent occurrence of the novel Arg2163 to His mutation in the
RT   factor VIII gene in three unrelated families with haemophilia A with
RT   different phenotypes.";
RL   Hum. Mutat. 11:334-334(1998).
RN   [61]
RP   VARIANTS HEMA ASP-132; PHE-253; ILE-314; VAL-331; ARG-474; ARG-498;
RP   VAL-644; VAL-699; ASP-720; PHE-727 AND ASN-2105.
RX   PubMed=9603440;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:6<470::AID-HUMU8>3.0.CO;2-A;
RA   Freson K., Peerlinck K., Aguirre T., Arnout J., Vermylen J.,
RA   Cassiman J.-J., Matthijs G.;
RT   "Fluorescent chemical cleavage of mismatches for efficient screening
RT   of the factor VIII gene.";
RL   Hum. Mutat. 11:470-479(1998).
RN   [62]
RP   VARIANTS HEMA GLY-550; THR-723; GLY-1894; SER-2107 AND THR-2204.
RX   PubMed=9452104;
RA   Tavassoli K., Eigel A., Dworniczak B., Valtseva E., Horst J.;
RT   "Identification of four novel mutations in the factor VIII gene: three
RT   missense mutations (E1875G, G2088S, I2185T) and a 2-bp deletion
RT   (1780delTC).";
RL   Hum. Mutat. Suppl. 1:S260-S262(1998).
RN   [63]
RP   VARIANTS HEMA.
RX   PubMed=9792405;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:5<301::AID-HUMU2>3.3.CO;2-3;
RA   Tavassoli K., Eigel A., Wilke K., Pollmann H., Horst J.;
RT   "Molecular diagnostics of 15 hemophilia A patients: characterization
RT   of eight novel mutations in the factor VIII gene, two of which result
RT   in exon skipping.";
RL   Hum. Mutat. 12:301-303(1998).
RN   [64]
RP   VARIANTS HEMA VAL-439; CYS-1800; HIS-2169; HIS-2182 AND SER-2319.
RX   PubMed=9829908;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<393::AID-HUMU5>3.0.CO;2-A;
RA   Laprise S.L., Mak E.K., Killoran K.A., Layman L.C., Gray M.R.;
RT   "Use of denaturing gradient gel blots to screen for point mutations in
RT   the factor VIII gene.";
RL   Hum. Mutat. 12:393-402(1998).
RN   [65]
RP   VARIANTS HEMA LYS-223; VAL-2045 AND CYS-2279, AND VARIANT VAL-2257.
RX   PubMed=9569180;
RA   Williams I.J., Abuzenadah A., Winship P.R., Preston F.E., Dolan G.,
RA   Wright J., Peake I.R., Goodeve A.C.;
RT   "Precise carrier diagnosis in families with haemophilia A: use of
RT   conformation sensitive gel electrophoresis for mutation screening and
RT   polymorphism analysis.";
RL   Thromb. Haemost. 79:723-726(1998).
RN   [66]
RP   VARIANTS HEMA CYS-612; PHE-682; ARG-2028; CYS-2124; HIS-2169;
RP   HIS-2182; ASP-2200; CYS-2248 AND ILE-2279.
RX   PubMed=9569189;
RG   UK haemophilia centre directors organisation;
RA   Hay C.R.M., Ludlam C.A., Colvin B.T., Hill F.G.H., Preston F.E.,
RA   Wasseem N., Bagnall R., Peake I.R., Berntorp E.,
RA   Mauser Bunschoten E.P., Fijnvandraat K., Kasper C.K., White G.,
RA   Santagostino E.;
RT   "Factor VIII inhibitors in mild and moderate-severity haemophilia A.";
RL   Thromb. Haemost. 79:762-766(1998).
RN   [67]
RP   VARIANT HEMA LEU-1973.
RX   PubMed=10554831; DOI=10.1046/j.1365-2141.1999.01460.x;
RA   Keeling D.M., Sukhu K., Kemball-Cook G., Waseem N., Bagnall R.,
RA   Lloyd J.V.;
RT   "Diagnostic importance of the two-stage factor VIII:C assay
RT   demonstrated by a case of mild haemophilia associated with
RT   His1954-->Leu substitution in the factor VIII A3 domain.";
RL   Br. J. Haematol. 105:1123-1126(1999).
RN   [68]
RP   VARIANTS HEMA ARG-19; HIS-301; LEU-308; HIS-2169; GLN-2228 AND
RP   GLN-2326.
RX   PubMed=10338101;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<413::AID-HUMU15>3.3.CO;2-5;
RA   Strmecki L., Benedik-Dolnicar M., Vouk K., Komel R.;
RT   "Screen of 55 Slovenian haemophilia A patients: identification of 2
RT   novel mutations (S-1R and IVS23+1G-->A) and discussion of mutation
RT   spectrum.";
RL   Hum. Mutat. 13:413-413(1999).
RN   [69]
RP   VARIANTS HEMA ARG-202 AND HIS-301.
RX   PubMed=10408784;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<504::AID-HUMU14>3.3.CO;2-0;
RA   Moeller-Morlang K., Tavassoli K., Eigel A., Pollmann H., Horst J.;
RT   "Mutational-screening in the factor VIII gene resulting in the
RT   identification of three novel mutations, one of which is a donor
RT   splice mutation.";
RL   Hum. Mutat. 13:504-504(1999).
RN   [70]
RP   VARIANTS HEMA CYS-24; ARG-26; TYR-113; SER-121; TRP-172; PRO-176;
RP   MET-181; VAL-214; THR-219; LYS-291; ALA-314; VAL-315; LYS-340;
RP   PHE-405; GLY-412; THR-470; GLU-474; ASN-478; CYS-484; GLY-490;
RP   ARG-498; TRP-546; CYS-550; HIS-561; ARG-584; THR-585; GLY-588;
RP   ASP-601; LYS-601; GLY-602; HIS-605; CYS-612; TRP-717; CYS-1708;
RP   GLN-1751; HIS-1800; CYS-1802; THR-1853; GLU-1864; PRO-1882; ILE-1888;
RP   LEU-1973; TRP-2016; ALA-2035; TYR-2040; CYS-2120; CYS-2145; HIS-2169;
RP   CYS-2178; HIS-2182; VAL-2183; VAL-2198; CYS-2248 AND GLY-2326.
RX   PubMed=10404764;
RG   The haemophilia centres;
RA   Waseem N.H., Bagnall R., Green P.M., Giannelli F.;
RT   "Start of UK confidential haemophilia A database: analysis of 142
RT   patients by solid phase fluorescent chemical cleavage of mismatch.";
RL   Thromb. Haemost. 81:900-905(1999).
RN   [71]
RP   VARIANTS HEMA SER-2117; TYR-2138; SER-2148; HIS-2169 AND GLN-2172, AND
RP   CHARACTERIZATION OF VARIANTS HEMA SER-2117; TYR-2138 AND HIS-2169.
RX   PubMed=10910910;
RA   Jacquemin M., Lavend'homme R., Benhida A., Vanzieleghem B.,
RA   d'Oiron R., Lavergne J.-M., Brackmann H.H., Schwaab R.,
RA   VandenDriessche T., Chuah M.K.L., Hoylaerts M., Gilles J.G.G.,
RA   Peerlinck K., Vermylen J., Saint-Remy J.-M.R.;
RT   "A novel cause of mild/moderate hemophilia A: mutations scattered in
RT   the factor VIII C1 domain reduce factor VIII binding to von Willebrand
RT   factor.";
RL   Blood 96:958-965(2000).
RN   [72]
RP   VARIANTS HEMA GLU-2106; CYS-2109; CYS-2169; CYS-2178; CYS-2182;
RP   ARG-2183; ILE-2192; PRO-2220; ALA-2251; LEU-2319; CYS-2323; GLY-2323;
RP   GLN-2326 AND THR-2339.
RX   PubMed=10910913;
RA   Liu M.-L., Shen B.W., Nakaya S., Pratt K.P., Fujikawa K., Davie E.W.,
RA   Stoddard B.L., Thompson A.R.;
RT   "Hemophilic factor VIII C1- and C2-domain missense mutations and their
RT   modeling to the 1.5-angstrom human C2-domain crystal structure.";
RL   Blood 96:979-987(2000).
RN   [73]
RP   VARIANTS HEMA CYS-612 AND SER-637, AND CHARACTERIZATION OF VARIANTS
RP   HEMA CYS-612 AND SER-637.
RX   PubMed=10691849; DOI=10.1046/j.1365-2141.2000.01834.x;
RA   Roelse J.C., De Laaf R.T.M., Timmermans S.M.H., Peters M.,
RA   Van Mourik J.A., Voorberg J.;
RT   "Intracellular accumulation of factor VIII induced by missense
RT   mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting
RT   material-reduced haemophilia A.";
RL   Br. J. Haematol. 108:241-246(2000).
RN   [74]
RP   VARIANT HEMA ILE-713.
RX   PubMed=10886198; DOI=10.1046/j.1365-2141.2000.02021.x;
RA   Schwaab R., Oldenburg J., Kemball-Cook G., Albert T., Juhler C.,
RA   Hanfland P., Ingerslev J.;
RT   "Assay discrepancy in mild haemophilia A due to a factor VIII missense
RT   mutation (Asn694Ile) in a large Danish family.";
RL   Br. J. Haematol. 109:523-528(2000).
RN   [75]
RP   VARIANTS HEMA HIS-35; LEU-295; SER-307; CYS-1909; PRO-2058; GLN-2228
RP   AND ARG-2332.
RX   PubMed=10800171;
RA   Tagariello G., Belvini D., Salviato R., Are A., De Biasi E.,
RA   Goodeve A., Davoli P.;
RT   "Experience of a single Italian center in genetic counseling for
RT   hemophilia: from linkage analysis to molecular diagnosis.";
RL   Haematologica 85:525-529(2000).
RN   [76]
RP   VARIANTS HEMA PRO-69; TYR-75; ARG-585; PRO-664; GLU-1779; ALA-2000;
RP   HIS-2169 AND PRO-2228.
RX   PubMed=10896236;
RG   Recombinate PUP study group;
RA   Goodeve A.C., Williams I., Bray G.L., Peake I.R.;
RT   "Relationship between factor VIII mutation type and inhibitor
RT   development in a cohort of previously untreated patients treated with
RT   recombinant factor VIII (Recombinate).";
RL   Thromb. Haemost. 83:844-848(2000).
RN   [77]
RP   VARIANTS HEMA TYR-561; VAL-1869 AND CYS-2344.
RX   PubMed=10612839;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<117::AID-HUMU27>3.0.CO;2-E;
RA   Akkarapatumwong V., Oranwiroon S., Pung-amritt P., Treesucon A.,
RA   Thanootarakul P., Veerakul G., Mahasandana C., Panyim S.,
RA   Yenchitsomanus P.;
RT   "Mutations of the factor VIII gene in Thai hemophilia A patients.";
RL   Hum. Mutat. 15:117-118(2000).
RN   [78]
RP   VARIANTS HEMA ASP-89; ASP-99; HIS-101; TYR-135; PRO-327; GLY-409;
RP   ARG-498; ARG-603; ASP-637; GLY-1894; VAL-2045; LEU-2067; ARG-2172;
RP   CYS-2182; SER-2185; CYS-2279; LEU-2319; LEU-2326 AND PRO-2326.
RX   PubMed=11410838; DOI=10.1086/321285;
RA   Leuer M., Oldenburg J., Lavergne J.-M., Ludwig M., Fregin A.,
RA   Eigel A., Ljung R., Goodeve A., Peake I., Olek K.;
RT   "Somatic mosaicism in hemophilia A: a fairly common event.";
RL   Am. J. Hum. Genet. 69:75-87(2001).
RN   [79]
RP   VARIANTS HEMA VAL-255; GLU-323; CYS-391; CYS-550; VAL-586; CYS-1708;
RP   CYS-1800; ALA-1942; PRO-1963; CYS-2036; CYS-2124; ARG-2172; CYS-2182;
RP   GLN-2228 AND ALA-2307.
RX   PubMed=11298607; DOI=10.1046/j.1365-2141.2001.02671.x;
RA   Ivaskevicius V., Jurgutis R., Rost S., Muller A., Schmitt C.,
RA   Wulff K., Herrmann F.H., Muller C.R., Schwaab R., Oldenburg J.;
RT   "Lithuanian haemophilia A and B registry comprising phenotypic and
RT   genotypic data.";
RL   Br. J. Haematol. 112:1062-1070(2001).
RN   [80]
RP   VARIANTS HEMA ASP-132; LYS-141; GLU-466; THR-470; HIS-503; GLY-602;
RP   THR-1853; GLN-1985; ARG-2004; TRP-2016; TYR-2093; HIS-2169; HIS-2182;
RP   VAL-2198 AND GLN-2228.
RX   PubMed=11442643; DOI=10.1046/j.1365-2516.2001.00528.x;
RA   Theophilus B.D.M., Enayat M.S., Williams M.D., Hill F.G.H.;
RT   "Site and type of mutations in the factor VIII gene in patients and
RT   carriers of haemophilia A.";
RL   Haemophilia 7:381-391(2001).
RN   [81]
RP   VARIANT HEMA ALA-92.
RX   PubMed=11442647;
RA   Bauduer F., Ducout L., Bendriss P., Falaises B., Lavergne J.-M.;
RT   "Mild haemophilia A discovered in a previously multi-operated 73-year-
RT   old man: characterization of a new mutation.";
RL   Haemophilia 7:419-421(2001).
RN   [82]
RP   VARIANTS HEMA ASN-67; PHE-117; ALA-137; TYR-267; CYS-301; HIS-301;
RP   TYR-348; LYS-475; ALA-579; CYS-612; CYS-683; LEU-698; TRP-710;
RP   CYS-1708; HIS-1788; LEU-1876; TRP-2016; GLU-2045; CYS-2178; CYS-2182;
RP   HIS-2182; PRO-2182; ALA-2307 AND LEU-2323.
RX   PubMed=11554935; DOI=10.1046/j.1365-2516.2001.00548.x;
RA   Timur A.A., Guergey A., Aktuglu G., Kavakli K., Canatan D., Olek K.,
RA   Caglayan S.H.;
RT   "Molecular pathology of haemophilia A in Turkish patients:
RT   identification of 36 independent mutations.";
RL   Haemophilia 7:475-481(2001).
RN   [83]
RP   VARIANTS HEMA MET-181; THR-339; CYS-455; TRP-546; CYS-554; CYS-2178
RP   AND PRO-2326.
RX   PubMed=11748850; DOI=10.1002/humu.1234;
RA   Bogdanova N., Lemcke B., Markoff A., Pollmann H., Dworniczak B.,
RA   Eigel A., Horst J.;
RT   "Seven novel and four recurrent point mutations in the factor VIII
RT   (F8C) gene.";
RL   Hum. Mutat. 18:546-546(2001).
RN   [84]
RP   VARIANTS HEMA ARG-193; CYS-391; CYS-550; CYS-612; HIS-1705; ARG-1782;
RP   GLU-1872; TRP-2016; PRO-2016; HIS-2169 AND HIS-2182.
RX   PubMed=11341489;
RA   Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.;
RT   "Rapid hemophilia A molecular diagnosis by a simple DNA sequencing
RT   procedure: identification of 14 novel mutations.";
RL   Thromb. Haemost. 85:580-583(2001).
RN   [85]
RP   ERRATUM.
RA   Vidal F., Farssac E., Altisent C., Puig L., Gallardo D.;
RL   Thromb. Haemost. 86:727-727(2001).
RN   [86]
RP   VARIANT HEMA CYS-35.
RX   PubMed=12351418; DOI=10.1182/blood-2002-01-0277;
RA   Valleix S., Vinciguerra C., Lavergne J.-M., Leuer M., Delpech M.,
RA   Negrier C.;
RT   "Skewed X-chromosome inactivation in monochorionic diamniotic twin
RT   sisters results in severe and mild hemophilia A.";
RL   Blood 100:3034-3036(2002).
RN   [87]
RP   VARIANT HEMA GLY-198.
RX   PubMed=12406074; DOI=10.1046/j.1365-2141.2002.03819.x;
RA   Mazurier C., Parquet-Gernez A., Gaucher C., Lavergne J.-M.,
RA   Goudemand J.;
RT   "Factor VIII deficiency not induced by FVIII gene mutation in a female
RT   first cousin of two brothers with haemophilia A.";
RL   Br. J. Haematol. 119:390-392(2002).
RN   [88]
RP   VARIANTS HEMA PRO-97 AND GLY-2193.
RX   PubMed=12199686; DOI=10.1046/j.1365-2516.2002.00661.x;
RA   Sukarova-Stefanovska E., Zisovski N., Muratovska O., Kostova S.,
RA   Efremov G.D.;
RT   "Three novel point mutations causing haemophilia A.";
RL   Haemophilia 8:715-718(2002).
RN   [89]
RP   VARIANTS HEMA THR-22; CYS-25; PRO-26; VAL-111; ARG-138; GLY-186;
RP   LYS-284; VAL-327; CYS-365; SER-431; PRO-437; CYS-455; HIS-579;
RP   HIS-584; PHE-650; ILE-681; GLN-725; VAL-1727; GLY-1740; CYS-1858;
RP   ASP-1869; ARG-1968; CYS-1998; ASN-2056; VAL-2070; ASN-2082; CYS-2145;
RP   ASP-2157; ALA-2173 AND PRO-2330.
RX   PubMed=11857744; DOI=10.1002/humu.10056;
RA   Cutler J.A., Mitchell M.J., Smith M.P., Savidge G.F.;
RT   "The identification and classification of 41 novel mutations in the
RT   factor VIII gene (F8C).";
RL   Hum. Mutat. 19:274-278(2002).
RN   [90]
RP   VARIANTS HEMA VAL-477; SER-1714; PRO-1777 AND PRO-2330.
RX   PubMed=12203998; DOI=10.1002/humu.9052;
RA   Frusconi S., Passerini I., Girolami F., Masieri M., Linari S.,
RA   Longo G., Morfini M., Torricelli F.;
RT   "Identification of seven novel mutations of F8C by DHPLC.";
RL   Hum. Mutat. 20:231-232(2002).
RN   [91]
RP   VARIANTS HEMA TRP-172; LYS-291; CYS-301; ALA-345; HIS-391; VAL-439;
RP   CYS-442; LEU-470; GLY-532; MET-653; CYS-683; LYS-1336; HIS-1708;
RP   PRO-1875; ARG-1877; ILE-1965; PHE-2117; CYS-2182; TRP-2185; LEU-2224;
RP   GLU-2251; LEU-2290; CYS-2323 AND TYR-2345.
RX   PubMed=12325022; DOI=10.1002/humu.10119;
RA   Citron M., Godmilow L., Ganguly T., Ganguly A.;
RT   "High throughput mutation screening of the factor VIII gene (F8C) in
RT   hemophilia A: 37 novel mutations and genotype-phenotype correlation.";
RL   Hum. Mutat. 20:267-274(2002).
RN   [92]
RP   VARIANTS HEMA GLU-67; 84-ARG-PRO-85 DEL; PRO-85 DEL; MET-181; TYR-186;
RP   GLY-220; LEU-262; ARG-412; PHE-438; ASP-439; ARG-470; SER-513;
RP   SER-541; CYS-550; GLY-554; SER-583; GLN-594; ILE-609; CYS-612;
RP   ASN-635; THR-699; ILE-701; ILE-721; ARG-1779; LEU-1780; THR-1791;
RP   PRO-1798; HIS-1800; GLY-1848; ARG-1907; CYS-1907; THR-1939; VAL-1939;
RP   ILE-1982; GLN-1985; CYS-2015; TRP-2016; SER-2038; HIS-2169; ILE-2192
RP   AND LEU-2326.
RX   PubMed=11858487;
RA   Liu M.-L., Nakaya S., Thompson A.R.;
RT   "Non-inversion factor VIII mutations in 80 hemophilia A families
RT   including 24 with alloimmune responses.";
RL   Thromb. Haemost. 87:273-276(2002).
RN   [93]
RP   VARIANTS HEMA ASP-147; CYS-301; CYS-612; VAL-1945; CYS-2178 AND
RP   GLN-2326, AND VARIANT GLU-1260.
RX   PubMed=12195713;
RA   Klopp N., Oldenburg J., Uen C., Schneppenheim R., Graw J.;
RT   "11 hemophilia A patients without mutations in the factor VIII
RT   encoding gene.";
RL   Thromb. Haemost. 88:357-360(2002).
RN   [94]
RP   VARIANTS HEMA LYS-72; HIS-155; GLU-181; ILE-254; SER-439; GLU-529;
RP   THR-567; SER-1804; SER-2051; ASN-2141 AND GLN-2262 INS.
RX   PubMed=12930394; DOI=10.1046/j.1365-2141.2003.04494.x;
RA   Bicocchi M.P., Pasino M., Lanza T., Bottini F., Boeri E., Mori P.G.,
RA   Molinari A.C., Rosano C., Acquila M.;
RT   "Analysis of 18 novel mutations in the factor VIII gene.";
RL   Br. J. Haematol. 122:810-817(2003).
RN   [95]
RP   VARIANTS HEMA ARG-26; PRO-326; PHE-329; HIS-391; GLY-401; TYR-522;
RP   THR-540; TRP-546; TYR-588; CYS-683; SER-720; TYR-1066; HIS-1768;
RP   PRO-1771; HIS-1800; ASP-1904; PRO-1980; CYS-2169; HIS-2169; ASP-2174;
RP   CYS-2178; HIS-2178; CYS-2182; GLY-2228; PHE-2229; LEU-2319; CYS-2323;
RP   HIS-2323 AND SER-2345.
RX   PubMed=12871415; DOI=10.1046/j.1538-7836.2003.00149.x;
RA   Habart D., Kalabova D., Novotny M., Vorlova Z.;
RT   "Thirty-four novel mutations detected in factor VIII gene by multiplex
RT   CSGE: modeling of 13 novel amino acid substitutions.";
RL   J. Thromb. Haemost. 1:773-781(2003).
RN   [96]
RP   VARIANTS HEMA ILE-252; TYR-561; VAL-1869; SER-2248 AND CYS-2344.
RX   PubMed=12614369; DOI=10.1046/j.1365-2516.2003.00729.x;
RA   Yenchitsomanus P., Akkarapatumwong V., Pung-Amritt P., Intorasoot S.,
RA   Thanootarakul P., Oranwiroon S., Veerakul G., Mahasandana C.;
RT   "Genotype and phenotype of haemophilia A in Thai patients.";
RL   Haemophilia 9:179-186(2003).
RN   [97]
RP   VARIANTS HEMA THR-111; ASP-450; CYS-612; HIS-1800; CYS-1802 AND
RP   ALA-2251.
RX   PubMed=15682412; DOI=10.1002/ajh.20234;
RA   Bicocchi M.P., Pasino M., Lanza T., Bottini F., Molinari A.C.,
RA   Caprino D., Rosano C., Acquila M.;
RT   "Small FVIII gene rearrangements in 18 hemophilia A patients: five
RT   novel mutations.";
RL   Am. J. Hematol. 78:117-122(2005).
RN   [98]
RP   VARIANTS HEMA CYS-365; THR-470; SER-541; GLY-602; TRP-717; LYS-1701;
RP   CYS-1708; VAL-1727; ILE-1888; VAL-1966; TRP-2016; GLY-2018; LEU-2067;
RP   LEU-2162 AND HIS-2182.
RX   PubMed=15810915; DOI=10.1111/j.1365-2516.2005.01069.x;
RA   Hill M., Deam S., Gordon B., Dolan G.;
RT   "Mutation analysis in 51 patients with haemophilia A: report of 10
RT   novel mutations and correlations between genotype and clinical
RT   phenotype.";
RL   Haemophilia 11:133-141(2005).
RN   [99]
RP   VARIANT HEMA PRO-1994.
RX   PubMed=16805874; DOI=10.1111/j.1538-7836.2006.02105.x;
RA   Cai X.-H., Wang X.-F., Dai J., Fang Y., Ding Q.-L., Xie F.,
RA   Wang H.-L.;
RT   "Female haemophilia A heterozygous for a de novo frameshift and a
RT   novel missense mutation of factor VIII.";
RL   J. Thromb. Haemost. 4:1969-1974(2006).
RN   [100]
RP   VARIANTS HEMA ARG-83; ASN-186; PRO-195; PRO-261; ASP-280; SER-394;
RP   VAL-474; ARG-496; VAL-513; ARG-569; ILE-637; VAL-1720; LEU-1762;
RP   ASP-2101; PRO-2106; VAL-2143; LEU-2172; GLY-2286 AND PHE-2336.
RX   PubMed=18184865; DOI=10.1182/blood-2007-08-108068;
RA   Vencesla A., Corral-Rodriguez M.A., Baena M., Cornet M., Domenech M.,
RA   Baiget M., Fuentes-Prior P., Tizzano E.F.;
RT   "Identification of 31 novel mutations in the F8 gene in Spanish
RT   hemophilia A patients: structural analysis of 20 missense mutations
RT   suggests new intermolecular binding sites.";
RL   Blood 111:3468-3478(2008).
RN   [101]
RP   VARIANTS HEMA PHE-191; TYR-1877; ARG-2013 AND ASP-2344.
RX   PubMed=21371196; DOI=10.1111/j.1365-2516.2011.02500.x;
RA   Albanez S., Ruiz-Saez A., Boadas A., De Bosch N., Porco A.;
RT   "Identification of factor VIII gene mutations in patients with severe
RT   haemophilia A in Venezuela: identification of seven novel mutations.";
RL   Haemophilia 17:913-918(2011).
RN   [102]
RP   VARIANTS HEMA SER-439 AND THR-723.
RX   PubMed=25550078; DOI=10.1177/1076029614562951;
RA   Nair P.S., Shetty S., Ghosh K.;
RT   "Factor VIII Antigen, Activity, and Mutations in Hemophilia A.";
RL   Clin. Appl. Thromb. Hemost. 0:0-0(2014).
CC   -!- FUNCTION: Factor VIII, along with calcium and phospholipid, acts
CC       as a cofactor for factor IXa when it converts factor X to the
CC       activated form, factor Xa.
CC   -!- SUBUNIT: Interacts with vWF. vWF binding is essential for the
CC       stabilization of F8 in circulation. {ECO:0000269|PubMed:1554716,
CC       ECO:0000269|PubMed:9218428}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P00451-1; Sequence=Displayed;
CC       Name=2; Synonyms=F8B;
CC         IsoId=P00451-2; Sequence=VSP_042656, VSP_042657;
CC   -!- DOMAIN: Domain F5/8 type C 2 is responsible for phospholipid-
CC       binding and essential for factor VIII activity.
CC   -!- PTM: Sulfation on Tyr-1699 is essential for binding vWF.
CC       {ECO:0000269|PubMed:10368977, ECO:0000269|PubMed:1554716,
CC       ECO:0000269|PubMed:1898735}.
CC   -!- MASS SPECTROMETRY: Mass=1367.6; Method=Electrospray; Range=356-
CC       378; Note=Nonsulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=1407.4; Method=Electrospray; Range=356-
CC       378; Note=Sulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=2975.4; Method=Electrospray; Range=400-
CC       424; Note=Nonsulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=3024; Method=Electrospray; Range=727-752;
CC       Note=Nonsulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=3104; Method=Electrospray; Range=727-752;
CC       Note=Monosulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=3183.5; Method=Electrospray; Range=727-
CC       752; Note=Disulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=3262.5; Method=Electrospray; Range=727-
CC       752; Note=Trisulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=2460.9; Method=Electrospray; Range=1672-
CC       1692; Note=Nonsulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=2540.7; Method=Electrospray; Range=1672-
CC       1692; Note=Sulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=2000.7; Method=Electrospray; Range=1691-
CC       1708; Note=Nonsulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- MASS SPECTROMETRY: Mass=2080.7; Method=Electrospray; Range=1691-
CC       1708; Note=Sulfated.; Evidence={ECO:0000269|PubMed:10368977};
CC   -!- DISEASE: Hemophilia A (HEMA) [MIM:306700]: A disorder of blood
CC       coagulation characterized by a permanent tendency to hemorrhage.
CC       About 50% of patients have severe hemophilia resulting in frequent
CC       spontaneous bleeding into joints, muscles and internal organs.
CC       Less severe forms are characterized by bleeding after trauma or
CC       surgery. {ECO:0000269|PubMed:10215414,
CC       ECO:0000269|PubMed:10338101, ECO:0000269|PubMed:10404764,
CC       ECO:0000269|PubMed:10408784, ECO:0000269|PubMed:10554831,
CC       ECO:0000269|PubMed:10612839, ECO:0000269|PubMed:10691849,
CC       ECO:0000269|PubMed:10800171, ECO:0000269|PubMed:10886198,
CC       ECO:0000269|PubMed:10896236, ECO:0000269|PubMed:10910910,
CC       ECO:0000269|PubMed:10910913, ECO:0000269|PubMed:11298607,
CC       ECO:0000269|PubMed:11341489, ECO:0000269|PubMed:11410838,
CC       ECO:0000269|PubMed:11442643, ECO:0000269|PubMed:11442647,
CC       ECO:0000269|PubMed:11554935, ECO:0000269|PubMed:11748850,
CC       ECO:0000269|PubMed:11857744, ECO:0000269|PubMed:11858487,
CC       ECO:0000269|PubMed:12195713, ECO:0000269|PubMed:12199686,
CC       ECO:0000269|PubMed:12203998, ECO:0000269|PubMed:12325022,
CC       ECO:0000269|PubMed:12351418, ECO:0000269|PubMed:12406074,
CC       ECO:0000269|PubMed:12614369, ECO:0000269|PubMed:12871415,
CC       ECO:0000269|PubMed:12930394, ECO:0000269|PubMed:1301194,
CC       ECO:0000269|PubMed:1301932, ECO:0000269|PubMed:1301960,
CC       ECO:0000269|PubMed:1349567, ECO:0000269|PubMed:1356412,
CC       ECO:0000269|PubMed:15682412, ECO:0000269|PubMed:15810915,
CC       ECO:0000269|PubMed:1639429, ECO:0000269|PubMed:16805874,
CC       ECO:0000269|PubMed:18184865, ECO:0000269|PubMed:1851341,
CC       ECO:0000269|PubMed:1908096, ECO:0000269|PubMed:1908817,
CC       ECO:0000269|PubMed:1973901, ECO:0000269|PubMed:2104766,
CC       ECO:0000269|PubMed:2105106, ECO:0000269|PubMed:2105906,
CC       ECO:0000269|PubMed:2106480, ECO:0000269|PubMed:2107542,
CC       ECO:0000269|PubMed:21371196, ECO:0000269|PubMed:2495245,
CC       ECO:0000269|PubMed:2498882, ECO:0000269|PubMed:2499363,
CC       ECO:0000269|PubMed:2506948, ECO:0000269|PubMed:2510835,
CC       ECO:0000269|PubMed:25550078, ECO:0000269|PubMed:2833855,
CC       ECO:0000269|PubMed:2835904, ECO:0000269|PubMed:3012775,
CC       ECO:0000269|PubMed:3122181, ECO:0000269|PubMed:7579394,
CC       ECO:0000269|PubMed:7759074, ECO:0000269|PubMed:7794769,
CC       ECO:0000269|PubMed:8322269, ECO:0000269|PubMed:8449505,
CC       ECO:0000269|PubMed:8639447, ECO:0000269|PubMed:8644728,
CC       ECO:0000269|PubMed:8759905, ECO:0000269|PubMed:9029040,
CC       ECO:0000269|PubMed:9326186, ECO:0000269|PubMed:9341862,
CC       ECO:0000269|PubMed:9450898, ECO:0000269|PubMed:9452104,
CC       ECO:0000269|PubMed:9569180, ECO:0000269|PubMed:9569189,
CC       ECO:0000269|PubMed:9603440, ECO:0000269|PubMed:9792405,
CC       ECO:0000269|PubMed:9829908, ECO:0000269|PubMed:9886318}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry. Of particular interest for the understanding of the
CC       function of F8 is the category of CRM (cross-reacting material)
CC       positive patients (approximately 5%) that have considerable amount
CC       of F8 in their plasma (at least 30% of normal), but the protein is
CC       non-functional; i.e. the F8 activity is much less than the plasma
CC       protein level. CRM-reduced is another category of patients in
CC       which the F8C antigen and activity are reduced to approximately
CC       the same level. Most mutations are CRM negative, and probably
CC       affect the folding and stability of the protein.
CC   -!- PHARMACEUTICAL: Available under the names Kogenate (Bayer) and
CC       Recombinate (Baxter and American Home Products). Used to treat
CC       hemophilia A.
CC   -!- SIMILARITY: Belongs to the multicopper oxidase family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 F5/8 type A domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 F5/8 type C domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00081}.
CC   -!- SIMILARITY: Contains 6 plastocyanin-like domains. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Factor VIII entry;
CC       URL="https://en.wikipedia.org/wiki/Factor_VIII";
CC   -!- WEB RESOURCE: Name=HAMSters; Note=Factor VIII mutation db;
CC       URL="http://hadb.org.uk/WebPages/Main/main.htm";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f8/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14113; AAA52485.1; -; mRNA.
DR   EMBL; X01179; CAA25619.1; -; mRNA.
DR   EMBL; M90707; AAA58466.1; -; mRNA.
DR   EMBL; K01740; AAA52484.1; -; mRNA.
DR   EMBL; M88648; AAA52420.1; -; Genomic_DNA.
DR   EMBL; M88628; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88629; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88630; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88631; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88632; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88633; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88634; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88635; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88636; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88638; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88639; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88640; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88641; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88642; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88643; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88644; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88645; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88646; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; M88647; AAA52420.1; JOINED; Genomic_DNA.
DR   EMBL; AY769950; AAV85964.1; -; Genomic_DNA.
DR   EMBL; AK289947; BAF82636.1; -; mRNA.
DR   EMBL; AK313707; BAG36452.1; -; mRNA.
DR   EMBL; BX470111; CAI41660.1; -; Genomic_DNA.
DR   EMBL; AC109993; CAI41660.1; JOINED; Genomic_DNA.
DR   EMBL; BX842559; CAI41660.1; JOINED; Genomic_DNA.
DR   EMBL; BX842564; CAI41660.1; JOINED; Genomic_DNA.
DR   EMBL; BX890586; CAI41660.1; JOINED; Genomic_DNA.
DR   EMBL; BX842564; CAI41666.1; -; Genomic_DNA.
DR   EMBL; AC109993; CAI41666.1; JOINED; Genomic_DNA.
DR   EMBL; BX470111; CAI41666.1; JOINED; Genomic_DNA.
DR   EMBL; BX842559; CAI41666.1; JOINED; Genomic_DNA.
DR   EMBL; BX890586; CAI41666.1; JOINED; Genomic_DNA.
DR   EMBL; BX842559; CAI41672.1; -; Genomic_DNA.
DR   EMBL; AC109993; CAI41672.1; JOINED; Genomic_DNA.
DR   EMBL; BX470111; CAI41672.1; JOINED; Genomic_DNA.
DR   EMBL; BX842564; CAI41672.1; JOINED; Genomic_DNA.
DR   EMBL; BX890586; CAI41672.1; JOINED; Genomic_DNA.
DR   EMBL; BX890586; CAI43241.1; -; Genomic_DNA.
DR   EMBL; AC109993; CAI43241.1; JOINED; Genomic_DNA.
DR   EMBL; BX470111; CAI43241.1; JOINED; Genomic_DNA.
DR   EMBL; BX842559; CAI43241.1; JOINED; Genomic_DNA.
DR   EMBL; BX842564; CAI43241.1; JOINED; Genomic_DNA.
DR   EMBL; BX842559; CAO03404.1; -; Genomic_DNA.
DR   EMBL; AC109993; CAO03404.1; JOINED; Genomic_DNA.
DR   EMBL; CH471172; EAW72645.1; -; Genomic_DNA.
DR   EMBL; BC022513; AAH22513.1; -; mRNA.
DR   EMBL; BC064380; AAH64380.1; -; mRNA.
DR   EMBL; BC098389; AAH98389.1; -; mRNA.
DR   EMBL; BC111967; AAI11968.1; -; mRNA.
DR   EMBL; BC111969; AAI11970.1; -; mRNA.
DR   EMBL; U80228; AAB61261.1; -; Genomic_DNA.
DR   CCDS; CCDS35457.1; -. [P00451-1]
DR   CCDS; CCDS44026.1; -. [P00451-2]
DR   PIR; I54318; EZHU.
DR   RefSeq; NP_000123.1; NM_000132.3. [P00451-1]
DR   RefSeq; NP_063916.1; NM_019863.2. [P00451-2]
DR   UniGene; Hs.632836; -.
DR   UniGene; Hs.654450; -.
DR   PDB; 1CFG; NMR; -; A=2322-2343.
DR   PDB; 1D7P; X-ray; 1.50 A; M=2190-2348.
DR   PDB; 1FAC; NMR; -; A=2322-2342.
DR   PDB; 1IQD; X-ray; 2.00 A; C=2193-2348.
DR   PDB; 2R7E; X-ray; 3.70 A; A=19-760, B=1582-2351.
DR   PDB; 3CDZ; X-ray; 3.98 A; A=20-759, B=1668-2351.
DR   PDB; 3HNB; X-ray; 1.15 A; M=2189-2347.
DR   PDB; 3HNY; X-ray; 1.07 A; M=2189-2347.
DR   PDB; 3HOB; X-ray; 2.07 A; A/M=2189-2347.
DR   PDB; 3J2Q; EM; 15.00 A; A=20-764, B=1668-2351.
DR   PDB; 3J2S; EM; 15.00 A; B=1710-2351.
DR   PDB; 4BDV; X-ray; 3.98 A; A=20-1666, B=1667-2351.
DR   PDB; 4KI5; X-ray; 2.47 A; M=2190-2351.
DR   PDB; 4PT6; X-ray; 2.10 A; A/B=2190-2215, A/B=2222-2351.
DR   PDB; 4XZU; X-ray; 2.61 A; G/M=2193-2346.
DR   PDBsum; 1CFG; -.
DR   PDBsum; 1D7P; -.
DR   PDBsum; 1FAC; -.
DR   PDBsum; 1IQD; -.
DR   PDBsum; 2R7E; -.
DR   PDBsum; 3CDZ; -.
DR   PDBsum; 3HNB; -.
DR   PDBsum; 3HNY; -.
DR   PDBsum; 3HOB; -.
DR   PDBsum; 3J2Q; -.
DR   PDBsum; 3J2S; -.
DR   PDBsum; 4BDV; -.
DR   PDBsum; 4KI5; -.
DR   PDBsum; 4PT6; -.
DR   PDBsum; 4XZU; -.
DR   ProteinModelPortal; P00451; -.
DR   SMR; P00451; 20-744, 1708-2351.
DR   BioGrid; 108455; 9.
DR   DIP; DIP-29774N; -.
DR   IntAct; P00451; 4.
DR   MINT; MINT-202317; -.
DR   STRING; 9606.ENSP00000353393; -.
DR   BindingDB; P00451; -.
DR   ChEMBL; CHEMBL3143; -.
DR   DrugBank; DB00100; Coagulation Factor IX.
DR   DrugBank; DB00055; Drotrecogin alfa.
DR   Allergome; 9868; Hom s Factor VIII.
DR   iPTMnet; P00451; -.
DR   PhosphoSite; P00451; -.
DR   UniCarbKB; P00451; -.
DR   BioMuta; F8; -.
DR   DMDM; 119767; -.
DR   PaxDb; P00451; -.
DR   PRIDE; P00451; -.
DR   DNASU; 2157; -.
DR   Ensembl; ENST00000330287; ENSP00000327895; ENSG00000185010. [P00451-2]
DR   Ensembl; ENST00000360256; ENSP00000353393; ENSG00000185010. [P00451-1]
DR   GeneID; 2157; -.
DR   KEGG; hsa:2157; -.
DR   UCSC; uc004fms.3; human. [P00451-2]
DR   UCSC; uc004fmt.3; human. [P00451-1]
DR   CTD; 2157; -.
DR   GeneCards; F8; -.
DR   GeneReviews; F8; -.
DR   HGNC; HGNC:3546; F8.
DR   HPA; CAB018777; -.
DR   MalaCards; F8; -.
DR   MIM; 134500; phenotype.
DR   MIM; 300841; gene.
DR   MIM; 306700; phenotype.
DR   neXtProt; NX_P00451; -.
DR   Orphanet; 169808; Mild hemophilia A.
DR   Orphanet; 169805; Moderately severe hemophilia A.
DR   Orphanet; 169802; Severe hemophilia A.
DR   Orphanet; 177926; Symptomatic form of hemophilia A in female carriers.
DR   PharmGKB; PA27952; -.
DR   eggNOG; ENOG410IJ6Y; Eukaryota.
DR   eggNOG; ENOG4111F6G; LUCA.
DR   GeneTree; ENSGT00760000119073; -.
DR   HOGENOM; HOG000231686; -.
DR   HOVERGEN; HBG106657; -.
DR   InParanoid; P00451; -.
DR   KO; K03899; -.
DR   OMA; WHVIGMG; -.
DR   PhylomeDB; P00451; -.
DR   TreeFam; TF329807; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-5694530; Cargo concentration in the ER.
DR   SABIO-RK; P00451; -.
DR   EvolutionaryTrace; P00451; -.
DR   GeneWiki; Factor_VIII; -.
DR   GenomeRNAi; 2157; -.
DR   NextBio; 8713; -.
DR   PRO; PR:P00451; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P00451; -.
DR   CleanEx; HS_F8; -.
DR   ExpressionAtlas; P00451; baseline and differential.
DR   Genevisible; P00451; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005507; F:copper ion binding; IEA:InterPro.
DR   GO; GO:0016491; F:oxidoreductase activity; IEA:InterPro.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0006888; P:ER to Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   Gene3D; 2.60.120.260; -; 2.
DR   Gene3D; 2.60.40.420; -; 6.
DR   InterPro; IPR001117; Cu-oxidase.
DR   InterPro; IPR011706; Cu-oxidase_2.
DR   InterPro; IPR011707; Cu-oxidase_3.
DR   InterPro; IPR002355; Cu_oxidase_Cu_BS.
DR   InterPro; IPR008972; Cupredoxin.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR024715; Factor_5/8.
DR   InterPro; IPR014707; Factor_8.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   PANTHER; PTHR10127:SF50; PTHR10127:SF50; 4.
DR   Pfam; PF00394; Cu-oxidase; 1.
DR   Pfam; PF07731; Cu-oxidase_2; 1.
DR   Pfam; PF07732; Cu-oxidase_3; 2.
DR   Pfam; PF00754; F5_F8_type_C; 2.
DR   PIRSF; PIRSF000354; Factors_V_VIII; 1.
DR   SMART; SM00231; FA58C; 2.
DR   SUPFAM; SSF49503; SSF49503; 6.
DR   SUPFAM; SSF49785; SSF49785; 2.
DR   PROSITE; PS01285; FA58C_1; 2.
DR   PROSITE; PS01286; FA58C_2; 2.
DR   PROSITE; PS50022; FA58C_3; 2.
DR   PROSITE; PS00079; MULTICOPPER_OXIDASE1; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Blood coagulation;
KW   Calcium; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hemophilia;
KW   Hemostasis; Metal-binding; Pharmaceutical; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal; Sulfation.
FT   SIGNAL        1     19
FT   CHAIN        20   2351       Coagulation factor VIII.
FT                                /FTId=PRO_0000002967.
FT   CHAIN        20   1332       Factor VIIIa heavy chain, 200 kDa
FT                                isoform.
FT                                /FTId=PRO_0000002968.
FT   CHAIN        20    759       Factor VIIIa heavy chain, 92 kDa isoform.
FT                                /FTId=PRO_0000002969.
FT   CHAIN       760   1332       Factor VIII B chain.
FT                                /FTId=PRO_0000002970.
FT   CHAIN      1668   2351       Factor VIIIa light chain.
FT                                /FTId=PRO_0000002971.
FT   DOMAIN       20    348       F5/8 type A 1.
FT   DOMAIN       20    198       Plastocyanin-like 1.
FT   DOMAIN      206    348       Plastocyanin-like 2.
FT   DOMAIN      399    730       F5/8 type A 2.
FT   DOMAIN      399    573       Plastocyanin-like 3.
FT   DOMAIN      583    730       Plastocyanin-like 4.
FT   DOMAIN     1713   2040       F5/8 type A 3.
FT   DOMAIN     1713   1877       Plastocyanin-like 5.
FT   DOMAIN     1887   2040       Plastocyanin-like 6.
FT   DOMAIN     2040   2188       F5/8 type C 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN     2193   2345       F5/8 type C 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   REGION      760   1667       B.
FT   SITE        391    392       Cleavage; by thrombin.
FT   SITE        759    760       Cleavage; by thrombin.
FT   SITE       1332   1333       Cleavage (activation).
FT   SITE       1667   1668       Cleavage (activation).
FT   SITE       1708   1709       Cleavage; by thrombin.
FT   MOD_RES     365    365       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977,
FT                                ECO:0000269|PubMed:1554716}.
FT   MOD_RES     737    737       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977}.
FT   MOD_RES     738    738       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977}.
FT   MOD_RES     742    742       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977}.
FT   MOD_RES    1683   1683       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977,
FT                                ECO:0000269|PubMed:1554716}.
FT   MOD_RES    1699   1699       Sulfotyrosine.
FT                                {ECO:0000269|PubMed:10368977,
FT                                ECO:0000269|PubMed:1554716,
FT                                ECO:0000269|PubMed:1898735}.
FT   CARBOHYD     60     60       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    601    601       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    776    776       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    803    803       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    847    847       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    919    919       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    962    962       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    982    982       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1020   1020       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1024   1024       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1074   1074       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1085   1085       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1204   1204       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1274   1274       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1278   1278       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1301   1301       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1319   1319       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1431   1431       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1461   1461       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1829   1829       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2137   2137       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    172    198       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID    267    348       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID    547    573       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID    649    730       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID   1851   1877       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID   1918   1922       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID   2040   2188       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:7613471}.
FT   DISULFID   2193   2345       {ECO:0000255|PROSITE-ProRule:PRU00081}.
FT   VAR_SEQ       1      8       MQIELSTC -> MRIQDPGK (in isoform 2).
FT                                {ECO:0000303|PubMed:1427887,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042656.
FT   VAR_SEQ       9   2143       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1427887,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042657.
FT   VARIANT      19     19       S -> R (in HEMA).
FT                                {ECO:0000269|PubMed:10338101}.
FT                                /FTId=VAR_028447.
FT   VARIANT      22     22       R -> T (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028448.
FT   VARIANT      24     24       Y -> C (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028449.
FT   VARIANT      25     25       Y -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028450.
FT   VARIANT      26     26       L -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028451.
FT   VARIANT      26     26       L -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001045.
FT   VARIANT      30     30       E -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001046.
FT   VARIANT      33     33       W -> G (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9341862}.
FT                                /FTId=VAR_028452.
FT   VARIANT      35     35       Y -> C (in HEMA; mild/severe).
FT                                {ECO:0000269|PubMed:12351418}.
FT                                /FTId=VAR_028453.
FT   VARIANT      35     35       Y -> H (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028454.
FT   VARIANT      41     41       G -> C (in HEMA; severe/moderate).
FT                                /FTId=VAR_001047.
FT   VARIANT      48     48       R -> C (in HEMA; severe).
FT                                /FTId=VAR_001048.
FT   VARIANT      48     48       R -> K (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028455.
FT   VARIANT      67     67       K -> E (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028456.
FT   VARIANT      67     67       K -> N (in HEMA).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028457.
FT   VARIANT      69     69       L -> P (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028458.
FT   VARIANT      72     72       E -> K (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017330.
FT   VARIANT      75     75       D -> E (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:7759074}.
FT                                /FTId=VAR_028459.
FT   VARIANT      75     75       D -> V (in dbSNP:rs1800288).
FT                                /FTId=VAR_001049.
FT   VARIANT      75     75       D -> Y (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028460.
FT   VARIANT      83     83       P -> R (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065303.
FT   VARIANT      84     85       Missing (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028461.
FT   VARIANT      85     85       Missing (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028462.
FT   VARIANT      89     89       G -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001050.
FT   VARIANT      89     89       G -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001051.
FT   VARIANT      92     92       G -> A (in HEMA).
FT                                {ECO:0000269|PubMed:11442647}.
FT                                /FTId=VAR_028463.
FT   VARIANT      92     92       G -> V (in HEMA; mild; dbSNP:rs28935204).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_028464.
FT   VARIANT      97     97       A -> P (in HEMA).
FT                                {ECO:0000269|PubMed:12199686}.
FT                                /FTId=VAR_017331.
FT   VARIANT      98     98       E -> K (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028465.
FT   VARIANT      99     99       V -> D (in HEMA; severe;
FT                                dbSNP:rs28935205).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001052.
FT   VARIANT     101    101       D -> G (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028466.
FT   VARIANT     101    101       D -> H (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838}.
FT                                /FTId=VAR_028467.
FT   VARIANT     101    101       D -> V (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028468.
FT   VARIANT     104    104       V -> D (in HEMA; mild; dbSNP:rs28935206).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001053.
FT   VARIANT     108    108       K -> T (in HEMA; mild; dbSNP:rs28935207).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001054.
FT   VARIANT     110    110       M -> V (in HEMA; moderate;
FT                                dbSNP:rs28936083).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001055.
FT   VARIANT     111    111       A -> T (in HEMA; severe).
FT                                {ECO:0000269|PubMed:15682412}.
FT                                /FTId=VAR_028469.
FT   VARIANT     111    111       A -> V (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028470.
FT   VARIANT     113    113       H -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028471.
FT   VARIANT     113    113       H -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028472.
FT   VARIANT     117    117       L -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028473.
FT   VARIANT     117    117       L -> R (in HEMA; severe;
FT                                dbSNP:rs28935208).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001056.
FT   VARIANT     121    121       G -> S (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028474.
FT   VARIANT     129    129       E -> V (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9450898}.
FT                                /FTId=VAR_001057.
FT   VARIANT     130    130       G -> R (in HEMA; severe).
FT                                /FTId=VAR_001058.
FT   VARIANT     132    132       E -> D (in HEMA; severe;
FT                                dbSNP:rs28935209).
FT                                {ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001059.
FT   VARIANT     133    133       Y -> C (in HEMA; mild; dbSNP:rs28935210).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001060.
FT   VARIANT     135    135       D -> G (in HEMA; severe;
FT                                dbSNP:rs28935211).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001061.
FT   VARIANT     135    135       D -> Y (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838}.
FT                                /FTId=VAR_028475.
FT   VARIANT     137    137       T -> A (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028476.
FT   VARIANT     137    137       T -> I (in HEMA; moderate).
FT                                /FTId=VAR_001062.
FT   VARIANT     138    138       S -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028477.
FT   VARIANT     141    141       E -> K (in HEMA; severe familial).
FT                                {ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028478.
FT   VARIANT     145    145       D -> H (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028479.
FT   VARIANT     147    147       V -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12195713}.
FT                                /FTId=VAR_028480.
FT   VARIANT     155    155       Y -> H (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017332.
FT   VARIANT     159    159       V -> A (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028481.
FT   VARIANT     163    163       N -> K (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028482.
FT   VARIANT     164    164       G -> D (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028483.
FT   VARIANT     164    164       G -> V (in HEMA; mild; dbSNP:rs28935212).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001063.
FT   VARIANT     165    165       P -> S (in HEMA; severe;
FT                                dbSNP:rs28935213).
FT                                /FTId=VAR_001064.
FT   VARIANT     172    172       C -> W (in HEMA).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028484.
FT   VARIANT     176    176       S -> P (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028485.
FT   VARIANT     179    179       S -> P (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028486.
FT   VARIANT     181    181       V -> E (in HEMA; mild).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017333.
FT   VARIANT     181    181       V -> M (in HEMA; mild/moderate).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11748850,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:7759074,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001065.
FT   VARIANT     185    185       K -> T (in HEMA; mild).
FT                                /FTId=VAR_001066.
FT   VARIANT     186    186       D -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028487.
FT   VARIANT     186    186       D -> N (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065304.
FT   VARIANT     186    186       D -> Y (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028488.
FT   VARIANT     189    189       S -> L (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:2510835,
FT                                ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_001067.
FT   VARIANT     191    191       L -> F (in HEMA).
FT                                {ECO:0000269|PubMed:21371196}.
FT                                /FTId=VAR_065305.
FT   VARIANT     193    193       G -> R (in HEMA; severe familial).
FT                                {ECO:0000269|PubMed:11341489}.
FT                                /FTId=VAR_028489.
FT   VARIANT     195    195       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065306.
FT   VARIANT     198    198       C -> G (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12406074}.
FT                                /FTId=VAR_028490.
FT   VARIANT     202    202       S -> N (in HEMA; mild).
FT                                {ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028491.
FT   VARIANT     202    202       S -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10408784}.
FT                                /FTId=VAR_008123.
FT   VARIANT     214    214       F -> V (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028492.
FT   VARIANT     217    217       L -> H (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:7794769}.
FT                                /FTId=VAR_028493.
FT   VARIANT     219    219       A -> D (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028494.
FT   VARIANT     219    219       A -> T (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028495.
FT   VARIANT     220    220       V -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028496.
FT   VARIANT     222    222       D -> V (in HEMA; moderate).
FT                                /FTId=VAR_001068.
FT   VARIANT     223    223       E -> K (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9569180}.
FT                                /FTId=VAR_028497.
FT   VARIANT     224    224       G -> W (in HEMA; moderate).
FT                                /FTId=VAR_001069.
FT   VARIANT     252    252       T -> I (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12614369}.
FT                                /FTId=VAR_028498.
FT   VARIANT     253    253       V -> F (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001070.
FT   VARIANT     254    254       N -> I (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017334.
FT   VARIANT     255    255       G -> V (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015127.
FT   VARIANT     261    261       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065307.
FT   VARIANT     262    262       P -> L (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028499.
FT   VARIANT     263    263       G -> S (in HEMA).
FT                                {ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_028500.
FT   VARIANT     266    266       G -> E (in HEMA; severe).
FT                                /FTId=VAR_001071.
FT   VARIANT     267    267       C -> Y (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028501.
FT   VARIANT     274    274       W -> C (in HEMA; dbSNP:rs34371500).
FT                                {ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_028502.
FT   VARIANT     275    275       H -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028503.
FT   VARIANT     278    278       G -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001072.
FT   VARIANT     280    280       G -> D (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065308.
FT   VARIANT     284    284       E -> K (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028504.
FT   VARIANT     285    285       V -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_001073.
FT   VARIANT     291    291       E -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:2835904}.
FT                                /FTId=VAR_001074.
FT   VARIANT     291    291       E -> K (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:1356412,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028505.
FT   VARIANT     294    294       T -> I (in HEMA; moderate).
FT                                /FTId=VAR_001075.
FT   VARIANT     295    295       F -> L (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028506.
FT   VARIANT     297    297       V -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028507.
FT   VARIANT     299    299       N -> I (in HEMA; mild; dbSNP:rs28935215).
FT                                {ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:8322269}.
FT                                /FTId=VAR_001076.
FT   VARIANT     301    301       R -> C (in HEMA; severe/mild).
FT                                {ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:12195713,
FT                                ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028508.
FT   VARIANT     301    301       R -> H (in HEMA; severe;
FT                                dbSNP:rs28935216).
FT                                {ECO:0000269|PubMed:10338101,
FT                                ECO:0000269|PubMed:10408784,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001077.
FT   VARIANT     301    301       R -> L (in HEMA; severe).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001078.
FT   VARIANT     302    302       Missing (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028509.
FT   VARIANT     303    303       A -> E (in HEMA; mild).
FT                                {ECO:0000269|PubMed:8759905,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028510.
FT   VARIANT     303    303       A -> P (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9029040}.
FT                                /FTId=VAR_028511.
FT   VARIANT     307    307       I -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028512.
FT   VARIANT     308    308       S -> L (in HEMA; moderate;
FT                                dbSNP:rs28937268).
FT                                {ECO:0000269|PubMed:10338101,
FT                                ECO:0000269|PubMed:8449505,
FT                                ECO:0000269|PubMed:8759905}.
FT                                /FTId=VAR_001079.
FT   VARIANT     312    312       F -> S (in HEMA; mild/moderate).
FT                                {ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001080.
FT   VARIANT     314    314       T -> A (in HEMA; mild; dbSNP:rs28937269).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_001081.
FT   VARIANT     314    314       T -> I (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001082.
FT   VARIANT     315    315       A -> V (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028513.
FT   VARIANT     320    320       Missing (in HEMA; severe).
FT                                /FTId=VAR_028514.
FT   VARIANT     323    323       G -> E (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015128.
FT   VARIANT     326    326       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028515.
FT   VARIANT     327    327       L -> P (in HEMA; severe;
FT                                dbSNP:rs28937270).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001083.
FT   VARIANT     327    327       L -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028516.
FT   VARIANT     329    329       C -> F (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028517.
FT   VARIANT     331    331       I -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001084.
FT   VARIANT     339    339       M -> T (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11748850}.
FT                                /FTId=VAR_028518.
FT   VARIANT     340    340       E -> K (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028519.
FT   VARIANT     345    345       V -> A (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028520.
FT   VARIANT     345    345       V -> L (in HEMA; severe).
FT                                {ECO:0000269|PubMed:2107542}.
FT                                /FTId=VAR_001085.
FT   VARIANT     348    348       C -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:2107542}.
FT                                /FTId=VAR_001086.
FT   VARIANT     348    348       C -> S (in HEMA; moderate).
FT                                /FTId=VAR_001087.
FT   VARIANT     348    348       C -> Y (in HEMA; mild/severe).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_001088.
FT   VARIANT     365    365       Y -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744,
FT                                ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028521.
FT   VARIANT     391    391       R -> C (in HEMA; Okayama; moderate/
FT                                severe; abolishes the normal cleavage by
FT                                thrombin). {ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:1973901,
FT                                ECO:0000269|PubMed:2506948}.
FT                                /FTId=VAR_001089.
FT   VARIANT     391    391       R -> H (in HEMA; Kumamoto; mild/moderate;
FT                                abolishes the normal cleavage by
FT                                thrombin; dbSNP:rs28935499).
FT                                {ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:2498882,
FT                                ECO:0000269|PubMed:8449505,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001090.
FT   VARIANT     391    391       R -> P (in HEMA; severe; abolishes the
FT                                normal cleavage by thrombin).
FT                                /FTId=VAR_001091.
FT   VARIANT     392    392       S -> L (in HEMA; mild; abolishes normal
FT                                cleavage by thrombin; dbSNP:rs28933668).
FT                                /FTId=VAR_001092.
FT   VARIANT     392    392       S -> P (in HEMA; mild; dbSNP:rs28933669).
FT                                /FTId=VAR_001093.
FT   VARIANT     394    394       A -> S (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065309.
FT   VARIANT     401    401       W -> G (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028522.
FT   VARIANT     405    405       I -> F (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028523.
FT   VARIANT     405    405       I -> S (in HEMA; severe;
FT                                dbSNP:rs28933670).
FT                                /FTId=VAR_001094.
FT   VARIANT     409    409       E -> G (in HEMA; severe/moderate;
FT                                dbSNP:rs28933671).
FT                                {ECO:0000269|PubMed:11410838}.
FT                                /FTId=VAR_001095.
FT   VARIANT     412    412       W -> G (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028524.
FT   VARIANT     412    412       W -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028525.
FT   VARIANT     427    427       K -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028526.
FT   VARIANT     431    431       L -> F (in HEMA; moderate;
FT                                dbSNP:rs28933672).
FT                                /FTId=VAR_001096.
FT   VARIANT     431    431       L -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028527.
FT   VARIANT     437    437       R -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028528.
FT   VARIANT     437    437       R -> W (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028529.
FT   VARIANT     438    438       I -> F (in HEMA; not severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028530.
FT   VARIANT     439    439       G -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028531.
FT   VARIANT     439    439       G -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12930394,
FT                                ECO:0000269|PubMed:25550078}.
FT                                /FTId=VAR_017335.
FT   VARIANT     439    439       G -> V (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:9829908}.
FT                                /FTId=VAR_001097.
FT   VARIANT     442    442       Y -> C (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028532.
FT   VARIANT     444    444       K -> R (in HEMA; severe;
FT                                dbSNP:rs28937272).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001098.
FT   VARIANT     450    450       Y -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:15682412}.
FT                                /FTId=VAR_028533.
FT   VARIANT     450    450       Y -> N (in HEMA; mild/moderate;
FT                                dbSNP:rs28937273).
FT                                {ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:8322269,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001099.
FT   VARIANT     454    454       T -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028534.
FT   VARIANT     455    455       F -> C (in HEMA; mild-moderate/severe).
FT                                {ECO:0000269|PubMed:11748850,
FT                                ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028535.
FT   VARIANT     466    466       G -> E (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028536.
FT   VARIANT     470    470       P -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028537.
FT   VARIANT     470    470       P -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028538.
FT   VARIANT     470    470       P -> T (in HEMA; mild sporadic).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028539.
FT   VARIANT     474    474       G -> E (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028540.
FT   VARIANT     474    474       G -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001100.
FT   VARIANT     474    474       G -> V (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065310.
FT   VARIANT     475    475       E -> K (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028541.
FT   VARIANT     477    477       G -> V (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12203998}.
FT                                /FTId=VAR_028542.
FT   VARIANT     478    478       D -> N (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028543.
FT   VARIANT     479    479       T -> R (in HEMA).
FT                                /FTId=VAR_028544.
FT   VARIANT     484    484       F -> C (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028545.
FT   VARIANT     488    488       A -> G (in HEMA; moderate).
FT                                /FTId=VAR_001101.
FT   VARIANT     490    490       R -> G (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028546.
FT   VARIANT     492    492       Y -> C (in HEMA; moderate;
FT                                dbSNP:rs28937275).
FT                                {ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_001103.
FT   VARIANT     492    492       Y -> H (in HEMA; mild; dbSNP:rs28937274).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001102.
FT   VARIANT     494    494       I -> T (in HEMA; mild; dbSNP:rs28936968).
FT                                /FTId=VAR_001104.
FT   VARIANT     496    496       P -> R (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065311.
FT   VARIANT     498    498       G -> R (in HEMA; severe/moderate;
FT                                dbSNP:rs28936969).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:9326186,
FT                                ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001105.
FT   VARIANT     503    503       R -> H (in HEMA; dbSNP:rs35383156).
FT                                {ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028547.
FT   VARIANT     513    513       G -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028548.
FT   VARIANT     513    513       G -> V (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065312.
FT   VARIANT     522    522       I -> Y (in HEMA; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028549.
FT   VARIANT     529    529       K -> E (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017336.
FT   VARIANT     532    532       W -> G (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028550.
FT   VARIANT     540    540       P -> T (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028551.
FT   VARIANT     541    541       T -> S (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028552.
FT   VARIANT     544    544       D -> N (in HEMA; moderate;
FT                                dbSNP:rs28937276).
FT                                /FTId=VAR_001106.
FT   VARIANT     546    546       R -> W (in HEMA; mild; dbSNP:rs28937277).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11748850,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:8449505,
FT                                ECO:0000269|PubMed:9029040,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001107.
FT   VARIANT     550    550       R -> C (in HEMA; mild/moderate;
FT                                dbSNP:rs28937278).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001108.
FT   VARIANT     550    550       R -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9452104}.
FT                                /FTId=VAR_001109.
FT   VARIANT     550    550       R -> H (in HEMA; mild/moderate;
FT                                dbSNP:rs28937279).
FT                                {ECO:0000269|PubMed:8759905,
FT                                ECO:0000269|PubMed:9029040,
FT                                ECO:0000269|PubMed:9326186,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001110.
FT   VARIANT     553    553       S -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028553.
FT   VARIANT     554    554       S -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11748850}.
FT                                /FTId=VAR_028554.
FT   VARIANT     554    554       S -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001111.
FT   VARIANT     556    556       V -> D (in HEMA; moderate).
FT                                /FTId=VAR_001112.
FT   VARIANT     560    560       R -> T (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028555.
FT   VARIANT     561    561       D -> G (in HEMA; severe).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_028556.
FT   VARIANT     561    561       D -> H (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028557.
FT   VARIANT     561    561       D -> Y (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10612839,
FT                                ECO:0000269|PubMed:12614369}.
FT                                /FTId=VAR_008967.
FT   VARIANT     567    567       I -> T (in HEMA; mild).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017337.
FT   VARIANT     569    569       P -> R (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065313.
FT   VARIANT     577    577       S -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:8449505}.
FT                                /FTId=VAR_001113.
FT   VARIANT     578    578       V -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028558.
FT   VARIANT     579    579       D -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028559.
FT   VARIANT     579    579       D -> H (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028560.
FT   VARIANT     583    583       N -> S (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028561.
FT   VARIANT     584    584       Q -> H (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028562.
FT   VARIANT     584    584       Q -> K (in HEMA; moderate).
FT                                /FTId=VAR_001114.
FT   VARIANT     584    584       Q -> R (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028563.
FT   VARIANT     585    585       I -> R (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028564.
FT   VARIANT     585    585       I -> T (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_001115.
FT   VARIANT     586    586       M -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015129.
FT   VARIANT     588    588       D -> G (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028565.
FT   VARIANT     588    588       D -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028566.
FT   VARIANT     594    594       L -> Q (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028567.
FT   VARIANT     596    596       S -> P (in HEMA; severe).
FT                                /FTId=VAR_001116.
FT   VARIANT     601    601       N -> D (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028568.
FT   VARIANT     601    601       N -> K (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028569.
FT   VARIANT     602    602       R -> G (in HEMA; mild familial).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028570.
FT   VARIANT     603    603       S -> I (in HEMA).
FT                                /FTId=VAR_001117.
FT   VARIANT     603    603       S -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028571.
FT   VARIANT     604    604       W -> C (in HEMA; severe).
FT                                /FTId=VAR_001118.
FT   VARIANT     605    605       Y -> H (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028572.
FT   VARIANT     605    605       Y -> S (in HEMA; severe).
FT                                /FTId=VAR_001119.
FT   VARIANT     609    609       N -> I (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028573.
FT   VARIANT     612    612       R -> C (in HEMA; mild/moderate; secretion
FT                                impaired). {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:10691849,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:12195713,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:15682412,
FT                                ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_001120.
FT   VARIANT     631    631       N -> K (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9450898}.
FT                                /FTId=VAR_001121.
FT   VARIANT     631    631       N -> S (in HEMA).
FT                                /FTId=VAR_001122.
FT   VARIANT     633    633       M -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028574.
FT   VARIANT     635    635       S -> N (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028575.
FT   VARIANT     637    637       N -> D (in HEMA; severe sporadic/
FT                                moderate). {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028576.
FT   VARIANT     637    637       N -> I (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065314.
FT   VARIANT     637    637       N -> S (in HEMA; mild; secretion
FT                                impaired). {ECO:0000269|PubMed:10691849}.
FT                                /FTId=VAR_028577.
FT   VARIANT     639    639       Y -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9341862}.
FT                                /FTId=VAR_028578.
FT   VARIANT     644    644       L -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001123.
FT   VARIANT     650    650       L -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028579.
FT   VARIANT     653    653       V -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:8449505}.
FT                                /FTId=VAR_001124.
FT   VARIANT     653    653       V -> M (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:8449505}.
FT                                /FTId=VAR_001125.
FT   VARIANT     659    659       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028580.
FT   VARIANT     663    663       A -> V (in HEMA; mild).
FT                                /FTId=VAR_001126.
FT   VARIANT     664    664       Q -> P (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028581.
FT   VARIANT     671    671       Missing (in HEMA; severe).
FT                                {ECO:0000269|PubMed:8449505}.
FT                                /FTId=VAR_001127.
FT   VARIANT     677    677       F -> L (in HEMA; moderate).
FT                                /FTId=VAR_001128.
FT   VARIANT     681    681       M -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028582.
FT   VARIANT     682    682       V -> F (in HEMA).
FT                                {ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_028583.
FT   VARIANT     683    683       Y -> C (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028584.
FT   VARIANT     683    683       Y -> N (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028585.
FT   VARIANT     686    686       T -> R (in HEMA).
FT                                {ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_028586.
FT   VARIANT     698    698       F -> L (in HEMA).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028587.
FT   VARIANT     699    699       M -> T (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028588.
FT   VARIANT     699    699       M -> V (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001129.
FT   VARIANT     701    701       M -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028589.
FT   VARIANT     705    705       G -> V (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:7794769}.
FT                                /FTId=VAR_028590.
FT   VARIANT     710    710       G -> W (in HEMA).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028591.
FT   VARIANT     713    713       N -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10886198}.
FT                                /FTId=VAR_028592.
FT   VARIANT     717    717       R -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:8759905}.
FT                                /FTId=VAR_028593.
FT   VARIANT     717    717       R -> W (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:8759905}.
FT                                /FTId=VAR_001130.
FT   VARIANT     720    720       G -> D (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:7759074,
FT                                ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001131.
FT   VARIANT     720    720       G -> S (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028594.
FT   VARIANT     721    721       M -> I (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028595.
FT   VARIANT     721    721       M -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028596.
FT   VARIANT     723    723       A -> T (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:25550078,
FT                                ECO:0000269|PubMed:9452104}.
FT                                /FTId=VAR_001132.
FT   VARIANT     725    725       L -> Q (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028597.
FT   VARIANT     727    727       V -> F (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001133.
FT   VARIANT     739    739       E -> K (in HEMA; mild; dbSNP:rs28937285).
FT                                /FTId=VAR_001134.
FT   VARIANT     742    742       Y -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028598.
FT   VARIANT     795    795       R -> G (in dbSNP:rs2228152).
FT                                /FTId=VAR_024380.
FT   VARIANT     947    947       P -> R (in HEMA).
FT                                {ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_028599.
FT   VARIANT    1012   1012       V -> L (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028600.
FT   VARIANT    1057   1057       E -> K (in HEMA; moderate;
FT                                dbSNP:rs28933673).
FT                                {ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_001135.
FT   VARIANT    1066   1066       H -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028601.
FT   VARIANT    1260   1260       D -> E (in dbSNP:rs1800291).
FT                                {ECO:0000269|PubMed:12195713,
FT                                ECO:0000269|PubMed:8644728,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_001136.
FT   VARIANT    1289   1289       K -> Q (in dbSNP:rs1800292).
FT                                /FTId=VAR_048438.
FT   VARIANT    1336   1336       Q -> K (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028602.
FT   VARIANT    1460   1460       N -> K (in HEMA).
FT                                {ECO:0000269|PubMed:8449505}.
FT                                /FTId=VAR_028603.
FT   VARIANT    1481   1481       L -> P (in dbSNP:rs1800294).
FT                                /FTId=VAR_001137.
FT   VARIANT    1610   1610       A -> S (in HEMA).
FT                                {ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_028604.
FT   VARIANT    1698   1698       I -> T (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028605.
FT   VARIANT    1699   1699       Y -> C (in HEMA; severe).
FT                                /FTId=VAR_001138.
FT   VARIANT    1699   1699       Y -> F (in HEMA; moderate;
FT                                dbSNP:rs28935203).
FT                                {ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:2105906}.
FT                                /FTId=VAR_001139.
FT   VARIANT    1701   1701       E -> K (in HEMA; mild).
FT                                {ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028606.
FT   VARIANT    1705   1705       Q -> H (in HEMA; mild sporadic).
FT                                {ECO:0000269|PubMed:11341489}.
FT                                /FTId=VAR_028607.
FT   VARIANT    1708   1708       R -> C (in HEMA; East Hartford; severe/
FT                                moderate/mild; abolishes thrombin
FT                                cleavage at the light chain).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:1851341,
FT                                ECO:0000269|PubMed:2104766,
FT                                ECO:0000269|PubMed:2105906,
FT                                ECO:0000269|PubMed:2499363,
FT                                ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:8644728,
FT                                ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_001140.
FT   VARIANT    1708   1708       R -> H (in HEMA; mild; abolishes thrombin
FT                                cleavage at the light chain;
FT                                dbSNP:rs28937286).
FT                                {ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:1851341}.
FT                                /FTId=VAR_001141.
FT   VARIANT    1714   1714       T -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12203998}.
FT                                /FTId=VAR_028608.
FT   VARIANT    1715   1715       R -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1349567,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001142.
FT   VARIANT    1720   1720       A -> V (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065315.
FT   VARIANT    1723   1723       E -> K (in HEMA; severe).
FT                                {ECO:0000269|PubMed:1908817}.
FT                                /FTId=VAR_001143.
FT   VARIANT    1727   1727       D -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744,
FT                                ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028609.
FT   VARIANT    1728   1728       Y -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:2106480}.
FT                                /FTId=VAR_001144.
FT   VARIANT    1740   1740       R -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028610.
FT   VARIANT    1751   1751       K -> Q (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028611.
FT   VARIANT    1762   1762       F -> L (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065316.
FT   VARIANT    1768   1768       R -> H (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028612.
FT   VARIANT    1769   1769       G -> R (in HEMA; mild).
FT                                /FTId=VAR_001145.
FT   VARIANT    1771   1771       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028613.
FT   VARIANT    1775   1775       L -> F (in HEMA; mild).
FT                                /FTId=VAR_001147.
FT   VARIANT    1775   1775       L -> V (in HEMA; moderate).
FT                                /FTId=VAR_001146.
FT   VARIANT    1777   1777       L -> P (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12203998}.
FT                                /FTId=VAR_028614.
FT   VARIANT    1779   1779       G -> E (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_001148.
FT   VARIANT    1779   1779       G -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028615.
FT   VARIANT    1780   1780       P -> L (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028616.
FT   VARIANT    1782   1782       I -> R (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11341489}.
FT                                /FTId=VAR_028617.
FT   VARIANT    1788   1788       D -> H (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028618.
FT   VARIANT    1791   1791       M -> T (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001149.
FT   VARIANT    1798   1798       A -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028619.
FT   VARIANT    1799   1799       S -> H (in HEMA; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_028620.
FT   VARIANT    1800   1800       R -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:1301960,
FT                                ECO:0000269|PubMed:9829908}.
FT                                /FTId=VAR_001151.
FT   VARIANT    1800   1800       R -> G (in HEMA; mild).
FT                                /FTId=VAR_001152.
FT   VARIANT    1800   1800       R -> H (in HEMA; moderate/severe).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:15682412,
FT                                ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:9341862,
FT                                ECO:0000269|PubMed:9450898,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001150.
FT   VARIANT    1801   1801       P -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028621.
FT   VARIANT    1802   1802       Y -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:15682412}.
FT                                /FTId=VAR_028622.
FT   VARIANT    1803   1803       S -> Y (in HEMA; severe).
FT                                {ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001153.
FT   VARIANT    1804   1804       F -> S (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017338.
FT   VARIANT    1808   1808       L -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_001154.
FT   VARIANT    1842   1842       M -> I (in HEMA; moderate;
FT                                dbSNP:rs28933674).
FT                                /FTId=VAR_001155.
FT   VARIANT    1844   1844       P -> S (in HEMA; mild; dbSNP:rs28933675).
FT                                /FTId=VAR_001156.
FT   VARIANT    1845   1845       T -> P (in HEMA; mild; dbSNP:rs28933676).
FT                                {ECO:0000269|PubMed:1639429}.
FT                                /FTId=VAR_001157.
FT   VARIANT    1848   1848       E -> G (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028623.
FT   VARIANT    1853   1853       A -> T (in HEMA; moderate/severe).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:7759074}.
FT                                /FTId=VAR_001158.
FT   VARIANT    1853   1853       A -> V (in HEMA; mild; dbSNP:rs28933677).
FT                                /FTId=VAR_001159.
FT   VARIANT    1858   1858       S -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028624.
FT   VARIANT    1864   1864       K -> E (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028625.
FT   VARIANT    1865   1865       D -> N (in HEMA; severe).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001160.
FT   VARIANT    1865   1865       D -> Y (in HEMA; severe).
FT                                /FTId=VAR_001161.
FT   VARIANT    1867   1867       H -> P (in HEMA; mild).
FT                                {ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028626.
FT   VARIANT    1867   1867       H -> R (in HEMA; moderate;
FT                                dbSNP:rs28933679).
FT                                /FTId=VAR_001162.
FT   VARIANT    1869   1869       G -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028627.
FT   VARIANT    1869   1869       G -> V (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10612839,
FT                                ECO:0000269|PubMed:12614369}.
FT                                /FTId=VAR_001163.
FT   VARIANT    1872   1872       G -> E (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11341489}.
FT                                /FTId=VAR_028628.
FT   VARIANT    1873   1873       P -> R (in HEMA; severe;
FT                                dbSNP:rs28933680).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001164.
FT   VARIANT    1875   1875       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028629.
FT   VARIANT    1876   1876       V -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028630.
FT   VARIANT    1877   1877       C -> R (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028631.
FT   VARIANT    1877   1877       C -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:21371196}.
FT                                /FTId=VAR_065317.
FT   VARIANT    1882   1882       L -> P (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028632.
FT   VARIANT    1888   1888       R -> I (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:7759074}.
FT                                /FTId=VAR_001165.
FT   VARIANT    1894   1894       E -> G (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:9452104}.
FT                                /FTId=VAR_001166.
FT   VARIANT    1901   1901       I -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028633.
FT   VARIANT    1904   1904       E -> D (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028634.
FT   VARIANT    1904   1904       E -> K (in HEMA; severe;
FT                                dbSNP:rs28933681).
FT                                /FTId=VAR_001167.
FT   VARIANT    1907   1907       S -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028635.
FT   VARIANT    1907   1907       S -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028636.
FT   VARIANT    1908   1908       W -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9341862}.
FT                                /FTId=VAR_028637.
FT   VARIANT    1909   1909       Y -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028638.
FT   VARIANT    1939   1939       A -> T (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028639.
FT   VARIANT    1939   1939       A -> V (in HEMA; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028640.
FT   VARIANT    1941   1941       N -> D (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:2106480}.
FT                                /FTId=VAR_001168.
FT   VARIANT    1941   1941       N -> S (in HEMA; severe/moderate;
FT                                dbSNP:rs28933682).
FT                                {ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001169.
FT   VARIANT    1942   1942       G -> A (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015130.
FT   VARIANT    1945   1945       M -> V (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12195713}.
FT                                /FTId=VAR_028641.
FT   VARIANT    1951   1951       L -> F (in HEMA; mild).
FT                                {ECO:0000269|PubMed:8759905}.
FT                                /FTId=VAR_028642.
FT   VARIANT    1960   1960       R -> L (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:1301194}.
FT                                /FTId=VAR_001171.
FT   VARIANT    1960   1960       R -> Q (in HEMA; mild/moderate;
FT                                dbSNP:rs28937294).
FT                                {ECO:0000269|PubMed:1356412,
FT                                ECO:0000269|PubMed:7579394,
FT                                ECO:0000269|PubMed:9326186,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001170.
FT   VARIANT    1963   1963       L -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015131.
FT   VARIANT    1965   1965       S -> I (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028643.
FT   VARIANT    1966   1966       M -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9029040}.
FT                                /FTId=VAR_028644.
FT   VARIANT    1966   1966       M -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028645.
FT   VARIANT    1967   1967       G -> D (in HEMA; moderate;
FT                                dbSNP:rs28937295).
FT                                /FTId=VAR_001172.
FT   VARIANT    1968   1968       S -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028646.
FT   VARIANT    1971   1971       N -> T (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028647.
FT   VARIANT    1973   1973       H -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:10554831}.
FT                                /FTId=VAR_028648.
FT   VARIANT    1979   1979       G -> V (in HEMA; moderate).
FT                                /FTId=VAR_001173.
FT   VARIANT    1980   1980       H -> P (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028649.
FT   VARIANT    1980   1980       H -> Y (in HEMA; mild).
FT                                /FTId=VAR_001174.
FT   VARIANT    1982   1982       F -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028650.
FT   VARIANT    1985   1985       R -> Q (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028651.
FT   VARIANT    1994   1994       L -> P (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:16805874}.
FT                                /FTId=VAR_028652.
FT   VARIANT    1998   1998       Y -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028653.
FT   VARIANT    2000   2000       G -> A (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028654.
FT   VARIANT    2004   2004       T -> R (in HEMA; sporadic).
FT                                {ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028655.
FT   VARIANT    2007   2007       M -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028656.
FT   VARIANT    2013   2013       G -> R (in HEMA).
FT                                {ECO:0000269|PubMed:21371196}.
FT                                /FTId=VAR_065318.
FT   VARIANT    2015   2015       W -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028657.
FT   VARIANT    2016   2016       R -> P (in HEMA; severe familial).
FT                                {ECO:0000269|PubMed:11341489}.
FT                                /FTId=VAR_028658.
FT   VARIANT    2016   2016       R -> W (in HEMA; severe/moderate/mild).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:7794769,
FT                                ECO:0000269|PubMed:8644728,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001175.
FT   VARIANT    2018   2018       E -> G (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028659.
FT   VARIANT    2022   2022       G -> D (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028660.
FT   VARIANT    2028   2028       G -> R (in HEMA).
FT                                {ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_028661.
FT   VARIANT    2030   2030       S -> N (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_028662.
FT   VARIANT    2035   2035       V -> A (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028663.
FT   VARIANT    2036   2036       Y -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:11298607}.
FT                                /FTId=VAR_015132.
FT   VARIANT    2038   2038       N -> S (in HEMA; mild/moderate).
FT                                {ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:9886318}.
FT                                /FTId=VAR_001176.
FT   VARIANT    2040   2040       C -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028664.
FT   VARIANT    2045   2045       G -> E (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028665.
FT   VARIANT    2045   2045       G -> V (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:9569180}.
FT                                /FTId=VAR_028666.
FT   VARIANT    2051   2051       I -> S (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017339.
FT   VARIANT    2056   2056       I -> N (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028667.
FT   VARIANT    2058   2058       A -> P (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028668.
FT   VARIANT    2065   2065       W -> R (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:1301932}.
FT                                /FTId=VAR_001177.
FT   VARIANT    2067   2067       P -> L (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028669.
FT   VARIANT    2070   2070       A -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028670.
FT   VARIANT    2082   2082       S -> N (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028671.
FT   VARIANT    2088   2088       S -> F (in HEMA; severe).
FT                                /FTId=VAR_001178.
FT   VARIANT    2093   2093       D -> G (in HEMA; mild).
FT                                /FTId=VAR_001179.
FT   VARIANT    2093   2093       D -> Y (in HEMA; severe familial).
FT                                {ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028672.
FT   VARIANT    2101   2101       H -> D (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065319.
FT   VARIANT    2105   2105       T -> N (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:9603440}.
FT                                /FTId=VAR_001180.
FT   VARIANT    2106   2106       Q -> E (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028673.
FT   VARIANT    2106   2106       Q -> P (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065320.
FT   VARIANT    2106   2106       Q -> R (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9341862}.
FT                                /FTId=VAR_028674.
FT   VARIANT    2107   2107       G -> S (in HEMA; severe).
FT                                {ECO:0000269|PubMed:9452104}.
FT                                /FTId=VAR_001181.
FT   VARIANT    2109   2109       R -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028675.
FT   VARIANT    2117   2117       I -> F (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028676.
FT   VARIANT    2117   2117       I -> S (in HEMA; mild-moderate; affinity
FT                                for VWF reduced 8-fold).
FT                                {ECO:0000269|PubMed:10910910}.
FT                                /FTId=VAR_028677.
FT   VARIANT    2119   2119       Q -> R (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:7794769}.
FT                                /FTId=VAR_028678.
FT   VARIANT    2120   2120       F -> C (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028679.
FT   VARIANT    2120   2120       F -> L (in HEMA; mild).
FT                                /FTId=VAR_001182.
FT   VARIANT    2124   2124       Y -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_001183.
FT   VARIANT    2135   2135       R -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:3122181}.
FT                                /FTId=VAR_001184.
FT   VARIANT    2138   2138       S -> Y (in HEMA; moderate; affinity for
FT                                VWF reduced 80-fold).
FT                                {ECO:0000269|PubMed:10910910}.
FT                                /FTId=VAR_001185.
FT   VARIANT    2141   2141       T -> N (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017340.
FT   VARIANT    2143   2143       M -> V (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065321.
FT   VARIANT    2145   2145       F -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028680.
FT   VARIANT    2148   2148       N -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10910910}.
FT                                /FTId=VAR_001186.
FT   VARIANT    2157   2157       N -> D (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028681.
FT   VARIANT    2162   2162       P -> L (in HEMA; severe).
FT                                {ECO:0000269|PubMed:15810915}.
FT                                /FTId=VAR_028682.
FT   VARIANT    2169   2169       R -> C (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028683.
FT   VARIANT    2169   2169       R -> H (in HEMA; severe/mild; affinity
FT                                for VWF reduced 3-fold).
FT                                {ECO:0000269|PubMed:10338101,
FT                                ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:10896236,
FT                                ECO:0000269|PubMed:10910910,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:7579394,
FT                                ECO:0000269|PubMed:8639447,
FT                                ECO:0000269|PubMed:9326186,
FT                                ECO:0000269|PubMed:9569189,
FT                                ECO:0000269|PubMed:9829908}.
FT                                /FTId=VAR_001187.
FT   VARIANT    2172   2172       P -> L (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065322.
FT   VARIANT    2172   2172       P -> Q (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10910910}.
FT                                /FTId=VAR_001188.
FT   VARIANT    2172   2172       P -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11410838}.
FT                                /FTId=VAR_015133.
FT   VARIANT    2173   2173       T -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11857744}.
FT                                /FTId=VAR_028684.
FT   VARIANT    2173   2173       T -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1301960}.
FT                                /FTId=VAR_001189.
FT   VARIANT    2174   2174       H -> D (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028685.
FT   VARIANT    2178   2178       R -> C (in HEMA; mild/moderate).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:11748850,
FT                                ECO:0000269|PubMed:12195713,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:7579394,
FT                                ECO:0000269|PubMed:8449505,
FT                                ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_001190.
FT   VARIANT    2178   2178       R -> H (in HEMA; mild).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_001191.
FT   VARIANT    2178   2178       R -> L (in HEMA; mild).
FT                                /FTId=VAR_001192.
FT   VARIANT    2182   2182       R -> C (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_001193.
FT   VARIANT    2182   2182       R -> H (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:10215414,
FT                                ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11341489,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:11554935,
FT                                ECO:0000269|PubMed:15810915,
FT                                ECO:0000269|PubMed:9569189,
FT                                ECO:0000269|PubMed:9829908}.
FT                                /FTId=VAR_001194.
FT   VARIANT    2182   2182       R -> P (in HEMA; moderate/severe).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028686.
FT   VARIANT    2183   2183       M -> R (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028687.
FT   VARIANT    2183   2183       M -> V (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_001195.
FT   VARIANT    2185   2185       L -> S (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11410838}.
FT                                /FTId=VAR_001196.
FT   VARIANT    2185   2185       L -> W (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028688.
FT   VARIANT    2192   2192       S -> I (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:11858487}.
FT                                /FTId=VAR_028689.
FT   VARIANT    2193   2193       C -> G (in HEMA).
FT                                {ECO:0000269|PubMed:12199686}.
FT                                /FTId=VAR_017341.
FT   VARIANT    2196   2196       P -> R (in HEMA).
FT                                /FTId=VAR_028690.
FT   VARIANT    2198   2198       G -> V (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:11442643}.
FT                                /FTId=VAR_028691.
FT   VARIANT    2200   2200       E -> D (in HEMA).
FT                                {ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_028692.
FT   VARIANT    2204   2204       I -> T (in HEMA; mild).
FT                                {ECO:0000269|PubMed:9452104}.
FT                                /FTId=VAR_001197.
FT   VARIANT    2209   2209       I -> N (in HEMA; moderate).
FT                                /FTId=VAR_001198.
FT   VARIANT    2211   2211       A -> P (in HEMA; moderate).
FT                                /FTId=VAR_001199.
FT   VARIANT    2220   2220       A -> P (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028693.
FT   VARIANT    2223   2223       Missing (in HEMA; severe/moderate).
FT                                /FTId=VAR_001200.
FT   VARIANT    2224   2224       P -> L (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028695.
FT   VARIANT    2224   2224       Missing (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:1639429}.
FT                                /FTId=VAR_028694.
FT   VARIANT    2228   2228       R -> G (in HEMA; severe).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_001201.
FT   VARIANT    2228   2228       R -> L (in HEMA; moderate).
FT                                /FTId=VAR_001202.
FT   VARIANT    2228   2228       R -> P (in HEMA; moderate-severe).
FT                                {ECO:0000269|PubMed:10896236}.
FT                                /FTId=VAR_028696.
FT   VARIANT    2228   2228       R -> Q (in HEMA; severe/moderate).
FT                                {ECO:0000269|PubMed:10338101,
FT                                ECO:0000269|PubMed:10800171,
FT                                ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11442643,
FT                                ECO:0000269|PubMed:1908096,
FT                                ECO:0000269|PubMed:2105106,
FT                                ECO:0000269|PubMed:2833855,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001203.
FT   VARIANT    2229   2229       L -> F (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028697.
FT   VARIANT    2242   2242       V -> M. {ECO:0000269|PubMed:8639447}.
FT                                /FTId=VAR_001204.
FT   VARIANT    2248   2248       W -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10404764,
FT                                ECO:0000269|PubMed:1301932,
FT                                ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_001205.
FT   VARIANT    2248   2248       W -> S (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12614369}.
FT                                /FTId=VAR_028698.
FT   VARIANT    2251   2251       V -> A (in HEMA; mild).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:15682412}.
FT                                /FTId=VAR_028699.
FT   VARIANT    2251   2251       V -> E (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028700.
FT   VARIANT    2257   2257       M -> V (in dbSNP:rs1800297).
FT                                {ECO:0000269|PubMed:7579394,
FT                                ECO:0000269|PubMed:9569180,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_021356.
FT   VARIANT    2262   2262       V -> VQ (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:12930394}.
FT                                /FTId=VAR_017342.
FT   VARIANT    2264   2264       T -> A (in HEMA).
FT                                {ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_028701.
FT   VARIANT    2265   2265       Q -> R (in HEMA; moderate).
FT                                /FTId=VAR_001206.
FT   VARIANT    2279   2279       F -> C (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:9569180}.
FT                                /FTId=VAR_028702.
FT   VARIANT    2279   2279       F -> I (in HEMA).
FT                                {ECO:0000269|PubMed:9569189}.
FT                                /FTId=VAR_028703.
FT   VARIANT    2281   2281       I -> T (in HEMA; severe).
FT                                {ECO:0000269|PubMed:7579394}.
FT                                /FTId=VAR_028704.
FT   VARIANT    2286   2286       D -> G (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065323.
FT   VARIANT    2290   2290       W -> L (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028705.
FT   VARIANT    2304   2304       G -> V (in HEMA).
FT                                {ECO:0000269|PubMed:9326186}.
FT                                /FTId=VAR_028706.
FT   VARIANT    2307   2307       D -> A (in HEMA; moderate/mild).
FT                                {ECO:0000269|PubMed:11298607,
FT                                ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_015134.
FT   VARIANT    2319   2319       P -> L (in HEMA; mild/severe).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_001207.
FT   VARIANT    2319   2319       P -> S (in HEMA; mild).
FT                                {ECO:0000269|PubMed:1908817,
FT                                ECO:0000269|PubMed:9829908}.
FT                                /FTId=VAR_001208.
FT   VARIANT    2323   2323       R -> C (in HEMA; severe/moderate; may
FT                                cause reduced phospholipid binding).
FT                                {ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:12325022,
FT                                ECO:0000269|PubMed:12871415,
FT                                ECO:0000269|PubMed:1908096}.
FT                                /FTId=VAR_001209.
FT   VARIANT    2323   2323       R -> G (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028707.
FT   VARIANT    2323   2323       R -> H (in HEMA; mild; may cause reduced
FT                                phospholipid binding).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_001210.
FT   VARIANT    2323   2323       R -> L (in HEMA; mild).
FT                                {ECO:0000269|PubMed:11554935}.
FT                                /FTId=VAR_028708.
FT   VARIANT    2326   2326       R -> G (in HEMA).
FT                                {ECO:0000269|PubMed:10404764}.
FT                                /FTId=VAR_028709.
FT   VARIANT    2326   2326       R -> L (in HEMA; severe/moderate; may
FT                                cause reduced phospholipid binding).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:11858487,
FT                                ECO:0000269|PubMed:2105106,
FT                                ECO:0000269|PubMed:2495245,
FT                                ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_001211.
FT   VARIANT    2326   2326       R -> P (in HEMA; severe sporadic).
FT                                {ECO:0000269|PubMed:11410838,
FT                                ECO:0000269|PubMed:11748850}.
FT                                /FTId=VAR_028710.
FT   VARIANT    2326   2326       R -> Q (in HEMA; moderate/mild; may cause
FT                                reduced phospholipid binding).
FT                                {ECO:0000269|PubMed:10338101,
FT                                ECO:0000269|PubMed:10910913,
FT                                ECO:0000269|PubMed:12195713,
FT                                ECO:0000269|PubMed:3012775}.
FT                                /FTId=VAR_001212.
FT   VARIANT    2330   2330       Q -> P (in HEMA; severe).
FT                                {ECO:0000269|PubMed:11857744,
FT                                ECO:0000269|PubMed:12203998}.
FT                                /FTId=VAR_028711.
FT   VARIANT    2332   2332       W -> R (in HEMA; severe).
FT                                {ECO:0000269|PubMed:10800171}.
FT                                /FTId=VAR_028712.
FT   VARIANT    2336   2336       I -> F (in HEMA).
FT                                {ECO:0000269|PubMed:18184865}.
FT                                /FTId=VAR_065324.
FT   VARIANT    2339   2339       R -> T (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10910913}.
FT                                /FTId=VAR_028713.
FT   VARIANT    2344   2344       G -> C (in HEMA; moderate).
FT                                {ECO:0000269|PubMed:10612839,
FT                                ECO:0000269|PubMed:12614369}.
FT                                /FTId=VAR_008968.
FT   VARIANT    2344   2344       G -> D (in HEMA).
FT                                {ECO:0000269|PubMed:21371196}.
FT                                /FTId=VAR_065325.
FT   VARIANT    2344   2344       G -> S (in HEMA).
FT                                {ECO:0000269|PubMed:8644728}.
FT                                /FTId=VAR_028714.
FT   VARIANT    2345   2345       C -> S (in HEMA).
FT                                {ECO:0000269|PubMed:12871415}.
FT                                /FTId=VAR_028715.
FT   VARIANT    2345   2345       C -> Y (in HEMA).
FT                                {ECO:0000269|PubMed:12325022}.
FT                                /FTId=VAR_028716.
FT   CONFLICT    768    768       P -> R (in Ref. 2; CAA25619).
FT                                {ECO:0000305}.
FT   CONFLICT   1922   1922       C -> S (in Ref. 5; AAA52420).
FT                                {ECO:0000305}.
FT   TURN       2199   2201       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2202   2204       {ECO:0000244|PDB:3HNY}.
FT   HELIX      2206   2208       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2209   2212       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2215   2217       {ECO:0000244|PDB:1D7P}.
FT   STRAND     2220   2222       {ECO:0000244|PDB:1D7P}.
FT   HELIX      2224   2226       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2233   2235       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2249   2265       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2267   2269       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2272   2289       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2306   2310       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2312   2335       {ECO:0000244|PDB:3HNY}.
FT   STRAND     2338   2346       {ECO:0000244|PDB:3HNY}.
SQ   SEQUENCE   2351 AA;  267009 MW;  75FB6A2955C74CB0 CRC64;
     MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL GELPVDARFP PRVPKSFPFN
     TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL LGPTIQAEVY DTVVITLKNM ASHPVSLHAV
     GVSYWKASEG AEYDDQTSQR EKEDDKVFPG GSHTYVWQVL KENGPMASDP LCLTYSYLSH
     VDLVKDLNSG LIGALLVCRE GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
     AASARAWPKM HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL EGHTFLVRNH
     RQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGME AYVKVDSCPE EPQLRMKNNE
     EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI RSVAKKHPKT WVHYIAAEEE DWDYAPLVLA
     PDDRSYKSQY LNNGPQRIGR KYKKVRFMAY TDETFKTREA IQHESGILGP LLYGEVGDTL
     LIIFKNQASR PYNIYPHGIT DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
     TKSDPRCLTR YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR NVILFSVFDE
     NRSWYLTENI QRFLPNPAGV QLEDPEFQAS NIMHSINGYV FDSLQLSVCL HEVAYWYILS
     IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF PFSGETVFMS MENPGLWILG CHNSDFRNRG
     MTALLKVSSC DKNTGDYYED SYEDISAYLL SKNNAIEPRS FSQNSRHPST RQKQFNATTI
     PENDIEKTDP WFAHRTPMPK IQNVSSSDLL MLLRQSPTPH GLSLSDLQEA KYETFSDDPS
     PGAIDSNNSL SEMTHFRPQL HHSGDMVFTP ESGLQLRLNE KLGTTAATEL KKLDFKVSST
     SNNLISTIPS DNLAAGTDNT SSLGPPSMPV HYDSQLDTTL FGKKSSPLTE SGGPLSLSEE
     NNDSKLLESG LMNSQESSWG KNVSSTESGR LFKGKRAHGP ALLTKDNALF KVSISLLKTN
     KTSNNSATNR KTHIDGPSLL IENSPSVWQN ILESDTEFKK VTPLIHDRML MDKNATALRL
     NHMSNKTTSS KNMEMVQQKK EGPIPPDAQN PDMSFFKMLF LPESARWIQR THGKNSLNSG
     QGPSPKQLVS LGPEKSVEGQ NFLSEKNKVV VGKGEFTKDV GLKEMVFPSS RNLFLTNLDN
     LHENNTHNQE KKIQEEIEKK ETLIQENVVL PQIHTVTGTK NFMKNLFLLS TRQNVEGSYD
     GAYAPVLQDF RSLNDSTNRT KKHTAHFSKK GEEENLEGLG NQTKQIVEKY ACTTRISPNT
     SQQNFVTQRS KRALKQFRLP LEETELEKRI IVDDTSTQWS KNMKHLTPST LTQIDYNEKE
     KGAITQSPLS DCLTRSHSIP QANRSPLPIA KVSSFPSIRP IYLTRVLFQD NSSHLPAASY
     RKKDSGVQES SHFLQGAKKN NLSLAILTLE MTGDQREVGS LGTSATNSVT YKKVENTVLP
     KPDLPKTSGK VELLPKVHIY QKDLFPTETS NGSPGHLDLV EGSLLQGTEG AIKWNEANRP
     GKVPFLRVAT ESSAKTPSKL LDPLAWDNHY GTQIPKEEWK SQEKSPEKTA FKKKDTILSL
     NACESNHAIA AINEGQNKPE IEVTWAKQGR TERLCSQNPP VLKRHQREIT RTTLQSDQEE
     IDYDDTISVE MKKEDFDIYD EDENQSPRSF QKKTRHYFIA AVERLWDYGM SSSPHVLRNR
     AQSGSVPQFK KVVFQEFTDG SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI MVTFRNQASR
     PYSFYSSLIS YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH HMAPTKDEFD CKAWAYFSDV
     DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV TVQEFALFFT IFDETKSWYF TENMERNCRA
     PCNIQMEDPT FKENYRFHAI NGYIMDTLPG LVMAQDQRIR WYLLSMGSNE NIHSIHFSGH
     VFTVRKKEEY KMALYNLYPG VFETVEMLPS KAGIWRVECL IGEHLHAGMS TLFLVYSNKC
     QTPLGMASGH IRDFQITASG QYGQWAPKLA RLHYSGSINA WSTKEPFSWI KVDLLAPMII
     HGIKTQGARQ KFSSLYISQF IIMYSLDGKK WQTYRGNSTG TLMVFFGNVD SSGIKHNIFN
     PPIIARYIRL HPTHYSIRST LRMELMGCDL NSCSMPLGME SKAISDAQIT ASSYFTNMFA
     TWSPSKARLH LQGRSNAWRP QVNNPKEWLQ VDFQKTMKVT GVTTQGVKSL LTSMYVKEFL
     ISSSQDGHQW TLFFQNGKVK VFQGNQDSFT PVVNSLDPPL LTRYLRIHPQ SWVHQIALRM
     EVLGCEAQDL Y
//
ID   EGFR_HUMAN              Reviewed;        1210 AA.
AC   P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2;
AC   Q9GZX1; Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   17-FEB-2016, entry version 226.
DE   RecName: Full=Epidermal growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene c-ErbB-1;
DE   AltName: Full=Receptor tyrosine-protein kinase erbB-1;
DE   Flags: Precursor;
GN   Name=EGFR; Synonyms=ERBB, ERBB1, HER1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6328312; DOI=10.1038/309418a0;
RA   Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W.,
RA   Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J.,
RA   Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H.;
RT   "Human epidermal growth factor receptor cDNA sequence and aberrant
RT   expression of the amplified gene in A431 epidermoid carcinoma cells.";
RL   Nature 309:418-425(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=7654368; DOI=10.1002/mrd.1080410205;
RA   Ilekis J.V., Stark B.C., Scoccia B.;
RT   "Possible role of variant RNA transcripts in the regulation of
RT   epidermal growth factor receptor expression in human placenta.";
RL   Mol. Reprod. Dev. 41:149-156(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=8918811; DOI=10.1093/nar/24.20.4050;
RA   Reiter J.L., Maihle N.J.;
RT   "A 1.8 kb alternative transcript from the human epidermal growth
RT   factor receptor gene encodes a truncated form of the receptor.";
RL   Nucleic Acids Res. 24:4050-4056(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=9103388; DOI=10.1006/gyno.1996.4526;
RA   Ilekis J.V., Gariti J., Niederberger C., Scoccia B.;
RT   "Expression of a truncated epidermal growth factor receptor-like
RT   protein (TEGFR) in ovarian cancer.";
RL   Gynecol. Oncol. 65:36-41(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=11161793; DOI=10.1006/geno.2000.6341;
RA   Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J.,
RA   Schehl Sinclair C., Pearsall R.S., Green P.J., Yee D., Lampland A.L.,
RA   Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D.,
RA   Maihle N.J.;
RT   "Comparative genomic sequence analysis and isolation of human and
RT   mouse alternative EGFR transcripts encoding truncated receptor
RT   isoforms.";
RL   Genomics 71:1-20(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Xu L., Hong A., He X.;
RT   "Cloning of the cDNA for a short EGF receptor from human placenta.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-98; ARG-266;
RP   LYS-521; ILE-674; GLY-962 AND PRO-988.
RG   NIEHS SNPs program;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 575-687.
RA   Reiter J.L., Threadgill D.W., Danielsen A.J., Schehl C.M.,
RA   Lampland A.L., Balasubramaniam S., Crossley T.O., Magnuson T.R.,
RA   Maihle N.J.;
RT   "Human and mouse alternative EGFR transcripts encoding only the
RT   extracellular domain of the receptor.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-924.
RX   PubMed=6326261; DOI=10.1126/science.6326261;
RA   Lin C.R., Chen W.S., Kruiger W., Stolarsky L.S., Weber W., Evans R.M.,
RA   Verma I.M., Gill G.N., Rosenfeld M.G.;
RT   "Expression cloning of human EGF receptor complementary DNA: gene
RT   amplification and three related messenger RNA products in A431
RT   cells.";
RL   Science 224:843-848(1984).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 150-962.
RX   PubMed=6330563; DOI=10.1038/309806a0;
RA   Xu Y.H., Ishii S., Clark A.J.L., Sullivan M., Wilson R.K., Ma D.P.,
RA   Roe B.A., Merlino G.T., Pastan I.;
RT   "Human epidermal growth factor receptor cDNA is homologous to a
RT   variety of RNAs overproduced in A431 carcinoma cells.";
RL   Nature 309:806-810(1984).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1210.
RX   PubMed=6093780;
RA   Simmen F.A., Gope M.L., Schulz T.Z., Wright D.A., Carpenter G.,
RA   O'Malley B.W.;
RT   "Isolation of an evolutionarily conserved epidermal growth factor
RT   receptor cDNA from human A431 carcinoma cells.";
RL   Biochem. Biophys. Res. Commun. 124:125-132(1984).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   PubMed=3329716;
RA   Haley J.D., Whittle N., Bennett P., Kinchington D., Ullrich A.,
RA   Waterfield M.D.;
RT   "The human EGF receptor gene: structure of the 110 kb locus and
RT   identification of sequences regulating its transcription.";
RL   Oncogene Res. 1:375-396(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   PubMed=1988448;
RA   Haley J.D., Waterfield M.D.;
RT   "Contributory effects of de novo transcription and premature
RT   transcript termination in the regulation of human epidermal growth
RT   factor receptor proto-oncogene RNA synthesis.";
RL   J. Biol. Chem. 266:1746-1753(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   PubMed=2991899; DOI=10.1073/pnas.82.15.4920;
RA   Ishii S., Xu Y.H., Stratton R.H., Roe B.A., Merlino G.T., Pastan I.;
RT   "Characterization and sequence of the promoter region of the human
RT   epidermal growth factor receptor gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4920-4924(1985).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-49.
RX   PubMed=6324343; DOI=10.1126/science.6324343;
RA   Weber W., Gill G.N., Spiess J.;
RT   "Production of an epidermal growth factor receptor-related protein.";
RL   Science 224:294-297(1984).
RN   [16]
RP   PROTEIN SEQUENCE OF 540.
RA   Kohda D.;
RL   Submitted (SEP-1997) to UniProtKB.
RN   [17]
RP   PROTEIN SEQUENCE OF 687-705; 986-998; 1000-1023; 1026-1030 AND
RP   1068-1077, AND PHOSPHORYLATION AT THR-693; SER-695; SER-1070 AND
RP   SER-1071.
RX   PubMed=3138233;
RA   Heisermann G.J., Gill G.N.;
RT   "Epidermal growth factor receptor threonine and serine residues
RT   phosphorylated in vivo.";
RL   J. Biol. Chem. 263:13152-13158(1988).
RN   [18]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [19]
RP   PROTEIN SEQUENCE OF 740-744 AND 746-747.
RX   PubMed=2985580;
RA   Russo M.W., Lukas T.J., Cohen S., Staros J.V.;
RT   "Identification of residues in the nucleotide binding site of the
RT   epidermal growth factor receptor/kinase.";
RL   J. Biol. Chem. 260:5205-5208(1985).
RN   [20]
RP   PROTEIN SEQUENCE OF 861-875 AND 914-932, UBIQUITINATION AT LYS-716;
RP   LYS-737; LYS-754; LYS-867; LYS-929 AND LYS-970, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=16543144; DOI=10.1016/j.molcel.2006.02.018;
RA   Huang F., Kirkpatrick D., Jiang X., Gygi S.P., Sorkin A.;
RT   "Differential regulation of EGF receptor internalization and
RT   degradation by multiubiquitination within the kinase domain.";
RL   Mol. Cell 21:737-748(2006).
RN   [21]
RP   PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX   PubMed=9556602; DOI=10.1074/jbc.273.18.11150;
RA   Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D.;
RT   "Disulfide bond structure of human epidermal growth factor receptor.";
RL   J. Biol. Chem. 273:11150-11157(1998).
RN   [22]
RP   RECEPTOR ACTIVITY.
RX   PubMed=6325948; DOI=10.1038/309270a0;
RA   Mroczkowski B., Mosig G., Cohen S.;
RT   "ATP-stimulated interaction between epidermal growth factor receptor
RT   and supercoiled DNA.";
RL   Nature 309:270-273(1984).
RN   [23]
RP   REVIEW.
RX   PubMed=3039909; DOI=10.1146/annurev.bi.56.070187.004313;
RA   Carpenter G.;
RT   "Receptors for epidermal growth factor and other polypeptide
RT   mitogens.";
RL   Annu. Rev. Biochem. 56:881-914(1987).
RN   [24]
RP   LIGAND-BINDING.
RX   PubMed=2790960; DOI=10.1016/0092-8674(89)90867-2;
RA   Chen W.S., Lazar C.S., Lund K.A., Welsh J.B., Chang C.P., Walton G.M.,
RA   Der C.J., Wiley H.S., Gill G.N., Rosenfeld M.G.;
RT   "Functional independence of the epidermal growth factor receptor from
RT   a domain required for ligand-induced internalization and calcium
RT   regulation.";
RL   Cell 59:33-43(1989).
RN   [25]
RP   PHOSPHORYLATION AT TYR-1110.
RX   PubMed=2543678;
RA   Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M.,
RA   Howk R., Givol D., Ullrich A., Schlessinger J.;
RT   "All autophosphorylation sites of epidermal growth factor (EGF)
RT   receptor and HER2/neu are located in their carboxyl-terminal tails.
RT   Identification of a novel site in EGF receptor.";
RL   J. Biol. Chem. 264:10667-10671(1989).
RN   [26]
RP   IDENTIFICATION OF AMPHIREGULIN AS LIGAND.
RX   PubMed=7679104;
RA   Johnson G.R., Kannan B., Shoyab M., Stromberg K.;
RT   "Amphiregulin induces tyrosine phosphorylation of the epidermal growth
RT   factor receptor and p185erbB2. Evidence that amphiregulin acts
RT   exclusively through the epidermal growth factor receptor at the
RT   surface of human epithelial cells.";
RL   J. Biol. Chem. 268:2924-2931(1993).
RN   [27]
RP   INTERACTION WITH ZPR1.
RX   PubMed=8650580; DOI=10.1126/science.272.5269.1797;
RA   Galcheva-Gargova Z., Konstantinov K.N., Wu I.-H., Klier F.G.,
RA   Barrett T., Davis R.J.;
RT   "Binding of zinc finger protein ZPR1 to the epidermal growth factor
RT   receptor.";
RL   Science 272:1797-1802(1996).
RN   [28]
RP   INTERACTION WITH ZPR1.
RX   PubMed=9852145; DOI=10.1083/jcb.143.6.1471;
RA   Gangwani L., Mikrut M., Galcheva-Gargova Z., Davis R.J.;
RT   "Interaction of ZPR1 with translation elongation factor-1alpha in
RT   proliferating cells.";
RL   J. Cell Biol. 143:1471-1484(1998).
RN   [29]
RP   PHOSPHORYLATION AT THR-678 AND THR-693.
RX   PubMed=10523301; DOI=10.1093/emboj/18.20.5567;
RA   Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A.;
RT   "Cell-type specific phosphorylation of threonines T654 and T669 by PKD
RT   defines the signal capacity of the EGF receptor.";
RL   EMBO J. 18:5567-5576(1999).
RN   [30]
RP   IDENTIFICATION OF BETACELLULIN/BTC AS LIGAND.
RX   PubMed=8144591;
RA   Watanabe T., Shintani A., Nakata M., Shing Y., Folkman J.,
RA   Igarashi K., Sasada R.;
RT   "Recombinant human betacellulin. Molecular structure, biological
RT   activities, and receptor interaction.";
RL   J. Biol. Chem. 269:9966-9973(1994).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, AND INTERACTION WITH CBL.
RX   PubMed=7657591; DOI=10.1074/jbc.270.35.20242;
RA   Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
RT   "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product
RT   and association with epidermal growth factor (EGF) receptor upon EGF
RT   stimulation.";
RL   J. Biol. Chem. 270:20242-20245(1995).
RN   [32]
RP   GLYCOSYLATION AT ASN-128; ASN-175; ASN-413; ASN-444 AND ASN-528.
RX   PubMed=8962717;
RA   Smith K.D., Davies M.J., Bailey D., Renouf D.V., Hounsell E.F.;
RT   "Analysis of the glycosylation patterns of the extracellular domain of
RT   the epidermal growth factor receptor expressed in Chinese hamster
RT   ovary fibroblasts.";
RL   Growth Factors 13:121-132(1996).
RN   [33]
RP   IDENTIFICATION OF EPIREGULIN/EREG AS LIGAND.
RX   PubMed=9419975; DOI=10.1038/sj.onc.1201458;
RA   Komurasaki T., Toyoda H., Uchida D., Morimoto S.;
RT   "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and
RT   induces tyrosine phosphorylation of epidermal growth factor receptor,
RT   ErbB-2, ErbB-3 and ErbB-4.";
RL   Oncogene 15:2841-2848(1997).
RN   [34]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2.
RX   PubMed=9488479;
RA   Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K.;
RT   "Epidermal growth factor receptor and the adaptor protein p52Shc are
RT   specific substrates of T-cell protein tyrosine phosphatase.";
RL   Mol. Cell. Biol. 18:1622-1634(1998).
RN   [35]
RP   INTERACTION WITH AP2M1.
RX   PubMed=10228163; DOI=10.1093/emboj/18.9.2489;
RA   Nesterov A., Carter R.E., Sorkina T., Gill G.N., Sorkin A.;
RT   "Inhibition of the receptor-binding function of clathrin adaptor
RT   protein AP-2 by dominant-negative mutant mu2 subunit and its effects
RT   on endocytosis.";
RL   EMBO J. 18:2489-2499(1999).
RN   [36]
RP   INTERACTION WITH GRB2; NCK1 AND NCK2.
RX   PubMed=10026169; DOI=10.1074/jbc.274.9.5542;
RA   Braverman L.E., Quilliam L.A.;
RT   "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-
RT   containing adapter protein having similar binding and biological
RT   properties to Nck.";
RL   J. Biol. Chem. 274:5542-5549(1999).
RN   [37]
RP   GLYCOSYLATION AT ASN-56; ASN-352; ASN-361; ASN-568 AND ASN-603.
RX   PubMed=10731668; DOI=10.1093/oxfordjournals.jbchem.a022585;
RA   Sato C., Kim J.-H., Abe Y., Saito K., Yokoyama S., Kohda D.;
RT   "Characterization of the N-oligosaccharides attached to the atypical
RT   Asn-X-Cys sequence of recombinant human epidermal growth factor
RT   receptor.";
RL   J. Biochem. 127:65-72(2000).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF RGS16.
RX   PubMed=11602604; DOI=10.1074/jbc.M108862200;
RA   Derrien A., Druey K.M.;
RT   "RGS16 function is regulated by epidermal growth factor receptor-
RT   mediated tyrosine phosphorylation.";
RL   J. Biol. Chem. 276:48532-48538(2001).
RN   [39]
RP   GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361;
RP   ASN-413; ASN-444; ASN-528; ASN-568; ASN-603 AND ASN-623.
RX   PubMed=12731890; DOI=10.1021/bi027101p;
RA   Zhen Y., Caprioli R.M., Staros J.V.;
RT   "Characterization of glycosylation sites of the epidermal growth
RT   factor receptor.";
RL   Biochemistry 42:5478-5492(2003).
RN   [40]
RP   FUNCTION IN CELL PROLIFERATION, INTERACTION WITH STAT3, AND
RP   PHOSPHORYLATION AT TYR-1092 AND TYR-1110.
RX   PubMed=12873986;
RA   Shao H., Cheng H.Y., Cook R.G., Tweardy D.J.;
RT   "Identification and characterization of signal transducer and
RT   activator of transcription 3 recruitment sites within the epidermal
RT   growth factor receptor.";
RL   Cancer Res. 63:3923-3930(2003).
RN   [41]
RP   ENZYME REGULATION, AND INTERACTION WITH LRIG1.
RX   PubMed=15282549; DOI=10.1038/sj.emboj.7600342;
RA   Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J.,
RA   Amariglio N., Henriksson R., Rechavi G., Hedman H., Wides R.,
RA   Yarden Y.;
RT   "LRIG1 restricts growth factor signaling by enhancing receptor
RT   ubiquitylation and degradation.";
RL   EMBO J. 23:3270-3281(2004).
RN   [42]
RP   FUNCTION IN EGFR SIGNALING, IDENTIFICATION IN A COMPLEX WITH PIK3C2A
RP   AND ERBB2, IDENTIFICATION IN A COMPLEX WITH PIK3C2B AND ERBB2,
RP   INTERACTION WITH PIK3C2B, AND MUTAGENESIS OF TYR-1016; TYR-1092;
RP   TYR-1110; TYR-1172 AND TYR-1197.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [43]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH RIPK1.
RX   PubMed=11116146; DOI=10.1074/jbc.M008458200;
RA   Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S.,
RA   Vartanian T.;
RT   "The epidermal growth factor receptor engages receptor interacting
RT   protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to
RT   activate NF-kappa B. Identification of a novel receptor-tyrosine
RT   kinase signalosome.";
RL   J. Biol. Chem. 276:8865-8874(2001).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF MUC1, AND INTERACTION WITH MUC1.
RX   PubMed=11483589; DOI=10.1074/jbc.C100359200;
RA   Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III,
RA   Kufe D.;
RT   "The epidermal growth factor receptor regulates interaction of the
RT   human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.";
RL   J. Biol. Chem. 276:35239-35242(2001).
RN   [45]
RP   ENZYME REGULATION, AND INTERACTION WITH SOCS5.
RX   PubMed=15590694; DOI=10.1074/jbc.M408575200;
RA   Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N.,
RA   Rechavi G., Yarden Y.;
RT   "Suppressors of cytokine signaling 4 and 5 regulate epidermal growth
RT   factor receptor signaling.";
RL   J. Biol. Chem. 280:7038-7048(2005).
RN   [46]
RP   IDENTIFICATION OF EPIGEN/EPGN AS A LIGAND.
RX   PubMed=15611079; DOI=10.1074/jbc.M413919200;
RA   Kochupurakkal B.S., Harari D., Di-Segni A., Maik-Rachline G.,
RA   Lyass L., Gur G., Kerber G., Citri A., Lavi S., Eilam R.,
RA   Chalifa-Caspi V., Eshhar Z., Pikarsky E., Pinkas-Kramarski R.,
RA   Bacus S.S., Yarden Y.;
RT   "Epigen, the last ligand of ErbB receptors, reveals intricate
RT   relationships between affinity and mitogenicity.";
RL   J. Biol. Chem. 280:8503-8512(2005).
RN   [47]
RP   GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361;
RP   ASN-413; ASN-444; ASN-528; ASN-568 AND ASN-603, PHOSPHORYLATION AT
RP   THR-693; SER-991 AND SER-1026, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=16083266; DOI=10.1021/pr050113n;
RA   Wu S.L., Kim J., Hancock W.S., Karger B.;
RT   "Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS
RT   platform for high sequence coverage of complex proteins with extensive
RT   post-translational modifications-comprehensive analysis of beta-casein
RT   and epidermal growth factor receptor (EGFR).";
RL   J. Proteome Res. 4:1155-1170(2005).
RN   [48]
RP   INTERACTION WITH PELP1.
RX   PubMed=16140940; DOI=10.1158/0008-5472.CAN-05-0614;
RA   Vadlamudi R.K., Manavathi B., Balasenthil S., Nair S.S., Yang Z.,
RA   Sahin A.A., Kumar R.;
RT   "Functional implications of altered subcellular localization of PELP1
RT   in breast cancer cells.";
RL   Cancer Res. 65:7724-7732(2005).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1172 AND TYR-1197, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [50]
RP   FUNCTION IN CELL PROLIFERATION, FUNCTION IN PCNA PHOSPHORYLATION,
RP   INTERACTION WITH PCNA, AND SUBCELLULAR LOCATION.
RX   PubMed=17115032; DOI=10.1038/ncb1501;
RA   Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C.,
RA   McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.;
RT   "Tyrosine phosphorylation controls PCNA function through protein
RT   stability.";
RL   Nat. Cell Biol. 8:1359-1368(2006).
RN   [51]
RP   TISSUE SPECIFICITY.
RX   PubMed=17671655; DOI=10.1172/JCI31680;
RA   Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D.,
RA   Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E.,
RA   Hoenderop J.G., Knoers N.V., Bindels R.J.;
RT   "Impaired basolateral sorting of pro-EGF causes isolated recessive
RT   renal hypomagnesemia.";
RL   J. Clin. Invest. 117:2260-2267(2007).
RN   [52]
RP   INTERACTION WITH TNF2, AND SUBCELLULAR LOCATION.
RX   PubMed=17182860; DOI=10.1091/mbc.E06-02-0142;
RA   Shen F., Lin Q., Gu Y., Childress C., Yang W.;
RT   "Activated Cdc42-associated kinase 1 is a component of EGF receptor
RT   signaling complex and regulates EGF receptor degradation.";
RL   Mol. Biol. Cell 18:732-742(2007).
RN   [53]
RP   INTERACTION WITH ATX2.
RX   PubMed=18602463; DOI=10.1016/j.cellsig.2008.05.018;
RA   Nonis D., Schmidt M.H., van de Loo S., Eich F., Dikic I., Nowock J.,
RA   Auburger G.;
RT   "Ataxin-2 associates with the endocytosis complex and affects EGF
RT   receptor trafficking.";
RL   Cell. Signal. 20:1725-1739(2008).
RN   [54]
RP   INTERACTION WITH GAB2.
RX   PubMed=19172738; DOI=10.1038/emboj.2008.159;
RA   Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P.,
RA   Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D.,
RA   Guilhaus M., James D.E., Daly R.J.;
RT   "Phosphorylation-dependent binding of 14-3-3 terminates signalling by
RT   the Gab2 docking protein.";
RL   EMBO J. 27:2305-2316(2008).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; SER-1064;
RP   SER-1081; SER-1166 AND TYR-1197, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [57]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991; SER-995; TYR-998;
RP   SER-1039; THR-1041; SER-1042; SER-1064 AND SER-1166, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [58]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [59]
RP   ENZYME REGULATION BY PTPRJ AND PTPRK, PHOSPHORYLATION AT TYR-1197,
RP   DEPHOSPHORYLATION BY PTPRJ, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   CBL AND GRB2.
RX   PubMed=19836242; DOI=10.1016/j.cub.2009.09.048;
RA   Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F.,
RA   Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.;
RT   "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase
RT   controlling EGFR endocytosis.";
RL   Curr. Biol. 19:1788-1798(2009).
RN   [60]
RP   INTERACTION WITH GAREM1.
RX   PubMed=19509291; DOI=10.1074/jbc.M109.021139;
RA   Tashiro K., Tsunematsu T., Okubo H., Ohta T., Sano E., Yamauchi E.,
RA   Taniguchi H., Konishi H.;
RT   "GAREM, a novel adaptor protein for growth factor receptor-bound
RT   protein 2, contributes to cellular transformation through the
RT   activation of extracellular signal-regulated kinase signaling.";
RL   J. Biol. Chem. 284:20206-20214(2009).
RN   [61]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352; ASN-413 AND ASN-568.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [63]
RP   INTERACTION WITH GPER1.
RX   PubMed=19749156; DOI=10.1210/me.2009-0120;
RA   Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S.,
RA   De Amicis F., Fuqua S.A., Ando S., Maggiolini M.;
RT   "G protein-coupled receptor 30 expression is up-regulated by EGF and
RT   TGF alpha in estrogen receptor alpha-positive cancer cells.";
RL   Mol. Endocrinol. 23:1815-1826(2009).
RN   [64]
RP   INTERACTION WITH COPG1, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=20674546; DOI=10.1016/j.bbrc.2010.07.096;
RA   Wang Y.N., Wang H., Yamaguchi H., Lee H.J., Lee H.H., Hung M.C.;
RT   "COPI-mediated retrograde trafficking from the Golgi to the ER
RT   regulates EGFR nuclear transport.";
RL   Biochem. Biophys. Res. Commun. 399:498-504(2010).
RN   [65]
RP   INTERACTION WITH GPER1, AND SUBCELLULAR LOCATION.
RX   PubMed=20551055; DOI=10.1158/0008-5472.CAN-10-0408;
RA   Madeo A., Maggiolini M.;
RT   "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-
RT   induced gene expression and migration in breast cancer-associated
RT   fibroblasts.";
RL   Cancer Res. 70:6036-6046(2010).
RN   [66]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1064
RP   AND TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [67]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [68]
RP   PHOSPHORYLATION AT SER-229.
RX   PubMed=21487020; DOI=10.1074/jbc.M111.240796;
RA   Huang W.C., Chen Y.J., Li L.Y., Wei Y.L., Hsu S.C., Tsai S.L.,
RA   Chiu P.C., Huang W.P., Wang Y.N., Chen C.H., Chang W.C., Chang W.C.,
RA   Chen A.J., Tsai C.H., Hung M.C.;
RT   "Nuclear translocation of epidermal growth factor receptor by Akt-
RT   dependent phosphorylation enhances breast cancer-resistant protein
RT   expression in gefitinib-resistant cells.";
RL   J. Biol. Chem. 286:20558-20568(2011).
RN   [69]
RP   FUNCTION IN CELL PROLIFERATION AND CELL MIGRATION, METHYLATION AT
RP   ARG-1199 BY PRMT5, AND INTERACTION WITH PRMT5 AND PTPN6.
RX   PubMed=21258366; DOI=10.1038/ncb2158;
RA   Hsu J.M., Chen C.T., Chou C.K., Kuo H.P., Li L.Y., Lin C.Y., Lee H.J.,
RA   Wang Y.N., Liu M., Liao H.W., Shi B., Lai C.C., Bedford M.T.,
RA   Tsai C.H., Hung M.C.;
RT   "Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation
RT   negatively modulates EGFR-mediated ERK activation.";
RL   Nat. Cell Biol. 13:174-181(2011).
RN   [70]
RP   INTERACTION WITH FER, AND PHOSPHORYLATION.
RX   PubMed=21518868; DOI=10.1073/pnas.1105369108;
RA   Guo C., Stark G.R.;
RT   "FER tyrosine kinase (FER) overexpression mediates resistance to
RT   quinacrine through EGF-dependent activation of NF-kappaB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:7968-7973(2011).
RN   [71]
RP   INTERACTION WITH ANKRD13A; ANKRD13B AND ALKRD13D, UBIQUITINATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=22298428; DOI=10.1091/mbc.E11-09-0817;
RA   Tanno H., Yamaguchi T., Goto E., Ishido S., Komada M.;
RT   "The Ankrd 13 family of UIM-bearing proteins regulates EGF receptor
RT   endocytosis from the plasma membrane.";
RL   Mol. Biol. Cell 23:1343-1353(2012).
RN   [72]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY OTUD7B.
RX   PubMed=22179831; DOI=10.1038/onc.2011.587;
RA   Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F.,
RA   Aulmann S., Ben-Chetrit N., Pines G., Navon R., Crosetto N.,
RA   Kostler W., Carvalho S., Lavi S., Schmitt F., Dikic I., Yakhini Z.,
RA   Sinn P., Mills G.B., Yarden Y.;
RT   "Deubiquitination of EGFR by Cezanne-1 contributes to cancer
RT   progression.";
RL   Oncogene 31:4599-4608(2012).
RN   [73]
RP   INTERACTION WITH RNF115 AND RNF126.
RX   PubMed=23418353; DOI=10.1242/jcs.116129;
RA   Smith C.J., Berry D.M., McGlade C.J.;
RT   "The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal
RT   sorting of the epidermal growth factor receptor.";
RL   J. Cell Sci. 126:1366-1380(2013).
RN   [74]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1026
RP   AND SER-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [75]
RP   INTERACTION WITH GPRC5A.
RX   PubMed=25311788; DOI=10.1186/1476-4598-13-233;
RA   Lin X., Zhong S., Ye X., Liao Y., Yao F., Yang X., Sun B., Zhang J.,
RA   Li Q., Gao Y., Wang Y., Liu J., Han B., Chin Y.E., Zhou B.P., Deng J.;
RT   "EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung
RT   cancer.";
RL   Mol. Cancer 13:233-233(2014).
RN   [76]
RP   INTERACTION WITH FAM83B.
RX   PubMed=23912460; DOI=10.1038/onc.2013.293;
RA   Cipriano R., Bryson B.L., Miskimen K.L., Bartel C.A.,
RA   Hernandez-Sanchez W., Bruntz R.C., Scott S.A., Lindsley C.W.,
RA   Brown H.A., Jackson M.W.;
RT   "Hyperactivation of EGFR and downstream effector phospholipase D1 by
RT   oncogenic FAM83B.";
RL   Oncogene 33:3298-3306(2014).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-646 IN COMPLEX WITH EGF,
RP   FUNCTION IN MAPK1 AND/OR MAPK3 ACTIVATION, SUBUNIT, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF TYR-275; PHE-287; ARG-309 AND ARG-429,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-56; ASN-175; ASN-196;
RP   ASN-352; ASN-361 AND ASN-444.
RX   PubMed=12297050; DOI=10.1016/S0092-8674(02)00963-7;
RA   Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H.,
RA   Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of the complex of human epidermal growth factor and
RT   receptor extracellular domains.";
RL   Cell 110:775-787(2002).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-642 IN COMPLEX WITH EGF,
RP   FUNCTION, SUBUNIT, MUTAGENESIS OF 587-ASP--HIS-590 AND LYS-609,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-352; ASN-361; ASN-444;
RP   ASN-528; ASN-568 AND ASN-603.
RX   PubMed=12620237; DOI=10.1016/S1097-2765(03)00047-9;
RA   Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J.,
RA   Lemmon M.A.;
RT   "EGF activates its receptor by removing interactions that autoinhibit
RT   ectodomain dimerization.";
RL   Mol. Cell 11:507-517(2003).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 695-1022 IN COMPLEX WITH
RP   GW572016, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=15374980; DOI=10.1158/0008-5472.CAN-04-1168;
RA   Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A.,
RA   Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K.,
RA   Alligood K.J., Rusnak D.W., Gilmer T.M., Shewchuk L.;
RT   "A unique structure for epidermal growth factor receptor bound to
RT   GW572016 (Lapatinib): relationships among protein conformation,
RT   inhibitor off-rate, and receptor activity in tumor cells.";
RL   Cancer Res. 64:6652-6659(2004).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-642 IN COMPLEX WITH
RP   CETUXIMAB.
RX   PubMed=15837620; DOI=10.1016/j.ccr.2005.03.003;
RA   Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P.,
RA   Ferguson K.M.;
RT   "Structural basis for inhibition of the epidermal growth factor
RT   receptor by cetuximab.";
RL   Cancer Cell 7:301-311(2005).
RN   [81]
RP   STRUCTURE BY NMR OF 669-721.
RX   PubMed=15840573; DOI=10.1074/jbc.M502698200;
RA   Choowongkomon K., Carlin C.R., Sonnichsen F.D.;
RT   "A structural model for the membrane-bound form of the juxtamembrane
RT   domain of the epidermal growth factor receptor.";
RL   J. Biol. Chem. 280:24043-24052(2005).
RN   [82]
RP   X-RAY CRYSTALLOGRAPHY (2.47 ANGSTROMS) OF 696-1022 OF WILD-TYPE AND
RP   VARIANTS SER-719 AND ARG-858 IN COMPLEXES WITH ATP ANALOGS AND
RP   SYNTHETIC INHIBITORS, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND
RP   CHARACTERIZATION OF VARIANTS SER-719 AND ARG-858.
RX   PubMed=17349580; DOI=10.1016/j.ccr.2006.12.017;
RA   Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M.,
RA   Eck M.J.;
RT   "Structures of lung cancer-derived EGFR mutants and inhibitor
RT   complexes: mechanism of activation and insights into differential
RT   inhibitor sensitivity.";
RL   Cancer Cell 11:217-227(2007).
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 702-1022 IN COMPLEX WITH
RP   ERRFI1, ENZYME REGULATION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION,
RP   SUBUNIT, AND INTERACTION WITH ERRFI1.
RX   PubMed=18046415; DOI=10.1038/nature05998;
RA   Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J.;
RT   "Inhibition of the EGF receptor by binding of MIG6 to an activating
RT   kinase domain interface.";
RL   Nature 450:741-744(2007).
RN   [84]
RP   X-RAY CRYSTALLOGRAPHY (3.05 ANGSTROMS) OF 695-1022 OF VARIANT MET-790,
RP   CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT MET-790.
RX   PubMed=18227510; DOI=10.1073/pnas.0709662105;
RA   Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H.,
RA   Wong K.K., Meyerson M., Eck M.J.;
RT   "The T790M mutation in EGFR kinase causes drug resistance by
RT   increasing the affinity for ATP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2070-2075(2008).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (2.96 ANGSTROMS) OF 696-1022, CATALYTIC
RP   ACTIVITY, PHOSPHORYLATION AT TYR-998; TYR-1016 AND TYR-1197,
RP   MUTAGENESIS OF LEU-688; GLU-690; LEU-692; ARG-977 AND
RP   1005-GLU-ASP-1006, AND SUBUNIT.
RX   PubMed=19563760; DOI=10.1016/j.cell.2009.04.025;
RA   Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H.,
RA   Wemmer D.E., Zhang X., Kuriyan J.;
RT   "Mechanism for activation of the EGF receptor catalytic domain by the
RT   juxtamembrane segment.";
RL   Cell 137:1293-1307(2009).
RN   [86]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 669-1022 OF MUTANT MET-745,
RP   CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-688; VAL-689; GLU-690;
RP   LEU-692; THR-693; PRO-694; PRO-699; ASN-700; LEU-704; ARG-705; ILE-706
RP   AND LYS-745.
RX   PubMed=19560417; DOI=10.1016/j.molcel.2009.04.034;
RA   Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A.,
RA   Lemmon M.A., Carpenter G.;
RT   "The juxtamembrane region of the EGF receptor functions as an
RT   activation domain.";
RL   Mol. Cell 34:641-651(2009).
RN   [87]
RP   STRUCTURE BY NMR OF 634-677 IN COMPLEX WITH ERBB2, AND SUBUNIT.
RX   PubMed=20471394; DOI=10.1016/j.jmb.2010.05.016;
RA   Mineev K.S., Bocharov E.V., Pustovalova Y.E., Bocharova O.V.,
RA   Chupin V.V., Arseniev A.S.;
RT   "Spatial structure of the transmembrane domain heterodimer of ErbB1
RT   and ErbB2 receptor tyrosine kinases.";
RL   J. Mol. Biol. 400:231-243(2010).
RN   [88]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-638 IN COMPLEX WITH EGF,
RP   FUNCTION, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-56;
RP   ASN-73; ASN-175; ASN-196; ASN-352; ASN-361; ASN-444 AND ASN-528.
RX   PubMed=20837704; DOI=10.1128/MCB.00742-10;
RA   Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S.,
RA   Springer T.A.;
RT   "Structural evidence for loose linkage between ligand binding and
RT   kinase activation in the epidermal growth factor receptor.";
RL   Mol. Cell. Biol. 30:5432-5443(2010).
RN   [89]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 1066-1076 IN COMPLEX WITH
RP   CBLB, AND INTERACTION WITH CBLB.
RG   Structural genomics consortium;
RT   "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069
RT   peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
RN   [90]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1062-1074 IN COMPLEX WITH
RP   CBLC, PHOSPHORYLATION AT TYR-1069, INTERACTION WITH CBLC, AND
RP   MUTAGENESIS OF GLN-1067; ARG-1068 AND TYR-1069.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of
RT   the tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
RN   [91]
RP   VARIANTS ALA-709; GLY-709; CYS-719; SER-719; 746-GLU--ALA-750 DEL;
RP   746-GLU--THR-751 DELINS ALA; 746-GLU--SER-752 DELINS ASP;
RP   747-LEU--THR-751 DEL; ILE-768; MET-769; VAL-833; LEU-835; VAL-838;
RP   ARG-858 AND GLN-861.
RX   PubMed=15623594; DOI=10.1158/1078-0432.CCR-04-1245;
RA   Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T.,
RA   Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., Tsai S.F.;
RT   "High frequency of epidermal growth factor receptor mutations with
RT   complex patterns in non-small cell lung cancers related to gefitinib
RT   responsiveness in Taiwan.";
RL   Clin. Cancer Res. 10:8195-8203(2004).
RN   [92]
RP   VARIANTS SER-719 AND ARG-858, AND POSSIBLE INVOLVEMENT IN LUNG CANCER.
RX   PubMed=15118125; DOI=10.1126/science.1099314;
RA   Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S.,
RA   Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H.,
RA   Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M.;
RT   "EGFR mutations in lung cancer: correlation with clinical response to
RT   gefitinib therapy.";
RL   Science 304:1497-1500(2004).
RN   [93]
RP   VARIANTS ALA-709; LYS-709; ALA-719; ASP-719; CYS-719; SER-719;
RP   SER-724; LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL; PRO-748;
RP   752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834; MET-858;
RP   ARG-858; GLN-861 AND GLU-873, AND POSSIBLE INVOLVEMENT IN LUNG CANCER.
RX   PubMed=16533793; DOI=10.1158/1078-0432.CCR-05-1981;
RA   Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K.,
RA   Lam W.K., Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.;
RT   "Distinct epidermal growth factor receptor and KRAS mutation patterns
RT   in non-small cell lung cancer patients with different tobacco exposure
RT   and clinicopathologic features.";
RL   Clin. Cancer Res. 12:1647-1653(2006).
RN   [94]
RP   CHARACTERIZATION OF VARIANTS ALA-709; GLY-709; SER-719; ILE-768;
RP   VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861.
RX   PubMed=16205628; DOI=10.1038/sj.onc.1209159;
RA   Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T.,
RA   Tsai S.F., Huang S.F.;
RT   "Distinctive activation patterns in constitutively active and
RT   gefitinib-sensitive EGFR mutants.";
RL   Oncogene 25:1205-1215(2006).
RN   [95]
RP   VARIANT 30-VAL--ARG-297 DEL, AND POSSIBLE INVOLVEMENT IN LUNG CANCER.
RX   PubMed=16672372; DOI=10.1073/pnas.0510284103;
RA   Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A.,
RA   Jung B.L., McNamara K., Xia H., Glatt K.A., Thomas R.K., Sasaki H.,
RA   Horner J.W., Eck M., Mitchell A., Sun Y., Al-Hashem R., Bronson R.T.,
RA   Rabindran S.K., Discafani C.M., Maher E., Shapiro G.I., Meyerson M.,
RA   Wong K.K.;
RT   "Epidermal growth factor receptor variant III mutations in lung
RT   tumorigenesis and sensitivity to tyrosine kinase inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7817-7822(2006).
RN   [96]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-521; ARG-1034 AND VAL-1210.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [97]
RP   VARIANT NISBD2 ASP-428, CHARACTERIZATION OF VARIANT NISBD2 ASP-428,
RP   AND INVOLVEMENT IN NISBD2.
RX   PubMed=24691054; DOI=10.1038/jid.2014.164;
RA   Campbell P., Morton P.E., Takeichi T., Salam A., Roberts N.,
RA   Proudfoot L.E., Mellerio J.E., Aminu K., Wellington C., Patil S.N.,
RA   Akiyama M., Liu L., McMillan J.R., Aristodemou S., Ishida-Yamamoto A.,
RA   Abdul-Wahab A., Petrof G., Fong K., Harnchoowong S., Stone K.L.,
RA   Harper J.I., McLean W.H., Simpson M.A., Parsons M., McGrath J.A.;
RT   "Epithelial inflammation resulting from an inherited loss-of-function
RT   mutation in EGFR.";
RL   J. Invest. Dermatol. 134:2570-2578(2014).
CC   -!- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF
CC       family and activating several signaling cascades to convert
CC       extracellular cues into appropriate cellular responses. Known
CC       ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN,
CC       BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF.
CC       Ligand binding triggers receptor homo- and/or heterodimerization
CC       and autophosphorylation on key cytoplasmic residues. The
CC       phosphorylated receptor recruits adapter proteins like GRB2 which
CC       in turn activates complex downstream signaling cascades. Activates
CC       at least 4 major downstream signaling cascades including the RAS-
CC       RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May
CC       also activate the NF-kappa-B signaling cascade. Also directly
CC       phosphorylates other proteins like RGS16, activating its GTPase
CC       activity and probably coupling the EGF receptor signaling to the G
CC       protein-coupled receptor signaling. Also phosphorylates MUC1 and
CC       increases its interaction with SRC and CTNNB1/beta-catenin.
CC   -!- FUNCTION: Isoform 2 may act as an antagonist of EGF action.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15374980,
CC       ECO:0000269|PubMed:17349580, ECO:0000269|PubMed:18046415,
CC       ECO:0000269|PubMed:18227510, ECO:0000269|PubMed:19560417,
CC       ECO:0000269|PubMed:19563760}.
CC   -!- ENZYME REGULATION: Endocytosis and inhibition of the activated
CC       EGFR by phosphatases like PTPRJ and PTPRK constitute immediate
CC       regulatory mechanisms. Upon EGF-binding phosphorylates EPS15 that
CC       regulates EGFR endocytosis and activity. Moreover, inducible
CC       feedback inhibitors including LRIG1, SOCS4, SOCS5 and ERRFI1
CC       constitute alternative regulatory mechanisms for the EGFR
CC       signaling. {ECO:0000269|PubMed:15282549,
CC       ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:18046415,
CC       ECO:0000269|PubMed:19836242}.
CC   -!- SUBUNIT: Binding of the ligand triggers homo- and/or
CC       heterodimerization of the receptor triggering its
CC       autophosphorylation. Heterodimer with ERBB2. Interacts with
CC       ERRFI1; inhibits dimerization of the kinase domain and
CC       autophosphorylation. Part of a complex with ERBB2 and either
CC       PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein
CC       coupling the receptor to downstream signaling pathways. Interacts
CC       with GAB2; involved in signaling downstream of EGFR. Interacts
CC       with STAT3; mediates EGFR downstream signaling in cell
CC       proliferation. Interacts with RIPK1; involved in NF-kappa-B
CC       activation. Interacts (autophosphorylated) with CBL, CBLB and
CC       CBLC; involved in EGFR ubiquitination and regulation. Interacts
CC       with SOCS5; regulates EGFR degradation through TCEB1- and TCEB2-
CC       mediated ubiquitination and proteasomal degradation. Interacts
CC       with PRMT5; methylates EGFR and enhances interaction with PTPN6.
CC       Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent
CC       activation of MAPK/ERK. Interacts with COPG1; essential for
CC       regulation of EGF-dependent nuclear transport of EGFR by
CC       retrograde trafficking from the Golgi to the ER. Interacts with
CC       TNK2; this interaction is dependent on EGF stimulation and kinase
CC       activity of EGFR. Interacts with PCNA; positively regulates PCNA.
CC       Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1.
CC       Interacts with FER. May interact with EPS8; mediates EPS8
CC       phosphorylation. Interacts (via SH2 domains) with GRB2, NCK1 and
CC       NCK2. Interacts with ATX2. Interacts with GAREM1. Interacts
CC       (ubiquitinated) with ANKRD13A/B/D; the interaction is direct and
CC       may regulate EGFR internalization after EGF stimulation. Interacts
CC       with GPER1; the interaction occurs in an estrogen-dependent
CC       manner. Interacts (via C-terminal cytoplasmic kinase domain) with
CC       ZPR1 (via zinc fingers). Interacts with RNF115 and RNF126.
CC       Interacts with GPRC5A (via its transmembrane
CC       domain)(PubMed:25311788). Interacts with FAM83B; positively
CC       regulates EGFR inducing its autophospharylation in absence of
CC       stimulation by EGF (PubMed:23912460).
CC       {ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:10228163,
CC       ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146,
CC       ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:12297050,
CC       ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986,
CC       ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15374980,
CC       ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15837620,
CC       ECO:0000269|PubMed:16140940, ECO:0000269|PubMed:17115032,
CC       ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:18046415,
CC       ECO:0000269|PubMed:18602463, ECO:0000269|PubMed:19172738,
CC       ECO:0000269|PubMed:19509291, ECO:0000269|PubMed:19560417,
CC       ECO:0000269|PubMed:19563760, ECO:0000269|PubMed:19749156,
CC       ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:20471394,
CC       ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:20674546,
CC       ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366,
CC       ECO:0000269|PubMed:21518868, ECO:0000269|PubMed:22298428,
CC       ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23418353,
CC       ECO:0000269|PubMed:23912460, ECO:0000269|PubMed:25311788,
CC       ECO:0000269|PubMed:7657591, ECO:0000269|PubMed:8650580,
CC       ECO:0000269|PubMed:9852145, ECO:0000269|Ref.89}.
CC   -!- INTERACTION:
CC       Self; NbExp=23; IntAct=EBI-297353, EBI-297353;
CC       Q53FC7:-; NbExp=3; IntAct=EBI-297353, EBI-9356749;
CC       Q96BE0:-; NbExp=2; IntAct=EBI-297353, EBI-9356686;
CC       P00519:ABL1; NbExp=2; IntAct=EBI-297353, EBI-375543;
CC       P42684:ABL2; NbExp=8; IntAct=EBI-297353, EBI-1102694;
CC       Q09666:AHNAK; NbExp=3; IntAct=EBI-297353, EBI-2555881;
CC       Q02952:AKAP12; NbExp=2; IntAct=EBI-297353, EBI-2562430;
CC       Q92625:ANKS1A; NbExp=5; IntAct=EBI-297353, EBI-1048612;
CC       Q96CW1:AP2M1; NbExp=4; IntAct=EBI-297353, EBI-297683;
CC       O00213:APBB1; NbExp=4; IntAct=EBI-297353, EBI-81694;
CC       Q92870:APBB2; NbExp=6; IntAct=EBI-297353, EBI-79277;
CC       O95704:APBB3; NbExp=2; IntAct=EBI-297353, EBI-286427;
CC       Q9UKG1:APPL1; NbExp=2; IntAct=EBI-297353, EBI-741243;
CC       O14965:AURKA; NbExp=4; IntAct=EBI-297353, EBI-448680;
CC       P30530:AXL; NbExp=4; IntAct=EBI-297353, EBI-2850927;
CC       Q14457:BECN1; NbExp=7; IntAct=EBI-297353, EBI-949378;
CC       P51451:BLK; NbExp=2; IntAct=EBI-297353, EBI-2105445;
CC       P62158:CALM3; NbExp=4; IntAct=EBI-297353, EBI-397435;
CC       P62161:Calm3 (xeno); NbExp=6; IntAct=EBI-297353, EBI-397530;
CC       P49069:CAMLG; NbExp=2; IntAct=EBI-297353, EBI-1748958;
CC       Q03135:CAV1; NbExp=5; IntAct=EBI-297353, EBI-603614;
CC       P22681:CBL; NbExp=17; IntAct=EBI-297353, EBI-518228;
CC       P22682:Cbl (xeno); NbExp=2; IntAct=EBI-297353, EBI-640919;
CC       Q16543:CDC37; NbExp=9; IntAct=EBI-297353, EBI-295634;
CC       P12830:CDH1; NbExp=3; IntAct=EBI-297353, EBI-727477;
CC       Q9NSE2:CISH; NbExp=3; IntAct=EBI-297353, EBI-617866;
CC       Q7Z7G1:CLNK; NbExp=2; IntAct=EBI-297353, EBI-7878194;
CC       P46108:CRK; NbExp=3; IntAct=EBI-297353, EBI-886;
CC       P46108-1:CRK; NbExp=3; IntAct=EBI-297353, EBI-287556;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-297353, EBI-910;
CC       P35221:CTNNA1; NbExp=4; IntAct=EBI-297353, EBI-701918;
CC       O60716:CTNND1; NbExp=4; IntAct=EBI-297353, EBI-701927;
CC       Q14247:CTTN; NbExp=3; IntAct=EBI-297353, EBI-351886;
CC       Q99418:CYTH2; NbExp=5; IntAct=EBI-297353, EBI-448974;
CC       Q6PKX4:DOK6; NbExp=2; IntAct=EBI-297353, EBI-2880244;
CC       P01133:EGF; NbExp=16; IntAct=EBI-297353, EBI-640857;
CC       Q12929:EPS8; NbExp=2; IntAct=EBI-297353, EBI-375576;
CC       P04626:ERBB2; NbExp=21; IntAct=EBI-297353, EBI-641062;
CC       P21860:ERBB3; NbExp=12; IntAct=EBI-297353, EBI-720706;
CC       Q15303:ERBB4; NbExp=2; IntAct=EBI-297353, EBI-80371;
CC       P07992:ERCC1; NbExp=21; IntAct=EBI-297353, EBI-750962;
CC       Q9UJM3:ERRFI1; NbExp=8; IntAct=EBI-297353, EBI-2941912;
CC       P03372:ESR1; NbExp=2; IntAct=EBI-297353, EBI-78473;
CC       P03372-4:ESR1; NbExp=4; IntAct=EBI-297353, EBI-4309277;
CC       Q96A65:EXOC4; NbExp=2; IntAct=EBI-297353, EBI-355383;
CC       P09769:FGR; NbExp=2; IntAct=EBI-297353, EBI-1383732;
CC       Q14318:FKBP8; NbExp=3; IntAct=EBI-297353, EBI-724839;
CC       Q13480:GAB1; NbExp=3; IntAct=EBI-297353, EBI-517684;
CC       P60520:GABARAPL2; NbExp=2; IntAct=EBI-297353, EBI-720116;
CC       P04406:GAPDH; NbExp=6; IntAct=EBI-297353, EBI-354056;
CC       O75791:GRAP2; NbExp=2; IntAct=EBI-297353, EBI-740418;
CC       P62993:GRB2; NbExp=32; IntAct=EBI-297353, EBI-401755;
CC       P08631:HCK; NbExp=2; IntAct=EBI-297353, EBI-346340;
CC       Q9UBN7:HDAC6; NbExp=11; IntAct=EBI-297353, EBI-301697;
CC       Q8WUI4:HDAC7; NbExp=2; IntAct=EBI-297353, EBI-1048378;
CC       P07900:HSP90AA1; NbExp=5; IntAct=EBI-297353, EBI-296047;
CC       P08238:HSP90AB1; NbExp=8; IntAct=EBI-297353, EBI-352572;
CC       Q6PK50:HSP90AB1; NbExp=2; IntAct=EBI-297353, EBI-9356629;
CC       P08107:HSPA1B; NbExp=6; IntAct=EBI-297353, EBI-629985;
CC       P11142:HSPA8; NbExp=5; IntAct=EBI-297353, EBI-351896;
CC       P38646:HSPA9; NbExp=4; IntAct=EBI-297353, EBI-354932;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-297353, EBI-352682;
CC       P17936:IGFBP3; NbExp=3; IntAct=EBI-297353, EBI-715709;
CC       P46940:IQGAP1; NbExp=4; IntAct=EBI-297353, EBI-297509;
CC       O14654:IRS4; NbExp=2; IntAct=EBI-297353, EBI-356594;
CC       Q92622:KIAA0226; NbExp=3; IntAct=EBI-297353, EBI-2952709;
CC       Q80U62:Kiaa0226 (xeno); NbExp=2; IntAct=EBI-297353, EBI-3506572;
CC       Q86VI4:LAPTM4B; NbExp=10; IntAct=EBI-297353, EBI-3267258;
CC       O43561:LAT; NbExp=2; IntAct=EBI-297353, EBI-1222766;
CC       Q13094:LCP2; NbExp=2; IntAct=EBI-297353, EBI-346946;
CC       Q38SD2:LRRK1; NbExp=2; IntAct=EBI-297353, EBI-1050422;
CC       P07948:LYN; NbExp=6; IntAct=EBI-297353, EBI-79452;
CC       P07948-1:LYN; NbExp=2; IntAct=EBI-297353, EBI-6895930;
CC       Q9UQF2:MAPK8IP1; NbExp=3; IntAct=EBI-297353, EBI-78404;
CC       Q13387:MAPK8IP2; NbExp=4; IntAct=EBI-297353, EBI-722813;
CC       Q9Y2H9:MAST1; NbExp=2; IntAct=EBI-297353, EBI-3385920;
CC       P08581:MET; NbExp=7; IntAct=EBI-297353, EBI-1039152;
CC       P15941:MUC1; NbExp=3; IntAct=EBI-297353, EBI-2804728;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-297353, EBI-389883;
CC       P04150:NR3C1; NbExp=2; IntAct=EBI-297353, EBI-493507;
CC       P16234:PDGFRA; NbExp=3; IntAct=EBI-297353, EBI-2861522;
CC       O00750:PIK3C2B; NbExp=9; IntAct=EBI-297353, EBI-641107;
CC       P27986:PIK3R1; NbExp=5; IntAct=EBI-297353, EBI-79464;
CC       O00459:PIK3R2; NbExp=3; IntAct=EBI-297353, EBI-346930;
CC       Q92569:PIK3R3; NbExp=6; IntAct=EBI-297353, EBI-79893;
CC       P19174:PLCG1; NbExp=6; IntAct=EBI-297353, EBI-79387;
CC       P16885:PLCG2; NbExp=5; IntAct=EBI-297353, EBI-617403;
CC       P17252:PRKCA; NbExp=2; IntAct=EBI-297353, EBI-1383528;
CC       P97313:Prkdc (xeno); NbExp=4; IntAct=EBI-297353, EBI-2272005;
CC       Q05397:PTK2; NbExp=3; IntAct=EBI-297353, EBI-702142;
CC       P18031:PTPN1; NbExp=7; IntAct=EBI-297353, EBI-968788;
CC       P20417:Ptpn1 (xeno); NbExp=11; IntAct=EBI-297353, EBI-916819;
CC       Q05209:PTPN12; NbExp=3; IntAct=EBI-297353, EBI-2266035;
CC       Q9Y2R2:PTPN22; NbExp=2; IntAct=EBI-297353, EBI-1211241;
CC       Q9UJ41:RABGEF1; NbExp=4; IntAct=EBI-297353, EBI-913954;
CC       Q70E73:RAPH1; NbExp=2; IntAct=EBI-297353, EBI-3940924;
CC       P20936:RASA1; NbExp=7; IntAct=EBI-297353, EBI-1026476;
CC       Q13671:RIN1; NbExp=3; IntAct=EBI-297353, EBI-366017;
CC       Q01973:ROR1; NbExp=8; IntAct=EBI-297353, EBI-6082337;
CC       P31947:SFN; NbExp=8; IntAct=EBI-297353, EBI-476295;
CC       Q9NRF2:SH2B1; NbExp=2; IntAct=EBI-297353, EBI-310491;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-297353, EBI-7879749;
CC       Q9BRG2:SH2D3A; NbExp=2; IntAct=EBI-297353, EBI-2339271;
CC       P29353:SHC1; NbExp=26; IntAct=EBI-297353, EBI-78835;
CC       P29353-7:SHC1; NbExp=4; IntAct=EBI-297353, EBI-9691288;
CC       P98077:SHC2; NbExp=3; IntAct=EBI-297353, EBI-7256023;
CC       Q6S5L8:SHC4; NbExp=2; IntAct=EBI-297353, EBI-9453524;
CC       Q13239:SLA; NbExp=2; IntAct=EBI-297353, EBI-726214;
CC       P13866:SLC5A1; NbExp=3; IntAct=EBI-297353, EBI-1772443;
CC       P12931:SRC; NbExp=7; IntAct=EBI-297353, EBI-621482;
CC       P42224:STAT1; NbExp=6; IntAct=EBI-297353, EBI-1057697;
CC       P40763:STAT3; NbExp=14; IntAct=EBI-297353, EBI-518675;
CC       P42229:STAT5A; NbExp=3; IntAct=EBI-297353, EBI-749537;
CC       P31948:STIP1; NbExp=2; IntAct=EBI-297353, EBI-1054052;
CC       Q9UNE7:STUB1; NbExp=3; IntAct=EBI-297353, EBI-357085;
CC       P43405:SYK; NbExp=6; IntAct=EBI-297353, EBI-78302;
CC       P01135:TGFA; NbExp=2; IntAct=EBI-297353, EBI-1034374;
CC       Q9Y490:TLN1; NbExp=2; IntAct=EBI-297353, EBI-2462036;
CC       O60603:TLR2; NbExp=2; IntAct=EBI-297353, EBI-973722;
CC       Q68CZ2:TNS3; NbExp=4; IntAct=EBI-297353, EBI-1220488;
CC       O75674:TOM1L1; NbExp=6; IntAct=EBI-297353, EBI-712991;
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-297353, EBI-355744;
CC       Q8K424:Trpv3 (xeno); NbExp=2; IntAct=EBI-297353, EBI-2650739;
CC       Q71U36:TUBA1A; NbExp=3; IntAct=EBI-297353, EBI-302552;
CC       P10599:TXN; NbExp=4; IntAct=EBI-297353, EBI-594644;
CC       P09936:UCHL1; NbExp=2; IntAct=EBI-297353, EBI-714860;
CC       Q9P0L0:VAPA; NbExp=2; IntAct=EBI-297353, EBI-1059156;
CC       P07947:YES1; NbExp=3; IntAct=EBI-297353, EBI-515331;
CC       P27348:YWHAQ; NbExp=6; IntAct=EBI-297353, EBI-359854;
CC       P63104:YWHAZ; NbExp=5; IntAct=EBI-297353, EBI-347088;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-297353, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum membrane; Single-pass type I
CC       membrane protein. Golgi apparatus membrane; Single-pass type I
CC       membrane protein. Nucleus membrane; Single-pass type I membrane
CC       protein. Endosome. Endosome membrane. Nucleus. Note=In response to
CC       EGF, translocated from the cell membrane to the nucleus via Golgi
CC       and ER. Endocytosed upon activation by ligand. Colocalized with
CC       GPER1 in the nucleus of estrogen agonist-induced cancer-associated
CC       fibroblasts (CAF).
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=p170;
CC         IsoId=P00533-1; Sequence=Displayed;
CC       Name=2; Synonyms=p60, Truncated, TEGFR;
CC         IsoId=P00533-2; Sequence=VSP_002887, VSP_002888;
CC       Name=3; Synonyms=p110;
CC         IsoId=P00533-3; Sequence=VSP_002889, VSP_002890;
CC       Name=4;
CC         IsoId=P00533-4; Sequence=VSP_002891, VSP_002892;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is also
CC       expressed in ovarian cancers. {ECO:0000269|PubMed:17671655}.
CC   -!- PTM: Phosphorylation at Ser-695 is partial and occurs only if Thr-
CC       693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by
CC       PRKD1 inhibits EGF-induced MAPK8/JNK1 activation.
CC       Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the
CC       receptor at the plasma membrane. Autophosphorylation at Tyr-1197
CC       is stimulated by methylation at Arg-1199 and enhances interaction
CC       with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110
CC       recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.
CC       {ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:12873986,
CC       ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19563760,
CC       ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:21258366,
CC       ECO:0000269|PubMed:2543678, ECO:0000269|PubMed:3138233}.
CC   -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation;
CC       which does not affect tyrosine kinase activity or signaling
CC       capacity but may play a role in lysosomal targeting. Polyubiquitin
CC       linkage is mainly through 'Lys-63', but linkage through 'Lys-48',
CC       'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B
CC       prevents degradation. Ubiquitinated by RNF115 and RNF126 (By
CC       similarity). {ECO:0000250|UniProtKB:Q01279,
CC       ECO:0000269|PubMed:16543144, ECO:0000269|PubMed:22179831,
CC       ECO:0000269|PubMed:22298428}.
CC   -!- PTM: Methylated. Methylation at Arg-1199 by PRMT5 stimulates
CC       phosphorylation at Tyr-1197. {ECO:0000269|PubMed:19563760,
CC       ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:21258366}.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis.
CC       {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793,
CC       ECO:0000269|PubMed:16672372}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Inflammatory skin and bowel disease, neonatal, 2 (NISBD2)
CC       [MIM:616069]: A disorder characterized by inflammatory features
CC       with neonatal onset, involving the skin, hair, and gut. The skin
CC       lesions involve perioral and perianal erythema, psoriasiform
CC       erythroderma, with flares of erythema, scaling, and widespread
CC       pustules. Gastrointestinal symptoms include malabsorptive diarrhea
CC       that is exacerbated by intercurrent gastrointestinal infections.
CC       The hair is short or broken, and the eyelashes and eyebrows are
CC       wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/egfr/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=EGFR entry;
CC       URL="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00588; CAA25240.1; -; mRNA.
DR   EMBL; U95089; AAB53063.1; -; mRNA.
DR   EMBL; U48722; AAC50802.1; -; mRNA.
DR   EMBL; U48723; AAC50804.1; -; Genomic_DNA.
DR   EMBL; U48724; AAC50796.1; -; Genomic_DNA.
DR   EMBL; U48725; AAC50797.1; -; Genomic_DNA.
DR   EMBL; U48726; AAC50798.1; -; Genomic_DNA.
DR   EMBL; U48727; AAC50799.1; -; Genomic_DNA.
DR   EMBL; U48728; AAC50800.1; -; Genomic_DNA.
DR   EMBL; U48729; AAC50801.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35786.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35787.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35788.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35789.1; -; Genomic_DNA.
DR   EMBL; AF288738; AAG35790.1; -; Genomic_DNA.
DR   EMBL; AY698024; AAT97979.1; -; mRNA.
DR   EMBL; AY588246; AAS83109.1; -; Genomic_DNA.
DR   EMBL; AF277897; AAK01080.1; -; mRNA.
DR   EMBL; AF125253; AAG43240.1; -; mRNA.
DR   EMBL; AF125539; AAG43243.1; -; Genomic_DNA.
DR   EMBL; AF125538; AAG43243.1; JOINED; Genomic_DNA.
DR   EMBL; X06370; CAA29668.1; -; Genomic_DNA.
DR   EMBL; X00663; CAA25282.1; -; mRNA.
DR   EMBL; M38425; AAA63171.1; -; Genomic_DNA.
DR   EMBL; M11234; AAA52370.1; -; Genomic_DNA.
DR   CCDS; CCDS47587.1; -. [P00533-2]
DR   CCDS; CCDS5514.1; -. [P00533-1]
DR   CCDS; CCDS5515.1; -. [P00533-3]
DR   CCDS; CCDS5516.1; -. [P00533-4]
DR   PIR; A00641; GQHUE.
DR   RefSeq; NP_005219.2; NM_005228.3. [P00533-1]
DR   RefSeq; NP_958439.1; NM_201282.1. [P00533-4]
DR   RefSeq; NP_958440.1; NM_201283.1. [P00533-2]
DR   RefSeq; NP_958441.1; NM_201284.1. [P00533-3]
DR   UniGene; Hs.488293; -.
DR   UniGene; Hs.605083; -.
DR   PDB; 1DNQ; Model; -; A=25-336.
DR   PDB; 1DNR; Model; -; A=337-645.
DR   PDB; 1IVO; X-ray; 3.30 A; A/B=25-646.
DR   PDB; 1M14; X-ray; 2.60 A; A=695-1022.
DR   PDB; 1M17; X-ray; 2.60 A; A=695-1022.
DR   PDB; 1MOX; X-ray; 2.50 A; A/B=25-525.
DR   PDB; 1NQL; X-ray; 2.80 A; A=25-642.
DR   PDB; 1XKK; X-ray; 2.40 A; A=695-1022.
DR   PDB; 1YY9; X-ray; 2.60 A; A=25-642.
DR   PDB; 1Z9I; NMR; -; A=669-721.
DR   PDB; 2EB2; X-ray; 2.50 A; A=695-1022.
DR   PDB; 2EB3; X-ray; 2.84 A; A=695-1022.
DR   PDB; 2EXP; Model; -; A=311-326.
DR   PDB; 2EXQ; Model; -; A=27-536.
DR   PDB; 2GS2; X-ray; 2.80 A; A=696-1022.
DR   PDB; 2GS6; X-ray; 2.60 A; A=696-1022.
DR   PDB; 2GS7; X-ray; 2.60 A; A/B=696-1022.
DR   PDB; 2ITN; X-ray; 2.47 A; A=696-1019.
DR   PDB; 2ITO; X-ray; 3.25 A; A=696-1022.
DR   PDB; 2ITP; X-ray; 2.74 A; A=696-1022.
DR   PDB; 2ITQ; X-ray; 2.68 A; A=696-1022.
DR   PDB; 2ITT; X-ray; 2.73 A; A=696-1022.
DR   PDB; 2ITU; X-ray; 2.80 A; A=696-1022.
DR   PDB; 2ITV; X-ray; 2.47 A; A=696-1022.
DR   PDB; 2ITW; X-ray; 2.88 A; A=696-1022.
DR   PDB; 2ITX; X-ray; 2.98 A; A=696-1022.
DR   PDB; 2ITY; X-ray; 3.42 A; A=696-1022.
DR   PDB; 2ITZ; X-ray; 2.72 A; A=696-1022.
DR   PDB; 2J5E; X-ray; 3.10 A; A=696-1022.
DR   PDB; 2J5F; X-ray; 3.00 A; A=696-1022.
DR   PDB; 2J6M; X-ray; 3.10 A; A=696-1022.
DR   PDB; 2JIT; X-ray; 3.10 A; A/B=696-1022.
DR   PDB; 2JIU; X-ray; 3.05 A; A/B=695-1022.
DR   PDB; 2JIV; X-ray; 3.50 A; A/B=695-1022.
DR   PDB; 2KS1; NMR; -; B=634-677.
DR   PDB; 2M0B; NMR; -; A/B=634-677.
DR   PDB; 2M20; NMR; -; A/B=642-697.
DR   PDB; 2N5S; NMR; -; A=642-690.
DR   PDB; 2RF9; X-ray; 3.50 A; A/B=696-1022.
DR   PDB; 2RFD; X-ray; 3.60 A; A/B=702-1022.
DR   PDB; 2RFE; X-ray; 2.90 A; A/B/C/D=702-1022.
DR   PDB; 2RGP; X-ray; 2.00 A; A=702-1016.
DR   PDB; 3B2U; X-ray; 2.58 A; A/B/E/I/M/P/S/V=335-538.
DR   PDB; 3B2V; X-ray; 3.30 A; A=25-642.
DR   PDB; 3BEL; X-ray; 2.30 A; A=702-1016.
DR   PDB; 3BUO; X-ray; 2.60 A; A/C=1063-1075.
DR   PDB; 3C09; X-ray; 3.20 A; A/D=336-538.
DR   PDB; 3G5V; X-ray; 2.00 A; C=311-326.
DR   PDB; 3G5Y; X-ray; 1.59 A; E=311-326.
DR   PDB; 3GOP; X-ray; 2.80 A; A=669-1022.
DR   PDB; 3GT8; X-ray; 2.96 A; A/B/C/D=696-1022.
DR   PDB; 3IKA; X-ray; 2.90 A; A/B=694-1022.
DR   PDB; 3LZB; X-ray; 2.70 A; A/B/C/D/E/F/G/H=696-983.
DR   PDB; 3NJP; X-ray; 3.30 A; A/B=25-638.
DR   PDB; 3OB2; X-ray; 2.10 A; A=1063-1074.
DR   PDB; 3OP0; X-ray; 2.52 A; C/D=1066-1076.
DR   PDB; 3P0Y; X-ray; 1.80 A; A=334-538.
DR   PDB; 3PFV; X-ray; 2.27 A; C/D=1066-1076.
DR   PDB; 3POZ; X-ray; 1.50 A; A=696-1022.
DR   PDB; 3QWQ; X-ray; 2.75 A; A=1-642.
DR   PDB; 3UG1; X-ray; 2.75 A; A=695-1022.
DR   PDB; 3UG2; X-ray; 2.50 A; A=695-1022.
DR   PDB; 3VJN; X-ray; 2.34 A; A=695-1022.
DR   PDB; 3VJO; X-ray; 2.64 A; A=695-1022.
DR   PDB; 3VRP; X-ray; 1.52 A; B=1062-1074.
DR   PDB; 3VRR; X-ray; 2.00 A; C=1062-1074.
DR   PDB; 3W2O; X-ray; 2.35 A; A=698-1022.
DR   PDB; 3W2P; X-ray; 2.05 A; A=698-1022.
DR   PDB; 3W2Q; X-ray; 2.20 A; A=698-1022.
DR   PDB; 3W2R; X-ray; 2.05 A; A=698-1022.
DR   PDB; 3W2S; X-ray; 1.90 A; A=696-1022.
DR   PDB; 3W32; X-ray; 1.80 A; A=696-1022.
DR   PDB; 3W33; X-ray; 1.70 A; A=696-1022.
DR   PDB; 4G5J; X-ray; 2.80 A; A=696-1022.
DR   PDB; 4G5P; X-ray; 3.17 A; A/B=696-1022.
DR   PDB; 4HJO; X-ray; 2.75 A; A=696-1022.
DR   PDB; 4I1Z; X-ray; 3.00 A; A=695-1022.
DR   PDB; 4I20; X-ray; 3.34 A; A=695-1022.
DR   PDB; 4I21; X-ray; 3.37 A; A/B=695-1022.
DR   PDB; 4I22; X-ray; 1.71 A; A=695-1022.
DR   PDB; 4I23; X-ray; 2.80 A; A=695-1022.
DR   PDB; 4I24; X-ray; 1.80 A; A/B=695-1022.
DR   PDB; 4JQ7; X-ray; 2.73 A; A=696-1021.
DR   PDB; 4JQ8; X-ray; 2.83 A; A=696-1021.
DR   PDB; 4JR3; X-ray; 2.70 A; A=696-1021.
DR   PDB; 4JRV; X-ray; 2.80 A; A=696-1021.
DR   PDB; 4KRL; X-ray; 2.85 A; A=335-538.
DR   PDB; 4KRM; X-ray; 2.66 A; A/C/E/G/I/K=335-538.
DR   PDB; 4KRO; X-ray; 3.05 A; A=25-642.
DR   PDB; 4KRP; X-ray; 2.82 A; A=25-642.
DR   PDB; 4LI5; X-ray; 2.64 A; A=696-1020.
DR   PDB; 4LL0; X-ray; 4.00 A; A/B=694-1022.
DR   PDB; 4LQM; X-ray; 2.50 A; A=694-1022.
DR   PDB; 4LRM; X-ray; 3.53 A; A/B/C/D/E=694-1022.
DR   PDB; 4R3P; X-ray; 2.90 A; A=696-1018.
DR   PDB; 4R3R; X-ray; 3.25 A; A=696-1018.
DR   PDB; 4R5S; X-ray; 3.00 A; A=696-1022.
DR   PDB; 4RIW; X-ray; 3.10 A; B/D=682-1022.
DR   PDB; 4RIX; X-ray; 3.10 A; B/D=682-1022.
DR   PDB; 4RIY; X-ray; 2.98 A; B/D=682-1022.
DR   PDB; 4RJ4; X-ray; 2.78 A; A=695-1022.
DR   PDB; 4RJ5; X-ray; 3.10 A; A=695-1022.
DR   PDB; 4RJ6; X-ray; 2.70 A; A=695-1022.
DR   PDB; 4RJ7; X-ray; 2.55 A; A=695-1022.
DR   PDB; 4RJ8; X-ray; 2.50 A; A=695-1022.
DR   PDB; 4TKS; X-ray; 3.20 A; A=695-1022.
DR   PDB; 4UIP; X-ray; 2.95 A; A=26-637.
DR   PDB; 4UV7; X-ray; 2.10 A; A=25-645.
DR   PDB; 4WKQ; X-ray; 1.85 A; A=696-1022.
DR   PDB; 4WRG; X-ray; 1.90 A; A=696-1022.
DR   PDB; 4ZAU; X-ray; 2.80 A; A=696-1022.
DR   PDB; 4ZJV; X-ray; 2.70 A; A/B=695-1022.
DR   PDB; 5C8K; X-ray; 3.00 A; A=695-1022.
DR   PDB; 5C8M; X-ray; 2.90 A; A=695-1022.
DR   PDB; 5C8N; X-ray; 2.40 A; A=695-1022.
DR   PDB; 5CAL; X-ray; 2.70 A; A=695-1022.
DR   PDB; 5CAN; X-ray; 2.80 A; A=695-1022.
DR   PDB; 5CAO; X-ray; 2.60 A; A=695-1022.
DR   PDB; 5CAP; X-ray; 2.40 A; A=695-1022.
DR   PDB; 5CAQ; X-ray; 2.50 A; A=695-1022.
DR   PDB; 5CAS; X-ray; 2.10 A; A=695-1022.
DR   PDB; 5CAU; X-ray; 2.25 A; A=695-1022.
DR   PDB; 5CAV; X-ray; 2.73 A; A=695-1022.
DR   PDB; 5CNN; X-ray; 1.90 A; A/B=696-1042.
DR   PDB; 5CNO; X-ray; 1.55 A; A/B/X=696-1022.
DR   PDB; 5CZH; X-ray; 2.80 A; A=694-1022.
DR   PDB; 5CZI; X-ray; 2.60 A; A=694-1022.
DR   PDB; 5EDP; X-ray; 2.90 A; A=695-1022.
DR   PDB; 5EDQ; X-ray; 2.80 A; A=695-1022.
DR   PDB; 5EDR; X-ray; 2.60 A; A=695-1022.
DR   PDB; 5EM5; X-ray; 2.65 A; A=695-1022.
DR   PDB; 5EM6; X-ray; 2.78 A; A=695-1022.
DR   PDB; 5EM7; X-ray; 2.81 A; A=695-1022.
DR   PDB; 5EM8; X-ray; 2.80 A; A=695-1022.
DR   PDBsum; 1DNQ; -.
DR   PDBsum; 1DNR; -.
DR   PDBsum; 1IVO; -.
DR   PDBsum; 1M14; -.
DR   PDBsum; 1M17; -.
DR   PDBsum; 1MOX; -.
DR   PDBsum; 1NQL; -.
DR   PDBsum; 1XKK; -.
DR   PDBsum; 1YY9; -.
DR   PDBsum; 1Z9I; -.
DR   PDBsum; 2EB2; -.
DR   PDBsum; 2EB3; -.
DR   PDBsum; 2EXP; -.
DR   PDBsum; 2EXQ; -.
DR   PDBsum; 2GS2; -.
DR   PDBsum; 2GS6; -.
DR   PDBsum; 2GS7; -.
DR   PDBsum; 2ITN; -.
DR   PDBsum; 2ITO; -.
DR   PDBsum; 2ITP; -.
DR   PDBsum; 2ITQ; -.
DR   PDBsum; 2ITT; -.
DR   PDBsum; 2ITU; -.
DR   PDBsum; 2ITV; -.
DR   PDBsum; 2ITW; -.
DR   PDBsum; 2ITX; -.
DR   PDBsum; 2ITY; -.
DR   PDBsum; 2ITZ; -.
DR   PDBsum; 2J5E; -.
DR   PDBsum; 2J5F; -.
DR   PDBsum; 2J6M; -.
DR   PDBsum; 2JIT; -.
DR   PDBsum; 2JIU; -.
DR   PDBsum; 2JIV; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 2M0B; -.
DR   PDBsum; 2M20; -.
DR   PDBsum; 2N5S; -.
DR   PDBsum; 2RF9; -.
DR   PDBsum; 2RFD; -.
DR   PDBsum; 2RFE; -.
DR   PDBsum; 2RGP; -.
DR   PDBsum; 3B2U; -.
DR   PDBsum; 3B2V; -.
DR   PDBsum; 3BEL; -.
DR   PDBsum; 3BUO; -.
DR   PDBsum; 3C09; -.
DR   PDBsum; 3G5V; -.
DR   PDBsum; 3G5Y; -.
DR   PDBsum; 3GOP; -.
DR   PDBsum; 3GT8; -.
DR   PDBsum; 3IKA; -.
DR   PDBsum; 3LZB; -.
DR   PDBsum; 3NJP; -.
DR   PDBsum; 3OB2; -.
DR   PDBsum; 3OP0; -.
DR   PDBsum; 3P0Y; -.
DR   PDBsum; 3PFV; -.
DR   PDBsum; 3POZ; -.
DR   PDBsum; 3QWQ; -.
DR   PDBsum; 3UG1; -.
DR   PDBsum; 3UG2; -.
DR   PDBsum; 3VJN; -.
DR   PDBsum; 3VJO; -.
DR   PDBsum; 3VRP; -.
DR   PDBsum; 3VRR; -.
DR   PDBsum; 3W2O; -.
DR   PDBsum; 3W2P; -.
DR   PDBsum; 3W2Q; -.
DR   PDBsum; 3W2R; -.
DR   PDBsum; 3W2S; -.
DR   PDBsum; 3W32; -.
DR   PDBsum; 3W33; -.
DR   PDBsum; 4G5J; -.
DR   PDBsum; 4G5P; -.
DR   PDBsum; 4HJO; -.
DR   PDBsum; 4I1Z; -.
DR   PDBsum; 4I20; -.
DR   PDBsum; 4I21; -.
DR   PDBsum; 4I22; -.
DR   PDBsum; 4I23; -.
DR   PDBsum; 4I24; -.
DR   PDBsum; 4JQ7; -.
DR   PDBsum; 4JQ8; -.
DR   PDBsum; 4JR3; -.
DR   PDBsum; 4JRV; -.
DR   PDBsum; 4KRL; -.
DR   PDBsum; 4KRM; -.
DR   PDBsum; 4KRO; -.
DR   PDBsum; 4KRP; -.
DR   PDBsum; 4LI5; -.
DR   PDBsum; 4LL0; -.
DR   PDBsum; 4LQM; -.
DR   PDBsum; 4LRM; -.
DR   PDBsum; 4R3P; -.
DR   PDBsum; 4R3R; -.
DR   PDBsum; 4R5S; -.
DR   PDBsum; 4RIW; -.
DR   PDBsum; 4RIX; -.
DR   PDBsum; 4RIY; -.
DR   PDBsum; 4RJ4; -.
DR   PDBsum; 4RJ5; -.
DR   PDBsum; 4RJ6; -.
DR   PDBsum; 4RJ7; -.
DR   PDBsum; 4RJ8; -.
DR   PDBsum; 4TKS; -.
DR   PDBsum; 4UIP; -.
DR   PDBsum; 4UV7; -.
DR   PDBsum; 4WKQ; -.
DR   PDBsum; 4WRG; -.
DR   PDBsum; 4ZAU; -.
DR   PDBsum; 4ZJV; -.
DR   PDBsum; 5C8K; -.
DR   PDBsum; 5C8M; -.
DR   PDBsum; 5C8N; -.
DR   PDBsum; 5CAL; -.
DR   PDBsum; 5CAN; -.
DR   PDBsum; 5CAO; -.
DR   PDBsum; 5CAP; -.
DR   PDBsum; 5CAQ; -.
DR   PDBsum; 5CAS; -.
DR   PDBsum; 5CAU; -.
DR   PDBsum; 5CAV; -.
DR   PDBsum; 5CNN; -.
DR   PDBsum; 5CNO; -.
DR   PDBsum; 5CZH; -.
DR   PDBsum; 5CZI; -.
DR   PDBsum; 5EDP; -.
DR   PDBsum; 5EDQ; -.
DR   PDBsum; 5EDR; -.
DR   PDBsum; 5EM5; -.
DR   PDBsum; 5EM6; -.
DR   PDBsum; 5EM7; -.
DR   PDBsum; 5EM8; -.
DR   DisProt; DP00309; -.
DR   ProteinModelPortal; P00533; -.
DR   SMR; P00533; 26-1017.
DR   BioGrid; 108276; 807.
DR   DIP; DIP-405N; -.
DR   IntAct; P00533; 472.
DR   MINT; MINT-206389; -.
DR   STRING; 9606.ENSP00000275493; -.
DR   BindingDB; P00533; -.
DR   ChEMBL; CHEMBL2363049; -.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB00002; Cetuximab.
DR   DrugBank; DB00530; Erlotinib.
DR   DrugBank; DB00317; Gefitinib.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB01269; Panitumumab.
DR   DrugBank; DB00072; Trastuzumab.
DR   DrugBank; DB05294; Vandetanib.
DR   GuidetoPHARMACOLOGY; 1797; -.
DR   iPTMnet; P00533; -.
DR   PhosphoSite; P00533; -.
DR   SwissPalm; P00533; -.
DR   UniCarbKB; P00533; -.
DR   BioMuta; EGFR; -.
DR   DMDM; 2811086; -.
DR   SWISS-2DPAGE; P00533; -.
DR   MaxQB; P00533; -.
DR   PaxDb; P00533; -.
DR   PeptideAtlas; P00533; -.
DR   PRIDE; P00533; -.
DR   DNASU; 1956; -.
DR   Ensembl; ENST00000275493; ENSP00000275493; ENSG00000146648. [P00533-1]
DR   Ensembl; ENST00000342916; ENSP00000342376; ENSG00000146648. [P00533-4]
DR   Ensembl; ENST00000344576; ENSP00000345973; ENSG00000146648. [P00533-3]
DR   Ensembl; ENST00000420316; ENSP00000413843; ENSG00000146648. [P00533-2]
DR   GeneID; 1956; -.
DR   KEGG; hsa:1956; -.
DR   UCSC; uc003tqh.3; human. [P00533-2]
DR   UCSC; uc003tqi.3; human. [P00533-4]
DR   UCSC; uc003tqj.3; human. [P00533-3]
DR   UCSC; uc003tqk.3; human. [P00533-1]
DR   CTD; 1956; -.
DR   GeneCards; EGFR; -.
DR   HGNC; HGNC:3236; EGFR.
DR   HPA; CAB000035; -.
DR   HPA; CAB068186; -.
DR   HPA; HPA001200; -.
DR   HPA; HPA018530; -.
DR   MalaCards; EGFR; -.
DR   MIM; 131550; gene.
DR   MIM; 211980; phenotype.
DR   MIM; 616069; phenotype.
DR   neXtProt; NX_P00533; -.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 294023; Neonatal inflammatory skin and bowel disease.
DR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.
DR   PharmGKB; PA7360; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P00533; -.
DR   KO; K04361; -.
DR   OMA; ANLDVNM; -.
DR   PhylomeDB; P00533; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-177929; Signaling by EGFR.
DR   Reactome; R-HSA-179812; GRB2 events in EGFR signaling.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-180336; SHC1 events in EGFR signaling.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma.
DR   Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5638303; Inhibition of Signaling by Overexpressed EGFR.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P00533; -.
DR   ChiTaRS; EGFR; human.
DR   EvolutionaryTrace; P00533; -.
DR   GeneWiki; Epidermal_growth_factor_receptor; -.
DR   GenomeRNAi; 1956; -.
DR   NextBio; 7931; -.
DR   PMAP-CutDB; P00533; -.
DR   PRO; PR:P00533; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P00533; -.
DR   ExpressionAtlas; P00533; baseline and differential.
DR   Genevisible; P00533; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0030139; C:endocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; NAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0097489; C:multivesicular body, internal vesicle lumen; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0070435; C:Shc-EGFR complex; ISS:BHF-UCL.
DR   GO; GO:0051015; F:actin filament binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; NAS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005006; F:epidermal growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0043006; P:activation of phospholipase A2 activity by calcium-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0008283; P:cell proliferation; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB.
DR   GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007611; P:learning or memory; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001503; P:ossification; NAS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IMP:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051205; P:protein insertion into membrane; TAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0006950; P:response to stress; NAS:UniProtKB.
DR   GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Developmental protein; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Golgi apparatus; Isopeptide bond; Kinase; Membrane;
KW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Tumor suppressor;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000269|PubMed:15340161,
FT                                ECO:0000269|Ref.16}.
FT   CHAIN        25   1210       Epidermal growth factor receptor.
FT                                /FTId=PRO_0000016665.
FT   TOPO_DOM     25    645       Extracellular. {ECO:0000255}.
FT   TRANSMEM    646    668       Helical. {ECO:0000255}.
FT   TOPO_DOM    669   1210       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       75    300       Approximate.
FT   REPEAT      390    600       Approximate.
FT   DOMAIN      712    979       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     718    726       ATP.
FT   NP_BIND     790    791       ATP.
FT   REGION      688    704       Important for dimerization,
FT                                phosphorylation and activation.
FT   ACT_SITE    837    837       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     745    745       ATP.
FT   BINDING     855    855       ATP.
FT   SITE       1016   1016       Important for interaction with PIK3C2B.
FT   MOD_RES     229    229       Phosphoserine.
FT                                {ECO:0000269|PubMed:21487020}.
FT   MOD_RES     678    678       Phosphothreonine; by PKC and PKD/PRKD1.
FT                                {ECO:0000269|PubMed:10523301}.
FT   MOD_RES     693    693       Phosphothreonine; by PKD/PRKD1.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:10523301,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:3138233}.
FT   MOD_RES     695    695       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:3138233}.
FT   MOD_RES     991    991       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:16083266}.
FT   MOD_RES     995    995       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     998    998       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:19563760}.
FT   MOD_RES    1016   1016       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19563760}.
FT   MOD_RES    1026   1026       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:16083266}.
FT   MOD_RES    1039   1039       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1041   1041       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1042   1042       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1064   1064       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1069   1069       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:22888118}.
FT   MOD_RES    1070   1070       Phosphoserine.
FT                                {ECO:0000269|PubMed:3138233}.
FT   MOD_RES    1071   1071       Phosphoserine.
FT                                {ECO:0000269|PubMed:3138233}.
FT   MOD_RES    1081   1081       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES    1092   1092       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12873986}.
FT   MOD_RES    1110   1110       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12873986,
FT                                ECO:0000269|PubMed:2543678}.
FT   MOD_RES    1166   1166       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1172   1172       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983}.
FT   MOD_RES    1197   1197       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:19563760,
FT                                ECO:0000269|PubMed:19836242}.
FT   MOD_RES    1199   1199       Omega-N-methylarginine.
FT                                {ECO:0000269|PubMed:21258366}.
FT   CARBOHYD     56     56       N-linked (GlcNAc...) (complex); atypical;
FT                                partial. {ECO:0000269|PubMed:10731668,
FT                                ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704}.
FT                                /FTId=CAR_000227.
FT   CARBOHYD     73     73       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:20837704}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:8962717}.
FT   CARBOHYD    175    175       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704,
FT                                ECO:0000269|PubMed:8962717}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704}.
FT   CARBOHYD    352    352       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10731668,
FT                                ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:20837704}.
FT   CARBOHYD    361    361       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:10731668,
FT                                ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:8962717}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12297050,
FT                                ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704,
FT                                ECO:0000269|PubMed:8962717}.
FT   CARBOHYD    528    528       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:20837704,
FT                                ECO:0000269|PubMed:8962717}.
FT   CARBOHYD    568    568       N-linked (GlcNAc...); partial.
FT                                {ECO:0000269|PubMed:10731668,
FT                                ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    603    603       N-linked (GlcNAc...); partial.
FT                                {ECO:0000269|PubMed:10731668,
FT                                ECO:0000269|PubMed:12620237,
FT                                ECO:0000269|PubMed:12731890,
FT                                ECO:0000269|PubMed:16083266}.
FT   CARBOHYD    623    623       N-linked (GlcNAc...) (high mannose).
FT                                {ECO:0000305|PubMed:12731890}.
FT   DISULFID     31     58
FT   DISULFID    157    187
FT   DISULFID    190    199
FT   DISULFID    194    207
FT   DISULFID    215    223
FT   DISULFID    219    231
FT   DISULFID    232    240
FT   DISULFID    236    248
FT   DISULFID    251    260
FT   DISULFID    264    291
FT   DISULFID    295    307
FT   DISULFID    311    326
FT   DISULFID    329    333
FT   DISULFID    337    362
FT   DISULFID    470    499
FT   DISULFID    506    515
FT   DISULFID    510    523
FT   DISULFID    526    535
FT   DISULFID    539    555
FT   DISULFID    558    571
FT   DISULFID    562    579
FT   DISULFID    582    591
FT   DISULFID    595    617
FT   DISULFID    620    628
FT   DISULFID    624    636
FT   CROSSLNK    716    716       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   CROSSLNK    737    737       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   CROSSLNK    754    754       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   CROSSLNK    867    867       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   CROSSLNK    929    929       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   CROSSLNK    970    970       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:16543144}.
FT   VAR_SEQ     404    405       FL -> LS (in isoform 2).
FT                                {ECO:0000303|PubMed:7654368,
FT                                ECO:0000303|PubMed:8918811,
FT                                ECO:0000303|PubMed:9103388,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_002887.
FT   VAR_SEQ     406   1210       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7654368,
FT                                ECO:0000303|PubMed:8918811,
FT                                ECO:0000303|PubMed:9103388,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_002888.
FT   VAR_SEQ     628    705       CTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFM
FT                                RRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLR ->
FT                                PGNESLKAMLFCLFKLSSCNQSNDGSVSHQSGSPAAQESCL
FT                                GWIPSLLPSEFQLGWGGCSHLHAWPSASVIITASSCH (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:11161793}.
FT                                /FTId=VSP_002889.
FT   VAR_SEQ     628    628       C -> S (in isoform 4).
FT                                {ECO:0000303|PubMed:11161793}.
FT                                /FTId=VSP_002891.
FT   VAR_SEQ     629   1210       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:11161793}.
FT                                /FTId=VSP_002892.
FT   VAR_SEQ     706   1210       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11161793}.
FT                                /FTId=VSP_002890.
FT   VARIANT      30    297       Missing (variant EGFR vIII; found in a
FT                                lung cancer sample; somatic mutation;
FT                                induces lung cancer when exogenously
FT                                expressed).
FT                                {ECO:0000269|PubMed:16672372}.
FT                                /FTId=VAR_066493.
FT   VARIANT      98     98       R -> Q (in dbSNP:rs17289589).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019293.
FT   VARIANT     266    266       P -> R (in dbSNP:rs17336639).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019294.
FT   VARIANT     428    428       G -> D (in NISBD2; loss of function; the
FT                                mutant does not localize to the cell
FT                                membrane; has diffuse cytoplasmic
FT                                localization).
FT                                {ECO:0000269|PubMed:24691054}.
FT                                /FTId=VAR_072435.
FT   VARIANT     521    521       R -> K (in dbSNP:rs2227983).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019295.
FT   VARIANT     674    674       V -> I (slightly increased
FT                                autophosphorylation; dbSNP:rs17337079).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019296.
FT   VARIANT     709    709       E -> A (found in a lung cancer sample;
FT                                more sensitive to gefitinib than wild-
FT                                type). {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628,
FT                                ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026084.
FT   VARIANT     709    709       E -> G (found in a lung cancer sample;
FT                                constitutively activated kinase with
FT                                higher levels of basal
FT                                autophosphorylation; more sensitive to
FT                                gefitinib than wild-type).
FT                                {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628}.
FT                                /FTId=VAR_069498.
FT   VARIANT     709    709       E -> K (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026085.
FT   VARIANT     719    719       G -> A (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026086.
FT   VARIANT     719    719       G -> C (found in a lung cancer sample;
FT                                dbSNP:rs28929495).
FT                                {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026087.
FT   VARIANT     719    719       G -> D (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026088.
FT   VARIANT     719    719       G -> S (found in a lung cancer sample;
FT                                somatic mutation; strongly increased
FT                                kinase activity; constitutively activated
FT                                kinase with higher levels of basal
FT                                autophosphorylation; more sensitive to
FT                                gefitinib than wild-type).
FT                                {ECO:0000269|PubMed:15118125,
FT                                ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628,
FT                                ECO:0000269|PubMed:16533793,
FT                                ECO:0000269|PubMed:17349580}.
FT                                /FTId=VAR_019297.
FT   VARIANT     724    724       G -> S (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026089.
FT   VARIANT     734    734       E -> K (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026090.
FT   VARIANT     746    752       ELREATS -> D (found in a lung cancer
FT                                sample). {ECO:0000269|PubMed:15623594}.
FT                                /FTId=VAR_069499.
FT   VARIANT     746    751       ELREAT -> A (found in a lung cancer
FT                                sample). {ECO:0000269|PubMed:15623594}.
FT                                /FTId=VAR_069500.
FT   VARIANT     746    750       Missing (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:15623594}.
FT                                /FTId=VAR_026092.
FT   VARIANT     746    746       Missing (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026091.
FT   VARIANT     747    751       Missing (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:15623594}.
FT                                /FTId=VAR_069501.
FT   VARIANT     747    749       Missing (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026094.
FT   VARIANT     747    747       L -> F (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026093.
FT   VARIANT     748    748       R -> P (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026095.
FT   VARIANT     752    759       Missing (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026096.
FT   VARIANT     768    768       S -> I (found in a lung cancer sample;
FT                                constitutively activated kinase with
FT                                higher levels of basal
FT                                autophosphorylation; more sensitive to
FT                                gefitinib than wild-type;
FT                                dbSNP:rs121913465).
FT                                {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628}.
FT                                /FTId=VAR_069502.
FT   VARIANT     769    769       V -> M (found in a lung cancer sample;
FT                                dbSNP:rs147149347).
FT                                {ECO:0000269|PubMed:15623594}.
FT                                /FTId=VAR_069503.
FT   VARIANT     787    787       Q -> R (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026097.
FT   VARIANT     790    790       T -> M (found in a lung cancer sample;
FT                                increased kinase activity).
FT                                {ECO:0000269|PubMed:16533793,
FT                                ECO:0000269|PubMed:18227510}.
FT                                /FTId=VAR_026098.
FT   VARIANT     833    833       L -> V (found in a lung cancer sample;
FT                                more sensitive to gefitinib than wild-
FT                                type). {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628,
FT                                ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026099.
FT   VARIANT     834    834       V -> L (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026100.
FT   VARIANT     835    835       H -> L (found in a lung cancer sample;
FT                                more sensitive to gefitinib than wild-
FT                                type). {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628}.
FT                                /FTId=VAR_069504.
FT   VARIANT     838    838       L -> V (found in a lung cancer sample;
FT                                more sensitive to gefitinib than wild-
FT                                type). {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628}.
FT                                /FTId=VAR_069505.
FT   VARIANT     858    858       L -> M (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026101.
FT   VARIANT     858    858       L -> R (found in a lung cancer sample;
FT                                somatic mutation; constitutively
FT                                activated enzyme with strongly increased
FT                                kinase activity; more sensitive to
FT                                gefitinib than wild-type;
FT                                dbSNP:rs121434568).
FT                                {ECO:0000269|PubMed:15118125,
FT                                ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628,
FT                                ECO:0000269|PubMed:16533793,
FT                                ECO:0000269|PubMed:17349580}.
FT                                /FTId=VAR_019298.
FT   VARIANT     861    861       L -> Q (found in a lung cancer sample;
FT                                constitutively activated kinase with
FT                                higher levels of basal
FT                                autophosphorylation; more sensitive to
FT                                gefitinib than wild-type;
FT                                dbSNP:rs121913444).
FT                                {ECO:0000269|PubMed:15623594,
FT                                ECO:0000269|PubMed:16205628,
FT                                ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026102.
FT   VARIANT     873    873       G -> E (found in a lung cancer sample).
FT                                {ECO:0000269|PubMed:16533793}.
FT                                /FTId=VAR_026103.
FT   VARIANT     962    962       R -> G (in dbSNP:rs17337451).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019299.
FT   VARIANT     988    988       H -> P (in dbSNP:rs17290699).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019300.
FT   VARIANT    1034   1034       L -> R (in dbSNP:rs34352568).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042095.
FT   VARIANT    1210   1210       A -> V (in dbSNP:rs35918369).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042096.
FT   MUTAGEN     275    275       Y->A: Strongly reduced
FT                                autophosphorylation and activation of
FT                                downstream kinases; when associated with
FT                                A-309. {ECO:0000269|PubMed:12297050}.
FT   MUTAGEN     287    287       F->A: Strongly reduced
FT                                autophosphorylation and activation of
FT                                downstream kinases; when associated with
FT                                A-309. {ECO:0000269|PubMed:12297050}.
FT   MUTAGEN     309    309       R->S: Strongly reduced
FT                                autophosphorylation and activation of
FT                                downstream kinases; when associated with
FT                                A-275. Strongly reduced
FT                                autophosphorylation and activation of
FT                                downstream kinases; when associated with
FT                                A-287. {ECO:0000269|PubMed:12297050}.
FT   MUTAGEN     429    429       R->E: Abolishes autophosphorylation and
FT                                activation of downstream kinases.
FT                                {ECO:0000269|PubMed:12297050}.
FT   MUTAGEN     587    590       DGPH->AGPA: Decreases intramolecular
FT                                interactions and facilitates EGF binding.
FT                                {ECO:0000269|PubMed:12620237}.
FT   MUTAGEN     609    609       K->A: Decreases intramolecular
FT                                interactions and facilitates EGF binding.
FT                                {ECO:0000269|PubMed:12620237}.
FT   MUTAGEN     688    688       L->A: Strongly reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417,
FT                                ECO:0000269|PubMed:19563760}.
FT   MUTAGEN     689    689       V->A: Reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     689    689       V->M: Constitutively activated kinase.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     690    690       E->A: Reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417,
FT                                ECO:0000269|PubMed:19563760}.
FT   MUTAGEN     692    692       L->A,P: Strongly reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417,
FT                                ECO:0000269|PubMed:19563760}.
FT   MUTAGEN     693    693       T->A: Increased phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     693    693       T->D: Strongly reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     694    694       P->A: Strongly reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     699    699       P->A: Reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     700    700       N->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     704    704       L->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     705    705       R->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     706    706       I->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     745    745       K->A,M: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:19560417}.
FT   MUTAGEN     974    974       D->A: Strongly reduced phosphorylation.
FT   MUTAGEN     977    977       R->A: Reduced phosphorylation.
FT                                {ECO:0000269|PubMed:19563760}.
FT   MUTAGEN    1005   1006       ED->RK: Constitutively activated kinase.
FT                                {ECO:0000269|PubMed:19563760}.
FT   MUTAGEN    1016   1016       Y->F: 50% decrease in interaction with
FT                                PIK3C2B. 65% decrease in interaction with
FT                                PIK3C2B; when associated with F-1197.
FT                                Abolishes interaction with PIK3C2B; when
FT                                associated with F-1197 and F-1092.
FT                                {ECO:0000269|PubMed:10805725}.
FT   MUTAGEN    1067   1067       Q->G: No effect on interaction with CBLC.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN    1068   1068       R->G: Strongly decreases interaction with
FT                                CBLC. {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN    1069   1069       Y->F: Abolishes interaction with CBLC.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN    1092   1092       Y->F: No change in interaction with
FT                                PIK3C2B. Abolishes interaction with
FT                                PIK3C2B; when associated with F-1197 and
FT                                F-1016. {ECO:0000269|PubMed:10805725}.
FT   MUTAGEN    1110   1110       Y->F: No change in interaction with
FT                                PIK3C2B. {ECO:0000269|PubMed:10805725}.
FT   MUTAGEN    1172   1172       Y->F: No change in interaction with
FT                                PIK3C2B. {ECO:0000269|PubMed:10805725}.
FT   MUTAGEN    1197   1197       Y->F: No change in interaction with
FT                                PIK3C2B. 65% decrease in interaction with
FT                                PIK3C2B; when associated with F-1016.
FT                                Abolishes interaction with PIK3C2B; when
FT                                associated with F-1092 and F-1016.
FT                                {ECO:0000269|PubMed:10805725}.
FT   CONFLICT    540    540       N -> K (in Ref. 1; CAA25240).
FT                                {ECO:0000305}.
FT   STRAND       40     43       {ECO:0000244|PDB:3QWQ}.
FT   HELIX        44     55       {ECO:0000244|PDB:4UV7}.
FT   STRAND       60     69       {ECO:0000244|PDB:4UV7}.
FT   HELIX        77     81       {ECO:0000244|PDB:4UV7}.
FT   STRAND       84     87       {ECO:0000244|PDB:4UV7}.
FT   STRAND       89     93       {ECO:0000244|PDB:4UV7}.
FT   HELIX       101    103       {ECO:0000244|PDB:1IVO}.
FT   TURN        114    116       {ECO:0000244|PDB:4UV7}.
FT   STRAND      117    122       {ECO:0000244|PDB:4UV7}.
FT   STRAND      125    129       {ECO:0000244|PDB:1MOX}.
FT   STRAND      145    152       {ECO:0000244|PDB:4UV7}.
FT   HELIX       159    161       {ECO:0000244|PDB:4UV7}.
FT   HELIX       164    166       {ECO:0000244|PDB:4UV7}.
FT   HELIX       170    173       {ECO:0000244|PDB:1MOX}.
FT   HELIX       195    197       {ECO:0000244|PDB:4UV7}.
FT   STRAND      199    204       {ECO:0000244|PDB:4UV7}.
FT   STRAND      211    214       {ECO:0000244|PDB:1MOX}.
FT   STRAND      223    227       {ECO:0000244|PDB:4UV7}.
FT   HELIX       228    230       {ECO:0000244|PDB:4UV7}.
FT   STRAND      236    238       {ECO:0000244|PDB:4UV7}.
FT   STRAND      240    244       {ECO:0000244|PDB:4UV7}.
FT   TURN        245    247       {ECO:0000244|PDB:4UV7}.
FT   STRAND      248    256       {ECO:0000244|PDB:4UV7}.
FT   STRAND      259    263       {ECO:0000244|PDB:4UV7}.
FT   STRAND      267    271       {ECO:0000244|PDB:4UV7}.
FT   TURN        272    275       {ECO:0000244|PDB:4UV7}.
FT   STRAND      276    279       {ECO:0000244|PDB:4UV7}.
FT   STRAND      285    287       {ECO:0000244|PDB:4UV7}.
FT   STRAND      290    294       {ECO:0000244|PDB:4UV7}.
FT   TURN        296    298       {ECO:0000244|PDB:3B2V}.
FT   STRAND      299    301       {ECO:0000244|PDB:4KRO}.
FT   STRAND      303    305       {ECO:0000244|PDB:4KRP}.
FT   STRAND      306    310       {ECO:0000244|PDB:4UV7}.
FT   STRAND      313    315       {ECO:0000244|PDB:3B2V}.
FT   STRAND      318    320       {ECO:0000244|PDB:3G5Y}.
FT   STRAND      323    325       {ECO:0000244|PDB:3G5Y}.
FT   STRAND      330    332       {ECO:0000244|PDB:4UV7}.
FT   STRAND      336    338       {ECO:0000244|PDB:3P0Y}.
FT   TURN        340    342       {ECO:0000244|PDB:3QWQ}.
FT   HELIX       343    345       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      349    351       {ECO:0000244|PDB:3P0Y}.
FT   TURN        353    355       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       356    359       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      363    367       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      369    371       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       373    377       {ECO:0000244|PDB:3P0Y}.
FT   TURN        380    383       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       389    397       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      400    403       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      405    407       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       418    420       {ECO:0000244|PDB:3P0Y}.
FT   TURN        433    435       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      436    442       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      458    464       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       472    474       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       477    480       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      481    483       {ECO:0000244|PDB:1YY9}.
FT   STRAND      488    494       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       496    501       {ECO:0000244|PDB:3P0Y}.
FT   TURN        507    509       {ECO:0000244|PDB:1IVO}.
FT   STRAND      515    519       {ECO:0000244|PDB:3P0Y}.
FT   HELIX       520    522       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      523    526       {ECO:0000244|PDB:3P0Y}.
FT   STRAND      531    533       {ECO:0000244|PDB:4KRL}.
FT   STRAND      535    537       {ECO:0000244|PDB:1YY9}.
FT   STRAND      540    546       {ECO:0000244|PDB:4UV7}.
FT   STRAND      548    551       {ECO:0000244|PDB:4UV7}.
FT   STRAND      554    557       {ECO:0000244|PDB:4UV7}.
FT   STRAND      560    562       {ECO:0000244|PDB:4KRO}.
FT   STRAND      566    568       {ECO:0000244|PDB:1YY9}.
FT   STRAND      570    575       {ECO:0000244|PDB:4UV7}.
FT   STRAND      578    587       {ECO:0000244|PDB:4UV7}.
FT   STRAND      590    594       {ECO:0000244|PDB:4UV7}.
FT   STRAND      597    602       {ECO:0000244|PDB:4UV7}.
FT   STRAND      606    611       {ECO:0000244|PDB:4UV7}.
FT   STRAND      615    619       {ECO:0000244|PDB:4UV7}.
FT   STRAND      629    632       {ECO:0000244|PDB:4UV7}.
FT   HELIX       633    635       {ECO:0000244|PDB:4UV7}.
FT   STRAND      643    646       {ECO:0000244|PDB:2KS1}.
FT   HELIX       648    669       {ECO:0000244|PDB:2KS1}.
FT   STRAND      671    673       {ECO:0000244|PDB:1Z9I}.
FT   HELIX       679    684       {ECO:0000244|PDB:3GOP}.
FT   HELIX       685    687       {ECO:0000244|PDB:3GOP}.
FT   STRAND      688    692       {ECO:0000244|PDB:1Z9I}.
FT   STRAND      694    697       {ECO:0000244|PDB:1Z9I}.
FT   STRAND      703    706       {ECO:0000244|PDB:3POZ}.
FT   HELIX       709    711       {ECO:0000244|PDB:3POZ}.
FT   STRAND      712    721       {ECO:0000244|PDB:3POZ}.
FT   STRAND      724    731       {ECO:0000244|PDB:3POZ}.
FT   TURN        734    736       {ECO:0000244|PDB:3W33}.
FT   STRAND      740    746       {ECO:0000244|PDB:3POZ}.
FT   STRAND      748    750       {ECO:0000244|PDB:2ITU}.
FT   TURN        753    755       {ECO:0000244|PDB:3W2S}.
FT   HELIX       756    768       {ECO:0000244|PDB:3POZ}.
FT   STRAND      772    774       {ECO:0000244|PDB:4I21}.
FT   STRAND      777    791       {ECO:0000244|PDB:3POZ}.
FT   STRAND      794    797       {ECO:0000244|PDB:4G5P}.
FT   HELIX       798    804       {ECO:0000244|PDB:3POZ}.
FT   TURN        805    808       {ECO:0000244|PDB:5CNO}.
FT   HELIX       811    830       {ECO:0000244|PDB:3POZ}.
FT   HELIX       840    842       {ECO:0000244|PDB:3POZ}.
FT   STRAND      843    847       {ECO:0000244|PDB:3POZ}.
FT   STRAND      850    853       {ECO:0000244|PDB:3POZ}.
FT   HELIX       858    862       {ECO:0000244|PDB:3POZ}.
FT   TURN        863    865       {ECO:0000244|PDB:3POZ}.
FT   HELIX       867    871       {ECO:0000244|PDB:3W32}.
FT   STRAND      873    876       {ECO:0000244|PDB:5CZI}.
FT   HELIX       878    880       {ECO:0000244|PDB:3POZ}.
FT   HELIX       883    888       {ECO:0000244|PDB:3POZ}.
FT   HELIX       893    908       {ECO:0000244|PDB:3POZ}.
FT   TURN        909    911       {ECO:0000244|PDB:2GS7}.
FT   TURN        914    917       {ECO:0000244|PDB:3POZ}.
FT   HELIX       920    922       {ECO:0000244|PDB:3POZ}.
FT   HELIX       923    928       {ECO:0000244|PDB:3POZ}.
FT   STRAND      937    939       {ECO:0000244|PDB:2JIV}.
FT   HELIX       941    950       {ECO:0000244|PDB:3POZ}.
FT   HELIX       955    957       {ECO:0000244|PDB:3POZ}.
FT   HELIX       961    972       {ECO:0000244|PDB:3POZ}.
FT   HELIX       975    978       {ECO:0000244|PDB:3POZ}.
FT   HELIX       984    986       {ECO:0000244|PDB:3POZ}.
FT   TURN        992    994       {ECO:0000244|PDB:3POZ}.
FT   HELIX       996   1002       {ECO:0000244|PDB:3POZ}.
FT   STRAND     1004   1010       {ECO:0000244|PDB:3W2S}.
FT   HELIX      1013   1016       {ECO:0000244|PDB:3POZ}.
FT   STRAND     1068   1070       {ECO:0000244|PDB:3PFV}.
SQ   SEQUENCE   1210 AA;  134277 MW;  D8A2A50B4EFB6ED2 CRC64;
     MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV
     VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA
     VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF
     QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC
     TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV
     VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK
     NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF
     ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL
     FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN
     LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM
     GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV
     ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS
     GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI
     CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA
     RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY
     GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK
     FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ
     QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED
     SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN
     TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV
     APQSSEFIGA
//
ID   SHH_MOUSE               Reviewed;         437 AA.
AC   Q62226;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 2.
DT   17-FEB-2016, entry version 174.
DE   RecName: Full=Sonic hedgehog protein;
DE            Short=SHH;
DE   AltName: Full=HHG-1;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein N-product;
DE     AltName: Full=Sonic hedgehog protein 19 kDa product;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein C-product;
DE     AltName: Full=Sonic hedgehog protein 27 kDa product;
DE   Flags: Precursor;
GN   Name=Shh; Synonyms=Hhg1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=7916661; DOI=10.1016/0092-8674(93)90627-3;
RA   Echelard Y., Epstein D.J., St Jacques B., Shen L., Mohler J.,
RA   McMahon J.A., McMahon A.P.;
RT   "Sonic hedgehog, a member of a family of putative signaling molecules,
RT   is implicated in the regulation of CNS polarity.";
RL   Cell 75:1417-1430(1993).
RN   [2]
RP   SEQUENCE REVISION TO 122.
RA   McMahon A.P.;
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEOLYTIC PROCESSING, AND AUTOCATALYTIC
RP   CLEAVAGE.
RX   PubMed=7720571;
RA   Chang D.T., Lopez A., von Kessler D.P., Chiang C., Simandl B.K.,
RA   Zhao R., Seldin M.F., Fallon J.F., Beachy P.A.;
RT   "Products, genetic linkage and limb patterning activity of a murine
RT   hedgehog gene.";
RL   Development 120:3339-3353(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Limb;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEOLYTIC PROCESSING, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=7891723;
RA   Bumcrot D.A., Takada R., McMahon A.P.;
RT   "Proteolytic processing yields two secreted forms of sonic hedgehog.";
RL   Mol. Cell. Biol. 15:2294-2303(1995).
RN   [7]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND AUTOCATALYTIC CLEAVAGE.
RX   PubMed=7736596; DOI=10.1016/0092-8674(95)90397-6;
RA   Roelink H., Porter J.A., Chiang C., Tanabe Y., Chang D.T.,
RA   Beachy P.A., Jessell T.M.;
RT   "Floor plate and motor neuron induction by different concentrations of
RT   the amino-terminal cleavage product of sonic hedgehog
RT   autoproteolysis.";
RL   Cell 81:445-455(1995).
RN   [8]
RP   CHOLESTERYLATION AT GLY-198.
RX   PubMed=8824192; DOI=10.1126/science.274.5285.255;
RA   Porter J.A., Young K.E., Beachy P.A.;
RT   "Cholesterol modification of hedgehog signaling proteins in animal
RT   development.";
RL   Science 274:255-259(1996).
RN   [9]
RP   PALMITOYLATION AT CYS-25, AND MUTAGENESIS OF CYS-25.
RX   PubMed=11486055; DOI=10.1126/science.1064437;
RA   Chamoun Z., Mann R.K., Nellen D., von Kessler D.P., Bellotto M.,
RA   Beachy P.A., Basler K.;
RT   "Skinny hedgehog, an acyltransferase required for palmitoylation and
RT   activity of the hedgehog signal.";
RL   Science 293:2080-2084(2001).
RN   [10]
RP   FUNCTION IN CEREBELLAR DEVELOPMENT.
RX   PubMed=14687547; DOI=10.1016/S0896-6273(03)00769-4;
RA   Gold D.A., Baek S.H., Schork N.J., Rose D.W., Larsen D.D., Sachs B.D.,
RA   Rosenfeld M.G., Hamilton B.A.;
RT   "RORalpha coordinates reciprocal signaling in cerebellar development
RT   through sonic hedgehog and calcium-dependent pathways.";
RL   Neuron 40:1119-1131(2003).
RN   [11]
RP   PALMITOYLATION AT CYS-25, MUTAGENESIS OF CYS-25, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15075292; DOI=10.1101/gad.1185804;
RA   Chen M.-H., Li Y.-J., Kawakami T., Xu S.-M., Chuang P.-T.;
RT   "Palmitoylation is required for the production of a soluble multimeric
RT   Hedgehog protein complex and long-range signaling in vertebrates.";
RL   Genes Dev. 18:641-659(2004).
RN   [12]
RP   MUTAGENESIS OF GLY-32; ASP-89; GLN-101; ASN-116; TRP-118 AND GLU-189.
RX   PubMed=16282375; DOI=10.1073/pnas.0507848102;
RA   Maity T., Fuse N., Beachy P.A.;
RT   "Molecular mechanisms of Sonic hedgehog mutant effects in
RT   holoprosencephaly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17026-17031(2005).
RN   [13]
RP   INTERACTION WITH HHATL.
RX   PubMed=18081866; DOI=10.1111/j.1742-4658.2007.06202.x;
RA   Abe Y., Kita Y., Niikura T.;
RT   "Mammalian Gup1, a homolog of Saccharomyces cerevisiae glycerol
RT   uptake/transporter 1, acts as a negative regulator for N-terminal
RT   palmitoylation of Sonic hedgehog.";
RL   FEBS J. 275:318-331(2008).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 34-195 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=7477329; DOI=10.1038/378212a0;
RA   Hall T.M.T., Porter J.A., Beachy P.A., Leahy D.J.;
RT   "A potential catalytic site revealed by the 1.7-A crystal structure of
RT   the amino-terminal signalling domain of Sonic hedgehog.";
RL   Nature 378:212-216(1995).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 26-189 IN COMPLEX WITH CDON;
RP   CALCIUM AND ZINC IONS, DOMAIN, AND INTERACTION WITH CDON.
RX   PubMed=18794898; DOI=10.1038/nature07358;
RA   McLellan J.S., Zheng X., Hauk G., Ghirlando R., Beachy P.A.,
RA   Leahy D.J.;
RT   "The mode of Hedgehog binding to Ihog homologues is not conserved
RT   across different phyla.";
RL   Nature 455:979-983(2008).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 40-191 IN COMPLEX WITH HHIP;
RP   CALCIUM AND ZINC IONS, DOMAIN, AND INTERACTION WITH HHIP.
RX   PubMed=19561611; DOI=10.1038/nsmb.1607;
RA   Bishop B., Aricescu A.R., Harlos K., O'Callaghan C.A., Jones E.Y.,
RA   Siebold C.;
RT   "Structural insights into hedgehog ligand sequestration by the human
RT   hedgehog-interacting protein HHIP.";
RL   Nat. Struct. Mol. Biol. 16:698-703(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 26-189 IN COMPLEX WITH
RP   CALCIUM AND ZINC IONS, DOMAIN, AND INTERACTION WITH BOC AND CDON.
RX   PubMed=20519495; DOI=10.1074/jbc.M110.131680;
RA   Kavran J.M., Ward M.D., Oladosu O.O., Mulepati S., Leahy D.J.;
RT   "All mammalian Hedgehog proteins interact with cell adhesion molecule,
RT   down-regulated by oncogenes (CDO) and brother of CDO (BOC) in a
RT   conserved manner.";
RL   J. Biol. Chem. 285:24584-24590(2010).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development: signal produced by the
CC       notochord that induces ventral cell fate in the neural tube and
CC       somites, and the polarizing signal for patterning of the anterior-
CC       posterior axis of the developing limb bud. Displays both floor
CC       plate- and motor neuron-inducing activity. The threshold
CC       concentration of N-product required for motor neuron induction is
CC       5-fold lower than that required for floor plate induction.
CC       Activates the transcription of target genes by interacting with
CC       its receptor PTCH1 to prevent normal inhibition by PTCH1 on the
CC       constitutive signaling activity of SMO.
CC       {ECO:0000269|PubMed:14687547, ECO:0000269|PubMed:7736596}.
CC   -!- SUBUNIT: Interacts with HHATL/GUP1 which negatively regulates
CC       HHAT-mediated palmitoylation of the SHH N-terminus. N-product is
CC       active as a multimer. Interacts with BOC and CDON. Interacts with
CC       HHIP. {ECO:0000269|PubMed:15075292, ECO:0000269|PubMed:18081866,
CC       ECO:0000269|PubMed:18794898, ECO:0000269|PubMed:19561611,
CC       ECO:0000269|PubMed:20519495, ECO:0000269|PubMed:7477329}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein C-product: Secreted,
CC       extracellular space {ECO:0000269|PubMed:7891723}. Note=The C-
CC       terminal peptide diffuses from the cell (PubMed:7891723).
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein N-product: Cell
CC       membrane {ECO:0000269|PubMed:7891723}; Lipid-anchor
CC       {ECO:0000269|PubMed:7891723}. Note=The N-product either remains
CC       associated with lipid rafts at the cell surface, or forms freely
CC       diffusible active multimers with its hydrophobic lipid-modified N-
CC       and C-termini buried inside (PubMed:7891723).
CC   -!- TISSUE SPECIFICITY: Expressed in a number of embryonic tissues
CC       including the notochord, ventral neural tube, floor plate, lung
CC       bud, zone of polarizing activity and posterior distal mesenchyme
CC       of limbs. In the adult, expressed in lung and neural retina.
CC   -!- DEVELOPMENTAL STAGE: First detectable during gastrulation.
CC   -!- INDUCTION: By retinoic acid.
CC   -!- DOMAIN: The sonic hedgehog protein N-product binds calcium and
CC       zinc ions; this stabilizes the protein fold and is essential for
CC       protein-protein interactions mediated by this domain.
CC       {ECO:0000269|PubMed:18794898, ECO:0000269|PubMed:19561611,
CC       ECO:0000269|PubMed:20519495}.
CC   -!- PTM: The C-terminal domain displays an autoproteolysis activity
CC       and a cholesterol transferase activity. Both activities result in
CC       the cleavage of the full-length protein and covalent attachment of
CC       a cholesterol moiety to the C-terminal of the newly generated N-
CC       terminal fragment (N-product). The N-product is the active species
CC       in both local and long-range signaling, whereas the C-product has
CC       no signaling activity. {ECO:0000269|PubMed:7720571,
CC       ECO:0000269|PubMed:7736596, ECO:0000269|PubMed:7891723}.
CC   -!- PTM: Cholesterylation is required for N-product targeting to lipid
CC       rafts and multimerization. {ECO:0000269|PubMed:8824192}.
CC   -!- PTM: N-palmitoylation of Cys-25 by HHAT is required for N-product
CC       multimerization and full activity. {ECO:0000269|PubMed:11486055,
CC       ECO:0000269|PubMed:15075292}.
CC   -!- MISCELLANEOUS: Mice overexpressing Shh display digit duplications
CC       in both forelimbs and hindlimbs.
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X76290; CAA53922.1; -; mRNA.
DR   EMBL; AK077688; BAC36956.1; -; mRNA.
DR   EMBL; BC063087; AAH63087.1; -; mRNA.
DR   CCDS; CCDS19146.1; -.
DR   PIR; A49425; A49425.
DR   RefSeq; NP_033196.1; NM_009170.3.
DR   UniGene; Mm.57202; -.
DR   PDB; 1VHH; X-ray; 1.70 A; A=34-195.
DR   PDB; 2WFX; X-ray; 3.20 A; A=40-191.
DR   PDB; 2WG4; X-ray; 3.15 A; A=40-191.
DR   PDB; 3D1M; X-ray; 1.70 A; A/B=26-189.
DR   PDB; 3N1R; X-ray; 2.13 A; A=40-195.
DR   PDB; 4C4M; X-ray; 1.74 A; A=40-195.
DR   PDB; 4C4N; X-ray; 2.36 A; A/B=40-195.
DR   PDBsum; 1VHH; -.
DR   PDBsum; 2WFX; -.
DR   PDBsum; 2WG4; -.
DR   PDBsum; 3D1M; -.
DR   PDBsum; 3N1R; -.
DR   PDBsum; 4C4M; -.
DR   PDBsum; 4C4N; -.
DR   ProteinModelPortal; Q62226; -.
DR   SMR; Q62226; 39-195, 199-351.
DR   BioGrid; 203220; 10.
DR   DIP; DIP-48537N; -.
DR   STRING; 10090.ENSMUSP00000002708; -.
DR   BindingDB; Q62226; -.
DR   ChEMBL; CHEMBL5387; -.
DR   MEROPS; C46.002; -.
DR   PhosphoSite; Q62226; -.
DR   SwissPalm; Q62226; -.
DR   MaxQB; Q62226; -.
DR   PaxDb; Q62226; -.
DR   PRIDE; Q62226; -.
DR   Ensembl; ENSMUST00000002708; ENSMUSP00000002708; ENSMUSG00000002633.
DR   GeneID; 20423; -.
DR   KEGG; mmu:20423; -.
DR   UCSC; uc008wua.2; mouse.
DR   CTD; 6469; -.
DR   MGI; MGI:98297; Shh.
DR   eggNOG; KOG3638; Eukaryota.
DR   eggNOG; ENOG410XQA3; LUCA.
DR   GeneTree; ENSGT00390000001117; -.
DR   HOGENOM; HOG000233428; -.
DR   HOVERGEN; HBG005480; -.
DR   InParanoid; Q62226; -.
DR   KO; K11988; -.
DR   OMA; EHSWAHR; -.
DR   OrthoDB; EOG779NZ5; -.
DR   PhylomeDB; Q62226; -.
DR   TreeFam; TF106458; -.
DR   Reactome; R-MMU-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-MMU-5362798; Release of Hh-Np from the secreting cell.
DR   Reactome; R-MMU-5632681; Ligand-receptor interactions.
DR   EvolutionaryTrace; Q62226; -.
DR   NextBio; 298432; -.
DR   PRO; PR:Q62226; -.
DR   Proteomes; UP000000589; Chromosome 5.
DR   Bgee; Q62226; -.
DR   CleanEx; MM_SHH; -.
DR   Genevisible; Q62226; MM.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0045121; C:membrane raft; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IDA:MGI.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:MGI.
DR   GO; GO:0043237; F:laminin-1 binding; IDA:MGI.
DR   GO; GO:0005113; F:patched binding; IPI:Roslin.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0048856; P:anatomical structure development; IMP:MGI.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IMP:MGI.
DR   GO; GO:0008209; P:androgen metabolic process; IMP:MGI.
DR   GO; GO:0001525; P:angiogenesis; IDA:MGI.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:Roslin.
DR   GO; GO:0060840; P:artery development; IMP:MGI.
DR   GO; GO:0007411; P:axon guidance; IDA:MGI.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IDA:MGI.
DR   GO; GO:0007596; P:blood coagulation; IMP:MGI.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; IDA:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IMP:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:MGI.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; IMP:MGI.
DR   GO; GO:0043010; P:camera-type eye development; IDA:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IMP:BHF-UCL.
DR   GO; GO:0048468; P:cell development; IMP:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IGI:MGI.
DR   GO; GO:0001708; P:cell fate specification; IDA:MGI.
DR   GO; GO:0008283; P:cell proliferation; IGI:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; IMP:MGI.
DR   GO; GO:0071285; P:cellular response to lithium ion; IDA:MGI.
DR   GO; GO:0007417; P:central nervous system development; IMP:MGI.
DR   GO; GO:0021930; P:cerebellar granule cell precursor proliferation; IDA:UniProtKB.
DR   GO; GO:0003140; P:determination of left/right asymmetry in lateral mesoderm; IMP:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0048589; P:developmental growth; IMP:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IMP:BHF-UCL.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IGI:MGI.
DR   GO; GO:0007398; P:ectoderm development; IMP:MGI.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:Roslin.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IMP:MGI.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:MGI.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IMP:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IMP:MGI.
DR   GO; GO:0048598; P:embryonic morphogenesis; IMP:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IMP:MGI.
DR   GO; GO:0048706; P:embryonic skeletal system development; IGI:MGI.
DR   GO; GO:0006897; P:endocytosis; IDA:MGI.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IMP:MGI.
DR   GO; GO:0060684; P:epithelial-mesenchymal cell signaling; IMP:MGI.
DR   GO; GO:0060738; P:epithelial-mesenchymal signaling involved in prostate gland development; IGI:MGI.
DR   GO; GO:0030010; P:establishment of cell polarity; IDA:MGI.
DR   GO; GO:0030900; P:forebrain development; IGI:MGI.
DR   GO; GO:0048859; P:formation of anatomical boundary; IMP:MGI.
DR   GO; GO:0001942; P:hair follicle development; IMP:MGI.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IMP:BHF-UCL.
DR   GO; GO:0030902; P:hindbrain development; IMP:MGI.
DR   GO; GO:0007442; P:hindgut morphogenesis; IMP:MGI.
DR   GO; GO:0048839; P:inner ear development; IMP:MGI.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0045109; P:intermediate filament organization; IMP:MGI.
DR   GO; GO:0001822; P:kidney development; IMP:MGI.
DR   GO; GO:0060459; P:left lung development; IMP:MGI.
DR   GO; GO:0060174; P:limb bud formation; IMP:MGI.
DR   GO; GO:0060173; P:limb development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060428; P:lung epithelium development; IMP:MGI.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IMP:MGI.
DR   GO; GO:0060425; P:lung morphogenesis; IMP:MGI.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IMP:MGI.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0030539; P:male genitalia development; IMP:MGI.
DR   GO; GO:0010463; P:mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IDA:MGI.
DR   GO; GO:0060783; P:mesenchymal smoothened signaling pathway involved in prostate gland development; IMP:MGI.
DR   GO; GO:0072136; P:metanephric mesenchymal cell proliferation involved in metanephros development; IMP:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IMP:UniProtKB.
DR   GO; GO:0030901; P:midbrain development; IGI:MGI.
DR   GO; GO:0080125; P:multicellular structure septum development; IMP:MGI.
DR   GO; GO:0045445; P:myoblast differentiation; IDA:MGI.
DR   GO; GO:0014902; P:myotube differentiation; IMP:MGI.
DR   GO; GO:0046639; P:negative regulation of alpha-beta T cell differentiation; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:Roslin.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:MGI.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; IMP:BHF-UCL.
DR   GO; GO:1904339; P:negative regulation of dopaminergic neuron differentiation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:2000357; P:negative regulation of kidney smooth muscle cell differentiation; IDA:UniProtKB.
DR   GO; GO:2001054; P:negative regulation of mesenchymal cell apoptotic process; IMP:MGI.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:MGI.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:MGI.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IMP:MGI.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:2000062; P:negative regulation of ureter smooth muscle cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0045060; P:negative thymic T cell selection; IMP:BHF-UCL.
DR   GO; GO:0001755; P:neural crest cell migration; IMP:MGI.
DR   GO; GO:0007405; P:neuroblast proliferation; IDA:MGI.
DR   GO; GO:0048663; P:neuron fate commitment; IMP:MGI.
DR   GO; GO:0042476; P:odontogenesis; IDA:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0014003; P:oligodendrocyte development; IDA:MGI.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IGI:MGI.
DR   GO; GO:0048645; P:organ formation; IMP:MGI.
DR   GO; GO:0002076; P:osteoblast development; IDA:MGI.
DR   GO; GO:0060021; P:palate development; IMP:MGI.
DR   GO; GO:0031016; P:pancreas development; IMP:MGI.
DR   GO; GO:0007389; P:pattern specification process; IMP:MGI.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:MGI.
DR   GO; GO:0009949; P:polarity specification of anterior/posterior axis; IMP:Roslin.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0051781; P:positive regulation of cell division; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0021940; P:positive regulation of cerebellar granule cell precursor proliferation; IDA:MGI.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; IMP:BHF-UCL.
DR   GO; GO:2000358; P:positive regulation of kidney smooth muscle cell differentiation; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:2000729; P:positive regulation of mesenchymal cell proliferation involved in ureter development; IMP:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IDA:MGI.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IDA:MGI.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IGI:MGI.
DR   GO; GO:0061189; P:positive regulation of sclerotome development; ISO:MGI.
DR   GO; GO:0014858; P:positive regulation of skeletal muscle cell proliferation; IMP:MGI.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IMP:MGI.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051155; P:positive regulation of striated muscle cell differentiation; IMP:MGI.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:2000063; P:positive regulation of ureter smooth muscle cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0045059; P:positive thymic T cell selection; IMP:BHF-UCL.
DR   GO; GO:0060516; P:primary prostatic bud elongation; IDA:MGI.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IDA:MGI.
DR   GO; GO:0030850; P:prostate gland development; IMP:MGI.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0060782; P:regulation of mesenchymal cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0042481; P:regulation of odontogenesis; IMP:BHF-UCL.
DR   GO; GO:0060685; P:regulation of prostatic bud formation; IDA:MGI.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; ISO:MGI.
DR   GO; GO:0030162; P:regulation of proteolysis; IDA:MGI.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:MGI.
DR   GO; GO:0030323; P:respiratory tube development; IMP:MGI.
DR   GO; GO:0060458; P:right lung development; IMP:MGI.
DR   GO; GO:0060662; P:salivary gland cavitation; IDA:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:MGI.
DR   GO; GO:0043588; P:skin development; IMP:MGI.
DR   GO; GO:0007224; P:smoothened signaling pathway; IDA:MGI.
DR   GO; GO:0021938; P:smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation; IDA:MGI.
DR   GO; GO:0061053; P:somite development; IMP:BHF-UCL.
DR   GO; GO:0021513; P:spinal cord dorsal/ventral patterning; IMP:MGI.
DR   GO; GO:0021522; P:spinal cord motor neuron differentiation; IGI:MGI.
DR   GO; GO:0048864; P:stem cell development; IMP:BHF-UCL.
DR   GO; GO:0051146; P:striated muscle cell differentiation; IDA:MGI.
DR   GO; GO:0014706; P:striated muscle tissue development; IMP:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IMP:BHF-UCL.
DR   GO; GO:0021978; P:telencephalon regionalization; IMP:MGI.
DR   GO; GO:0021794; P:thalamus development; IMP:MGI.
DR   GO; GO:0048538; P:thymus development; IMP:BHF-UCL.
DR   GO; GO:0030878; P:thyroid gland development; IMP:MGI.
DR   GO; GO:0060438; P:trachea development; IMP:MGI.
DR   GO; GO:0060439; P:trachea morphogenesis; IMP:MGI.
DR   GO; GO:0001944; P:vasculature development; IMP:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IDA:MGI.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; TAS:DFLAT.
DR   GO; GO:0021521; P:ventral spinal cord interneuron specification; ISO:MGI.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Cell membrane;
KW   Complete proteome; Developmental protein; Glycoprotein; Hydrolase;
KW   Lipoprotein; Membrane; Metal-binding; Palmitate; Protease;
KW   Reference proteome; Secreted; Signal; Zinc.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    437       Sonic hedgehog protein.
FT                                /FTId=PRO_0000013211.
FT   CHAIN        25    198       Sonic hedgehog protein N-product.
FT                                /FTId=PRO_0000013212.
FT   CHAIN       199    437       Sonic hedgehog protein C-product.
FT                                /FTId=PRO_0000013213.
FT   COMPBIAS    383    387       Poly-Gly.
FT   METAL        90     90       Calcium 1. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL        91     91       Calcium 1. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL        91     91       Calcium 2. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL        96     96       Calcium 1. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       126    126       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       127    127       Calcium 1. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       127    127       Calcium 2. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       130    130       Calcium 2. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       132    132       Calcium 2. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495}.
FT   METAL       141    141       Zinc. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495,
FT                                ECO:0000269|PubMed:7477329}.
FT   METAL       148    148       Zinc. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495,
FT                                ECO:0000269|PubMed:7477329}.
FT   METAL       183    183       Zinc. {ECO:0000269|PubMed:18794898,
FT                                ECO:0000269|PubMed:19561611,
FT                                ECO:0000269|PubMed:20519495,
FT                                ECO:0000269|PubMed:7477329}.
FT   SITE        198    199       Cleavage; by autolysis. {ECO:0000250}.
FT   SITE        244    244       Involved in cholesterol transfer.
FT                                {ECO:0000250}.
FT   SITE        268    268       Involved in auto-cleavage. {ECO:0000250}.
FT   SITE        271    271       Essential for auto-cleavage.
FT                                {ECO:0000250}.
FT   LIPID        25     25       N-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:11486055,
FT                                ECO:0000269|PubMed:15075292}.
FT   LIPID       198    198       Cholesterol glycine ester.
FT                                {ECO:0000269|PubMed:8824192}.
FT   CARBOHYD    279    279       N-linked (GlcNAc...). {ECO:0000255}.
FT   MUTAGEN      25     25       C->S: Strongly reduces effects of in vivo
FT                                overexpression; impairs multimer
FT                                formation; does not affect subcellular
FT                                location to lipid rafts. Homozygous mice
FT                                are characterized by a smaller size and
FT                                holoprosencephaly at E10.5, and
FT                                shortening of limbs at E13.5. They die
FT                                soon after birth.
FT                                {ECO:0000269|PubMed:11486055,
FT                                ECO:0000269|PubMed:15075292}.
FT   MUTAGEN      32     32       G->R: Introduces a cleavage site for a
FT                                furin-like protease resulting in abnormal
FT                                protein processing; cleavage at this site
FT                                removes 11 amino acids from the N-
FT                                terminal domain and reduces affinity of
FT                                Shh for Ptch1 and signaling potency in
FT                                assays using chicken embryo neural plate
FT                                explants and mouse C3H10T1/2 stem cells.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN      89     89       D->V: Moderately reduces Ptch1 binding in
FT                                vitro and signaling potency in chicken
FT                                embryo neural plate explant assays
FT                                compared with wild-type sequence.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN     101    101       Q->H: Does not affect signaling activity
FT                                in any of Shh signaling assays and causes
FT                                no apparent defects in cholesterol-
FT                                mediated autoprocessing reactions.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN     116    116       N->K: Shows no change in activities at
FT                                different temperatures.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN     118    118       W->G: Causes a failure of Shh processing
FT                                leading to retention of the immature
FT                                glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; drastically
FT                                reduces signaling potency in chicken
FT                                embryo neural plate explant assays.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN     118    118       W->R: Causes a failure of Shh processing
FT                                leading to retention of the immature
FT                                glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; drastically
FT                                reduces signaling potency in chicken
FT                                embryo neural plate explant assays.
FT                                {ECO:0000269|PubMed:16282375}.
FT   MUTAGEN     189    189       E->Q: Does not affect signaling activity
FT                                in any of Shh signaling assays and causes
FT                                no apparent defects in cholesterol-
FT                                mediated autoprocessing reactions.
FT                                {ECO:0000269|PubMed:16282375}.
FT   STRAND       48     52       {ECO:0000244|PDB:1VHH}.
FT   TURN         57     60       {ECO:0000244|PDB:1VHH}.
FT   STRAND       69     71       {ECO:0000244|PDB:3N1R}.
FT   HELIX        72     76       {ECO:0000244|PDB:1VHH}.
FT   STRAND       85     87       {ECO:0000244|PDB:1VHH}.
FT   STRAND       92     94       {ECO:0000244|PDB:1VHH}.
FT   HELIX        95     97       {ECO:0000244|PDB:1VHH}.
FT   HELIX       101    117       {ECO:0000244|PDB:1VHH}.
FT   STRAND      123    127       {ECO:0000244|PDB:1VHH}.
FT   STRAND      131    135       {ECO:0000244|PDB:2WG4}.
FT   HELIX       140    143       {ECO:0000244|PDB:1VHH}.
FT   STRAND      146    151       {ECO:0000244|PDB:1VHH}.
FT   HELIX       156    158       {ECO:0000244|PDB:1VHH}.
FT   HELIX       159    168       {ECO:0000244|PDB:1VHH}.
FT   STRAND      172    178       {ECO:0000244|PDB:1VHH}.
FT   STRAND      181    185       {ECO:0000244|PDB:1VHH}.
FT   HELIX       189    192       {ECO:0000244|PDB:1VHH}.
SQ   SEQUENCE   437 AA;  47773 MW;  D0EB72F08E7860EF CRC64;
     MLLLLARCFL VILASSLLVC PGLACGPGRG FGKRRHPKKL TPLAYKQFIP NVAEKTLGAS
     GRYEGKITRN SERFKELTPN YNPDIIFKDE ENTGADRLMT QRCKDKLNAL AISVMNQWPG
     VKLRVTEGWD EDGHHSEESL HYEGRAVDIT TSDRDRSKYG MLARLAVEAG FDWVYYESKA
     HIHCSVKAEN SVAAKSGGCF PGSATVHLEQ GGTKLVKDLR PGDRVLAADD QGRLLYSDFL
     TFLDRDEGAK KVFYVIETLE PRERLLLTAA HLLFVAPHND SGPTPGPSAL FASRVRPGQR
     VYVVAERGGD RRLLPAAVHS VTLREEEAGA YAPLTAHGTI LINRVLASCY AVIEEHSWAH
     RAFAPFRLAH ALLAALAPAR TDGGGGGSIP AAQSATEARG AEPTAGIHWY SQLLYHIGTW
     LLDSETMHPL GMAVKSS
//
ID   NOTC1_MOUSE             Reviewed;        2531 AA.
AC   Q01705; Q06007; Q3TZW2; Q3U3Y2; Q61905; Q7TQ50; Q7TQ51; Q7TQ52;
AC   Q8K428; Q99JC2; Q9QW58; Q9R0X7;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   18-APR-2012, sequence version 3.
DT   20-JAN-2016, entry version 181.
DE   RecName: Full=Neurogenic locus notch homolog protein 1;
DE            Short=Notch 1;
DE   AltName: Full=Motch A;
DE   AltName: Full=mT14;
DE   AltName: Full=p300;
DE   Contains:
DE     RecName: Full=Notch 1 extracellular truncation;
DE              Short=NEXT;
DE   Contains:
DE     RecName: Full=Notch 1 intracellular domain;
DE              Short=NICD;
DE   Flags: Precursor;
GN   Name=Notch1; Synonyms=Motch;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=8449489; DOI=10.1006/geno.1993.1055;
RA   Franco del Amo F., Gendron-Maguire M., Swiatek P.J., Jenkins N.A.,
RA   Copeland N.G., Gridley T.;
RT   "Cloning, analysis, and chromosomal localization of Notch-1, a mouse
RT   homolog of Drosophila Notch.";
RL   Genomics 15:259-264(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=BALB/cJ; TISSUE=Thymus;
RX   PubMed=7956822;
RA   Nye J.S., Kopan R., Axel R.;
RT   "An activated Notch suppresses neurogenesis and myogenesis but not
RT   gliogenesis in mammalian cells.";
RL   Development 120:2421-2430(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=BALB/cJ; TISSUE=Thymus;
RX   PubMed=12123574; DOI=10.1016/S0960-9822(02)00888-6;
RA   Foltz D.R., Santiago M.C., Berechid B.E., Nye J.S.;
RT   "Glycogen synthase kinase-3beta modulates notch signaling and
RT   stability.";
RL   Curr. Biol. 12:1006-1011(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=CB-17/SCID; TISSUE=Thymus;
RX   PubMed=12807718; DOI=10.1093/carcin/bgg071;
RA   Tsuji H., Ishii-Ohba H., Ukai H., Katsube T., Ogiu T.;
RT   "Radiation-induced deletions in the 5' end region of Notch1 lead to
RT   the formation of truncated proteins and are involved in the
RT   development of mouse thymic lymphomas.";
RL   Carcinogenesis 24:1257-1268(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 731-1899 (ISOFORM 2), AND DEVELOPMENTAL
RP   STAGE.
RC   STRAIN=CD-1; TISSUE=Embryo;
RX   PubMed=1426644; DOI=10.1016/0012-1606(92)90076-S;
RA   Reaume A.G., Conlon R.A., Zirngibl R., Yamaguchi T.P., Rossant J.;
RT   "Expression analysis of a Notch homologue in the mouse embryo.";
RL   Dev. Biol. 154:377-387(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1161-1547.
RC   STRAIN=C57BL/6 X CBA; TISSUE=Embryo;
RX   PubMed=8440332; DOI=10.1006/excr.1993.1044;
RA   Lardelli M., Lendahl U.;
RT   "Motch A and Motch B-two mouse Notch homologues coexpressed in a wide
RT   variety of tissues.";
RL   Exp. Cell Res. 204:364-372(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1373-2531.
RC   STRAIN=NOD;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1551-1647 (ISOFORM 1), AND DEVELOPMENTAL
RP   STAGE.
RC   TISSUE=Embryo;
RX   PubMed=1425352;
RA   Franco del Amo F., Smith D.E., Swiatek P.J., Gendron-Maguire M.,
RA   Greenspan R.J., McMahon A.P., Gridley T.;
RT   "Expression pattern of Motch, a mouse homolog of Drosophila Notch,
RT   suggests an important role in early postimplantation mouse
RT   development.";
RL   Development 115:737-744(1992).
RN   [12]
RP   PROTEIN SEQUENCE OF 1655-1659, CLEAVAGE BY FURIN-LIKE CONVERTASE, AND
RP   MUTAGENESIS OF 1651-ARG--ARG-1654.
RX   PubMed=9653148; DOI=10.1073/pnas.95.14.8108;
RA   Logeat F., Bessia C., Brou C., LeBail O., Jarriault S., Seidah N.G.,
RA   Israel A.;
RT   "The Notch1 receptor is cleaved constitutively by a furin-like
RT   convertase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8108-8112(1998).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1659-1673.
RX   PubMed=10437788; DOI=10.1016/S0014-5793(99)00901-1;
RA   Lee J.S., Ishimoto A., Yanagawa S.;
RT   "Murine leukemia provirus-mediated activation of the Notch1 gene leads
RT   to induction of HES-1 in a mouse T lymphoma cell line, DL-3.";
RL   FEBS Lett. 455:276-280(1999).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1865-2076, AND DEVELOPMENTAL STAGE IN
RP   HAIR FOLLICLES.
RX   PubMed=8486742; DOI=10.1083/jcb.121.3.631;
RA   Kopan R., Weintraub H.;
RT   "Mouse notch: expression in hair follicles correlates with cell fate
RT   determination.";
RL   J. Cell Biol. 121:631-641(1993).
RN   [15]
RP   PROTEIN SEQUENCE OF 1937-1952 AND 1995-2019, FUNCTION, INTERACTION
RP   WITH HIF1AN, HYDROXYLATION AT ASN-1945 AND ASN-2012 BY HIF1AN,
RP   MUTAGENESIS OF ASN-1945 AND ASN-2012, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J.,
RA   Peet D.J., Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode
RT   of cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1951-2201.
RX   PubMed=9384671;
RA   Messerle M., Follo M., Nehls M., Eggert H., Boehm T.;
RT   "Dynamic changes in gene expression during in vitro differentiation of
RT   mouse embryonic stem cells.";
RL   Cytokines Cell. Mol. Ther. 1:139-143(1995).
RN   [17]
RP   PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC PROCESSING.
RX   PubMed=11518718; DOI=10.1074/jbc.M107234200;
RA   Saxena M.T., Schroeter E.H., Mumm J.S., Kopan R.;
RT   "Murine notch homologs (N1-4) undergo presenilin-dependent
RT   proteolysis.";
RL   J. Biol. Chem. 276:40268-40273(2001).
RN   [18]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=11459941; DOI=10.1073/pnas.161269998;
RA   Mizutani T., Taniguchi Y., Aoki T., Hashimoto N., Honjo T.;
RT   "Conservation of the biochemical mechanisms of signal transduction
RT   among mammalian Notch family members.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9026-9031(2001).
RN   [19]
RP   INTERACTION WITH DTX1 AND DTX2.
RX   PubMed=11226752; DOI=10.1016/S0736-5748(00)00071-X;
RA   Kishi N., Tang Z., Maeda Y., Hirai A., Mo R., Ito M., Suzuki S.,
RA   Nakao K., Kinoshita T., Kadesch T., Hui C.-C., Artavanis-Tsakonas S.,
RA   Okano H., Matsuno K.;
RT   "Murine homologs of deltex define a novel gene family involved in
RT   vertebrate Notch signaling and neurogenesis.";
RL   Int. J. Dev. Neurosci. 19:21-35(2001).
RN   [20]
RP   INTERACTION WITH NOV.
RX   PubMed=12050162; DOI=10.1074/jbc.M203727200;
RA   Sakamoto K., Yamaguchi S., Ando R., Miyawaki A., Kabasawa Y.,
RA   Takagi M., Li C.L., Perbal B., Katsube K.;
RT   "The nephroblastoma overexpressed gene (NOV/ccn3) protein associates
RT   with Notch1 extracellular domain and inhibits myoblast differentiation
RT   via Notch signaling pathway.";
RL   J. Biol. Chem. 277:29399-29405(2002).
RN   [21]
RP   INTERACTION WITH MAML1.
RX   PubMed=15019995; DOI=10.1016/j.gene.2003.12.007;
RA   Wu L., Kobayashi K., Sun T., Gao P., Liu J., Nakamura M., Weisberg E.,
RA   Mukhopadhyay N.K., Griffin J.D.;
RT   "Cloning and functional characterization of the murine mastermind-like
RT   1 (Maml1) gene.";
RL   Gene 328:153-165(2004).
RN   [22]
RP   UBIQUITINATION AT LYS-1749, AND ENDOCYTOSIS.
RX   PubMed=15240571; DOI=10.1083/jcb.200310098;
RA   Gupta-Rossi N., Six E., LeBail O., Logeat F., Chastagner P., Olry A.,
RA   Israel A., Brou C.;
RT   "Monoubiquitination and endocytosis direct gamma-secretase cleavage of
RT   activated Notch receptor.";
RL   J. Cell Biol. 166:73-83(2004).
RN   [23]
RP   INTERACTION WITH DNER, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15965470; DOI=10.1038/nn1492;
RA   Eiraku M., Tohgo A., Ono K., Kaneko M., Fujishima K., Hirano T.,
RA   Kengaku M.;
RT   "DNER acts as a neuron-specific Notch ligand during Bergmann glial
RT   development.";
RL   Nat. Neurosci. 8:873-880(2005).
RN   [24]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=18628966; DOI=10.1371/journal.pone.0002735;
RA   Chastagner P., Israel A., Brou C.;
RT   "AIP4/Itch regulates Notch receptor degradation in the absence of
RT   ligand.";
RL   PLoS ONE 3:E2735-E2735(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1851, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pancreas;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [26]
RP   INTERACTION WITH AAK1.
RX   PubMed=21464124; DOI=10.1074/jbc.M110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [27]
RP   GLYCOSYLATION AT SER-65; THR-73; THR-116; SER-146; THR-194; SER-341;
RP   SER-378; SER-458; THR-466; SER-496; SER-534; SER-609; SER-647;
RP   SER-722; SER-759; THR-767; SER-797; THR-805; SER-951; SER-1027;
RP   THR-1035; SER-1065; SER-1189; THR-1197; SER-1273 AND THR-1362, AND
RP   MUTAGENESIS OF SER-65; SER-146; SER-341; SER-378; SER-458; SER-496;
RP   SER-534; SER-609; SER-647; SER-722; SER-759; SER-797; SER-951;
RP   SER-1027; SER-1065; SER-1189 AND SER-1273.
RX   PubMed=21757702; DOI=10.1074/jbc.M111.268243;
RA   Rana N.A., Nita-Lazar A., Takeuchi H., Kakuda S., Luther K.B.,
RA   Haltiwanger R.S.;
RT   "O-glucose trisaccharide is present at high but variable stoichiometry
RT   at multiple sites on mouse Notch1.";
RL   J. Biol. Chem. 286:31623-31637(2011).
RN   [28]
RP   FUNCTION AS NEUROGENESIS REPRESSOR, AND INTERACTION WITH BCL6.
RX   PubMed=23160044; DOI=10.1038/nn.3264;
RA   Tiberi L., van den Ameele J., Dimidschstein J., Piccirilli J.,
RA   Gall D., Herpoel A., Bilheu A., Bonnefont J., Iacovino M., Kyba M.,
RA   Bouschet T., Vanderhaeghen P.;
RT   "BCL6 controls neurogenesis through Sirt1-dependent epigenetic
RT   repression of selective Notch targets.";
RL   Nat. Neurosci. 15:1627-1635(2012).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH THBS4.
RX   PubMed=23615612; DOI=10.1038/nature12069;
RA   Benner E.J., Luciano D., Jo R., Abdi K., Paez-Gonzalez P., Sheng H.,
RA   Warner D.S., Liu C., Eroglu C., Kuo C.T.;
RT   "Protective astrogenesis from the SVZ niche after injury is controlled
RT   by Notch modulator Thbs4.";
RL   Nature 497:369-373(2013).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1971-2104.
RX   PubMed=15802643; DOI=10.1110/ps.041184105;
RA   Lubman O.Y., Kopan R., Waksman G., Korolev S.;
RT   "The crystal structure of a partial mouse Notch-1 ankyrin domain:
RT   repeats 4 through 7 preserve an ankyrin fold.";
RL   Protein Sci. 14:1274-1281(2005).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 1899-2106 IN COMPLEX WITH
RP   HIF1AN; IRON AND 2-OXOGLUTARATE, HYDROXYLATION AT ASN-1945 AND
RP   ASN-2012, MUTAGENESIS OF ASN-1945 AND ASN-2012, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs. Involved in angiogenesis; negatively regulates
CC       endothelial cell proliferation and migration and angiogenic
CC       sprouting. Involved in the maturation of both CD4+ and CD8+ cells
CC       in the thymus. Important for follicular differentiation and
CC       possibly cell fate selection within the follicle. During
CC       cerebellar development, functions as a receptor for neuronal DNER
CC       and is involved in the differentiation of Bergmann glia. Represses
CC       neuronal and myogenic differentiation. May play an essential role
CC       in postimplantation development, probably in some aspect of cell
CC       specification and/or differentiation. May be involved in mesoderm
CC       development, somite formation and neurogenesis. May enhance HIF1A
CC       function by sequestering HIF1AN away from HIF1A. Required for the
CC       THBS4 function in regulating protective astrogenesis from the
CC       subventricular zone (SVZ) niche after injury. Involved in
CC       determination of left/right symmetry by modulating the balance
CC       between motile and immotile (sensory) cilia at the left-right
CC       organiser (LRO). {ECO:0000269|PubMed:15965470,
CC       ECO:0000269|PubMed:18299578, ECO:0000269|PubMed:23160044,
CC       ECO:0000269|PubMed:23615612}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds. Interacts with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also
CC       interacts with MAML1, MAML2 and MAML3 which act as transcriptional
CC       coactivators for NOTCH1. Notch 1 intracellular domain interacts
CC       with SNW1; the interaction involves multimerized NOTCH1 NICD and
CC       is implicated in a formation of an intermediate preactivation
CC       complex which associates with DNA-bound CBF-1/RBPJ. The activated
CC       membrane-bound form interacts with AAK1 which promotes NOTCH1
CC       stabilization. Forms a trimeric complex with FBXW7 and SGK1.
CC       Interacts with HIF1AN. HIF1AN negatively regulates the function of
CC       notch intracellular domain (NICD), accelerating myogenic
CC       differentiation. Interacts (via NICD) with SNAI1 (via zinc
CC       fingers); the interaction induces SNAI1 degradation via MDM2-
CC       mediated ubiquitination and inhibits SNAI1-induced cell invasion.
CC       Interacts (via NICD) with MDM2A. Interacts (via NICD) with BCL6;
CC       the interaction decreases MAML1 recruitment by NOTCH1 NICD on
CC       target genes DNA and inhibits NOTCH1 transcractivation activity.
CC       Interacts with THBS4. Interacts (via the EGF-like repeat region)
CC       with NOV (via CTCK domain) (PubMed:12050162).
CC       {ECO:0000269|PubMed:11226752, ECO:0000269|PubMed:12050162,
CC       ECO:0000269|PubMed:15019995, ECO:0000269|PubMed:15965470,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578,
CC       ECO:0000269|PubMed:21464124, ECO:0000269|PubMed:23160044,
CC       ECO:0000269|PubMed:23615612}.
CC   -!- INTERACTION:
CC       Q77CA8:LRORF2 (xeno); NbExp=3; IntAct=EBI-11292892, EBI-11292862;
CC       Q06330:RBPJ (xeno); NbExp=3; IntAct=EBI-1392707, EBI-632552;
CC       P31266:Rbpj; NbExp=6; IntAct=EBI-1392707, EBI-1392666;
CC       P28159:Su(H) (xeno); NbExp=3; IntAct=EBI-1392707, EBI-92180;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Notch 1 intracellular domain: Nucleus.
CC       Note=Following proteolytical processing NICD is translocated to
CC       the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q01705-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q01705-2; Sequence=VSP_001402, VSP_001403, VSP_001404;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q01705-3; Sequence=VSP_043064;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q01705-4; Sequence=VSP_043065;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the brain, lung and
CC       thymus. Expressed at lower levels in the spleen, bone-marrow,
CC       spinal cord, eyes, mammary gland, liver, intestine, skeletal
CC       muscle, kidney and heart. In the hair follicle, highly expressed
CC       exclusively in the epithelial compartment.
CC       {ECO:0000269|PubMed:15965470}.
CC   -!- DEVELOPMENTAL STAGE: First detected in the mesoderm at 7.5 dpc By
CC       8.5 dpc highly expressed in presomitic mesoderm, mesenchyme and
CC       endothelial cells, while much lower levels are seen in the
CC       neuroepithelium. Between 9.5-10.5 dpc expressed at high levels in
CC       the neuroepithelium. At 13.5 dpc expressed in the surface
CC       ectoderm, eye and developing whisker follicles. Hair follicle
CC       matrix cells expression starts as different cell types become
CC       distinguishable in the developing follicle. Expression persists
CC       throughout the growth phase of the follicle and maintains the same
CC       expression profile in the second hair cycle. The cells in the
CC       follicle that undergo a phase of high level expression are in
CC       transition from mitotic precursors to several discrete,
CC       differentiating cell types. Specifically expressed in cerebellar
CC       Bergmann glial cells during postnatal development.
CC       {ECO:0000269|PubMed:1425352, ECO:0000269|PubMed:1426644,
CC       ECO:0000269|PubMed:8486742}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by ADAM17 to yield a membrane-
CC       associated intermediate fragment called notch extracellular
CC       truncation (NEXT). Following endocytosis, this fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane.
CC   -!- PTM: Phosphorylated.
CC   -!- PTM: O-linked glycosylation by GALNT11 is involved in
CC       determination of left/right symmetry: glycosylation promotes
CC       activation of NOTCH1, possibly by promoting cleavage by ADAM17,
CC       modulating the balance between motile and immotile (sensory) cilia
CC       at the left-right organiser (LRO) (By similarity) O-glycosylated
CC       on the EGF-like domains. Contains both O-linked fucose and O-
CC       linked glucose. O-glycosylation at Ser-1027 is only partial.
CC       {ECO:0000250|UniProtKB:P46531, ECO:0000269|PubMed:21757702}.
CC   -!- PTM: Ubiquitinated; undergoes 'Lys-29'-linked polyubiquitination
CC       catalyzed by ITCH. Monoubiquitination at Lys-1749 is required for
CC       activation by gamma-secretase cleavage, it promotes interaction
CC       with AAK1, which stabilizes it. Deubiquitination by EIF3F is
CC       necessary for nuclear import of activated Notch.
CC       {ECO:0000269|PubMed:15240571, ECO:0000269|PubMed:18628966}.
CC   -!- PTM: Hydroxylated at Asn-1945 and Asn-2012 by HIF1AN.
CC       Hydroxylation reduces affinity for HI1AN and may thus indirectly
CC       modulate negative regulation of NICD.
CC       {ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578}.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 5 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023}.
CC   -!- SIMILARITY: Contains 36 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z11886; CAA77941.1; -; mRNA.
DR   EMBL; AF508809; AAM28905.1; -; mRNA.
DR   EMBL; AB100603; BAC77038.1; -; Genomic_DNA.
DR   EMBL; AB100603; BAC77039.1; -; Genomic_DNA.
DR   EMBL; AB100603; BAC77040.1; -; Genomic_DNA.
DR   EMBL; AL732541; CAM20304.1; -; Genomic_DNA.
DR   EMBL; CH466542; EDL08321.1; -; Genomic_DNA.
DR   EMBL; BC138441; AAI38442.1; -; mRNA.
DR   EMBL; BC138442; AAI38443.1; -; mRNA.
DR   EMBL; L02613; AAK14898.1; -; mRNA.
DR   EMBL; X68278; CAA48339.1; -; mRNA.
DR   EMBL; AK154528; BAE32653.1; -; mRNA.
DR   EMBL; AK157475; BAE34095.1; -; mRNA.
DR   EMBL; AJ238029; CAB40733.1; -; mRNA.
DR   EMBL; X82562; CAA57909.1; -; mRNA.
DR   CCDS; CCDS15806.1; -. [Q01705-1]
DR   PIR; A46438; A46438.
DR   PIR; B49175; B49175.
DR   RefSeq; NP_032740.3; NM_008714.3. [Q01705-1]
DR   UniGene; Mm.290610; -.
DR   PDB; 1YMP; X-ray; 2.20 A; A/B=1971-2105.
DR   PDB; 2QC9; X-ray; 2.35 A; A/B=1899-2106.
DR   PDB; 2RQZ; NMR; -; A=452-489.
DR   PDB; 2RR0; NMR; -; A=452-489.
DR   PDB; 2RR2; NMR; -; A=452-489.
DR   PDB; 3P3N; X-ray; 2.40 A; B=1930-1949.
DR   PDB; 3P3P; X-ray; 2.60 A; B=1999-2016.
DR   PDBsum; 1YMP; -.
DR   PDBsum; 2QC9; -.
DR   PDBsum; 2RQZ; -.
DR   PDBsum; 2RR0; -.
DR   PDBsum; 2RR2; -.
DR   PDBsum; 3P3N; -.
DR   PDBsum; 3P3P; -.
DR   ProteinModelPortal; Q01705; -.
DR   SMR; Q01705; 412-526, 1446-1718, 1873-2112.
DR   BioGrid; 201808; 21.
DR   DIP; DIP-214N; -.
DR   IntAct; Q01705; 6.
DR   MINT; MINT-142586; -.
DR   STRING; 10090.ENSMUSP00000028288; -.
DR   iPTMnet; Q01705; -.
DR   PhosphoSite; Q01705; -.
DR   MaxQB; Q01705; -.
DR   PaxDb; Q01705; -.
DR   PRIDE; Q01705; -.
DR   Ensembl; ENSMUST00000028288; ENSMUSP00000028288; ENSMUSG00000026923. [Q01705-1]
DR   GeneID; 18128; -.
DR   KEGG; mmu:18128; -.
DR   UCSC; uc008ivl.2; mouse. [Q01705-1]
DR   CTD; 4851; -.
DR   MGI; MGI:97363; Notch1.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; Q01705; -.
DR   KO; K02599; -.
DR   OMA; ILDYSFV; -.
DR   OrthoDB; EOG7992RD; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-MMU-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-MMU-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-MMU-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-MMU-350054; Notch-HLH transcription pathway.
DR   EvolutionaryTrace; Q01705; -.
DR   NextBio; 293356; -.
DR   PRO; PR:Q01705; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   Bgee; Q01705; -.
DR   CleanEx; MM_NOTCH1; -.
DR   ExpressionAtlas; Q01705; baseline and differential.
DR   Genevisible; Q01705; MM.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071944; C:cell periphery; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:AgBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0001726; C:ruffle; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:MGI.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0004857; F:enzyme inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0005112; F:Notch binding; IPI:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:MGI.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; IDA:BHF-UCL.
DR   GO; GO:0003180; P:aortic valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IMP:MGI.
DR   GO; GO:0060842; P:arterial endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0048708; P:astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003162; P:atrioventricular node development; IMP:BHF-UCL.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IMP:MGI.
DR   GO; GO:0007409; P:axonogenesis; IDA:MGI.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:MGI.
DR   GO; GO:0003209; P:cardiac atrium morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003207; P:cardiac chamber formation; IMP:BHF-UCL.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003213; P:cardiac right atrium morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003219; P:cardiac right ventricle formation; IMP:MGI.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; IMP:BHF-UCL.
DR   GO; GO:0003208; P:cardiac ventricle morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IMP:MGI.
DR   GO; GO:0021515; P:cell differentiation in spinal cord; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0001708; P:cell fate specification; IMP:MGI.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; IMP:BHF-UCL.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; ISO:MGI.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0060271; P:cilium morphogenesis; ISS:UniProtKB.
DR   GO; GO:0072044; P:collecting duct development; IEP:UniProtKB.
DR   GO; GO:0007386; P:compartment pattern specification; IMP:MGI.
DR   GO; GO:0060982; P:coronary artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003169; P:coronary vein morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0072017; P:distal tubule development; IEP:UniProtKB.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IMP:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IGI:MGI.
DR   GO; GO:0060956; P:endocardial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0003197; P:endocardial cushion development; IMP:MGI.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003157; P:endocardium development; IMP:BHF-UCL.
DR   GO; GO:0003160; P:endocardium morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007492; P:endoderm development; IMP:MGI.
DR   GO; GO:0008544; P:epidermis development; IGI:MGI.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:MGI.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IMP:BHF-UCL.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0007440; P:foregut morphogenesis; IMP:MGI.
DR   GO; GO:0010001; P:glial cell differentiation; IMP:MGI.
DR   GO; GO:0072144; P:glomerular mesangial cell development; IEP:UniProtKB.
DR   GO; GO:0003241; P:growth involved in heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0007507; P:heart development; ISO:MGI.
DR   GO; GO:0001947; P:heart looping; IGI:BHF-UCL.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IGI:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IGI:MGI.
DR   GO; GO:0072602; P:interleukin-4 secretion; IGI:MGI.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:MGI.
DR   GO; GO:0070986; P:left/right axis specification; IGI:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0014031; P:mesenchymal cell development; IMP:BHF-UCL.
DR   GO; GO:0003192; P:mitral valve formation; ISO:MGI.
DR   GO; GO:2000811; P:negative regulation of anoikis; ISO:MGI.
DR   GO; GO:0045608; P:negative regulation of auditory receptor cell differentiation; IMP:MGI.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IMP:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; IDA:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; ISO:MGI.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; ISO:MGI.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; IDA:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IDA:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IMP:MGI.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0030279; P:negative regulation of ossification; IMP:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IMP:MGI.
DR   GO; GO:2000974; P:negative regulation of pro-B cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0021915; P:neural tube development; IMP:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IMP:MGI.
DR   GO; GO:0048663; P:neuron fate commitment; IGI:MGI.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IC:UniProtKB.
DR   GO; GO:0003270; P:Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation; IMP:MGI.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0002051; P:osteoblast fate commitment; NAS:BHF-UCL.
DR   GO; GO:0003344; P:pericardium morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:MGI.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:1901189; P:positive regulation of ephrin receptor signaling pathway; IC:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IGI:MGI.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IDA:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IDA:MGI.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; IGI:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:AgBase.
DR   GO; GO:0050434; P:positive regulation of viral transcription; IMP:AgBase.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IMP:MGI.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; ISO:MGI.
DR   GO; GO:0045607; P:regulation of auditory receptor cell differentiation; IMP:MGI.
DR   GO; GO:0061344; P:regulation of cell adhesion involved in heart morphogenesis; IC:BHF-UCL.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; IMP:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0050767; P:regulation of neurogenesis; IMP:MGI.
DR   GO; GO:0008593; P:regulation of Notch signaling pathway; IGI:MGI.
DR   GO; GO:0014807; P:regulation of somitogenesis; IMP:MGI.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0031960; P:response to corticosteroid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IDA:BHF-UCL.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IMP:MGI.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IMP:MGI.
DR   GO; GO:0048103; P:somatic stem cell division; IDA:MGI.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:MGI.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IDA:GOC.
DR   GO; GO:0035148; P:tube formation; ISS:UniProtKB.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060843; P:venous endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISO:MGI.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; IMP:BHF-UCL.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR022362; Notch_1.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 23.
DR   Pfam; PF07645; EGF_CA; 5.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01984; NOTCH1.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00181; EGF; 11.
DR   SMART; SM00179; EGF_CA; 25.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 35.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 21.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Angiogenesis;
KW   ANK repeat; Calcium; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Hydroxylation;
KW   Isopeptide bond; Membrane; Metal-binding; Notch signaling pathway;
KW   Nucleus; Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   2531       Neurogenic locus notch homolog protein 1.
FT                                /FTId=PRO_0000007677.
FT   CHAIN      1711   2531       Notch 1 extracellular truncation.
FT                                /FTId=PRO_0000007678.
FT   CHAIN      1744   2531       Notch 1 intracellular domain.
FT                                /FTId=PRO_0000007679.
FT   TOPO_DOM     19   1725       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1726   1746       Helical. {ECO:0000255}.
FT   TOPO_DOM   1747   2531       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20     58       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       59     99       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      102    139       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      140    176       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      178    216       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      218    255       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      257    293       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      295    333       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      335    371       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      372    410       EGF-like 10; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      412    450       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      452    488       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      490    526       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      528    564       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      566    601       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      603    639       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      641    676       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      678    714       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      716    751       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      753    789       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      791    827       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      829    867       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      869    905       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      907    943       EGF-like 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      945    981       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      983   1019       EGF-like 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1021   1057       EGF-like 27; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1059   1095       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1097   1143       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1145   1181       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1183   1219       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1221   1265       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1267   1305       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1307   1346       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1348   1384       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1387   1426       EGF-like 36. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1449   1489       LNR 1.
FT   REPEAT     1490   1531       LNR 2.
FT   REPEAT     1532   1571       LNR 3.
FT   REPEAT     1917   1946       ANK 1.
FT   REPEAT     1950   1980       ANK 2.
FT   REPEAT     1984   2013       ANK 3.
FT   REPEAT     2017   2046       ANK 4.
FT   REPEAT     2050   2079       ANK 5.
FT   REGION     1937   1945       HIF1AN-binding.
FT   REGION     2004   2012       HIF1AN-binding.
FT   METAL      1457   1457       Calcium; via carbonyl oxygen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   METAL      1460   1460       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL      1475   1475       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL      1478   1478       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   SITE       1654   1655       Cleavage; by furin-like protease.
FT   SITE       1710   1711       Cleavage; by ADAM17. {ECO:0000250}.
FT   MOD_RES    1851   1851       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   MOD_RES    1945   1945       (3S)-3-hydroxyasparagine; by HIF1AN;
FT                                partial. {ECO:0000269|PubMed:17573339,
FT                                ECO:0000269|PubMed:18299578}.
FT   MOD_RES    2012   2012       (3S)-3-hydroxyasparagine; by HIF1AN;
FT                                partial. {ECO:0000269|PubMed:17573339,
FT                                ECO:0000269|PubMed:18299578}.
FT   CARBOHYD     65     65       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD     73     73       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    116    116       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    146    146       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    194    194       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    232    232       O-linked (Fuc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    232    232       O-linked (GalNAc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    341    341       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    378    378       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    458    458       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    466    466       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    496    496       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    534    534       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    609    609       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    647    647       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    722    722       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    759    759       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    767    767       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    797    797       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    805    805       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    888    888       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    951    951       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD    959    959       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1027   1027       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1035   1035       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1065   1065       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1179   1179       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1189   1189       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1197   1197       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1241   1241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1273   1273       O-linked (Glc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1362   1362       O-linked (Fuc...).
FT                                {ECO:0000269|PubMed:21757702}.
FT   CARBOHYD   1402   1402       O-linked (Fuc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD   1402   1402       O-linked (GalNAc...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD   1489   1489       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1587   1587       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     24     37       {ECO:0000250}.
FT   DISULFID     31     46       {ECO:0000250}.
FT   DISULFID     63     74       {ECO:0000250}.
FT   DISULFID     68     87       {ECO:0000250}.
FT   DISULFID     89     98       {ECO:0000250}.
FT   DISULFID    106    117       {ECO:0000250}.
FT   DISULFID    111    127       {ECO:0000250}.
FT   DISULFID    129    138       {ECO:0000250}.
FT   DISULFID    144    155       {ECO:0000250}.
FT   DISULFID    149    164       {ECO:0000250}.
FT   DISULFID    166    175       {ECO:0000250}.
FT   DISULFID    182    195       {ECO:0000250}.
FT   DISULFID    189    204       {ECO:0000250}.
FT   DISULFID    206    215       {ECO:0000250}.
FT   DISULFID    222    233       {ECO:0000250}.
FT   DISULFID    227    243       {ECO:0000250}.
FT   DISULFID    245    254       {ECO:0000250}.
FT   DISULFID    261    272       {ECO:0000250}.
FT   DISULFID    266    281       {ECO:0000250}.
FT   DISULFID    283    292       {ECO:0000250}.
FT   DISULFID    299    312       {ECO:0000250}.
FT   DISULFID    306    321       {ECO:0000250}.
FT   DISULFID    323    332       {ECO:0000250}.
FT   DISULFID    339    350       {ECO:0000250}.
FT   DISULFID    344    359       {ECO:0000250}.
FT   DISULFID    361    370       {ECO:0000250}.
FT   DISULFID    376    387       {ECO:0000250}.
FT   DISULFID    381    398       {ECO:0000250}.
FT   DISULFID    400    409       {ECO:0000250}.
FT   DISULFID    416    429       {ECO:0000250}.
FT   DISULFID    423    438       {ECO:0000250}.
FT   DISULFID    440    449       {ECO:0000250}.
FT   DISULFID    456    467       {ECO:0000250}.
FT   DISULFID    461    476       {ECO:0000250}.
FT   DISULFID    478    487       {ECO:0000250}.
FT   DISULFID    494    505       {ECO:0000250}.
FT   DISULFID    499    514       {ECO:0000250}.
FT   DISULFID    516    525       {ECO:0000250}.
FT   DISULFID    532    543       {ECO:0000250}.
FT   DISULFID    537    552       {ECO:0000250}.
FT   DISULFID    554    563       {ECO:0000250}.
FT   DISULFID    570    580       {ECO:0000250}.
FT   DISULFID    575    589       {ECO:0000250}.
FT   DISULFID    591    600       {ECO:0000250}.
FT   DISULFID    607    618       {ECO:0000250}.
FT   DISULFID    612    627       {ECO:0000250}.
FT   DISULFID    629    638       {ECO:0000250}.
FT   DISULFID    645    655       {ECO:0000250}.
FT   DISULFID    650    664       {ECO:0000250}.
FT   DISULFID    666    675       {ECO:0000250}.
FT   DISULFID    682    693       {ECO:0000250}.
FT   DISULFID    687    702       {ECO:0000250}.
FT   DISULFID    704    713       {ECO:0000250}.
FT   DISULFID    720    730       {ECO:0000250}.
FT   DISULFID    725    739       {ECO:0000250}.
FT   DISULFID    741    750       {ECO:0000250}.
FT   DISULFID    757    768       {ECO:0000250}.
FT   DISULFID    762    777       {ECO:0000250}.
FT   DISULFID    779    788       {ECO:0000250}.
FT   DISULFID    795    806       {ECO:0000250}.
FT   DISULFID    800    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    833    844       {ECO:0000250}.
FT   DISULFID    838    855       {ECO:0000250}.
FT   DISULFID    857    866       {ECO:0000250}.
FT   DISULFID    873    884       {ECO:0000250}.
FT   DISULFID    878    893       {ECO:0000250}.
FT   DISULFID    895    904       {ECO:0000250}.
FT   DISULFID    911    922       {ECO:0000250}.
FT   DISULFID    916    931       {ECO:0000250}.
FT   DISULFID    933    942       {ECO:0000250}.
FT   DISULFID    949    960       {ECO:0000250}.
FT   DISULFID    954    969       {ECO:0000250}.
FT   DISULFID    971    980       {ECO:0000250}.
FT   DISULFID    987    998       {ECO:0000250}.
FT   DISULFID    992   1007       {ECO:0000250}.
FT   DISULFID   1009   1018       {ECO:0000250}.
FT   DISULFID   1025   1036       {ECO:0000250}.
FT   DISULFID   1030   1045       {ECO:0000250}.
FT   DISULFID   1047   1056       {ECO:0000250}.
FT   DISULFID   1063   1074       {ECO:0000250}.
FT   DISULFID   1068   1083       {ECO:0000250}.
FT   DISULFID   1085   1094       {ECO:0000250}.
FT   DISULFID   1101   1122       {ECO:0000250}.
FT   DISULFID   1116   1131       {ECO:0000250}.
FT   DISULFID   1133   1142       {ECO:0000250}.
FT   DISULFID   1149   1160       {ECO:0000250}.
FT   DISULFID   1154   1169       {ECO:0000250}.
FT   DISULFID   1171   1180       {ECO:0000250}.
FT   DISULFID   1187   1198       {ECO:0000250}.
FT   DISULFID   1192   1207       {ECO:0000250}.
FT   DISULFID   1209   1218       {ECO:0000250}.
FT   DISULFID   1225   1244       {ECO:0000250}.
FT   DISULFID   1238   1253       {ECO:0000250}.
FT   DISULFID   1255   1264       {ECO:0000250}.
FT   DISULFID   1271   1284       {ECO:0000250}.
FT   DISULFID   1276   1293       {ECO:0000250}.
FT   DISULFID   1295   1304       {ECO:0000250}.
FT   DISULFID   1311   1322       {ECO:0000250}.
FT   DISULFID   1316   1334       {ECO:0000250}.
FT   DISULFID   1336   1345       {ECO:0000250}.
FT   DISULFID   1352   1363       {ECO:0000250}.
FT   DISULFID   1357   1372       {ECO:0000250}.
FT   DISULFID   1374   1383       {ECO:0000250}.
FT   DISULFID   1391   1403       {ECO:0000250}.
FT   DISULFID   1397   1414       {ECO:0000250}.
FT   DISULFID   1416   1425       {ECO:0000250}.
FT   DISULFID   1449   1472       {ECO:0000250}.
FT   DISULFID   1454   1467       {ECO:0000250}.
FT   DISULFID   1463   1479       {ECO:0000250}.
FT   DISULFID   1490   1514       {ECO:0000250}.
FT   DISULFID   1496   1509       {ECO:0000250}.
FT   DISULFID   1505   1521       {ECO:0000250}.
FT   DISULFID   1536   1549       {ECO:0000250}.
FT   DISULFID   1545   1561       {ECO:0000250}.
FT   CROSSLNK   1749   1749       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:15240571}.
FT   VAR_SEQ       1     47       MPRLLTPLLCLTLLPALAARGLRCSQPSGTCLNGGRCEVAN
FT                                GTEACV -> MQTPLLSLAGATTELCFLPASVLASSLPGPS
FT                                L (in isoform 4). {ECO:0000305}.
FT                                /FTId=VSP_043065.
FT   VAR_SEQ       1     21       MPRLLTPLLCLTLLPALAARG -> MKNSNTLTNKWRMEQC
FT                                (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_043064.
FT   VAR_SEQ     857    914       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1426644}.
FT                                /FTId=VSP_001402.
FT   VAR_SEQ    1329   1355       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1426644}.
FT                                /FTId=VSP_001403.
FT   VAR_SEQ    1636   1854       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1426644}.
FT                                /FTId=VSP_001404.
FT   MUTAGEN      65     65       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     146    146       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     341    341       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     378    378       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     458    458       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     496    496       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     534    534       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     609    609       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     647    647       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     722    722       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     759    759       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     797    797       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN     951    951       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN    1027   1027       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN    1065   1065       S->A: Reduced activity.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN    1189   1189       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN    1273   1273       S->A: No effect.
FT                                {ECO:0000269|PubMed:21757702}.
FT   MUTAGEN    1651   1654       RQRR->AAAA: Processing by furin-like
FT                                convertase abolished.
FT                                {ECO:0000269|PubMed:9653148}.
FT   MUTAGEN    1744   1744       V->L: NICD processing severely reduced.
FT   MUTAGEN    1945   1945       N->A: Reduced ability to promote HIF1AN-
FT                                dependent 2-oxoglutarate decarboxylation
FT                                and greatly reduced transactivation
FT                                capacity. Abolished ability to promote
FT                                HIF1AN-dependent 2-oxoglutarate
FT                                decarboxylation; when associated with G-
FT                                2012. Almost abolished transactivation
FT                                capacity; when associated with A-2012.
FT                                {ECO:0000269|PubMed:17573339,
FT                                ECO:0000269|PubMed:18299578}.
FT   MUTAGEN    2012   2012       N->A: Slightly reduced ability to promote
FT                                HIF1AN-dependent 2-oxoglutarate
FT                                decarboxylation. Abolished ability to
FT                                promote HIF1AN-dependent 2-oxoglutarate
FT                                decarboxylation and almost abolished
FT                                transactivation capacity; when associated
FT                                with A-1945.
FT                                {ECO:0000269|PubMed:17573339,
FT                                ECO:0000269|PubMed:18299578}.
FT   MUTAGEN    2012   2012       N->G: Reduced ability to promote HIF1AN-
FT                                dependent 2-oxoglutarate decarboxylation.
FT                                Abolished ability to promote HIF1AN-
FT                                dependent 2-oxoglutarate decarboxylation;
FT                                when associated with A-1945.
FT                                {ECO:0000269|PubMed:17573339,
FT                                ECO:0000269|PubMed:18299578}.
FT   CONFLICT     17     17       L -> R (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     41     41       N -> S (in Ref. 1; CAA77941 and 3;
FT                                AAM28905). {ECO:0000305}.
FT   CONFLICT     48     48       C -> A (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     51     51       A -> S (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     60     60       S -> P (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     67     67       P -> R (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     75     75       H -> Y (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT     82     82       T -> I (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    104    105       NA -> KP (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    130    130       P -> S (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       T -> H (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    207    207       R -> C (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    231    231       G -> A (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    287    287       W -> V (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    309    309       G -> A (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    373    374       ND -> KH (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    396    396       A -> R (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    417    417       A -> D (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    422    422       P -> R (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    448    448       R -> G (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    510    510       N -> H (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT    835    835       T -> I (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT    933    934       CL -> SV (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1050   1050       G -> R (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1104   1106       Missing (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1155   1155       Q -> L (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1209   1209       C -> W (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1438   1438       R -> P (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   1545   1545       C -> S (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1556   1556       W -> R (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1572   1572       G -> R (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1576   1576       L -> V (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1609   1609       D -> H (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1661   1661       I -> T (in Ref. 10; BAE32653).
FT                                {ECO:0000305}.
FT   CONFLICT   1864   1864       V -> D (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1890   1890       S -> R (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1896   1898       APA -> RPG (in Ref. 8; AAK14898).
FT                                {ECO:0000305}.
FT   CONFLICT   1933   1934       AA -> RR (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   1938   1938       Missing (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   1997   1997       V -> L (in Ref. 3; AAM28905).
FT                                {ECO:0000305}.
FT   CONFLICT   2046   2047       MQ -> IE (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2054   2054       P -> S (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2058   2062       AAREG -> SIRRE (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2075   2075       A -> G (in Ref. 16; CAA57909).
FT                                {ECO:0000305}.
FT   CONFLICT   2086   2086       L -> M (in Ref. 10; BAE34095).
FT                                {ECO:0000305}.
FT   CONFLICT   2136   2136       L -> P (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2172   2172       K -> S (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2179   2179       C -> W (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2185   2185       S -> SS (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2206   2206       P -> H (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2258   2258       P -> H (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2273   2273       S -> C (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2347   2347       N -> S (in Ref. 10; BAE34095).
FT                                {ECO:0000305}.
FT   CONFLICT   2380   2380       Q -> P (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   CONFLICT   2483   2484       HP -> PT (in Ref. 1; CAA77941).
FT                                {ECO:0000305}.
FT   TURN        456    458       {ECO:0000244|PDB:2RR0}.
FT   STRAND      462    464       {ECO:0000244|PDB:2RQZ}.
FT   STRAND      466    469       {ECO:0000244|PDB:2RQZ}.
FT   STRAND      471    477       {ECO:0000244|PDB:2RQZ}.
FT   TURN        484    487       {ECO:0000244|PDB:2RQZ}.
FT   HELIX      1921   1927       {ECO:0000244|PDB:2QC9}.
FT   HELIX      1931   1939       {ECO:0000244|PDB:2QC9}.
FT   HELIX      1954   1961       {ECO:0000244|PDB:2QC9}.
FT   HELIX      1964   1972       {ECO:0000244|PDB:2QC9}.
FT   HELIX      1975   1977       {ECO:0000244|PDB:1YMP}.
FT   HELIX      1988   1995       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2000   2006       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2021   2027       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2031   2039       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2054   2061       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2064   2072       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2087   2093       {ECO:0000244|PDB:1YMP}.
FT   HELIX      2097   2103       {ECO:0000244|PDB:1YMP}.
SQ   SEQUENCE   2531 AA;  270835 MW;  97C91F69BABF02BF CRC64;
     MPRLLTPLLC LTLLPALAAR GLRCSQPSGT CLNGGRCEVA NGTEACVCSG AFVGQRCQDS
     NPCLSTPCKN AGTCHVVDHG GTVDYACSCP LGFSGPLCLT PLDNACLANP CRNGGTCDLL
     TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA NGGQCLPFES SYICRCPPGF HGPTCRQDVN
     ECSQNPGLCR HGGTCHNEIG SYRCACRATH TGPHCELPYV PCSPSPCQNG GTCRPTGDTT
     HECACLPGFA GQNCEENVDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
     LMPNACQNGG TCHNTHGGYN CVCVNGWTGE DCSENIDDCA SAACFQGATC HDRVASFYCE
     CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC PSGYTGPACS QDVDECALGA
     NPCEHAGKCL NTLGSFECQC LQGYTGPRCE IDVNECISNP CQNDATCLDQ IGEFQCICMP
     GYEGVYCEIN TDECASSPCL HNGHCMDKIN EFQCQCPKGF NGHLCQYDVD ECASTPCKNG
     AKCLDGPNTY TCVCTEGYTG THCEVDIDEC DPDPCHYGSC KDGVATFTCL CQPGYTGHHC
     ETNINECHSQ PCRHGGTCQD RDNSYLCLCL KGTTGPNCEI NLDDCASNPC DSGTCLDKID
     GYECACEPGY TGSMCNVNID ECAGSPCHNG GTCEDGIAGF TCRCPEGYHD PTCLSEVNEC
     NSNPCIHGAC RDGLNGYKCD CAPGWSGTNC DINNNECESN PCVNGGTCKD MTSGYVCTCR
     EGFSGPNCQT NINECASNPC LNQGTCIDDV AGYKCNCPLP YTGATCEVVL APCATSPCKN
     SGVCKESEDY ESFSCVCPTG WQGQTCEVDI NECVKSPCRH GASCQNTNGS YRCLCQAGYT
     GRNCESDIDD CRPNPCHNGG SCTDGINTAF CDCLPGFQGA FCEEDINECA SNPCQNGANC
     TDCVDSYTCT CPVGFNGIHC ENNTPDCTES SCFNGGTCVD GINSFTCLCP PGFTGSYCQY
     DVNECDSRPC LHGGTCQDSY GTYKCTCPQG YTGLNCQNLV RWCDSAPCKN GGRCWQTNTQ
     YHCECRSGWT GVNCDVLSVS CEVAAQKRGI DVTLLCQHGG LCVDEGDKHY CHCQAGYTGS
     YCEDEVDECS PNPCQNGATC TDYLGGFSCK CVAGYHGSNC SEEINECLSQ PCQNGGTCID
     LTNSYKCSCP RGTQGVHCEI NVDDCHPPLD PASRSPKCFN NGTCVDQVGG YTCTCPPGFV
     GERCEGDVNE CLSNPCDPRG TQNCVQRVND FHCECRAGHT GRRCESVING CRGKPCKNGG
     VCAVASNTAR GFICRCPAGF EGATCENDAR TCGSLRCLNG GTCISGPRSP TCLCLGSFTG
     PECQFPASSP CVGSNPCYNQ GTCEPTSENP FYRCLCPAKF NGLLCHILDY SFTGGAGRDI
     PPPQIEEACE LPECQVDAGN KVCNLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
     SDGHCDSQCN SAGCLFDGFD CQLTEGQCNP LYDQYCKDHF SDGHCDQGCN SAECEWDGLD
     CAEHVPERLA AGTLVLVVLL PPDQLRNNSF HFLRELSHVL HTNVVFKRDA QGQQMIFPYY
     GHEEELRKHP IKRSTVGWAT SSLLPGTSGG RQRRELDPMD IRGSIVYLEI DNRQCVQSSS
     QCFQSATDVA AFLGALASLG SLNIPYKIEA VKSEPVEPPL PSQLHLMYVA AAAFVLLFFV
     GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA SDGALMDDNQ
     NEWGDEDLET KKFRFEEPVV LPDLSDQTDH RQWTQQHLDA ADLRMSAMAP TPPQGEVDAD
     CMDVNVRGPD GFTPLMIASC SGGGLETGNS EEEEDAPAVI SDFIYQGASL HNQTDRTGET
     ALHLAARYSR SDAAKRLLEA SADANIQDNM GRTPLHAAVS ADAQGVFQIL LRNRATDLDA
     RMHDGTTPLI LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN VDAAVVLLKN
     GANKDMQNNK EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI AQERMHHDIV
     RLLDEYNLVR SPQLHGTALG GTPTLSPTLC SPNGYLGNLK SATQGKKARK PSTKGLACGS
     KEAKDLKARR KKSQDGKGCL LDSSSMLSPV DSLESPHGYL SDVASPPLLP SPFQQSPSMP
     LSHLPGMPDT HLGISHLNVA AKPEMAALAG GSRLAFEPPP PRLSHLPVAS SASTVLSTNG
     TGAMNFTVGA PASLNGQCEW LPRLQNGMVP SQYNPLRPGV TPGTLSTQAA GLQHSMMGPL
     HSSLSTNTLS PIIYQGLPNT RLATQPHLVQ TQQVQPQNLQ LQPQNLQPPS QPHLSVSSAA
     NGHLGRSFLS GEPSQADVQP LGPSSLPVHT ILPQESQALP TSLPSSMVPP MTTTQFLTPP
     SQHSYSSSPV DNTPSHQLQV PEHPFLTPSP ESPDQWSSSS PHSNISDWSE GISSPPTTMP
     SQITHIPEAF K
//
ID   A4_HUMAN                Reviewed;         770 AA.
AC   P05067; B2R5V1; B4DII8; D3DSD1; D3DSD2; D3DSD3; P09000; P78438;
AC   Q13764; Q13778; Q13793; Q16011; Q16014; Q16019; Q16020; Q6GSC0;
AC   Q8WZ99; Q9BT38; Q9UC33; Q9UCA9; Q9UCB6; Q9UCC8; Q9UCD1; Q9UQ58;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 3.
DT   17-FEB-2016, entry version 247.
DE   RecName: Full=Amyloid beta A4 protein;
DE   AltName: Full=ABPP;
DE   AltName: Full=APPI;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid protein;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Beta-amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Cerebral vascular amyloid peptide;
DE            Short=CVAP;
DE   AltName: Full=PreA4;
DE   AltName: Full=Protease nexin-II;
DE            Short=PN-II;
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Beta-amyloid protein 40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=Amyloid intracellular domain 59;
DE              Short=AICD-59;
DE              Short=AID(59);
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=Amyloid intracellular domain 57;
DE              Short=AICD-57;
DE              Short=AID(57);
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Amyloid intracellular domain 50;
DE              Short=AICD-50;
DE              Short=AID(50);
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=APP; Synonyms=A4, AD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=2881207; DOI=10.1038/325733a0;
RA   Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L.,
RA   Grzeschik K.-H., Multhaup G., Beyreuther K., Mueller-Hill B.;
RT   "The precursor of Alzheimer's disease amyloid A4 protein resembles a
RT   cell-surface receptor.";
RL   Nature 325:733-736(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2893289; DOI=10.1038/331525a0;
RA   Ponte P., Gonzalez-Dewhitt P., Schilling J., Miller J., Hsu D.,
RA   Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F.,
RA   Cordell B.;
RT   "A new A4 amyloid mRNA contains a domain homologous to serine
RT   proteinase inhibitors.";
RL   Nature 331:525-527(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP695).
RX   PubMed=2783775; DOI=10.1093/nar/17.2.517;
RA   Lemaire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,
RA   Unterbeck A., Beyreuther K., Mueller-Hill B.;
RT   "The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is
RT   encoded by 16 exons.";
RL   Nucleic Acids Res. 17:517-522(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=2110105; DOI=10.1016/0378-1119(90)90310-N;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RT   "Genomic organization of the human amyloid beta-protein precursor
RT   gene.";
RL   Gene 87:257-263(1990).
RN   [5]
RP   ERRATUM.
RX   PubMed=1908403; DOI=10.1016/0378-1119(91)90093-Q;
RA   Yoshikai S., Sasaki H., Doh-ura K., Furuya H., Sakaki Y.;
RL   Gene 102:291-292(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-APP733).
RC   TISSUE=Leukocyte;
RX   PubMed=1587857;
RA   Koenig G., Moenning U., Czech C., Prior R., Banati R.,
RA   Schreiter-Gasser U., Bauer J., Masters C.L., Beyreuther K.;
RT   "Identification and differential expression of a novel alternative
RT   splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in
RT   leukocytes and brain microglial cells.";
RL   J. Biol. Chem. 267:10804-10809(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM APP770).
RX   PubMed=9108164; DOI=10.1093/nar/25.9.1802;
RA   Hattori M., Tsukahara F., Furuhata Y., Tanahashi H., Hirose M.,
RA   Saito M., Tsukuni S., Sakaki Y.;
RT   "A novel method for making nested deletions and its application for
RT   sequencing of a 300 kb region of human APP locus.";
RL   Nucleic Acids Res. 25:1802-1808(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP639), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=12859342; DOI=10.1046/j.1460-9568.2003.02731.x;
RA   Tang K., Wang C., Shen C., Sheng S., Ravid R., Jing N.;
RT   "Identification of a novel alternative splicing isoform of human
RT   amyloid precursor protein gene, APP639.";
RL   Eur. J. Neurosci. 18:102-108(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP770 AND 11).
RC   TISSUE=Cerebellum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-501.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS APP305 AND APP751).
RC   TISSUE=Eye, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-10.
RC   TISSUE=Liver;
RX   PubMed=3140222; DOI=10.1093/nar/16.19.9351;
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RT   "A cDNA specifying the human amyloid beta precursor protein (ABPP)
RT   encodes a 95-kDa polypeptide.";
RL   Nucleic Acids Res. 16:9351-9351(1988).
RN   [15]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Schon E.A., Mita S., Sadlock J., Herbert J.;
RL   Nucleic Acids Res. 16:11402-11402(1988).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-75.
RX   PubMed=2538123; DOI=10.1016/0006-291X(89)92437-6;
RA   La Fauci G., Lahiri D.K., Salton S.R., Robakis N.K.;
RT   "Characterization of the 5'-end region and the first two exons of the
RT   beta-protein precursor gene.";
RL   Biochem. Biophys. Res. Commun. 159:297-304(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 18-50.
RC   TISSUE=Fibroblast;
RX   PubMed=3597385;
RA   van Nostrand W.E., Cunningham D.D.;
RT   "Purification of protease nexin II from human fibroblasts.";
RL   J. Biol. Chem. 262:8508-8514(1987).
RN   [18]
RP   PROTEIN SEQUENCE OF 18-40.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 286-366.
RX   PubMed=2893290; DOI=10.1038/331528a0;
RA   Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L.,
RA   Gusella J.F., Neve R.L.;
RT   "Protease inhibitor domain encoded by an amyloid protein precursor
RT   mRNA associated with Alzheimer's disease.";
RL   Nature 331:528-530(1988).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 287-367.
RX   PubMed=2893291; DOI=10.1038/331530a0;
RA   Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H.;
RT   "Novel precursor of Alzheimer's disease amyloid protein shows protease
RT   inhibitory activity.";
RL   Nature 331:530-532(1988).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 507-770.
RC   TISSUE=Brain cortex;
RX   PubMed=2893379; DOI=10.1073/pnas.85.3.929;
RA   Zain S.B., Salim M., Chou W.G., Sajdel-Sulkowska E.M., Majocha R.E.,
RA   Marotta C.A.;
RT   "Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer
RT   disease brain: coding and noncoding regions of the fetal precursor
RT   mRNA are expressed in the cortex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:929-933(1988).
RN   [22]
RP   PROTEIN SEQUENCE OF 523-555, AND DOMAIN COLLAGEN-BINDING.
RX   PubMed=8576160; DOI=10.1074/jbc.271.3.1613;
RA   Beher D., Hesse L., Masters C.L., Multhaup G.;
RT   "Regulation of amyloid protein precursor (APP) binding to collagen and
RT   mapping of the binding sites on APP and collagen type I.";
RL   J. Biol. Chem. 271:1613-1620(1996).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 655-737, AND VARIANTS AD1 GLY-717;
RP   ILE-717 AND PHE-717.
RX   PubMed=8476439; DOI=10.1006/bbrc.1993.1386;
RA   Denman R.B., Rosenzcwaig R., Miller D.L.;
RT   "A system for studying the effect(s) of familial Alzheimer disease
RT   mutations on the processing of the beta-amyloid peptide precursor.";
RL   Biochem. Biophys. Res. Commun. 192:96-103(1993).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.
RX   PubMed=2675837; DOI=10.1016/0006-291X(89)91112-1;
RA   Johnstone E.M., Chaney M.O., Moore R.E., Ward K.E., Norris F.H.,
RA   Little S.P.;
RT   "Alzheimer's disease amyloid peptide is encoded by two exons and shows
RT   similarity to soybean trypsin inhibitor.";
RL   Biochem. Biophys. Res. Commun. 163:1248-1255(1989).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 672-723, AND VARIANT AD1 ASN-678.
RX   PubMed=15201367; DOI=10.1136/jnnp.2003.010611;
RA   Wakutani Y., Watanabe K., Adachi Y., Wada-Isoe K., Urakami K.,
RA   Ninomiya H., Saido T.C., Hashimoto T., Iwatsubo T., Nakashima K.;
RT   "Novel amyloid precursor protein gene missense mutation (D678N) in
RT   probable familial Alzheimer's disease.";
RL   J. Neurol. Neurosurg. Psych. 75:1039-1042(2004).
RN   [26]
RP   PROTEIN SEQUENCE OF 672-713.
RC   TISSUE=Blood vessel;
RX   PubMed=8248178; DOI=10.1073/pnas.90.22.10836;
RA   Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J.,
RA   Gowing E., Ball M.J.;
RT   "Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid
RT   deposits: implications for the pathology of Alzheimer disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10836-10840(1993).
RN   [27]
RP   PROTEIN SEQUENCE OF 672-704, AND TISSUE SPECIFICITY.
RX   PubMed=1406936; DOI=10.1038/359325a0;
RA   Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA   Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT   "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT   biological fluids.";
RL   Nature 359:325-327(1992).
RN   [28]
RP   PROTEIN SEQUENCE OF 672-701 AND 707-713.
RX   PubMed=8109908; DOI=10.1002/ana.410350223;
RA   Wisniewski T., Lalowski M., Levy E., Marques M.R.F., Frangione B.;
RT   "The amino acid sequence of neuritic plaque amyloid from a familial
RT   Alzheimer's disease patient.";
RL   Ann. Neurol. 35:245-246(1994).
RN   [29]
RP   PROTEIN SEQUENCE OF 672-701.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=8229004; DOI=10.1111/j.1471-4159.1993.tb09841.x;
RA   Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D.B.;
RT   "Characterization of beta-amyloid peptide from human cerebrospinal
RT   fluid.";
RL   J. Neurochem. 61:1965-1968(1993).
RN   [30]
RP   PROTEIN SEQUENCE OF 672-681.
RC   TISSUE=Brain cortex;
RX   PubMed=3312495; DOI=10.1111/j.1471-4159.1987.tb01005.x;
RA   Pardridge W.M., Vinters H.V., Yang J., Eisenberg J., Choi T.B.,
RA   Tourtellotte W.W., Huebner V., Shively J.E.;
RT   "Amyloid angiopathy of Alzheimer's disease: amino acid composition and
RT   partial sequence of a 4,200-dalton peptide isolated from cortical
RT   microvessels.";
RL   J. Neurochem. 49:1394-1401(1987).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-770.
RC   TISSUE=Brain;
RX   PubMed=3810169; DOI=10.1126/science.3810169;
RA   Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D.C.;
RT   "Characterization and chromosomal localization of a cDNA encoding
RT   brain amyloid of Alzheimer's disease.";
RL   Science 235:877-880(1987).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-703.
RC   TISSUE=Fetal brain;
RX   PubMed=2949367; DOI=10.1126/science.2949367;
RA   Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.,
RA   St George-Hyslop P.H., Van Keuren M.L., Patterson D., Pagan S.,
RA   Kurnit D.M., Neve R.L.;
RT   "Amyloid beta protein gene: cDNA, mRNA distribution, and genetic
RT   linkage near the Alzheimer locus.";
RL   Science 235:880-884(1987).
RN   [33]
RP   PROTEIN SEQUENCE OF 609-713, AND GLYCOSYLATION AT SER-614; SER-623;
RP   SER-628; SER-679 AND SER-697.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=22576872; DOI=10.1002/jms.2987;
RA   Brinkmalm G., Portelius E., Ohrfelt A., Mattsson N., Persson R.,
RA   Gustavsson M.K., Vite C.H., Gobom J., Mansson J.E., Nilsson J.,
RA   Halim A., Larson G., Ruetschi U., Zetterberg H., Blennow K.,
RA   Brinkmalm A.;
RT   "An online nano-LC-ESI-FTICR-MS method for comprehensive
RT   characterization of endogenous fragments from amyloid beta and amyloid
RT   precursor protein in human and cat cerebrospinal fluid.";
RL   J. Mass Spectrom. 47:591-603(2012).
RN   [34]
RP   PROTEIN SEQUENCE OF 691-698, AND CLEAVAGE BY THETA-SECRETASE.
RX   PubMed=16816112; DOI=10.1096/fj.05-5632com;
RA   Sun X., He G., Song W.;
RT   "BACE2, as a novel APP theta-secretase, is not responsible for the
RT   pathogenesis of Alzheimer's disease in Down syndrome.";
RL   FASEB J. 20:1369-1376(2006).
RN   [35]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP751).
RC   TISSUE=Brain;
RX   PubMed=2569763; DOI=10.1126/science.2569763;
RA   de Sauvage F., Octave J.-N.;
RT   "A novel mRNA of the A4 amyloid precursor gene coding for a possibly
RT   secreted protein.";
RL   Science 245:651-653(1989).
RN   [36]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=3035574; DOI=10.1073/pnas.84.12.4190;
RA   Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M.;
RT   "Molecular cloning and characterization of a cDNA encoding the
RT   cerebrovascular and the neuritic plaque amyloid peptides.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4190-4194(1987).
RN   [37]
RP   CHARACTERIZATION OF L-APP733, AND MUTAGENESIS OF SER-656.
RX   PubMed=7737970; DOI=10.1074/jbc.270.18.10388;
RA   Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
RT   "The chondroitin sulfate attachment site of appican is formed by
RT   splicing out exon 15 of the amyloid precursor gene.";
RL   J. Biol. Chem. 270:10388-10391(1995).
RN   [38]
RP   FUNCTION OF BETA-AMYLOID PEPTIDE AS LIPID PEROXIDATION INHIBITOR, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=9168929; DOI=10.1006/bbrc.1997.6547;
RA   Walter M.F., Mason P.E., Mason R.P.;
RT   "Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid
RT   peroxidation as a result of its membrane interactions.";
RL   Biochem. Biophys. Res. Commun. 233:760-764(1997).
RN   [39]
RP   REVIEW ON FUNCTION OF BETA-AMYLOID AS ANTIOXIDANT.
RX   PubMed=11775062; DOI=10.1023/A:1012629603390;
RA   Kontush A.;
RT   "Alzheimer's amyloid-beta as a preventive antioxidant for brain
RT   lipoproteins.";
RL   Cell. Mol. Neurobiol. 21:299-315(2001).
RN   [40]
RP   IDENTITY OF APP WITH NEXIN-II.
RX   PubMed=2506449; DOI=10.1038/341144a0;
RA   Oltersdorf T., Fritz L.C., Schenk D.B., Lieberburg I.,
RA   Johnson-Wood K.L., Beattie E.C., Ward P.J., Blacher R.W., Dovey H.F.,
RA   Sinha S.;
RT   "The secreted form of the Alzheimer's amyloid precursor protein with
RT   the Kunitz domain is protease nexin-II.";
RL   Nature 341:144-147(1989).
RN   [41]
RP   PROTEASE-SPECIFICITY OF INHIBITOR DOMAIN.
RX   PubMed=1969731; DOI=10.1016/0006-291X(90)92084-D;
RA   Kido H., Fukutomi A., Schilling J., Wang Y., Cordell B., Katunuma N.;
RT   "Protease-specificity of Kunitz inhibitor domain of Alzheimer's
RT   disease amyloid protein precursor.";
RL   Biochem. Biophys. Res. Commun. 167:716-721(1990).
RN   [42]
RP   EXTRACELLULAR ZINC-BINDING DOMAIN.
RX   PubMed=8344894;
RA   Bush A.I., Multhaup G., Moir R.D., Williamson T.G., Small D.H.,
RA   Rumble B., Pollwein P., Beyreuther K., Masters C.L.;
RT   "A novel zinc(II) binding site modulates the function of the beta A4
RT   amyloid protein precursor of Alzheimer's disease.";
RL   J. Biol. Chem. 268:16109-16112(1993).
RN   [43]
RP   INTERACTION WITH G(O).
RX   PubMed=8446172; DOI=10.1038/362075a0;
RA   Nishimoto I., Okamoto T., Matsuura Y., Takahashi S., Okamoto T.,
RA   Murayama Y., Ogata E.;
RT   "Alzheimer amyloid protein precursor complexes with brain GTP-binding
RT   protein G(o).";
RL   Nature 362:75-79(1993).
RN   [44]
RP   EXTRACELLULAR COPPER-BINDING DOMAIN, AND MUTAGENESIS OF HIS-137;
RP   MET-141; CYS-144; HIS-147 AND HIS-151.
RX   PubMed=7913895; DOI=10.1016/0014-5793(94)00658-X;
RA   Hesse L., Beher D., Masters C.L., Multhaup G.;
RT   "The beta A4 amyloid precursor protein binding to copper.";
RL   FEBS Lett. 349:109-116(1994).
RN   [45]
RP   N-TERMINAL HEPARIN-BINDING DOMAIN, AND MUTAGENESIS OF 99-LYS--ARG-102.
RX   PubMed=8158260;
RA   Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K.,
RA   Masters C.L.;
RT   "A heparin-binding domain in the amyloid protein precursor of
RT   Alzheimer's disease is involved in the regulation of neurite
RT   outgrowth.";
RL   J. Neurosci. 14:2117-2127(1994).
RN   [46]
RP   MUTAGENESIS OF VAL-717.
RX   PubMed=8886002; DOI=10.1006/bbrc.1996.1577;
RA   Maruyama K., Tomita T., Shinozaki K., Kume H., Asada H., Saido T.C.,
RA   Ishiura S., Iwatsubo T., Obata K.;
RT   "Familial Alzheimer's disease-linked mutations at Val717 of amyloid
RT   precursor protein are specific for the increased secretion of A beta
RT   42(43).";
RL   Biochem. Biophys. Res. Commun. 227:730-735(1996).
RN   [47]
RP   INTERACTION WITH APP-BP1.
RX   PubMed=8626687; DOI=10.1074/jbc.271.19.11339;
RA   Chow N., Korenberg J.R., Chen X.-N., Neve R.L.;
RT   "APP-BP1, a novel protein that binds to the carboxyl-terminal region
RT   of the amyloid precursor protein.";
RL   J. Biol. Chem. 271:11339-11346(1996).
RN   [48]
RP   INTERACTION WITH APBA1 AND APBB1, AND MUTAGENESIS OF TYR-728; TYR-757;
RP   ASN-759 AND TYR-762.
RX   PubMed=8887653;
RA   Borg J.-P., Ooi J., Levy E., Margolis B.;
RT   "The phosphotyrosine interaction domains of X11 and FE65 bind to
RT   distinct sites on the YENPTY motif of amyloid precursor protein.";
RL   Mol. Cell. Biol. 16:6229-6241(1996).
RN   [49]
RP   INTERACTION WITH APBB2.
RX   PubMed=8855266; DOI=10.1073/pnas.93.20.10832;
RA   Guenette S.Y., Chen J., Jondro P.D., Tanzi R.E.;
RT   "Association of a novel human FE65-like protein with the cytoplasmic
RT   domain of the beta-amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10832-10837(1996).
RN   [50]
RP   HEPARIN-BINDING DOMAINS.
RX   PubMed=9357988; DOI=10.1016/S0014-5793(97)01146-0;
RA   Mok S.S., Sberna G., Heffernan D., Cappai R., Galatis D.,
RA   Clarris H.J., Sawyer W.H., Beyreuther K., Masters C.L., Small D.H.;
RT   "Expression and analysis of heparin-binding regions of the amyloid
RT   precursor protein of Alzheimer's disease.";
RL   FEBS Lett. 415:303-307(1997).
RN   [51]
RP   INTERACTION OF BETA-AMYLOID PEPTIDE WITH HADH2.
RC   TISSUE=Brain;
RX   PubMed=9338779; DOI=10.1038/39522;
RA   Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F.,
RA   Collinson K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S.,
RA   Roher A., Stern D.;
RT   "An intracellular protein that binds amyloid-beta peptide and mediates
RT   neurotoxicity in Alzheimer's disease.";
RL   Nature 389:689-695(1997).
RN   [52]
RP   INTERACTION WITH APPBP2, AND MUTAGENESIS OF TYR-728.
RX   PubMed=9843960; DOI=10.1073/pnas.95.25.14745;
RA   Zheng P., Eastman J., Vande Pol S., Pimplikar S.W.;
RT   "PAT1, a microtubule-interacting protein, recognizes the basolateral
RT   sorting signal of amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14745-14750(1998).
RN   [53]
RP   BETA-AMYLOID ZINC-BINDING, AND MUTAGENESIS OF ARG-676; TYR-681 AND
RP   HIS-684.
RX   PubMed=10413512; DOI=10.1021/bi990205o;
RA   Liu S.T., Howlett G., Barrow C.J.;
RT   "Histidine-13 is a crucial residue in the zinc ion-induced aggregation
RT   of the A beta peptide of Alzheimer's disease.";
RL   Biochemistry 38:9373-9378(1999).
RN   [54]
RP   IMPORTANCE OF MET-706 IN FREE RADICAL OXIDATIVE STRESS, AND
RP   MUTAGENESIS OF MET-706.
RX   PubMed=10535332; DOI=10.1016/S0361-9230(99)00093-3;
RA   Varadarajan S., Yatin S., Kanski J., Jahanshahi F., Butterfield D.A.;
RT   "Methionine residue 35 is important in amyloid beta-peptide-associated
RT   free radical oxidative stress.";
RL   Brain Res. Bull. 50:133-141(1999).
RN   [55]
RP   INTERACTION WITH APBA2.
RX   PubMed=9890987; DOI=10.1074/jbc.274.4.2243;
RA   Tomita S., Ozaki T., Taru H., Oguchi S., Takeda S., Yagi Y.,
RA   Sakiyama S., Kirino Y., Suzuki T.;
RT   "Interaction of a neuron-specific protein containing PDZ domains with
RT   Alzheimer's amyloid precursor protein.";
RL   J. Biol. Chem. 274:2243-2254(1999).
RN   [56]
RP   ENDOCYTOSIS SIGNAL, AND MUTAGENESIS OF TYR-728; GLY-756; TYR-757;
RP   ASN-759; PRO-760 AND TYR-762.
RX   PubMed=10383380; DOI=10.1074/jbc.274.27.18851;
RA   Perez R.G., Soriano S., Hayes J.D., Ostaszewski B., Xia W.,
RA   Selkoe D.J., Chen X., Stokin G.B., Koo E.H.;
RT   "Mutagenesis identifies new signals for beta-amyloid precursor protein
RT   endocytosis, turnover, and the generation of secreted fragments,
RT   including Abeta42.";
RL   J. Biol. Chem. 274:18851-18856(1999).
RN   [57]
RP   IMPORTANCE OF CYS-144 IN COPPER REDUCTION, AND MUTAGENESIS OF CYS-144
RP   AND 147-HIS--HIS-149.
RX   PubMed=10461923; DOI=10.1046/j.1471-4159.1999.0731288.x;
RA   Ruiz F.H., Gonzalez M., Bodini M., Opazo C., Inestrosa N.C.;
RT   "Cysteine 144 is a key residue in the copper reduction by the beta-
RT   amyloid precursor protein.";
RL   J. Neurochem. 73:1288-1292(1999).
RN   [58]
RP   INTERACTION OF BETA-AMYLOID WITH APOE.
RX   PubMed=10816430; DOI=10.1042/0264-6021:3480359;
RA   Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B.,
RA   Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., Frangione B.,
RA   Ghiso J.;
RT   "Lipidation of apolipoprotein E influences its isoform-specific
RT   interaction with Alzheimer's amyloid beta peptides.";
RL   Biochem. J. 348:359-365(2000).
RN   [59]
RP   INTERACTION OF BETA-APP42 WITH CHRNA7.
RX   PubMed=10681545; DOI=10.1074/jbc.275.8.5626;
RA   Wang H.-Y., Lee D.H.S., D'Andrea M.R., Peterson P.A., Shank R.P.,
RA   Reitz A.B.;
RT   "Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor
RT   with high affinity. Implications for Alzheimer's disease pathology.";
RL   J. Biol. Chem. 275:5626-5632(2000).
RN   [60]
RP   IDENTIFICATION OF GAMMA-CTFS BY MASS SPECTROMETRY, AND MUTAGENESIS OF
RP   ASP-739.
RX   PubMed=12214090;
RA   Passer B., Pellegrini L., Russo C., Siegel R.M., Lenardo M.J.,
RA   Schettini G., Bachmann M., Tabaton M., D'Adamio L.;
RT   "Generation of an apoptotic intracellular peptide by gamma-secretase
RT   cleavage of Alzheimer's amyloid beta protein precursor.";
RL   J. Alzheimers Dis. 2:289-301(2000).
RN   [61]
RP   INTERACTION WITH FPRL1.
RX   PubMed=11689470; DOI=10.1096/fj.01-0251com;
RA   Yazawa H., Yu Z.-X., Takeda K., Le Y., Gong W., Ferrans V.J.,
RA   Oppenheim J.J., Li C.C.H., Wang J.M.;
RT   "Beta amyloid peptide (Abeta42) is internalized via the G-protein-
RT   coupled receptor FPRL1 and forms fibrillar aggregates in
RT   macrophages.";
RL   FASEB J. 15:2454-2462(2001).
RN   [62]
RP   INTERACTION WITH BBP.
RX   PubMed=11278849; DOI=10.1074/jbc.M011161200;
RA   Kajkowski E.M., Lo C.F., Ning X., Walker S., Sofia H.J., Wang W.,
RA   Edris W., Chanda P., Wagner E., Vile S., Ryan K., McHendry-Rinde B.,
RA   Smith S.C., Wood A., Rhodes K.J., Kennedy J.D., Bard J.,
RA   Jacobsen J.S., Ozenberger B.A.;
RT   "Beta-amyloid peptide-induced apoptosis regulated by a novel protein
RT   containing a G protein activation module.";
RL   J. Biol. Chem. 276:18748-18756(2001).
RN   [63]
RP   BETA-AMYLOID COPPER AND ZINC-BINDING.
RX   PubMed=11274207; DOI=10.1074/jbc.M100175200;
RA   Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S.,
RA   Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., Barnham K.J.;
RT   "Alzheimer's disease amyloid-beta binds copper and zinc to generate an
RT   allosterically ordered structure containing superoxide dismutase-like
RT   subunits.";
RL   J. Biol. Chem. 276:20466-20473(2001).
RN   [64]
RP   SUBUNIT.
RX   PubMed=11438549; DOI=10.1074/jbc.M105410200;
RA   Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D.,
RA   Bayer T.A., Beyreuther K., Multhaup G.;
RT   "Homodimerization of amyloid precursor protein and its implication in
RT   the amyloidogenic pathway of Alzheimer's disease.";
RL   J. Biol. Chem. 276:33923-33929(2001).
RN   [65]
RP   INTERACTION WITH APBB1, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11544248; DOI=10.1074/jbc.C100447200;
RA   Kimberly W.T., Zheng J.B., Guenette S.Y., Selkoe D.J.;
RT   "The intracellular domain of the beta-amyloid precursor protein is
RT   stabilized by Fe65 and translocates to the nucleus in a notch-like
RT   manner.";
RL   J. Biol. Chem. 276:40288-40292(2001).
RN   [66]
RP   INTERACTION WITH FBLN1.
RX   PubMed=11238726; DOI=10.1046/j.1471-4159.2001.00144.x;
RA   Ohsawa I., Takamura C., Kohsaka S.;
RT   "Fibulin-1 binds the amino-terminal head of beta-amyloid precursor
RT   protein and modulates its physiological function.";
RL   J. Neurochem. 76:1411-1420(2001).
RN   [67]
RP   INTERACTION WITH MAPT, AND FUNCTION.
RX   PubMed=11943163; DOI=10.1016/S0014-5793(02)02376-1;
RA   Rank K.B., Pauley A.M., Bhattacharya K., Wang Z., Evans D.B.,
RA   Fleck T.J., Johnston J.A., Sharma S.K.;
RT   "Direct interaction of soluble human recombinant tau protein with
RT   Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau
RT   protein kinase II.";
RL   FEBS Lett. 514:263-268(2002).
RN   [68]
RP   INTERACTION WITH MAPK8IP1, AND MUTAGENESIS OF TYR-757.
RX   PubMed=11724784; DOI=10.1074/jbc.M108357200;
RA   Scheinfeld M.H., Roncarati R., Vito P., Lopez P.A., Abdallah M.,
RA   D'Adamio L.;
RT   "Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the
RT   cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein
RT   (APP).";
RL   J. Biol. Chem. 277:3767-3775(2002).
RN   [69]
RP   COPPER-MEDIATED LIPID PEROXIDATION, AND MUTAGENESIS OF HIS-147 AND
RP   HIS-151.
RX   PubMed=11784781;
RA   White A.R., Multhaup G., Galatis D., McKinstry W.J., Parker M.W.,
RA   Pipkorn R., Beyreuther K., Masters C.L., Cappai R.;
RT   "Contrasting species-dependent modulation of copper-mediated
RT   neurotoxicity by the Alzheimer's disease amyloid precursor protein.";
RL   J. Neurosci. 22:365-376(2002).
RN   [70]
RP   REVIEW ON ZINC-BINDING.
RX   PubMed=12032279; DOI=10.1073/pnas.122249699;
RA   Bush A.I., Tanzi R.E.;
RT   "The galvanization of beta-amyloid in Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7317-7319(2002).
RN   [71]
RP   SUBCELLULAR LOCATION, AND ASSOCIATION OF AMYLOID FIBRILS WITH GCP1.
RX   PubMed=15084524; DOI=10.1096/fj.03-1040fje;
RA   Watanabe N., Araki W., Chui D.H., Makifuchi T., Ihara Y., Tabira T.;
RT   "Glypican-1 as an Abeta binding HSPG in the human brain: its
RT   localization in DIG domains and possible roles in the pathogenesis of
RT   Alzheimer's disease.";
RL   FASEB J. 18:1013-1015(2004).
RN   [72]
RP   INTERACTION WITH ANKS1B.
RX   PubMed=15347684; DOI=10.1074/jbc.M405329200;
RA   Ghersi E., Noviello C., D'Adamio L.;
RT   "Amyloid-beta protein precursor (AbetaPP) intracellular domain-
RT   associated protein-1 proteins bind to AbetaPP and modulate its
RT   processing in an isoform-specific manner.";
RL   J. Biol. Chem. 279:49105-49112(2004).
RN   [73]
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=8131745;
RA   Suzuki T., Oishi M., Marshak D.R., Czernik A.J., Nairn A.C.,
RA   Greengard P.;
RT   "Cell cycle-dependent regulation of the phosphorylation and metabolism
RT   of the Alzheimer amyloid precursor protein.";
RL   EMBO J. 13:1114-1122(1994).
RN   [74]
RP   PHOSPHORYLATION AT SER-198 AND SER-206 BY CASEIN KINASES, AND
RP   MUTAGENESIS OF SER-198 AND SER-206.
RX   PubMed=8999878; DOI=10.1074/jbc.272.3.1896;
RA   Walter J., Capell A., Hung A.Y., Langen H., Schnoelzer M.,
RA   Thinakaran G., Sisodia S.S., Selkoe D.J., Haass C.;
RT   "Ectodomain phosphorylation of beta-amyloid precursor protein at two
RT   distinct cellular locations.";
RL   J. Biol. Chem. 272:1896-1903(1997).
RN   [75]
RP   COPPER-BINDING, AND DISULFIDE BOND FORMATION.
RX   PubMed=9585534; DOI=10.1021/bi980022m;
RA   Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Bill E.,
RA   Pipkorn R., Masters C.L., Beyreuther K.;
RT   "Copper-binding amyloid precursor protein undergoes a site-specific
RT   fragmentation in the reduction of hydrogen peroxide.";
RL   Biochemistry 37:7224-7230(1998).
RN   [76]
RP   CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.
RX   PubMed=10319819; DOI=10.1016/S0092-8674(00)80748-5;
RA   Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y.,
RA   Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E.,
RA   Zheng H., van der Ploeg L.H.T., Ruffolo S.C., Thornberry N.A.,
RA   Xanthoudakis S., Zamboni R.J., Roy S., Nicholson D.W.;
RT   "Involvement of caspases in proteolytic cleavage of Alzheimer's
RT   amyloid-beta precursor protein and amyloidogenic A beta peptide
RT   formation.";
RL   Cell 97:395-406(1999).
RN   [77]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF THR-743.
RX   PubMed=10341243;
RA   Ando K., Oishi M., Takeda S., Iijima K., Isohara T., Nairn A.C.,
RA   Kirino Y., Greengard P., Suzuki T.;
RT   "Role of phosphorylation of Alzheimer's amyloid precursor protein
RT   during neuronal differentiation.";
RL   J. Neurosci. 19:4421-4427(1999).
RN   [78]
RP   CHARACTERIZATION OF CASEIN KINASE PHOSPHORYLATION, AND MUTAGENESIS OF
RP   SER-198 AND SER-206.
RX   PubMed=10806211; DOI=10.1074/jbc.M002850200;
RA   Walter J., Schindzielorz A., Hartung B., Haass C.;
RT   "Phosphorylation of the beta-amyloid precursor protein at the cell
RT   surface by ectocasein kinases 1 and 2.";
RL   J. Biol. Chem. 275:23523-23529(2000).
RN   [79]
RP   CLEAVAGE BY CASPASES, AND MUTAGENESIS OF ASP-739.
RX   PubMed=10742146; DOI=10.1038/74656;
RA   Lu D.C., Rabizadeh S., Chandra S., Shayya R.F., Ellerby L.M., Ye X.,
RA   Salvesen G.S., Koo E.H., Bredesen D.E.;
RT   "A second cytotoxic proteolytic peptide derived from amyloid beta-
RT   protein precursor.";
RL   Nat. Med. 6:397-404(2000).
RN   [80]
RP   PHOSPHORYLATION, INTERACTION WITH APBB1, AND MUTAGENESIS OF THR-743.
RX   PubMed=11517218; DOI=10.1074/jbc.M104059200;
RA   Ando K., Iijima K., Elliott J.I., Kirino Y., Suzuki T.;
RT   "Phosphorylation-dependent regulation of the interaction of amyloid
RT   precursor protein with Fe65 affects the production of beta-amyloid.";
RL   J. Biol. Chem. 276:40353-40361(2001).
RN   [81]
RP   PHOSPHORYLATION BY MAPK10, AND MUTAGENESIS OF THR-743.
RX   PubMed=11146006; DOI=10.1046/j.1471-4159.2001.00102.x;
RA   Standen C.L., Brownlees J., Grierson A.J., Kesavapany S., Lau K.-F.,
RA   McLoughlin D.M., Miller C.C.J.;
RT   "Phosphorylation of thr(668) in the cytoplasmic domain of the
RT   Alzheimer's disease amyloid precursor protein by stress-activated
RT   protein kinase 1b (Jun N-terminal kinase-3).";
RL   J. Neurochem. 76:316-320(2001).
RN   [82]
RP   CLEAVAGE AT LEU-720.
RX   PubMed=11851430; DOI=10.1021/bi015794o;
RA   Weidemann A., Eggert S., Reinhard F.B.M., Vogel M., Paliga K.,
RA   Baier G., Masters C.L., Beyreuther K., Evin G.;
RT   "A novel epsilon-cleavage within the transmembrane domain of the
RT   Alzheimer amyloid precursor protein demonstrates homology with Notch
RT   processing.";
RL   Biochemistry 41:2825-2835(2002).
RN   [83]
RP   PHOSPHORYLATION AT TYR-757, INTERACTION WITH SHC1, AND MUTAGENESIS OF
RP   THR-743 AND TYR-757.
RX   PubMed=11877420; DOI=10.1074/jbc.M110286200;
RA   Tarr P.E., Roncarati R., Pelicci G., Pelicci P.G., D'Adamio L.;
RT   "Tyrosine phosphorylation of the beta-amyloid precursor protein
RT   cytoplasmic tail promotes interaction with Shc.";
RL   J. Biol. Chem. 277:16798-16804(2002).
RN   [84]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-542.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [85]
RP   SIGNAL SEQUENCE CLEAVAGE SITE, AND TOPOLOGY.
RX   PubMed=2900137;
RA   Dyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.-G.,
RA   Kang J., Mueller-Hill B., Masters C.L., Beyreuther K.;
RT   "Identification, transmembrane orientation and biogenesis of the
RT   amyloid A4 precursor of Alzheimer's disease.";
RL   EMBO J. 7:949-957(1988).
RN   [86]
RP   REVIEW.
RX   PubMed=12142279; DOI=10.1146/annurev.cellbio.18.020402.142302;
RA   Annaert W., De Strooper B.;
RT   "A cell biological perspective on Alzheimer's disease.";
RL   Annu. Rev. Cell Dev. Biol. 18:25-51(2002).
RN   [87]
RP   INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R.,
RA   Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X.,
RA   Bales K.R., Cappai R., Masters C.L., Gliemann J., Mufson E.J.,
RA   Hyman B.T., Paul S.M., Nykjaer A., Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates
RT   processing of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [88]
RP   INTERACTION WITH APBB1.
RX   PubMed=18468999; DOI=10.1074/jbc.M801827200;
RA   Nakaya T., Kawai T., Suzuki T.;
RT   "Regulation of FE65 nuclear translocation and function by amyloid
RT   beta-protein precursor in osmotically stressed cells.";
RL   J. Biol. Chem. 283:19119-19131(2008).
RN   [89]
RP   INTERACTION WITH ITM2C.
RX   PubMed=19366692; DOI=10.1074/jbc.M109.006403;
RA   Matsuda S., Matsuda Y., D'Adamio L.;
RT   "BRI3 inhibits amyloid precursor protein processing in a
RT   mechanistically distinct manner from its homologue dementia gene
RT   BRI2.";
RL   J. Biol. Chem. 284:15815-15825(2009).
RN   [90]
RP   FUNCTION, CLEAVAGE, AND INTERACTION WITH TNFRSF21.
RX   PubMed=19225519; DOI=10.1038/nature07767;
RA   Nikolaev A., McLaughlin T., O'Leary D.D.M., Tessier-Lavigne M.;
RT   "APP binds DR6 to trigger axon pruning and neuron death via distinct
RT   caspases.";
RL   Nature 457:981-989(2009).
RN   [91]
RP   FUNCTION, AND INTERACTION WITH AGER.
RX   PubMed=19901339; DOI=10.1073/pnas.0905686106;
RA   Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A.,
RA   McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D.,
RA   Hori O., Ogawa S., Stern D.M., Yamada K., Yan S.S.;
RT   "RAGE-mediated signaling contributes to intraneuronal transport of
RT   amyloid-{beta} and neuronal dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:20021-20026(2009).
RN   [92]
RP   INTERACTION WITH GSAP.
RX   PubMed=20811458; DOI=10.1038/nature09325;
RA   He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J.,
RA   Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., Greengard P.;
RT   "Gamma-secretase activating protein is a therapeutic target for
RT   Alzheimer's disease.";
RL   Nature 467:95-98(2010).
RN   [93]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [94]
RP   GLYCOSYLATION AT THR-633; THR-651; THR-652; SER-656; THR-663 AND
RP   SER-667 PROTEOLYTIC PROCESSING, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21712440; DOI=10.1073/pnas.1102664108;
RA   Halim A., Brinkmalm G., Ruetschi U., Westman-Brinkmalm A.,
RA   Portelius E., Zetterberg H., Blennow K., Larson G., Nilsson J.;
RT   "Site-specific characterization of threonine, serine, and tyrosine
RT   glycosylations of amyloid precursor protein/amyloid beta-peptides in
RT   human cerebrospinal fluid.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11848-11853(2011).
RN   [95]
RP   INTERACTION WITH S100A9.
RX   PubMed=22457725; DOI=10.1371/journal.pone.0032953;
RA   Zhang C., Liu Y., Gilthorpe J., van der Maarel J.R.;
RT   "MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide
RT   and induces its fibrillization.";
RL   PLoS ONE 7:E32953-E32953(2012).
RN   [96]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-743, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [97]
RP   INTERACTION WITH PLD3.
RX   PubMed=24336208; DOI=10.1038/nature12825;
RG   UK Brain Expression Consortium;
RA   Cruchaga C., Karch C.M., Jin S.C., Benitez B.A., Cai Y., Guerreiro R.,
RA   Harari O., Norton J., Budde J., Bertelsen S., Jeng A.T., Cooper B.,
RA   Skorupa T., Carrell D., Levitch D., Hsu S., Choi J., Ryten M.,
RA   Hardy J., Ryten M., Trabzuni D., Weale M.E., Ramasamy A., Smith C.,
RA   Sassi C., Bras J., Gibbs J.R., Hernandez D.G., Lupton M.K., Powell J.,
RA   Forabosco P., Ridge P.G., Corcoran C.D., Tschanz J.T., Norton M.C.,
RA   Munger R.G., Schmutz C., Leary M., Demirci F.Y., Bamne M.N., Wang X.,
RA   Lopez O.L., Ganguli M., Medway C., Turton J., Lord J., Braae A.,
RA   Barber I., Brown K., Passmore P., Craig D., Johnston J.,
RA   McGuinness B., Todd S., Heun R., Kolsch H., Kehoe P.G., Hooper N.M.,
RA   Vardy E.R., Mann D.M., Pickering-Brown S., Brown K., Kalsheker N.,
RA   Lowe J., Morgan K., David Smith A., Wilcock G., Warden D., Holmes C.,
RA   Pastor P., Lorenzo-Betancor O., Brkanac Z., Scott E., Topol E.,
RA   Morgan K., Rogaeva E., Singleton A.B., Hardy J., Kamboh M.I.,
RA   St George-Hyslop P., Cairns N., Morris J.C., Kauwe J.S., Goate A.M.;
RT   "Rare coding variants in the phospholipase D3 gene confer risk for
RT   Alzheimer's disease.";
RL   Nature 505:550-554(2014).
RN   [98]
RP   INTERACTION WITH VDAC1.
RX   PubMed=25168729; DOI=10.1016/j.neuroscience.2014.07.079;
RA   Fernandez-Echevarria C., Diaz M., Ferrer I., Canerina-Amaro A.,
RA   Marin R.;
RT   "Abeta promotes VDAC1 channel dephosphorylation in neuronal lipid
RT   rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's
RT   disease.";
RL   Neuroscience 278:354-366(2014).
RN   [99]
RP   PHOSPHORYLATION AT SER-441 AND TYR-497.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [100]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 287-344.
RX   PubMed=2125487; DOI=10.1021/bi00495a002;
RA   Hynes T.R., Randal M., Kennedy L.A., Eigenbrot C., Kossiakof A.A.;
RT   "X-ray crystal structure of the protease inhibitor domain of
RT   Alzheimer's amyloid beta-protein precursor.";
RL   Biochemistry 29:10018-10022(1990).
RN   [101]
RP   STRUCTURE BY NMR OF 289-344.
RX   PubMed=1718421; DOI=10.1021/bi00107a015;
RA   Heald S.L., Tilton R.F. Jr., Hammond L.S., Lee A., Bayney R.M.,
RA   Kamarck M.E., Ramabhadran T.V., Dreyer R.N., Davis G., Unterbeck A.,
RA   Tamburini P.P.;
RT   "Sequential NMR resonance assignment and structure determination of
RT   the Kunitz-type inhibitor domain of the Alzheimer's beta-amyloid
RT   precursor protein.";
RL   Biochemistry 30:10467-10478(1991).
RN   [102]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=7516706; DOI=10.1021/bi00191a006;
RA   Talafous J., Marcinowski K.J., Klopman G., Zagorski M.G.;
RT   "Solution structure of residues 1-28 of the amyloid beta-peptide.";
RL   Biochemistry 33:7788-7796(1994).
RN   [103]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=7588758; DOI=10.1111/j.1432-1033.1995.293_1.x;
RA   Sticht H., Bayer P., Willbold D., Dames S., Hilbich C., Beyreuther K.,
RA   Frank R.W., Rosch P.;
RT   "Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease.";
RL   Eur. J. Biochem. 233:293-298(1995).
RN   [104]
RP   STRUCTURE BY NMR OF 696-706.
RX   PubMed=8973180; DOI=10.1021/bi961598j;
RA   Kohno T., Kobayashi K., Maeda T., Sato K., Takashima A.;
RT   "Three-dimensional structures of the amyloid beta peptide (25-35) in
RT   membrane-mimicking environment.";
RL   Biochemistry 35:16094-16104(1996).
RN   [105]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF KUNITZ DOMAIN IN COMPLEX WITH
RP   CHYMOTRYPSIN; TRYPSIN AND BASIC PANCREATIC TRYPSIN INHIBITOR.
RX   PubMed=9300481; DOI=10.1002/pro.5560060902;
RA   Scheidig A.J., Hynes T.R., Pelletier L.A., Wells J.A.,
RA   Kossiakoff A.A.;
RT   "Crystal structures of bovine chymotrypsin and trypsin complexed to
RT   the inhibitor domain of Alzheimer's amyloid beta-protein precursor
RT   (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of
RT   inhibitors with altered specificities.";
RL   Protein Sci. 6:1806-1824(1997).
RN   [106]
RP   STRUCTURE BY NMR OF 672-711.
RX   PubMed=9693002; DOI=10.1021/bi972979f;
RA   Coles M., Bicknell W., Watson A.A., Fairlie D.P., Craik D.J.;
RT   "Solution structure of amyloid beta-peptide(1-40) in a water-micelle
RT   environment. Is the membrane-spanning domain where we think it is?";
RL   Biochemistry 37:11064-11077(1998).
RN   [107]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 28-123.
RX   PubMed=10201399; DOI=10.1038/7562;
RA   Rossjohn J., Cappai R., Feil S.C., Henry A., McKinstry W.J.,
RA   Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C.L.,
RA   Parker M.W.;
RT   "Crystal structure of the N-terminal, growth factor-like domain of
RT   Alzheimer amyloid precursor protein.";
RL   Nat. Struct. Biol. 6:327-331(1999).
RN   [108]
RP   STRUCTURE OF CAA-APP VARIANTS.
RX   PubMed=10821838; DOI=10.1074/jbc.M003154200;
RA   Miravalle L., Tokuda T., Chiarle R., Giaccone G., Bugiani O.,
RA   Tagliavini F., Frangione B., Ghiso J.;
RT   "Substitutions at codon 22 of Alzheimer's Abeta peptide induce diverse
RT   conformational changes and apoptotic effects in human cerebral
RT   endothelial cells.";
RL   J. Biol. Chem. 275:27110-27116(2000).
RN   [109]
RP   STRUCTURE BY NMR OF 681-706.
RX   PubMed=10940221; DOI=10.1006/jsbi.2000.4288;
RA   Zhang S., Iwata K., Lachenmann M.J., Peng J.W., Li S., Stimson E.R.,
RA   Lu Y., Felix A.M., Maggio J.E., Lee J.P.;
RT   "The Alzheimer's peptide a beta adopts a collapsed coil structure in
RT   water.";
RL   J. Struct. Biol. 130:130-141(2000).
RN   [110]
RP   STRUCTURE BY NMR OF 672-699.
RX   PubMed=10940222; DOI=10.1006/jsbi.2000.4267;
RA   Poulsen S.-A., Watson A.A., Craik D.J.;
RT   "Solution structures in aqueous SDS micelles of two amyloid beta
RT   peptides of Abeta(1-28) mutated at the alpha-secretase cleavage
RT   site.";
RL   J. Struct. Biol. 130:142-152(2000).
RN   [111]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 346-551, PARTIAL PROTEIN
RP   SEQUENCE, MUTAGENESIS OF ARG-499 AND LYS-503, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=15304215; DOI=10.1016/j.molcel.2004.06.037;
RA   Wang Y., Ha Y.;
RT   "The X-ray structure of an antiparallel dimer of the human amyloid
RT   precursor protein E2 domain.";
RL   Mol. Cell 15:343-353(2004).
RN   [112]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 672-711 IN COMPLEX WITH IDE.
RX   PubMed=17051221; DOI=10.1038/nature05143;
RA   Shen Y., Joachimiak A., Rosner M.R., Tang W.-J.;
RT   "Structures of human insulin-degrading enzyme reveal a new substrate
RT   recognition mechanism.";
RL   Nature 443:870-874(2006).
RN   [113]
RP   X-RAY CRYSTALLOGRAPHY (0.85 ANGSTROMS) OF 133-189, AND DISULFIDE
RP   BONDS.
RX   PubMed=17909280; DOI=10.1107/S1744309107041139;
RA   Kong G.K., Adams J.J., Cappai R., Parker M.W.;
RT   "Structure of Alzheimer's disease amyloid precursor protein copper-
RT   binding domain at atomic resolution.";
RL   Acta Crystallogr. F 63:819-824(2007).
RN   [114]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 133-189 IN COMPLEXES WITH
RP   COPPER IONS, AND DISULFIDE BONDS.
RX   PubMed=17239395; DOI=10.1016/j.jmb.2006.12.041;
RA   Kong G.K., Adams J.J., Harris H.H., Boas J.F., Curtain C.C.,
RA   Galatis D., Masters C.L., Barnham K.J., McKinstry W.J., Cappai R.,
RA   Parker M.W.;
RT   "Structural studies of the Alzheimer's amyloid precursor protein
RT   copper-binding domain reveal how it binds copper ions.";
RL   J. Mol. Biol. 367:148-161(2007).
RN   [115]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 672-679 IN COMPLEX WITH IGG.
RX   PubMed=17895381; DOI=10.1073/pnas.0705888104;
RA   Gardberg A.S., Dice L.T., Ou S., Rich R.L., Helmbrecht E., Ko J.,
RA   Wetzel R., Myszka D.G., Patterson P.H., Dealwis C.;
RT   "Molecular basis for passive immunotherapy of Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:15659-15664(2007).
RN   [116]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 672-678 IN COMPLEXES WITH
RP   ANTIBODY FAB FRAGMENTS.
RX   PubMed=19923222; DOI=10.1074/jbc.M109.045187;
RA   Basi G.S., Feinberg H., Oshidari F., Anderson J., Barbour R.,
RA   Baker J., Comery T.A., Diep L., Gill D., Johnson-Wood K., Goel A.,
RA   Grantcharova K., Lee M., Li J., Partridge A., Griswold-Prenner I.,
RA   Piot N., Walker D., Widom A., Pangalos M.N., Seubert P.,
RA   Jacobsen J.S., Schenk D., Weis W.I.;
RT   "Structural correlates of antibodies associated with acute reversal of
RT   amyloid beta-related behavioral deficits in a mouse model of Alzheimer
RT   disease.";
RL   J. Biol. Chem. 285:3417-3427(2010).
RN   [117]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 18-190, PARTIAL PROTEIN
RP   SEQUENCE, SUBUNIT, DISULFIDE BONDS, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20212142; DOI=10.1073/pnas.0911326107;
RA   Dahms S.O., Hoefgen S., Roeser D., Schlott B., Guhrs K.H., Than M.E.;
RT   "Structure and biochemical analysis of the heparin-induced E1 dimer of
RT   the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:5381-5386(2010).
RN   [118]
RP   REVIEW ON VARIANTS.
RX   PubMed=1363811; DOI=10.1038/ng0792-233;
RA   Hardy J.;
RT   "Framing beta-amyloid.";
RL   Nat. Genet. 1:233-234(1992).
RN   [119]
RP   VARIANT CAA-APP GLN-693.
RX   PubMed=2111584; DOI=10.1126/science.2111584;
RA   Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D.,
RA   Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W.,
RA   Frangione B.;
RT   "Mutation of the Alzheimer's disease amyloid gene in hereditary
RT   cerebral hemorrhage, Dutch type.";
RL   Science 248:1124-1126(1990).
RN   [120]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1671712; DOI=10.1038/349704a0;
RA   Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F.,
RA   Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R.,
RA   Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M.,
RA   Roses A.D., Williamson R., Rossor M., Owen M., Hardy J.;
RT   "Segregation of a missense mutation in the amyloid precursor protein
RT   gene with familial Alzheimer's disease.";
RL   Nature 349:704-706(1991).
RN   [121]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1908231; DOI=10.1016/0006-291X(91)91011-Z;
RA   Yoshioka K., Miki T., Katsuya T., Ogihara T., Sakaki Y.;
RT   "The 717Val-->Ile substitution in amyloid precursor protein is
RT   associated with familial Alzheimer's disease regardless of ethnic
RT   groups.";
RL   Biochem. Biophys. Res. Commun. 178:1141-1146(1991).
RN   [122]
RP   VARIANT AD1 ILE-717.
RX   PubMed=1678058; DOI=10.1016/0140-6736(91)91612-X;
RA   Naruse S., Igarashi S., Kobayashi H., Aoki K., Inuzuka T., Kaneko K.,
RA   Shimizu T., Iihara K., Kojima T., Miyatake T., Tsuji S.;
RT   "Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein
RT   gene in Japanese familial Alzheimer's disease.";
RL   Lancet 337:978-979(1991).
RN   [123]
RP   VARIANT AD1 GLY-717.
RX   PubMed=1944558; DOI=10.1038/353844a0;
RA   Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D.,
RA   Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M.;
RT   "Early-onset Alzheimer's disease caused by mutations at codon 717 of
RT   the beta-amyloid precursor protein gene.";
RL   Nature 353:844-846(1991).
RN   [124]
RP   VARIANT AD1 PHE-717.
RX   PubMed=1925564; DOI=10.1126/science.1925564;
RA   Murrell J.R., Farlow M., Ghetti B., Benson M.D.;
RT   "A mutation in the amyloid precursor protein associated with
RT   hereditary Alzheimer's disease.";
RL   Science 254:97-99(1991).
RN   [125]
RP   VARIANT AD1 GLY-693.
RX   PubMed=1415269;
RA   Kamino K., Orr H.T., Payami H., Wijsman E.M., Alonso M.E., Pulst S.M.,
RA   Anderson L., O'Dahl S., Nemens E., White J.A., Sadovnick A.D.,
RA   Ball M.J., Kaye J., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Korenberg J.R., Sharma V., Kukull W., Larson E., Heston L.L.,
RA   Martin G.M., Bird T.D., Schellenberg G.D.;
RT   "Linkage and mutational analysis of familial Alzheimer disease
RT   kindreds for the APP gene region.";
RL   Am. J. Hum. Genet. 51:998-1014(1992).
RN   [126]
RP   VARIANT AD1 GLY-692.
RX   PubMed=1303239; DOI=10.1038/ng0692-218;
RA   Hendriks L., van Duijn C.M., Cras P., Cruts M., Van Hul W.,
RA   van Harskamp F., Warren A., McInnis M.G., Antonarakis S.E.,
RA   Martin J.J., Hofman A., Van Broeckhoven C.;
RT   "Presenile dementia and cerebral haemorrhage linked to a mutation at
RT   codon 692 of the beta-amyloid precursor protein gene.";
RL   Nat. Genet. 1:218-221(1992).
RN   [127]
RP   VARIANT AD1 670-ASN-LEU-671.
RX   PubMed=1302033; DOI=10.1038/ng0892-345;
RA   Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B.,
RA   Lannfelt L.;
RT   "A pathogenic mutation for probable Alzheimer's disease in the APP
RT   gene at the N-terminus of beta-amyloid.";
RL   Nat. Genet. 1:345-347(1992).
RN   [128]
RP   VARIANT VAL-713.
RX   PubMed=1307241; DOI=10.1038/ng0792-306;
RA   Jones C.T., Morris S., Yates C.M., Moffoot A., Sharpe C.,
RA   Brock D.J.H., St Clair D.;
RT   "Mutation in codon 713 of the beta amyloid precursor protein gene
RT   presenting with schizophrenia.";
RL   Nat. Genet. 1:306-309(1992).
RN   [129]
RP   VARIANT AD1 THR-713.
RX   PubMed=1303275; DOI=10.1038/ng1292-255;
RA   Carter D.A., Desmarais E., Bellis M., Campion D., Clerget-Darpoux F.,
RA   Brice A., Agid Y., Jaillard-Serradt A., Mallet J.;
RT   "More missense in amyloid gene.";
RL   Nat. Genet. 2:255-256(1992).
RN   [130]
RP   VARIANTS AD1 ILE-717 AND PHE-717.
RX   PubMed=8267572; DOI=10.1006/bbrc.1993.2491;
RA   Liepnieks J.J., Ghetti B., Farlow M., Roses A.D., Benson M.D.;
RT   "Characterization of amyloid fibril beta-peptide in familial
RT   Alzheimer's disease with APP717 mutations.";
RL   Biochem. Biophys. Res. Commun. 197:386-392(1993).
RN   [131]
RP   VARIANT ASP-665.
RX   PubMed=8154870; DOI=10.1002/ana.410350410;
RA   Peacock M.L., Murman D.L., Sima A.A.F., Warren J.T. Jr., Roses A.D.,
RA   Fink J.K.;
RT   "Novel amyloid precursor protein gene mutation (codon 665Asp) in a
RT   patient with late-onset Alzheimer's disease.";
RL   Ann. Neurol. 35:432-438(1994).
RN   [132]
RP   VARIANT AD1 PHE-717.
RX   PubMed=8290042; DOI=10.1212/WNL.44.1.105;
RA   Farlow M., Murrell J., Ghetti B., Unverzagt F., Zeldenrust S.,
RA   Benson M.D.;
RT   "Clinical characteristics in a kindred with early-onset Alzheimer's
RT   disease and their linkage to a G-->T change at position 2149 of the
RT   amyloid precursor protein gene.";
RL   Neurology 44:105-111(1994).
RN   [133]
RP   VARIANT AD1 ILE-717.
RX   PubMed=8577393; DOI=10.1016/0304-3940(95)12046-7;
RA   Brooks W.S., Martins R.N., De Voecht J., Nicholson G.A.,
RA   Schofield P.R., Kwok J.B.J., Fisher C., Yeung L.U.,
RA   Van Broeckhoven C.;
RT   "A mutation in codon 717 of the amyloid precursor protein gene in an
RT   Australian family with Alzheimer's disease.";
RL   Neurosci. Lett. 199:183-186(1995).
RN   [134]
RP   VARIANT AD1 VAL-716.
RX   PubMed=9328472; DOI=10.1093/hmg/6.12.2087;
RA   Eckman C.B., Mehta N.D., Crook R., Perez-Tur J., Prihar G.,
RA   Pfeiffer E., Graff-Radford N., Hinder P., Yager D., Zenk B.,
RA   Refolo L.M., Prada C.M., Younkin S.G., Hutton M., Hardy J.;
RT   "A new pathogenic mutation in the APP gene (I716V) increases the
RT   relative proportion of A beta 42(43).";
RL   Hum. Mol. Genet. 6:2087-2089(1997).
RN   [135]
RP   VARIANT AD1 GLY-692, AND CHARACTERIZATION OF PHENOTYPE.
RX   PubMed=9754958; DOI=10.1007/s004010050892;
RA   Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C.M.,
RA   Stefanko S.Z., Hofman A., Kros J.M., Van Broeckhoven C., Martin J.J.;
RT   "Presenile Alzheimer dementia characterized by amyloid angiopathy and
RT   large amyloid core type senile plaques in the APP 692Ala-->Gly
RT   mutation.";
RL   Acta Neuropathol. 96:253-260(1998).
RN   [136]
RP   VARIANT AD1 MET-715, AND CHARACTERIZATION OF VARIANT AD1 MET-715.
RX   PubMed=10097173; DOI=10.1073/pnas.96.7.4119;
RA   Ancolio K., Dumanchin C., Barelli H., Warter J.-M., Brice A.,
RA   Campion D., Frebourg T., Checler F.;
RT   "Unusual phenotypic alteration of beta amyloid precursor protein
RT   (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation
RT   responsible for probable early-onset Alzheimer's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4119-4124(1999).
RN   [137]
RP   VARIANT AD1 ILE-717.
RX   PubMed=10631141; DOI=10.1086/302702;
RA   Finckh U., Mueller-Thomsen T., Mann U., Eggers C., Marksteiner J.,
RA   Meins W., Binetti G., Alberici A., Hock C., Nitsch R.M., Gal A.;
RT   "High prevalence of pathogenic mutations in patients with early-onset
RT   dementia detected by sequence analyses of four different genes.";
RL   Am. J. Hum. Genet. 66:110-117(2000).
RN   [138]
RP   VARIANT AD1 PRO-723.
RX   PubMed=10665499;
RX   DOI=10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.0.CO;2-8;
RA   Kwok J.B.J., Li Q.X., Hallupp M., Whyte S., Ames D., Beyreuther K.,
RA   Masters C.L., Schofield P.R.;
RT   "Novel Leu723Pro amyloid precursor protein mutation increases amyloid
RT   beta42(43) peptide levels and induces apoptosis.";
RL   Ann. Neurol. 47:249-253(2000).
RN   [139]
RP   VARIANT AD1 LEU-717.
RX   PubMed=10867787; DOI=10.1001/archneur.57.6.885;
RA   Murrell J.R., Hake A.M., Quaid K.A., Farlow M.R., Ghetti B.;
RT   "Early-onset Alzheimer disease caused by a new mutation (V717L) in the
RT   amyloid precursor protein gene.";
RL   Arch. Neurol. 57:885-887(2000).
RN   [140]
RP   VARIANT AD1 ILE-714, CHARACTERIZATION OF VARIANT AD1 ILE-714, AND
RP   MUTAGENESIS OF VAL-717.
RX   PubMed=11063718; DOI=10.1093/hmg/9.18.2589;
RA   Kumar-Singh S., De Jonghe C., Cruts M., Kleinert R., Wang R.,
RA   Mercken M., De Strooper B., Vanderstichele H., Loefgren A.,
RA   Vanderhoeven I., Backhovens H., Vanmechelen E., Kroisel P.M.,
RA   Van Broeckhoven C.;
RT   "Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase
RT   site mutation points to an essential role for N-truncated A beta(42)
RT   in Alzheimer's disease.";
RL   Hum. Mol. Genet. 9:2589-2598(2000).
RN   [141]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=11409420; DOI=10.1002/ana.1009;
RA   Grabowski T.J., Cho H.S., Vonsattel J.P.G., Rebeck G.W.,
RA   Greenberg S.M.;
RT   "Novel amyloid precursor protein mutation in an Iowa family with
RT   dementia and severe cerebral amyloid angiopathy.";
RL   Ann. Neurol. 49:697-705(2001).
RN   [142]
RP   CHARACTERIZATION OF VARIANT AD1 GLY-692.
RX   PubMed=11311152;
RA   Walsh D.M., Hartley D.M., Condron M.M., Selkoe D.J., Teplow D.B.;
RT   "In vitro studies of amyloid beta-protein fibril assembly and toxicity
RT   provide clues to the aetiology of Flemish variant (Ala692-->Gly)
RT   Alzheimer's disease.";
RL   Biochem. J. 355:869-877(2001).
RN   [143]
RP   VARIANT AD1 GLY-693.
RX   PubMed=11528419; DOI=10.1038/nn0901-887;
RA   Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M.,
RA   Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B.,
RA   Younkin S.G., Naeslund J., Lannfelt L.;
RT   "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by
RT   enhanced Abeta protofibril formation.";
RL   Nat. Neurosci. 4:887-893(2001).
RN   [144]
RP   VARIANT AD1 ALA-714.
RX   PubMed=12034808; DOI=10.1212/WNL.58.10.1574;
RA   Pasalar P., Najmabadi H., Noorian A.R., Moghimi B., Jannati A.,
RA   Soltanzadeh A., Krefft T., Crook R., Hardy J.;
RT   "An Iranian family with Alzheimer's disease caused by a novel APP
RT   mutation (Thr714Ala).";
RL   Neurology 58:1574-1575(2002).
RN   [145]
RP   VARIANT CAA-APP ASN-694.
RX   PubMed=12654973; DOI=10.1212/01.WNL.0000050140.10044.A8;
RA   Greenberg S.M., Shin Y., Grabowski T.J., Cooper G.E., Rebeck G.W.,
RA   Iglesias S., Chapon F., Tournier-Lasserve E., Baron J.-C.;
RT   "Hemorrhagic stroke associated with the Iowa amyloid precursor protein
RT   mutation.";
RL   Neurology 60:1020-1022(2003).
RN   [146]
RP   VARIANT AD1 THR-713.
RX   PubMed=15365148; DOI=10.1212/01.WNL.0000137048.80666.86;
RA   Rossi G., Giaccone G., Maletta R., Morbin M., Capobianco R.,
RA   Mangieri M., Giovagnoli A.R., Bizzi A., Tomaino C., Perri M.,
RA   Di Natale M., Tagliavini F., Bugiani O., Bruni A.C.;
RT   "A family with Alzheimer disease and strokes associated with A713T
RT   mutation of the APP gene.";
RL   Neurology 63:910-912(2004).
RN   [147]
RP   VARIANT CAA-APP VAL-705.
RX   PubMed=16178030; DOI=10.1002/ana.20571;
RA   Obici L., Demarchi A., de Rosa G., Bellotti V., Marciano S.,
RA   Donadei S., Arbustini E., Palladini G., Diegoli M., Genovese E.,
RA   Ferrari G., Coverlizza S., Merlini G.;
RT   "A novel AbetaPP mutation exclusively associated with cerebral amyloid
RT   angiopathy.";
RL   Ann. Neurol. 58:639-644(2005).
RN   [148]
RP   VARIANT AD1 ILE-714.
RX   PubMed=15668448; DOI=10.1212/01.WNL.0000149761.70566.3E;
RA   Edwards-Lee T., Ringman J.M., Chung J., Werner J., Morgan A.,
RA   St George-Hyslop P.H., Thompson P., Dutton R., Mlikotic A.,
RA   Rogaeva E., Hardy J.;
RT   "An African American family with early-onset Alzheimer disease and an
RT   APP (T714I) mutation.";
RL   Neurology 64:377-379(2005).
RN   [149]
RP   VARIANT CAA-APP LYS-693.
RX   PubMed=20697050; DOI=10.1001/archneurol.2010.178;
RA   Bugiani O., Giaccone G., Rossi G., Mangieri M., Capobianco R.,
RA   Morbin M., Mazzoleni G., Cupidi C., Marcon G., Giovagnoli A.,
RA   Bizzi A., Di Fede G., Puoti G., Carella F., Salmaggi A., Romorini A.,
RA   Patruno G.M., Magoni M., Padovani A., Tagliavini F.;
RT   "Hereditary cerebral hemorrhage with amyloidosis associated with the
RT   E693K mutation of APP.";
RL   Arch. Neurol. 67:987-995(2010).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to
CC       neurite growth, neuronal adhesion and axonogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions. Can promote transcription activation through binding
CC       to APBB1-KAT5 and inhibits Notch signaling through interaction
CC       with Numb. Couples to apoptosis-inducing pathways such as those
CC       mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By
CC       similarity). Acts as a kinesin I membrane receptor, mediating the
CC       axonal transport of beta-secretase and presenilin 1. Involved in
CC       copper homeostasis/oxidative stress through copper ion reduction.
CC       In vitro, copper-metallated APP induces neuronal death directly or
CC       is potentiated through Cu(2+)-mediated low-density lipoprotein
CC       oxidation. Can regulate neurite outgrowth through binding to
CC       components of the extracellular matrix such as heparin and
CC       collagen I and IV. The splice isoforms that contain the BPTI
CC       domain possess protease inhibitor activity. Induces a AGER-
CC       dependent pathway that involves activation of p38 MAPK, resulting
CC       in internalization of amyloid-beta peptide and leading to
CC       mitochondrial dysfunction in cultured cortical neurons. Provides
CC       Cu(2+) ions for GPC1 which are required for release of nitric
CC       oxide (NO) and subsequent degradation of the heparan sulfate
CC       chains on GPC1. {ECO:0000250}.
CC   -!- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators
CC       with metal-reducing activity. Bind transient metals such as
CC       copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to
CC       Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more
CC       effective reductant than beta-amyloid 40. Beta-amyloid peptides
CC       bind to lipoproteins and apolipoproteins E and J in the CSF and to
CC       HDL particles in plasma, inhibiting metal-catalyzed oxidation of
CC       lipoproteins. Beta-APP42 may activate mononuclear phagocytes in
CC       the brain and elicit inflammatory responses. Promotes both tau
CC       aggregation and TPK II-mediated phosphorylation. Interaction with
CC       overexpressed HADH2 leads to oxidative stress and neurotoxicity.
CC       Also binds GPC1 in lipid rafts.
CC   -!- FUNCTION: Appicans elicit adhesion of neural cells to the
CC       extracellular matrix and may regulate neurite outgrowth in the
CC       brain. {ECO:0000250}.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal
CC       apoptosis.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and
CC       axons (via caspase-6).
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA
CC       family, MAPK8IP1, SHC1 and, NUMB and DAB1 (By similarity). Binding
CC       to DAB1 inhibits its serine phosphorylation (By similarity).
CC       Interacts (via NPXY motif) with DAB2 (via PID domain); the
CC       interaction is impaired by tyrosine phosphorylation of the NPXY
CC       motif. Also interacts with GPCR-like protein BPP, FPRL1, APPBP1,
CC       IB1, KNS2 (via its TPR domains) (By similarity), APPBP2 (via BaSS)
CC       and DDB1. In vitro, it binds MAPT via the MT-binding domains (By
CC       similarity). Associates with microtubules in the presence of ATP
CC       and in a kinesin-dependent manner (By similarity). Interacts,
CC       through a C-terminal domain, with GNAO1. Amyloid beta-42 binds
CC       CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2.
CC       Soluble APP binds, via its N-terminal head, to FBLN1. Interacts
CC       with CPEB1 and AGER (By similarity). Interacts with ANKS1B and
CC       TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts
CC       with IDE. Can form homodimers; this is promoted by heparin
CC       binding. Beta-amyloid protein 40 interacts with S100A9. CTF-alpha
CC       product of APP interacts with GSAP. Interacts with SORL1.
CC       Interacts with PLD3. Interacts with VDAC1 (PubMed:25168729).
CC       {ECO:0000250, ECO:0000269|PubMed:10681545,
CC       ECO:0000269|PubMed:10816430, ECO:0000269|PubMed:11238726,
CC       ECO:0000269|PubMed:11278849, ECO:0000269|PubMed:11438549,
CC       ECO:0000269|PubMed:11517218, ECO:0000269|PubMed:11544248,
CC       ECO:0000269|PubMed:11689470, ECO:0000269|PubMed:11724784,
CC       ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:11943163,
CC       ECO:0000269|PubMed:15347684, ECO:0000269|PubMed:16174740,
CC       ECO:0000269|PubMed:17051221, ECO:0000269|PubMed:17895381,
CC       ECO:0000269|PubMed:18468999, ECO:0000269|PubMed:19225519,
CC       ECO:0000269|PubMed:19366692, ECO:0000269|PubMed:19901339,
CC       ECO:0000269|PubMed:20212142, ECO:0000269|PubMed:20811458,
CC       ECO:0000269|PubMed:22457725, ECO:0000269|PubMed:24336208,
CC       ECO:0000269|PubMed:25168729, ECO:0000269|PubMed:8446172,
CC       ECO:0000269|PubMed:8626687, ECO:0000269|PubMed:8855266,
CC       ECO:0000269|PubMed:8887653, ECO:0000269|PubMed:9300481,
CC       ECO:0000269|PubMed:9338779, ECO:0000269|PubMed:9843960,
CC       ECO:0000269|PubMed:9890987}.
CC   -!- INTERACTION:
CC       Self; NbExp=104; IntAct=EBI-77613, EBI-77613;
CC       Q306T3:- (xeno); NbExp=3; IntAct=EBI-77613, EBI-8294101;
CC       P31696:AGRN (xeno); NbExp=3; IntAct=EBI-2431589, EBI-457650;
CC       Q02410:APBA1; NbExp=3; IntAct=EBI-77613, EBI-368690;
CC       O00213:APBB1; NbExp=5; IntAct=EBI-77613, EBI-81694;
CC       Q92870:APBB2; NbExp=2; IntAct=EBI-77613, EBI-79277;
CC       P51693:APLP1; NbExp=2; IntAct=EBI-302641, EBI-74648;
CC       Q06481:APLP2; NbExp=2; IntAct=EBI-302641, EBI-79306;
CC       P02647:APOA1; NbExp=5; IntAct=EBI-77613, EBI-701692;
CC       Q13867:BLMH; NbExp=2; IntAct=EBI-302641, EBI-718504;
CC       P15253:CALR (xeno); NbExp=3; IntAct=EBI-77613, EBI-9005200;
CC       P27797:CALR; NbExp=2; IntAct=EBI-77613, EBI-1049597;
CC       Q8K3H7:CALR (xeno); NbExp=2; IntAct=EBI-3894543, EBI-9005068;
CC       P39060:COL18A1; NbExp=2; IntAct=EBI-821758, EBI-2566375;
CC       P07339:CTSD; NbExp=2; IntAct=EBI-77613, EBI-2115097;
CC       O75955:FLOT1; NbExp=5; IntAct=EBI-77613, EBI-603643;
CC       P01100:FOS; NbExp=3; IntAct=EBI-77613, EBI-852851;
CC       P46089:GPR3; NbExp=2; IntAct=EBI-302641, EBI-3909653;
CC       Q9NSC5:HOMER3; NbExp=3; IntAct=EBI-302661, EBI-748420;
CC       Q99714:HSD17B10; NbExp=4; IntAct=EBI-77613, EBI-79964;
CC       O43736:ITM2A; NbExp=3; IntAct=EBI-302641, EBI-2431769;
CC       P05412:JUN; NbExp=2; IntAct=EBI-77613, EBI-852823;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-77613, EBI-476263;
CC       P10636:MAPT; NbExp=9; IntAct=EBI-77613, EBI-366182;
CC       Q93074:MED12; NbExp=2; IntAct=EBI-77613, EBI-394357;
CC       P03897:MT-ND3; NbExp=2; IntAct=EBI-821758, EBI-1246249;
CC       P07196:NEFL; NbExp=2; IntAct=EBI-77613, EBI-475646;
CC       P21359:NF1; NbExp=3; IntAct=EBI-77613, EBI-1172917;
CC       P08138:NGFR; NbExp=2; IntAct=EBI-77613, EBI-1387782;
CC       P07174:Ngfr (xeno); NbExp=2; IntAct=EBI-2431589, EBI-1038810;
CC       P61457:PCBD1; NbExp=2; IntAct=EBI-77613, EBI-740475;
CC       Q15113:PCOLCE; NbExp=3; IntAct=EBI-821758, EBI-8869614;
CC       P30101:PDIA3; NbExp=3; IntAct=EBI-77613, EBI-979862;
CC       Q13526:PIN1; NbExp=2; IntAct=EBI-302641, EBI-714158;
CC       P04156:PRNP; NbExp=3; IntAct=EBI-77613, EBI-977302;
CC       P49768:PSEN1; NbExp=6; IntAct=EBI-77613, EBI-297277;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-77613, EBI-78835;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-77613, EBI-79084;
CC       Q9NP59:SLC40A1; NbExp=5; IntAct=EBI-77613, EBI-725153;
CC       Q8BGY9:Slc5a7 (xeno); NbExp=2; IntAct=EBI-77613, EBI-2010752;
CC       Q9HCB6:SPON1; NbExp=3; IntAct=EBI-302641, EBI-2431846;
CC       P01137:TGFB1; NbExp=3; IntAct=EBI-77613, EBI-779636;
CC       P61812:TGFB2; NbExp=7; IntAct=EBI-77613, EBI-779581;
CC       O75509:TNFRSF21; NbExp=3; IntAct=EBI-77613, EBI-2313231;
CC       Q13625:TP53BP2; NbExp=3; IntAct=EBI-77613, EBI-77642;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Membrane, clathrin-coated pit. Note=Cell surface protein
CC       that rapidly becomes internalized via clathrin-coated pits. During
CC       maturation, the immature APP (N-glycosylated in the endoplasmic
CC       reticulum) moves to the Golgi complex where complete maturation
CC       occurs (O-glycosylated and sulfated). After alpha-secretase
CC       cleavage, soluble APP is released into the extracellular space and
CC       the C-terminal is internalized to endosomes and lysosomes. Some
CC       APP accumulates in secretory transport vesicles leaving the late
CC       Golgi compartment and returns to the cell surface. Gamma-CTF(59)
CC       peptide is located to both the cytoplasm and nuclei of neurons. It
CC       can be translocated to the nucleus through association with APBB1
CC       (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and
CC       the complex is then rapidly internalized. APP sorts to the
CC       basolateral surface in epithelial cells. During neuronal
CC       differentiation, the Thr-743 phosphorylated form is located mainly
CC       in growth cones, moderately in neurites and sparingly in the cell
CC       body. Casein kinase phosphorylation can occur either at the cell
CC       surface or within a post-Golgi compartment. Associates with GPC1
CC       in perinuclear compartments. Colocalizes with SORL1 in a vesicular
CC       pattern in cytoplasm and perinuclear regions.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist. Experimental
CC         confirmation may be lacking for some isoforms.;
CC       Name=APP770; Synonyms=PreA4 770;
CC         IsoId=P05067-1; Sequence=Displayed;
CC         Note=A major isoform.;
CC       Name=APP305;
CC         IsoId=P05067-2; Sequence=VSP_000005, VSP_000006;
CC       Name=L-APP677;
CC         IsoId=P05067-3; Sequence=VSP_000002, VSP_000004, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP695; Synonyms=PreA4 695;
CC         IsoId=P05067-4; Sequence=VSP_000002, VSP_000004;
CC         Note=A major isoform.;
CC       Name=L-APP696;
CC         IsoId=P05067-5; Sequence=VSP_000002, VSP_000003, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP714;
CC         IsoId=P05067-6; Sequence=VSP_000002, VSP_000003;
CC       Name=L-APP733;
CC         IsoId=P05067-7; Sequence=VSP_000007, VSP_000008, VSP_000009;
CC         Note=The L-isoforms are referred to as appicans.;
CC       Name=APP751; Synonyms=PreA4 751;
CC         IsoId=P05067-8; Sequence=VSP_000007, VSP_000008;
CC         Note=A major isoform.;
CC       Name=L-APP752;
CC         IsoId=P05067-9; Sequence=VSP_000009;
CC       Name=APP639;
CC         IsoId=P05067-10; Sequence=VSP_009116, VSP_009117, VSP_009118;
CC       Name=11;
CC         IsoId=P05067-11; Sequence=VSP_045446, VSP_045447;
CC   -!- TISSUE SPECIFICITY: Expressed in all fetal tissues examined with
CC       highest levels in brain, kidney, heart and spleen. Weak expression
CC       in liver. In adult brain, highest expression found in the frontal
CC       lobe of the cortex and in the anterior perisylvian cortex-
CC       opercular gyri. Moderate expression in the cerebellar cortex, the
CC       posterior perisylvian cortex-opercular gyri and the temporal
CC       associated cortex. Weak expression found in the striate, extra-
CC       striate and motor cortices. Expressed in cerebrospinal fluid, and
CC       plasma. Isoform APP695 is the predominant form in neuronal tissue,
CC       isoform APP751 and isoform APP770 are widely expressed in non-
CC       neuronal cells. Isoform APP751 is the most abundant form in T-
CC       lymphocytes. Appican is expressed in astrocytes.
CC       {ECO:0000269|PubMed:12859342, ECO:0000269|PubMed:1406936}.
CC   -!- INDUCTION: Increased levels during neuronal differentiation.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for
CC       sorting of membrane proteins to the basolateral surface of
CC       epithelial cells. {ECO:0000269|PubMed:8576160}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-
CC       phosphorylated proteins is required for the specific binding of
CC       the PID domain. However, additional amino acids either N- or C-
CC       terminal to the NPXY motif are often required for complete
CC       interaction. The PID domain-containing proteins which bind APP
CC       require the YENPTY motif for full interaction. These interactions
CC       are independent of phosphorylation on the terminal tyrosine
CC       residue. The NPXY site is also involved in clathrin-mediated
CC       endocytosis. {ECO:0000269|PubMed:8576160}.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-
CC       secretase leads to generation and extracellular release of soluble
CC       APP peptides, S-APP-alpha and S-APP-beta, and the retention of
CC       corresponding membrane-anchored C-terminal fragments, C80, C83 and
CC       C99. Subsequent processing of C80 and C83 by gamma-secretase
CC       yields P3 peptides. This is the major secretory pathway and is
CC       non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated
CC       gamma-secretase processing of C99 releases the amyloid beta
CC       proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),
CC       major components of amyloid plaques, and the cytotoxic C-terminal
CC       fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Many
CC       other minor beta-amyloid peptides, beta-amyloid 1-X peptides, are
CC       found in cerebral spinal fluid (CSF) including the beta-amyloid X-
CC       15 peptides, produced from the cleavage by alpha-secretase and all
CC       terminatiing at Gln-686.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal
CC       apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9
CC       results in the production of the neurotoxic C31 peptide and the
CC       increased production of beta-amyloid peptides.
CC   -!- PTM: N- and O-glycosylated. O-glycosylation on Ser and Thr
CC       residues with core 1 or possibly core 8 glycans. Partial tyrosine
CC       glycosylation (Tyr-681) is found on some minor, short beta-amyloid
CC       peptides (beta-amyloid 1-15, 1-16, 1-17, 1-18, 1-19 and 1-20) but
CC       not found on beta-amyloid 38, beta-amyloid 40 nor on beta-amyloid
CC       42. Modification on a tyrosine is unusual and is more prevelant in
CC       AD patients. Glycans had Neu5AcHex(Neu5Ac)HexNAc-O-Tyr,
CC       Neu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr and O-
CC       AcNeu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr structures, where O-Ac is O-
CC       acetylation of Neu5Ac. Neu5AcNeu5Ac is most likely Neu5Ac
CC       2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage
CC       sites may influence the proteolytic processing. Appicans are L-APP
CC       isoforms with O-linked chondroitin sulfate.
CC       {ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:21712440,
CC       ECO:0000269|PubMed:22576872}.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific. Phosphorylation can affect APP
CC       processing, neuronal differentiation and interaction with other
CC       proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5
CC       kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-
CC       cycle dependent manner with maximal levels at the G2/M phase and,
CC       in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a
CC       conformational change which reduces binding of Fe65 family
CC       members. Phosphorylation on Tyr-757 is required for SHC binding.
CC       Phosphorylated in the extracellular domain by casein kinases on
CC       both soluble and membrane-bound APP. This phosphorylation is
CC       inhibited by heparin. {ECO:0000269|PubMed:10341243,
CC       ECO:0000269|PubMed:11146006, ECO:0000269|PubMed:11517218,
CC       ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:8131745,
CC       ECO:0000269|PubMed:8999878}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation
CC       of a disulfide bond. In vitro, the APP-Cu(+) complex in the
CC       presence of hydrogen peroxide results in an increased production
CC       of beta-amyloid-containing peptides.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface
CC       APP by beta-secretase to release sAPP-beta which is further
CC       cleaved to release an N-terminal fragment of APP (N-APP).
CC   -!- PTM: Beta-amyloid peptides are degraded by IDE.
CC   -!- MASS SPECTROMETRY: Mass=6461.6; Method=MALDI; Range=712-767;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=6451.6; Method=MALDI; Range=714-770;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=6436.8; Method=MALDI; Range=715-769;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- MASS SPECTROMETRY: Mass=5752.5; Method=MALDI; Range=719-767;
CC       Evidence={ECO:0000269|PubMed:12214090};
CC   -!- DISEASE: Alzheimer disease 1 (AD1) [MIM:104300]: A familial early-
CC       onset form of Alzheimer disease. It can be associated with
CC       cerebral amyloid angiopathy. Alzheimer disease is a
CC       neurodegenerative disorder characterized by progressive dementia,
CC       loss of cognitive abilities, and deposition of fibrillar amyloid
CC       proteins as intraneuronal neurofibrillary tangles, extracellular
CC       amyloid plaques and vascular amyloid deposits. The major
CC       constituent of these plaques is the neurotoxic amyloid-beta-APP
CC       40-42 peptide (s), derived proteolytically from the transmembrane
CC       precursor protein APP by sequential secretase processing. The
CC       cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved
CC       products such as C31 derived from APP, are also implicated in
CC       neuronal death. {ECO:0000269|PubMed:10097173,
CC       ECO:0000269|PubMed:10631141, ECO:0000269|PubMed:10665499,
CC       ECO:0000269|PubMed:10867787, ECO:0000269|PubMed:11063718,
CC       ECO:0000269|PubMed:11528419, ECO:0000269|PubMed:12034808,
CC       ECO:0000269|PubMed:1302033, ECO:0000269|PubMed:1303239,
CC       ECO:0000269|PubMed:1303275, ECO:0000269|PubMed:1415269,
CC       ECO:0000269|PubMed:15201367, ECO:0000269|PubMed:15365148,
CC       ECO:0000269|PubMed:15668448, ECO:0000269|PubMed:1671712,
CC       ECO:0000269|PubMed:1678058, ECO:0000269|PubMed:1908231,
CC       ECO:0000269|PubMed:1925564, ECO:0000269|PubMed:1944558,
CC       ECO:0000269|PubMed:8267572, ECO:0000269|PubMed:8290042,
CC       ECO:0000269|PubMed:8476439, ECO:0000269|PubMed:8577393,
CC       ECO:0000269|PubMed:9328472, ECO:0000269|PubMed:9754958}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cerebral amyloid angiopathy, APP-related (CAA-APP)
CC       [MIM:605714]: A hereditary localized amyloidosis due to amyloid-
CC       beta A4 peptide(s) deposition in the cerebral vessels. The
CC       principal clinical characteristics are recurrent cerebral and
CC       cerebellar hemorrhages, recurrent strokes, cerebral ischemia,
CC       cerebral infarction, and progressive mental deterioration.
CC       Patients develop cerebral hemorrhage because of the severe
CC       cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare
CC       and largely in the form of pre-amyloid lesions or diffuse plaque-
CC       like structures. They are Congo red negative and lack the dense
CC       amyloid cores commonly present in Alzheimer disease. Some affected
CC       individuals manifest progressive aphasic dementia,
CC       leukoencephalopathy, and occipital calcifications.
CC       {ECO:0000269|PubMed:11409420, ECO:0000269|PubMed:12654973,
CC       ECO:0000269|PubMed:16178030, ECO:0000269|PubMed:20697050,
CC       ECO:0000269|PubMed:2111584}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and
CC       zinc, can induce histidine-bridging between beta-amyloid molecules
CC       resulting in beta-amyloid-metal aggregates. The affinity for
CC       copper is much higher than for other transient metals and is
CC       increased under acidic conditions. Extracellular zinc-binding
CC       increases binding of heparin to APP and inhibits collagen-binding.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00031}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58727.1; Type=Miscellaneous discrepancy; Note=Contamination by an Alu repeat.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Alzforum; Note=APP mutations;
CC       URL="http://alzforum.org/mutations/search?genes%5B%5D=348";
CC   -!- WEB RESOURCE: Name=AD mutations;
CC       URL="http://www.molgen.ua.ac.be/ADmutations/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/app/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Amyloid beta entry;
CC       URL="https://en.wikipedia.org/wiki/Amyloid_beta";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00264; CAA68374.1; -; mRNA.
DR   EMBL; X13466; CAA31830.1; -; Genomic_DNA.
DR   EMBL; X13467; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13468; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13469; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13470; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13471; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13472; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13473; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13474; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13475; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13476; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13477; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13478; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13479; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13487; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X13488; CAA31830.1; JOINED; Genomic_DNA.
DR   EMBL; X06989; CAA30050.1; -; mRNA.
DR   EMBL; M33112; AAB59502.1; -; Genomic_DNA.
DR   EMBL; M34862; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34874; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34876; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34877; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34878; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34879; AAB59502.1; JOINED; Genomic_DNA.
DR   EMBL; M34875; AAB59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M34862; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34863; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34864; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34865; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34866; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34867; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34868; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34869; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34870; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34871; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34872; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; M34873; AAB59501.1; JOINED; Genomic_DNA.
DR   EMBL; D87675; BAA22264.1; -; Genomic_DNA.
DR   EMBL; AK312326; BAG35248.1; -; mRNA.
DR   EMBL; AK295621; BAG58500.1; -; mRNA.
DR   EMBL; AY919674; AAW82435.1; -; Genomic_DNA.
DR   EMBL; AP001439; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001440; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001441; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001442; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001443; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09958.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09959.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09960.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09961.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09963.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09965.1; -; Genomic_DNA.
DR   EMBL; BC004369; AAH04369.1; -; mRNA.
DR   EMBL; BC065529; AAH65529.1; -; mRNA.
DR   EMBL; M35675; AAA60163.1; ALT_SEQ; mRNA.
DR   EMBL; M24547; AAC13654.1; -; Genomic_DNA.
DR   EMBL; M24546; AAC13654.1; JOINED; Genomic_DNA.
DR   EMBL; M28373; AAA58727.1; ALT_SEQ; mRNA.
DR   EMBL; X06982; CAA30042.1; -; mRNA.
DR   EMBL; X06981; CAA30041.1; -; mRNA.
DR   EMBL; M18734; AAA51726.1; -; mRNA.
DR   EMBL; M29270; AAA51768.1; -; Genomic_DNA.
DR   EMBL; M29269; AAA51768.1; JOINED; Genomic_DNA.
DR   EMBL; AB066441; BAB71958.2; -; mRNA.
DR   EMBL; M15533; AAA35540.1; -; mRNA.
DR   EMBL; M15532; AAA51564.1; -; mRNA.
DR   EMBL; M37896; AAA51727.1; -; Genomic_DNA.
DR   EMBL; M37895; AAA51727.1; JOINED; Genomic_DNA.
DR   EMBL; S45136; AAB23646.1; -; Genomic_DNA.
DR   EMBL; S60317; AAC60601.2; -; Genomic_DNA.
DR   EMBL; AF282245; AAQ14327.1; -; mRNA.
DR   EMBL; S60721; AAB26263.2; -; mRNA.
DR   EMBL; S61380; AAB26264.2; -; mRNA.
DR   EMBL; S61383; AAB26265.2; -; mRNA.
DR   EMBL; M16765; AAA51722.1; -; mRNA.
DR   CCDS; CCDS13576.1; -. [P05067-1]
DR   CCDS; CCDS13577.1; -. [P05067-4]
DR   CCDS; CCDS33523.1; -. [P05067-8]
DR   CCDS; CCDS46638.1; -. [P05067-10]
DR   CCDS; CCDS56212.1; -. [P05067-11]
DR   CCDS; CCDS56213.1; -. [P05067-9]
DR   PIR; S01442; S01442.
DR   PIR; S02260; QRHUA4.
DR   RefSeq; NP_000475.1; NM_000484.3. [P05067-1]
DR   RefSeq; NP_001129488.1; NM_001136016.3. [P05067-11]
DR   RefSeq; NP_001129601.1; NM_001136129.2. [P05067-10]
DR   RefSeq; NP_001129602.1; NM_001136130.2.
DR   RefSeq; NP_001129603.1; NM_001136131.2.
DR   RefSeq; NP_001191230.1; NM_001204301.1. [P05067-9]
DR   RefSeq; NP_001191231.1; NM_001204302.1. [P05067-7]
DR   RefSeq; NP_001191232.1; NM_001204303.1. [P05067-3]
DR   RefSeq; NP_958816.1; NM_201413.2. [P05067-8]
DR   RefSeq; NP_958817.1; NM_201414.2. [P05067-4]
DR   UniGene; Hs.434980; -.
DR   PDB; 1AAP; X-ray; 1.50 A; A/B=287-344.
DR   PDB; 1AMB; NMR; -; A=672-699.
DR   PDB; 1AMC; NMR; -; A=672-699.
DR   PDB; 1AML; NMR; -; A=672-711.
DR   PDB; 1BA4; NMR; -; A=672-711.
DR   PDB; 1BA6; NMR; -; A=672-711.
DR   PDB; 1BJB; NMR; -; A=672-699.
DR   PDB; 1BJC; NMR; -; A=672-699.
DR   PDB; 1BRC; X-ray; 2.50 A; I=287-342.
DR   PDB; 1CA0; X-ray; 2.10 A; D/I=289-342.
DR   PDB; 1HZ3; NMR; -; A=681-706.
DR   PDB; 1IYT; NMR; -; A=672-713.
DR   PDB; 1MWP; X-ray; 1.80 A; A=28-123.
DR   PDB; 1OWT; NMR; -; A=124-189.
DR   PDB; 1QCM; NMR; -; A=696-706.
DR   PDB; 1QWP; NMR; -; A=696-706.
DR   PDB; 1QXC; NMR; -; A=696-706.
DR   PDB; 1QYT; NMR; -; A=696-706.
DR   PDB; 1TAW; X-ray; 1.80 A; B=287-344.
DR   PDB; 1TKN; NMR; -; A=460-569.
DR   PDB; 1UO7; Model; -; A=672-713.
DR   PDB; 1UO8; Model; -; A=672-713.
DR   PDB; 1UOA; Model; -; A=672-713.
DR   PDB; 1UOI; Model; -; A=672-713.
DR   PDB; 1X11; X-ray; 2.50 A; C/D=754-766.
DR   PDB; 1Z0Q; NMR; -; A=672-713.
DR   PDB; 1ZE7; NMR; -; A=672-687.
DR   PDB; 1ZE9; NMR; -; A=672-687.
DR   PDB; 1ZJD; X-ray; 2.60 A; B=289-344.
DR   PDB; 2BEG; NMR; -; A/B/C/D/E=672-713.
DR   PDB; 2BOM; Model; -; A/B=681-713.
DR   PDB; 2BP4; NMR; -; A=672-687.
DR   PDB; 2FJZ; X-ray; 1.61 A; A=133-189.
DR   PDB; 2FK1; X-ray; 1.60 A; A=133-189.
DR   PDB; 2FK2; X-ray; 1.65 A; A=133-189.
DR   PDB; 2FK3; X-ray; 2.40 A; A/B/C/D/E/F/G/H=133-189.
DR   PDB; 2FKL; X-ray; 2.50 A; A/B=124-189.
DR   PDB; 2FMA; X-ray; 0.85 A; A=133-189.
DR   PDB; 2G47; X-ray; 2.10 A; C/D=672-711.
DR   PDB; 2IPU; X-ray; 1.65 A; P/Q=672-679.
DR   PDB; 2LFM; NMR; -; A=672-711.
DR   PDB; 2LLM; NMR; -; A=686-726.
DR   PDB; 2LMN; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMO; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-711.
DR   PDB; 2LMP; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LMQ; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=672-711.
DR   PDB; 2LNQ; NMR; -; A/B/C/D/E/F/G/H=672-711.
DR   PDB; 2LOH; NMR; -; A/B=686-726.
DR   PDB; 2LP1; NMR; -; A=671-770.
DR   PDB; 2LZ3; NMR; -; A/B=699-726.
DR   PDB; 2LZ4; NMR; -; A/B=699-726.
DR   PDB; 2M4J; NMR; -; A/B/C/D/E/F/G/H/I=672-711.
DR   PDB; 2M9R; NMR; -; A=672-711.
DR   PDB; 2M9S; NMR; -; A=672-711.
DR   PDB; 2MGT; NMR; -; A/B=672-687.
DR   PDB; 2MJ1; NMR; -; A=688-705.
DR   PDB; 2MPZ; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a=686-711.
DR   PDB; 2MVX; NMR; -; A/B/C/D/E/F/G/H/I/J=672-711.
DR   PDB; 2MXU; NMR; -; A/B/C/D/E/F/G/H/I/J/K/L=672-713.
DR   PDB; 2OTK; NMR; -; C=672-711.
DR   PDB; 2R0W; X-ray; 2.50 A; Q=672-679.
DR   PDB; 2WK3; X-ray; 2.59 A; C/D=672-713.
DR   PDB; 2Y29; X-ray; 2.30 A; A=687-692.
DR   PDB; 2Y2A; X-ray; 1.91 A; A=687-692.
DR   PDB; 2Y3J; X-ray; 1.99 A; A/B/C/D/E/F/G/H=701-706.
DR   PDB; 2Y3K; X-ray; 1.90 A; A/B/C/D/E/F/G/H=706-713.
DR   PDB; 2Y3L; X-ray; 2.10 A; A/B/C/G=706-713.
DR   PDB; 3AYU; X-ray; 2.00 A; B=586-595.
DR   PDB; 3BAE; X-ray; 1.59 A; A=672-699.
DR   PDB; 3BKJ; X-ray; 1.59 A; A=672-687.
DR   PDB; 3DXC; X-ray; 2.10 A; B/D=739-770.
DR   PDB; 3DXD; X-ray; 2.20 A; B/D=739-770.
DR   PDB; 3DXE; X-ray; 2.00 A; B/D=739-770.
DR   PDB; 3GCI; X-ray; 2.04 A; P=707-713.
DR   PDB; 3IFL; X-ray; 1.50 A; P=672-678.
DR   PDB; 3IFN; X-ray; 1.50 A; P=672-711.
DR   PDB; 3IFO; X-ray; 2.15 A; P/Q=672-678.
DR   PDB; 3IFP; X-ray; 2.95 A; P/Q/R/S=672-678.
DR   PDB; 3JQ5; X-ray; 2.03 A; B=672-679.
DR   PDB; 3JQL; X-ray; 1.20 A; B=687-692.
DR   PDB; 3JTI; X-ray; 1.80 A; B=699-706.
DR   PDB; 3KTM; X-ray; 2.70 A; A/B/C/D/E/F/G/H=18-190.
DR   PDB; 3L33; X-ray; 2.48 A; E/F/G/H=290-341.
DR   PDB; 3L81; X-ray; 1.60 A; B=761-767.
DR   PDB; 3MOQ; X-ray; 2.05 A; A/B/C/D=689-712.
DR   PDB; 3MXC; X-ray; 2.00 A; L=754-762.
DR   PDB; 3MXY; X-ray; 2.30 A; L=754-762.
DR   PDB; 3NYJ; X-ray; 3.20 A; A=365-567.
DR   PDB; 3NYL; X-ray; 2.80 A; A=365-570.
DR   PDB; 3OVJ; X-ray; 1.80 A; A/B/C/D=687-692.
DR   PDB; 3OW9; X-ray; 1.80 A; A/B=687-692.
DR   PDB; 3SV1; X-ray; 3.30 A; D/E/F=754-767.
DR   PDB; 3U0T; X-ray; 2.50 A; E/F=701-711.
DR   PDB; 3UMH; X-ray; 2.00 A; A=370-575.
DR   PDB; 3UMI; X-ray; 2.40 A; A=370-575.
DR   PDB; 3UMK; X-ray; 2.60 A; A=370-575.
DR   PDB; 4HIX; X-ray; 2.20 A; A=672-699.
DR   PDB; 4JFN; X-ray; 1.75 A; A=23-185.
DR   PDB; 4M1C; X-ray; 3.50 A; G/H=672-711.
DR   PDB; 4MDR; X-ray; 1.85 A; B=758-767.
DR   PDB; 4MVI; X-ray; 1.70 A; B=672-711.
DR   PDB; 4MVK; X-ray; 1.50 A; B=689-694.
DR   PDB; 4MVL; X-ray; 2.30 A; E/F/G/H=672-711.
DR   PDB; 4NGE; X-ray; 2.70 A; B/E=672-711.
DR   PDB; 4OJF; X-ray; 2.00 A; A=672-679.
DR   PDB; 4ONF; X-ray; 2.00 A; P=672-678.
DR   PDB; 4ONG; X-ray; 2.20 A; P=672-711.
DR   PDB; 4PQD; X-ray; 1.33 A; A=22-126.
DR   PDB; 4PWQ; X-ray; 1.40 A; A/B=18-190.
DR   PDB; 4XXD; X-ray; 2.41 A; C/F=683-699.
DR   PDB; 5AEF; EM; 5.00 A; A/B=686-713.
DR   PDB; 5CSZ; X-ray; 1.80 A; D/E=672-682.
DR   PDBsum; 1AAP; -.
DR   PDBsum; 1AMB; -.
DR   PDBsum; 1AMC; -.
DR   PDBsum; 1AML; -.
DR   PDBsum; 1BA4; -.
DR   PDBsum; 1BA6; -.
DR   PDBsum; 1BJB; -.
DR   PDBsum; 1BJC; -.
DR   PDBsum; 1BRC; -.
DR   PDBsum; 1CA0; -.
DR   PDBsum; 1HZ3; -.
DR   PDBsum; 1IYT; -.
DR   PDBsum; 1MWP; -.
DR   PDBsum; 1OWT; -.
DR   PDBsum; 1QCM; -.
DR   PDBsum; 1QWP; -.
DR   PDBsum; 1QXC; -.
DR   PDBsum; 1QYT; -.
DR   PDBsum; 1TAW; -.
DR   PDBsum; 1TKN; -.
DR   PDBsum; 1UO7; -.
DR   PDBsum; 1UO8; -.
DR   PDBsum; 1UOA; -.
DR   PDBsum; 1UOI; -.
DR   PDBsum; 1X11; -.
DR   PDBsum; 1Z0Q; -.
DR   PDBsum; 1ZE7; -.
DR   PDBsum; 1ZE9; -.
DR   PDBsum; 1ZJD; -.
DR   PDBsum; 2BEG; -.
DR   PDBsum; 2BOM; -.
DR   PDBsum; 2BP4; -.
DR   PDBsum; 2FJZ; -.
DR   PDBsum; 2FK1; -.
DR   PDBsum; 2FK2; -.
DR   PDBsum; 2FK3; -.
DR   PDBsum; 2FKL; -.
DR   PDBsum; 2FMA; -.
DR   PDBsum; 2G47; -.
DR   PDBsum; 2IPU; -.
DR   PDBsum; 2LFM; -.
DR   PDBsum; 2LLM; -.
DR   PDBsum; 2LMN; -.
DR   PDBsum; 2LMO; -.
DR   PDBsum; 2LMP; -.
DR   PDBsum; 2LMQ; -.
DR   PDBsum; 2LNQ; -.
DR   PDBsum; 2LOH; -.
DR   PDBsum; 2LP1; -.
DR   PDBsum; 2LZ3; -.
DR   PDBsum; 2LZ4; -.
DR   PDBsum; 2M4J; -.
DR   PDBsum; 2M9R; -.
DR   PDBsum; 2M9S; -.
DR   PDBsum; 2MGT; -.
DR   PDBsum; 2MJ1; -.
DR   PDBsum; 2MPZ; -.
DR   PDBsum; 2MVX; -.
DR   PDBsum; 2MXU; -.
DR   PDBsum; 2OTK; -.
DR   PDBsum; 2R0W; -.
DR   PDBsum; 2WK3; -.
DR   PDBsum; 2Y29; -.
DR   PDBsum; 2Y2A; -.
DR   PDBsum; 2Y3J; -.
DR   PDBsum; 2Y3K; -.
DR   PDBsum; 2Y3L; -.
DR   PDBsum; 3AYU; -.
DR   PDBsum; 3BAE; -.
DR   PDBsum; 3BKJ; -.
DR   PDBsum; 3DXC; -.
DR   PDBsum; 3DXD; -.
DR   PDBsum; 3DXE; -.
DR   PDBsum; 3GCI; -.
DR   PDBsum; 3IFL; -.
DR   PDBsum; 3IFN; -.
DR   PDBsum; 3IFO; -.
DR   PDBsum; 3IFP; -.
DR   PDBsum; 3JQ5; -.
DR   PDBsum; 3JQL; -.
DR   PDBsum; 3JTI; -.
DR   PDBsum; 3KTM; -.
DR   PDBsum; 3L33; -.
DR   PDBsum; 3L81; -.
DR   PDBsum; 3MOQ; -.
DR   PDBsum; 3MXC; -.
DR   PDBsum; 3MXY; -.
DR   PDBsum; 3NYJ; -.
DR   PDBsum; 3NYL; -.
DR   PDBsum; 3OVJ; -.
DR   PDBsum; 3OW9; -.
DR   PDBsum; 3SV1; -.
DR   PDBsum; 3U0T; -.
DR   PDBsum; 3UMH; -.
DR   PDBsum; 3UMI; -.
DR   PDBsum; 3UMK; -.
DR   PDBsum; 4HIX; -.
DR   PDBsum; 4JFN; -.
DR   PDBsum; 4M1C; -.
DR   PDBsum; 4MDR; -.
DR   PDBsum; 4MVI; -.
DR   PDBsum; 4MVK; -.
DR   PDBsum; 4MVL; -.
DR   PDBsum; 4NGE; -.
DR   PDBsum; 4OJF; -.
DR   PDBsum; 4ONF; -.
DR   PDBsum; 4ONG; -.
DR   PDBsum; 4PQD; -.
DR   PDBsum; 4PWQ; -.
DR   PDBsum; 4XXD; -.
DR   PDBsum; 5AEF; -.
DR   PDBsum; 5CSZ; -.
DR   ProteinModelPortal; P05067; -.
DR   SMR; P05067; 28-189, 287-342, 385-567, 683-728, 741-768.
DR   BioGrid; 106848; 2088.
DR   DIP; DIP-574N; -.
DR   IntAct; P05067; 122.
DR   MINT; MINT-150767; -.
DR   STRING; 9606.ENSP00000284981; -.
DR   BindingDB; P05067; -.
DR   ChEMBL; CHEMBL2487; -.
DR   MEROPS; I02.015; -.
DR   TCDB; 1.C.50.1.2; the amyloid Beta-protein peptide (aBetapp) family.
DR   iPTMnet; P05067; -.
DR   PhosphoSite; P05067; -.
DR   SwissPalm; P05067; -.
DR   UniCarbKB; P05067; -.
DR   BioMuta; APP; -.
DR   DMDM; 112927; -.
DR   SWISS-2DPAGE; P05067; -.
DR   MaxQB; P05067; -.
DR   PaxDb; P05067; -.
DR   PRIDE; P05067; -.
DR   DNASU; 351; -.
DR   Ensembl; ENST00000346798; ENSP00000284981; ENSG00000142192. [P05067-1]
DR   Ensembl; ENST00000348990; ENSP00000345463; ENSG00000142192. [P05067-4]
DR   Ensembl; ENST00000354192; ENSP00000346129; ENSG00000142192. [P05067-10]
DR   Ensembl; ENST00000357903; ENSP00000350578; ENSG00000142192. [P05067-8]
DR   Ensembl; ENST00000358918; ENSP00000351796; ENSG00000142192. [P05067-9]
DR   Ensembl; ENST00000440126; ENSP00000387483; ENSG00000142192. [P05067-11]
DR   GeneID; 351; -.
DR   KEGG; hsa:351; -.
DR   UCSC; uc002ylz.3; human. [P05067-1]
DR   UCSC; uc002yma.3; human. [P05067-8]
DR   UCSC; uc002ymb.3; human. [P05067-4]
DR   UCSC; uc010glj.3; human. [P05067-10]
DR   UCSC; uc010glk.3; human.
DR   UCSC; uc011acj.2; human. [P05067-2]
DR   UCSC; uc021whz.1; human. [P05067-9]
DR   UCSC; uc021wia.1; human. [P05067-7]
DR   UCSC; uc021wib.1; human. [P05067-3]
DR   CTD; 351; -.
DR   GeneCards; APP; -.
DR   GeneReviews; APP; -.
DR   HGNC; HGNC:620; APP.
DR   HPA; CAB000157; -.
DR   HPA; HPA001462; -.
DR   MalaCards; APP; -.
DR   MIM; 104300; phenotype.
DR   MIM; 104760; gene.
DR   MIM; 605714; phenotype.
DR   neXtProt; NX_P05067; -.
DR   Orphanet; 1020; Early-onset autosomal dominant Alzheimer disease.
DR   Orphanet; 324723; Hereditary cerebral hemorrhage with amyloidosis, Arctic type.
DR   Orphanet; 100006; Hereditary cerebral hemorrhage with amyloidosis, Dutch type.
DR   Orphanet; 324718; Hereditary cerebral hemorrhage with amyloidosis, Flemish type.
DR   Orphanet; 324708; Hereditary cerebral hemorrhage with amyloidosis, Iowa type.
DR   Orphanet; 324713; Hereditary cerebral hemorrhage with amyloidosis, Italian type.
DR   Orphanet; 324703; Hereditary cerebral hemorrhage with amyloidosis, Piedmont type.
DR   PharmGKB; PA24910; -.
DR   eggNOG; KOG3540; Eukaryota.
DR   eggNOG; ENOG410ZW2A; LUCA.
DR   GeneTree; ENSGT00530000063252; -.
DR   HOGENOM; HOG000232190; -.
DR   HOVERGEN; HBG000051; -.
DR   InParanoid; P05067; -.
DR   KO; K04520; -.
DR   OMA; TKTCIGT; -.
DR   OrthoDB; EOG7RNJZP; -.
DR   PhylomeDB; P05067; -.
DR   TreeFam; TF317274; -.
DR   BioCyc; MetaCyc:ENSG00000142192-MONOMER; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3134963; DEx/H-box helicases activate type I IFN and inflammatory cytokines production.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-HSA-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-844456; The NLRP3 inflammasome.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SABIO-RK; P05067; -.
DR   ChiTaRS; APP; human.
DR   EvolutionaryTrace; P05067; -.
DR   GeneWiki; Amyloid_precursor_protein; -.
DR   GenomeRNAi; 351; -.
DR   NextBio; 1445; -.
DR   PMAP-CutDB; P05067; -.
DR   PRO; PR:P05067; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; P05067; -.
DR   ExpressionAtlas; P05067; baseline and differential.
DR   Genevisible; P05067; HS.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0097449; C:astrocyte projection; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0035253; C:ciliary rootlet; IEA:Ensembl.
DR   GO; GO:0005905; C:coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043198; C:dendritic shaft; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0031904; C:endosome lumen; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:1990812; C:growth cone filopodium; IEA:Ensembl.
DR   GO; GO:1990761; C:growth cone lamellipodium; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0044304; C:main axon; IEA:Ensembl.
DR   GO; GO:0045121; C:membrane raft; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0005641; C:nuclear envelope lumen; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0051233; C:spindle midzone; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0051425; F:PTB domain binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019732; P:antifungal humoral response; IMP:UniProtKB.
DR   GO; GO:0008088; P:axon cargo transport; ISS:UniProtKB.
DR   GO; GO:0016199; P:axon midline choice point recognition; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006878; P:cellular copper ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071874; P:cellular response to norepinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; ISS:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0016358; P:dendrite development; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IMP:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007617; P:mating behavior; ISS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006378; P:mRNA polyadenylation; ISS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:GOC.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0006892; P:post-Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0007176; P:regulation of epidermal growth factor-activated receptor activity; ISS:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; ISS:UniProtKB.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0001878; P:response to yeast; IMP:UniProtKB.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   GO; GO:0051124; P:synaptic growth at neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   Gene3D; 3.30.1490.140; -; 1.
DR   Gene3D; 3.90.570.10; -; 1.
DR   Gene3D; 4.10.230.10; -; 1.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR019744; Amyloid_glyco_extracell_CS.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR028866; APP.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103:SF7; PTHR23103:SF7; 2.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF109843; SSF109843; 1.
DR   SUPFAM; SSF56491; SSF56491; 1.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   SUPFAM; SSF89811; SSF89811; 1.
DR   PROSITE; PS00319; A4_EXTRA; 1.
DR   PROSITE; PS00320; A4_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Alzheimer disease; Amyloid;
KW   Amyloidosis; Apoptosis; Cell adhesion; Coated pit; Complete proteome;
KW   Copper; Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Endocytosis; Glycoprotein; Heparin-binding; Iron; Isopeptide bond;
KW   Membrane; Metal-binding; Neurodegeneration; Notch signaling pathway;
KW   Oxidation; Phosphoprotein; Polymorphism; Protease inhibitor;
KW   Proteoglycan; Reference proteome; Serine protease inhibitor; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation; Zinc.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:2900137,
FT                                ECO:0000269|PubMed:3597385}.
FT   CHAIN        18    770       Amyloid beta A4 protein.
FT                                /FTId=PRO_0000000088.
FT   CHAIN        18    687       Soluble APP-alpha.
FT                                /FTId=PRO_0000000089.
FT   CHAIN        18    671       Soluble APP-beta.
FT                                /FTId=PRO_0000000090.
FT   CHAIN        18    286       N-APP.
FT                                /FTId=PRO_0000381966.
FT   CHAIN       672    770       C99.
FT                                /FTId=PRO_0000000091.
FT   CHAIN       672    713       Beta-amyloid protein 42.
FT                                /FTId=PRO_0000000092.
FT   CHAIN       672    711       Beta-amyloid protein 40.
FT                                /FTId=PRO_0000000093.
FT   CHAIN       688    770       C83.
FT                                /FTId=PRO_0000000094.
FT   PEPTIDE     688    713       P3(42).
FT                                /FTId=PRO_0000000095.
FT   PEPTIDE     688    711       P3(40).
FT                                /FTId=PRO_0000000096.
FT   CHAIN       691    770       C80.
FT                                /FTId=PRO_0000384574.
FT   CHAIN       712    770       Gamma-secretase C-terminal fragment 59.
FT                                /FTId=PRO_0000000097.
FT   CHAIN       714    770       Gamma-secretase C-terminal fragment 57.
FT                                /FTId=PRO_0000000098.
FT   CHAIN       721    770       Gamma-secretase C-terminal fragment 50.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000000099.
FT   CHAIN       740    770       C31.
FT                                /FTId=PRO_0000000100.
FT   TOPO_DOM     18    699       Extracellular. {ECO:0000255}.
FT   TRANSMEM    700    723       Helical. {ECO:0000255}.
FT   TOPO_DOM    724    770       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      291    341       BPTI/Kunitz inhibitor.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   REGION       96    110       Heparin-binding.
FT   REGION      181    188       Zinc-binding.
FT   REGION      391    423       Heparin-binding.
FT   REGION      491    522       Heparin-binding.
FT   REGION      523    540       Collagen-binding.
FT   REGION      732    751       Interaction with G(o)-alpha.
FT   MOTIF       724    734       Basolateral sorting signal.
FT   MOTIF       759    762       NPXY motif; contains endocytosis signal.
FT   COMPBIAS    230    260       Asp/Glu-rich (acidic).
FT   COMPBIAS    274    280       Poly-Thr.
FT   METAL       147    147       Copper 1.
FT   METAL       151    151       Copper 1.
FT   METAL       168    168       Copper 1.
FT   METAL       677    677       Copper or zinc 2.
FT   METAL       681    681       Copper or zinc 2. {ECO:0000305}.
FT   METAL       684    684       Copper or zinc 2.
FT   METAL       685    685       Copper or zinc 2.
FT   SITE        144    144       Required for Cu(2+) reduction.
FT   SITE        301    302       Reactive bond.
FT   SITE        671    672       Cleavage; by beta-secretase.
FT   SITE        672    673       Cleavage; by caspase-6; when associated
FT                                with variant 670-N-L-671.
FT   SITE        687    688       Cleavage; by alpha-secretase.
FT   SITE        690    691       Cleavage; by theta-secretase.
FT   SITE        704    704       Implicated in free radical propagation.
FT                                {ECO:0000250}.
FT   SITE        706    706       Susceptible to oxidation.
FT                                {ECO:0000269|PubMed:10535332}.
FT   SITE        711    712       Cleavage; by gamma-secretase; site 1.
FT   SITE        713    714       Cleavage; by gamma-secretase; site 2.
FT   SITE        720    721       Cleavage; by gamma-secretase; site 3.
FT   SITE        739    740       Cleavage; by caspase-6, caspase-8 or
FT                                caspase-9.
FT   MOD_RES     198    198       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:8999878}.
FT   MOD_RES     206    206       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:8999878}.
FT   MOD_RES     441    441       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     497    497       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     729    729       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   MOD_RES     730    730       Phosphoserine; by APP-kinase I.
FT                                {ECO:0000250}.
FT   MOD_RES     743    743       Phosphothreonine; by CDK5 and MAPK10.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:8131745}.
FT   MOD_RES     757    757       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11877420}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...). {ECO:0000305}.
FT   CARBOHYD    614    614       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    623    623       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    628    628       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    633    633       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:21712440}.
FT   CARBOHYD    651    651       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:21712440}.
FT   CARBOHYD    652    652       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:21712440}.
FT   CARBOHYD    656    656       O-linked (Xyl...) (chondroitin sulfate);
FT                                in L-APP isoforms.
FT                                {ECO:0000269|PubMed:21712440}.
FT   CARBOHYD    659    659       O-linked (GalNAc...).
FT   CARBOHYD    663    663       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:21712440}.
FT   CARBOHYD    667    667       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:21712440}.
FT   CARBOHYD    679    679       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22576872}.
FT   CARBOHYD    697    697       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22576872}.
FT   DISULFID     38     62
FT   DISULFID     73    117
FT   DISULFID     98    105
FT   DISULFID    133    187
FT   DISULFID    144    174
FT   DISULFID    158    186
FT   DISULFID    291    341
FT   DISULFID    300    324
FT   DISULFID    316    337
FT   CROSSLNK    763    763       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P08592}.
FT   VAR_SEQ       1     19       MLPGLALLLLAAWTARALE -> MDQLEDLLVLFINY (in
FT                                isoform 11).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045446.
FT   VAR_SEQ      19     74       Missing (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009116.
FT   VAR_SEQ     289    363       Missing (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009117.
FT   VAR_SEQ     289    289       E -> V (in isoform APP695, isoform L-
FT                                APP696, isoform L-APP677 and isoform
FT                                APP714). {ECO:0000303|PubMed:2881207}.
FT                                /FTId=VSP_000002.
FT   VAR_SEQ     290    364       Missing (in isoform APP695 and isoform L-
FT                                APP677). {ECO:0000303|PubMed:2881207}.
FT                                /FTId=VSP_000004.
FT   VAR_SEQ     290    345       Missing (in isoform L-APP696 and isoform
FT                                APP714). {ECO:0000305}.
FT                                /FTId=VSP_000003.
FT   VAR_SEQ     290    305       VCSEQAETGPCRAMIS -> KWYKEVHSGQARWLML (in
FT                                isoform APP305).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000005.
FT   VAR_SEQ     306    770       Missing (in isoform APP305).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_000006.
FT   VAR_SEQ     345    364       MSQSLLKTTQEPLARDPVKL -> I (in isoform
FT                                11). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045447.
FT   VAR_SEQ     345    345       M -> I (in isoform L-APP733 and isoform
FT                                APP751). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1587857,
FT                                ECO:0000303|PubMed:2893289}.
FT                                /FTId=VSP_000007.
FT   VAR_SEQ     346    364       Missing (in isoform L-APP733 and isoform
FT                                APP751). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1587857,
FT                                ECO:0000303|PubMed:2893289}.
FT                                /FTId=VSP_000008.
FT   VAR_SEQ     364    364       L -> V (in isoform APP639).
FT                                {ECO:0000303|PubMed:12859342}.
FT                                /FTId=VSP_009118.
FT   VAR_SEQ     637    654       Missing (in isoform L-APP677, isoform L-
FT                                APP696, isoform L-APP733 and isoform L-
FT                                APP752). {ECO:0000303|PubMed:1587857}.
FT                                /FTId=VSP_000009.
FT   VARIANT     501    501       E -> K (in dbSNP:rs45588932).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_022315.
FT   VARIANT     665    665       E -> D (in a patient with late onset
FT                                Alzheimer disease).
FT                                {ECO:0000269|PubMed:8154870}.
FT                                /FTId=VAR_010107.
FT   VARIANT     670    671       KM -> NL (in AD1).
FT                                /FTId=VAR_000015.
FT   VARIANT     678    678       D -> N (in AD1).
FT                                {ECO:0000269|PubMed:15201367}.
FT                                /FTId=VAR_044424.
FT   VARIANT     692    692       A -> G (in AD1; Flemish mutation;
FT                                increases the solubility of processed
FT                                beta-amyloid peptides and increases the
FT                                stability of peptide oligomers).
FT                                {ECO:0000269|PubMed:11311152,
FT                                ECO:0000269|PubMed:1303239,
FT                                ECO:0000269|PubMed:9754958}.
FT                                /FTId=VAR_000016.
FT   VARIANT     693    693       E -> G (in AD1).
FT                                {ECO:0000269|PubMed:11528419,
FT                                ECO:0000269|PubMed:1415269}.
FT                                /FTId=VAR_014215.
FT   VARIANT     693    693       E -> K (in CAA-APP; Italian type).
FT                                {ECO:0000269|PubMed:20697050}.
FT                                /FTId=VAR_014216.
FT   VARIANT     693    693       E -> Q (in CAA-APP; Dutch type).
FT                                {ECO:0000269|PubMed:2111584}.
FT                                /FTId=VAR_000017.
FT   VARIANT     694    694       D -> N (in CAA-APP; Iowa type).
FT                                {ECO:0000269|PubMed:11409420,
FT                                ECO:0000269|PubMed:12654973}.
FT                                /FTId=VAR_014217.
FT   VARIANT     705    705       L -> V (in CAA-APP; Italian type).
FT                                {ECO:0000269|PubMed:16178030}.
FT                                /FTId=VAR_032276.
FT   VARIANT     713    713       A -> T (in AD1).
FT                                {ECO:0000269|PubMed:1303275,
FT                                ECO:0000269|PubMed:15365148}.
FT                                /FTId=VAR_000019.
FT   VARIANT     713    713       A -> V (in one chronic schizophrenia
FT                                patient; unknown pathological
FT                                significance; dbSNP:rs1800557).
FT                                {ECO:0000269|PubMed:1307241}.
FT                                /FTId=VAR_000018.
FT   VARIANT     714    714       T -> A (in AD1).
FT                                {ECO:0000269|PubMed:12034808}.
FT                                /FTId=VAR_032277.
FT   VARIANT     714    714       T -> I (in AD1; increased beta-APP42/
FT                                beta-APP40 ratio).
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:15668448}.
FT                                /FTId=VAR_014218.
FT   VARIANT     715    715       V -> M (in AD1; decreased beta-APP40/
FT                                total APP-beta).
FT                                {ECO:0000269|PubMed:10097173}.
FT                                /FTId=VAR_010108.
FT   VARIANT     716    716       I -> V (in AD1).
FT                                {ECO:0000269|PubMed:9328472}.
FT                                /FTId=VAR_000020.
FT   VARIANT     717    717       V -> F (in AD1).
FT                                {ECO:0000269|PubMed:1925564,
FT                                ECO:0000269|PubMed:8267572,
FT                                ECO:0000269|PubMed:8290042,
FT                                ECO:0000269|PubMed:8476439}.
FT                                /FTId=VAR_000023.
FT   VARIANT     717    717       V -> G (in AD1).
FT                                {ECO:0000269|PubMed:1944558,
FT                                ECO:0000269|PubMed:8476439}.
FT                                /FTId=VAR_000022.
FT   VARIANT     717    717       V -> I (in AD1).
FT                                {ECO:0000269|PubMed:10631141,
FT                                ECO:0000269|PubMed:1671712,
FT                                ECO:0000269|PubMed:1678058,
FT                                ECO:0000269|PubMed:1908231,
FT                                ECO:0000269|PubMed:8267572,
FT                                ECO:0000269|PubMed:8476439,
FT                                ECO:0000269|PubMed:8577393}.
FT                                /FTId=VAR_000021.
FT   VARIANT     717    717       V -> L (in AD1).
FT                                {ECO:0000269|PubMed:10867787}.
FT                                /FTId=VAR_014219.
FT   VARIANT     723    723       L -> P (in AD1).
FT                                {ECO:0000269|PubMed:10665499}.
FT                                /FTId=VAR_010109.
FT   MUTAGEN      99    102       KRGR->NQGG: Reduced heparin-binding.
FT                                {ECO:0000269|PubMed:8158260}.
FT   MUTAGEN     137    137       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     141    141       M->T: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     144    144       C->S: Binds copper. No dimer formation.
FT                                No copper reducing activity.
FT                                {ECO:0000269|PubMed:10461923,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    149       HLH->ALA: 50% decrease in copper reducing
FT                                activity. {ECO:0000269|PubMed:10461923}.
FT   MUTAGEN     147    147       H->A: Some decrease in copper reducing
FT                                activity. {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    147       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     147    147       H->Y: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     151    151       H->K: Greatly reduced copper-mediated
FT                                low-density lipoprotein oxidation.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     151    151       H->N: Binds copper. Forms dimer.
FT                                {ECO:0000269|PubMed:11784781,
FT                                ECO:0000269|PubMed:7913895}.
FT   MUTAGEN     198    198       S->A: Greatly reduced casein kinase
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:10806211,
FT                                ECO:0000269|PubMed:8999878}.
FT   MUTAGEN     206    206       S->A: Reduced casein kinase
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:10806211,
FT                                ECO:0000269|PubMed:8999878}.
FT   MUTAGEN     499    499       R->A: Reduced affinity for heparin; when
FT                                associated with A-503.
FT                                {ECO:0000269|PubMed:15304215}.
FT   MUTAGEN     503    503       K->A: Reduced affinity for heparin; when
FT                                associated with A-499.
FT                                {ECO:0000269|PubMed:15304215}.
FT   MUTAGEN     656    656       S->A: Abolishes chondroitin sulfate
FT                                binding in L-APP733 isoform.
FT                                {ECO:0000269|PubMed:7737970}.
FT   MUTAGEN     676    676       R->G: 60-70% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     681    681       Y->F: 60-70% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     684    684       H->R: Only 23% zinc-induced beta-APP (28)
FT                                peptide aggregation.
FT                                {ECO:0000269|PubMed:10413512}.
FT   MUTAGEN     704    704       G->V: Reduced protein oxidation. No
FT                                hippocampal neuron toxicity.
FT   MUTAGEN     706    706       M->L: Reduced lipid peroxidation
FT                                inhibition. {ECO:0000269|PubMed:10535332,
FT                                ECO:0000269|PubMed:9168929}.
FT   MUTAGEN     706    706       M->V: No free radical production. No
FT                                hippocampal neuron toxicity.
FT                                {ECO:0000269|PubMed:10535332,
FT                                ECO:0000269|PubMed:9168929}.
FT   MUTAGEN     717    717       V->C,S: Unchanged beta-APP42/total APP-
FT                                beta ratio. {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     717    717       V->F,G,I: Increased beta-APP42/beta-APP40
FT                                ratio. {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     717    717       V->K: Decreased beta-APP42/total APP-beta
FT                                ratio. {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     717    717       V->M: Increased beta-APP42/beta-APP40
FT                                ratio. No change in apoptosis after
FT                                caspase cleavage.
FT                                {ECO:0000269|PubMed:11063718,
FT                                ECO:0000269|PubMed:8886002}.
FT   MUTAGEN     728    728       Y->A: No effect on APBA1 nor APBB1
FT                                binding. Greatly reduces the binding to
FT                                APPBP2. APP internalization unchanged. No
FT                                change in beta-APP42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653,
FT                                ECO:0000269|PubMed:9843960}.
FT   MUTAGEN     739    739       D->A: No cleavage by caspases during
FT                                apoptosis. {ECO:0000269|PubMed:10319819,
FT                                ECO:0000269|PubMed:10742146,
FT                                ECO:0000269|PubMed:12214090}.
FT   MUTAGEN     739    739       D->N: No effect on FADD-induced
FT                                apoptosis. {ECO:0000269|PubMed:10319819,
FT                                ECO:0000269|PubMed:10742146,
FT                                ECO:0000269|PubMed:12214090}.
FT   MUTAGEN     743    743       T->A: Greatly reduces the binding to SHC1
FT                                and APBB family members; no effect on
FT                                NGF-stimulated neurite extension.
FT                                {ECO:0000269|PubMed:10341243,
FT                                ECO:0000269|PubMed:11146006,
FT                                ECO:0000269|PubMed:11517218,
FT                                ECO:0000269|PubMed:11877420}.
FT   MUTAGEN     743    743       T->E: Reduced NGF-stimulated neurite
FT                                extension. No effect on APP maturation.
FT                                {ECO:0000269|PubMed:10341243,
FT                                ECO:0000269|PubMed:11146006,
FT                                ECO:0000269|PubMed:11517218,
FT                                ECO:0000269|PubMed:11877420}.
FT   MUTAGEN     756    756       G->A: APP internalization unchanged. No
FT                                change in beta-APP42 secretion.
FT                                {ECO:0000269|PubMed:10383380}.
FT   MUTAGEN     757    757       Y->A: Little APP internalization. Reduced
FT                                beta-APP42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:11724784,
FT                                ECO:0000269|PubMed:11877420,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     757    757       Y->G: Loss of binding to MAPK8IP1, APBA1,
FT                                APBB1, APPBP2 and SHC1.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:11724784,
FT                                ECO:0000269|PubMed:11877420,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     759    759       N->A: No binding to APBA1, no effect on
FT                                APBB1 binding. Little APP
FT                                internalization. Reduced beta-APP42
FT                                secretion. {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653}.
FT   MUTAGEN     760    760       P->A: Little APP internalization. Reduced
FT                                beta-APP42 secretion.
FT                                {ECO:0000269|PubMed:10383380}.
FT   MUTAGEN     762    762       Y->A: Loss of binding to APBA1 and APBB1.
FT                                APP internalization unchanged. No change
FT                                in beta-APP42 secretion.
FT                                {ECO:0000269|PubMed:10383380,
FT                                ECO:0000269|PubMed:8887653}.
FT   CONFLICT     15     16       AR -> VW (in Ref. 3; CAA31830).
FT                                {ECO:0000305}.
FT   CONFLICT    647    647       D -> E (in Ref. 36; AAA51722).
FT                                {ECO:0000305}.
FT   CONFLICT    724    724       Missing (in Ref. 23; AAB26263/AAB26264).
FT                                {ECO:0000305}.
FT   CONFLICT    731    731       I -> N (in Ref. 23; AAB26263/AAB26264/
FT                                AAB26265). {ECO:0000305}.
FT   CONFLICT    757    757       Y -> S (in Ref. 31; AAA35540).
FT                                {ECO:0000305}.
FT   HELIX        26     28       {ECO:0000244|PDB:4PQD}.
FT   STRAND       33     35       {ECO:0000244|PDB:4PQD}.
FT   STRAND       43     45       {ECO:0000244|PDB:4PQD}.
FT   TURN         47     49       {ECO:0000244|PDB:4PQD}.
FT   STRAND       52     54       {ECO:0000244|PDB:4PQD}.
FT   STRAND       56     58       {ECO:0000244|PDB:4PWQ}.
FT   HELIX        66     76       {ECO:0000244|PDB:4PQD}.
FT   STRAND       82     87       {ECO:0000244|PDB:4PQD}.
FT   STRAND       92     94       {ECO:0000244|PDB:4PQD}.
FT   STRAND       97     99       {ECO:0000244|PDB:4PQD}.
FT   TURN        100    102       {ECO:0000244|PDB:4PQD}.
FT   STRAND      103    106       {ECO:0000244|PDB:4PQD}.
FT   STRAND      110    112       {ECO:0000244|PDB:4PQD}.
FT   STRAND      115    119       {ECO:0000244|PDB:4PQD}.
FT   STRAND      134    139       {ECO:0000244|PDB:2FMA}.
FT   HELIX       147    160       {ECO:0000244|PDB:2FMA}.
FT   STRAND      163    174       {ECO:0000244|PDB:2FMA}.
FT   TURN        175    177       {ECO:0000244|PDB:2FMA}.
FT   STRAND      178    188       {ECO:0000244|PDB:2FMA}.
FT   HELIX       288    292       {ECO:0000244|PDB:1AAP}.
FT   STRAND      299    301       {ECO:0000244|PDB:1AAP}.
FT   STRAND      304    310       {ECO:0000244|PDB:1AAP}.
FT   TURN        311    314       {ECO:0000244|PDB:1AAP}.
FT   STRAND      315    321       {ECO:0000244|PDB:1AAP}.
FT   STRAND      323    325       {ECO:0000244|PDB:1AAP}.
FT   STRAND      331    333       {ECO:0000244|PDB:1AAP}.
FT   HELIX       334    341       {ECO:0000244|PDB:1AAP}.
FT   HELIX       374    380       {ECO:0000244|PDB:3NYL}.
FT   HELIX       389    418       {ECO:0000244|PDB:3UMH}.
FT   STRAND      421    423       {ECO:0000244|PDB:3UMH}.
FT   HELIX       425    480       {ECO:0000244|PDB:3UMH}.
FT   STRAND      482    484       {ECO:0000244|PDB:3NYJ}.
FT   HELIX       487    518       {ECO:0000244|PDB:3UMH}.
FT   HELIX       520    546       {ECO:0000244|PDB:3UMH}.
FT   HELIX       547    550       {ECO:0000244|PDB:3UMH}.
FT   HELIX       552    566       {ECO:0000244|PDB:3UMH}.
FT   HELIX       673    675       {ECO:0000244|PDB:4OJF}.
FT   STRAND      676    678       {ECO:0000244|PDB:2MVX}.
FT   STRAND      679    682       {ECO:0000244|PDB:1BA6}.
FT   STRAND      683    685       {ECO:0000244|PDB:1BA4}.
FT   STRAND      688    691       {ECO:0000244|PDB:3OVJ}.
FT   STRAND      692    694       {ECO:0000244|PDB:4MVI}.
FT   TURN        695    698       {ECO:0000244|PDB:4MVI}.
FT   STRAND      702    705       {ECO:0000244|PDB:2Y3J}.
FT   STRAND      707    712       {ECO:0000244|PDB:2Y3K}.
FT   HELIX       744    754       {ECO:0000244|PDB:3DXE}.
FT   STRAND      755    758       {ECO:0000244|PDB:1X11}.
FT   STRAND      763    765       {ECO:0000244|PDB:3L81}.
SQ   SEQUENCE   770 AA;  86943 MW;  A12EE761403740F5 CRC64;
     MLPGLALLLL AAWTARALEV PTDGNAGLLA EPQIAMFCGR LNMHMNVQNG KWDSDPSGTK
     TCIDTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHPH FVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDNVDSAD AEEDDSDVWW GGADTDYADG SEDKVVEVAE EEEVAEVEEE
     EADDDEDDED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSAMSQSLL KTTQEPLARD
     PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPRHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHSFGADSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
ID   FGFR2_HUMAN             Reviewed;         821 AA.
AC   P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300;
AC   Q14301; Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719;
AC   Q1KHY5; Q86YI4; Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2;
AC   Q9NZU3; Q9UD01; Q9UD02; Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7;
AC   Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   20-JAN-2016, entry version 212.
DE   RecName: Full=Fibroblast growth factor receptor 2;
DE            Short=FGFR-2;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610};
DE   AltName: Full=K-sam;
DE            Short=KGFR;
DE   AltName: Full=Keratinocyte growth factor receptor;
DE   AltName: CD_antigen=CD332;
DE   Flags: Precursor;
GN   Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Neonatal brain stem;
RX   PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 16).
RX   PubMed=2172978; DOI=10.1073/pnas.87.20.8180;
RA   Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C.,
RA   Torriglia A., Courtois Y., Breathnach R.;
RT   "Related fibroblast growth factor receptor genes exist in the human
RT   genome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17).
RX   PubMed=1647213; DOI=10.1016/0167-4781(91)90015-E;
RA   Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.;
RT   "Two cDNAs encoding novel human FGF receptor.";
RL   Biochim. Biophys. Acta 1089:244-246(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=2377625; DOI=10.1073/pnas.87.15.5983;
RA   Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K.,
RA   Sakamoto H., Katoh O., Yoshida T., Sugimura T., Terada M.;
RT   "K-sam, an amplified gene in stomach cancer, is a member of the
RT   heparin-binding growth factor receptor genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 14 AND 15).
RX   PubMed=1313574; DOI=10.1073/pnas.89.7.2960;
RA   Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y.,
RA   Sugimura T., Terada M.;
RT   "K-sam gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), DOMAIN, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=1400433;
RA   Dell K.R., Williams L.T.;
RT   "A novel form of fibroblast growth factor receptor 2. Alternative
RT   splicing of the third immunoglobulin-like domain confers ligand
RT   binding specificity.";
RL   J. Biol. Chem. 267:21225-21229(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 19), SUBUNIT, DOMAIN, AND
RP   VARIANT ARG-613.
RC   TISSUE=Mammary gland;
RX   PubMed=1309608; DOI=10.1073/pnas.89.1.246;
RA   Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H.,
RA   Chan A.M.-L., Aaronson S.A.;
RT   "Determination of ligand-binding specificity by alternative splicing:
RT   two distinct growth factor receptors encoded by a single gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19).
RC   TISSUE=Cornea, and Mammary gland;
RX   PubMed=7866434;
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RT   "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and
RT   their receptors in human breast cells and tissues: alternative
RT   receptors.";
RL   Cell. Mol. Biol. Res. 40:337-350(1994).
RN   [9]
RP   ERRATUM.
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RL   Cell. Mol. Biol. Res. 40:707-707(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342.
RC   TISSUE=Blood;
RA   Steinberger D., Mueller U.;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 9; 10; 11; 12 AND 13), AND
RP   VARIANT ARG-613.
RX   PubMed=10626794;
RA   Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H.,
RA   Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.;
RT   "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short
RT   homology-mediated recombination, generating preferential expression of
RT   specific messenger RNAs.";
RL   Cancer Res. 59:6080-6086(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 8; 14 AND 18).
RX   PubMed=11856867;
RA   Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G.,
RA   Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and
RT   variations.";
RL   Cytogenet. Cell Genet. 94:121-126(2001).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3).
RA   Lind D.L., Cox D.R.;
RT   "Sequence and polymorphisms in fibroblast growth factor receptor 2
RT   (FGFR2) gene in humans.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 23).
RA   Jang J.;
RT   "Identification of a novel variant of FGFR2.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186.
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 21).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 20).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427.
RX   PubMed=10712195; DOI=10.1086/302831;
RA   Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A.,
RA   Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A.,
RA   Wilkie A.O.M., Jabs E.W.;
RT   "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon
RT   syndrome and Pfeiffer syndrome.";
RL   Am. J. Hum. Genet. 66:768-777(2000).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821
RP   (ISOFORMS 5; 14 AND 18).
RX   PubMed=10196476; DOI=10.1016/S0378-1119(99)00047-5;
RA   Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.;
RT   "Genomic organization of the human fibroblast growth factor receptor 2
RT   (FGFR2) gene and comparative analysis of the human FGFR gene family.";
RL   Gene 230:69-79(1999).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS
RP   TRP-252 AND ARG-253.
RX   PubMed=7668257;
RA   Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S.,
RA   Dufresne C., Cohen M.M. Jr., Jabs E.W.;
RT   "Analysis of phenotypic features and FGFR2 mutations in Apert
RT   syndrome.";
RL   Am. J. Hum. Genet. 57:321-328(1995).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259.
RX   PubMed=8676562;
RA   Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F.,
RA   Yamazaki Y., Ohtani H.;
RT   "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast
RT   growth factor receptor 2 and rapid mutational analysis in Apert
RT   syndrome.";
RL   Rinsho Byori 44:435-438(1996).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318.
RX   PubMed=8673103; DOI=10.1038/ng0596-48;
RA   Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P.,
RA   Stenman G., Wilkie A.O.M.;
RT   "Exclusive paternal origin of new mutations in Apert syndrome.";
RL   Nat. Genet. 13:48-53(1996).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289;
RP   ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354.
RX   PubMed=7581378; DOI=10.1093/hmg/4.8.1387;
RA   Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K.,
RA   Losken H.W., Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.;
RT   "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common
RT   point mutation shared with Jackson-Weiss syndrome.";
RL   Hum. Mol. Genet. 4:1387-1390(1995).
RN   [25]
RP   FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN.
RX   PubMed=8961926; DOI=10.1021/bi961942c;
RA   Gray T.E., Eisenstein M., Yayon A., Givol D.;
RT   "Asparagine-344 is a key residue for ligand binding in keratinocyte
RT   growth factor receptor.";
RL   Biochemistry 35:15640-15645(1996).
RN   [26]
RP   INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION
RP   AND APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4.
RX   PubMed=12529371; DOI=10.1074/jbc.M205875200;
RA   Lu Y., Pan Z.-Z., Devaux Y., Ray P.;
RT   "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte
RT   growth factor receptor and participates in keratinocyte growth factor-
RT   mediated inhibition of oxidant-induced cell death.";
RL   J. Biol. Chem. 278:10374-10380(2003).
RN   [28]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL,
RP   INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT
RP   APRS TRP-252.
RX   PubMed=15190072; DOI=10.1074/jbc.M402469200;
RA   Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.;
RT   "Cbl-mediated degradation of Lyn and Fyn induced by constitutive
RT   fibroblast growth factor receptor-2 activation supports osteoblast
RT   differentiation.";
RL   J. Biol. Chem. 279:36259-36267(2004).
RN   [29]
RP   FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS,
RP   MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION
RP   WITH PLCG1.
RX   PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031;
RA   Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.;
RT   "Tyrosine 769 of the keratinocyte growth factor receptor is required
RT   for receptor signaling but not endocytosis.";
RL   Biochem. Biophys. Res. Commun. 327:523-532(2005).
RN   [30]
RP   INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22
RP   AND FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657,
RP   UBIQUITINATION, AND CHARACTERIZATION OF VARIANT PS PHE-278.
RX   PubMed=16844695; DOI=10.1074/jbc.M600448200;
RA   Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.;
RT   "Intracellular retention, degradation, and signaling of glycosylation-
RT   deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.";
RL   J. Biol. Chem. 281:27292-27305(2006).
RN   [32]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION
RP   OF FRS2 AND ACTIVATION OF MAP KINASES.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [33]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [34]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18374639; DOI=10.1016/j.bone.2008.02.009;
RA   Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.;
RT   "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt
RT   signaling and osteoblast survival.";
RL   Bone 42:1032-1039(2008).
RN   [35]
RP   FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2,
RP   CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588;
RP   TYR-656 AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004;
RA   Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.;
RT   "Novel phosphotyrosine targets of FGFR2IIIb signaling.";
RL   Cell. Signal. 21:1370-1378(2009).
RN   [36]
RP   FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND
RP   PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769.
RX   PubMed=19103595; DOI=10.1074/jbc.M803998200;
RA   Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.;
RT   "Aberrant receptor internalization and enhanced FRS2-dependent
RT   signaling contribute to the transforming activity of the fibroblast
RT   growth factor receptor 2 IIIb C3 isoform.";
RL   J. Biol. Chem. 284:6227-6240(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [38]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [39]
RP   REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND
RP   ROLE IN DISEASE.
RX   PubMed=19387476; DOI=10.1038/jid.2009.97;
RA   Katoh M.;
RT   "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer
RT   pathologies.";
RL   J. Invest. Dermatol. 129:1861-1867(2009).
RN   [41]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2.
RX   PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1
RP   AND HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN.
RX   PubMed=11069186; DOI=10.1038/35039551;
RA   Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.;
RT   "Crystal structure of fibroblast growth factor receptor ectodomain
RT   bound to ligand and heparin.";
RL   Nature 407:1029-1034(2000).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1.
RX   PubMed=10618369; DOI=10.1073/pnas.97.1.49;
RA   Stauber D.J., DiGabriele A.D., Hendrickson W.A.;
RT   "Structural interactions of fibroblast growth factor receptor with its
RT   ligands.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS
RP   TRP-252 AND ARG-253 IN COMPLEX WITH FGF2.
RX   PubMed=11390973; DOI=10.1073/pnas.121183798;
RA   Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M.,
RA   Mohammadi M.;
RT   "Structural basis for fibroblast growth factor receptor 2 activation
RT   in Apert syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH
RP   FGF10.
RX   PubMed=12591959; DOI=10.1073/pnas.0436500100;
RA   Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I.,
RA   Ron D., Aaronson S.A., Mohammadi M.;
RT   "Structural basis by which alternative splicing confers specificity in
RT   fibroblast growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH
RP   FGF8, FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE
RP   BONDS.
RX   PubMed=16384934; DOI=10.1101/gad.1365406;
RA   Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A.,
RA   Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.;
RT   "Structural basis by which alternative splicing modulates the
RT   organizer activity of FGF8 in the brain.";
RL   Genes Dev. 20:185-198(2006).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP
RP   ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ENZYME REGULATION,
RP   PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF
RP   ASN-549 AND GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526,
RP   CHARACTERIZATION OF VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS
RP   PS GLY-565 AND ARG-641, AND CHARACTERIZATION OF VARIANT
RP   CRANIOSYNOSTOSIS ASN-659.
RX   PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028;
RA   Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A.,
RA   Miller W.T., Mohammadi M.;
RT   "A molecular brake in the kinase hinge region regulates the activity
RT   of receptor tyrosine kinases.";
RL   Mol. Cell 27:717-730(2007).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADDS
RP   THR-628 IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=18056630; DOI=10.1073/pnas.0709905104;
RA   Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.;
RT   "Structural basis for reduced FGFR2 activity in LADD syndrome:
RT   Implications for FGFR autoinhibition and activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP,
RP   ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION,
RP   AND PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND
RP   TYR-769.
RX   PubMed=19060208; DOI=10.1073/pnas.0807752105;
RA   Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M.,
RA   Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.;
RT   "A crystallographic snapshot of tyrosine trans-phosphorylation in
RT   action.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ENZYME
RP   REGULATION.
RX   PubMed=21454610; DOI=10.1074/jbc.M110.213736;
RA   Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J.,
RA   Chen C.R., Chan T.C., France D.S., Ashwell M.A.;
RT   "A novel mode of protein kinase inhibition exploiting hydrophobic
RT   motifs of autoinhibited kinases: discovery of ATP-independent
RT   inhibitors of fibroblast growth factor receptor.";
RL   J. Biol. Chem. 286:20677-20687(2011).
RN   [53]
RP   VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354.
RX   PubMed=7987400; DOI=10.1038/ng0994-98;
RA   Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M.,
RA   Malcolm S.;
RT   "Mutations in the fibroblast growth factor receptor 2 gene cause
RT   Crouzon syndrome.";
RL   Nat. Genet. 8:98-103(1994).
RN   [54]
RP   VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344.
RX   PubMed=7874170; DOI=10.1038/ng1194-275;
RA   Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J.,
RA   Charnas L.R., Jackson C.E., Jaye M.;
RT   "Jackson-Weiss and Crouzon syndromes are allelic with mutations in
RT   fibroblast growth factor receptor 2.";
RL   Nat. Genet. 8:275-279(1994).
RN   [55]
RP   VARIANTS CS.
RX   PubMed=7655462; DOI=10.1093/hmg/4.6.1077;
RA   Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J.,
RA   Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M.,
RA   Reardon W., Malcolm S.;
RT   "Mutations in the third immunoglobulin domain of the fibroblast growth
RT   factor receptor-2 gene in Crouzon syndrome.";
RL   Hum. Mol. Genet. 4:1077-1082(1995).
RN   [56]
RP   VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342.
RX   PubMed=8528214; DOI=10.1093/hmg/4.7.1229;
RA   Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J.,
RA   Jones M.C., Jabs E.W.;
RT   "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show
RT   allelic heterogeneity and phenotypic variability.";
RL   Hum. Mol. Genet. 4:1229-1233(1995).
RN   [57]
RP   VARIANT PS ALA-321.
RX   PubMed=7719333; DOI=10.1038/ng0295-108;
RA   Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M.,
RA   Renier D.;
RT   "FGFR2 mutations in Pfeiffer syndrome.";
RL   Nat. Genet. 9:108-108(1995).
RN   [58]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   PubMed=7719344; DOI=10.1038/ng0295-165;
RA   Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J.,
RA   Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P.,
RA   Malcolm S., Winter R.M., Reardon W.;
RT   "Apert syndrome results from localized mutations of FGFR2 and is
RT   allelic with Crouzon syndrome.";
RL   Nat. Genet. 9:165-172(1995).
RN   [59]
RP   VARIANTS PS PRO-341; ARG-342 AND TYR-342.
RX   PubMed=7719345; DOI=10.1038/ng0295-173;
RA   Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R.,
RA   Jones B.M., Malcolm S., Winter R.M., Oldridge M., Slaney S.F.,
RA   Poole M.D., Wilkie A.O.M.;
RT   "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon
RT   syndrome phenotypes.";
RL   Nat. Genet. 9:173-176(1995).
RN   [60]
RP   VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278;
RP   ARG-342; SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289.
RX   PubMed=8644708;
RA   Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A.,
RA   Abrams L.J., Graham J.M. Jr., Feingold M., Moeschler J.B.,
RA   Rawnsley E., Scott A.F., Jabs E.W.;
RT   "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and
RT   Pfeiffer syndromes: evidence for missense changes, insertions, and a
RT   deletion due to alternative RNA splicing.";
RL   Am. J. Hum. Genet. 58:491-498(1996).
RN   [61]
RP   VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384.
RX   PubMed=8946174;
RA   Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M.,
RA   Hayward R., Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S.,
RA   Winter R.M.;
RT   "Spectrum of craniosynostosis phenotypes associated with novel
RT   mutations at the fibroblast growth factor receptor 2 locus.";
RL   Eur. J. Hum. Genet. 4:283-291(1996).
RN   [62]
RP   VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL.
RX   PubMed=8956050;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<386::AID-HUMU18>3.3.CO;2-A;
RA   Steinberger D., Mulliken J.B., Mueller U.;
RT   "Crouzon syndrome: previously unrecognized deletion, duplication, and
RT   point mutation within FGFR2 gene.";
RL   Hum. Mutat. 8:386-390(1996).
RN   [63]
RP   VARIANTS BSTVS CYS-372 AND CYS-375.
RX   PubMed=8696350; DOI=10.1038/ng0896-492;
RA   Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W.,
RA   Bamshad M.J., Carey J.C., Hall B.D., Stevenson R., Orlow S.J.,
RA   Cohen M.M. Jr., Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson
RT   cutis gyrata syndrome.";
RL   Nat. Genet. 13:492-494(1996).
RN   [64]
RP   VARIANT PS CYS-290.
RX   PubMed=9150725; DOI=10.1007/s004390050413;
RA   Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.;
RT   "Trp290Cys mutation in exon IIIa of the fibroblast growth factor
RT   receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome.";
RL   Hum. Genet. 99:602-606(1997).
RN   [65]
RP   VARIANT JWS SER-342.
RX   PubMed=9385368; DOI=10.1007/s004390050584;
RA   Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F.,
RA   Battaglia P.A.;
RT   "Jackson-Weiss syndrome: identification of two novel FGFR2 missense
RT   mutations shared with Crouzon and Pfeiffer craniosynostotic
RT   disorders.";
RL   Hum. Genet. 101:47-50(1997).
RN   [66]
RP   VARIANT CS LEU-252, VARIANT APRS PHE-252, AND VARIANT PS
RP   252-PHE-SER-253.
RX   PubMed=9002682; DOI=10.1093/hmg/6.1.137;
RA   Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M.,
RA   Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G.,
RA   Gagnon D.M., Jabs E.W., Wilkie A.O.M.;
RT   "Genotype-phenotype correlation for nucleotide substitutions in the
RT   IgII-IgIII linker of FGFR2.";
RL   Hum. Mol. Genet. 6:137-143(1997).
RN   [67]
RP   VARIANT CS GLU-292.
RX   PubMed=9152842; DOI=10.1136/jmg.34.5.420;
RA   Steinberger D., Collmann H., Schmalenberger B., Mueller U.;
RT   "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family
RT   with Crouzon phenotype and plagiocephaly.";
RL   J. Med. Genet. 34:420-422(1997).
RN   [68]
RP   VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342,
RP   VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278.
RX   PubMed=9677057;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<237::AID-AJMG5>3.3.CO;2-5;
RA   Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G.,
RA   Zatz M., Alonso N., Brunoni D., Ribeiro S.F.M.;
RT   "Description of a new mutation and characterization of FGFR1, FGFR2,
RT   and FGFR3 mutations among Brazilian patients with syndromic
RT   craniosynostoses.";
RL   Am. J. Med. Genet. 78:237-241(1998).
RN   [69]
RP   VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314.
RX   PubMed=9521581; DOI=10.1007/s004390050668;
RA   Steinberger D., Vriend G., Mulliken J.B., Mueller U.;
RT   "The mutations in FGFR2-associated craniosynostoses are clustered in
RT   five structural elements of immunoglobulin-like domain III of the
RT   receptor.";
RL   Hum. Genet. 102:145-150(1998).
RN   [70]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   PubMed=9452027;
RA   Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.;
RT   "Two common mutations 934C to G and 937C to G of fibroblast growth
RT   factor receptor 2 (FGFR2) gene in Chinese patients with Apert
RT   syndrome.";
RL   Hum. Mutat. Suppl. 1:S18-S19(1998).
RN   [71]
RP   VARIANT PS CYS-351.
RX   PubMed=9693549;
RA   Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J.,
RA   Hesseling-Janssen A.L.W., van den Ouweland A.M.W.;
RT   "Pfeiffer's syndrome resulting from an S351C mutation in the
RT   fibroblast growth factor receptor-2 gene.";
RL   J. Craniofac. Surg. 9:207-209(1998).
RN   [72]
RP   VARIANT PS TRP-252.
RX   PubMed=9719378; DOI=10.1136/jmg.35.8.677;
RA   Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.;
RT   "Presence of the Apert canonical S252W FGFR2 mutation in a patient
RT   without severe syndactyly.";
RL   J. Med. Genet. 35:677-679(1998).
RN   [73]
RP   VARIANT CS SER-362.
RX   PubMed=10574673; DOI=10.1597/1545-1569(1999)036<0533:ANFGMI>2.3.CO;2;
RA   Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.;
RT   "A novel FGFR2 gene mutation in Crouzon syndrome associated with
RT   apparent nonpenetrance.";
RL   Cleft Palate Craniofac. J. 36:533-541(1999).
RN   [74]
RP   VARIANTS PS CYS-340 AND GLY-342.
RX   PubMed=10394936; DOI=10.1007/s004390050979;
RA   Cornejo-Roldan L.R., Roessler E., Muenke M.;
RT   "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer
RT   syndrome.";
RL   Hum. Genet. 104:425-431(1999).
RN   [75]
RP   VARIANT PS ASP-273 DEL.
RX   PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x;
RA   Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A.,
RA   Capra V., Silengo M.;
RT   "Pfeiffer syndrome type 2 associated with a single amino acid deletion
RT   in the FGFR2 gene.";
RL   Clin. Genet. 58:81-83(2000).
RN   [76]
RP   VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276;
RP   PHE-278; TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354
RP   AND PHE-359, AND VARIANT PS SER-342.
RX   PubMed=11173845;
RA   Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.;
RT   "Clustering of FGFR2 gene mutations in patients with Pfeiffer and
RT   Crouzon syndromes (FGFR2-associated craniosynostoses).";
RL   Cytogenet. Cell Genet. 91:134-137(2000).
RN   [77]
RP   VARIANT SER-315.
RX   PubMed=10951518; DOI=10.1038/sj.ejhg.5200499;
RA   Johnson D., Wall S.A., Mann S., Wilkie A.O.M.;
RT   "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction
RT   leading to craniosynostosis?";
RL   Eur. J. Hum. Genet. 8:571-577(2000).
RN   [78]
RP   VARIANTS ABS2 ARG-342; SER-342 AND CYS-351.
RX   PubMed=10633130; DOI=10.1136/jmg.37.1.26;
RA   Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G.,
RA   Nelson I., Malcolm S., Ades L., Sillence D., Kumar D.,
RA   DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M.,
RA   Winter R.M.;
RT   "Evidence for digenic inheritance in some cases of Antley-Bixler
RT   syndrome?";
RL   J. Med. Genet. 37:26-32(2000).
RN   [79]
RP   VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342.
RX   PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x;
RA   Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.;
RT   "Mutation analysis of Crouzon syndrome and identification of one novel
RT   mutation in Taiwanese patients.";
RL   Pediatr. Int. 43:263-266(2001).
RN   [80]
RP   VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338;
RP   HIS-340; PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678,
RP   VARIANTS PS PHE-172; 252-PHE-SER-253; CYS-290; CYS-340; PRO-341;
RP   ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS
RP   TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT
RP   CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315.
RX   PubMed=11781872; DOI=10.1086/338758;
RA   Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J.,
RA   Reich E.W., Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S.,
RA   McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M.,
RA   Wilkie A.O.M.;
RT   "Genomic screening of fibroblast growth-factor receptor 2 reveals a
RT   wide spectrum of mutations in patients with syndromic
RT   craniosynostosis.";
RL   Am. J. Hum. Genet. 70:472-486(2002).
RN   [81]
RP   VARIANT BSTVS CYS-375.
RX   PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x;
RA   Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.;
RT   "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-
RT   Stevenson cutis gyrata syndrome.";
RL   Clin. Genet. 61:218-221(2002).
RN   [82]
RP   VARIANT FSPC GLU-526.
RX   PubMed=16061565; DOI=10.1136/jmg.2004.027888;
RA   McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R.,
RA   Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.;
RT   "Familial scaphocephaly syndrome caused by a novel mutation in the
RT   FGFR2 tyrosine kinase domain.";
RL   J. Med. Genet. 42:656-662(2005).
RN   [83]
RP   VARIANTS LADDS THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [84]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-203.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [85]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272;
RP   ASN-283; CYS-290 AND THR-612.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [86]
RP   VARIANTS BBDS ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT
RP   BBDS ARG-391.
RX   PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005;
RA   Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N.,
RA   Estrada K.D., Lyons K.M., Deixler H., Robinson H., Chitayat D.,
RA   Curry C.J., Lachman R.S., Wilcox W.R., Krakow D.;
RT   "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has
RT   deficient canonical FGF signaling.";
RL   Am. J. Hum. Genet. 90:550-557(2012).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of cell proliferation, differentiation,
CC       migration and apoptosis, and in the regulation of embryonic
CC       development. Required for normal embryonic patterning, trophoblast
CC       function, limb bud development, lung morphogenesis, osteogenesis
CC       and skin development. Plays an essential role in the regulation of
CC       osteoblast differentiation, proliferation and apoptosis, and is
CC       required for normal skeleton development. Promotes cell
CC       proliferation in keratinocytes and immature osteoblasts, but
CC       promotes apoptosis in differentiated osteoblasts. Phosphorylates
CC       PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of
CC       several signaling cascades. Activation of PLCG1 leads to the
CC       production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers
CC       recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates
CC       activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase
CC       signaling pathway, as well as of the AKT1 signaling pathway. FGFR2
CC       signaling is down-regulated by ubiquitination, internalization and
CC       degradation. Mutations that lead to constitutive kinase activation
CC       or impair normal FGFR2 maturation, internalization and degradation
CC       lead to aberrant signaling. Over-expressed FGFR2 promotes
CC       activation of STAT1. {ECO:0000269|PubMed:12529371,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145,
CC       ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595,
CC       ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646,
CC       ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646,
CC       ECO:0000269|PubMed:21454610}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues. Inhibited
CC       by ARQ 523 and ARQ 069; these compounds maintain the kinase in an
CC       inactive conformation and inhibit autophosphorylation.
CC       {ECO:0000269|PubMed:17803937, ECO:0000269|PubMed:21454610}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in
CC       vitro). Ligand specificity is determined by tissue-specific
CC       expression of isoforms, and differences in the third Ig-like
CC       domain are crucial for ligand specificity. Isoform 1 has high
CC       affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3
CC       has high affinity for FGF1 and FGF7, and has much higher affinity
CC       for FGF7 than isoform 1 (in vitro). Affinity for fibroblast growth
CC       factors (FGFs) is increased by heparan sulfate glycosaminoglycans
CC       that function as coreceptors. Likewise, KLB increases the affinity
CC       for FGF19 and FGF21. Interacts with PLCG1, GRB2 and PAK4.
CC       Interacts with FLRT2 (By similarity).
CC       {ECO:0000250|UniProtKB:P21803, ECO:0000269|PubMed:10618369,
CC       ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11069186,
CC       ECO:0000269|PubMed:11390973, ECO:0000269|PubMed:12529371,
CC       ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:1309608,
CC       ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:15190072,
CC       ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:17803937,
CC       ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19060208,
CC       ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:21454610,
CC       ECO:0000269|PubMed:8663044, ECO:0000269|PubMed:8961926}.
CC   -!- INTERACTION:
CC       P03968:FGF1 (xeno); NbExp=2; IntAct=EBI-1028658, EBI-6358090;
CC       P05230:FGF1; NbExp=3; IntAct=EBI-1028658, EBI-698068;
CC       O15520:FGF10; NbExp=2; IntAct=EBI-1028658, EBI-1035684;
CC       P09038:FGF2; NbExp=3; IntAct=EBI-1028658, EBI-977447;
CC       P21781:FGF7; NbExp=2; IntAct=EBI-6354683, EBI-3937699;
CC       P62993:GRB2; NbExp=5; IntAct=EBI-1028658, EBI-401755;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on
CC       osteoblast plasma membrane lipid rafts. After ligand binding, the
CC       activated receptor is rapidly internalized and degraded.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Note=After ligand binding, the activated
CC       receptor is rapidly internalized and degraded.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cell membrane; Single-pass type I
CC       membrane protein. Note=After ligand binding, the activated
CC       receptor is rapidly internalized and degraded.
CC   -!- SUBCELLULAR LOCATION: Isoform 14: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 19: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=23;
CC       Name=1; Synonyms=BEK, FGFR2IIIc;
CC         IsoId=P21802-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P21802-2; Sequence=VSP_002978;
CC       Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR;
CC         IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972;
CC       Name=4; Synonyms=K-sam;
CC         IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970,
CC                                  VSP_002971, VSP_002972, VSP_002975,
CC                                  VSP_002976;
CC       Name=5; Synonyms=K-sam-I, BEK, IgIIIc;
CC         IsoId=P21802-5; Sequence=VSP_002975;
CC       Name=6; Synonyms=K-sam-IIC2;
CC         IsoId=P21802-6; Sequence=VSP_002975, VSP_002984;
CC       Name=7; Synonyms=K-sam-IIO2;
CC         IsoId=P21802-7; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002979;
CC       Name=8; Synonyms=K-sam-IIC3;
CC         IsoId=P21802-8; Sequence=VSP_002975, VSP_002978;
CC       Name=9; Synonyms=K-sam-IIH1;
CC         IsoId=P21802-9; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002980;
CC       Name=10; Synonyms=K-sam-IIH2;
CC         IsoId=P21802-10; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002981;
CC       Name=11; Synonyms=K-sam-IIH3, K-sam-IIO4;
CC         IsoId=P21802-11; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002982;
CC       Name=12; Synonyms=K-sam-IIO1;
CC         IsoId=P21802-12; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002983;
CC       Name=13; Synonyms=K-sam-IIO3;
CC         IsoId=P21802-13; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002977;
CC       Name=14; Synonyms=K-sam-IV, Soluble KGFR;
CC         IsoId=P21802-14; Sequence=VSP_002965, VSP_002966;
CC       Name=15; Synonyms=K-sam-III;
CC         IsoId=P21802-15; Sequence=VSP_002968;
CC       Name=16; Synonyms=TK14;
CC         IsoId=P21802-16; Sequence=VSP_002967, VSP_002975;
CC         Note=Ref.2 (AAA61188) sequence is in conflict in position:
CC         315:T->L. {ECO:0000305};
CC       Name=17;
CC         IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002978;
CC       Name=18; Synonyms=K-sam-IIC1, KGFR, IgIIIb;
CC         IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002975;
CC       Name=19; Synonyms=Soluble KGFR;
CC         IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002973, VSP_002974;
CC       Name=20;
CC         IsoId=P21802-20; Sequence=VSP_019608, VSP_019609;
CC       Name=21;
CC         IsoId=P21802-21; Sequence=VSP_002964, VSP_041915;
CC       Name=22;
CC         IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970,
CC                                   VSP_002971, VSP_002972, VSP_002978;
CC       Name=23;
CC         IsoId=P21802-23; Sequence=VSP_041914;
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. Alternative splicing events affecting the third Ig-
CC       like domain are crucial for ligand selectivity.
CC       {ECO:0000269|PubMed:1309608, ECO:0000269|PubMed:1400433,
CC       ECO:0000269|PubMed:8961926}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on several tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. Phosphorylation at Tyr-769 is essential for
CC       interaction with PLCG1. {ECO:0000269|PubMed:15629145,
CC       ECO:0000269|PubMed:19060208}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:17311277}.
CC   -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after
CC       autophosphorylation, leading to internalization and degradation.
CC       Subject to degradation both in lysosomes and by the proteasome.
CC       {ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:21596750}.
CC   -!- DISEASE: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant
CC       syndrome characterized by craniosynostosis, hypertelorism,
CC       exophthalmos and external strabismus, parrot-beaked nose, short
CC       upper lip, hypoplastic maxilla, and a relative mandibular
CC       prognathism. {ECO:0000269|PubMed:10574673,
CC       ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921,
CC       ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378,
CC       ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:7874170,
CC       ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214,
CC       ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:8946174,
CC       ECO:0000269|PubMed:8956050, ECO:0000269|PubMed:9002682,
CC       ECO:0000269|PubMed:9152842, ECO:0000269|PubMed:9521581,
CC       ECO:0000269|PubMed:9677057, ECO:0000269|Ref.10}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal
CC       dominant craniosynostosis syndrome characterized by craniofacial
CC       abnormalities and abnormality of the feet: broad great toes with
CC       medial deviation and tarsal-metatarsal coalescence.
CC       {ECO:0000269|PubMed:7874170, ECO:0000269|PubMed:8528214,
CC       ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368,
CC       ECO:0000269|PubMed:9677057}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Apert syndrome (APRS) [MIM:101200]: A syndrome
CC       characterized by facio-cranio-synostosis, osseous and membranous
CC       syndactyly of the four extremities, and midface hypoplasia. The
CC       craniosynostosis is bicoronal and results in acrocephaly of
CC       brachysphenocephalic type. Syndactyly of the fingers and toes may
CC       be total (mitten hands and sock feet) or partial affecting the
CC       second, third, and fourth digits. Intellectual deficit is frequent
CC       and often severe, usually being associated with cerebral
CC       malformations. {ECO:0000269|PubMed:11781872,
CC       ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344,
CC       ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9452027,
CC       ECO:0000269|PubMed:9677057}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome
CC       characterized by the association of craniosynostosis, broad and
CC       deviated thumbs and big toes, and partial syndactyly of the
CC       fingers and toes. Three subtypes are known: mild autosomal
CC       dominant form (type 1); cloverleaf skull, elbow ankylosis, early
CC       death, sporadic (type 2); craniosynostosis, early demise, sporadic
CC       (type 3). {ECO:0000269|PubMed:10394936,
CC       ECO:0000269|PubMed:10945669, ECO:0000269|PubMed:11173845,
CC       ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719333,
CC       ECO:0000269|PubMed:7719345, ECO:0000269|PubMed:8644708,
CC       ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9150725,
CC       ECO:0000269|PubMed:9693549, ECO:0000269|PubMed:9719378}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS)
CC       [MIM:123790]: An autosomal dominant disease characterized by
CC       craniofacial anomalies, particularly craniosynostosis, and ear
CC       defects, cutis gyrata, acanthosis nigricans, anogenital anomalies,
CC       skin tags, and prominent umbilical stump. The skin furrows have a
CC       corrugated appearance and are widespread. Cutis gyrata variably
CC       affects the scalp, forehead, face, preauricular area, neck, trunk,
CC       hands, and feet. {ECO:0000269|PubMed:12000365,
CC       ECO:0000269|PubMed:8696350}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An
CC       autosomal dominant craniosynostosis syndrome characterized by
CC       scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion,
CC       and mild intellectual disability. Scaphocephaly is the most common
CC       of the craniosynostosis conditions and is characterized by a long,
CC       narrow head. It is due to premature fusion of the sagittal suture
CC       or from external deformation. {ECO:0000269|PubMed:16061565}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS)
CC       [MIM:149730]: An autosomal dominant ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. Lacrimo-auriculo-dento-digital
CC       syndrome is characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed. {ECO:0000269|PubMed:16501574}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Antley-Bixler syndrome, without genital anomalies or
CC       disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome
CC       characterized by craniosynostosis, radiohumeral synostosis present
CC       from the perinatal period, midface hypoplasia, choanal stenosis or
CC       atresia, femoral bowing and multiple joint contractures.
CC       Arachnodactyly and/or camptodactyly have also been reported.
CC       {ECO:0000269|PubMed:10633130}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Bent bone dysplasia syndrome (BBDS) [MIM:614592]: A
CC       perinatal lethal skeletal dysplasia characterized by poor
CC       mineralization of the calvarium, craniosynostosis, dysmorphic
CC       facial features, prenatal teeth, hypoplastic pubis and clavicles,
CC       osteopenia, and bent long bones. Dysmorphic facial features
CC       included low-set ears, hypertelorism, midface hypoplasia,
CC       prematurely erupted fetal teeth, and micrognathia.
CC       {ECO:0000269|PubMed:22387015}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG57383.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR2ID40570ch10q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52832; CAA37014.1; -; mRNA.
DR   EMBL; M55614; AAA61188.1; -; mRNA.
DR   EMBL; X56191; CAA39654.1; -; mRNA.
DR   EMBL; M35718; AAA36152.1; -; mRNA.
DR   EMBL; M87770; AAA59470.1; -; mRNA.
DR   EMBL; M87771; AAA59471.1; -; mRNA.
DR   EMBL; M87772; AAA59472.1; -; mRNA.
DR   EMBL; M97193; AAA52449.1; -; mRNA.
DR   EMBL; U11814; AAA68514.1; -; mRNA.
DR   EMBL; M80634; AAA36147.1; -; mRNA.
DR   EMBL; Z71929; CAA96492.1; -; mRNA.
DR   EMBL; AB030073; BAA89296.1; -; mRNA.
DR   EMBL; AB030074; BAA89297.1; -; mRNA.
DR   EMBL; AB030075; BAA89298.1; -; mRNA.
DR   EMBL; AB030076; BAA89299.1; -; mRNA.
DR   EMBL; AB030077; BAA89300.1; -; mRNA.
DR   EMBL; AB030078; BAA89301.1; -; mRNA.
DR   EMBL; AF360695; AAK94205.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94206.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94207.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94208.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA.
DR   EMBL; AF360695; AAK94209.1; -; Genomic_DNA.
DR   EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA.
DR   EMBL; AF487553; AAM74056.1; -; Genomic_DNA.
DR   EMBL; AB084153; BAC45037.1; -; mRNA.
DR   EMBL; DQ493927; ABE96832.1; -; Genomic_DNA.
DR   EMBL; AK294026; BAG57383.1; ALT_INIT; mRNA.
DR   EMBL; AC009988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC039243; AAH39243.2; -; mRNA.
DR   EMBL; AF169399; AAF43273.1; -; Genomic_DNA.
DR   EMBL; AF169399; AAF43274.1; -; Genomic_DNA.
DR   EMBL; AF097353; AAD31560.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA.
DR   EMBL; AF097353; AAD31561.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA.
DR   EMBL; AF097340; AAD31562.1; -; Genomic_DNA.
DR   EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA.
DR   EMBL; AF097354; AAD31565.1; -; Genomic_DNA.
DR   EMBL; AF097341; AAD31567.1; -; Genomic_DNA.
DR   EMBL; S82438; AAD14392.1; -; Genomic_DNA.
DR   EMBL; Y17131; CAA76643.1; -; Genomic_DNA.
DR   EMBL; L49237; AAC41933.1; -; Genomic_DNA.
DR   EMBL; L49242; AAC41934.1; -; Genomic_DNA.
DR   EMBL; L49238; AAC41935.1; -; Genomic_DNA.
DR   EMBL; L49239; AAC41936.1; -; Genomic_DNA.
DR   EMBL; L49240; AAC41937.1; -; Genomic_DNA.
DR   EMBL; L49241; AAC41938.1; -; Genomic_DNA.
DR   CCDS; CCDS31298.1; -. [P21802-1]
DR   CCDS; CCDS44485.1; -. [P21802-20]
DR   CCDS; CCDS44486.1; -. [P21802-23]
DR   CCDS; CCDS44487.1; -. [P21802-15]
DR   CCDS; CCDS44488.1; -. [P21802-22]
DR   CCDS; CCDS44489.1; -. [P21802-17]
DR   CCDS; CCDS53584.1; -. [P21802-21]
DR   CCDS; CCDS7620.2; -. [P21802-3]
DR   PIR; A35969; A35969.
DR   PIR; A42691; TVHUF2.
DR   PIR; A45081; A45081.
DR   PIR; C42691; C42691.
DR   PIR; S16236; S16236.
DR   RefSeq; NP_000132.3; NM_000141.4. [P21802-1]
DR   RefSeq; NP_001138385.1; NM_001144913.1. [P21802-17]
DR   RefSeq; NP_001138386.1; NM_001144914.1. [P21802-23]
DR   RefSeq; NP_001138387.1; NM_001144915.1. [P21802-21]
DR   RefSeq; NP_001138388.1; NM_001144916.1.
DR   RefSeq; NP_001138389.1; NM_001144917.1. [P21802-15]
DR   RefSeq; NP_001138390.1; NM_001144918.1. [P21802-20]
DR   RefSeq; NP_001138391.1; NM_001144919.1. [P21802-22]
DR   RefSeq; NP_075259.4; NM_022970.3. [P21802-3]
DR   RefSeq; NP_075418.1; NM_023029.2.
DR   UniGene; Hs.533683; -.
DR   PDB; 1DJS; X-ray; 2.40 A; A=32-362.
DR   PDB; 1E0O; X-ray; 2.80 A; B/D=148-366.
DR   PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366.
DR   PDB; 1GJO; X-ray; 2.40 A; A=456-768.
DR   PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366.
DR   PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366.
DR   PDB; 1NUN; X-ray; 2.90 A; B=140-368.
DR   PDB; 1OEC; X-ray; 2.40 A; A=456-768.
DR   PDB; 1WVZ; NMR; -; A=147-249.
DR   PDB; 2FDB; X-ray; 2.28 A; P/R=149-368.
DR   PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768.
DR   PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778.
DR   PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768.
DR   PDB; 2PWL; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PY3; X-ray; 2.30 A; A/B=458-768.
DR   PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PZP; X-ray; 2.40 A; A/B=458-768.
DR   PDB; 2PZR; X-ray; 3.00 A; A/B=458-768.
DR   PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768.
DR   PDB; 3B2T; X-ray; 1.80 A; A/B=458-766.
DR   PDB; 3CAF; X-ray; 1.96 A; A=150-249.
DR   PDB; 3CLY; X-ray; 2.00 A; A=458-778.
DR   PDB; 3CU1; X-ray; 2.60 A; A/C=150-249.
DR   PDB; 3DAR; X-ray; 2.20 A; A/B=146-249.
DR   PDB; 3EUU; X-ray; 2.34 A; A/B=150-249.
DR   PDB; 3OJ2; X-ray; 2.20 A; C/D=140-313.
DR   PDB; 3OJM; X-ray; 2.10 A; B=140-313.
DR   PDB; 3RI1; X-ray; 2.10 A; A/B=458-768.
DR   PDB; 4J23; X-ray; 3.88 A; A=147-366.
DR   PDB; 4J95; X-ray; 2.38 A; A/B/C/D=458-768.
DR   PDB; 4J96; X-ray; 2.30 A; A/B=458-768.
DR   PDB; 4J97; X-ray; 2.55 A; A/B/C/D=458-768.
DR   PDB; 4J98; X-ray; 2.31 A; A/B=458-768.
DR   PDB; 4J99; X-ray; 1.85 A; A/B/C/D=458-768.
DR   PDB; 4WV1; X-ray; 2.36 A; C/F=153-251.
DR   PDBsum; 1DJS; -.
DR   PDBsum; 1E0O; -.
DR   PDBsum; 1EV2; -.
DR   PDBsum; 1GJO; -.
DR   PDBsum; 1II4; -.
DR   PDBsum; 1IIL; -.
DR   PDBsum; 1NUN; -.
DR   PDBsum; 1OEC; -.
DR   PDBsum; 1WVZ; -.
DR   PDBsum; 2FDB; -.
DR   PDBsum; 2PSQ; -.
DR   PDBsum; 2PVF; -.
DR   PDBsum; 2PVY; -.
DR   PDBsum; 2PWL; -.
DR   PDBsum; 2PY3; -.
DR   PDBsum; 2PZ5; -.
DR   PDBsum; 2PZP; -.
DR   PDBsum; 2PZR; -.
DR   PDBsum; 2Q0B; -.
DR   PDBsum; 3B2T; -.
DR   PDBsum; 3CAF; -.
DR   PDBsum; 3CLY; -.
DR   PDBsum; 3CU1; -.
DR   PDBsum; 3DAR; -.
DR   PDBsum; 3EUU; -.
DR   PDBsum; 3OJ2; -.
DR   PDBsum; 3OJM; -.
DR   PDBsum; 3RI1; -.
DR   PDBsum; 4J23; -.
DR   PDBsum; 4J95; -.
DR   PDBsum; 4J96; -.
DR   PDBsum; 4J97; -.
DR   PDBsum; 4J98; -.
DR   PDBsum; 4J99; -.
DR   PDBsum; 4WV1; -.
DR   ProteinModelPortal; P21802; -.
DR   SMR; P21802; 5-364, 462-801.
DR   BioGrid; 108554; 56.
DR   DIP; DIP-3788N; -.
DR   IntAct; P21802; 28.
DR   MINT; MINT-118359; -.
DR   STRING; 9606.ENSP00000410294; -.
DR   BindingDB; P21802; -.
DR   ChEMBL; CHEMBL4142; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01041; Thalidomide.
DR   GuidetoPHARMACOLOGY; 1809; -.
DR   iPTMnet; P21802; -.
DR   PhosphoSite; P21802; -.
DR   BioMuta; FGFR2; -.
DR   DMDM; 120049; -.
DR   MaxQB; P21802; -.
DR   PaxDb; P21802; -.
DR   PRIDE; P21802; -.
DR   Ensembl; ENST00000346997; ENSP00000263451; ENSG00000066468. [P21802-5]
DR   Ensembl; ENST00000356226; ENSP00000348559; ENSG00000066468. [P21802-20]
DR   Ensembl; ENST00000357555; ENSP00000350166; ENSG00000066468. [P21802-21]
DR   Ensembl; ENST00000358487; ENSP00000351276; ENSG00000066468. [P21802-1]
DR   Ensembl; ENST00000359354; ENSP00000352309; ENSG00000066468. [P21802-14]
DR   Ensembl; ENST00000360144; ENSP00000353262; ENSG00000066468. [P21802-22]
DR   Ensembl; ENST00000369056; ENSP00000358052; ENSG00000066468. [P21802-17]
DR   Ensembl; ENST00000369058; ENSP00000358054; ENSG00000066468. [P21802-13]
DR   Ensembl; ENST00000369060; ENSP00000358056; ENSG00000066468. [P21802-15]
DR   Ensembl; ENST00000369061; ENSP00000358057; ENSG00000066468. [P21802-23]
DR   Ensembl; ENST00000457416; ENSP00000410294; ENSG00000066468. [P21802-3]
DR   GeneID; 2263; -.
DR   KEGG; hsa:2263; -.
DR   UCSC; uc001lfg.4; human. [P21802-20]
DR   UCSC; uc001lfn.5; human. [P21802-1]
DR   UCSC; uc010qtl.2; human. [P21802-15]
DR   UCSC; uc021pzv.1; human. [P21802-23]
DR   UCSC; uc021pzx.1; human. [P21802-21]
DR   UCSC; uc021pzy.1; human. [P21802-3]
DR   UCSC; uc021qaa.1; human. [P21802-17]
DR   UCSC; uc021qab.1; human. [P21802-22]
DR   UCSC; uc021qac.1; human. [P21802-4]
DR   CTD; 2263; -.
DR   GeneCards; FGFR2; -.
DR   GeneReviews; FGFR2; -.
DR   HGNC; HGNC:3689; FGFR2.
DR   HPA; CAB010886; -.
DR   HPA; HPA035305; -.
DR   HPA; HPA056562; -.
DR   MalaCards; FGFR2; -.
DR   MIM; 101200; phenotype.
DR   MIM; 101600; phenotype.
DR   MIM; 123150; phenotype.
DR   MIM; 123500; phenotype.
DR   MIM; 123790; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 176943; gene.
DR   MIM; 207410; phenotype.
DR   MIM; 609579; phenotype.
DR   MIM; 614592; phenotype.
DR   neXtProt; NX_P21802; -.
DR   Orphanet; 83; Antley-Bixler syndrome.
DR   Orphanet; 87; Apert syndrome.
DR   Orphanet; 207; Crouzon disease.
DR   Orphanet; 1555; Cutis gyrata - acanthosis nigricans - craniosynostosis.
DR   Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type.
DR   Orphanet; 313855; FGFR2-related bent bone dysplasia.
DR   Orphanet; 1540; Jackson-Weiss syndrome.
DR   Orphanet; 2363; Lacrimoauriculodentodigital syndrome.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   Orphanet; 93259; Pfeiffer syndrome type 2.
DR   Orphanet; 93260; Pfeiffer syndrome type 3.
DR   Orphanet; 794; Saethre-Chotzen syndrome.
DR   PharmGKB; PA28128; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P21802; -.
DR   KO; K05093; -.
DR   OrthoDB; EOG7NGQ9N; -.
DR   PhylomeDB; P21802; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-190375; FGFR2c ligand binding and activation.
DR   Reactome; R-HSA-190377; FGFR2b ligand binding and activation.
DR   Reactome; R-HSA-2023837; Signaling by FGFR2 amplification mutants.
DR   Reactome; R-HSA-2033519; Activated point mutants of FGFR2.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-HSA-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2.
DR   Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P21802; -.
DR   ChiTaRS; FGFR2; human.
DR   EvolutionaryTrace; P21802; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_2; -.
DR   GenomeRNAi; 2263; -.
DR   NextBio; 9189; -.
DR   PRO; PR:P21802; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P21802; -.
DR   ExpressionAtlas; P21802; baseline and differential.
DR   Genevisible; P21802; HS.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0030282; P:bone mineralization; ISS:UniProtKB.
DR   GO; GO:0060349; P:bone morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; ISS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB.
DR   GO; GO:0060365; P:coronal suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; ISS:UniProtKB.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048568; P:embryonic organ development; ISS:UniProtKB.
DR   GO; GO:0048562; P:embryonic organ morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB.
DR   GO; GO:0061031; P:endodermal digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048730; P:epidermis morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0060595; P:fibroblast growth factor receptor signaling pathway involved in mammary gland specification; ISS:UniProtKB.
DR   GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow; ISS:UniProtKB.
DR   GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; ISS:UniProtKB.
DR   GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; ISS:UniProtKB.
DR   GO; GO:0022612; P:gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0032808; P:lacrimal gland development; ISS:UniProtKB.
DR   GO; GO:0060601; P:lateral sprouting from an epithelium; ISS:UniProtKB.
DR   GO; GO:0070307; P:lens fiber cell development; IEA:Ensembl.
DR   GO; GO:0060174; P:limb bud formation; ISS:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0060463; P:lung lobe morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; ISS:UniProtKB.
DR   GO; GO:0060615; P:mammary gland bud formation; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0003149; P:membranous septum morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; ISS:UniProtKB.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; ISS:UniProtKB.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; ISS:UniProtKB.
DR   GO; GO:0016331; P:morphogenesis of embryonic epithelium; ISS:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042476; P:odontogenesis; ISS:UniProtKB.
DR   GO; GO:0021769; P:orbitofrontal cortex development; ISS:UniProtKB.
DR   GO; GO:0035265; P:organ growth; ISS:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030916; P:otic vesicle formation; ISS:UniProtKB.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; ISS:UniProtKB.
DR   GO; GO:0060512; P:prostate gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; ISS:UniProtKB.
DR   GO; GO:0010453; P:regulation of cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0040036; P:regulation of fibroblast growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060688; P:regulation of morphogenesis of a branching structure; ISS:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0045667; P:regulation of osteoblast differentiation; TAS:UniProtKB.
DR   GO; GO:0033688; P:regulation of osteoblast proliferation; TAS:UniProtKB.
DR   GO; GO:0051150; P:regulation of smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048608; P:reproductive structure development; ISS:UniProtKB.
DR   GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISS:UniProtKB.
DR   GO; GO:0048489; P:synaptic vesicle transport; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:UniProtKB.
DR   GO; GO:0021847; P:ventricular zone neuroblast division; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell membrane; Complete proteome; Craniosynostosis;
KW   Cytoplasmic vesicle; Disease mutation; Disulfide bond;
KW   Ectodermal dysplasia; Glycoprotein; Golgi apparatus; Heparin-binding;
KW   Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Mental retardation;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    821       Fibroblast growth factor receptor 2.
FT                                /FTId=PRO_0000016783.
FT   TOPO_DOM     22    377       Extracellular. {ECO:0000255}.
FT   TRANSMEM    378    398       Helical. {ECO:0000255}.
FT   TOPO_DOM    399    821       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    125       Ig-like C2-type 1.
FT   DOMAIN      154    247       Ig-like C2-type 2.
FT   DOMAIN      256    358       Ig-like C2-type 3.
FT   DOMAIN      481    770       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     487    495       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:19060208}.
FT   NP_BIND     565    567       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:19060208}.
FT   REGION      161    178       Heparin-binding.
FT   ACT_SITE    626    626       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028,
FT                                ECO:0000269|PubMed:19060208}.
FT   BINDING     517    517       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:19060208}.
FT   BINDING     571    571       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:19060208}.
FT   MOD_RES     466    466       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19060208,
FT                                ECO:0000269|PubMed:19410646}.
FT   MOD_RES     586    586       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17803937,
FT                                ECO:0000269|PubMed:19060208,
FT                                ECO:0000269|PubMed:19410646}.
FT   MOD_RES     588    588       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19060208,
FT                                ECO:0000269|PubMed:19410646}.
FT   MOD_RES     656    656       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17803937,
FT                                ECO:0000269|PubMed:19060208,
FT                                ECO:0000269|PubMed:19410646}.
FT   MOD_RES     657    657       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17803937,
FT                                ECO:0000269|PubMed:19060208,
FT                                ECO:0000269|PubMed:19410646}.
FT   MOD_RES     769    769       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15629145,
FT                                ECO:0000269|PubMed:19060208}.
FT   MOD_RES     780    780       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     83     83       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    123    123       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    228    228       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    297    297       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    331    331       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     62    107       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    179    231       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:16384934}.
FT   DISULFID    278    342       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:16384934}.
FT   VAR_SEQ      37    152       EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGV
FT                                HLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETW
FT                                YFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKR -> G
FT                                (in isoform 20).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_019608.
FT   VAR_SEQ      37    125       Missing (in isoform 4, isoform 21 and
FT                                isoform 22).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:2377625}.
FT                                /FTId=VSP_002964.
FT   VAR_SEQ     250    361       Missing (in isoform 23).
FT                                {ECO:0000303|Ref.14}.
FT                                /FTId=VSP_041914.
FT   VAR_SEQ     250    254       ERSPH -> GSQGL (in isoform 14).
FT                                {ECO:0000303|PubMed:1313574}.
FT                                /FTId=VSP_002965.
FT   VAR_SEQ     255    821       Missing (in isoform 14).
FT                                {ECO:0000303|PubMed:1313574}.
FT                                /FTId=VSP_002966.
FT   VAR_SEQ     313    313       K -> KVTK (in isoform 16).
FT                                {ECO:0000303|PubMed:2172978}.
FT                                /FTId=VSP_002967.
FT   VAR_SEQ     314    429       Missing (in isoform 15).
FT                                {ECO:0000303|PubMed:1313574}.
FT                                /FTId=VSP_002968.
FT   VAR_SEQ     314    330       AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in
FT                                isoform 3, isoform 4, isoform 7, isoform
FT                                9, isoform 10, isoform 11, isoform 12,
FT                                isoform 13, isoform 17, isoform 18,
FT                                isoform 19 and isoform 22).
FT                                {ECO:0000303|PubMed:10626794,
FT                                ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:1400433,
FT                                ECO:0000303|PubMed:1647213,
FT                                ECO:0000303|PubMed:2377625,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002969.
FT   VAR_SEQ     334    335       FE -> EA (in isoform 3, isoform 4,
FT                                isoform 7, isoform 9, isoform 10, isoform
FT                                11, isoform 12, isoform 13, isoform 17,
FT                                isoform 18, isoform 19 and isoform 22).
FT                                {ECO:0000303|PubMed:10626794,
FT                                ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:1400433,
FT                                ECO:0000303|PubMed:1647213,
FT                                ECO:0000303|PubMed:2377625,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002970.
FT   VAR_SEQ     341    353       TCLAGNSIGISFH -> ICKVSNYIGQANQ (in
FT                                isoform 3, isoform 4, isoform 7, isoform
FT                                9, isoform 10, isoform 11, isoform 12,
FT                                isoform 13, isoform 17, isoform 18,
FT                                isoform 19 and isoform 22).
FT                                {ECO:0000303|PubMed:10626794,
FT                                ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:1400433,
FT                                ECO:0000303|PubMed:1647213,
FT                                ECO:0000303|PubMed:2377625,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002971.
FT   VAR_SEQ     361    361       P -> PKQQ (in isoform 3, isoform 4,
FT                                isoform 7, isoform 9, isoform 10, isoform
FT                                11, isoform 12, isoform 13, isoform 17,
FT                                isoform 18, isoform 19 and isoform 22).
FT                                {ECO:0000303|PubMed:10626794,
FT                                ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:1400433,
FT                                ECO:0000303|PubMed:1647213,
FT                                ECO:0000303|PubMed:2377625,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002972.
FT   VAR_SEQ     362    365       APGR -> GRRC (in isoform 19).
FT                                {ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002973.
FT   VAR_SEQ     366    821       Missing (in isoform 19).
FT                                {ECO:0000303|PubMed:1309608,
FT                                ECO:0000303|PubMed:7866434}.
FT                                /FTId=VSP_002974.
FT   VAR_SEQ     428    429       Missing (in isoform 4, isoform 5, isoform
FT                                6, isoform 8, isoform 16 and isoform 18).
FT                                {ECO:0000303|PubMed:1313574,
FT                                ECO:0000303|PubMed:2172978,
FT                                ECO:0000303|PubMed:2377625}.
FT                                /FTId=VSP_002975.
FT   VAR_SEQ     429    430       Missing (in isoform 20).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_019609.
FT   VAR_SEQ     761    821       LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPD
FT                                PMPYEPCLPQYPHINGSVKT -> PPNPSLMSIFRK (in
FT                                isoform 4). {ECO:0000303|PubMed:2377625}.
FT                                /FTId=VSP_002976.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> SFQSSLKSSSTGIPGWPPGSEVFS
FT                                EVAFRGILNYDIERPILCAGSKKIYDI (in isoform
FT                                10). {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002981.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> GRLPAWASQEKENSQTSLFAISHV
FT                                TLSSISKTRSSAKRDEKPGSSPHLALVRSQGLPQSVVP
FT                                (in isoform 11).
FT                                {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002982.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> PLS (in isoform 12).
FT                                {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002983.
FT   VAR_SEQ     768    821       Missing (in isoform 13).
FT                                {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002977.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> I (in isoform 2, isoform
FT                                8, isoform 17 and isoform 22).
FT                                {ECO:0000303|PubMed:1647213}.
FT                                /FTId=VSP_002978.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> RYKLLPCPDKHNKRCKPEERGDLT
FT                                EAGAAGSSRCVDSRKRVRQEKISTG (in isoform 7).
FT                                {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002979.
FT   VAR_SEQ     768    821       EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPC
FT                                LPQYPHINGSVKT -> RILTLTTNENFQSTSGREGTEIHA
FT                                LQCLRSEVTPAISCESPLADTGSKVPN (in isoform
FT                                9). {ECO:0000303|PubMed:10626794}.
FT                                /FTId=VSP_002980.
FT   VAR_SEQ     769    821       YLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCL
FT                                PQYPHINGSVKT -> EKKVSGAVDCHKPPCNPSHLPCVLA
FT                                VDQ (in isoform 21).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041915.
FT   VAR_SEQ     778    821       QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGS
FT                                VKT -> PYSPCYPDPR (in isoform 6).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002984.
FT   VARIANT       6      6       R -> P (in dbSNP:rs3750819).
FT                                {ECO:0000269|Ref.15}.
FT                                /FTId=VAR_017258.
FT   VARIANT      57     57       S -> L (in dbSNP:rs56226109).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042204.
FT   VARIANT     105    105       Y -> C (in CS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:8946174}.
FT                                /FTId=VAR_004112.
FT   VARIANT     172    172       A -> F (in PS; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017259.
FT   VARIANT     186    186       M -> T (in dbSNP:rs755793).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.15}.
FT                                /FTId=VAR_017260.
FT   VARIANT     203    203       R -> C (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_036380.
FT   VARIANT     252    253       SP -> FS (in PS).
FT                                /FTId=VAR_004116.
FT   VARIANT     252    252       S -> F (in APRS; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:9002682}.
FT                                /FTId=VAR_004114.
FT   VARIANT     252    252       S -> L (in CS).
FT                                {ECO:0000269|PubMed:9002682}.
FT                                /FTId=VAR_004113.
FT   VARIANT     252    252       S -> W (in APRS and PS; common mutation).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:15190072,
FT                                ECO:0000269|PubMed:7668257,
FT                                ECO:0000269|PubMed:7719344,
FT                                ECO:0000269|PubMed:9452027,
FT                                ECO:0000269|PubMed:9677057,
FT                                ECO:0000269|PubMed:9719378}.
FT                                /FTId=VAR_004115.
FT   VARIANT     253    253       P -> R (in APRS; common mutation).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7668257,
FT                                ECO:0000269|PubMed:7719344,
FT                                ECO:0000269|PubMed:9452027,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_004117.
FT   VARIANT     263    263       P -> L (in CS).
FT                                {ECO:0000269|PubMed:11173845}.
FT                                /FTId=VAR_017261.
FT   VARIANT     267    267       S -> P (in CS).
FT                                {ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_004118.
FT   VARIANT     268    268       T -> TG (in CS).
FT                                {ECO:0000269|PubMed:8644708}.
FT                                /FTId=VAR_004119.
FT   VARIANT     272    272       G -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042205.
FT   VARIANT     273    273       Missing (in PS; type 2).
FT                                {ECO:0000269|PubMed:10945669}.
FT                                /FTId=VAR_017262.
FT   VARIANT     276    276       F -> V (in CS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:9521581}.
FT                                /FTId=VAR_004120.
FT   VARIANT     278    278       C -> F (in CS, JWS and PS; forms
FT                                disulfide-linked dimers with constitutive
FT                                kinase activity, is retained in an
FT                                intracellular compartment and not
FT                                detected at the cell surface).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:16844695,
FT                                ECO:0000269|PubMed:8644708,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_004121.
FT   VARIANT     278    278       C -> Y (in CS).
FT                                {ECO:0000269|PubMed:11173845}.
FT                                /FTId=VAR_017263.
FT   VARIANT     281    281       Y -> C (in CS).
FT                                {ECO:0000269|PubMed:11380921,
FT                                ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017264.
FT   VARIANT     283    283       D -> N (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042206.
FT   VARIANT     287    289       Missing (in CS).
FT                                /FTId=VAR_004122.
FT   VARIANT     288    288       I -> S (in CS).
FT                                {ECO:0000269|PubMed:11173845}.
FT                                /FTId=VAR_017265.
FT   VARIANT     289    289       Q -> P (in CS and JWS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11380921,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:8644708}.
FT                                /FTId=VAR_004123.
FT   VARIANT     290    290       W -> C (in PS; severe; also in a lung
FT                                squamous cell carcinoma sample; somatic
FT                                mutation). {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9150725}.
FT                                /FTId=VAR_004124.
FT   VARIANT     290    290       W -> G (in CS).
FT                                {ECO:0000269|PubMed:8528214}.
FT                                /FTId=VAR_017266.
FT   VARIANT     290    290       W -> R (in CS).
FT                                /FTId=VAR_004125.
FT   VARIANT     292    292       K -> E (in CS).
FT                                {ECO:0000269|PubMed:9152842}.
FT                                /FTId=VAR_004126.
FT   VARIANT     301    301       Y -> C (in CS).
FT                                {ECO:0000269|PubMed:9521581}.
FT                                /FTId=VAR_004127.
FT   VARIANT     314    314       A -> S (in craniosynostosis).
FT                                {ECO:0000269|PubMed:9521581}.
FT                                /FTId=VAR_004128.
FT   VARIANT     315    315       A -> S (in a non-syndromic
FT                                craniosynostosis patient with abnormal
FT                                intrauterine history; confers
FT                                predisposition to craniosynostosis).
FT                                {ECO:0000269|PubMed:10951518,
FT                                ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017267.
FT   VARIANT     321    321       D -> A (in PS).
FT                                {ECO:0000269|PubMed:7719333}.
FT                                /FTId=VAR_004129.
FT   VARIANT     328    328       Y -> C (in CS).
FT                                {ECO:0000269|PubMed:7874170}.
FT                                /FTId=VAR_004130.
FT   VARIANT     331    331       N -> I (in CS).
FT                                {ECO:0000269|PubMed:8956050}.
FT                                /FTId=VAR_004131.
FT   VARIANT     337    337       A -> ANA (in CS).
FT                                /FTId=VAR_004132.
FT   VARIANT     337    337       A -> P (in CS).
FT                                {ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_017268.
FT   VARIANT     338    338       G -> E (in CS).
FT                                {ECO:0000269|PubMed:8946174}.
FT                                /FTId=VAR_004133.
FT   VARIANT     338    338       G -> R (in CS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_015011.
FT   VARIANT     340    340       Y -> C (in PS).
FT                                {ECO:0000269|PubMed:10394936,
FT                                ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017269.
FT   VARIANT     340    340       Y -> H (in CS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7987400}.
FT                                /FTId=VAR_004134.
FT   VARIANT     341    341       T -> P (in PS and CS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7719345}.
FT                                /FTId=VAR_004135.
FT   VARIANT     342    342       C -> F (in CS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:8644708,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_004136.
FT   VARIANT     342    342       C -> G (in PS).
FT                                {ECO:0000269|PubMed:10394936}.
FT                                /FTId=VAR_017270.
FT   VARIANT     342    342       C -> R (in CS, JWS, PS and ABS2).
FT                                {ECO:0000269|PubMed:10633130,
FT                                ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11380921,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7719345,
FT                                ECO:0000269|PubMed:7987400,
FT                                ECO:0000269|PubMed:8528214,
FT                                ECO:0000269|PubMed:8644708,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_004137.
FT   VARIANT     342    342       C -> S (in CS, JWS, PS and ABS2).
FT                                {ECO:0000269|PubMed:10633130,
FT                                ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:7987400,
FT                                ECO:0000269|PubMed:8644708,
FT                                ECO:0000269|PubMed:9385368,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_004138.
FT   VARIANT     342    342       C -> W (in CS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:8528214}.
FT                                /FTId=VAR_017271.
FT   VARIANT     342    342       C -> Y (in CS and PS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11380921,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:7719345,
FT                                ECO:0000269|PubMed:7987400,
FT                                ECO:0000269|PubMed:8644708,
FT                                ECO:0000269|PubMed:9677057}.
FT                                /FTId=VAR_004139.
FT   VARIANT     344    344       A -> G (in CS and JWS).
FT                                {ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:7874170}.
FT                                /FTId=VAR_004140.
FT   VARIANT     344    344       A -> P (in CS and PS).
FT                                {ECO:0000269|PubMed:8644708}.
FT                                /FTId=VAR_004141.
FT   VARIANT     347    347       S -> C (in CS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7874170}.
FT                                /FTId=VAR_004142.
FT   VARIANT     351    351       S -> C (in CS, PS and ABS2).
FT                                {ECO:0000269|PubMed:10633130,
FT                                ECO:0000269|PubMed:8946174,
FT                                ECO:0000269|PubMed:9693549}.
FT                                /FTId=VAR_004143.
FT   VARIANT     354    354       S -> C (in CS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:7581378,
FT                                ECO:0000269|PubMed:7987400,
FT                                ECO:0000269|PubMed:8528214}.
FT                                /FTId=VAR_004144.
FT   VARIANT     354    354       S -> Y (in CS).
FT                                {ECO:0000269|PubMed:11173845}.
FT                                /FTId=VAR_017272.
FT   VARIANT     356    358       Missing (in CS).
FT                                {ECO:0000269|PubMed:8956050}.
FT                                /FTId=VAR_004145.
FT   VARIANT     359    359       V -> F (in CS and PS).
FT                                {ECO:0000269|PubMed:11173845,
FT                                ECO:0000269|PubMed:8644708}.
FT                                /FTId=VAR_004146.
FT   VARIANT     362    362       A -> S (in CS).
FT                                {ECO:0000269|PubMed:10574673}.
FT                                /FTId=VAR_017273.
FT   VARIANT     372    372       S -> C (in BSTVS).
FT                                {ECO:0000269|PubMed:8696350}.
FT                                /FTId=VAR_017274.
FT   VARIANT     375    375       Y -> C (in PS and BSTVS).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:12000365,
FT                                ECO:0000269|PubMed:8696350}.
FT                                /FTId=VAR_017275.
FT   VARIANT     381    381       Y -> D (in BBDS).
FT                                {ECO:0000269|PubMed:22387015}.
FT                                /FTId=VAR_067977.
FT   VARIANT     384    384       G -> R (in CS).
FT                                {ECO:0000269|PubMed:8946174}.
FT                                /FTId=VAR_004147.
FT   VARIANT     391    391       M -> R (in BBDS; the mutation selectively
FT                                reduces plasma-membrane levels of the
FT                                protein and markedly diminishes the
FT                                receptor's responsiveness to
FT                                extracellular FGF).
FT                                {ECO:0000269|PubMed:22387015}.
FT                                /FTId=VAR_067978.
FT   VARIANT     526    526       K -> E (in FSPC; constitutive kinase
FT                                activity). {ECO:0000269|PubMed:16061565,
FT                                ECO:0000269|PubMed:17803937}.
FT                                /FTId=VAR_023788.
FT   VARIANT     549    549       N -> H (in CS; constitutive kinase
FT                                activity). {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17803937}.
FT                                /FTId=VAR_017276.
FT   VARIANT     565    565       E -> G (in PS; constitutive kinase
FT                                activity). {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17803937}.
FT                                /FTId=VAR_017277.
FT   VARIANT     612    612       R -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046071.
FT   VARIANT     613    613       G -> R. {ECO:0000269|PubMed:10626794,
FT                                ECO:0000269|PubMed:1309608}.
FT                                /FTId=VAR_015012.
FT   VARIANT     628    628       A -> T (in LADDS; strongly reduced kinase
FT                                activity). {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029884.
FT   VARIANT     641    641       K -> R (in PS; constitutive kinase
FT                                activity). {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17803937}.
FT                                /FTId=VAR_017278.
FT   VARIANT     648    648       A -> T (in LADDS).
FT                                {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029885.
FT   VARIANT     649    650       RD -> S (in LADDS).
FT                                {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029886.
FT   VARIANT     659    659       K -> N (in craniosynostosis; constitutive
FT                                kinase activity).
FT                                {ECO:0000269|PubMed:11781872,
FT                                ECO:0000269|PubMed:17803937}.
FT                                /FTId=VAR_017279.
FT   VARIANT     663    663       G -> E (in PS).
FT                                {ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017280.
FT   VARIANT     678    678       R -> G (in CS).
FT                                {ECO:0000269|PubMed:11781872}.
FT                                /FTId=VAR_017281.
FT   MUTAGEN     265    265       N->Q: Reduced N-glycosylation. Reduced
FT                                expression at the cell surface.
FT                                {ECO:0000269|PubMed:16844695}.
FT   MUTAGEN     549    549       N->T: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:17803937}.
FT   MUTAGEN     565    565       E->A: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:17803937}.
FT   MUTAGEN     656    657       Missing: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:16844695}.
FT   MUTAGEN     769    769       Y->F: Increases fibroblast proliferation.
FT                                Decreases phosphorylation of PLCG1 and
FT                                FRS2. Decreases activation of MAP
FT                                kinases. {ECO:0000269|PubMed:15629145,
FT                                ECO:0000269|PubMed:19103595}.
FT   CONFLICT    246    246       L -> P (in Ref. 16; BAG57383).
FT                                {ECO:0000305}.
FT   CONFLICT    310    310       K -> N (in Ref. 16; BAG57383).
FT                                {ECO:0000305}.
FT   STRAND      152    157       {ECO:0000244|PDB:3CAF}.
FT   TURN        159    162       {ECO:0000244|PDB:3CAF}.
FT   STRAND      166    170       {ECO:0000244|PDB:3CAF}.
FT   STRAND      175    178       {ECO:0000244|PDB:3CAF}.
FT   STRAND      181    185       {ECO:0000244|PDB:3CAF}.
FT   STRAND      188    193       {ECO:0000244|PDB:3CAF}.
FT   HELIX       200    202       {ECO:0000244|PDB:3CAF}.
FT   STRAND      203    205       {ECO:0000244|PDB:4WV1}.
FT   STRAND      208    210       {ECO:0000244|PDB:3CAF}.
FT   HELIX       211    213       {ECO:0000244|PDB:3CAF}.
FT   STRAND      215    218       {ECO:0000244|PDB:3CAF}.
FT   HELIX       223    225       {ECO:0000244|PDB:3CAF}.
FT   STRAND      227    235       {ECO:0000244|PDB:3CAF}.
FT   STRAND      238    249       {ECO:0000244|PDB:3CAF}.
FT   STRAND      266    269       {ECO:0000244|PDB:3OJM}.
FT   STRAND      274    277       {ECO:0000244|PDB:3OJM}.
FT   STRAND      287    293       {ECO:0000244|PDB:3OJM}.
FT   STRAND      296    298       {ECO:0000244|PDB:3OJ2}.
FT   STRAND      299    301       {ECO:0000244|PDB:3OJM}.
FT   STRAND      303    305       {ECO:0000244|PDB:1IIL}.
FT   STRAND      309    313       {ECO:0000244|PDB:3OJM}.
FT   STRAND      315    319       {ECO:0000244|PDB:2FDB}.
FT   TURN        321    325       {ECO:0000244|PDB:1EV2}.
FT   STRAND      326    329       {ECO:0000244|PDB:1EV2}.
FT   HELIX       334    336       {ECO:0000244|PDB:1EV2}.
FT   STRAND      338    345       {ECO:0000244|PDB:1EV2}.
FT   STRAND      350    357       {ECO:0000244|PDB:1EV2}.
FT   TURN        463    465       {ECO:0000244|PDB:4J96}.
FT   TURN        472    474       {ECO:0000244|PDB:2PVF}.
FT   HELIX       478    480       {ECO:0000244|PDB:2PVF}.
FT   STRAND      481    489       {ECO:0000244|PDB:2PVF}.
FT   STRAND      494    500       {ECO:0000244|PDB:2PVF}.
FT   STRAND      504    506       {ECO:0000244|PDB:3CLY}.
FT   STRAND      513    518       {ECO:0000244|PDB:2PVF}.
FT   HELIX       525    541       {ECO:0000244|PDB:2PVF}.
FT   STRAND      550    554       {ECO:0000244|PDB:2PVF}.
FT   STRAND      556    558       {ECO:0000244|PDB:2PVF}.
FT   STRAND      561    565       {ECO:0000244|PDB:2PVF}.
FT   STRAND      568    571       {ECO:0000244|PDB:1OEC}.
FT   HELIX       572    577       {ECO:0000244|PDB:2PVF}.
FT   TURN        585    588       {ECO:0000244|PDB:4J99}.
FT   HELIX       594    596       {ECO:0000244|PDB:2PVY}.
FT   HELIX       600    619       {ECO:0000244|PDB:2PVF}.
FT   HELIX       629    631       {ECO:0000244|PDB:2PVF}.
FT   STRAND      632    634       {ECO:0000244|PDB:2PVF}.
FT   TURN        636    638       {ECO:0000244|PDB:2PVY}.
FT   STRAND      640    642       {ECO:0000244|PDB:2PVF}.
FT   HELIX       645    647       {ECO:0000244|PDB:4J96}.
FT   TURN        652    654       {ECO:0000244|PDB:2PVF}.
FT   STRAND      655    658       {ECO:0000244|PDB:2PVF}.
FT   TURN        659    664       {ECO:0000244|PDB:3RI1}.
FT   HELIX       667    669       {ECO:0000244|PDB:2PVF}.
FT   HELIX       672    677       {ECO:0000244|PDB:2PVF}.
FT   HELIX       682    697       {ECO:0000244|PDB:2PVF}.
FT   HELIX       709    718       {ECO:0000244|PDB:2PVF}.
FT   STRAND      726    728       {ECO:0000244|PDB:2PZ5}.
FT   HELIX       730    739       {ECO:0000244|PDB:2PVF}.
FT   HELIX       744    746       {ECO:0000244|PDB:2PVF}.
FT   HELIX       750    764       {ECO:0000244|PDB:2PVF}.
SQ   SEQUENCE   821 AA;  92025 MW;  6CD5001C960ED82F CRC64;
     MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV
     RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF
     MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP
     AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI
     NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK
     YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL
     PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK
     RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK
     LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM
     IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF
     KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT
     TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH
     RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS
     PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T
//
ID   TGFB1_HUMAN             Reviewed;         390 AA.
AC   P01137; A8K792; Q9UCG4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 2.
DT   17-FEB-2016, entry version 214.
DE   RecName: Full=Transforming growth factor beta-1;
DE            Short=TGF-beta-1;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=TGFB1; Synonyms=TGFB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3470709; DOI=10.1093/nar/15.7.3188;
RA   Derynck R., Rhee L., Chen E.Y., van Tilburg A.;
RT   "Intron-exon structure of the human transforming growth factor-beta
RT   precursor gene.";
RL   Nucleic Acids Res. 15:3188-3189(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS PRO-10 AND PRO-25.
RX   PubMed=3861940; DOI=10.1038/316701a0;
RA   Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R.,
RA   Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V.;
RT   "Human transforming growth factor-beta complementary DNA sequence and
RT   expression in normal and transformed cells.";
RL   Nature 316:701-705(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Duodenum, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 279-390.
RC   TISSUE=Carcinoma;
RA   Urushizaki Y., Niitsu Y., Terui T., Koshida Y., Mahara K., Kohgo Y.,
RA   Urushizaki I., Takahashi Y., Ito H.;
RT   "Cloning and expression of the gene for human transforming growth
RT   factor-beta in Escherichia coli.";
RL   Tumor Res. 22:41-55(1987).
RN   [8]
RP   PROTEIN SEQUENCE OF 279-329.
RC   TISSUE=Urinary bladder carcinoma;
RX   PubMed=8471846; DOI=10.1006/prep.1993.1019;
RA   Bourdrel L., Lin C.-H., Lauren S.L., Elmore R.H., Sugarman B.J.,
RA   Hu S., Westcott K.R.;
RT   "Recombinant human transforming growth factor-beta 1: expression by
RT   Chinese hamster ovary cells, isolation, and characterization.";
RL   Protein Expr. Purif. 4:130-140(1993).
RN   [9]
RP   PROTEIN SEQUENCE OF 279-301.
RX   PubMed=2982829;
RA   Massague J., Like B.;
RT   "Cellular receptors for type beta transforming growth factor. Ligand
RT   binding and affinity labeling in human and rodent cell lines.";
RL   J. Biol. Chem. 260:2636-2645(1985).
RN   [10]
RP   PROTEIN SEQUENCE OF 30-42 AND 279-290, AND CHARACTERIZATION.
RX   PubMed=3162913;
RA   Miyazono K., Hellman U., Wernstedt C., Heldin C.H.;
RT   "Latent high molecular weight complex of transforming growth factor
RT   beta 1. Purification from human platelets and structural
RT   characterization.";
RL   J. Biol. Chem. 263:6407-6415(1988).
RN   [11]
RP   REVIEW.
RX   PubMed=9150447; DOI=10.1038/ki.1997.188;
RA   Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I.,
RA   Rifkin D.B.;
RT   "Latent transforming growth factor-beta: structural features and
RT   mechanisms of activation.";
RL   Kidney Int. 51:1376-1382(1997).
RN   [12]
RP   INTERACTION WITH DPT.
RX   PubMed=9895299; DOI=10.1042/0264-6021:3370537;
RA   Okamoto O., Fujiwara S., Abe M., Sato Y.;
RT   "Dermatopontin interacts with transforming growth factor beta and
RT   enhances its biological activity.";
RL   Biochem. J. 337:537-541(1999).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=11746498; DOI=10.1002/jcb.1249;
RA   Shur I., Lokiec F., Bleiberg I., Benayahu D.;
RT   "Differential gene expression of cultured human osteoblasts.";
RL   J. Cell. Biochem. 83:547-553(2001).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-82.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [15]
RP   INTERACTION WITH CD109.
RX   PubMed=16754747; DOI=10.1096/fj.05-5229fje;
RA   Finnson K.W., Tam B.Y.Y., Liu K., Marcoux A., Lepage P., Roy S.,
RA   Bizet A.A., Philip A.;
RT   "Identification of CD109 as part of the TGF-beta receptor system in
RT   human keratinocytes.";
RL   FASEB J. 20:1525-1527(2006).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-82.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [17]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION WITH ASPN.
RX   PubMed=17827158; DOI=10.1074/jbc.M700522200;
RA   Nakajima M., Kizawa H., Saitoh M., Kou I., Miyazono K., Ikegawa S.;
RT   "Mechanisms for asporin function and regulation in articular
RT   cartilage.";
RL   J. Biol. Chem. 282:32185-32192(2007).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   STRUCTURE BY NMR OF 279-390.
RX   PubMed=8424942; DOI=10.1021/bi00055a021;
RA   Archer S.J., Bax A., Roberts A.B., Sporn M.B., Ogawa Y., Piez K.A.,
RA   Weatherbee J.A., Tsang M.L.-S., Lucas R., Zheng B.-L., Wenker J.,
RA   Torchia D.A.;
RT   "Transforming growth factor beta 1: NMR signal assignments of the
RT   recombinant protein expressed and isotopically enriched using Chinese
RT   hamster ovary cells.";
RL   Biochemistry 32:1152-1163(1993).
RN   [21]
RP   STRUCTURE BY NMR OF 279-390.
RX   PubMed=8424943; DOI=10.1021/bi00055a022;
RA   Archer S.J., Bax A., Roberts A.B., Sporn M.B., Ogawa Y., Piez K.A.,
RA   Weatherbee J.A., Tsang M.L.-S., Lucas R., Zheng B.-L., Wenker J.,
RA   Torchia D.A.;
RT   "Transforming growth factor beta 1: secondary structure as determined
RT   by heteronuclear magnetic resonance spectroscopy.";
RL   Biochemistry 32:1164-1171(1993).
RN   [22]
RP   STRUCTURE BY NMR OF 279-390.
RX   PubMed=8679613; DOI=10.1021/bi9604946;
RA   Hinck A.P., Archer S.J., Qian S.W., Roberts A.B., Sporn M.B.,
RA   Weatherbee J.A., Tsang M.L.-S., Lucas R., Zheng B.-L., Wenker J.,
RA   Torchia D.A.;
RT   "Transforming growth factor beta 1: three-dimensional structure in
RT   solution and comparison with the X-ray structure of transforming
RT   growth factor beta 2.";
RL   Biochemistry 35:8517-8534(1996).
RN   [23]
RP   VARIANT PRO-10.
RX   PubMed=9783545; DOI=10.1359/jbmr.1998.13.10.1569;
RA   Yamada Y., Miyauchi A., Goto J., Takagi Y., Okuizumi H., Kanematsu M.,
RA   Hase M., Takai H., Harada A., Ikeda K.;
RT   "Association of a polymorphism of the transforming growth factor-beta1
RT   gene with genetic susceptibility to osteoporosis in postmenopausal
RT   Japanese women.";
RL   J. Bone Miner. Res. 13:1569-1576(1998).
RN   [24]
RP   VARIANTS CAEND CYS-218; HIS-218 AND ARG-225.
RX   PubMed=10973241; DOI=10.1038/79128;
RA   Kinoshita A., Saito T., Tomita H., Makita Y., Yoshida K., Ghadami M.,
RA   Yamada K., Kondo S., Ikegawa S., Nishimura G., Fukushima Y.,
RA   Nakagomi T., Saito H., Sugimoto T., Kamegaya M., Hisa K., Murray J.C.,
RA   Taniguchi N., Niikawa N., Yoshiura K.;
RT   "Domain-specific mutations in TGFB1 result in Camurati-Engelmann
RT   disease.";
RL   Nat. Genet. 26:19-20(2000).
RN   [25]
RP   VARIANTS CAEND HIS-81; CYS-218 AND ARG-225.
RX   PubMed=11062463; DOI=10.1038/81563;
RA   Janssens K., Gershoni-Baruch R., Guanabens N., Migone N., Ralston S.,
RA   Bonduelle M., Lissens W., Van Maldergem L., Vanhoenacker F.,
RA   Verbruggen L., Van Hul W.;
RT   "Mutations in the gene encoding the latency-associated peptide of TGF-
RT   beta 1 cause Camurati-Engelmann disease.";
RL   Nat. Genet. 26:273-275(2000).
RN   [26]
RP   VARIANT PRO-10.
RX   PubMed=12202987; DOI=10.1007/s100380200069;
RA   Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T.,
RA   Matsumoto N., Ishikawa M., Niikawa N., Yoshiura K.;
RT   "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other
RT   types of variations in genes for transforming growth factor-beta1
RT   (TGF-beta1) and its signaling pathway.";
RL   J. Hum. Genet. 47:478-483(2002).
RN   [27]
RP   CHARACTERIZATION OF VARIANTS CAEND HIS-81; CYS-218; ASP-222 AND
RP   ARG-225.
RX   PubMed=12493741; DOI=10.1074/jbc.M208857200;
RA   Janssens K., ten Dijke P., Ralston S.H., Bergmann C., Van Hul W.;
RT   "Transforming growth factor-beta-1 mutations in Camurati-Engelmann
RT   disease lead to increased signaling by altering either activation or
RT   secretion of the mutant protein.";
RL   J. Biol. Chem. 278:7718-7724(2003).
RN   [28]
RP   CHARACTERIZATION OF VARIANT CAEND CYS-218.
RX   PubMed=12843182; DOI=10.1210/jc.2002-020564;
RA   McGowan N.W., MacPherson H., Janssens K., Van Hul W., Frith J.C.,
RA   Fraser W.D., Ralston S.H., Helfrich M.H.;
RT   "A mutation affecting the latency-associated peptide of TGFbeta1 in
RT   Camurati-Engelmann disease enhances osteoclast formation in vitro.";
RL   J. Clin. Endocrinol. Metab. 88:3321-3326(2003).
RN   [29]
RP   VARIANTS CAEND GLY-223 AND ARG-223.
RX   PubMed=15103729; DOI=10.1002/ajmg.a.20671;
RA   Kinoshita A., Fukumaki Y., Shirahama S., Miyahara A., Nishimura G.,
RA   Haga N., Namba A., Ueda H., Hayashi H., Ikegawa S., Seidel J.,
RA   Niikawa N., Yoshiura K.;
RT   "TGFB1 mutations in four new families with Camurati-Engelmann disease:
RT   confirmation of independently arising LAP-domain-specific mutations.";
RL   Am. J. Med. Genet. 127A:104-107(2004).
CC   -!- FUNCTION: Multifunctional protein that controls proliferation,
CC       differentiation and other functions in many cell types. Many cells
CC       synthesize TGFB1 and have specific receptors for it. It positively
CC       and negatively regulates many other growth factors. It plays an
CC       important role in bone remodeling as it is a potent stimulator of
CC       osteoblastic bone formation, causing chemotaxis, proliferation and
CC       differentiation in committed osteoblasts. Can promote either T-
CC       helper 17 cells (Th17) or regulatory T-cells (Treg) lineage
CC       differentiation in a concentration-dependent manner. At high
CC       concentrations, leads to FOXP3-mediated suppression of RORC and
CC       down-regulation of IL-17 expression, favoring Treg cell
CC       development. At low concentrations in concert with IL-6 and IL-21,
CC       leads to expression of the IL-17 and IL-23 receptors, favoring
CC       differentiation to Th17 cells. {ECO:0000250|UniProtKB:P04202}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked, or heterodimer with TGFB2
CC       (By similarity). Secreted and stored as a biologically inactive
CC       form in the extracellular matrix in a 290 kDa complex (large
CC       latent TGF-beta1 complex) containing the TGFB1 homodimer, the
CC       latency-associated peptide (LAP), and the latent TGFB1 binding
CC       protein-1 (LTBP1). The complex without LTBP1 is known as the'small
CC       latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is
CC       required for growth factor activation and biological activity.
CC       Release of the large latent TGF-beta1 complex from the
CC       extracellular matrix is carried out by the matrix
CC       metalloproteinase MMP3 (By similarity). May interact with THSD4;
CC       this interaction may lead to sequestration by FBN1 microfibril
CC       assembly and attenuation of TGFB signaling. Interacts with the
CC       serine proteases, HTRA1 and HTRA3: the interaction with either
CC       inhibits TGFB1-mediated signaling. The HTRA protease activity is
CC       required for this inhibition (By similarity). Latency-associated
CC       peptide interacts with NREP; the interaction results in a decrease
CC       in TGFB1 autoinduction (By similarity). Interacts with CD109, DPT
CC       and ASPN. {ECO:0000250, ECO:0000269|PubMed:16754747,
CC       ECO:0000269|PubMed:17827158, ECO:0000269|PubMed:9895299}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=3; IntAct=EBI-779636, EBI-77613;
CC       Q14689:DIP2A; NbExp=2; IntAct=EBI-779636, EBI-2564275;
CC       P17813:ENG; NbExp=2; IntAct=EBI-779636, EBI-2834630;
CC       Q12841:FSTL1; NbExp=2; IntAct=EBI-779636, EBI-2349801;
CC       A4D127:MEOX2; NbExp=3; IntAct=EBI-779636, EBI-10172134;
CC       P36897:TGFBR1; NbExp=2; IntAct=EBI-779636, EBI-1027557;
CC       P37173:TGFBR2; NbExp=6; IntAct=EBI-779636, EBI-296151;
CC       Q03167:TGFBR3; NbExp=2; IntAct=EBI-779636, EBI-2852679;
CC       Q90998:TGFBR3 (xeno); NbExp=2; IntAct=EBI-779636, EBI-6620843;
CC       P07996:THBS1; NbExp=2; IntAct=EBI-779636, EBI-2530274;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000269|PubMed:17827158}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in bone. Abundantly expressed
CC       in articular cartilage and chondrocytes and is increased in
CC       osteoarthritis (OA). Colocalizes with ASPN in chondrocytes within
CC       OA lesions of articular cartilage. {ECO:0000269|PubMed:11746498,
CC       ECO:0000269|PubMed:17827158}.
CC   -!- INDUCTION: Activated in vitro at pH below 3.5 and over 12.5.
CC   -!- DOMAIN: The 'straitjacket' and 'arm' domains encircle the growth
CC       factor monomers and are fastened together by strong bonding
CC       between Lys-56 and Tyr-103/Tyr-104. Activation of TGF-beta1
CC       requires the binding of integrin alpha-V to an RGD sequence in the
CC       prodomain and exertion of force on this domain, which is held in
CC       the extracellular matrix by latent TGF-beta binding proteins. The
CC       sheer physical force unfastens the straitjacket and releases the
CC       active growth factor dimer (By similarity). {ECO:0000250}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:16263699,
CC       ECO:0000269|PubMed:16335952}.
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-1 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-1 rendering
CC       it inactive.
CC   -!- POLYMORPHISM: In post-menopausal Japanese women, the frequency of
CC       Leu-10 is higher in subjects with osteoporosis than in controls.
CC       {ECO:0000269|PubMed:9783545}.
CC   -!- DISEASE: Camurati-Engelmann disease (CAEND) [MIM:131300]: An
CC       autosomal dominant disorder characterized by hyperostosis and
CC       sclerosis of the diaphyses of long bones. The disease typically
CC       presents in early childhood with pain, muscular weakness and
CC       waddling gait, and in some cases other features such as
CC       exophthalmos, facial paralysis, hearing difficulties and loss of
CC       vision. {ECO:0000269|PubMed:10973241, ECO:0000269|PubMed:11062463,
CC       ECO:0000269|PubMed:15103729}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=TGF beta-1 entry;
CC       URL="https://en.wikipedia.org/wiki/TGF_beta_1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05839; CAA29283.1; -; Genomic_DNA.
DR   EMBL; X05840; CAA29283.1; JOINED; Genomic_DNA.
DR   EMBL; X05843; CAA29283.1; JOINED; Genomic_DNA.
DR   EMBL; X05844; CAA29283.1; JOINED; Genomic_DNA.
DR   EMBL; X05849; CAA29283.1; JOINED; Genomic_DNA.
DR   EMBL; X05850; CAA29283.1; JOINED; Genomic_DNA.
DR   EMBL; X02812; CAA26580.1; -; mRNA.
DR   EMBL; BT007245; AAP35909.1; -; mRNA.
DR   EMBL; AK291907; BAF84596.1; -; mRNA.
DR   EMBL; CH471126; EAW57032.1; -; Genomic_DNA.
DR   EMBL; BC001180; AAH01180.1; -; mRNA.
DR   EMBL; BC000125; AAH00125.1; -; mRNA.
DR   EMBL; BC022242; AAH22242.1; -; mRNA.
DR   EMBL; M38449; AAA36735.1; -; mRNA.
DR   CCDS; CCDS33031.1; -.
DR   PIR; A27513; WFHU2.
DR   RefSeq; NP_000651.3; NM_000660.5.
DR   UniGene; Hs.645227; -.
DR   PDB; 1KLA; NMR; -; A/B=279-390.
DR   PDB; 1KLC; NMR; -; A/B=279-390.
DR   PDB; 1KLD; NMR; -; A/B=279-390.
DR   PDB; 3KFD; X-ray; 3.00 A; A/B/C/D=279-390.
DR   PDB; 4KV5; X-ray; 3.00 A; A/B/C/D=279-390.
DR   PDBsum; 1KLA; -.
DR   PDBsum; 1KLC; -.
DR   PDBsum; 1KLD; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 4KV5; -.
DR   ProteinModelPortal; P01137; -.
DR   SMR; P01137; 30-390.
DR   BioGrid; 112898; 48.
DR   DIP; DIP-5934N; -.
DR   IntAct; P01137; 59.
DR   MINT; MINT-6806111; -.
DR   STRING; 9606.ENSP00000221930; -.
DR   BindingDB; P01137; -.
DR   ChEMBL; CHEMBL1795178; -.
DR   DrugBank; DB00070; Hyaluronidase.
DR   DrugBank; DB06205; Hyaluronidase (Human Recombinant).
DR   iPTMnet; P01137; -.
DR   PhosphoSite; P01137; -.
DR   BioMuta; TGFB1; -.
DR   DMDM; 135674; -.
DR   OGP; P01137; -.
DR   MaxQB; P01137; -.
DR   PaxDb; P01137; -.
DR   PRIDE; P01137; -.
DR   DNASU; 7040; -.
DR   Ensembl; ENST00000221930; ENSP00000221930; ENSG00000105329.
DR   GeneID; 7040; -.
DR   KEGG; hsa:7040; -.
DR   UCSC; uc002oqh.2; human.
DR   CTD; 7040; -.
DR   GeneCards; TGFB1; -.
DR   GeneReviews; TGFB1; -.
DR   H-InvDB; HIX0015152; -.
DR   HGNC; HGNC:11766; TGFB1.
DR   HPA; CAB000361; -.
DR   HPA; HPA047516; -.
DR   MalaCards; TGFB1; -.
DR   MIM; 131300; phenotype.
DR   MIM; 190180; gene.
DR   neXtProt; NX_P01137; -.
DR   Orphanet; 1328; Camurati-Engelmann disease.
DR   Orphanet; 586; Cystic fibrosis.
DR   PharmGKB; PA350; -.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   HOGENOM; HOG000290198; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; P01137; -.
DR   KO; K13375; -.
DR   PhylomeDB; P01137; -.
DR   TreeFam; TF318514; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-168277; Influenza Virus Induced Apoptosis.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   SignaLink; P01137; -.
DR   ChiTaRS; TGFB1; human.
DR   EvolutionaryTrace; P01137; -.
DR   GeneWiki; TGF_beta_1; -.
DR   GenomeRNAi; 7040; -.
DR   NextBio; 27507; -.
DR   PRO; PR:P01137; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P01137; -.
DR   CleanEx; HS_TGFB1; -.
DR   ExpressionAtlas; P01137; baseline and differential.
DR   Genevisible; P01137; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IMP:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; ISS:UniProtKB.
DR   GO; GO:0003823; F:antigen binding; IPI:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; TAS:AgBase.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IEA:Ensembl.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IMP:AgBase.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IMP:AgBase.
DR   GO; GO:0046732; P:active induction of host immune response by virus; TAS:Reactome.
DR   GO; GO:0002460; P:adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006754; P:ATP biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060751; P:branch elongation involved in mammary gland duct branching; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0048468; P:cell development; IBA:GO_Central.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0045216; P:cell-cell junction organization; IDA:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0002062; P:chondrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0002248; P:connective tissue replacement involved in inflammatory response wound healing; TAS:BHF-UCL.
DR   GO; GO:0009817; P:defense response to fungus, incompatible interaction; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0019049; P:evasion or tolerance of host defenses by virus; IDA:BHF-UCL.
DR   GO; GO:0085029; P:extracellular matrix assembly; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060364; P:frontal suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030214; P:hyaluronan catabolic process; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IDA:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048535; P:lymph node development; ISS:UniProtKB.
DR   GO; GO:0010742; P:macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; IDA:BHF-UCL.
DR   GO; GO:0019048; P:modulation by virus of host morphology or physiology; TAS:Reactome.
DR   GO; GO:0032943; P:mononuclear cell proliferation; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:HGNC.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IEP:CACAO.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010716; P:negative regulation of extracellular matrix disassembly; IC:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0060965; P:negative regulation of gene silencing by miRNA; IGI:BHF-UCL.
DR   GO; GO:1900126; P:negative regulation of hyaluronan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IEA:Ensembl.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; IDA:DFLAT.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0030279; P:negative regulation of ossification; IEA:Ensembl.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051280; P:negative regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0048642; P:negative regulation of skeletal muscle tissue development; IDA:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0043932; P:ossification involved in bone remodeling; IEP:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IEP:BHF-UCL.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IEA:Ensembl.
DR   GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IC:BHF-UCL.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IDA:BHF-UCL.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IEA:Ensembl.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IDA:BHF-UCL.
DR   GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IDA:MGI.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:1901666; P:positive regulation of NAD+ ADP-ribosyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IEA:Ensembl.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:BHF-UCL.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1903911; P:positive regulation of receptor clustering; IEA:Ensembl.
DR   GO; GO:0045591; P:positive regulation of regulatory T cell differentiation; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051152; P:positive regulation of smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; TAS:BHF-UCL.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IDA:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032801; P:receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0051098; P:regulation of binding; ISS:UniProtKB.
DR   GO; GO:0060312; P:regulation of blood vessel remodeling; NAS:BHF-UCL.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0061035; P:regulation of cartilage development; IEA:Ensembl.
DR   GO; GO:0030334; P:regulation of cell migration; TAS:BHF-UCL.
DR   GO; GO:0051101; P:regulation of DNA binding; ISS:UniProtKB.
DR   GO; GO:0032667; P:regulation of interleukin-23 production; IEA:Ensembl.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045066; P:regulatory T cell differentiation; IEA:Ensembl.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IDA:BHF-UCL.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEP:BHF-UCL.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IEP:BHF-UCL.
DR   GO; GO:0007183; P:SMAD protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0002513; P:tolerance induction to self antigen; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR003939; TGFb1.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01424; TGFBETA1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Growth factor; Mitogen;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     29       {ECO:0000269|PubMed:3162913}.
FT   CHAIN        30    278       Latency-associated peptide.
FT                                /FTId=PRO_0000033762.
FT   CHAIN       279    390       Transforming growth factor beta-1.
FT                                /FTId=PRO_0000033763.
FT   REGION       30     74       Straightjacket domain. {ECO:0000250}.
FT   REGION       75    271       Arm domain. {ECO:0000250}.
FT   MOTIF       244    246       Cell attachment site. {ECO:0000255}.
FT   CARBOHYD     82     82       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    176    176       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     33     33       Interchain (with C-1359 or C-1384 in
FT                                LTBP1); in inactive form. {ECO:0000250}.
FT   DISULFID    223    223       Interchain (with C-225). {ECO:0000250}.
FT   DISULFID    225    225       Interchain (with C-223). {ECO:0000250}.
FT   DISULFID    285    294
FT   DISULFID    293    356
FT   DISULFID    322    387
FT   DISULFID    326    389
FT   DISULFID    355    355       Interchain.
FT   VARIANT      10     10       L -> P (associated with higher bone
FT                                mineral density and lower frequency of
FT                                vertebral fractures in Japanese post-
FT                                menopausal women; dbSNP:rs1800470).
FT                                {ECO:0000269|PubMed:12202987,
FT                                ECO:0000269|PubMed:3861940,
FT                                ECO:0000269|PubMed:9783545}.
FT                                /FTId=VAR_016171.
FT   VARIANT      25     25       R -> P (in dbSNP:rs1800471).
FT                                {ECO:0000269|PubMed:3861940}.
FT                                /FTId=VAR_016172.
FT   VARIANT      81     81       Y -> H (in CAEND; leads to TGF-beta-1
FT                                intracellular accumulation).
FT                                {ECO:0000269|PubMed:11062463,
FT                                ECO:0000269|PubMed:12493741}.
FT                                /FTId=VAR_017607.
FT   VARIANT     218    218       R -> C (in CAEND; higher levels of active
FT                                TGF-beta-1 in the culture medium;
FT                                enhances osteoclast formation in vitro).
FT                                {ECO:0000269|PubMed:10973241,
FT                                ECO:0000269|PubMed:11062463,
FT                                ECO:0000269|PubMed:12493741,
FT                                ECO:0000269|PubMed:12843182}.
FT                                /FTId=VAR_017608.
FT   VARIANT     218    218       R -> H (in CAEND).
FT                                {ECO:0000269|PubMed:10973241}.
FT                                /FTId=VAR_017609.
FT   VARIANT     222    222       H -> D (in CAEND; sporadic case; higher
FT                                levels of active TGF-beta-1 in the
FT                                culture medium).
FT                                {ECO:0000269|PubMed:12493741}.
FT                                /FTId=VAR_017610.
FT   VARIANT     223    223       C -> G (in CAEND).
FT                                {ECO:0000269|PubMed:15103729}.
FT                                /FTId=VAR_067303.
FT   VARIANT     223    223       C -> R (in CAEND).
FT                                {ECO:0000269|PubMed:15103729}.
FT                                /FTId=VAR_067304.
FT   VARIANT     225    225       C -> R (in CAEND; higher levels of active
FT                                TGF-beta-1 in the culture medium).
FT                                {ECO:0000269|PubMed:10973241,
FT                                ECO:0000269|PubMed:11062463,
FT                                ECO:0000269|PubMed:12493741}.
FT                                /FTId=VAR_017611.
FT   VARIANT     263    263       T -> I (in dbSNP:rs1800472).
FT                                /FTId=VAR_016173.
FT   CONFLICT    159    159       R -> RR (in Ref. 2; CAA26580).
FT                                {ECO:0000305}.
FT   HELIX       282    285       {ECO:0000244|PDB:3KFD}.
FT   STRAND      291    296       {ECO:0000244|PDB:3KFD}.
FT   STRAND      299    301       {ECO:0000244|PDB:3KFD}.
FT   HELIX       302    306       {ECO:0000244|PDB:3KFD}.
FT   STRAND      311    313       {ECO:0000244|PDB:3KFD}.
FT   STRAND      315    318       {ECO:0000244|PDB:3KFD}.
FT   STRAND      321    324       {ECO:0000244|PDB:3KFD}.
FT   STRAND      330    332       {ECO:0000244|PDB:3KFD}.
FT   HELIX       335    346       {ECO:0000244|PDB:3KFD}.
FT   STRAND      347    349       {ECO:0000244|PDB:3KFD}.
FT   STRAND      356    370       {ECO:0000244|PDB:3KFD}.
FT   STRAND      373    389       {ECO:0000244|PDB:3KFD}.
SQ   SEQUENCE   390 AA;  44341 MW;  75391614250288FE CRC64;
     MPPSGLRLLL LLLPLLWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA
     SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESAEPEPEPE ADYYAKEVTR VLMVETHNEI
     YDKFKQSTHS IYMFFNTSEL REAVPEPVLL SRAELRLLRL KLKVEQHVEL YQKYSNNSWR
     YLSNRLLAPS DSPEWLSFDV TGVVRQWLSR GGEIEGFRLS AHCSCDSRDN TLQVDINGFT
     TGRRGDLATI HGMNRPFLLL MATPLERAQH LQSSRHRRAL DTNYCFSSTE KNCCVRQLYI
     DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SAAPCCVPQA
     LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS
//
ID   WNT5A_MOUSE             Reviewed;         380 AA.
AC   P22725; Q8BM17; Q8BMF9; Q8VCV6;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   17-FEB-2016, entry version 148.
DE   RecName: Full=Protein Wnt-5a;
DE   Flags: Precursor;
GN   Name=Wnt5a; Synonyms=Wnt-5a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=2279700; DOI=10.1101/gad.4.12b.2319;
RA   Gavin B.J., McMahon J.A., McMahon A.P.;
RT   "Expression of multiple novel Wnt-1/int-1-related genes during fetal
RT   and adult mouse development.";
RL   Genes Dev. 4:2319-2332(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J; TISSUE=Testis, and Vagina;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 62-82, AND FUNCTION.
RX   PubMed=16602827; DOI=10.1371/journal.pbio.0040115;
RA   Mikels A.J., Nusse R.;
RT   "Purified Wnt5a protein activates or inhibits beta-catenin-TCF
RT   signaling depending on receptor context.";
RL   PLoS Biol. 4:E115-E115(2006).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=10021340;
RA   Yamaguchi T.P., Bradley A., McMahon A.P., Jones S.;
RT   "A Wnt5a pathway underlies outgrowth of multiple structures in the
RT   vertebrate embryo.";
RL   Development 126:1211-1223(1999).
RN   [7]
RP   INTERACTION WITH PORCN.
RX   PubMed=10866835; DOI=10.1046/j.1432-1033.2000.01478.x;
RA   Tanaka K., Okabayashi H., Asashima M., Perrimon N., Kadowaki T.;
RT   "The evolutionarily conserved porcupine gene family is involved in the
RT   processing of the Wnt family.";
RL   Eur. J. Biochem. 267:4300-4311(2000).
RN   [8]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=12952940; DOI=10.1083/jcb.200303158;
RA   Topol L., Jiang X., Choi H., Garrett-Beal L., Carolan P.J., Yang Y.;
RT   "Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-
RT   independent beta-catenin degradation.";
RL   J. Cell Biol. 162:899-908(2003).
RN   [9]
RP   FUNCTION, PRELIMINARY CYSTEINE PALMITOYLATION, GLYCOSYLATION AT
RP   ASN-114; ASN-120; ASN-312 AND ASN-326, AND MUTAGENESIS OF CYS-104;
RP   ASN-114; ASN-120; ASN-312 AND ASN-326.
RX   PubMed=17117926; DOI=10.1042/BJ20061476;
RA   Kurayoshi M., Yamamoto H., Izumi S., Kikuchi A.;
RT   "Post-translational palmitoylation and glycosylation of Wnt-5a are
RT   necessary for its signalling.";
RL   Biochem. J. 402:515-523(2007).
RN   [10]
RP   INTERACTION WITH WLS.
RX   PubMed=19841259; DOI=10.1073/pnas.0904894106;
RA   Fu J., Jiang M., Mirando A.J., Yu H.-M., Hsu W.;
RT   "Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for
RT   embryonic axis formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:18598-18603(2009).
RN   [11]
RP   PROTEOLYTIC PROCESSING BY TIKI1 AND TIKI2, DISULFIDE BONDS, AND
RP   SUBUNIT.
RX   PubMed=22726442; DOI=10.1016/j.cell.2012.04.039;
RA   Zhang X., Abreu J.G., Yokota C., Macdonald B.T., Singh S.,
RA   Coburn K.L., Cheong S.M., Zhang M.M., Ye Q.Z., Hang H.C., Steen H.,
RA   He X.;
RT   "Tiki1 is required for head formation via Wnt cleavage-oxidation and
RT   inactivation.";
RL   Cell 149:1565-1577(2012).
CC   -!- FUNCTION: Ligand for members of the frizzled family of seven
CC       transmembrane receptors. Can activate or inhibit canonical Wnt
CC       signaling, depending on receptor context. In the presence of FZD4,
CC       activates beta-catenin signaling. In the presence of ROR2,
CC       inhibits the canonical Wnt pathway by promoting beta-catenin
CC       degradation through a GSK3-independent pathway which involves
CC       down-regulation of beta-catenin-induced reporter gene expression.
CC       Suppression of the canonical pathway allows chondrogenesis to
CC       occur and inhibits tumor formation. Stimulates cell migration.
CC       Decreases proliferation, migration, invasiveness and clonogenicity
CC       of carcinoma cells and may act as a tumor suppressor. Mediates
CC       motility of melanoma cells. Required during embryogenesis for
CC       extension of the primary anterior-posterior axis and for outgrowth
CC       of limbs and the genital tubercle. Inhibits type II collagen
CC       expression in chondrocytes. {ECO:0000269|PubMed:10021340,
CC       ECO:0000269|PubMed:12952940, ECO:0000269|PubMed:16602827,
CC       ECO:0000269|PubMed:17117926}.
CC   -!- SUBUNIT: Homooligomer; disulfide-linked, leading to inactivation.
CC       Interacts with PORCN. Interacts with WLS.
CC       {ECO:0000269|PubMed:10866835, ECO:0000269|PubMed:19841259,
CC       ECO:0000269|PubMed:22726442}.
CC   -!- INTERACTION:
CC       O35082:Kl; NbExp=2; IntAct=EBI-1570983, EBI-1570828;
CC       Q9Y5W5:WIF1 (xeno); NbExp=7; IntAct=EBI-1570983, EBI-3922719;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P22725-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P22725-2; Sequence=VSP_035595;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in a gradient at the caudal end of
CC       the embryo during gastrulation and later in the distal-most aspect
CC       of several structures that extend from the body such as the limbs
CC       and genital tubercle. {ECO:0000269|PubMed:10021340}.
CC   -!- PTM: Glycosylation is necessary for secretion but not for
CC       activity. {ECO:0000269|PubMed:17117926}.
CC   -!- PTM: Palmitoleylation is required for efficient binding to
CC       frizzled receptors. Depalmitoleylation leads to Wnt signaling
CC       pathway inhibition. {ECO:0000250|UniProtKB:P27467,
CC       ECO:0000250|UniProtKB:P56704}.
CC   -!- PTM: Proteolytic processing by TIKI1 and TIKI2 promotes oxidation
CC       and formation of large disulfide-bond oligomers, leading to
CC       inactivation of WNT5A. {ECO:0000269|PubMed:22726442}.
CC   -!- DISRUPTION PHENOTYPE: Mice display perinatal lethality and display
CC       gross morphological defects in outgrowing tissues. They are
CC       truncated caudally, displaying loss of the tail and a significant
CC       shortening of the anterior-posterior axis. The shape of the head
CC       is abnormal with truncated snout, mandible and tongue and reduced
CC       outgrowth of the external ear. Fore- and hindlimbs lack digits,
CC       the genital tubercle is missing and chondrocyte differentiation is
CC       inhibited. {ECO:0000269|PubMed:10021340,
CC       ECO:0000269|PubMed:12952940}.
CC   -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}.
CC   -!- CAUTION: A palmitoylation site was proposed at Cys-104, but it was
CC       later shown that this cysteine is engaged in a disulfide bond.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M89798; AAA40567.1; -; mRNA.
DR   EMBL; AK031512; BAC27430.1; -; mRNA.
DR   EMBL; AK031597; BAC27468.1; -; mRNA.
DR   EMBL; AK036824; BAC29593.1; -; mRNA.
DR   EMBL; CT025649; CAM27826.1; -; Genomic_DNA.
DR   EMBL; CT025649; CAM27827.1; -; Genomic_DNA.
DR   EMBL; BC018425; AAH18425.1; -; mRNA.
DR   CCDS; CCDS26888.1; -. [P22725-1]
DR   CCDS; CCDS56946.1; -. [P22725-2]
DR   PIR; D36470; D36470.
DR   RefSeq; NP_001243153.1; NM_001256224.1. [P22725-2]
DR   RefSeq; NP_033550.2; NM_009524.3. [P22725-1]
DR   RefSeq; XP_006518987.1; XM_006518924.2. [P22725-2]
DR   RefSeq; XP_006518988.1; XM_006518925.2. [P22725-2]
DR   UniGene; Mm.287544; -.
DR   ProteinModelPortal; P22725; -.
DR   SMR; P22725; 94-309.
DR   BioGrid; 204577; 7.
DR   DIP; DIP-39893N; -.
DR   IntAct; P22725; 4.
DR   MINT; MINT-6476731; -.
DR   STRING; 10090.ENSMUSP00000064878; -.
DR   SwissPalm; P22725; -.
DR   MaxQB; P22725; -.
DR   PaxDb; P22725; -.
DR   PRIDE; P22725; -.
DR   DNASU; 22418; -.
DR   Ensembl; ENSMUST00000063465; ENSMUSP00000064878; ENSMUSG00000021994. [P22725-1]
DR   Ensembl; ENSMUST00000112272; ENSMUSP00000107891; ENSMUSG00000021994. [P22725-2]
DR   GeneID; 22418; -.
DR   KEGG; mmu:22418; -.
DR   UCSC; uc007sug.2; mouse. [P22725-1]
DR   CTD; 7474; -.
DR   MGI; MGI:98958; Wnt5a.
DR   eggNOG; KOG3913; Eukaryota.
DR   eggNOG; ENOG410XQZ1; LUCA.
DR   GeneTree; ENSGT00760000118943; -.
DR   HOGENOM; HOG000039529; -.
DR   HOVERGEN; HBG001595; -.
DR   InParanoid; P22725; -.
DR   KO; K00444; -.
DR   OMA; IVERCHC; -.
DR   OrthoDB; EOG7C8GJ8; -.
DR   PhylomeDB; P22725; -.
DR   TreeFam; TF105310; -.
DR   Reactome; R-MMU-3238698; WNT ligand biogenesis and trafficking.
DR   Reactome; R-MMU-4086398; Ca2+ pathway.
DR   Reactome; R-MMU-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-MMU-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-MMU-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2.
DR   ChiTaRS; Wnt5a; mouse.
DR   NextBio; 302841; -.
DR   PRO; PR:P22725; -.
DR   Proteomes; UP000000589; Chromosome 14.
DR   Bgee; P22725; -.
DR   CleanEx; MM_WNT5A; -.
DR   Genevisible; P22725; MM.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:MGI.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0005109; F:frizzled binding; IPI:BHF-UCL.
DR   GO; GO:0005110; F:frizzled-2 binding; IDA:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:MGI.
DR   GO; GO:0005115; F:receptor tyrosine kinase-like orphan receptor binding; ISO:MGI.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; ISO:MGI.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007257; P:activation of JUN kinase activity; ISO:MGI.
DR   GO; GO:0000187; P:activation of MAPK activity; ISO:MGI.
DR   GO; GO:0032148; P:activation of protein kinase B activity; ISO:MGI.
DR   GO; GO:0001667; P:ameboidal-type cell migration; IMP:MGI.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; IDA:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0003401; P:axis elongation; IMP:MGI.
DR   GO; GO:0007411; P:axon guidance; IDA:UniProtKB.
DR   GO; GO:0007413; P:axonal fasciculation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007409; P:axonogenesis; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051216; P:cartilage development; IEA:UniProtKB-KW.
DR   GO; GO:0045165; P:cell fate commitment; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:MGI.
DR   GO; GO:0034613; P:cellular protein localization; IMP:MGI.
DR   GO; GO:0071277; P:cellular response to calcium ion; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; IDA:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0060067; P:cervix development; IMP:MGI.
DR   GO; GO:0061643; P:chemorepulsion of axon; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090103; P:cochlea morphogenesis; IMP:MGI.
DR   GO; GO:0060026; P:convergent extension; IMP:MGI.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; IMP:MGI.
DR   GO; GO:0060029; P:convergent extension involved in organogenesis; IGI:MGI.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0046546; P:development of primary male sexual characteristics; IMP:MGI.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IMP:MGI.
DR   GO; GO:0048706; P:embryonic skeletal system development; ISO:MGI.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IDA:MGI.
DR   GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IGI:MGI.
DR   GO; GO:0001736; P:establishment of planar polarity; IMP:MGI.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; ISO:MGI.
DR   GO; GO:0048806; P:genitalia development; ISO:MGI.
DR   GO; GO:0001947; P:heart looping; IGI:MGI.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; IDA:MGI.
DR   GO; GO:0007442; P:hindgut morphogenesis; IMP:MGI.
DR   GO; GO:0048850; P:hypophysis morphogenesis; IMP:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IDA:MGI.
DR   GO; GO:0007254; P:JNK cascade; IDA:MGI.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060599; P:lateral sprouting involved in mammary gland duct morphogenesis; IDA:MGI.
DR   GO; GO:0035108; P:limb morphogenesis; IMP:MGI.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0008584; P:male gonad development; IMP:MGI.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IDA:MGI.
DR   GO; GO:0097325; P:melanocyte proliferation; IDA:CACAO.
DR   GO; GO:0060638; P:mesenchymal-epithelial cell signaling; IMP:MGI.
DR   GO; GO:0060809; P:mesodermal to mesenchymal transition involved in gastrulation; IGI:MGI.
DR   GO; GO:0030901; P:midbrain development; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007494; P:midgut development; IMP:MGI.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IMP:MGI.
DR   GO; GO:0050919; P:negative chemotaxis; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IGI:MGI.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IMP:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IDA:MGI.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISO:MGI.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0048022; P:negative regulation of melanin biosynthetic process; IDA:CACAO.
DR   GO; GO:0072201; P:negative regulation of mesenchymal cell proliferation; ISO:MGI.
DR   GO; GO:0060686; P:negative regulation of prostatic bud formation; IMP:MGI.
DR   GO; GO:0051964; P:negative regulation of synapse assembly; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR   GO; GO:0001843; P:neural tube closure; IGI:MGI.
DR   GO; GO:0021915; P:neural tube development; IGI:MGI.
DR   GO; GO:0022008; P:neurogenesis; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IDA:UniProtKB.
DR   GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0038031; P:non-canonical Wnt signaling pathway via JNK cascade; IMP:BHF-UCL.
DR   GO; GO:0048570; P:notochord morphogenesis; IGI:MGI.
DR   GO; GO:0021891; P:olfactory bulb interneuron development; IMP:UniProtKB.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:MGI.
DR   GO; GO:0060021; P:palate development; ISO:MGI.
DR   GO; GO:0048341; P:paraxial mesoderm formation; IGI:MGI.
DR   GO; GO:0003344; P:pericardium morphogenesis; IGI:MGI.
DR   GO; GO:0003402; P:planar cell polarity pathway involved in axis elongation; IMP:MGI.
DR   GO; GO:0061350; P:planar cell polarity pathway involved in cardiac muscle tissue morphogenesis; IMP:MGI.
DR   GO; GO:0061349; P:planar cell polarity pathway involved in cardiac right atrium morphogenesis; IMP:MGI.
DR   GO; GO:0060775; P:planar cell polarity pathway involved in gastrula mediolateral intercalation; IGI:MGI.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IMP:MGI.
DR   GO; GO:0061347; P:planar cell polarity pathway involved in outflow tract morphogenesis; IMP:MGI.
DR   GO; GO:0061354; P:planar cell polarity pathway involved in pericardium morphogenesis; IMP:MGI.
DR   GO; GO:0061348; P:planar cell polarity pathway involved in ventricular septum morphogenesis; IMP:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:MGI.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IDA:MGI.
DR   GO; GO:0030825; P:positive regulation of cGMP metabolic process; ISO:MGI.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; ISO:MGI.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:MGI.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; ISO:MGI.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IDA:MGI.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISO:MGI.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISO:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISO:MGI.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:MGI.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IMP:BHF-UCL.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; IDA:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:2000484; P:positive regulation of interleukin-8 secretion; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:BHF-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:MGI.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; ISO:MGI.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; ISO:MGI.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; IGI:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISO:MGI.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IDA:CACAO.
DR   GO; GO:0045778; P:positive regulation of ossification; ISO:MGI.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IGI:MGI.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IGI:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; ISO:MGI.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1900020; P:positive regulation of protein kinase C activity; ISO:MGI.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060760; P:positive regulation of response to cytokine stimulus; ISO:MGI.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; ISO:MGI.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISO:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IMP:MGI.
DR   GO; GO:0090009; P:primitive streak formation; IGI:MGI.
DR   GO; GO:0030850; P:prostate gland development; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IGI:MGI.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IDA:MGI.
DR   GO; GO:1903827; P:regulation of cellular protein localization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032880; P:regulation of protein localization; IDA:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:MGI.
DR   GO; GO:0061053; P:somite development; IGI:MGI.
DR   GO; GO:0001756; P:somitogenesis; IGI:MGI.
DR   GO; GO:0060606; P:tube closure; IMP:MGI.
DR   GO; GO:0003323; P:type B pancreatic cell development; IMP:MGI.
DR   GO; GO:0060157; P:urinary bladder development; IMP:MGI.
DR   GO; GO:0060065; P:uterus development; IMP:MGI.
DR   GO; GO:0060068; P:vagina development; IMP:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; IDA:BHF-UCL.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; IDA:MGI.
DR   GO; GO:0042060; P:wound healing; ISO:MGI.
DR   InterPro; IPR005817; Wnt.
DR   InterPro; IPR026538; Wnt5a.
DR   InterPro; IPR018161; Wnt_CS.
DR   PANTHER; PTHR12027; PTHR12027; 1.
DR   PANTHER; PTHR12027:SF33; PTHR12027:SF33; 1.
DR   Pfam; PF00110; wnt; 1.
DR   PRINTS; PR01349; WNTPROTEIN.
DR   SMART; SM00097; WNT1; 1.
DR   PROSITE; PS00246; WNT1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chondrogenesis; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Extracellular matrix; Glycoprotein; Lipoprotein;
KW   Reference proteome; Secreted; Signal; Wnt signaling pathway.
FT   SIGNAL        1     37       {ECO:0000255}.
FT   PROPEP       38     61       {ECO:0000269|PubMed:16602827}.
FT                                /FTId=PRO_0000352797.
FT   CHAIN        62    380       Protein Wnt-5a.
FT                                /FTId=PRO_0000041428.
FT   LIPID       244    244       O-palmitoleyl serine; by PORCN.
FT                                {ECO:0000250|UniProtKB:P56704}.
FT   CARBOHYD    114    114       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17117926}.
FT   CARBOHYD    120    120       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17117926}.
FT   CARBOHYD    312    312       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17117926}.
FT   CARBOHYD    326    326       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17117926}.
FT   DISULFID    104    115       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    154    162       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    164    182       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    238    252       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    240    247       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    325    340       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    355    370       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    357    367       {ECO:0000250|UniProtKB:P28026}.
FT   DISULFID    362    363       {ECO:0000250|UniProtKB:P28026}.
FT   VAR_SEQ       1     20       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_035595.
FT   MUTAGEN     104    104       C->A: No effect on secretion.
FT                                {ECO:0000269|PubMed:17117926}.
FT   MUTAGEN     114    114       N->Q: Abolishes glycosylation; when
FT                                associated with Q-120, Q-312 and Q-326.
FT                                {ECO:0000269|PubMed:17117926}.
FT   MUTAGEN     120    120       N->Q: Abolishes glycosylation; when
FT                                associated with Q-114, Q-312 and Q-326.
FT                                {ECO:0000269|PubMed:17117926}.
FT   MUTAGEN     312    312       N->Q: Abolishes glycosylation; when
FT                                associated with Q-114, Q-120 and Q-326.
FT                                {ECO:0000269|PubMed:17117926}.
FT   MUTAGEN     326    326       N->Q: Abolishes glycosylation; when
FT                                associated with Q-114, Q-120 and Q-312.
FT                                {ECO:0000269|PubMed:17117926}.
FT   CONFLICT    168    168       Missing (in Ref. 1; AAA40567).
FT                                {ECO:0000305}.
FT   CONFLICT    190    191       YR -> HP (in Ref. 1; AAA40567).
FT                                {ECO:0000305}.
FT   CONFLICT    377    377       F -> L (in Ref. 2; BAC27430).
FT                                {ECO:0000305}.
SQ   SEQUENCE   380 AA;  42309 MW;  64CA36C516D22D8A CRC64;
     MKKPIGILSP GVALGTAGGA MSSKFFLMAL ATFFSFAQVV IEANSWWSLG MNNPVQMSEV
     YIIGAQPLCS QLAGLSQGQK KLCHLYQDHM QYIGEGAKTG IKECQYQFRH RRWNCSTVDN
     TSVFGRVMQI GSRETAFTYA VSAAGVVNAM SRACREGELS TCGCSRAARP KDLPRDWLWG
     GCGDNIDYGY RFAKEFVDAR ERERIHAKGS YESARILMNL HNNEAGRRTV YNLADVACKC
     HGVSGSCSLK TCWLQLADFR KVGDALKEKY DSAAAMRLNS RGKLVQVNSR FNSPTTQDLV
     YIDPSPDYCV RNESTGSLGT QGRLCNKTSE GMDGCELMCC GRGYDQFKTV QTERCHCKFH
     WCCYVKCKKC TEIVDQFVCK
//
ID   FBN1_HUMAN              Reviewed;        2871 AA.
AC   P35555; B2RUU0; D2JYH6; Q15972; Q75N87;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   17-FEB-2016, entry version 196.
DE   RecName: Full=Fibrillin-1;
DE   Flags: Precursor;
GN   Name=FBN1; Synonyms=FBN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-472.
RC   TISSUE=Placenta;
RX   PubMed=8364578; DOI=10.1093/hmg/2.7.961;
RA   Pereira L.V., D'Alessio M., Ramirez F., Lynch J.R., Sykes B.,
RA   Pangilinan T., Bonadio J.;
RT   "Genomic organization of the sequence coding for fibrillin, the
RT   defective gene product in Marfan syndrome.";
RL   Hum. Mol. Genet. 2:961-968(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MFS SER-2663.
RX   PubMed=15221638; DOI=10.1007/s10038-004-0168-x;
RA   Uyeda T., Takahashi T., Eto S., Sato T., Xu G., Kanezaki R., Toki T.,
RA   Yonesaka S., Ito E.;
RT   "Three novel mutations of the fibrillin-1 gene and ten single
RT   nucleotide polymorphisms of the fibrillin-3 gene in Marfan syndrome
RT   patients.";
RL   J. Hum. Genet. 49:404-407(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TYR-472.
RA   Rieder M.J., Bertucci C., Stanaway I.B., Johnson E.J., Swanson J.E.,
RA   Siegel D.L., da Ponte S.H., Igartua C., Patterson K., Nickerson D.A.;
RL   Submitted (SEP-2009) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TYR-472.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TYR-472.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-55,
RP   AND VARIANT TYR-472.
RC   TISSUE=Fibroblast, and Placenta;
RX   PubMed=7691719; DOI=10.1006/geno.1993.1350;
RA   Corson G.M., Chalberg S.C., Dietz H.C., Charbonneau N.L., Sakai L.Y.;
RT   "Fibrillin binds calcium and is coded by cDNAs that reveal a
RT   multidomain structure and alternatively spliced exons at the 5' end.";
RL   Genomics 17:476-484(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 899-2871.
RX   PubMed=1852207; DOI=10.1038/352334a0;
RA   Maslen C.L., Corson G.M., Maddox B.K., Glanville R.W., Sakai L.Y.;
RT   "Partial sequence of a candidate gene for the Marfan syndrome.";
RL   Nature 352:334-337(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 813-1313.
RX   PubMed=1852206; DOI=10.1038/352330a0;
RA   Lee B., Godfrey M., Vitale E., Hori H., Mattei M.-G., Sarfarazi M.,
RA   Tsipouras P., Ramirez F., Hollister D.W.;
RT   "Linkage of Marfan syndrome and a phenotypically related disorder to
RT   two different fibrillin genes.";
RL   Nature 352:330-334(1991).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2086-2194.
RX   PubMed=8430317; DOI=10.1126/science.8430317;
RA   Dietz H.C., Valle D., Francomano C.A., Kendzior R.J. Jr.,
RA   Pyeritz R.E., Cutting G.R.;
RT   "The skipping of constitutive exons in vivo induced by nonsense
RT   mutations.";
RL   Science 259:680-683(1993).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=1860873;
RA   Sakai L.Y., Keene D.R., Glanville R.W., Bachinger H.P.;
RT   "Purification and partial characterization of fibrillin, a cysteine-
RT   rich structural component of connective tissue microfibrils.";
RL   J. Biol. Chem. 266:14763-14770(1991).
RN   [12]
RP   INTERACTION WITH COL16A1.
RX   PubMed=15165854; DOI=10.1016/j.jmb.2004.03.042;
RA   Kassner A., Tiedemann K., Notbohm H., Ludwig T., Morgelin M.,
RA   Reinhardt D.P., Chu M.-L., Bruckner P., Grassel S.;
RT   "Molecular structure and interaction of recombinant human type XVI
RT   collagen.";
RL   J. Mol. Biol. 339:835-853(2004).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-448; ASN-1067; ASN-1484
RP   AND ASN-1581.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   INTERACTION WITH ADAMTS10.
RX   PubMed=21402694; DOI=10.1074/jbc.M111.231571;
RA   Kutz W.E., Wang L.W., Bader H.L., Majors A.K., Iwata K.,
RA   Traboulsi E.I., Sakai L.Y., Keene D.R., Apte S.S.;
RT   "ADAMTS10 protein interacts with fibrillin-1 and promotes its
RT   deposition in extracellular matrix of cultured fibroblasts.";
RL   J. Biol. Chem. 286:17156-17167(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2702, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   STRUCTURE BY NMR OF 2054-2125.
RX   PubMed=9362480; DOI=10.1093/emboj/16.22.6659;
RA   Yuan X., Downing A.K., Knott V., Handford P.A.;
RT   "Solution structure of the transforming growth factor beta-binding
RT   protein-like module, a domain associated with matrix fibrils.";
RL   EMBO J. 16:6659-6666(1997).
RN   [17]
RP   STRUCTURE BY NMR OF 2124-2205.
RX   PubMed=8568869; DOI=10.1006/jmbi.1996.0003;
RA   Knott V., Downing A.K., Cardy C.M., Handford P.A.;
RT   "Calcium binding properties of an epidermal growth factor-like domain
RT   pair from human fibrillin-1.";
RL   J. Mol. Biol. 255:22-27(1996).
RN   [18]
RP   STRUCTURE BY NMR OF 2124-2205.
RX   PubMed=8653794; DOI=10.1016/S0092-8674(00)81259-3;
RA   Downing A.K., Knott V., Werner J.M., Cardy C.M., Campbell I.D.,
RA   Handford P.A.;
RT   "Solution structure of a pair of calcium-binding epidermal growth
RT   factor-like domains: implications for the Marfan syndrome and other
RT   genetic disorders.";
RL   Cell 85:597-605(1996).
RN   [19]
RP   REVIEW ON MFS VARIANTS.
RX   PubMed=8594563; DOI=10.1093/nar/24.1.137;
RA   Collod G., Beroud C., Soussi T., Junien C., Boileau C.;
RT   "Software and database for the analysis of mutations in the human FBN1
RT   gene.";
RL   Nucleic Acids Res. 24:137-141(1996).
RN   [20]
RP   REVIEW ON MFS VARIANTS.
RX   PubMed=9016526; DOI=10.1093/nar/25.1.147;
RA   Collod-Beroud G., Beroud C., Ades L., Black C., Boxer M., Brock D.J.,
RA   Godfrey M., Hayward C., Karttunen L., Milewicz D., Peltonen L.,
RA   Richards R.I., Wang W., Junien C., Boileau C.;
RT   "Marfan Database (second edition): software and database for the
RT   analysis of mutations in the human FBN1 gene.";
RL   Nucleic Acids Res. 25:147-150(1997).
RN   [21]
RP   REVIEW ON VARIANTS.
RX   PubMed=9401003;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:6<415::AID-HUMU1>3.3.CO;2-2;
RA   Hayward C., Brock D.J.H.;
RT   "Fibrillin-1 mutations in Marfan syndrome and other type-1
RT   fibrillinopathies.";
RL   Hum. Mutat. 10:415-423(1997).
RN   [22]
RP   REVIEW ON MFS.
RX   PubMed=10633129; DOI=10.1136/jmg.37.1.9;
RA   Robinson P.N., Godfrey M.;
RT   "The molecular genetics of Marfan syndrome and related
RT   microfibrillopathies.";
RL   J. Med. Genet. 37:9-25(2000).
RN   [23]
RP   REVIEW ON VARIANTS.
RX   PubMed=12203987; DOI=10.1002/humu.10113;
RA   Robinson P.N., Booms P., Katzke S., Ladewig M., Neumann L., Palz M.,
RA   Pregla R., Tiecke F., Rosenberg T.;
RT   "Mutations of FBN1 and genotype-phenotype correlations in Marfan
RT   syndrome and related fibrillinopathies.";
RL   Hum. Mutat. 20:153-161(2002).
RN   [24]
RP   INVOLVEMENT IN OCTD.
RX   PubMed=2739055; DOI=10.1001/jama.262.4.523;
RA   Glesby M.J., Pyeritz R.E.;
RT   "Association of mitral valve prolapse and systemic abnormalities of
RT   connective tissue: a phenotypic continuum.";
RL   JAMA 262:523-528(1989).
RN   [25]
RP   PHOSPHORYLATION AT SER-2702.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1486-1647 IN COMPLEX WITH
RP   CALCIUM IONS, FUNCTION, INTERACTION WITH INTEGRIN ALPHA-V/BETA-3, AND
RP   DISULFIDE BONDS.
RX   PubMed=15062093; DOI=10.1016/j.str.2004.02.023;
RA   Lee S.S., Knott V., Jovanovic J., Harlos K., Grimes J.M., Choulier L.,
RA   Mardon H.J., Stuart D.I., Handford P.A.;
RT   "Structure of the integrin binding fragment from fibrillin-1 gives new
RT   insights into microfibril organization.";
RL   Structure 12:717-729(2004).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 807-951 IN COMPLEX WITH
RP   CALCIUM, AND DISULFIDE BONDS.
RX   PubMed=19446531; DOI=10.1016/j.str.2009.03.014;
RA   Jensen S.A., Iqbal S., Lowe E.D., Redfield C., Handford P.A.;
RT   "Structure and interdomain interactions of a hybrid domain: a
RT   disulphide-rich module of the fibrillin/LTBP superfamily of matrix
RT   proteins.";
RL   Structure 17:759-768(2009).
RN   [28]
RP   VARIANT MFS PRO-1137.
RX   PubMed=1852208; DOI=10.1038/352337a0;
RA   Dietz H.C., Cutting G.R., Pyeritz R.E., Maslen C.L., Sakai L.Y.,
RA   Corson G.M., Puffenberger E.G., Hamosh A., Nanthakumar E.J.,
RA   Curristin S.M., Stetten G., Meyers D.A., Francomano C.A.;
RT   "Marfan syndrome caused by a recurrent de novo missense mutation in
RT   the fibrillin gene.";
RL   Nature 352:337-339(1991).
RN   [29]
RP   VARIANTS MFS SER-1249; ARG-1663; SER-2221 AND SER-2307.
RX   PubMed=1301946; DOI=10.1002/humu.1380010504;
RA   Dietz H.C., Saraiva J.M., Pyeritz R.E., Cutting G.R., Francomano C.A.;
RT   "Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome
RT   patients at cysteine residues in EGF-like domains.";
RL   Hum. Mutat. 1:366-374(1992).
RN   [30]
RP   VARIANT MFS SER-2307.
RX   PubMed=1569206; DOI=10.1172/JCI115766;
RA   Dietz H.C., Pyeritz R.E., Puffenberger E.G., Kendzior R.J. Jr.,
RA   Corson G.M., Maslen C.L., Sakai L.Y., Francomano C.A., Cutting G.R.;
RT   "Marfan phenotype variability in a family segregating a missense
RT   mutation in the epidermal growth factor-like motif of the fibrillin
RT   gene.";
RL   J. Clin. Invest. 89:1674-1680(1992).
RN   [31]
RP   VARIANTS MFS ILE-548 AND ALA-723.
RX   PubMed=8406497; DOI=10.1006/geno.1993.1349;
RA   Dietz H.C., McIntosh I., Sakai L.Y., Corson G.M., Chalberg S.C.,
RA   Pyeritz R.E., Francomano C.A.;
RT   "Four novel FBN1 mutations: significance for mutant transcript level
RT   and EGF-like domain calcium binding in the pathogenesis of Marfan
RT   syndrome.";
RL   Genomics 17:468-475(1993).
RN   [32]
RP   VARIANT MFS SER-2144.
RX   PubMed=8504310; DOI=10.1093/hmg/2.4.475;
RA   Hewett D.R., Lynch J.R., Smith R., Sykes B.C.;
RT   "A novel fibrillin mutation in the Marfan syndrome which could disrupt
RT   calcium binding of the epidermal growth factor-like module.";
RL   Hum. Mol. Genet. 2:475-477(1993).
RN   [33]
RP   VARIANTS MFS ARG-862; TYR-1117; PRO-1137 AND PHE-1589, AND VARIANT
RP   ALA-1148.
RX   PubMed=8281141; DOI=10.1093/hmg/2.11.1813;
RA   Tynan K., Comeau K., Pearson M., Wilgenbus P., Levitt D., Gasner C.,
RA   Berg M.A., Miller D.C., Francke U.;
RT   "Mutation screening of complete fibrillin-1 coding sequence: report of
RT   five new mutations, including two in 8-cysteine domains.";
RL   Hum. Mol. Genet. 2:1813-1821(1993).
RN   [34]
RP   VARIANTS MFS GLY-217 AND ARG-2627.
RX   PubMed=7977366;
RA   Karttunen L., Raghunath M., Loennqvist L., Peltonen L.;
RT   "A compound-heterozygous Marfan patient: two defective fibrillin
RT   alleles result in a lethal phenotype.";
RL   Am. J. Hum. Genet. 55:1083-1091(1994).
RN   [35]
RP   VARIANT ECTOL1 LYS-2447.
RX   PubMed=8188302; DOI=10.1006/geno.1994.1110;
RA   Lonnqvist L., Child A., Kainulainen K., Davidson R., Puhakka L.,
RA   Peltonen L.;
RT   "A novel mutation of the fibrillin gene causing ectopia lentis.";
RL   Genomics 19:573-576(1994).
RN   [36]
RP   VARIANT MFS CYS-627.
RX   PubMed=8004112; DOI=10.1093/hmg/3.2.373;
RA   Hayward C., Rae A.L., Porteous M.E.M., Logie L.J., Brock L.J.;
RT   "Two novel mutations and a neutral polymorphism in EGF-like domains of
RT   the fibrillin gene (FBN1): SSCP screening of exons 15-21 in Marfan
RT   syndrome patients.";
RL   Hum. Mol. Genet. 3:373-375(1994).
RN   [37]
RP   VARIANT MFS CYS-122.
RX   PubMed=8040326; DOI=10.1172/JCI117389;
RA   Stahl-Hallengren C., Ukkonen T., Kainulainen K., Kristofersson U.,
RA   Saxne T., Tornqvist K., Peltonen L.;
RT   "An extra cysteine in one of the non-calcium-binding epidermal growth
RT   factor-like motifs of the FBN1 polypeptide is connected to a novel
RT   variant of Marfan syndrome.";
RL   J. Clin. Invest. 94:709-713(1994).
RN   [38]
RP   VARIANT MFS TYR-1223.
RX   PubMed=8071963; DOI=10.1136/jmg.31.4.338;
RA   Hewett D.R., Lynch J.R., Child A., Sykes B.C.;
RT   "A new missense mutation of fibrillin in a patient with Marfan
RT   syndrome.";
RL   J. Med. Genet. 31:338-339(1994).
RN   [39]
RP   VARIANT MFS HIS-1170.
RX   PubMed=7870075; DOI=10.1006/mcpr.1994.1045;
RA   Hayward C., Porteous M.E.M., Brock D.J.H.;
RT   "A novel mutation in the fibrillin gene (FBN1) in familial
RT   arachnodactyly.";
RL   Mol. Cell. Probes 8:325-327(1994).
RN   [40]
RP   VARIANTS MFS GLY-217; ASN-1023; ARG-1074; TYR-1242; ARG-1513;
RP   GLU-2127; TRP-2151; LYS-2447 AND ARG-2511.
RX   PubMed=8136837; DOI=10.1038/ng0194-64;
RA   Kainulainen K., Karttunen L., Puhakka L., Sakai L., Peltonen L.;
RT   "Mutations in the fibrillin gene responsible for dominant ectopia
RT   lentis and neonatal Marfan syndrome.";
RL   Nat. Genet. 6:64-69(1994).
RN   [41]
RP   VARIANT MFS SER-1127.
RX   PubMed=7762551;
RA   Francke U., Berg M.A., Tynan K., Brenn T., Liu W., Aoyama T.,
RA   Gasner C., Miller D.C., Furthmayr H.;
RT   "A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene
RT   is a risk factor for ascending aortic aneurysm and dissection.";
RL   Am. J. Hum. Genet. 56:1287-1296(1995).
RN   [42]
RP   VARIANTS MFS TYR-129; PHE-166; CYS-746; ARG-926; ARG-1013; LYS-1073;
RP   SER-1382 AND ARG-1928.
RX   PubMed=7611299;
RA   Nijbroek G., Sood S., McIntosh I., Francomano C.A., Bull E.,
RA   Pereira L., Ramirez F., Pyeritz R.E., Dietz H.C.;
RT   "Fifteen novel FBN1 mutations causing Marfan syndrome detected by
RT   heteroduplex analysis of genomic amplicons.";
RL   Am. J. Hum. Genet. 57:8-21(1995).
RN   [43]
RP   VARIANT MFS TYR-1223.
RA   Dietz H.C., Sood I., McIntosh I.;
RT   "The phenotypic continuum associated with FBN1 mutations includes the
RT   Shprintzen-Goldberg syndrome.";
RL   Am. J. Hum. Genet. 57:A211-A211(1995).
RN   [44]
RP   VARIANT MFS TRP-2726.
RX   PubMed=7738200; DOI=10.1172/JCI117930;
RA   Milewicz D.M., Grossfield J., Cao S.-N., Kielty C., Covitz W.,
RA   Jewett T.;
RT   "A mutation in FBN1 disrupts profibrillin processing and results in
RT   isolated skeletal features of the Marfan syndrome.";
RL   J. Clin. Invest. 95:2373-2378(1995).
RN   [45]
RP   VARIANTS MFS ARG-1053; GLY-1072; LYS-1073 AND GLY-1117.
RX   PubMed=8882780;
RX   DOI=10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U;
RA   Putnam E.A., Cho M., Zinn A.B., Towbin J.A., Byers P.H.,
RA   Milewicz D.M.;
RT   "Delineation of the Marfan phenotype associated with mutations in
RT   exons 23-32 of the FBN1 gene.";
RL   Am. J. Med. Genet. 62:233-242(1996).
RN   [46]
RP   VARIANTS MFS THR-705; TYR-711; GLY-1055 AND TYR-1153.
RX   PubMed=8863159; DOI=10.1136/jmg.33.8.665;
RA   Ades L.C., Haan E.A., Colley A.F., Richards R.I.;
RT   "Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan
RT   syndrome.";
RL   J. Med. Genet. 33:665-671(1996).
RN   [47]
RP   VARIANT MFS TYR-587.
RX   PubMed=9254848; DOI=10.1007/s004390050489;
RA   Booms P., Withers A.P., Boxer M., Kaufmann U.C., Hagemeier C.,
RA   Vetter U., Robinson P.N.;
RT   "A novel de novo mutation in exon 14 of the fibrillin-1 gene
RT   associated with delayed secretion of fibrillin in a patient with a
RT   mild Marfan phenotype.";
RL   Hum. Genet. 100:195-200(1997).
RN   [48]
RP   VARIANT ALA-1148.
RX   PubMed=9150726; DOI=10.1007/s004390050414;
RA   Schrijver I., Liu W., Francke U.;
RT   "The pathogenicity of the Pro1148Ala substitution in the FBN1 gene:
RT   causing or predisposing to Marfan syndrome and aortic aneurysm, or
RT   clinically innocent?";
RL   Hum. Genet. 99:607-611(1997).
RN   [49]
RP   VARIANTS MFS ARG-111; CYS-545; CYS-627; GLY-750; ARG-1074; HIS-1170;
RP   TRP-1171; LYS-1173; TYR-1404; GLY-1610; LYS-1893; TRP-2099; TYR-2111;
RP   ARG-2258; TRP-2282 AND ARG-2489.
RX   PubMed=9338581;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:4<280::AID-HUMU3>3.3.CO;2-L;
RA   Hayward C., Porteous M.E.M., Brock D.J.H.;
RT   "Mutation screening of all 65 exons of the fibrillin-1 gene in 60
RT   patients with Marfan syndrome: report of 12 novel mutations.";
RL   Hum. Mutat. 10:280-289(1997).
RN   [50]
RP   VARIANT ALA-1148.
RX   PubMed=9338588;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:4<326::AID-HUMU10>3.0.CO;2-1;
RA   Watanabe Y., Yano S., Koga Y., Yukizane S., Nishiyori A., Yoshino M.,
RA   Kato H.;
RT   "P1148A in fibrillin-1 is not a mutation leading to Shprintzen-
RT   Goldberg syndrome.";
RL   Hum. Mutat. 10:326-327(1997).
RN   [51]
RP   VARIANT ALA-1148.
RX   PubMed=8988160; DOI=10.1038/ng0197-12;
RA   Wang M., Mathews K.R., Imaizumi K., Beiraghi S., Blumberg B.,
RA   Scheuner M., Graham J.M. Jr., Godfrey M.;
RT   "P1148A in fibrillin-1 is not a mutation anymore.";
RL   Nat. Genet. 15:12-12(1997).
RN   [52]
RP   VARIANT MFS ARG-1265.
RX   PubMed=9837823; DOI=10.1086/302144;
RA   Montgomery R.A., Geraghty M.T., Bull E., Gelb B.D., Johnson M.,
RA   McIntosh I., Francomano C.A., Dietz H.C.;
RT   "Multiple molecular mechanisms underlying subdiagnostic variants of
RT   Marfan syndrome.";
RL   Am. J. Hum. Genet. 63:1703-1711(1998).
RN   [53]
RP   VARIANT MFS CYS-122.
RX   PubMed=9452085;
RA   Black C., Withers A.P., Gray J.R., Bridges A.B., Craig A., Baty D.U.,
RA   Boxer M.;
RT   "Correlation of a recurrent FBN1 mutation (R122C) with an atypical
RT   familial Marfan syndrome phenotype.";
RL   Hum. Mutat. Suppl. 1:S198-S200(1998).
RN   [54]
RP   VARIANT MFS ILE-984.
RX   PubMed=10694921;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU14>3.3.CO;2-G;
RA   Grau U., Klein H.-G., Detter C., Mair H., Welz A., Seidel D.,
RA   Reichart B.;
RT   "A novel mutation in the neonatal region of the fibrillin (FBN) 1 gene
RT   associated with a classical phenotype of Marfan syndrome (MfS).";
RL   Hum. Mutat. 12:137-137(1998).
RN   [55]
RP   VARIANT MFS GLU-985.
RX   PubMed=10441597; DOI=10.1086/302545;
RA   Collod-Beroud G., Lackmy-Port-Lys M., Jondeau G., Mathieu M.,
RA   Maingourd Y., Coulon M., Guillotel M., Junien C., Boileau C.;
RT   "Demonstration of the recurrence of Marfan-like skeletal and
RT   cardiovascular manifestations due to germline mosaicism for an FBN1
RT   mutation.";
RL   Am. J. Hum. Genet. 65:917-921(1999).
RN   [56]
RP   VARIANTS MFS PHE-504; TYR-1129; CYS-1261; SER-1833 AND TYR-2142.
RX   PubMed=10425041;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:2<181::AID-HUMU10>3.3.CO;2-Y;
RA   El-Aleem A.A., Karck M., Haverich A., Schmidtke J.,
RA   Arslan-Kirchner M.;
RT   "Identification of 9 novel FBN1 mutations in German patients with
RT   Marfan syndrome.";
RL   Hum. Mutat. 14:181-181(1999).
RN   [57]
RP   VARIANTS MFS PHE-89; CYS-122; CYS-240; CYS-366; CYS-545; SER-560;
RP   TYR-570; ASP-592; TRP-598; TYR-776; ARG-781; GLY-913; ARG-985;
RP   ARG-1013; TRP-1055; TYR-1055; CYS-1101; PRO-1337; TYR-1339; SER-1429;
RP   PRO-1790; TYR-1791; TYR-1835; THR-1909; SER-1915; TYR-1971; TYR-1977;
RP   HIS-2223; TRP-2282; TYR-2406; PHE-2581; THR-2585; ARG-2618; LYS-2624
RP   AND CYS-2668, VARIANT ECTOL1 ARG-2154, VARIANT MITRAL VALVE PROLAPSE
RP   ILE-1128, AND VARIANT CYS-1530.
RX   PubMed=11700157; DOI=10.1001/archinte.161.20.2447;
RA   Loeys B., Nuytinck L., Delvaux I., De Bie S., De Paepe A.;
RT   "Genotype and phenotype analysis of 171 patients referred for
RT   molecular study of the fibrillin-1 gene FBN1 because of suspected
RT   Marfan syndrome.";
RL   Arch. Intern. Med. 161:2447-2454(2001).
RN   [58]
RP   VARIANTS MFS CYS-62; TYR-587; TYR-596; ASN-654; TYR-681; ARG-683;
RP   TRP-685; VAL-723; PHE-734; TYR-748; GLY-776; ARG-781; ARG-908;
RP   GLY-921; PRO-1790; SER-1806; VAL-1931 DEL; TYR-1998; GLY-2221;
RP   THR-2269 AND TRP-2335, VARIANTS ECTOL1 CYS-115; TYR-661 AND TYR-2339,
RP   AND VARIANT MET-2101.
RX   PubMed=12203992; DOI=10.1002/humu.10112;
RA   Katzke S., Booms P., Tiecke F., Palz M., Pletschacher A., Turkmen S.,
RA   Neumann L.M., Pregla R., Leitner C., Schramm C., Lorenz P.,
RA   Hagemeier C., Fuchs J., Skovby F., Rosenberg T., Robinson P.N.;
RT   "TGGE screening of the entire FBN1 coding sequence in 126 individuals
RT   with Marfan syndrome and related fibrillinopathies.";
RL   Hum. Mutat. 20:197-208(2002).
RN   [59]
RP   VARIANTS MFS CYS-114; ARG-890; GLY-1200; TYR-1835; ARG-2111; CYS-2474
RP   AND GLY-2652, AND VARIANT ECTOL1 CYS-240.
RX   PubMed=11826022; DOI=10.1136/jmg.39.1.34;
RA   Koerkkoe J., Kaitila I., Loennqvist L., Peltonen L., Ala-Kokko L.;
RT   "Sensitivity of conformation sensitive gel electrophoresis in
RT   detecting mutations in Marfan syndrome and related conditions.";
RL   J. Med. Genet. 39:34-41(2002).
RN   [60]
RP   VARIANT WMS2 1692-ARG--TYR-1699 DEL.
RX   PubMed=12525539; DOI=10.1136/jmg.40.1.34;
RA   Faivre L., Gorlin R.J., Wirtz M.K., Godfrey M., Dagoneau N.,
RA   Samples J.R., Le Merrer M., Collod-Beroud G., Boileau C., Munnich A.,
RA   Cormier-Daire V.;
RT   "In frame fibrillin-1 gene deletion in autosomal dominant Weill-
RT   Marchesani syndrome.";
RL   J. Med. Genet. 40:34-36(2003).
RN   [61]
RP   VARIANTS MFS SER-154; SER-166; CYS-240; SER-652; THR-705; TYR-711;
RP   SER-816; ARG-1013; TYR-1044; GLY-1055; CYS-1101; TYR-1117; TYR-1153;
RP   ASN-1155; GLN-1325; LYS-1366; SER-1374; ARG-1389; 1394-GLY--THR-1396
RP   DEL; ALA-1424; TYR-1564; PHE-1770; TRP-1793; GLU-1796; TRP-2442;
RP   THR-2585 AND PRO-2623, AND VARIANT CYS-1530.
RX   PubMed=14695540; DOI=10.1002/humu.9207;
RA   Biggin A., Holman K., Brett M., Bennetts B., Ades L.;
RT   "Detection of thirty novel FBN1 mutations in patients with Marfan
RT   syndrome or a related fibrillinopathy.";
RL   Hum. Mutat. 23:99-99(2004).
RN   [62]
RP   CHARACTERIZATION OF VARIANTS MFS CYS-627; GLY-750 AND ARG-926.
RX   PubMed=15161917; DOI=10.1074/jbc.M405239200;
RA   Vollbrandt T., Tiedemann K., El-Hallous E., Lin G., Brinckmann J.,
RA   John H., Baetge B., Notbohm H., Reinhardt D.P.;
RT   "Consequences of cysteine mutations in calcium-binding epidermal
RT   growth factor modules of fibrillin-1.";
RL   J. Biol. Chem. 279:32924-32931(2004).
RN   [63]
RP   VARIANTS MFS CYS-20; TYR-123; ARG-177; ARG-224; GLY-439;
RP   629-VAL--GLY-633 DEL; CYS-635; ILE-636; TYR-832; GLY-890; ASP-1058;
RP   SER-1153; PHE-1211 DEL; CYS-1219; ASP-1261; SER-1278; SER-1333;
RP   ARG-1402; SER-1424; PHE-1564; GLY-1631; TYR-1663; TYR-1876; ILE-1887;
RP   ARG-1895; TYR-1900; PRO-2160; PHE-2221; THR-2385; ARG-2500; TYR-2500;
RP   TRP-2535; LYS-2570; ARG-2571; SER-2592; LYS-2610 AND CYS-2629.
RX   PubMed=16222657; DOI=10.1002/humu.9377;
RA   Arbustini E., Grasso M., Ansaldi S., Malattia C., Pilotto A.,
RA   Porcu E., Disabella E., Marziliano N., Pisani A., Lanzarini L.,
RA   Mannarino S., Larizza D., Mosconi M., Antoniazzi E., Zoia M.C.,
RA   Meloni G., Magrassi L., Brega A., Bedeschi M.F., Torrente I., Mari F.,
RA   Tavazzi L.;
RT   "Identification of sixty-two novel and twelve known FBN1 mutations in
RT   eighty-one unrelated probands with Marfan syndrome and other
RT   fibrillinopathies.";
RL   Hum. Mutat. 26:494-494(2005).
RN   [64]
RP   VARIANTS MFS ASN-507 DEL; TYR-541; CYS-627; TYR-781; ARG-985;
RP   ARG-1013; VAL-1113; GLY-1284; SER-1475; GLU-1475; THR-1576; ARG-1791;
RP   GLY-1928; TYR-1928; TYR-2038; ARG-2085; SER-2144; ARG-2536 AND
RP   TYR-2605.
RX   PubMed=16220557; DOI=10.1002/humu.20239;
RA   Rommel K., Karck M., Haverich A., von Kodolitsch Y., Rybczynski M.,
RA   Muller G., Singh K.K., Schmidtke J., Arslan-Kirchner M.;
RT   "Identification of 29 novel and nine recurrent fibrillin-1 (FBN1)
RT   mutations and genotype-phenotype correlations in 76 patients with
RT   Marfan syndrome.";
RL   Hum. Mutat. 26:529-539(2005).
RN   [65]
RP   VARIANT MFS GLY-1068.
RX   PubMed=20803651; DOI=10.1002/ajmg.a.33406;
RA   Barnett C.P., Wilson G.J., Chiasson D.A., Gross G.J., Hinek A.,
RA   Hawkins C., Chitayat D.;
RT   "Central nervous system abnormalities in two cases with neonatal
RT   Marfan syndrome with novel mutations in the fibrillin-1 gene.";
RL   Am. J. Med. Genet. A 152:2409-2412(2010).
RN   [66]
RP   VARIANT ALA-1148.
RX   PubMed=20547088; DOI=10.1016/j.legalmed.2010.04.001;
RA   Yuasa I., Umetsu K., Matsusue A., Nishimukai H., Harihara S.,
RA   Fukumori Y., Saitou N., Jin F., Chattopadhyay P.K., Henke L.,
RA   Henke J.;
RT   "A Japanese-specific allele in the GALNT11 gene.";
RL   Leg. Med. 12:208-211(2010).
RN   [67]
RP   VARIANTS SSKS SER-1564; CYS-1570; GLY-1577 AND ASP-1594.
RX   PubMed=20375004; DOI=10.1126/scitranslmed.3000488;
RA   Loeys B.L., Gerber E.E., Riegert-Johnson D., Iqbal S., Whiteman P.,
RA   McConnell V., Chillakuri C.R., Macaya D., Coucke P.J., De Paepe A.,
RA   Judge D.P., Wigley F., Davis E.C., Mardon H.J., Handford P.,
RA   Keene D.R., Sakai L.Y., Dietz H.C.;
RT   "Mutations in fibrillin-1 cause congenital scleroderma: stiff skin
RT   syndrome.";
RL   Sci. Transl. Med. 2:23RA20-23RA20(2010).
RN   [68]
RP   VARIANTS GPHYSD2 CYS-1696; ASP-1699; CYS-1699; TYR-1706; TRP-1719;
RP   THR-1728; VAL-1728; TYR-1733 AND SER-1762, AND VARIANTS ACMICD
RP   CYS-1699; CYS-1700; ARG-1714; CYS-1722; VAL-1726; THR-1728; GLN-1735
RP   INS; ARG-1750 AND VAL-1758.
RX   PubMed=21683322; DOI=10.1016/j.ajhg.2011.05.012;
RA   Le Goff C., Mahaut C., Wang L.W., Allali S., Abhyankar A., Jensen S.,
RA   Zylberberg L., Collod-Beroud G., Bonnet D., Alanay Y., Brady A.F.,
RA   Cordier M.P., Devriendt K., Genevieve D., Kiper P.O., Kitoh H.,
RA   Krakow D., Lynch S.A., Le Merrer M., Megarbane A., Mortier G.,
RA   Odent S., Polak M., Rohrbach M., Sillence D., Stolte-Dijkstra I.,
RA   Superti-Furga A., Rimoin D.L., Topouchian V., Unger S., Zabel B.,
RA   Bole-Feysot C., Nitschke P., Handford P., Casanova J.L., Boileau C.,
RA   Apte S.S., Munnich A., Cormier-Daire V.;
RT   "Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are
RT   responsible for acromicric and geleophysic dysplasias.";
RL   Am. J. Hum. Genet. 89:7-14(2011).
RN   [69]
RP   VARIANTS MFS GLY-80; TYR-490; TYR-499; ARG-611; GLY-617; TRP-685;
RP   TYR-685; TYR-790; TYR-811; SER-853; TYR-926; SER-1090; ASP-1185;
RP   TYR-1284; PHE-1350; ALA-1401; TRP-1431; TYR-1431; ALA-1487; LYS-1489;
RP   CYS-1838; TYR-1900; THR-1909; SER-1934; GLY-1976; ARG-1984; ASN-2166;
RP   THR-2185; GLY-2247; ARG-2318; TYR-2406; SER-2442; ARG-2511; VAL-2606
RP   DEL; LYS-2610 AND ARG-2646, AND VARIANTS GLY-1481 AND HIS-2793.
RX   PubMed=21542060; DOI=10.1002/humu.21525;
RA   Baetens M., Van Laer L., De Leeneer K., Hellemans J., De Schrijver J.,
RA   Van De Voorde H., Renard M., Dietz H., Lacro R.V., Menten B.,
RA   Van Criekinge W., De Backer J., De Paepe A., Loeys B., Coucke P.J.;
RT   "Applying massive parallel sequencing to molecular diagnosis of Marfan
RT   and Loeys-Dietz syndromes.";
RL   Hum. Mutat. 32:1053-1062(2011).
CC   -!- FUNCTION: Fibrillins are structural components of 10-12 nm
CC       extracellular calcium-binding microfibrils, which occur either in
CC       association with elastin or in elastin-free bundles. Fibrillin-1-
CC       containing microfibrils provide long-term force bearing structural
CC       support. Regulates osteoblast maturation by controlling TGF-beta
CC       bioavailability and calibrating TGF-beta and BMP levels,
CC       respectively. {ECO:0000269|PubMed:15062093}.
CC   -!- SUBUNIT: Interacts with COL16A1 (PubMed:15165854). Interacts with
CC       integrin alpha-V/beta-3 (PubMed:15062093). Interacts with
CC       ADAMTS10; this interaction promotes microfibril assembly
CC       (PubMed:21402694). Interacts with THSD4; this interaction promotes
CC       fibril formation (By similarity). {ECO:0000250|UniProtKB:Q61554,
CC       ECO:0000269|PubMed:15062093, ECO:0000269|PubMed:15165854,
CC       ECO:0000269|PubMed:21402694}.
CC   -!- INTERACTION:
CC       O95967:EFEMP2; NbExp=3; IntAct=EBI-2505934, EBI-743414;
CC       Q9UBX5:FBLN5; NbExp=3; IntAct=EBI-2505934, EBI-947897;
CC       P35556:FBN2; NbExp=2; IntAct=EBI-2505934, EBI-6164392;
CC       P02751:FN1; NbExp=2; IntAct=EBI-2505934, EBI-1220319;
CC       P28300:LOX; NbExp=2; IntAct=EBI-2505934, EBI-3893481;
CC       Q14766-2:LTBP1; NbExp=2; IntAct=EBI-2505934, EBI-11173832;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000250|UniProtKB:P98133}.
CC   -!- PTM: Forms intermolecular disulfide bonds either with other
CC       fibrillin-1 molecules or with other components of the
CC       microfibrils.
CC   -!- DISEASE: Marfan syndrome (MFS) [MIM:154700]: A hereditary disorder
CC       of connective tissue that affects the skeletal, ocular, and
CC       cardiovascular systems. A wide variety of skeletal abnormalities
CC       occurs with Marfan syndrome, including scoliosis, chest wall
CC       deformity, tall stature, abnormal joint mobility. Ectopia lentis
CC       occurs in most of the patients and is almost always bilateral. The
CC       leading cause of premature death is progressive dilation of the
CC       aortic root and ascending aorta, causing aortic incompetence and
CC       dissection. Neonatal Marfan syndrome is the most severe form
CC       resulting in death from cardiorespiratory failure in the first few
CC       years of life. {ECO:0000269|PubMed:10425041,
CC       ECO:0000269|PubMed:10441597, ECO:0000269|PubMed:10694921,
CC       ECO:0000269|PubMed:11700157, ECO:0000269|PubMed:11826022,
CC       ECO:0000269|PubMed:12203992, ECO:0000269|PubMed:1301946,
CC       ECO:0000269|PubMed:14695540, ECO:0000269|PubMed:15221638,
CC       ECO:0000269|PubMed:1569206, ECO:0000269|PubMed:16220557,
CC       ECO:0000269|PubMed:16222657, ECO:0000269|PubMed:1852208,
CC       ECO:0000269|PubMed:20803651, ECO:0000269|PubMed:21542060,
CC       ECO:0000269|PubMed:7611299, ECO:0000269|PubMed:7738200,
CC       ECO:0000269|PubMed:7870075, ECO:0000269|PubMed:7977366,
CC       ECO:0000269|PubMed:8004112, ECO:0000269|PubMed:8040326,
CC       ECO:0000269|PubMed:8071963, ECO:0000269|PubMed:8136837,
CC       ECO:0000269|PubMed:8281141, ECO:0000269|PubMed:8406497,
CC       ECO:0000269|PubMed:8504310, ECO:0000269|PubMed:8863159,
CC       ECO:0000269|PubMed:8882780, ECO:0000269|PubMed:9254848,
CC       ECO:0000269|PubMed:9338581, ECO:0000269|PubMed:9452085,
CC       ECO:0000269|PubMed:9837823, ECO:0000269|Ref.43}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry. The majority of the more than 600 mutations in FBN1
CC       currently known are point mutations, the rest are frameshifts and
CC       splice site mutations. Marfan syndrome has been suggested in at
CC       least 2 historical figures, Abraham Lincoln and Paganini.
CC   -!- DISEASE: Ectopia lentis 1, isolated, autosomal dominant (ECTOL1)
CC       [MIM:129600]: An ocular abnormality characterized by partial or
CC       complete displacement of the lens from its space resulting from
CC       defective zonule formation. {ECO:0000269|PubMed:11700157,
CC       ECO:0000269|PubMed:11826022, ECO:0000269|PubMed:12203992,
CC       ECO:0000269|PubMed:8188302}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Weill-Marchesani syndrome 2 (WMS2) [MIM:608328]: A rare
CC       connective tissue disorder characterized by short stature,
CC       brachydactyly, joint stiffness, and eye abnormalities including
CC       microspherophakia, ectopia lentis, severe myopia and glaucoma.
CC       {ECO:0000269|PubMed:12525539}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Overlap connective tissue disease (OCTD) [MIM:604308]:
CC       Heritable disorder of connective tissue characterized by
CC       involvement of the mitral valve, aorta, skeleton, and skin. MASS
CC       syndrome is closely resembling both the Marfan syndrome and the
CC       Barlow syndrome. However, no dislocation of the lenses or
CC       aneurysmal changes occur in the aorta, and the mitral valve
CC       prolapse is by no means invariable. {ECO:0000269|PubMed:2739055}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Stiff skin syndrome (SSKS) [MIM:184900]: A syndrome
CC       characterized by hard, thick skin, usually over the entire body,
CC       which limits joint mobility and causes flexion contractures. Other
CC       occasional findings include lipodystrophy and muscle weakness.
CC       {ECO:0000269|PubMed:20375004}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Geleophysic dysplasia 2 (GPHYSD2) [MIM:614185]: An
CC       autosomal dominant disorder characterized by severe short stature,
CC       short hands and feet, joint limitations, and skin thickening.
CC       Radiologic features include delayed bone age, cone-shaped
CC       epiphyses, shortened long tubular bones, and ovoid vertebral
CC       bodies. Affected individuals have characteristic facial features
CC       including a 'happy' face with full cheeks, shortened nose,
CC       hypertelorism, long and flat philtrum, and thin upper lip. Other
CC       distinctive features include progressive cardiac valvular
CC       thickening often leading to an early death, toe walking, tracheal
CC       stenosis, respiratory insufficiency, and lysosomal-like storage
CC       vacuoles in various tissues. {ECO:0000269|PubMed:21683322}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Acromicric dysplasia (ACMICD) [MIM:102370]: An autosomal
CC       dominant disorder characterized by severe short stature, short
CC       hands and feet, joint limitations, and skin thickening. Radiologic
CC       features include delayed bone age, cone-shaped epiphyses,
CC       shortened long tubular bones, and ovoid vertebral bodies. Affected
CC       individuals have distinct facial features, including round face,
CC       well-defined eyebrows, long eyelashes, bulbous nose with
CC       anteverted nostrils, long and prominent philtrum, and thick lips
CC       with a small mouth. Other characteristic features include hoarse
CC       voice and pseudomuscular build, and there are distinct skeletal
CC       features as well, including an internal notch of the femoral head,
CC       internal notch of the second metacarpal, and external notch of the
CC       fifth metacarpal. {ECO:0000269|PubMed:21683322}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the fibrillin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 47 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 9 TB (TGF-beta binding) domains.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA45118.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L13923; AAB02036.1; -; mRNA.
DR   EMBL; AB177803; BAD16739.1; -; Genomic_DNA.
DR   EMBL; GU143398; ACZ58372.1; -; Genomic_DNA.
DR   EMBL; AC022467; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084757; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084758; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471082; EAW77354.1; -; Genomic_DNA.
DR   EMBL; BC146854; AAI46855.1; -; mRNA.
DR   EMBL; L19896; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X63556; CAA45118.1; ALT_INIT; mRNA.
DR   EMBL; X62008; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54426; AAB25244.1; -; Genomic_DNA.
DR   EMBL; S54425; AAB25244.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS32232.1; -.
DR   PIR; A47221; A47221.
DR   RefSeq; NP_000129.3; NM_000138.4.
DR   UniGene; Hs.591133; -.
DR   PDB; 1APJ; NMR; -; A=2052-2125.
DR   PDB; 1EMN; NMR; -; A=2124-2205.
DR   PDB; 1EMO; NMR; -; A=2124-2205.
DR   PDB; 1LMJ; NMR; -; A=1069-1154.
DR   PDB; 1UZJ; X-ray; 2.25 A; A/B/C=1486-1647.
DR   PDB; 1UZK; X-ray; 1.35 A; A=1486-1647.
DR   PDB; 1UZP; X-ray; 1.78 A; A=1486-1647.
DR   PDB; 1UZQ; X-ray; 2.40 A; A=1486-1647.
DR   PDB; 2M74; NMR; -; A=45-178.
DR   PDB; 2W86; X-ray; 1.80 A; A=807-951.
DR   PDBsum; 1APJ; -.
DR   PDBsum; 1EMN; -.
DR   PDBsum; 1EMO; -.
DR   PDBsum; 1LMJ; -.
DR   PDBsum; 1UZJ; -.
DR   PDBsum; 1UZK; -.
DR   PDBsum; 1UZP; -.
DR   PDBsum; 1UZQ; -.
DR   PDBsum; 2M74; -.
DR   PDBsum; 2W86; -.
DR   ProteinModelPortal; P35555; -.
DR   SMR; P35555; 45-178, 807-951, 1069-1154, 1486-1647, 2054-2205.
DR   BioGrid; 108494; 10.
DR   DIP; DIP-29985N; -.
DR   IntAct; P35555; 23.
DR   MINT; MINT-206075; -.
DR   STRING; 9606.ENSP00000325527; -.
DR   iPTMnet; P35555; -.
DR   PhosphoSite; P35555; -.
DR   BioMuta; FBN1; -.
DR   DMDM; 311033452; -.
DR   MaxQB; P35555; -.
DR   PaxDb; P35555; -.
DR   PRIDE; P35555; -.
DR   Ensembl; ENST00000316623; ENSP00000325527; ENSG00000166147.
DR   GeneID; 2200; -.
DR   KEGG; hsa:2200; -.
DR   UCSC; uc001zwx.2; human.
DR   CTD; 2200; -.
DR   GeneCards; FBN1; -.
DR   GeneReviews; FBN1; -.
DR   HGNC; HGNC:3603; FBN1.
DR   HPA; CAB002670; -.
DR   HPA; CAB058696; -.
DR   HPA; CAB068188; -.
DR   HPA; HPA017759; -.
DR   HPA; HPA021057; -.
DR   MalaCards; FBN1; -.
DR   MIM; 102370; phenotype.
DR   MIM; 129600; phenotype.
DR   MIM; 134797; gene.
DR   MIM; 154700; phenotype.
DR   MIM; 184900; phenotype.
DR   MIM; 604308; phenotype.
DR   MIM; 608328; phenotype.
DR   MIM; 614185; phenotype.
DR   neXtProt; NX_P35555; -.
DR   Orphanet; 969; Acromicric dysplasia.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 2623; Geleophysic dysplasia.
DR   Orphanet; 2084; Glaucoma - ectopia - microspherophakia - stiff joints - short stature.
DR   Orphanet; 1885; Isolated ectopia lentis.
DR   Orphanet; 284963; Marfan syndrome type 1.
DR   Orphanet; 284979; Neonatal Marfan syndrome.
DR   Orphanet; 300382; Progeroid and marfanoid aspect-lipodystrophy syndrome.
DR   Orphanet; 2462; Shprintzen-Goldberg syndrome.
DR   Orphanet; 2833; Stiff skin syndrome.
DR   Orphanet; 3449; Weill-Marchesani syndrome.
DR   PharmGKB; PA28016; -.
DR   eggNOG; ENOG410IR7H; Eukaryota.
DR   eggNOG; ENOG410XSTY; LUCA.
DR   HOGENOM; HOG000231768; -.
DR   HOVERGEN; HBG005643; -.
DR   InParanoid; P35555; -.
DR   KO; K06825; -.
DR   OrthoDB; EOG7RV9F6; -.
DR   PhylomeDB; P35555; -.
DR   TreeFam; TF316849; -.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   ChiTaRS; FBN1; human.
DR   EvolutionaryTrace; P35555; -.
DR   GeneWiki; FBN1; -.
DR   GenomeRNAi; 2200; -.
DR   NextBio; 8891; -.
DR   PRO; PR:P35555; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; P35555; -.
DR   CleanEx; HS_FBN1; -.
DR   ExpressionAtlas; P35555; baseline and differential.
DR   Genevisible; P35555; HS.
DR   GO; GO:0005604; C:basement membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0001527; C:microfibril; IDA:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0030023; F:extracellular matrix constituent conferring elasticity; IC:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IPI:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; IEP:UniProtKB.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IEP:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0048050; P:post-embryonic eye morphogenesis; IEP:UniProtKB.
DR   GO; GO:0090287; P:regulation of cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0035582; P:sequestering of BMP in extracellular matrix; ISS:BHF-UCL.
DR   GO; GO:0035583; P:sequestering of TGFbeta in extracellular matrix; ISS:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; IMP:UniProtKB.
DR   Gene3D; 3.90.290.10; -; 10.
DR   InterPro; IPR026823; cEGF.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR011398; FBN.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR017878; TB_dom.
DR   PANTHER; PTHR24039; PTHR24039; 1.
DR   Pfam; PF12662; cEGF; 2.
DR   Pfam; PF07645; EGF_CA; 38.
DR   Pfam; PF00683; TB; 9.
DR   PIRSF; PIRSF036312; Fibrillin; 1.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00179; EGF_CA; 42.
DR   SUPFAM; SSF57184; SSF57184; 10.
DR   SUPFAM; SSF57581; SSF57581; 9.
DR   PROSITE; PS00010; ASX_HYDROXYL; 43.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 38.
DR   PROSITE; PS50026; EGF_3; 44.
DR   PROSITE; PS01187; EGF_CA; 43.
DR   PROSITE; PS51364; TB; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Aortic aneurysm; Calcium; Complete proteome;
KW   Disease mutation; Disulfide bond; Dwarfism; EGF-like domain;
KW   Extracellular matrix; Glycoprotein; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   CHAIN        28   2871       Fibrillin-1.
FT                                /FTId=PRO_0000007581.
FT   DOMAIN       81    112       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      115    146       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      147    178       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      184    236       TB 1.
FT   DOMAIN      246    287       EGF-like 4; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      288    329       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      334    389       TB 2.
FT   DOMAIN      449    489       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      490    529       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      530    571       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      572    612       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      613    653       EGF-like 10; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      659    711       TB 3.
FT   DOMAIN      723    764       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      765    806       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      807    846       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      851    902       TB 4.
FT   DOMAIN      910    951       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      956   1008       TB 5.
FT   DOMAIN     1028   1069       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1070   1112       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1113   1154       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1155   1196       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1197   1237       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1238   1279       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1280   1321       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1322   1362       EGF-like 22; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1363   1403       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1404   1445       EGF-like 24; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1446   1486       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1487   1527       EGF-like 26; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1532   1589       TB 6.
FT   DOMAIN     1606   1647       EGF-like 27; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1648   1688       EGF-like 28; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1693   1748       TB 7.
FT   DOMAIN     1766   1807       EGF-like 29; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1808   1848       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1849   1890       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1891   1929       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1930   1972       EGF-like 33; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1973   2012       EGF-like 34; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2013   2054       EGF-like 35; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2059   2111       TB 8.
FT   DOMAIN     2127   2165       EGF-like 36; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2166   2205       EGF-like 37; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2206   2246       EGF-like 38; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2247   2290       EGF-like 39; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2291   2332       EGF-like 40; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2337   2390       TB 9.
FT   DOMAIN     2402   2443       EGF-like 41; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2444   2484       EGF-like 42; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2485   2523       EGF-like 43; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2524   2566       EGF-like 44; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2567   2606       EGF-like 45; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2607   2647       EGF-like 46; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     2648   2687       EGF-like 47; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   COMPBIAS    402    446       Pro-rich.
FT   MOD_RES    2702   2702       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    448    448       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1067   1067       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1149   1149       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1369   1369       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1484   1484       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1581   1581       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1669   1669       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1703   1703       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1713   1713       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1902   1902       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2077   2077       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2178   2178       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2734   2734       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2750   2750       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2767   2767       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     85     94       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID     89    100       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    102    111       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    119    129       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    123    134       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    136    145       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    150    160       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    154    166       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    168    177       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    250    262       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    257    271       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    273    286       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    292    304       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    299    313       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    315    328       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    453    465       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    460    474       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    476    488       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    494    504       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    499    513       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    515    528       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    534    546       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    541    555       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    557    570       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    576    587       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    582    596       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    598    611       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    617    628       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    623    637       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    639    652       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    727    739       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    734    748       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    750    763       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    769    781       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    776    790       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    792    805       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    811    821
FT   DISULFID    816    830
FT   DISULFID    832    845
FT   DISULFID    853    875
FT   DISULFID    862    887
FT   DISULFID    876    890
FT   DISULFID    896    908
FT   DISULFID    914    926
FT   DISULFID    921    935
FT   DISULFID    937    950
FT   DISULFID   1032   1044       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1039   1053       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1055   1068       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1074   1086       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1081   1095       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1097   1111       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1117   1129       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1124   1138       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1140   1153       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1159   1171       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1166   1180       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1182   1195       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1201   1212       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1208   1221       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1223   1236       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1242   1254       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1249   1263       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1265   1278       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1284   1296       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1291   1305       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1307   1320       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1326   1339       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1333   1348       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1350   1361       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1367   1380       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1374   1389       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1391   1402       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1408   1420       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1415   1429       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1431   1444       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1450   1461       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1456   1470       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1472   1485       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1491   1502
FT   DISULFID   1497   1511
FT   DISULFID   1513   1526
FT   DISULFID   1534   1562
FT   DISULFID   1549   1574
FT   DISULFID   1563   1577
FT   DISULFID   1564   1589
FT   DISULFID   1610   1622
FT   DISULFID   1617   1631
FT   DISULFID   1633   1646
FT   DISULFID   1652   1663       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1658   1672       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1674   1687       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1770   1782       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1777   1791       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1793   1806       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1812   1824       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1818   1833       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1835   1847       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1853   1865       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1860   1874       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1876   1889       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1895   1905       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1900   1914       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1916   1928       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1934   1947       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1942   1956       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1958   1971       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1977   1989       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   1984   1998       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2000   2011       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2017   2029       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2024   2038       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2040   2053       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2061   2083
FT   DISULFID   2070   2096
FT   DISULFID   2084   2099
FT   DISULFID   2085   2111
FT   DISULFID   2131   2142       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2137   2151       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2153   2164       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2170   2181       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2176   2190       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2192   2204       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2210   2221       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2217   2230       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2232   2245       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2251   2265       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2258   2274       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2276   2289       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2295   2307       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2302   2316       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2318   2331       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2406   2418       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2413   2427       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2429   2442       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2448   2459       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2455   2468       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2470   2483       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2489   2500       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2496   2509       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2511   2522       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2528   2541       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2535   2550       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2552   2565       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2571   2581       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2577   2590       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2592   2605       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2611   2622       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2617   2631       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2633   2646       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2652   2663       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2659   2672       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID   2674   2686       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   VARIANT      20     20       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023859.
FT   VARIANT      27     27       A -> T (in dbSNP:rs25397).
FT                                /FTId=VAR_014663.
FT   VARIANT      62     62       R -> C (in MFS; also in a patient with
FT                                ectopia lentis and retinal detachment;
FT                                dbSNP:rs25403).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017967.
FT   VARIANT      80     80       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065981.
FT   VARIANT      89     89       C -> F (in MFS; dbSNP:rs112660651).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017968.
FT   VARIANT     111    111       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002276.
FT   VARIANT     114    114       R -> C (in MFS).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_017969.
FT   VARIANT     115    115       S -> C (in ECTOL1).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017970.
FT   VARIANT     122    122       R -> C (in MFS; dbSNP:rs137854467).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:8040326,
FT                                ECO:0000269|PubMed:9452085}.
FT                                /FTId=VAR_002277.
FT   VARIANT     123    123       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023860.
FT   VARIANT     129    129       C -> Y (in MFS; severe neonatal).
FT                                {ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002278.
FT   VARIANT     133    133       H -> Q (in dbSNP:rs363850).
FT                                /FTId=VAR_055723.
FT   VARIANT     154    154       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_017971.
FT   VARIANT     166    166       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002279.
FT   VARIANT     166    166       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_002280.
FT   VARIANT     177    177       C -> R (in MFS; dbSNP:rs363853).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023861.
FT   VARIANT     217    217       W -> G (in MFS).
FT                                {ECO:0000269|PubMed:7977366,
FT                                ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002281.
FT   VARIANT     224    224       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023862.
FT   VARIANT     240    240       R -> C (in MFS and ECTOL1;
FT                                dbSNP:rs137854480).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:11826022,
FT                                ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_017972.
FT   VARIANT     329    329       I -> T (in dbSNP:rs12324002).
FT                                /FTId=VAR_055724.
FT   VARIANT     363    363       G -> S (in dbSNP:rs363855).
FT                                /FTId=VAR_055725.
FT   VARIANT     366    366       W -> C (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017973.
FT   VARIANT     439    439       R -> G (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023863.
FT   VARIANT     472    472       C -> Y (in dbSNP:rs4775765).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7691719,
FT                                ECO:0000269|PubMed:8364578,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_058090.
FT   VARIANT     476    476       C -> G (in MFS).
FT                                /FTId=VAR_002282.
FT   VARIANT     490    490       D -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_002283.
FT   VARIANT     499    499       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065982.
FT   VARIANT     504    504       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:10425041}.
FT                                /FTId=VAR_010776.
FT   VARIANT     507    507       Missing (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023864.
FT   VARIANT     541    541       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023865.
FT   VARIANT     545    545       R -> C (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002284.
FT   VARIANT     548    548       N -> I (in MFS; dbSNP:rs137854462).
FT                                {ECO:0000269|PubMed:8406497}.
FT                                /FTId=VAR_002285.
FT   VARIANT     560    560       G -> S (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017974.
FT   VARIANT     570    570       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017975.
FT   VARIANT     587    587       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:12203992,
FT                                ECO:0000269|PubMed:9254848}.
FT                                /FTId=VAR_002286.
FT   VARIANT     592    592       G -> D (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017976.
FT   VARIANT     596    596       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017977.
FT   VARIANT     598    598       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017978.
FT   VARIANT     611    611       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065983.
FT   VARIANT     617    617       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065984.
FT   VARIANT     627    627       R -> C (in MFS; enhances proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:15161917,
FT                                ECO:0000269|PubMed:16220557,
FT                                ECO:0000269|PubMed:8004112,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002287.
FT   VARIANT     628    628       C -> K (in MFS; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_023866.
FT   VARIANT     629    633       Missing (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023867.
FT   VARIANT     635    635       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023868.
FT   VARIANT     636    636       R -> I (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023869.
FT   VARIANT     652    652       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_017979.
FT   VARIANT     654    654       D -> N (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017980.
FT   VARIANT     661    661       C -> R (in MFS).
FT                                /FTId=VAR_002288.
FT   VARIANT     661    661       C -> Y (in ECTOL1; patient presenting
FT                                also mitral valve prolapse).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017981.
FT   VARIANT     681    681       S -> Y (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017982.
FT   VARIANT     683    683       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017983.
FT   VARIANT     685    685       C -> W (in MFS; dbSNP:rs140603).
FT                                {ECO:0000269|PubMed:12203992,
FT                                ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_017984.
FT   VARIANT     685    685       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065985.
FT   VARIANT     705    705       A -> T (in MFS).
FT                                {ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:8863159}.
FT                                /FTId=VAR_002289.
FT   VARIANT     711    711       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:8863159}.
FT                                /FTId=VAR_002290.
FT   VARIANT     723    723       D -> A (in MFS; dbSNP:rs137854463).
FT                                {ECO:0000269|PubMed:8406497}.
FT                                /FTId=VAR_002291.
FT   VARIANT     723    723       D -> V (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017985.
FT   VARIANT     734    734       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017986.
FT   VARIANT     746    746       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002292.
FT   VARIANT     748    748       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017987.
FT   VARIANT     750    750       C -> G (in MFS; enhances proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:15161917,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002293.
FT   VARIANT     776    776       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017988.
FT   VARIANT     776    776       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017989.
FT   VARIANT     781    781       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017990.
FT   VARIANT     781    781       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023870.
FT   VARIANT     790    790       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065986.
FT   VARIANT     811    811       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065987.
FT   VARIANT     816    816       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_017991.
FT   VARIANT     832    832       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023871.
FT   VARIANT     853    853       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065988.
FT   VARIANT     862    862       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:8281141}.
FT                                /FTId=VAR_002294.
FT   VARIANT     890    890       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023872.
FT   VARIANT     890    890       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_017992.
FT   VARIANT     908    908       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017993.
FT   VARIANT     913    913       E -> G (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017994.
FT   VARIANT     921    921       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_017995.
FT   VARIANT     926    926       C -> R (in MFS; enhances proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:15161917,
FT                                ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002295.
FT   VARIANT     926    926       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065989.
FT   VARIANT     984    984       V -> I (in MFS).
FT                                {ECO:0000269|PubMed:10694921}.
FT                                /FTId=VAR_002296.
FT   VARIANT     985    985       G -> E (in MFS; atypical;
FT                                dbSNP:rs137854477).
FT                                {ECO:0000269|PubMed:10441597}.
FT                                /FTId=VAR_018319.
FT   VARIANT     985    985       G -> R (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_017996.
FT   VARIANT     996    996       C -> R (in MFS; dbSNP:rs140592).
FT                                /FTId=VAR_002297.
FT   VARIANT    1013   1013       G -> R (in MFS; severe neonatal;
FT                                dbSNP:rs140593).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:16220557,
FT                                ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002298.
FT   VARIANT    1023   1023       K -> N (in MFS; severe neonatal).
FT                                {ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002299.
FT   VARIANT    1043   1043       K -> R (in MFS; dbSNP:rs137854472).
FT                                /FTId=VAR_002300.
FT   VARIANT    1044   1044       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_017997.
FT   VARIANT    1048   1048       I -> T (in MFS).
FT                                /FTId=VAR_002301.
FT   VARIANT    1048   1048       I -> V (in dbSNP:rs2229324).
FT                                /FTId=VAR_055726.
FT   VARIANT    1048   1048       Missing (in MFS).
FT                                /FTId=VAR_002302.
FT   VARIANT    1053   1053       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:8882780}.
FT                                /FTId=VAR_002303.
FT   VARIANT    1055   1055       C -> G (in MFS; neonatal).
FT                                {ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:8863159}.
FT                                /FTId=VAR_002304.
FT   VARIANT    1055   1055       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017998.
FT   VARIANT    1055   1055       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_017999.
FT   VARIANT    1058   1058       G -> D (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023873.
FT   VARIANT    1058   1058       G -> GC (in MFS).
FT                                /FTId=VAR_002305.
FT   VARIANT    1068   1068       C -> G (in MFS; neonatal form).
FT                                {ECO:0000269|PubMed:20803651}.
FT                                /FTId=VAR_064503.
FT   VARIANT    1072   1072       D -> G (in MFS).
FT                                {ECO:0000269|PubMed:8882780}.
FT                                /FTId=VAR_002306.
FT   VARIANT    1073   1073       E -> K (in MFS; severe neonatal;
FT                                dbSNP:rs137854478).
FT                                {ECO:0000269|PubMed:7611299,
FT                                ECO:0000269|PubMed:8882780}.
FT                                /FTId=VAR_002307.
FT   VARIANT    1074   1074       C -> R (in MFS; severe neonatal;
FT                                dbSNP:rs137854465).
FT                                {ECO:0000269|PubMed:8136837,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002308.
FT   VARIANT    1086   1086       C -> W (in MFS).
FT                                /FTId=VAR_002309.
FT   VARIANT    1090   1090       P -> S (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065990.
FT   VARIANT    1101   1101       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018000.
FT   VARIANT    1113   1113       D -> G (in dbSNP:rs140597).
FT                                /FTId=VAR_055727.
FT   VARIANT    1113   1113       D -> V (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023874.
FT   VARIANT    1117   1117       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:8882780}.
FT                                /FTId=VAR_002310.
FT   VARIANT    1117   1117       C -> Y (in MFS; dbSNP:rs137854470).
FT                                {ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:8281141}.
FT                                /FTId=VAR_002311.
FT   VARIANT    1127   1127       G -> S (in MFS; mild form;
FT                                dbSNP:rs137854468).
FT                                {ECO:0000269|PubMed:7762551}.
FT                                /FTId=VAR_002312.
FT   VARIANT    1128   1128       V -> I (in a patient with mitral valve
FT                                prolapse). {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018001.
FT   VARIANT    1129   1129       C -> Y (in MFS; dbSNP:rs137854482).
FT                                {ECO:0000269|PubMed:10425041}.
FT                                /FTId=VAR_010777.
FT   VARIANT    1131   1131       N -> Y (in MFS; dbSNP:rs137854473).
FT                                /FTId=VAR_002313.
FT   VARIANT    1137   1137       R -> P (in MFS; dbSNP:rs137854456).
FT                                {ECO:0000269|PubMed:1852208,
FT                                ECO:0000269|PubMed:8281141}.
FT                                /FTId=VAR_002314.
FT   VARIANT    1148   1148       P -> A (in dbSNP:rs140598).
FT                                {ECO:0000269|PubMed:20547088,
FT                                ECO:0000269|PubMed:8281141,
FT                                ECO:0000269|PubMed:8988160,
FT                                ECO:0000269|PubMed:9150726,
FT                                ECO:0000269|PubMed:9338588}.
FT                                /FTId=VAR_002315.
FT   VARIANT    1153   1153       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023875.
FT   VARIANT    1153   1153       C -> Y (in MFS; severe; dbSNP:rs140599).
FT                                {ECO:0000269|PubMed:14695540,
FT                                ECO:0000269|PubMed:8863159}.
FT                                /FTId=VAR_002316.
FT   VARIANT    1155   1155       D -> N (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_002317.
FT   VARIANT    1170   1170       R -> H (in MFS; mild; dbSNP:rs137854475).
FT                                {ECO:0000269|PubMed:7870075,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002318.
FT   VARIANT    1171   1171       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002319.
FT   VARIANT    1173   1173       N -> K (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002320.
FT   VARIANT    1185   1185       G -> D (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065991.
FT   VARIANT    1200   1200       E -> G (in MFS).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_018002.
FT   VARIANT    1211   1211       Missing (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023876.
FT   VARIANT    1219   1219       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023877.
FT   VARIANT    1223   1223       C -> Y (in MFS; also found in a patient
FT                                with Shprintzen-Goldberg craniosynostosis
FT                                syndrome; dbSNP:rs137854469).
FT                                {ECO:0000269|PubMed:8071963,
FT                                ECO:0000269|Ref.43}.
FT                                /FTId=VAR_002321.
FT   VARIANT    1242   1242       C -> Y (in MFS; dbSNP:rs137854471).
FT                                {ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002322.
FT   VARIANT    1249   1249       C -> S (in MFS; dbSNP:rs137854458).
FT                                {ECO:0000269|PubMed:1301946}.
FT                                /FTId=VAR_002323.
FT   VARIANT    1261   1261       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:10425041}.
FT                                /FTId=VAR_010778.
FT   VARIANT    1261   1261       Y -> D (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023878.
FT   VARIANT    1265   1265       C -> R (in MFS; dbSNP:rs137854474).
FT                                {ECO:0000269|PubMed:9837823}.
FT                                /FTId=VAR_018320.
FT   VARIANT    1278   1278       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023879.
FT   VARIANT    1282   1282       N -> S (in dbSNP:rs140647).
FT                                /FTId=VAR_055728.
FT   VARIANT    1284   1284       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023880.
FT   VARIANT    1284   1284       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065992.
FT   VARIANT    1325   1325       E -> Q (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018003.
FT   VARIANT    1333   1333       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023881.
FT   VARIANT    1337   1337       A -> P (in MFS; neonatal).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018004.
FT   VARIANT    1339   1339       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018005.
FT   VARIANT    1350   1350       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065993.
FT   VARIANT    1366   1366       E -> K (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018006.
FT   VARIANT    1374   1374       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018007.
FT   VARIANT    1382   1382       N -> S (in MFS).
FT                                {ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002324.
FT   VARIANT    1389   1389       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018008.
FT   VARIANT    1394   1396       Missing (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018009.
FT   VARIANT    1401   1401       T -> A (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065994.
FT   VARIANT    1402   1402       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023882.
FT   VARIANT    1404   1404       D -> Y (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002325.
FT   VARIANT    1424   1424       P -> A (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018010.
FT   VARIANT    1424   1424       P -> S (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023883.
FT   VARIANT    1429   1429       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018011.
FT   VARIANT    1431   1431       C -> W (in MFS; dbSNP:rs112375043).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065995.
FT   VARIANT    1431   1431       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065996.
FT   VARIANT    1475   1475       G -> E (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023884.
FT   VARIANT    1475   1475       G -> S (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023885.
FT   VARIANT    1481   1481       S -> G (in dbSNP:rs61730054).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065997.
FT   VARIANT    1487   1487       D -> A (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065998.
FT   VARIANT    1489   1489       N -> K (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_065999.
FT   VARIANT    1513   1513       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002326.
FT   VARIANT    1530   1530       R -> C (found in patients with ectopia
FT                                lensis; dbSNP:rs111401431).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018012.
FT   VARIANT    1564   1564       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023886.
FT   VARIANT    1564   1564       C -> S (in SSKS).
FT                                {ECO:0000269|PubMed:20375004}.
FT                                /FTId=VAR_064046.
FT   VARIANT    1564   1564       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018013.
FT   VARIANT    1570   1570       W -> C (in SSKS).
FT                                {ECO:0000269|PubMed:20375004}.
FT                                /FTId=VAR_064047.
FT   VARIANT    1576   1576       M -> T (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023887.
FT   VARIANT    1577   1577       C -> G (in SSKS).
FT                                {ECO:0000269|PubMed:20375004}.
FT                                /FTId=VAR_064048.
FT   VARIANT    1589   1589       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:8281141}.
FT                                /FTId=VAR_002327.
FT   VARIANT    1594   1594       G -> D (in SSKS).
FT                                {ECO:0000269|PubMed:20375004}.
FT                                /FTId=VAR_064049.
FT   VARIANT    1610   1610       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002328.
FT   VARIANT    1631   1631       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023888.
FT   VARIANT    1663   1663       C -> R (in MFS; dbSNP:rs137854459).
FT                                {ECO:0000269|PubMed:1301946}.
FT                                /FTId=VAR_002329.
FT   VARIANT    1663   1663       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023889.
FT   VARIANT    1672   1672       C -> F (in dbSNP:rs140627).
FT                                /FTId=VAR_055729.
FT   VARIANT    1692   1699       Missing (in WMS2).
FT                                {ECO:0000269|PubMed:12525539}.
FT                                /FTId=VAR_018014.
FT   VARIANT    1696   1696       Y -> C (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066527.
FT   VARIANT    1699   1699       Y -> C (in GPHYSD2 and ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066528.
FT   VARIANT    1699   1699       Y -> D (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066529.
FT   VARIANT    1700   1700       Y -> C (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066530.
FT   VARIANT    1706   1706       C -> Y (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066531.
FT   VARIANT    1714   1714       M -> R (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066532.
FT   VARIANT    1719   1719       C -> W (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066533.
FT   VARIANT    1722   1722       S -> C (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066534.
FT   VARIANT    1726   1726       G -> V (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066535.
FT   VARIANT    1728   1728       A -> T (in GPHYSD2 and ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066536.
FT   VARIANT    1728   1728       A -> V (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066537.
FT   VARIANT    1733   1733       C -> Y (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066538.
FT   VARIANT    1735   1735       Q -> QQ (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066539.
FT   VARIANT    1750   1750       S -> R (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066540.
FT   VARIANT    1758   1758       D -> V (in ACMICD).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066541.
FT   VARIANT    1762   1762       G -> S (in GPHYSD2).
FT                                {ECO:0000269|PubMed:21683322}.
FT                                /FTId=VAR_066542.
FT   VARIANT    1770   1770       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018015.
FT   VARIANT    1790   1790       R -> P (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018016.
FT   VARIANT    1791   1791       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023890.
FT   VARIANT    1791   1791       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018017.
FT   VARIANT    1793   1793       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018018.
FT   VARIANT    1796   1796       G -> E (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018019.
FT   VARIANT    1806   1806       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018020.
FT   VARIANT    1806   1806       C -> Y (in MFS).
FT                                /FTId=VAR_023891.
FT   VARIANT    1833   1833       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:10425041}.
FT                                /FTId=VAR_010779.
FT   VARIANT    1835   1835       C -> Y (in MFS; dbSNP:rs111929350).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_018021.
FT   VARIANT    1837   1837       P -> S (in MFS).
FT                                /FTId=VAR_002330.
FT   VARIANT    1838   1838       G -> C (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066000.
FT   VARIANT    1876   1876       C -> Y (in MFS; dbSNP:rs112728248).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023892.
FT   VARIANT    1887   1887       T -> I (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023893.
FT   VARIANT    1893   1893       N -> K (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002331.
FT   VARIANT    1895   1895       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023894.
FT   VARIANT    1900   1900       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16222657,
FT                                ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_023895.
FT   VARIANT    1909   1909       I -> T (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_018022.
FT   VARIANT    1915   1915       R -> S (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018023.
FT   VARIANT    1928   1928       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023896.
FT   VARIANT    1928   1928       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:7611299}.
FT                                /FTId=VAR_002332.
FT   VARIANT    1928   1928       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023897.
FT   VARIANT    1931   1931       Missing (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018024.
FT   VARIANT    1934   1934       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066001.
FT   VARIANT    1971   1971       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018025.
FT   VARIANT    1976   1976       E -> G (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066002.
FT   VARIANT    1977   1977       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018026.
FT   VARIANT    1984   1984       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066003.
FT   VARIANT    1998   1998       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018027.
FT   VARIANT    2018   2018       V -> I (in dbSNP:rs363802).
FT                                /FTId=VAR_055730.
FT   VARIANT    2038   2038       C -> Y (in MFS; dbSNP:rs363804).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023898.
FT   VARIANT    2053   2053       C -> F (in dbSNP:rs363805).
FT                                /FTId=VAR_055731.
FT   VARIANT    2085   2085       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023899.
FT   VARIANT    2099   2099       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002333.
FT   VARIANT    2101   2101       T -> M (in dbSNP:rs200816828).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018028.
FT   VARIANT    2111   2111       C -> R (in MFS; dbSNP:rs363815).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_018029.
FT   VARIANT    2111   2111       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002334.
FT   VARIANT    2113   2113       Y -> F (in dbSNP:rs363816).
FT                                /FTId=VAR_055732.
FT   VARIANT    2127   2127       D -> E (in MFS).
FT                                {ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002335.
FT   VARIANT    2142   2142       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:10425041}.
FT                                /FTId=VAR_010780.
FT   VARIANT    2144   2144       N -> S (in MFS; dbSNP:rs137854461).
FT                                {ECO:0000269|PubMed:16220557,
FT                                ECO:0000269|PubMed:8504310}.
FT                                /FTId=VAR_002336.
FT   VARIANT    2151   2151       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002337.
FT   VARIANT    2154   2154       P -> R (in ECTOL1).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018030.
FT   VARIANT    2160   2160       A -> P (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023900.
FT   VARIANT    2166   2166       D -> N (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066004.
FT   VARIANT    2170   2170       C -> F (in dbSNP:rs363821).
FT                                /FTId=VAR_055733.
FT   VARIANT    2185   2185       I -> T (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066005.
FT   VARIANT    2221   2221       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023901.
FT   VARIANT    2221   2221       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018031.
FT   VARIANT    2221   2221       C -> S (in MFS; dbSNP:rs137854460).
FT                                {ECO:0000269|PubMed:1301946}.
FT                                /FTId=VAR_002338.
FT   VARIANT    2223   2223       N -> H (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018032.
FT   VARIANT    2247   2247       D -> G (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066006.
FT   VARIANT    2251   2251       C -> R (in MFS; dbSNP:rs112836174).
FT                                /FTId=VAR_023902.
FT   VARIANT    2258   2258       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002339.
FT   VARIANT    2269   2269       I -> T (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018033.
FT   VARIANT    2278   2278       P -> S (in dbSNP:rs363835).
FT                                /FTId=VAR_055734.
FT   VARIANT    2282   2282       R -> W (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002340.
FT   VARIANT    2307   2307       C -> S (in MFS; dbSNP:rs137854457).
FT                                {ECO:0000269|PubMed:1301946,
FT                                ECO:0000269|PubMed:1569206}.
FT                                /FTId=VAR_002341.
FT   VARIANT    2318   2318       C -> R (in MFS; dbSNP:rs111588631).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066007.
FT   VARIANT    2329   2329       D -> E (in dbSNP:rs363831).
FT                                /FTId=VAR_055735.
FT   VARIANT    2335   2335       R -> W (in MFS).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018034.
FT   VARIANT    2339   2339       C -> Y (in ECTOL1; patient presenting
FT                                also flat corneas).
FT                                {ECO:0000269|PubMed:12203992}.
FT                                /FTId=VAR_018035.
FT   VARIANT    2385   2385       A -> T (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023903.
FT   VARIANT    2406   2406       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_018036.
FT   VARIANT    2442   2442       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066008.
FT   VARIANT    2442   2442       C -> W (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018037.
FT   VARIANT    2447   2447       E -> K (in ECTOL1; dbSNP:rs137854464).
FT                                {ECO:0000269|PubMed:8136837,
FT                                ECO:0000269|PubMed:8188302}.
FT                                /FTId=VAR_002342.
FT   VARIANT    2474   2474       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_018038.
FT   VARIANT    2489   2489       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:9338581}.
FT                                /FTId=VAR_002343.
FT   VARIANT    2500   2500       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023904.
FT   VARIANT    2500   2500       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023905.
FT   VARIANT    2511   2511       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:21542060,
FT                                ECO:0000269|PubMed:8136837}.
FT                                /FTId=VAR_002344.
FT   VARIANT    2535   2535       C -> W (in MFS; dbSNP:rs113544411).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023906.
FT   VARIANT    2536   2536       G -> R (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023907.
FT   VARIANT    2570   2570       E -> K (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023908.
FT   VARIANT    2571   2571       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023909.
FT   VARIANT    2581   2581       C -> F (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018039.
FT   VARIANT    2585   2585       I -> T (in MFS).
FT                                {ECO:0000269|PubMed:11700157,
FT                                ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_018040.
FT   VARIANT    2592   2592       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023910.
FT   VARIANT    2605   2605       C -> R (in MFS).
FT                                /FTId=VAR_023911.
FT   VARIANT    2605   2605       C -> Y (in MFS).
FT                                {ECO:0000269|PubMed:16220557}.
FT                                /FTId=VAR_023912.
FT   VARIANT    2606   2606       Missing (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066009.
FT   VARIANT    2610   2610       E -> K (in MFS; unclear pathological
FT                                significance; dbSNP:rs111984349).
FT                                {ECO:0000269|PubMed:16222657,
FT                                ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_023913.
FT   VARIANT    2618   2618       G -> R (in MFS; dbSNP:rs141133182).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018041.
FT   VARIANT    2623   2623       H -> P (in MFS).
FT                                {ECO:0000269|PubMed:14695540}.
FT                                /FTId=VAR_002345.
FT   VARIANT    2624   2624       N -> K (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018042.
FT   VARIANT    2627   2627       G -> R (in MFS).
FT                                {ECO:0000269|PubMed:7977366}.
FT                                /FTId=VAR_002346.
FT   VARIANT    2629   2629       Y -> C (in MFS).
FT                                {ECO:0000269|PubMed:16222657}.
FT                                /FTId=VAR_023914.
FT   VARIANT    2646   2646       C -> R (in MFS).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066010.
FT   VARIANT    2652   2652       C -> G (in MFS).
FT                                {ECO:0000269|PubMed:11826022}.
FT                                /FTId=VAR_018043.
FT   VARIANT    2663   2663       C -> S (in MFS).
FT                                {ECO:0000269|PubMed:15221638}.
FT                                /FTId=VAR_023915.
FT   VARIANT    2668   2668       G -> C (in MFS).
FT                                {ECO:0000269|PubMed:11700157}.
FT                                /FTId=VAR_018044.
FT   VARIANT    2680   2680       R -> C (in MFS).
FT                                /FTId=VAR_002347.
FT   VARIANT    2726   2726       R -> W (in MFS; defects in protein
FT                                processing; dbSNP:rs61746008).
FT                                {ECO:0000269|PubMed:7738200}.
FT                                /FTId=VAR_002348.
FT   VARIANT    2793   2793       Y -> H (found in a patient with Marfan
FT                                syndrome; unclear pathological
FT                                significance; dbSNP:rs113722038).
FT                                {ECO:0000269|PubMed:21542060}.
FT                                /FTId=VAR_066011.
FT   CONFLICT    207    207       T -> Q (in Ref. 1; AAB02036).
FT                                {ECO:0000305}.
FT   CONFLICT   2158   2158       I -> T (in Ref. 1; AAB02036 and 7;
FT                                CAA45118). {ECO:0000305}.
FT   STRAND       50     52       {ECO:0000244|PDB:2M74}.
FT   STRAND       54     56       {ECO:0000244|PDB:2M74}.
FT   STRAND       58     60       {ECO:0000244|PDB:2M74}.
FT   STRAND       92     96       {ECO:0000244|PDB:2M74}.
FT   STRAND       99    101       {ECO:0000244|PDB:2M74}.
FT   STRAND      107    110       {ECO:0000244|PDB:2M74}.
FT   TURN        118    120       {ECO:0000244|PDB:2M74}.
FT   TURN        142    145       {ECO:0000244|PDB:2M74}.
FT   STRAND      155    157       {ECO:0000244|PDB:2M74}.
FT   STRAND      159    162       {ECO:0000244|PDB:2M74}.
FT   STRAND      165    167       {ECO:0000244|PDB:2M74}.
FT   STRAND      174    176       {ECO:0000244|PDB:2M74}.
FT   HELIX       810    813       {ECO:0000244|PDB:2W86}.
FT   STRAND      819    824       {ECO:0000244|PDB:2W86}.
FT   STRAND      827    831       {ECO:0000244|PDB:2W86}.
FT   STRAND      836    838       {ECO:0000244|PDB:2W86}.
FT   STRAND      842    847       {ECO:0000244|PDB:2W86}.
FT   STRAND      851    858       {ECO:0000244|PDB:2W86}.
FT   STRAND      861    870       {ECO:0000244|PDB:2W86}.
FT   HELIX       872    876       {ECO:0000244|PDB:2W86}.
FT   TURN        877    879       {ECO:0000244|PDB:2W86}.
FT   STRAND      881    883       {ECO:0000244|PDB:2W86}.
FT   TURN        884    887       {ECO:0000244|PDB:2W86}.
FT   TURN        894    896       {ECO:0000244|PDB:2W86}.
FT   STRAND      900    904       {ECO:0000244|PDB:2W86}.
FT   STRAND      907    910       {ECO:0000244|PDB:2W86}.
FT   HELIX       913    916       {ECO:0000244|PDB:2W86}.
FT   STRAND      921    929       {ECO:0000244|PDB:2W86}.
FT   STRAND      932    936       {ECO:0000244|PDB:2W86}.
FT   TURN       1073   1076       {ECO:0000244|PDB:1LMJ}.
FT   TURN       1080   1083       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1086   1089       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1092   1095       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1099   1103       {ECO:0000244|PDB:1LMJ}.
FT   TURN       1105   1107       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1108   1113       {ECO:0000244|PDB:1LMJ}.
FT   HELIX      1116   1119       {ECO:0000244|PDB:1LMJ}.
FT   TURN       1123   1126       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1127   1132       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1135   1140       {ECO:0000244|PDB:1LMJ}.
FT   STRAND     1148   1150       {ECO:0000244|PDB:1LMJ}.
FT   HELIX      1490   1492       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1496   1498       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1500   1505       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1508   1512       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1523   1527       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1532   1537       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1544   1546       {ECO:0000244|PDB:1UZJ}.
FT   STRAND     1550   1557       {ECO:0000244|PDB:1UZK}.
FT   HELIX      1559   1563       {ECO:0000244|PDB:1UZK}.
FT   TURN       1564   1566       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1568   1570       {ECO:0000244|PDB:1UZP}.
FT   TURN       1571   1574       {ECO:0000244|PDB:1UZK}.
FT   HELIX      1583   1588       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1595   1597       {ECO:0000244|PDB:1UZK}.
FT   TURN       1599   1601       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1604   1606       {ECO:0000244|PDB:1UZK}.
FT   HELIX      1609   1612       {ECO:0000244|PDB:1UZK}.
FT   HELIX      1614   1617       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1620   1624       {ECO:0000244|PDB:1UZK}.
FT   STRAND     1629   1632       {ECO:0000244|PDB:1UZK}.
FT   TURN       1641   1643       {ECO:0000244|PDB:1UZK}.
FT   HELIX      2054   2056       {ECO:0000244|PDB:1APJ}.
FT   STRAND     2061   2065       {ECO:0000244|PDB:1APJ}.
FT   STRAND     2070   2073       {ECO:0000244|PDB:1APJ}.
FT   HELIX      2080   2084       {ECO:0000244|PDB:1APJ}.
FT   STRAND     2090   2092       {ECO:0000244|PDB:1APJ}.
FT   TURN       2093   2096       {ECO:0000244|PDB:1APJ}.
FT   HELIX      2105   2110       {ECO:0000244|PDB:1APJ}.
FT   STRAND     2130   2133       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2138   2142       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2157   2160       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2163   2166       {ECO:0000244|PDB:1EMN}.
FT   HELIX      2169   2171       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2177   2179       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2181   2183       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2185   2190       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2193   2196       {ECO:0000244|PDB:1EMN}.
FT   STRAND     2200   2202       {ECO:0000244|PDB:1EMN}.
SQ   SEQUENCE   2871 AA;  312237 MW;  3E6BEF0F1E9A479F CRC64;
     MRRGRLLEIA LGFTVLLASY TSHGADANLE AGNVKETRAS RAKRRGGGGH DALKGPNVCG
     SRYNAYCCPG WKTLPGGNQC IVPICRHSCG DGFCSRPNMC TCPSGQIAPS CGSRSIQHCN
     IRCMNGGSCS DDHCLCQKGY IGTHCGQPVC ESGCLNGGRC VAPNRCACTY GFTGPQCERD
     YRTGPCFTVI SNQMCQGQLS GIVCTKTLCC ATVGRAWGHP CEMCPAQPHP CRRGFIPNIR
     TGACQDVDEC QAIPGLCQGG NCINTVGSFE CKCPAGHKLN EVSQKCEDID ECSTIPGICE
     GGECTNTVSS YFCKCPPGFY TSPDGTRCID VRPGYCYTAL TNGRCSNQLP QSITKMQCCC
     DAGRCWSPGV TVAPEMCPIR ATEDFNKLCS VPMVIPGRPE YPPPPLGPIP PVLPVPPGFP
     PGPQIPVPRP PVEYLYPSRE PPRVLPVNVT DYCQLVRYLC QNGRCIPTPG SCRCECNKGF
     QLDLRGECID VDECEKNPCA GGECINNQGS YTCQCRAGYQ STLTRTECRD IDECLQNGRI
     CNNGRCINTD GSFHCVCNAG FHVTRDGKNC EDMDECSIRN MCLNGMCINE DGSFKCICKP
     GFQLASDGRY CKDINECETP GICMNGRCVN TDGSYRCECF PGLAVGLDGR VCVDTHMRST
     CYGGYKRGQC IKPLFGAVTK SECCCASTEY AFGEPCQPCP AQNSAEYQAL CSSGPGMTSA
     GSDINECALD PDICPNGICE NLRGTYKCIC NSGYEVDSTG KNCVDINECV LNSLLCDNGQ
     CRNTPGSFVC TCPKGFIYKP DLKTCEDIDE CESSPCINGV CKNSPGSFIC ECSSESTLDP
     TKTICIETIK GTCWQTVIDG RCEININGAT LKSQCCSSLG AAWGSPCTLC QVDPICGKGY
     SRIKGTQCED IDECEVFPGV CKNGLCVNTR GSFKCQCPSG MTLDATGRIC LDIRLETCFL
     RYEDEECTLP IAGRHRMDAC CCSVGAAWGT EECEECPMRN TPEYEELCPR GPGFATKEIT
     NGKPFFKDIN ECKMIPSLCT HGKCRNTIGS FKCRCDSGFA LDSEERNCTD IDECRISPDL
     CGRGQCVNTP GDFECKCDEG YESGFMMMKN CMDIDECQRD PLLCRGGVCH NTEGSYRCEC
     PPGHQLSPNI SACIDINECE LSAHLCPNGR CVNLIGKYQC ACNPGYHSTP DRLFCVDIDE
     CSIMNGGCET FCTNSEGSYE CSCQPGFALM PDQRSCTDID ECEDNPNICD GGQCTNIPGE
     YRCLCYDGFM ASEDMKTCVD VNECDLNPNI CLSGTCENTK GSFICHCDMG YSGKKGKTGC
     TDINECEIGA HNCGKHAVCT NTAGSFKCSC SPGWIGDGIK CTDLDECSNG THMCSQHADC
     KNTMGSYRCL CKEGYTGDGF TCTDLDECSE NLNLCGNGQC LNAPGGYRCE CDMGFVPSAD
     GKACEDIDEC SLPNICVFGT CHNLPGLFRC ECEIGYELDR SGGNCTDVNE CLDPTTCISG
     NCVNTPGSYI CDCPPDFELN PTRVGCVDTR SGNCYLDIRP RGDNGDTACS NEIGVGVSKA
     SCCCSLGKAW GTPCEMCPAV NTSEYKILCP GGEGFRPNPI TVILEDIDEC QELPGLCQGG
     KCINTFGSFQ CRCPTGYYLN EDTRVCDDVN ECETPGICGP GTCYNTVGNY TCICPPDYMQ
     VNGGNNCMDM RRSLCYRNYY ADNQTCDGEL LFNMTKKMCC CSYNIGRAWN KPCEQCPIPS
     TDEFATLCGS QRPGFVIDIY TGLPVDIDEC REIPGVCENG VCINMVGSFR CECPVGFFYN
     DKLLVCEDID ECQNGPVCQR NAECINTAGS YRCDCKPGYR FTSTGQCNDR NECQEIPNIC
     SHGQCIDTVG SFYCLCHTGF KTNDDQTMCL DINECERDAC GNGTCRNTIG SFNCRCNHGF
     ILSHNNDCID VDECASGNGN LCRNGQCINT VGSFQCQCNE GYEVAPDGRT CVDINECLLE
     PRKCAPGTCQ NLDGSYRCIC PPGYSLQNEK CEDIDECVEE PEICALGTCS NTEGSFKCLC
     PEGFSLSSSG RRCQDLRMSY CYAKFEGGKC SSPKSRNHSK QECCCALKGE GWGDPCELCP
     TEPDEAFRQI CPYGSGIIVG PDDSAVDMDE CKEPDVCKHG QCINTDGSYR CECPFGYILA
     GNECVDTDEC SVGNPCGNGT CKNVIGGFEC TCEEGFEPGP MMTCEDINEC AQNPLLCAFR
     CVNTYGSYEC KCPVGYVLRE DRRMCKDEDE CEEGKHDCTE KQMECKNLIG TYMCICGPGY
     QRRPDGEGCV DENECQTKPG ICENGRCLNT RGSYTCECND GFTASPNQDE CLDNREGYCF
     TEVLQNMCQI GSSNRNPVTK SECCCDGGRG WGPHCEICPF QGTVAFKKLC PHGRGFMTNG
     ADIDECKVIH DVCRNGECVN DRGSYHCICK TGYTPDITGT SCVDLNECNQ APKPCNFICK
     NTEGSYQCSC PKGYILQEDG RSCKDLDECA TKQHNCQFLC VNTIGGFTCK CPPGFTQHHT
     SCIDNNECTS DINLCGSKGI CQNTPGSFTC ECQRGFSLDQ TGSSCEDVDE CEGNHRCQHG
     CQNIIGGYRC SCPQGYLQHY QWNQCVDENE CLSAHICGGA SCHNTLGSYK CMCPAGFQYE
     QFSGGCQDIN ECGSAQAPCS YGCSNTEGGY LCGCPPGYFR IGQGHCVSGM GMGRGNPEPP
     VSGEMDDNSL SPEACYECKI NGYPKRGRKR RSTNETDASN IEDQSETEAN VSLASWDVEK
     TAIFAFNISH VSNKVRILEL LPALTTLTNH NRYLIESGNE DGFFKINQKE GISYLHFTKK
     KPVAGTYSLQ ISSTPLYKKK ELNQLEDKYD KDYLSGELGD NLKMKIQVLL H
//
ID   FGFR1_HUMAN             Reviewed;         822 AA.
AC   P11362; A8K6T9; A8K8V5; C1KBH8; P17049; Q02063; Q02065; Q14306;
AC   Q14307; Q53H63; Q59H40; Q5BJG2; Q8N685; Q9UD50; Q9UDF0; Q9UDF1;
AC   Q9UDF2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 3.
DT   17-FEB-2016, entry version 216.
DE   RecName: Full=Fibroblast growth factor receptor 1;
DE            Short=FGFR-1;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1379697, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:8622701};
DE   AltName: Full=Basic fibroblast growth factor receptor 1;
DE            Short=BFGFR;
DE            Short=bFGF-R-1;
DE   AltName: Full=Fms-like tyrosine kinase 2;
DE            Short=FLT-2;
DE   AltName: Full=N-sam;
DE   AltName: Full=Proto-oncogene c-Fgr;
DE   AltName: CD_antigen=CD331;
DE   Flags: Precursor;
GN   Name=FGFR1; Synonyms=BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 15).
RC   TISSUE=Placenta;
RX   PubMed=2162671; DOI=10.1016/0006-291X(90)90384-Y;
RA   Itoh N., Terachi T., Ohta M., Seo M.K.;
RT   "The complete amino acid sequence of the shorter form of human basic
RT   fibroblast growth factor receptor deduced from its cDNA.";
RL   Biochem. Biophys. Res. Commun. 169:680-685(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH FGF1 AND
RP   FGF2.
RC   TISSUE=Neonatal brain stem;
RX   PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 15; 17 AND 18).
RX   PubMed=2167437;
RA   Johnson D.E., Lee P.L., Lu J., Williams L.T.;
RT   "Diverse forms of a receptor for acidic and basic fibroblast growth
RT   factors.";
RL   Mol. Cell. Biol. 10:4728-4736(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2159626; DOI=10.1093/nar/18.7.1906;
RA   Isacchi A., Bergonzoni L., Sarmientos P.;
RT   "Complete sequence of a human receptor for acidic and basic fibroblast
RT   growth factors.";
RL   Nucleic Acids Res. 18:1906-1906(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), AND INTERACTION WITH FGF1 AND
RP   FGF2.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=1722683;
RA   Wennstroem S., Sandstroem C., Claesson-Welsh L.;
RT   "cDNA cloning and expression of a human FGF receptor which binds
RT   acidic and basic FGF.";
RL   Growth Factors 4:197-208(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14).
RX   PubMed=1662973;
RA   Kiefer M.C., Baird A., George-Nascimento C., Nguyen T., Mason O.B.,
RA   Boley L.J., Valenzuela P., Barr P.J.;
RT   "Molecular cloning of a human basic fibroblast growth factor receptor
RT   cDNA and expression of a biologically active extracellular domain in a
RT   baculovirus system.";
RL   Growth Factors 5:115-127(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 6; 14; 15 AND 16).
RC   TISSUE=Lung;
RX   PubMed=1650441;
RA   Eisemann A., Ahn J.A., Graziani G., Tronick S.R., Ron D.;
RT   "Alternative splicing generates at least five different isoforms of
RT   the human basic-FGF receptor.";
RL   Oncogene 6:1195-1202(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10;
RP   11; 12 AND 13).
RC   TISSUE=Liver;
RX   PubMed=1846977; DOI=10.1126/science.1846977;
RA   Hou J., Kan M., McKeehan K., McBride G., Adams P., McKeehan W.L.;
RT   "Fibroblast growth factor receptors from liver vary in three
RT   structural domains.";
RL   Science 251:665-668(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1317750;
RA   Hattori Y., Odagiri H., Katoh O., Sakamoto H., Morita T.,
RA   Shimotohno K., Tobinai K., Sugimura T., Terada M.;
RT   "K-sam-related gene, N-sam, encodes fibroblast growth factor receptor
RT   and is expressed in T-lymphocytic tumors.";
RL   Cancer Res. 52:3367-3371(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19), AND ROLE IN DISEASE.
RX   PubMed=20139426; DOI=10.1093/humrep/deq006;
RA   Miura K., Miura S., Yoshiura K., Seminara S., Hamaguchi D.,
RA   Niikawa N., Masuzaki H.;
RT   "A case of Kallmann syndrome carrying a missense mutation in
RT   alternatively spliced exon 8A encoding the immunoglobulin-like domain
RT   IIIb of fibroblast growth factor receptor 1.";
RL   Hum. Reprod. 25:1076-1080(2010).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 14 AND 21).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 14 AND 20).
RC   TISSUE=Brain, and Colon;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-22; ARG-818 AND
RP   CYS-822.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 14 AND 15), AND
RP   VARIANT GLY-213.
RC   TISSUE=Pancreas, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-370 (ISOFORM 15), AND PROTEIN SEQUENCE
RP   OF 22-129 (ISOFORM 15).
RX   PubMed=7520751; DOI=10.1021/bi00200a003;
RA   Pantoliano M.W., Horlick R.A., Springer B.A., Van Dyk D.E., Tobery T.,
RA   Wetmore D.R., Lear J.D., Nahapetian A.T., Bradley J.D., Sisk W.P.;
RT   "Multivalent ligand-receptor binding interactions in the fibroblast
RT   growth factor system produce a cooperative growth factor and heparin
RT   mechanism for receptor dimerization.";
RL   Biochemistry 33:10229-10248(1994).
RN   [17]
RP   PROTEIN SEQUENCE OF 81-100 (ISOFORMS 1/2/4/5/14/16).
RX   PubMed=8074689; DOI=10.1006/bbrc.1994.2203;
RA   Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G.,
RA   Oreste P., Valsasina B., Presta M.;
RT   "Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the
RT   formation of the ternary complex with basic fibroblast growth factor
RT   and soluble FGF receptor-1.";
RL   Biochem. Biophys. Res. Commun. 203:450-458(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 201-822 (ISOFORMS 1/6/10/14/15).
RA   Ruta M., Howk R., Ricca G., Drohan W., Zabelshansky M., Laureys G.,
RA   Barton D.E., Francke U., Schlessinger J., Givol D.;
RT   "A novel protein tyrosine kinase gene whose expression is modulated
RT   during endothelial cell differentiation.";
RL   Oncogene 3:9-15(1988).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-391 (ISOFORMS 17/18),
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-360 (ISOFORMS
RP   1/2/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [GENOMIC DNA /
RP   MRNA] OF 313-360 (ISOFORM 19), AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin fibroblast, and Umbilical vein;
RX   PubMed=1652059;
RA   Johnson D.E., Lu J., Chen H., Werner S., Williams L.T.;
RT   "The human fibroblast growth factor receptor genes: a common
RT   structural arrangement underlies the mechanisms for generating
RT   receptor forms that differ in their third immunoglobulin domain.";
RL   Mol. Cell. Biol. 11:4627-4634(1991).
RN   [20]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1847500;
RA   Gutkind S.J., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J.,
RA   Robbins K.C.;
RT   "A novel c-fgr exon utilized in Epstein-Barr virus-infected B
RT   lymphocytes but not in normal monocytes.";
RL   Mol. Cell. Biol. 11:1500-1507(1991).
RN   [21]
RP   INTERACTION WITH PLCG1.
RX   PubMed=1656221;
RA   Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W.,
RA   Dionne C.A., Jaye M., Rubinstein M., Schlessinger J.;
RT   "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast
RT   growth factor receptor (Flg) is a binding site for the SH2 domain of
RT   phospholipase C-gamma 1.";
RL   Mol. Cell. Biol. 11:5068-5078(1991).
RN   [22]
RP   MUTAGENESIS OF TYR-766, FUNCTION, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, AND INTERACTION WITH PLCG1.
RX   PubMed=1379697; DOI=10.1038/358678a0;
RA   Peters K.G., Marie J., Wilson E., Ives H.E., Escobedo J.,
RA   del Rosario M., Mirda D., Williams L.T.;
RT   "Point mutation of an FGF receptor abolishes phosphatidylinositol
RT   turnover and Ca2+ flux but not mitogenesis.";
RL   Nature 358:678-681(1992).
RN   [23]
RP   MUTAGENESIS OF TYR-766, AND FUNCTION IN CELL PROLIFERATION.
RX   PubMed=1379698; DOI=10.1038/358681a0;
RA   Mohammadi M., Dionne C.A., Li W., Lin N., Spivak T., Honegger A.M.,
RA   Jaye M., Schlessinger J.;
RT   "Point mutation in FGF receptor eliminates phosphatidylinositol
RT   hydrolysis without affecting mitogenesis.";
RL   Nature 358:681-684(1992).
RN   [24]
RP   MUTAGENESIS OF TYR-766, AND SUBCELLULAR LOCATION.
RX   PubMed=7516330;
RA   Sorokin A., Mohammadi M., Huang J., Schlessinger J.;
RT   "Internalization of fibroblast growth factor receptor is inhibited by
RT   a point mutation at tyrosine 766.";
RL   J. Biol. Chem. 269:17056-17061(1994).
RN   [25]
RP   PHOSPHORYLATION AT TYR-463; TYR-583; TYR-585; TYR-653; TYR-654 AND
RP   TYR-730, CATALYTIC ACTIVITY, ENZYME REGULATION, FUNCTION IN
RP   PHOSPHORYLATION OF PLCG1 AND SHC1; ACTIVATION OF MAP KINASES AND
RP   REGULATION OF CELL PROLIFERATION AND DIFFERENTIATION, AND MUTAGENESIS
RP   OF TYR-653 AND TYR-654.
RX   PubMed=8622701;
RA   Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M.,
RA   Schlessinger J.;
RT   "Identification of six novel autophosphorylation sites on fibroblast
RT   growth factor receptor 1 and elucidation of their importance in
RT   receptor activation and signal transduction.";
RL   Mol. Cell. Biol. 16:977-989(1996).
RN   [26]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF5; FGF6, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [27]
RP   CHROMOSOMAL TRANSLOCATION WITH ZMYM2.
RX   PubMed=9716603;
RA   Reiter A., Sohal J., Kulkarni S., Chase A., Macdonald D.H.C.,
RA   Aguiar R.C.T., Goncalves C., Hernandez J.M., Jennings B.A.,
RA   Goldman J.M., Cross N.C.P.;
RT   "Consistent fusion of ZNF198 to the fibroblast growth factor receptor-
RT   1 in the t(8;13)(p11;q12) myeloproliferative syndrome.";
RL   Blood 92:1735-1742(1998).
RN   [28]
RP   INTERACTION WITH FGF1, AND PHOSPHORYLATION.
RX   PubMed=9655399; DOI=10.1038/31741;
RA   DiGabriele A.D., Lax I., Chen D.I., Svahn C.M., Jaye M.,
RA   Schlessinger J., Hendrickson W.A.;
RT   "Structure of a heparin-linked biologically active dimer of fibroblast
RT   growth factor.";
RL   Nature 393:812-817(1998).
RN   [29]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP.
RX   PubMed=9949182;
RA   Popovici C., Zhang B., Gregoire M.-J., Jonveaux P.,
RA   Lafage-Pochitaloff M., Birnbaum D., Pebusque M.-J.;
RT   "The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative
RT   disorder fuses a novel gene, FOP, to fibroblast growth factor receptor
RT   1.";
RL   Blood 93:1381-1389(1999).
RN   [30]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [31]
RP   CHROMOSOMAL TRANSLOCATION WITH CNTRL.
RX   PubMed=10688839;
RA   Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D.,
RA   Rattner J.B., Pebusque M.-J.;
RT   "FGFR1 is fused to the centrosome-associated protein CEP110 in the
RT   8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).";
RL   Blood 95:1788-1796(2000).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2 AND GAB1 AND IN ACTIVATION OF
RP   PIK3R1.
RX   PubMed=11353842; DOI=10.1073/pnas.111114298;
RA   Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., Lax I.;
RT   "Stimulation of phosphatidylinositol 3-kinase by fibroblast growth
RT   factor receptors is mediated by coordinated recruitment of multiple
RT   docking proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6074-6079(2001).
RN   [33]
RP   FUNCTION IN ACTIVATION OF SIGNALING VIA RAS AND MAP KINASES AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2; SHB AND
RP   PTPN11/SHP2, INTERACTION WITH SHB AND FGF2, AND MUTAGENESIS OF
RP   TYR-766.
RX   PubMed=12181353; DOI=10.1091/mbc.E02-02-0103;
RA   Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M.,
RA   Claesson-Welsh L.;
RT   "The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and
RT   regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in
RT   endothelial cells.";
RL   Mol. Biol. Cell 13:2881-2893(2002).
RN   [34]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=15034873; DOI=10.1002/gcc.20023;
RA   Grand E.K., Grand F.H., Chase A.J., Ross F.M., Corcoran M.M.,
RA   Oscier D.G., Cross N.C.P.;
RT   "Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11
RT   myeloproliferative syndrome.";
RL   Genes Chromosomes Cancer 40:78-83(2004).
RN   [35]
RP   FUNCTION IN ACTIVATION OF RPS6KA1 AND CREB1, CATALYTIC ACTIVITY,
RP   INTERACTION WITH RPS6KA1, MUTAGENESIS OF LYS-514, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15117958; DOI=10.1074/jbc.M311144200;
RA   Hu Y., Fang X., Dunham S.M., Prada C., Stachowiak E.K.,
RA   Stachowiak M.K.;
RT   "90-kDa ribosomal S6 kinase is a direct target for the nuclear
RT   fibroblast growth factor receptor 1 (FGFR1): role in FGFR1
RT   signaling.";
RL   J. Biol. Chem. 279:29325-29335(2004).
RN   [36]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-296.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [37]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=16946300; DOI=10.1182/blood-2006-06-026666;
RA   Gu T.-L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J.,
RA   Walters D.K., Wang Y., Rush J., Comb M.J., Druker B.J.,
RA   Polakiewicz R.D.;
RT   "Phosphotyrosine profiling identifies the KG-1 cell line as a model
RT   for the study of FGFR1 fusions in acute myeloid leukemia.";
RL   Blood 108:4202-4204(2006).
RN   [38]
RP   INTERACTION WITH FGF1; FGF8; FGF10; FGF19; FGF21; FGF22 AND FGF23, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [39]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=16481405; DOI=10.1091/mbc.E05-08-0749;
RA   Dunham-Ems S.M., Pudavar H.E., Myers J.M., Maher P.A., Prasad P.N.,
RA   Stachowiak M.K.;
RT   "Factors controlling fibroblast growth factor receptor-1's cytoplasmic
RT   trafficking and its regulation as revealed by FRAP analysis.";
RL   Mol. Biol. Cell 17:2223-2235(2006).
RN   [40]
RP   PHOSPHORYLATION AT TYR-463; TYR-653; TYR-654; TYR-583 AND TYR-585, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16507368; DOI=10.1016/j.molcel.2006.01.022;
RA   Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S.;
RT   "Autophosphorylation of FGFR1 kinase is mediated by a sequential and
RT   precisely ordered reaction.";
RL   Mol. Cell 21:711-717(2006).
RN   [41]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=17389761; DOI=10.1182/blood-2006-12-065615;
RA   Dong S., Kang S., Gu T., Kardar S., Fu H., Lonial S., Khoury H.J.,
RA   Khuri F., Chen J.;
RT   "14-3-3 integrates pro-survival signals mediated by the AKT and MAPK
RT   pathways in ZNF198-FGFR1 transformed hematopoietic cells.";
RL   Blood 110:360-369(2007).
RN   [42]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN REGULATION OF
RP   GLUCOSE UPTAKE IN ADIPOCYTES.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [43]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [44]
RP   UBIQUITINATION, CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN
RP   ACTIVATION OF PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ENZYME
RP   REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.E07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for
RT   its intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [45]
RP   INTERACTION WITH ANOS1.
RX   PubMed=19696444; DOI=10.1074/jbc.M109.049155;
RA   Hu Y., Guimond S.E., Travers P., Cadman S., Hohenester E.,
RA   Turnbull J.E., Kim S.H., Bouloux P.M.;
RT   "Novel mechanisms of fibroblast growth factor receptor 1 regulation by
RT   extracellular matrix protein anosmin-1.";
RL   J. Biol. Chem. 284:29905-29920(2009).
RN   [46]
RP   FUNCTION IN CHROMATIN BINDING AND TRANSCRIPTION REGULATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19261810; DOI=10.1091/mbc.E08-06-0600;
RA   Dunham-Ems S.M., Lee Y.W., Stachowiak E.K., Pudavar H., Claus P.,
RA   Prasad P.N., Stachowiak M.K.;
RT   "Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a
RT   novel mechanism in transcription control.";
RL   Mol. Biol. Cell 20:2401-2412(2009).
RN   [47]
RP   FUNCTION AS PROTO-ONCOGENE, ACTIVE SITE, MUTAGENESIS OF ASN-546 AND
RP   ASP-623, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-463; TYR-653;
RP   TYR-654; TYR-583; TYR-585 AND TYR-730, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND ENZYME REGULATION.
RX   PubMed=19224897; DOI=10.1126/scisignal.2000021;
RA   Lew E.D., Furdui C.M., Anderson K.S., Schlessinger J.;
RT   "The precise sequence of FGF receptor autophosphorylation is
RT   kinetically driven and is disrupted by oncogenic mutations.";
RL   Sci. Signal. 2:RA6-RA6(2009).
RN   [48]
RP   INTERACTION WITH FGF23 AND KLB.
RX   PubMed=19966287; DOI=10.1073/pnas.0902006107;
RA   Goetz R., Nakada Y., Hu M.C., Kurosu H., Wang L., Nakatani T., Shi M.,
RA   Eliseenkova A.V., Razzaque M.S., Moe O.W., Kuro-o M., Mohammadi M.;
RT   "Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by
RT   inhibiting FGF23-FGFR-Klotho complex formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:407-412(2010).
RN   [49]
RP   FUNCTION IN ACTIVATION OF AKT1; PLCG1; MAPK1/ERK2, MAPK3/ERK1 AND MAP
RP   KINASE SIGNALING, FUNCTION IN REGULATION OF NEURONAL DIFFERENTIATION
RP   AND EMBRYONIC DEVELOPMENT, SUBCELLULAR LOCATION, INTERACTION WITH
RP   NEDD4; PLCG1 AND FRS2, UBIQUITINATION, AND DEGRADATION.
RX   PubMed=21765395; DOI=10.1038/emboj.2011.234;
RA   Persaud A., Alberts P., Hayes M., Guettler S., Clarke I., Sicheri F.,
RA   Dirks P., Ciruna B., Rotin D.;
RT   "Nedd4-1 binds and ubiquitylates activated FGFR1 to control its
RT   endocytosis and function.";
RL   EMBO J. 30:3259-3273(2011).
RN   [50]
RP   REVIEW ON ALTERNATIVE SPLICE FORMS; LIGANDS; SIGNALING PATHWAYS AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12141425;
RA   Groth C., Lardelli M.;
RT   "The structure and function of vertebrate fibroblast growth factor
RT   receptor 1.";
RL   Int. J. Dev. Biol. 46:393-400(2002).
RN   [51]
RP   REVIEW ON FUNCTION; ROLE IN DISEASE; SIGNALING PATHWAYS; SUBUNIT;
RP   DOMAIN STRUCTURE; LIGAND SELECTIVITY AND ENZYME REGULATION.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [52]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [53]
RP   REVIEW ON SIGNALING AND ROLE IN KALLMAN SYNDROME.
RX   PubMed=20117945; DOI=10.1016/j.tem.2010.01.004;
RA   Hu Y., Bouloux P.M.;
RT   "Novel insights in FGFR1 regulation: lessons from Kallmann syndrome.";
RL   Trends Endocrinol. Metab. 21:385-393(2010).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 464-762.
RX   PubMed=8752212; DOI=10.1016/S0092-8674(00)80131-2;
RA   Mohammadi M., Schlessinger J., Hubbard S.R.;
RT   "Structure of the FGF receptor tyrosine kinase domain reveals a novel
RT   autoinhibitory mechanism.";
RL   Cell 86:577-587(1996).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 464-762 IN COMPLEX WITH
RP   SU4984.
RX   PubMed=9139660; DOI=10.1126/science.276.5314.955;
RA   Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K.,
RA   Hubbard S.R., Schlessinger J.;
RT   "Structures of the tyrosine kinase domain of fibroblast growth factor
RT   receptor in complex with inhibitors.";
RL   Science 276:955-960(1997).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 141-365 IN COMPLEX WITH FGF1,
RP   FUNCTION, AND DISULFIDE BONDS.
RX   PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 143-364 IN COMPLEX WITH FGF2
RP   AND HEPARIN, AND DISULFIDE BONDS.
RX   PubMed=11030354; DOI=10.1016/S1097-2765(00)00073-3;
RA   Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V.,
RA   Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M.;
RT   "Crystal structure of a ternary FGF-FGFR-heparin complex reveals a
RT   dual role for heparin in FGFR binding and dimerization.";
RL   Mol. Cell 6:743-750(2000).
RN   [58]
RP   STRUCTURE BY NMR OF 38-124.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first Ig-like domain of human fibroblast
RT   growth factor receptor 1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 458-774 IN COMPLEX WITH PLCG1
RP   AND ATP ANALOG, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-653; TYR-654 AND
RP   TYR-766.
RX   PubMed=19665973; DOI=10.1016/j.cell.2009.05.028;
RA   Bae J.H., Lew E.D., Yuzawa S., Tome F., Lax I., Schlessinger J.;
RT   "The selectivity of receptor tyrosine kinase signaling is controlled
RT   by a secondary SH2 domain binding site.";
RL   Cell 138:514-524(2009).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 458-765 OF MUTANT GLU-577,
RP   FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND MUTAGENESIS OF ARG-577.
RX   PubMed=20133753; DOI=10.1073/pnas.0914157107;
RA   Bae J.H., Boggon T.J., Tome F., Mandiyan V., Lax I., Schlessinger J.;
RT   "Asymmetric receptor contact is required for tyrosine
RT   autophosphorylation of fibroblast growth factor receptor in living
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2866-2871(2010).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 461-765 IN COMPLEX WITH ARQ
RP   069, AND ENZYME REGULATION.
RX   PubMed=21454610; DOI=10.1074/jbc.M110.213736;
RA   Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J.,
RA   Chen C.R., Chan T.C., France D.S., Ashwell M.A.;
RT   "A novel mode of protein kinase inhibition exploiting hydrophobic
RT   motifs of autoinhibited kinases: discovery of ATP-independent
RT   inhibitors of fibroblast growth factor receptor.";
RL   J. Biol. Chem. 286:20677-20687(2011).
RN   [62]
RP   VARIANT PS ARG-252.
RX   PubMed=7874169; DOI=10.1038/ng1194-269;
RA   Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A.,
RA   Pulleyn L.J., Rutland P., Reardon W., Malcolm S., Winter R.M.;
RT   "A common mutation in the fibroblast growth factor receptor 1 gene in
RT   Pfeiffer syndrome.";
RL   Nat. Genet. 8:269-274(1994).
RN   [63]
RP   VARIANT TRIGNO1 THR-300.
RX   PubMed=11173846;
RA   Kress W., Petersen B., Collmann H., Grimm T.;
RT   "An unusual FGFR1 mutation (fibroblast growth factor receptor 1
RT   mutation) in a girl with non-syndromic trigonocephaly.";
RL   Cytogenet. Cell Genet. 91:138-140(2000).
RN   [64]
RP   VARIANTS HH2 ASP-97; CYS-99; SER-167; TYR-277; MET-607; ARG-666;
RP   ARG-719 AND SER-772.
RX   PubMed=12627230; DOI=10.1038/ng1122;
RA   Dode C., Levilliers J., Dupont J.-M., De Paepe A., Le Du N.,
RA   Soussi-Yanicostas N., Coimbra R.S., Delmaghani S.,
RA   Compain-Nouaille S., Baverel F., Pecheux C., Le Tessier D., Cruaud C.,
RA   Delpech M., Speleman F., Vermeulen S., Amalfitano A., Bachelot Y.,
RA   Bouchard P., Cabrol S., Carel J.-C., Delemarre-van de Waal H.,
RA   Goulet-Salmon B., Kottler M.-L., Richard O., Sanchez-Franco F.,
RA   Saura R., Young J., Petit C., Hardelin J.-P.;
RT   "Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann
RT   syndrome.";
RL   Nat. Genet. 33:463-465(2003).
RN   [65]
RP   VARIANT HH2 SER-745.
RX   PubMed=15001591; DOI=10.1210/jc.2003-030476;
RA   Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S.,
RA   Minowada S., Shimotsuka A., Shishiba Y., Yokozawa M., Yasuda T.,
RA   Nagasaki K., Hasegawa D., Hasegawa Y., Tachibana K., Naiki Y.,
RA   Horikawa R., Tanaka T., Ogata T.;
RT   "Clinical assessment and mutation analysis of Kallmann syndrome 1
RT   (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in
RT   five families and 18 sporadic patients.";
RL   J. Clin. Endocrinol. Metab. 89:1079-1088(2004).
RN   [66]
RP   VARIANTS OGD ILE-330; CYS-374 AND ARG-381, AND CHARACTERIZATION OF
RP   VARIANT OGD CYS-374.
RX   PubMed=15625620; DOI=10.1086/427956;
RA   White K.E., Cabral J.M., Davis S.I., Fishburn T., Evans W.E.,
RA   Ichikawa S., Fields J., Yu X., Shaw N.J., McLellan N.J., McKeown C.,
RA   FitzPatrick D., Yu K., Ornitz D.M., Econs M.J.;
RT   "Mutations that cause osteoglophonic dysplasia define novel roles for
RT   FGFR1 in bone elongation.";
RL   Am. J. Hum. Genet. 76:361-367(2005).
RN   [67]
RP   VARIANTS HH2 ILE-102; ALA-129; MET-273 AND THR-520.
RX   PubMed=15605412; DOI=10.1002/humu.9298;
RA   Albuisson J., Pecheux C., Carel J.-C., Lacombe D., Leheup B.,
RA   Lapuzina P., Bouchard P., Legius E., Matthijs G., Wasniewska M.,
RA   Delpech M., Young J., Hardelin J.-P., Dode C.;
RT   "Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2).";
RL   Hum. Mutat. 25:98-99(2005).
RN   [68]
RP   VARIANTS HH2 ARG-687 AND SER-745.
RX   PubMed=15845591; DOI=10.1093/humrep/dei052;
RA   Sato N., Hasegawa T., Hori N., Fukami M., Yoshimura Y., Ogata T.;
RT   "Gonadotrophin therapy in Kallmann syndrome caused by heterozygous
RT   mutations of the gene for fibroblast growth factor receptor 1: report
RT   of three families: case report.";
RL   Hum. Reprod. 20:2173-2178(2005).
RN   [69]
RP   VARIANTS OGD ILE-330 AND ARG-381.
RX   PubMed=16470795; DOI=10.1002/ajmg.a.31106;
RA   Farrow E.G., Davis S.I., Mooney S.D., Beighton P., Mascarenhas L.,
RA   Gutierrez Y.R., Pitukcheewanont P., White K.E.;
RT   "Extended mutational analyses of FGFR1 in osteoglophonic dysplasia.";
RL   Am. J. Med. Genet. A 140:537-539(2006).
RN   [70]
RP   VARIANTS HH2 SER-48; PRO-245; TRP-250; VAL-343; LEU-366; SER-722 AND
RP   ILE-795.
RX   PubMed=16882753; DOI=10.1210/jc.2005-2793;
RA   Trarbach E.B., Costa E.M.F., Versiani B., de Castro M.,
RA   Baptista M.T.M., Garmes H.M., de Mendonca B.B., Latronico A.C.;
RT   "Novel fibroblast growth factor receptor 1 mutations in patients with
RT   congenital hypogonadotropic hypogonadism with and without anosmia.";
RL   J. Clin. Endocrinol. Metab. 91:4006-4012(2006).
RN   [71]
RP   VARIANTS HH2 CYS-78; ILE-102; HIS-224; ASP-237; GLN-254; MET-273;
RP   GLY-274 CYS-339; CYS-346; VAL-538; ARG-703 AND SER-703, AND VARIANT
RP   VAL-769.
RX   PubMed=16764984; DOI=10.1016/j.mce.2006.04.021;
RA   Pitteloud N., Meysing A., Quinton R., Acierno J.S. Jr., Dwyer A.A.,
RA   Plummer L., Fliers E., Boepple P., Hayes F., Seminara S., Hughes V.A.,
RA   Ma J., Bouloux P., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause Kallmann
RT   syndrome with a wide spectrum of reproductive phenotypes.";
RL   Mol. Cell. Endocrinol. 254:60-69(2006).
RN   [72]
RP   VARIANTS HH2 SER-178; GLY-622 AND GLN-622.
RX   PubMed=16757108; DOI=10.1016/j.mce.2006.04.006;
RA   Zenaty D., Bretones P., Lambe C., Guemas I., David M., Leger J.,
RA   de Roux N.;
RT   "Paediatric phenotype of Kallmann syndrome due to mutations of
RT   fibroblast growth factor receptor 1 (FGFR1).";
RL   Mol. Cell. Endocrinol. 254:78-83(2006).
RN   [73]
RP   VARIANTS HH2 SER-237; HIS-722 AND LYS-724, AND CHARACTERIZATION OF
RP   VARIANTS HH2 SER-237; HIS-722 AND LYS-724.
RX   PubMed=16606836; DOI=10.1073/pnas.0600962103;
RA   Pitteloud N., Acierno J.S. Jr., Meysing A., Eliseenkova A.V., Ma J.,
RA   Ibrahimi O.A., Metzger D.L., Hayes F.J., Dwyer A.A., Hughes V.A.,
RA   Yialamas M., Hall J.E., Grant E., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause both Kallmann
RT   syndrome and normosmic idiopathic hypogonadotropic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6281-6286(2006).
RN   [74]
RP   VARIANTS HH2 PHE-101; TRP-250; ASP-270; ARG-283; CYS-332; ARG-621;
RP   PHE-685; PHE-693 AND SER-772, AND VARIANTS LYS-77 AND CYS-822.
RX   PubMed=17154279; DOI=10.1002/humu.9470;
RA   Dode C., Fouveaut C., Mortier G., Janssens S., Bertherat J.,
RA   Mahoudeau J., Kottler M.-L., Chabrolle C., Gancel A., Francois I.,
RA   Devriendt K., Wolczynski S., Pugeat M., Pineiro-Garcia A., Murat A.,
RA   Bouchard P., Young J., Delpech M., Hardelin J.-P.;
RT   "Novel FGFR1 sequence variants in Kallmann syndrome, and genetic
RT   evidence that the FGFR1c isoform is required in olfactory bulb and
RT   palate morphogenesis.";
RL   Hum. Mutat. 28:97-98(2007).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-125; THR-252 AND LEU-664.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [76]
RP   VARIANTS HH2 CYS-99; SER-117; ASP-228; THR-239; GLN-250; LEU-470;
RP   ASN-618 AND PRO-671, AND CHARACTERIZATION OF VARIANTS HH2 CYS-99;
RP   SER-117; ASP-228; THR-239; GLN-250; LEU-470; ASN-618 AND PRO-671.
RX   PubMed=19820032; DOI=10.1210/jc.2009-0179;
RA   Raivio T., Sidis Y., Plummer L., Chen H., Ma J., Mukherjee A.,
RA   Jacobson-Dickman E., Quinton R., Van Vliet G., Lavoie H., Hughes V.A.,
RA   Dwyer A., Hayes F.J., Xu S., Sparks S., Kaiser U.B., Mohammadi M.,
RA   Pitteloud N.;
RT   "Impaired fibroblast growth factor receptor 1 signaling as a cause of
RT   normosmic idiopathic hypogonadotropic hypogonadism.";
RL   J. Clin. Endocrinol. Metab. 94:4380-4390(2009).
RN   [77]
RP   VARIANT HH2 GLN-250.
RX   PubMed=21700882; DOI=10.1073/pnas.1102284108;
RA   Tornberg J., Sykiotis G.P., Keefe K., Plummer L., Hoang X., Hall J.E.,
RA   Quinton R., Seminara S.B., Hughes V., Van Vliet G., Van Uum S.,
RA   Crowley W.F., Habuchi H., Kimata K., Pitteloud N., Bulow H.E.;
RT   "Heparan sulfate 6-O-sulfotransferase 1, a gene involved in
RT   extracellular sugar modifications, is mutated in patients with
RT   idiopathic hypogonadotrophic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11524-11529(2011).
RN   [78]
RP   VARIANT HH2 ARG-687.
RX   PubMed=22927827; DOI=10.1371/journal.pgen.1002896;
RA   Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C.,
RA   Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F.,
RA   Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C.,
RA   Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P.,
RA   Prevot V., Dode C.;
RT   "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients
RT   with Kallmann syndrome.";
RL   PLoS Genet. 8:E1002896-E1002896(2012).
RN   [79]
RP   VARIANTS HH2 SER-117; ASP-228; THR-239; GLN-250; SER-342; ARG-348;
RP   LEU-470; THR-483; ASN-618; LYS-670; GLY-692; HIS-722; LYS-724 AND
RP   TYR-768.
RX   PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008;
RA   Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B.,
RA   Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K.,
RA   Niedziela M., Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R.,
RA   Hughes V.A., Kumanov P., Young J., Yialamas M.A., Hall J.E.,
RA   Van Vliet G., Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S.,
RA   Sidis Y., Lage K., Pitteloud N.;
RT   "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in
RT   individuals with congenital hypogonadotropic hypogonadism.";
RL   Am. J. Hum. Genet. 92:725-743(2013).
RN   [80]
RP   INVOLVEMENT IN HRTFDS, AND VARIANTS HRTFDS SER-165; SER-191; ARG-490;
RP   TYR-623; LYS-628 AND TYR-725.
RX   PubMed=23812909; DOI=10.1136/jmedgenet-2013-101603;
RA   Simonis N., Migeotte I., Lambert N., Perazzolo C., de Silva D.C.,
RA   Dimitrov B., Heinrichs C., Janssens S., Kerr B., Mortier G.,
RA   Van Vliet G., Lepage P., Casimir G., Abramowicz M., Smits G.,
RA   Vilain C.;
RT   "FGFR1 mutations cause Hartsfield syndrome, the unique association of
RT   holoprosencephaly and ectrodactyly.";
RL   J. Med. Genet. 50:585-592(2013).
RN   [81]
RP   VARIANT HRTFDS THR-627.
RX   PubMed=24888332; DOI=10.1002/ajmg.a.36621;
RA   Dhamija R., Kirmani S., Wang X., Ferber M.J., Wieben E.D.,
RA   Lazaridis K.N., Babovic-Vuksanovic D.;
RT   "Novel de novo heterozygous FGFR1 mutation in two siblings with
RT   Hartsfield syndrome: A case of gonadal mosaicism.";
RL   Am. J. Med. Genet. A 164:2356-2359(2014).
RN   [82]
RP   VARIANTS HH2 ARG-70; ILE-116; ALA-174; GLN-250 AND ARG-348.
RX   PubMed=25077900; DOI=10.1210/jc.2014-2110;
RA   Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C.,
RA   Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O.,
RA   Perrin L., Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T.,
RA   Lacombe D., Christin-Maitre S., Touraine P., Hieronimus S.,
RA   Dewailly D., Young J., Pugeat M., Hardelin J.P., Dode C.;
RT   "The prevalence of CHD7 missense versus truncating mutations is higher
RT   in patients with Kallmann syndrome than in typical CHARGE patients.";
RL   J. Clin. Endocrinol. Metab. 99:E2138-2143(2014).
RN   [83]
RP   VARIANTS HH2 CYS-4; CYS-96 AND VAL-719, AND VARIANT HH2 THR-353
RP   (ISOFORM 19).
RX   PubMed=26277103; DOI=10.1016/j.fertnstert.2015.07.1142;
RA   Goncalves C., Bastos M., Pignatelli D., Borges T., Araguees J.M.,
RA   Fonseca F., Pereira B.D., Socorro S., Lemos M.C.;
RT   "Novel FGFR1 mutations in Kallmann syndrome and normosmic idiopathic
RT   hypogonadotropic hypogonadism: evidence for the involvement of an
RT   alternatively spliced isoform.";
RL   Fertil. Steril. 0:0-0(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of embryonic development, cell proliferation,
CC       differentiation and migration. Required for normal mesoderm
CC       patterning and correct axial organization during embryonic
CC       development, normal skeletogenesis and normal development of the
CC       gonadotropin-releasing hormone (GnRH) neuronal system.
CC       Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2.
CC       In the nucleus, enhances RPS6KA1 and CREB1 activity and
CC       contributes to the regulation of transcription. FGFR1 signaling is
CC       down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination,
CC       internalization and degradation. {ECO:0000250|UniProtKB:P16092,
CC       ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11353842,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:1379698, ECO:0000269|PubMed:15117958,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19261810,
CC       ECO:0000269|PubMed:19665973, ECO:0000269|PubMed:20133753,
CC       ECO:0000269|PubMed:20139426, ECO:0000269|PubMed:21765395,
CC       ECO:0000269|PubMed:8622701, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
CC       ECO:0000269|PubMed:20133753, ECO:0000269|PubMed:8622701}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by sequential autophosphorylation on tyrosine residues.
CC       Inhibited by ARQ 069; this compound maintains the kinase in an
CC       inactive conformation and inhibits autophosphorylation. Inhibited
CC       by PD173074. {ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:21454610,
CC       ECO:0000269|PubMed:8622701}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF5, FGF6, FGF8, FGF10, FGF19, FGF21, FGF22 and FGF23 (in
CC       vitro) (PubMed:1697263, PubMed:1722683, PubMed:8663044,
CC       PubMed:9655399, PubMed:12181353, PubMed:16597617,
CC       PubMed:17623664). Ligand specificity is determined by tissue-
CC       specific expression of isoforms, and differences in the third Ig-
CC       like domain are crucial for ligand specificity. Affinity for
CC       fibroblast growth factors (FGFs) is increased by heparan sulfate
CC       glycosaminoglycans that function as coreceptors. Likewise, KLB
CC       increases the affinity for FGF19, FGF21 and FGF23
CC       (PubMed:19966287). Interacts (phosphorylated on Tyr-766) with
CC       PLCG1 (via SH2 domains) (PubMed:1656221, PubMed:1379697,
CC       PubMed:21765395). Interacts with FRS2 (PubMed:21765395). Interacts
CC       with RPS6KA1 (PubMed:15117958). Interacts (via C-terminus) with
CC       NEDD4 (via WW3 domain) (PubMed:21765395). Interacts with KL (By
CC       similarity). Interacts with SHB (via SH2 domain)
CC       (PubMed:12181353). Interacts with GRB10 (PubMed:10454568).
CC       Interacts with ANOS1; this interaction does not interfere with
CC       FGF2-binding to FGFR1, but prevents binding of heparin-bound FGF2
CC       (PubMed:19696444). Interacts with SOX2 and SOX3. Interacts with
CC       FLRT1, FLRT2 and FLRT3 (By similarity).
CC       {ECO:0000250|UniProtKB:P16092, ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:12181353, ECO:0000269|PubMed:1379697,
CC       ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:1656221,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:1697263,
CC       ECO:0000269|PubMed:1722683, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:19696444, ECO:0000269|PubMed:19966287,
CC       ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8663044,
CC       ECO:0000269|PubMed:9655399}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1028277, EBI-1028277;
CC       P23352:ANOS1; NbExp=7; IntAct=EBI-1028277, EBI-5272188;
CC       P12830:CDH1; NbExp=3; IntAct=EBI-1028277, EBI-727477;
CC       P46108:CRK; NbExp=2; IntAct=EBI-1028277, EBI-886;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1028277, EBI-491549;
CC       P05230:FGF1; NbExp=3; IntAct=EBI-1028277, EBI-698068;
CC       P09038:FGF2; NbExp=4; IntAct=EBI-1028277, EBI-977447;
CC       O88900:Grb14 (xeno); NbExp=3; IntAct=EBI-1028277, EBI-7639197;
CC       P08908:HTR1A; NbExp=11; IntAct=EBI-1028277, EBI-6570214;
CC       P46934:NEDD4; NbExp=26; IntAct=EBI-1028277, EBI-726944;
CC       Q8IVI9:NOSTRIN; NbExp=5; IntAct=EBI-1028277, EBI-1391643;
CC       P27986:PIK3R1; NbExp=5; IntAct=EBI-1028277, EBI-79464;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-1028277, EBI-79387;
CC       P10686:Plcg1 (xeno); NbExp=4; IntAct=EBI-1028277, EBI-520788;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Nucleus. Cytoplasm, cytosol. Cytoplasmic vesicle.
CC       Note=After ligand binding, both receptor and ligand are rapidly
CC       internalized. Can translocate to the nucleus after
CC       internalization, or by translocation from the endoplasmic
CC       reticulum or Golgi apparatus to the cytosol, and from there to the
CC       nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=21;
CC       Name=1; Synonyms=Alpha A1, IV;
CC         IsoId=P11362-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha A2;
CC         IsoId=P11362-8; Sequence=VSP_009842, VSP_009843;
CC       Name=3; Synonyms=Alpha A3;
CC         IsoId=P11362-17; Sequence=VSP_009836, VSP_009837;
CC       Name=4; Synonyms=Alpha B1;
CC         IsoId=P11362-2; Sequence=VSP_002960;
CC       Name=5; Synonyms=Alpha B2;
CC         IsoId=P11362-9; Sequence=VSP_002960, VSP_009842, VSP_009843;
CC       Name=6; Synonyms=Beta A1, II, H2;
CC         IsoId=P11362-3; Sequence=VSP_002958;
CC       Name=7; Synonyms=Beta A2;
CC         IsoId=P11362-10; Sequence=VSP_002958, VSP_009842, VSP_009843;
CC       Name=8; Synonyms=Beta B1;
CC         IsoId=P11362-4; Sequence=VSP_002958, VSP_002960;
CC       Name=9; Synonyms=Beta B2;
CC         IsoId=P11362-11; Sequence=VSP_002958, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=10; Synonyms=Gamma A1;
CC         IsoId=P11362-5; Sequence=VSP_002957;
CC       Name=11; Synonyms=Gamma A2;
CC         IsoId=P11362-12; Sequence=VSP_002957, VSP_009842, VSP_009843;
CC       Name=12; Synonyms=Gamma B1;
CC         IsoId=P11362-6; Sequence=VSP_002957, VSP_002960;
CC       Name=13; Synonyms=Gamma B2;
CC         IsoId=P11362-13; Sequence=VSP_002957, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=14; Synonyms=A, III;
CC         IsoId=P11362-7; Sequence=VSP_002959;
CC       Name=15; Synonyms=I, H3;
CC         IsoId=P11362-14; Sequence=VSP_002958, VSP_002959;
CC       Name=16; Synonyms=V;
CC         IsoId=P11362-15; Sequence=VSP_009838, VSP_009839;
CC       Name=17; Synonyms=H4;
CC         IsoId=P11362-16; Sequence=VSP_002958, VSP_009840, VSP_009841;
CC       Name=18; Synonyms=H5;
CC         IsoId=P11362-18; Sequence=VSP_002958, VSP_002959, VSP_009840,
CC                                   VSP_009841;
CC       Name=19;
CC         IsoId=P11362-19; Sequence=VSP_038470, VSP_002959, VSP_038471;
CC         Note=Variant in position: 353:A->T (in HH2, unknown pathological
CC         significance). {ECO:0000269|PubMed:26277103};
CC       Name=20;
CC         IsoId=P11362-20; Sequence=VSP_041916, VSP_041918;
CC       Name=21;
CC         IsoId=P11362-21; Sequence=VSP_041917, VSP_002959;
CC   -!- TISSUE SPECIFICITY: Detected in astrocytoma, neuroblastoma and
CC       adrenal cortex cell lines. Some isoforms are detected in foreskin
CC       fibroblast cell lines, however isoform 17, isoform 18 and isoform
CC       19 are not detected in these cells. {ECO:0000269|PubMed:1652059}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. Isoforms lacking the first Ig-like domain have
CC       higher affinity for fibroblast growth factors (FGF) and heparan
CC       sulfate proteoglycans than isoforms with all three Ig-like
CC       domains.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer and proceeds in a highly ordered manner.
CC       Initial autophosphorylation at Tyr-653 increases the kinase
CC       activity by a factor of 50 to 100. After this, Tyr-583 becomes
CC       phosphorylated, followed by phosphorylation of Tyr-463, Tyr-766,
CC       Tyr-583 and Tyr-585. In a third stage, Tyr-654 is
CC       autophosphorylated, resulting in a further tenfold increase of
CC       kinase activity. Phosphotyrosine residues provide docking sites
CC       for interacting proteins and so are crucial for FGFR1 function and
CC       its regulation. {ECO:0000269|PubMed:16507368,
CC       ECO:0000269|PubMed:19224897, ECO:0000269|PubMed:19665973,
CC       ECO:0000269|PubMed:8622701}.
CC   -!- PTM: Ubiquitinated. FGFR1 is rapidly ubiquitinated by NEDD4 after
CC       autophosphorylation, leading to internalization and lysosomal
CC       degradation. CBL is recruited to activated FGFR1 via FRS2 and
CC       GRB2, and mediates ubiquitination and subsequent degradation of
CC       FGFR1. {ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:21765395}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:16481405, ECO:0000269|PubMed:17311277}.
CC   -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome
CC       characterized by the association of craniosynostosis, broad and
CC       deviated thumbs and big toes, and partial syndactyly of the
CC       fingers and toes. Three subtypes are known: mild autosomal
CC       dominant form (type 1); cloverleaf skull, elbow ankylosis, early
CC       death, sporadic (type 2); craniosynostosis, early demise, sporadic
CC       (type 3). {ECO:0000269|PubMed:7874169}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypogonadotropic hypogonadism 2 with or without anosmia
CC       (HH2) [MIM:147950]: A disorder characterized by absent or
CC       incomplete sexual maturation by the age of 18 years, in
CC       conjunction with low levels of circulating gonadotropins and
CC       testosterone and no other abnormalities of the hypothalamic-
CC       pituitary axis. In some cases, it is associated with non-
CC       reproductive phenotypes, such as anosmia, cleft palate, and
CC       sensorineural hearing loss. Anosmia or hyposmia is related to the
CC       absence or hypoplasia of the olfactory bulbs and tracts.
CC       Hypogonadism is due to deficiency in gonadotropin-releasing
CC       hormone and probably results from a failure of embryonic migration
CC       of gonadotropin-releasing hormone-synthesizing neurons. In the
CC       presence of anosmia, idiopathic hypogonadotropic hypogonadism is
CC       referred to as Kallmann syndrome, whereas in the presence of a
CC       normal sense of smell, it has been termed normosmic idiopathic
CC       hypogonadotropic hypogonadism (nIHH).
CC       {ECO:0000269|PubMed:12627230, ECO:0000269|PubMed:15001591,
CC       ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:15845591,
CC       ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:16757108,
CC       ECO:0000269|PubMed:16764984, ECO:0000269|PubMed:16882753,
CC       ECO:0000269|PubMed:17154279, ECO:0000269|PubMed:19820032,
CC       ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:22927827,
CC       ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900,
CC       ECO:0000269|PubMed:26277103}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry. Some patients carrying mutations in
CC       FGFR1 also have a mutation other HH-associated genes including
CC       DUSP6, FGF8, FGF17, FLRT3, GNRH1, GNRHR, HS6ST1, IL17RD, ANOS1,
CC       KISS1R, NSMF, PROKR2, SPRY4 and TACR3 (PubMed:23643382).
CC       {ECO:0000269|PubMed:23643382}.
CC   -!- DISEASE: Osteoglophonic dysplasia (OGD) [MIM:166250]:
CC       Characterized by craniosynostosis, prominent supraorbital ridge,
CC       and depressed nasal bridge, as well as by rhizomelic dwarfism and
CC       nonossifying bone lesions. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:15625620, ECO:0000269|PubMed:16470795}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hartsfield syndrome (HRTFDS) [MIM:615465]: A syndrome
CC       characterized by the triad of holoprosencephaly, ectrodactyly, and
CC       cleft/lip palate. Profound mental retardation is also present.
CC       Multiple other congenital anomalies usually occur.
CC       {ECO:0000269|PubMed:23812909, ECO:0000269|PubMed:24888332}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Trigonocephaly 1 (TRIGNO1) [MIM:190440]: A keel-shaped
CC       deformation of the forehead, caused by premature fusion of the
CC       metopic sutures. It results in a triangular shape of the head.
CC       {ECO:0000269|PubMed:11173846}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell leukemia lymphoma syndrome (SCLL).
CC       Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents
CC       as lymphoblastic lymphoma in association with a myeloproliferative
CC       disorder, often accompanied by pronounced peripheral eosinophilia
CC       and/or prominent eosinophilic infiltrates in the affected bone
CC       marrow. {ECO:0000269|PubMed:9716603}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion
CC       ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or
CC       FGFR1-FGFR1OP may exhibit constitutive kinase activity and be
CC       responsible for the transforming activity.
CC       {ECO:0000269|PubMed:10688839, ECO:0000269|PubMed:15034873,
CC       ECO:0000269|PubMed:16946300, ECO:0000269|PubMed:17389761,
CC       ECO:0000269|PubMed:9949182}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(8;9)(p12;q33) with CNTRL. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion protein CNTRL-FGFR1 is found in the
CC       cytoplasm, exhibits constitutive kinase activity and may be
CC       responsible for the transforming activity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92156.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR1ID113.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M37722; AAA75007.1; -; mRNA.
DR   EMBL; X52833; CAA37015.1; -; mRNA.
DR   EMBL; M34185; AAA35836.1; -; mRNA.
DR   EMBL; M34186; AAA35837.1; -; mRNA.
DR   EMBL; M34187; AAA35838.1; -; mRNA.
DR   EMBL; M34188; AAA35839.1; -; mRNA.
DR   EMBL; X51803; CAA36101.1; -; mRNA.
DR   EMBL; M34641; AAA35835.1; -; mRNA.
DR   EMBL; M60485; AAA35840.1; -; mRNA.
DR   EMBL; X57118; CAA40400.1; -; mRNA.
DR   EMBL; X57119; CAA40401.1; -; mRNA.
DR   EMBL; X57120; CAA40402.1; -; mRNA.
DR   EMBL; X57121; CAA40403.1; -; mRNA.
DR   EMBL; X57122; CAA40404.1; -; mRNA.
DR   EMBL; M63887; AAA35958.1; -; mRNA.
DR   EMBL; M63888; AAA35959.1; -; mRNA.
DR   EMBL; M63889; AAA35960.1; -; mRNA.
DR   EMBL; X66945; CAA47375.1; -; mRNA.
DR   EMBL; FJ809917; ACO38646.1; -; mRNA.
DR   EMBL; AK291754; BAF84443.1; -; mRNA.
DR   EMBL; AK292470; BAF85159.1; -; mRNA.
DR   EMBL; AK309947; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB208919; BAD92156.1; ALT_INIT; mRNA.
DR   EMBL; AK222718; BAD96438.1; -; mRNA.
DR   EMBL; AY585209; AAS79322.1; -; Genomic_DNA.
DR   EMBL; AC087623; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015035; AAH15035.1; -; mRNA.
DR   EMBL; BC018128; AAH18128.1; -; mRNA.
DR   EMBL; BC091494; AAH91494.1; -; mRNA.
DR   EMBL; Y00665; CAA68679.1; -; mRNA.
DR   CCDS; CCDS43730.1; -. [P11362-3]
DR   CCDS; CCDS43731.1; -. [P11362-14]
DR   CCDS; CCDS43732.1; -. [P11362-7]
DR   CCDS; CCDS55221.1; -. [P11362-20]
DR   CCDS; CCDS55222.1; -. [P11362-2]
DR   CCDS; CCDS55223.1; -. [P11362-21]
DR   CCDS; CCDS6107.2; -. [P11362-1]
DR   PIR; A41266; A41266.
DR   PIR; C36464; C36464.
DR   PIR; C40862; C40862.
DR   PIR; S11692; TVHUFG.
DR   PIR; S19167; A40862.
DR   RefSeq; NP_001167534.1; NM_001174063.1. [P11362-2]
DR   RefSeq; NP_001167535.1; NM_001174064.1. [P11362-20]
DR   RefSeq; NP_001167536.1; NM_001174065.1. [P11362-7]
DR   RefSeq; NP_001167537.1; NM_001174066.1. [P11362-3]
DR   RefSeq; NP_001167538.1; NM_001174067.1. [P11362-21]
DR   RefSeq; NP_056934.2; NM_015850.3. [P11362-7]
DR   RefSeq; NP_075593.1; NM_023105.2. [P11362-3]
DR   RefSeq; NP_075594.1; NM_023106.2. [P11362-14]
DR   RefSeq; NP_075598.2; NM_023110.2. [P11362-1]
DR   UniGene; Hs.264887; -.
DR   PDB; 1AGW; X-ray; 2.40 A; A/B=456-765.
DR   PDB; 1CVS; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1EVT; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 1FGK; X-ray; 2.00 A; A/B=456-765.
DR   PDB; 1FQ9; X-ray; 3.00 A; C/D=141-365.
DR   PDB; 1XR0; NMR; -; A=409-430.
DR   PDB; 2CR3; NMR; -; A=38-123.
DR   PDB; 2FGI; X-ray; 2.50 A; A/B=456-765.
DR   PDB; 3C4F; X-ray; 2.07 A; A/B=464-765.
DR   PDB; 3DPK; X-ray; 1.95 A; A=577-615.
DR   PDB; 3GQI; X-ray; 2.50 A; A=458-774.
DR   PDB; 3GQL; X-ray; 2.80 A; A/B/C=458-774.
DR   PDB; 3JS2; X-ray; 2.20 A; A/B=458-765.
DR   PDB; 3KRJ; X-ray; 2.10 A; A=577-597.
DR   PDB; 3KRL; X-ray; 2.40 A; A=577-597.
DR   PDB; 3KXX; X-ray; 3.20 A; A/B/C/D=458-765.
DR   PDB; 3KY2; X-ray; 2.70 A; A/B=458-765.
DR   PDB; 3OJV; X-ray; 2.60 A; C/D=142-365.
DR   PDB; 3RHX; X-ray; 2.01 A; A/B=461-765.
DR   PDB; 3TT0; X-ray; 2.80 A; A/B=456-765.
DR   PDB; 3WJ6; X-ray; 2.15 A; A/B=456-765.
DR   PDB; 4F63; X-ray; 2.55 A; A/B=458-765.
DR   PDB; 4F64; X-ray; 2.05 A; A/B=458-765.
DR   PDB; 4F65; X-ray; 2.26 A; A/B=458-765.
DR   PDB; 4NK9; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4NKA; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4NKS; X-ray; 2.50 A; A/B=458-765.
DR   PDB; 4RWI; X-ray; 2.29 A; A/B=458-765.
DR   PDB; 4RWJ; X-ray; 2.49 A; A/B=458-765.
DR   PDB; 4RWK; X-ray; 2.98 A; A/B=458-765.
DR   PDB; 4RWL; X-ray; 2.19 A; A/B=458-765.
DR   PDB; 4UWB; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4UWC; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 4UWY; X-ray; 2.31 A; A/B=458-765.
DR   PDB; 4V01; X-ray; 2.33 A; A/B=458-765.
DR   PDB; 4V04; X-ray; 2.12 A; A/B=458-765.
DR   PDB; 4V05; X-ray; 2.57 A; A/B=458-765.
DR   PDB; 4WUN; X-ray; 1.65 A; A/B=459-765.
DR   PDB; 4ZSA; X-ray; 2.00 A; A/B=458-765.
DR   PDB; 5A46; X-ray; 2.63 A; A/B=437-822.
DR   PDB; 5A4C; X-ray; 2.09 A; A/B=461-765.
DR   PDB; 5AM6; X-ray; 1.96 A; A/B=458-765.
DR   PDB; 5AM7; X-ray; 1.96 A; A/B=458-765.
DR   PDBsum; 1AGW; -.
DR   PDBsum; 1CVS; -.
DR   PDBsum; 1EVT; -.
DR   PDBsum; 1FGI; -.
DR   PDBsum; 1FGK; -.
DR   PDBsum; 1FQ9; -.
DR   PDBsum; 1XR0; -.
DR   PDBsum; 2CR3; -.
DR   PDBsum; 2FGI; -.
DR   PDBsum; 3C4F; -.
DR   PDBsum; 3DPK; -.
DR   PDBsum; 3GQI; -.
DR   PDBsum; 3GQL; -.
DR   PDBsum; 3JS2; -.
DR   PDBsum; 3KRJ; -.
DR   PDBsum; 3KRL; -.
DR   PDBsum; 3KXX; -.
DR   PDBsum; 3KY2; -.
DR   PDBsum; 3OJV; -.
DR   PDBsum; 3RHX; -.
DR   PDBsum; 3TT0; -.
DR   PDBsum; 3WJ6; -.
DR   PDBsum; 4F63; -.
DR   PDBsum; 4F64; -.
DR   PDBsum; 4F65; -.
DR   PDBsum; 4NK9; -.
DR   PDBsum; 4NKA; -.
DR   PDBsum; 4NKS; -.
DR   PDBsum; 4RWI; -.
DR   PDBsum; 4RWJ; -.
DR   PDBsum; 4RWK; -.
DR   PDBsum; 4RWL; -.
DR   PDBsum; 4UWB; -.
DR   PDBsum; 4UWC; -.
DR   PDBsum; 4UWY; -.
DR   PDBsum; 4V01; -.
DR   PDBsum; 4V04; -.
DR   PDBsum; 4V05; -.
DR   PDBsum; 4WUN; -.
DR   PDBsum; 4ZSA; -.
DR   PDBsum; 5A46; -.
DR   PDBsum; 5A4C; -.
DR   PDBsum; 5AM6; -.
DR   PDBsum; 5AM7; -.
DR   ProteinModelPortal; P11362; -.
DR   SMR; P11362; 38-397, 420-801.
DR   BioGrid; 108551; 63.
DR   DIP; DIP-4019N; -.
DR   IntAct; P11362; 26.
DR   MINT; MINT-1499363; -.
DR   STRING; 9606.ENSP00000393312; -.
DR   BindingDB; P11362; -.
DR   ChEMBL; CHEMBL2095217; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   GuidetoPHARMACOLOGY; 1808; -.
DR   iPTMnet; P11362; -.
DR   PhosphoSite; P11362; -.
DR   SwissPalm; P11362; -.
DR   BioMuta; FGFR1; -.
DR   DMDM; 120046; -.
DR   MaxQB; P11362; -.
DR   PaxDb; P11362; -.
DR   PRIDE; P11362; -.
DR   DNASU; 2260; -.
DR   Ensembl; ENST00000326324; ENSP00000327229; ENSG00000077782. [P11362-14]
DR   Ensembl; ENST00000335922; ENSP00000337247; ENSG00000077782. [P11362-20]
DR   Ensembl; ENST00000356207; ENSP00000348537; ENSG00000077782. [P11362-3]
DR   Ensembl; ENST00000397091; ENSP00000380280; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397108; ENSP00000380297; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000397113; ENSP00000380302; ENSG00000077782. [P11362-7]
DR   Ensembl; ENST00000425967; ENSP00000393312; ENSG00000077782. [P11362-21]
DR   Ensembl; ENST00000447712; ENSP00000400162; ENSG00000077782. [P11362-1]
DR   Ensembl; ENST00000484370; ENSP00000433163; ENSG00000077782. [P11362-15]
DR   Ensembl; ENST00000532791; ENSP00000432972; ENSG00000077782. [P11362-2]
DR   GeneID; 2260; -.
DR   KEGG; hsa:2260; -.
DR   UCSC; uc003xlp.3; human. [P11362-2]
DR   UCSC; uc003xlu.3; human. [P11362-18]
DR   UCSC; uc003xlv.3; human. [P11362-16]
DR   UCSC; uc010lwk.3; human. [P11362-20]
DR   UCSC; uc011lbu.2; human. [P11362-21]
DR   UCSC; uc011lbv.2; human. [P11362-7]
DR   UCSC; uc011lbw.2; human. [P11362-3]
DR   UCSC; uc022aua.1; human. [P11362-1]
DR   UCSC; uc022aud.1; human. [P11362-14]
DR   CTD; 2260; -.
DR   GeneCards; FGFR1; -.
DR   GeneReviews; FGFR1; -.
DR   HGNC; HGNC:3688; FGFR1.
DR   HPA; CAB033614; -.
DR   HPA; HPA056402; -.
DR   MalaCards; FGFR1; -.
DR   MIM; 101600; phenotype.
DR   MIM; 136350; gene.
DR   MIM; 147950; phenotype.
DR   MIM; 166250; phenotype.
DR   MIM; 190440; phenotype.
DR   MIM; 615465; phenotype.
DR   neXtProt; NX_P11362; -.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 2117; Hartsfield-Bixler-Demyer syndrome.
DR   Orphanet; 2227; Hypodontia.
DR   Orphanet; 3366; Isolated trigonocephaly.
DR   Orphanet; 478; Kallmann syndrome.
DR   Orphanet; 168953; Myeloid neoplasm associated with FGFR1 rearrangement.
DR   Orphanet; 432; Normosmic congenital hypogonadotropic hypogonadism.
DR   Orphanet; 99798; Oligodontia.
DR   Orphanet; 2645; Osteoglophonic dwarfism.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   Orphanet; 251612; Pilocytic astrocytoma.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   Orphanet; 3157; Septo-optic dysplasia.
DR   PharmGKB; PA28127; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P11362; -.
DR   KO; K04362; -.
DR   OMA; KVRDHMW; -.
DR   OrthoDB; EOG7NGQ9N; -.
DR   PhylomeDB; P11362; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839120; Signaling by FGFR1 amplification mutants.
DR   Reactome; R-HSA-1839122; Signaling by activated point mutants of FGFR1.
DR   Reactome; R-HSA-190370; FGFR1b ligand binding and activation.
DR   Reactome; R-HSA-190373; FGFR1c ligand binding and activation.
DR   Reactome; R-HSA-190374; FGFR1c and Klotho ligand binding and activation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P11362; -.
DR   ChiTaRS; FGFR1; human.
DR   EvolutionaryTrace; P11362; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_1; -.
DR   GenomeRNAi; 2260; -.
DR   NextBio; 9163; -.
DR   PMAP-CutDB; P11362; -.
DR   PRO; PR:P11362; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; P11362; -.
DR   CleanEx; HS_FGFR1; -.
DR   CleanEx; HS_FLG; -.
DR   ExpressionAtlas; P11362; baseline and differential.
DR   Genevisible; P11362; HS.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0060117; P:auditory receptor cell development; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0043009; P:chordate embryonic development; TAS:UniProtKB.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0021837; P:motogenic signaling involved in postnatal olfactory bulb interneuron migration; IEA:Ensembl.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; TAS:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001759; P:organ induction; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0048339; P:paraxial mesoderm development; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000546; P:positive regulation of endothelial cell chemotaxis to fibroblast growth factor; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090080; P:positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0060665; P:regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling; IEA:Ensembl.
DR   GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:2001239; P:regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0019827; P:stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0021847; P:ventricular zone neuroblast division; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR028174; FGF_rcpt_1.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR24416:SF131; PTHR24416:SF131; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Craniosynostosis;
KW   Cytoplasm; Cytoplasmic vesicle; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Dwarfism; Glycoprotein;
KW   Heparin-binding; Holoprosencephaly; Hypogonadotropic hypogonadism;
KW   Immunoglobulin domain; Kallmann syndrome; Kinase; Membrane;
KW   Mental retardation; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     21
FT   CHAIN        22    822       Fibroblast growth factor receptor 1.
FT                                /FTId=PRO_0000016780.
FT   TOPO_DOM     22    376       Extracellular. {ECO:0000255}.
FT   TRANSMEM    377    397       Helical. {ECO:0000255}.
FT   TOPO_DOM    398    822       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    119       Ig-like C2-type 1.
FT   DOMAIN      158    246       Ig-like C2-type 2.
FT   DOMAIN      255    357       Ig-like C2-type 3.
FT   DOMAIN      478    767       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     484    490       ATP.
FT   NP_BIND     562    564       ATP.
FT   REGION      160    177       Heparin-binding.
FT   ACT_SITE    623    623       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028,
FT                                ECO:0000269|PubMed:19224897}.
FT   BINDING     514    514       ATP.
FT   BINDING     568    568       ATP.
FT   BINDING     627    627       ATP.
FT   BINDING     641    641       ATP.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                CNTRL-FGFR1 OR FGFR1-CNTRL fusion
FT                                proteins. {ECO:0000269|PubMed:10688839}.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP-FGFR1 or FGFR1-FGFR1OP fusion
FT                                proteins. {ECO:0000269|PubMed:9949182}.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP2-FGFR1.
FT                                {ECO:0000269|PubMed:15034873,
FT                                ECO:0000269|PubMed:16946300,
FT                                ECO:0000269|PubMed:17389761}.
FT   SITE        766    766       Mediates interaction with PLCG1 and SHB.
FT   MOD_RES     463    463       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     583    583       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     585    585       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     653    653       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:19665973,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     654    654       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16507368,
FT                                ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:19665973,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     730    730       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19224897,
FT                                ECO:0000269|PubMed:8622701}.
FT   MOD_RES     766    766       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19665973}.
FT   CARBOHYD     77     77       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    117    117       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    227    227       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    317    317       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    330    330       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     55    101       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    178    230
FT   DISULFID    277    341
FT   VAR_SEQ       1    160       Missing (in isoform 10, isoform 11,
FT                                isoform 12 and isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_002957.
FT   VAR_SEQ       1     30       MWSWKCLLFWAVLVTATLCTARPSPTLPEQ -> MAAVTRD
FT                                FGEMLLHSGRVLPAE (in isoform 20).
FT                                {ECO:0000303|Ref.12}.
FT                                /FTId=VSP_041916.
FT   VAR_SEQ       1      1       M -> MEARVSLKRRIELTVEYPWRCGALSPTSNCRTGM
FT                                (in isoform 21).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041917.
FT   VAR_SEQ      31    119       Missing (in isoform 6, isoform 7, isoform
FT                                8, isoform 9, isoform 15, isoform 17 and
FT                                isoform 18).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1650441,
FT                                ECO:0000303|PubMed:1846977,
FT                                ECO:0000303|PubMed:2162671,
FT                                ECO:0000303|PubMed:2167437,
FT                                ECO:0000303|PubMed:7520751}.
FT                                /FTId=VSP_002958.
FT   VAR_SEQ      32     61       QPWGAPVEVESFLVHPGDLLQLRCRLRDDV -> CPDLQEA
FT                                KSCSASFHSITPLPFGLGTRLSD (in isoform 3).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009836.
FT   VAR_SEQ      62    822       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009837.
FT   VAR_SEQ     119    119       S -> SVPI (in isoform 19).
FT                                {ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:20139426}.
FT                                /FTId=VSP_038470.
FT   VAR_SEQ     120    150       DALPSSEDDDDDDDSSSEEKETDNTKPNRMP -> ACPDLQ
FT                                EAKWCSASFHSITPLPFGLGTRLSD (in isoform
FT                                16). {ECO:0000303|PubMed:1650441}.
FT                                /FTId=VSP_009838.
FT   VAR_SEQ     148    149       Missing (in isoform 14, isoform 15,
FT                                isoform 18, isoform 19 and isoform 21).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1650441,
FT                                ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:1662973,
FT                                ECO:0000303|PubMed:1722683,
FT                                ECO:0000303|PubMed:20139426,
FT                                ECO:0000303|PubMed:2162671,
FT                                ECO:0000303|PubMed:2167437,
FT                                ECO:0000303|PubMed:7520751,
FT                                ECO:0000303|Ref.12}.
FT                                /FTId=VSP_002959.
FT   VAR_SEQ     151    822       Missing (in isoform 16).
FT                                {ECO:0000303|PubMed:1650441}.
FT                                /FTId=VSP_009839.
FT   VAR_SEQ     313    391       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMV ->
FT                                VIMAPVFVGQSTGKETTVSGAQVPVGRLSCPRMGSFLTLQA
FT                                HTLHLSRDLATSPRTSNRGHKVEVSWEQRAAGMGGAGL
FT                                (in isoform 17 and isoform 18).
FT                                {ECO:0000303|PubMed:2167437}.
FT                                /FTId=VSP_009840.
FT   VAR_SEQ     313    360       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLE -> HSGINSSDAEVLTLFNVTEAQSGEYVCKVS
FT                                NYIGEANQSAWLTVTRP (in isoform 19).
FT                                {ECO:0000303|PubMed:1652059,
FT                                ECO:0000303|PubMed:20139426}.
FT                                /FTId=VSP_038471.
FT   VAR_SEQ     392    822       Missing (in isoform 17 and isoform 18).
FT                                {ECO:0000303|PubMed:2167437}.
FT                                /FTId=VSP_009841.
FT   VAR_SEQ     427    428       Missing (in isoform 20).
FT                                {ECO:0000303|Ref.12}.
FT                                /FTId=VSP_041918.
FT   VAR_SEQ     428    429       Missing (in isoform 4, isoform 5, isoform
FT                                8, isoform 9, isoform 12 and isoform 13).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_002960.
FT   VAR_SEQ     619    662       CIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTN
FT                                GRL -> VWNLKAPLVHTPRPGSQECPGDRGQCDEDSRLWP
FT                                RTGHSPHRLL (in isoform 2, isoform 5,
FT                                isoform 7, isoform 9, isoform 11 and
FT                                isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009842.
FT   VAR_SEQ     663    822       Missing (in isoform 2, isoform 5, isoform
FT                                7, isoform 9, isoform 11 and isoform 13).
FT                                {ECO:0000303|PubMed:1846977}.
FT                                /FTId=VSP_009843.
FT   VARIANT       4      4       W -> C (in HH2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074012.
FT   VARIANT      22     22       R -> S (in dbSNP:rs17175750).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019290.
FT   VARIANT      48     48       G -> S (in HH2; phenotype consistent with
FT                                normosmic idiopathic hypogonadotropic
FT                                hypogonadism).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030968.
FT   VARIANT      70     70       G -> R (in HH2).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072993.
FT   VARIANT      77     77       N -> K. {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030969.
FT   VARIANT      78     78       R -> C (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030970.
FT   VARIANT      96     96       S -> C (in HH2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074013.
FT   VARIANT      97     97       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017885.
FT   VARIANT      99     99       Y -> C (in HH2; impairs the tertiary
FT                                folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:12627230,
FT                                ECO:0000269|PubMed:19820032}.
FT                                /FTId=VAR_017886.
FT   VARIANT     101    101       C -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030971.
FT   VARIANT     102    102       V -> I (in HH2; dbSNP:rs55642501).
FT                                {ECO:0000269|PubMed:15605412,
FT                                ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030972.
FT   VARIANT     116    116       V -> I (in HH2).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072994.
FT   VARIANT     117    117       N -> S (in HH2; some patients also carry
FT                                GNRHR mutations).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069288.
FT   VARIANT     125    125       S -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042201.
FT   VARIANT     129    129       D -> A (in HH2).
FT                                {ECO:0000269|PubMed:15605412}.
FT                                /FTId=VAR_030973.
FT   VARIANT     165    165       L -> S (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070851.
FT   VARIANT     167    167       A -> S (in HH2; with cleft palate, corpus
FT                                callosum agenesis, unilateral deafness
FT                                and fusion of fourth and fifth metacarpal
FT                                bones). {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017887.
FT   VARIANT     174    174       V -> A (in HH2).
FT                                {ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_072995.
FT   VARIANT     178    178       C -> S (in HH2; with severe ear
FT                                anomalies).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030974.
FT   VARIANT     191    191       L -> S (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070852.
FT   VARIANT     213    213       W -> G (in dbSNP:rs17851623).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030975.
FT   VARIANT     224    224       D -> H (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030976.
FT   VARIANT     228    228       Y -> D (in HH2; some patients also carry
FT                                KISS1R mutations; impairs the tertiary
FT                                folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069289.
FT   VARIANT     237    237       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030977.
FT   VARIANT     237    237       G -> S (in HH2; with or without anosmia;
FT                                also found in a family member with
FT                                isolated anosmia; may impair proper
FT                                folding). {ECO:0000269|PubMed:16606836}.
FT                                /FTId=VAR_030978.
FT   VARIANT     239    239       I -> T (in HH2; some patients also carry
FT                                PROKR2 and GNRH1 mutations; impairs the
FT                                tertiary folding resulting in incomplete
FT                                glycosylation and reduced cell surface
FT                                expression).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069290.
FT   VARIANT     245    245       L -> P (in HH2).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030979.
FT   VARIANT     250    250       R -> Q (in HH2; with or without anosmia;
FT                                results in Kallmann syndrome in the
FT                                presence of HS6ST1 mutation TRP-306;
FT                                reduces receptor affinity for fibroblast
FT                                growth factor).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:21700882,
FT                                ECO:0000269|PubMed:23643382,
FT                                ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_069291.
FT   VARIANT     250    250       R -> W (in HH2).
FT                                {ECO:0000269|PubMed:16882753,
FT                                ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030980.
FT   VARIANT     252    252       P -> R (in PS).
FT                                {ECO:0000269|PubMed:7874169}.
FT                                /FTId=VAR_004111.
FT   VARIANT     252    252       P -> T (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042202.
FT   VARIANT     254    254       R -> Q (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030981.
FT   VARIANT     270    270       G -> D (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030982.
FT   VARIANT     273    273       V -> M (in HH2).
FT                                {ECO:0000269|PubMed:15605412,
FT                                ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030983.
FT   VARIANT     274    274       E -> G (in HH2; also found in a family
FT                                member with isolated anosmia).
FT                                /FTId=VAR_030984.
FT   VARIANT     277    277       C -> Y (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017888.
FT   VARIANT     283    283       P -> R (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030985.
FT   VARIANT     300    300       I -> T (in TRIGNO1).
FT                                {ECO:0000269|PubMed:11173846}.
FT                                /FTId=VAR_030986.
FT   VARIANT     330    330       N -> I (in OGD).
FT                                {ECO:0000269|PubMed:15625620,
FT                                ECO:0000269|PubMed:16470795}.
FT                                /FTId=VAR_030987.
FT   VARIANT     332    332       S -> C (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030988.
FT   VARIANT     339    339       Y -> C (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030989.
FT   VARIANT     342    342       L -> S (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a splice site mutation in NSMF).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069954.
FT   VARIANT     343    343       A -> V (in HH2).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030990.
FT   VARIANT     346    346       S -> C (in HH2; also found in a family
FT                                member with isolated anosmia).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030991.
FT   VARIANT     348    348       G -> R (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a mutation in IL17RD).
FT                                {ECO:0000269|PubMed:23643382,
FT                                ECO:0000269|PubMed:25077900}.
FT                                /FTId=VAR_069955.
FT   VARIANT     366    366       P -> L (in HH2; with or without anosmia).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_030992.
FT   VARIANT     374    374       Y -> C (in OGD; elevated basal activity
FT                                and increased FGF2-mediated activity).
FT                                {ECO:0000269|PubMed:15625620}.
FT                                /FTId=VAR_030993.
FT   VARIANT     381    381       C -> R (in OGD).
FT                                {ECO:0000269|PubMed:15625620,
FT                                ECO:0000269|PubMed:16470795}.
FT                                /FTId=VAR_030994.
FT   VARIANT     470    470       R -> L (in HH2; some patients also carry
FT                                GNRHR mutations).
FT                                {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069292.
FT   VARIANT     483    483       P -> T (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in SPRY4).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069956.
FT   VARIANT     490    490       G -> R (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070853.
FT   VARIANT     520    520       A -> T (in HH2).
FT                                {ECO:0000269|PubMed:15605412}.
FT                                /FTId=VAR_030995.
FT   VARIANT     538    538       I -> V (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_030996.
FT   VARIANT     607    607       V -> M (in HH2; with bimanual
FT                                synkinesis).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017889.
FT   VARIANT     618    618       K -> N (in HH2; some patients also carry
FT                                GNRHR mutations; impairs tyrosine kinase
FT                                activity). {ECO:0000269|PubMed:19820032,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069293.
FT   VARIANT     621    621       H -> R (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_030997.
FT   VARIANT     622    622       R -> G (in HH2; with severe ear
FT                                anomalies).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030998.
FT   VARIANT     622    622       R -> Q (in HH2).
FT                                {ECO:0000269|PubMed:16757108}.
FT                                /FTId=VAR_030999.
FT   VARIANT     623    623       D -> Y (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070854.
FT   VARIANT     627    627       R -> T (in HRTFDS).
FT                                {ECO:0000269|PubMed:24888332}.
FT                                /FTId=VAR_071460.
FT   VARIANT     628    628       N -> K (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070855.
FT   VARIANT     664    664       V -> L (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042203.
FT   VARIANT     666    666       W -> R (in HH2; with cleft palate).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017890.
FT   VARIANT     670    670       E -> K (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in FLRT3).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069957.
FT   VARIANT     671    671       A -> P (in HH2).
FT                                {ECO:0000269|PubMed:19820032}.
FT                                /FTId=VAR_069294.
FT   VARIANT     685    685       S -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_031000.
FT   VARIANT     687    687       G -> R (in HH2).
FT                                {ECO:0000269|PubMed:15845591,
FT                                ECO:0000269|PubMed:22927827}.
FT                                /FTId=VAR_031001.
FT   VARIANT     692    692       E -> G (in HH2; phenotype consistent with
FT                                Kallmann syndrome; the patient also
FT                                carries a rare variant in DUSP6).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069958.
FT   VARIANT     693    693       I -> F (in HH2).
FT                                {ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_031002.
FT   VARIANT     703    703       G -> R (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031003.
FT   VARIANT     703    703       G -> S (in HH2).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031004.
FT   VARIANT     719    719       M -> R (in HH2).
FT                                {ECO:0000269|PubMed:12627230}.
FT                                /FTId=VAR_017891.
FT   VARIANT     719    719       M -> V (in HH2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26277103}.
FT                                /FTId=VAR_074014.
FT   VARIANT     722    722       P -> H (in HH2; associated with K-724;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity). {ECO:0000269|PubMed:16606836,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_031005.
FT   VARIANT     722    722       P -> S (in HH2).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_031006.
FT   VARIANT     724    724       N -> K (in HH2; associated with H-722;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity). {ECO:0000269|PubMed:16606836,
FT                                ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_031007.
FT   VARIANT     725    725       C -> Y (in HRTFDS).
FT                                {ECO:0000269|PubMed:23812909}.
FT                                /FTId=VAR_070856.
FT   VARIANT     745    745       P -> S (in HH2).
FT                                {ECO:0000269|PubMed:15001591,
FT                                ECO:0000269|PubMed:15845591}.
FT                                /FTId=VAR_031008.
FT   VARIANT     768    768       D -> Y (in HH2; the patient also carries
FT                                a rare variant in FGF8).
FT                                {ECO:0000269|PubMed:23643382}.
FT                                /FTId=VAR_069959.
FT   VARIANT     769    769       L -> V (in dbSNP:rs2956723).
FT                                {ECO:0000269|PubMed:16764984}.
FT                                /FTId=VAR_031009.
FT   VARIANT     772    772       P -> S (in HH2; with cleft palate,
FT                                unilateral absence of nasal cartilage,
FT                                iris coloboma; dbSNP:rs56234888).
FT                                {ECO:0000269|PubMed:12627230,
FT                                ECO:0000269|PubMed:17154279}.
FT                                /FTId=VAR_017892.
FT   VARIANT     795    795       V -> I (in HH2; also found in a family
FT                                member with isolated anosmia).
FT                                {ECO:0000269|PubMed:16882753}.
FT                                /FTId=VAR_031010.
FT   VARIANT     818    818       G -> R (in dbSNP:rs17182456).
FT                                {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019291.
FT   VARIANT     822    822       R -> C (in dbSNP:rs17182463).
FT                                {ECO:0000269|PubMed:17154279,
FT                                ECO:0000269|Ref.13}.
FT                                /FTId=VAR_019292.
FT   MUTAGEN     514    514       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15117958}.
FT   MUTAGEN     546    546       N->K: Strongly increased speed of the
FT                                first autophosphorylation, and loss of
FT                                the normal sequential order of
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:19224897}.
FT   MUTAGEN     577    577       R->E: Strongly reduced
FT                                autophosphorylation in response to FGF
FT                                signaling. No effect on in vitro kinase
FT                                activity. {ECO:0000269|PubMed:20133753}.
FT   MUTAGEN     609    609       R->V: Abolishes interaction with PLCG1.
FT   MUTAGEN     623    623       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19224897}.
FT   MUTAGEN     653    653       Y->F: No effect on kinase activity. Loss
FT                                of autophosphorylation and kinase
FT                                activity; when associated with F-654.
FT                                {ECO:0000269|PubMed:8622701}.
FT   MUTAGEN     654    654       Y->F: Reduced kinase activity. Loss of
FT                                autophosphorylation and kinase activity;
FT                                when associated with F-653.
FT                                {ECO:0000269|PubMed:8622701}.
FT   MUTAGEN     755    755       D->V: Abolishes interaction with PLCG1.
FT   MUTAGEN     766    766       Y->F: Abolishes interaction with PLCG1
FT                                and SHB. Decreases phosphorylation of
FT                                FRS2, activation of RAS and MAP kinase
FT                                signaling and stimulation of cell
FT                                proliferation.
FT                                {ECO:0000269|PubMed:12181353,
FT                                ECO:0000269|PubMed:1379697,
FT                                ECO:0000269|PubMed:1379698,
FT                                ECO:0000269|PubMed:7516330}.
FT   CONFLICT     24     24       S -> C (in Ref. 8; AAA35958/AAA35959).
FT                                {ECO:0000305}.
FT   CONFLICT    192    192       K -> E (in Ref. 3; AAA35837).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       G -> S (in Ref. 5; AAA35835).
FT                                {ECO:0000305}.
FT   CONFLICT    196    196       E -> G (in Ref. 16; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    223    223       S -> F (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    308    308       V -> A (in Ref. 8; AAA35958/AAA35959).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       E -> Q (in Ref. 18; CAA68679).
FT                                {ECO:0000305}.
FT   CONFLICT    469    469       P -> L (in Ref. 1; AAA75007).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       K -> R (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    576    576       R -> W (in Ref. 12; BAD96438).
FT                                {ECO:0000305}.
FT   CONFLICT    817    817       G -> R (in Ref. 4; CAA36101).
FT                                {ECO:0000305}.
FT   STRAND       40     42       {ECO:0000244|PDB:2CR3}.
FT   STRAND       51     54       {ECO:0000244|PDB:2CR3}.
FT   STRAND       63     72       {ECO:0000244|PDB:2CR3}.
FT   STRAND       77     81       {ECO:0000244|PDB:2CR3}.
FT   STRAND       83     88       {ECO:0000244|PDB:2CR3}.
FT   TURN         93     95       {ECO:0000244|PDB:2CR3}.
FT   STRAND       97    105       {ECO:0000244|PDB:2CR3}.
FT   STRAND      108    116       {ECO:0000244|PDB:2CR3}.
FT   STRAND      151    156       {ECO:0000244|PDB:1CVS}.
FT   HELIX       158    161       {ECO:0000244|PDB:1CVS}.
FT   STRAND      165    169       {ECO:0000244|PDB:1CVS}.
FT   STRAND      174    177       {ECO:0000244|PDB:1CVS}.
FT   STRAND      180    184       {ECO:0000244|PDB:1CVS}.
FT   STRAND      187    192       {ECO:0000244|PDB:1CVS}.
FT   HELIX       199    201       {ECO:0000244|PDB:1CVS}.
FT   STRAND      207    209       {ECO:0000244|PDB:1CVS}.
FT   TURN        210    213       {ECO:0000244|PDB:1CVS}.
FT   STRAND      214    219       {ECO:0000244|PDB:1CVS}.
FT   HELIX       222    224       {ECO:0000244|PDB:1CVS}.
FT   STRAND      226    234       {ECO:0000244|PDB:1CVS}.
FT   STRAND      237    248       {ECO:0000244|PDB:1CVS}.
FT   STRAND      265    267       {ECO:0000244|PDB:1CVS}.
FT   STRAND      273    276       {ECO:0000244|PDB:1CVS}.
FT   STRAND      286    293       {ECO:0000244|PDB:1CVS}.
FT   STRAND      295    297       {ECO:0000244|PDB:1CVS}.
FT   STRAND      306    313       {ECO:0000244|PDB:1CVS}.
FT   HELIX       320    323       {ECO:0000244|PDB:1CVS}.
FT   STRAND      325    328       {ECO:0000244|PDB:1CVS}.
FT   HELIX       333    335       {ECO:0000244|PDB:1CVS}.
FT   STRAND      337    344       {ECO:0000244|PDB:1CVS}.
FT   STRAND      349    358       {ECO:0000244|PDB:1CVS}.
FT   HELIX       460    462       {ECO:0000244|PDB:4UWC}.
FT   TURN        469    471       {ECO:0000244|PDB:4WUN}.
FT   HELIX       475    477       {ECO:0000244|PDB:4WUN}.
FT   STRAND      478    483       {ECO:0000244|PDB:4WUN}.
FT   TURN        486    489       {ECO:0000244|PDB:4ZSA}.
FT   STRAND      490    501       {ECO:0000244|PDB:4WUN}.
FT   STRAND      508    515       {ECO:0000244|PDB:4WUN}.
FT   HELIX       522    538       {ECO:0000244|PDB:4WUN}.
FT   STRAND      547    551       {ECO:0000244|PDB:4WUN}.
FT   STRAND      553    556       {ECO:0000244|PDB:4WUN}.
FT   STRAND      558    562       {ECO:0000244|PDB:4WUN}.
FT   HELIX       569    574       {ECO:0000244|PDB:4WUN}.
FT   STRAND      579    583       {ECO:0000244|PDB:4RWI}.
FT   STRAND      584    586       {ECO:0000244|PDB:5A4C}.
FT   HELIX       591    593       {ECO:0000244|PDB:3KXX}.
FT   HELIX       597    616       {ECO:0000244|PDB:4WUN}.
FT   HELIX       626    628       {ECO:0000244|PDB:4WUN}.
FT   STRAND      629    631       {ECO:0000244|PDB:4WUN}.
FT   STRAND      637    639       {ECO:0000244|PDB:4WUN}.
FT   STRAND      641    643       {ECO:0000244|PDB:3JS2}.
FT   HELIX       648    650       {ECO:0000244|PDB:5AM7}.
FT   STRAND      653    655       {ECO:0000244|PDB:4UWY}.
FT   STRAND      658    660       {ECO:0000244|PDB:5AM7}.
FT   STRAND      661    663       {ECO:0000244|PDB:3KXX}.
FT   HELIX       664    666       {ECO:0000244|PDB:4WUN}.
FT   HELIX       669    674       {ECO:0000244|PDB:4WUN}.
FT   STRAND      676    678       {ECO:0000244|PDB:3GQI}.
FT   HELIX       679    694       {ECO:0000244|PDB:4WUN}.
FT   HELIX       706    714       {ECO:0000244|PDB:4WUN}.
FT   STRAND      722    724       {ECO:0000244|PDB:4RWL}.
FT   HELIX       727    736       {ECO:0000244|PDB:4WUN}.
FT   HELIX       741    743       {ECO:0000244|PDB:4WUN}.
FT   HELIX       747    760       {ECO:0000244|PDB:4WUN}.
SQ   SEQUENCE   822 AA;  91868 MW;  93A01B5D78C3E72C CRC64;
     MWSWKCLLFW AVLVTATLCT ARPSPTLPEQ AQPWGAPVEV ESFLVHPGDL LQLRCRLRDD
     VQSINWLRDG VQLAESNRTR ITGEEVEVQD SVPADSGLYA CVTSSPSGSD TTYFSVNVSD
     ALPSSEDDDD DDDSSSEEKE TDNTKPNRMP VAPYWTSPEK MEKKLHAVPA AKTVKFKCPS
     SGTPNPTLRW LKNGKEFKPD HRIGGYKVRY ATWSIIMDSV VPSDKGNYTC IVENEYGSIN
     HTYQLDVVER SPHRPILQAG LPANKTVALG SNVEFMCKVY SDPQPHIQWL KHIEVNGSKI
     GPDNLPYVQI LKTAGVNTTD KEMEVLHLRN VSFEDAGEYT CLAGNSIGLS HHSAWLTVLE
     ALEERPAVMT SPLYLEIIIY CTGAFLISCM VGSVIVYKMK SGTKKSDFHS QMAVHKLAKS
     IPLRRQVTVS ADSSASMNSG VLLVRPSRLS SSGTPMLAGV SEYELPEDPR WELPRDRLVL
     GKPLGEGCFG QVVLAEAIGL DKDKPNRVTK VAVKMLKSDA TEKDLSDLIS EMEMMKMIGK
     HKNIINLLGA CTQDGPLYVI VEYASKGNLR EYLQARRPPG LEYCYNPSHN PEEQLSSKDL
     VSCAYQVARG MEYLASKKCI HRDLAARNVL VTEDNVMKIA DFGLARDIHH IDYYKKTTNG
     RLPVKWMAPE ALFDRIYTHQ SDVWSFGVLL WEIFTLGGSP YPGVPVEELF KLLKEGHRMD
     KPSNCTNELY MMMRDCWHAV PSQRPTFKQL VEDLDRIVAL TSNQEYLDLS MPLDQYSPSF
     PDTRSSTCSS GEDSVFSHEP LPEEPCLPRH PAQLANGGLK RR
//
ID   ERBB2_HUMAN             Reviewed;        1255 AA.
AC   P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   17-FEB-2016, entry version 210.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Metastatic lymph node gene 19 protein;
DE            Short=MLN 19;
DE   AltName: Full=Proto-oncogene Neu;
DE   AltName: Full=Proto-oncogene c-ErbB-2;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER2;
DE   AltName: Full=p185erbB2;
DE   AltName: CD_antigen=CD340;
DE   Flags: Precursor;
GN   Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3003577; DOI=10.1038/319230a0;
RA   Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N.,
RA   Saito T., Toyoshima K.;
RT   "Similarity of protein encoded by the human c-erb-B-2 gene to
RT   epidermal growth factor receptor.";
RL   Nature 319:230-234(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-1170.
RX   PubMed=2999974; DOI=10.1126/science.2999974;
RA   Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J.,
RA   Seeburg P.H., Libermann T.A., Schlessinger J., Francke U.,
RA   Levinson A., Ullrich A.;
RT   "Tyrosine kinase receptor with extensive homology to EGF receptor
RT   shares chromosomal location with neu oncogene.";
RL   Science 230:1132-1139(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND
RP   ALA-1170.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1).
RX   PubMed=3039351;
RA   Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.;
RT   "Human HER2 (neu) promoter: evidence for multiple mechanisms for
RT   transcriptional initiation.";
RL   Mol. Cell. Biol. 7:2597-2601(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6).
RC   TISSUE=Fetal brain;
RX   PubMed=24722188; DOI=10.1038/ncomms4650;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L.,
RA   Broly M., Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S.,
RA   Tasan M., Lemmens I., Kuang X., Zhao N., Malhotra D., Michaelson J.J.,
RA   Vacic V., Calderwood M.A., Roth F.P., Tavernier J., Horvath S.,
RA   Salehi-Ashtiani K., Korkin D., Sebat J., Hill D.E., Hao T., Vidal M.,
RA   Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from
RT   brain links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031.
RX   PubMed=2995967; DOI=10.1073/pnas.82.19.6497;
RA   Semba K., Kamata N., Toyoshima K., Yamamoto T.;
RT   "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-
RT   erbB-1/epidermal growth factor-receptor gene and is amplified in a
RT   human salivary gland adenocarcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2992089; DOI=10.1126/science.2992089;
RA   King C.R., Kraus M.H., Aaronson S.A.;
RT   "Amplification of a novel v-erbB-related gene in a human mammary
RT   carcinoma.";
RL   Science 229:974-976(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170.
RX   PubMed=8104414; DOI=10.1089/dna.1993.12.611;
RA   Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.;
RT   "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2)
RT   gene.";
RL   DNA Cell Biol. 12:611-615(1993).
RN   [12]
RP   INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is
RT   mediated by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A
RP   COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [14]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012;
RA   Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z.,
RA   Ali-Seyed M., Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K.,
RA   Hung M.C.;
RT   "Binding at and transactivation of the COX-2 promoter by nuclear
RT   tyrosine kinase receptor ErbB-2.";
RL   Cancer Cell 6:251-261(2004).
RN   [16]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15210733; DOI=10.1083/jcb.200312094;
RA   Swiercz J.M., Kuner R., Offermanns S.;
RT   "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor
RT   tyrosine kinase ErbB-2.";
RL   J. Cell Biol. 165:869-880(2004).
RN   [17]
RP   INTERACTION WITH MEMO1.
RX   PubMed=15156151; DOI=10.1038/ncb1134;
RA   Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.;
RT   "Memo mediates ErbB2-driven cell motility.";
RL   Nat. Cell Biol. 6:515-522(2004).
RN   [18]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION
RP   WITH KPNB1; RANBP2; CRM1; EEA1 AND CLTC.
RX   PubMed=16314522; DOI=10.1128/MCB.25.24.11005-11018.2005;
RA   Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G.,
RA   Wang S.C., Hung M.C.;
RT   "Endosomal transport of ErbB-2: mechanism for nuclear entry of the
RT   cell surface receptor.";
RL   Mol. Cell. Biol. 25:11005-11018(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712.
RX   PubMed=16794579; DOI=10.1038/sj.emboj.7601191;
RA   Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B.,
RA   Todo F.R., Baselga J., Arribas J.;
RT   "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative
RT   initiation of translation.";
RL   EMBO J. 25:3234-3244(2006).
RN   [21]
RP   INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [22]
RP   PHOSPHORYLATION AT TYR-1248.
RX   PubMed=17554007; DOI=10.1523/JNEUROSCI.5381-06.2007;
RA   Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A.,
RA   Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L.,
RA   Offermanns S., Kuner R.;
RT   "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration
RT   and patterning of the developing nervous system in vivo.";
RL   J. Neurosci. 27:6333-6347(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   INTERACTION WITH PTK6, AND ENZYME REGULATION.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [26]
RP   FUNCTION IN NUCLEUS.
RX   PubMed=19372587; DOI=10.1158/1541-7786.MCR-08-0316;
RA   Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.;
RT   "ErbB2-mediated Src and signal transducer and activator of
RT   transcription 3 activation leads to transcriptional up-regulation of
RT   p21Cip1 and chemoresistance in breast cancer cells.";
RL   Mol. Cancer Res. 7:592-600(2009).
RN   [27]
RP   INTERACTION WITH CPNE3.
RX   PubMed=20010870; DOI=10.1038/onc.2009.456;
RA   Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R.,
RA   Lienhard S., Duss S., Hofsteenge J., Hynes N.E.;
RT   "Copine-III interacts with ErbB2 and promotes tumor cell migration.";
RL   Oncogene 29:1598-1610(2010).
RN   [28]
RP   FUNCTION.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   CHROMOSOMAL REARRANGEMENT WITH CDK12.
RX   PubMed=21097718; DOI=10.1158/0008-5472.CAN-10-1749;
RA   Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D.,
RA   Ler L.D., Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A.,
RA   Grabsch H., Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.;
RT   "Genetic and structural variation in the gastric cancer kinome
RT   revealed through targeted deep sequencing.";
RL   Cancer Res. 71:29-39(2011).
RN   [31]
RP   FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21555369; DOI=10.1158/0008-5472.CAN-10-3504;
RA   Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H.,
RA   Chen H.Y., Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P.,
RA   Lien H.C., Tsai C.H., Hung M.C.;
RT   "Nuclear ErbB2 enhances translation and cell growth by activating
RT   transcription of ribosomal RNA genes.";
RL   Cancer Res. 71:4269-4279(2011).
RN   [32]
RP   INTERACTION WITH EGFR.
RX   PubMed=21190959; DOI=10.1210/en.2010-0940;
RA   Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N.,
RA   Qiu X., Kumar U.;
RT   "Dissociation of epidermal growth factor receptor and ErbB2
RT   heterodimers in the presence of somatostatin receptor 5 modulate
RT   signaling pathways.";
RL   Endocrinology 152:931-945(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA
RP   AND BETA-2 MICROGLOBULIN.
RX   PubMed=10593938; DOI=10.1074/jbc.274.51.36422;
RA   Kuhns J.J., Batalia M.A., Yan S., Collins E.J.;
RT   "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a
RT   lack of interactions with the center of the peptide.";
RL   J. Biol. Chem. 274:36422-36427(1999).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH
RP   ERBB2IP, AND INTERACTION WITH ERBB2IP.
RX   PubMed=12444095; DOI=10.1074/jbc.C200571200;
RA   Birrane G., Chung J., Ladias J.A.;
RT   "Novel mode of ligand recognition by the Erbin PDZ domain.";
RL   J. Biol. Chem. 278:1399-1402(2003).
RN   [37]
RP   STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION
RP   WITH GRB7.
RX   PubMed=12975581; DOI=10.1023/A:1025498409113;
RA   Ivancic M., Daly R.J., Lyons B.A.;
RT   "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex
RT   and structural basis for Grb7 binding to ErbB2.";
RL   J. Biomol. NMR 27:205-219(2003).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN.
RX   PubMed=12610629; DOI=10.1038/nature01392;
RA   Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B.,
RA   Denney D.W. Jr., Leahy D.J.;
RT   "Structure of the extracellular region of HER2 alone and in complex
RT   with the Herceptin Fab.";
RL   Nature 421:756-760(2003).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF
RP   317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187;
RP   ASN-259 AND ASN-530.
RX   PubMed=15093539; DOI=10.1016/S1535-6108(04)00083-2;
RA   Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M.,
RA   Sliwkowski M.X.;
RT   "Insights into ErbB signaling from the structure of the ErbB2-
RT   pertuzumab complex.";
RL   Cancer Cell 5:317-328(2004).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND
RP   ASN-530.
RX   PubMed=19299620; DOI=10.1126/science.1165480;
RA   Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K.,
RA   Man W., Peale F., Ross S., Wiesmann C., Fuh G.;
RT   "Variants of the antibody herceptin that interact with HER2 and VEGF
RT   at the antigen binding site.";
RL   Science 323:1610-1614(2009).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH
RP   ENGINEERED ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-68; ASN-259 AND ASN-571.
RX   PubMed=20696930; DOI=10.1073/pnas.1005025107;
RA   Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.;
RT   "Structural basis for high-affinity HER2 receptor binding by an
RT   engineered protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH
RP   INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ENZYME
RP   REGULATION.
RX   PubMed=21454582; DOI=10.1074/jbc.M110.206193;
RA   Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G.,
RA   Jennings A., Iwamoto K., Habuka N., Hirokawa A., Ishikawa T.,
RA   Tanaka T., Miki H., Ohta Y., Sogabe S.;
RT   "Structural analysis of the mechanism of inhibition and allosteric
RT   activation of the kinase domain of HER2 protein.";
RL   J. Biol. Chem. 286:18756-18765(2011).
RN   [43]
RP   VARIANTS VAL-654 AND VAL-655.
RX   PubMed=8095488; DOI=10.1006/geno.1993.1081;
RA   Ehsani A., Low J., Wallace R.B., Wu A.M.;
RT   "Characterization of a new allele of the human ERBB2 gene by allele-
RT   specific competition hybridization.";
RL   Genomics 15:426-429(1993).
RN   [44]
RP   VARIANTS PRO-755; SER-776; ALA-TYR-VAL-MET-774 INS AND VAL-GLY-SER-779
RP   INS; SER-857 AND LYS-914, AND INVOLVEMENT IN CANCER.
RX   PubMed=15457249; DOI=10.1038/431525b;
RG   Cancer genome project and collaborative group;
RA   Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J.,
RA   Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M.,
RA   Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A.,
RA   Drozd A., Edwards K., Forbes S., Foster R., Gray K., Greenman C.,
RA   Halliday K., Hills K., Kosmidou V., Lugg R., Menzies A., Perry J.,
RA   Petty R., Raine K., Ratford L., Shepherd R., Small A., Stephens Y.,
RA   Tofts C., Varian J., West S., Widaa S., Yates A., Brasseur F.,
RA   Cooper C.S., Flanagan A.M., Knowles M., Leung S.Y., Louis D.N.,
RA   Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.,
RA   Chenevix-Trench G., Weber B.L., Yuen S.T., Harris G., Goldstraw P.,
RA   Nicholson A.G., Futreal P.A., Wooster R., Stratton M.R.;
RT   "Lung cancer: intragenic ERBB2 kinase mutations in tumours.";
RL   Nature 431:525-526(2004).
RN   [45]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; SER-776;
RP   SER-857; ALA-1170 AND ASP-1216.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein tyrosine kinase that is part of several cell
CC       surface receptor complexes, but that apparently needs a coreceptor
CC       for ligand binding. Essential component of a neuregulin-receptor
CC       complex, although neuregulins do not interact with it alone. GP30
CC       is a potential ligand for this receptor. Regulates outgrowth and
CC       stabilization of peripheral microtubules (MTs). Upon ERBB2
CC       activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the
CC       phosphorylation and thus the inhibition of GSK3B at cell membrane.
CC       This prevents the phosphorylation of APC and CLASP2, allowing its
CC       association with the cell membrane. In turn, membrane-bound APC
CC       allows the localization of MACF1 to the cell membrane, which is
CC       required for microtubule capture and stabilization.
CC   -!- FUNCTION: In the nucleus is involved in transcriptional
CC       regulation. Associates with the 5'-TCAAATTC-3' sequence in the
CC       PTGS2/COX-2 promoter and activates its transcription. Implicated
CC       in transcriptional activation of CDKN1A; the function involves
CC       STAT3 and SRC. Involved in the transcription of rRNA genes by RNA
CC       Pol I and enhances protein synthesis and cell growth.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:21454582}.
CC   -!- ENZYME REGULATION: Activated by dimerization. Not activated by
CC       EGF, TGF-alpha and amphiregulin. Interaction with PTK6 increases
CC       its intrinsic kinase activity. {ECO:0000269|PubMed:18719096,
CC       ECO:0000269|PubMed:21454582}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with EGFR, ERBB3 and ERBB4. Part
CC       of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact
CC       with PIK3C2B when phosphorylated on Tyr-1196. Interacts with
CC       PRKCABP and PLXNB1. Interacts (when phosphorylated on Tyr-1248)
CC       with MEMO1. Interacts with MUC1; the interaction is enhanced by
CC       heregulin (HRG). Interacts (when phosphorylated on Tyr-1139) with
CC       GRB7 (via SH2 domain). Interacts (when phosphorylated on Tyr-1248)
CC       with ERBB2IP. Interacts with KPNB1, RANBP2, EEA1, CRM1, CLTC,
CC       PTK6, RPA94 and ACTB. Interacts with SRC and MYOC (By similarity).
CC       Interacts (preferentially with the tyrosine phosphorylated form)
CC       with CPNE3; this interaction occurs at the cell membrane and is
CC       increased in a growth factor heregulin-dependent manner
CC       (PubMed:20010870). {ECO:0000250, ECO:0000269|PubMed:20010870}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-641062, EBI-641062;
CC       P00519:ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543;
CC       P42684:ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694;
CC       P60709:ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944;
CC       Q92625:ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612;
CC       O00213:APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694;
CC       O75815:BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-641062, EBI-295634;
CC       Q9NSE2:CISH; NbExp=4; IntAct=EBI-641062, EBI-617866;
CC       Q7Z7G1:CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-641062, EBI-910;
CC       Q99704:DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360;
CC       Q8TEW6:DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542;
CC       Q15075:EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113;
CC       P98172:EFNB1; NbExp=11; IntAct=EBI-641062, EBI-538287;
CC       P00533:EGFR; NbExp=21; IntAct=EBI-641062, EBI-297353;
CC       P21860:ERBB3; NbExp=25; IntAct=EBI-641062, EBI-720706;
CC       Q15303:ERBB4; NbExp=3; IntAct=EBI-641062, EBI-80371;
CC       Q9UJM3:ERRFI1; NbExp=3; IntAct=EBI-641062, EBI-2941912;
CC       P09769:FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732;
CC       P06241:FYN; NbExp=2; IntAct=EBI-641062, EBI-515315;
CC       O75791:GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418;
CC       P62993:GRB2; NbExp=4; IntAct=EBI-641062, EBI-401755;
CC       Q14451:GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191;
CC       O75367:H2AFY; NbExp=6; IntAct=EBI-641062, EBI-2868511;
CC       O75367-3:H2AFY; NbExp=3; IntAct=EBI-641062, EBI-6250866;
CC       P07900:HSP90AA1; NbExp=4; IntAct=EBI-641062, EBI-296047;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-641062, EBI-352572;
CC       P46940:IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509;
CC       P35568:IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592;
CC       Q08881:ITK; NbExp=2; IntAct=EBI-641062, EBI-968552;
CC       P23458:JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438;
CC       Q14974:KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758;
CC       Q9UQF2:MAPK8IP1; NbExp=3; IntAct=EBI-641062, EBI-78404;
CC       Q13387:MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813;
CC       P42679:MATK; NbExp=2; IntAct=EBI-641062, EBI-751664;
CC       Q9Y316:MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635;
CC       Q02297-7:NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927;
CC       O00750:PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107;
CC       P27986:PIK3R1; NbExp=11; IntAct=EBI-641062, EBI-79464;
CC       O00459:PIK3R2; NbExp=6; IntAct=EBI-641062, EBI-346930;
CC       Q92569:PIK3R3; NbExp=9; IntAct=EBI-641062, EBI-79893;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387;
CC       P16885:PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403;
CC       O95602:POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472;
CC       Q05397:PTK2; NbExp=2; IntAct=EBI-641062, EBI-702142;
CC       Q13882:PTK6; NbExp=2; IntAct=EBI-641062, EBI-1383632;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-641062, EBI-297779;
CC       Q05209:PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035;
CC       P23467:PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766;
CC       P08575:PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500;
CC       Q15262:PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052;
CC       Q16827:PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739;
CC       P49792:RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138;
CC       P20936:RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476;
CC       O95980:RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742;
CC       Q9NP31:SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630;
CC       P29353:SHC1; NbExp=9; IntAct=EBI-641062, EBI-78835;
CC       P98077:SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084;
CC       Q9H6Q3:SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854;
CC       O15524:SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198;
CC       P12931:SRC; NbExp=11; IntAct=EBI-641062, EBI-621482;
CC       P42224:STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697;
CC       P40763:STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675;
CC       Q7KZ85:SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547;
CC       P43405:SYK; NbExp=7; IntAct=EBI-641062, EBI-78302;
CC       Q9Y490:TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036;
CC       Q63HR2:TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488;
CC       Q96D37:VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353;
CC       P52735:VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549;
CC       O14980:XPO1; NbExp=2; IntAct=EBI-641062, EBI-355867;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm, perinuclear region. Nucleus.
CC       Note=Translocation to the nucleus requires endocytosis, probably
CC       endosomal sorting and is mediated by importin beta-1/KPNB1.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=6;
CC       Name=1; Synonyms=ERBB2, HER2;
CC         IsoId=P04626-1; Sequence=Displayed;
CC       Name=2; Synonyms=CTF-611;
CC         IsoId=P04626-2; Sequence=VSP_039249;
CC         Note=Produced by alternative initiation at Met-611 of isoform
CC         1.;
CC       Name=3; Synonyms=CTF-687;
CC         IsoId=P04626-3; Sequence=VSP_039250;
CC         Note=Produced by alternative initiation at Met-687 of isoform
CC         1.;
CC       Name=4;
CC         IsoId=P04626-4; Sequence=VSP_039248;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=5;
CC         IsoId=P04626-5; Sequence=VSP_054787;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on partial mRNA and EST data.;
CC       Name=6; Synonyms=B;
CC         IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904;
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues
CC       including primary breast tumors and tumors from small bowel,
CC       esophagus, kidney and mouth. {ECO:0000269|PubMed:15380516}.
CC   -!- PTM: Autophosphorylated. Ligand-binding increases phosphorylation
CC       on tyrosine residues. Autophosphorylation occurs in trans, i.e.
CC       one subunit of the dimeric receptor phosphorylates tyrosine
CC       residues on the other subunit. Signaling via SEMA4C promotes
CC       phosphorylation at Tyr-1248. {ECO:0000269|PubMed:17554007}.
CC   -!- POLYMORPHISM: There are four alleles due to the variations in
CC       positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency
CC       of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206;
CC       allele B3 (Val-654/Val-655) has a frequency of 0.012.
CC   -!- DISEASE: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A
CC       cancer predisposition syndrome with increased susceptibility to
CC       diffuse gastric cancer. Diffuse gastric cancer is a malignant
CC       disease characterized by poorly differentiated infiltrating
CC       lesions resulting in thickening of the stomach. Malignant tumors
CC       start in the stomach, can spread to the esophagus or the small
CC       intestine, and can extend through the stomach wall to nearby lymph
CC       nodes and organs. It also can metastasize to other parts of the
CC       body. Note=The gene represented in this entry is involved in
CC       disease pathogenesis.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer
CC       defines malignancies originating from ovarian tissue. Although
CC       many histologic types of ovarian tumors have been described,
CC       epithelial ovarian carcinoma is the most common form. Ovarian
CC       cancers are often asymptomatic and the recognized signs and
CC       symptoms, even of late-stage disease, are vague. Consequently,
CC       most patients are diagnosed with advanced disease. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis. Note=The
CC       gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease
CC       which starts in the stomach, can spread to the esophagus or the
CC       small intestine, and can extend through the stomach wall to nearby
CC       lymph nodes and organs. It also can metastasize to other parts of
CC       the body. The term gastric cancer or gastric carcinoma refers to
CC       adenocarcinoma of the stomach that accounts for most of all
CC       gastric malignant tumors. Two main histologic types are
CC       recognized, diffuse type and intestinal type carcinomas. Diffuse
CC       tumors are poorly differentiated infiltrating lesions, resulting
CC       in thickening of the stomach. In contrast, intestinal tumors are
CC       usually exophytic, often ulcerating, and associated with
CC       intestinal metaplasia of the stomach, most often observed in
CC       sporadic disease. Note=The gene represented in this entry is
CC       involved in disease pathogenesis.
CC   -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a
CC       cause gastric cancer. Deletions within 17q12 region producing
CC       fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion
CC       leading to truncated CDK12 protein not in-frame with ERBB2.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/erbb2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry;
CC       URL="https://en.wikipedia.org/wiki/ERBB2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AH001455; AAA35808.1; -; Genomic_DNA.
DR   EMBL; X03363; CAA27060.1; -; mRNA.
DR   EMBL; M11730; AAA75493.1; -; mRNA.
DR   EMBL; M12036; AAA35978.1; -; Genomic_DNA.
DR   EMBL; AY208911; AAO18082.1; -; Genomic_DNA.
DR   EMBL; AK295195; BAG58195.1; -; mRNA.
DR   EMBL; CH471152; EAW60597.1; -; Genomic_DNA.
DR   EMBL; BC167147; AAI67147.1; -; mRNA.
DR   EMBL; M16792; AAA58637.1; -; Genomic_DNA.
DR   EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; KJ534964; AHW56604.1; -; mRNA.
DR   EMBL; L29395; AAA35809.1; -; Genomic_DNA.
DR   EMBL; M95667; AAC37531.1; -; Genomic_DNA.
DR   CCDS; CCDS32642.1; -. [P04626-1]
DR   CCDS; CCDS45667.1; -. [P04626-5]
DR   CCDS; CCDS74052.1; -. [P04626-4]
DR   PIR; A24571; A24571.
DR   RefSeq; NP_001005862.1; NM_001005862.2. [P04626-5]
DR   RefSeq; NP_001276865.1; NM_001289936.1. [P04626-4]
DR   RefSeq; NP_001276867.1; NM_001289938.1.
DR   RefSeq; NP_004439.2; NM_004448.3. [P04626-1]
DR   UniGene; Hs.446352; -.
DR   PDB; 1MFG; X-ray; 1.25 A; B=1247-1255.
DR   PDB; 1MFL; X-ray; 1.88 A; B=1247-1255.
DR   PDB; 1MW4; NMR; -; B=1135-1144.
DR   PDB; 1N8Z; X-ray; 2.52 A; C=23-629.
DR   PDB; 1OVC; Model; -; A=737-1031.
DR   PDB; 1QR1; X-ray; 2.40 A; C/F=654-662.
DR   PDB; 1S78; X-ray; 3.25 A; A/B=23-646.
DR   PDB; 2A91; X-ray; 2.50 A; A=22-530.
DR   PDB; 2JWA; NMR; -; A/B=641-684.
DR   PDB; 2KS1; NMR; -; A=641-684.
DR   PDB; 2L4K; NMR; -; B=1135-1144.
DR   PDB; 3BE1; X-ray; 2.90 A; A=23-646.
DR   PDB; 3H3B; X-ray; 2.45 A; A/B=23-214.
DR   PDB; 3MZW; X-ray; 2.90 A; A=23-646.
DR   PDB; 3N85; X-ray; 3.20 A; A=23-646.
DR   PDB; 3PP0; X-ray; 2.25 A; A/B=703-1009.
DR   PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028.
DR   PDB; 3WLW; X-ray; 3.09 A; A/B=23-586.
DR   PDB; 3WSQ; X-ray; 3.50 A; A=23-586.
DR   PDB; 4GFU; X-ray; 2.00 A; F=1246-1252.
DR   PDB; 4HRL; X-ray; 2.55 A; C=24-219.
DR   PDB; 4HRM; X-ray; 3.20 A; A/C=24-219.
DR   PDB; 4HRN; X-ray; 2.65 A; C/D=529-625.
DR   PDBsum; 1MFG; -.
DR   PDBsum; 1MFL; -.
DR   PDBsum; 1MW4; -.
DR   PDBsum; 1N8Z; -.
DR   PDBsum; 1OVC; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1S78; -.
DR   PDBsum; 2A91; -.
DR   PDBsum; 2JWA; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 2L4K; -.
DR   PDBsum; 3BE1; -.
DR   PDBsum; 3H3B; -.
DR   PDBsum; 3MZW; -.
DR   PDBsum; 3N85; -.
DR   PDBsum; 3PP0; -.
DR   PDBsum; 3RCD; -.
DR   PDBsum; 3WLW; -.
DR   PDBsum; 3WSQ; -.
DR   PDBsum; 4GFU; -.
DR   PDBsum; 4HRL; -.
DR   PDBsum; 4HRM; -.
DR   PDBsum; 4HRN; -.
DR   ProteinModelPortal; P04626; -.
DR   SMR; P04626; 22-629, 641-1009.
DR   BioGrid; 108376; 125.
DR   DIP; DIP-8N; -.
DR   IntAct; P04626; 243.
DR   MINT; MINT-158636; -.
DR   STRING; 9606.ENSP00000269571; -.
DR   BindingDB; P04626; -.
DR   ChEMBL; CHEMBL2363049; -.
DR   DrugBank; DB05773; ado-trastuzumab emtansine.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB06366; Pertuzumab.
DR   DrugBank; DB00072; Trastuzumab.
DR   GuidetoPHARMACOLOGY; 2019; -.
DR   iPTMnet; P04626; -.
DR   PhosphoSite; P04626; -.
DR   BioMuta; ERBB2; -.
DR   DMDM; 119533; -.
DR   PaxDb; P04626; -.
DR   PRIDE; P04626; -.
DR   DNASU; 2064; -.
DR   Ensembl; ENST00000269571; ENSP00000269571; ENSG00000141736. [P04626-1]
DR   Ensembl; ENST00000406381; ENSP00000385185; ENSG00000141736. [P04626-5]
DR   Ensembl; ENST00000541774; ENSP00000446466; ENSG00000141736. [P04626-4]
DR   Ensembl; ENST00000584601; ENSP00000462438; ENSG00000141736. [P04626-5]
DR   GeneID; 2064; -.
DR   KEGG; hsa:2064; -.
DR   UCSC; uc002hsm.3; human. [P04626-1]
DR   UCSC; uc010cwa.3; human. [P04626-4]
DR   CTD; 2064; -.
DR   GeneCards; ERBB2; -.
DR   HGNC; HGNC:3430; ERBB2.
DR   HPA; CAB000043; -.
DR   HPA; CAB020416; -.
DR   HPA; CAB062555; -.
DR   HPA; HPA001338; -.
DR   HPA; HPA001383; -.
DR   MalaCards; ERBB2; -.
DR   MIM; 137215; phenotype.
DR   MIM; 137800; phenotype.
DR   MIM; 164870; gene.
DR   MIM; 167000; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 613659; phenotype.
DR   neXtProt; NX_P04626; -.
DR   PharmGKB; PA27844; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P04626; -.
DR   KO; K05083; -.
DR   OMA; ACYPLCA; -.
DR   OrthoDB; EOG7V49XM; -.
DR   PhylomeDB; P04626; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P04626; -.
DR   ChiTaRS; ERBB2; human.
DR   EvolutionaryTrace; P04626; -.
DR   GeneWiki; HER2/neu; -.
DR   GenomeRNAi; 2064; -.
DR   NextBio; 8385; -.
DR   PMAP-CutDB; P04626; -.
DR   PRO; PR:P04626; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P04626; -.
DR   CleanEx; HS_ERBB2; -.
DR   ExpressionAtlas; P04626; baseline and differential.
DR   Genevisible; P04626; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0007167; P:enzyme linked receptor protein signaling pathway; TAS:ProtInc.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:GOC.
DR   GO; GO:0007422; P:peripheral nervous system development; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:0045943; P:positive regulation of transcription from RNA polymerase I promoter; IMP:UniProtKB.
DR   GO; GO:0045945; P:positive regulation of transcription from RNA polymerase III promoter; IDA:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative initiation; Alternative splicing;
KW   ATP-binding; Cell membrane; Chromosomal rearrangement;
KW   Complete proteome; Cytoplasm; Disulfide bond; Glycoprotein; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Signal; Transcription;
KW   Transcription regulation; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1255       Receptor tyrosine-protein kinase erbB-2.
FT                                /FTId=PRO_0000016669.
FT   TOPO_DOM     23    652       Extracellular. {ECO:0000255}.
FT   TRANSMEM    653    675       Helical. {ECO:0000255}.
FT   TOPO_DOM    676   1255       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      720    987       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     726    734       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      676    689       Required for interaction with KPNB1 and
FT                                EEA1.
FT   REGION     1195   1197       Interaction with PIK3C2B. {ECO:0000305}.
FT   MOTIF       676    689       Nuclear localization signal.
FT   ACT_SITE    845    845       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     753    753       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1054   1054       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1078   1078       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06494}.
FT   MOD_RES    1083   1083       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06494}.
FT   MOD_RES    1107   1107       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1139   1139       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1151   1151       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1196   1196       Phosphotyrosine. {ECO:0000255}.
FT   MOD_RES    1248   1248       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000269|PubMed:17554007}.
FT   CARBOHYD     68     68       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    124    124       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    187    187       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    259    259       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15093539,
FT                                ECO:0000269|PubMed:19299620,
FT                                ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    530    530       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15093539,
FT                                ECO:0000269|PubMed:19299620}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    629    629       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     26     53
FT   DISULFID    162    192
FT   DISULFID    195    204
FT   DISULFID    199    212
FT   DISULFID    220    227
FT   DISULFID    224    235
FT   DISULFID    236    244
FT   DISULFID    240    252
FT   DISULFID    255    264
FT   DISULFID    268    295
FT   DISULFID    299    311
FT   DISULFID    315    331
FT   DISULFID    334    338
FT   DISULFID    342    367
FT   DISULFID    475    504
FT   DISULFID    511    520
FT   DISULFID    515    528
FT   DISULFID    531    540
FT   DISULFID    544    560
FT   DISULFID    563    576
FT   DISULFID    567    584
FT   DISULFID    587    596
FT   DISULFID    600    623
FT   DISULFID    626    634       {ECO:0000250}.
FT   DISULFID    630    642       {ECO:0000250}.
FT   VAR_SEQ       1    686       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_039250.
FT   VAR_SEQ       1    610       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_039249.
FT   VAR_SEQ       1     30       Missing (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_054787.
FT   VAR_SEQ       1     23       MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in
FT                                isoform 4). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_039248.
FT   VAR_SEQ     633    648       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055902.
FT   VAR_SEQ     771    883       AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVR
FT                                ENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVL
FT                                VKSPNHVKITDFGLARLLDIDETEYHADGGK -> TISNLF
FT                                SNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLW
FT                                GCRGEPRVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTR
FT                                AGGSTQHLQRDTYGREPRVPGSGRASVNQKAKSAEALMCPQ
FT                                GAGKA (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055903.
FT   VAR_SEQ     884   1255       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055904.
FT   VARIANT     452    452       W -> C (in dbSNP:rs4252633).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_016317.
FT   VARIANT     654    654       I -> V (in allele B3; dbSNP:rs1801201).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8095488}.
FT                                /FTId=VAR_004077.
FT   VARIANT     655    655       I -> V (in allele B2 and allele B3;
FT                                dbSNP:rs1136201).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8095488,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_004078.
FT   VARIANT     755    755       L -> P (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055432.
FT   VARIANT     768    768       L -> S (in dbSNP:rs56366519).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042097.
FT   VARIANT     774    774       M -> MAYVM (in a lung adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_055433.
FT   VARIANT     776    776       G -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs28933369).
FT                                {ECO:0000269|PubMed:15457249,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042098.
FT   VARIANT     779    779       S -> SVGS (in a lung adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_055434.
FT   VARIANT     857    857       N -> S (in an ovarian cancer sample;
FT                                somatic mutation; dbSNP:rs28933370).
FT                                {ECO:0000269|PubMed:15457249,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042099.
FT   VARIANT     914    914       E -> K (in a glioblastoma sample; somatic
FT                                mutation; dbSNP:rs28933368).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055435.
FT   VARIANT    1170   1170       P -> A (in dbSNP:rs61552325).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:2999974,
FT                                ECO:0000269|PubMed:8104414,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_016318.
FT   VARIANT    1216   1216       A -> D (in dbSNP:rs55943169).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042100.
FT   MUTAGEN     317    318       LH->AA: Reduces dimerization with ERBB3.
FT                                {ECO:0000269|PubMed:15093539}.
FT   MUTAGEN     611    611       M->A: Prevents synthesis of isoform 2.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     687    687       M->A: Prevents synthesis of isoform 3.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     706    706       M->A: No effect on isoform production.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     712    712       M->A: No effect on isoform production.
FT                                {ECO:0000269|PubMed:16794579}.
FT   STRAND       25     27       {ECO:0000244|PDB:3H3B}.
FT   HELIX        39     50       {ECO:0000244|PDB:3H3B}.
FT   STRAND       54     58       {ECO:0000244|PDB:3H3B}.
FT   STRAND       60     64       {ECO:0000244|PDB:3H3B}.
FT   HELIX        72     74       {ECO:0000244|PDB:3H3B}.
FT   STRAND       79     82       {ECO:0000244|PDB:3H3B}.
FT   STRAND       84     88       {ECO:0000244|PDB:3H3B}.
FT   STRAND       92     95       {ECO:0000244|PDB:3H3B}.
FT   TURN        109    111       {ECO:0000244|PDB:3H3B}.
FT   STRAND      112    117       {ECO:0000244|PDB:3H3B}.
FT   TURN        130    132       {ECO:0000244|PDB:3H3B}.
FT   STRAND      139    141       {ECO:0000244|PDB:3H3B}.
FT   STRAND      150    156       {ECO:0000244|PDB:3H3B}.
FT   TURN        164    166       {ECO:0000244|PDB:3H3B}.
FT   HELIX       169    172       {ECO:0000244|PDB:3H3B}.
FT   HELIX       175    177       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      182    184       {ECO:0000244|PDB:3H3B}.
FT   STRAND      199    202       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      204    208       {ECO:0000244|PDB:3H3B}.
FT   HELIX       209    211       {ECO:0000244|PDB:4HRL}.
FT   STRAND      217    219       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      221    223       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      227    231       {ECO:0000244|PDB:2A91}.
FT   HELIX       232    234       {ECO:0000244|PDB:2A91}.
FT   STRAND      240    248       {ECO:0000244|PDB:2A91}.
FT   STRAND      251    260       {ECO:0000244|PDB:2A91}.
FT   STRAND      263    267       {ECO:0000244|PDB:2A91}.
FT   STRAND      271    274       {ECO:0000244|PDB:2A91}.
FT   TURN        276    278       {ECO:0000244|PDB:2A91}.
FT   STRAND      281    283       {ECO:0000244|PDB:2A91}.
FT   STRAND      289    291       {ECO:0000244|PDB:2A91}.
FT   STRAND      294    298       {ECO:0000244|PDB:2A91}.
FT   STRAND      303    305       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      309    314       {ECO:0000244|PDB:2A91}.
FT   STRAND      320    323       {ECO:0000244|PDB:2A91}.
FT   STRAND      325    327       {ECO:0000244|PDB:3MZW}.
FT   STRAND      329    332       {ECO:0000244|PDB:2A91}.
FT   STRAND      335    337       {ECO:0000244|PDB:2A91}.
FT   HELIX       348    352       {ECO:0000244|PDB:2A91}.
FT   TURN        358    360       {ECO:0000244|PDB:2A91}.
FT   HELIX       361    364       {ECO:0000244|PDB:2A91}.
FT   STRAND      368    376       {ECO:0000244|PDB:2A91}.
FT   HELIX       378    382       {ECO:0000244|PDB:2A91}.
FT   HELIX       385    387       {ECO:0000244|PDB:2A91}.
FT   HELIX       396    402       {ECO:0000244|PDB:2A91}.
FT   STRAND      405    408       {ECO:0000244|PDB:2A91}.
FT   STRAND      410    413       {ECO:0000244|PDB:2A91}.
FT   HELIX       423    425       {ECO:0000244|PDB:2A91}.
FT   STRAND      430    435       {ECO:0000244|PDB:3WLW}.
FT   TURN        438    440       {ECO:0000244|PDB:2A91}.
FT   STRAND      441    447       {ECO:0000244|PDB:2A91}.
FT   STRAND      463    469       {ECO:0000244|PDB:2A91}.
FT   TURN        477    479       {ECO:0000244|PDB:3WLW}.
FT   HELIX       482    485       {ECO:0000244|PDB:2A91}.
FT   STRAND      486    488       {ECO:0000244|PDB:3N85}.
FT   STRAND      493    499       {ECO:0000244|PDB:2A91}.
FT   HELIX       501    506       {ECO:0000244|PDB:2A91}.
FT   TURN        507    509       {ECO:0000244|PDB:3N85}.
FT   HELIX       516    518       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      520    524       {ECO:0000244|PDB:2A91}.
FT   HELIX       525    527       {ECO:0000244|PDB:2A91}.
FT   STRAND      528    536       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      539    542       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      545    551       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      553    556       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      559    562       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      565    567       {ECO:0000244|PDB:3WSQ}.
FT   STRAND      571    573       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      575    580       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      583    592       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      595    599       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      602    604       {ECO:0000244|PDB:3N85}.
FT   STRAND      615    617       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      621    625       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      628    632       {ECO:0000244|PDB:3N85}.
FT   STRAND      635    637       {ECO:0000244|PDB:3N85}.
FT   HELIX       651    678       {ECO:0000244|PDB:2JWA}.
FT   HELIX       717    719       {ECO:0000244|PDB:3PP0}.
FT   STRAND      720    728       {ECO:0000244|PDB:3PP0}.
FT   STRAND      730    739       {ECO:0000244|PDB:3PP0}.
FT   STRAND      748    755       {ECO:0000244|PDB:3PP0}.
FT   HELIX       761    774       {ECO:0000244|PDB:3PP0}.
FT   STRAND      785    799       {ECO:0000244|PDB:3PP0}.
FT   HELIX       806    812       {ECO:0000244|PDB:3PP0}.
FT   TURN        814    816       {ECO:0000244|PDB:3PP0}.
FT   HELIX       819    838       {ECO:0000244|PDB:3PP0}.
FT   HELIX       848    850       {ECO:0000244|PDB:3PP0}.
FT   STRAND      851    855       {ECO:0000244|PDB:3PP0}.
FT   STRAND      858    861       {ECO:0000244|PDB:3PP0}.
FT   HELIX       886    888       {ECO:0000244|PDB:3PP0}.
FT   HELIX       891    896       {ECO:0000244|PDB:3PP0}.
FT   HELIX       901    916       {ECO:0000244|PDB:3PP0}.
FT   TURN        922    925       {ECO:0000244|PDB:3PP0}.
FT   HELIX       928    930       {ECO:0000244|PDB:3PP0}.
FT   HELIX       931    936       {ECO:0000244|PDB:3PP0}.
FT   HELIX       949    958       {ECO:0000244|PDB:3PP0}.
FT   HELIX       963    965       {ECO:0000244|PDB:3PP0}.
FT   HELIX       969    980       {ECO:0000244|PDB:3PP0}.
FT   HELIX       983    986       {ECO:0000244|PDB:3PP0}.
FT   HELIX       989    992       {ECO:0000244|PDB:3PP0}.
FT   HELIX      1003   1007       {ECO:0000244|PDB:3PP0}.
FT   STRAND     1140   1142       {ECO:0000244|PDB:1MW4}.
SQ   SEQUENCE   1255 AA;  137910 MW;  39E9DFDA04DCF962 CRC64;
     MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
     ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
     DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
     LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
     AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
     IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP
     DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV
     PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC
     VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
     ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL
     RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
     YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR
     LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT
     HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
     IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
     EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG
     AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
     NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
     GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV
//
ID   BMP4_MOUSE              Reviewed;         408 AA.
AC   P21275;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 2.
DT   20-JAN-2016, entry version 167.
DE   RecName: Full=Bone morphogenetic protein 4;
DE            Short=BMP-4;
DE   AltName: Full=Bone morphogenetic protein 2B;
DE            Short=BMP-2B;
DE   Flags: Precursor;
GN   Name=Bmp4; Synonyms=Bmp-4, Dvr-4;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Dickinson M.E., van der Meer-De Jong R., Hogan B.L.M.;
RT   "Nucleotide sequence of the mouse bone morphogenetic protein-4 (BMP-4)
RT   cDNA.";
RL   Submitted (OCT-1992) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8507180; DOI=10.1006/bbrc.1993.1523;
RA   Kurihara T., Kitamura K., Takaoka K., Nakazato H.;
RT   "Murine bone morphogenetic protein-4 gene: existence of multiple
RT   promoters and exons for the 5'-untranslated region.";
RL   Biochem. Biophys. Res. Commun. 192:1049-1056(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8358941;
RA   Takaoka K., Yoshikawa H., Hasimoto J., Masuhara K., Miyamoto S.,
RA   Suzuki S., Ono K., Matsui M., Oikawa S., Tsuruoka N.;
RT   "Gene cloning and expression of a bone morphogenetic protein derived
RT   from a murine osteosarcoma.";
RL   Clin. Orthop. Relat. Res. 294:344-352(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=129/Sv; TISSUE=Liver;
RX   PubMed=7499338; DOI=10.1074/jbc.270.47.28364;
RA   Feng J.Q., Chen D., Cooney A.J., Tsai M., Harris M.A., Tsai S.Y.,
RA   Feng M., Mundy G.R., Harris S.E.;
RT   "The mouse bone morphogenetic protein-4 gene. Analysis of promoter
RT   utilization in fetal rat calvarial osteoblasts and regulation by COUP-
RT   TFI orphan receptor.";
RL   J. Biol. Chem. 270:28364-28373(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C3H/He, and FVB/N;
RC   TISSUE=Colon, Osteoblast, and Salivary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE OF 241-408.
RX   PubMed=1970330; DOI=10.1016/0888-7543(90)90480-I;
RA   Dickinson M.E., Kobrin M.S., Silan C.M., Kingsley D.M., Justice M.J.,
RA   Miller D.A., Ceci J.D., Lock L.F., Lee A., Buchberg A.M.,
RA   Siracusa L.D., Lyons K.M., Derynck R., Hogan B.L.M., Copeland N.G.,
RA   Jenkins N.A.;
RT   "Chromosomal localization of seven members of the murine TGF-beta
RT   superfamily suggests close linkage to several morphogenetic mutant
RT   loci.";
RL   Genomics 6:505-520(1990).
RN   [7]
RP   INTERACTION WITH TWSG1 AND CHRD.
RX   PubMed=11260715; DOI=10.1038/35068572;
RA   Scott I.C., Blitz I.L., Pappano W.N., Maas S.A., Cho K.W.Y.,
RA   Greenspan D.S.;
RT   "Homologues of Twisted gastrulation are extracellular cofactors in
RT   antagonism of BMP signalling.";
RL   Nature 410:475-478(2001).
RN   [8]
RP   INTERACTION WITH SOSTDC1.
RX   PubMed=14623234; DOI=10.1016/j.ydbio.2003.08.011;
RA   Laurikkala J., Kassai Y., Pakkasjaervi L., Thesleff I., Itoh N.;
RT   "Identification of a secreted BMP antagonist, ectodin, integrating
RT   BMP, FGF, and SHH signals from the tooth enamel knot.";
RL   Dev. Biol. 264:91-105(2003).
RN   [9]
RP   INTERACTION WITH HTRA3, AND FUNCTION.
RX   PubMed=15206957; DOI=10.1111/j.1440-169X.2004.00743.x;
RA   Tocharus J., Tsuchiya A., Kajikawa M., Ueta Y., Oka C., Kawaichi M.;
RT   "Developmentally regulated expression of mouse HtrA3 and its role as
RT   an inhibitor of TGF-beta signaling.";
RL   Dev. Growth Differ. 46:257-274(2004).
RN   [10]
RP   INTERACTION WITH HTRA1, AND FUNCTION.
RX   PubMed=14973287; DOI=10.1242/dev.00999;
RA   Oka C., Tsujimoto R., Kajikawa M., Koshiba-Takeuchi K., Ina J.,
RA   Yano M., Tsuchiya A., Ueta Y., Soma A., Kanda H., Matsumoto M.,
RA   Kawaichi M.;
RT   "HtrA1 serine protease inhibits signaling mediated by Tgfbeta family
RT   proteins.";
RL   Development 131:1041-1053(2004).
RN   [11]
RP   INTERACTION WITH GREM2.
RX   PubMed=15039429; DOI=10.1074/jbc.M402376200;
RA   Sudo S., Avsian-Kretchmer O., Wang L.S., Hsueh A.J.;
RT   "Protein related to DAN and cerberus is a bone morphogenetic protein
RT   antagonist that participates in ovarian paracrine regulation.";
RL   J. Biol. Chem. 279:23134-23141(2004).
RN   [12]
RP   INTERACTION WITH RGMB.
RX   PubMed=15671031; DOI=10.1074/jbc.M410034200;
RA   Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis Y., Jeong S.-J.,
RA   Campagna J.A., Perusini S., Fabrizio D.A., Schneyer A.L., Lin H.Y.,
RA   Brivanlou A.H., Attisano L., Woolf C.J.;
RT   "DRAGON, a bone morphogenetic protein co-receptor.";
RL   J. Biol. Chem. 280:14122-14129(2005).
RN   [13]
RP   INTERACTION WITH RGMA.
RX   PubMed=15975920; DOI=10.1074/jbc.M503511200;
RA   Babitt J.L., Zhang Y., Samad T.A., Xia Y., Tang J., Campagna J.A.,
RA   Schneyer A.L., Woolf C.J., Lin H.Y.;
RT   "Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone
RT   morphogenetic protein co-receptor.";
RL   J. Biol. Chem. 280:29820-29827(2005).
RN   [14]
RP   INTERACTION WITH RGMC.
RX   PubMed=16604073; DOI=10.1038/ng1777;
RA   Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A.,
RA   Campagna J.A., Chung R.T., Schneyer A.L., Woolf C.J., Andrews N.C.,
RA   Lin H.Y.;
RT   "Bone morphogenetic protein signaling by hemojuvelin regulates
RT   hepcidin expression.";
RL   Nat. Genet. 38:531-539(2006).
RN   [15]
RP   FUNCTION.
RX   PubMed=17301089; DOI=10.1242/dev.000182;
RA   Hens J.R., Dann P., Zhang J.P., Harris S., Robinson G.W.,
RA   Wysolmerski J.;
RT   "BMP4 and PTHrP interact to stimulate ductal outgrowth during
RT   embryonic mammary development and to inhibit hair follicle
RT   induction.";
RL   Development 134:1221-1230(2007).
RN   [16]
RP   INTERACTION WITH RGMA.
RX   PubMed=17472960; DOI=10.1074/jbc.M701679200;
RA   Xia Y., Yu P.B., Sidis Y., Beppu H., Bloch K.D., Schneyer A.L.,
RA   Lin H.Y.;
RT   "Repulsive guidance molecule RGMa alters utilization of bone
RT   morphogenetic protein (BMP) type II receptors by BMP2 and BMP4.";
RL   J. Biol. Chem. 282:18129-18140(2007).
CC   -!- FUNCTION: Induces cartilage and bone formation. Acts in concert
CC       with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic
CC       mammary development and to inhibit hair follicle induction.
CC       {ECO:0000269|PubMed:14973287, ECO:0000269|PubMed:15206957,
CC       ECO:0000269|PubMed:17301089}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Interacts
CC       with SOSTDC1, GREM2, RGMA, RGMB and RGMC. Part of a complex
CC       consisting of TWSG1 and CHRD. Interacts with the serine proteases,
CC       HTRA1 and HTRA3; the interaction with either inhibits BMP4-
CC       mediated signaling. The HTRA protease activity is required for
CC       this inhibition. {ECO:0000250, ECO:0000269|PubMed:11260715,
CC       ECO:0000269|PubMed:14623234, ECO:0000269|PubMed:14973287,
CC       ECO:0000269|PubMed:15039429, ECO:0000269|PubMed:15206957,
CC       ECO:0000269|PubMed:15671031, ECO:0000269|PubMed:15975920,
CC       ECO:0000269|PubMed:16604073, ECO:0000269|PubMed:17472960}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC37698.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56848; CAA40179.1; -; mRNA.
DR   EMBL; D14814; BAA03555.1; -; Genomic_DNA.
DR   EMBL; S65032; AAB28021.1; -; mRNA.
DR   EMBL; L47480; AAC37698.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC013459; AAH13459.1; -; mRNA.
DR   EMBL; BC034053; AAH34053.1; -; mRNA.
DR   EMBL; BC052846; AAH52846.1; -; mRNA.
DR   CCDS; CCDS36897.1; -.
DR   PIR; I49541; I49541.
DR   PIR; JH0801; JH0801.
DR   RefSeq; NP_001303289.1; NM_001316360.1.
DR   RefSeq; NP_031580.2; NM_007554.3.
DR   RefSeq; XP_006518530.1; XM_006518467.2.
DR   RefSeq; XP_006518531.1; XM_006518468.2.
DR   RefSeq; XP_011243236.1; XM_011244934.1.
DR   RefSeq; XP_011243237.1; XM_011244935.1.
DR   UniGene; Mm.6813; -.
DR   ProteinModelPortal; P21275; -.
DR   SMR; P21275; 307-408.
DR   BioGrid; 198364; 3.
DR   STRING; 10090.ENSMUSP00000073720; -.
DR   BindingDB; P21275; -.
DR   ChEMBL; CHEMBL2384894; -.
DR   iPTMnet; P21275; -.
DR   PhosphoSite; P21275; -.
DR   MaxQB; P21275; -.
DR   PaxDb; P21275; -.
DR   PRIDE; P21275; -.
DR   Ensembl; ENSMUST00000074077; ENSMUSP00000073720; ENSMUSG00000021835.
DR   Ensembl; ENSMUST00000100676; ENSMUSP00000098242; ENSMUSG00000021835.
DR   GeneID; 12159; -.
DR   KEGG; mmu:12159; -.
DR   UCSC; uc007thd.2; mouse.
DR   CTD; 652; -.
DR   MGI; MGI:88180; Bmp4.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   HOGENOM; HOG000249478; -.
DR   HOVERGEN; HBG004860; -.
DR   InParanoid; P21275; -.
DR   KO; K04662; -.
DR   OMA; TRLVRHN; -.
DR   OrthoDB; EOG7WHH9D; -.
DR   PhylomeDB; P21275; -.
DR   TreeFam; TF351789; -.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   NextBio; 280503; -.
DR   PRO; PR:P21275; -.
DR   Proteomes; UP000000589; Chromosome 14.
DR   Bgee; P21275; -.
DR   CleanEx; MM_BMP4; -.
DR   ExpressionAtlas; P21275; baseline and differential.
DR   Genevisible; P21275; MM.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; IDA:MGI.
DR   GO; GO:0031988; C:membrane-bounded vesicle; IEA:Ensembl.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0070700; F:BMP receptor binding; ISS:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; ISS:UniProtKB.
DR   GO; GO:0039706; F:co-receptor binding; ISO:MGI.
DR   GO; GO:0005125; F:cytokine activity; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; IDA:MGI.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0000186; P:activation of MAPKK activity; ISS:UniProtKB.
DR   GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IGI:MGI.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IMP:MGI.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IGI:MGI.
DR   GO; GO:0001568; P:blood vessel development; IDA:MGI.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0030509; P:BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0003130; P:BMP signaling pathway involved in heart induction; ISS:UniProtKB.
DR   GO; GO:0071893; P:BMP signaling pathway involved in nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0061151; P:BMP signaling pathway involved in renal system segmentation; IMP:UniProtKB.
DR   GO; GO:0061149; P:BMP signaling pathway involved in ureter morphogenesis; IDA:UniProtKB.
DR   GO; GO:0060348; P:bone development; IDA:MGI.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0060433; P:bronchus development; ISO:MGI.
DR   GO; GO:0060503; P:bud dilation involved in lung branching; ISO:MGI.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; IDA:MGI.
DR   GO; GO:0043010; P:camera-type eye development; IMP:MGI.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IMP:MGI.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; NAS:UniProtKB.
DR   GO; GO:0045165; P:cell fate commitment; IDA:MGI.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; ISO:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:MGI.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0060197; P:cloacal septation; IEP:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060363; P:cranial suture morphogenesis; IDA:MGI.
DR   GO; GO:0035993; P:deltoid tuberosity development; IMP:UniProtKB.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IDA:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:MGI.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IGI:MGI.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IGI:MGI.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IMP:MGI.
DR   GO; GO:0048598; P:embryonic morphogenesis; IMP:MGI.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IMP:MGI.
DR   GO; GO:0048706; P:embryonic skeletal system development; IMP:MGI.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; IMP:MGI.
DR   GO; GO:0001958; P:endochondral ossification; IMP:UniProtKB.
DR   GO; GO:0060502; P:epithelial cell proliferation involved in lung morphogenesis; ISO:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; ISO:MGI.
DR   GO; GO:0060684; P:epithelial-mesenchymal cell signaling; IDA:MGI.
DR   GO; GO:0060429; P:epithelium development; IDA:MGI.
DR   GO; GO:0030218; P:erythrocyte differentiation; IDA:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0007281; P:germ cell development; IMP:MGI.
DR   GO; GO:0072104; P:glomerular capillary formation; IMP:UniProtKB.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; IEP:UniProtKB.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0060113; P:inner ear receptor cell differentiation; IGI:MGI.
DR   GO; GO:0048392; P:intermediate mesodermal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IGI:UniProtKB.
DR   GO; GO:0060235; P:lens induction in camera-type eye; IMP:MGI.
DR   GO; GO:0048286; P:lung alveolus development; ISO:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060462; P:lung lobe development; IEA:Ensembl.
DR   GO; GO:0060425; P:lung morphogenesis; ISO:MGI.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; ISO:MGI.
DR   GO; GO:0060592; P:mammary gland formation; IMP:MGI.
DR   GO; GO:0072161; P:mesenchymal cell differentiation involved in kidney development; IMP:UniProtKB.
DR   GO; GO:2001012; P:mesenchymal cell differentiation involved in renal system development; IMP:UniProtKB.
DR   GO; GO:0072198; P:mesenchymal cell proliferation involved in ureter development; IEP:UniProtKB.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; IEP:UniProtKB.
DR   GO; GO:0003337; P:mesenchymal to epithelial transition involved in metanephros morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001707; P:mesoderm formation; IDA:MGI.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IDA:MGI.
DR   GO; GO:0007500; P:mesodermal cell fate determination; IMP:MGI.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0072205; P:metanephric collecting duct development; IMP:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IDA:MGI.
DR   GO; GO:0030224; P:monocyte differentiation; ISO:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0072097; P:negative regulation of branch elongation involved in ureteric bud branching by BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0090191; P:negative regulation of branching involved in ureteric bud morphogenesis; IDA:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IGI:MGI.
DR   GO; GO:2000137; P:negative regulation of cell proliferation involved in heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IDA:MGI.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:MGI.
DR   GO; GO:0072125; P:negative regulation of glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0090194; P:negative regulation of glomerulus development; ISS:UniProtKB.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; ISS:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0072200; P:negative regulation of mesenchymal cell proliferation involved in ureter development; ISS:UniProtKB.
DR   GO; GO:2000007; P:negative regulation of metanephric comma-shaped body morphogenesis; ISS:UniProtKB.
DR   GO; GO:2000005; P:negative regulation of metanephric S-shaped body morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; ISO:MGI.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060686; P:negative regulation of prostatic bud formation; IDA:MGI.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; ISO:MGI.
DR   GO; GO:0033085; P:negative regulation of T cell differentiation in thymus; ISO:MGI.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; IDA:MGI.
DR   GO; GO:0048663; P:neuron fate commitment; IDA:MGI.
DR   GO; GO:0042476; P:odontogenesis; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IDA:MGI.
DR   GO; GO:0001759; P:organ induction; IMP:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IMP:MGI.
DR   GO; GO:0050918; P:positive chemotaxis; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IMP:UniProtKB.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl.
DR   GO; GO:0055020; P:positive regulation of cardiac muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0061036; P:positive regulation of cartilage development; ISO:MGI.
DR   GO; GO:0010942; P:positive regulation of cell death; ISO:MGI.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:CACAO.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISS:UniProtKB.
DR   GO; GO:2000105; P:positive regulation of DNA-dependent DNA replication; ISS:UniProtKB.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IDA:DFLAT.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045606; P:positive regulation of epidermal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CACAO.
DR   GO; GO:0070368; P:positive regulation of hepatocyte differentiation; IEA:Ensembl.
DR   GO; GO:0090184; P:positive regulation of kidney development; ISS:UniProtKB.
DR   GO; GO:1902462; P:positive regulation of mesenchymal stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:MGI.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISO:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:MGI.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:1901341; P:positive regulation of store-operated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; TAS:DFLAT.
DR   GO; GO:0009791; P:post-embryonic development; IMP:MGI.
DR   GO; GO:0060512; P:prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0034504; P:protein localization to nucleus; ISS:UniProtKB.
DR   GO; GO:0061155; P:pulmonary artery endothelial tube morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0061035; P:regulation of cartilage development; IDA:MGI.
DR   GO; GO:0045595; P:regulation of cell differentiation; IGI:MGI.
DR   GO; GO:0010453; P:regulation of cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0060688; P:regulation of morphogenesis of a branching structure; IMP:MGI.
DR   GO; GO:0042487; P:regulation of odontogenesis of dentin-containing tooth; IGI:MGI.
DR   GO; GO:0060393; P:regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; ISO:MGI.
DR   GO; GO:0051150; P:regulation of smooth muscle cell differentiation; IDA:MGI.
DR   GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IDA:MGI.
DR   GO; GO:0072001; P:renal system development; IGI:MGI.
DR   GO; GO:0003014; P:renal system process; IMP:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0071731; P:response to nitric oxide; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0003139; P:secondary heart field specification; ISS:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IDA:MGI.
DR   GO; GO:0060395; P:SMAD protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IDA:MGI.
DR   GO; GO:0048745; P:smooth muscle tissue development; IMP:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0010159; P:specification of organ position; IMP:MGI.
DR   GO; GO:0072101; P:specification of ureteric bud anterior/posterior symmetry by BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043401; P:steroid hormone mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0021537; P:telencephalon development; ISO:MGI.
DR   GO; GO:0021978; P:telencephalon regionalization; IDA:MGI.
DR   GO; GO:0035990; P:tendon cell differentiation; IMP:UniProtKB.
DR   GO; GO:0009888; P:tissue development; IGI:MGI.
DR   GO; GO:0043587; P:tongue morphogenesis; IEA:Ensembl.
DR   GO; GO:0060438; P:trachea development; ISO:MGI.
DR   GO; GO:0060440; P:trachea formation; IMP:MGI.
DR   GO; GO:0003323; P:type B pancreatic cell development; ISS:UniProtKB.
DR   GO; GO:0072192; P:ureter epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0072193; P:ureter smooth muscle cell differentiation; IMP:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; IDA:MGI.
DR   GO; GO:0001944; P:vasculature development; IMP:MGI.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR017948; TGFb_CS.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Chondrogenesis; Cleavage on pair of basic residues; Complete proteome;
KW   Cytokine; Developmental protein; Differentiation; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Growth factor; Osteogenesis;
KW   Phosphoprotein; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   PROPEP       20    292
FT                                /FTId=PRO_0000033858.
FT   CHAIN       293    408       Bone morphogenetic protein 4.
FT                                /FTId=PRO_0000033859.
FT   MOD_RES      91     91       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P12644}.
FT   CARBOHYD    144    144       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    209    209       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    365    365       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    308    373       {ECO:0000250}.
FT   DISULFID    337    405       {ECO:0000250}.
FT   DISULFID    341    407       {ECO:0000250}.
FT   DISULFID    372    372       Interchain. {ECO:0000250}.
FT   CONFLICT    407    407       C -> S (in Ref. 2; BAA03555).
FT                                {ECO:0000305}.
SQ   SEQUENCE   408 AA;  46497 MW;  35053D844624EF9D CRC64;
     MIPGNRMLMV VLLCQVLLGG ASHASLIPET GKKKVAEIQG HAGGRRSGQS HELLRDFEAT
     LLQMFGLRRR PQPSKSAVIP DYMRDLYRLQ SGEEEEEEQS QGTGLEYPER PASRANTVRS
     FHHEEHLENI PGTSESSAFR FLFNLSSIPE NEVISSAELR LFREQVDQGP DWEQGFHRIN
     IYEVMKPPAE MVPGHLITRL LDTRLVHHNV TRWETFDVSP AVLRWTREKQ PNYGLAIEVT
     HLHQTRTHQG QHVRISRSLP QGSGDWAQLR PLLVTFGHDG RGHTLTRRRA KRSPKHHPQR
     SRKKNKNCRR HSLYVDFSDV GWNDWIVAPP GYQAFYCHGD CPFPLADHLN STNHAIVQTL
     VNSVNSSIPK ACCVPTELSA ISMLYLDEYD KVVLKNYQEM VVEGCGCR
//
ID   APOE_HUMAN              Reviewed;         317 AA.
AC   P02649; B2RC15; C0JYY5; Q9P2S4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 209.
DE   RecName: Full=Apolipoprotein E;
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=APOE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (VARIANT E3).
RX   PubMed=6325438;
RA   Zannis V.I., McPherson J., Goldberger G., Karathanasis S.K.,
RA   Breslow J.L.;
RT   "Synthesis, intracellular processing, and signal peptide of human
RT   apolipoprotein E.";
RL   J. Biol. Chem. 259:5495-5499(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (VARIANT E3).
RX   PubMed=6327682;
RA   McLean J.W., Elshourbagy N.A., Chang D.J., Mahley R.W., Taylor J.M.;
RT   "Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing
RT   of a new variant.";
RL   J. Biol. Chem. 259:6498-6504(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT E4).
RX   PubMed=2987927; DOI=10.1073/pnas.82.10.3445;
RA   Paik Y.-K., Chang D.J., Reardon C.A., Davies G.E., Mahley R.W.,
RA   Taylor J.M.;
RT   "Nucleotide sequence and structure of the human apolipoprotein E
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3445-3449(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT E2).
RX   PubMed=3243553; DOI=10.1016/0888-7543(88)90130-9;
RA   Emi M., Wu L.L., Robertson M.A., Myers R.L., Hegele R.A.,
RA   Williams R.R., White R., Lalouel J.-M.;
RT   "Genotyping and sequence analysis of apolipoprotein E isoforms.";
RL   Genomics 3:373-379(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10520737;
RA   Freitas E.M., Zhang W.J., Lalonde J.P., Tay G.K., Gaudieri S.,
RA   Ashworth L.K., Van Bockxmeer F.M., Dawkins R.L.;
RT   "Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene:
RT   PEREC1.";
RL   DNA Seq. 9:89-100(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-46; ARG-130;
RP   CYS-163 AND CYS-176.
RX   PubMed=11042151; DOI=10.1101/gr.146900;
RA   Nickerson D.A., Taylor S.L., Fullerton S.M., Weiss K.M., Clark A.G.,
RA   Stengard J.H., Salomaa V., Boerwinkle E., Sing C.F.;
RT   "Sequence diversity and large-scale typing of SNPs in the human
RT   apolipoprotein E gene.";
RL   Genome Res. 10:1532-1545(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-78, AND VARIANT HIS-64.
RC   TISSUE=Blood;
RA   Imura T., Kimura H., Kawasaki M.;
RT   "A new apolipoprotein E variant (Gln46-->His).";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 99-317 (VARIANT E3).
RX   PubMed=6897404;
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W.,
RA   Lofquist-Kahl F., Karathanasis S.K., Zannis V.I.;
RT   "Identification and DNA sequence of a human apolipoprotein E cDNA
RT   clone.";
RL   J. Biol. Chem. 257:14639-14641(1982).
RN   [12]
RP   ERRATUM.
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W.,
RA   Lofquist-Kahl F., Karathanasis S.K., Zannis V.I.;
RL   J. Biol. Chem. 258:11422-11422(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-317 (VARIANT E2).
RX   PubMed=7068630;
RA   Rall S.C. Jr., Weisgraber K.H., Mahley R.W.;
RT   "Human apolipoprotein E. The complete amino acid sequence.";
RL   J. Biol. Chem. 257:4171-4178(1982).
RN   [14]
RP   REVIEW.
RX   PubMed=3283935; DOI=10.1126/science.3283935;
RA   Mahley R.W.;
RT   "Apolipoprotein E: cholesterol transport protein with expanding role
RT   in cell biology.";
RL   Science 240:622-630(1988).
RN   [15]
RP   HEPARIN-BINDING SITES.
RX   PubMed=3947350; DOI=10.1016/S0006-291X(86)80489-2;
RA   Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L.,
RA   Harmony J.A.K., Sparrow D.A., Sparrow J.T.;
RT   "Binding of a high reactive heparin to human apolipoprotein E:
RT   identification of two heparin-binding domains.";
RL   Biochem. Biophys. Res. Commun. 134:783-789(1986).
RN   [16]
RP   ASSOCIATION OF APOE*4 WITH ALZHEIMER DISEASE.
RX   PubMed=8346443; DOI=10.1126/science.8346443;
RA   Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E.,
RA   Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A.;
RT   "Gene dose of apolipoprotein E type 4 allele and the risk of
RT   Alzheimer's disease in late onset families.";
RL   Science 261:921-923(1993).
RN   [17]
RP   GLYCATION AT LYS-93, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10452964; DOI=10.1016/S0925-4439(99)00047-2;
RA   Shuvaev V.V., Fujii J., Kawasaki Y., Itoh H., Hamaoka R., Barbier A.,
RA   Ziegler O., Siest G., Taniguchi N.;
RT   "Glycation of apolipoprotein E impairs its binding to heparin:
RT   identification of the major glycation site.";
RL   Biochim. Biophys. Acta 1454:296-308(1999).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT THR-212; THR-307 AND SER-308,
RP   AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [21]
RP   GLYCOSYLATION AT THR-26; THR-36 AND SER-314, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   PHOSPHORYLATION AT SER-147.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 41-184, AND LDL RECEPTOR
RP   BINDING REGION.
RX   PubMed=2063194; DOI=10.1126/science.2063194;
RA   Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A.;
RT   "Three-dimensional structure of the LDL receptor-binding domain of
RT   human apolipoprotein E.";
RL   Science 252:1817-1822(1991).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 41-181.
RX   PubMed=8756331; DOI=10.1038/nsb0896-718;
RA   Dong L.-M., Parkin S., Trakhanov S.D., Rupp B., Simmons T.,
RA   Arnold K.S., Newhouse Y.M., Innerarity T.L., Weisgraber K.H.;
RT   "Novel mechanism for defective receptor binding of apolipoprotein E2
RT   in type III hyperlipoproteinemia.";
RL   Nat. Struct. Biol. 3:718-722(1996).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 22-165.
RX   PubMed=10850798; DOI=10.1110/ps.9.5.886;
RA   Segelke B.W., Forstner M., Knapp M., Trakhanov S.D., Parkin S.,
RA   Newhouse Y.M., Bellamy H.D., Weisgraber K.H., Rupp B.;
RT   "Conformational flexibility in the apolipoprotein E amino-terminal
RT   domain structure determined from three new crystal forms: implications
RT   for lipid binding.";
RL   Protein Sci. 9:886-897(2000).
RN   [27]
RP   REVIEW ON VARIANTS.
RX   PubMed=7833947; DOI=10.1002/humu.1380040303;
RA   de Knijff P., van den Maagdenberg A.M.J.M., Frants R.R., Havekes L.M.;
RT   "Genetic heterogeneity of apolipoprotein E and its influence on plasma
RT   lipid and lipoprotein levels.";
RL   Hum. Mutat. 4:178-194(1994).
RN   [28]
RP   VARIANT E5 LYS-21.
RX   PubMed=2760009;
RA   Maeda H., Nakamura H., Kobori S., Okada M., Niki H., Ogura T.,
RA   Hiraga S.;
RT   "Molecular cloning of a human apolipoprotein E variant: E5 (Glu-
RT   3-->Lys).";
RL   J. Biochem. 105:491-493(1989).
RN   [29]
RP   VARIANT HLPP3 E3 LEIDEN GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS.
RX   PubMed=2556398;
RA   Wardell M.R., Weisgraber K.H., Havekes L.M., Rall S.C. Jr.;
RT   "Apolipoprotein E3-Leiden contains a seven-amino acid insertion that
RT   is a tandem repeat of residues 121-127.";
RL   J. Biol. Chem. 264:21205-21210(1989).
RN   [30]
RP   VARIANTS HLPP3 E4 PHILADELPHIA LYS-31 AND CYS-163.
RX   PubMed=1674745;
RA   Lohse P., Mann W.A., Stein E.A., Brewer H.B. Jr.;
RT   "Apolipoprotein E-4 Philadelphia (Glu-13-->Lys,Arg-145-->Cys).
RT   Homozygosity for two rare point mutations in the apolipoprotein E gene
RT   combined with severe type III hyperlipoproteinemia.";
RL   J. Biol. Chem. 266:10479-10484(1991).
RN   [31]
RP   VARIANTS GLU-254; GLY-269; GLU-270; HIS-292 AND ARG-314.
RX   PubMed=8488843;
RA   van den Maagdenberg A.M.J.M., Weng W., de Bruijn I.H., de Knijff P.,
RA   Funke H., Smelt A.H.M., Leuven J.A.G., van 't Hooft F.M., Assmann G.,
RA   Hofker M.H., Havekes L.M., Frants R.R.;
RT   "Characterization of five new mutants in the carboxyl-terminal domain
RT   of human apolipoprotein E: no cosegregation with severe
RT   hyperlipidemia.";
RL   Am. J. Hum. Genet. 52:937-946(1993).
RN   [32]
RP   VARIANTS HLPP3 ARG-130; ASP-145; SER-154; CYS-160 AND CYS-176.
RX   PubMed=8287539;
RA   Richard P., Thomas G., de Zulueta M.P., de Gennes J.-L., Thomas M.,
RA   Cassaigne A., Bereziat G., Iron A.;
RT   "Common and rare genotypes of human apolipoprotein E determined by
RT   specific restriction profiles of polymerase chain reaction-amplified
RT   DNA.";
RL   Clin. Chem. 40:24-29(1994).
RN   [33]
RP   VARIANT LPG PRO-163.
RX   PubMed=9176854;
RA   Oikawa S., Matsunaga A., Saito T., Sato H., Seki T., Hoshi K.,
RA   Hayasaka K., Kotake H., Midorikawa H., Sekikawa A., Hara S., Abe K.,
RA   Toyota T., Jingami H., Nakamura H., Sasaki J.;
RT   "Apolipoprotein E Sendai (arginine 145-->proline): a new variant
RT   associated with lipoprotein glomerulopathy.";
RL   J. Am. Soc. Nephrol. 8:820-823(1997).
RN   [34]
RP   VARIANTS E4/3 ARG-130 AND GLY-269.
RX   PubMed=9360638; DOI=10.1016/S1383-5726(97)00009-5;
RA   Kang A.K., Jenkins D.J.A., Wolever T.M.S., Huff M.W., Maguire G.F.,
RA   Connelly P.W., Hegele R.A.;
RT   "Apolipoprotein E R112; R251G: a carboxy-terminal variant found in
RT   patients with hyperlipidemia and coronary heart disease.";
RL   Mutat. Res. 382:57-65(1997).
RN   [35]
RP   VARIANT LPG CYS-43.
RX   PubMed=10432380; DOI=10.1046/j.1523-1755.1999.00572.x;
RA   Matsunaga A., Sasaki J., Komatsu T., Kanatsu K., Tsuji E.,
RA   Moriyama K., Koga T., Arakawa K., Oikawa S., Saito T., Kita T.,
RA   Doi T.;
RT   "A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein
RT   glomerulopathy.";
RL   Kidney Int. 56:421-427(1999).
RN   [36]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=11095479; DOI=10.1210/jc.85.11.4354;
RA   Nguyen T.T., Kruckeberg K.E., O'Brien J.F., Ji Z.-S., Karnes P.S.,
RA   Crotty T.B., Hay I.D., Mahley R.W., O'Brien T.;
RT   "Familial splenomegaly: macrophage hypercatabolism of lipoproteins
RT   associated with apolipoprotein E mutation [apolipoprotein E (delta149
RT   Leu)].";
RL   J. Clin. Endocrinol. Metab. 85:4354-4358(2000).
RN   [37]
RP   VARIANT E3 BASEL VAL-124.
RX   PubMed=12864777; DOI=10.1046/j.1365-2362.2003.01180.x;
RA   Miserez A.R., Scharnagl H., Muller P.Y., Mirsaidi R., Stahelin H.B.,
RA   Monsch A., Marz W., Hoffmann M.M.;
RT   "Apolipoprotein E3Basel: new insights into a highly conserved protein
RT   region.";
RL   Eur. J. Clin. Invest. 33:677-685(2003).
RN   [38]
RP   VARIANTS ARG-130 AND CYS-176.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [39]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=16094309; DOI=10.1038/sj.ejhg.5201480;
RA   Faivre L., Saugier-Veber P., Pais de Barros J.-P., Verges B.,
RA   Couret B., Lorcerie B., Thauvin C., Charbonnier F., Huet F.,
RA   Gambert P., Frebourg T., Duvillard L.;
RT   "Variable expressivity of the clinical and biochemical phenotype
RT   associated with the apolipoprotein E p.Leu149del mutation.";
RL   Eur. J. Hum. Genet. 13:1186-1191(2005).
RN   [40]
RP   VARIANT LPG CYS-43.
RX   PubMed=18077821; DOI=10.1056/NEJMc072088;
RA   Rovin B.H., Roncone D., McKinley A., Nadasdy T., Korbet S.M.,
RA   Schwartz M.M.;
RT   "APOE Kyoto mutation in European Americans with lipoprotein
RT   glomerulopathy.";
RL   N. Engl. J. Med. 357:2522-2524(2007).
RN   [41]
RP   VARIANT HIS-64, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [42]
RP   VARIANT HLPP3 SER-154, AND VARIANT LEU-167 DEL.
RX   PubMed=22481068; DOI=10.1016/j.atherosclerosis.2012.03.011;
RA   Solanas-Barca M., de Castro-Oros I., Mateo-Gallego R., Cofan M.,
RA   Plana N., Puzo J., Burillo E., Martin-Fuentes P., Ros E., Masana L.,
RA   Pocovi M., Civeira F., Cenarro A.;
RT   "Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia
RT   and a clinical diagnosis of familial combined hyperlipidemia.";
RL   Atherosclerosis 222:449-455(2012).
RN   [43]
RP   VARIANT FH LEU-167 DEL.
RX   PubMed=22949395; DOI=10.1002/humu.22215;
RA   Marduel M., Ouguerram K., Serre V., Bonnefont-Rousselot D.,
RA   Marques-Pinheiro A., Erik Berge K., Devillers M., Luc G., Lecerf J.M.,
RA   Tosolini L., Erlich D., Peloso G.M., Stitziel N., Nitchke P.,
RA   Jais J.P., Abifadel M., Kathiresan S., Leren T.P., Rabes J.P.,
RA   Boileau C., Varret M.;
RT   "Description of a large family with autosomal dominant
RT   hypercholesterolemia associated with the APOE p.Leu167del mutation.";
RL   Hum. Mutat. 34:83-87(2013).
CC   -!- FUNCTION: Mediates the binding, internalization, and catabolism of
CC       lipoprotein particles. It can serve as a ligand for the LDL (apo
CC       B/E) receptor and for the specific apo-E receptor (chylomicron
CC       remnant) of hepatic tissues. {ECO:0000303|PubMed:3283935}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-1222467, EBI-6904269;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-1222467, EBI-295634;
CC       Q9BQ95:ECSIT; NbExp=4; IntAct=EBI-1222467, EBI-712452;
CC       P00738:HP; NbExp=7; IntAct=EBI-1222467, EBI-1220767;
CC       P01130:LDLR; NbExp=2; IntAct=EBI-1222467, EBI-988319;
CC       Q14114:LRP8; NbExp=2; IntAct=EBI-1222467, EBI-2681187;
CC       P10636:MAPT; NbExp=3; IntAct=EBI-9209835, EBI-366182;
CC       Q53EL6:PDCD4; NbExp=3; IntAct=EBI-1222467, EBI-935824;
CC       P50502:ST13; NbExp=3; IntAct=EBI-1222467, EBI-357285;
CC       O75069:TMCC2; NbExp=5; IntAct=EBI-1222467, EBI-726731;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:3283935}.
CC   -!- TISSUE SPECIFICITY: Occurs in all lipoprotein fractions in plasma.
CC       It constitutes 10-20% of very low density lipoproteins (VLDL) and
CC       1-2% of high density lipoproteins (HDL). APOE is produced in most
CC       organs. Significant quantities are produced in liver, brain,
CC       spleen, lung, adrenal, ovary, kidney and muscle.
CC   -!- PTM: Synthesized with the sialic acid attached by O-glycosidic
CC       linkage and is subsequently desialylated in plasma. O-glycosylated
CC       with core 1 or possibly core 8 glycans. Thr-307 and Ser-314 are
CC       minor glycosylation sites compared to Ser-308.
CC       {ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:23234360}.
CC   -!- PTM: Glycated in plasma VLDL of normal subjects, and of
CC       hyperglycemic diabetic patients at a higher level (2-3 fold).
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- POLYMORPHISM: Three common APOE alleles have been identified:
CC       APOE*2, APOE*3, and APOE*4. The corresponding three major
CC       isoforms, E2, E3, and E4, are recognized according to their
CC       relative position after isoelectric focusing. Different mutations
CC       causing the same migration pattern after isoelectric focusing
CC       define different isoform subtypes. The most common isoform is E3
CC       and is present in 40-90% of the population. Common APOE variants
CC       influence lipoprotein metabolism in healthy individuals.
CC       {ECO:0000305}.
CC   -!- DISEASE: Hyperlipoproteinemia 3 (HLPP3) [MIM:107741]: A disorder
CC       characterized by the accumulation of intermediate-density
CC       lipoprotein particles (IDL or broad-beta-lipoprotein) rich in
CC       cholesterol. Clinical features include xanthomas, yellowish lipid
CC       deposits in the palmar crease, or less specific on tendons and on
CC       elbows. The disorder rarely manifests before the third decade in
CC       men. In women, it is usually expressed only after the menopause.
CC       {ECO:0000269|PubMed:1674745, ECO:0000269|PubMed:22481068,
CC       ECO:0000269|PubMed:2556398, ECO:0000269|PubMed:8287539}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry. The vast majority of the patients are homozygous for
CC       APOE*2 alleles. More severe cases of HLPP3 have also been observed
CC       in individuals heterozygous for rare APOE variants. The influence
CC       of APOE on lipid levels is often suggested to have major
CC       implications for the risk of coronary artery disease (CAD).
CC       Individuals carrying the common APOE*4 variant are at higher risk
CC       of CAD.
CC   -!- DISEASE: Alzheimer disease 2 (AD2) [MIM:104310]: A late-onset
CC       neurodegenerative disorder characterized by progressive dementia,
CC       loss of cognitive abilities, and deposition of fibrillar amyloid
CC       proteins as intraneuronal neurofibrillary tangles, extracellular
CC       amyloid plaques and vascular amyloid deposits. The major
CC       constituent of these plaques is the neurotoxic amyloid-beta-APP
CC       40-42 peptide (s), derived proteolytically from the transmembrane
CC       precursor protein APP by sequential secretase processing. The
CC       cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved
CC       products such as C31 derived from APP, are also implicated in
CC       neuronal death. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry. The
CC       APOE*4 allele is genetically associated with the common late onset
CC       familial and sporadic forms of Alzheimer disease. Risk for AD
CC       increased from 20% to 90% and mean age at onset decreased from 84
CC       to 68 years with increasing number of APOE*4 alleles in 42
CC       families with late onset AD. Thus APOE*4 gene dose is a major risk
CC       factor for late onset AD and, in these families, homozygosity for
CC       APOE*4 was virtually sufficient to cause AD by age 80. The
CC       mechanism by which APOE*4 participates in pathogenesis is not
CC       known.
CC   -!- DISEASE: Sea-blue histiocyte disease (SBHD) [MIM:269600]:
CC       Characterized by splenomegaly, mild thrombocytopenia and, in the
CC       bone marrow, numerous histiocytes containing cytoplasmic granules
CC       which stain bright blue with the usual hematologic stains. The
CC       syndrome is the consequence of an inherited metabolic defect
CC       analogous to Gaucher disease and other sphingolipidoses.
CC       {ECO:0000269|PubMed:11095479, ECO:0000269|PubMed:16094309}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Lipoprotein glomerulopathy (LPG) [MIM:611771]: Uncommon
CC       kidney disease characterized by proteinuria, progressive kidney
CC       failure, and distinctive lipoprotein thrombi in glomerular
CC       capillaries. {ECO:0000269|PubMed:10432380,
CC       ECO:0000269|PubMed:18077821, ECO:0000269|PubMed:9176854}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Familial hypercholesterolemia (FH) [MIM:143890]: Common
CC       autosomal semi-dominant disease that affects about 1 in 500
CC       individuals. The receptor defect impairs the catabolism of LDL,
CC       and the resultant elevation in plasma LDL-cholesterol promotes
CC       deposition of cholesterol in the skin (xanthelasma), tendons
CC       (xanthomas), and coronary arteries (atherosclerosis).
CC       {ECO:0000269|PubMed:22949395}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOE";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Apolipoprotein E entry;
CC       URL="https://en.wikipedia.org/wiki/Apolipoprotein_E";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Tangled - Issue 83 of
CC       June 2007;
CC       URL="http://web.expasy.org/spotlight/back_issues/083";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M12529; AAB59518.1; -; mRNA.
DR   EMBL; K00396; AAB59546.1; -; mRNA.
DR   EMBL; M10065; AAB59397.1; -; Genomic_DNA.
DR   EMBL; AF050154; AAD02505.1; -; Genomic_DNA.
DR   EMBL; AF261279; AAG27089.1; -; Genomic_DNA.
DR   EMBL; AK314898; BAG37412.1; -; mRNA.
DR   EMBL; FJ525876; ACN81314.1; -; Genomic_DNA.
DR   EMBL; BC003557; AAH03557.1; -; mRNA.
DR   EMBL; AB035149; BAA96080.1; -; Genomic_DNA.
DR   CCDS; CCDS12647.1; -.
DR   PIR; A92478; LPHUE.
DR   RefSeq; NP_000032.1; NM_000041.3.
DR   RefSeq; NP_001289617.1; NM_001302688.1.
DR   RefSeq; NP_001289618.1; NM_001302689.1.
DR   RefSeq; NP_001289619.1; NM_001302690.1.
DR   RefSeq; NP_001289620.1; NM_001302691.1.
DR   UniGene; Hs.654439; -.
DR   PDB; 1B68; X-ray; 2.00 A; A=19-209.
DR   PDB; 1BZ4; X-ray; 1.85 A; A=40-183.
DR   PDB; 1EA8; X-ray; 1.95 A; A=19-209.
DR   PDB; 1GS9; X-ray; 1.70 A; A=19-183.
DR   PDB; 1H7I; X-ray; 1.90 A; A=19-209.
DR   PDB; 1LE2; X-ray; 3.00 A; A=41-184.
DR   PDB; 1LE4; X-ray; 2.50 A; A=41-184.
DR   PDB; 1LPE; X-ray; 2.25 A; A=41-184.
DR   PDB; 1NFN; X-ray; 1.80 A; A=19-209.
DR   PDB; 1NFO; X-ray; 2.00 A; A=19-209.
DR   PDB; 1OEF; NMR; -; A=281-304.
DR   PDB; 1OEG; NMR; -; A=285-307.
DR   PDB; 1OR2; X-ray; 2.50 A; A=19-183.
DR   PDB; 1OR3; X-ray; 1.73 A; A=19-183.
DR   PDB; 2KC3; NMR; -; A=19-201.
DR   PDB; 2KNY; NMR; -; A=147-167.
DR   PDB; 2L7B; NMR; -; A=19-317.
DR   PDBsum; 1B68; -.
DR   PDBsum; 1BZ4; -.
DR   PDBsum; 1EA8; -.
DR   PDBsum; 1GS9; -.
DR   PDBsum; 1H7I; -.
DR   PDBsum; 1LE2; -.
DR   PDBsum; 1LE4; -.
DR   PDBsum; 1LPE; -.
DR   PDBsum; 1NFN; -.
DR   PDBsum; 1NFO; -.
DR   PDBsum; 1OEF; -.
DR   PDBsum; 1OEG; -.
DR   PDBsum; 1OR2; -.
DR   PDBsum; 1OR3; -.
DR   PDBsum; 2KC3; -.
DR   PDBsum; 2KNY; -.
DR   PDBsum; 2L7B; -.
DR   DisProt; DP00355; -.
DR   ProteinModelPortal; P02649; -.
DR   SMR; P02649; 19-317.
DR   BioGrid; 106845; 57.
DR   DIP; DIP-1120N; -.
DR   IntAct; P02649; 30.
DR   MINT; MINT-4999641; -.
DR   STRING; 9606.ENSP00000252486; -.
DR   DrugBank; DB00062; Human Serum Albumin.
DR   DrugBank; DB00064; Serum albumin iodonated.
DR   iPTMnet; P02649; -.
DR   PhosphoSite; P02649; -.
DR   UniCarbKB; P02649; -.
DR   BioMuta; APOE; -.
DR   DMDM; 114039; -.
DR   DOSAC-COBS-2DPAGE; P02649; -.
DR   SWISS-2DPAGE; P02649; -.
DR   MaxQB; P02649; -.
DR   PaxDb; P02649; -.
DR   PeptideAtlas; P02649; -.
DR   PRIDE; P02649; -.
DR   DNASU; 348; -.
DR   Ensembl; ENST00000252486; ENSP00000252486; ENSG00000130203.
DR   GeneID; 348; -.
DR   KEGG; hsa:348; -.
DR   UCSC; uc002pab.3; human.
DR   CTD; 348; -.
DR   GeneCards; APOE; -.
DR   HGNC; HGNC:613; APOE.
DR   HPA; CAB008363; -.
DR   MalaCards; APOE; -.
DR   MIM; 104310; phenotype.
DR   MIM; 107741; gene+phenotype.
DR   MIM; 143890; phenotype.
DR   MIM; 269600; phenotype.
DR   MIM; 611771; phenotype.
DR   neXtProt; NX_P02649; -.
DR   Orphanet; 238616; Alzheimer disease.
DR   Orphanet; 1648; Dementia with Lewy body.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 412; Hyperlipoproteinemia type 3.
DR   Orphanet; 329481; Lipoprotein glomerulopathy.
DR   Orphanet; 158029; Sea-blue histiocytosis.
DR   PharmGKB; PA55; -.
DR   eggNOG; ENOG410IVK0; Eukaryota.
DR   eggNOG; ENOG4111MYC; LUCA.
DR   GeneTree; ENSGT00730000111315; -.
DR   HOGENOM; HOG000034006; -.
DR   HOVERGEN; HBG010582; -.
DR   InParanoid; P02649; -.
DR   KO; K04524; -.
DR   OMA; PLQERAQ; -.
DR   OrthoDB; EOG793B87; -.
DR   PhylomeDB; P02649; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   ChiTaRS; APOE; human.
DR   EvolutionaryTrace; P02649; -.
DR   GeneWiki; Apolipoprotein_E; -.
DR   GenomeRNAi; 348; -.
DR   NextBio; 1435; -.
DR   PMAP-CutDB; P02649; -.
DR   PRO; PR:P02649; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P02649; -.
DR   CleanEx; HS_APOE; -.
DR   ExpressionAtlas; P02649; baseline and differential.
DR   Genevisible; P02649; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; NAS:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:AgBase.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; NAS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016209; F:antioxidant activity; IDA:BHF-UCL.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IBA:GO_Central.
DR   GO; GO:0017127; F:cholesterol transporter activity; IBA:GO_Central.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IDA:UniProtKB.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0046911; F:metal chelating activity; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0048156; F:tau protein binding; IPI:BHF-UCL.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0098869; P:cellular oxidant detoxification; IDA:GOC.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006707; P:cholesterol catabolic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0034382; P:chylomicron remnant clearance; IMP:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IGI:BHF-UCL.
DR   GO; GO:0046907; P:intracellular transport; TAS:UniProtKB.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IBA:GO_Central.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0015909; P:long-chain fatty acid transport; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl.
DR   GO; GO:1902430; P:negative regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061000; P:negative regulation of dendritic spine development; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902951; P:negative regulation of dendritic spine maintenance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0051055; P:negative regulation of lipid biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1903001; P:negative regulation of lipid transport across blood brain barrier; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902999; P:negative regulation of phospholipid efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:BHF-UCL.
DR   GO; GO:1901627; P:negative regulation of postsynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901630; P:negative regulation of presynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IDA:BHF-UCL.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0044794; P:positive regulation by host of viral process; IMP:AgBase.
DR   GO; GO:1902004; P:positive regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030828; P:positive regulation of cGMP biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood brain barrier; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901628; P:positive regulation of postsynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901631; P:positive regulation of presynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0017038; P:protein import; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:0030516; P:regulation of axon extension; TAS:UniProtKB.
DR   GO; GO:1900221; P:regulation of beta-amyloid clearance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1901214; P:regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; TAS:UniProtKB.
DR   GO; GO:1902947; P:regulation of tau-protein kinase activity; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0000302; P:response to reactive oxygen species; NAS:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; TAS:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0006641; P:triglyceride metabolic process; IDA:BHF-UCL.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0019068; P:virion assembly; IMP:AgBase.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alzheimer disease; Amyloidosis; Cholesterol metabolism;
KW   Chylomicron; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glycation; Glycoprotein; HDL; Heparin-binding;
KW   Hyperlipidemia; Lipid metabolism; Lipid transport; Neurodegeneration;
KW   Oxidation; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Secreted; Signal; Steroid metabolism; Sterol metabolism; Transport;
KW   VLDL.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:7068630}.
FT   CHAIN        19    317       Apolipoprotein E.
FT                                /FTId=PRO_0000001987.
FT   REPEAT       80    101       1.
FT   REPEAT      102    123       2.
FT   REPEAT      124    145       3.
FT   REPEAT      146    167       4.
FT   REPEAT      168    189       5.
FT   REPEAT      190    211       6.
FT   REPEAT      212    233       7.
FT   REPEAT      234    255       8.
FT   REGION       80    255       8 X 22 AA approximate tandem repeats.
FT   REGION      158    168       LDL receptor binding.
FT                                {ECO:0000269|PubMed:2063194}.
FT   REGION      162    165       Heparin-binding.
FT                                {ECO:0000269|PubMed:3947350}.
FT   REGION      229    236       Heparin-binding.
FT                                {ECO:0000269|PubMed:3947350}.
FT   MOD_RES     143    143       Methionine sulfoxide.
FT                                {ECO:0000250|UniProtKB:P08226}.
FT   MOD_RES     147    147       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD     26     26       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD     36     36       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD     93     93       N-linked (Glc) (glycation).
FT   CARBOHYD    212    212       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    307    307       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    308    308       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    314    314       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23234360}.
FT   VARIANT      21     21       E -> K (in form E5; associated with
FT                                hyperlipoproteinemia and atherosclerosis;
FT                                dbSNP:rs121918392).
FT                                {ECO:0000269|PubMed:2760009}.
FT                                /FTId=VAR_000645.
FT   VARIANT      31     31       E -> K (in HLPP3; form E4 Philadelphia
FT                                and form E5-type; only form E4
FT                                Philadelphia is disease-linked;
FT                                dbSNP:rs201672011).
FT                                {ECO:0000269|PubMed:1674745}.
FT                                /FTId=VAR_000646.
FT   VARIANT      43     43       R -> C (in LPG; form E2 Kyoto).
FT                                {ECO:0000269|PubMed:10432380,
FT                                ECO:0000269|PubMed:18077821}.
FT                                /FTId=VAR_042734.
FT   VARIANT      46     46       L -> P (in form E4 Freiburg;
FT                                dbSNP:rs769452).
FT                                {ECO:0000269|PubMed:11042151}.
FT                                /FTId=VAR_000647.
FT   VARIANT      60     60       T -> A (in form E3 Freiburg;
FT                                dbSNP:rs28931576).
FT                                /FTId=VAR_000648.
FT   VARIANT      64     64       Q -> H (polymorphism, confirmed at
FT                                protein level; dbSNP:rs370594287).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_014114.
FT   VARIANT      99     99       Q -> K (in form E5 Frankfurt).
FT                                /FTId=VAR_000649.
FT   VARIANT     102    102       P -> R (in form E5-type; no
FT                                hyperlipidemia; dbSNP:rs28931578).
FT                                /FTId=VAR_000650.
FT   VARIANT     117    117       A -> T (in form E3*; dbSNP:rs28931577).
FT                                /FTId=VAR_000651.
FT   VARIANT     124    124       A -> V (in form E3 Basel).
FT                                {ECO:0000269|PubMed:12864777}.
FT                                /FTId=VAR_016789.
FT   VARIANT     130    130       C -> R (in HLPP3; form E3**, form E4,
FT                                form E4/3 and some forms E5-type; only
FT                                form E3** is disease-linked;
FT                                dbSNP:rs429358).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8287539,
FT                                ECO:0000269|PubMed:9360638}.
FT                                /FTId=VAR_000652.
FT   VARIANT     145    145       G -> D (in form E1 Weisgraber).
FT                                {ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000653.
FT   VARIANT     145    145       G -> GEVQAMLG (in HLPP3; form E3 Leiden).
FT                                {ECO:0000269|PubMed:2556398}.
FT                                /FTId=VAR_000654.
FT   VARIANT     152    152       R -> Q (in form E2-type; no
FT                                hyperlipidemia; dbSNP:rs28931578).
FT                                /FTId=VAR_000655.
FT   VARIANT     154    154       R -> C (in HLPP3; form E2-type).
FT                                /FTId=VAR_000657.
FT   VARIANT     154    154       R -> S (in HLPP3; form E2 Christchurch).
FT                                {ECO:0000269|PubMed:22481068,
FT                                ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000656.
FT   VARIANT     160    160       R -> C (in HLPP3; form E3**).
FT                                {ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000658.
FT   VARIANT     163    163       R -> C (in HLPP3; form E4 Philadelphia
FT                                and form E2-type; only form E4
FT                                Philadelphia is disease-linked;
FT                                dbSNP:rs769455).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:1674745}.
FT                                /FTId=VAR_000659.
FT   VARIANT     163    163       R -> H (in E3 Kochi).
FT                                /FTId=VAR_000660.
FT   VARIANT     163    163       R -> P (in LPG; form E2 Sendai).
FT                                {ECO:0000269|PubMed:9176854}.
FT                                /FTId=VAR_042735.
FT   VARIANT     164    164       K -> E (in HLPP3; form E1 Harrisburg).
FT                                /FTId=VAR_000662.
FT   VARIANT     164    164       K -> Q (in HLPP3; form E2**).
FT                                /FTId=VAR_000661.
FT   VARIANT     167    167       Missing (in SBHD and FH; also found in
FT                                patients with a diagnosis of familial
FT                                combined hyperlipidemia).
FT                                {ECO:0000269|PubMed:11095479,
FT                                ECO:0000269|PubMed:16094309,
FT                                ECO:0000269|PubMed:22481068,
FT                                ECO:0000269|PubMed:22949395}.
FT                                /FTId=VAR_035015.
FT   VARIANT     170    170       A -> P (in form E3*).
FT                                /FTId=VAR_000663.
FT   VARIANT     176    176       R -> C (in HLPP3; forms E1 Weisgraber,
FT                                form E2 and form E3**; dbSNP:rs7412).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000664.
FT   VARIANT     242    242       R -> Q (in form E2 Fukuoka).
FT                                /FTId=VAR_000665.
FT   VARIANT     246    246       R -> C (in form E2 Dunedin).
FT                                /FTId=VAR_000666.
FT   VARIANT     254    254       V -> E (in form E2 WG).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000667.
FT   VARIANT     262    263       EE -> KK (in HLPP3; form E7 Suita).
FT                                /FTId=VAR_000668.
FT   VARIANT     269    269       R -> G (in form E3 HB and form E4/3).
FT                                {ECO:0000269|PubMed:8488843,
FT                                ECO:0000269|PubMed:9360638}.
FT                                /FTId=VAR_000669.
FT   VARIANT     270    270       L -> E (in form E1 HE; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000670.
FT   VARIANT     292    292       R -> H (in form E4 PD).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000671.
FT   VARIANT     314    314       S -> R (in form E4 HG; dbSNP:rs28931579).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000672.
FT   STRAND       22     24       {ECO:0000244|PDB:2KC3}.
FT   HELIX        31     39       {ECO:0000244|PDB:2KC3}.
FT   TURN         40     42       {ECO:0000244|PDB:2KC3}.
FT   HELIX        43     60       {ECO:0000244|PDB:1GS9}.
FT   HELIX        63     70       {ECO:0000244|PDB:1GS9}.
FT   HELIX        73     96       {ECO:0000244|PDB:1GS9}.
FT   TURN         97     99       {ECO:0000244|PDB:1LE4}.
FT   HELIX       106    141       {ECO:0000244|PDB:1GS9}.
FT   TURN        143    145       {ECO:0000244|PDB:1NFN}.
FT   HELIX       149    179       {ECO:0000244|PDB:1GS9}.
FT   TURN        180    182       {ECO:0000244|PDB:1BZ4}.
FT   TURN        187    190       {ECO:0000244|PDB:2KC3}.
FT   HELIX       193    198       {ECO:0000244|PDB:2KC3}.
FT   STRAND      200    202       {ECO:0000244|PDB:2L7B}.
FT   HELIX       209    217       {ECO:0000244|PDB:2L7B}.
FT   HELIX       228    241       {ECO:0000244|PDB:2L7B}.
FT   HELIX       257    283       {ECO:0000244|PDB:2L7B}.
FT   HELIX       286    303       {ECO:0000244|PDB:1OEF}.
FT   STRAND      307    309       {ECO:0000244|PDB:2L7B}.
SQ   SEQUENCE   317 AA;  36154 MW;  91AFC04210A30689 CRC64;
     MKVLWAALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT
     LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA
     RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY
     QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG
     SRTRDRLDEV KEQVAEVRAK LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
     VQAAVGTSAA PVPSDNH
//
ID   KIT_HUMAN               Reviewed;         976 AA.
AC   P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   17-FEB-2016, entry version 198.
DE   RecName: Full=Mast/stem cell growth factor receptor Kit;
DE            Short=SCFR;
DE            EC=2.7.10.1;
DE   AltName: Full=Piebald trait protein;
DE            Short=PBT;
DE   AltName: Full=Proto-oncogene c-Kit;
DE   AltName: Full=Tyrosine-protein kinase Kit;
DE   AltName: Full=p145 c-kit;
DE   AltName: Full=v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
DE   AltName: CD_antigen=CD117;
DE   Flags: Precursor;
GN   Name=KIT; Synonyms=SCFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain, and Term placenta;
RX   PubMed=2448137;
RA   Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S.,
RA   Dull T.J., Chen E., Schlessinger J., Francke U., Ullrich A.;
RT   "Human proto-oncogene c-kit: a new cell surface receptor tyrosine
RT   kinase for an unidentified ligand.";
RL   EMBO J. 6:3341-3351(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RX   PubMed=1279499;
RA   Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.;
RT   "Organization and nucleotide sequence of the human KIT (mast/stem cell
RT   growth factor receptor) proto-oncogene.";
RL   Oncogene 7:2207-2217(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   INDUCTION.
RX   PubMed=20658618; DOI=10.1002/pbc.22603;
RA   Neumann I., Foell J.L., Bremer M., Volkmer I., Korholz D., Burdach S.,
RA   Staege M.S.;
RT   "Retinoic acid enhances sensitivity of neuroblastoma cells for
RT   imatinib mesylate.";
RL   Pediatr. Blood Cancer 55:464-470(2010).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Staege M.S., Neumann I., Volkmer I.;
RT   "Sequence of KIT mRNA from all-trans retinoic acid treated
RT   neuroblastoma cell lines.";
RL   Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7506248; DOI=10.1111/j.1349-7006.1993.tb02813.x;
RA   Yamamoto K., Tojo A., Aoki N., Shibuya M.;
RT   "Characterization of the promoter region of the human c-kit proto-
RT   oncogene.";
RL   Jpn. J. Cancer Res. 84:1136-1144(1993).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF PIK3R1; RAF1 AND MAPK1, INTERACTION
RP   WITH GRB2; PIK3R1 AND PIK3 CATALYTIC SUBUNIT, ENZYME REGULATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=7520444;
RA   Blume-Jensen P., Ronnstrand L., Gout I., Waterfield M.D., Heldin C.H.;
RT   "Modulation of Kit/stem cell factor receptor-induced signaling by
RT   protein kinase C.";
RL   J. Biol. Chem. 269:21793-21802(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-741; SER-746; SER-821 AND SER-959, ENZYME
RP   REGULATION, PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF SER-741 AND
RP   SER-746.
RX   PubMed=7539802; DOI=10.1074/jbc.270.23.14192;
RA   Blume-Jensen P., Wernstedt C., Heldin C.H., Ronnstrand L.;
RT   "Identification of the major phosphorylation sites for protein kinase
RT   C in kit/stem cell factor receptor in vitro and in intact cells.";
RL   J. Biol. Chem. 270:14192-14200(1995).
RN   [13]
RP   INTERACTION WITH PIK3R1; MATK/CHK; FYN AND SHC1, AND PHOSPHORYLATION
RP   AT TYR-568; TYR-570 AND TYR-721.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [14]
RP   INTERACTION WITH LYN.
RX   PubMed=9341198; DOI=10.1074/jbc.272.43.27450;
RA   Linnekin D., DeBerry C.S., Mou S.;
RT   "Lyn associates with the juxtamembrane region of c-Kit and is
RT   activated by stem cell factor in hematopoietic cell lines and normal
RT   progenitor cells.";
RL   J. Biol. Chem. 272:27450-27455(1997).
RN   [15]
RP   INTERACTION WITH PTPN6, AUTOPHOSPHORYLATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF PTPN6.
RX   PubMed=9528781;
RA   Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R.,
RA   Siminovitch K.A.;
RT   "SHP-1 binds and negatively modulates the c-Kit receptor by
RT   interaction with tyrosine 569 in the c-Kit juxtamembrane domain.";
RL   Mol. Cell. Biol. 18:2089-2099(1998).
RN   [16]
RP   INTERACTION WITH GRB2 AND GRB7, PARTIAL PROTEIN SEQUENCE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-703 AND TYR-936.
RX   PubMed=10377264; DOI=10.1042/0264-6021:3410211;
RA   Thommes K., Lennartsson J., Carlberg M., Ronnstrand L.;
RT   "Identification of Tyr-703 and Tyr-936 as the primary association
RT   sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor.";
RL   Biochem. J. 341:211-216(1999).
RN   [17]
RP   INTERACTION WITH PTPRU, AND FUNCTION IN PHOSPHORYLATION OF PTPRU.
RX   PubMed=10397721;
RA   Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.;
RT   "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated
RT   during megakaryocyte differentiation and is associated with the c-Kit
RT   receptor.";
RL   Blood 94:539-549(1999).
RN   [18]
RP   INTERACTION WITH MPDZ, CHARACTERIZATION OF VARIANT VAL-816, AND
RP   MUTAGENESIS OF LYS-623.
RX   PubMed=11018522; DOI=10.1016/S0014-5793(00)02036-6;
RA   Mancini A., Koch A., Stefan M., Niemann H., Tamura T.;
RT   "The direct association of the multiple PDZ domain containing proteins
RT   (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine
RT   kinase activity.";
RL   FEBS Lett. 482:54-58(2000).
RN   [19]
RP   INTERACTION WITH LYN; TEC AND DOK1.
RX   PubMed=11825908; DOI=10.1074/jbc.M200277200;
RA   Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B.,
RA   Resh M.D.;
RT   "Phosphatidylinositol 3-kinase and Src family kinases are required for
RT   phosphorylation and membrane recruitment of Dok-1 in c-Kit
RT   signaling.";
RL   J. Biol. Chem. 277:13732-13738(2002).
RN   [20]
RP   INTERACTION WITH SH2B2/APS, FUNCTION IN PHOSPHORYLATION OF SH2B2/APS,
RP   AND MUTAGENESIS OF ILE-571 AND LEU-939.
RX   PubMed=12444928; DOI=10.1042/BJ20020716;
RA   Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A.,
RA   Ronnstrand L.;
RT   "The adapter protein APS associates with the multifunctional docking
RT   sites Tyr-568 and Tyr-936 in c-Kit.";
RL   Biochem. J. 370:1033-1038(2003).
RN   [21]
RP   PHOSPHORYLATION AT SER-891 AND TYR-900, PARTIAL PROTEIN SEQUENCE,
RP   INTERACTION WITH CRK AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF CRK;
RP   AKT1 AND MAP KINASES, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12878163; DOI=10.1016/S0014-4827(03)00206-4;
RA   Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.;
RT   "Identification of Tyr900 in the kinase domain of c-Kit as a Src-
RT   dependent phosphorylation site mediating interaction with c-Crk.";
RL   Exp. Cell Res. 288:110-118(2003).
RN   [22]
RP   FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=12511554; DOI=10.1074/jbc.M211726200;
RA   Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S.,
RA   Ashman L.K., Ronnstrand L.;
RT   "Src family kinases are involved in the differential signaling from
RT   two splice forms of c-Kit.";
RL   J. Biol. Chem. 278:9159-9166(2003).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-130.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [24]
RP   INTERACTION WITH FES/FPS, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V
RT   proliferation signal.";
RL   Blood 110:2593-2599(2007).
RN   [25]
RP   INTERACTION WITH GRB2 AND CBL, UBIQUITINATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF CBL.
RX   PubMed=17904548; DOI=10.1016/j.yexcr.2007.08.021;
RA   Sun J., Pedersen M., Bengtsson S., Ronnstrand L.;
RT   "Grb2 mediates negative regulation of stem cell factor receptor/c-Kit
RT   signaling by recruitment of Cbl.";
RL   Exp. Cell Res. 313:3935-3942(2007).
RN   [26]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS AND CELL SURVIVAL,
RP   FUNCTION IN PHOSPHORYLATION OF CBL, PHOSPHORYLATION AT TYR-568;
RP   TYR-703; TYR-721 AND TYR-936, UBIQUITINATION, SUBCELLULAR LOCATION,
RP   AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=19265199; DOI=10.1074/jbc.M808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-959, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=20601678; DOI=10.1093/humrep/deq168;
RA   Muciaccia B., Sette C., Paronetto M.P., Barchi M., Pensini S.,
RA   D'Agostino A., Gandini L., Geremia R., Stefanini M., Rossi P.;
RT   "Expression of a truncated form of KIT tyrosine kinase in human
RT   spermatozoa correlates with sperm DNA integrity.";
RL   Hum. Reprod. 25:2188-2202(2010).
RN   [29]
RP   PHOSPHORYLATION AT TYR-547; TYR-553; TYR-703; TYR-721; TYR-730;
RP   TYR-823 AND TYR-900, IDENTIFICATION BY MASS SPECTROMETRY, MUTAGENESIS
RP   OF TYR-823, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=20147452; DOI=10.1093/jb/mvq015;
RA   DiNitto J.P., Deshmukh G.D., Zhang Y., Jacques S.L., Coli R.,
RA   Worrall J.W., Diehl W., English J.M., Wu J.C.;
RT   "Function of activation loop tyrosine phosphorylation in the mechanism
RT   of c-Kit auto-activation and its implication in sunitinib
RT   resistance.";
RL   J. Biochem. 147:601-609(2010).
RN   [30]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   SUBUNIT, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=21640708; DOI=10.1016/j.bbrc.2011.05.111;
RA   Kim S.Y., Kang J.J., Lee H.H., Kang J.J., Kim B., Kim C.G., Park T.K.,
RA   Kang H.;
RT   "Mechanism of activation of human c-KIT kinase by internal tandem
RT   duplications of the juxtamembrane domain and point mutations at
RT   aspartic acid 816.";
RL   Biochem. Biophys. Res. Commun. 410:224-228(2011).
RN   [31]
RP   FUNCTION IN ACTIVATION AND PHOSPHORYLATION OF STAT1; STAT3; STAT5A AND
RP   STAT5B.
RX   PubMed=21135090; DOI=10.1074/jbc.M110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [32]
RP   REVIEW.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [33]
RP   REVIEW ON KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [34]
RP   REVIEW.
RX   PubMed=15625120; DOI=10.1634/stemcells.2004-0117;
RA   Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.;
RT   "Normal and oncogenic forms of the receptor tyrosine kinase kit.";
RL   Stem Cells 23:16-43(2005).
RN   [35]
RP   REVIEW.
RX   PubMed=18381929; DOI=10.1158/1078-0432.CCR-07-5134;
RA   Kent D., Copley M., Benz C., Dykstra B., Bowie M., Eaves C.;
RT   "Regulation of hematopoietic stem cells by the steel factor/KIT
RT   signaling pathway.";
RL   Clin. Cancer Res. 14:1926-1930(2008).
RN   [36]
RP   REVIEW.
RX   PubMed=21057534; DOI=10.1038/onc.2010.494;
RA   Pittoni P., Piconese S., Tripodo C., Colombo M.P.;
RT   "Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the
RT   primary off-target of tyrosine kinase inhibitors.";
RL   Oncogene 30:757-769(2011).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 549-931 IN COMPLEX WITH ADP
RP   AND MAGNESIUM IONS, SUBUNIT, PHOSPHORYLATION AT TYR-568 AND TYR-570,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12824176; DOI=10.1074/jbc.C300186200;
RA   Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C.,
RA   Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E.;
RT   "Structure of a c-kit product complex reveals the basis for kinase
RT   transactivation.";
RL   J. Biol. Chem. 278:31461-31464(2003).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 565-935 IN COMPLEXES WITH
RP   INHIBITOR IMATINIB AND PHOSPHATE, AND ENZYME REGULATION.
RX   PubMed=15123710; DOI=10.1074/jbc.M403319200;
RA   Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L.,
RA   Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P.;
RT   "Structural basis for the autoinhibition and STI-571 inhibition of c-
RT   Kit tyrosine kinase.";
RL   J. Biol. Chem. 279:31655-31663(2004).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-519 IN COMPLEX WITH
RP   KITLG/SCF, INTERACTION WITH KITLG/SCF, SUBUNIT, DISULFIDE BONDS,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, MUTAGENESIS OF ARG-381 AND
RP   GLU-386, AND GLYCOSYLATION AT ASN-130; ASN-283; ASN-293; ASN-300;
RP   ASN-320; ASN-352 AND ASN-367.
RX   PubMed=17662946; DOI=10.1016/j.cell.2007.05.055;
RA   Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I.,
RA   Schlessinger J.;
RT   "Structural basis for activation of the receptor tyrosine kinase KIT
RT   by stem cell factor.";
RL   Cell 130:323-334(2007).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 544-935 IN COMPLEX WITH
RP   SUNITINIB, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, CHARACTERIZATION
RP   OF VARIANTS HIS-816 AND VAL-816, AND ENZYME REGULATION.
RX   PubMed=19164557; DOI=10.1073/pnas.0812413106;
RA   Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W.,
RA   DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L.,
RA   Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X.,
RA   Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M.,
RA   Demetri G.D.;
RT   "KIT kinase mutants show unique mechanisms of drug resistance to
RT   imatinib and sunitinib in gastrointestinal stromal tumor patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1542-1547(2009).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 564-574 IN COMPLEX WITH
RP   SOCS6, AND PHOSPHORYLATION AT TYR-568.
RX   PubMed=21030588; DOI=10.1074/jbc.M110.173526;
RA   Zadjali F., Pike A.C., Vesterlund M., Sun J., Wu C., Li S.S.,
RA   Ronnstrand L., Knapp S., Bullock A.N., Flores-Morales A.;
RT   "Structural basis for c-KIT inhibition by the suppressor of cytokine
RT   signaling 6 (SOCS6) ubiquitin ligase.";
RL   J. Biol. Chem. 286:480-490(2011).
RN   [42]
RP   VARIANT PBT LYS-583.
RX   PubMed=1376329; DOI=10.1172/JCI115772;
RA   Fleischman R.A.;
RT   "Human piebald trait resulting from a dominant negative mutant allele
RT   of the c-kit membrane receptor gene.";
RL   J. Clin. Invest. 89:1713-1717(1992).
RN   [43]
RP   VARIANT PBT LEU-584.
RX   PubMed=1370874;
RA   Spritz R.A., Giebel L.B., Holmes S.A.;
RT   "Dominant negative and loss of function mutations of the c-kit
RT   (mast/stem cell growth factor receptor) proto-oncogene in human
RT   piebaldism.";
RL   Am. J. Hum. Genet. 50:261-269(1992).
RN   [44]
RP   VARIANT PBT ARG-664.
RX   PubMed=1717985; DOI=10.1073/pnas.88.19.8696;
RA   Giebel L.B., Spritz R.A.;
RT   "Mutation of the KIT (mast/stem cell growth factor receptor)
RT   protooncogene in human piebaldism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8696-8699(1991).
RN   [45]
RP   VARIANT MAST CELL LEUKEMIA VAL-816.
RX   PubMed=7691885; DOI=10.1172/JCI116761;
RA   Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H.,
RA   Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y.,
RA   Matsuzawa Y., Kitamura Y., Kanakura Y.;
RT   "Identification of mutations in the coding sequence of the proto-
RT   oncogene c-kit in a human mast cell leukemia cell line causing ligand-
RT   independent activation of c-kit product.";
RL   J. Clin. Invest. 92:1736-1744(1993).
RN   [46]
RP   VARIANTS PBT GLY-791 AND VAL-812.
RX   PubMed=7687267; DOI=10.1111/1523-1747.ep12358440;
RA   Spritz R.A., Holmes S.A., Itin P., Kuester W.;
RT   "Novel mutations of the KIT (mast/stem cell growth factor receptor)
RT   proto-oncogene in human piebaldism.";
RL   J. Invest. Dermatol. 101:22-25(1993).
RN   [47]
RP   VARIANT PBT 893-GLU--PRO-896 DEL.
RX   PubMed=8680409; DOI=10.1002/humu.1380060409;
RA   Riva P., Milani N., Gandolfi P., Larizza L.;
RT   "A 12-bp deletion (7818del12) in the c-kit protooncogene in a large
RT   Italian kindred with piebaldism.";
RL   Hum. Mutat. 6:343-345(1995).
RN   [48]
RP   VARIANT MAST CELL DISEASE GLY-820.
RX   PubMed=9029028; DOI=10.1046/j.1365-2141.1997.d01-2042.x;
RA   Pignon J.-M., Giraudier S., Duquesnoy P., Jouault H., Imbert M.,
RA   Vainchenker W., Vernant J.-P., Tulliez M.;
RT   "A new c-kit mutation in a case of aggressive mast cell disease.";
RL   Br. J. Haematol. 96:374-376(1997).
RN   [49]
RP   VARIANT PBT GLY-796.
RX   PubMed=9450866;
RX   DOI=10.1002/(SICI)1096-8628(19980106)75:1<101::AID-AJMG20>3.0.CO;2-P;
RA   Spritz R.A., Beighton P.;
RT   "Piebaldism with deafness: molecular evidence for an expanded
RT   syndrome.";
RL   Am. J. Med. Genet. 75:101-103(1998).
RN   [50]
RP   VARIANT ACUTE MYELOID LEUKEMIA TYR-816.
RX   PubMed=9657776;
RA   Beghini A., Larizza L., Cairoli R., Morra E.;
RT   "c-kit activating mutations and mast cell proliferation in human
RT   leukemia.";
RL   Blood 92:701-702(1998).
RN   [51]
RP   VARIANT PBT PRO-847.
RX   PubMed=9699740; DOI=10.1046/j.1523-1747.1998.00269.x;
RA   Nomura K., Hatayama I., Narita T., Kaneko T., Shiraishi M.;
RT   "A novel KIT gene missense mutation in a Japanese family with
RT   piebaldism.";
RL   J. Invest. Dermatol. 111:337-338(1998).
RN   [52]
RP   VARIANT GIST VAL-559 DEL.
RX   PubMed=9697690; DOI=10.1038/1209;
RA   Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K.,
RA   Nakamura H., Kanakura Y., Tanaka T., Takabayashi A., Matsuda H.,
RA   Kitamura Y.;
RT   "Familial gastrointestinal stromal tumours with germline mutation of
RT   the KIT gene.";
RL   Nat. Genet. 19:323-324(1998).
RN   [53]
RP   VARIANTS GIST ILE-550; 550-LYS--LYS-558 DEL; 551-PRO--VAL-555 DEL;
RP   ASP-559 AND 559-VAL-VAL-560 DEL.
RX   PubMed=9438854; DOI=10.1126/science.279.5350.577;
RA   Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T.,
RA   Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M.,
RA   Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y.,
RA   Kitamura Y.;
RT   "Gain-of-function mutations of c-kit in human gastrointestinal stromal
RT   tumors.";
RL   Science 279:577-580(1998).
RN   [54]
RP   VARIANT HIS-816, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=10362788; DOI=10.1016/S0002-9440(10)65419-3;
RA   Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A.;
RT   "Activating c-kit gene mutations in human germ cell tumors.";
RL   Am. J. Pathol. 154:1643-1647(1999).
RN   [55]
RP   VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816 AND LYS-839, AND
RP   CHARACTERIZATION OF VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816
RP   AND LYS-839.
RX   PubMed=9990072; DOI=10.1073/pnas.96.4.1609;
RA   Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L.,
RA   Lu S.-Z., Heitjan D., Ma Y.;
RT   "Activating and dominant inactivating c-KIT catalytic domain mutations
RT   in distinct clinical forms of human mastocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1609-1614(1999).
RN   [56]
RP   VARIANTS PBT CYS-584; ARG-601 AND PRO-656.
RX   PubMed=11074500;
RX   DOI=10.1002/1096-8628(20001106)95:1<79::AID-AJMG16>3.0.CO;2-4;
RA   Syrris P., Malik N.M., Murday V.A., Patton M.A., Carter N.D.,
RA   Hughes H.E., Metcalfe K.;
RT   "Three novel mutations of the proto-oncogene KIT cause human
RT   piebaldism.";
RL   Am. J. Med. Genet. 95:79-81(2000).
RN   [57]
RP   VARIANT GIST ALA-559.
RX   PubMed=11505412;
RX   DOI=10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D;
RA   Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G.,
RA   Capella C., Larizza L.;
RT   "Germline mutation in the juxtamembrane domain of the kit gene in a
RT   family with gastrointestinal stromal tumors and urticaria
RT   pigmentosa.";
RL   Cancer 92:657-662(2001).
RN   [58]
RP   VARIANT GIST 550-LYS--LYS-558 DEL.
RX   PubMed=15824741; DOI=10.1038/sj.onc.1208587;
RA   Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N.,
RA   Frazier M.L.;
RT   "A mutation-created novel intra-exonic pre-mRNA splice site causes
RT   constitutive activation of KIT in human gastrointestinal stromal
RT   tumors.";
RL   Oncogene 24:4271-4280(2005).
RN   [59]
RP   VARIANTS TYR-816; LYS-822 AND PRO-829.
RX   PubMed=16175573; DOI=10.1002/gcc.20265;
RA   Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C.,
RA   Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R.,
RA   Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R.,
RA   Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A.,
RA   West S., Widaa S., Yates A., Gillis A.J.M., Stoop H.J.,
RA   van Gurp R.J.H.L.M., Oosterhuis J.W., Looijenga L.H.J., Futreal P.A.,
RA   Wooster R., Stratton M.R.;
RT   "Sequence analysis of the protein kinase gene family in human
RT   testicular germ-cell tumors of adolescents and adults.";
RL   Genes Chromosomes Cancer 45:42-46(2006).
RN   [60]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-532; LEU-541; SER-691; ASN-715;
RP   ASN-737; TRP-804; TYR-816; LYS-822 AND PRO-829.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for the cytokine KITLG/SCF and plays an essential role in
CC       the regulation of cell survival and proliferation, hematopoiesis,
CC       stem cell maintenance, gametogenesis, mast cell development,
CC       migration and function, and in melanogenesis. In response to
CC       KITLG/SCF binding, KIT can activate several signaling pathways.
CC       Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the
CC       AKT1 signaling pathway by phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT
CC       also transmits signals via GRB2 and activation of RAS, RAF1 and
CC       the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation
CC       of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT
CC       signaling is modulated by protein phosphatases, and by rapid
CC       internalization and degradation of the receptor. Activated KIT
CC       promotes phosphorylation of the protein phosphatases PTPN6/SHP-1
CC       and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A
CC       and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform
CC       Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.
CC       {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928,
CC       ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163,
CC       ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:17662946,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:2448137}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. KITLG/SCF binding leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues.
CC       Activity is down-regulated by PRKCA-mediated phosphorylation on
CC       serine residues. Inhibited by imatinib/STI-571 (Gleevec) and
CC       sunitinib; these compounds maintain the kinase in an inactive
CC       conformation. {ECO:0000269|PubMed:15123710,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:7539802}.
CC   -!- SUBUNIT: Monomer in the absence of bound KITLG/SCF. Homodimer in
CC       the presence of bound KITLG/SCF, forming a heterotetramer with two
CC       KITLG/SCF molecules. Interacts (via phosphorylated tyrosine
CC       residues) with the adapter proteins GRB2 and GRB7 (via SH2
CC       domain), and SH2B2/APS. Interacts (via C-terminus) with MPDZ (via
CC       the tenth PDZ domain). Interacts (via phosphorylated tyrosine
CC       residues) with PIK3R1 and PIK3 catalytic subunit. Interacts (via
CC       phosphorylated tyrosine) with CRK (isoform Crk-II), FYN, SHC1 and
CC       MATK/CHK (via SH2 domain). Interacts with LYN and FES/FPS.
CC       Interacts (via phosphorylated tyrosine residues) with the protein
CC       phosphatases PTPN6/SHP-1 (via SH2 domain), PTPN11/SHP-2 (via SH2
CC       domain) and PTPRU. Interacts with PLCG1. Interacts with DOK1 and
CC       TEC. {ECO:0000269|PubMed:10377264, ECO:0000269|PubMed:10397721,
CC       ECO:0000269|PubMed:11018522, ECO:0000269|PubMed:11825908,
CC       ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12824176,
CC       ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:17662946, ECO:0000269|PubMed:17904548,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21030588,
CC       ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444,
CC       ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9341198,
CC       ECO:0000269|PubMed:9528781}.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=2; IntAct=EBI-1379503, EBI-375543;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-1379503, EBI-1102694;
CC       O75815:BCAR3; NbExp=3; IntAct=EBI-1379503, EBI-702336;
CC       P51451:BLK; NbExp=5; IntAct=EBI-1379503, EBI-2105445;
CC       Q8WV28:BLNK; NbExp=2; IntAct=EBI-1379503, EBI-2623522;
CC       P46108:CRK; NbExp=4; IntAct=EBI-1379503, EBI-886;
CC       P07332:FES; NbExp=2; IntAct=EBI-1379503, EBI-1055635;
CC       P09769:FGR; NbExp=2; IntAct=EBI-1379503, EBI-1383732;
CC       O75791:GRAP2; NbExp=2; IntAct=EBI-1379503, EBI-740418;
CC       P62993:GRB2; NbExp=6; IntAct=EBI-1379503, EBI-401755;
CC       Q14451:GRB7; NbExp=4; IntAct=EBI-1379503, EBI-970191;
CC       P08631:HCK; NbExp=2; IntAct=EBI-1379503, EBI-346340;
CC       Q96JZ2:HSH2D; NbExp=5; IntAct=EBI-1379503, EBI-3919324;
CC       P21583:KITLG; NbExp=2; IntAct=EBI-1379503, EBI-1379527;
CC       P06239:LCK; NbExp=8; IntAct=EBI-1379503, EBI-1348;
CC       P07948:LYN; NbExp=7; IntAct=EBI-1379503, EBI-79452;
CC       Q8VBX6:Mpdz (xeno); NbExp=4; IntAct=EBI-1379503, EBI-8026435;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-1379503, EBI-389883;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-1379503, EBI-713635;
CC       P27986:PIK3R1; NbExp=19; IntAct=EBI-1379503, EBI-79464;
CC       O00459:PIK3R2; NbExp=19; IntAct=EBI-1379503, EBI-346930;
CC       Q92569:PIK3R3; NbExp=31; IntAct=EBI-1379503, EBI-79893;
CC       P19174:PLCG1; NbExp=31; IntAct=EBI-1379503, EBI-79387;
CC       P16885:PLCG2; NbExp=8; IntAct=EBI-1379503, EBI-617403;
CC       Q13882:PTK6; NbExp=4; IntAct=EBI-1379503, EBI-1383632;
CC       Q06124:PTPN11; NbExp=29; IntAct=EBI-1379503, EBI-297779;
CC       P35235:Ptpn11 (xeno); NbExp=2; IntAct=EBI-1379503, EBI-397236;
CC       Q92729:PTPRU; NbExp=2; IntAct=EBI-1379503, EBI-7052301;
CC       P20936:RASA1; NbExp=16; IntAct=EBI-1379503, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-1379503, EBI-7879749;
CC       O14796:SH2D1B; NbExp=8; IntAct=EBI-1379503, EBI-3923013;
CC       Q9NP31:SH2D2A; NbExp=10; IntAct=EBI-1379503, EBI-490630;
CC       Q8N5H7:SH2D3C; NbExp=4; IntAct=EBI-1379503, EBI-745980;
CC       P78314:SH3BP2; NbExp=3; IntAct=EBI-1379503, EBI-727062;
CC       Q15464:SHB; NbExp=2; IntAct=EBI-1379503, EBI-4402156;
CC       P29353:SHC1; NbExp=8; IntAct=EBI-1379503, EBI-78835;
CC       P98077:SHC2; NbExp=5; IntAct=EBI-1379503, EBI-7256023;
CC       Q92529:SHC3; NbExp=3; IntAct=EBI-1379503, EBI-79084;
CC       Q9H6Q3:SLA2; NbExp=2; IntAct=EBI-1379503, EBI-1222854;
CC       O14508:SOCS2; NbExp=4; IntAct=EBI-1379503, EBI-617737;
CC       O14543:SOCS3; NbExp=3; IntAct=EBI-1379503, EBI-714146;
CC       O14544:SOCS6; NbExp=12; IntAct=EBI-1379503, EBI-3929549;
CC       P12931:SRC; NbExp=5; IntAct=EBI-1379503, EBI-621482;
CC       Q9ULZ2:STAP1; NbExp=3; IntAct=EBI-1379503, EBI-6083058;
CC       Q9HBL0:TNS1; NbExp=2; IntAct=EBI-1379503, EBI-3389814;
CC       Q63HR2:TNS2; NbExp=2; IntAct=EBI-1379503, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=5; IntAct=EBI-1379503, EBI-1220488;
CC       P42681:TXK; NbExp=3; IntAct=EBI-1379503, EBI-7877438;
CC       P07947:YES1; NbExp=7; IntAct=EBI-1379503, EBI-515331;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-1379503, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Note=Detected in the
CC       cytoplasm of spermatozoa, especially in the equatorial and
CC       subacrosomal region of the sperm head.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=GNNK(+), Kit(+);
CC         IsoId=P10721-1; Sequence=Displayed;
CC       Name=2; Synonyms=GNNK(-), KitA(+);
CC         IsoId=P10721-2; Sequence=VSP_038385;
CC       Name=3; Synonyms=TR-KIT;
CC         IsoId=P10721-3; Sequence=VSP_041866, VSP_041867;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are detected in
CC       spermatogonia and Leydig cells. Isoform 3 is detected in round
CC       spermatids, elongating spermatids and spermatozoa (at protein
CC       level). Widely expressed. Detected in the hematopoietic system,
CC       the gastrointestinal system, in melanocytes and in germ cells.
CC       {ECO:0000269|PubMed:20601678, ECO:0000269|PubMed:2448137}.
CC   -!- INDUCTION: Up-regulated by cis-retinoic acid in neuroblastoma cell
CC       lines. {ECO:0000269|PubMed:20658618}.
CC   -!- PTM: Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after
CC       autophosphorylation induced by KITLG/SCF binding, leading to
CC       internalization and degradation. {ECO:0000269|PubMed:17904548,
CC       ECO:0000269|PubMed:19265199}.
CC   -!- PTM: Autophosphorylated on tyrosine residues. KITLG/SCF binding
CC       enhances autophosphorylation. Isoform 1 shows low levels of
CC       tyrosine phosphorylation in the absence of added KITLG/SCF (in
CC       vitro). Kinase activity is down-regulated by phosphorylation on
CC       serine residues by protein kinase C family members.
CC       Phosphorylation at Tyr-568 is required for interaction with
CC       PTPN11/SHP-2, CRK (isoform Crk-II) and members of the SRC
CC       tyrosine-protein kinase family. Phosphorylation at Tyr-570 is
CC       required for interaction with PTPN6/SHP-1. Phosphorylation at Tyr-
CC       703, Tyr-823 and Tyr-936 is important for interaction with GRB2.
CC       Phosphorylation at Tyr-721 is important for interaction with
CC       PIK3R1. Phosphorylation at Tyr-823 and Tyr-936 is important for
CC       interaction with GRB7. {ECO:0000269|PubMed:10377264,
CC       ECO:0000269|PubMed:12824176, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:20147452, ECO:0000269|PubMed:21030588,
CC       ECO:0000269|PubMed:9038210}.
CC   -!- DISEASE: Piebald trait (PBT) [MIM:172800]: Autosomal dominant
CC       genetic developmental abnormality of pigmentation characterized by
CC       congenital patches of white skin and hair that lack melanocytes.
CC       {ECO:0000269|PubMed:11074500, ECO:0000269|PubMed:1370874,
CC       ECO:0000269|PubMed:1376329, ECO:0000269|PubMed:1717985,
CC       ECO:0000269|PubMed:7687267, ECO:0000269|PubMed:8680409,
CC       ECO:0000269|PubMed:9450866, ECO:0000269|PubMed:9699740}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]:
CC       Common mesenchymal neoplasms arising in the gastrointestinal
CC       tract, most often in the stomach. They are histologically,
CC       immunohistochemically, and genetically different from typical
CC       leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are
CC       composed of a fairly uniform population of spindle-shaped cells.
CC       Some tumors are dominated by epithelioid cells or contain a
CC       mixture of spindle and epithelioid morphologies. Primary GISTs in
CC       the gastrointestinal tract commonly metastasize in the omentum and
CC       mesenteries, often as multiple nodules. However, primary tumors
CC       may also occur outside of the gastrointestinal tract, in other
CC       intra-abdominal locations, especially in the omentum and
CC       mesentery. {ECO:0000269|PubMed:11505412,
CC       ECO:0000269|PubMed:15824741, ECO:0000269|PubMed:9438854,
CC       ECO:0000269|PubMed:9697690}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes. Note=The gene represented in
CC       this entry is involved in disease pathogenesis. Somatic mutations
CC       that lead to constitutive activation of KIT are detected in AML
CC       patients. These mutations fall into two classes, the most common
CC       being in-frame internal tandem duplications of variable length in
CC       the juxtamembrane region that disrupt the normal regulation of the
CC       kinase activity. Likewise, point mutations in the kinase domain
CC       can result in a constitutively activated kinase.
CC   -!- MISCELLANEOUS: Numerous proteins are phosphorylated in response to
CC       KIT signaling, but it is not evident to determine which are
CC       directly phosphorylated by KIT under in vivo conditions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KITID127.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD117 entry;
CC       URL="https://en.wikipedia.org/wiki/CD117";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=two's company - Issue
CC       163 of August 2014;
CC       URL="http://web.expasy.org/spotlight/back_issues/163/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06182; CAA29548.1; -; mRNA.
DR   EMBL; X69301; CAA49159.1; -; Genomic_DNA.
DR   EMBL; X69302; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69303; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69304; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69305; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69306; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69307; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69308; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69309; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69310; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69311; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69312; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69313; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69314; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69315; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69316; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; U63834; AAC50968.1; -; Genomic_DNA.
DR   EMBL; U63834; AAC50969.1; -; Genomic_DNA.
DR   EMBL; EU826594; ACF47630.1; -; mRNA.
DR   EMBL; GU983671; ADF36702.1; -; mRNA.
DR   EMBL; HM015525; ADF50068.1; -; mRNA.
DR   EMBL; HM015526; ADF50069.1; -; mRNA.
DR   EMBL; AK304031; BAG64945.1; -; mRNA.
DR   EMBL; AC006552; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071593; AAH71593.1; -; mRNA.
DR   EMBL; S67773; AAB29529.1; -; Genomic_DNA.
DR   CCDS; CCDS3496.1; -. [P10721-1]
DR   CCDS; CCDS47058.1; -. [P10721-2]
DR   PIR; S01426; TVHUKT.
DR   RefSeq; NP_000213.1; NM_000222.2. [P10721-1]
DR   RefSeq; NP_001087241.1; NM_001093772.1. [P10721-2]
DR   UniGene; Hs.479754; -.
DR   PDB; 1PKG; X-ray; 2.90 A; A/B=549-935.
DR   PDB; 1QZJ; Model; -; A=576-932.
DR   PDB; 1QZK; Model; -; A=576-932.
DR   PDB; 1R01; Model; -; A=576-932.
DR   PDB; 1T45; X-ray; 1.90 A; A=547-693, A=754-935.
DR   PDB; 1T46; X-ray; 1.60 A; A=565-693, A=754-935.
DR   PDB; 2E9W; X-ray; 3.50 A; A/B=26-514.
DR   PDB; 2EC8; X-ray; 3.00 A; A=1-519.
DR   PDB; 2VIF; X-ray; 1.45 A; P=564-574.
DR   PDB; 3G0E; X-ray; 1.60 A; A=544-693, A=754-935.
DR   PDB; 3G0F; X-ray; 2.60 A; A/B=544-693, A/B=754-935.
DR   PDB; 4HVS; X-ray; 1.90 A; A=551-934.
DR   PDB; 4K94; X-ray; 2.40 A; C=308-518.
DR   PDB; 4K9E; X-ray; 2.70 A; C=308-518.
DR   PDB; 4PGZ; X-ray; 2.40 A; A/B/C=308-518.
DR   PDB; 4U0I; X-ray; 2.00 A; A=563-693, A=754-935.
DR   PDBsum; 1PKG; -.
DR   PDBsum; 1QZJ; -.
DR   PDBsum; 1QZK; -.
DR   PDBsum; 1R01; -.
DR   PDBsum; 1T45; -.
DR   PDBsum; 1T46; -.
DR   PDBsum; 2E9W; -.
DR   PDBsum; 2EC8; -.
DR   PDBsum; 2VIF; -.
DR   PDBsum; 3G0E; -.
DR   PDBsum; 3G0F; -.
DR   PDBsum; 4HVS; -.
DR   PDBsum; 4K94; -.
DR   PDBsum; 4K9E; -.
DR   PDBsum; 4PGZ; -.
DR   PDBsum; 4U0I; -.
DR   ProteinModelPortal; P10721; -.
DR   SMR; P10721; 33-507, 547-933.
DR   BioGrid; 110015; 39.
DR   DIP; DIP-1055N; -.
DR   IntAct; P10721; 65.
DR   MINT; MINT-146746; -.
DR   STRING; 9606.ENSP00000288135; -.
DR   BindingDB; P10721; -.
DR   ChEMBL; CHEMBL1936; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1805; -.
DR   iPTMnet; P10721; -.
DR   PhosphoSite; P10721; -.
DR   BioMuta; KIT; -.
DR   DMDM; 125472; -.
DR   MaxQB; P10721; -.
DR   PaxDb; P10721; -.
DR   PRIDE; P10721; -.
DR   DNASU; 3815; -.
DR   Ensembl; ENST00000288135; ENSP00000288135; ENSG00000157404. [P10721-1]
DR   Ensembl; ENST00000412167; ENSP00000390987; ENSG00000157404. [P10721-2]
DR   GeneID; 3815; -.
DR   KEGG; hsa:3815; -.
DR   UCSC; uc010igr.3; human. [P10721-1]
DR   UCSC; uc010igs.3; human. [P10721-2]
DR   CTD; 3815; -.
DR   GeneCards; KIT; -.
DR   HGNC; HGNC:6342; KIT.
DR   HPA; CAB003288; -.
DR   HPA; CAB068253; -.
DR   HPA; HPA004471; -.
DR   MalaCards; KIT; -.
DR   MIM; 164920; gene.
DR   MIM; 172800; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 606764; phenotype.
DR   neXtProt; NX_P10721; -.
DR   Orphanet; 98829; 'Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)'.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 158799; Aleukemic mast cell leukemia.
DR   Orphanet; 280785; Bullous diffuse cutaneous mastocytosis.
DR   Orphanet; 158796; Classic mast cell leukemia.
DR   Orphanet; 79455; Cutaneous mastocytoma.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 158778; Isolated bone marrow mastocytosis.
DR   Orphanet; 158793; Lymphoadenopathic mastocytosis with eosinophilia.
DR   Orphanet; 158772; Nodular urticaria pigmentosa.
DR   Orphanet; 2884; Piebaldism.
DR   Orphanet; 158769; Plaque-form urticaria pigmentosa.
DR   Orphanet; 280794; Pseudoxanthomatous diffuse cutaneous mastocytosis.
DR   Orphanet; 158775; Smouldering systemic mastocytosis.
DR   Orphanet; 98849; Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease.
DR   Orphanet; 90389; Telangiectasia macularis eruptiva perstans.
DR   Orphanet; 158766; Typical urticaria pigmentosa.
DR   PharmGKB; PA30128; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG104348; -.
DR   InParanoid; P10721; -.
DR   KO; K05091; -.
DR   OMA; YFCPGTE; -.
DR   OrthoDB; EOG7S7SCZ; -.
DR   PhylomeDB; P10721; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P10721; -.
DR   ChiTaRS; KIT; human.
DR   EvolutionaryTrace; P10721; -.
DR   GeneWiki; CD117; -.
DR   GenomeRNAi; 3815; -.
DR   NextBio; 14995; -.
DR   PRO; PR:P10721; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P10721; -.
DR   CleanEx; HS_KIT; -.
DR   ExpressionAtlas; P10721; baseline and differential.
DR   Genevisible; P10721; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0042629; C:mast cell granule; IMP:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005020; F:stem cell factor receptor activity; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002371; P:dendritic cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISS:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; ISS:UniProtKB.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0038162; P:erythropoietin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038093; P:Fc receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0002327; P:immature B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038109; P:Kit signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030032; P:lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0002551; P:mast cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0032762; P:mast cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; ISS:UniProtKB.
DR   GO; GO:0070662; P:mast cell proliferation; TAS:UniProtKB.
DR   GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB.
DR   GO; GO:0097326; P:melanocyte adhesion; ISS:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0097324; P:melanocyte migration; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001541; P:ovarian follicle development; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0043473; P:pigmentation; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IMP:UniProtKB.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; TAS:UniProtKB.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:UniProtKB.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:0048070; P:regulation of developmental pigmentation; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR027263; SCGF_receptor.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500951; SCGF_recepter; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    976       Mast/stem cell growth factor receptor
FT                                Kit.
FT                                /FTId=PRO_0000016754.
FT   TOPO_DOM     26    524       Extracellular. {ECO:0000255}.
FT   TRANSMEM    525    545       Helical. {ECO:0000255}.
FT   TOPO_DOM    546    976       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    112       Ig-like C2-type 1.
FT   DOMAIN      121    205       Ig-like C2-type 2.
FT   DOMAIN      212    308       Ig-like C2-type 3.
FT   DOMAIN      317    410       Ig-like C2-type 4.
FT   DOMAIN      413    507       Ig-like C2-type 5.
FT   DOMAIN      589    937       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     596    603       ATP.
FT   NP_BIND     671    677       ATP.
FT   REGION      568    570       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT   ACT_SITE    792    792       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       568    568       Magnesium.
FT   METAL       797    797       Magnesium.
FT   METAL       810    810       Magnesium.
FT   BINDING     623    623       ATP.
FT   BINDING     796    796       ATP.
FT   SITE        936    936       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT   MOD_RES     547    547       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     553    553       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     568    568       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12824176,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:21030588,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     570    570       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12824176,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     703    703       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10377264,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:20147452}.
FT   MOD_RES     721    721       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:20147452,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     730    730       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     741    741       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     746    746       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     821    821       Phosphoserine.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     823    823       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20147452}.
FT   MOD_RES     891    891       Phosphoserine.
FT                                {ECO:0000269|PubMed:12878163}.
FT   MOD_RES     900    900       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12878163,
FT                                ECO:0000269|PubMed:20147452}.
FT   MOD_RES     936    936       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10377264,
FT                                ECO:0000269|PubMed:19265199}.
FT   MOD_RES     959    959       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:7539802}.
FT   CARBOHYD    130    130       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    145    145       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    283    283       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    293    293       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    320    320       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    352    352       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    367    367       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    463    463       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    486    486       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     58     97       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    136    186       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    151    183       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    233    290       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    428    491       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   VAR_SEQ     412    413       KP -> SL (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041866.
FT   VAR_SEQ     414    976       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041867.
FT   VAR_SEQ     510    513       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:20658618,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_038385.
FT   VARIANT     532    532       V -> I (in dbSNP:rs55792975).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042021.
FT   VARIANT     541    541       M -> L (in dbSNP:rs3822214).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042022.
FT   VARIANT     541    541       M -> V (in dbSNP:rs3822214).
FT                                /FTId=VAR_061289.
FT   VARIANT     550    558       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:15824741,
FT                                ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033124.
FT   VARIANT     550    550       K -> I (in GIST; somatic mutation;
FT                                dbSNP:rs28933968).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033123.
FT   VARIANT     551    555       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033125.
FT   VARIANT     559    560       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033128.
FT   VARIANT     559    559       V -> A (in GIST).
FT                                {ECO:0000269|PubMed:11505412}.
FT                                /FTId=VAR_033126.
FT   VARIANT     559    559       V -> D (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033127.
FT   VARIANT     559    559       Missing (in GIST).
FT                                {ECO:0000269|PubMed:9697690}.
FT                                /FTId=VAR_007965.
FT   VARIANT     583    583       E -> K (in PBT).
FT                                {ECO:0000269|PubMed:1376329}.
FT                                /FTId=VAR_004104.
FT   VARIANT     584    584       F -> C (in PBT; dbSNP:rs28933371).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033129.
FT   VARIANT     584    584       F -> L (in PBT).
FT                                {ECO:0000269|PubMed:1370874}.
FT                                /FTId=VAR_004105.
FT   VARIANT     601    601       G -> R (in PBT).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033130.
FT   VARIANT     656    656       L -> P (in PBT).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033131.
FT   VARIANT     664    664       G -> R (in PBT).
FT                                {ECO:0000269|PubMed:1717985}.
FT                                /FTId=VAR_004106.
FT   VARIANT     691    691       C -> S (in dbSNP:rs35200131).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042023.
FT   VARIANT     715    715       S -> N (in dbSNP:rs56094246).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042024.
FT   VARIANT     737    737       D -> N (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042025.
FT   VARIANT     791    791       R -> G (in PBT).
FT                                {ECO:0000269|PubMed:7687267}.
FT                                /FTId=VAR_004107.
FT   VARIANT     796    796       R -> G (in PBT; with sensorineural
FT                                deafness). {ECO:0000269|PubMed:9450866}.
FT                                /FTId=VAR_033132.
FT   VARIANT     804    804       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042026.
FT   VARIANT     812    812       G -> V (in PBT).
FT                                {ECO:0000269|PubMed:7687267}.
FT                                /FTId=VAR_004108.
FT   VARIANT     816    816       D -> F (in mastocytosis; requires 2
FT                                nucleotide substitutions; somatic
FT                                mutation; constitutively activated and is
FT                                much more rapidly autophosphorylated than
FT                                wild type). {ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_033133.
FT   VARIANT     816    816       D -> H (in a testicular tumor; seminoma;
FT                                somatic mutation; constitutively
FT                                activated; dbSNP:rs28933969).
FT                                {ECO:0000269|PubMed:10362788,
FT                                ECO:0000269|PubMed:19164557,
FT                                ECO:0000269|PubMed:20147452}.
FT                                /FTId=VAR_033134.
FT   VARIANT     816    816       D -> V (in mast cell leukemia and
FT                                mastocytosis; somatic mutation;
FT                                constitutively activated; loss of
FT                                interaction with MPDZ).
FT                                {ECO:0000269|PubMed:11018522,
FT                                ECO:0000269|PubMed:17595334,
FT                                ECO:0000269|PubMed:19164557,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:21640708,
FT                                ECO:0000269|PubMed:7691885,
FT                                ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_004109.
FT   VARIANT     816    816       D -> Y (in acute myeloid leukemia,
FT                                mastocytosis and a germ cell tumor of the
FT                                testis; somatic mutation; constitutively
FT                                activated). {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9657776,
FT                                ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_023828.
FT   VARIANT     820    820       D -> G (in mast cell disease; systemic).
FT                                {ECO:0000269|PubMed:9029028}.
FT                                /FTId=VAR_033135.
FT   VARIANT     822    822       N -> K (in a germ cell tumor of the
FT                                testis; somatic mutation).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_023829.
FT   VARIANT     829    829       A -> P (in a germ cell tumor of the
FT                                testis; somatic mutation).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_023830.
FT   VARIANT     839    839       E -> K (in mastocytosis; somatic
FT                                mutation; dominant negative mutation;
FT                                loss of autophosphorylation).
FT                                {ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_033136.
FT   VARIANT     847    847       T -> P (in PBT).
FT                                {ECO:0000269|PubMed:9699740}.
FT                                /FTId=VAR_033137.
FT   VARIANT     893    896       Missing (in PBT; severe).
FT                                {ECO:0000269|PubMed:8680409}.
FT                                /FTId=VAR_004110.
FT   MUTAGEN     381    381       R->A: Reduces autophosphorylation in
FT                                response to KITLG/SCF.
FT                                {ECO:0000269|PubMed:17662946}.
FT   MUTAGEN     386    386       E->A: Reduces autophosphorylation in
FT                                response to KITLG/SCF.
FT                                {ECO:0000269|PubMed:17662946}.
FT   MUTAGEN     571    571       I->A: Reduction in SH2B2/APS binding.
FT                                Abolishes SH2B2/APS binding; when
FT                                associated with A-939.
FT                                {ECO:0000269|PubMed:12444928}.
FT   MUTAGEN     623    623       K->M: Stronger interaction with MPDZ.
FT                                {ECO:0000269|PubMed:11018522}.
FT   MUTAGEN     741    741       S->A: Abolishes down-regulation of kinase
FT                                activity by PKC/PRKCA-mediated
FT                                phosphorylation; when associated with A-
FT                                746. {ECO:0000269|PubMed:7539802}.
FT   MUTAGEN     746    746       S->A: Abolishes down-regulation of kinase
FT                                activity by PKC/PRKCA-mediated
FT                                phosphorylation; when associated with A-
FT                                741. {ECO:0000269|PubMed:7539802}.
FT   MUTAGEN     823    823       Y->F: No decrease in activity. Leads to
FT                                autophosphorylation at Tyr-900.
FT                                {ECO:0000269|PubMed:20147452}.
FT   MUTAGEN     939    939       L->A: Reduction in SH2B2/APS binding.
FT                                Abolishes SH2B2/APS binding; when
FT                                associated with A-571.
FT                                {ECO:0000269|PubMed:12444928}.
FT   CONFLICT    764    764       L -> I (in Ref. 9; AAH71593).
FT                                {ECO:0000305}.
FT   CONFLICT    838    838       P -> H (in Ref. 9; AAH71593).
FT                                {ECO:0000305}.
FT   STRAND       38     41       {ECO:0000244|PDB:2EC8}.
FT   STRAND       44     47       {ECO:0000244|PDB:2EC8}.
FT   STRAND       54     59       {ECO:0000244|PDB:2EC8}.
FT   STRAND       63     72       {ECO:0000244|PDB:2EC8}.
FT   STRAND       75     77       {ECO:0000244|PDB:2EC8}.
FT   STRAND       79     86       {ECO:0000244|PDB:2EC8}.
FT   HELIX        89     91       {ECO:0000244|PDB:2E9W}.
FT   STRAND       93     99       {ECO:0000244|PDB:2EC8}.
FT   STRAND      104    110       {ECO:0000244|PDB:2EC8}.
FT   STRAND      125    130       {ECO:0000244|PDB:2E9W}.
FT   STRAND      132    134       {ECO:0000244|PDB:2EC8}.
FT   STRAND      146    149       {ECO:0000244|PDB:2EC8}.
FT   STRAND      151    153       {ECO:0000244|PDB:2EC8}.
FT   STRAND      161    165       {ECO:0000244|PDB:2EC8}.
FT   TURN        166    168       {ECO:0000244|PDB:2EC8}.
FT   STRAND      169    174       {ECO:0000244|PDB:2EC8}.
FT   HELIX       177    179       {ECO:0000244|PDB:2EC8}.
FT   STRAND      183    188       {ECO:0000244|PDB:2EC8}.
FT   STRAND      193    200       {ECO:0000244|PDB:2E9W}.
FT   STRAND      203    205       {ECO:0000244|PDB:2E9W}.
FT   STRAND      213    215       {ECO:0000244|PDB:2EC8}.
FT   STRAND      219    224       {ECO:0000244|PDB:2EC8}.
FT   STRAND      229    239       {ECO:0000244|PDB:2EC8}.
FT   STRAND      243    248       {ECO:0000244|PDB:2EC8}.
FT   STRAND      258    263       {ECO:0000244|PDB:2EC8}.
FT   STRAND      265    267       {ECO:0000244|PDB:2EC8}.
FT   STRAND      269    279       {ECO:0000244|PDB:2EC8}.
FT   TURN        282    284       {ECO:0000244|PDB:2EC8}.
FT   STRAND      286    293       {ECO:0000244|PDB:2EC8}.
FT   STRAND      298    310       {ECO:0000244|PDB:2EC8}.
FT   STRAND      312    319       {ECO:0000244|PDB:4K94}.
FT   STRAND      321    325       {ECO:0000244|PDB:4K94}.
FT   STRAND      331    341       {ECO:0000244|PDB:4K94}.
FT   STRAND      344    350       {ECO:0000244|PDB:4K94}.
FT   STRAND      356    364       {ECO:0000244|PDB:4K94}.
FT   STRAND      367    369       {ECO:0000244|PDB:2EC8}.
FT   STRAND      372    379       {ECO:0000244|PDB:4K94}.
FT   HELIX       384    386       {ECO:0000244|PDB:4K94}.
FT   STRAND      388    395       {ECO:0000244|PDB:4K94}.
FT   STRAND      400    409       {ECO:0000244|PDB:4K94}.
FT   STRAND      411    420       {ECO:0000244|PDB:4K94}.
FT   HELIX       422    424       {ECO:0000244|PDB:4K94}.
FT   STRAND      425    434       {ECO:0000244|PDB:4K94}.
FT   STRAND      437    444       {ECO:0000244|PDB:4K94}.
FT   STRAND      445    449       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      452    454       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      458    462       {ECO:0000244|PDB:4K94}.
FT   STRAND      465    468       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      472    479       {ECO:0000244|PDB:4K94}.
FT   HELIX       481    483       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      485    494       {ECO:0000244|PDB:4K94}.
FT   STRAND      499    506       {ECO:0000244|PDB:4K94}.
FT   STRAND      558    564       {ECO:0000244|PDB:3G0E}.
FT   STRAND      567    570       {ECO:0000244|PDB:3G0E}.
FT   TURN        573    575       {ECO:0000244|PDB:1T46}.
FT   HELIX       580    582       {ECO:0000244|PDB:1T46}.
FT   HELIX       586    588       {ECO:0000244|PDB:1T46}.
FT   STRAND      589    597       {ECO:0000244|PDB:1T46}.
FT   STRAND      599    613       {ECO:0000244|PDB:1T46}.
FT   STRAND      617    625       {ECO:0000244|PDB:1T46}.
FT   HELIX       631    647       {ECO:0000244|PDB:1T46}.
FT   STRAND      656    660       {ECO:0000244|PDB:1T46}.
FT   STRAND      662    665       {ECO:0000244|PDB:1T46}.
FT   STRAND      667    671       {ECO:0000244|PDB:1T46}.
FT   HELIX       678    684       {ECO:0000244|PDB:1T46}.
FT   TURN        685    688       {ECO:0000244|PDB:1T46}.
FT   STRAND      757    759       {ECO:0000244|PDB:4HVS}.
FT   HELIX       760    762       {ECO:0000244|PDB:4HVS}.
FT   HELIX       766    785       {ECO:0000244|PDB:1T46}.
FT   STRAND      788    790       {ECO:0000244|PDB:3G0F}.
FT   HELIX       795    797       {ECO:0000244|PDB:1T46}.
FT   STRAND      798    801       {ECO:0000244|PDB:1T46}.
FT   TURN        802    804       {ECO:0000244|PDB:1T46}.
FT   STRAND      805    808       {ECO:0000244|PDB:1T46}.
FT   HELIX       812    814       {ECO:0000244|PDB:1T46}.
FT   HELIX       817    819       {ECO:0000244|PDB:3G0E}.
FT   STRAND      823    825       {ECO:0000244|PDB:1T46}.
FT   STRAND      827    831       {ECO:0000244|PDB:1T46}.
FT   HELIX       833    835       {ECO:0000244|PDB:1T46}.
FT   HELIX       838    843       {ECO:0000244|PDB:1T46}.
FT   HELIX       848    863       {ECO:0000244|PDB:1T46}.
FT   TURN        864    866       {ECO:0000244|PDB:1T46}.
FT   HELIX       877    885       {ECO:0000244|PDB:1T46}.
FT   HELIX       897    906       {ECO:0000244|PDB:1T46}.
FT   HELIX       911    913       {ECO:0000244|PDB:1T46}.
FT   HELIX       917    930       {ECO:0000244|PDB:1T46}.
FT   TURN        931    933       {ECO:0000244|PDB:1T45}.
SQ   SEQUENCE   976 AA;  109865 MW;  81B0CD76817F3454 CRC64;
     MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD
     PGFVKWTFEI LDETNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV
     DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH
     RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS
     SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN
     VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE
     DYPKSENESN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR
     LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
     SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV
     MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF
     GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC
     TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE
     YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM
     AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPES
     IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY
     DIMKTCWDAD PLKRPTFKQI VQLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV
     GSTASSSQPL LVHDDV
//
ID   LDLR_HUMAN              Reviewed;         860 AA.
AC   P01130; B4DII3; B4DJZ8; B4DR00; B4DTQ3; C0JYY8; H0YLU8; H0YNT7;
AC   Q53ZD9; Q59FQ1; Q9UDH7;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   20-JAN-2016, entry version 203.
DE   RecName: Full=Low-density lipoprotein receptor;
DE            Short=LDL receptor;
DE   Flags: Precursor;
GN   Name=LDLR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=6091915; DOI=10.1016/0092-8674(84)90188-0;
RA   Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L.,
RA   Goldstein J.L., Russell D.W.;
RT   "The human LDL receptor: a cysteine-rich protein with multiple Alu
RT   sequences in its mRNA.";
RL   Cell 39:27-38(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2988123; DOI=10.1126/science.2988123;
RA   Suedhof T.C., Goldstein J.L., Brown M.S., Russell D.W.;
RT   "The LDL receptor gene: a mosaic of exons shared with different
RT   proteins.";
RL   Science 228:815-822(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Jia S., Lv L., Sun H., Wang Q., Wang H., Zhan L., Yang Z.;
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3; 4 AND 6).
RC   TISSUE=Hippocampus, Placenta, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rieder M.J., da Ponte S.H., Kuldanek S.A., Rajkumar N., Smith J.D.,
RA   Toth E.J., Krauss R.M., Nickerson D.A.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 186-210; 394-405; 441-449; 472-495; 521-541 AND
RP   605-617.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8127891; DOI=10.1073/pnas.91.5.1839;
RA   Hofer F., Gruenberger M., Kowalski H., Machat H., Huettinger M.,
RA   Kuechler E., Blaas D.;
RT   "Members of the low density lipoprotein receptor family mediate cell
RT   entry of a minor-group common cold virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1839-1842(1994).
RN   [13]
RP   IDENTIFICATION OF AN O-GLYCOSYLATED SITES.
RX   PubMed=3005267;
RA   Davis C.G., Elhammer A., Russell D.W., Schneider W.J., Kornfeld S.,
RA   Brown M.S., Goldstein J.L.;
RT   "Deletion of clustered O-linked carbohydrates does not impair function
RT   of low density lipoprotein receptor in transfected fibroblasts.";
RL   J. Biol. Chem. 261:2828-2838(1986).
RN   [14]
RP   MUTAGENESIS OF CYTOPLASMIC DOMAIN.
RX   PubMed=3104336;
RA   Davis C.G., van Driel I.R., Russell D.W., Brown M.S., Goldstein J.L.;
RT   "The low density lipoprotein receptor. Identification of amino acids
RT   in cytoplasmic domain required for rapid endocytosis.";
RL   J. Biol. Chem. 262:4075-4082(1987).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION) AS RECEPTOR OF HEPATITIS C VIRUS.
RX   PubMed=10535997; DOI=10.1073/pnas.96.22.12766;
RA   Agnello V., Abel G., Elfahal M., Knight G.B., Zhang Q.X.;
RT   "Hepatitis C virus and other flaviviridae viruses enter cells via low
RT   density lipoprotein receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12766-12771(1999).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 TAT.
RX   PubMed=11100124; DOI=10.1038/82199;
RA   Liu Y., Jones M., Hingtgen C.M., Bu G., Laribee N., Tanzi R.E.,
RA   Moir R.D., Nath A., He J.J.;
RT   "Uptake of HIV-1 tat protein mediated by low-density lipoprotein
RT   receptor-related protein disrupts the neuronal metabolic balance of
RT   the receptor ligands.";
RL   Nat. Med. 6:1380-1387(2000).
RN   [17]
RP   INTERACTION WITH LDLRAP1.
RX   PubMed=12221107; DOI=10.1074/jbc.M208539200;
RA   He G., Gupta S., Yi M., Michaely P., Hobbs H.H., Cohen J.C.;
RT   "ARH is a modular adaptor protein that interacts with the LDL
RT   receptor, clathrin, and AP-2.";
RL   J. Biol. Chem. 277:44044-44049(2002).
RN   [18]
RP   INTERACTION WITH ARRB1, AND MUTAGENESIS OF TYR-828 AND SER-854.
RX   PubMed=12944399; DOI=10.1074/jbc.M309450200;
RA   Wu J.-H., Peppel K., Nelson C.D., Lin F.-T., Kohout T.A., Miller W.E.,
RA   Exum S.T., Freedman N.J.;
RT   "The adaptor protein beta-arrestin2 enhances endocytosis of the low
RT   density lipoprotein receptor.";
RL   J. Biol. Chem. 278:44238-44245(2003).
RN   [19]
RP   GLYCOSYLATION AT ASN-657.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [20]
RP   FUNCTION (MICROBIAL INFECTION) AS RECEPTOR OF HEPATITIS C VIRUS.
RX   PubMed=12615904; DOI=10.1084/jem.20021756;
RA   Bartosch B., Dubuisson J., Cosset F.-L.;
RT   "Infectious hepatitis C virus pseudo-particles containing functional
RT   E1-E2 envelope protein complexes.";
RL   J. Exp. Med. 197:633-642(2003).
RN   [21]
RP   INTERACTION WITH SNX17.
RX   PubMed=14739284; DOI=10.1074/jbc.M313689200;
RA   Burden J.J., Sun X.-M., Garcia Garcia A.B., Soutar A.K.;
RT   "Sorting motifs in the intracellular domain of the low density
RT   lipoprotein receptor interact with a novel domain of sorting nexin-
RT   17.";
RL   J. Biol. Chem. 279:16237-16245(2004).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-657.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PCSK9.
RX   PubMed=17461796; DOI=10.1111/j.1600-0854.2007.00562.x;
RA   Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J.,
RA   Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G.;
RT   "The cellular trafficking of the secretory proprotein convertase PCSK9
RT   and its dependence on the LDLR.";
RL   Traffic 8:718-732(2007).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-657.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, CHARACTERIZATION OF VARIANT SAINT
RP   OMER ASP-546, MUTAGENESIS OF LYS-811; LYS-816; LYS-830 AND CYS-839,
RP   AND UBIQUITINATION.
RX   PubMed=19520913; DOI=10.1126/science.1168974;
RA   Zelcer N., Hong C., Boyadjian R., Tontonoz P.;
RT   "LXR regulates cholesterol uptake through Idol-dependent
RT   ubiquitination of the LDL receptor.";
RL   Science 325:100-104(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   INTERACTION WITH PCSK9.
RX   PubMed=21149300; DOI=10.1074/jbc.M110.199042;
RA   Yamamoto T., Lu C., Ryan R.O.;
RT   "A two-step binding model of PCSK9 interaction with the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 286:5464-5470(2011).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH VESICULAR
RP   STOMATITIS VIRUS GLYCOPROTEIN.
RX   PubMed=23589850; DOI=10.1073/pnas.1214441110;
RA   Finkelshtein D., Werman A., Novick D., Barak S., Rubinstein M.;
RT   "LDL receptor and its family members serve as the cellular receptors
RT   for vesicular stomatitis virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:7306-7311(2013).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   STRUCTURE BY NMR OF 20-67.
RX   PubMed=7603991; DOI=10.1073/pnas.92.14.6334;
RA   Daly N.L., Scanlon M.J., Djordjevic J.T., Kroon P.A., Smith R.;
RT   "Three-dimensional structure of a cysteine-rich repeat from the low-
RT   density lipoprotein receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6334-6338(1995).
RN   [33]
RP   STRUCTURE BY NMR OF 65-104.
RX   PubMed=7578052; DOI=10.1021/bi00044a025;
RA   Daly N.L., Djordjevic J.T., Kroon P.A., Smith R.;
RT   "Three-dimensional structure of the second cysteine-rich repeat from
RT   the human low-density lipoprotein receptor.";
RL   Biochemistry 34:14474-14481(1995).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 196-232.
RX   PubMed=9262405; DOI=10.1038/41798;
RA   Fass D., Blacklow S.C., Kim P.S., Berger J.M.;
RT   "Molecular basis of familial hypercholesterolaemia from structure of
RT   LDL receptor module.";
RL   Nature 388:691-693(1997).
RN   [35]
RP   STRUCTURE BY NMR OF 20-104, AND DISULFIDE BONDS.
RX   PubMed=10933493; DOI=10.1110/ps.9.7.1282;
RA   Kurniawan N.D., Atkins A.R., Bieri S., Brown C.J., Brereton I.M.,
RA   Kroon P.A., Smith R.;
RT   "NMR structure of a concatemer of the first and second ligand-binding
RT   modules of the human low-density lipoprotein receptor.";
RL   Protein Sci. 9:1282-1293(2000).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.7 ANGSTROMS) OF 22-720, AND DISULFIDE BONDS.
RX   PubMed=12459547; DOI=10.1126/science.1078124;
RA   Rudenko G., Henry L., Henderson K., Ichtchenko K., Brown M.S.,
RA   Goldstein J.L., Deisenhofer J.;
RT   "Structure of the LDL receptor extracellular domain at endosomal pH.";
RL   Science 298:2353-2358(2002).
RN   [37]
RP   REVIEW ON FH VARIANTS.
RX   PubMed=1301956; DOI=10.1002/humu.1380010602;
RA   Hobbs H.H., Brown M.S., Goldstein J.L.;
RT   "Molecular genetics of the LDL receptor gene in familial
RT   hypercholesterolemia.";
RL   Hum. Mutat. 1:445-466(1992).
RN   [38]
RP   REVIEW ON FH VARIANTS.
RX   PubMed=9016531; DOI=10.1093/nar/25.1.172;
RA   Varret M., Rabes J.-P., Collod-Beroud G., Junien J., Boileau C.,
RA   Beroud C.;
RT   "Software and database for the analysis of mutations in the human LDL
RT   receptor gene.";
RL   Nucleic Acids Res. 25:172-180(1997).
RN   [39]
RP   VARIANT FH 47-ASP-GLY-48 DEL.
RX   PubMed=3263645; DOI=10.1073/pnas.85.21.7912;
RA   Leitersdorf E., Hobbs H.H., Fourie A.M., Jacobs M.,
RA   van der Westhuyzen D.R., Coetzee G.A.;
RT   "Deletion in the first cysteine-rich repeat of low density lipoprotein
RT   receptor impairs its transport but not lipoprotein binding in
RT   fibroblasts from a subject with familial hypercholesterolemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7912-7916(1988).
RN   [40]
RP   VARIANTS FH ASN-175; GLU-227 AND MET-429.
RX   PubMed=2569482; DOI=10.1172/JCI114258;
RA   Leitersdorf E., van der Westhuyzen D.R., Coetzee G.A., Hobbs H.H.;
RT   "Two common low density lipoprotein receptor gene mutations cause
RT   familial hypercholesterolemia in Afrikaners.";
RL   J. Clin. Invest. 84:954-961(1989).
RN   [41]
RP   VARIANT FH CYS-828.
RX   PubMed=3955657; DOI=10.1016/0092-8674(86)90533-7;
RA   Davis C.G., Lehrman M.A., Russell D.W., Anderson R.G.W., Brown M.S.,
RA   Goldstein J.L.;
RT   "The J.D. mutation in familial hypercholesterolemia: amino acid
RT   substitution in cytoplasmic domain impedes internalization of LDL
RT   receptors.";
RL   Cell 45:15-24(1986).
RN   [42]
RP   VARIANTS FH TYR-90 AND LYS-140.
RX   PubMed=8347689; DOI=10.1016/0925-4439(93)90156-U;
RA   Rubinsztein D.C., Jialal I., Leitersdorf E., Coetzee G.A.,
RA   van der Westhuyzen D.R.;
RT   "Identification of two new LDL-receptor mutations causing homozygous
RT   familial hypercholesterolemia in a South African of Indian origin.";
RL   Biochim. Biophys. Acta 1182:75-82(1993).
RN   [43]
RP   VARIANTS FH GLY-87; LYS-228 AND TYR-667.
RX   PubMed=2318961; DOI=10.1172/JCI114531;
RA   Leitersdorf E., Tobin E.J., Davignon J., Hobbs H.H.;
RT   "Common low-density lipoprotein receptor mutations in the French
RT   Canadian population.";
RL   J. Clin. Invest. 85:1014-1023(1990).
RN   [44]
RP   VARIANT FH HIS-433.
RX   PubMed=1446662; DOI=10.1111/j.1432-1033.1992.tb17383.x;
RA   Miyake Y., Tajima S., Funahashi T., Yamamura T., Yamamoto A.;
RT   "A point mutation of low-density-lipoprotein receptor causing rapid
RT   degradation of the receptor.";
RL   Eur. J. Biochem. 210:1-7(1992).
RN   [45]
RP   VARIANT FH GLY-218 DEL.
RX   PubMed=1867200;
RA   Meiner V., Landsberger D., Berkman N., Reshef A., Segal P.,
RA   Seftel H.C., van der Westhuyzen D.R., Jeenah M.S., Coetzee G.A.,
RA   Leitersdorf E.;
RT   "A common Lithuanian mutation causing familial hypercholesterolemia in
RT   Ashkenazi Jews.";
RL   Am. J. Hum. Genet. 49:443-449(1991).
RN   [46]
RP   VARIANT FH HIS-168.
RX   PubMed=8462973; DOI=10.1007/BF00222714;
RA   Leitersdorf E., Reshef A., Meiner V., Dann E.J., Beigel Y.,
RA   van Roggen F.G., van der Westhuyzen D.R., Coetzee G.A.;
RT   "A missense mutation in the low density lipoprotein receptor gene
RT   causes familial hypercholesterolemia in Sephardic Jews.";
RL   Hum. Genet. 91:141-147(1993).
RN   [47]
RP   VARIANT FH PHE-318.
RX   PubMed=8168830; DOI=10.1007/BF00202819;
RA   Lelli N., Garuti R., Pedrazzi P., Ghisellini M., Simone M.L.,
RA   Tiozzo R., Cattin L., Valenti M., Rolleri M., Bertolini S.,
RA   Stefanutti C., Calandra S.;
RT   "A new missense mutation (Cys297-->Phe) of the low density lipoprotein
RT   receptor in Italian patients with familial hypercholesterolemia
RT   (FHTrieste).";
RL   Hum. Genet. 93:538-540(1994).
RN   [48]
RP   VARIANT FH LEU-685.
RX   PubMed=2726768; DOI=10.1073/pnas.86.11.4166;
RA   Soutar A.K., Knight B.L., Patel D.D.;
RT   "Identification of a point mutation in growth factor repeat C of the
RT   low density lipoprotein-receptor gene in a patient with homozygous
RT   familial hypercholesterolemia that affects ligand binding and
RT   intracellular movement of receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4166-4170(1989).
RN   [49]
RP   VARIANT FH LEU-685.
RX   PubMed=1464748;
RA   Rubinsztein D.C., Coetzee G.A., Marais A.D., Leitersdorf E.,
RA   Seftel H.C., van der Westhuyzen D.R.;
RT   "Identification and properties of the proline664-leucine mutant LDL
RT   receptor in South Africans of Indian origin.";
RL   J. Lipid Res. 33:1647-1655(1992).
RN   [50]
RP   VARIANTS FH PORI HIS-401 AND TURKU ASP-844.
RX   PubMed=7573037;
RA   Koivisto U.-M., Viikari J.S., Kontula K.;
RT   "Molecular characterization of minor gene rearrangements in Finnish
RT   patients with heterozygous familial hypercholesterolemia:
RT   identification of two common missense mutations (Gly823-->Asp and
RT   Leu380-->His) and eight rare mutations of the LDL receptor gene.";
RL   Am. J. Hum. Genet. 57:789-797(1995).
RN   [51]
RP   VARIANTS FH LYS-140; SER-338 AND LEU-685.
RX   PubMed=7583548; DOI=10.1161/01.ATV.15.10.1713;
RA   Maruyama T., Miyake Y., Tajima S., Harada-Shiba M., Yamamura T.,
RA   Tsushima M., Kishino B., Horiguchi Y., Funahashi T., Matsuzawa Y.,
RA   Yamamoto A.;
RT   "Common mutations in the low-density-lipoprotein-receptor gene causing
RT   familial hypercholesterolemia in the Japanese population.";
RL   Arterioscler. Thromb. Vasc. Biol. 15:1713-1718(1995).
RN   [52]
RP   VARIANT FH FRENCH HIS-564.
RX   PubMed=7550239; DOI=10.1002/humu.1380060117;
RA   Tricot-Guerber F., Saint-Jore B., Valenti K., Foulon T., Bost M.,
RA   Hadjian A.J.;
RT   "Identification of a mutation, N543H, in exon 11 of the low-density
RT   lipoprotein receptor gene in a French family with familial
RT   hypercholesterolemia.";
RL   Hum. Mutat. 6:87-88(1995).
RN   [53]
RP   VARIANTS FH LYS-277; THR-423 AND ASN-579.
RX   PubMed=7635461; DOI=10.1007/BF00207370;
RA   Ekstroem U., Abrahamson M., Sveger T., Lombardi P., Nilsson-Ehle P.;
RT   "An efficient screening procedure detecting six novel mutations in the
RT   LDL receptor gene in Swedish children with hypercholesterolemia.";
RL   Hum. Genet. 96:147-150(1995).
RN   [54]
RP   VARIANT FH NORWEGIAN ASN-487 DEL.
RX   PubMed=7635482; DOI=10.1007/BF00207391;
RA   Leren T.P., Solberg K., Rodningen O.K., Tonstad S., Ose L.;
RT   "Two novel point mutations in the EGF precursor homology domain of the
RT   LDL receptor gene causing familial hypercholesterolemia.";
RL   Hum. Genet. 96:241-242(1995).
RN   [55]
RP   VARIANTS FH COLOGNE GLY-221; TYR-221 AND VAL-224.
RX   PubMed=7649546;
RA   Geisel J., Holzem G., Oette K.;
RT   "Screening for mutations in exon 4 of the LDL receptor gene in a
RT   German population with severe hypercholesterolemia.";
RL   Hum. Genet. 96:301-304(1995).
RN   [56]
RP   VARIANTS FH LA HABANA LYS-277; MET-429 AND MET-797.
RX   PubMed=7649549; DOI=10.1007/BF00210415;
RA   Pereira E., Ferreira R., Hermelin B., Thomas G., Bernard C.,
RA   Bertrand V., Nassiff H., Mendez del Castillo D., Bereziat G.,
RA   Benlian P.;
RT   "Recurrent and novel LDL receptor gene mutations causing heterozygous
RT   familial hypercholesterolemia in La Habana.";
RL   Hum. Genet. 96:319-322(1995).
RN   [57]
RP   VARIANTS FH TYR-168 AND ARG-366.
RX   PubMed=8740918;
RA   Gundersen K.E., Solberg K., Rodningen O.K., Tonstad S., Ose L.,
RA   Berg K., Leren T.P.;
RT   "Two novel missense mutations in the LDL receptor gene causing
RT   familial hypercholesterolemia.";
RL   Clin. Genet. 49:85-87(1996).
RN   [58]
RP   VARIANT FH GLY-231.
RX   PubMed=8664907;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<70::AID-HUMU12>3.3.CO;2-G;
RA   Sundvold H., Solberg K., Tonstad S., Rodningen O.K., Ose L., Berg K.,
RA   Leren T.P.;
RT   "A common missense mutation (C210G) in the LDL receptor gene among
RT   Norwegian familial hypercholesterolemia subjects.";
RL   Hum. Mutat. 7:70-71(1996).
RN   [59]
RP   VARIANTS FH ARG-197; TYR-248; ALA-301; TRP-302 AND PRO-350.
RX   PubMed=9026534;
RA   Webb J.C., Sun X.-M., McCarthy S.N., Neuwirth C., Thompson G.R.,
RA   Knigh B., Soutar A.K.;
RT   "Characterization of mutations in the low density lipoprotein (LDL)-
RT   receptor gene in patients with homozygous familial
RT   hypercholesterolemia, and frequency of these mutations in FH patients
RT   in the United Kingdom.";
RL   J. Lipid Res. 37:368-381(1996).
RN   [60]
RP   VARIANT FH LEU-685.
RX   PubMed=9254862; DOI=10.1007/s004390050503;
RA   Peeters A.V., van Gaal L.F., du Plessis L., Lombardi M.P.R.,
RA   Havekes L.M., Kotze M.J.;
RT   "Mutational and genetic origin of LDL receptor gene mutations detected
RT   in both Belgian and Dutch familial hypercholesterolemics.";
RL   Hum. Genet. 100:266-270(1997).
RN   [61]
RP   VARIANTS FH HIS-564 AND 799-LEU--PHE-801 DEL.
RX   PubMed=9143924;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:5<437::AID-HUMU10>3.3.CO;2-O;
RA   Jensen H.K., Jensen T.G., Faergeman O., Jensen L.G., Andresen B.S.,
RA   Corydon M.J., Andreasen P.H., Hansen P.S., Heath F., Bolund L.,
RA   Gregersen N.;
RT   "Two mutations in the same low-density lipoprotein receptor allele act
RT   in synergy to reduce receptor function in heterozygous familial
RT   hypercholesterolemia.";
RL   Hum. Mutat. 9:437-444(1997).
RN   [62]
RP   VARIANTS FH TRP-27; CYS-78; GLY-87; TYR-89; ASN-90; GLY-90; LYS-101;
RP   TYR-160; ASN-168; LEU-177; GLY-221; GLU-227; ARG-286; TYR-313;
RP   TYR-327; ASN-342; PRO-350; ASP-399; TRP-416; HIS-482; ARG-483;
RP   SER-526; ASP-549; CYS-633; LEU-649 AND ILE-726.
RX   PubMed=9259195;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<116::AID-HUMU4>3.3.CO;2-#;
RA   Day I.N.M., Whittall R.A., O'Dell S.D., Haddad L., Bolla M.K.,
RA   Gudnason V., Humphries S.E.;
RT   "Spectrum of LDL receptor gene mutations in heterozygous familial
RT   hypercholesterolemia.";
RL   Hum. Mutat. 10:116-127(1997).
RN   [63]
RP   VARIANTS FH PRO-56; TYR-175; TYR-356; VAL-401 AND TRP-416.
RX   PubMed=9104431; DOI=10.1046/j.1365-2796.1997.78119000.x;
RA   Leren T.P., Tonstad S., Gundersen K.E., Bakken K.S., Rodningen O.K.,
RA   Sundvold H., Ose L., Berg K.;
RT   "Molecular genetics of familial hypercholesterolaemia in Norway.";
RL   J. Intern. Med. 241:185-194(1997).
RN   [64]
RP   VARIANTS FH LEU-177; GLY-218 DEL; SER-564 AND GLU-592.
RX   PubMed=9654205; DOI=10.1007/s004390050740;
RA   Gorski B., Kubalska J., Naruszewicz M., Lubinski J.;
RT   "LDL-R and Apo-B-100 gene mutations in Polish familial
RT   hypercholesterolemias.";
RL   Hum. Genet. 102:562-565(1998).
RN   [65]
RP   VARIANTS FH TRP-173 AND ARG-368.
RX   PubMed=9452094;
RA   Couture P., Vohl M.-C., Gagne C., Gaudet D., Torres A.L., Lupien P.J.,
RA   Despres J.-P., Labrie F., Simard J., Moorjani S.;
RT   "Identification of three mutations in the low-density lipoprotein
RT   receptor gene causing familial hypercholesterolemia among French
RT   Canadians.";
RL   Hum. Mutat. Suppl. 1:S226-S231(1998).
RN   [66]
RP   VARIANTS FH GLN-416 AND MET-429.
RX   PubMed=9452095;
RA   Thiart R., Loubser O., de Villiers J.N.P., Marx M.P., Zaire R.,
RA   Raal F.J., Kotze M.J.;
RT   "Two novel and two known low-density lipoprotein receptor gene
RT   mutations in German patients with familial hypercholesterolemia.";
RL   Hum. Mutat. Suppl. 1:S232-S233(1998).
RN   [67]
RP   VARIANTS FH TYR-329; ARG-414 AND MET-429.
RX   PubMed=9452118;
RA   Mak Y.T., Zhang J., Chan Y.S., Mak T.W.L., Tomlinson B.,
RA   Masarei J.R.L., Pang C.P.;
RT   "Possible common mutations in the low density lipoprotein receptor
RT   gene in Chinese.";
RL   Hum. Mutat. Suppl. 1:S310-S313(1998).
RN   [68]
RP   VARIANTS FH GLU-92; GLY-95; ARG-116; LEU-177; GLY-221; TYR-221;
RP   LYS-277; TYR-302; LYS-434; TYR-667 AND GLU-700.
RX   PubMed=10206683;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<413::AID-HUMU17>3.3.CO;2-6;
RA   Cenarro A., Jensen H.K., Casao E., Civeira F., Gonzalez-Bonillo J.,
RA   Rodriguez-Rey J.C., Gregersen N., Pocovi M.;
RT   "Identification of recurrent and novel mutations in the LDL receptor
RT   gene in Spanish patients with familial hypercholesterolemia.";
RL   Hum. Mutat. 11:413-413(1998).
RN   [69]
RP   VARIANT FH CHIETI-3 GLU-228 DELINS CYS-LYS.
RX   PubMed=10660340;
RA   Motti C., Bertolini S., Rampa P., Trovatello G., Liberatoscioli L.,
RA   Calandra S., Federici G., Cortese C.;
RT   "Two novel mutations consisting in minor gene rearrangements in the
RT   human low density lipoprotein receptor gene in Italian patients
RT   affected by familial hypercholesterolemia.";
RL   Hum. Mutat. 12:290-290(1998).
RN   [70]
RP   VARIANT FH TYR-276.
RA   Vergopoulos A., Bajari T., Jouma M., Aydin A., Boehring S., Luft F.C.,
RA   Schuster H.;
RT   "A novel single amino acid substitution in exon 6 of the low-density
RT   lipoprotein receptor gene in a Syrian family.";
RL   Hum. Mutat. 12:365-365(1998).
RN   [71]
RP   VARIANTS FH TYR-379 AND SER-608.
RX   PubMed=9852677; DOI=10.1007/s100380050083;
RA   Hirayama T., Yamaki E., Hata A., Tsuji M., Hashimoto K., Yamamoto M.,
RA   Emi M.;
RT   "Five familial hypercholesterolemic kindreds in Japan with novel
RT   mutations of the LDL receptor gene.";
RL   J. Hum. Genet. 43:250-254(1998).
RN   [72]
RP   VARIANT FH GLASCO TYR-184.
RX   PubMed=9678702; DOI=10.1136/jmg.35.7.573;
RA   Lee W.K., Haddad L., Macleod M.J., Dorrance A.M., Wilson D.J.,
RA   Gaffney D., Dominiczak M.H., Packard C.J., Day I.N., Humphries S.E.,
RA   Dominiczak A.F.;
RT   "Identification of a common low density lipoprotein receptor mutation
RT   (C163Y) in the west of Scotland.";
RL   J. Med. Genet. 35:573-578(1998).
RN   [73]
RP   VARIANTS FH GLY-87; LYS-140; ASN-172; ARG-243; LEU-306; PRO-404;
RP   HIS-564; SER-577; ASN-579; ILE-726 AND LYS-825.
RX   PubMed=10532689; DOI=10.1016/S0021-9150(99)00158-6;
RA   Jensen H.K., Jensen L.G., Meinertz H., Hansen P.S., Gregersen N.,
RA   Faergeman O.;
RT   "Spectrum of LDL receptor gene mutations in Denmark: implications for
RT   molecular diagnostic strategy in heterozygous familial
RT   hypercholesterolemia.";
RL   Atherosclerosis 146:337-344(1999).
RN   [74]
RP   VARIANT FH PHE-261.
RX   PubMed=10422803; DOI=10.1034/j.1399-0004.1999.550506.x;
RA   Ekstroem U., Abrahamson M., Floren C.-H., Tollig H., Wettrell G.,
RA   Nilsson G., Sun X.-M., Soutar A.K., Nilsson-Ehle P.;
RT   "An individual with a healthy phenotype in spite of a pathogenic LDL
RT   receptor mutation (C240F).";
RL   Clin. Genet. 55:332-339(1999).
RN   [75]
RP   VARIANTS FH SER-50; ASN-221; LYS-288; VAL-432 AND HIS-564.
RX   PubMed=10090484;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:3<257::AID-HUMU14>3.3.CO;2-4;
RA   Ebhardt M., Schmidt H., Doerk T., Tietge U., Haas R., Manns M.-P.,
RA   Schmidtke J., Stuhrmann M.;
RT   "Mutation analysis in 46 German families with familial
RT   hypercholesterolemia: identification of 8 new mutations.";
RL   Hum. Mutat. 13:257-257(1999).
RN   [76]
RP   VARIANTS FH SER-338; LEU-403; THR-431; VAL-568 AND LYS-714.
RX   PubMed=10447263;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<87::AID-HUMU13>3.3.CO;2-H;
RA   Hattori H., Nagano M., Iwata F., Homma Y., Egashira T., Okada T.;
RT   "Identification of recurrent and novel mutations in the LDL receptor
RT   gene in Japanese familial hypercholesterolemia.";
RL   Hum. Mutat. 14:87-87(1999).
RN   [77]
RP   VARIANTS ARG-2; ILE-468 AND GLN-814.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [78]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [79]
RP   VARIANTS FH PHE-134; TRP-134; TYR-222; PRO-254; ARG-276; ARG-318;
RP   THR-370; GLY-415 AND TYR-579.
RX   PubMed=10978268; DOI=10.1161/01.ATV.20.9.e41;
RA   Bertolini S., Cantafora A., Averna M., Cortese C., Motti C.,
RA   Martini S., Pes G., Postiglione A., Stefanutti C., Blotta I.,
RA   Pisciotta L., Rolleri M., Langheim S., Ghisellini M., Rabbone I.,
RA   Calandra S.;
RT   "Clinical expression of familial hypercholesterolemia in clusters of
RT   mutations of the LDL receptor gene that cause a receptor-defective or
RT   receptor-negative phenotype.";
RL   Arterioscler. Thromb. Vasc. Biol. 20:E41-E52(2000).
RN   [80]
RP   VARIANT FH THR-451.
RX   PubMed=10980548;
RX   DOI=10.1002/1098-1004(200009)16:3<277::AID-HUMU24>3.0.CO;2-Y;
RA   Miltiadous G., Elisaf M., Xenophontos S., Manoli P., Cariolou M.A.;
RT   "Segregation of a novel LDLR gene mutation (I430T) with familial
RT   hypercholesterolaemia in a Greek pedigree.";
RL   Hum. Mutat. 16:277-277(2000).
RN   [81]
RP   VARIANT FH 47-ASP-GLY-48 DEL, AND VARIANTS HIS-172; TRP-253; GLN-406;
RP   LYS-408; LEU-699 AND GLN-814.
RX   PubMed=10882754; DOI=10.1136/jmg.37.7.514;
RA   Thiart R., Scholtz C.L., Vergotine J., Hoogendijk C.F.,
RA   de Villiers J.N.P., Nissen H., Brusgaard K., Gaffney D., Hoffs M.S.,
RA   Vermaak W.J.H., Kotze M.J.;
RT   "Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in
RT   Africans with familial hypercholesterolaemia.";
RL   J. Med. Genet. 37:514-519(2000).
RN   [82]
RP   VARIANT FH SER-46.
RX   PubMed=11298688; DOI=10.1034/j.1399-0004.2001.590414.x;
RA   Takahashi M., Ikeda U., Takahashi S., Hattori H., Iwasaki T.,
RA   Ishihara M., Egashira T., Honma S., Asano Y., Shimada K.A.;
RT   "A novel mutation in exon 2 of the low-density lipoprotein-receptor
RT   gene in a patient with homozygous familial hypercholesterolemia.";
RL   Clin. Genet. 59:290-292(2001).
RN   [83]
RP   INVOLVEMENT IN FH, VARIANTS FH ARG-143; TYR-148; TRP-184; CYS-574;
RP   ASP-639 AND ASP-806, AND VARIANTS TRP-257 AND ILE-742.
RX   PubMed=11462246; DOI=10.1002/humu.1171;
RA   Nauck M.S., Koester W., Doerfer K., Eckes J., Scharnagl H.,
RA   Gierens H., Nissen H., Nauck M.A., Wieland H., Maerz W.;
RT   "Identification of recurrent and novel mutations in the LDL receptor
RT   gene in German patients with familial hypercholesterolemia.";
RL   Hum. Mutat. 18:165-166(2001).
RN   [84]
RP   VARIANTS FH TYR-89; LYS-101; GLY-218 DEL; GLY-221; ASN-221; TYR-358;
RP   PRO-479; HIS-482; ARG-677 AND LEU-685.
RX   PubMed=17142622; DOI=10.1136/jmg.2006.038356;
RG   Simon Broome familial hyperlipidemia register group and scientific steering committee;
RA   Humphries S.E., Whittall R.A., Hubbart C.S., Maplebeck S.,
RA   Cooper J.A., Soutar A.K., Naoumova R., Thompson G.R., Seed M.,
RA   Durrington P.N., Miller J.P., Betteridge D.J.B., Neil H.A.W.;
RT   "Genetic causes of familial hypercholesterolaemia in patients in the
RT   UK: relation to plasma lipid levels and coronary heart disease risk.";
RL   J. Med. Genet. 43:943-949(2006).
RN   [85]
RP   VARIANTS FH THR-50; LEU-211; GLY-221; GLU-266; LYS-277; ARG-286;
RP   ARG-314; ARG-352; LYS-408; THR-431; HIS-442; MET-523; GLY-577; THR-585
RP   AND LEU-685.
RX   PubMed=17347910; DOI=10.1007/s10545-007-0563-5;
RA   Widhalm K., Dirisamer A., Lindemayr A., Kostner G.;
RT   "Diagnosis of families with familial hypercholesterolaemia and/or Apo
RT   B-100 defect by means of DNA analysis of LDL-receptor gene
RT   mutations.";
RL   J. Inherit. Metab. Dis. 30:239-247(2007).
RN   [86]
RP   VARIANTS FH TYR-155; GLY-300; GLY-301; TRP-416 AND ASN-454.
RX   PubMed=19318025; DOI=10.1016/j.clinbiochem.2009.01.017;
RA   Alonso R., Defesche J.C., Tejedor D., Castillo S., Stef M., Mata N.,
RA   Gomez-Enterria P., Martinez-Faedo C., Forga L., Mata P.;
RT   "Genetic diagnosis of familial hypercholesterolemia using a DNA-array
RT   based platform.";
RL   Clin. Biochem. 42:899-903(2009).
RN   [87]
RP   VARIANTS FH PRO-254; TYR-356; TYR-358; THR-451 AND SER-826.
RX   PubMed=19319977; DOI=10.1002/humu.21002;
RA   Abifadel M., Rabes J.-P., Jambart S., Halaby G., Gannage-Yared M.-H.,
RA   Sarkis A., Beaino G., Varret M., Salem N., Corbani S., Aydenian H.,
RA   Junien C., Munnich A., Boileau C.;
RT   "The molecular basis of familial hypercholesterolemia in Lebanon:
RT   spectrum of LDLR mutations and role of PCSK9 as a modifier gene.";
RL   Hum. Mutat. 30:E682-E691(2009).
RN   [88]
RP   VARIANTS HIS-139; LYS-201; SER-255; ASN-304 AND GLY-471.
RX   PubMed=21418584; DOI=10.1186/1471-2350-12-40;
RA   Al-Khateeb A., Zahri M.K., Mohamed M.S., Sasongko T.H., Ibrahim S.,
RA   Yusof Z., Zilfalil B.A.;
RT   "Analysis of sequence variations in low-density lipoprotein receptor
RT   gene among Malaysian patients with familial hypercholesterolemia.";
RL   BMC Med. Genet. 12:40-40(2011).
RN   [89]
RP   VARIANT FH PHE-329.
RX   PubMed=22160468; DOI=10.1007/s11033-011-1314-0;
RA   Walus-Miarka M., Sanak M., Idzior-Walus B., Miarka P., Witek P.,
RA   Malecki M.T., Czarnecka D.;
RT   "A novel mutation (Cys308Phe) of the LDL receptor gene in families
RT   from the South-Eastern part of Poland.";
RL   Mol. Biol. Rep. 39:5181-5186(2012).
RN   [90]
RP   VARIANTS FH TYR-160; ALA-168; LEU-177; TYR-184; GLY-221; GLN-228;
RP   LYS-228; TRP-276; TYR-285; GLY-301; PHE-318; CYS-326; SER-343;
RP   TYR-368; ASP-373; TRP-406; MET-429; ASN-492; ASP-549; HIS-564;
RP   HIS-574; TRP-595; HIS-601; LEU-685; LEU-699; MET-797 AND GLN-814.
RX   PubMed=24529145; DOI=10.1016/j.atherosclerosis.2013.12.028;
RA   Santos P.C., Morgan A.C., Jannes C.E., Turolla L., Krieger J.E.,
RA   Santos R.D., Pereira A.C.;
RT   "Presence and type of low density lipoprotein receptor (LDLR) mutation
RT   influences the lipid profile and response to lipid-lowering therapy in
RT   Brazilian patients with heterozygous familial hypercholesterolemia.";
RL   Atherosclerosis 233:206-210(2014).
RN   [91]
RP   CHARACTERIZATION OF VARIANTS FH ARG-116; ASN-168; ASN-172; GLY-300 AND
RP   GLY-301, AND CHARACTERIZATION OF VARIANT TRP-257.
RX   PubMed=25545329; DOI=10.1016/j.atherosclerosis.2014.12.026;
RA   Etxebarria A., Benito-Vicente A., Stef M., Ostolaza H., Palacios L.,
RA   Martin C.;
RT   "Activity-associated effect of LDL receptor missense variants located
RT   in the cysteine-rich repeats.";
RL   Atherosclerosis 238:304-312(2015).
RN   [92]
RP   CHARACTERIZATION OF VARIANTS FH TYR-155; TRP-416; ASN-454; GLY-577 AND
RP   LYS-825.
RX   PubMed=25378237; DOI=10.1002/humu.22721;
RA   Etxebarria A., Benito-Vicente A., Palacios L., Stef M., Cenarro A.,
RA   Civeira F., Ostolaza H., Martin C.;
RT   "Functional characterization and classification of frequent low-
RT   density lipoprotein receptor variants.";
RL   Hum. Mutat. 36:129-141(2015).
CC   -!- FUNCTION: Binds LDL, the major cholesterol-carrying lipoprotein of
CC       plasma, and transports it into cells by endocytosis. In order to
CC       be internalized, the receptor-ligand complexes must first cluster
CC       into clathrin-coated pits.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C
CC       virus in hepatocytes, but not through a direct interaction with
CC       viral proteins (PubMed:10535997, PubMed:12615904). Acts as a
CC       receptor for vesicular stomatitis virus (PubMed:23589850). In case
CC       of HIV-1 infection, may function as a receptor for extracellular
CC       Tat in neurons, mediating its internalization in uninfected cells
CC       (PubMed:11100124). {ECO:0000269|PubMed:10535997,
CC       ECO:0000269|PubMed:11100124, ECO:0000269|PubMed:12615904,
CC       ECO:0000269|PubMed:23589850}.
CC   -!- SUBUNIT: Interacts with LDLRAP1, ARRB1, SNX17. Interacts (via NPXY
CC       motif) with DAB2 (via PID domain); the interaction is impaired by
CC       tyrosine phosphorylation of the NPXY motif. Interacts with the
CC       full length immature form of PCSK9 (via C-terminus). (Microbial
CC       infection) Interacts with vesicular stomatitis virus glycoprotein
CC       (PubMed:23589850). (Microbial infection) May interact with HIV-1
CC       Tat (PubMed:11100124). {ECO:0000269|PubMed:11100124,
CC       ECO:0000269|PubMed:12221107, ECO:0000269|PubMed:12944399,
CC       ECO:0000269|PubMed:14739284, ECO:0000269|PubMed:17461796,
CC       ECO:0000269|PubMed:21149300, ECO:0000269|PubMed:23589850}.
CC   -!- INTERACTION:
CC       P04114:APOB; NbExp=4; IntAct=EBI-988319, EBI-3926040;
CC       P02649:APOE; NbExp=2; IntAct=EBI-988319, EBI-1222467;
CC       Q8NBP7:PCSK9; NbExp=10; IntAct=EBI-988319, EBI-7539251;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endomembrane system; Single-pass type I membrane protein.
CC       Membrane, clathrin-coated pit; Single-pass type I membrane
CC       protein. Golgi apparatus. Early endosome. Late endosome. Cell
CC       surface. Lysosome. Note=Found distributed from the plasma membrane
CC       to intracellular compartments. Localizes to the Golgi apparatus,
CC       early and late endosomes/lysosomes and cell surface in the
CC       presence of PCSK9.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=P01130-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01130-2; Sequence=VSP_043053, VSP_043054;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P01130-3; Sequence=VSP_055014, VSP_055015;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P01130-4; Sequence=VSP_043595;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P01130-5; Sequence=VSP_045525;
CC         Note=No experimental confirmation available.;
CC       Name=6;
CC         IsoId=P01130-6; Sequence=VSP_047413;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The NPXY motif mediates the interaction with the clathrin
CC       adaptor DAB2 involved in receptor internalization. {ECO:0000250}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19520913}.
CC   -!- PTM: Ubiquitinated by MYLIP leading to degradation.
CC       {ECO:0000269|PubMed:19520913}.
CC   -!- DISEASE: Familial hypercholesterolemia (FH) [MIM:143890]: Common
CC       autosomal semi-dominant disease that affects about 1 in 500
CC       individuals. The receptor defect impairs the catabolism of LDL,
CC       and the resultant elevation in plasma LDL-cholesterol promotes
CC       deposition of cholesterol in the skin (xanthelasma), tendons
CC       (xanthomas), and coronary arteries (atherosclerosis).
CC       {ECO:0000269|PubMed:10090484, ECO:0000269|PubMed:10206683,
CC       ECO:0000269|PubMed:10422803, ECO:0000269|PubMed:10447263,
CC       ECO:0000269|PubMed:10532689, ECO:0000269|PubMed:10660340,
CC       ECO:0000269|PubMed:10882754, ECO:0000269|PubMed:10978268,
CC       ECO:0000269|PubMed:10980548, ECO:0000269|PubMed:11298688,
CC       ECO:0000269|PubMed:11462246, ECO:0000269|PubMed:1446662,
CC       ECO:0000269|PubMed:1464748, ECO:0000269|PubMed:17142622,
CC       ECO:0000269|PubMed:17347910, ECO:0000269|PubMed:1867200,
CC       ECO:0000269|PubMed:19318025, ECO:0000269|PubMed:19319977,
CC       ECO:0000269|PubMed:22160468, ECO:0000269|PubMed:2318961,
CC       ECO:0000269|PubMed:24529145, ECO:0000269|PubMed:2569482,
CC       ECO:0000269|PubMed:2726768, ECO:0000269|PubMed:3263645,
CC       ECO:0000269|PubMed:3955657, ECO:0000269|PubMed:7550239,
CC       ECO:0000269|PubMed:7573037, ECO:0000269|PubMed:7583548,
CC       ECO:0000269|PubMed:7635461, ECO:0000269|PubMed:7635482,
CC       ECO:0000269|PubMed:7649546, ECO:0000269|PubMed:7649549,
CC       ECO:0000269|PubMed:8168830, ECO:0000269|PubMed:8347689,
CC       ECO:0000269|PubMed:8462973, ECO:0000269|PubMed:8664907,
CC       ECO:0000269|PubMed:8740918, ECO:0000269|PubMed:9026534,
CC       ECO:0000269|PubMed:9104431, ECO:0000269|PubMed:9143924,
CC       ECO:0000269|PubMed:9254862, ECO:0000269|PubMed:9259195,
CC       ECO:0000269|PubMed:9452094, ECO:0000269|PubMed:9452095,
CC       ECO:0000269|PubMed:9452118, ECO:0000269|PubMed:9654205,
CC       ECO:0000269|PubMed:9678702, ECO:0000269|PubMed:9852677,
CC       ECO:0000269|Ref.70}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the LDLR family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 7 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 6 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92646.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=LDLR; Note=LDLR mutation database;
CC       URL="http://www.ucl.ac.uk/fh/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=LDLR";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L00352; AAA56833.1; -; Genomic_DNA.
DR   EMBL; L00336; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00337; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00338; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00339; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00340; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00341; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00343; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00344; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00345; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00346; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00347; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00348; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00349; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00350; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L00351; AAA56833.1; JOINED; Genomic_DNA.
DR   EMBL; L29401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY114155; AAM56036.1; -; mRNA.
DR   EMBL; AK295612; BAG58495.1; -; mRNA.
DR   EMBL; AK296312; BAG59010.1; -; mRNA.
DR   EMBL; AK299038; BAG61112.1; -; mRNA.
DR   EMBL; AK300313; BAG62065.1; -; mRNA.
DR   EMBL; BT007361; AAP36025.1; -; mRNA.
DR   EMBL; AY324609; AAP72971.1; -; Genomic_DNA.
DR   EMBL; AB209409; BAD92646.1; ALT_INIT; mRNA.
DR   EMBL; FJ525879; ACN81317.1; -; Genomic_DNA.
DR   EMBL; AC011485; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471106; EAW84169.1; -; Genomic_DNA.
DR   EMBL; BC014514; AAH14514.1; -; mRNA.
DR   CCDS; CCDS12254.1; -. [P01130-1]
DR   CCDS; CCDS56083.1; -. [P01130-2]
DR   CCDS; CCDS56084.1; -. [P01130-3]
DR   CCDS; CCDS56085.1; -. [P01130-4]
DR   CCDS; CCDS58651.1; -. [P01130-5]
DR   PIR; A01383; QRHULD.
DR   RefSeq; NP_000518.1; NM_000527.4. [P01130-1]
DR   RefSeq; NP_001182727.1; NM_001195798.1. [P01130-5]
DR   RefSeq; NP_001182728.1; NM_001195799.1. [P01130-4]
DR   RefSeq; NP_001182729.1; NM_001195800.1. [P01130-3]
DR   RefSeq; NP_001182732.1; NM_001195803.1. [P01130-2]
DR   UniGene; Hs.213289; -.
DR   UniGene; Hs.713981; -.
DR   PDB; 1AJJ; X-ray; 1.70 A; A=196-232.
DR   PDB; 1D2J; NMR; -; A=233-272.
DR   PDB; 1F5Y; NMR; -; A=22-104.
DR   PDB; 1F8Z; NMR; -; A=234-272.
DR   PDB; 1HJ7; NMR; -; A=314-393.
DR   PDB; 1HZ8; NMR; -; A=314-395.
DR   PDB; 1I0U; NMR; -; A=314-395.
DR   PDB; 1IJQ; X-ray; 1.50 A; A/B=398-713.
DR   PDB; 1LDL; NMR; -; A=20-67.
DR   PDB; 1LDR; NMR; -; A=64-104.
DR   PDB; 1LRX; Model; -; B=396-659.
DR   PDB; 1N7D; X-ray; 3.70 A; A=22-720.
DR   PDB; 1XFE; NMR; -; A=272-353.
DR   PDB; 2FCW; X-ray; 1.26 A; B=107-186.
DR   PDB; 2KRI; NMR; -; B=147-186.
DR   PDB; 2LGP; NMR; -; A=144-235.
DR   PDB; 2M7P; NMR; -; A=82-104.
DR   PDB; 2MG9; NMR; -; A=314-339.
DR   PDB; 2W2M; X-ray; 2.40 A; E=314-393.
DR   PDB; 2W2N; X-ray; 2.30 A; E=314-393.
DR   PDB; 2W2O; X-ray; 2.62 A; E=314-393.
DR   PDB; 2W2P; X-ray; 2.62 A; E=314-393.
DR   PDB; 2W2Q; X-ray; 2.33 A; E=314-393.
DR   PDB; 3BPS; X-ray; 2.41 A; E=314-393.
DR   PDB; 3GCW; X-ray; 2.70 A; E=314-393.
DR   PDB; 3GCX; X-ray; 2.70 A; E=314-393.
DR   PDB; 3M0C; X-ray; 7.01 A; C=4-788.
DR   PDB; 3P5B; X-ray; 3.30 A; L=316-715.
DR   PDB; 3P5C; X-ray; 4.20 A; L=276-715.
DR   PDB; 3SO6; X-ray; 1.37 A; Q=819-832.
DR   PDB; 4NE9; X-ray; 2.60 A; D=314-339.
DR   PDBsum; 1AJJ; -.
DR   PDBsum; 1D2J; -.
DR   PDBsum; 1F5Y; -.
DR   PDBsum; 1F8Z; -.
DR   PDBsum; 1HJ7; -.
DR   PDBsum; 1HZ8; -.
DR   PDBsum; 1I0U; -.
DR   PDBsum; 1IJQ; -.
DR   PDBsum; 1LDL; -.
DR   PDBsum; 1LDR; -.
DR   PDBsum; 1LRX; -.
DR   PDBsum; 1N7D; -.
DR   PDBsum; 1XFE; -.
DR   PDBsum; 2FCW; -.
DR   PDBsum; 2KRI; -.
DR   PDBsum; 2LGP; -.
DR   PDBsum; 2M7P; -.
DR   PDBsum; 2MG9; -.
DR   PDBsum; 2W2M; -.
DR   PDBsum; 2W2N; -.
DR   PDBsum; 2W2O; -.
DR   PDBsum; 2W2P; -.
DR   PDBsum; 2W2Q; -.
DR   PDBsum; 3BPS; -.
DR   PDBsum; 3GCW; -.
DR   PDBsum; 3GCX; -.
DR   PDBsum; 3M0C; -.
DR   PDBsum; 3P5B; -.
DR   PDBsum; 3P5C; -.
DR   PDBsum; 3SO6; -.
DR   PDBsum; 4NE9; -.
DR   ProteinModelPortal; P01130; -.
DR   SMR; P01130; 20-715.
DR   BioGrid; 110141; 33.
DR   DIP; DIP-29695N; -.
DR   IntAct; P01130; 14.
DR   MINT; MINT-3003796; -.
DR   STRING; 9606.ENSP00000454071; -.
DR   BindingDB; P01130; -.
DR   ChEMBL; CHEMBL3311; -.
DR   DrugBank; DB00707; Porfimer.
DR   iPTMnet; P01130; -.
DR   PhosphoSite; P01130; -.
DR   UniCarbKB; P01130; -.
DR   BioMuta; LDLR; -.
DR   DMDM; 126073; -.
DR   MaxQB; P01130; -.
DR   PaxDb; P01130; -.
DR   PRIDE; P01130; -.
DR   DNASU; 3949; -.
DR   Ensembl; ENST00000455727; ENSP00000397829; ENSG00000130164. [P01130-3]
DR   Ensembl; ENST00000535915; ENSP00000440520; ENSG00000130164. [P01130-4]
DR   Ensembl; ENST00000545707; ENSP00000437639; ENSG00000130164. [P01130-2]
DR   Ensembl; ENST00000558013; ENSP00000453346; ENSG00000130164. [P01130-5]
DR   Ensembl; ENST00000558518; ENSP00000454071; ENSG00000130164. [P01130-1]
DR   GeneID; 3949; -.
DR   KEGG; hsa:3949; -.
DR   UCSC; uc002mqk.4; human. [P01130-1]
DR   UCSC; uc010xll.2; human. [P01130-4]
DR   UCSC; uc010xln.2; human. [P01130-2]
DR   UCSC; uc010xlo.2; human. [P01130-3]
DR   CTD; 3949; -.
DR   GeneCards; LDLR; -.
DR   GeneReviews; LDLR; -.
DR   HGNC; HGNC:6547; LDLR.
DR   HPA; HPA009647; -.
DR   HPA; HPA013159; -.
DR   MalaCards; LDLR; -.
DR   MIM; 143890; phenotype.
DR   MIM; 606945; gene.
DR   neXtProt; NX_P01130; -.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 391665; Homozygous familial hypercholesterolemia.
DR   PharmGKB; PA227; -.
DR   eggNOG; ENOG410IPSW; Eukaryota.
DR   eggNOG; ENOG410Z5FJ; LUCA.
DR   GeneTree; ENSGT00760000118968; -.
DR   HOGENOM; HOG000115656; -.
DR   HOVERGEN; HBG006250; -.
DR   InParanoid; P01130; -.
DR   KO; K12473; -.
DR   OrthoDB; EOG7NGQ9P; -.
DR   PhylomeDB; P01130; -.
DR   TreeFam; TF351700; -.
DR   Reactome; R-HSA-171052; LDL-mediated lipid transport.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   ChiTaRS; LDLR; human.
DR   EvolutionaryTrace; P01130; -.
DR   GeneWiki; LDL_receptor; -.
DR   GenomeRNAi; 3949; -.
DR   NextBio; 15493; -.
DR   PRO; PR:P01130; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P01130; -.
DR   CleanEx; HS_LDLR; -.
DR   ExpressionAtlas; P01130; baseline and differential.
DR   Genevisible; P01130; HS.
DR   GO; GO:0045177; C:apical part of cell; ISS:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005905; C:coated pit; IDA:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:1990666; C:PCSK9-LDLR complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0032050; F:clathrin heavy chain binding; TAS:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0005041; F:low-density lipoprotein receptor activity; IDA:BHF-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0004872; F:receptor activity; IC:BHF-UCL.
DR   GO; GO:0030229; F:very-low-density lipoprotein particle receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0070508; P:cholesterol import; ISS:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0030301; P:cholesterol transport; IMP:HGNC.
DR   GO; GO:0006897; P:endocytosis; TAS:ProtInc.
DR   GO; GO:0030299; P:intestinal cholesterol absorption; IMP:HGNC.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0015914; P:phospholipid transport; ISS:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0010867; P:positive regulation of triglyceride biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:2000188; P:regulation of cholesterol homeostasis; IEA:Ensembl.
DR   GO; GO:0010899; P:regulation of phosphatidylcholine catabolic process; ISS:BHF-UCL.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 2.120.10.30; -; 1.
DR   Gene3D; 4.10.400.10; -; 7.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   Pfam; PF07645; EGF_CA; 1.
DR   Pfam; PF00057; Ldl_recept_a; 7.
DR   Pfam; PF00058; Ldl_recept_b; 5.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00179; EGF_CA; 1.
DR   SMART; SM00192; LDLa; 7.
DR   SMART; SM00135; LY; 5.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   SUPFAM; SSF57424; SSF57424; 7.
DR   PROSITE; PS00010; ASX_HYDROXYL; 2.
DR   PROSITE; PS01186; EGF_2; 2.
DR   PROSITE; PS50026; EGF_3; 2.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS01209; LDLRA_1; 7.
DR   PROSITE; PS50068; LDLRA_2; 7.
DR   PROSITE; PS51120; LDLRB; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Cholesterol metabolism; Coated pit; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Endocytosis; Endosome; Glycoprotein; Golgi apparatus;
KW   Host cell receptor for virus entry; Host-virus interaction; LDL;
KW   Lipid metabolism; Lipid transport; Lysosome; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Steroid metabolism; Sterol metabolism; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   SIGNAL        1     21
FT   CHAIN        22    860       Low-density lipoprotein receptor.
FT                                /FTId=PRO_0000017312.
FT   TOPO_DOM     22    788       Extracellular. {ECO:0000255}.
FT   TRANSMEM    789    810       Helical. {ECO:0000255}.
FT   TOPO_DOM    811    860       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25     65       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN       66    106       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      107    145       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      146    186       LDL-receptor class A 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      195    233       LDL-receptor class A 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      234    272       LDL-receptor class A 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      274    313       LDL-receptor class A 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN      314    353       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      354    393       EGF-like 2; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   REPEAT      397    438       LDL-receptor class B 1.
FT   REPEAT      439    485       LDL-receptor class B 2.
FT   REPEAT      486    528       LDL-receptor class B 3.
FT   REPEAT      529    572       LDL-receptor class B 4.
FT   REPEAT      573    615       LDL-receptor class B 5.
FT   REPEAT      616    658       LDL-receptor class B 6.
FT   DOMAIN      663    712       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REGION      721    768       Clustered O-linked oligosaccharides.
FT   REGION      811    860       Required for MYLIP-triggered down-
FT                                regulation of LDLR.
FT   MOTIF       823    828       NPXY motif.
FT   MOD_RES     724    724       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P35952}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    156    156       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19520913}.
FT   CARBOHYD    272    272       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19520913}.
FT   CARBOHYD    515    515       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    657    657       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID     27     39
FT   DISULFID     34     52
FT   DISULFID     46     63
FT   DISULFID     68     82
FT   DISULFID     75     95
FT   DISULFID     89    104
FT   DISULFID    109    121       {ECO:0000250}.
FT   DISULFID    116    134
FT   DISULFID    128    143
FT   DISULFID    148    160
FT   DISULFID    155    173
FT   DISULFID    167    184
FT   DISULFID    197    209
FT   DISULFID    204    222
FT   DISULFID    216    231
FT   DISULFID    236    248
FT   DISULFID    243    261
FT   DISULFID    255    270
FT   DISULFID    276    289
FT   DISULFID    284    302
FT   DISULFID    296    313
FT   DISULFID    318    329
FT   DISULFID    325    338
FT   DISULFID    340    352
FT   DISULFID    358    368
FT   DISULFID    364    377
FT   DISULFID    379    392
FT   DISULFID    667    681
FT   DISULFID    677    696
FT   DISULFID    698    711
FT   VAR_SEQ      35    155       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047413.
FT   VAR_SEQ      64    105       LSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGC
FT                                P -> S (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043595.
FT   VAR_SEQ     105    272       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055014.
FT   VAR_SEQ     106    232       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043053.
FT   VAR_SEQ     273    273       V -> L (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055015.
FT   VAR_SEQ     663    713       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043054.
FT   VAR_SEQ     850    851       Missing (in isoform 5).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_045525.
FT   VARIANT       2      2       G -> R (in dbSNP:rs5931).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_011862.
FT   VARIANT      27     27       C -> W (in FH; San Francisco).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005304.
FT   VARIANT      46     46       C -> S (in FH; Japanese patient).
FT                                {ECO:0000269|PubMed:11298688}.
FT                                /FTId=VAR_013949.
FT   VARIANT      47     48       Missing (in FH; Cape Town-1; retards
FT                                receptor transport from the endoplasmic
FT                                reticulum to the cell surface).
FT                                {ECO:0000269|PubMed:10882754,
FT                                ECO:0000269|PubMed:3263645}.
FT                                /FTId=VAR_005305.
FT   VARIANT      50     50       A -> S (in FH; German patient;
FT                                dbSNP:rs137853960).
FT                                {ECO:0000269|PubMed:10090484}.
FT                                /FTId=VAR_007979.
FT   VARIANT      50     50       A -> T (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072827.
FT   VARIANT      52     52       C -> Y (in Paris-4).
FT                                /FTId=VAR_005306.
FT   VARIANT      56     56       S -> P (in FH).
FT                                {ECO:0000269|PubMed:9104431}.
FT                                /FTId=VAR_007980.
FT   VARIANT      78     78       R -> C (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005307.
FT   VARIANT      87     87       W -> G (in FH; French Canadian-4).
FT                                {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:2318961,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005308.
FT   VARIANT      89     89       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005309.
FT   VARIANT      90     90       D -> G (in FH; London-4).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005310.
FT   VARIANT      90     90       D -> N (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005311.
FT   VARIANT      90     90       D -> Y (in FH; Durban-1).
FT                                {ECO:0000269|PubMed:8347689}.
FT                                /FTId=VAR_005312.
FT   VARIANT      92     92       Q -> E (in FH; Spanish patient).
FT                                {ECO:0000269|PubMed:10206683}.
FT                                /FTId=VAR_005313.
FT   VARIANT      95     95       C -> G (in FH; Spanish patient).
FT                                {ECO:0000269|PubMed:10206683}.
FT                                /FTId=VAR_005314.
FT   VARIANT     101    101       E -> K (in FH; Lancashire; 6% of American
FT                                English). {ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005315.
FT   VARIANT     105    105       P -> S (in dbSNP:rs13306510).
FT                                /FTId=VAR_059375.
FT   VARIANT     109    109       C -> R (in Munster-1).
FT                                /FTId=VAR_005316.
FT   VARIANT     116    116       C -> R (in FH; does not affect receptor
FT                                expression at the cell surface; results
FT                                in reduced LDL binding; results in
FT                                reduced LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:25545329}.
FT                                /FTId=VAR_005317.
FT   VARIANT     134    134       C -> F (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062371.
FT   VARIANT     134    134       C -> W (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062372.
FT   VARIANT     139    139       D -> H (found in a patient with
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:21418584}.
FT                                /FTId=VAR_065780.
FT   VARIANT     140    140       E -> K (in FH; Philippines/Durban-2/
FT                                Japan). {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:7583548,
FT                                ECO:0000269|PubMed:8347689}.
FT                                /FTId=VAR_005318.
FT   VARIANT     143    143       C -> R (in FH).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072828.
FT   VARIANT     148    148       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072829.
FT   VARIANT     155    155       C -> G (in Germany).
FT                                /FTId=VAR_005319.
FT   VARIANT     155    155       C -> Y (in FH; results in defective LDL
FT                                binding; does not affect receptor
FT                                expression at the cell surface).
FT                                {ECO:0000269|PubMed:19318025,
FT                                ECO:0000269|PubMed:25378237}.
FT                                /FTId=VAR_072830.
FT   VARIANT     160    160       C -> Y (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005320.
FT   VARIANT     168    168       D -> A (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072831.
FT   VARIANT     168    168       D -> H (in FH; Sephardic/Safed; 10% of
FT                                the Sephardic Jews).
FT                                {ECO:0000269|PubMed:8462973}.
FT                                /FTId=VAR_005321.
FT   VARIANT     168    168       D -> N (in FH; does not affect receptor
FT                                expression at the cell surface; results
FT                                in reduced LDL binding; results in
FT                                reduced LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:25545329,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005322.
FT   VARIANT     168    168       D -> Y (in FH).
FT                                {ECO:0000269|PubMed:8740918}.
FT                                /FTId=VAR_005323.
FT   VARIANT     172    172       D -> H (may contribute to familial
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:10882754}.
FT                                /FTId=VAR_013950.
FT   VARIANT     172    172       D -> N (in FH; does not affect receptor
FT                                expression at the cell surface; results
FT                                in reduced LDL binding; results in
FT                                reduced LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:25545329}.
FT                                /FTId=VAR_072832.
FT   VARIANT     173    173       C -> R (in Greece-1).
FT                                /FTId=VAR_005324.
FT   VARIANT     173    173       C -> W (in FH).
FT                                {ECO:0000269|PubMed:9452094}.
FT                                /FTId=VAR_005325.
FT   VARIANT     175    175       D -> N (in FH; Afrikaner-3; 5-10% of
FT                                Afrikaners).
FT                                {ECO:0000269|PubMed:2569482}.
FT                                /FTId=VAR_005326.
FT   VARIANT     175    175       D -> Y (in FH).
FT                                {ECO:0000269|PubMed:9104431}.
FT                                /FTId=VAR_007981.
FT   VARIANT     177    177       S -> L (in FH; Puerto Rico).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:9259195,
FT                                ECO:0000269|PubMed:9654205}.
FT                                /FTId=VAR_005327.
FT   VARIANT     184    184       C -> W (in FH).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072833.
FT   VARIANT     184    184       C -> Y (in FH; Glasco).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:9678702}.
FT                                /FTId=VAR_013951.
FT   VARIANT     197    197       C -> F (in Shreveport).
FT                                /FTId=VAR_005328.
FT   VARIANT     197    197       C -> R (in FH; British patient).
FT                                {ECO:0000269|PubMed:9026534}.
FT                                /FTId=VAR_005330.
FT   VARIANT     197    197       C -> Y (in El Salvador-1).
FT                                /FTId=VAR_005329.
FT   VARIANT     201    201       E -> K (found in a patient with
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:21418584}.
FT                                /FTId=VAR_065781.
FT   VARIANT     211    211       H -> L (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072834.
FT   VARIANT     218    218       Missing (in FH; Piscataway/Lithuania).
FT                                {ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:1867200,
FT                                ECO:0000269|PubMed:9654205}.
FT                                /FTId=VAR_005331.
FT   VARIANT     221    221       D -> G (in FH; Padova).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:17347910,
FT                                ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:7649546,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005332.
FT   VARIANT     221    221       D -> N (in FH; German patient).
FT                                {ECO:0000269|PubMed:10090484,
FT                                ECO:0000269|PubMed:17142622}.
FT                                /FTId=VAR_007982.
FT   VARIANT     221    221       D -> Y (in FH; Cologne patient).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:7649546}.
FT                                /FTId=VAR_005333.
FT   VARIANT     222    222       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062373.
FT   VARIANT     224    224       D -> G (in Italy-2).
FT                                /FTId=VAR_005335.
FT   VARIANT     224    224       D -> N (in Portugal).
FT                                /FTId=VAR_005334.
FT   VARIANT     224    224       D -> V (in FH; Cologne patient).
FT                                {ECO:0000269|PubMed:7649546}.
FT                                /FTId=VAR_005336.
FT   VARIANT     226    226       S -> P (in Miami-1).
FT                                /FTId=VAR_005337.
FT   VARIANT     227    227       D -> E (in FH; Afrikaner-1/Maine; 65-70%
FT                                of Afrikaner Americans).
FT                                {ECO:0000269|PubMed:2569482,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005338.
FT   VARIANT     228    228       E -> CK (in Chieti-3).
FT                                {ECO:0000269|PubMed:10660340}.
FT                                /FTId=VAR_005339.
FT   VARIANT     228    228       E -> K (in FH; French Canadian-3/Mexico;
FT                                2% of French Canadians).
FT                                {ECO:0000269|PubMed:2318961,
FT                                ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_005341.
FT   VARIANT     228    228       E -> Q (in FH; Tulsa-2; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_005340.
FT   VARIANT     231    231       C -> G (in FH; Norwegian patient).
FT                                {ECO:0000269|PubMed:8664907}.
FT                                /FTId=VAR_005342.
FT   VARIANT     240    240       E -> K (in Charlotte).
FT                                /FTId=VAR_005343.
FT   VARIANT     243    243       C -> R (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10532689}.
FT                                /FTId=VAR_072835.
FT   VARIANT     248    248       C -> F (in Bretagne-1).
FT                                /FTId=VAR_005344.
FT   VARIANT     248    248       C -> Y (in FH; British patient).
FT                                {ECO:0000269|PubMed:9026534}.
FT                                /FTId=VAR_005345.
FT   VARIANT     253    253       R -> W (may contribute to familial
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:10882754}.
FT                                /FTId=VAR_013952.
FT   VARIANT     254    254       Q -> P (in FH).
FT                                {ECO:0000269|PubMed:10978268,
FT                                ECO:0000269|PubMed:19319977}.
FT                                /FTId=VAR_062374.
FT   VARIANT     255    255       C -> S (found in a patient with
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:21418584}.
FT                                /FTId=VAR_065782.
FT   VARIANT     256    256       D -> G (in Nevers).
FT                                /FTId=VAR_005346.
FT   VARIANT     257    257       R -> W (polymorphism; does not affect
FT                                receptor expression at the cell surface;
FT                                does not affect LDL binding; does not
FT                                affect LDL uptake and internalization;
FT                                dbSNP:rs200990725).
FT                                {ECO:0000269|PubMed:11462246,
FT                                ECO:0000269|PubMed:25545329}.
FT                                /FTId=VAR_072836.
FT   VARIANT     261    261       C -> F (in FH; rare mutation; strongly
FT                                reduced receptor activity).
FT                                {ECO:0000269|PubMed:10422803}.
FT                                /FTId=VAR_013953.
FT   VARIANT     266    266       D -> E (in FH; Cincinnati-1; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_005347.
FT   VARIANT     270    270       C -> Y (in Miami-2).
FT                                /FTId=VAR_005348.
FT   VARIANT     276    276       C -> R (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062375.
FT   VARIANT     276    276       C -> W (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072837.
FT   VARIANT     276    276       C -> Y (in FH; Syrian patient).
FT                                {ECO:0000269|Ref.70}.
FT                                /FTId=VAR_005349.
FT   VARIANT     277    277       E -> K (in FH; patients from Sweden and
FT                                La Havana; unknown pathological
FT                                significance; dbSNP:rs148698650).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:17347910,
FT                                ECO:0000269|PubMed:7635461,
FT                                ECO:0000269|PubMed:7649549}.
FT                                /FTId=VAR_005350.
FT   VARIANT     285    285       H -> Y (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072838.
FT   VARIANT     286    286       S -> R (in FH; Greece-2; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:17347910,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005351.
FT   VARIANT     288    288       E -> K (in FH; German patient).
FT                                {ECO:0000269|PubMed:10090484}.
FT                                /FTId=VAR_007983.
FT   VARIANT     300    300       R -> G (in FH; does not affect receptor
FT                                expression at the cell surface; results
FT                                in reduced LDL binding; results in
FT                                reduced LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:19318025,
FT                                ECO:0000269|PubMed:25545329}.
FT                                /FTId=VAR_072839.
FT   VARIANT     301    301       D -> A (in FH; Greek patient).
FT                                {ECO:0000269|PubMed:9026534}.
FT                                /FTId=VAR_005352.
FT   VARIANT     301    301       D -> G (in FH; does not affect receptor
FT                                expression at the cell surface; results
FT                                in reduced LDL binding; results in
FT                                reduced LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:19318025,
FT                                ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:25545329}.
FT                                /FTId=VAR_072840.
FT   VARIANT     302    302       C -> W (in FH; Iraki patient).
FT                                {ECO:0000269|PubMed:9026534}.
FT                                /FTId=VAR_005354.
FT   VARIANT     302    302       C -> Y (in FH; Spanish patient).
FT                                {ECO:0000269|PubMed:10206683}.
FT                                /FTId=VAR_005353.
FT   VARIANT     304    304       D -> E (in Baltimore-1).
FT                                /FTId=VAR_005356.
FT   VARIANT     304    304       D -> N (in Denver-2).
FT                                {ECO:0000269|PubMed:21418584}.
FT                                /FTId=VAR_005355.
FT   VARIANT     306    306       S -> L (in FH; Amsterdam; unknown
FT                                pathological significance;
FT                                dbSNP:rs11547917).
FT                                {ECO:0000269|PubMed:10532689}.
FT                                /FTId=VAR_005357.
FT   VARIANT     313    313       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005358.
FT   VARIANT     314    314       G -> R (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072841.
FT   VARIANT     318    318       C -> F (in FH; Trieste).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:8168830}.
FT                                /FTId=VAR_005360.
FT   VARIANT     318    318       C -> R (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062376.
FT   VARIANT     318    318       C -> Y (in Mexico-1; leads to a defect in
FT                                the intracellular transport of the
FT                                receptor).
FT                                /FTId=VAR_005359.
FT   VARIANT     326    326       S -> C (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072842.
FT   VARIANT     327    327       H -> Y (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005361.
FT   VARIANT     329    329       C -> F (in FH).
FT                                {ECO:0000269|PubMed:22160468}.
FT                                /FTId=VAR_067196.
FT   VARIANT     329    329       C -> Y (in FH; Chinese patient).
FT                                {ECO:0000269|PubMed:9452118}.
FT                                /FTId=VAR_005362.
FT   VARIANT     335    335       G -> S (in Paris-6).
FT                                /FTId=VAR_005363.
FT   VARIANT     338    338       C -> S (in FH; Japanese patients).
FT                                {ECO:0000269|PubMed:10447263,
FT                                ECO:0000269|PubMed:7583548}.
FT                                /FTId=VAR_005364.
FT   VARIANT     342    342       D -> E (in New York-1).
FT                                /FTId=VAR_005365.
FT   VARIANT     342    342       D -> N (in FH; unknown pathological
FT                                significance; dbSNP:rs139361635).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005366.
FT   VARIANT     343    343       G -> S (in FH; Picardie; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_005367.
FT   VARIANT     350    350       R -> P (in FH).
FT                                {ECO:0000269|PubMed:9026534,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005368.
FT   VARIANT     352    352       C -> R (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072843.
FT   VARIANT     352    352       C -> Y (in Mexico-2).
FT                                /FTId=VAR_005369.
FT   VARIANT     354    354       D -> G (in Munster-2).
FT                                /FTId=VAR_005370.
FT   VARIANT     354    354       D -> V (in Oklahoma).
FT                                /FTId=VAR_005371.
FT   VARIANT     356    356       D -> Y (in FH).
FT                                {ECO:0000269|PubMed:19319977,
FT                                ECO:0000269|PubMed:9104431}.
FT                                /FTId=VAR_007984.
FT   VARIANT     357    357       E -> K (in Paris-7).
FT                                /FTId=VAR_005372.
FT   VARIANT     358    358       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:19319977}.
FT                                /FTId=VAR_062377.
FT   VARIANT     364    364       C -> R (in Mexico-3).
FT                                /FTId=VAR_005373.
FT   VARIANT     366    366       Q -> R (in FH).
FT                                {ECO:0000269|PubMed:8740918}.
FT                                /FTId=VAR_007985.
FT   VARIANT     368    368       C -> R (in FH; French Canadian patient).
FT                                {ECO:0000269|PubMed:9452094}.
FT                                /FTId=VAR_005374.
FT   VARIANT     368    368       C -> Y (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072844.
FT   VARIANT     370    370       N -> T (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062378.
FT   VARIANT     373    373       G -> D (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072845.
FT   VARIANT     379    379       C -> R (in Naples-1).
FT                                /FTId=VAR_005375.
FT   VARIANT     379    379       C -> Y (in FH).
FT                                {ECO:0000269|PubMed:9852677}.
FT                                /FTId=VAR_007986.
FT   VARIANT     391    391       A -> T (in dbSNP:rs11669576).
FT                                /FTId=VAR_024519.
FT   VARIANT     399    399       A -> D (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005376.
FT   VARIANT     401    401       L -> H (in Pori).
FT                                {ECO:0000269|PubMed:7573037}.
FT                                /FTId=VAR_005377.
FT   VARIANT     401    401       L -> V (in FH).
FT                                {ECO:0000269|PubMed:9104431}.
FT                                /FTId=VAR_007987.
FT   VARIANT     403    403       F -> L (in FH; Japanese patient).
FT                                {ECO:0000269|PubMed:10447263}.
FT                                /FTId=VAR_008995.
FT   VARIANT     404    404       T -> P (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10532689}.
FT                                /FTId=VAR_072846.
FT   VARIANT     406    406       R -> Q (may contribute to familial
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:10882754}.
FT                                /FTId=VAR_013954.
FT   VARIANT     406    406       R -> W (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072847.
FT   VARIANT     408    408       E -> K (in FH; Algeria-1; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:10882754,
FT                                ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_005378.
FT   VARIANT     414    414       L -> R (in FH; Chinese patient).
FT                                {ECO:0000269|PubMed:9452118}.
FT                                /FTId=VAR_005379.
FT   VARIANT     415    415       D -> G (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062379.
FT   VARIANT     416    416       R -> Q (in FH; German patient).
FT                                {ECO:0000269|PubMed:9452095}.
FT                                /FTId=VAR_005380.
FT   VARIANT     416    416       R -> W (in FH; results in reduced
FT                                receptor expression at the cell surface
FT                                due to defective receptor recycling).
FT                                {ECO:0000269|PubMed:19318025,
FT                                ECO:0000269|PubMed:25378237,
FT                                ECO:0000269|PubMed:9104431,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005381.
FT   VARIANT     423    423       I -> T (in FH; Swedish patient).
FT                                {ECO:0000269|PubMed:7635461}.
FT                                /FTId=VAR_005382.
FT   VARIANT     429    429       V -> M (in FH; Afrikaner-2; 20-30% of
FT                                Afrikaners and 2% of FH Dutch;
FT                                dbSNP:rs28942078).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:2569482,
FT                                ECO:0000269|PubMed:7649549,
FT                                ECO:0000269|PubMed:9452095,
FT                                ECO:0000269|PubMed:9452118}.
FT                                /FTId=VAR_005383.
FT   VARIANT     431    431       A -> T (in FH; Algeria-2; unknown
FT                                pathological significance;
FT                                dbSNP:rs28942079).
FT                                {ECO:0000269|PubMed:10447263,
FT                                ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_005384.
FT   VARIANT     432    432       L -> V (in FH; German patient).
FT                                {ECO:0000269|PubMed:10090484}.
FT                                /FTId=VAR_007988.
FT   VARIANT     433    433       D -> H (in FH; Osaka-3).
FT                                {ECO:0000269|PubMed:1446662}.
FT                                /FTId=VAR_005385.
FT   VARIANT     434    434       T -> K (in FH; Algeria-3; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:10206683}.
FT                                /FTId=VAR_005386.
FT   VARIANT     441    441       I -> M (in Rouen).
FT                                /FTId=VAR_005388.
FT   VARIANT     441    441       I -> N (in Russia-1).
FT                                /FTId=VAR_005387.
FT   VARIANT     442    442       Y -> H (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072848.
FT   VARIANT     443    443       W -> C (in North Platt).
FT                                /FTId=VAR_005389.
FT   VARIANT     451    451       I -> T (in FH).
FT                                {ECO:0000269|PubMed:10980548,
FT                                ECO:0000269|PubMed:19319977}.
FT                                /FTId=VAR_062380.
FT   VARIANT     454    454       T -> N (in FH; results in reduced
FT                                receptor expression at the cell surface
FT                                due to defective receptor recycling).
FT                                {ECO:0000269|PubMed:19318025,
FT                                ECO:0000269|PubMed:25378237}.
FT                                /FTId=VAR_072849.
FT   VARIANT     468    468       V -> I (in dbSNP:rs5932).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_011863.
FT   VARIANT     471    471       R -> G (found in a patient with
FT                                hypercholesterolemia).
FT                                {ECO:0000269|PubMed:21418584}.
FT                                /FTId=VAR_065783.
FT   VARIANT     478    478       G -> R (in New York-2).
FT                                /FTId=VAR_005390.
FT   VARIANT     479    479       L -> P (in FH).
FT                                {ECO:0000269|PubMed:17142622}.
FT                                /FTId=VAR_062381.
FT   VARIANT     482    482       D -> H (in FH).
FT                                {ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005391.
FT   VARIANT     483    483       W -> R (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005392.
FT   VARIANT     485    485       H -> R (in Milan).
FT                                /FTId=VAR_005394.
FT   VARIANT     487    487       Missing (in FH; Norwegian patient).
FT                                {ECO:0000269|PubMed:7635482}.
FT                                /FTId=VAR_005393.
FT   VARIANT     492    492       D -> N (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072850.
FT   VARIANT     523    523       V -> M (in FH; Kuwait; dbSNP:rs28942080).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_005395.
FT   VARIANT     526    526       P -> S (in FH; Cincinnati-3; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005396.
FT   VARIANT     546    546       G -> D (in Saint Omer; retention in the
FT                                ER; dbSNP:rs28942081).
FT                                {ECO:0000269|PubMed:19520913}.
FT                                /FTId=VAR_005397.
FT   VARIANT     549    549       G -> D (in FH; Genoa; dbSNP:rs28941776).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005398.
FT   VARIANT     564    564       N -> H (in FH; French, German and Danish
FT                                patients; dbSNP:rs28942086).
FT                                {ECO:0000269|PubMed:10090484,
FT                                ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:7550239,
FT                                ECO:0000269|PubMed:9143924}.
FT                                /FTId=VAR_005399.
FT   VARIANT     564    564       N -> S (in FH; Sicily).
FT                                {ECO:0000269|PubMed:9654205}.
FT                                /FTId=VAR_005400.
FT   VARIANT     565    565       G -> V (in Naples-2; dbSNP:rs28942082).
FT                                /FTId=VAR_005401.
FT   VARIANT     568    568       L -> V (in FH; Japanese patient).
FT                                {ECO:0000269|PubMed:10447263}.
FT                                /FTId=VAR_008996.
FT   VARIANT     574    574       R -> C (in FH).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072851.
FT   VARIANT     574    574       R -> H (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072852.
FT   VARIANT     577    577       W -> G (in FH; results in loss of
FT                                receptor expression at the cell surface).
FT                                {ECO:0000269|PubMed:17347910,
FT                                ECO:0000269|PubMed:25378237}.
FT                                /FTId=VAR_072853.
FT   VARIANT     577    577       W -> S (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10532689}.
FT                                /FTId=VAR_072854.
FT   VARIANT     579    579       D -> N (in FH; Cincinnati-4; less than 2%
FT                                receptor activity).
FT                                {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:7635461}.
FT                                /FTId=VAR_005402.
FT   VARIANT     579    579       D -> Y (in FH).
FT                                {ECO:0000269|PubMed:10978268}.
FT                                /FTId=VAR_062382.
FT   VARIANT     585    585       I -> T (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17347910}.
FT                                /FTId=VAR_072855.
FT   VARIANT     592    592       G -> E (in FH; Sicily).
FT                                {ECO:0000269|PubMed:9654205}.
FT                                /FTId=VAR_005403.
FT   VARIANT     595    595       R -> W (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072856.
FT   VARIANT     599    599       L -> S (in London-5).
FT                                /FTId=VAR_005404.
FT   VARIANT     601    601       D -> H (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_072857.
FT   VARIANT     608    608       P -> S (in FH).
FT                                {ECO:0000269|PubMed:9852677}.
FT                                /FTId=VAR_007989.
FT   VARIANT     633    633       R -> C (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005405.
FT   VARIANT     639    639       V -> D (in FH).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072858.
FT   VARIANT     649    649       P -> L (in FH).
FT                                {ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005406.
FT   VARIANT     667    667       C -> Y (in FH; French Canadian-2; 5% of
FT                                French Canadians; dbSNP:rs28942083).
FT                                {ECO:0000269|PubMed:10206683,
FT                                ECO:0000269|PubMed:2318961}.
FT                                /FTId=VAR_005407.
FT   VARIANT     677    677       C -> R (in FH; New York-3).
FT                                {ECO:0000269|PubMed:17142622}.
FT                                /FTId=VAR_005408.
FT   VARIANT     682    682       L -> P (in Issoire).
FT                                /FTId=VAR_005409.
FT   VARIANT     685    685       P -> L (in FH; Gujerat/Zambia/Belgian/
FT                                Dutch/Sweden/Japan; dbSNP:rs28942084).
FT                                {ECO:0000269|PubMed:1464748,
FT                                ECO:0000269|PubMed:17142622,
FT                                ECO:0000269|PubMed:17347910,
FT                                ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:2726768,
FT                                ECO:0000269|PubMed:7583548,
FT                                ECO:0000269|PubMed:9254862}.
FT                                /FTId=VAR_005410.
FT   VARIANT     699    699       P -> L (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10882754,
FT                                ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_013955.
FT   VARIANT     700    700       D -> E (in FH; Spanish patient).
FT                                {ECO:0000269|PubMed:10206683}.
FT                                /FTId=VAR_005412.
FT   VARIANT     714    714       E -> K (in FH; Japanese patient).
FT                                {ECO:0000269|PubMed:10447263}.
FT                                /FTId=VAR_008997.
FT   VARIANT     726    726       T -> I (in FH; Paris-9; unknown
FT                                pathological significance;
FT                                dbSNP:rs45508991).
FT                                {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:9259195}.
FT                                /FTId=VAR_005413.
FT   VARIANT     742    742       T -> I. {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072859.
FT   VARIANT     792    792       I -> F (in Russia-2).
FT                                /FTId=VAR_005414.
FT   VARIANT     797    797       V -> M (in FH; La Havana patient).
FT                                {ECO:0000269|PubMed:24529145,
FT                                ECO:0000269|PubMed:7649549}.
FT                                /FTId=VAR_005415.
FT   VARIANT     799    801       Missing (in FH; Danish patient).
FT                                {ECO:0000269|PubMed:9143924}.
FT                                /FTId=VAR_005416.
FT   VARIANT     806    806       V -> D (in FH; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11462246}.
FT                                /FTId=VAR_072860.
FT   VARIANT     814    814       R -> Q (in FH; unknown pathological
FT                                significance; dbSNP:rs5928).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10882754,
FT                                ECO:0000269|PubMed:24529145}.
FT                                /FTId=VAR_011864.
FT   VARIANT     820    822       Missing (in FH).
FT                                /FTId=VAR_005417.
FT   VARIANT     825    825       N -> K (in FH; does not affect receptor
FT                                expression at the cell surface; does not
FT                                affect LDL binding; results in impaired
FT                                LDL uptake and internalization).
FT                                {ECO:0000269|PubMed:10532689,
FT                                ECO:0000269|PubMed:25378237}.
FT                                /FTId=VAR_072861.
FT   VARIANT     826    826       P -> S (in FH).
FT                                {ECO:0000269|PubMed:19319977}.
FT                                /FTId=VAR_062383.
FT   VARIANT     827    827       V -> I (in New York-5;
FT                                dbSNP:rs137853964).
FT                                /FTId=VAR_005418.
FT   VARIANT     828    828       Y -> C (in FH; J.D.Bari/Syria;
FT                                dbSNP:rs28942085).
FT                                {ECO:0000269|PubMed:3955657}.
FT                                /FTId=VAR_005419.
FT   VARIANT     844    844       G -> D (in Turku).
FT                                {ECO:0000269|PubMed:7573037}.
FT                                /FTId=VAR_005420.
FT   MUTAGEN     811    811       K->R: No change. No change; when
FT                                associated with R-816 and R-830.
FT                                Insensitive to MYLIP-triggered
FT                                degradation; when associated with R-816;
FT                                R-830 and A-839.
FT                                {ECO:0000269|PubMed:19520913}.
FT   MUTAGEN     816    816       K->R: No change. No change; when
FT                                associated with R-830. No change; when
FT                                associated with R-811 and R-830.
FT                                Insensitive to MYLIP-triggered
FT                                degradation; when associated with R-830
FT                                and A-839. Insensitive to MYLIP-triggered
FT                                degradation; when associated with R-811;
FT                                R-830 and A-839.
FT                                {ECO:0000269|PubMed:19520913}.
FT   MUTAGEN     828    828       Y->A: Abolishes interaction with ARRB2.
FT                                {ECO:0000269|PubMed:12944399}.
FT   MUTAGEN     830    830       K->R: No change. No change; when
FT                                associated with R-816. No change; when
FT                                associated with R-811 and R-816.
FT                                Insensitive to MYLIP-triggered
FT                                degradation; when associated with A-839.
FT                                Insensitive to MYLIP-triggered
FT                                degradation; when associated with R-816
FT                                and A-839. Insensitive to MYLIP-triggered
FT                                degradation; when associated with R-811;
FT                                R-816 and A-839.
FT                                {ECO:0000269|PubMed:19520913}.
FT   MUTAGEN     839    839       C->A: No change. Insensitive to MYLIP-
FT                                triggered degradation; when associated
FT                                with R-830. Insensitive to MYLIP-
FT                                triggered degradation; when associated
FT                                with R-816 and R-830. Insensitive to
FT                                MYLIP-triggered degradation; when
FT                                associated with R-811; R-816 and R-830.
FT                                {ECO:0000269|PubMed:19520913}.
FT   MUTAGEN     854    854       S->A: No effect on receptor
FT                                internalization.
FT                                {ECO:0000269|PubMed:12944399}.
FT   MUTAGEN     854    854       S->D: Enhances interaction with ARRB2 and
FT                                receptor internalization.
FT                                {ECO:0000269|PubMed:12944399}.
FT   CONFLICT     31     31       E -> D (in Ref. 4; BAG58495).
FT                                {ECO:0000305}.
FT   STRAND       29     33       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       35     37       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       39     41       {ECO:0000244|PDB:1LDL}.
FT   TURN         42     46       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       47     49       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       51     55       {ECO:0000244|PDB:1F5Y}.
FT   HELIX        56     58       {ECO:0000244|PDB:1F5Y}.
FT   TURN         60     62       {ECO:0000244|PDB:1LDL}.
FT   TURN         63     67       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       70     72       {ECO:0000244|PDB:1LDR}.
FT   STRAND       75     77       {ECO:0000244|PDB:1LDR}.
FT   STRAND       79     81       {ECO:0000244|PDB:1LDR}.
FT   HELIX        85     87       {ECO:0000244|PDB:1F5Y}.
FT   STRAND       88     90       {ECO:0000244|PDB:1LDR}.
FT   STRAND       95     97       {ECO:0000244|PDB:1F5Y}.
FT   TURN         99    103       {ECO:0000244|PDB:1F5Y}.
FT   STRAND      113    115       {ECO:0000244|PDB:2FCW}.
FT   STRAND      121    123       {ECO:0000244|PDB:2FCW}.
FT   HELIX       124    126       {ECO:0000244|PDB:2FCW}.
FT   STRAND      129    131       {ECO:0000244|PDB:2FCW}.
FT   TURN        138    142       {ECO:0000244|PDB:2FCW}.
FT   HELIX       143    147       {ECO:0000244|PDB:2FCW}.
FT   STRAND      148    151       {ECO:0000244|PDB:2LGP}.
FT   STRAND      152    154       {ECO:0000244|PDB:2FCW}.
FT   TURN        156    158       {ECO:0000244|PDB:2LGP}.
FT   STRAND      160    162       {ECO:0000244|PDB:2FCW}.
FT   HELIX       163    165       {ECO:0000244|PDB:2FCW}.
FT   STRAND      168    170       {ECO:0000244|PDB:2FCW}.
FT   STRAND      173    176       {ECO:0000244|PDB:2LGP}.
FT   HELIX       177    179       {ECO:0000244|PDB:2FCW}.
FT   HELIX       181    183       {ECO:0000244|PDB:2FCW}.
FT   TURN        189    191       {ECO:0000244|PDB:2LGP}.
FT   STRAND      201    204       {ECO:0000244|PDB:2LGP}.
FT   TURN        205    207       {ECO:0000244|PDB:2LGP}.
FT   STRAND      208    211       {ECO:0000244|PDB:2LGP}.
FT   HELIX       212    214       {ECO:0000244|PDB:1AJJ}.
FT   STRAND      217    219       {ECO:0000244|PDB:1AJJ}.
FT   STRAND      222    224       {ECO:0000244|PDB:2LGP}.
FT   HELIX       226    228       {ECO:0000244|PDB:1AJJ}.
FT   STRAND      241    243       {ECO:0000244|PDB:1D2J}.
FT   TURN        244    246       {ECO:0000244|PDB:1D2J}.
FT   STRAND      247    249       {ECO:0000244|PDB:1D2J}.
FT   HELIX       251    253       {ECO:0000244|PDB:1D2J}.
FT   STRAND      254    258       {ECO:0000244|PDB:1D2J}.
FT   STRAND      260    264       {ECO:0000244|PDB:1D2J}.
FT   HELIX       265    267       {ECO:0000244|PDB:1F8Z}.
FT   STRAND      268    270       {ECO:0000244|PDB:1F8Z}.
FT   STRAND      281    283       {ECO:0000244|PDB:1XFE}.
FT   STRAND      289    292       {ECO:0000244|PDB:1XFE}.
FT   TURN        293    296       {ECO:0000244|PDB:1XFE}.
FT   STRAND      306    308       {ECO:0000244|PDB:1XFE}.
FT   TURN        310    312       {ECO:0000244|PDB:1XFE}.
FT   HELIX       317    319       {ECO:0000244|PDB:2W2N}.
FT   HELIX       321    324       {ECO:0000244|PDB:2W2N}.
FT   STRAND      326    330       {ECO:0000244|PDB:2W2N}.
FT   STRAND      333    335       {ECO:0000244|PDB:2W2N}.
FT   STRAND      337    339       {ECO:0000244|PDB:2W2N}.
FT   STRAND      341    343       {ECO:0000244|PDB:1HZ8}.
FT   STRAND      345    347       {ECO:0000244|PDB:2W2N}.
FT   TURN        348    350       {ECO:0000244|PDB:2W2N}.
FT   STRAND      351    353       {ECO:0000244|PDB:2W2N}.
FT   HELIX       357    359       {ECO:0000244|PDB:1HJ7}.
FT   STRAND      363    369       {ECO:0000244|PDB:1HJ7}.
FT   STRAND      372    374       {ECO:0000244|PDB:3P5B}.
FT   STRAND      376    378       {ECO:0000244|PDB:1HJ7}.
FT   STRAND      381    385       {ECO:0000244|PDB:1HZ8}.
FT   TURN        387    389       {ECO:0000244|PDB:3P5B}.
FT   STRAND      392    394       {ECO:0000244|PDB:1HZ8}.
FT   STRAND      400    404       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      406    413       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      420    423       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      427    435       {ECO:0000244|PDB:1IJQ}.
FT   TURN        436    439       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      440    445       {ECO:0000244|PDB:1IJQ}.
FT   TURN        446    449       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      450    455       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      466    469       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      478    482       {ECO:0000244|PDB:1IJQ}.
FT   TURN        483    486       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      487    492       {ECO:0000244|PDB:1IJQ}.
FT   TURN        493    496       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      497    502       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      505    513       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      519    525       {ECO:0000244|PDB:1IJQ}.
FT   TURN        526    529       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      530    535       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      537    539       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      541    546       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      552    556       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      563    569       {ECO:0000244|PDB:1IJQ}.
FT   TURN        570    573       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      574    579       {ECO:0000244|PDB:1IJQ}.
FT   TURN        580    583       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      584    589       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      596    600       {ECO:0000244|PDB:1IJQ}.
FT   TURN        602    605       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      606    614       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      617    622       {ECO:0000244|PDB:1IJQ}.
FT   TURN        623    626       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      627    632       {ECO:0000244|PDB:1IJQ}.
FT   TURN        633    635       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      640    643       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      652    656       {ECO:0000244|PDB:1IJQ}.
FT   HELIX       657    659       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      668    672       {ECO:0000244|PDB:1IJQ}.
FT   HELIX       673    676       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      678    683       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      693    697       {ECO:0000244|PDB:1IJQ}.
FT   STRAND      708    713       {ECO:0000244|PDB:3P5B}.
FT   STRAND      821    824       {ECO:0000244|PDB:3SO6}.
FT   TURN        826    829       {ECO:0000244|PDB:3SO6}.
SQ   SEQUENCE   860 AA;  95376 MW;  A4C28E9B8BADAD5E CRC64;
     MGPWGWKLRW TVALLLAAAG TAVGDRCERN EFQCQDGKCI SYKWVCDGSA ECQDGSDESQ
     ETCLSVTCKS GDFSCGGRVN RCIPQFWRCD GQVDCDNGSD EQGCPPKTCS QDEFRCHDGK
     CISRQFVCDS DRDCLDGSDE ASCPVLTCGP ASFQCNSSTC IPQLWACDND PDCEDGSDEW
     PQRCRGLYVF QGDSSPCSAF EFHCLSGECI HSSWRCDGGP DCKDKSDEEN CAVATCRPDE
     FQCSDGNCIH GSRQCDREYD CKDMSDEVGC VNVTLCEGPN KFKCHSGECI TLDKVCNMAR
     DCRDWSDEPI KECGTNECLD NNGGCSHVCN DLKIGYECLC PDGFQLVAQR RCEDIDECQD
     PDTCSQLCVN LEGGYKCQCE EGFQLDPHTK ACKAVGSIAY LFFTNRHEVR KMTLDRSEYT
     SLIPNLRNVV ALDTEVASNR IYWSDLSQRM ICSTQLDRAH GVSSYDTVIS RDIQAPDGLA
     VDWIHSNIYW TDSVLGTVSV ADTKGVKRKT LFRENGSKPR AIVVDPVHGF MYWTDWGTPA
     KIKKGGLNGV DIYSLVTENI QWPNGITLDL LSGRLYWVDS KLHSISSIDV NGGNRKTILE
     DEKRLAHPFS LAVFEDKVFW TDIINEAIFS ANRLTGSDVN LLAENLLSPE DMVLFHNLTQ
     PRGVNWCERT TLSNGGCQYL CLPAPQINPH SPKFTCACPD GMLLARDMRS CLTEAEAAVA
     TQETSTVRLK VSSTAVRTQH TTTRPVPDTS RLPGATPGLT TVEIVTMSHQ ALGDVAGRGN
     EKKPSSVRAL SIVLPIVLLV FLCLGVFLLW KNWRLKNINS INFDNPVYQK TTEDEVHICH
     NQDGYSYPSR QMVSLEDDVA
//
ID   INSR_HUMAN              Reviewed;        1382 AA.
AC   P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 4.
DT   17-FEB-2016, entry version 222.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=INSR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2;
RP   HIS-171; THR-448 AND LYS-492.
RX   PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4;
RA   Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E.,
RA   Ou J.-H., Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.;
RT   "The human insulin receptor cDNA: the structural basis for hormone-
RT   activated transmembrane signalling.";
RL   Cell 40:747-758(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49
RP   AND 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2.
RX   PubMed=2983222; DOI=10.1038/313756a0;
RA   Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M.,
RA   Dull T.J., Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A.,
RA   Seeburg P.H., Grunfeld C., Rosen O.M., Ramachandran J.;
RT   "Human insulin receptor and its relationship to the tyrosine kinase
RT   family of oncogenes.";
RL   Nature 313:756-761(1985).
RN   [3]
RP   SEQUENCE REVISION TO 899-900.
RA   Chen E.Y.;
RL   Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2.
RC   TISSUE=Fetal liver;
RX   PubMed=2210055; DOI=10.2337/diacare.39.1.123;
RA   Seino S., Seino M., Bell G.I.;
RT   "Human insulin-receptor gene. Partial sequence and amplification of
RT   exons by polymerase chain reaction.";
RL   Diabetes 39:123-128(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT
RP   GLY-2.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=3680248;
RA   Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene. Evidence for promoter activity.";
RL   J. Biol. Chem. 262:16186-16191(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5;
RA   Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene.";
RL   Diabetes Res. Clin. Pract. 7:S31-S33(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   PubMed=2777789;
RA   Tewari D.S., Cook D.M., Taub R.;
RT   "Characterization of the promoter region and 3' end of the human
RT   insulin receptor gene.";
RL   J. Biol. Chem. 264:16238-16245(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RC   TISSUE=Skin fibroblast;
RX   PubMed=2280779; DOI=10.1210/mend-4-4-647;
RA   McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D.,
RA   Taylor S.I.;
RT   "Structural and functional analysis of the insulin receptor
RT   promoter.";
RL   Mol. Endocrinol. 4:647-656(1990).
RN   [11]
RP   PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780,
RP   ENZYME REGULATION, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=2211730;
RA   Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.;
RT   "Substructural analysis of the insulin receptor by microsequence
RT   analyses of limited tryptic fragments isolated by sodium dodecyl
RT   sulfate-polyacrylamide gel electrophoresis in the absence or presence
RT   of dithiothreitol.";
RL   J. Biol. Chem. 265:18673-18681(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH IGF1R.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=2538124; DOI=10.1016/0006-291X(89)92439-X;
RA   Seino S., Bell G.I.;
RT   "Alternative splicing of human insulin receptor messenger RNA.";
RL   Biochem. Biophys. Res. Commun. 159:312-316(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE
RP   SPECIFICITY, LIGAND-BINDING, AND AUTOPHOSPHORYLATION.
RX   PubMed=2369896;
RA   Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A.,
RA   McClain D.A.;
RT   "Functionally distinct insulin receptors generated by tissue-specific
RT   alternative splicing.";
RL   EMBO J. 9:2409-2413(1990).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085.
RX   PubMed=2566545; DOI=10.2337/diab.38.6.737;
RA   Elbein S.C.;
RT   "Molecular and clinical characterization of an insertional
RT   polymorphism of the insulin-receptor gene.";
RL   Diabetes 38:737-743(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND
RP   PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361.
RC   TISSUE=Placenta;
RX   PubMed=3166375;
RA   Tavare J.M., Denton R.M.;
RT   "Studies on the autophosphorylation of the insulin receptor from human
RT   placenta. Analysis of the sites phosphorylated by two-dimensional
RT   peptide mapping.";
RL   Biochem. J. 252:607-615(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123.
RX   PubMed=2544997; DOI=10.1126/science.2544997;
RA   Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A.,
RA   Nakamura F., Ebina Y., Tatibana M., Makino H.;
RT   "Human diabetes associated with a deletion of the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:63-66(1989).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3447155;
RA   Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.;
RT   "Partial amino acid sequence analyses of human placental insulin
RT   receptor.";
RL   Protein Seq. Data Anal. 1:3-6(1987).
RN   [20]
RP   MUTAGENESIS OF LYS-1057.
RX   PubMed=3101064; DOI=10.1073/pnas.84.3.704;
RA   Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S.,
RA   Siddle K., Pierce S.B., Roth R.A., Rutter W.J.;
RT   "Replacement of lysine residue 1030 in the putative ATP-binding region
RT   of the insulin receptor abolishes insulin- and antibody-stimulated
RT   glucose uptake and receptor kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987).
RN   [21]
RP   MUTAGENESIS OF TYR-999.
RX   PubMed=2842060; DOI=10.1016/S0092-8674(88)80008-4;
RA   White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J.,
RA   Ullrich A., Kahn C.R.;
RT   "Mutation of the insulin receptor at tyrosine 960 inhibits signal
RT   transmission but does not affect its tyrosine kinase activity.";
RL   Cell 54:641-649(1988).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1321605; DOI=10.1016/S0006-291X(05)80799-5;
RA   Dickens M., Tavare J.M.;
RT   "Analysis of the order of autophosphorylation of human insulin
RT   receptor tyrosines 1158, 1162 and 1163.";
RL   Biochem. Biophys. Res. Commun. 186:244-250(1992).
RN   [23]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541.
RX   PubMed=1472036; DOI=10.1016/0006-291X(92)92250-2;
RA   Schaeffer L., Ljungqvist L.;
RT   "Identification of a disulfide bridge connecting the alpha-subunits of
RT   the extracellular domain of the insulin receptor.";
RL   Biochem. Biophys. Res. Commun. 189:650-653(1992).
RN   [24]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=8452530;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PIK3R1.
RX   PubMed=8276809;
RA   Van Horn D.J., Myers M.G. Jr., Backer J.M.;
RT   "Direct activation of the phosphatidylinositol 3'-kinase by the
RT   insulin receptor.";
RL   J. Biol. Chem. 269:29-32(1994).
RN   [26]
RP   INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992;
RP   ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002.
RX   PubMed=7559478; DOI=10.1074/jbc.270.40.23258;
RA   He W., O'Neill T.J., Gustafson T.A.;
RT   "Distinct modes of interaction of SHC and insulin receptor substrate-1
RT   with the insulin receptor NPEY region via non-SH2 domains.";
RL   J. Biol. Chem. 270:23258-23262(1995).
RN   [27]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996;
RP   PRO-997; GLU-998; TYR-999 AND LYS-1057.
RX   PubMed=7537849;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel
RT   non-SH2 domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [28]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9355755;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND
RP   INTERACTION WITH STAT5B; IRS1 AND IRS2.
RX   PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x;
RA   Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I.,
RA   Van Obberghen E.;
RT   "Identification of Stat 5B as a substrate of the insulin receptor.";
RL   Eur. J. Biochem. 250:411-417(1997).
RN   [30]
RP   INTERACTION WITH PTPRF.
RX   PubMed=8995282; DOI=10.1074/jbc.272.11.7519;
RA   Ahmad F., Goldstein B.J.;
RT   "Functional association between the insulin receptor and the
RT   transmembrane protein-tyrosine phosphatase LAR in intact cells.";
RL   J. Biol. Chem. 272:448-457(1997).
RN   [31]
RP   INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=8999839; DOI=10.1074/jbc.272.3.1639;
RA   Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J.,
RA   Gustafson T.A., Kusari J.;
RT   "Protein-tyrosine phosphatase 1B complexes with the insulin receptor
RT   in vivo and is tyrosine-phosphorylated in the presence of insulin.";
RL   J. Biol. Chem. 272:1639-1645(1997).
RN   [32]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [33]
RP   TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM
RP   SHORT).
RX   PubMed=10207053;
RA   Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A.,
RA   Goldfine I.D., Belfiore A., Vigneri R.;
RT   "Insulin receptor isoform A, a newly recognized, high-affinity
RT   insulin-like growth factor II receptor in fetal and cancer cells.";
RL   Mol. Cell. Biol. 19:3278-3288(1999).
RN   [34]
RP   INTERACTION WITH ENPP1, AND ENZYME REGULATION.
RX   PubMed=10615944; DOI=10.2337/diabetes.49.1.13;
RA   Maddux B.A., Goldfine I.D.;
RT   "Membrane glycoprotein PC-1 inhibition of insulin receptor function
RT   occurs via direct interaction with the receptor alpha-subunit.";
RL   Diabetes 49:13-19(2000).
RN   [35]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2.
RX   PubMed=10734133; DOI=10.1074/jbc.275.13.9792;
RA   Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S.,
RA   Hooft van Huijsduijnen R.;
RT   "Identification of tyrosine phosphatases that dephosphorylate the
RT   insulin receptor. A brute force approach based on 'substrate-trapping'
RT   mutants.";
RL   J. Biol. Chem. 275:9792-9796(2000).
RN   [36]
RP   INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=10803466; DOI=10.1038/sj.onc.1203469;
RA   Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.;
RT   "Evidence for an interaction between the insulin receptor and Grb7. A
RT   role for two of its binding domains, PIR and SH2.";
RL   Oncogene 19:2052-2059(2000).
RN   [37]
RP   INTERACTION WITH SORBS1.
RX   PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [38]
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ENZYME
RP   REGULATION.
RX   PubMed=11598120; DOI=10.1074/jbc.M107236200;
RA   Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.;
RT   "Multiple activation loop conformations and their regulatory
RT   properties in the insulin receptor's kinase domain.";
RL   J. Biol. Chem. 276:46933-46940(2001).
RN   [39]
RP   INTERACTION WITH GRB14, AND ENZYME REGULATION.
RX   PubMed=11726652; DOI=10.1074/jbc.M106574200;
RA   Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J.,
RA   Burnol A.F.;
RT   "Inhibition of insulin receptor catalytic activity by the molecular
RT   adapter Grb14.";
RL   J. Biol. Chem. 277:4845-4852(2002).
RN   [40]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [41]
RP   INTERACTION WITH GRB10, AND ENZYME REGULATION.
RX   PubMed=12493740; DOI=10.1074/jbc.M208518200;
RA   Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q.,
RA   Shoelson S.E., Liu F.;
RT   "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-
RT   phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the
RT   association of IRS-1/IRS-2 with the insulin receptor.";
RL   J. Biol. Chem. 278:8460-8467(2003).
RN   [42]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=12612081; DOI=10.1128/MCB.23.6.2096-2108.2003;
RA   Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A.,
RA   Meng T.C., Tonks N.K., Tiganis T.;
RT   "Regulation of insulin receptor signaling by the protein tyrosine
RT   phosphatase TCPTP.";
RL   Mol. Cell. Biol. 23:2096-2108(2003).
RN   [43]
RP   INTERACTION WITH SOCS7.
RX   PubMed=16127460; DOI=10.1172/JCI23853;
RA   Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D.,
RA   Rothman P.B.;
RT   "Deletion of SOCS7 leads to enhanced insulin action and enlarged
RT   islets of Langerhans.";
RL   J. Clin. Invest. 115:2462-2471(2005).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=16314505; DOI=10.1128/MCB.25.24.10803-10814.2005;
RA   Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I.,
RA   Corbo V., Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S.,
RA   Formisano P., Beguinot F.;
RT   "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by
RT   the insulin receptor is necessary for insulin metabolic signaling.";
RL   Mol. Cell. Biol. 25:10803-10814(2005).
RN   [45]
RP   DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=15738637; DOI=10.2108/zsj.22.169;
RA   Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N.,
RA   Miyazaki H.;
RT   "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a
RT   negative regulator of insulin signaling in primary hepatocytes and
RT   liver.";
RL   Zool. Sci. 22:169-175(2005).
RN   [46]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [47]
RP   REVIEW ON SIGNALING PATHWAYS.
RX   PubMed=16493415; DOI=10.1038/nrg1767;
RA   Taniguchi C.M., Emanuelli B., Kahn C.R.;
RT   "Critical nodes in signalling pathways: insights into insulin
RT   action.";
RL   Nat. Rev. Mol. Cell Biol. 7:85-96(2006).
RN   [48]
RP   REVIEW ON REGULATION OF INSR FUNCTION.
RX   PubMed=17347799; DOI=10.1007/s00018-007-6359-9;
RA   Youngren J.F.;
RT   "Regulation of insulin receptor function.";
RL   Cell. Mol. Life Sci. 64:873-891(2007).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND
RP   SER-407, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [50]
RP   DOMAIN, AND INSULIN-BINDING SITE.
RX   PubMed=19459609; DOI=10.1021/bi900261q;
RA   Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.;
RT   "A thermodynamic study of ligand binding to the first three domains of
RT   the human insulin receptor: relationship between the receptor alpha-
RT   chain C-terminal peptide and the site 1 insulin mimetic peptides.";
RL   Biochemistry 48:5492-5500(2009).
RN   [51]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [52]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [53]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310.
RX   PubMed=7997262; DOI=10.1038/372746a0;
RA   Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.;
RT   "Crystal structure of the tyrosine kinase domain of the human insulin
RT   receptor.";
RL   Nature 372:746-754(1994).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=9312016; DOI=10.1093/emboj/16.18.5572;
RA   Hubbard S.R.;
RT   "Crystal structure of the activated insulin receptor tyrosine kinase
RT   in complex with peptide substrate and ATP analog.";
RL   EMBO J. 16:5572-5581(1997).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP ANALOG, AND CATALYTIC ACTIVITY.
RX   PubMed=11124964; DOI=10.1074/jbc.M010161200;
RA   Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A.,
RA   Hubbard S.R.;
RT   "Crystallographic and solution studies of an activation loop mutant of
RT   the insulin receptor tyrosine kinase: insights into kinase
RT   mechanism.";
RL   J. Biol. Chem. 276:10049-10055(2001).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT
RP   ASN-1159, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   TYR-1011.
RX   PubMed=12707268; DOI=10.1074/jbc.M302425200;
RA   Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.;
RT   "Structural and biochemical evidence for an autoinhibitory role for
RT   tyrosine 984 in the juxtamembrane region of the insulin receptor.";
RL   J. Biol. Chem. 278:26007-26014(2003).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP
RP   ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=14690593; DOI=10.1016/S1097-2765(03)00487-8;
RA   Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.;
RT   "Structural basis for recruitment of the adaptor protein APS to the
RT   activated insulin receptor.";
RL   Mol. Cell 12:1379-1389(2003).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   GRB14, INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND
RP   PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001;
RA   Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J.,
RA   Hubbard S.R.;
RT   "Structural basis for inhibition of the insulin receptor by the
RT   adaptor protein Grb14.";
RL   Mol. Cell 20:325-333(2005).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   PTPN1, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190.
RX   PubMed=16271887; DOI=10.1016/j.str.2005.07.019;
RA   Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.;
RT   "Crystal structure of a complex between protein tyrosine phosphatase
RT   1B and the insulin receptor tyrosine kinase.";
RL   Structure 13:1643-1651(2005).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH
RP   INSULIN ANALOG, DOMAIN, AND DISULFIDE BONDS.
RX   PubMed=16957736; DOI=10.1038/nature05106;
RA   McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E.,
RA   Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A.,
RA   Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E.,
RA   Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J.,
RA   Sparrow L.G., Fernley R.T., Epa V.C., Ward C.W.;
RT   "Structure of the insulin receptor ectodomain reveals a folded-over
RT   conformation.";
RL   Nature 443:218-221(2006).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT
RP   ASN-43; ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND
RP   ASN-445, AND DISULFIDE BONDS.
RX   PubMed=16894147; DOI=10.1073/pnas.0605395103;
RA   Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D.,
RA   Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.;
RT   "The first three domains of the insulin receptor differ structurally
RT   from the insulin-like growth factor 1 receptor in the regions
RT   governing ligand specificity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   ATP AND IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185;
RP   TYR-1189 AND TYR-1190, AND INTERACTION WITH IRS2.
RX   PubMed=18278056; DOI=10.1038/nsmb.1388;
RA   Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.;
RT   "Structural and biochemical characterization of the KRLB region in
RT   insulin receptor substrate-2.";
RL   Nat. Struct. Mol. Biol. 15:251-258(2008).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH
RP   INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND
RP   TYR-1190.
RX   PubMed=18767165; DOI=10.1002/prot.22207;
RA   Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S.,
RA   Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.;
RT   "Identification of a key element for hydrogen-bonding patterns between
RT   protein kinases and their inhibitors.";
RL   Proteins 73:795-801(2008).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077;
RA   Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B.,
RA   Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M.,
RA   Shewchuk L.M., Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C.,
RA   Groy A., Rowand J.L., Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.;
RT   "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R
RT   tyrosine kinase inhibitors towards JNK selectivity.";
RL   Bioorg. Med. Chem. Lett. 19:360-364(2009).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046;
RA   Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M.,
RA   Yang B., Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A.,
RA   Atkins C., Gerding R., Hassell A.M., Lei H., Mook R.A. Jr.,
RA   Moorthy G., Rowand J.L., Stevens K.L., Kumar R., Shotwell J.B.;
RT   "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent
RT   inhibitors of the IGF-1R receptor tyrosine kinase.";
RL   Bioorg. Med. Chem. Lett. 19:469-473(2009).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110;
RA   Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B.,
RA   Tang J., Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M.,
RA   Shewchuck L.M., Kumar R., Lei H., Chamberlain S.D.;
RT   "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent
RT   inhibitors of the insulin-like growth factor-1 receptor (IGF-1R)
RT   tyrosine kinase.";
RL   Bioorg. Med. Chem. Lett. 19:3136-3140(2009).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING
RP   REGION, AND DISULFIDE BONDS.
RX   PubMed=20348418; DOI=10.1073/pnas.1001813107;
RA   Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G.,
RA   Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W.,
RA   Weiss M.A., Lawrence M.C.;
RT   "Structural resolution of a tandem hormone-binding element in the
RT   insulin receptor and its implications for design of peptide
RT   agonists.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH
RP   INSULIN, DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND
RP   ASN-282, AND DISULFIDE BONDS.
RX   PubMed=23302862; DOI=10.1038/nature11781;
RA   Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K.,
RA   Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J.,
RA   Chan S.J., Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A.,
RA   Ward C.W., Lawrence M.C.;
RT   "How insulin engages its primary binding site on the insulin
RT   receptor.";
RL   Nature 493:241-245(2013).
RN   [71]
RP   VARIANT IRAN TYPE A SER-762.
RX   PubMed=3283938; DOI=10.1126/science.3283938;
RA   Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H.,
RA   Imura H., Bell G.I., Steiner D.F.;
RT   "Insulin-resistant diabetes due to a point mutation that prevents
RT   insulin proreceptor processing.";
RL   Science 240:784-787(1988).
RN   [72]
RP   VARIANT LEPRCH GLU-487.
RX   PubMed=2834824; DOI=10.1126/science.2834824;
RA   Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B.,
RA   Kadowaki H., Beitz L., McKeon C., Taylor S.I.;
RT   "Two mutant alleles of the insulin receptor gene in a patient with
RT   extreme insulin resistance.";
RL   Science 240:787-790(1988).
RN   [73]
RP   VARIANT LEPRCH PRO-260.
RX   PubMed=2479553;
RA   Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D.,
RA   Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.;
RT   "A leucine-to-proline mutation in the insulin receptor in a family
RT   with insulin resistance.";
RL   EMBO J. 8:2503-2507(1989).
RN   [74]
RP   VARIANT IRAN TYPE A VAL-1035.
RX   PubMed=2544998; DOI=10.1126/science.2544998;
RA   Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K.,
RA   Accili D., Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F.,
RA   Taylor S.I., Kasuga M.;
RT   "Human diabetes associated with a mutation in the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:66-68(1989).
RN   [75]
RP   VARIANT IRAN TYPE A THR-1161.
RX   PubMed=2168397;
RA   Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.;
RT   "A naturally occurring mutation of insulin receptor alanine 1134
RT   impairs tyrosine kinase function and is associated with dominantly
RT   inherited insulin resistance.";
RL   J. Biol. Chem. 265:14979-14985(1990).
RN   [76]
RP   CHARACTERIZATION OF VARIANT RMS LYS-42.
RX   PubMed=2121734;
RA   Kadowaki T., Kadowaki H., Accili D., Taylor S.I.;
RT   "Substitution of lysine for asparagine at position 15 in the alpha-
RT   subunit of the human insulin receptor. A mutation that impairs
RT   transport of receptors to the cell surface and decreases the affinity
RT   of insulin binding.";
RL   J. Biol. Chem. 265:19143-19150(1990).
RN   [77]
RP   VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A
RP   SER-489.
RX   PubMed=2365819; DOI=10.1172/JCI114693;
RA   Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J.,
RA   Gorden P., Taylor S.I.;
RT   "Five mutant alleles of the insulin receptor gene in patients with
RT   genetic forms of insulin resistance.";
RL   J. Clin. Invest. 86:254-264(1990).
RN   [78]
RP   VARIANT IRAN TYPE A SER-1227.
RX   PubMed=1963473; DOI=10.1210/mend-4-8-1183;
RA   Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.;
RT   "Functional properties of a naturally occurring Trp1200-->Ser1200
RT   mutation of the insulin receptor.";
RL   Mol. Endocrinol. 4:1183-1191(1990).
RN   [79]
RP   VARIANT GLU-1095.
RX   PubMed=2040394; DOI=10.2337/diab.40.6.777;
RA   O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S.,
RA   Moller D.E.;
RT   "Detection of mutations in insulin-receptor gene in NIDDM patients by
RT   analysis of single-stranded conformation polymorphisms.";
RL   Diabetes 40:777-782(1991).
RN   [80]
RP   VARIANT IRAN TYPE A GLN-1020.
RX   PubMed=2002058;
RA   Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O.,
RA   Olefsky J.M.;
RT   "Insulin resistance and diabetes due to different mutations in the
RT   tyrosine kinase domain of both insulin receptor gene alleles.";
RL   J. Biol. Chem. 266:5260-5267(1991).
RN   [81]
RP   VARIANT INS RESISTANCE ILE-1180.
RX   PubMed=1890161; DOI=10.1210/jcem-73-4-894;
RA   Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P.,
RA   Imperato-Mcginley J., Taylor S.I.;
RT   "A mutation in the tyrosine kinase domain of the insulin receptor
RT   associated with insulin resistance in an obese woman.";
RL   J. Clin. Endocrinol. Metab. 73:894-901(1991).
RN   [82]
RP   VARIANTS LEPRCH ALA-55 AND ARG-393.
RX   PubMed=1607067; DOI=10.2337/diab.41.4.408;
RA   Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E.,
RA   Pizzo P., Moghetti P., Muggeo M., Roth J.;
RT   "Detection of mutations in insulin receptor gene by denaturing
RT   gradient gel electrophoresis.";
RL   Diabetes 41:408-415(1992).
RN   [83]
RP   VARIANT NIDDM GLN-1191.
RX   PubMed=1607076; DOI=10.2337/diab.41.4.521;
RA   Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G.,
RA   Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.;
RT   "NIDDM associated with mutation in tyrosine kinase domain of insulin
RT   receptor gene.";
RL   Diabetes 41:521-526(1992).
RN   [84]
RP   VARIANT IRAN TYPE A LEU-1205.
RX   PubMed=1563582; DOI=10.1007/BF00400927;
RA   Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y.,
RA   Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I.,
RA   Kadowaki T.;
RT   "Detection of mutations in the insulin receptor gene in patients with
RT   insulin resistance by analysis of single-stranded conformational
RT   polymorphisms.";
RL   Diabetologia 35:261-266(1992).
RN   [85]
RP   VARIANT LEPRCH ARG-58.
RX   PubMed=1730625;
RA   van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J.,
RA   Lindhout D., Maassen J.A.;
RT   "An Arg for Gly substitution at position 31 in the insulin receptor,
RT   linked to insulin resistance, inhibits receptor processing and
RT   transport.";
RL   J. Biol. Chem. 267:66-71(1992).
RN   [86]
RP   VARIANT NIDDM GLN-1158.
RX   PubMed=1470163;
RA   Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T.,
RA   Hagino H., Shii K.;
RT   "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic
RT   loop of insulin receptor observed in insulin resistant diabetes.";
RL   Nihon Geka Gakkai Zasshi 93:968-971(1992).
RN   [87]
RP   VARIANT MET-1012.
RX   PubMed=8432414; DOI=10.2337/diab.42.3.429;
RA   Elbein S.C., Sorensen L.K., Schumacher M.C.;
RT   "Methionine for valine substitution in exon 17 of the insulin receptor
RT   gene in a pedigree with familial NIDDM.";
RL   Diabetes 42:429-434(1993).
RN   [88]
RP   VARIANT IRAN TYPE A ASP-1075.
RX   PubMed=8243830; DOI=10.2337/diab.42.12.1837;
RA   Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K.,
RA   Itazu T., Kobayashi M.;
RT   "Ala1048-->Asp mutation in the kinase domain of insulin receptor
RT   causes defective kinase activity and insulin resistance.";
RL   Diabetes 42:1837-1844(1993).
RN   [89]
RP   VARIANT MET-1012.
RX   PubMed=8458533; DOI=10.1007/BF00400701;
RA   van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J.,
RA   van Maldergem L., Herwig J., Maassen J.A.;
RT   "Patients with lipodystrophic diabetes mellitus of the Seip-
RT   Berardinelli type, express normal insulin receptors.";
RL   Diabetologia 36:172-174(1993).
RN   [90]
RP   VARIANT INS RESISTANCE LEU-1220.
RX   PubMed=8390949; DOI=10.1007/BF00402277;
RA   Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K.,
RA   Imamura T., Naitou K., Itazu T., Kobayashi M.;
RT   "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the
RT   insulin receptor associated with type A syndrome of insulin
RT   resistance.";
RL   Diabetologia 36:414-422(1993).
RN   [91]
RP   VARIANT INS RESISTANCE LEU-220.
RX   PubMed=8242067; DOI=10.1093/hmg/2.9.1437;
RA   Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R.,
RA   Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I.,
RA   Micossi P., Barbetti F.;
RT   "Substitution of Leu for Pro-193 in the insulin receptor in a patient
RT   with a genetic form of severe insulin resistance.";
RL   Hum. Mol. Genet. 2:1437-1441(1993).
RN   [92]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162.
RX   PubMed=8096518;
RA   Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P.,
RA   Taylor S.I.;
RT   "Substitution of glutamic acid for alanine 1135 in the putative
RT   'catalytic loop' of the tyrosine kinase domain of the human insulin
RT   receptor. A mutation that impairs proteolytic processing into subunits
RT   and inhibits receptor tyrosine kinase activity.";
RL   J. Biol. Chem. 268:8060-8069(1993).
RN   [93]
RP   VARIANT IRAN TYPE A VAL-409.
RX   PubMed=8388389;
RA   Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J.,
RA   Taylor S.I., Accili D., van Obberghen E.;
RT   "Antibodies to the extracellular receptor domain restore the hormone-
RT   insensitive kinase and conformation of the mutant insulin receptor
RT   valine 382.";
RL   J. Biol. Chem. 268:11272-11277(1993).
RN   [94]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=8326490; DOI=10.1136/jmg.30.6.470;
RA   Al-Gazali L.I., Khalil M., Devadas K.;
RT   "A syndrome of insulin resistance resembling leprechaunism in five
RT   sibs of consanguineous parents.";
RL   J. Med. Genet. 30:470-475(1993).
RN   [95]
RP   VARIANT LEPRCH PRO-113.
RX   PubMed=8419945; DOI=10.1073/pnas.90.1.60;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Activation of glucose transport by a natural mutation in the human
RT   insulin receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993).
RN   [96]
RP   VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8288049; DOI=10.2337/diab.43.2.247;
RA   Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F.,
RA   Eberle A., Morrow L.A., Moses A.C., Flier J.S.;
RT   "Prevalence of mutations in the insulin receptor gene in subjects with
RT   features of the type A syndrome of insulin resistance.";
RL   Diabetes 43:247-255(1994).
RN   [97]
RP   VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND
RP   GLN-1378, AND VARIANT MET-1012.
RX   PubMed=8314008; DOI=10.2337/diab.43.3.357;
RA   Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.;
RT   "Molecular scanning of the insulin receptor gene in syndromes of
RT   insulin resistance.";
RL   Diabetes 43:357-368(1994).
RN   [98]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201.
RX   PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0;
RA   Moritz W., Froesch E.R., Boeni-Schnetzler M.;
RT   "Functional properties of a heterozygous mutation (Arg1174-->Gln) in
RT   the tyrosine kinase domain of the insulin receptor from a type A
RT   insulin resistant patient.";
RL   FEBS Lett. 351:276-280(1994).
RN   [99]
RP   VARIANT LEPRCH SER-439.
RX   PubMed=8188715;
RA   van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J.,
RA   Moller W., Maassen J.A.;
RT   "A mutation in the insulin receptor that impairs proreceptor
RT   processing but not insulin binding.";
RL   J. Biol. Chem. 269:14297-14302(1994).
RN   [100]
RP   CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220.
RX   PubMed=7983039;
RA   Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T.,
RA   Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.;
RT   "Two naturally occurring mutations in the kinase domain of insulin
RT   receptor accelerate degradation of the insulin receptor and impair the
RT   kinase activity.";
RL   J. Biol. Chem. 269:31019-31027(1994).
RN   [101]
RP   VARIANT LEPRCH MET-146.
RX   PubMed=7815442; DOI=10.1136/jmg.31.9.715;
RA   Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T.,
RA   Taylor S.I.;
RT   "Homozygosity for a new mutation (Ile119-->Met) in the insulin
RT   receptor gene in five sibs with familial insulin resistance.";
RL   J. Med. Genet. 31:715-716(1994).
RN   [102]
RP   VARIANT NIDDM ALA-858, AND VARIANT CYS-1361.
RX   PubMed=7657032; DOI=10.2337/diab.44.9.1081;
RA   Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T.,
RA   Ito K., Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T.,
RA   Kagawa S., Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.;
RT   "Frequency of mutations of insulin receptor gene in Japanese patients
RT   with NIDDM.";
RL   Diabetes 44:1081-1086(1995).
RN   [103]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=7538143; DOI=10.1210/jcem.80.5.7538143;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Two mutations in the insulin receptor gene of a patient with
RT   leprechaunism: application to prenatal diagnosis.";
RL   J. Clin. Endocrinol. Metab. 80:1496-1501(1995).
RN   [104]
RP   VARIANT PHE-1023.
RX   PubMed=8890729; DOI=10.1530/eje.0.1350357;
RA   Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.;
RT   "In-frame exon 2 deletion in insulin receptor RNA in a family with
RT   extreme insulin resistance in association with defective insulin
RT   binding: a case report.";
RL   Eur. J. Endocrinol. 135:357-363(1996).
RN   [105]
RP   VARIANT LEPRCH ASN-308 DEL.
RX   PubMed=8636294; DOI=10.1210/jc.81.2.719;
RA   Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J.,
RA   Flori E., Besmond C., Capeau J., Caron M.;
RT   "Deletion of Asn281 in the alpha-subunit of the human insulin receptor
RT   causes constitutive activation of the receptor and insulin
RT   desensitization.";
RL   J. Clin. Endocrinol. Metab. 81:719-727(1996).
RN   [106]
RP   VARIANT MET-1012.
RX   PubMed=9199575; DOI=10.1086/515464;
RA   Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A.,
RA   Rasmussen S.K., Pedersen O.;
RT   "The Val985Met insulin-receptor variant in the Danish Caucasian
RT   population: lack of associations with non-insulin-dependent diabetes
RT   mellitus or insulin resistance.";
RL   Am. J. Hum. Genet. 60:1532-1535(1997).
RN   [107]
RP   VARIANTS IRAN TYPE A GLY-86 AND PRO-89.
RX   PubMed=9175790; DOI=10.1006/bbrc.1997.6695;
RA   Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P.,
RA   Renard E., Bringer J., Jaffiol C., Grigorescu F.;
RT   "Identification of two novel insulin receptor mutations, Asp59Gly and
RT   Leu62Pro, in type A syndrome of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 234:764-768(1997).
RN   [108]
RP   CHARACTERIZATION OF VARIANT LEPRCH MET-937.
RX   PubMed=9299395; DOI=10.1006/bbrc.1997.7181;
RA   Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y.,
RA   Quin J.D., MacCuish A.C., Koda N., Fukushima Y., Taylor S.I.,
RA   Akanuma Y., Yazaki Y., Kadowaki T.;
RT   "Four mutant alleles of the insulin receptor gene associated with
RT   genetic syndromes of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 237:516-520(1997).
RN   [109]
RP   VARIANTS LEPRCH TRP-1119 AND LYS-1206.
RX   PubMed=9249867;
RX   DOI=10.1002/(SICI)1097-0223(199707)17:7<657::AID-PD132>3.3.CO;2-#;
RA   Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A.,
RA   Conteville P., Magre J., Besmond C., Goossens M., Capeau J.,
RA   Amselem S.;
RT   "Molecular analysis of the insulin receptor gene for prenatal
RT   diagnosis of leprechaunism in two families.";
RL   Prenat. Diagn. 17:657-663(1997).
RN   [110]
RP   VARIANTS LEPRCH TYR-301 AND TRP-1201.
RX   PubMed=9703342; DOI=10.2337/diab.47.8.1362;
RA   Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M.,
RA   O'Rahilly S.;
RT   "Multiple molecular mechanisms of insulin receptor dysfunction in a
RT   patient with Donohue syndrome.";
RL   Diabetes 47:1362-1364(1998).
RN   [111]
RP   VARIANTS RMS THR-1143 AND TRP-1158.
RX   PubMed=10443650; DOI=10.1210/jc.84.8.2623;
RA   Longo N., Wang Y., Pasquali M.;
RT   "Progressive decline in insulin levels in Rabson-Mendenhall
RT   syndrome.";
RL   J. Clin. Endocrinol. Metab. 84:2623-2629(1999).
RN   [112]
RP   VARIANTS IRAN TYPE A LEU-167 AND VAL-1055.
RX   PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x;
RA   Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J.,
RA   Carrascosa A., Potau N.;
RT   "Identification of three novel mutations in the insulin receptor gene
RT   in type A insulin resistant patients.";
RL   Clin. Genet. 57:67-69(2000).
RN   [113]
RP   VARIANT IRAN TYPE A TYR-280.
RX   PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x;
RA   Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F.,
RA   Kaino Y., Kida K., Makino H.;
RT   "Identification of novel C253Y missense and Y864X nonsense mutations
RT   in the insulin receptor gene in type A insulin-resistant patients.";
RL   Clin. Genet. 59:194-197(2001).
RN   [114]
RP   VARIANT IRAN TYPE A CYS-279.
RX   PubMed=12107746; DOI=10.1007/s00125-002-0798-5;
RA   Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J.,
RA   De Meyts P., Maeder C., Kahn C.R., Carpentier J.-L.;
RT   "An arginine to cysteine(252) mutation in insulin receptors from a
RT   patient with severe insulin resistance inhibits receptor
RT   internalisation but preserves signalling events.";
RL   Diabetologia 45:657-667(2002).
RN   [115]
RP   CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL;
RP   THR-925 AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND
RP   TRP-1201.
RX   PubMed=12023989; DOI=10.1093/hmg/11.12.1465;
RA   Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A.,
RA   Giannella-Neto D.;
RT   "Genotype-phenotype correlation in inherited severe insulin
RT   resistance.";
RL   Hum. Mol. Genet. 11:1465-1475(2002).
RN   [116]
RP   VARIANT LEPRCH VAL-362 DEL.
RX   PubMed=12538626; DOI=10.1210/en.2002-220815;
RA   George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S.,
RA   Saudek V., Siddle K., Hansen L., O'Rahilly S.;
RT   "Deletion of V335 from the L2 domain of the insulin receptor results
RT   in a conformationally abnormal receptor that is unable to bind insulin
RT   and causes Donohue's syndrome in a human subject.";
RL   Endocrinology 144:631-637(2003).
RN   [117]
RP   VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458
RP   AND TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND
RP   CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458.
RX   PubMed=12970295; DOI=10.1210/jc.2003-030034;
RA   Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M.,
RA   D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.;
RT   "Identification and functional assessment of novel and known insulin
RT   receptor mutations in five patients with syndromes of severe insulin
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 88:4251-4257(2003).
RN   [118]
RP   VARIANT HHF5 GLN-1201.
RX   PubMed=15161766; DOI=10.2337/diabetes.53.6.1592;
RA   Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K.,
RA   Lindholm J., Pedersen O., Bech-Nielsen H.;
RT   "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia
RT   linked to a mutation in the human insulin receptor gene.";
RL   Diabetes 53:1592-1598(2004).
RN   [119]
RP   VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS
RP   ARG-236 AND SER-386.
RX   PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x;
RA   Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J.,
RA   Didi M., O'Rahilly S.;
RT   "Functional characterization of a novel insulin receptor mutation
RT   contributing to Rabson-Mendenhall syndrome.";
RL   Clin. Endocrinol. (Oxf.) 66:21-26(2007).
RN   [120]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012;
RP   VAL-1065 AND ALA-1282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic
CC       actions of insulin. Binding of insulin leads to phosphorylation of
CC       several intracellular substrates, including, insulin receptor
CC       substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling
CC       intermediates. Each of these phosphorylated proteins serve as
CC       docking proteins for other signaling proteins that contain Src-
CC       homology-2 domains (SH2 domain) that specifically recognize
CC       different phosphotyrosines residues, including the p85 regulatory
CC       subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to
CC       the activation of two main signaling pathways: the PI3K-AKT/PKB
CC       pathway, which is responsible for most of the metabolic actions of
CC       insulin, and the Ras-MAPK pathway, which regulates expression of
CC       some genes and cooperates with the PI3K pathway to control cell
CC       growth and differentiation. Binding of the SH2 domains of PI3K to
CC       phosphotyrosines on IRS1 leads to the activation of PI3K and the
CC       generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3),
CC       a lipid second messenger, which activates several PIP3-dependent
CC       serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB.
CC       The net effect of this pathway is to produce a translocation of
CC       the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to
CC       the cell membrane to facilitate glucose transport. Moreover, upon
CC       insulin stimulation, activated AKT/PKB is responsible for: anti-
CC       apoptotic effect of insulin by inducing phosphorylation of BAD;
CC       regulates the expression of gluconeogenic and lipogenic enzymes by
CC       controlling the activity of the winged helix or forkhead (FOX)
CC       class of transcription factors. Another pathway regulated by PI3K-
CC       AKT/PKB activation is mTORC1 signaling pathway which regulates
CC       cell growth and metabolism and integrates signals from insulin.
CC       AKT mediates insulin-stimulated protein synthesis by
CC       phosphorylating TSC2 thereby activating mTORC1 pathway. The
CC       Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell
CC       growth, survival and cellular differentiation of insulin.
CC       Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the
CC       activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to
CC       binding insulin, the insulin receptor can bind insulin-like growth
CC       factors (IGFI and IGFII). Isoform Short has a higher affinity for
CC       IGFII binding. When present in a hybrid receptor with IGF1R, binds
CC       IGF1. PubMed:12138094 shows that hybrid receptors composed of
CC       IGF1R and INSR isoform Long are activated with a high affinity by
CC       IGF1, with low affinity by IGF2 and not significantly activated by
CC       insulin, and that hybrid receptors composed of IGF1R and INSR
CC       isoform Short are activated by IGF1, IGF2 and insulin. In
CC       contrast, PubMed:16831875 shows that hybrid receptors composed of
CC       IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R
CC       and INSR isoform Short have similar binding characteristics, both
CC       bind IGF1 and have a low affinity for insulin.
CC       {ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688,
CC       ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530,
CC       ECO:0000269|PubMed:9428692}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11124964,
CC       ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:12707268,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:19056263,
CC       ECO:0000269|PubMed:19071018, ECO:0000269|PubMed:19394223,
CC       ECO:0000269|PubMed:9312016}.
CC   -!- ENZYME REGULATION: Activated in response to insulin.
CC       Autophosphorylation activates the kinase activity. PTPN1, PTPRE
CC       and PTPRF dephosphorylate important tyrosine residues, thereby
CC       reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14
CC       inhibit the catalytic activity of the INSR, they block access of
CC       substrates to the activated receptor. SOCS1 and SOCS3 act as
CC       negative regulators of INSR activity, they bind to the activated
CC       INRS and interfere with the phosphorylation of INSR substrates.
CC       {ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:11598120,
CC       ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740,
CC       ECO:0000269|PubMed:2211730}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains carry the insulin-binding regions, while
CC       the beta chains carry the kinase domain. Forms a hybrid receptor
CC       with IGF1R, the hybrid is a tetramer consisting of 1 alpha chain
CC       and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of
CC       IGF1R. Interacts with SORBS1 but dissociates from it following
CC       insulin stimulation. Binds SH2B2. Activated form of INSR interacts
CC       (via Tyr-999) with the PTB/PID domains of IRS1 and SHC1. The
CC       sequences surrounding the phosphorylated NPXY motif contribute
CC       differentially to either IRS1 or SHC1 recognition. Interacts (via
CC       tyrosines in the C-terminus) with IRS2 (via PTB domain and 591-786
CC       AA); the 591-786 would be the primary anchor of IRS2 to INSR while
CC       the PTB domain would have a stabilizing action on the interaction
CC       with INSR. Interacts with the SH2 domains of the 85 kDa regulatory
CC       subunit of PI3K (PIK3R1) in vitro, when autophosphorylated on
CC       tyrosine residues. Interacts with SOCS7. Interacts (via the
CC       phosphorylated Tyr-999), with SOCS3. Interacts (via the
CC       phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts
CC       with CAV2 (tyrosine-phosphorylated form); the interaction is
CC       increased with 'Tyr-27'phosphorylation of CAV2 (By similarity).
CC       Interacts with ARRB2 (By similarity). Interacts with GRB10; this
CC       interaction blocks the association between IRS1/IRS2 and INSR,
CC       significantly reduces insulin-stimulated tyrosine phosphorylation
CC       of IRS1 and IRS2 and thus decreases insulin signaling. Interacts
CC       with GRB7. Interacts with PDPK1. Interacts (via Tyr-1190) with
CC       GRB14 (via BPS domain); this interaction protects the tyrosines in
CC       the activation loop from dephosphorylation, but promotes
CC       dephosphorylation of Tyr-999, this results in decreased
CC       interaction with, and phosphorylation of, IRS1. Interacts (via
CC       subunit alpha) with ENPP1 (via 485-599 AA); this interaction
CC       blocks autophosphorylation. Interacts with PTPRE; this interaction
CC       is dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR.
CC       Interacts with STAT5B (via SH2 domain). Interacts with PTPRF.
CC       Interacts with ATIC; ATIC together with PRKAA2/AMPK2 and
CC       HACD3/PTPLAD1 is proposed to be part of a signaling netwok
CC       regulating INSR autophosphorylation and endocytosis (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:P15127,
CC       ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466,
CC       ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898,
CC       ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740,
CC       ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460,
CC       ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
CC       ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
CC       ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018,
CC       ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:2211730,
CC       ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:7537849,
CC       ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809,
CC       ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839,
CC       ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}.
CC   -!- INTERACTION:
CC       Q99490:AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824;
CC       P22413:ENPP1; NbExp=2; IntAct=EBI-475899, EBI-3197846;
CC       Q13322:GRB10; NbExp=3; IntAct=EBI-475899, EBI-80275;
CC       P05019:IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275;
CC       P01317:INS (xeno); NbExp=5; IntAct=EBI-475899, EBI-3989070;
CC       P35568:IRS1; NbExp=3; IntAct=EBI-475899, EBI-517592;
CC       P35570:Irs1 (xeno); NbExp=5; IntAct=EBI-475899, EBI-520230;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001;
CC       P27986:PIK3R1; NbExp=3; IntAct=EBI-475899, EBI-79464;
CC       P19174:PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387;
CC       P18031:PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-475899, EBI-297779;
CC       Q9NRF2:SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491;
CC       P29353:SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=HIR-B;
CC         IsoId=P06213-1; Sequence=Displayed;
CC       Name=Short; Synonyms=HIR-A;
CC         IsoId=P06213-2; Sequence=VSP_002898;
CC   -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are
CC       predominantly expressed in tissue targets of insulin metabolic
CC       effects: liver, adipose tissue and skeletal muscle but are also
CC       expressed in the peripheral nerve, kidney, pulmonary alveoli,
CC       pancreatic acini, placenta vascular endothelium, fibroblasts,
CC       monocytes, granulocytes, erythrocytes and skin. Isoform Short is
CC       preferentially expressed in fetal cells such as fetal fibroblasts,
CC       muscle, liver and kidney. Found as a hybrid receptor with IGF1R in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Overexpressed
CC       in several tumors, including breast, colon, lung, ovary, and
CC       thyroid carcinomas. {ECO:0000269|PubMed:10207053,
CC       ECO:0000269|PubMed:2369896, ECO:0000269|PubMed:9202395,
CC       ECO:0000269|PubMed:9355755}.
CC   -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-
CC       identical regions from two alpha chains, primarily via the C-
CC       terminal region of the first INSR alpha chain. Residues from the
CC       leucine-rich N-terminus of the other INSR alpha chain also
CC       contribute to this insulin binding site. A secondary insulin-
CC       binding site is formed by residues at the junction of fibronectin
CC       type-III domain 1 and 2. {ECO:0000269|PubMed:16957736,
CC       ECO:0000269|PubMed:19459609, ECO:0000269|PubMed:23302862}.
CC   -!- PTM: After being transported from the endoplasmic reticulum to the
CC       Golgi apparatus, the single glycosylated precursor is further
CC       glycosylated and then cleaved, followed by its transport to the
CC       plasma membrane. {ECO:0000269|PubMed:1472036,
CC       ECO:0000269|PubMed:16894147, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:23302862,
CC       ECO:0000269|PubMed:2983222}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin. Phosphorylation of Tyr-999 is required for binding to
CC       IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-
CC       1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1.
CC       Dephosphorylated by PTPN2; down-regulates insulin-induced
CC       signaling. {ECO:0000269|PubMed:10734133,
CC       ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593,
CC       ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887,
CC       ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165,
CC       ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016}.
CC   -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe
CC       insulin resistance syndrome characterized by insulin-resistant
CC       diabetes mellitus with pineal hyperplasia and somatic
CC       abnormalities. Typical features include coarse, senile-appearing
CC       facies, dental and skin abnormalities, abdominal distension, and
CC       phallic enlargement. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989,
CC       ECO:0000269|PubMed:17201797, ECO:0000269|PubMed:2365819,
CC       ECO:0000269|PubMed:8314008}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most
CC       severe form of insulin resistance syndrome, characterized by
CC       intrauterine and postnatal growth retardation and death in early
CC       infancy. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:12538626, ECO:0000269|PubMed:12970295,
CC       ECO:0000269|PubMed:1607067, ECO:0000269|PubMed:1730625,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2479553,
CC       ECO:0000269|PubMed:2834824, ECO:0000269|PubMed:7538143,
CC       ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715,
CC       ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945,
CC       ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867,
CC       ECO:0000269|PubMed:9703342}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:1470163,
CC       ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 5 (HHF5)
CC       [MIM:609968]: Familial hyperinsulinemic hypoglycemia [MIM:256450],
CC       also referred to as congenital hyperinsulinism, nesidioblastosis,
CC       or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is
CC       the most common cause of persistent hypoglycemia in infancy and is
CC       due to defective negative feedback regulation of insulin secretion
CC       by low glucose levels. {ECO:0000269|PubMed:15161766}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis
CC       nigricans type A (IRAN type A) [MIM:610549]: Characterized by the
CC       association of severe insulin resistance (manifested by marked
CC       hyperinsulinemia and a failure to respond to exogenous insulin)
CC       with the skin lesion acanthosis nigricans and ovarian
CC       hyperandrogenism in adolescent female subjects. Women frequently
CC       present with hirsutism, acne, amenorrhea or oligomenorrhea, and
CC       virilization. This syndrome is different from the type B that has
CC       been demonstrated to be secondary to the presence of circulating
CC       autoantibodies against the insulin receptor.
CC       {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230,
CC       ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295,
CC       ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473,
CC       ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397,
CC       ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998,
CC       ECO:0000269|PubMed:3283938, ECO:0000269|PubMed:8243830,
CC       ECO:0000269|PubMed:8288049, ECO:0000269|PubMed:8314008,
CC       ECO:0000269|PubMed:8388389, ECO:0000269|PubMed:9175790}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Insulin_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M10051; AAA59174.1; -; mRNA.
DR   EMBL; X02160; CAA26096.1; -; mRNA.
DR   EMBL; M32972; AAA59452.1; -; Genomic_DNA.
DR   EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117172; AAI17173.1; -; mRNA.
DR   EMBL; J03466; AAA59175.1; -; Genomic_DNA.
DR   EMBL; J05043; AAA59190.1; -; Genomic_DNA.
DR   EMBL; M76592; AAC37604.1; -; Genomic_DNA.
DR   EMBL; AB208861; BAD92098.1; -; mRNA.
DR   EMBL; M24555; AAA59178.1; -; mRNA.
DR   EMBL; M29929; AAA59176.1; -; Genomic_DNA.
DR   EMBL; M29930; AAA59177.1; -; Genomic_DNA.
DR   EMBL; M27197; AAA86791.1; -; Genomic_DNA.
DR   EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS12176.1; -. [P06213-1]
DR   CCDS; CCDS42487.1; -. [P06213-2]
DR   PIR; A37348; INHUR.
DR   RefSeq; NP_000199.2; NM_000208.3. [P06213-1]
DR   RefSeq; NP_001073285.1; NM_001079817.2. [P06213-2]
DR   UniGene; Hs.465744; -.
DR   PDB; 1GAG; X-ray; 2.70 A; A=1005-1310.
DR   PDB; 1I44; X-ray; 2.40 A; A=1005-1310.
DR   PDB; 1IR3; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1IRK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 1P14; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310.
DR   PDB; 2AUH; X-ray; 3.20 A; A=1005-1310.
DR   PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310.
DR   PDB; 2DTG; X-ray; 3.80 A; E=28-955.
DR   PDB; 2HR7; X-ray; 2.32 A; A/B=28-512.
DR   PDB; 2MFR; NMR; -; A=940-988.
DR   PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310.
DR   PDB; 3BU3; X-ray; 1.65 A; A=1005-1310.
DR   PDB; 3BU5; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3BU6; X-ray; 1.95 A; A=1005-1310.
DR   PDB; 3EKK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3EKN; X-ray; 2.20 A; A=1005-1310.
DR   PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322.
DR   PDB; 3LOH; X-ray; 3.80 A; E=28-956.
DR   PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744.
DR   PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744.
DR   PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744.
DR   PDB; 3W14; X-ray; 4.40 A; E/F=28-746.
DR   PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310.
DR   PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744.
DR   PDB; 4XLV; X-ray; 2.30 A; A=983-1310.
DR   PDB; 4XSS; X-ray; 3.00 A; E=28-337.
DR   PDB; 4XST; X-ray; 3.00 A; E=28-337.
DR   PDB; 5E1S; X-ray; 2.26 A; A=1005-1310.
DR   PDBsum; 1GAG; -.
DR   PDBsum; 1I44; -.
DR   PDBsum; 1IR3; -.
DR   PDBsum; 1IRK; -.
DR   PDBsum; 1P14; -.
DR   PDBsum; 1RQQ; -.
DR   PDBsum; 2AUH; -.
DR   PDBsum; 2B4S; -.
DR   PDBsum; 2DTG; -.
DR   PDBsum; 2HR7; -.
DR   PDBsum; 2MFR; -.
DR   PDBsum; 2Z8C; -.
DR   PDBsum; 3BU3; -.
DR   PDBsum; 3BU5; -.
DR   PDBsum; 3BU6; -.
DR   PDBsum; 3EKK; -.
DR   PDBsum; 3EKN; -.
DR   PDBsum; 3ETA; -.
DR   PDBsum; 3LOH; -.
DR   PDBsum; 3W11; -.
DR   PDBsum; 3W12; -.
DR   PDBsum; 3W13; -.
DR   PDBsum; 3W14; -.
DR   PDBsum; 4IBM; -.
DR   PDBsum; 4OGA; -.
DR   PDBsum; 4XLV; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 4XST; -.
DR   PDBsum; 5E1S; -.
DR   ProteinModelPortal; P06213; -.
DR   SMR; P06213; 28-988, 1009-1309.
DR   BioGrid; 109854; 76.
DR   DIP; DIP-480N; -.
DR   IntAct; P06213; 50.
DR   MINT; MINT-1516246; -.
DR   STRING; 9606.ENSP00000303830; -.
DR   BindingDB; P06213; -.
DR   ChEMBL; CHEMBL1981; -.
DR   DrugBank; DB01306; Insulin Aspart.
DR   DrugBank; DB01307; Insulin Detemir.
DR   DrugBank; DB00047; Insulin Glargine.
DR   DrugBank; DB01309; Insulin Glulisine.
DR   DrugBank; DB00046; Insulin Lispro.
DR   DrugBank; DB00030; Insulin Regular.
DR   DrugBank; DB01277; Mecasermin.
DR   GuidetoPHARMACOLOGY; 1800; -.
DR   iPTMnet; P06213; -.
DR   PhosphoSite; P06213; -.
DR   BioMuta; INSR; -.
DR   DMDM; 308153655; -.
DR   MaxQB; P06213; -.
DR   PaxDb; P06213; -.
DR   PRIDE; P06213; -.
DR   DNASU; 3643; -.
DR   Ensembl; ENST00000302850; ENSP00000303830; ENSG00000171105. [P06213-1]
DR   Ensembl; ENST00000341500; ENSP00000342838; ENSG00000171105. [P06213-2]
DR   GeneID; 3643; -.
DR   KEGG; hsa:3643; -.
DR   UCSC; uc002mgd.1; human. [P06213-1]
DR   UCSC; uc002mge.1; human. [P06213-2]
DR   CTD; 3643; -.
DR   GeneCards; INSR; -.
DR   H-InvDB; HIX0040111; -.
DR   HGNC; HGNC:6091; INSR.
DR   HPA; HPA036302; -.
DR   HPA; HPA036303; -.
DR   MalaCards; INSR; -.
DR   MIM; 125853; phenotype.
DR   MIM; 147670; gene.
DR   MIM; 246200; phenotype.
DR   MIM; 262190; phenotype.
DR   MIM; 609968; phenotype.
DR   MIM; 610549; phenotype.
DR   neXtProt; NX_P06213; -.
DR   Orphanet; 263458; Hyperinsulinism due to INSR deficiency.
DR   Orphanet; 2297; Insulin-resistance syndrome type A.
DR   Orphanet; 508; Leprechaunism.
DR   Orphanet; 769; Rabson-Mendenhall syndrome.
DR   PharmGKB; PA202; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P06213; -.
DR   KO; K04527; -.
DR   OMA; GAAGHLY; -.
DR   OrthoDB; EOG73RB9N; -.
DR   PhylomeDB; P06213; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-74713; IRS activation.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-74751; Insulin receptor signalling cascade.
DR   Reactome; R-HSA-74752; Signaling by Insulin receptor.
DR   Reactome; R-HSA-77387; Insulin receptor recycling.
DR   SABIO-RK; P06213; -.
DR   SignaLink; P06213; -.
DR   ChiTaRS; INSR; human.
DR   EvolutionaryTrace; P06213; -.
DR   GeneWiki; Insulin_receptor; -.
DR   GenomeRNAi; 3643; -.
DR   NextBio; 14259; -.
DR   PRO; PR:P06213; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P06213; -.
DR   CleanEx; HS_INSR; -.
DR   ExpressionAtlas; P06213; baseline and differential.
DR   Genevisible; P06213; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005899; C:insulin receptor complex; IMP:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IC:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0005525; F:GTP binding; IDA:BHF-UCL.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005009; F:insulin-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0031405; F:lipoic acid binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:BHF-UCL.
DR   GO; GO:0032147; P:activation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0008544; P:epidermis development; IEA:Ensembl.
DR   GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0010560; P:positive regulation of glycoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL.
DR   GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0010042; P:response to manganese ion; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0023014; P:signal transduction by protein phosphorylation; IDA:GOC.
DR   GO; GO:0019087; P:transformation of host cell by virus; IMP:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Carbohydrate metabolism; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Diabetes mellitus; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     27       {ECO:0000269|PubMed:2211730,
FT                                ECO:0000269|PubMed:2983222,
FT                                ECO:0000269|PubMed:8257688}.
FT   CHAIN        28    758       Insulin receptor subunit alpha.
FT                                /FTId=PRO_0000016687.
FT   CHAIN       763   1382       Insulin receptor subunit beta.
FT                                /FTId=PRO_0000016689.
FT   TOPO_DOM     28    758       Extracellular. {ECO:0000305}.
FT   TOPO_DOM    763    956       Extracellular. {ECO:0000305}.
FT   TRANSMEM    957    979       Helical. {ECO:0000255}.
FT   TOPO_DOM    980   1382       Cytoplasmic. {ECO:0000305}.
FT   DOMAIN      624    726       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      757    842       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      853    947       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1023   1298       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1104   1110       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   NP_BIND    1163   1164       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   REGION      733    741       Insulin-binding.
FT   REGION      999    999       Important for interaction with IRS1, SHC1
FT                                and STAT5B.
FT   REGION     1361   1364       PIK3R1-binding.
FT   COMPBIAS     28    174       Leu-rich.
FT   COMPBIAS    182    339       Cys-rich.
FT   ACT_SITE   1159   1159       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:9312016}.
FT   BINDING    1033   1033       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   BINDING    1057   1057       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   BINDING    1177   1177       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18278056}.
FT   SITE         66     66       Insulin-binding. {ECO:0000305}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     401    401       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     992    992       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES     999    999       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   MOD_RES    1011   1011       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305}.
FT   MOD_RES    1185   1185       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1189   1189       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1190   1190       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14690593,
FT                                ECO:0000269|PubMed:16246733,
FT                                ECO:0000269|PubMed:16271887,
FT                                ECO:0000269|PubMed:18278056,
FT                                ECO:0000269|PubMed:18767165,
FT                                ECO:0000269|PubMed:3166375,
FT                                ECO:0000269|PubMed:9312016}.
FT   MOD_RES    1355   1355       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   MOD_RES    1361   1361       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:3166375}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862,
FT                                ECO:0000269|PubMed:2983222}.
FT   CARBOHYD     52     52       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    105    105       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    242    242       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    282    282       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:23302862}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    364    364       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147}.
FT   CARBOHYD    424    424       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16894147,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    541    541       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:1472036,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    633    633       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    651    651       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    698    698       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    769    769       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:2983222}.
FT   CARBOHYD    782    782       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    920    920       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    933    933       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     35     53
FT   DISULFID    153    182
FT   DISULFID    186    209
FT   DISULFID    196    215
FT   DISULFID    219    228
FT   DISULFID    223    234
FT   DISULFID    235    243
FT   DISULFID    239    252
FT   DISULFID    255    264
FT   DISULFID    268    280
FT   DISULFID    286    311
FT   DISULFID    293    301
FT   DISULFID    315    328
FT   DISULFID    331    335
FT   DISULFID    339    360
FT   DISULFID    462    495       {ECO:0000269|PubMed:1472036}.
FT   DISULFID    551    551       Interchain. {ECO:0000269|PubMed:1472036}.
FT   DISULFID    674    899
FT   DISULFID    825    834
FT   VAR_SEQ     745    756       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2983222,
FT                                ECO:0000303|Ref.13}.
FT                                /FTId=VSP_002898.
FT   VARIANT       2      2       A -> G (in dbSNP:rs7508518).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2210055,
FT                                ECO:0000269|PubMed:2280779,
FT                                ECO:0000269|PubMed:2777789,
FT                                ECO:0000269|PubMed:2806055,
FT                                ECO:0000269|PubMed:2859121,
FT                                ECO:0000269|PubMed:2983222,
FT                                ECO:0000269|PubMed:3680248}.
FT                                /FTId=VAR_058395.
FT   VARIANT      42     42       N -> K (in RMS; impairs transport to the
FT                                plasma membrane and reduces the affinity
FT                                to bind insulin).
FT                                {ECO:0000269|PubMed:2121734,
FT                                ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004079.
FT   VARIANT      55     55       V -> A (in LEPRCH; Verona-1).
FT                                {ECO:0000269|PubMed:1607067}.
FT                                /FTId=VAR_004080.
FT   VARIANT      58     58       G -> R (in LEPRCH; Helmond; inhibits
FT                                processing and transport;
FT                                dbSNP:rs52836744).
FT                                {ECO:0000269|PubMed:1730625}.
FT                                /FTId=VAR_004081.
FT   VARIANT      86     86       D -> G (in IRAN type A).
FT                                {ECO:0000269|PubMed:9175790}.
FT                                /FTId=VAR_015907.
FT   VARIANT      89     89       L -> P (in IRAN type A).
FT                                {ECO:0000269|PubMed:9175790}.
FT                                /FTId=VAR_015908.
FT   VARIANT     113    113       R -> P (in LEPRCH; Atlanta-1; abolishes
FT                                insulin binding).
FT                                {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:8419945}.
FT                                /FTId=VAR_004082.
FT   VARIANT     119    119       A -> V (in LEPRCH; markedly impairs
FT                                insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015909.
FT   VARIANT     120    120       L -> Q (in LEPRCH; inhibits receptor
FT                                processing).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031518.
FT   VARIANT     146    146       I -> M (in LEPRCH; mild).
FT                                {ECO:0000269|PubMed:7815442,
FT                                ECO:0000269|PubMed:8326490}.
FT                                /FTId=VAR_015539.
FT   VARIANT     167    167       V -> L (in IRAN type A).
FT                                {ECO:0000269|PubMed:10733238}.
FT                                /FTId=VAR_015910.
FT   VARIANT     171    171       Y -> H (in dbSNP:rs1051692).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_058396.
FT   VARIANT     220    220       P -> L (in Ins resistance; severe).
FT                                {ECO:0000269|PubMed:8242067}.
FT                                /FTId=VAR_004083.
FT   VARIANT     228    228       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041429.
FT   VARIANT     236    236       H -> R (in RMS and LEPRCH; Winnipeg; may
FT                                impair receptor processing).
FT                                {ECO:0000269|PubMed:17201797,
FT                                ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004084.
FT   VARIANT     260    260       L -> P (in LEPRCH; Geldeimalsen).
FT                                {ECO:0000269|PubMed:2479553}.
FT                                /FTId=VAR_004085.
FT   VARIANT     279    279       R -> C (in IRAN type A; inhibits receptor
FT                                internalization).
FT                                {ECO:0000269|PubMed:12107746}.
FT                                /FTId=VAR_015540.
FT   VARIANT     279    279       R -> H (in IRAN type A; interferes with
FT                                receptor processing).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031519.
FT   VARIANT     280    280       C -> Y (in IRAN type A).
FT                                {ECO:0000269|PubMed:11260230}.
FT                                /FTId=VAR_015911.
FT   VARIANT     301    301       C -> Y (in LEPRCH).
FT                                {ECO:0000269|PubMed:9703342}.
FT                                /FTId=VAR_015912.
FT   VARIANT     308    308       Missing (in LEPRCH; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:7538143,
FT                                ECO:0000269|PubMed:8636294}.
FT                                /FTId=VAR_015913.
FT   VARIANT     350    350       S -> L (in RMS and LEPRCH).
FT                                {ECO:0000269|PubMed:12970295,
FT                                ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_015914.
FT   VARIANT     362    362       Missing (in LEPRCH).
FT                                {ECO:0000269|PubMed:12538626}.
FT                                /FTId=VAR_015541.
FT   VARIANT     386    386       G -> S (in RMS; may impair receptor
FT                                processing).
FT                                {ECO:0000269|PubMed:17201797}.
FT                                /FTId=VAR_031520.
FT   VARIANT     393    393       G -> R (in LEPRCH; Verona-1).
FT                                {ECO:0000269|PubMed:1607067}.
FT                                /FTId=VAR_004086.
FT   VARIANT     409    409       F -> V (in IRAN type A).
FT                                {ECO:0000269|PubMed:8388389}.
FT                                /FTId=VAR_004087.
FT   VARIANT     439    439       W -> S (in LEPRCH; impairs transport of
FT                                the receptor to the cell surface).
FT                                {ECO:0000269|PubMed:8188715}.
FT                                /FTId=VAR_015542.
FT   VARIANT     448    448       I -> T (in dbSNP:rs1051691).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_015915.
FT   VARIANT     458    458       N -> D (in LEPRCH; partially inhibits
FT                                receptor processing and
FT                                autophosphorylation; strongly impairs ERK
FT                                phosphorylation; induces wild-type levels
FT                                of IRS-1 phosphorylation).
FT                                {ECO:0000269|PubMed:12970295}.
FT                                /FTId=VAR_031521.
FT   VARIANT     487    487       K -> E (in LEPRCH; ARK-1;
FT                                dbSNP:rs28933083).
FT                                {ECO:0000269|PubMed:2834824}.
FT                                /FTId=VAR_004088.
FT   VARIANT     489    489       N -> S (in IRAN type A;
FT                                dbSNP:rs28933085).
FT                                {ECO:0000269|PubMed:2365819}.
FT                                /FTId=VAR_004089.
FT   VARIANT     492    492       Q -> K (in dbSNP:rs1131851).
FT                                {ECO:0000269|PubMed:2859121}.
FT                                /FTId=VAR_015916.
FT   VARIANT     695    695       Q -> R (in dbSNP:rs55906835).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041430.
FT   VARIANT     762    762       R -> S (in IRAN type A).
FT                                {ECO:0000269|PubMed:3283938}.
FT                                /FTId=VAR_004090.
FT   VARIANT     811    811       G -> S (in dbSNP:rs35045353).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041431.
FT   VARIANT     830    830       P -> L (in dbSNP:rs2162771).
FT                                /FTId=VAR_055986.
FT   VARIANT     858    858       T -> A (in NIDDM; dbSNP:rs182552223).
FT                                {ECO:0000269|PubMed:7657032}.
FT                                /FTId=VAR_015917.
FT   VARIANT     925    925       I -> T (in LEPRCH; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015918.
FT   VARIANT     926    926       R -> W (in LEPRCH; markedly impairs
FT                                insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015919.
FT   VARIANT     937    937       T -> M (in LEPRCH; impaired receptor
FT                                processing).
FT                                {ECO:0000269|PubMed:9299395}.
FT                                /FTId=VAR_015920.
FT   VARIANT     997    997       P -> T (in RMS; reduces insulin binding).
FT                                {ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015921.
FT   VARIANT    1012   1012       V -> M (rare polymorphism;
FT                                dbSNP:rs1799816).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8314008,
FT                                ECO:0000269|PubMed:8432414,
FT                                ECO:0000269|PubMed:8458533,
FT                                ECO:0000269|PubMed:9199575}.
FT                                /FTId=VAR_004091.
FT   VARIANT    1020   1020       R -> Q (in IRAN type A).
FT                                {ECO:0000269|PubMed:2002058}.
FT                                /FTId=VAR_004092.
FT   VARIANT    1023   1023       I -> F. {ECO:0000269|PubMed:8890729}.
FT                                /FTId=VAR_015922.
FT   VARIANT    1035   1035       G -> V (in IRAN type A).
FT                                {ECO:0000269|PubMed:2544998}.
FT                                /FTId=VAR_004093.
FT   VARIANT    1055   1055       A -> V (in IRAN type A).
FT                                {ECO:0000269|PubMed:10733238}.
FT                                /FTId=VAR_015923.
FT   VARIANT    1065   1065       L -> V (in dbSNP:rs56395521).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041432.
FT   VARIANT    1075   1075       A -> D (in IRAN type A).
FT                                {ECO:0000269|PubMed:8243830}.
FT                                /FTId=VAR_004094.
FT   VARIANT    1095   1095       K -> E (in a NIDDM subject).
FT                                {ECO:0000269|PubMed:2040394}.
FT                                /FTId=VAR_015924.
FT   VARIANT    1119   1119       R -> W (in LEPRCH).
FT                                {ECO:0000269|PubMed:12970295,
FT                                ECO:0000269|PubMed:9249867}.
FT                                /FTId=VAR_015925.
FT   VARIANT    1143   1143       I -> T (in RMS; reduces insulin binding).
FT                                {ECO:0000269|PubMed:10443650,
FT                                ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015926.
FT   VARIANT    1158   1158       R -> Q (in NIDDM).
FT                                {ECO:0000269|PubMed:1470163}.
FT                                /FTId=VAR_015927.
FT   VARIANT    1158   1158       R -> W (in RMS; abolishes insulin
FT                                binding). {ECO:0000269|PubMed:10443650,
FT                                ECO:0000269|PubMed:12023989}.
FT                                /FTId=VAR_015928.
FT   VARIANT    1161   1161       A -> T (in IRAN type A;
FT                                dbSNP:rs28933084).
FT                                {ECO:0000269|PubMed:2168397}.
FT                                /FTId=VAR_004095.
FT   VARIANT    1162   1162       A -> E (in IRAN type A; impairs
FT                                proteolytic processing).
FT                                {ECO:0000269|PubMed:8096518}.
FT                                /FTId=VAR_004096.
FT   VARIANT    1180   1180       M -> I (in a patient with insulin
FT                                resistance).
FT                                {ECO:0000269|PubMed:1890161}.
FT                                /FTId=VAR_004097.
FT   VARIANT    1191   1191       R -> Q (in NIDDM).
FT                                {ECO:0000269|PubMed:1607076}.
FT                                /FTId=VAR_004098.
FT   VARIANT    1201   1201       R -> Q (in HHF5 and IRAN type A;
FT                                interferes with kinase activation by
FT                                insulin; dbSNP:rs28933086).
FT                                {ECO:0000269|PubMed:15161766,
FT                                ECO:0000269|PubMed:8082780,
FT                                ECO:0000269|PubMed:8288049}.
FT                                /FTId=VAR_015929.
FT   VARIANT    1201   1201       R -> W (in LEPRCH and RMS; reduces
FT                                insulin binding possibly due to reduced
FT                                receptor levels on the cell surface).
FT                                {ECO:0000269|PubMed:12023989,
FT                                ECO:0000269|PubMed:9703342}.
FT                                /FTId=VAR_015930.
FT   VARIANT    1205   1205       P -> L (in IRAN type A; moderate).
FT                                {ECO:0000269|PubMed:1563582,
FT                                ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_004099.
FT   VARIANT    1206   1206       E -> D (in IRAN type A; accelerates
FT                                degradation of the protein and impairs
FT                                kinase activity).
FT                                {ECO:0000269|PubMed:7983039}.
FT                                /FTId=VAR_015931.
FT   VARIANT    1206   1206       E -> K (in LEPRCH).
FT                                {ECO:0000269|PubMed:9249867}.
FT                                /FTId=VAR_015932.
FT   VARIANT    1220   1220       W -> L (in IRAN type A; accelerates
FT                                degradation of the protein and impairs
FT                                kinase activity; dbSNP:rs52800171).
FT                                {ECO:0000269|PubMed:7983039,
FT                                ECO:0000269|PubMed:8390949}.
FT                                /FTId=VAR_004100.
FT   VARIANT    1227   1227       W -> S (in IRAN type A).
FT                                {ECO:0000269|PubMed:1963473}.
FT                                /FTId=VAR_004101.
FT   VARIANT    1282   1282       T -> A (in dbSNP:rs55875349).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041433.
FT   VARIANT    1361   1361       Y -> C (in dbSNP:rs13306449).
FT                                {ECO:0000269|PubMed:7657032}.
FT                                /FTId=VAR_015933.
FT   VARIANT    1378   1378       R -> Q (in IRAN type A;
FT                                dbSNP:rs52826008).
FT                                {ECO:0000269|PubMed:8314008}.
FT                                /FTId=VAR_015934.
FT   MUTAGEN     991    991       L->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     992    992       Y->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     996    997       NP->AA: Abolishes interaction with IRS1.
FT                                Severely disrupts, but does not abolish
FT                                interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     996    996       N->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1. {ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     997    997       P->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1. {ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478}.
FT   MUTAGEN     998    998       E->A: Does not affect interaction with
FT                                IRS1, SHC1 or PIK3R1.
FT                                {ECO:0000269|PubMed:7537849}.
FT   MUTAGEN     999    999       Y->E: Abolishes interaction with IRS1 and
FT                                SHC1. {ECO:0000269|PubMed:2842060,
FT                                ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478,
FT                                ECO:0000269|PubMed:9428692}.
FT   MUTAGEN     999    999       Y->F: Has no effect on insulin-stimulated
FT                                autophosphorylation, but inhibits the
FT                                biological activity of the receptor.
FT                                Abolishes interaction with IRS1 and
FT                                almost completely prevents interaction
FT                                with SHC1. Has no effect on interaction
FT                                with PIK3R1. Abolishes interaction with
FT                                STAT5B. {ECO:0000269|PubMed:2842060,
FT                                ECO:0000269|PubMed:7537849,
FT                                ECO:0000269|PubMed:7559478,
FT                                ECO:0000269|PubMed:9428692}.
FT   MUTAGEN    1000   1000       L->A,R: Severely reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                IRS1. {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN    1002   1002       A->D: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT                                {ECO:0000269|PubMed:7559478}.
FT   MUTAGEN    1011   1011       Y->A: Increases kinase activity.
FT                                {ECO:0000269|PubMed:12707268}.
FT   MUTAGEN    1057   1057       K->A: Abolishes the kinase activity and
FT                                abolishes interaction with IRS1, SHC1,
FT                                GRB7 and PIK3R1.
FT                                {ECO:0000269|PubMed:10803466,
FT                                ECO:0000269|PubMed:3101064,
FT                                ECO:0000269|PubMed:7537849}.
FT   MUTAGEN    1057   1057       K->M,R: Abolishes the kinase activity.
FT                                {ECO:0000269|PubMed:10803466,
FT                                ECO:0000269|PubMed:3101064,
FT                                ECO:0000269|PubMed:7537849}.
FT   MUTAGEN    1159   1159       D->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11598120}.
FT   MUTAGEN    1163   1163       R->Q: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11598120}.
FT   MUTAGEN    1189   1189       Y->F: Reduced interaction with GRB7.
FT                                {ECO:0000269|PubMed:10803466}.
FT   MUTAGEN    1190   1190       Y->F: Strongly reduced interaction with
FT                                GRB7. {ECO:0000269|PubMed:10803466}.
FT   CONFLICT    601    601       D -> N (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    830    830       P -> E (in Ref. 19; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1278   1278       K -> N (in Ref. 2; CAA26096).
FT                                {ECO:0000305}.
FT   STRAND       33     42       {ECO:0000244|PDB:2HR7}.
FT   HELIX        45     50       {ECO:0000244|PDB:2HR7}.
FT   STRAND       53     65       {ECO:0000244|PDB:2HR7}.
FT   HELIX        70     72       {ECO:0000244|PDB:2HR7}.
FT   TURN         73     75       {ECO:0000244|PDB:2HR7}.
FT   STRAND       83     86       {ECO:0000244|PDB:2HR7}.
FT   STRAND       88     93       {ECO:0000244|PDB:2HR7}.
FT   TURN        100    102       {ECO:0000244|PDB:2HR7}.
FT   STRAND      118    124       {ECO:0000244|PDB:2HR7}.
FT   STRAND      141    149       {ECO:0000244|PDB:2HR7}.
FT   HELIX       160    162       {ECO:0000244|PDB:2HR7}.
FT   STRAND      171    175       {ECO:0000244|PDB:2HR7}.
FT   HELIX       176    178       {ECO:0000244|PDB:2HR7}.
FT   TURN        187    192       {ECO:0000244|PDB:2HR7}.
FT   STRAND      199    201       {ECO:0000244|PDB:2HR7}.
FT   STRAND      204    206       {ECO:0000244|PDB:2HR7}.
FT   STRAND      209    211       {ECO:0000244|PDB:2HR7}.
FT   HELIX       221    223       {ECO:0000244|PDB:2HR7}.
FT   STRAND      243    247       {ECO:0000244|PDB:2HR7}.
FT   STRAND      251    260       {ECO:0000244|PDB:2HR7}.
FT   STRAND      263    267       {ECO:0000244|PDB:2HR7}.
FT   STRAND      273    275       {ECO:0000244|PDB:2HR7}.
FT   TURN        276    278       {ECO:0000244|PDB:2HR7}.
FT   STRAND      279    281       {ECO:0000244|PDB:2HR7}.
FT   HELIX       283    295       {ECO:0000244|PDB:2HR7}.
FT   STRAND      298    300       {ECO:0000244|PDB:2HR7}.
FT   STRAND      305    307       {ECO:0000244|PDB:2HR7}.
FT   STRAND      310    314       {ECO:0000244|PDB:2HR7}.
FT   STRAND      319    321       {ECO:0000244|PDB:2HR7}.
FT   STRAND      327    330       {ECO:0000244|PDB:2HR7}.
FT   STRAND      332    334       {ECO:0000244|PDB:2HR7}.
FT   STRAND      338    348       {ECO:0000244|PDB:2HR7}.
FT   HELIX       351    355       {ECO:0000244|PDB:2HR7}.
FT   TURN        356    359       {ECO:0000244|PDB:2HR7}.
FT   STRAND      361    369       {ECO:0000244|PDB:2HR7}.
FT   HELIX       377    385       {ECO:0000244|PDB:2HR7}.
FT   STRAND      390    393       {ECO:0000244|PDB:2HR7}.
FT   STRAND      395    399       {ECO:0000244|PDB:2HR7}.
FT   STRAND      404    406       {ECO:0000244|PDB:2HR7}.
FT   TURN        422    424       {ECO:0000244|PDB:2HR7}.
FT   STRAND      425    430       {ECO:0000244|PDB:2HR7}.
FT   TURN        441    443       {ECO:0000244|PDB:2HR7}.
FT   STRAND      452    458       {ECO:0000244|PDB:2HR7}.
FT   HELIX       463    472       {ECO:0000244|PDB:2HR7}.
FT   TURN        476    478       {ECO:0000244|PDB:2HR7}.
FT   TURN        481    483       {ECO:0000244|PDB:2HR7}.
FT   STRAND      486    490       {ECO:0000244|PDB:2HR7}.
FT   HELIX       733    740       {ECO:0000244|PDB:4OGA}.
FT   HELIX       941    946       {ECO:0000244|PDB:2MFR}.
FT   HELIX       953    979       {ECO:0000244|PDB:2MFR}.
FT   TURN       1003   1005       {ECO:0000244|PDB:4XLV}.
FT   HELIX      1009   1011       {ECO:0000244|PDB:1IR3}.
FT   HELIX      1014   1016       {ECO:0000244|PDB:1IRK}.
FT   HELIX      1020   1022       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1023   1031       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1033   1043       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1046   1048       {ECO:0000244|PDB:2Z8C}.
FT   STRAND     1050   1057       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1065   1078       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1089   1093       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1095   1098       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1100   1104       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1111   1117       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1119   1121       {ECO:0000244|PDB:3ETA}.
FT   HELIX      1133   1152       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1154   1156       {ECO:0000244|PDB:2AUH}.
FT   HELIX      1162   1164       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1165   1167       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1173   1175       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1181   1183       {ECO:0000244|PDB:1IRK}.
FT   TURN       1185   1187       {ECO:0000244|PDB:3BU3}.
FT   STRAND     1190   1192       {ECO:0000244|PDB:4IBM}.
FT   STRAND     1194   1198       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1200   1202       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1205   1210       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1215   1230       {ECO:0000244|PDB:3BU3}.
FT   TURN       1236   1239       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1242   1250       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1263   1272       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1277   1279       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1283   1290       {ECO:0000244|PDB:3BU3}.
FT   HELIX      1291   1293       {ECO:0000244|PDB:4IBM}.
FT   HELIX      1298   1301       {ECO:0000244|PDB:3BU3}.
FT   TURN       1303   1305       {ECO:0000244|PDB:4XLV}.
FT   HELIX      1307   1309       {ECO:0000244|PDB:1I44}.
SQ   SEQUENCE   1382 AA;  156333 MW;  709A955660739066 CRC64;
     MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL
     QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL
     VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE
     ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL
     GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG
     CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC
     TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL
     EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE
     RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ
     NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS
     DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE
     RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL
     KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF
     PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV
     SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV
     SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG
     PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR
     EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG
     FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA
     AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV
     RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN
     CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME
     FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN
     PS
//
ID   SHH_HUMAN               Reviewed;         462 AA.
AC   Q15465; A4D247; Q75MC9;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   17-FEB-2016, entry version 189.
DE   RecName: Full=Sonic hedgehog protein;
DE            Short=SHH;
DE   AltName: Full=HHG-1;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein N-product;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein C-product;
DE   Flags: Precursor;
GN   Name=SHH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal lung;
RX   PubMed=7590746; DOI=10.1006/geno.1995.1104;
RA   Marigo V., Roberts D.J., Lee S.M.K., Tsukurov O., Levi T.,
RA   Gastier J.M., Epstein D.J., Gilbert D.J., Copeland N.G., Seidman C.E.,
RA   Jenkins N.A., Seidman J.G., McMahon A.P., Tabin C.;
RT   "Cloning, expression, and chromosomal location of SHH and IHH: two
RT   human homologues of the Drosophila segment polarity gene hedgehog.";
RL   Genomics 28:44-51(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Tate G., Kishimoto K., Mitsuya T.;
RT   "Expression of Sonic hedgehog and its receptor Patched/Smoothened in
RT   human cancer cell lines and embryonic organs.";
RL   J. Biochem. Mol. Biol. Biophys. 4:27-34(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   PROTEIN SEQUENCE OF 24-32, PALMITOYLATION AT CYS-24, CHOLESTERYLATION,
RP   MUTAGENESIS OF CYS-24, AND MASS SPECTROMETRY.
RX   PubMed=9593755; DOI=10.1074/jbc.273.22.14037;
RA   Pepinsky R.B., Zeng C., Wen D., Rayhorn P., Baker D.P., Williams K.P.,
RA   Bixler S.A., Ambrose C.M., Garber E.A., Miatkowski K., Taylor F.R.,
RA   Wang E.A., Galdes A.;
RT   "Identification of a palmitic acid-modified form of human Sonic
RT   hedgehog.";
RL   J. Biol. Chem. 273:14037-14045(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 119-167.
RX   PubMed=7720571;
RA   Chang D.T., Lopez A., von Kessler D.P., Chiang C., Simandl B.K.,
RA   Zhao R., Seldin M.F., Fallon J.F., Beachy P.A.;
RT   "Products, genetic linkage and limb patterning activity of a murine
RT   hedgehog gene.";
RL   Development 120:3339-3353(1994).
RN   [8]
RP   INVOLVEMENT IN TPTPS, AND INVOLVEMENT IN PPD2.
RX   PubMed=12837695; DOI=10.1093/hmg/ddg180;
RA   Lettice L.A., Heaney S.J.H., Purdie L.A., Li L., de Beer P.,
RA   Oostra B.A., Goode D., Elgar G., Hill R.E., de Graaff E.;
RT   "A long-range Shh enhancer regulates expression in the developing limb
RT   and fin and is associated with preaxial polydactyly.";
RL   Hum. Mol. Genet. 12:1725-1735(2003).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-278.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [10]
RP   INVOLVEMENT IN TPTPS.
RX   PubMed=18417549; DOI=10.1136/jmg.2008.057646;
RA   Sun M., Ma F., Zeng X., Liu Q., Zhao X.-L., Wu F.-X., Wu G.-P.,
RA   Zhang Z.-F., Gu B., Zhao Y.-F., Tian S.-H., Lin B., Kong X.-Y.,
RA   Zhang X.-L., Yang W., Lo W.H.-Y., Zhang X.;
RT   "Triphalangeal thumb-polysyndactyly syndrome and syndactyly type IV
RT   are caused by genomic duplications involving the long range, limb-
RT   specific SHH enhancer.";
RL   J. Med. Genet. 45:589-595(2008).
RN   [11]
RP   INVOLVEMENT IN THYP.
RX   PubMed=19847792; DOI=10.1002/humu.21142;
RA   Wieczorek D., Pawlik B., Li Y., Akarsu N.A., Caliebe A., May K.J.,
RA   Schweiger B., Vargas F.R., Balci S., Gillessen-Kaesbach G.,
RA   Wollnik B.;
RT   "A specific mutation in the distant sonic hedgehog (SHH) cis-regulator
RT   (ZRS) causes Werner mesomelic syndrome (WMS) while complete ZRS
RT   duplications underlie Haas type polysyndactyly and preaxial
RT   polydactyly (PPD) with or without triphalangeal thumb.";
RL   Hum. Mutat. 31:81-89(2010).
RN   [12]
RP   INVOLVEMENT IN LSS.
RX   PubMed=24456159; DOI=10.1111/cge.12352;
RA   Lohan S., Spielmann M., Doelken S.C., Floettmann R., Muhammad F.,
RA   Baig S.M., Wajid M., Huelsemann W., Habenicht R., Kjaer K.W.,
RA   Patil S.J., Girisha K.M., Abarca-Barriga H.H., Mundlos S.,
RA   Klopocki E.;
RT   "Microduplications encompassing the Sonic hedgehog limb enhancer ZRS
RT   are associated with Haas-type polysyndactyly and Laurin-Sandrow
RT   syndrome.";
RL   Clin. Genet. 86:318-325(2014).
RN   [13]
RP   INVOLVEMENT IN THYP.
RX   PubMed=24965254; DOI=10.1038/jhg.2014.50;
RA   Norbnop P., Srichomthong C., Suphapeetiporn K., Shotelersuk V.;
RT   "ZRS 406A>G mutation in patients with tibial hypoplasia, polydactyly
RT   and triphalangeal first fingers.";
RL   J. Hum. Genet. 59:467-470(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 25-197 IN COMPLEX WITH ZINC
RP   IONS, FUNCTION, AND DOMAIN.
RX   PubMed=10753901; DOI=10.1074/jbc.275.15.10995;
RA   Pepinsky R.B., Rayhorn P., Day E.S., Dergay A., Williams K.P.,
RA   Galdes A., Taylor F.R., Boriack-Sjodin P.A., Garber E.A.;
RT   "Mapping sonic hedgehog-receptor interactions by steric
RT   interference.";
RL   J. Biol. Chem. 275:10995-11001(2000).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) OF 29-197 IN COMPLEX WITH HHIP;
RP   ZINC AND CALCIUM IONS, DOMAIN, AND INTERACTION WITH HHIP.
RX   PubMed=19561609; DOI=10.1038/nsmb.1632;
RA   Bosanac I., Maun H.R., Scales S.J., Wen X., Lingel A., Bazan J.F.,
RA   de Sauvage F.J., Hymowitz S.G., Lazarus R.A.;
RT   "The structure of SHH in complex with HHIP reveals a recognition role
RT   for the Shh pseudo active site in signaling.";
RL   Nat. Struct. Mol. Biol. 16:691-697(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 29-197 IN COMPLEX WITH
RP   MONOCLONAL ANTIBODY; ZINC AND CALCIUM IONS, AND DOMAIN.
RX   PubMed=20504762; DOI=10.1074/jbc.M110.112284;
RA   Maun H.R., Wen X., Lingel A., de Sauvage F.J., Lazarus R.A.,
RA   Scales S.J., Hymowitz S.G.;
RT   "Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active
RT   site.";
RL   J. Biol. Chem. 285:26570-26580(2010).
RN   [17]
RP   VARIANTS HPE3 ARG-31; GLY-117 AND ARG-117.
RX   PubMed=8896572; DOI=10.1038/ng1196-357;
RA   Roessler E., Belloni E., Gaudenz K., Jay P., Berta P., Scherer S.W.,
RA   Tsui L.-C., Muenke M.;
RT   "Mutations in the human Sonic hedgehog gene cause holoprosencephaly.";
RL   Nat. Genet. 14:357-360(1996).
RN   [18]
RP   VARIANTS HPE3 ARG-31; GLY-117; ARG-117; GLU-224; THR-226 AND THR-383.
RX   PubMed=9302262; DOI=10.1093/hmg/6.11.1847;
RA   Roessler E., Belloni E., Gaudenz K., Vargas F., Scherer S.W.,
RA   Tsui L.-C., Muenke M.;
RT   "Mutations in the C-terminal domain of Sonic hedgehog cause
RT   holoprosencephaly.";
RL   Hum. Mol. Genet. 6:1847-1853(1997).
RN   [19]
RP   VARIANTS HPE3 HIS-100; GLN-188 AND ASN-222.
RX   PubMed=10441331; DOI=10.1093/hmg/8.9.1683;
RA   Odent S., Atti-Bitach T., Blayau M., Mathieu M., Aug J.,
RA   Delezo de A.L., Gall J.Y., Le Marec B., Munnich A., David V.,
RA   Vekemans M.;
RT   "Expression of the Sonic hedgehog (SHH) gene during early human
RT   development and phenotypic expression of new mutations causing
RT   holoprosencephaly.";
RL   Hum. Mol. Genet. 8:1683-1689(1999).
RN   [20]
RP   VARIANTS HPE3 VAL-88; LYS-115; ARG-236; 263-ARG--ALA-269 DEL; ASP-290;
RP   ALA-424 AND LEU-436.
RX   PubMed=10556296; DOI=10.1093/hmg/8.13.2479;
RA   Nanni L., Ming J.E., Bocian M., Steinhaus K., Bianchi D.W.,
RA   Die-Smulders C., Giannotti A., Imaizumi K., Jones K.L., Campo M.D.,
RA   Martin R.A., Meinecke P., Pierpont M.E.M., Robin N.H., Young I.D.,
RA   Roessler E., Muenke M.;
RT   "The mutational spectrum of the sonic hedgehog gene in
RT   holoprosencephaly: SHH mutations cause a significant proportion of
RT   autosomal dominant holoprosencephaly.";
RL   Hum. Mol. Genet. 8:2479-2488(1999).
RN   [21]
RP   VARIANT SMMCI PHE-111.
RX   PubMed=11471164;
RX   DOI=10.1002/1096-8628(20010722)102:1<1::AID-AJMG1336>3.0.CO;2-U;
RA   Nanni L., Ming J.E., Du Y., Hall R.K., Aldred M., Bankier A.,
RA   Muenke M.;
RT   "SHH mutation is associated with solitary median maxillary central
RT   incisor: a study of 13 patients and review of the literature.";
RL   Am. J. Med. Genet. 102:1-10(2001).
RN   [22]
RP   VARIANTS HPE3 PRO-140 AND PHE-183.
RX   PubMed=11479728; DOI=10.1007/s004390100537;
RA   Orioli I.M., Castilla E.E., Ming J.E., Nazer J., Burle de Aguiar M.J.,
RA   Llerena J.C., Muenke M.;
RT   "Identification of novel mutations in SHH and ZIC2 in a South American
RT   (ECLAMC) population with holoprosencephaly.";
RL   Hum. Genet. 109:1-6(2001).
RN   [23]
RP   VARIANT MCOPCB5 401-SER--GLY-408 DEL.
RX   PubMed=12503095; DOI=10.1002/ajmg.a.10884;
RA   Schimmenti L.A., de la Cruz J., Lewis R.A., Karkera J.D.,
RA   Manligas G.S., Roessler E., Muenke M.;
RT   "Novel mutation in sonic hedgehog in non-syndromic colobomatous
RT   microphthalmia.";
RL   Am. J. Med. Genet. A 116:215-221(2003).
RN   [24]
RP   VARIANT SMMCI ALA-332.
RX   PubMed=15103725; DOI=10.1002/ajmg.a.20685;
RA   Garavelli L., Zanacca C., Caselli G., Banchini G., Dubourg C.,
RA   David V., Odent S., Gurrieri F., Neri G.;
RT   "Solitary median maxillary central incisor syndrome: clinical case
RT   with a novel mutation of sonic hedgehog.";
RL   Am. J. Med. Genet. A 127:93-95(2004).
RN   [25]
RP   VARIANTS HPE3 ALA-27; ILE-267 AND THR-373.
RX   PubMed=15107988; DOI=10.1007/s00431-004-1459-0;
RA   Hehr U., Gross C., Diebold U., Wahl D., Beudt U., Heidemann P.,
RA   Hehr A., Mueller D.;
RT   "Wide phenotypic variability in families with holoprosencephaly and a
RT   sonic hedgehog mutation.";
RL   Eur. J. Pediatr. 163:347-352(2004).
RN   [26]
RP   VARIANTS HPE3 THR-6; HIS-100; 106-LEU-ASN-107 DEL; ASP-110; ARG-150;
RP   176-GLU--LYS-178 DEL; GLN-188; ASN-222; PRO-271; ALA-332; GLN-347;
RP   THR-354 AND PRO-381.
RX   PubMed=15221788; DOI=10.1002/humu.20056;
RA   Dubourg C., Lazaro L., Pasquier L., Bendavid C., Blayau M.,
RA   Le Duff F., Durou M.-R., Odent S., David V.;
RT   "Molecular screening of SHH, ZIC2, SIX3, and TGIF genes in patients
RT   with features of holoprosencephaly spectrum: mutation review and
RT   genotype-phenotype correlations.";
RL   Hum. Mutat. 24:43-51(2004).
RN   [27]
RP   VARIANT HPE3 ASN-111.
RX   PubMed=15942952; DOI=10.1002/ajmg.a.30624;
RA   El-Jaick K.B., Brunoni D., Castilla E.E., Moreira M.A., Orioli I.M.;
RT   "SHH Ile111Asp in alobar holoprosencephaly in a proposita, whose
RT   mother had only a solitary median maxillary incisor.";
RL   Am. J. Med. Genet. A 136:345-345(2005).
RN   [28]
RP   VARIANT HPE3 GLN-140.
RX   PubMed=15942953; DOI=10.1002/ajmg.a.30625;
RA   Ribeiro L.A., Richieri-Costa A.;
RT   "Single median maxillary central incisor, hypophyseal tumor, and SHH
RT   mutation.";
RL   Am. J. Med. Genet. A 136:346-347(2005).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HPE3 ARG-31; VAL-88; HIS-100; LYS-115;
RP   ARG-117; GLY-117 AND GLN-188.
RX   PubMed=16282375; DOI=10.1073/pnas.0507848102;
RA   Maity T., Fuse N., Beachy P.A.;
RT   "Molecular mechanisms of Sonic hedgehog mutant effects in
RT   holoprosencephaly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17026-17031(2005).
RN   [30]
RP   VARIANTS HPE3 GLN-140; PRO-218 AND TYR-363.
RX   PubMed=17001669; DOI=10.1002/ajmg.a.31378;
RA   Richieri-Costa A., Ribeiro L.A.;
RT   "Holoprosencephaly-like phenotype: clinical and genetic
RT   perspectives.";
RL   Am. J. Med. Genet. A 140:2587-2593(2006).
RN   [31]
RP   VARIANTS HPE3 THR-6; PRO-17; LEU-26; ALA-27; ARG-31; PRO-39; LYS-53;
RP   VAL-83; PHE-84; VAL-88; HIS-100; ARG-102; TYR-102; 106-LEU-ASN-107
RP   DEL; PHE-109; THR-110; ASP-110; PHE-111; ASN-111; LYS-115; GLY-117;
RP   ARG-117; MET-124; LYS-136; PRO-140; GLN-140; ASP-143; PRO-144;
RP   ASN-147; ARG-150; LYS-150; ARG-156; CYS-170; HIS-171; 176-GLU--LYS-178
RP   DEL; ARG-183; PHE-183; TYR-183; LEU-184; GLN-188; GLU-196;
RP   196-GLY--PRO-200 DEL; VAL-197; SER-198; PHE-198; PRO-218; ASN-222;
RP   GLU-224; THR-226; VAL-231; GLY-232; PRO-234; ARG-236; ASN-236;
RP   VAL-241; LEU-241; ASN-255; 263-ARG--ALA-269 DEL; ILE-267; PRO-271;
RP   GLU-275; TRP-280; ASP-290; ALA-296; CYS-310; SER-321; ALA-332;
RP   VAL-346; ARG-347; GLN-347; LEU-347; THR-354; LEU-362; TYR-363;
RP   CYS-364; THR-373; ARG-374; ASP-376; SER-377; 378-ALA--PHE-380 DEL;
RP   PRO-381; PRO-382; THR-383; THR-391; 402-GLY--GLY-409 DEL;
RP   405-ASP--GLY-409 DEL; GLY-411 INS; ALA-416; ALA-424; ASN-435; LEU-436
RP   AND ARG-456.
RX   PubMed=19603532; DOI=10.1002/humu.21090;
RA   Roessler E., El-Jaick K.B., Dubourg C., Velez J.I., Solomon B.D.,
RA   Pineda-Alvarez D.E., Lacbawan F., Zhou N., Ouspenskaia M.,
RA   Paulussen A., Smeets H.J., Hehr U., Bendavid C., Bale S., Odent S.,
RA   David V., Muenke M.;
RT   "The mutational spectrum of holoprosencephaly-associated changes
RT   within the SHH gene in humans predicts loss-of-function through either
RT   key structural alterations of the ligand or its altered synthesis.";
RL   Hum. Mutat. 30:E921-E935(2009).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development: signal produced by the
CC       notochord that induces ventral cell fate in the neural tube and
CC       somites, and the polarizing signal for patterning of the anterior-
CC       posterior axis of the developing limb bud. Displays both floor
CC       plate- and motor neuron-inducing activity. The threshold
CC       concentration of N-product required for motor neuron induction is
CC       5-fold lower than that required for floor plate induction.
CC       Activates the transcription of target genes by interacting with
CC       its receptor PTCH1 to prevent normal inhibition by PTCH1 on the
CC       constitutive signaling activity of SMO (By similarity).
CC       {ECO:0000250, ECO:0000269|PubMed:10753901}.
CC   -!- SUBUNIT: Interacts with HHATL/GUP1 which negatively regulates
CC       HHAT-mediated palmitoylation of the SHH N-terminus. N-product is
CC       active as a multimer. Interacts with BOC and CDON (By similarity).
CC       Interacts with HHIP. {ECO:0000250, ECO:0000269|PubMed:10753901,
CC       ECO:0000269|PubMed:19561609, ECO:0000269|PubMed:20504762}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein C-product: Secreted,
CC       extracellular space {ECO:0000250|UniProtKB:Q62226}. Note=The C-
CC       terminal peptide diffuses from the cell.
CC       {ECO:0000250|UniProtKB:Q62226}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein N-product: Cell
CC       membrane {ECO:0000250|UniProtKB:Q62226}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:Q62226}. Note=The N-product either remains
CC       associated with lipid rafts at the cell surface, or forms freely
CC       diffusible active multimers with its hydrophobic lipid-modified N-
CC       and C-termini buried inside. {ECO:0000250|UniProtKB:Q62226}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal intestine, liver, lung, and
CC       kidney. Not expressed in adult tissues.
CC   -!- DOMAIN: The sonic hedgehog protein N-product binds calcium and
CC       zinc ions; this stabilizes the protein fold and is essential for
CC       protein-protein interactions mediated by this domain.
CC       {ECO:0000269|PubMed:10753901, ECO:0000269|PubMed:19561609,
CC       ECO:0000269|PubMed:20504762}.
CC   -!- PTM: The C-terminal domain displays an autoproteolysis activity
CC       and a cholesterol transferase activity. Both activities result in
CC       the cleavage of the full-length protein and covalent attachment of
CC       a cholesterol moiety to the C-terminal of the newly generated N-
CC       terminal fragment (N-product). The N-product is the active species
CC       in both local and long-range signaling, whereas the C-product has
CC       no signaling activity.
CC   -!- PTM: Cholesterylation is required for N-product targeting to lipid
CC       rafts and multimerization. {ECO:0000250}.
CC   -!- PTM: N-palmitoylation of Cys-24 by HHAT is required for N-product
CC       multimerization and full activity. {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=19.560; Method=Electrospray; Range=24-197;
CC       Note=Soluble N-product, purified from insect cells.;
CC       Evidence={ECO:0000269|PubMed:9593755};
CC   -!- MASS SPECTROMETRY: Mass=20.167; Method=Electrospray; Range=24-197;
CC       Note=Membrane-bound N-product, purified from insect cells.;
CC       Evidence={ECO:0000269|PubMed:9593755};
CC   -!- DISEASE: Microphthalmia, isolated, with coloboma, 5 (MCOPCB5)
CC       [MIM:611638]: A disorder of eye formation, ranging from small size
CC       of a single eye to complete bilateral absence of ocular tissues.
CC       Ocular abnormalities like opacities of the cornea and lens,
CC       scaring of the retina and choroid, and other abnormalities may
CC       also be present. Ocular colobomas are a set of malformations
CC       resulting from abnormal morphogenesis of the optic cup and stalk,
CC       and the fusion of the fetal fissure (optic fissure).
CC       {ECO:0000269|PubMed:12503095}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Holoprosencephaly 3 (HPE3) [MIM:142945]: A structural
CC       anomaly of the brain, in which the developing forebrain fails to
CC       correctly separate into right and left hemispheres.
CC       Holoprosencephaly is genetically heterogeneous and associated with
CC       several distinct facies and phenotypic variability. The majority
CC       of holoprosencephaly type 3 cases are apparently sporadic,
CC       although clear examples of autosomal dominant inheritance have
CC       been described. {ECO:0000269|PubMed:10441331,
CC       ECO:0000269|PubMed:10556296, ECO:0000269|PubMed:11479728,
CC       ECO:0000269|PubMed:15107988, ECO:0000269|PubMed:15221788,
CC       ECO:0000269|PubMed:15942952, ECO:0000269|PubMed:15942953,
CC       ECO:0000269|PubMed:17001669, ECO:0000269|PubMed:19603532,
CC       ECO:0000269|PubMed:8896572, ECO:0000269|PubMed:9302262}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Solitary median maxillary central incisor (SMMCI)
CC       [MIM:147250]: Rare dental anomaly characterized by the congenital
CC       absence of one maxillary central incisor.
CC       {ECO:0000269|PubMed:11471164, ECO:0000269|PubMed:15103725}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Triphalangeal thumb-polysyndactyly syndrome (TPTPS)
CC       [MIM:174500]: Autosomal dominant syndrome. It is characterized by
CC       a wide spectrum of pre- and post-axial abnormalities due to
CC       altered SHH expression pattern during limb development.
CC       {ECO:0000269|PubMed:12837695, ECO:0000269|PubMed:18417549}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Mutations located in intron 5 of LMBR1 disrupt a
CC       long-range, cis-regulatory element of SHH expression.
CC   -!- DISEASE: Preaxial polydactyly 2 (PPD2) [MIM:174500]: Polydactyly
CC       consists of duplication of the distal phalanx. The thumb in PPD2
CC       is usually opposable and possesses a normal metacarpal.
CC       {ECO:0000269|PubMed:12837695}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis. Mutations located in
CC       intron 5 of LMBR1 disrupt a long-range, cis-regulatory element of
CC       SHH and result in abnormal, ectopic SHH expression with
CC       pathological consequences (PubMed:12837695).
CC       {ECO:0000269|PubMed:12837695}.
CC   -!- DISEASE: Hypoplasia or aplasia of tibia with polydactyly (THYP)
CC       [MIM:188740]: An autosomal dominant disease characterized by
CC       hypoplastic or absent tibia, and polydactyly.
CC       {ECO:0000269|PubMed:19847792, ECO:0000269|PubMed:24965254}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Mutations located in intron 5 of LMBR1 disrupt a
CC       long-range, cis-regulatory element of SHH and result in abnormal,
CC       ectopic SHH expression with pathological consequences.
CC       {ECO:0000303|PubMed:19847792, ECO:0000303|PubMed:24965254}.
CC   -!- DISEASE: Laurin-Sandrow syndrome (LSS) [MIM:135750]: A rare
CC       autosomal dominant disorder characterized by polysyndactyly of
CC       hands and/or feet, mirror image duplication of the feet, nasal
CC       defects, and loss of identity between fibula and tibia. Some
CC       patients do not have nasal abnormalities (segmental Laurin-Sandrow
CC       syndrome). {ECO:0000269|PubMed:24456159}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis.
CC       Abnormal SHH limb expression with pathological consequences is
CC       caused by duplications (16-75 kb) involving the ZPA regulatory
CC       sequence (ZRS), a SHH long-range cis-regulatory element, located
CC       in LMBR1 intron 5 (PubMed:24456159).
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SHHID378.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/shh/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L38518; AAA62179.1; -; mRNA.
DR   EMBL; AY422195; AAQ87879.1; -; Genomic_DNA.
DR   EMBL; AC002484; AAB67604.1; -; Genomic_DNA.
DR   EMBL; AC078834; AAS01990.1; -; Genomic_DNA.
DR   EMBL; CH236954; EAL23913.1; -; Genomic_DNA.
DR   CCDS; CCDS5942.1; -.
DR   RefSeq; NP_000184.1; NM_000193.3.
DR   UniGene; Hs.164537; -.
DR   UniGene; Hs.606487; -.
DR   UniGene; Hs.738995; -.
DR   PDB; 3HO5; X-ray; 3.01 A; H=29-197.
DR   PDB; 3M1N; X-ray; 1.85 A; A/B=23-197.
DR   PDB; 3MXW; X-ray; 1.83 A; A=29-197.
DR   PDBsum; 3HO5; -.
DR   PDBsum; 3M1N; -.
DR   PDBsum; 3MXW; -.
DR   ProteinModelPortal; Q15465; -.
DR   SMR; Q15465; 25-190, 198-365.
DR   BioGrid; 112365; 5.
DR   STRING; 9606.ENSP00000297261; -.
DR   BindingDB; Q15465; -.
DR   ChEMBL; CHEMBL5602; -.
DR   MEROPS; C46.002; -.
DR   iPTMnet; Q15465; -.
DR   PhosphoSite; Q15465; -.
DR   BioMuta; SHH; -.
DR   DMDM; 6094283; -.
DR   PaxDb; Q15465; -.
DR   PRIDE; Q15465; -.
DR   DNASU; 6469; -.
DR   Ensembl; ENST00000297261; ENSP00000297261; ENSG00000164690.
DR   GeneID; 6469; -.
DR   KEGG; hsa:6469; -.
DR   UCSC; uc003wmj.1; human.
DR   CTD; 6469; -.
DR   GeneCards; SHH; -.
DR   GeneReviews; SHH; -.
DR   HGNC; HGNC:10848; SHH.
DR   HPA; CAB018966; -.
DR   MalaCards; SHH; -.
DR   MIM; 135750; phenotype.
DR   MIM; 142945; phenotype.
DR   MIM; 147250; phenotype.
DR   MIM; 174500; phenotype.
DR   MIM; 188740; phenotype.
DR   MIM; 600725; gene.
DR   MIM; 611638; phenotype.
DR   neXtProt; NX_Q15465; -.
DR   Orphanet; 93925; Alobar holoprosencephaly.
DR   Orphanet; 98938; Colobomatous microphthalmia.
DR   Orphanet; 3332; Hypoplastic tibiae - postaxial polydactyly.
DR   Orphanet; 93924; Lobar holoprosencephaly.
DR   Orphanet; 280200; Microform holoprosencephaly.
DR   Orphanet; 93926; Midline interhemispheric variant of holoprosencephaly.
DR   Orphanet; 194; Ocular coloboma.
DR   Orphanet; 295150; Polydactyly of a triphalangeal thumb, bilateral.
DR   Orphanet; 295148; Polydactyly of a triphalangeal thumb, unilateral.
DR   Orphanet; 295071; Radial hemimelia, bilateral.
DR   Orphanet; 295069; Radial hemimelia, unilateral.
DR   Orphanet; 799; Schizencephaly.
DR   Orphanet; 220386; Semilobar holoprosencephaly.
DR   Orphanet; 280195; Septopreoptic holoprosencephaly.
DR   Orphanet; 2286; Solitary median maxillary central incisor syndrome.
DR   Orphanet; 93405; Syndactyly type 4.
DR   Orphanet; 2950; Triphalangeal thumb - polysyndactyly syndrome.
DR   PharmGKB; PA35752; -.
DR   eggNOG; KOG3638; Eukaryota.
DR   eggNOG; ENOG410XQA3; LUCA.
DR   GeneTree; ENSGT00390000001117; -.
DR   HOGENOM; HOG000233428; -.
DR   HOVERGEN; HBG005480; -.
DR   InParanoid; Q15465; -.
DR   KO; K11988; -.
DR   OMA; EHSWAHR; -.
DR   OrthoDB; EOG779NZ5; -.
DR   PhylomeDB; Q15465; -.
DR   TreeFam; TF106458; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-HSA-5362768; Hh mutants that don't undergo autocatalytic processing are degraded by ERAD.
DR   Reactome; R-HSA-5362798; Release of Hh-Np from the secreting cell.
DR   Reactome; R-HSA-5632681; Ligand-receptor interactions.
DR   Reactome; R-HSA-5658034; HHAT G278V abrogates palmitoylation of Hh-Np.
DR   SignaLink; Q15465; -.
DR   ChiTaRS; SHH; human.
DR   EvolutionaryTrace; Q15465; -.
DR   GeneWiki; Sonic_hedgehog; -.
DR   GenomeRNAi; 6469; -.
DR   NextBio; 25129; -.
DR   PRO; PR:Q15465; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; Q15465; -.
DR   CleanEx; HS_SHH; -.
DR   ExpressionAtlas; Q15465; baseline and differential.
DR   Genevisible; Q15465; HS.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IEA:Ensembl.
DR   GO; GO:0043237; F:laminin-1 binding; ISS:UniProtKB.
DR   GO; GO:0016015; F:morphogen activity; NAS:BHF-UCL.
DR   GO; GO:0005113; F:patched binding; IDA:BHF-UCL.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0008209; P:androgen metabolic process; ISS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060840; P:artery development; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; IEA:Ensembl.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IDA:BHF-UCL.
DR   GO; GO:0048468; P:cell development; ISS:UniProtKB.
DR   GO; GO:0001708; P:cell fate specification; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0021930; P:cerebellar granule cell precursor proliferation; ISS:UniProtKB.
DR   GO; GO:0003140; P:determination of left/right asymmetry in lateral mesoderm; ISS:BHF-UCL.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; ISS:UniProtKB.
DR   GO; GO:0007398; P:ectoderm development; IEA:Ensembl.
DR   GO; GO:0009790; P:embryo development; ISS:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; TAS:BHF-UCL.
DR   GO; GO:0048706; P:embryonic skeletal system development; IEA:Ensembl.
DR   GO; GO:0006897; P:endocytosis; IEA:Ensembl.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0060738; P:epithelial-mesenchymal signaling involved in prostate gland development; IDA:MGI.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; ISS:UniProtKB.
DR   GO; GO:0048859; P:formation of anatomical boundary; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0030902; P:hindbrain development; ISS:UniProtKB.
DR   GO; GO:0007442; P:hindgut morphogenesis; IEA:Ensembl.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0045109; P:intermediate filament organization; IEA:Ensembl.
DR   GO; GO:0060459; P:left lung development; IEA:Ensembl.
DR   GO; GO:0060174; P:limb bud formation; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0060428; P:lung epithelium development; IEA:Ensembl.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IEA:Ensembl.
DR   GO; GO:0060783; P:mesenchymal smoothened signaling pathway involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0072136; P:metanephric mesenchymal cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; ISS:UniProtKB.
DR   GO; GO:0030901; P:midbrain development; ISS:UniProtKB.
DR   GO; GO:0080125; P:multicellular structure septum development; IEA:Ensembl.
DR   GO; GO:0045445; P:myoblast differentiation; IEA:Ensembl.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0046639; P:negative regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; ISS:BHF-UCL.
DR   GO; GO:1904339; P:negative regulation of dopaminergic neuron differentiation; IEA:Ensembl.
DR   GO; GO:2000357; P:negative regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2001054; P:negative regulation of mesenchymal cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:2000062; P:negative regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0007405; P:neuroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0048645; P:organ formation; IEA:Ensembl.
DR   GO; GO:0002076; P:osteoblast development; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0031016; P:pancreas development; IEA:Ensembl.
DR   GO; GO:0007389; P:pattern specification process; ISS:UniProtKB.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:UniProtKB.
DR   GO; GO:0009949; P:polarity specification of anterior/posterior axis; ISS:UniProtKB.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; ISS:BHF-UCL.
DR   GO; GO:2000358; P:positive regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000729; P:positive regulation of mesenchymal cell proliferation involved in ureter development; ISS:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0061189; P:positive regulation of sclerotome development; IDA:BHF-UCL.
DR   GO; GO:0014858; P:positive regulation of skeletal muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051155; P:positive regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:2000063; P:positive regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045059; P:positive thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0060516; P:primary prostatic bud elongation; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0030850; P:prostate gland development; ISS:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0060782; P:regulation of mesenchymal cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1900175; P:regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry; NAS:BHF-UCL.
DR   GO; GO:0042481; P:regulation of odontogenesis; ISS:BHF-UCL.
DR   GO; GO:0060685; P:regulation of prostatic bud formation; IEA:Ensembl.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IDA:BHF-UCL.
DR   GO; GO:0030162; P:regulation of proteolysis; ISS:UniProtKB.
DR   GO; GO:0072001; P:renal system development; IEP:UniProtKB.
DR   GO; GO:0060458; P:right lung development; IEA:Ensembl.
DR   GO; GO:0060662; P:salivary gland cavitation; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEP:UniProtKB.
DR   GO; GO:0021938; P:smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0061053; P:somite development; ISS:BHF-UCL.
DR   GO; GO:0021522; P:spinal cord motor neuron differentiation; IEA:Ensembl.
DR   GO; GO:0048864; P:stem cell development; ISS:UniProtKB.
DR   GO; GO:0014706; P:striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:BHF-UCL.
DR   GO; GO:0021978; P:telencephalon regionalization; IEA:Ensembl.
DR   GO; GO:0021794; P:thalamus development; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060439; P:trachea morphogenesis; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0007418; P:ventral midline development; TAS:BHF-UCL.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Cell membrane;
KW   Complete proteome; Developmental protein; Direct protein sequencing;
KW   Disease mutation; Glycoprotein; Holoprosencephaly; Hydrolase;
KW   Lipoprotein; Membrane; Metal-binding; Microphthalmia; Palmitate;
KW   Protease; Reference proteome; Secreted; Signal; Zinc.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:9593755}.
FT   CHAIN        24    462       Sonic hedgehog protein.
FT                                /FTId=PRO_0000013208.
FT   CHAIN        24    197       Sonic hedgehog protein N-product.
FT                                /FTId=PRO_0000013209.
FT   CHAIN       198    462       Sonic hedgehog protein C-product.
FT                                /FTId=PRO_0000013210.
FT   COMPBIAS    407    411       Poly-Gly.
FT   METAL        89     89       Calcium 1. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL        90     90       Calcium 1. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL        90     90       Calcium 2. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL        95     95       Calcium 1. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       125    125       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       126    126       Calcium 1. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       126    126       Calcium 2. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       129    129       Calcium 2. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       131    131       Calcium 2. {ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       140    140       Zinc. {ECO:0000244|PDB:3M1N,
FT                                ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:10753901,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       147    147       Zinc. {ECO:0000244|PDB:3M1N,
FT                                ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:10753901,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       182    182       Zinc. {ECO:0000244|PDB:3M1N,
FT                                ECO:0000244|PDB:3MXW,
FT                                ECO:0000269|PubMed:10753901,
FT                                ECO:0000269|PubMed:20504762}.
FT   SITE        197    198       Cleavage; by autolysis. {ECO:0000250}.
FT   SITE        243    243       Involved in cholesterol transfer.
FT                                {ECO:0000250}.
FT   SITE        267    267       Involved in auto-cleavage. {ECO:0000250}.
FT   SITE        270    270       Essential for auto-cleavage.
FT                                {ECO:0000250}.
FT   LIPID        24     24       N-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:9593755}.
FT   LIPID       197    197       Cholesterol glycine ester. {ECO:0000250}.
FT   CARBOHYD    278    278       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   VARIANT       6      6       R -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023804.
FT   VARIANT      17     17       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062592.
FT   VARIANT      26     26       P -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062593.
FT   VARIANT      27     27       G -> A (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039888.
FT   VARIANT      31     31       G -> R (in HPE3; the same mutation in the
FT                                mouse sequence introduces a cleavage site
FT                                for a furin-like protease resulting in
FT                                abnormal protein processing; cleavage at
FT                                this site removes 11 amino acids from the
FT                                N-terminal domain and reduces affinity of
FT                                Shh for Ptch1 and signaling potency in
FT                                assays using chicken embryo neural plate
FT                                explants and mouse C3H10T1/2 stem cells;
FT                                dbSNP:rs28936675).
FT                                {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003619.
FT   VARIANT      39     39       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062594.
FT   VARIANT      53     53       E -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062595.
FT   VARIANT      83     83       D -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062596.
FT   VARIANT      84     84       I -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062597.
FT   VARIANT      88     88       D -> V (in HPE3; familial; the same
FT                                mutation in the mouse sequence moderately
FT                                reduces Ptch1 binding in vitro and
FT                                signaling potency in chicken embryo
FT                                neural plate explant assays compared with
FT                                wild-type sequence).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009163.
FT   VARIANT     100    100       Q -> H (in HPE3; sporadic; in the mouse
FT                                sequence does not affect signaling
FT                                activity in any of Shh signaling assays
FT                                and causes no apparent defects in
FT                                cholesterol-mediated autoprocessing
FT                                reactions). {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009164.
FT   VARIANT     102    102       C -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062598.
FT   VARIANT     102    102       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062599.
FT   VARIANT     106    107       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023805.
FT   VARIANT     109    109       L -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062600.
FT   VARIANT     110    110       A -> D (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023806.
FT   VARIANT     110    110       A -> T (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062601.
FT   VARIANT     111    111       I -> F (in SMMCI).
FT                                {ECO:0000269|PubMed:11471164,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_017883.
FT   VARIANT     111    111       I -> N (in HPE3).
FT                                {ECO:0000269|PubMed:15942952,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039889.
FT   VARIANT     115    115       N -> K (in HPE3; familial; in the mouse
FT                                sequence shows no change in activities at
FT                                different temperatures).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009165.
FT   VARIANT     117    117       W -> G (in HPE3; the same mutation in the
FT                                mouse sequence causes a failure of Shh
FT                                processing leading to retention of the
FT                                immature glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; the mutation
FT                                drastically reduces signaling potency in
FT                                chicken embryo neural plate explant
FT                                assays). {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003620.
FT   VARIANT     117    117       W -> R (in HPE3; the same mutation in the
FT                                mouse sequence causes a failure of Shh
FT                                processing leading to retention of the
FT                                immature glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; drastically
FT                                reduces signaling potency in chicken
FT                                embryo neural plate explant assays).
FT                                {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003621.
FT   VARIANT     124    124       V -> M (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062602.
FT   VARIANT     136    136       E -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062603.
FT   VARIANT     140    140       H -> P (in HPE3).
FT                                {ECO:0000269|PubMed:11479728,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039890.
FT   VARIANT     140    140       H -> Q (in HPE3).
FT                                {ECO:0000269|PubMed:15942953,
FT                                ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039891.
FT   VARIANT     143    143       G -> D (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062604.
FT   VARIANT     144    144       R -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062605.
FT   VARIANT     147    147       D -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062606.
FT   VARIANT     150    150       T -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062607.
FT   VARIANT     150    150       T -> R (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023807.
FT   VARIANT     156    156       S -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062608.
FT   VARIANT     170    170       F -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062609.
FT   VARIANT     171    171       D -> H (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062610.
FT   VARIANT     176    178       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023808.
FT   VARIANT     183    183       C -> F (in HPE3).
FT                                {ECO:0000269|PubMed:11479728,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039892.
FT   VARIANT     183    183       C -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062611.
FT   VARIANT     183    183       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062612.
FT   VARIANT     184    184       S -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062613.
FT   VARIANT     188    188       E -> Q (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009166.
FT   VARIANT     196    200       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062614.
FT   VARIANT     196    196       G -> E (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062615.
FT   VARIANT     197    197       G -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062616.
FT   VARIANT     198    198       C -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062617.
FT   VARIANT     198    198       C -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062618.
FT   VARIANT     218    218       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062619.
FT   VARIANT     222    222       D -> N (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009167.
FT   VARIANT     224    224       V -> E (in HPE3).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009168.
FT   VARIANT     226    226       A -> T (in HPE3; familial).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009169.
FT   VARIANT     231    231       G -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062620.
FT   VARIANT     232    232       R -> G (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062621.
FT   VARIANT     234    234       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062622.
FT   VARIANT     236    236       S -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062623.
FT   VARIANT     236    236       S -> R (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009170.
FT   VARIANT     241    241       F -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062624.
FT   VARIANT     241    241       F -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062625.
FT   VARIANT     255    255       I -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062626.
FT   VARIANT     263    269       Missing (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009171.
FT   VARIANT     267    267       T -> I (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039893.
FT   VARIANT     271    271       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023809.
FT   VARIANT     275    275       A -> E (in HPE3; dbSNP:rs556192490).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062627.
FT   VARIANT     280    280       S -> W (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062628.
FT   VARIANT     290    290       G -> D (in HPE3; sporadic;
FT                                dbSNP:rs104894047).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009172.
FT   VARIANT     296    296       G -> A (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062629.
FT   VARIANT     310    310       R -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062630.
FT   VARIANT     321    321       R -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062631.
FT   VARIANT     332    332       V -> A (in HPE3 and SMMCI).
FT                                {ECO:0000269|PubMed:15103725,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023810.
FT   VARIANT     346    346       A -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062632.
FT   VARIANT     347    347       P -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062633.
FT   VARIANT     347    347       P -> Q (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023811.
FT   VARIANT     347    347       P -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062634.
FT   VARIANT     354    354       I -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023812.
FT   VARIANT     362    362       S -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062635.
FT   VARIANT     363    363       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062636.
FT   VARIANT     364    364       Y -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062637.
FT   VARIANT     373    373       A -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039894.
FT   VARIANT     374    374       H -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062638.
FT   VARIANT     376    376       A -> D (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062639.
FT   VARIANT     377    377       F -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062640.
FT   VARIANT     378    380       Missing (in HPE3; familial).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009173.
FT   VARIANT     381    381       R -> P (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023813.
FT   VARIANT     382    382       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062641.
FT   VARIANT     383    383       A -> T (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009174.
FT   VARIANT     391    391       A -> T (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062642.
FT   VARIANT     401    408       Missing (in ocular coloboma).
FT                                {ECO:0000269|PubMed:12503095}.
FT                                /FTId=VAR_017884.
FT   VARIANT     402    409       Missing (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062643.
FT   VARIANT     404    408       Missing (in HPE3; familial).
FT                                /FTId=VAR_009175.
FT   VARIANT     405    409       Missing (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062644.
FT   VARIANT     411    411       G -> GG (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062645.
FT   VARIANT     416    416       T -> A (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062646.
FT   VARIANT     424    424       P -> A (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009176.
FT   VARIANT     435    435       Y -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062647.
FT   VARIANT     436    436       S -> L (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009177.
FT   VARIANT     456    456       G -> R (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062648.
FT   MUTAGEN      24     24       C->S: Abolishes palmitoylation.
FT                                {ECO:0000269|PubMed:9593755}.
FT   STRAND       30     32       {ECO:0000244|PDB:3M1N}.
FT   STRAND       47     51       {ECO:0000244|PDB:3MXW}.
FT   TURN         56     59       {ECO:0000244|PDB:3MXW}.
FT   HELIX        72     75       {ECO:0000244|PDB:3MXW}.
FT   STRAND       84     86       {ECO:0000244|PDB:3MXW}.
FT   STRAND       91     93       {ECO:0000244|PDB:3MXW}.
FT   HELIX        94     96       {ECO:0000244|PDB:3MXW}.
FT   HELIX       100    116       {ECO:0000244|PDB:3MXW}.
FT   STRAND      122    128       {ECO:0000244|PDB:3MXW}.
FT   HELIX       139    142       {ECO:0000244|PDB:3MXW}.
FT   STRAND      145    150       {ECO:0000244|PDB:3MXW}.
FT   HELIX       155    157       {ECO:0000244|PDB:3MXW}.
FT   HELIX       158    167       {ECO:0000244|PDB:3MXW}.
FT   STRAND      171    177       {ECO:0000244|PDB:3MXW}.
FT   STRAND      180    184       {ECO:0000244|PDB:3MXW}.
FT   HELIX       188    190       {ECO:0000244|PDB:3MXW}.
SQ   SEQUENCE   462 AA;  49607 MW;  DD687AFA582A4749 CRC64;
     MLLLARCLLL VLVSSLLVCS GLACGPGRGF GKRRHPKKLT PLAYKQFIPN VAEKTLGASG
     RYEGKISRNS ERFKELTPNY NPDIIFKDEE NTGADRLMTQ RCKDKLNALA ISVMNQWPGV
     KLRVTEGWDE DGHHSEESLH YEGRAVDITT SDRDRSKYGM LARLAVEAGF DWVYYESKAH
     IHCSVKAENS VAAKSGGCFP GSATVHLEQG GTKLVKDLSP GDRVLAADDQ GRLLYSDFLT
     FLDRDDGAKK VFYVIETREP RERLLLTAAH LLFVAPHNDS ATGEPEASSG SGPPSGGALG
     PRALFASRVR PGQRVYVVAE RDGDRRLLPA AVHSVTLSEE AAGAYAPLTA QGTILINRVL
     ASCYAVIEEH SWAHRAFAPF RLAHALLAAL APARTDRGGD SGGGDRGGGG GRVALTAPGA
     ADAPGAGATA GIHWYSQLLY QIGTWLLDSE ALHPLGMAVK SS
//
ID   CO1A1_HUMAN             Reviewed;        1464 AA.
AC   P02452; O76045; P78441; Q13896; Q13902; Q13903; Q14037; Q14992;
AC   Q15176; Q15201; Q16050; Q59F64; Q7KZ30; Q7KZ34; Q8IVI5; Q8N473;
AC   Q9UML6; Q9UMM7;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 5.
DT   17-FEB-2016, entry version 204.
DE   RecName: Full=Collagen alpha-1(I) chain;
DE   AltName: Full=Alpha-1 type I collagen;
DE   Flags: Precursor;
GN   Name=COL1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ALA-1019; ALA-1075; LYS-1391
RP   AND SER-1434.
RA   Dalgleish R.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-1075 AND LYS-1391.
RX   PubMed=9443882; DOI=10.1086/301689;
RA   Korkko J.M., Ala-Kokko L., De Paepe A., Nuytinck L., Earley J.J.,
RA   Prockop D.J.;
RT   "Analysis of the COL1A1 and COL1A2 genes by PCR amplification and
RT   scanning by conformation-sensitive gel electrophoresis identifies only
RT   COL1A1 mutations in 15 patients with osteogenesis imperfecta type I:
RT   identification of common sequences of null-allele mutations.";
RL   Am. J. Hum. Genet. 62:98-110(1998).
RN   [3]
RP   SEQUENCE REVISION TO 1049.
RA   Korkko J.M., Earley J.J., Nuytinck L., DePaepe A., Prockop D.J.,
RA   Ala-Kokko L.;
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-1075.
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ALA-1075;
RP   ARG-1438 AND HIS-1460.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-589.
RX   PubMed=2843432; DOI=10.1016/0378-1119(88)90013-3;
RA   D'Alessio M., Bernard M.P., Pretorius P.J., de Wet W., Ramirez F.,
RA   Pretorious P.J.;
RT   "Complete nucleotide sequence of the region encompassing the first
RT   twenty-five exons of the human pro alpha 1(I) collagen gene
RT   (COL1A1).";
RL   Gene 67:105-115(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-472.
RX   PubMed=3178743;
RA   Tromp G., Kuivaniemi H., Stacey A., Shikata H., Baldwin C.T.,
RA   Jaenisch R., Prockup D.J.;
RT   "Structure of a full-length cDNA clone for the prepro alpha 1(I) chain
RT   of human type I procollagen.";
RL   Biochem. J. 253:919-922(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-181.
RX   PubMed=6462220; DOI=10.1038/310337a0;
RA   Chu M.-L., de Wet W.J., Bernard M.P., Ding J.-F., Morabito M.,
RA   Myers J., Williams C., Ramirez F.;
RT   "Human pro alpha 1(I) collagen gene structure reveals evolutionary
RT   conservation of a pattern of introns and exons.";
RL   Nature 310:337-340(1984).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-44.
RX   PubMed=2822714;
RA   Rossouw C.M.S., Vergeer W.P., du Plooy S.J., Bernard M.P., Ramirez F.,
RA   de Wet W.;
RT   "DNA sequences in the first intron of the human pro-alpha 1(I)
RT   collagen gene enhance transcription.";
RL   J. Biol. Chem. 262:15151-15157(1987).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-34.
RX   PubMed=2857713;
RA   Chu M.-L., de Wet W., Bernard M.P., Ramirez F.;
RT   "Fine structural analysis of the human pro-alpha 1 (I) collagen gene.
RT   Promoter structure, AluI repeats, and polymorphic transcripts.";
RL   J. Biol. Chem. 260:2315-2320(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-34.
RX   PubMed=3480516; DOI=10.1073/pnas.84.24.8869;
RA   Bornstein P., McKay J., Morishima J.K., Devarayalu S., Gelinas R.E.;
RT   "Regulatory elements in the first intron contribute to transcriptional
RT   control of the human alpha 1(I) collagen gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8869-8873(1987).
RN   [12]
RP   PROTEIN SEQUENCE OF 33-52.
RX   PubMed=2318855;
RA   Wirtz M.K., Keene D.R., Hori H., Glanville R.W., Steinmann B.,
RA   Rao V.H., Hollister D.W.;
RT   "In vivo and in vitro noncovalent association of excised alpha 1 (I)
RT   amino-terminal propeptides with mutant pN alpha 2(I) collagen chains
RT   in native mutant collagen in a case of Ehlers-Danlos syndrome, type
RT   VII.";
RL   J. Biol. Chem. 265:6312-6317(1990).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 156-183.
RX   PubMed=2767050;
RA   Weil D., D'Alessio M., Ramirez F., de Wet W., Cole W.G., Chan D.,
RA   Bateman J.F.;
RT   "A base substitution in the exon of a collagen gene causes alternative
RT   splicing and generates a structurally abnormal polypeptide in a
RT   patient with Ehlers-Danlos syndrome type VII.";
RL   EMBO J. 8:1705-1710(1989).
RN   [14]
RP   PROTEIN SEQUENCE OF 162-301, ALLYSINE AT LYS-170, AND PYROGLUTAMATE
RP   FORMATION AT GLN-162.
RC   TISSUE=Skin;
RX   PubMed=5529814; DOI=10.1021/bi00826a012;
RA   Click E.M., Bornstein P.;
RT   "Isolation and characterization of the cyanogen bromide peptides from
RT   the alpha 1 and alpha 2 chains of human skin collagen.";
RL   Biochemistry 9:4699-4706(1970).
RN   [15]
RP   PROTEIN SEQUENCE OF 175-187 AND 274-289.
RX   PubMed=2169412; DOI=10.1111/j.1432-1033.1990.tb19208.x;
RA   Baetge B., Notbohm H., Diebold J., Lehmann H., Bodo M., Deutzmann R.,
RA   Muller P.K.;
RT   "A critical crosslink region in human-bone-derived collagen type I.
RT   Specific cleavage site at residue Leu95.";
RL   Eur. J. Biochem. 192:153-159(1990).
RN   [16]
RP   PROTEIN SEQUENCE OF 263-268, HYDROXYLATION AT LYS-265, AND
RP   GLYCOSYLATION AT LYS-265.
RC   TISSUE=Skin;
RX   PubMed=4319110;
RA   Morgan P.H., Jacobs H.G., Segrest J.P., Cunningham L.W.;
RT   "A comparative study of glycopeptides derived from selected vertebrate
RT   collagens. A possible role of the carbohydrate in fibril formation.";
RL   J. Biol. Chem. 245:5042-5048(1970).
RN   [17]
RP   NUCLEOTIDE SEQUENCE OF 281-302; 402-420; 823-842; 924-944; 1026-1045
RP   AND 1143-1162.
RX   PubMed=2374517;
RA   Labhard M.E., Hollister D.W.;
RT   "Segmental amplification of the entire helical and telopeptide regions
RT   of the cDNA for human alpha 1 (I) collagen.";
RL   Matrix 10:124-130(1990).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 425-1464, AND VARIANTS ALA-1019 AND
RP   ALA-1075.
RX   PubMed=6689127; DOI=10.1021/bi00291a023;
RA   Bernard M.P., Chu M.-L., Myers J.C., Ramirez F., Eikenberry E.F.,
RA   Prockop D.J.;
RT   "Nucleotide sequences of complementary deoxyribonucleic acids for the
RT   pro alpha 1 chain of human type I procollagen. Statistical evaluation
RT   of structures that are conserved during evolution.";
RL   Biochemistry 22:5213-5223(1983).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 425-490; 965-1024; 999-1039 AND
RP   1453-1464.
RX   PubMed=6183642; DOI=10.1093/nar/10.19.5925;
RA   Chu M.-L., Myers J.C., Bernard M.P., Ding J.-F., Ramirez F.;
RT   "Cloning and characterization of five overlapping cDNAs specific for
RT   the human pro alpha 1(I) collagen chain.";
RL   Nucleic Acids Res. 10:5925-5934(1982).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 472-607.
RX   PubMed=2981843;
RA   Chu M.-L., Gargiulo V., Williams C.J., Ramirez F.;
RT   "Multiexon deletion in an osteogenesis imperfecta variant with
RT   increased type III collagen mRNA.";
RL   J. Biol. Chem. 260:691-694(1985).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 488-625.
RX   PubMed=3857621; DOI=10.1073/pnas.82.9.2870;
RA   Barsh G.S., Roush C.L., Bonadio J., Byers P.H., Gelinas R.E.;
RT   "Intron-mediated recombination may cause a deletion in an alpha 1 type
RT   I collagen chain in a lethal form of osteogenesis imperfecta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2870-2874(1985).
RN   [22]
RP   NUCLEOTIDE SEQUENCE OF 710-745, AND VARIANT OI2 ARG-728.
RX   PubMed=2339700;
RA   Wallis G.A., Starman B.J., Zinn A.B., Byers P.H.;
RT   "Variable expression of osteogenesis imperfecta in a nuclear family is
RT   explained by somatic mosaicism for a lethal point mutation in the
RT   alpha 1(I) gene (COL1A1) of type I collagen in a parent.";
RL   Am. J. Hum. Genet. 46:1034-1040(1990).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 746-781, AND VARIANT OI3 SER-767.
RX   PubMed=7881420; DOI=10.1093/hmg/3.12.2201;
RA   Forlino A., Zolezzi F., Valli M., Pignatti P.F., Cetta G.,
RA   Brunelli P.C., Mottes M.;
RT   "Severe (type III) osteogenesis imperfecta due to glycine
RT   substitutions in the central domain of the collagen triple helix.";
RL   Hum. Mol. Genet. 3:2201-2206(1994).
RN   [24]
RP   PROTEIN SEQUENCE OF 1063-1084, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND VARIANT ALA-1075.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1179-1464, VARIANTS OI2 HIS-1277;
RP   ARG-1388 AND 1337-GLU-TYR-1338 DEL, AND VARIANTS THR-1251 AND
RP   SER-1434.
RX   PubMed=8349697;
RA   Chessler S.D., Wallis G.A., Byers P.H.;
RT   "Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I)
RT   chain of type I collagen result in defective chain association and
RT   produce lethal osteogenesis imperfecta.";
RL   J. Biol. Chem. 268:18218-18225(1993).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1187-1220, AND VARIANT CYS-1195.
RX   PubMed=3170557;
RA   Cohn D.H., Apone S., Eyre D.R., Starman B.J., Andreassen P.,
RA   Charbonneau H., Nicholls A.C., Pope F.M., Byers P.H.;
RT   "Substitution of cysteine for glycine within the carboxyl-terminal
RT   telopeptide of the alpha 1 chain of type I collagen produces mild
RT   osteogenesis imperfecta.";
RL   J. Biol. Chem. 263:14605-14607(1988).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1229-1454, AND VARIANT LYS-1391.
RC   TISSUE=Bone;
RX   PubMed=3340531; DOI=10.1093/nar/16.1.349;
RA   Maekelae J.K., Raassina M., Virta A., Vuorio E.;
RT   "Human pro alpha 1(I) collagen: cDNA sequence for the C-propeptide
RT   domain.";
RL   Nucleic Acids Res. 16:349-349(1988).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1440-1464.
RX   PubMed=2295701; DOI=10.1172/JCI114424;
RA   Willing M.C., Cohn D.H., Byers P.H.;
RT   "Frameshift mutation near the 3' end of the COL1A1 gene of type I
RT   collagen predicts an elongated Pro alpha 1(I) chain and results in
RT   osteogenesis imperfecta type I.";
RL   J. Clin. Invest. 85:282-290(1990).
RN   [29]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1454-1464, AND VARIANT ALA-1075.
RX   PubMed=1995349; DOI=10.1016/0014-5793(91)80237-W;
RA   Maatta A., Bornstein P., Penttinen R.P.;
RT   "Highly conserved sequences in the 3'-untranslated region of the
RT   COL1A1 gene bind cell-specific nuclear proteins.";
RL   FEBS Lett. 279:9-13(1991).
RN   [30]
RP   REVIEW ON VARIANTS.
RX   PubMed=2010058;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in collagen genes: causes of rare and some common diseases
RT   in humans.";
RL   FASEB J. 5:2052-2060(1991).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=9101290;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9;
RA   Kuivaniemi H., Tromp G., Prockop D.J.;
RT   "Mutations in fibrillar collagens (types I, II, III, and XI), fibril-
RT   associated collagen (type IX), and network-forming collagen (type X)
RT   cause a spectrum of diseases of bone, cartilage, and blood vessels.";
RL   Hum. Mutat. 9:300-315(1997).
RN   [32]
RP   REVIEW ON VARIANTS.
RX   PubMed=1895312; DOI=10.1136/jmg.28.7.433;
RA   Byers P.H., Wallis G.A., Willing M.C.;
RT   "Osteogenesis imperfecta: translation of mutation to phenotype.";
RL   J. Med. Genet. 28:433-442(1991).
RN   [33]
RP   INTERACTION WITH TRAM2.
RX   PubMed=14749390; DOI=10.1128/MCB.24.4.1758-1768.2004;
RA   Stefanovic B., Stefanovic L., Schnabl B., Bataller R., Brenner D.A.;
RT   "TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b
RT   and is necessary for collagen type I synthesis.";
RL   Mol. Cell. Biol. 24:1758-1768(2004).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   VARIANT OI2 CYS-1166.
RX   PubMed=3016737; DOI=10.1073/pnas.83.16.6045;
RA   Cohn D.H., Byers P.H., Steinmann B., Gelinas R.E.;
RT   "Lethal osteogenesis imperfecta resulting from a single nucleotide
RT   change in one human pro alpha 1(I) collagen allele.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6045-6047(1986).
RN   [37]
RP   VARIANT OI2 ARG-569.
RX   PubMed=3108247;
RA   Bateman J.F., Chan D., Walkers I.D., Rogers J.G., Cole W.G.;
RT   "Lethal perinatal osteogenesis imperfecta due to the substitution of
RT   arginine for glycine at residue 391 of the alpha 1(I) chain of type I
RT   collagen.";
RL   J. Biol. Chem. 262:7021-7027(1987).
RN   [38]
RP   VARIANT OI2 CYS-926.
RX   PubMed=3667599;
RA   Vogel B.E., Minor R.R., Freund M., Prockop D.J.;
RT   "A point mutation in a type I procollagen gene converts glycine 748 of
RT   the alpha 1 chain to cysteine and destabilizes the triple helix in a
RT   lethal variant of osteogenesis imperfecta.";
RL   J. Biol. Chem. 262:14737-14744(1987).
RN   [39]
RP   VARIANT OI2 ARG-842.
RX   PubMed=3403550;
RA   Bateman J.F., Lamande S.R., Dahl H.-H.M., Chan D., Cole W.G.;
RT   "Substitution of arginine for glycine 664 in the collagen alpha 1(I)
RT   chain in lethal perinatal osteogenesis imperfecta. Demonstration of
RT   the peptide defect by in vitro expression of the mutant cDNA.";
RL   J. Biol. Chem. 263:11627-11630(1988).
RN   [40]
RP   VARIANT OI1 CYS-1195.
RX   PubMed=3244312;
RA   Labhard M.E., Wirtz M.K., Pope F.M., Nicholls A.C., Hollister D.W.;
RT   "A cysteine for glycine substitution at position 1017 in an alpha 1(I)
RT   chain of type I collagen in a patient with mild dominantly inherited
RT   osteogenesis imperfecta.";
RL   Mol. Biol. Med. 5:197-207(1988).
RN   [41]
RP   VARIANT OI2 VAL-434.
RX   PubMed=2470760;
RA   Patterson E., Smiley E., Bonadio J.;
RT   "RNA sequence analysis of a perinatal lethal osteogenesis imperfecta
RT   mutation.";
RL   J. Biol. Chem. 264:10083-10087(1989).
RN   [42]
RP   VARIANT OI4 SER-1010.
RX   PubMed=2745420;
RA   Marini J.C., Grange D.K., Gottesman G.S., Lewis M.B., Koeplin D.A.;
RT   "Osteogenesis imperfecta type IV. Detection of a point mutation in one
RT   alpha 1(I) collagen allele (COL1A1) by RNA/RNA hybrid analysis.";
RL   J. Biol. Chem. 264:11893-11900(1989).
RN   [43]
RP   VARIANTS OI2 ALA-1106; VAL-1151; ARG-1154 AND VAL-1184.
RX   PubMed=2777764;
RA   Lamande S.R., Dahl H.-H.M., Cole W.G., Bateman J.F.;
RT   "Characterization of point mutations in the collagen COL1A1 and COL1A2
RT   genes causing lethal perinatal osteogenesis imperfecta.";
RL   J. Biol. Chem. 264:15809-15812(1989).
RN   [44]
RP   VARIANT OI3 SER-1022.
RX   PubMed=2511192;
RA   Pack M., Constantinou C.D., Kalia K., Nielsen K.B., Prockop D.J.;
RT   "Substitution of serine for alpha 1(I)-glycine 844 in a severe variant
RT   of osteogenesis imperfecta minimally destabilizes the triple helix of
RT   type I procollagen. The effects of glycine substitutions on thermal
RT   stability are either position of amino acid specific.";
RL   J. Biol. Chem. 264:19694-19699(1989).
RN   [45]
RP   VARIANT OI2 CYS-1082.
RX   PubMed=2913053; DOI=10.1172/JCI113920;
RA   Constantinou C.D., Nielsen K.B., Prockop D.J.;
RT   "A lethal variant of osteogenesis imperfecta has a single base
RT   mutation that substitutes cysteine for glycine 904 of the alpha 1(I)
RT   chain of type I procollagen. The asymptomatic mother has an
RT   unidentified mutation producing an overmodified and unstable type I
RT   procollagen.";
RL   J. Clin. Invest. 83:574-584(1989).
RN   [46]
RP   VARIANT OI1 CYS-272, VARIANT OI3 CYS-704, AND VARIANT OI2 CYS-896.
RX   PubMed=2794057; DOI=10.1172/JCI114286;
RA   Starman B.J., Eyre D.R., Charbonneau H., Harrylock M., Weis M.A.,
RA   Weiss L., Graham J.M. Jr., Byers P.H.;
RT   "Osteogenesis imperfecta. The position of substitution for glycine by
RT   cysteine in the triple helical domain of the pro alpha 1(I) chains of
RT   type I collagen determines the clinical phenotype.";
RL   J. Clin. Invest. 84:1206-1214(1989).
RN   [47]
RP   VARIANT OI2 CYS-422.
RA   Fertala A., Westerhausen A., Morris G.M., Rooney J.E., Prockop D.J.;
RT   "Two cysteine substitutions in the type I procollagen genes (COL1A1
RT   and COL1A2) that cause lethal osteogenesis imperfecta. The location of
RT   glycine substitutions does not in any simple way predict their effects
RT   on protein function or phenotype.";
RL   Am. J. Hum. Genet. 47:A216-A216(1990).
RN   [48]
RP   VARIANTS OI2 SER-776 AND SER-809.
RX   PubMed=2116413;
RA   Westerhausen A., Kishi J., Prockop D.J.;
RT   "Mutations that substitute serine for glycine alpha 1-598 and glycine
RT   alpha 1-631 in type I procollagen. The effects on thermal unfolding of
RT   the triple helix are position-specific and demonstrate that the
RT   protein unfolds through a series of cooperative blocks.";
RL   J. Biol. Chem. 265:13995-14000(1990).
RN   [49]
RP   VARIANT OI2 ARG-1025.
RX   PubMed=2211725;
RA   Wallis G.A., Starman B.J., Schwartz M.F., Byers P.H.;
RT   "Substitution of arginine for glycine at position 847 in the triple-
RT   helical domain of the alpha 1 (I) chain of type I collagen produces
RT   lethal osteogenesis imperfecta. Molecules that contain one or two
RT   abnormal chains differ in stability and secretion.";
RL   J. Biol. Chem. 265:18628-18633(1990).
RN   [50]
RP   VARIANTS OI2 SER-1091; SER-1181; SER-1187 AND VAL-1187.
RA   Cohn D.H., Wallis G.A., Zhang X., Byers P.H.;
RT   "Serine for glycine substitutions in the alpha1(I) chain of type I
RT   collagen: biological plasticity in the Gly-Pro-Hyp clamp at the
RT   carboxyl-terminal end of triple helicalH domain.";
RL   Matrix 10:236-236(1990).
RN   [51]
RP   VARIANT OI2 ASP-719.
RX   PubMed=2035536;
RA   Zhuang J., Constantinou C.D., Ganguly A., Prockop D.J.;
RT   "A single base mutation in type I procollagen (COL1A1) that converts
RT   glycine alpha 1-541 to aspartate in a lethal variant of osteogenesis
RT   imperfecta: detection of the mutation with a carbodiimide reaction of
RT   DNA heteroduplexes and direct sequencing of products of the PCR.";
RL   Am. J. Hum. Genet. 48:1186-1191(1991).
RN   [52]
RP   VARIANT OI2 CYS-869.
RX   PubMed=1953667;
RA   Steinmann B., Westerhausen A., Constantinou C.D., Superti-Furga A.,
RA   Prockop D.J.;
RT   "Substitution of cysteine for glycine-alpha 1-691 in the pro alpha
RT   1(I) chain of type I procollagen in a proband with lethal osteogenesis
RT   imperfecta destabilizes the triple helix at a site C-terminal to the
RT   substitution.";
RL   Biochem. J. 279:747-752(1991).
RN   [53]
RP   VARIANT OI2 CYS-926.
RX   PubMed=2036375; DOI=10.1021/bi00234a035;
RA   Kadler K.E., Torre-Blanco A., Adachi E., Vogel B.E., Hojima Y.,
RA   Prockop D.J.;
RT   "A type I collagen with substitution of a cysteine for glycine-748 in
RT   the alpha 1(I) chain copolymerizes with normal type I collagen and can
RT   generate fractallike structures.";
RL   Biochemistry 30:5081-5088(1991).
RN   [54]
RP   VARIANT OI3 ARG-332, AND VARIANT OI2 SER-1181.
RX   PubMed=2037280; DOI=10.1007/BF01213088;
RA   Pruchno C.J., Cohn D.H., Wallis G.A., Willing M.C., Starman B.J.,
RA   Zhang X., Byers P.H.;
RT   "Osteogenesis imperfecta due to recurrent point mutations at CpG
RT   dinucleotides in the COL1A1 gene of type I collagen.";
RL   Hum. Genet. 87:33-40(1991).
RN   [55]
RP   VARIANT OI4 CYS-356.
RX   PubMed=1988452;
RA   Valli M., Mottes M., Tenni R., Sangalli A., Gomez Lira M., Rossi A.,
RA   Antoniazzi F., Cetta G., Pignatti P.F.;
RT   "A de novo G to T transversion in a pro-alpha 1 (I) collagen gene for
RT   a moderate case of osteogenesis imperfecta. Substitution of cysteine
RT   for glycine 178 in the triple helical domain.";
RL   J. Biol. Chem. 266:1872-1878(1991).
RN   [56]
RP   VARIANT OI2 VAL-815.
RX   PubMed=1874719;
RA   Tsuneyoshi T., Westerhausen A., Constantinou C.D., Prockop D.J.;
RT   "Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of type
RT   I procollagen in lethal osteogenesis imperfecta. The conformational
RT   strain on the triple helix introduced by a glycine substitution can be
RT   transmitted along the helix.";
RL   J. Biol. Chem. 266:15608-15613(1991).
RN   [57]
RP   VARIANT OI1 ARG-263.
RX   PubMed=1718984;
RA   Deak S.B., Scholz P.M., Amenta P.S., Constantinou C.D.,
RA   Levi-Minzi S.A., Gonzalez-Lavin L., MacKenzie J.W.;
RT   "The substitution of arginine for glycine 85 of the alpha 1(I)
RT   procollagen chain results in mild osteogenesis imperfecta. The
RT   mutation provides direct evidence for three discrete domains of
RT   cooperative melting of intact type I collagen.";
RL   J. Biol. Chem. 266:21827-21832(1991).
RN   [58]
RP   VARIANT OI2 1046-GLY--PRO-1048 DEL.
RX   PubMed=1939261;
RA   Hawkins J.R., Superti-Furga A., Steinmann B., Dalgleish R.;
RT   "A 9-base pair deletion in COL1A1 in a lethal variant of osteogenesis
RT   imperfecta.";
RL   J. Biol. Chem. 266:22370-22374(1991).
RN   [59]
RP   VARIANT OI3 CYS-593, AND VARIANT OI4 CYS-593.
RX   PubMed=1770532; DOI=10.1136/jmg.28.11.757;
RA   Nicholls A.C., Oliver J.E., Renouf D.V., Keston M., Pope F.M.;
RT   "Substitution of cysteine for glycine at residue 415 of one allele of
RT   the alpha 1(I) chain of type I procollagen in type III/IV osteogenesis
RT   imperfecta.";
RL   J. Med. Genet. 28:757-764(1991).
RN   [60]
RP   VARIANT ALA-1075.
RX   PubMed=1870989; DOI=10.1093/nar/19.15.4302;
RA   Sokolov B.P., Constantinou C.D., Tsuneyoshi T., Zhuang J.,
RA   Prockop D.J.;
RT   "G to A polymorphism in exon 45 of the COL1A1 gene.";
RL   Nucleic Acids Res. 19:4302-4302(1991).
RN   [61]
RP   VARIANT OI1 SER-1079.
RX   PubMed=1634225; DOI=10.1007/BF00219169;
RA   Mottes M., Sangalli A., Valli M., Gomez Lira M., Tenni R.,
RA   Buttitta P., Pignatti P.F., Cetta G.;
RT   "Mild dominant osteogenesis imperfecta with intrafamilial variability:
RT   the cause is a serine for glycine alpha 1(I) 901 substitution in a
RT   type-I collagen gene.";
RL   Hum. Genet. 89:480-484(1992).
RN   [62]
RP   VARIANT OI2 VAL-980.
RX   PubMed=1511982; DOI=10.1007/BF00221955;
RA   Bonaventure J., Cohen-Solal L., Lasselin C., Maroteaux P.;
RT   "A dominant mutation in the COL1A1 gene that substitutes glycine for
RT   valine causes recurrent lethal osteogenesis imperfecta.";
RL   Hum. Genet. 89:640-646(1992).
RN   [63]
RP   VARIANT OI2 1046-GLY--PRO-1048 DEL.
RX   PubMed=1460047;
RA   Wallis G.A., Kadler K.E., Starman B.J., Byers P.H.;
RT   "A tripeptide deletion in the triple-helical domain of the pro alpha
RT   1(I) chain of type I procollagen in a patient with lethal osteogenesis
RT   imperfecta does not alter cleavage of the molecule by N-proteinase.";
RL   J. Biol. Chem. 267:25529-25534(1992).
RN   [64]
RP   VARIANT OI1 CYS-221.
RX   PubMed=1737847; DOI=10.1172/JCI115622;
RA   Shapiro J.R., Stover M.L., Burn V.E., McKinstry M.B., Burshell A.L.,
RA   Chipman S.D., Rowe D.W.;
RT   "An osteopenic nonfracture syndrome with features of mild osteogenesis
RT   imperfecta associated with the substitution of a cysteine for glycine
RT   at triple helix position 43 in the pro alpha 1(I) chain of type I
RT   collagen.";
RL   J. Clin. Invest. 89:567-573(1992).
RN   [65]
RP   VARIANTS OI2 VAL-434; VAL-1151 AND VAL-1184.
RX   PubMed=1613761; DOI=10.1136/jmg.29.2.112;
RA   Cole W.G., Patterson E., Bonadio J., Campbell P.E., Fortune D.W.;
RT   "The clinicopathological features of three babies with osteogenesis
RT   imperfecta resulting from the substitution of glycine by valine in the
RT   pro alpha 1 (I) chain of type I procollagen.";
RL   J. Med. Genet. 29:112-118(1992).
RN   [66]
RP   VARIANT OI2 CYS-1312.
RX   PubMed=8456808; DOI=10.1002/ajmg.1320450216;
RA   Bateman J.F., Lamande S.R., Hannagan M., Moeller I., Dahl H.-H.M.,
RA   Cole W.G.;
RT   "Chemical cleavage method for the detection of RNA base changes:
RT   experience in the application to collagen mutations in osteogenesis
RT   imperfecta.";
RL   Am. J. Med. Genet. 45:233-240(1993).
RN   [67]
RP   VARIANT OI3 SER-530.
RX   PubMed=8456809; DOI=10.1002/ajmg.1320450217;
RA   Marini J.C., Lewis M.B., Chen K.J.;
RT   "Moderately severe osteogenesis imperfecta associated with
RT   substitutions of serine for glycine in the alpha 1(I) chain of type I
RT   collagen.";
RL   Am. J. Med. Genet. 45:241-245(1993).
RN   [68]
RP   VARIANT OI4 CYS-353.
RX   PubMed=8339541; DOI=10.3109/03008209309061961;
RA   Wirtz M.K., Rao V.H., Glanville R.W., Labhard M.E., Pretorius P.J.,
RA   de Vries W.N., de Wet W., Hollister D.W.;
RT   "A cysteine for glycine substitution at position 175 in an alpha 1 (I)
RT   chain of type I collagen produces a clinically heterogeneous form of
RT   osteogenesis imperfecta.";
RL   Connect. Tissue Res. 29:1-11(1993).
RN   [69]
RP   VARIANT OI2 ALA-1088.
RX   PubMed=7679635; DOI=10.1111/j.1432-1033.1993.tb17565.x;
RA   Valli M., Sangalli A., Rossi A., Mottes M., Forlino A., Tenni R.,
RA   Pignatti P.F., Cetta G.;
RT   "Osteogenesis imperfecta and type-I collagen mutations. A lethal
RT   variant caused by a Gly910-->Ala substitution in the alpha 1 (I)
RT   chain.";
RL   Eur. J. Biochem. 211:415-419(1993).
RN   [70]
RP   VARIANT OI1 VAL-263.
RX   PubMed=8223589; DOI=10.1111/j.1432-1033.1993.tb18220.x;
RA   Valli M., Zolezzi F., Mottes M., Antoniazzi F., Stanzial F., Tenni R.,
RA   Pignatti P.F., Cetta G.;
RT   "Gly85 to Val substitution in pro alpha 1(I) chain causes mild
RT   osteogenesis imperfecta and introduces a susceptibility to protease
RT   digestion.";
RL   Eur. J. Biochem. 217:77-82(1993).
RN   [71]
RP   VARIANT OI2 VAL-743.
RX   PubMed=8100209; DOI=10.1007/BF00217768;
RA   Mackay K., Lund A.M., Raghunath M., Steinmann B., Dalgleish R.;
RT   "SSCP detection of a Gly565Val substitution in the pro alpha 1(I)
RT   collagen chain resulting in osteogenesis imperfecta type II.";
RL   Hum. Genet. 91:439-444(1993).
RN   [72]
RP   VARIANTS OI2 SER-425 AND SER-530, VARIANT OI4 SER-560, VARIANT OI3
RP   SER-719, AND VARIANT ALA-823.
RX   PubMed=7691343; DOI=10.1093/hmg/2.8.1155;
RA   Mackay K., Byers P.H., Dalgleish R.;
RT   "An RT-PCR-SSCP screening strategy for detection of mutations in the
RT   gene encoding the alpha 1 chain of type I collagen: application to
RT   four patients with osteogenesis imperfecta.";
RL   Hum. Mol. Genet. 2:1155-1160(1993).
RN   [73]
RP   VARIANT OI2 SER-593, AND VARIANT OI3 SER-593.
RX   PubMed=8364588; DOI=10.1002/humu.1380020308;
RA   Mottes M., Gomez Lira M., Valli M., Scarano G., Lonardo F.,
RA   Forlino A., Cetta G., Pignatti P.F.;
RT   "Paternal mosaicism for a COL1A1 dominant mutation (alpha 1 Ser-415)
RT   causes recurrent osteogenesis imperfecta.";
RL   Hum. Mutat. 2:196-204(1993).
RN   [74]
RP   VARIANT OI4 SER-530.
RX   PubMed=8094076;
RA   Marini J.C., Lewis M.B., Wang Q., Chen K.J., Orrison B.M.;
RT   "Serine for glycine substitutions in type I collagen in two cases of
RT   type IV osteogenesis imperfecta (OI). Additional evidence for a
RT   regional model of OI pathophysiology.";
RL   J. Biol. Chem. 268:2667-2673(1993).
RN   [75]
RP   VARIANTS OI2.
RX   PubMed=8349698;
RA   Chessler S.D., Byers P.H.;
RT   "BiP binds type I procollagen pro alpha chains with mutations in the
RT   carboxyl-terminal propeptide synthesized by cells from patients with
RT   osteogenesis imperfecta.";
RL   J. Biol. Chem. 268:18226-18233(1993).
RN   [76]
RP   VARIANT OI2 ARG-389.
RX   PubMed=7520724; DOI=10.1016/8756-3282(94)90295-X;
RA   Sztrolovics R., Glorieux F.H., Travers R., van der Rest M.,
RA   Roughley P.J.;
RT   "Osteogenesis imperfecta: comparison of molecular defects with bone
RT   histological changes.";
RL   Bone 15:321-328(1994).
RN   [77]
RP   VARIANT OI3 ARG-350.
RX   PubMed=8019571; DOI=10.1002/humu.1380030327;
RA   Mackay K., de Paepe A., Nuytinck L., Dalgleish R.;
RT   "Substitution of glycine-172 by arginine in the alpha 1 chain of type
RT   I collagen in a patient with osteogenesis imperfecta, type III.";
RL   Hum. Mutat. 3:324-326(1994).
RN   [78]
RP   VARIANT OI2 CYS-1124.
RX   PubMed=7961597;
RA   Kurosaka D., Hattori S., Hori H., Yamaguchi N., Hasegawa T.,
RA   Akimoto H., Nagai Y.;
RT   "Substitution of cysteine for glycine-946 in the alpha 1(I) chain of
RT   type I procollagen causes lethal osteogenesis imperfecta.";
RL   J. Biochem. 115:853-857(1994).
RN   [79]
RP   VARIANT OI4 SER-1061.
RX   PubMed=7982948;
RA   Lightfoot S.J., Atkinson M.S., Murphy G., Byers P.H., Kadler K.E.;
RT   "Substitution of serine for glycine 883 in the triple helix of the pro
RT   alpha 1 (I) chain of type I procollagen produces osteogenesis
RT   imperfecta type IV and introduces a structural change in the triple
RT   helix that does not alter cleavage of the molecule by procollagen N-
RT   proteinase.";
RL   J. Biol. Chem. 269:30352-30357(1994).
RN   [80]
RP   VARIANT OI3 ARG-332.
RX   PubMed=8669434;
RX   DOI=10.1002/(SICI)1096-8628(19960111)61:2<111::AID-AJMG1>3.0.CO;2-#;
RA   Zhuang J., Tromp G., Kuivaniemi H., Castells S., Prockop D.J.;
RT   "Substitution of arginine for glycine at position 154 of the alpha 1
RT   chain of type I collagen in a variant of osteogenesis imperfecta:
RT   comparison to previous cases with the same mutation.";
RL   Am. J. Med. Genet. 61:111-116(1996).
RN   [81]
RP   VARIANT OI2 SER-839.
RX   PubMed=8786074; DOI=10.1007/BF02185764;
RA   Nuytinck L., Dalgleish R., Spotila L., Renard J.-P.,
RA   van Regemorter N., de Paepe A.;
RT   "Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I)
RT   chains of type I collagen results in different clinical and
RT   biochemical phenotypes.";
RL   Hum. Genet. 97:324-329(1996).
RN   [82]
RP   VARIANT OI3 PRO-1464.
RX   PubMed=8723681;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<318::AID-HUMU5>3.0.CO;2-4;
RA   Oliver J.E., Thompson E.M., Pope F.M., Nicholls A.C.;
RT   "Mutation in the carboxy-terminal propeptide of the Pro alpha 1(I)
RT   chain of type I collagen in a child with severe osteogenesis
RT   imperfecta (OI type III): possible implications for protein folding.";
RL   Hum. Mutat. 7:318-326(1996).
RN   [83]
RP   INVOLVEMENT IN OSTEOPOROSIS.
RX   PubMed=8841196; DOI=10.1038/ng1096-203;
RA   Grant S.F.A., Reid D.M., Blake G., Herd R., Fogelman I., Ralston S.H.;
RT   "Reduced bone density and osteoporosis associated with a polymorphic
RT   Sp1 binding site in the collagen type I alpha 1 gene.";
RL   Nat. Genet. 14:203-205(1996).
RN   [84]
RP   VARIANTS OI3 SER-821; SER-1040; SER-1049; SER-1058 AND SER-1076.
RX   PubMed=9101304;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<378::AID-HUMU16>3.3.CO;2-5;
RA   Lund A.M., Skovby F., Schwartz M.;
RT   "Serine for glycine substitutions in the C-terminal third of the alpha
RT   1(I) chain of collagen I in five patients with nonlethal osteogenesis
RT   imperfecta.";
RL   Hum. Mutat. 9:378-382(1997).
RN   [85]
RP   VARIANT OI2 VAL-764.
RX   PubMed=9143923;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:5<431::AID-HUMU9>3.0.CO;2-6;
RA   Lund A.M., Skovby F., Schwartz M.;
RT   "(G586V) substitutions in the alpha 1 and alpha 2 chains of collagen
RT   I: effect of alpha-chain stoichiometry on the phenotype of
RT   osteogenesis imperfecta?";
RL   Hum. Mutat. 9:431-436(1997).
RN   [86]
RP   VARIANTS OI4 ALA-398; CYS-527 AND CYS-701.
RX   PubMed=9600458;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<395::AID-HUMU7>3.0.CO;2-4;
RA   Sarafova A.P., Choi H., Forlino A., Gajko A., Cabral W.A., Tosi L.,
RA   Reing C.M., Marini J.C.;
RT   "Three novel type I collagen mutations in osteogenesis imperfecta type
RT   IV probands are associated with discrepancies between electrophoretic
RT   migration of osteoblast and fibroblast collagen.";
RL   Hum. Mutat. 11:395-403(1998).
RN   [87]
RP   VARIANTS OI2 SER-656 AND ASP-1172.
RX   PubMed=10627137;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<71::AID-HUMU16>3.0.CO;2-4;
RA   Mottes M., Gomez Lira M., Zolezzi F., Valli M., Lisi V., Freising P.;
RT   "Four new cases of lethal osteogenesis imperfecta due to glycine
RT   substitutions in COL1A1 and genes.";
RL   Hum. Mutat. 12:71-72(1998).
RN   [88]
RP   INVOLVEMENT IN INVOLUTIONAL OSTEOPOROSIS.
RX   PubMed=9535665; DOI=10.1056/NEJM199804093381502;
RA   Uitterlinden A.G., Burger H., Huang Q., Yue F., McGuigan F.E.A.,
RA   Grant S.F.A., Hofman A., van Leeuwen J.P.T.M., Pols H.A.P.,
RA   Ralston S.H.;
RT   "Relation of alleles of the collagen type Ialpha1 gene to bone density
RT   and the risk of osteoporotic fractures in postmenopausal women.";
RL   N. Engl. J. Med. 338:1016-1021(1998).
RN   [89]
RP   VARIANT OI3 SER-866.
RX   PubMed=10408781;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<503::AID-HUMU11>3.0.CO;2-L;
RA   Lund A.M., Astroem E., Soederhaell S., Schwartz M., Skovby F.;
RT   "Osteogenesis imperfecta: mosaicism and refinement of the genotype-
RT   phenotype map in OI type III.";
RL   Hum. Mutat. 13:503-503(1999).
RN   [90]
RP   VARIANT EDS CYS-312.
RX   PubMed=10739762; DOI=10.1086/302859;
RA   Nuytinck L., Freund M., Lagae L., Pierard G.E., Hermanns-Le T.,
RA   De Paepe A.;
RT   "Classical Ehlers-Danlos syndrome caused by a mutation in type I
RT   collagen.";
RL   Am. J. Hum. Genet. 66:1398-1402(2000).
RN   [91]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH PDGFB.
RX   PubMed=8988177; DOI=10.1038/ng0197-95;
RA   Simon M.-P., Pedeutour F., Sirvent N., Grosgeorge J., Minoletti F.,
RA   Coindre J.-M., Terrier-Lacombe M.-J., Mandahl N., Craver R.D.,
RA   Blin N., Sozzi G., Turc-Carel C., O'Brien K.P., Kedra D., Fransson I.,
RA   Guilbaud C., Dumanski J.P.;
RT   "Deregulation of the platelet-derived growth factor B-chain gene via
RT   fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans
RT   and giant-cell fibroblastoma.";
RL   Nat. Genet. 15:95-98(1997).
RN   [92]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH PDGFB.
RX   PubMed=12660034; DOI=10.1016/S0165-4608(02)00844-0;
RA   Sandberg A.A., Anderson W.D., Fredenberg C., Hashimoto H.;
RT   "Dermatofibrosarcoma protuberans of breast.";
RL   Cancer Genet. Cytogenet. 142:56-59(2003).
RN   [93]
RP   VARIANT CAFFD CYS-1014.
RX   PubMed=15864348; DOI=10.1172/JCI22760;
RA   Gensure R.C., Maekitie O., Barclay C., Chan C., Depalma S.R.,
RA   Bastepe M., Abuzahra H., Couper R., Mundlos S., Sillence D.,
RA   Ala-Kokko L., Seidman J.G., Cole W.G., Jueppner H.;
RT   "A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey
RT   disease) expands the spectrum of collagen-related disorders.";
RL   J. Clin. Invest. 115:1250-1257(2005).
RN   [94]
RP   VARIANTS OI3 VAL-203 AND SER-821, AND VARIANTS OI4 ARG-257 AND
RP   SER-683.
RX   PubMed=16879195; DOI=10.1111/j.1399-0004.2006.00646.x;
RA   Venturi G., Tedeschi E., Mottes M., Valli M., Camilot M., Viglio S.,
RA   Antoniazzi F., Tato L.;
RT   "Osteogenesis imperfecta: clinical, biochemical and molecular
RT   findings.";
RL   Clin. Genet. 70:131-139(2006).
RN   [95]
RP   VARIANTS OI1/OI3/OI4 ARG-194; ASP-242; ARG-257; SER-722; SER-767;
RP   SER-821 AND SER-1058.
RX   PubMed=16705691; DOI=10.1002/humu.9423;
RA   Lee K.S., Song H.R., Cho T.J., Kim H.J., Lee T.M., Jin H.S.,
RA   Park H.Y., Kang S., Jung S.C., Koo S.K.;
RT   "Mutational spectrum of type I collagen genes in Korean patients with
RT   osteogenesis imperfecta.";
RL   Hum. Mutat. 27:599-599(2006).
RN   [96]
RP   VARIANTS OI2 ARG-22; ARG-581; VAL-734 AND ASN-1413, VARIANTS OI4
RP   ARG-197 AND CYS-338, VARIANTS OI1 VAL-320; ARG-555; SER-647 AND
RP   GLU-1219, AND VARIANTS ALA-205; LYS-288; SER-906 AND HIS-1356.
RX   PubMed=16786509; DOI=10.1002/humu.9430;
RA   Pollitt R., McMahon R., Nunn J., Bamford R., Afifi A., Bishop N.,
RA   Dalton A.;
RT   "Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with
RT   osteogenesis imperfecta type I-IV.";
RL   Hum. Mutat. 27:716-716(2006).
RN   [97]
RP   VARIANT OI2 ASP-833.
RX   PubMed=16566045; DOI=10.1002/pd.1428;
RA   Aerts M., Van Holsbeke C., de Ravel T., Devlieger R.;
RT   "Prenatal diagnosis of type II osteogenesis imperfecta, describing a
RT   new mutation in the COL1A1 gene.";
RL   Prenat. Diagn. 26:394-394(2006).
RN   [98]
RP   VARIANT OI1 ASP-1157.
RX   PubMed=16638323;
RA   Wang Z., Xu D.L., Chen Z., Hu J.Y., Yang Z., Wang L.T.;
RT   "A new mutation in COL1A1 gene in a family with osteogenesis
RT   imperfecta.";
RL   Zhonghua Yi Xue Za Zhi 86:170-173(2006).
RN   [99]
RP   VARIANT EDS CYS-312, AND VARIANTS CYS-574 AND CYS-1093.
RX   PubMed=17211858; DOI=10.1002/humu.20455;
RA   Malfait F., Symoens S., De Backer J., Hermanns-Le T., Sakalihasan N.,
RA   Lapiere C.M., Coucke P., De Paepe A.;
RT   "Three arginine to cysteine substitutions in the pro-alpha (I)-
RT   collagen chain cause Ehlers-Danlos syndrome with a propensity to
RT   arterial rupture in early adulthood.";
RL   Hum. Mutat. 28:387-395(2007).
RN   [100]
RP   VARIANT CYS-1066.
RX   PubMed=17206620; DOI=10.1002/humu.20456;
RA   Cabral W.A., Makareeva E., Letocha A.D., Scribanu N., Fertala A.,
RA   Steplewski A., Keene D.R., Persikov A.V., Leikin S., Marini J.C.;
RT   "Y-position cysteine substitution in type I collagen (alpha1(I)
RT   R888C/p.R1066C) is associated with osteogenesis imperfecta/Ehlers-
RT   Danlos syndrome phenotype.";
RL   Hum. Mutat. 28:396-405(2007).
RN   [101]
RP   VARIANTS OI1 GLU-266 AND SER-287, AND VARIANT OI4 SER-353.
RX   PubMed=17875077; DOI=10.1111/j.1442-200X.2007.02422.x;
RA   Kataoka K., Ogura E., Hasegawa K., Inoue M., Seino Y., Morishima T.,
RA   Tanaka H.;
RT   "Mutations in type I collagen genes in Japanese osteogenesis
RT   imperfecta patients.";
RL   Pediatr. Int. 49:564-569(2007).
RN   [102]
RP   VARIANTS ALA-1075; GLN-1141 AND ILE-1177.
RX   PubMed=18272325; DOI=10.1016/j.ygeno.2007.12.008;
RA   Chan T.F., Poon A., Basu A., Addleman N.R., Chen J., Phong A.,
RA   Byers P.H., Klein T.E., Kwok P.Y.;
RT   "Natural variation in four human collagen genes across an ethnically
RT   diverse population.";
RL   Genomics 91:307-314(2008).
RN   [103]
RP   VARIANTS OI1 VAL-200 AND PHE-349, VARIANT OI2 SER-866, AND VARIANT OI3
RP   SER-1040.
RX   PubMed=18670065; DOI=10.1007/BF03195625;
RA   Witecka J., Augusciak-Duma A.M., Kruczek A., Szydlo A., Lesiak M.,
RA   Krzak M., Pietrzyk J.J., Mannikko M., Sieron A.L.;
RT   "Two novel COL1A1 mutations in patients with osteogenesis imperfecta
RT   (OI) affect the stability of the collagen type I triple-helix.";
RL   J. Appl. Genet. 49:283-295(2008).
RN   [104]
RP   VARIANTS OI2 THR-146; VAL-288; ASP-353; VAL-368; THR-390; SER-425;
RP   ASP-455; VAL-470; VAL-509; ALA-548; ARG-602; ASP-605; ARG-614;
RP   ARG-740; SER-809; ARG-824; ARG-845; ARG-848; HIS-855; SER-866;
RP   SER-875; SER-884; ASP-896; CYS-947; ASP-977; CYS-1001; VAL-1022;
RP   ALA-PRO-GLY-1052 INS; ASP-1055; SER-1094; ASP-1100 AND ASN-1413, AND
RP   VARIANT ALA-1075.
RX   PubMed=18996919; DOI=10.1093/hmg/ddn374;
RA   Bodian D.L., Chan T.F., Poon A., Schwarze U., Yang K., Byers P.H.,
RA   Kwok P.Y., Klein T.E.;
RT   "Mutation and polymorphism spectrum in osteogenesis imperfecta type
RT   II: implications for genotype-phenotype relationships.";
RL   Hum. Mol. Genet. 18:463-471(2009).
RN   [105]
RP   VARIANT ASN-1219, AND CHARACTERIZATION OF VARIANT ASN-1219.
RX   PubMed=21344539; DOI=10.1002/humu.21475;
RA   Lindahl K., Barnes A.M., Fratzl-Zelman N., Whyte M.P., Hefferan T.E.,
RA   Makareeva E., Brusel M., Yaszemski M.J., Rubin C.J., Kindmark A.,
RA   Roschger P., Klaushofer K., McAlister W.H., Mumm S., Leikin S.,
RA   Kessler E., Boskey A.L., Ljunggren O., Marini J.C.;
RT   "COL1 C-propeptide cleavage site mutations cause high bone mass
RT   osteogenesis imperfecta.";
RL   Hum. Mutat. 32:598-609(2011).
RN   [106]
RP   VARIANT OI1 GLU-1088.
RX   PubMed=24682174; DOI=10.3892/mmr.2014.2084;
RA   Xia X.Y., Li W.W., Li N., Wu Q.Y., Cui Y.X., Li X.J.;
RT   "A novel mild variant of osteogenesis imperfecta type I caused by a
RT   Gly1088Glu mutation in COL1A1.";
RL   Mol. Med. Report. 9:2187-2190(2014).
RN   [107]
RP   VARIANT OI2 CYS-773.
RX   PubMed=25958000; DOI=10.1186/s40246-015-0028-0;
RA   Maasalu K., Nikopensius T., Koks S., Noukas M., Kals M., Prans E.,
RA   Zhytnik L., Metspalu A., Maertson A.;
RT   "Whole-exome sequencing identifies de novo mutation in the COL1A1 gene
RT   to underlie the severe osteogenesis imperfecta.";
RL   Hum. Genomics 9:6-6(2015).
CC   -!- FUNCTION: Type I collagen is a member of group I collagen
CC       (fibrillar forming collagen).
CC   -!- SUBUNIT: Trimers of one alpha 2(I) and two alpha 1(I) chains.
CC       Interacts with MRC2 (By similarity). Interacts with TRAM2.
CC       {ECO:0000250, ECO:0000269|PubMed:14749390}.
CC   -!- INTERACTION:
CC       O01949:AAEL010235 (xeno); NbExp=5; IntAct=EBI-982999, EBI-7685554;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- TISSUE SPECIFICITY: Forms the fibrils of tendon, ligaments and
CC       bones. In bones the fibrils are mineralized with calcium
CC       hydroxyapatite.
CC   -!- DOMAIN: The C-terminal propeptide, also known as COLFI domain,
CC       have crucial roles in tissue growth and repair by controlling both
CC       the intracellular assembly of procollagen molecules and the
CC       extracellular assembly of collagen fibrils. It binds a calcium ion
CC       which is essential for its function (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Proline residues at the third position of the tripeptide
CC       repeating unit (G-X-P) are hydroxylated in some or all of the
CC       chains. Proline residues at the second position of the tripeptide
CC       repeating unit (G-P-X) are hydroxylated in some of the chains.
CC       {ECO:0000269|PubMed:4319110}.
CC   -!- PTM: O-linked glycan consists of a Glc-Gal disaccharide bound to
CC       the oxygen atom of a post-translationally added hydroxyl group.
CC       {ECO:0000269|PubMed:4319110}.
CC   -!- DISEASE: Caffey disease (CAFFD) [MIM:114000]: Characterized by an
CC       infantile episode of massive subperiosteal new bone formation that
CC       typically involves the diaphyses of the long bones, mandible, and
CC       clavicles. The involved bones may also appear inflamed, with
CC       painful swelling and systemic fever often accompanying the
CC       illness. The bone changes usually begin before 5 months of age and
CC       resolve before 2 years of age. {ECO:0000269|PubMed:15864348}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Ehlers-Danlos syndrome, classic type (EDS) [MIM:130000]:
CC       A connective tissue disorder characterized by hyperextensible
CC       skin, atrophic cutaneous scars due to tissue fragility and joint
CC       hyperlaxity. {ECO:0000269|PubMed:10739762,
CC       ECO:0000269|PubMed:17211858}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ehlers-Danlos syndrome 7A (EDS7A) [MIM:130060]: A
CC       connective tissue disorder characterized by hyperextensible skin,
CC       atrophic cutaneous scars due to tissue fragility and joint
CC       hyperlaxity. Marked by bilateral congenital hip dislocation,
CC       hyperlaxity of the joints, and recurrent partial dislocations.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 1 (OI1) [MIM:166200]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI1 is a non-deforming
CC       form with normal height or mild short stature, and no
CC       dentinogenesis imperfecta. {ECO:0000269|PubMed:1634225,
CC       ECO:0000269|PubMed:16638323, ECO:0000269|PubMed:16705691,
CC       ECO:0000269|PubMed:16786509, ECO:0000269|PubMed:1718984,
CC       ECO:0000269|PubMed:1737847, ECO:0000269|PubMed:17875077,
CC       ECO:0000269|PubMed:18670065, ECO:0000269|PubMed:24682174,
CC       ECO:0000269|PubMed:2794057, ECO:0000269|PubMed:3244312,
CC       ECO:0000269|PubMed:8223589}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 2 (OI2) [MIM:166210]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI2 is characterized
CC       by bone fragility, with many perinatal fractures, severe bowing of
CC       long bones, undermineralization, and death in the perinatal period
CC       due to respiratory insufficiency. {ECO:0000269|PubMed:10627137,
CC       ECO:0000269|PubMed:1460047, ECO:0000269|PubMed:1511982,
CC       ECO:0000269|PubMed:1613761, ECO:0000269|PubMed:16566045,
CC       ECO:0000269|PubMed:16786509, ECO:0000269|PubMed:18670065,
CC       ECO:0000269|PubMed:1874719, ECO:0000269|PubMed:18996919,
CC       ECO:0000269|PubMed:1939261, ECO:0000269|PubMed:1953667,
CC       ECO:0000269|PubMed:2035536, ECO:0000269|PubMed:2036375,
CC       ECO:0000269|PubMed:2037280, ECO:0000269|PubMed:2116413,
CC       ECO:0000269|PubMed:2211725, ECO:0000269|PubMed:2339700,
CC       ECO:0000269|PubMed:2470760, ECO:0000269|PubMed:25958000,
CC       ECO:0000269|PubMed:2777764, ECO:0000269|PubMed:2794057,
CC       ECO:0000269|PubMed:2913053, ECO:0000269|PubMed:3016737,
CC       ECO:0000269|PubMed:3108247, ECO:0000269|PubMed:3403550,
CC       ECO:0000269|PubMed:3667599, ECO:0000269|PubMed:7520724,
CC       ECO:0000269|PubMed:7679635, ECO:0000269|PubMed:7691343,
CC       ECO:0000269|PubMed:7961597, ECO:0000269|PubMed:8100209,
CC       ECO:0000269|PubMed:8349697, ECO:0000269|PubMed:8349698,
CC       ECO:0000269|PubMed:8364588, ECO:0000269|PubMed:8456808,
CC       ECO:0000269|PubMed:8786074, ECO:0000269|PubMed:9143923,
CC       ECO:0000269|Ref.47, ECO:0000269|Ref.50}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 3 (OI3) [MIM:259420]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI3 is characterized
CC       by progressively deforming bones, very short stature, a triangular
CC       face, severe scoliosis, grayish sclera and dentinogenesis
CC       imperfecta. {ECO:0000269|PubMed:10408781,
CC       ECO:0000269|PubMed:16879195, ECO:0000269|PubMed:1770532,
CC       ECO:0000269|PubMed:18670065, ECO:0000269|PubMed:2037280,
CC       ECO:0000269|PubMed:2511192, ECO:0000269|PubMed:2794057,
CC       ECO:0000269|PubMed:7691343, ECO:0000269|PubMed:7881420,
CC       ECO:0000269|PubMed:8019571, ECO:0000269|PubMed:8364588,
CC       ECO:0000269|PubMed:8456809, ECO:0000269|PubMed:8669434,
CC       ECO:0000269|PubMed:8723681, ECO:0000269|PubMed:9101304}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Osteogenesis imperfecta 4 (OI4) [MIM:166220]: An
CC       autosomal dominant form of osteogenesis imperfecta, a connective
CC       tissue disorder characterized by low bone mass, bone fragility and
CC       susceptibility to fractures after minimal trauma. Disease severity
CC       ranges from very mild forms without fractures to intrauterine
CC       fractures and perinatal lethality. Extraskeletal manifestations,
CC       which affect a variable number of patients, are dentinogenesis
CC       imperfecta, hearing loss, and blue sclerae. OI4 is characterized
CC       by moderately short stature, mild to moderate scoliosis, grayish
CC       or white sclera and dentinogenesis imperfecta.
CC       {ECO:0000269|PubMed:16786509, ECO:0000269|PubMed:16879195,
CC       ECO:0000269|PubMed:1770532, ECO:0000269|PubMed:17875077,
CC       ECO:0000269|PubMed:1988452, ECO:0000269|PubMed:2745420,
CC       ECO:0000269|PubMed:7691343, ECO:0000269|PubMed:7982948,
CC       ECO:0000269|PubMed:8094076, ECO:0000269|PubMed:8339541,
CC       ECO:0000269|PubMed:9600458}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal
CC       disorder characterized by decreased bone mass and deterioration of
CC       bone microarchitecture without alteration in the composition of
CC       bone. The result is fragile bones and an increased risk of
CC       fractures, even after minimal trauma. Osteoporosis is a chronic
CC       condition of multifactorial etiology and is usually clinically
CC       silent until a fracture occurs. {ECO:0000269|PubMed:8841196,
CC       ECO:0000269|PubMed:9535665}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving COL1A1 is found
CC       in dermatofibrosarcoma protuberans. Translocation
CC       t(17;22)(q22;q13) with PDGF.
CC   -!- SIMILARITY: Belongs to the fibrillar collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 fibrillar collagen NC1 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00793}.
CC   -!- SIMILARITY: Contains 1 VWFC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00220}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92834.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Osteogenesis imperfecta variant database;
CC       Note=Collagen type I alpha 1 (COL1A1);
CC       URL="http://oi.gene.le.ac.uk/home.php?select_db=COL1A1";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/COL1A1ID186.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Type-I collagen entry;
CC       URL="https://en.wikipedia.org/wiki/Type-I_collagen";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z74615; CAA98968.1; -; mRNA.
DR   EMBL; AF017178; AAB94054.3; -; Genomic_DNA.
DR   EMBL; AB209597; BAD92834.1; ALT_INIT; mRNA.
DR   EMBL; BC036531; AAH36531.1; -; mRNA.
DR   EMBL; M20789; AAB59373.1; -; Genomic_DNA.
DR   EMBL; M36546; AAA60150.1; -; mRNA.
DR   EMBL; X07884; CAA30731.1; -; mRNA.
DR   EMBL; X00820; CAA25394.1; -; Genomic_DNA.
DR   EMBL; J02829; AAA51993.1; -; Genomic_DNA.
DR   EMBL; M10627; AAA51992.1; -; Genomic_DNA.
DR   EMBL; J03559; AAA52052.1; -; Genomic_DNA.
DR   EMBL; K01228; AAA51995.1; -; mRNA.
DR   EMBL; J00110; AAA52289.1; -; mRNA.
DR   EMBL; J00111; AAA52290.1; -; mRNA.
DR   EMBL; J00112; AAA52291.1; -; mRNA.
DR   EMBL; J00113; AAN86574.1; -; mRNA.
DR   EMBL; K03179; AAA51847.1; -; Genomic_DNA.
DR   EMBL; M11162; AAA75386.1; -; Genomic_DNA.
DR   EMBL; L47667; AAB59576.1; -; Genomic_DNA.
DR   EMBL; S64596; AAB27856.1; -; mRNA.
DR   EMBL; M23213; AAB59363.1; -; Genomic_DNA.
DR   EMBL; X06269; CAA29605.1; -; mRNA.
DR   EMBL; M32798; AAA52049.1; -; mRNA.
DR   EMBL; M55998; AAA52036.1; -; Genomic_DNA.
DR   CCDS; CCDS11561.1; -.
DR   PIR; I60114; CGHU1S.
DR   RefSeq; NP_000079.2; NM_000088.3.
DR   UniGene; Hs.172928; -.
DR   UniGene; Hs.681002; -.
DR   PDB; 1Q7D; X-ray; 1.80 A; A/B/C=677-685.
DR   PDB; 2LLP; NMR; -; A/B/C=949-965.
DR   PDB; 3EJH; X-ray; 2.10 A; E/F=956-977.
DR   PDB; 3GXE; X-ray; 2.60 A; E/F=254-275.
DR   PDBsum; 1Q7D; -.
DR   PDBsum; 2LLP; -.
DR   PDBsum; 3EJH; -.
DR   PDBsum; 3GXE; -.
DR   ProteinModelPortal; P02452; -.
DR   SMR; P02452; 1247-1464.
DR   BioGrid; 107674; 45.
DR   DIP; DIP-36077N; -.
DR   IntAct; P02452; 18.
DR   STRING; 9606.ENSP00000225964; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   DrugBank; DB00048; Collagenase clostridium histolyticum.
DR   iPTMnet; P02452; -.
DR   PhosphoSite; P02452; -.
DR   BioMuta; COL1A1; -.
DR   DMDM; 296439504; -.
DR   DOSAC-COBS-2DPAGE; P02452; -.
DR   MaxQB; P02452; -.
DR   PaxDb; P02452; -.
DR   PRIDE; P02452; -.
DR   DNASU; 1277; -.
DR   Ensembl; ENST00000225964; ENSP00000225964; ENSG00000108821.
DR   GeneID; 1277; -.
DR   KEGG; hsa:1277; -.
DR   UCSC; uc002iqm.3; human.
DR   CTD; 1277; -.
DR   GeneCards; COL1A1; -.
DR   GeneReviews; COL1A1; -.
DR   HGNC; HGNC:2197; COL1A1.
DR   HPA; HPA008405; -.
DR   HPA; HPA011795; -.
DR   MalaCards; COL1A1; -.
DR   MIM; 114000; phenotype.
DR   MIM; 120150; gene.
DR   MIM; 130000; phenotype.
DR   MIM; 130060; phenotype.
DR   MIM; 166200; phenotype.
DR   MIM; 166210; phenotype.
DR   MIM; 166220; phenotype.
DR   MIM; 166710; phenotype.
DR   MIM; 259420; phenotype.
DR   MIM; 607907; phenotype.
DR   neXtProt; NX_P02452; -.
DR   Orphanet; 1310; Caffey disease.
DR   Orphanet; 31112; Dermatofibrosarcoma protuberans.
DR   Orphanet; 90309; Ehlers-Danlos syndrome type 1.
DR   Orphanet; 99875; Ehlers-Danlos syndrome type 7A.
DR   Orphanet; 230845; Ehlers-Danlos syndrome, vascular-like type.
DR   Orphanet; 230857; Ehlers-Danlos/osteogenesis imperfecta syndrome.
DR   Orphanet; 314029; High bone mass osteogenesis imperfecta.
DR   Orphanet; 216796; Osteogenesis imperfecta type 1.
DR   Orphanet; 216804; Osteogenesis imperfecta type 2.
DR   Orphanet; 216812; Osteogenesis imperfecta type 3.
DR   Orphanet; 216820; Osteogenesis imperfecta type 4.
DR   PharmGKB; PA35041; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P02452; -.
DR   KO; K06236; -.
DR   OrthoDB; EOG7TJ3HH; -.
DR   PhylomeDB; P02452; -.
DR   TreeFam; TF344135; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2214320; Anchoring fibril formation.
DR   Reactome; R-HSA-2243919; Crosslinking of collagen fibrils.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   ChiTaRS; COL1A1; human.
DR   EvolutionaryTrace; P02452; -.
DR   GeneWiki; Collagen,_type_I,_alpha_1; -.
DR   GenomeRNAi; 1277; -.
DR   NextBio; 5161; -.
DR   PMAP-CutDB; P02452; -.
DR   PRO; PR:P02452; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P02452; -.
DR   ExpressionAtlas; P02452; baseline and differential.
DR   Genevisible; P02452; HS.
DR   GO; GO:0005584; C:collagen type I trimer; IMP:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:MGI.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0001568; P:blood vessel development; IMP:UniProtKB.
DR   GO; GO:0060346; P:bone trabecula formation; IEA:Ensembl.
DR   GO; GO:0060351; P:cartilage development involved in endochondral bone morphogenesis; IEA:Ensembl.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1902618; P:cellular response to fluoride; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0071306; P:cellular response to vitamin E; IEA:Ensembl.
DR   GO; GO:0032964; P:collagen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0030199; P:collagen fibril organization; IMP:UniProtKB.
DR   GO; GO:0048706; P:embryonic skeletal system development; IMP:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0001957; P:intramembranous ossification; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0070208; P:protein heterotrimerization; IEA:Ensembl.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0031960; P:response to corticosteroid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IMP:UniProtKB.
DR   GO; GO:0043589; P:skin morphogenesis; IMP:UniProtKB.
DR   GO; GO:0044691; P:tooth eruption; IEA:Ensembl.
DR   GO; GO:0034505; P:tooth mineralization; IMP:UniProtKB.
DR   GO; GO:0007601; P:visual perception; IMP:UniProtKB.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR000885; Fib_collagen_C.
DR   InterPro; IPR001007; VWF_dom.
DR   Pfam; PF01410; COLFI; 1.
DR   Pfam; PF01391; Collagen; 11.
DR   Pfam; PF00093; VWC; 1.
DR   ProDom; PD002078; Fib_collagen_C; 1.
DR   SMART; SM00038; COLFI; 1.
DR   SMART; SM00214; VWC; 1.
DR   PROSITE; PS51461; NC1_FIB; 1.
DR   PROSITE; PS01208; VWFC_1; 1.
DR   PROSITE; PS50184; VWFC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Chromosomal rearrangement; Collagen;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Dwarfism; Ehlers-Danlos syndrome;
KW   Extracellular matrix; Glycoprotein; Hydroxylation; Metal-binding;
KW   Osteogenesis imperfecta; Phosphoprotein; Polymorphism;
KW   Pyrrolidone carboxylic acid; Reference proteome; Repeat; Secreted;
KW   Signal.
FT   SIGNAL        1     22
FT   PROPEP       23    161       N-terminal propeptide.
FT                                {ECO:0000269|PubMed:5529814}.
FT                                /FTId=PRO_0000005719.
FT   CHAIN       162   1218       Collagen alpha-1(I) chain.
FT                                /FTId=PRO_0000005720.
FT   PROPEP     1219   1464       C-terminal propeptide.
FT                                /FTId=PRO_0000005721.
FT   DOMAIN       38     96       VWFC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00220}.
FT   DOMAIN     1229   1464       Fibrillar collagen NC1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   REGION      162    178       Nonhelical region (N-terminal).
FT   REGION      179   1192       Triple-helical region.
FT   REGION     1193   1218       Nonhelical region (C-terminal).
FT   MOTIF       745    747       Cell attachment site. {ECO:0000255}.
FT   MOTIF      1093   1095       Cell attachment site. {ECO:0000255}.
FT   METAL      1277   1277       Calcium. {ECO:0000250}.
FT   METAL      1279   1279       Calcium. {ECO:0000250}.
FT   METAL      1280   1280       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1282   1282       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL      1285   1285       Calcium. {ECO:0000250}.
FT   SITE        161    162       Cleavage; by procollagen N-endopeptidase.
FT   SITE        953    954       Cleavage; by collagenase. {ECO:0000250}.
FT   SITE       1218   1219       Cleavage; by procollagen C-endopeptidase.
FT   MOD_RES     162    162       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:5529814}.
FT   MOD_RES     170    170       Allysine.
FT   MOD_RES     171    171       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P02454}.
FT   MOD_RES     265    265       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:4319110}.
FT   MOD_RES     271    271       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P02454}.
FT   MOD_RES     787    787       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P02454}.
FT   MOD_RES    1108   1108       5-hydroxylysine; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES    1164   1164       3-hydroxyproline. {ECO:0000250}.
FT   MOD_RES    1208   1208       Allysine. {ECO:0000250}.
FT   CARBOHYD    265    265       O-linked (Gal...); alternate.
FT                                {ECO:0000269|PubMed:4319110}.
FT   CARBOHYD   1108   1108       O-linked (Gal...); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD   1365   1365       N-linked (GlcNAc...).
FT   DISULFID   1259   1291       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1265   1265       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00793}.
FT   DISULFID   1282   1282       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00793}.
FT   DISULFID   1299   1462       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   DISULFID   1370   1415       {ECO:0000255|PROSITE-ProRule:PRU00793}.
FT   VARIANT      22     22       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063290.
FT   VARIANT     146    146       P -> T (in OI2; rare variant; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063291.
FT   VARIANT     194    194       G -> R (in OI1).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063292.
FT   VARIANT     197    197       G -> C (in dbSNP:rs8179178).
FT                                /FTId=VAR_001642.
FT   VARIANT     197    197       G -> R (in OI4).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063293.
FT   VARIANT     200    200       G -> V (in OI1; patient diagnosed with
FT                                OI1/OI4). {ECO:0000269|PubMed:18670065}.
FT                                /FTId=VAR_063294.
FT   VARIANT     203    203       G -> V (in OI3).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063295.
FT   VARIANT     205    205       P -> A (in dbSNP:rs72667032).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_001643.
FT   VARIANT     221    221       G -> C (in OI1; mild form).
FT                                {ECO:0000269|PubMed:1737847}.
FT                                /FTId=VAR_001644.
FT   VARIANT     224    224       G -> C (in OI1; mild phenotype).
FT                                /FTId=VAR_001645.
FT   VARIANT     242    242       G -> D (in OI).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063296.
FT   VARIANT     257    257       G -> R (in OI4).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063297.
FT   VARIANT     263    263       G -> R (in OI1; mild form).
FT                                {ECO:0000269|PubMed:1718984}.
FT                                /FTId=VAR_001646.
FT   VARIANT     263    263       G -> V (in OI1; mild form).
FT                                {ECO:0000269|PubMed:8223589}.
FT                                /FTId=VAR_001647.
FT   VARIANT     266    266       G -> E (in OI1).
FT                                {ECO:0000269|PubMed:17875077}.
FT                                /FTId=VAR_063298.
FT   VARIANT     272    272       G -> C (in OI1).
FT                                {ECO:0000269|PubMed:2794057}.
FT                                /FTId=VAR_001648.
FT   VARIANT     275    275       G -> D (in OI2).
FT                                /FTId=VAR_001649.
FT   VARIANT     287    287       G -> S (in OI1).
FT                                {ECO:0000269|PubMed:17875077}.
FT                                /FTId=VAR_063299.
FT   VARIANT     288    288       E -> K (in OI1; the patient also has
FT                                mutation Glu-1219; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063300.
FT   VARIANT     288    288       E -> V (in OI2; rare variant; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063301.
FT   VARIANT     312    312       R -> C (in EDS).
FT                                {ECO:0000269|PubMed:10739762,
FT                                ECO:0000269|PubMed:17211858}.
FT                                /FTId=VAR_013579.
FT   VARIANT     320    320       G -> V (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063302.
FT   VARIANT     332    332       G -> R (in OI3; mild to moderate form).
FT                                {ECO:0000269|PubMed:2037280,
FT                                ECO:0000269|PubMed:8669434}.
FT                                /FTId=VAR_001650.
FT   VARIANT     338    338       G -> C (in OI4).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063303.
FT   VARIANT     349    349       V -> F (in OI1).
FT                                {ECO:0000269|PubMed:18670065}.
FT                                /FTId=VAR_063304.
FT   VARIANT     350    350       G -> R (in OI3).
FT                                {ECO:0000269|PubMed:8019571}.
FT                                /FTId=VAR_001651.
FT   VARIANT     353    353       G -> C (in OI4).
FT                                {ECO:0000269|PubMed:8339541}.
FT                                /FTId=VAR_001652.
FT   VARIANT     353    353       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063305.
FT   VARIANT     353    353       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:17875077}.
FT                                /FTId=VAR_063306.
FT   VARIANT     356    356       G -> C (in OI4; mild form).
FT                                {ECO:0000269|PubMed:1988452}.
FT                                /FTId=VAR_001653.
FT   VARIANT     368    368       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063307.
FT   VARIANT     383    383       G -> C (in OI4).
FT                                /FTId=VAR_001654.
FT   VARIANT     389    389       G -> C (in OI; moderate form).
FT                                /FTId=VAR_001655.
FT   VARIANT     389    389       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:7520724}.
FT                                /FTId=VAR_001656.
FT   VARIANT     390    390       A -> T (in OI2; rare variant; unknown
FT                                pathological significance;
FT                                dbSNP:rs116794104).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063308.
FT   VARIANT     398    398       G -> A (in OI4).
FT                                {ECO:0000269|PubMed:9600458}.
FT                                /FTId=VAR_001657.
FT   VARIANT     398    398       G -> D (in OI2).
FT                                /FTId=VAR_001658.
FT   VARIANT     401    401       G -> C (in OI4).
FT                                /FTId=VAR_001659.
FT   VARIANT     404    404       G -> C (in OI; moderate form).
FT                                /FTId=VAR_001660.
FT   VARIANT     422    422       G -> C (in OI2). {ECO:0000269|Ref.47}.
FT                                /FTId=VAR_001661.
FT   VARIANT     425    425       G -> S (in OI2; lethal form).
FT                                {ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:7691343}.
FT                                /FTId=VAR_001662.
FT   VARIANT     434    434       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:1613761,
FT                                ECO:0000269|PubMed:2470760}.
FT                                /FTId=VAR_001663.
FT   VARIANT     455    455       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063309.
FT   VARIANT     470    470       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063310.
FT   VARIANT     476    476       G -> R (in OI2; dbSNP:rs57377812).
FT                                /FTId=VAR_001664.
FT   VARIANT     509    509       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063311.
FT   VARIANT     527    527       G -> C (in OI4).
FT                                {ECO:0000269|PubMed:9600458}.
FT                                /FTId=VAR_001665.
FT   VARIANT     530    530       G -> S (in OI2, OI3 and OI4; mild to
FT                                lethal form).
FT                                {ECO:0000269|PubMed:7691343,
FT                                ECO:0000269|PubMed:8094076,
FT                                ECO:0000269|PubMed:8456809}.
FT                                /FTId=VAR_001666.
FT   VARIANT     533    533       G -> D (in OI2).
FT                                /FTId=VAR_001667.
FT   VARIANT     548    548       G -> A (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063312.
FT   VARIANT     555    555       P -> R (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063313.
FT   VARIANT     560    560       G -> C (in OI4).
FT                                /FTId=VAR_001669.
FT   VARIANT     560    560       G -> R (in OI2).
FT                                /FTId=VAR_001670.
FT   VARIANT     560    560       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:7691343}.
FT                                /FTId=VAR_001668.
FT   VARIANT     564    564       R -> H (in dbSNP:rs1800211).
FT                                /FTId=VAR_001671.
FT   VARIANT     569    569       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:3108247}.
FT                                /FTId=VAR_001672.
FT   VARIANT     574    574       R -> C (found in a patient with isolated
FT                                osteopenia and vascular rupture; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:17211858}.
FT                                /FTId=VAR_063314.
FT   VARIANT     581    581       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063315.
FT   VARIANT     593    593       G -> C (in OI3 and OI4).
FT                                {ECO:0000269|PubMed:1770532}.
FT                                /FTId=VAR_001673.
FT   VARIANT     593    593       G -> S (in OI2 and OI3; moderate to
FT                                lethal form).
FT                                {ECO:0000269|PubMed:8364588}.
FT                                /FTId=VAR_001674.
FT   VARIANT     602    602       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063316.
FT   VARIANT     605    605       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063317.
FT   VARIANT     614    614       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063318.
FT   VARIANT     647    647       G -> S (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063319.
FT   VARIANT     656    656       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:10627137}.
FT                                /FTId=VAR_001676.
FT   VARIANT     683    683       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:16879195}.
FT                                /FTId=VAR_063320.
FT   VARIANT     701    701       G -> C (in OI4).
FT                                {ECO:0000269|PubMed:9600458}.
FT                                /FTId=VAR_001677.
FT   VARIANT     704    704       G -> C (in OI3).
FT                                {ECO:0000269|PubMed:2794057}.
FT                                /FTId=VAR_001678.
FT   VARIANT     719    719       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:2035536}.
FT                                /FTId=VAR_001679.
FT   VARIANT     719    719       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:7691343}.
FT                                /FTId=VAR_001680.
FT   VARIANT     722    722       G -> S (in OI1).
FT                                {ECO:0000269|PubMed:16705691}.
FT                                /FTId=VAR_063321.
FT   VARIANT     728    728       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:2339700}.
FT                                /FTId=VAR_001681.
FT   VARIANT     734    734       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063322.
FT   VARIANT     737    737       G -> D (in OI2).
FT                                /FTId=VAR_001682.
FT   VARIANT     740    740       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063323.
FT   VARIANT     743    743       G -> S (in OI2).
FT                                /FTId=VAR_001683.
FT   VARIANT     743    743       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:8100209}.
FT                                /FTId=VAR_001684.
FT   VARIANT     764    764       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:9143923}.
FT                                /FTId=VAR_001685.
FT   VARIANT     767    767       G -> S (in OI3; severe).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:7881420}.
FT                                /FTId=VAR_001686.
FT   VARIANT     773    773       G -> C (in OI2; de novo mutation).
FT                                {ECO:0000269|PubMed:25958000}.
FT                                /FTId=VAR_074158.
FT   VARIANT     776    776       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:2116413}.
FT                                /FTId=VAR_001687.
FT   VARIANT     809    809       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:2116413}.
FT                                /FTId=VAR_001688.
FT   VARIANT     815    815       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:1874719}.
FT                                /FTId=VAR_001689.
FT   VARIANT     821    821       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:16879195,
FT                                ECO:0000269|PubMed:9101304}.
FT                                /FTId=VAR_001690.
FT   VARIANT     823    823       P -> A (in dbSNP:rs1800214).
FT                                {ECO:0000269|PubMed:7691343}.
FT                                /FTId=VAR_001691.
FT   VARIANT     824    824       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063324.
FT   VARIANT     833    833       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:16566045}.
FT                                /FTId=VAR_063325.
FT   VARIANT     839    839       G -> S (in OI2; mild to moderate form).
FT                                {ECO:0000269|PubMed:8786074}.
FT                                /FTId=VAR_001692.
FT   VARIANT     842    842       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:3403550}.
FT                                /FTId=VAR_001693.
FT   VARIANT     845    845       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_001694.
FT   VARIANT     848    848       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063342.
FT   VARIANT     851    851       G -> D (in OI2).
FT                                /FTId=VAR_001695.
FT   VARIANT     855    855       N -> H (in OI2; rare variant; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063326.
FT   VARIANT     866    866       G -> S (in OI3 and OI2).
FT                                {ECO:0000269|PubMed:10408781,
FT                                ECO:0000269|PubMed:18670065,
FT                                ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_008118.
FT   VARIANT     869    869       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:1953667}.
FT                                /FTId=VAR_001696.
FT   VARIANT     875    875       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063327.
FT   VARIANT     884    884       G -> S (in OI2 and OI3; extremely severe
FT                                form). {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_001697.
FT   VARIANT     896    896       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:2794057}.
FT                                /FTId=VAR_001698.
FT   VARIANT     896    896       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063328.
FT   VARIANT     906    906       G -> S (found in a patient with mild
FT                                osteogenesis imperfecta; uncertain
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063329.
FT   VARIANT     926    926       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:2036375,
FT                                ECO:0000269|PubMed:3667599}.
FT                                /FTId=VAR_001699.
FT   VARIANT     947    947       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063330.
FT   VARIANT     977    977       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063331.
FT   VARIANT     980    980       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:1511982}.
FT                                /FTId=VAR_001700.
FT   VARIANT    1001   1001       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063332.
FT   VARIANT    1010   1010       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:2745420}.
FT                                /FTId=VAR_001701.
FT   VARIANT    1014   1014       R -> C (in CAFFD).
FT                                {ECO:0000269|PubMed:15864348}.
FT                                /FTId=VAR_033097.
FT   VARIANT    1019   1019       G -> A (in dbSNP:rs1135348).
FT                                {ECO:0000269|PubMed:6689127,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_030013.
FT   VARIANT    1022   1022       G -> S (in OI3; severe form).
FT                                {ECO:0000269|PubMed:2511192}.
FT                                /FTId=VAR_001702.
FT   VARIANT    1022   1022       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_001703.
FT   VARIANT    1025   1025       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:2211725}.
FT                                /FTId=VAR_001704.
FT   VARIANT    1040   1040       G -> S (in OI2 and OI3; moderate to
FT                                lethal form).
FT                                {ECO:0000269|PubMed:18670065,
FT                                ECO:0000269|PubMed:9101304}.
FT                                /FTId=VAR_001705.
FT   VARIANT    1043   1043       G -> S (in OI2).
FT                                /FTId=VAR_001706.
FT   VARIANT    1046   1048       Missing (in OI2).
FT                                {ECO:0000269|PubMed:1460047,
FT                                ECO:0000269|PubMed:1939261}.
FT                                /FTId=VAR_001707.
FT   VARIANT    1049   1049       G -> S (in OI3).
FT                                {ECO:0000269|PubMed:9101304}.
FT                                /FTId=VAR_001708.
FT   VARIANT    1052   1052       G -> GAPG (in OI2).
FT                                /FTId=VAR_063333.
FT   VARIANT    1055   1055       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063334.
FT   VARIANT    1058   1058       G -> S (in OI3 and OI4; mild form).
FT                                {ECO:0000269|PubMed:16705691,
FT                                ECO:0000269|PubMed:9101304}.
FT                                /FTId=VAR_001709.
FT   VARIANT    1061   1061       G -> D (in OI2).
FT                                /FTId=VAR_001710.
FT   VARIANT    1061   1061       G -> S (in OI4).
FT                                {ECO:0000269|PubMed:7982948}.
FT                                /FTId=VAR_001711.
FT   VARIANT    1066   1066       R -> C (probable disease-associated
FT                                mutation found in a patient with
FT                                overlapping features of osteogenesis
FT                                imperfecta and Ehlers-Danlos syndrome;
FT                                affects dimer formation, helix stability
FT                                and organization of collagen fibrils).
FT                                {ECO:0000269|PubMed:17206620}.
FT                                /FTId=VAR_063335.
FT   VARIANT    1075   1075       T -> A (in dbSNP:rs1800215).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18272325,
FT                                ECO:0000269|PubMed:1870989,
FT                                ECO:0000269|PubMed:18996919,
FT                                ECO:0000269|PubMed:1995349,
FT                                ECO:0000269|PubMed:6689127,
FT                                ECO:0000269|PubMed:9443882,
FT                                ECO:0000269|Ref.1, ECO:0000269|Ref.24,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_001712.
FT   VARIANT    1076   1076       G -> S (in OI3; severe form).
FT                                {ECO:0000269|PubMed:9101304}.
FT                                /FTId=VAR_001713.
FT   VARIANT    1079   1079       G -> S (in OI1 and OI2; mild to moderate
FT                                form). {ECO:0000269|PubMed:1634225}.
FT                                /FTId=VAR_001714.
FT   VARIANT    1082   1082       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:2913053}.
FT                                /FTId=VAR_001715.
FT   VARIANT    1088   1088       G -> A (in OI2).
FT                                {ECO:0000269|PubMed:7679635}.
FT                                /FTId=VAR_001716.
FT   VARIANT    1088   1088       G -> E (in OI1; de novo mutation; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24682174}.
FT                                /FTId=VAR_074159.
FT   VARIANT    1091   1091       G -> S (in OI2). {ECO:0000269|Ref.50}.
FT                                /FTId=VAR_001717.
FT   VARIANT    1093   1093       R -> C (found in a patient with isolated
FT                                osteopenia and vascular rupture; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:17211858}.
FT                                /FTId=VAR_063336.
FT   VARIANT    1094   1094       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063337.
FT   VARIANT    1100   1100       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_001718.
FT   VARIANT    1106   1106       G -> A (in OI2).
FT                                {ECO:0000269|PubMed:2777764}.
FT                                /FTId=VAR_001719.
FT   VARIANT    1124   1124       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:7961597}.
FT                                /FTId=VAR_001720.
FT   VARIANT    1141   1141       R -> Q (in dbSNP:rs41316713).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033778.
FT   VARIANT    1142   1142       G -> S (in OI2).
FT                                /FTId=VAR_001721.
FT   VARIANT    1151   1151       G -> S (in OI3).
FT                                /FTId=VAR_001722.
FT   VARIANT    1151   1151       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:1613761,
FT                                ECO:0000269|PubMed:2777764}.
FT                                /FTId=VAR_001723.
FT   VARIANT    1154   1154       G -> R (in OI2).
FT                                {ECO:0000269|PubMed:2777764}.
FT                                /FTId=VAR_001724.
FT   VARIANT    1157   1157       G -> D (in OI1).
FT                                {ECO:0000269|PubMed:16638323}.
FT                                /FTId=VAR_063338.
FT   VARIANT    1166   1166       G -> C (in OI2).
FT                                {ECO:0000269|PubMed:3016737}.
FT                                /FTId=VAR_001725.
FT   VARIANT    1172   1172       G -> D (in OI2).
FT                                {ECO:0000269|PubMed:10627137}.
FT                                /FTId=VAR_001726.
FT   VARIANT    1177   1177       V -> I (in dbSNP:rs41316719).
FT                                {ECO:0000269|PubMed:18272325}.
FT                                /FTId=VAR_033779.
FT   VARIANT    1181   1181       G -> S (in OI2).
FT                                {ECO:0000269|PubMed:2037280,
FT                                ECO:0000269|Ref.50}.
FT                                /FTId=VAR_001727.
FT   VARIANT    1184   1184       G -> V (in OI2).
FT                                {ECO:0000269|PubMed:1613761,
FT                                ECO:0000269|PubMed:2777764}.
FT                                /FTId=VAR_001728.
FT   VARIANT    1187   1187       G -> S (in OI2 and OI3; extremely severe
FT                                form). {ECO:0000269|Ref.50}.
FT                                /FTId=VAR_001729.
FT   VARIANT    1187   1187       G -> V (in OI2). {ECO:0000269|Ref.50}.
FT                                /FTId=VAR_001730.
FT   VARIANT    1195   1195       G -> C (in OI1; mild form).
FT                                {ECO:0000269|PubMed:3170557,
FT                                ECO:0000269|PubMed:3244312}.
FT                                /FTId=VAR_001731.
FT   VARIANT    1219   1219       D -> E (in OI1).
FT                                {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063339.
FT   VARIANT    1219   1219       D -> N (found in a patient with mild
FT                                osteogenesis imperfecta associated with
FT                                increased bone mineral density; results
FT                                in defective type I procollagen
FT                                processing; incorporation of the immature
FT                                procollagen into the matrix leads to
FT                                increased bone matrix mineralization and
FT                                altered collagen fibril structure).
FT                                {ECO:0000269|PubMed:21344539}.
FT                                /FTId=VAR_066385.
FT   VARIANT    1251   1251       S -> T (in dbSNP:rs3205325).
FT                                {ECO:0000269|PubMed:8349697}.
FT                                /FTId=VAR_030014.
FT   VARIANT    1277   1277       D -> H (in OI2; impaired pro-alpha chain
FT                                association).
FT                                {ECO:0000269|PubMed:8349697}.
FT                                /FTId=VAR_001732.
FT   VARIANT    1312   1312       W -> C (in OI2).
FT                                {ECO:0000269|PubMed:8456808}.
FT                                /FTId=VAR_001733.
FT   VARIANT    1337   1338       Missing (in OI2; impaired pro-alpha chain
FT                                association).
FT                                {ECO:0000269|PubMed:8349697}.
FT                                /FTId=VAR_001734.
FT   VARIANT    1356   1356       R -> H. {ECO:0000269|PubMed:16786509}.
FT                                /FTId=VAR_063340.
FT   VARIANT    1388   1388       L -> R (in OI2; impaired pro-alpha chain
FT                                association).
FT                                {ECO:0000269|PubMed:8349697}.
FT                                /FTId=VAR_001735.
FT   VARIANT    1391   1391       Q -> K (in dbSNP:rs2586486).
FT                                {ECO:0000269|PubMed:3340531,
FT                                ECO:0000269|PubMed:9443882,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_030015.
FT   VARIANT    1413   1413       D -> N (in OI2).
FT                                {ECO:0000269|PubMed:16786509,
FT                                ECO:0000269|PubMed:18996919}.
FT                                /FTId=VAR_063341.
FT   VARIANT    1430   1430       K -> N (in dbSNP:rs1059454).
FT                                /FTId=VAR_033780.
FT   VARIANT    1431   1431       T -> P (in dbSNP:rs1059454).
FT                                /FTId=VAR_033781.
FT   VARIANT    1434   1434       T -> S (in dbSNP:rs1800220).
FT                                {ECO:0000269|PubMed:8349697,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_001736.
FT   VARIANT    1438   1438       P -> R (in dbSNP:rs17857117).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030016.
FT   VARIANT    1460   1460       P -> H (in dbSNP:rs17853657).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030017.
FT   VARIANT    1464   1464       L -> P (in OI3).
FT                                {ECO:0000269|PubMed:8723681}.
FT                                /FTId=VAR_001737.
FT   CONFLICT     59     59       R -> Q (in Ref. 8; CAA25394).
FT                                {ECO:0000305}.
FT   CONFLICT    112    114       Missing (in Ref. 2; AAB94054).
FT                                {ECO:0000305}.
FT   CONFLICT    288    288       E -> P (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    370    370       R -> L (in Ref. 6; AAB59373).
FT                                {ECO:0000305}.
FT   CONFLICT    484    484       P -> L (in Ref. 19; AAA52289).
FT                                {ECO:0000305}.
FT   CONFLICT    595    595       A -> R (in Ref. 20; AAA51847).
FT                                {ECO:0000305}.
FT   CONFLICT    721    721       Q -> E (in Ref. 22; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    738    738       L -> E (in Ref. 22; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    975    976       LP -> PL (in Ref. 19; AAA52291).
FT                                {ECO:0000305}.
FT   CONFLICT   1081   1081       V -> A (in Ref. 18; AAA51995).
FT                                {ECO:0000305}.
FT   CONFLICT   1329   1329       S -> T (in Ref. 25; AAB27856).
FT                                {ECO:0000305}.
FT   STRAND      264    266       {ECO:0000244|PDB:3GXE}.
FT   STRAND      966    968       {ECO:0000244|PDB:3EJH}.
SQ   SEQUENCE   1464 AA;  138941 MW;  F0EC4DE778FFFC11 CRC64;
     MFSFVDLRLL LLLAATALLT HGQEEGQVEG QDEDIPPITC VQNGLRYHDR DVWKPEPCRI
     CVCDNGKVLC DDVICDETKN CPGAEVPEGE CCPVCPDGSE SPTDQETTGV EGPKGDTGPR
     GPRGPAGPPG RDGIPGQPGL PGPPGPPGPP GPPGLGGNFA PQLSYGYDEK STGGISVPGP
     MGPSGPRGLP GPPGAPGPQG FQGPPGEPGE PGASGPMGPR GPPGPPGKNG DDGEAGKPGR
     PGERGPPGPQ GARGLPGTAG LPGMKGHRGF SGLDGAKGDA GPAGPKGEPG SPGENGAPGQ
     MGPRGLPGER GRPGAPGPAG ARGNDGATGA AGPPGPTGPA GPPGFPGAVG AKGEAGPQGP
     RGSEGPQGVR GEPGPPGPAG AAGPAGNPGA DGQPGAKGAN GAPGIAGAPG FPGARGPSGP
     QGPGGPPGPK GNSGEPGAPG SKGDTGAKGE PGPVGVQGPP GPAGEEGKRG ARGEPGPTGL
     PGPPGERGGP GSRGFPGADG VAGPKGPAGE RGSPGPAGPK GSPGEAGRPG EAGLPGAKGL
     TGSPGSPGPD GKTGPPGPAG QDGRPGPPGP PGARGQAGVM GFPGPKGAAG EPGKAGERGV
     PGPPGAVGPA GKDGEAGAQG PPGPAGPAGE RGEQGPAGSP GFQGLPGPAG PPGEAGKPGE
     QGVPGDLGAP GPSGARGERG FPGERGVQGP PGPAGPRGAN GAPGNDGAKG DAGAPGAPGS
     QGAPGLQGMP GERGAAGLPG PKGDRGDAGP KGADGSPGKD GVRGLTGPIG PPGPAGAPGD
     KGESGPSGPA GPTGARGAPG DRGEPGPPGP AGFAGPPGAD GQPGAKGEPG DAGAKGDAGP
     PGPAGPAGPP GPIGNVGAPG AKGARGSAGP PGATGFPGAA GRVGPPGPSG NAGPPGPPGP
     AGKEGGKGPR GETGPAGRPG EVGPPGPPGP AGEKGSPGAD GPAGAPGTPG PQGIAGQRGV
     VGLPGQRGER GFPGLPGPSG EPGKQGPSGA SGERGPPGPM GPPGLAGPPG ESGREGAPGA
     EGSPGRDGSP GAKGDRGETG PAGPPGAPGA PGAPGPVGPA GKSGDRGETG PAGPTGPVGP
     VGARGPAGPQ GPRGDKGETG EQGDRGIKGH RGFSGLQGPP GPPGSPGEQG PSGASGPAGP
     RGPPGSAGAP GKDGLNGLPG PIGPPGPRGR TGDAGPVGPP GPPGPPGPPG PPSAGFDFSF
     LPQPPQEKAH DGGRYYRADD ANVVRDRDLE VDTTLKSLSQ QIENIRSPEG SRKNPARTCR
     DLKMCHSDWK SGEYWIDPNQ GCNLDAIKVF CNMETGETCV YPTQPSVAQK NWYISKNPKD
     KRHVWFGESM TDGFQFEYGG QGSDPADVAI QLTFLRLMST EASQNITYHC KNSVAYMDQQ
     TGNLKKALLL QGSNEIEIRA EGNSRFTYSV TVDGCTSHTG AWGKTVIEYK TTKTSRLPII
     DVAPLDVGAP DQEFGFDVGP VCFL
//
ID   BMP4_HUMAN              Reviewed;         408 AA.
AC   P12644; Q9UM80;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   20-JAN-2016, entry version 182.
DE   RecName: Full=Bone morphogenetic protein 4;
DE            Short=BMP-4;
DE   AltName: Full=Bone morphogenetic protein 2B;
DE            Short=BMP-2B;
DE   Flags: Precursor;
GN   Name=BMP4; Synonyms=BMP2B, DVR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3201241; DOI=10.1126/science.3201241;
RA   Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J.,
RA   Kriz R.W., Hewick R.M., Wang E.A.;
RT   "Novel regulators of bone formation: molecular clones and
RT   activities.";
RL   Science 242:1528-1534(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-152.
RX   PubMed=9701626; DOI=10.1007/s002239900518;
RA   Shore E.M., Xu M., Shah P.B., Janoff H.B., Hahn G.V., Deardorff M.A.,
RA   Sovinsky L., Spinner N.B., Zasloff M.A., Wozney J.M., Kaplan F.S.;
RT   "The human bone morphogenetic protein 4 (BMP-4) gene: molecular
RT   structure and transcriptional regulation.";
RL   Calcif. Tissue Int. 63:221-229(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-152.
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-408.
RC   TISSUE=Placenta;
RX   PubMed=7579580;
RA   Oida S., Iimura T., Maruoka Y., Takeda K., Sasaki S.;
RT   "Cloning and sequence of bone morphogenetic protein 4 (BMP-4) from a
RT   human placental cDNA library.";
RL   DNA Seq. 5:273-275(1995).
RN   [5]
RP   INTERACTION WITH SOSTDC1.
RX   PubMed=15020244; DOI=10.1016/j.bbrc.2004.02.075;
RA   Yanagita M., Oka M., Watabe T., Iguchi H., Niida A., Takahashi S.,
RA   Akiyama T., Miyazono K., Yanagisawa M., Sakurai T.;
RT   "USAG-1: a bone morphogenetic protein antagonist abundantly expressed
RT   in the kidney.";
RL   Biochem. Biophys. Res. Commun. 316:490-500(2004).
RN   [6]
RP   PHOSPHORYLATION AT SER-91.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [7]
RP   VARIANTS CYS-91; ALA-152; ALA-225; TRP-226 AND THR-367.
RX   PubMed=12404109; DOI=10.1038/sj.ejhg.5200875;
RA   Felder B., Stegmann K., Schultealbert A., Geller F., Strehl E.,
RA   Ermert A., Koch M.C.;
RT   "Evaluation of BMP4 and its specific inhibitor NOG as candidates in
RT   human neural tube defects (NTDs).";
RL   Eur. J. Hum. Genet. 10:753-756(2002).
RN   [8]
RP   VARIANT MCOPS6 GLY-93.
RX   PubMed=18252212; DOI=10.1016/j.ajhg.2007.09.023;
RA   Bakrania P., Efthymiou M., Klein J.C., Salt A., Bunyan D.J., Wyatt A.,
RA   Ponting C.P., Martin A., Williams S., Lindley V., Gilmore J.,
RA   Restori M., Robson A.G., Neveu M.M., Holder G.E., Collin J.R.O.,
RA   Robinson D.O., Farndon P., Johansen-Berg H., Gerrelli D., Ragge N.K.;
RT   "Mutations in BMP4 cause eye, brain, and digit developmental
RT   anomalies: overlap between the BMP4 and hedgehog signaling pathways.";
RL   Am. J. Hum. Genet. 82d:304-319(2008).
RN   [9]
RP   VARIANTS CYS-91; SER-116 AND LYS-150.
RX   PubMed=18305125; DOI=10.1681/ASN.2006111282;
RA   Weber S., Taylor J.C., Winyard P., Baker K.F., Sullivan-Brown J.,
RA   Schild R., Knueppel T., Zurowska A.M., Caldas-Alfonso A., Litwin M.,
RA   Emre S., Ghiggeri G.M., Bakkaloglu A., Mehls O., Antignac C.,
RA   Schaefer F., Burdine R.D.;
RT   "SIX2 and BMP4 mutations associate with anomalous kidney
RT   development.";
RL   J. Am. Soc. Nephrol. 19:891-903(2008).
RN   [10]
RP   VARIANTS OFC11 CYS-91; GLN-162; HIS-287 AND VAL-346, AND VARIANTS
RP   ALA-102; ALA-152 AND ALA-168.
RX   PubMed=19249007; DOI=10.1016/j.ajhg.2009.02.002;
RA   Suzuki S., Marazita M.L., Cooper M.E., Miwa N., Hing A., Jugessur A.,
RA   Natsume N., Shimozato K., Ohbayashi N., Suzuki Y., Niimi T.,
RA   Minami K., Yamamoto M., Altannamar T.J., Erkhembaatar T., Furukawa H.,
RA   Daack-Hirsch S., L'heureux J., Brandon C.A., Weinberg S.M.,
RA   Neiswanger K., Deleyiannis F.W., de Salamanca J.E., Vieira A.R.,
RA   Lidral A.C., Martin J.F., Murray J.C.;
RT   "Mutations in BMP4 are associated with subepithelial, microform, and
RT   overt cleft lip.";
RL   Am. J. Hum. Genet. 84:406-411(2009).
CC   -!- FUNCTION: Induces cartilage and bone formation. Also act in
CC       mesoderm induction, tooth development, limb formation and fracture
CC       repair. Acts in concert with PTHLH/PTHRP to stimulate ductal
CC       outgrowth during embryonic mammary development and to inhibit hair
CC       follicle induction (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (By similarity). Interacts
CC       with GREM2. Part of a complex consisting of TWSG1 and CHRD.
CC       Interacts with the serine proteases, HTRA1 and HTRA3; the
CC       interaction with either inhibits BMP4-mediated signaling. The HTRA
CC       protease activity is required for this inhibition (By similarity).
CC       Interacts with SOSTDC1. {ECO:0000250,
CC       ECO:0000269|PubMed:15020244}.
CC   -!- INTERACTION:
CC       P36894:BMPR1A; NbExp=2; IntAct=EBI-1998134, EBI-1029237;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- TISSUE SPECIFICITY: Expressed in the lung and lower levels seen in
CC       the kidney. Present also in normal and neoplastic prostate
CC       tissues, and prostate cancer cell lines.
CC   -!- DISEASE: Microphthalmia, syndromic, 6 (MCOPS6) [MIM:607932]: A
CC       disease characterized by microphthalmia/anophthalmia associated
CC       with facial, genital, skeletal, neurologic and endocrine
CC       anomalies. Microphthalmia is a disorder of eye formation, ranging
CC       from small size of a single eye to complete bilateral absence of
CC       ocular tissues (anophthalmia). In many cases,
CC       microphthalmia/anophthalmia occurs in association with syndromes
CC       that include non-ocular abnormalities.
CC       {ECO:0000269|PubMed:18252212}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Non-syndromic orofacial cleft 11 (OFC11) [MIM:600625]: A
CC       birth defect consisting of cleft lips with or without cleft
CC       palate. Cleft lips are associated with cleft palate in two-third
CC       of cases. A cleft lip can occur on one or both sides and range in
CC       severity from a simple notch in the upper lip to a complete
CC       opening in the lip extending into the floor of the nostril and
CC       involving the upper gum. {ECO:0000269|PubMed:19249007}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Bone morphogenetic protein 4
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Bone_morphogenetic_protein_4";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BMP4ID811ch14q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22490; AAA51835.1; -; mRNA.
DR   EMBL; U43842; AAC72278.1; -; Genomic_DNA.
DR   EMBL; BC020546; AAH20546.1; -; mRNA.
DR   EMBL; D30751; BAA06410.1; -; mRNA.
DR   CCDS; CCDS9715.1; -.
DR   PIR; C37278; BMHU4.
DR   RefSeq; NP_001193.2; NM_001202.4.
DR   RefSeq; NP_570911.2; NM_130850.3.
DR   RefSeq; XP_005268072.1; XM_005268015.3.
DR   UniGene; Hs.68879; -.
DR   ProteinModelPortal; P12644; -.
DR   SMR; P12644; 80-278, 307-408.
DR   BioGrid; 107120; 13.
DR   DIP; DIP-5795N; -.
DR   IntAct; P12644; 8.
DR   MINT; MINT-1184353; -.
DR   STRING; 9606.ENSP00000245451; -.
DR   BindingDB; P12644; -.
DR   ChEMBL; CHEMBL5350; -.
DR   iPTMnet; P12644; -.
DR   PhosphoSite; P12644; -.
DR   BioMuta; BMP4; -.
DR   DMDM; 115073; -.
DR   PaxDb; P12644; -.
DR   PRIDE; P12644; -.
DR   DNASU; 652; -.
DR   Ensembl; ENST00000245451; ENSP00000245451; ENSG00000125378.
DR   Ensembl; ENST00000417573; ENSP00000394165; ENSG00000125378.
DR   Ensembl; ENST00000558984; ENSP00000454134; ENSG00000125378.
DR   Ensembl; ENST00000559087; ENSP00000453485; ENSG00000125378.
DR   GeneID; 652; -.
DR   KEGG; hsa:652; -.
DR   UCSC; uc001xal.4; human.
DR   CTD; 652; -.
DR   GeneCards; BMP4; -.
DR   GeneReviews; BMP4; -.
DR   HGNC; HGNC:1071; BMP4.
DR   HPA; CAB006863; -.
DR   MalaCards; BMP4; -.
DR   MIM; 112262; gene.
DR   MIM; 600625; phenotype.
DR   MIM; 607932; phenotype.
DR   neXtProt; NX_P12644; -.
DR   Orphanet; 264200; 14q22q23 microdeletion syndrome.
DR   Orphanet; 1991; Cleft lip with or without cleft palate.
DR   Orphanet; 139471; Microphthalmia with brain and digit anomalies.
DR   Orphanet; 93100; Unilateral renal agenesis.
DR   PharmGKB; PA25381; -.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   HOGENOM; HOG000249478; -.
DR   HOVERGEN; HBG004860; -.
DR   InParanoid; P12644; -.
DR   KO; K04662; -.
DR   OMA; TRLVRHN; -.
DR   OrthoDB; EOG7WHH9D; -.
DR   PhylomeDB; P12644; -.
DR   TreeFam; TF351789; -.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   SignaLink; P12644; -.
DR   GeneWiki; Bone_morphogenetic_protein_4; -.
DR   GenomeRNAi; 652; -.
DR   NextBio; 2648; -.
DR   PRO; PR:P12644; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; P12644; -.
DR   CleanEx; HS_BMP4; -.
DR   ExpressionAtlas; P12644; baseline and differential.
DR   Genevisible; P12644; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0031988; C:membrane-bounded vesicle; IEA:Ensembl.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0070700; F:BMP receptor binding; IDA:MGI.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:UniProtKB.
DR   GO; GO:0039706; F:co-receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005125; F:cytokine activity; IDA:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:Ensembl.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003130; P:BMP signaling pathway involved in heart induction; IMP:BHF-UCL.
DR   GO; GO:0071893; P:BMP signaling pathway involved in nephric duct formation; IDA:UniProtKB.
DR   GO; GO:0061151; P:BMP signaling pathway involved in renal system segmentation; ISS:UniProtKB.
DR   GO; GO:0061149; P:BMP signaling pathway involved in ureter morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IDA:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IDA:UniProtKB.
DR   GO; GO:0060433; P:bronchus development; IDA:MGI.
DR   GO; GO:0060503; P:bud dilation involved in lung branching; IDA:MGI.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; IEA:Ensembl.
DR   GO; GO:0003279; P:cardiac septum development; TAS:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0060363; P:cranial suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0035993; P:deltoid tuberosity development; ISS:UniProtKB.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IEA:Ensembl.
DR   GO; GO:0003197; P:endocardial cushion development; TAS:BHF-UCL.
DR   GO; GO:0001958; P:endochondral ossification; ISS:UniProtKB.
DR   GO; GO:0060502; P:epithelial cell proliferation involved in lung morphogenesis; IDA:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IDA:MGI.
DR   GO; GO:0060684; P:epithelial-mesenchymal cell signaling; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0072104; P:glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0072015; P:glomerular visceral epithelial cell development; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IDA:UniProtKB.
DR   GO; GO:0060113; P:inner ear receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0048392; P:intermediate mesodermal cell differentiation; IDA:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0060235; P:lens induction in camera-type eye; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; IDA:MGI.
DR   GO; GO:0060462; P:lung lobe development; IEA:Ensembl.
DR   GO; GO:0060425; P:lung morphogenesis; IDA:MGI.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0030225; P:macrophage differentiation; IDA:DFLAT.
DR   GO; GO:0060592; P:mammary gland formation; IEA:Ensembl.
DR   GO; GO:0072161; P:mesenchymal cell differentiation involved in kidney development; IEA:Ensembl.
DR   GO; GO:0072198; P:mesenchymal cell proliferation involved in ureter development; IEA:Ensembl.
DR   GO; GO:0072138; P:mesenchymal cell proliferation involved in ureteric bud development; IEA:Ensembl.
DR   GO; GO:0003337; P:mesenchymal to epithelial transition involved in metanephros morphogenesis; IDA:UniProtKB.
DR   GO; GO:0007500; P:mesodermal cell fate determination; IEA:Ensembl.
DR   GO; GO:0001823; P:mesonephros development; IEP:UniProtKB.
DR   GO; GO:0072205; P:metanephric collecting duct development; ISS:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; IDA:DFLAT.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0072097; P:negative regulation of branch elongation involved in ureteric bud branching by BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0090191; P:negative regulation of branching involved in ureteric bud morphogenesis; IDA:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:HGNC.
DR   GO; GO:0060548; P:negative regulation of cell death; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:MGI.
DR   GO; GO:2000137; P:negative regulation of cell proliferation involved in heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0072125; P:negative regulation of glomerular mesangial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0090194; P:negative regulation of glomerulus development; IDA:UniProtKB.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IMP:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0072200; P:negative regulation of mesenchymal cell proliferation involved in ureter development; IDA:UniProtKB.
DR   GO; GO:2000007; P:negative regulation of metanephric comma-shaped body morphogenesis; IDA:UniProtKB.
DR   GO; GO:2000005; P:negative regulation of metanephric S-shaped body morphogenesis; IDA:UniProtKB.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IDA:MGI.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IDA:UniProtKB.
DR   GO; GO:0060686; P:negative regulation of prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; IDA:MGI.
DR   GO; GO:0033085; P:negative regulation of T cell differentiation in thymus; IMP:BHF-UCL.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0048663; P:neuron fate commitment; IEA:Ensembl.
DR   GO; GO:0042476; P:odontogenesis; IGI:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:GOC.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IDA:UniProtKB.
DR   GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; ISS:UniProtKB.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl.
DR   GO; GO:0055020; P:positive regulation of cardiac muscle fiber development; IMP:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IDA:MGI.
DR   GO; GO:0010942; P:positive regulation of cell death; IDA:MGI.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:2000105; P:positive regulation of DNA-dependent DNA replication; IDA:BHF-UCL.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045606; P:positive regulation of epidermal cell differentiation; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0070368; P:positive regulation of hepatocyte differentiation; IEA:Ensembl.
DR   GO; GO:0090184; P:positive regulation of kidney development; IDA:UniProtKB.
DR   GO; GO:1902462; P:positive regulation of mesenchymal stem cell proliferation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:MGI.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:1901341; P:positive regulation of store-operated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IDA:MGI.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:UniProtKB.
DR   GO; GO:0061155; P:pulmonary artery endothelial tube morphogenesis; IDA:UniProtKB.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0010453; P:regulation of cell fate commitment; IDA:UniProtKB.
DR   GO; GO:0042487; P:regulation of odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0060393; P:regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IDA:MGI.
DR   GO; GO:0051150; P:regulation of smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0072001; P:renal system development; IEP:UniProtKB.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0071731; P:response to nitric oxide; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0003139; P:secondary heart field specification; IMP:BHF-UCL.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0048745; P:smooth muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEP:UniProtKB.
DR   GO; GO:0010159; P:specification of organ position; IEA:Ensembl.
DR   GO; GO:0072101; P:specification of ureteric bud anterior/posterior symmetry by BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043401; P:steroid hormone mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021537; P:telencephalon development; IDA:MGI.
DR   GO; GO:0021978; P:telencephalon regionalization; IEA:Ensembl.
DR   GO; GO:0035990; P:tendon cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043587; P:tongue morphogenesis; IEA:Ensembl.
DR   GO; GO:0060438; P:trachea development; IDA:MGI.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   GO; GO:0003323; P:type B pancreatic cell development; IDA:BHF-UCL.
DR   GO; GO:0072192; P:ureter epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072193; P:ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; IDA:MGI.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Chondrogenesis; Cleavage on pair of basic residues; Complete proteome;
KW   Cytokine; Developmental protein; Differentiation; Disease mutation;
KW   Disulfide bond; Extracellular matrix; Glycoprotein; Growth factor;
KW   Microphthalmia; Osteogenesis; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   PROPEP       20    292
FT                                /FTId=PRO_0000033856.
FT   CHAIN       293    408       Bone morphogenetic protein 4.
FT                                /FTId=PRO_0000033857.
FT   MOD_RES      91     91       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    143    143       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    208    208       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    365    365       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    308    373       {ECO:0000250}.
FT   DISULFID    337    405       {ECO:0000250}.
FT   DISULFID    341    407       {ECO:0000250}.
FT   DISULFID    372    372       Interchain. {ECO:0000250}.
FT   VARIANT      91     91       S -> C (in OFC11; also found in renal
FT                                hypodysplasia patients).
FT                                {ECO:0000269|PubMed:12404109,
FT                                ECO:0000269|PubMed:18305125,
FT                                ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_043531.
FT   VARIANT      93     93       E -> G (in MCOPS6).
FT                                {ECO:0000269|PubMed:18252212}.
FT                                /FTId=VAR_043532.
FT   VARIANT     102    102       T -> A (in dbSNP:rs202159001).
FT                                {ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_058314.
FT   VARIANT     116    116       T -> S (in a renal hypodysplasia
FT                                patient). {ECO:0000269|PubMed:18305125}.
FT                                /FTId=VAR_043533.
FT   VARIANT     150    150       N -> K (in a renal hypodysplasia
FT                                patient). {ECO:0000269|PubMed:18305125}.
FT                                /FTId=VAR_043534.
FT   VARIANT     152    152       V -> A (in dbSNP:rs17563).
FT                                {ECO:0000269|PubMed:12404109,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19249007,
FT                                ECO:0000269|PubMed:9701626}.
FT                                /FTId=VAR_016174.
FT   VARIANT     162    162       R -> Q (in OFC11).
FT                                {ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_058315.
FT   VARIANT     168    168       G -> A. {ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_058316.
FT   VARIANT     225    225       T -> A. {ECO:0000269|PubMed:12404109}.
FT                                /FTId=VAR_043535.
FT   VARIANT     226    226       R -> W. {ECO:0000269|PubMed:12404109}.
FT                                /FTId=VAR_043536.
FT   VARIANT     287    287       R -> H (in OFC11; dbSNP:rs121912768).
FT                                {ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_058317.
FT   VARIANT     346    346       A -> V (in OFC11).
FT                                {ECO:0000269|PubMed:19249007}.
FT                                /FTId=VAR_058318.
FT   VARIANT     367    367       S -> T. {ECO:0000269|PubMed:12404109}.
FT                                /FTId=VAR_043537.
SQ   SEQUENCE   408 AA;  46555 MW;  79B01179DBB98204 CRC64;
     MIPGNRMLMV VLLCQVLLGG ASHASLIPET GKKKVAEIQG HAGGRRSGQS HELLRDFEAT
     LLQMFGLRRR PQPSKSAVIP DYMRDLYRLQ SGEEEEEQIH STGLEYPERP ASRANTVRSF
     HHEEHLENIP GTSENSAFRF LFNLSSIPEN EVISSAELRL FREQVDQGPD WERGFHRINI
     YEVMKPPAEV VPGHLITRLL DTRLVHHNVT RWETFDVSPA VLRWTREKQP NYGLAIEVTH
     LHQTRTHQGQ HVRISRSLPQ GSGNWAQLRP LLVTFGHDGR GHALTRRRRA KRSPKHHSQR
     ARKKNKNCRR HSLYVDFSDV GWNDWIVAPP GYQAFYCHGD CPFPLADHLN STNHAIVQTL
     VNSVNSSIPK ACCVPTELSA ISMLYLDEYD KVVLKNYQEM VVEGCGCR
//
ID   NOTCH_DROME             Reviewed;        2703 AA.
AC   P07207; O97458; P04154; Q9W4T8;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2001, sequence version 3.
DT   20-JAN-2016, entry version 202.
DE   RecName: Full=Neurogenic locus Notch protein;
DE   Contains:
DE     RecName: Full=Processed neurogenic locus Notch protein;
DE   Flags: Precursor;
GN   Name=N; ORFNames=CG3936;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=3935325; DOI=10.1016/0092-8674(85)90229-6;
RA   Wharton K.A., Johansen K.M., Xu T., Artavanis-Tsakonas S.;
RT   "Nucleotide sequence from the neurogenic locus notch implies a gene
RT   product that shares homology with proteins containing EGF-like
RT   repeats.";
RL   Cell 43:567-581(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Canton-S, and Oregon-R; TISSUE=Embryo;
RX   PubMed=3097517;
RA   Kidd S., Kelley M.R., Young M.W.;
RT   "Sequence of the notch locus of Drosophila melanogaster: relationship
RT   of the encoded protein to mammalian clotting and growth factors.";
RL   Mol. Cell. Biol. 6:3094-3108(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Oregon-R;
RX   PubMed=10731137; DOI=10.1126/science.287.5461.2220;
RA   Benos P.V., Gatt M.K., Ashburner M., Murphy L., Harris D.,
RA   Barrell B.G., Ferraz C., Vidal S., Brun C., Demailles J., Cadieu E.,
RA   Dreano S., Gloux S., Lelaure V., Mottier S., Galibert F., Borkova D.,
RA   Minana B., Kafatos F.C., Louis C., Siden-Kiamos I., Bolshakov S.,
RA   Papagiannakis G., Spanos L., Cox S., Madueno E., de Pablos B.,
RA   Modolell J., Peter A., Schoettler P., Werner M., Mourkioti F.,
RA   Beinert N., Dowe G., Schaefer U., Jaeckle H., Bucheton A.,
RA   Callister D.M., Campbell L.A., Darlamitsou A., Henderson N.S.,
RA   McMillan P.J., Salles C., Tait E.A., Valenti P., Saunders R.D.C.,
RA   Glover D.M.;
RT   "From sequence to chromosome: the tip of the X chromosome of D.
RT   melanogaster.";
RL   Science 287:2220-2222(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-8.
RX   PubMed=3037327;
RA   Kelley M.R., Kidd S., Berg R.L., Young M.W.;
RT   "Restriction of P-element insertions at the Notch locus of Drosophila
RT   melanogaster.";
RL   Mol. Cell. Biol. 7:1545-1548(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2505-2611.
RC   STRAIN=Oregon-R; TISSUE=Embryo;
RX   PubMed=2981631; DOI=10.1016/0092-8674(85)90308-3;
RA   Wharton K.A., Yedvobnick B., Finnerty V.G., Artavanis-Tsakonas S.;
RT   "opa: a novel family of transcribed repeats shared by the Notch locus
RT   and other developmentally regulated loci in D. melanogaster.";
RL   Cell 40:55-62(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2505-2604.
RX   PubMed=2780284; DOI=10.1093/nar/17.16.6463;
RA   Tautz D.;
RT   "Hypervariability of simple sequences as a general source for
RT   polymorphic DNA markers.";
RL   Nucleic Acids Res. 17:6463-6471(1989).
RN   [9]
RP   INTERACTION WITH DX, AND MUTANT SU42C.
RX   PubMed=8162848;
RA   Diederich R.J., Matsuno K., Hing H., Artavanis-Tsakonas S.;
RT   "Cytosolic interaction between deltex and Notch ankyrin repeats
RT   implicates deltex in the Notch signaling pathway.";
RL   Development 120:473-481(1994).
RN   [10]
RP   INTERACTION WITH DX.
RX   PubMed=7671825;
RA   Matsuno K., Diederich R.J., Go M.J., Blaumueller C.M.,
RA   Artavanis-Tsakonas S.;
RT   "Deltex acts as a positive regulator of Notch signaling through
RT   interactions with the Notch ankyrin repeats.";
RL   Development 121:2633-2644(1995).
RN   [11]
RP   S3 CLEAVAGE BY PSN.
RX   PubMed=10206646; DOI=10.1038/19091;
RA   Struhl G., Greenwald I.;
RT   "Presenilin is required for activity and nuclear access of Notch in
RT   Drosophila.";
RL   Nature 398:522-525(1999).
RN   [12]
RP   S3 CLEAVAGE BY PSN.
RX   PubMed=10206647; DOI=10.1038/19096;
RA   Ye Y., Lukinova N., Fortini M.E.;
RT   "Neurogenic phenotypes and altered Notch processing in Drosophila
RT   Presenilin mutants.";
RL   Nature 398:525-529(1999).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH DL.
RX   PubMed=10935637; DOI=10.1038/35019075;
RA   Bruckner K., Perez L., Clausen H., Cohen S.;
RT   "Glycosyltransferase activity of Fringe modulates Notch-Delta
RT   interactions.";
RL   Nature 406:411-415(2000).
RN   [14]
RP   MUTANT MCD5.
RX   PubMed=11719214; DOI=10.1016/S0960-9822(01)00562-0;
RA   Ramain P., Khechumian K., Seugnet L., Arbogast N., Ackermann C.,
RA   Heitzler P.;
RT   "Novel Notch alleles reveal a Deltex-dependent pathway repressing
RT   neural fate.";
RL   Curr. Biol. 11:1729-1738(2001).
RN   [15]
RP   S2 CLEAVAGE BY KUZ.
RX   PubMed=11799064; DOI=10.1101/gad.942302;
RA   Lieber T., Kidd S., Young M.W.;
RT   "Kuzbanian-mediated cleavage of Drosophila Notch.";
RL   Genes Dev. 16:209-221(2002).
RN   [16]
RP   REVIEW.
RX   PubMed=12369105; DOI=10.1034/j.1601-5223.2002.1360201.x;
RA   Portin P.;
RT   "General outlines of the molecular genetics of the Notch signalling
RT   pathway in Drosophila melanogaster: a review.";
RL   Hereditas 136:89-96(2002).
RN   [17]
RP   GLYCOSYLATION, AND LIGAND-BINDING.
RX   PubMed=12909620; DOI=10.1074/jbc.M308687200;
RA   Okajima T., Xu A., Irvine K.D.;
RT   "Modulation of notch-ligand binding by protein O-fucosyltransferase 1
RT   and fringe.";
RL   J. Biol. Chem. 278:42340-42345(2003).
RN   [18]
RP   INTERACTION WITH NEDD4, UBIQUITINATION, AND MUTAGENESIS OF TYR-2328.
RX   PubMed=15620649; DOI=10.1016/j.cub.2004.12.028;
RA   Sakata T., Sakaguchi H., Tsuda L., Higashitani A., Aigaki T.,
RA   Matsuno K., Hayashi S.;
RT   "Drosophila Nedd4 regulates endocytosis of notch and suppresses its
RT   ligand-independent activation.";
RL   Curr. Biol. 14:2228-2236(2004).
RN   [19]
RP   INTERACTION WITH SU(DX).
RX   PubMed=15620650; DOI=10.1016/j.cub.2004.11.030;
RA   Wilkin M.B., Carbery A.-M., Fostier M., Aslam H., Mazaleyrat S.L.,
RA   Higgs J., Myat A., Evans D.A.P., Cornell M., Baron M.;
RT   "Regulation of notch endosomal sorting and signaling by Drosophila
RT   Nedd4 family proteins.";
RL   Curr. Biol. 14:2237-2244(2004).
RN   [20]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH O-FUT1.
RX   PubMed=17329366; DOI=10.1242/dev.02811;
RA   Sasamura T., Ishikawa H.O., Sasaki N., Higashi S., Kanai M., Nakao S.,
RA   Ayukawa T., Aigaki T., Noda K., Miyoshi E., Taniguchi N., Matsuno K.;
RT   "The O-fucosyltransferase O-fut1 is an extracellular component that is
RT   essential for the constitutive endocytic trafficking of Notch in
RT   Drosophila.";
RL   Development 134:1347-1356(2007).
RN   [21]
RP   FUNCTION.
RX   PubMed=18243100; DOI=10.1016/j.cell.2007.12.016;
RA   Acar M., Jafar-Nejad H., Takeuchi H., Rajan A., Ibrani D., Rana N.A.,
RA   Pan H., Haltiwanger R.S., Bellen H.J.;
RT   "Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is
RT   required for Notch signaling.";
RL   Cell 132:247-258(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2447, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Embryo;
RX   PubMed=18327897; DOI=10.1021/pr700696a;
RA   Zhai B., Villen J., Beausoleil S.A., Mintseris J., Gygi S.P.;
RT   "Phosphoproteome analysis of Drosophila melanogaster embryos.";
RL   J. Proteome Res. 7:1675-1682(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1901-2139, DOMAIN ANK
RP   REPEATS, AND SUBUNIT.
RX   PubMed=14573873; DOI=10.1110/ps.03279003;
RA   Zweifel M.E., Leahy D.J., Hughson F.M., Barrick D.;
RT   "Structure and stability of the ankyrin domain of the Drosophila Notch
RT   receptor.";
RL   Protein Sci. 12:2622-2632(2003).
CC   -!- FUNCTION: Signaling protein, which regulates, with both positive
CC       and negative signals, the differentiation of at least central and
CC       peripheral nervous system and eye, wing disk, oogenesis, segmental
CC       appendages such as antennae and legs, and muscles, through lateral
CC       inhibition or induction. Functions as a receptor for membrane-
CC       bound ligands Delta and Serrate to regulate cell-fate
CC       determination. Upon ligand activation, and releasing from the cell
CC       membrane, the Notch intracellular domain (NICD) forms a
CC       transcriptional activator complex with Su(H) (Suppressor of
CC       hairless) and activates genes of the E(spl) complex. Essential for
CC       proper differentiation of ectoderm. Fringe (fng) acts in the Golgi
CC       to determine the type of O-linked fucose on the EGF modules in N,
CC       altering the ability of N to bind with Delta (Dl). O-fut1 also has
CC       a role in modulating the interaction. Rumi acts in the endoplasmic
CC       reticulum to glucosylate the EGF modules in N, this is required
CC       for correct folding and cleavage of N.
CC       {ECO:0000269|PubMed:10935637, ECO:0000269|PubMed:18243100}.
CC   -!- SUBUNIT: Homomer. Interacts with Su(H) when activated. Interacts
CC       with Dx via its ANK repeats. Interacts with Dl via the EGF repeats
CC       and the Dl EGF repeats. Interacts with Nedd4 and Su(dx). Interacts
CC       with O-fut1; the interaction glycosylates N and transports N to
CC       early endosomes. {ECO:0000269|PubMed:10935637,
CC       ECO:0000269|PubMed:14573873, ECO:0000269|PubMed:15620649,
CC       ECO:0000269|PubMed:15620650, ECO:0000269|PubMed:17329366,
CC       ECO:0000269|PubMed:7671825, ECO:0000269|PubMed:8162848}.
CC   -!- INTERACTION:
CC       Q24279:cno; NbExp=3; IntAct=EBI-103438, EBI-868783;
CC       P10041:Dl; NbExp=2; IntAct=EBI-103438, EBI-115346;
CC       P28159:Su(H); NbExp=4; IntAct=EBI-103438, EBI-92180;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17329366};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:17329366}.
CC       Endosome {ECO:0000269|PubMed:17329366}. Note=Transported to early
CC       endosomes by O-fut1 (PubMed:17329366).
CC   -!- SUBCELLULAR LOCATION: Processed neurogenic locus Notch protein:
CC       Nucleus. Note=Upon activation and S3 cleavage, it is released from
CC       the cell membrane and enters into the nucleus in conjunction with
CC       Su(H).
CC   -!- DOMAIN: Crystal structure of the ANK repeat domain shows that
CC       there are 7 repeats and the stabilizing C-terminal repeat enhances
CC       the protein stability by extending the ankyrin domain.
CC       {ECO:0000269|PubMed:14573873}.
CC   -!- PTM: Upon binding its ligands such as Delta or Serrate, it is
CC       cleaved (S2 cleavage) in its extracellular domain, close to the
CC       transmembrane domain. S2 cleavage is probably mediated by Kuz. It
CC       is then cleaved (S3 cleavage) downstream of its transmembrane
CC       domain, releasing it from the cell membrane. S3 cleavage requires
CC       Psn.
CC   -!- PTM: O-glycosylated. O-fucosylated by O-fut1 in the EGF repeat
CC       doamin which inhibits both Serrate/Ser- and Delta/Dl-binding.
CC       {ECO:0000269|PubMed:12909620}.
CC   -!- PTM: Ubiquitinated by Nedd4; which promotes ligand-independent
CC       endocytosis and proteasomal degradation. May also be ubiquitinated
CC       by Su(dx). {ECO:0000269|PubMed:15620649}.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 7 ANK repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00023}.
CC   -!- SIMILARITY: Contains 36 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 3 LNR (Lin/Notch) repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00525}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16152; AAB59220.1; -; Genomic_DNA.
DR   EMBL; M16153; AAB59220.1; JOINED; Genomic_DNA.
DR   EMBL; M16149; AAB59220.1; JOINED; Genomic_DNA.
DR   EMBL; M16150; AAB59220.1; JOINED; Genomic_DNA.
DR   EMBL; M16151; AAB59220.1; JOINED; Genomic_DNA.
DR   EMBL; K03508; AAA28725.1; -; Genomic_DNA.
DR   EMBL; M13689; AAA28725.1; JOINED; Genomic_DNA.
DR   EMBL; K03507; AAA28725.1; JOINED; Genomic_DNA.
DR   EMBL; AE014298; AAF45848.2; -; Genomic_DNA.
DR   EMBL; AL035436; CAB37610.1; -; Genomic_DNA.
DR   EMBL; AL035395; CAB37610.1; JOINED; Genomic_DNA.
DR   EMBL; M16025; AAA28726.1; -; Genomic_DNA.
DR   EMBL; M12175; AAA74496.1; -; Genomic_DNA.
DR   PIR; A24420; A24420.
DR   RefSeq; NP_001245510.1; NM_001258581.2.
DR   RefSeq; NP_476859.2; NM_057511.4.
DR   PDB; 1OT8; X-ray; 2.00 A; A/B/C=1902-2139.
DR   PDB; 2JMF; NMR; -; B=2318-2333.
DR   PDBsum; 1OT8; -.
DR   PDBsum; 2JMF; -.
DR   ProteinModelPortal; P07207; -.
DR   SMR; P07207; 1904-2139.
DR   BioGrid; 57823; 138.
DR   DIP; DIP-5N; -.
DR   IntAct; P07207; 233.
DR   MINT; MINT-133064; -.
DR   STRING; 7227.FBpp0070483; -.
DR   iPTMnet; P07207; -.
DR   PaxDb; P07207; -.
DR   PRIDE; P07207; -.
DR   EnsemblMetazoa; FBtr0070507; FBpp0070483; FBgn0004647.
DR   EnsemblMetazoa; FBtr0304659; FBpp0293201; FBgn0004647.
DR   GeneID; 31293; -.
DR   KEGG; dme:Dmel_CG3936; -.
DR   CTD; 109544; -.
DR   FlyBase; FBgn0004647; N.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   InParanoid; P07207; -.
DR   KO; K02599; -.
DR   OMA; INECESH; -.
DR   OrthoDB; EOG7992RD; -.
DR   PhylomeDB; P07207; -.
DR   Reactome; R-DME-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-DME-1980148; Signaling by NOTCH3.
DR   Reactome; R-DME-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-DME-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   SignaLink; P07207; -.
DR   ChiTaRS; N; fly.
DR   EvolutionaryTrace; P07207; -.
DR   GenomeRNAi; 31293; -.
DR   NextBio; 772898; -.
DR   PRO; PR:P07207; -.
DR   Proteomes; UP000000803; Chromosome X.
DR   Bgee; P07207; -.
DR   Genevisible; P07207; DM.
DR   GO; GO:0005912; C:adherens junction; IDA:FlyBase.
DR   GO; GO:0009986; C:cell surface; IDA:FlyBase.
DR   GO; GO:0005737; C:cytoplasm; IDA:FlyBase.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:FlyBase.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:FlyBase.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; TAS:FlyBase.
DR   GO; GO:0005622; C:intracellular; IDA:FlyBase.
DR   GO; GO:0005770; C:late endosome; IDA:FlyBase.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0005886; C:plasma membrane; IDA:FlyBase.
DR   GO; GO:0043234; C:protein complex; IPI:FlyBase.
DR   GO; GO:0035003; C:subapical complex; IDA:FlyBase.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0003682; F:chromatin binding; IDA:FlyBase.
DR   GO; GO:0004872; F:receptor activity; TAS:FlyBase.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:FlyBase.
DR   GO; GO:0007015; P:actin filament organization; IMP:FlyBase.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; TAS:FlyBase.
DR   GO; GO:0008356; P:asymmetric cell division; TAS:FlyBase.
DR   GO; GO:0007411; P:axon guidance; IMP:FlyBase.
DR   GO; GO:0007298; P:border follicle cell migration; IMP:FlyBase.
DR   GO; GO:0007155; P:cell adhesion; TAS:FlyBase.
DR   GO; GO:0001708; P:cell fate specification; NAS:FlyBase.
DR   GO; GO:0022416; P:chaeta development; IMP:FlyBase.
DR   GO; GO:0008407; P:chaeta morphogenesis; IMP:FlyBase.
DR   GO; GO:0042676; P:compound eye cone cell fate commitment; TAS:FlyBase.
DR   GO; GO:0048749; P:compound eye development; IMP:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0046667; P:compound eye retinal cell programmed cell death; TAS:FlyBase.
DR   GO; GO:0042688; P:crystal cell differentiation; IMP:FlyBase.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:FlyBase.
DR   GO; GO:0046843; P:dorsal appendage formation; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; TAS:FlyBase.
DR   GO; GO:0007451; P:dorsal/ventral lineage restriction, imaginal disc; TAS:FlyBase.
DR   GO; GO:0007450; P:dorsal/ventral pattern formation, imaginal disc; TAS:FlyBase.
DR   GO; GO:0007398; P:ectoderm development; TAS:FlyBase.
DR   GO; GO:0035165; P:embryonic crystal cell differentiation; TAS:FlyBase.
DR   GO; GO:0035162; P:embryonic hemopoiesis; IMP:FlyBase.
DR   GO; GO:0061331; P:epithelial cell proliferation involved in Malpighian tubule morphogenesis; IMP:FlyBase.
DR   GO; GO:0035153; P:epithelial cell type specification, open tracheal system; IMP:FlyBase.
DR   GO; GO:0060429; P:epithelium development; IMP:FlyBase.
DR   GO; GO:0042067; P:establishment of ommatidial planar polarity; NAS:FlyBase.
DR   GO; GO:0035214; P:eye-antennal disc development; IMP:FlyBase.
DR   GO; GO:0036099; P:female germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0007440; P:foregut morphogenesis; IMP:FlyBase.
DR   GO; GO:0060288; P:formation of a compartment boundary; IMP:FlyBase.
DR   GO; GO:0030718; P:germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0060250; P:germ-line stem-cell niche homeostasis; IMP:FlyBase.
DR   GO; GO:0007293; P:germarium-derived egg chamber formation; IMP:FlyBase.
DR   GO; GO:0030708; P:germarium-derived female germ-line cyst encapsulation; TAS:FlyBase.
DR   GO; GO:0010001; P:glial cell differentiation; IMP:FlyBase.
DR   GO; GO:0007403; P:glial cell fate determination; IMP:FlyBase.
DR   GO; GO:0008347; P:glial cell migration; IMP:FlyBase.
DR   GO; GO:0035172; P:hemocyte proliferation; IMP:FlyBase.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:FlyBase.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IMP:FlyBase.
DR   GO; GO:0007446; P:imaginal disc growth; TAS:FlyBase.
DR   GO; GO:0007447; P:imaginal disc pattern formation; TAS:FlyBase.
DR   GO; GO:0016348; P:imaginal disc-derived leg joint morphogenesis; IMP:FlyBase.
DR   GO; GO:0036011; P:imaginal disc-derived leg segmentation; IMP:FlyBase.
DR   GO; GO:0048803; P:imaginal disc-derived male genitalia morphogenesis; IMP:FlyBase.
DR   GO; GO:0008587; P:imaginal disc-derived wing margin morphogenesis; IMP:FlyBase.
DR   GO; GO:0007476; P:imaginal disc-derived wing morphogenesis; IMP:FlyBase.
DR   GO; GO:0007474; P:imaginal disc-derived wing vein specification; IMP:FlyBase.
DR   GO; GO:0036335; P:intestinal stem cell homeostasis; IMP:FlyBase.
DR   GO; GO:0035171; P:lamellocyte differentiation; IMP:FlyBase.
DR   GO; GO:0035167; P:larval lymph gland hemopoiesis; IMP:FlyBase.
DR   GO; GO:0046331; P:lateral inhibition; IMP:FlyBase.
DR   GO; GO:0007478; P:leg disc morphogenesis; TAS:FlyBase.
DR   GO; GO:0007616; P:long-term memory; IMP:FlyBase.
DR   GO; GO:0035170; P:lymph gland crystal cell differentiation; TAS:FlyBase.
DR   GO; GO:0048542; P:lymph gland development; IMP:FlyBase.
DR   GO; GO:0061382; P:Malpighian tubule tip cell differentiation; IMP:FlyBase.
DR   GO; GO:0007498; P:mesoderm development; IMP:FlyBase.
DR   GO; GO:0016333; P:morphogenesis of follicular epithelium; NAS:FlyBase.
DR   GO; GO:0008045; P:motor neuron axon guidance; IMP:FlyBase.
DR   GO; GO:0007521; P:muscle cell fate determination; IMP:FlyBase.
DR   GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IMP:FlyBase.
DR   GO; GO:0045316; P:negative regulation of compound eye photoreceptor development; IMP:FlyBase.
DR   GO; GO:0035157; P:negative regulation of fusion cell fate specification; TAS:FlyBase.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:FlyBase.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; NAS:FlyBase.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IMP:FlyBase.
DR   GO; GO:0035155; P:negative regulation of terminal cell fate specification, open tracheal system; TAS:FlyBase.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:FlyBase.
DR   GO; GO:0007400; P:neuroblast fate determination; IDA:FlyBase.
DR   GO; GO:0050877; P:neurological system process; IMP:FlyBase.
DR   GO; GO:0048666; P:neuron development; IMP:FlyBase.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0007314; P:oocyte anterior/posterior axis specification; TAS:FlyBase.
DR   GO; GO:0030720; P:oocyte localization involved in germarium-derived egg chamber formation; IMP:FlyBase.
DR   GO; GO:0048477; P:oogenesis; IMP:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; TAS:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; IMP:FlyBase.
DR   GO; GO:0007297; P:ovarian follicle cell migration; IMP:FlyBase.
DR   GO; GO:0030713; P:ovarian follicle cell stalk formation; IMP:FlyBase.
DR   GO; GO:0007422; P:peripheral nervous system development; IMP:FlyBase.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:FlyBase.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:FlyBase.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IMP:FlyBase.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:FlyBase.
DR   GO; GO:0048052; P:R1/R6 cell differentiation; IMP:FlyBase.
DR   GO; GO:0007464; P:R3/R4 cell fate commitment; NAS:FlyBase.
DR   GO; GO:0045466; P:R7 cell differentiation; IMP:FlyBase.
DR   GO; GO:0045463; P:R8 cell development; TAS:FlyBase.
DR   GO; GO:0045465; P:R8 cell differentiation; NAS:FlyBase.
DR   GO; GO:0007460; P:R8 cell fate commitment; TAS:FlyBase.
DR   GO; GO:0042686; P:regulation of cardioblast cell fate specification; IMP:FlyBase.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:FlyBase.
DR   GO; GO:0042689; P:regulation of crystal cell differentiation; TAS:FlyBase.
DR   GO; GO:0051489; P:regulation of filopodium assembly; IMP:FlyBase.
DR   GO; GO:0040008; P:regulation of growth; IMP:FlyBase.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; TAS:FlyBase.
DR   GO; GO:0050767; P:regulation of neurogenesis; IMP:FlyBase.
DR   GO; GO:0045468; P:regulation of R8 cell spacing in compound eye; NAS:FlyBase.
DR   GO; GO:0009608; P:response to symbiont; IMP:FlyBase.
DR   GO; GO:0046666; P:retinal cell programmed cell death; TAS:FlyBase.
DR   GO; GO:0016330; P:second mitotic wave involved in compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0007423; P:sensory organ development; IMP:FlyBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IMP:FlyBase.
DR   GO; GO:0048863; P:stem cell differentiation; IMP:FlyBase.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007419; P:ventral cord development; NAS:FlyBase.
DR   GO; GO:0048190; P:wing disc dorsal/ventral pattern formation; IMP:FlyBase.
DR   GO; GO:0035222; P:wing disc pattern formation; IMP:FlyBase.
DR   GO; GO:0007473; P:wing disc proximal/distal pattern formation; TAS:FlyBase.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF00023; Ank; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 24.
DR   Pfam; PF07645; EGF_CA; 5.
DR   Pfam; PF12661; hEGF; 1.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   SMART; SM00248; ANK; 7.
DR   SMART; SM00181; EGF; 12.
DR   SMART; SM00179; EGF_CA; 24.
DR   SMART; SM00004; NL; 3.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 5.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 5.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 34.
DR   PROSITE; PS01186; EGF_2; 28.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 21.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cell membrane; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond;
KW   EGF-like domain; Endosome; Glycoprotein; Membrane; Neurogenesis;
KW   Notch signaling pathway; Nucleus; Oogenesis; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     52       {ECO:0000255}.
FT   CHAIN        53   2703       Neurogenic locus Notch protein.
FT                                /FTId=PRO_0000007673.
FT   CHAIN         ?   2703       Processed neurogenic locus Notch protein.
FT                                /FTId=PRO_0000296234.
FT   TOPO_DOM     53   1745       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1746   1766       Helical. {ECO:0000255}.
FT   TOPO_DOM   1767   2703       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       58     95       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       96    136       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      139    176       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      177    215       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      217    253       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      255    291       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      293    329       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      331    370       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      372    408       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      409    447       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      449    486       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      488    524       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      526    562       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      564    600       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      602    637       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      639    675       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      677    713       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      715    751       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      753    789       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      791    827       EGF-like 20; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      829    865       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      867    905       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      907    944       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      946    982       EGF-like 24; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      984   1020       EGF-like 25. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1022   1058       EGF-like 26; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1060   1096       EGF-like 27. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1098   1134       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1136   1181       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1183   1219       EGF-like 30; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1221   1257       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1259   1295       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1297   1335       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1337   1373       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1375   1412       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1415   1451       EGF-like 36. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1482   1521       LNR 1.
FT   REPEAT     1522   1557       LNR 2.
FT   REPEAT     1559   1599       LNR 3.
FT   REPEAT     1901   1945       ANK 1.
FT   REPEAT     1950   1979       ANK 2.
FT   REPEAT     1983   2013       ANK 3.
FT   REPEAT     2017   2046       ANK 4.
FT   REPEAT     2050   2079       ANK 5.
FT   REPEAT     2083   2112       ANK 6.
FT   REPEAT     2116   2139       ANK 7.
FT   REGION     2325   2328       Interaction with Nedd4.
FT   COMPBIAS   2486   2498       Poly-Gly.
FT   COMPBIAS   2538   2568       Poly-Gln (OPA repeat).
FT   COMPBIAS   2664   2667       Poly-Ser.
FT   MOD_RES    2447   2447       Phosphoserine.
FT                                {ECO:0000269|PubMed:18327897}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    430    430       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    475    475       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1045   1045       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1157   1157       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1242   1242       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1271   1271       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1521   1521       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1594   1594       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1627   1627       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     62     73       {ECO:0000250}.
FT   DISULFID     67     83       {ECO:0000250}.
FT   DISULFID     85     94       {ECO:0000250}.
FT   DISULFID    100    111       {ECO:0000250}.
FT   DISULFID    105    124       {ECO:0000250}.
FT   DISULFID    126    135       {ECO:0000250}.
FT   DISULFID    143    154       {ECO:0000250}.
FT   DISULFID    148    164       {ECO:0000250}.
FT   DISULFID    166    175       {ECO:0000250}.
FT   DISULFID    181    192       {ECO:0000250}.
FT   DISULFID    186    203       {ECO:0000250}.
FT   DISULFID    205    214       {ECO:0000250}.
FT   DISULFID    221    232       {ECO:0000250}.
FT   DISULFID    226    241       {ECO:0000250}.
FT   DISULFID    243    252       {ECO:0000250}.
FT   DISULFID    259    270       {ECO:0000250}.
FT   DISULFID    264    279       {ECO:0000250}.
FT   DISULFID    281    290       {ECO:0000250}.
FT   DISULFID    297    308       {ECO:0000250}.
FT   DISULFID    302    317       {ECO:0000250}.
FT   DISULFID    319    328       {ECO:0000250}.
FT   DISULFID    335    349       {ECO:0000250}.
FT   DISULFID    343    358       {ECO:0000250}.
FT   DISULFID    360    369       {ECO:0000250}.
FT   DISULFID    376    387       {ECO:0000250}.
FT   DISULFID    381    396       {ECO:0000250}.
FT   DISULFID    398    407       {ECO:0000250}.
FT   DISULFID    413    424       {ECO:0000250}.
FT   DISULFID    418    435       {ECO:0000250}.
FT   DISULFID    437    446       {ECO:0000250}.
FT   DISULFID    453    465       {ECO:0000250}.
FT   DISULFID    459    474       {ECO:0000250}.
FT   DISULFID    476    485       {ECO:0000250}.
FT   DISULFID    492    503       {ECO:0000250}.
FT   DISULFID    497    512       {ECO:0000250}.
FT   DISULFID    514    523       {ECO:0000250}.
FT   DISULFID    530    541       {ECO:0000250}.
FT   DISULFID    535    550       {ECO:0000250}.
FT   DISULFID    552    561       {ECO:0000250}.
FT   DISULFID    568    579       {ECO:0000250}.
FT   DISULFID    573    588       {ECO:0000250}.
FT   DISULFID    590    599       {ECO:0000250}.
FT   DISULFID    606    616       {ECO:0000250}.
FT   DISULFID    611    625       {ECO:0000250}.
FT   DISULFID    627    636       {ECO:0000250}.
FT   DISULFID    643    654       {ECO:0000250}.
FT   DISULFID    648    663       {ECO:0000250}.
FT   DISULFID    665    674       {ECO:0000250}.
FT   DISULFID    681    692       {ECO:0000250}.
FT   DISULFID    686    701       {ECO:0000250}.
FT   DISULFID    703    712       {ECO:0000250}.
FT   DISULFID    719    730       {ECO:0000250}.
FT   DISULFID    724    739       {ECO:0000250}.
FT   DISULFID    741    750       {ECO:0000250}.
FT   DISULFID    757    768       {ECO:0000250}.
FT   DISULFID    762    777       {ECO:0000250}.
FT   DISULFID    779    788       {ECO:0000250}.
FT   DISULFID    795    806       {ECO:0000250}.
FT   DISULFID    800    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    833    844       {ECO:0000250}.
FT   DISULFID    838    853       {ECO:0000250}.
FT   DISULFID    855    864       {ECO:0000250}.
FT   DISULFID    871    882       {ECO:0000250}.
FT   DISULFID    876    893       {ECO:0000250}.
FT   DISULFID    895    904       {ECO:0000250}.
FT   DISULFID    911    923       {ECO:0000250}.
FT   DISULFID    917    932       {ECO:0000250}.
FT   DISULFID    934    943       {ECO:0000250}.
FT   DISULFID    950    961       {ECO:0000250}.
FT   DISULFID    955    970       {ECO:0000250}.
FT   DISULFID    972    981       {ECO:0000250}.
FT   DISULFID    988    999       {ECO:0000250}.
FT   DISULFID    993   1008       {ECO:0000250}.
FT   DISULFID   1010   1019       {ECO:0000250}.
FT   DISULFID   1026   1037       {ECO:0000250}.
FT   DISULFID   1031   1046       {ECO:0000250}.
FT   DISULFID   1048   1057       {ECO:0000250}.
FT   DISULFID   1064   1075       {ECO:0000250}.
FT   DISULFID   1069   1084       {ECO:0000250}.
FT   DISULFID   1086   1095       {ECO:0000250}.
FT   DISULFID   1102   1113       {ECO:0000250}.
FT   DISULFID   1107   1122       {ECO:0000250}.
FT   DISULFID   1124   1133       {ECO:0000250}.
FT   DISULFID   1140   1160       {ECO:0000250}.
FT   DISULFID   1155   1169       {ECO:0000250}.
FT   DISULFID   1171   1180       {ECO:0000250}.
FT   DISULFID   1187   1198       {ECO:0000250}.
FT   DISULFID   1192   1207       {ECO:0000250}.
FT   DISULFID   1209   1218       {ECO:0000250}.
FT   DISULFID   1225   1236       {ECO:0000250}.
FT   DISULFID   1230   1245       {ECO:0000250}.
FT   DISULFID   1247   1256       {ECO:0000250}.
FT   DISULFID   1263   1274       {ECO:0000250}.
FT   DISULFID   1268   1283       {ECO:0000250}.
FT   DISULFID   1285   1294       {ECO:0000250}.
FT   DISULFID   1301   1314       {ECO:0000250}.
FT   DISULFID   1306   1323       {ECO:0000250}.
FT   DISULFID   1325   1334       {ECO:0000250}.
FT   DISULFID   1341   1352       {ECO:0000250}.
FT   DISULFID   1346   1361       {ECO:0000250}.
FT   DISULFID   1363   1372       {ECO:0000250}.
FT   DISULFID   1379   1389       {ECO:0000250}.
FT   DISULFID   1384   1400       {ECO:0000250}.
FT   DISULFID   1402   1411       {ECO:0000250}.
FT   DISULFID   1419   1430       {ECO:0000250}.
FT   DISULFID   1424   1439       {ECO:0000250}.
FT   DISULFID   1441   1450       {ECO:0000250}.
FT   DISULFID   1482   1505       {ECO:0000250}.
FT   DISULFID   1487   1500       {ECO:0000250}.
FT   DISULFID   1496   1512       {ECO:0000250}.
FT   DISULFID   1522   1545       {ECO:0000250}.
FT   DISULFID   1527   1540       {ECO:0000250}.
FT   DISULFID   1536   1552       {ECO:0000250}.
FT   DISULFID   1559   1585       {ECO:0000250}.
FT   DISULFID   1567   1580       {ECO:0000250}.
FT   DISULFID   1576   1592       {ECO:0000250}.
FT   VARIANT     578    578       I -> T.
FT   VARIANT    2044   2044       I -> R.
FT   VARIANT    2265   2265       A -> V.
FT   VARIANT    2407   2407       H -> R.
FT   VARIANT    2445   2445       R -> L.
FT   VARIANT    2568   2568       Q -> QQQQQ.
FT   MUTAGEN     739    739       C->Y: In mcd5; induces loss of
FT                                microchaetae sensory precursors.
FT   MUTAGEN    2060   2060       A->V: In su42c; deltex-like mutation that
FT                                induces outstreched wings and
FT                                variability-fused ocelli.
FT   MUTAGEN    2328   2328       Y->F: Abolishes interaction with Nedd4
FT                                and reduces ubiquitination.
FT                                {ECO:0000269|PubMed:15620649}.
FT   CONFLICT      9      9       R -> G (in Ref. 5; CAB37610).
FT                                {ECO:0000305}.
FT   CONFLICT     84     84       A -> G (in Ref. 5; CAB37610).
FT                                {ECO:0000305}.
FT   CONFLICT    103    103       M -> I (in Ref. 1; AAB59220).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       R -> H (in Ref. 2; AAA28725).
FT                                {ECO:0000305}.
FT   CONFLICT    231    231       T -> I (in Ref. 1; AAB59220).
FT                                {ECO:0000305}.
FT   CONFLICT    240    240       Q -> R (in Ref. 5; CAB37610).
FT                                {ECO:0000305}.
FT   CONFLICT    267    267       G -> A (in Ref. 1; AAB59220).
FT                                {ECO:0000305}.
FT   CONFLICT   1561   1561       S -> T (in Ref. 1; AAB59220 and 2;
FT                                AAA28725). {ECO:0000305}.
FT   CONFLICT   2257   2257       G -> S (in Ref. 2; AAA28725).
FT                                {ECO:0000305}.
FT   CONFLICT   2577   2577       A -> E (in Ref. 7; AAA74496).
FT                                {ECO:0000305}.
FT   HELIX      1930   1950       {ECO:0000244|PDB:1OT8}.
FT   HELIX      1954   1960       {ECO:0000244|PDB:1OT8}.
FT   HELIX      1964   1972       {ECO:0000244|PDB:1OT8}.
FT   HELIX      1987   1993       {ECO:0000244|PDB:1OT8}.
FT   HELIX      1997   2004       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2021   2027       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2033   2039       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2054   2060       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2064   2072       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2087   2093       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2097   2105       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2120   2126       {ECO:0000244|PDB:1OT8}.
FT   HELIX      2130   2136       {ECO:0000244|PDB:1OT8}.
SQ   SEQUENCE   2703 AA;  288853 MW;  0EAE23F426FECD7B CRC64;
     MQSQRSRRRS RAPNTWICFW INKMHAVASL PASLPLLLLT LAFANLPNTV RGTDTALVAA
     SCTSVGCQNG GTCVTQLNGK TYCACDSHYV GDYCEHRNPC NSMRCQNGGT CQVTFRNGRP
     GISCKCPLGF DESLCEIAVP NACDHVTCLN GGTCQLKTLE EYTCACANGY TGERCETKNL
     CASSPCRNGA TCTALAGSSS FTCSCPPGFT GDTCSYDIEE CQSNPCKYGG TCVNTHGSYQ
     CMCPTGYTGK DCDTKYKPCS PSPCQNGGIC RSNGLSYECK CPKGFEGKNC EQNYDDCLGH
     LCQNGGTCID GISDYTCRCP PNFTGRFCQD DVDECAQRDH PVCQNGATCT NTHGSYSCIC
     VNGWAGLDCS NNTDDCKQAA CFYGATCIDG VGSFYCQCTK GKTGLLCHLD DACTSNPCHA
     DAICDTSPIN GSYACSCATG YKGVDCSEDI DECDQGSPCE HNGICVNTPG SYRCNCSQGF
     TGPRCETNIN ECESHPCQNE GSCLDDPGTF RCVCMPGFTG TQCEIDIDEC QSNPCLNDGT
     CHDKINGFKC SCALGFTGAR CQINIDDCQS QPCRNRGICH DSIAGYSCEC PPGYTGTSCE
     ININDCDSNP CHRGKCIDDV NSFKCLCDPG YTGYICQKQI NECESNPCQF DGHCQDRVGS
     YYCQCQAGTS GKNCEVNVNE CHSNPCNNGA TCIDGINSYK CQCVPGFTGQ HCEKNVDECI
     SSPCANNGVC IDQVNGYKCE CPRGFYDAHC LSDVDECASN PCVNEGRCED GINEFICHCP
     PGYTGKRCEL DIDECSSNPC QHGGTCYDKL NAFSCQCMPG YTGQKCETNI DDCVTNPCGN
     GGTCIDKVNG YKCVCKVPFT GRDCESKMDP CASNRCKNEA KCTPSSNFLD FSCTCKLGYT
     GRYCDEDIDE CSLSSPCRNG ASCLNVPGSY RCLCTKGYEG RDCAINTDDC ASFPCQNGGT
     CLDGIGDYSC LCVDGFDGKH CETDINECLS QPCQNGATCS QYVNSYTCTC PLGFSGINCQ
     TNDEDCTESS CLNGGSCIDG INGYNCSCLA GYSGANCQYK LNKCDSNPCL NGATCHEQNN
     EYTCHCPSGF TGKQCSEYVD WCGQSPCENG ATCSQMKHQF SCKCSAGWTG KLCDVQTISC
     QDAADRKGLS LRQLCNNGTC KDYGNSHVCY CSQGYAGSYC QKEIDECQSQ PCQNGGTCRD
     LIGAYECQCR QGFQGQNCEL NIDDCAPNPC QNGGTCHDRV MNFSCSCPPG TMGIICEINK
     DDCKPGACHN NGSCIDRVGG FECVCQPGFV GARCEGDINE CLSNPCSNAG TLDCVQLVNN
     YHCNCRPGHM GRHCEHKVDF CAQSPCQNGG NCNIRQSGHH CICNNGFYGK NCELSGQDCD
     SNPCRVGNCV VADEGFGYRC ECPRGTLGEH CEIDTLDECS PNPCAQGAAC EDLLGDYECL
     CPSKWKGKRC DIYDANYPGW NGGSGSGNDR YAADLEQQRA MCDKRGCTEK QGNGICDSDC
     NTYACNFDGN DCSLGINPWA NCTANECWNK FKNGKCNEEC NNAACHYDGH DCERKLKSCD
     SLFDAYCQKH YGDGFCDYGC NNAECSWDGL DCENKTQSPV LAEGAMSVVM LMNVEAFREI
     QAQFLRNMSH MLRTTVRLKK DALGHDIIIN WKDNVRVPEI EDTDFARKNK ILYTQQVHQT
     GIQIYLEIDN RKCTECFTHA VEAAEFLAAT AAKHQLRNDF QIHSVRGIKN PGDEDNGEPP
     ANVKYVITGI ILVIIALAFF GMVLSTQRKR AHGVTWFPEG FRAPAAVMSR RRRDPHGQEM
     RNLNKQVAMQ SQGVGQPGAH WSDDESDMPL PKRQRSDPVS GVGLGNNGGY ASDHTMVSEY
     EEADQRVWSQ AHLDVVDVRA IMTPPAHQDG GKHDVDARGP CGLTPLMIAA VRGGGLDTGE
     DIENNEDSTA QVISDLLAQG AELNATMDKT GETSLHLAAR FARADAAKRL LDAGADANCQ
     DNTGRTPLHA AVAADAMGVF QILLRNRATN LNARMHDGTT PLILAARLAI EGMVEDLITA
     DADINAADNS GKTALHWAAA VNNTEAVNIL LMHHANRDAQ DDKDETPLFL AAREGSYEAC
     KALLDNFANR EITDHMDRLP RDVASERLHH DIVRLLDEHV PRSPQMLSMT PQAMIGSPPP
     GQQQPQLITQ PTVISAGNGG NNGNGNASGK QSNQTAKQKA AKKAKLIEGS PDNGLDATGS
     LRRKASSKKT SAASKKAANL NGLNPGQLTG GVSGVPGVPP TNSAAQAAAA AAAAVAAMSH
     ELEGSPVGVG MGGNLPSPYD TSSMYSNAMA APLANGNPNT GAKQPPSYED CIKNAQSMQS
     LQGNGLDMIK LDNYAYSMGS PFQQELLNGQ GLGMNGNGQR NGVGPGVLPG GLCGMGGLSG
     AGNGNSHEQG LSPPYSNQSP PHSVQSSLAL SPHAYLGSPS PAKSRPSLPT SPTHIQAMRH
     ATQQKQFGGS NLNSLLGGAN GGGVVGGGGG GGGGVGQGPQ NSPVSLGIIS PTGSDMGIML
     APPQSSKNSA IMQTISPQQQ QQQQQQQQQQ HQQQQQQQQQ QQQQQQQQLG GLEFGSAGLD
     LNGFCGSPDS FHSGQMNPPS IQSSMSGSSP STNMLSPSSQ HNQQAFYQYL TPSSQHSGGH
     TPQHLVQTLD SYPTPSPESP GHWSSSSPRS NSDWSEGVQS PAANNLYISG GHQANKGSEA
     IYI
//
ID   RET_HUMAN               Reviewed;        1114 AA.
AC   P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 3.
DT   17-FEB-2016, entry version 213.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret;
DE            EC=2.7.10.1;
DE   AltName: Full=Cadherin family member 12;
DE   AltName: Full=Proto-oncogene c-Ret;
DE   Contains:
DE     RecName: Full=Soluble RET kinase fragment;
DE   Contains:
DE     RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment;
DE   Flags: Precursor;
GN   Name=RET; Synonyms=CDHF12, CDHR16, PTC, RET51;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   CYS-982.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2).
RX   PubMed=2660074;
RA   Takahashi M.;
RT   "Isolation of ret proto-oncogene cDNA with an amino-terminal signal
RT   sequence.";
RL   Oncogene 4:805-806(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1).
RX   PubMed=3078962;
RA   Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.;
RT   "Cloning and expression of the ret proto-oncogene encoding a tyrosine
RT   kinase with two potential transmembrane domains.";
RL   Oncogene 3:571-578(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH TRIM27.
RX   PubMed=3037315;
RA   Takahashi M., Cooper G.M.;
RT   "ret transforming gene encodes a fusion protein homologous to tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 7:1378-1385(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH GOLGA5.
RC   TISSUE=Fibroblast;
RX   PubMed=2734021;
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RT   "Activation of the ret-II oncogene without a sequence encoding a
RT   transmembrane domain and transforming activity of two ret-II oncogene
RT   products differing in carboxy-termini due to alternative splicing.";
RL   Oncogene 4:789-794(1989).
RN   [8]
RP   ERRATUM.
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RL   Oncogene 4:1415-1415(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CCDC6.
RC   TISSUE=Thyroid papillary carcinoma;
RX   PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3;
RA   Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R.,
RA   Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.;
RT   "PTC is a novel rearranged form of the ret proto-oncogene and is
RT   frequently detected in vivo in human thyroid papillary carcinomas.";
RL   Cell 60:557-563(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH PCM1.
RX   PubMed=10980597; DOI=10.1038/sj.onc.1203772;
RA   Corvi R., Berger N., Balczon R., Romeo G.;
RT   "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.";
RL   Oncogene 19:4236-4242(2000).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24.
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused
RT   to the RET receptor tyrosine kinase in childhood papillary thyroid
RT   carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [12]
RP   PHOSPHORYLATION AT TYR-1015 AND TYR-1062.
RX   PubMed=11061555; DOI=10.1210/jc.85.10.3898;
RA   Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G.,
RA   Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.;
RT   "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret
RT   and ret-derived oncoproteins.";
RL   J. Clin. Endocrinol. Metab. 85:3898-3907(2000).
RN   [13]
RP   PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981;
RP   TYR-1015; TYR-1062; TYR-1090 AND TYR-1096.
RX   PubMed=14711813; DOI=10.1074/jbc.M312600200;
RA   Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R.,
RA   Kato M., Suzuki H., Takahashi M., Nakashima I.;
RT   "Identification of RET autophosphorylation sites by mass
RT   spectrometry.";
RL   J. Biol. Chem. 279:14213-14224(2004).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM27.
RX   PubMed=12787916; DOI=10.1016/S0027-5107(03)00056-3;
RA   Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A.,
RA   Lushnikov E., Roumiantsev P., Matsumoto N., Nakashima M.,
RA   Meirmanov S., Ohtsuru A., Namba H., Tsyb A., Yamashita S.;
RT   "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary
RT   thyroid carcinoma from externally irradiated patient.";
RL   Mutat. Res. 527:81-90(2003).
RN   [15]
RP   PHOSPHORYLATION AT TYR-905; TYR-1015 AND TYR-1062, AND
RP   DEPHOSPHORYLATION AT TYR-905; TYR-1015 AND TYR-1062 BY PTPRJ.
RX   PubMed=16778204; DOI=10.1158/0008-5472.CAN-06-0228;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RT   "The receptor-type protein tyrosine phosphatase J antagonizes the
RT   biochemical and biological effects of RET-derived oncoproteins.";
RL   Cancer Res. 66:6280-6287(2006).
RN   [16]
RP   ENZYME REGULATION.
RX   PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104;
RA   Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L.,
RA   Lackey K.;
RT   "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as
RT   potent RET kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:5886-5893(2007).
RN   [17]
RP   ENZYME REGULATION BY SORAFENIB.
RX   PubMed=17664273; DOI=10.1074/jbc.M703461200;
RA   Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C.,
RA   Magee A.I., Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.;
RT   "Sorafenib functions to potently suppress RET tyrosine kinase activity
RT   by direct enzymatic inhibition and promoting RET lysosomal degradation
RT   independent of proteasomal targeting.";
RL   J. Biol. Chem. 282:29230-29240(2007).
RN   [18]
RP   ENZYME REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES.
RX   PubMed=19053769; DOI=10.1021/jm8007823;
RA   Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L.,
RA   Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.;
RT   "Synthesis, modeling, and RET protein kinase inhibitory activity of 3-
RT   and 4-substituted beta-carbolin-1-ones.";
RL   J. Med. Chem. 51:7777-7787(2008).
RN   [19]
RP   INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758.
RX   PubMed=18753381; DOI=10.1523/JNEUROSCI.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the
RT   regulation of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [20]
RP   INTERACTION WITH AIP.
RX   PubMed=19366855; DOI=10.1210/jc.2008-1980;
RA   Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R.,
RA   Morra I., Melcarne A., Rimondini R., Romeo G., Bonora E.;
RT   "The tyrosine kinase receptor RET interacts in vivo with aryl
RT   hydrocarbon receptor-interacting protein to alter survivin
RT   availability.";
RL   J. Clin. Endocrinol. Metab. 94:2571-2578(2009).
RN   [21]
RP   INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3.
RX   PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055;
RA   Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H.,
RA   Tam P.K.H., Garcia-Barcelo M.M.;
RT   "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and
RT   Pax3.";
RL   J. Pediatr. Surg. 44:1904-1912(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS.
RX   PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014;
RA   Ma Q.;
RT   "RETouching upon mechanoreceptors.";
RL   Neuron 64:773-776(2009).
RN   [24]
RP   ENZYME REGULATION, AND REVIEW ON KINASE INHIBITORS.
RX   PubMed=20605972; DOI=10.1210/er.2009-0031;
RA   Ye L., Santarpia L., Gagel R.F.;
RT   "The evolving field of tyrosine kinase inhibitors in the treatment of
RT   endocrine tumors.";
RL   Endocr. Rev. 31:578-599(2010).
RN   [25]
RP   ENZYME REGULATION.
RX   PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017;
RA   Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C.,
RA   Kunick C.;
RT   "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-
RT   (3-thienyl)nicotinonitrile scaffold.";
RL   Eur. J. Med. Chem. 45:2919-2927(2010).
RN   [26]
RP   FUNCTION IN PITUITARY.
RX   PubMed=20616503; DOI=10.1159/000318502;
RA   Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E.,
RA   Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.;
RT   "Functional role of the RET dependence receptor, GFRa co-receptors and
RT   ligands in the pituitary.";
RL   Front. Horm. Res. 38:127-138(2010).
RN   [27]
RP   FUNCTION IN CELL ADHESION/MIGRATION.
RX   PubMed=20702524; DOI=10.1210/jc.2010-0771;
RA   Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.;
RT   "RET-mediated cell adhesion and migration require multiple integrin
RT   subunits.";
RL   J. Clin. Endocrinol. Metab. 95:E342-E346(2010).
RN   [28]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19823924; DOI=10.1007/s10895-009-0548-x;
RA   Richardson D.S., Mulligan L.M.;
RT   "Direct visualization of vesicle maturation and plasma membrane
RT   protein trafficking.";
RL   J. Fluoresc. 20:401-405(2010).
RN   [29]
RP   ENZYME REGULATION.
RX   PubMed=21134556; DOI=10.1016/j.surg.2010.09.026;
RA   Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.;
RT   "A novel RET inhibitor with potent efficacy against medullary thyroid
RT   cancer in vivo.";
RL   Surgery 148:1228-1236(2010).
RN   [30]
RP   FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC
RP   PROCESSING BY CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF
RP   ASP-707; LYS-758 AND 708-ALA--SER-1114, AND SUBUNIT.
RX   PubMed=21357690; DOI=10.1074/jbc.M110.195461;
RA   Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.;
RT   "RET modulates cell adhesion via its cleavage by caspase in
RT   sympathetic neurons.";
RL   J. Biol. Chem. 286:14628-14638(2011).
RN   [31]
RP   INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION.
RX   PubMed=21454698; DOI=10.1074/jbc.M110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain,
RT   priming a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX
RP   WITH INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION AT TYR-900 AND TYR-905.
RX   PubMed=16928683; DOI=10.1074/jbc.M605604200;
RA   Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S.,
RA   Santoro M., Ibanez C.F., McDonald N.Q.;
RT   "Structure and chemical inhibition of the RET tyrosine kinase
RT   domain.";
RL   J. Biol. Chem. 281:33577-33587(2006).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH
RP   INHIBITORS, ENZYME REGULATION, AND PHOSPHORYLATION AT TYR-905.
RX   PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011;
RA   Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S.,
RA   Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q.,
RA   Lucchini V., Gambacorti-Passerini C.;
RT   "Synthesis, structure-activity relationship and crystallographic
RT   studies of 3-substituted indolin-2-one RET inhibitors.";
RL   Bioorg. Med. Chem. 18:1482-1496(2010).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT
RP   ASN-151, AND DISULFIDE BOND.
RX   PubMed=20473317; DOI=10.1038/nsmb.1808;
RA   Kjaer S., Hanrahan S., Totty N., McDonald N.Q.;
RT   "Mammal-restricted elements predispose human RET to folding impairment
RT   by HSCR mutations.";
RL   Nat. Struct. Mol. Biol. 17:726-731(2010).
RN   [35]
RP   REVIEW ON HSCR VARIANTS.
RX   PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to
RT   the phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [36]
RP   REVIEW ON VARIANTS.
RX   PubMed=9067749;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.0.CO;2-M;
RA   Eng C., Mulligan L.M.;
RT   "Mutations of the RET proto-oncogene in the multiple endocrine
RT   neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:97-109(1997).
RN   [37]
RP   VARIANTS MEN2A/MTC TRP-611; SER-618; ARG-620; TYR-620 AND ARG-634.
RX   PubMed=8103403; DOI=10.1093/hmg/2.7.851;
RA   Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K.,
RA   Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.;
RT   "Mutations in the RET proto-oncogene are associated with MEN 2A and
RT   FMTC.";
RL   Hum. Mol. Genet. 2:851-856(1993).
RN   [38]
RP   VARIANTS MEN2A GLY-618; 632-ASP--ARG-634; GLY-634; PHE-634; TYR-634
RP   AND SER-634.
RX   PubMed=8099202; DOI=10.1038/363458a0;
RA   Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C.,
RA   Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A.,
RA   Telenius H., Tunnacliffe A., Ponder B.A.J.;
RT   "Germ-line mutations of the RET proto-oncogene in multiple endocrine
RT   neoplasia type 2A.";
RL   Nature 363:458-460(1993).
RN   [39]
RP   VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND
RP   LEU-973.
RX   PubMed=7704557;
RA   Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I.,
RA   Pasini B., Tocco T., Lerone M., Cywes S., Moore S.,
RA   Vanderwinden J.-M., Abramowicz M.J., Kristoffersson U., Larsson L.T.,
RA   Hamel B.C.J., Silengo M., Martucciello G., Romeo G.;
RT   "Heterogeneity and low detection rate of RET mutations in Hirschsprung
RT   disease.";
RL   Eur. J. Hum. Genet. 2:272-280(1994).
RN   [40]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7911697; DOI=10.1093/hmg/3.2.237;
RA   Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S.,
RA   Ponder M.A., Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A.,
RA   Ponder B.A.J.;
RT   "Point mutation within the tyrosine kinase domain of the RET proto-
RT   oncogene in multiple endocrine neoplasia type 2B and related sporadic
RT   tumours.";
RL   Hum. Mol. Genet. 3:237-241(1994).
RN   [41]
RP   VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634;
RP   GLY-634 AND TYR-634.
RX   PubMed=7915165; DOI=10.1093/hmg/3.4.635;
RA   Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N.,
RA   Schuster M.K., Browden D.W., Mao J.-I., Noll W.W.;
RT   "Germline RET mutations in MEN 2A and FMTC and their detection by
RT   simple DNA diagnostic tests.";
RL   Hum. Mol. Genet. 3:635-638(1994).
RN   [42]
RP   VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620.
RX   PubMed=7849720; DOI=10.1093/hmg/3.10.1895;
RA   Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B.,
RA   Hruban R.H., Sidransky D.;
RT   "RET proto-oncogene mutations in inherited and sporadic medullary
RT   thyroid cancer.";
RL   Hum. Mol. Genet. 3:1895-1897(1994).
RN   [43]
RP   VARIANTS MTC, AND VARIANTS MEN2A.
RX   PubMed=7874109; DOI=10.1093/hmg/3.11.1939;
RA   Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N.,
RA   Calmettes C., Modigliani E., Lenoir G.M.;
RT   "RET proto-oncogene mutations in French MEN 2A and FMTC families.";
RL   Hum. Mol. Genet. 3:1939-1943(1994).
RN   [44]
RP   VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618,
RP   AND VARIANT MTC ARG-620.
RX   PubMed=7881414; DOI=10.1093/hmg/3.12.2163;
RA   Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J.,
RA   Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A.,
RA   Venter D.J., Munnich A., Ponder B.A.J.;
RT   "Diverse phenotypes associated with exon 10 mutations of the RET
RT   proto-oncogene.";
RL   Hum. Mol. Genet. 3:2163-2167(1994).
RN   [45]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906866; DOI=10.1038/367375a0;
RA   Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P.,
RA   Stelwagen T., Luo Y., Pasini B., Hoeppener J.W.M.,
RA   Ploos van Amstel H.K., Romeo G., Lips C.J.M., Buys C.H.C.M.;
RT   "A mutation in the RET proto-oncogene associated with multiple
RT   endocrine neoplasia type 2B and sporadic medullary thyroid
RT   carcinoma.";
RL   Nature 367:375-376(1994).
RN   [46]
RP   VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972.
RX   PubMed=8114938; DOI=10.1038/367377a0;
RA   Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I.,
RA   Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.;
RT   "Point mutations affecting the tyrosine kinase domain of the RET
RT   proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:377-378(1994).
RN   [47]
RP   VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393.
RX   PubMed=8114939; DOI=10.1038/367378a0;
RA   Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L.,
RA   Holder S., Nihoul-Fkete C., Ponder B.A.J., Munnich A.;
RT   "Mutations of the RET proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:378-380(1994).
RN   [48]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906417; DOI=10.1073/pnas.91.4.1579;
RA   Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E.,
RA   Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.;
RT   "Single missense mutation in the tyrosine kinase catalytic domain of
RT   the RET protooncogene is associated with multiple endocrine neoplasia
RT   type 2B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994).
RN   [49]
RP   VARIANTS MTC; MEN2A AND MEN2B.
RX   PubMed=8625130;
RX   DOI=10.1002/1097-0142(19950801)76:3<479::AID-CNCR2820760319>3.0.CO;2-M;
RA   Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G.,
RA   Colomer A., Roth J., Heitz P.U.;
RT   "Analysis of RET protooncogene point mutations distinguishes heritable
RT   from nonheritable medullary thyroid carcinomas.";
RL   Cancer 76:479-489(1995).
RN   [50]
RP   VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634.
RX   PubMed=7860065; DOI=10.1007/BF00209399;
RA   Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S.,
RA   Takami H., Hikiji K., Nakamura Y.;
RT   "Germline mutations of the RET proto-oncogene in eight Japanese
RT   patients with multiple endocrine neoplasia type 2A (MEN2A).";
RL   Hum. Genet. 95:187-190(1995).
RN   [51]
RP   VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND
RP   VARIANT CYS-982.
RC   TISSUE=Blood;
RX   PubMed=7633441; DOI=10.1093/hmg/4.5.821;
RA   Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W.,
RA   Buys C.H.C.M., Cass D.T., Chakravarti A.;
RT   "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:821-830(1995).
RN   [52]
RP   VARIANTS HSCR1.
RC   TISSUE=Leukocyte;
RX   PubMed=7581377; DOI=10.1093/hmg/4.8.1381;
RA   Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J.,
RA   Boutrand L., Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J.,
RA   Lyonnet S.;
RT   "Diversity of RET proto-oncogene mutations in familial and sporadic
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 4:1381-1386(1995).
RN   [53]
RP   VARIANT MEN2B THR-918, AND VARIANT TYR-922.
RX   PubMed=8595427; DOI=10.1093/hmg/4.10.1987;
RA   Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E.,
RA   Goodfellow P.J.;
RT   "Two maternally derived missense mutations in the tyrosine kinase
RT   domain of the RET protooncogene in a patient with de novo MEN 2B.";
RL   Hum. Mol. Genet. 4:1987-1988(1995).
RN   [54]
RP   VARIANT MTC ASP-768.
RX   PubMed=7845675;
RA   Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J.,
RA   Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D.,
RA   Ponder B.A.J.;
RT   "A novel point mutation in the tyrosine kinase domain of the RET
RT   proto-oncogene in sporadic medullary thyroid carcinoma and in a family
RT   with FMTC.";
RL   Oncogene 10:509-513(1995).
RN   [55]
RP   VARIANTS MTC ASP-768 AND LEU-804.
RX   PubMed=7784092;
RA   Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T.,
RA   Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J.,
RA   Lenoir G.M., Romeo G.;
RT   "RET mutations in exons 13 and 14 of FMTC patients.";
RL   Oncogene 10:2415-2419(1995).
RN   [56]
RP   VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND
RP   PRO-1061.
RA   Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C.,
RA   Buys C.H.C.M.;
RT   "Mutations in three genes are found associated with the development of
RT   Hirschsprung disease: RET, EDNRB and EDN3.";
RL   Am. J. Hum. Genet. 59:A263-A263(1996).
RN   [57]
RP   VARIANTS HSCR1 PRO-40 AND PRO-765.
RX   PubMed=9043870;
RA   Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.;
RT   "Prevalence and parental origin of de novo RET mutations in
RT   Hirschsprung's disease.";
RL   Eur. J. Hum. Genet. 4:356-358(1996).
RN   [58]
RP   VARIANTS MTC/MEN2A.
RX   PubMed=8557249; DOI=10.1007/BF00218825;
RA   Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M.,
RA   Lips C.J.M., van Amstel H.K.P.;
RT   "Mutation analysis of the RET proto-oncogene in Dutch families with
RT   MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation
RT   for MEN 2A.";
RL   Hum. Genet. 97:11-14(1996).
RN   [59]
RP   VARIANTS MEN2A, VARIANT MTC ASP-768, AND VARIANT MEN2B THR-918.
RX   PubMed=8807338;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.3.CO;2-N;
RA   Kambouris M., Jackson C.E., Feldman G.L.;
RT   "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial
RT   medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex
RT   analyses of RET proto-oncogene mutations.";
RL   Hum. Mutat. 8:64-70(1996).
RN   [60]
RP   VARIANTS MEN2A.
RX   PubMed=8626834; DOI=10.1210/jc.81.5.1780;
RA   Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H.,
RA   Haase R., Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F.,
RA   Ritter M.M., Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U.,
RA   Brabant G., Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J.,
RA   Doerr A.G., Hoehne T., Hoernig-Franz I., Huefner M., Kress J.,
RA   Langer H.J., Lottermoser K., Schweikert H.U., Kusterer K., Menken U.,
RA   Mercier J., Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.;
RT   "Mutations of the ret protooncogene in German multiple endocrine
RT   neoplasia families: relation between genotype and phenotype.";
RL   J. Clin. Endocrinol. Metab. 81:1780-1783(1996).
RN   [61]
RP   VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS.
RX   PubMed=9097963; DOI=10.1093/hmg/6.4.587;
RA   Hoeppner W., Ritter M.M.;
RT   "A duplication of 12 bp in the critical cysteine rich domain of the
RT   RET proto-oncogene results in a distinct phenotype of multiple
RT   endocrine neoplasia type 2A.";
RL   Hum. Mol. Genet. 6:587-590(1997).
RN   [62]
RP   VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791.
RX   PubMed=9090527;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<243::AID-HUMU5>3.3.CO;2-N;
RA   Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R.,
RA   Pasini B., Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T.,
RA   Casasa J.M., Cass D.T., Abramowicz M.J., Vanderwinden J.-M.,
RA   Kravcenkiene I., Baric I., Silengo M., Martucciello G., Romeo G.;
RT   "Frequency of RET mutations in long- and short-segment Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:243-249(1997).
RN   [63]
RP   VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618.
RX   PubMed=9259198;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<155::AID-HUMU7>3.3.CO;2-G;
RA   Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S.,
RA   Grynberg E., Yakobson E., Graff E., Lapidot M.;
RT   "Cys 618 Arg mutation in the RET proto-oncogene associated with
RT   familial medullary thyroid carcinoma and maternally transmitted
RT   Hirschsprung's disease suggesting a role for imprinting.";
RL   Hum. Mutat. 10:155-159(1997).
RN   [64]
RP   VARIANT MEN2B PHE-883.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=9360560; DOI=10.1210/jc.82.11.3902;
RA   Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M.,
RA   Mulligan L.M., Zajac J.D., Robinson B.G., Eng C.;
RT   "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene
RT   in multiple endocrine neoplasia type 2B without codon 918 mutation.";
RL   J. Clin. Endocrinol. Metab. 82:3902-3904(1997).
RN   [65]
RP   VARIANT MTC ALA-891.
RX   PubMed=9398735; DOI=10.1210/jc.82.12.4176;
RA   Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U.,
RA   Colantuoni V., Buys C.H.C.M.;
RT   "A novel point mutation in the intracellular domain of the ret
RT   protooncogene in a family with medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:4176-4178(1997).
RN   [66]
RP   VARIANTS HSCR1 SER-174 AND TYR-197.
RX   PubMed=9094028; DOI=10.1016/S0022-3468(97)90616-3;
RA   Kusafuka T., Wang Y., Puri P.;
RT   "Mutation analysis of the RET, the endothelin-B receptor, and the
RT   endothelin-3 genes in sporadic cases of Hirschsprung's disease.";
RL   J. Pediatr. Surg. 32:501-504(1997).
RN   [67]
RP   VARIANTS MTC; MEN2A AND MEN2B, AND VARIANT SER-691.
RX   PubMed=9223675; DOI=10.1038/sj.onc.1201102;
RA   Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K.,
RA   Kitagawa W., Akasu H., Takami H., Tanaka S., Wells S.A. Jr.;
RT   "Novel germline RET proto-oncogene mutations associated with medullary
RT   thyroid carcinoma (MTC): mutation analysis in Japanese patients with
RT   MTC.";
RL   Oncogene 14:3103-3106(1997).
RN   [68]
RP   VARIANT MEN2B PHE-883.
RX   PubMed=9294615; DOI=10.1038/sj.onc.1201481;
RA   Smith D.P., Houghton C., Ponder B.A.J.;
RT   "Germline mutation of RET codon 883 in two cases of de novo MEN 2B.";
RL   Oncogene 15:1213-1217(1997).
RN   [69]
RP   VARIANT CCHS LEU-1039, AND VARIANT SER-691.
RX   PubMed=9497256; DOI=10.1086/301759;
RA   Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M.,
RA   Gaultier C., Munnich A., Lyonnet S.;
RT   "Mutations of the RET-GDNF signaling pathway in Ondine's curse.";
RL   Am. J. Hum. Genet. 62:715-717(1998).
RN   [70]
RP   VARIANT MTC GLY-611.
RX   PubMed=9677065;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<271::AID-AJMG13>3.0.CO;2-C;
RA   Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V.,
RA   Rivera-Fillat F.;
RT   "Novel point mutation in exon 10 of the RET proto-oncogene in a family
RT   with medullary thyroid carcinoma.";
RL   Am. J. Med. Genet. 78:271-273(1998).
RN   [71]
RP   VARIANT CYS-982.
RX   PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [72]
RP   VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS
RP   HSCR1 TYR-609; SER-618; ARG-620 AND TRP-620.
RX   PubMed=9384613; DOI=10.1093/hmg/7.1.129;
RA   Decker R.A., Peacock M.L., Watson P.;
RT   "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10
RT   genotypes and strong genotype-phenotype correlation.";
RL   Hum. Mol. Genet. 7:129-134(1998).
RN   [73]
RP   VARIANT MEN2A CYS-ARG-THR-636 INS.
RX   PubMed=9452064;
RA   Hoeppner W., Dralle H., Brabant G.;
RT   "Duplication of 9 base pairs in the critical cysteine-rich domain of
RT   the RET proto-oncogene causes multiple endocrine neoplasia type 2A.";
RL   Hum. Mutat. Suppl. 1:S128-S130(1998).
RN   [74]
RP   VARIANT MTC MET-804.
RX   PubMed=9452077;
RA   Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E.,
RA   Colantuoni V.;
RT   "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET
RT   proto-oncogene in two families affected by familial medullary thyroid
RT   carcinoma.";
RL   Hum. Mutat. Suppl. 1:S167-S171(1998).
RN   [75]
RP   VARIANTS MTC/MEN2A PHE-790 AND PHE-791.
RX   PubMed=9506724; DOI=10.1210/jc.83.3.770;
RA   Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P.,
RA   Grussendorf M., Raue F., Ritter M.M., Hoeppner W.;
RT   "A new hot spot for mutations in the ret protooncogene causing
RT   familial medullary thyroid carcinoma and multiple endocrine neoplasia
RT   type 2A.";
RL   J. Clin. Endocrinol. Metab. 83:770-774(1998).
RN   [76]
RP   VARIANTS MTC AND MEN2A.
RX   PubMed=9621513; DOI=10.1007/s100380050048;
RA   Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A.,
RA   Nakamura Y.;
RT   "Mutational analysis of the RET proto-oncogene in 71 Japanese patients
RT   with medullary thyroid carcinoma.";
RL   J. Hum. Genet. 43:101-106(1998).
RN   [77]
RP   VARIANTS HSCR1 LYS-626 AND GLN-813.
RX   PubMed=10090908; DOI=10.1086/302329;
RA   Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A.,
RA   Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A.,
RA   Ceccherini I.;
RT   "Double heterozygosity for a RET substitution interfering with
RT   splicing and an EDNRB missense mutation in Hirschsprung disease.";
RL   Am. J. Hum. Genet. 64:1216-1221(1999).
RN   [78]
RP   VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061.
RX   PubMed=10484767; DOI=10.1093/hmg/8.11.1989;
RA   Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S.,
RA   Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.;
RT   "Two distinct mutations of the RET receptor causing Hirschsprung's
RT   disease impair the binding of signalling effectors to a
RT   multifunctional docking site.";
RL   Hum. Mol. Genet. 8:1989-1999(1999).
RN   [79]
RP   VARIANT MTC GLU-GLU-CYS-531 INS.
RX   PubMed=10323403; DOI=10.1210/jc.84.5.1700;
RA   Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P.,
RA   Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.;
RT   "A novel 9-base pair duplication in RET exon 8 in familial medullary
RT   thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:1700-1704(1999).
RN   [80]
RP   VARIANT MEN2A GLY-640.
RX   PubMed=10522989; DOI=10.1210/jc.84.10.3522;
RA   Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D.,
RA   Bellastella A., Colantuoni V.;
RT   "A novel case of multiple endocrine neoplasia type 2A associated with
RT   two de novo mutations of the RET protooncogene.";
RL   J. Clin. Endocrinol. Metab. 84:3522-3527(1999).
RN   [81]
RP   VARIANTS MTC MET-804 AND LEU-844.
RX   PubMed=10826520; DOI=10.1055/s-2000-5806;
RA   Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.;
RT   "A RET double mutation in the germline of a kindred with FMTC.";
RL   Exp. Clin. Endocrinol. Diabetes 108:128-132(2000).
RN   [82]
RP   VARIANT GLN-600.
RX   PubMed=10612852;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<122::AID-HUMU41>3.0.CO;2-7;
RA   Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G.,
RA   Borrego S.;
RT   "A new germline mutation, R600Q, within the coding region of RET
RT   proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?";
RL   Hum. Mutat. 15:122-122(2000).
RN   [83]
RP   VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394.
RX   PubMed=10618407; DOI=10.1073/pnas.97.1.268;
RA   Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D.,
RA   Buys C.H.C.M., Lyonnet S., Chakravarti A.;
RT   "A human model for multigenic inheritance: phenotypic expression in
RT   Hirschsprung disease requires both the RET gene and a new 9q31
RT   locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000).
RN   [84]
RP   VARIANTS MTC GLY-639; GLY-641 AND PHE-922.
RX   PubMed=11692159; DOI=10.1007/s001090100250;
RA   Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N.,
RA   Hosch S.B., Garkavtseva R.F., Izbicki J.R.;
RT   "Three novel mutations in the RET proto-oncogene.";
RL   J. Mol. Med. 79:609-612(2001).
RN   [85]
RP   VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634;
RP   TRP-634 AND PHE-791.
RX   PubMed=12000816; DOI=10.1056/NEJMoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O.,
RA   Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K.,
RA   Januszewicz A., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W.,
RA   Treier M., Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M.,
RA   Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M.,
RA   Peczkowska M., Szmigielski C., Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [86]
RP   VARIANT CCHS HIS-114.
RX   PubMed=12086152; DOI=10.1620/tjem.196.241;
RA   Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K.,
RA   Hashimoto M., Hasegawa H., Shirasawa S., Hayasaka K.;
RT   "Congenital central hypoventilation syndrome: a novel mutation of the
RT   RET gene in an isolated case.";
RL   Tohoku J. Exp. Med. 196:241-246(2002).
RN   [87]
RP   VARIANTS ASN-489; SER-691 AND CYS-982, AND VARIANTS CCHS HIS-67;
RP   HIS-114 AND GLU-432.
RX   PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [88]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [89]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489;
RP   SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [90]
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918;
RP   LEU-1049 AND SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND
RP   CHARACTERIZATION OF VARIANTS THR-198; ALA-376; HIS-394; ILE-778;
RP   SER-894; LEU-1049 AND SER-1067.
RX   PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008;
RA   Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E.,
RA   Freemerman A.J.;
RT   "Renal aplasia in humans is associated with RET mutations.";
RL   Am. J. Hum. Genet. 82:344-351(2008).
RN   [91]
RP   VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; HIS-114; GLY-145;
RP   LEU-155; PRO-175; ALA-278; PRO-278; ASN-300; GLN-313; ILE-316;
RP   LEU-339; TYR-353; GLN-360; MET-397; MET-412; ARG-423; LYS-480;
RP   GLN-595; LEU-679; GLN-694; SER-783; ARG-830; THR-907; LEU-961;
RP   VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS ASN-278 AND MET-292.
RX   PubMed=22174939; DOI=10.1371/journal.pone.0028986;
RA   So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K.,
RA   Diem N.N., Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H.,
RA   Yuan Z.W., Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L.,
RA   Chan I.H., Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C.,
RA   Cherny S.S., Tam P.K., Garcia-Barcelo M.M.;
RT   "RET mutational spectrum in Hirschsprung disease: evaluation of 601
RT   Chinese patients.";
RL   PLoS ONE 6:E28986-E28986(2011).
CC   -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous
CC       cellular mechanisms including cell proliferation, neuronal
CC       navigation, cell migration, and cell differentiation upon binding
CC       with glial cell derived neurotrophic factor family ligands.
CC       Phosphorylates PTK2/FAK1. Regulates both cell death/survival
CC       balance and positional information. Required for the molecular
CC       mechanisms orchestration during intestine organogenesis; involved
CC       in the development of enteric nervous system and renal
CC       organogenesis during embryonic life, and promotes the formation of
CC       Peyer's patch-like structures, a major component of the gut-
CC       associated lymphoid tissue. Modulates cell adhesion via its
CC       cleavage by caspase in sympathetic neurons and mediates cell
CC       migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner.
CC       Involved in the development of the neural crest. Active in the
CC       absence of ligand, triggering apoptosis through a mechanism that
CC       requires receptor intracellular caspase cleavage. Acts as a
CC       dependence receptor; in the presence of the ligand GDNF in
CC       somatotrophs (within pituitary), promotes survival and down
CC       regulates growth hormone (GH) production, but triggers apoptosis
CC       in absence of GDNF. Regulates nociceptor survival and size.
CC       Triggers the differentiation of rapidly adapting (RA)
CC       mechanoreceptors. Mediator of several diseases such as
CC       neuroendocrine cancers; these diseases are characterized by
CC       aberrant integrins-regulated cell migration.
CC       {ECO:0000269|PubMed:20064382, ECO:0000269|PubMed:20616503,
CC       ECO:0000269|PubMed:20702524, ECO:0000269|PubMed:21357690,
CC       ECO:0000269|PubMed:21454698}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines
CC       derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-
CC       thienyl) nicotinonitrile analogs, 3- and 4-substituted beta-
CC       carbolin-1-ones, vandetanib, motesanib, sorafenib (BAY 43-9006),
CC       cabozantinib (XL184), sunitinib, and withaferin A (WA).
CC       Inactivation by sorafenib both reduces kinase activity and
CC       promotes lysosomal degradation. {ECO:0000269|PubMed:17664273,
CC       ECO:0000269|PubMed:17884497, ECO:0000269|PubMed:19053769,
CC       ECO:0000269|PubMed:20117004, ECO:0000269|PubMed:20409618,
CC       ECO:0000269|PubMed:20605972, ECO:0000269|PubMed:21134556}.
CC   -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of
CC       DOK2, DOK4 and DOK5. The phosphorylated form interacts with PLCG1
CC       and GRB7. Interacts (not phosphorylated) with CC PTK2/FAK1 (via
CC       FERM domain). Extracellular cell-membrane anchored RET cadherin
CC       fragments form complex in neurons with reduced trophic status,
CC       preferentially at the contact sites between somas. Interacts with
CC       AIP in the pituitary gland; this interaction prevents the
CC       formation of the AIP-survivin complex. Binds to ARTN. Interacts
CC       (inactive) with CBLC and CD2AP; dissociates upon activation by
CC       GDNF which increases CBLC:CD2AP interaction.
CC       {ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:19366855, ECO:0000269|PubMed:20117004,
CC       ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}.
CC   -!- INTERACTION:
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-2480756, EBI-945833;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-2480756, EBI-79387;
CC       Q62985:Sh2b1 (xeno); NbExp=3; IntAct=EBI-2480756, EBI-7395583;
CC       P40763:STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}.
CC       Endosome membrane {ECO:0000269|PubMed:19823924}; Single-pass type
CC       I membrane protein {ECO:0000269|PubMed:19823924}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RET51;
CC         IsoId=P07949-1; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=2; Synonyms=RET9;
CC         IsoId=P07949-2; Sequence=VSP_040735;
CC   -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3.
CC       {ECO:0000269|PubMed:19853745}.
CC   -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon
CC       ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015
CC       and Tyr-1062. {ECO:0000269|PubMed:11061555,
CC       ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:16778204,
CC       ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004}.
CC   -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase
CC       fragment is able to induce cell death. The extracellular cell-
CC       membrane anchored RET cadherin fragment accelerates cell adhesion
CC       in sympathetic neurons. {ECO:0000269|PubMed:21357690}.
CC   -!- POLYMORPHISM: The Cys-982 polymorphism may be associated with an
CC       increased risk for developing Hirschsprung disease.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder
CC       of neural crest development characterized by absence of enteric
CC       ganglia along a variable length of the intestine. It is the most
CC       common cause of congenital intestinal obstruction. Early symptoms
CC       range from complete acute neonatal obstruction, characterized by
CC       vomiting, abdominal distention and failure to pass stool, to
CC       chronic constipation in the older child.
CC       {ECO:0000269|PubMed:10090908, ECO:0000269|PubMed:10484767,
CC       ECO:0000269|PubMed:10618407, ECO:0000269|PubMed:22174939,
CC       ECO:0000269|PubMed:7581377, ECO:0000269|PubMed:7633441,
CC       ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:7881414,
CC       ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939,
CC       ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527,
CC       ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9259198,
CC       ECO:0000269|PubMed:9384613, ECO:0000269|Ref.56}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare
CC       tumor derived from the C cells of the thyroid. Three hereditary
CC       forms are known, that are transmitted in an autosomal dominant
CC       fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple
CC       neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which
CC       occurs in 25-30% of MTC cases and where MTC is the only clinical
CC       manifestation. {ECO:0000269|PubMed:10323403,
CC       ECO:0000269|PubMed:10826520, ECO:0000269|PubMed:11692159,
CC       ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675,
CC       ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
CC       ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249,
CC       ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198,
CC       ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077,
CC       ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513,
CC       ECO:0000269|PubMed:9677065}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon
CC       inherited cancer syndrome characterized by predisposition to MTC
CC       and phaeochromocytoma which is associated with marfanoid habitus,
CC       mucosal neuromas, skeletal and ophthalmic abnormalities, and
CC       ganglioneuromas of the intestine tract. Then the disease
CC       progresses rapidly with the development of metastatic MTC and a
CC       pheochromocytome in 50% of cases. {ECO:0000269|PubMed:7906417,
CC       ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697,
CC       ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-
CC       producing tumor of chromaffin tissue of the adrenal medulla or
CC       sympathetic paraganglia. The cardinal symptom, reflecting the
CC       increased secretion of epinephrine and norepinephrine, is
CC       hypertension, which may be persistent or intermittent.
CC       {ECO:0000269|PubMed:12000816}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most
CC       frequent form of medullary thyroid cancer (MTC). It is an
CC       inherited cancer syndrome characterized by MTC, phaeochromocytoma
CC       and/or hyperparathyroidism. {ECO:0000269|PubMed:10522989,
CC       ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:8099202,
CC       ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9097963, ECO:0000269|PubMed:9384613,
CC       ECO:0000269|PubMed:9452064}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Various chromosomal aberrations involving RET are
CC       known. Some of them have been found in papillary thyroid
CC       carcinomas (PTCs) (PubMed:12787916, PubMed:2406025,
CC       PubMed:10980597, PubMed:10439047). Inversion inv(10)(q11.2;q21)
CC       generates the RET/CCDC6 (PTC1) oncogene (PubMed:2406025).
CC       Inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3)
CC       oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 generates
CC       the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). Translocation
CC       t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion
CC       (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with
CC       TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916).
CC       Translocation t(1;10)(p13;q11) with TRIM33 generates the
CC       TRIM33/RET (PTC7) oncogene (PubMed:10439047). Translocation
CC       t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6)
CC       oncogene (PubMed:10439047). Translocation t(6;10)(p21.3;q11.2)
CC       with TRIM27/RFP generates the TRIM27/RET oncogene
CC       (PubMed:3037315). {ECO:0000269|PubMed:10439047,
CC       ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916,
CC       ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021,
CC       ECO:0000269|PubMed:3037315}.
CC   -!- DISEASE: Note=Mutations in RET have been detected in patients with
CC       renal agenesis suggesting a possible involvement of this gene in
CC       disease pathogenesis.
CC   -!- DISEASE: Congenital central hypoventilation syndrome (CCHS)
CC       [MIM:209880]: Rare disorder characterized by abnormal control of
CC       respiration in the absence of neuromuscular or lung disease, or an
CC       identifiable brain stem lesion. A deficiency in autonomic control
CC       of respiration results in inadequate or negligible ventilatory and
CC       arousal responses to hypercapnia and hypoxemia.
CC       {ECO:0000269|PubMed:12086152, ECO:0000269|PubMed:14566559,
CC       ECO:0000269|PubMed:9497256}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor
CC       regression in medullary thyroid carcinomas (MTC).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 cadherin domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00043}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36524.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAA36786.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAA33787.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAC14882.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RETID76.html";
CC   -!- WEB RESOURCE: Name=MEN2 RET database;
CC       URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK291807; BAF84496.1; -; mRNA.
DR   EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004257; AAH04257.1; -; mRNA.
DR   EMBL; X15262; CAA33333.1; -; mRNA.
DR   EMBL; X12949; CAA31408.1; -; mRNA.
DR   EMBL; M16029; AAA36786.1; ALT_INIT; mRNA.
DR   EMBL; X15786; CAA33787.1; ALT_INIT; mRNA.
DR   EMBL; M31213; AAA36524.1; ALT_INIT; mRNA.
DR   EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA.
DR   CCDS; CCDS53525.1; -. [P07949-2]
DR   CCDS; CCDS7200.1; -. [P07949-1]
DR   PIR; A27203; TVHURE.
DR   PIR; A34630; A34630.
DR   PIR; B34735; B34735.
DR   PIR; S05582; S05582.
DR   RefSeq; NP_065681.1; NM_020630.4. [P07949-2]
DR   RefSeq; NP_066124.1; NM_020975.4. [P07949-1]
DR   RefSeq; XP_011538329.1; XM_011540027.1. [P07949-1]
DR   UniGene; Hs.350321; -.
DR   PDB; 1XPD; Model; -; A=709-1013.
DR   PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013.
DR   PDB; 2IVT; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2IVU; X-ray; 2.50 A; A=705-1013.
DR   PDB; 2IVV; X-ray; 2.25 A; A=705-1013.
DR   PDB; 2X2K; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2X2L; X-ray; 2.00 A; A=705-1013.
DR   PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013.
DR   PDB; 2X2U; X-ray; 2.00 A; A=29-270.
DR   PDB; 4CKI; X-ray; 2.12 A; A=705-1013.
DR   PDB; 4CKJ; X-ray; 1.65 A; A=705-1013.
DR   PDB; 4UX8; EM; 24.00 A; A/B=29-635.
DR   PDBsum; 1XPD; -.
DR   PDBsum; 2IVS; -.
DR   PDBsum; 2IVT; -.
DR   PDBsum; 2IVU; -.
DR   PDBsum; 2IVV; -.
DR   PDBsum; 2X2K; -.
DR   PDBsum; 2X2L; -.
DR   PDBsum; 2X2M; -.
DR   PDBsum; 2X2U; -.
DR   PDBsum; 4CKI; -.
DR   PDBsum; 4CKJ; -.
DR   PDBsum; 4UX8; -.
DR   ProteinModelPortal; P07949; -.
DR   SMR; P07949; 29-508, 713-1012.
DR   BioGrid; 111911; 29.
DR   DIP; DIP-41449N; -.
DR   IntAct; P07949; 29.
DR   MINT; MINT-1217685; -.
DR   STRING; 9606.ENSP00000347942; -.
DR   BindingDB; P07949; -.
DR   ChEMBL; CHEMBL2041; -.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   GuidetoPHARMACOLOGY; 2185; -.
DR   iPTMnet; P07949; -.
DR   PhosphoSite; P07949; -.
DR   BioMuta; RET; -.
DR   DMDM; 547807; -.
DR   MaxQB; P07949; -.
DR   PaxDb; P07949; -.
DR   PRIDE; P07949; -.
DR   DNASU; 5979; -.
DR   Ensembl; ENST00000340058; ENSP00000344798; ENSG00000165731. [P07949-2]
DR   Ensembl; ENST00000355710; ENSP00000347942; ENSG00000165731. [P07949-1]
DR   GeneID; 5979; -.
DR   KEGG; hsa:5979; -.
DR   UCSC; uc001jak.1; human. [P07949-2]
DR   UCSC; uc001jal.3; human. [P07949-1]
DR   CTD; 5979; -.
DR   GeneCards; RET; -.
DR   GeneReviews; RET; -.
DR   HGNC; HGNC:9967; RET.
DR   HPA; CAB002581; -.
DR   HPA; CAB018342; -.
DR   HPA; HPA008356; -.
DR   MalaCards; RET; -.
DR   MIM; 114500; phenotype.
DR   MIM; 142623; phenotype.
DR   MIM; 155240; phenotype.
DR   MIM; 162300; phenotype.
DR   MIM; 164761; gene.
DR   MIM; 171300; phenotype.
DR   MIM; 171400; phenotype.
DR   MIM; 209880; phenotype.
DR   neXtProt; NX_P07949; -.
DR   Orphanet; 1848; Bilateral renal agenesis.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 99803; Haddad syndrome.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 247698; Multiple endocrine neoplasia type 2A.
DR   Orphanet; 247709; Multiple endocrine neoplasia type 2B.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   Orphanet; 93100; Unilateral renal agenesis.
DR   PharmGKB; PA34335; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000010301; -.
DR   HOVERGEN; HBG002609; -.
DR   InParanoid; P07949; -.
DR   KO; K05126; -.
DR   OMA; WRQGDGK; -.
DR   OrthoDB; EOG7NGQ9N; -.
DR   PhylomeDB; P07949; -.
DR   TreeFam; TF317640; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   SignaLink; P07949; -.
DR   ChiTaRS; RET; human.
DR   EvolutionaryTrace; P07949; -.
DR   GeneWiki; RET_proto-oncogene; -.
DR   GenomeRNAi; 5979; -.
DR   NextBio; 23271; -.
DR   PRO; PR:P07949; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P07949; -.
DR   CleanEx; HS_RET; -.
DR   ExpressionAtlas; P07949; baseline and differential.
DR   Genevisible; P07949; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:FlyBase.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl.
DR   GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   GO; GO:0060384; P:innervation; IEA:Ensembl.
DR   GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0042551; P:neuron maturation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; TAS:GOC.
DR   GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB.
DR   GO; GO:0014042; P:positive regulation of neuron maturation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:1903263; P:positive regulation of serine phosphorylation of STAT3 protein; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0007497; P:posterior midgut development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:Ensembl.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   Gene3D; 2.60.40.60; -; 1.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016249; Tyr_kinase_Ret_rcpt.
DR   Pfam; PF00028; Cadherin; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00112; CA; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49313; SSF49313; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50268; CADHERIN_2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Disease mutation; Disulfide bond; Endosome; Glycoprotein;
KW   Hirschsprung disease; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   CHAIN        29   1114       Proto-oncogene tyrosine-protein kinase
FT                                receptor Ret.
FT                                /FTId=PRO_0000024450.
FT   CHAIN        29    707       Extracellular cell-membrane anchored RET
FT                                cadherin 120 kDa fragment.
FT                                /FTId=PRO_0000415292.
FT   CHAIN       708   1017       Soluble RET kinase fragment.
FT                                /FTId=PRO_0000415293.
FT   TOPO_DOM     29    635       Extracellular. {ECO:0000255}.
FT   TRANSMEM    636    657       Helical. {ECO:0000255}.
FT   TOPO_DOM    658   1114       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      168    272       Cadherin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      724   1016       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     730    738       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      805    807       Inhibitors binding.
FT   ACT_SITE    874    874       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     758    758       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     892    892       Inhibitor.
FT   SITE        587    588       Breakpoint for translocation to form the
FT                                TRIM27/RET oncogene.
FT   SITE        707    708       Cleavage; by caspase-3.
FT   SITE        712    713       Breakpoint for translocation to form
FT                                PCM1-RET; RET-CCDC6; RET-GOLGA5; RET-
FT                                TRIM24 and RET-TRIM33 oncogenes.
FT   SITE       1017   1018       Cleavage; by caspase-3.
FT   MOD_RES     696    696       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     806    806       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES     900    900       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16928683}.
FT   MOD_RES     905    905       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204,
FT                                ECO:0000269|PubMed:16928683,
FT                                ECO:0000269|PubMed:20117004}.
FT   MOD_RES     981    981       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES    1015   1015       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11061555,
FT                                ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204}.
FT   MOD_RES    1062   1062       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11061555,
FT                                ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204}.
FT   MOD_RES    1090   1090       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES    1096   1096       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    151    151       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20473317}.
FT   CARBOHYD    199    199       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    343    343       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    361    361       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    367    367       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    377    377       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    394    394       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    448    448       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    554    554       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    137    142       {ECO:0000269|PubMed:20473317}.
FT   VAR_SEQ    1064   1114       MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPS
FT                                AAKLMDTFDS -> RISHAFTRF (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3037315}.
FT                                /FTId=VSP_040735.
FT   VARIANT      20     20       P -> L (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7633441}.
FT                                /FTId=VAR_009459.
FT   VARIANT      32     32       S -> L (in HSCR1; familial form;
FT                                dbSNP:rs76764689).
FT                                {ECO:0000269|PubMed:10618407,
FT                                ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006295.
FT   VARIANT      40     40       L -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:9043870}.
FT                                /FTId=VAR_009492.
FT   VARIANT      64     64       P -> L (in HSCR1; familial form;
FT                                dbSNP:rs77596424).
FT                                {ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006296.
FT   VARIANT      67     67       R -> H (in CCHS; dbSNP:rs192489011).
FT                                {ECO:0000269|PubMed:14566559}.
FT                                /FTId=VAR_018153.
FT   VARIANT      77     77       R -> C (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407}.
FT                                /FTId=VAR_009460.
FT   VARIANT      93     93       G -> S (in HSCR1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:7633441}.
FT                                /FTId=VAR_006297.
FT   VARIANT     114    114       R -> C (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067101.
FT   VARIANT     114    114       R -> H (in CCHS and HSCR1).
FT                                {ECO:0000269|PubMed:12086152,
FT                                ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_018154.
FT   VARIANT     142    142       C -> S (in HSCR1; sporadic form).
FT                                /FTId=VAR_006298.
FT   VARIANT     145    145       V -> G (in HSCR1; also in a colorectal
FT                                cancer sample; somatic mutation).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_035711.
FT   VARIANT     155    155       P -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067102.
FT   VARIANT     157    157       C -> Y (in HSCR1; unknown pathological
FT                                significance). {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009461.
FT   VARIANT     163    163       R -> Q (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs149403911).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041762.
FT   VARIANT     174    174       F -> S (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9094028}.
FT                                /FTId=VAR_009462.
FT   VARIANT     175    175       R -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067103.
FT   VARIANT     180    180       R -> P (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9090527}.
FT                                /FTId=VAR_009463.
FT   VARIANT     197    197       C -> Y (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9094028}.
FT                                /FTId=VAR_009464.
FT   VARIANT     198    198       P -> T (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF; dbSNP:rs76736111).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044392.
FT   VARIANT     231    231       R -> H (in HSCR1; familial form;
FT                                dbSNP:rs79661516).
FT                                /FTId=VAR_006299.
FT   VARIANT     251    251       E -> K (in HSCR1; familial form).
FT                                /FTId=VAR_006300.
FT   VARIANT     278    278       T -> A (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067104.
FT   VARIANT     278    278       T -> N (found in two patients with
FT                                Hirschsprung disease; dbSNP:rs35118262).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_041763.
FT   VARIANT     278    278       T -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067105.
FT   VARIANT     287    287       R -> Q (in HSCR1; sporadic form).
FT                                /FTId=VAR_006301.
FT   VARIANT     292    292       V -> M (found in patients with
FT                                Hirschsprung disease; unknown
FT                                pathological significance;
FT                                dbSNP:rs34682185).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_041764.
FT   VARIANT     300    300       D -> N (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067106.
FT   VARIANT     313    313       R -> Q (in HSCR1; dbSNP:rs77702891).
FT                                {ECO:0000269|PubMed:22174939,
FT                                ECO:0000269|PubMed:9090527}.
FT                                /FTId=VAR_009465.
FT   VARIANT     316    316       S -> I (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067107.
FT   VARIANT     330    330       R -> Q (in HSCR1; dbSNP:rs80236571).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006302.
FT   VARIANT     339    339       S -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067108.
FT   VARIANT     353    353       D -> Y (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067109.
FT   VARIANT     359    359       N -> K (in HSCR1; unknown pathological
FT                                significance). {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009466.
FT   VARIANT     360    360       R -> Q (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067110.
FT   VARIANT     360    360       R -> W (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_009467.
FT   VARIANT     376    376       V -> A (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044393.
FT   VARIANT     393    393       F -> L (in HSCR1; familial form;
FT                                dbSNP:rs78098482).
FT                                {ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006303.
FT   VARIANT     394    394       N -> H (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF). {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044394.
FT   VARIANT     394    394       N -> K (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407}.
FT                                /FTId=VAR_009468.
FT   VARIANT     397    397       V -> M (in HSCR1; dbSNP:rs183729115).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067111.
FT   VARIANT     399    399       P -> L (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_006304.
FT   VARIANT     412    412       V -> M (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067112.
FT   VARIANT     423    423       G -> R (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067113.
FT   VARIANT     432    432       A -> E (in CCHS).
FT                                {ECO:0000269|PubMed:14566559}.
FT                                /FTId=VAR_018155.
FT   VARIANT     475    475       R -> Q (in HSCR1; sporadic form;
FT                                dbSNP:rs138624658).
FT                                /FTId=VAR_006305.
FT   VARIANT     480    480       E -> K (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067114.
FT   VARIANT     489    489       D -> N (in dbSNP:rs9282834).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018156.
FT   VARIANT     531    531       C -> CEEC (in MTC; familial form).
FT                                {ECO:0000269|PubMed:10323403}.
FT                                /FTId=VAR_009469.
FT   VARIANT     549    550       Missing (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067115.
FT   VARIANT     593    593       G -> E (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035712.
FT   VARIANT     595    595       E -> Q (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067116.
FT   VARIANT     600    600       R -> Q. {ECO:0000269|PubMed:10612852}.
FT                                /FTId=VAR_008966.
FT   VARIANT     609    609       C -> G (in MEN2A).
FT                                /FTId=VAR_009470.
FT   VARIANT     609    609       C -> R (in MEN2A; dbSNP:rs77558292).
FT                                /FTId=VAR_009471.
FT   VARIANT     609    609       C -> W (in HSCR1; familial form).
FT                                {ECO:0000269|PubMed:7881414}.
FT                                /FTId=VAR_006307.
FT   VARIANT     609    609       C -> Y (in MTC, MEN2A and HSCR1; familial
FT                                and sporadic forms; dbSNP:rs77939446).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:9384613,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_006306.
FT   VARIANT     611    611       C -> G (in MTC; familial form).
FT                                {ECO:0000269|PubMed:9677065}.
FT                                /FTId=VAR_009472.
FT   VARIANT     611    611       C -> R (in MEN2A).
FT                                /FTId=VAR_009473.
FT   VARIANT     611    611       C -> S (in MEN2A).
FT                                /FTId=VAR_009474.
FT   VARIANT     611    611       C -> W (in MEN2A and MTC; familial form;
FT                                dbSNP:rs80069458).
FT                                {ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006308.
FT   VARIANT     611    611       C -> Y (in MEN2A).
FT                                /FTId=VAR_006309.
FT   VARIANT     618    618       C -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006312.
FT   VARIANT     618    618       C -> G (in MEN2A).
FT                                {ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006310.
FT   VARIANT     618    618       C -> R (in MEN2A, MTC and HSCR1;
FT                                dbSNP:rs76262710).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7881414,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:9259198}.
FT                                /FTId=VAR_006311.
FT   VARIANT     618    618       C -> S (in MEN2A, HSCR1 and MTC; familial
FT                                and sporadic forms; dbSNP:rs79781594).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8103403,
FT                                ECO:0000269|PubMed:9384613}.
FT                                /FTId=VAR_006313.
FT   VARIANT     618    618       C -> Y (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006314.
FT   VARIANT     620    620       C -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs77503355).
FT                                {ECO:0000269|PubMed:7915165}.
FT                                /FTId=VAR_006318.
FT   VARIANT     620    620       C -> G (in MEN2A and MTC; familial and
FT                                sporadic forms).
FT                                /FTId=VAR_006315.
FT   VARIANT     620    620       C -> R (in MEN2A, MTC and HSCR1; familial
FT                                and sporadic forms).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:7881414,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8103403,
FT                                ECO:0000269|PubMed:9090527,
FT                                ECO:0000269|PubMed:9384613,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_006316.
FT   VARIANT     620    620       C -> S (in MEN2A and MTC; familial form).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7860065}.
FT                                /FTId=VAR_006317.
FT   VARIANT     620    620       C -> W (in MEN2A and HSCR1).
FT                                {ECO:0000269|PubMed:9384613}.
FT                                /FTId=VAR_009475.
FT   VARIANT     620    620       C -> Y (in MEN2A).
FT                                {ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006319.
FT   VARIANT     626    626       Q -> K (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:10090908}.
FT                                /FTId=VAR_009476.
FT   VARIANT     630    630       C -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006320.
FT   VARIANT     630    630       C -> S (in MTC; sporadic form).
FT                                /FTId=VAR_009477.
FT   VARIANT     630    630       C -> Y (in MTC; familial and sporadic
FT                                forms).
FT                                /FTId=VAR_009478.
FT   VARIANT     631    631       D -> G (in thyroid carcinoma; somatic
FT                                mutation; dbSNP:rs121913308).
FT                                /FTId=VAR_006321.
FT   VARIANT     632    634       ELC -> DVR (in MEN2A).
FT                                /FTId=VAR_006322.
FT   VARIANT     634    635       CR -> WG (in MEN2A).
FT                                /FTId=VAR_006329.
FT   VARIANT     634    634       C -> CHELC (in MEN2A).
FT                                {ECO:0000269|PubMed:9097963}.
FT                                /FTId=VAR_009479.
FT   VARIANT     634    634       C -> F (in MEN2A and pheochromocytoma).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006324.
FT   VARIANT     634    634       C -> G (in MEN2A and pheochromocytoma).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006323.
FT   VARIANT     634    634       C -> R (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; also found as somatic
FT                                mutation in a sporadic thyroid
FT                                carcinoma). {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006326.
FT   VARIANT     634    634       C -> S (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006327.
FT   VARIANT     634    634       C -> W (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                {ECO:0000269|PubMed:12000816}.
FT                                /FTId=VAR_006328.
FT   VARIANT     634    634       C -> Y (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006325.
FT   VARIANT     636    636       T -> TCRT (in MEN2A).
FT                                {ECO:0000269|PubMed:9452064}.
FT                                /FTId=VAR_006330.
FT   VARIANT     639    639       A -> G (in MTC; sporadic form).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012743.
FT   VARIANT     640    640       A -> G (in MEN2A; dbSNP:rs78935588).
FT                                {ECO:0000269|PubMed:10522989}.
FT                                /FTId=VAR_009480.
FT   VARIANT     641    641       A -> G (in MTC; sporadic form).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012744.
FT   VARIANT     679    679       P -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067117.
FT   VARIANT     690    690       S -> P (in HSCR1; sporadic form).
FT                                /FTId=VAR_006331.
FT   VARIANT     691    691       G -> S (in dbSNP:rs1799939).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9223675,
FT                                ECO:0000269|PubMed:9497256}.
FT                                /FTId=VAR_006332.
FT   VARIANT     694    694       R -> Q (in HSCR1; dbSNP:rs141185224).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067118.
FT   VARIANT     749    749       R -> T (in dbSNP:rs34288963).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041765.
FT   VARIANT     762    762       E -> Q (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_009481.
FT   VARIANT     765    765       S -> P (in HSCR1; dbSNP:rs75075748).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938,
FT                                ECO:0000269|PubMed:9043870}.
FT                                /FTId=VAR_009493.
FT   VARIANT     767    767       S -> R (in HSCR1; sporadic form).
FT                                /FTId=VAR_006334.
FT   VARIANT     768    768       E -> D (in MTC; familial and sporadic
FT                                forms; dbSNP:rs78014899).
FT                                {ECO:0000269|PubMed:7784092,
FT                                ECO:0000269|PubMed:7845675,
FT                                ECO:0000269|PubMed:8807338}.
FT                                /FTId=VAR_006335.
FT   VARIANT     778    778       V -> I (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated;
FT                                dbSNP:rs75686697).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044395.
FT   VARIANT     783    783       N -> S (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067119.
FT   VARIANT     790    790       L -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs75030001).
FT                                {ECO:0000269|PubMed:9506724}.
FT                                /FTId=VAR_009482.
FT   VARIANT     791    791       Y -> F (in HSCR1, pheochromocytoma, MTC
FT                                and MEN2A; familial form;
FT                                dbSNP:rs77724903).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:9090527,
FT                                ECO:0000269|PubMed:9506724}.
FT                                /FTId=VAR_009483.
FT   VARIANT     804    804       V -> L (in MTC; familial form;
FT                                dbSNP:rs79658334).
FT                                {ECO:0000269|PubMed:7784092}.
FT                                /FTId=VAR_006336.
FT   VARIANT     804    804       V -> M (in MTC; familial form;
FT                                dbSNP:rs79658334).
FT                                {ECO:0000269|PubMed:10826520,
FT                                ECO:0000269|PubMed:9452077}.
FT                                /FTId=VAR_006337.
FT   VARIANT     813    813       R -> Q (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:10090908}.
FT                                /FTId=VAR_009484.
FT   VARIANT     826    826       Y -> S (in dbSNP:rs34617196).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041766.
FT   VARIANT     830    830       G -> R (in HSCR1; dbSNP:rs200127630).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067120.
FT   VARIANT     844    844       R -> L (in MTC; familial form;
FT                                dbSNP:rs55947360).
FT                                {ECO:0000269|PubMed:10826520,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_011582.
FT   VARIANT     873    873       R -> Q (in HSCR1; sporadic form).
FT                                /FTId=VAR_006338.
FT   VARIANT     883    883       A -> F (in MEN2B; somatic mutation in
FT                                sporadic medullary thyroid carcinoma;
FT                                requires 2 nucleotide substitutions).
FT                                {ECO:0000269|PubMed:9294615,
FT                                ECO:0000269|PubMed:9360560}.
FT                                /FTId=VAR_009485.
FT   VARIANT     891    891       S -> A (in MTC; familial form;
FT                                dbSNP:rs75234356).
FT                                {ECO:0000269|PubMed:9398735}.
FT                                /FTId=VAR_009486.
FT   VARIANT     893    893       F -> L (in HSCR1; sporadic form).
FT                                /FTId=VAR_006339.
FT   VARIANT     894    894       G -> S (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044396.
FT   VARIANT     897    897       R -> Q (in HSCR1; sporadic form;
FT                                dbSNP:rs76087194).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938}.
FT                                /FTId=VAR_006340.
FT   VARIANT     907    907       K -> E (in HSCR1; sporadic form).
FT                                /FTId=VAR_006341.
FT   VARIANT     907    907       K -> T (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067121.
FT   VARIANT     918    918       M -> T (in MEN2B and MTC; sporadic form;
FT                                somatic mutation; also found in a patient
FT                                with renal agenesis; dbSNP:rs74799832).
FT                                {ECO:0000269|PubMed:18252215,
FT                                ECO:0000269|PubMed:7906417,
FT                                ECO:0000269|PubMed:7906866,
FT                                ECO:0000269|PubMed:7911697,
FT                                ECO:0000269|PubMed:8595427,
FT                                ECO:0000269|PubMed:8807338}.
FT                                /FTId=VAR_006342.
FT   VARIANT     921    921       E -> K (in HSCR1; sporadic form).
FT                                /FTId=VAR_006343.
FT   VARIANT     922    922       S -> F (in MTC; sporadic form).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012745.
FT   VARIANT     922    922       S -> Y (rare polymorphism).
FT                                {ECO:0000269|PubMed:8595427}.
FT                                /FTId=VAR_009487.
FT   VARIANT     946    946       T -> M (in MEN2B and MTC; familial form).
FT                                /FTId=VAR_006345.
FT   VARIANT     961    961       F -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067122.
FT   VARIANT     972    972       R -> G (in HSCR1; familial form;
FT                                dbSNP:rs76534745).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938}.
FT                                /FTId=VAR_006346.
FT   VARIANT     973    973       P -> L (in HSCR1; familial form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_006347.
FT   VARIANT     980    980       M -> T (in HSCR1; sporadic form).
FT                                /FTId=VAR_006348.
FT   VARIANT     982    982       R -> C (in dbSNP:rs17158558).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:9760196}.
FT                                /FTId=VAR_006349.
FT   VARIANT    1039   1039       P -> L (in CCHS; with colonic
FT                                aganglionosis; dbSNP:rs79853121).
FT                                {ECO:0000269|PubMed:9497256}.
FT                                /FTId=VAR_018157.
FT   VARIANT    1039   1039       P -> Q.
FT                                /FTId=VAR_009488.
FT   VARIANT    1049   1049       P -> L (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF). {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044397.
FT   VARIANT    1052   1052       L -> V (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067123.
FT   VARIANT    1059   1059       Missing (in HSCR1).
FT                                {ECO:0000269|PubMed:10484767,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009489.
FT   VARIANT    1061   1061       L -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:10484767,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009490.
FT   VARIANT    1062   1062       Y -> C (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067124.
FT   VARIANT    1064   1064       M -> T (in HSCR1; familial form).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_009491.
FT   VARIANT    1067   1067       P -> S (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF). {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044398.
FT   VARIANT    1112   1112       F -> Y (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041767.
FT   MUTAGEN     707    707       D->N: Impaired cleavage by caspase-3 and
FT                                loss of induced cell death.
FT                                {ECO:0000269|PubMed:21357690}.
FT   MUTAGEN     708   1114       Missing: Loss of induced cell death, but
FT                                increased cell aggregation.
FT                                {ECO:0000269|PubMed:21357690}.
FT   MUTAGEN     758    758       K->R: Loss of kinase activity. No effect
FT                                on interaction with and dissociation from
FT                                CBLC and CD2AP.
FT                                {ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:21357690}.
FT   CONFLICT    647    647       I -> V (in Ref. 6; AAA36786).
FT                                {ECO:0000305}.
FT   CONFLICT    664    664       A -> S (in Ref. 1; BAF84496).
FT                                {ECO:0000305}.
FT   CONFLICT    750    750       A -> G (in Ref. 9; AAA36524).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       S -> P (in Ref. 6; AAA36786).
FT                                {ECO:0000305}.
FT   STRAND       30     32       {ECO:0000244|PDB:2X2U}.
FT   STRAND       34     41       {ECO:0000244|PDB:2X2U}.
FT   STRAND       49     52       {ECO:0000244|PDB:2X2U}.
FT   STRAND       70     73       {ECO:0000244|PDB:2X2U}.
FT   HELIX        75     77       {ECO:0000244|PDB:2X2U}.
FT   STRAND       79     82       {ECO:0000244|PDB:2X2U}.
FT   STRAND       85     88       {ECO:0000244|PDB:2X2U}.
FT   TURN         90     92       {ECO:0000244|PDB:2X2U}.
FT   STRAND       94     99       {ECO:0000244|PDB:2X2U}.
FT   HELIX       103    111       {ECO:0000244|PDB:2X2U}.
FT   STRAND      120    126       {ECO:0000244|PDB:2X2U}.
FT   TURN        139    141       {ECO:0000244|PDB:2X2U}.
FT   STRAND      142    152       {ECO:0000244|PDB:2X2U}.
FT   HELIX       157    159       {ECO:0000244|PDB:2X2U}.
FT   HELIX       162    166       {ECO:0000244|PDB:2X2U}.
FT   STRAND      174    178       {ECO:0000244|PDB:2X2U}.
FT   STRAND      184    187       {ECO:0000244|PDB:2X2U}.
FT   HELIX       191    196       {ECO:0000244|PDB:2X2U}.
FT   STRAND      202    208       {ECO:0000244|PDB:2X2U}.
FT   STRAND      212    215       {ECO:0000244|PDB:2X2U}.
FT   STRAND      222    227       {ECO:0000244|PDB:2X2U}.
FT   TURN        231    233       {ECO:0000244|PDB:2X2U}.
FT   STRAND      235    245       {ECO:0000244|PDB:2X2U}.
FT   STRAND      252    263       {ECO:0000244|PDB:2X2U}.
FT   HELIX       705    711       {ECO:0000244|PDB:4CKJ}.
FT   TURN        715    717       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       721    723       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      724    732       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      734    744       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       746    748       {ECO:0000244|PDB:2IVS}.
FT   STRAND      750    760       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       766    779       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      790    794       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      796    798       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      801    805       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       812    817       {ECO:0000244|PDB:4CKJ}.
FT   TURN        819    821       {ECO:0000244|PDB:2IVS}.
FT   STRAND      844    846       {ECO:0000244|PDB:4CKI}.
FT   HELIX       848    867       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       877    879       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      880    883       {ECO:0000244|PDB:4CKJ}.
FT   TURN        884    886       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      887    890       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       893    895       {ECO:0000244|PDB:2IVV}.
FT   TURN        900    902       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       915    917       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       920    925       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       930    945       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       957    959       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       960    965       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       978    987       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       992    994       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       998   1012       {ECO:0000244|PDB:4CKJ}.
SQ   SEQUENCE   1114 AA;  124319 MW;  A3DA0CE01A19A441 CRC64;
     MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP
     EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT
     VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR
     PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV
     AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD
     ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR
     NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA
     QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE
     LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR
     CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR
     GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY
     HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP
     RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK
     QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH
     PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
     EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL
     FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA
     STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA
     DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS
//
ID   PKD1_HUMAN              Reviewed;        4303 AA.
AC   P98161; Q15140; Q15141;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 3.
DT   17-FEB-2016, entry version 199.
DE   RecName: Full=Polycystin-1;
DE   AltName: Full=Autosomal dominant polycystic kidney disease 1 protein;
DE   Flags: Precursor;
GN   Name=PKD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-1092.
RX   PubMed=7736581;
RA   Gluecksmann-Kuis M.A., Tayber O., Woolf E.A., Bougueleret L., Deng N.,
RA   Alperin G.D., Iris F., Hawkins F., Munro C., Lakey N., Duyk G.,
RA   Schneider M.C., Geng L., Zhang F., Zhao Z., Torosian S., Reeders S.T.,
RA   Bork P., Pohlschmidt M., Loehning C., Kraus B., Nowicka U.,
RA   Leung A.L.S., Frischauf A.-M.;
RT   "Polycystic kidney disease: the complete structure of the PKD1 gene
RT   and its protein.";
RL   Cell 81:289-298(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2 AND 3), AND
RP   VARIANT GLN-739.
RX   PubMed=7663510; DOI=10.1038/ng0695-151;
RA   Hughes J., Ward C.J., Peral B., Aspinwall R., Clark K.,
RA   San Millan J.L., Gamble V., Harris P.C.;
RT   "The polycystic kidney disease 1 (PKD1) gene encodes a novel protein
RT   with multiple cell recognition domains.";
RL   Nat. Genet. 10:151-160(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 2769-4303.
RX   PubMed=8004675;
RA   Ward C.J., Peral B., Hughes J., Thomas S., Gamble V., Maccarthy A.B.,
RA   Sloane-Stanley J., Buckle V.J., Kearney L., Higgs D.R.,
RA   Ratcliffe P.J., Harris P.C., Roelfsema J.H., Spruit L.L., Saris J.J.,
RA   Dauwerse H.G., Peters D.J.M., Breuning M.H., Nellist M.,
RA   Brook-Carter P.T., Maheshwar M.M., Cordeiro I., Santos H., Cabral P.,
RA   Sampson J.R., Janssen B., Hesseling-Janssen A.L.W.,
RA   van den Ouweland A.M.W., Eussen B., Verhoef S., Lindhout D.,
RA   Halley D.J.J.;
RT   "The polycystic kidney disease 1 gene encodes a 14 kb transcript and
RT   lies within a duplicated region on chromosome 16.";
RL   Cell 77:881-894(1994).
RN   [5]
RP   ERRATUM.
RX   PubMed=8069919;
RA   Ward C.J., Peral B., Hughes J., Thomas S., Gamble V., Maccarthy A.B.,
RA   Sloane-Stanley J., Buckle V.J., Kearney L., Higgs D.R.,
RA   Ratcliffe P.J., Harris P.C., Roelfsema J.H., Spruit L.L., Saris J.J.,
RA   Dauwerse H.G., Peters D.J.M., Breuning M.H., Nellist M.,
RA   Brook-Carter P.T., Maheshwar M.M., Cordeiro I., Santos H., Cabral P.,
RA   Sampson J.R., Janssen B., Hesseling-Janssen A.L.W.,
RA   van den Ouweland A.M.W., Eussen B., Verhoef S., Lindhout D.,
RA   Halley D.J.J.;
RL   Cell 78:725-725(1994).
RN   [6]
RP   INTERACTION WITH RGS7, AND SUBCELLULAR LOCATION.
RX   PubMed=10339594; DOI=10.1073/pnas.96.11.6371;
RA   Kim E., Arnould T., Sellin L., Benzing T., Comella N., Kocher O.,
RA   Tsiokas L., Sukhatme V.P., Walz G.;
RT   "Interaction between RGS7 and polycystin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6371-6376(1999).
RN   [7]
RP   FUNCTION IN RENAL TUBULOGENESIS, CLEAVAGE AT GPS DOMAIN,
RP   CHARACTERIZATION OF VARIANTS PKD1 LYS-2771; PRO-2921; PRO-2993 AND
RP   ARG-3016, AND CHARACTERIZATION OF VARIANT GLN-2791.
RX   PubMed=12482949; DOI=10.1073/pnas.252484899;
RA   Qian F., Boletta A., Bhunia A.K., Xu H., Liu L., Ahrabi A.K.,
RA   Watnick T.J., Zhou F., Germino G.G.;
RT   "Cleavage of polycystin-1 requires the receptor for egg jelly domain
RT   and is disrupted by human autosomal-dominant polycystic kidney disease
RT   1-associated mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16981-16986(2002).
RN   [8]
RP   AUTOPROTEOLYTIC CLEAVAGE, DETERMINATION OF AUTOPROTEOLYTIC CLEAVAGE
RP   SITE, AND MUTAGENESIS OF THR-3049.
RX   PubMed=17525154; DOI=10.1074/jbc.M703218200;
RA   Wei W., Hackmann K., Xu H., Germino G., Qian F.;
RT   "Characterization of cis-autoproteolysis of polycystin-1, the product
RT   of human polycystic kidney disease 1 gene.";
RL   J. Biol. Chem. 282:21729-21737(2007).
RN   [9]
RP   PHOSPHORYLATION AT SER-4166, AND INTERACTION WITH PRKX.
RX   PubMed=17980165; DOI=10.1016/j.bbadis.2007.09.003;
RA   Li X., Burrow C.R., Polgar K., Hyink D.P., Gusella G.L., Wilson P.D.;
RT   "Protein kinase X (PRKX) can rescue the effects of polycystic kidney
RT   disease-1 gene (PKD1) deficiency.";
RL   Biochim. Biophys. Acta 1782:1-9(2008).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20980620; DOI=10.1091/mbc.E10-05-0407;
RA   Chapin H.C., Rajendran V., Caplan M.J.;
RT   "Polycystin-1 surface localization is stimulated by polycystin-2 and
RT   cleavage at the G protein-coupled receptor proteolytic site.";
RL   Mol. Biol. Cell 21:4338-4348(2010).
RN   [11]
RP   INTERACTION WITH NPHP1.
RX   PubMed=20856870; DOI=10.1371/journal.pone.0012719;
RA   Wodarczyk C., Distefano G., Rowe I., Gaetani M., Bricoli B.,
RA   Muorah M., Spitaleri A., Mannella V., Ricchiuto P., Pema M.,
RA   Castelli M., Casanova A.E., Mollica L., Banzi M., Boca M.,
RA   Antignac C., Saunier S., Musco G., Boletta A.;
RT   "Nephrocystin-1 forms a complex with polycystin-1 via a polyproline
RT   motif/SH3 domain interaction and regulates the apoptotic response in
RT   mammals.";
RL   PLoS ONE 5:E12719-E12719(2010).
RN   [12]
RP   INTERACTION WITH BBS1; BBS4; BBS5 AND TTC8.
RX   PubMed=24939912; DOI=10.1093/hmg/ddu267;
RA   Su X., Driscoll K., Yao G., Raed A., Wu M., Beales P.L., Zhou J.;
RT   "Bardet-Biedl syndrome proteins 1 and 3 regulate the ciliary
RT   trafficking of polycystic kidney disease 1 protein.";
RL   Hum. Mol. Genet. 23:5441-5451(2014).
RN   [13]
RP   STRUCTURE BY NMR OF 275-354.
RX   PubMed=9889186; DOI=10.1093/emboj/18.2.297;
RA   Bycroft M., Bateman A., Clarke J., Hamill S.J., Sandford R.,
RA   Thomas R.L., Chothia C.;
RT   "The structure of a PKD domain from polycystin-1: implications for
RT   polycystic kidney disease.";
RL   EMBO J. 18:297-305(1999).
RN   [14]
RP   REVIEW.
RX   PubMed=11698076; DOI=10.1016/S0165-6147(00)01832-0;
RA   Stayner C., Zhou J.;
RT   "Polycystin channels and kidney disease.";
RL   Trends Pharmacol. Sci. 22:543-546(2001).
RN   [15]
RP   VARIANT PKD1 3748-ARG--VAL-3752 DEL, AND VARIANT ASP-3632.
RX   PubMed=8554072;
RA   Peral B., San Millan J.L., Ong A.C.M., Gamble V., Ward C.J.,
RA   Strong C., Harris P.C.;
RT   "Screening the 3' region of the polycystic kidney disease 1 (PKD1)
RT   gene reveals six novel mutations.";
RL   Am. J. Hum. Genet. 58:86-96(1996).
RN   [16]
RP   VARIANTS PKD1 PRO-2993; ARG-3016 AND VAL-3511, AND VARIANTS MET-3510
RP   AND PHE-4190.
RX   PubMed=9199561; DOI=10.1086/515467;
RA   Peral B., Gamble V., Strong C., Ong A.C.M., Sloane-Stanley J.,
RA   Zerres K., Winearls C.G., Harris P.C.;
RT   "Identification of mutations in the duplicated region of the
RT   polycystic kidney disease 1 gene (PKD1) by a novel approach.";
RL   Am. J. Hum. Genet. 60:1399-1410(1997).
RN   [17]
RP   VARIANT ALA-4058.
RX   PubMed=9150733; DOI=10.1007/s004390050421;
RA   Constantinides R., Xenophontos S.L., Neophytou P., Nomura S.,
RA   Pierides A., Constantinou-Deltas C.D.;
RT   "New amino acid polymorphism, Ala/Val4058, in exon 45 of the
RT   polycystic kidney disease 1 gene: evolution of alleles.";
RL   Hum. Genet. 99:644-647(1997).
RN   [18]
RP   VARIANTS PKD1 VAL-2763; THR-2826 AND LEU-3008, AND VARIANTS THR-2760;
RP   PRO-2761; THR-2764; GLN-2791 AND LEU-3066.
RX   PubMed=9285784; DOI=10.1093/hmg/6.9.1473;
RA   Watnick T.J., Piontek K.B., Cordal T.M., Weber H., Gandolph M.A.,
RA   Qian F., Lens X.M., Neumann H.P.H., Germino G.G.;
RT   "An unusual pattern of mutation in the duplicated portion of PKD1 is
RT   revealed by use of a novel strategy for mutation detection.";
RL   Hum. Mol. Genet. 6:1473-1481(1997).
RN   [19]
RP   VARIANT PKD1 THR-3678.
RX   PubMed=9259200;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<164::AID-HUMU9>3.0.CO;2-K;
RA   Turco A.E., Rossetti S., Bresin E., Englisch S., Corra S.,
RA   Pignatti P.F.;
RT   "Three novel mutations of the PKD1 gene in Italian families with
RT   autosomal dominant polycystic kidney disease.";
RL   Hum. Mutat. 10:164-167(1997).
RN   [20]
RP   VARIANT PKD1 ASP-4032, AND VARIANT VAL-4045.
RX   PubMed=9521593; DOI=10.1007/s004390050681;
RA   Daniells C., Maheshwar M.M., Lazarou L., Davies F., Coles G.,
RA   Ravine D.;
RT   "Novel and recurrent mutations in the PKD1 (polycystic kidney disease)
RT   gene.";
RL   Hum. Genet. 102:216-220(1998).
RN   [21]
RP   VARIANT PKD1 MET-3375.
RX   PubMed=9921908; DOI=10.1007/s004390050896;
RA   Koptides M., Constantinides R., Kyriakides G., Hadjigavriel M.,
RA   Patsalis P.C., Pierides A., Deltas C.C.;
RT   "Loss of heterozygosity in polycystic kidney disease with a missense
RT   mutation in the repeated region of PKD1.";
RL   Hum. Genet. 103:709-717(1998).
RN   [22]
RP   VARIANTS PKD1 LEU-324 AND SER-845, AND VARIANTS ARG-1399 AND LEU-1786.
RX   PubMed=10364515; DOI=10.1086/302460;
RA   Thomas R.L., McConnell R., Whittacker J., Kirkpatrick P., Bradley J.,
RA   Sandford R.;
RT   "Identification of mutations in the repeated part of the autosomal
RT   dominant polycystic kidney disease type 1 gene, PKD1, by long-range
RT   PCR.";
RL   Am. J. Hum. Genet. 65:39-49(1999).
RN   [23]
RP   VARIANTS PKD1 PRO-2392 AND PHE-2423, AND VARIANTS ARG-1399; GLN-2548
RP   AND ARG-2638.
RX   PubMed=10577909; DOI=10.1086/302657;
RA   Watnick T., Phakdeekitcharoen B., Johnson A., Gandolph M.A., Wang M.,
RA   Briefel G., Klinger K.W., Kimberling W., Gabow P., Germino G.G.;
RT   "Mutation detection of PKD1 identifies a novel mutation common to
RT   three families with aneurysms and/or very-early-onset disease.";
RL   Am. J. Hum. Genet. 65:1561-1571(1999).
RN   [24]
RP   VARIANTS PKD1 LEU-LEU-PHE-3996 INS; GLY-4136 AND CYS-4154, AND
RP   VARIANTS.
RX   PubMed=10987650; DOI=10.1007/s004390051094;
RA   Perrichot R.A., Mercier B., Simon P.M., Whebe B., Cledes J., Ferec C.;
RT   "DGGE screening of PKD1 gene reveals novel mutations in a large cohort
RT   of 146 unrelated patients.";
RL   Hum. Genet. 105:231-239(1999).
RN   [25]
RP   VARIANTS PKD1 3748-ARG--VAL-3752 DEL AND LEU-4132 DEL, AND VARIANT
RP   VAL-4045.
RX   PubMed=10647901; DOI=10.1007/s004399900177;
RA   Afzal A.R., Hand M., Ternes-Pereira E., Saggar-Malik A., Taylor R.,
RA   Jeffery S.;
RT   "Novel mutations in the 3 region of the polycystic kidney disease 1
RT   (PKD1) gene.";
RL   Hum. Genet. 105:648-653(1999).
RN   [26]
RP   VARIANTS PKD1 PRO-4225 AND TRP-4276.
RX   PubMed=10200984; DOI=10.1046/j.1523-1755.1999.00368.x;
RA   Badenas C., Torra R., San Millan J.L., Lucero L., Mila M.,
RA   Estivill X., Darnell A.;
RT   "Mutational analysis within the 3' region of the PKD1 gene.";
RL   Kidney Int. 55:1225-1233(1999).
RN   [27]
RP   VARIANTS PKD1 MET-2250; TRP-2329 AND CYS-2379, AND VARIANTS LEU-3066;
RP   VAL-3139 AND LEU-3193.
RX   PubMed=10854095; DOI=10.1038/sj.ejhg.5200459;
RA   Perrichot R., Mercier B., Quere I., Carre A., Simon P., Whebe B.,
RA   Cledes J., Ferec C.;
RT   "Novel mutations in the duplicated region of PKD1 gene.";
RL   Eur. J. Hum. Genet. 8:353-359(2000).
RN   [28]
RP   VARIANTS PKD1 HIS-3247 AND MET-3382.
RX   PubMed=11216660; DOI=10.1089/109065700750065108;
RA   Afzal A.R., Florencio R.N., Taylor R., Patton M.A., Saggar-Malik A.,
RA   Jeffery S.;
RT   "Novel mutations in the duplicated region of the polycystic kidney
RT   disease 1 (PKD1) gene provides supporting evidence for gene
RT   conversion.";
RL   Genet. Test. 4:365-370(2000).
RN   [29]
RP   VARIANTS PKD1 PRO-2921 AND MET-3375, AND VARIANT LEU-3066.
RX   PubMed=10923040;
RX   DOI=10.1002/1098-1004(200008)16:2<176::AID-HUMU11>3.0.CO;2-H;
RA   Koptides M., Mean R., Demetriou K., Constantinides R., Pierides A.,
RA   Harris P.C., Deltas C.C.;
RT   "Screening of the PKD1 duplicated region reveals multiple single
RT   nucleotide polymorphisms and a de novo mutation in Hellenic polycystic
RT   kidney disease families.";
RL   Hum. Mutat. 16:176-176(2000).
RN   [30]
RP   VARIANTS PKD1 GLN-3719 AND PRO-3852, AND VARIANT VAL-4045.
RX   PubMed=11058904;
RX   DOI=10.1002/1098-1004(200011)16:5<444::AID-HUMU11>3.0.CO;2-C;
RA   Aguiari G., Savelli S., Garbo M., Bozza A., Augello G., Penolazzi L.,
RA   De Paoli Vitali E., La Torre C., Cappelli G., Piva R., del Senno L.;
RT   "Novel splicing and missense mutations in autosomal dominant
RT   polycystic kidney disease 1 (PKD1) gene: expression of mutated
RT   genes.";
RL   Hum. Mutat. 16:444-445(2000).
RN   [31]
RP   VARIANTS PKD1 SER-1166; GLU-1956; CYS-2408 AND GLY-2442--2443 INS, AND
RP   VARIANTS HIS-1995 AND ASN-2604.
RX   PubMed=11012875; DOI=10.1046/j.1523-1755.2000.00302.x;
RA   Phakdeekitcharoen B., Watnick T.J., Ahn C., Whang D.-Y., Burkhart B.,
RA   Germino G.G.;
RT   "Thirteen novel mutations of the replicated region of PKD1 in an Asian
RT   population.";
RL   Kidney Int. 58:1400-1412(2000).
RN   [32]
RP   VARIANTS PKD1 TRP-3753 AND ASN-3815.
RX   PubMed=10729710; DOI=10.1016/S1383-5726(99)00013-8;
RA   Kim U.K., Jin D.K., Ahn C., Shin J.H., Lee K.B., Kim S.H., Chae J.J.,
RA   Hwang D.Y., Lee J.G., Namkoong Y., Lee C.C.;
RT   "Novel mutations of the PKD1 gene in Korean patients with autosomal
RT   dominant polycystic kidney disease.";
RL   Mutat. Res. 432:39-45(2000).
RN   [33]
RP   VARIANTS PKD1 GLN-13; PHE-75; CYS-139; 1992-PHE-THR-1993 DELINS LEU;
RP   2220-ARG--PRO-2224 DEL; ASP-2336; ASP-2752; ILE-LEU-MET-ARG-2765 INS;
RP   MET-2768; LYS-2771; PRO-2816; SER-2858; 3012-THR--TYR-3017 DEL AND
RP   3748-LEU--ARG-3752 DEL, AND VARIANTS SER-2674; MET-2708; THR-2734;
RP   LEU-2735; CYS-2765; MET-2782; ARG-2814; GLY-2888; ILE-2905; ASP-2966
RP   AND LEU-3066.
RX   PubMed=11115377; DOI=10.1086/316939;
RA   Rossetti S., Strmecki L., Gamble V., Burton S., Sneddon V., Peral B.,
RA   Roy S., Bakkaloglu A., Komel R., Winearls C.G., Harris P.C.;
RT   "Mutation analysis of the entire PKD1 gene: genetic and diagnostic
RT   implications.";
RL   Am. J. Hum. Genet. 68:46-63(2001).
RN   [34]
RP   VARIANTS PKD1 LEU-2471; LEU-2519; GLY-2579 DEL; LEU-2613 DEL; ILE-2649
RP   AND PHE-2978 DEL, AND VARIANTS MET-2582; ARG-2638; ASN-2972 AND
RP   LEU-3066.
RX   PubMed=11571556; DOI=10.1038/sj.ejhg.5200696;
RA   Bouba I., Koptides M., Mean R., Costi C.-E., Demetriou K.,
RA   Georgiou I., Pierides A., Siamopoulos K., Deltas C.C.;
RT   "Novel PKD1 deletions and missense variants in a cohort of Hellenic
RT   polycystic kidney disease families.";
RL   Eur. J. Hum. Genet. 9:677-684(2001).
RN   [35]
RP   VARIANTS PKD1 ARG-967; ARG-2696; GLY-2985; CYS-3039 AND ILE-3285, AND
RP   VARIANTS VAL-88 AND ARG-3311.
RX   PubMed=11316854;
RA   Phakdeekitcharoen B., Watnick T.J., Germino G.G.;
RT   "Mutation analysis of the entire replicated portion of PKD1 using
RT   genomic DNA samples.";
RL   J. Am. Soc. Nephrol. 12:955-963(2001).
RN   [36]
RP   VARIANT PKD1 MET-3510, AND VARIANT MET-3008.
RX   PubMed=11558899; DOI=10.1007/s100380170032;
RA   Mizoguchi M., Tamura T., Yamaki A., Higashihara E., Shimizu Y.;
RT   "Mutations of the PKD1 gene among Japanese autosomal dominant
RT   polycystic kidney disease patients, including one heterozygous
RT   mutation identified in members of the same family.";
RL   J. Hum. Genet. 46:511-517(2001).
RN   [37]
RP   VARIANTS PKD1 ARG-3560; GLN-3719 AND TRP-3753, AND VARIANT MET-3510.
RX   PubMed=11691639; DOI=10.1016/S0027-5107(01)00226-3;
RA   Tsuchiya K., Komeda M., Takahashi M., Yamashita N., Cigira M.,
RA   Suzuki T., Suzuki K., Nihei H., Mochizuki T.;
RT   "Mutational analysis within the 3' region of the PKD1 gene in Japanese
RT   families.";
RL   Mutat. Res. 458:77-84(2001).
RN   [38]
RP   VARIANTS PKD1 SER-3602 AND SER-4255.
RX   PubMed=12220456; DOI=10.1034/j.1399-0004.2002.620211.x;
RA   Eo H.-S., Lee J.G., Ahn C., Cho J.T., Hwang D.Y., Hwang Y.H.,
RA   Lee E.J., Kim Y.S., Han J.S., Kim S., Lee J.S., Jeoung D.I., Lee S.E.,
RA   Kim U.K.;
RT   "Three novel mutations of the PKD1 gene in Korean patients with
RT   autosomal dominant polycystic kidney disease.";
RL   Clin. Genet. 62:169-174(2002).
RN   [39]
RP   VARIANTS PKD1 CYS-381; ASP-2185; THR-2421 DEL; ASP-2785 AND
RP   3027-THR--ARG-3039 DEL, AND VARIANTS GLN-739; THR-1092; ARG-1399;
RP   MET-1649; ARG-2638; CYS-2765 AND LEU-3066.
RX   PubMed=11857740; DOI=10.1002/humu.10045;
RA   McCluskey M., Schiavello T., Hunter M., Hantke J., Angelicheva D.,
RA   Bogdanova N., Markoff A., Thomas M., Dworniczak B., Horst J.,
RA   Kalaydjieva L.;
RT   "Mutation detection in the duplicated region of the polycystic kidney
RT   disease 1 (PKD1) gene in PKD1-linked Australian families.";
RL   Hum. Mutat. 19:240-250(2002).
RN   [40]
RP   VARIANTS PKD1 ILE-2083; ARG-2814 AND PRO-2816, AND VARIANTS MET-87 AND
RP   MET-3510.
RX   PubMed=12007219; DOI=10.1002/humu.10080;
RA   Inoue S., Inoue K., Utsunomiya M., Nozaki J., Yamada Y., Iwasa T.,
RA   Mori E., Yoshinaga T., Koizumi A.;
RT   "Mutation analysis in PKD1 of Japanese autosomal dominant polycystic
RT   kidney disease patients.";
RL   Hum. Mutat. 19:622-628(2002).
RN   [41]
RP   VARIANT PKD1 HIS-987, AND VARIANTS ARG-1399 AND VAL-4045.
RX   PubMed=12070253; DOI=10.1136/jmg.39.6.422;
RA   Burtey S., Lossi A.M., Bayle J., Berland Y., Fontes M.;
RT   "Mutation screening of the PKD1 transcript by RT-PCR.";
RL   J. Med. Genet. 39:422-429(2002).
RN   [42]
RP   VARIANTS PKD1 TRP-1340; LYS-1811; CYS-2092; ILE-2260 DEL; PHE-3167 AND
RP   PRO-3852, AND VARIANTS LEU-61; SER-572; THR-1092; SER-1168; ARG-1399;
RP   LEU-1684; ILE-1943; ARG-2638; SER-2674; MET-2708; ARG-2814; LEU-2958;
RP   ASN-2977; MET-3057; GLN-3435; VAL-3512; VAL-4045; VAL-4059; SER-4124;
RP   ILE-4146 AND PHE-4190.
RX   PubMed=11967008; DOI=10.1046/j.1523-1755.2002.00326.x;
RA   Rossetti S., Chauveau D., Walker D., Saggar-Malik A., Winearls C.G.,
RA   Torres V.E., Harris P.C.;
RT   "A complete mutation screen of the ADPKD genes by DHPLC.";
RL   Kidney Int. 61:1588-1599(2002).
RN   [43]
RP   VARIANTS PKD1 ASP-3632; LEU-3649 AND THR-3678, AND VARIANTS VAL-4045;
RP   VAL-4059; GLU-4102; PRO-4106 AND ILE-4146.
RX   PubMed=11773467; DOI=10.1093/ndt/17.1.75;
RA   Ding L., Zhang S., Qiu W., Xiao C., Wu S., Zhang G., Cheng L.,
RA   Zhang S.;
RT   "Novel mutations of PKD1 gene in Chinese patients with autosomal
RT   dominant polycystic kidney disease.";
RL   Nephrol. Dial. Transplant. 17:75-80(2002).
RN   [44]
RP   VARIANTS PKD1 ARG-164; GLY-210; ARG-508; ASP-690; ASN-1240 DEL;
RP   PRO-1667; LYS-1811; CYS-2092; CYS-2200; ILE-2260 DEL; ARG-2370;
RP   TYR-2373; LYS-2771; LEU-2802; ASN-3188 DEL; LEU-3355; PRO-3682 AND
RP   ARG-3751.
RX   PubMed=12842373; DOI=10.1016/S0140-6736(03)13773-7;
RA   Rossetti S., Chauveau D., Kubly V., Slezak J.M., Saggar-Malik A.K.,
RA   Pei Y., Ong A.C.M., Stewart F., Watson M.L., Bergstralh E.J.,
RA   Winearls C.G., Torres V.E., Harris P.C.;
RT   "Association of mutation position in polycystic kidney disease 1
RT   (PKD1) gene and development of a vascular phenotype.";
RL   Lancet 361:2196-2201(2003).
RN   [45]
RP   VARIANTS PKD1 SER-845; MET-3138 AND PRO-3954, AND VARIANTS HIS-36;
RP   ARG-2638; LEU-3066; MET-3510; VAL-3512; VAL-4045 AND VAL-4059.
RX   PubMed=15772804; DOI=10.1007/s00109-005-0644-6;
RA   Peltola P., Lumiaho A., Miettinen R., Pihlajamaeki J., Sandford R.,
RA   Laakso M.;
RT   "Genetics and phenotypic characteristics of autosomal dominant
RT   polycystic kidney disease in Finns.";
RL   J. Mol. Med. 83:638-646(2005).
RN   [46]
RP   VARIANTS PKD1 LEU-61; ILE-99; TYR-594; THR-1092; MET-1242; CYS-2200;
RP   LYS-2422; ARG-2638; LEU-3066; SER-3726 AND VAL-4155, AND VARIANTS
RP   HIS-36; GLN-739; ARG-1399; THR-1516; THR-1871; VAL-1926; ASP-1952;
RP   MET-2708; ARG-2814; VAL-3512; VAL-4045 AND VAL-4059.
RX   PubMed=18837007; DOI=10.1002/humu.20842;
RA   Tan Y.-C., Blumenfeld J.D., Anghel R., Donahue S., Belenkaya R.,
RA   Balina M., Parker T., Levine D., Leonard D.G.B., Rennert H.;
RT   "Novel method for genomic analysis of PKD1 and PKD2 mutations in
RT   autosomal dominant polycystic kidney disease.";
RL   Hum. Mutat. 30:264-273(2009).
RN   [47]
RP   VARIANTS PKD1 GLY-97; ARG-436; PRO-442; ARG-727; PRO-727; ASP-2391;
RP   TRP-2434; TYR-2546; CYS-2569; THR-2646; ARG-2889; PRO-3154; ARG-3603
RP   AND GLN-3750.
RX   PubMed=21115670; DOI=10.1093/ndt/gfq720;
RA   Hoefele J., Mayer K., Scholz M., Klein H.G.;
RT   "Novel PKD1 and PKD2 mutations in autosomal dominant polycystic kidney
RT   disease (ADPKD).";
RL   Nephrol. Dial. Transplant. 26:2181-2188(2011).
RN   [48]
RP   VARIANTS PKD1 CYS-325; TRP-611; ASP-698; PRO-727; GLY-1206; CYS-2379;
RP   CYS-2767; LYS-2771; ARG-2995; SER-3651; GLN-3750; TRP-3753; CYS-4150
RP   AND TRP-4276.
RX   PubMed=22508176; DOI=10.1002/humu.22103;
RA   Audrezet M.P., Gall E.C., Chen J.M., Redon S., Quere I., Creff J.,
RA   Benech C., Maestri S., Meur Y.L., Ferec C.;
RT   "Autosomal dominant polycystic kidney disease: Comprehensive mutation
RT   analysis of PKD1 and PKD2 in 700 unrelated patients.";
RL   Hum. Mutat. 33:1239-1250(2012).
CC   -!- FUNCTION: Involved in renal tubulogenesis (PubMed:12482949).
CC       Involved in fluid-flow mechanosensation by the primary cilium in
CC       renal epithelium (By similarity). Acts as a regulator of cilium
CC       length, together with PKD2 (By similarity). The dynamic control of
CC       cilium length is essential in the regulation of
CC       mechanotransductive signaling (By similarity). The cilium length
CC       response creates a negative feedback loop whereby fluid shear-
CC       mediated deflection of the primary cilium, which decreases
CC       intracellular cAMP, leads to cilium shortening and thus decreases
CC       flow-induced signaling (By similarity). May be an ion-channel
CC       regulator. Involved in adhesive protein-protein and protein-
CC       carbohydrate interactions. {ECO:0000250|UniProtKB:O08852,
CC       ECO:0000269|PubMed:12482949}.
CC   -!- SUBUNIT: Interacts with PKD2 and PKD2L1 (By similarity). Interacts
CC       with PRKX; involved in differentiation and controlled
CC       morphogenesis of the kidney (PubMed:17980165). Interacts with
CC       NPHP1 (via SH3 domain) (PubMed:20856870). Interacts with BBS1,
CC       BBS4, BBS5 and TTC8 (PubMed:24939912). Interacts with RGS7
CC       (PubMed:10339594). {ECO:0000250|UniProtKB:O08852,
CC       ECO:0000269|PubMed:10339594, ECO:0000269|PubMed:17980165,
CC       ECO:0000269|PubMed:20856870, ECO:0000269|PubMed:24939912}.
CC   -!- INTERACTION:
CC       O15259:NPHP1; NbExp=2; IntAct=EBI-1752013, EBI-953828;
CC       Q13563:PKD2; NbExp=8; IntAct=EBI-1752013, EBI-7813714;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10339594,
CC       ECO:0000269|PubMed:20980620}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20980620}. Cell projection, cilium
CC       {ECO:0000250|UniProtKB:O08852}. Note=PKD1 localization to the
CC       plasma and ciliary membranes requires PKD2, is independent of PKD2
CC       channel activity, and involves stimulation of PKD1 autoproteolytic
CC       cleavage at the GPS domain (By similarity). Ciliary localization
CC       of PKD1 requires BBS1 and ARL6/BBS3 (By similarity).
CC       {ECO:0000250|UniProtKB:O08852}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P98161-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P98161-2; Sequence=VSP_009677, VSP_009678;
CC       Name=3;
CC         IsoId=P98161-3; Sequence=VSP_009678;
CC   -!- DOMAIN: The LDL-receptor class A domain is atypical; the potential
CC       calcium-binding site is missing.
CC   -!- PTM: After synthesis, undergoes cleavage between Leu-3048 and Thr-
CC       3049 in the GPS domain. Cleavage at the GPS domain occurs through
CC       a cis-autoproteolytic mechanism involving an ester-intermediate
CC       via N-O acyl rearrangement. This process takes place in the early
CC       secretory pathway, depends on initial N-glycosylation, and
CC       requires the REJ domain. There is evidence that cleavage at GPS
CC       domain is incomplete. Uncleaved and cleaved products may have
CC       different functions in vivo. {ECO:0000269|PubMed:12482949}.
CC   -!- DISEASE: Polycystic kidney disease 1 (PKD1) [MIM:173900]: A
CC       disorder characterized by renal cysts, liver cysts and
CC       intracranial aneurysm. Clinical variability is due to differences
CC       in the rate of loss of glomerular filtration, the age of reaching
CC       end-stage renal disease and the occurrence of hypertension,
CC       symptomatic extrarenal cysts, and subarachnoid hemorrhage from
CC       intracranial 'berry' aneurysm. {ECO:0000269|PubMed:10200984,
CC       ECO:0000269|PubMed:10364515, ECO:0000269|PubMed:10577909,
CC       ECO:0000269|PubMed:10647901, ECO:0000269|PubMed:10729710,
CC       ECO:0000269|PubMed:10854095, ECO:0000269|PubMed:10923040,
CC       ECO:0000269|PubMed:10987650, ECO:0000269|PubMed:11012875,
CC       ECO:0000269|PubMed:11058904, ECO:0000269|PubMed:11115377,
CC       ECO:0000269|PubMed:11216660, ECO:0000269|PubMed:11316854,
CC       ECO:0000269|PubMed:11558899, ECO:0000269|PubMed:11571556,
CC       ECO:0000269|PubMed:11691639, ECO:0000269|PubMed:11773467,
CC       ECO:0000269|PubMed:11857740, ECO:0000269|PubMed:11967008,
CC       ECO:0000269|PubMed:12007219, ECO:0000269|PubMed:12070253,
CC       ECO:0000269|PubMed:12220456, ECO:0000269|PubMed:12842373,
CC       ECO:0000269|PubMed:15772804, ECO:0000269|PubMed:18837007,
CC       ECO:0000269|PubMed:21115670, ECO:0000269|PubMed:22508176,
CC       ECO:0000269|PubMed:8554072, ECO:0000269|PubMed:9199561,
CC       ECO:0000269|PubMed:9259200, ECO:0000269|PubMed:9285784,
CC       ECO:0000269|PubMed:9521593, ECO:0000269|PubMed:9921908}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the polycystin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 C-type lectin domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00040}.
CC   -!- SIMILARITY: Contains 1 GPS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00098}.
CC   -!- SIMILARITY: Contains 1 LDL-receptor class A domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRNT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 17 PKD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00151}.
CC   -!- SIMILARITY: Contains 1 PLAT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00152}.
CC   -!- SIMILARITY: Contains 1 REJ domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00511}.
CC   -!- SIMILARITY: Contains 1 WSC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00558}.
CC   -!- CAUTION: Variant Cys-2379 has been originally described as a
CC       benign polymorphism (PubMed:10854095). However, it is a likely
CC       pathogenic mutation (PubMed:PubMed:22508176).
CC       {ECO:0000305|PubMed:10854095}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Polycystin-1;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_204";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PKD1ID41725ch16p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24497; AAC50128.1; -; mRNA.
DR   EMBL; L33243; AAC37576.1; -; mRNA.
DR   EMBL; L43619; AAC41765.1; -; Genomic_DNA.
DR   EMBL; L43601; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43602; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43604; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43605; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43610; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43617; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; L43618; AAC41765.1; JOINED; Genomic_DNA.
DR   EMBL; AC093513; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC009065; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS32369.1; -. [P98161-1]
DR   CCDS; CCDS45385.1; -. [P98161-3]
DR   PIR; A38971; A38971.
DR   RefSeq; NP_000287.3; NM_000296.3.
DR   RefSeq; NP_001009944.2; NM_001009944.2.
DR   UniGene; Hs.75813; -.
DR   PDB; 1B4R; NMR; -; A=275-354.
DR   PDBsum; 1B4R; -.
DR   ProteinModelPortal; P98161; -.
DR   SMR; P98161; 275-354.
DR   BioGrid; 111327; 16.
DR   DIP; DIP-52317N; -.
DR   IntAct; P98161; 7.
DR   MINT; MINT-1199187; -.
DR   STRING; 9606.ENSP00000262304; -.
DR   ChEMBL; CHEMBL5772; -.
DR   MEROPS; P02.038; -.
DR   TCDB; 1.A.5.1.1; the polycystin cation channel (pcc) family.
DR   iPTMnet; P98161; -.
DR   PhosphoSite; P98161; -.
DR   BioMuta; PKD1; -.
DR   DMDM; 292495072; -.
DR   MaxQB; P98161; -.
DR   PaxDb; P98161; -.
DR   PRIDE; P98161; -.
DR   Ensembl; ENST00000262304; ENSP00000262304; ENSG00000008710. [P98161-1]
DR   Ensembl; ENST00000423118; ENSP00000399501; ENSG00000008710. [P98161-3]
DR   GeneID; 5310; -.
DR   KEGG; hsa:5310; -.
DR   UCSC; uc002cos.1; human. [P98161-1]
DR   UCSC; uc002cot.1; human. [P98161-3]
DR   CTD; 5310; -.
DR   GeneCards; PKD1; -.
DR   GeneReviews; PKD1; -.
DR   H-InvDB; HIX0173395; -.
DR   H-InvDB; HIX0202314; -.
DR   HGNC; HGNC:9008; PKD1.
DR   HPA; CAB046448; -.
DR   MalaCards; PKD1; -.
DR   MIM; 173900; phenotype.
DR   MIM; 601313; gene+phenotype.
DR   neXtProt; NX_P98161; -.
DR   Orphanet; 730; Autosomal dominant polycystic kidney disease.
DR   Orphanet; 88924; Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis.
DR   PharmGKB; PA35521; -.
DR   eggNOG; KOG3599; Eukaryota.
DR   eggNOG; ENOG410XTGE; LUCA.
DR   GeneTree; ENSGT00700000104221; -.
DR   HOGENOM; HOG000168445; -.
DR   HOVERGEN; HBG049412; -.
DR   InParanoid; P98161; -.
DR   KO; K04985; -.
DR   OMA; VSCKAQS; -.
DR   OrthoDB; EOG76X5Z6; -.
DR   PhylomeDB; P98161; -.
DR   TreeFam; TF316484; -.
DR   Reactome; R-HSA-5620916; VxPx cargo-targeting to cilium.
DR   SignaLink; P98161; -.
DR   EvolutionaryTrace; P98161; -.
DR   GeneWiki; PKD1; -.
DR   GenomeRNAi; 5310; -.
DR   NextBio; 20530; -.
DR   PRO; PR:P98161; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; P98161; -.
DR   CleanEx; HS_PKD1; -.
DR   ExpressionAtlas; P98161; baseline and differential.
DR   Genevisible; P98161; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0060170; C:ciliary membrane; TAS:Reactome.
DR   GO; GO:0005929; C:cilium; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030660; C:Golgi-associated vesicle membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0031512; C:motile primary cilium; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0002133; C:polycystin complex; ISS:BHF-UCL.
DR   GO; GO:0072372; C:primary cilium; ISS:UniProtKB.
DR   GO; GO:0005262; F:calcium channel activity; ISS:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IDA:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISS:BHF-UCL.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; TAS:ProtInc.
DR   GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:BHF-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; TAS:ProtInc.
DR   GO; GO:0042994; P:cytoplasmic sequestering of transcription factor; ISS:BHF-UCL.
DR   GO; GO:0050982; P:detection of mechanical stimulus; ISS:BHF-UCL.
DR   GO; GO:0048565; P:digestive tract development; IEP:UniProtKB.
DR   GO; GO:0001892; P:embryonic placenta development; ISS:BHF-UCL.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0048806; P:genitalia development; IEP:UniProtKB.
DR   GO; GO:0007507; P:heart development; IEP:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; TAS:ProtInc.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:BHF-UCL.
DR   GO; GO:0007259; P:JAK-STAT cascade; ISS:BHF-UCL.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0060428; P:lung epithelium development; IEP:UniProtKB.
DR   GO; GO:0036303; P:lymph vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0072177; P:mesonephric duct development; IEP:UniProtKB.
DR   GO; GO:0072164; P:mesonephric tubule development; IEP:UniProtKB.
DR   GO; GO:0072218; P:metanephric ascending thin limb development; IEP:UniProtKB.
DR   GO; GO:0072205; P:metanephric collecting duct development; IEP:UniProtKB.
DR   GO; GO:0072287; P:metanephric distal tubule morphogenesis; IEP:UniProtKB.
DR   GO; GO:0072237; P:metanephric proximal tubule development; IEP:UniProtKB.
DR   GO; GO:0021915; P:neural tube development; IEP:UniProtKB.
DR   GO; GO:0006807; P:nitrogen compound metabolic process; IEA:Ensembl.
DR   GO; GO:0006996; P:organelle organization; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0060674; P:placenta blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0006611; P:protein export from nucleus; ISS:BHF-UCL.
DR   GO; GO:0030155; P:regulation of cell adhesion; IEA:Ensembl.
DR   GO; GO:0060236; P:regulation of mitotic spindle organization; IEA:Ensembl.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IDA:MGI.
DR   GO; GO:0034405; P:response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0043588; P:skin development; IEP:UniProtKB.
DR   GO; GO:0021510; P:spinal cord development; IEP:UniProtKB.
DR   Gene3D; 2.60.40.670; -; 14.
DR   Gene3D; 2.60.60.20; -; 1.
DR   Gene3D; 3.10.100.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR001304; C-type_lectin.
DR   InterPro; IPR016186; C-type_lectin-like.
DR   InterPro; IPR016187; C-type_lectin_fold.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR000434; PC1.
DR   InterPro; IPR022409; PKD/Chitinase_dom.
DR   InterPro; IPR002859; PKD/REJ-like.
DR   InterPro; IPR013122; PKD1_2_channel.
DR   InterPro; IPR000601; PKD_dom.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR006228; Polycystin_cat.
DR   InterPro; IPR014010; REJ_dom.
DR   InterPro; IPR002889; WSC_carb-bd.
DR   InterPro; IPR013994; WSC_carb-bd_subgr.
DR   Pfam; PF00059; Lectin_C; 1.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF00801; PKD; 15.
DR   Pfam; PF08016; PKD_channel; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   Pfam; PF02010; REJ; 1.
DR   Pfam; PF01822; WSC; 1.
DR   PRINTS; PR00500; POLYCYSTIN1.
DR   SMART; SM00034; CLECT; 1.
DR   SMART; SM00303; GPS; 1.
DR   SMART; SM00308; LH2; 1.
DR   SMART; SM00369; LRR_TYP; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00089; PKD; 15.
DR   SMART; SM00321; WSC; 1.
DR   SUPFAM; SSF49299; SSF49299; 13.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF56436; SSF56436; 1.
DR   TIGRFAMs; TIGR00864; PCC; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
DR   PROSITE; PS50221; GPS; 1.
DR   PROSITE; PS51450; LRR; 2.
DR   PROSITE; PS50093; PKD; 12.
DR   PROSITE; PS50095; PLAT; 1.
DR   PROSITE; PS51111; REJ; 1.
DR   PROSITE; PS51212; WSC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage;
KW   Cell membrane; Cell projection; Ciliopathy; Cilium; Coiled coil;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Lectin; Leucine-rich repeat; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24   4303       Polycystin-1.
FT                                /FTId=PRO_0000024298.
FT   TOPO_DOM     24   3074       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3075   3095       Helical. {ECO:0000255}.
FT   TOPO_DOM   3096   3282       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   3283   3303       Helical. {ECO:0000255}.
FT   TOPO_DOM   3304   3323       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3324   3344       Helical. {ECO:0000255}.
FT   TOPO_DOM   3345   3559       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   3560   3580       Helical. {ECO:0000255}.
FT   TOPO_DOM   3581   3582       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3583   3603       Helical. {ECO:0000255}.
FT   TOPO_DOM   3604   3673       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   3674   3694       Helical. {ECO:0000255}.
FT   TOPO_DOM   3695   3896       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3897   3917       Helical. {ECO:0000255}.
FT   TOPO_DOM   3918   3938       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   3939   3959       Helical. {ECO:0000255}.
FT   TOPO_DOM   3960   3979       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3980   4000       Helical. {ECO:0000255}.
FT   TOPO_DOM   4001   4027       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   4028   4048       Helical. {ECO:0000255}.
FT   TOPO_DOM   4049   4085       Extracellular. {ECO:0000255}.
FT   TRANSMEM   4086   4106       Helical. {ECO:0000255}.
FT   TOPO_DOM   4107   4303       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24     67       LRRNT.
FT   REPEAT       68     91       LRR 1.
FT   REPEAT       92    113       LRR 2.
FT   DOMAIN      125    178       LRRCT.
FT   DOMAIN      177    271       WSC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00558}.
FT   DOMAIN      272    359       PKD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN      415    531       C-type lectin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00040}.
FT   DOMAIN      638    671       LDL-receptor class A; atypical.
FT   DOMAIN      743    817       PKD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN      855    928       PKD 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN      935   1020       PKD 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1023   1129       PKD 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1127   1215       PKD 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1213   1298       PKD 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1294   1383       PKD 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1382   1469       PKD 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1468   1551       PKD 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1550   1635       PKD 11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1634   1721       PKD 12. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1719   1805       PKD 13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1807   1890       PKD 14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1889   1974       PKD 15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     1977   2057       PKD 16. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     2060   2148       PKD 17. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00151}.
FT   DOMAIN     2146   2833       REJ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00511}.
FT   DOMAIN     3012   3061       GPS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00098}.
FT   DOMAIN     3118   3233       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   COILED     4220   4251       {ECO:0000255}.
FT   MOTIF      3744   3756       Polycystin motif.
FT   SITE       3048   3049       Cleavage; by autolysis.
FT   MOD_RES    4166   4166       Phosphoserine; by PRKX; in vitro.
FT                                {ECO:0000269|PubMed:17980165}.
FT   CARBOHYD     50     50       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    116    116       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    187    187       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    621    621       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    632    632       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    746    746       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    810    810       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    841    841       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    854    854       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    890    890       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    921    921       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1004   1004       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1010   1010       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1034   1034       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1072   1072       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1113   1113       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1178   1178       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1194   1194       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1240   1240       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1269   1269       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1336   1336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1348   1348       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1382   1382       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1450   1450       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1455   1455       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1474   1474       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1518   1518       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1541   1541       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1554   1554       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1563   1563       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1647   1647       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1661   1661       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1733   1733       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1791   1791       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1834   1834       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1867   1867       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1880   1880       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1991   1991       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2050   2050       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2074   2074       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2125   2125       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2248   2248       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2353   2353       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2395   2395       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2412   2412       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2567   2567       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2578   2578       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2645   2645       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2718   2718       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2754   2754       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2841   2841       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2878   2878       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2925   2925       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2956   2956       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2994   2994       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3738   3738       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3790   3790       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   3845   3845       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    436    530       {ECO:0000250}.
FT   DISULFID    508    522       {ECO:0000250}.
FT   DISULFID    640    653       {ECO:0000250}.
FT   DISULFID    647    665       {ECO:0000250}.
FT   DISULFID    660    669       {ECO:0000250}.
FT   VAR_SEQ    2497   2507       GWHDAEDAGAP -> A (in isoform 2).
FT                                {ECO:0000303|PubMed:7663510}.
FT                                /FTId=VSP_009677.
FT   VAR_SEQ    3390   3390       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:7663510}.
FT                                /FTId=VSP_009678.
FT   VARIANT      13     13       L -> Q (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011030.
FT   VARIANT      36     36       P -> H. {ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058759.
FT   VARIANT      61     61       P -> L (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058760.
FT   VARIANT      75     75       S -> F (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011031.
FT   VARIANT      87     87       L -> M. {ECO:0000269|PubMed:12007219}.
FT                                /FTId=VAR_058761.
FT   VARIANT      88     88       A -> V. {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012452.
FT   VARIANT      97     97       D -> G (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064380.
FT   VARIANT      99     99       S -> I (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058762.
FT   VARIANT     139    139       W -> C (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011032.
FT   VARIANT     164    164       Q -> R (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058763.
FT   VARIANT     210    210       C -> G (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058764.
FT   VARIANT     324    324       R -> L (in PKD1).
FT                                {ECO:0000269|PubMed:10364515}.
FT                                /FTId=VAR_010085.
FT   VARIANT     325    325       Y -> C (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068024.
FT   VARIANT     381    381       G -> C (in PKD1).
FT                                {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058765.
FT   VARIANT     436    436       C -> R (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064381.
FT   VARIANT     442    442       A -> P (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064382.
FT   VARIANT     508    508       C -> R (in PKD1; dbSNP:rs58598099).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058766.
FT   VARIANT     572    572       P -> S (in dbSNP:rs149022148).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058767.
FT   VARIANT     594    594       F -> Y (in PKD1).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058768.
FT   VARIANT     611    611       R -> W (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068025.
FT   VARIANT     690    690       V -> D (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058769.
FT   VARIANT     698    698       Y -> D (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068026.
FT   VARIANT     727    727       L -> P (in PKD1).
FT                                {ECO:0000269|PubMed:21115670,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_064383.
FT   VARIANT     727    727       L -> R (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064384.
FT   VARIANT     738    738       P -> R.
FT                                /FTId=VAR_058770.
FT   VARIANT     739    739       R -> Q (in dbSNP:rs40433).
FT                                {ECO:0000269|PubMed:11857740,
FT                                ECO:0000269|PubMed:18837007,
FT                                ECO:0000269|PubMed:7663510}.
FT                                /FTId=VAR_058771.
FT   VARIANT     845    845       L -> S (in PKD1).
FT                                {ECO:0000269|PubMed:10364515,
FT                                ECO:0000269|PubMed:15772804}.
FT                                /FTId=VAR_010086.
FT   VARIANT     950    950       L -> P (in dbSNP:rs2369063).
FT                                /FTId=VAR_056696.
FT   VARIANT     967    967       W -> R (in PKD1).
FT                                {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012453.
FT   VARIANT     987    987       Q -> H (in PKD1).
FT                                {ECO:0000269|PubMed:12070253}.
FT                                /FTId=VAR_058772.
FT   VARIANT    1092   1092       M -> T (in PKD1; dbSNP:rs2549677).
FT                                {ECO:0000269|PubMed:11857740,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:18837007,
FT                                ECO:0000269|PubMed:7736581}.
FT                                /FTId=VAR_056697.
FT   VARIANT    1114   1114       L -> R (in dbSNP:rs241573).
FT                                /FTId=VAR_056698.
FT   VARIANT    1166   1166       G -> S (in PKD1).
FT                                {ECO:0000269|PubMed:11012875}.
FT                                /FTId=VAR_011033.
FT   VARIANT    1168   1168       P -> S (in dbSNP:rs146887330).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058773.
FT   VARIANT    1206   1206       V -> G (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068027.
FT   VARIANT    1240   1240       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058774.
FT   VARIANT    1242   1242       T -> M (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058775.
FT   VARIANT    1340   1340       R -> W (in PKD1; dbSNP:rs143690392).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058776.
FT   VARIANT    1399   1399       W -> R (in dbSNP:rs116092985).
FT                                {ECO:0000269|PubMed:10364515,
FT                                ECO:0000269|PubMed:10577909,
FT                                ECO:0000269|PubMed:11857740,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12070253,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_010087.
FT   VARIANT    1516   1516       A -> T (in dbSNP:rs148164067).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058777.
FT   VARIANT    1557   1557       R -> P (in dbSNP:rs241572).
FT                                /FTId=VAR_056699.
FT   VARIANT    1649   1649       T -> M. {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058778.
FT   VARIANT    1667   1667       T -> P (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058779.
FT   VARIANT    1684   1684       S -> L (in dbSNP:rs139520275).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058780.
FT   VARIANT    1734   1734       T -> K (in dbSNP:rs241571).
FT                                /FTId=VAR_056700.
FT   VARIANT    1786   1786       P -> L (rare polymorphism).
FT                                {ECO:0000269|PubMed:10364515}.
FT                                /FTId=VAR_010088.
FT   VARIANT    1811   1811       E -> K (in PKD1).
FT                                {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058781.
FT   VARIANT    1871   1871       A -> T. {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058782.
FT   VARIANT    1926   1926       A -> V. {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058783.
FT   VARIANT    1943   1943       V -> I (in dbSNP:rs137978188).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058784.
FT   VARIANT    1952   1952       G -> D. {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058785.
FT   VARIANT    1956   1956       V -> E (in PKD1).
FT                                {ECO:0000269|PubMed:11012875}.
FT                                /FTId=VAR_011034.
FT   VARIANT    1992   1993       FT -> L (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011035.
FT   VARIANT    1995   1995       R -> H. {ECO:0000269|PubMed:11012875}.
FT                                /FTId=VAR_011036.
FT   VARIANT    2083   2083       T -> I (in PKD1).
FT                                {ECO:0000269|PubMed:12007219}.
FT                                /FTId=VAR_058786.
FT   VARIANT    2092   2092       Y -> C (in PKD1).
FT                                {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058787.
FT   VARIANT    2185   2185       Y -> D (in PKD1).
FT                                {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058788.
FT   VARIANT    2200   2200       R -> C (in PKD1; dbSNP:rs140869992).
FT                                {ECO:0000269|PubMed:12842373,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058789.
FT   VARIANT    2220   2224       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011037.
FT   VARIANT    2250   2250       T -> M (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10854095}.
FT                                /FTId=VAR_011038.
FT   VARIANT    2260   2260       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058790.
FT   VARIANT    2329   2329       R -> W (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:10854095}.
FT                                /FTId=VAR_011039.
FT   VARIANT    2336   2336       Y -> D (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011040.
FT   VARIANT    2370   2370       C -> R (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058791.
FT   VARIANT    2373   2373       C -> Y (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058792.
FT   VARIANT    2379   2379       Y -> C (in PKD1).
FT                                {ECO:0000269|PubMed:10854095,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_011041.
FT   VARIANT    2391   2391       G -> D (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064385.
FT   VARIANT    2392   2392       R -> P (in PKD1).
FT                                {ECO:0000269|PubMed:10577909}.
FT                                /FTId=VAR_012454.
FT   VARIANT    2408   2408       R -> C (in PKD1).
FT                                {ECO:0000269|PubMed:11012875}.
FT                                /FTId=VAR_011042.
FT   VARIANT    2421   2421       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058793.
FT   VARIANT    2422   2422       T -> K (in PKD1).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058794.
FT   VARIANT    2423   2423       S -> F (in PKD1).
FT                                {ECO:0000269|PubMed:10577909}.
FT                                /FTId=VAR_012455.
FT   VARIANT    2434   2434       R -> W (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064386.
FT   VARIANT    2443   2443       G -> GG (in PKD1).
FT                                /FTId=VAR_011043.
FT   VARIANT    2471   2471       P -> L (in PKD1).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012456.
FT   VARIANT    2515   2515       R -> Q (in dbSNP:rs2432404).
FT                                /FTId=VAR_056701.
FT   VARIANT    2519   2519       Q -> L (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012457.
FT   VARIANT    2534   2534       S -> G (in dbSNP:rs3874655).
FT                                /FTId=VAR_056702.
FT   VARIANT    2546   2546       H -> Y (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064387.
FT   VARIANT    2548   2548       E -> Q (in dbSNP:rs28369051).
FT                                {ECO:0000269|PubMed:10577909}.
FT                                /FTId=VAR_012458.
FT   VARIANT    2569   2569       S -> C (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064388.
FT   VARIANT    2579   2579       Missing (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012459.
FT   VARIANT    2582   2582       T -> M (in dbSNP:rs2432405).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012460.
FT   VARIANT    2604   2604       D -> N. {ECO:0000269|PubMed:11012875}.
FT                                /FTId=VAR_011044.
FT   VARIANT    2613   2613       Missing (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012461.
FT   VARIANT    2638   2638       H -> R (in PKD1; dbSNP:rs9936785).
FT                                {ECO:0000269|PubMed:10577909,
FT                                ECO:0000269|PubMed:11571556,
FT                                ECO:0000269|PubMed:11857740,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_012462.
FT   VARIANT    2646   2646       I -> T (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064389.
FT   VARIANT    2649   2649       T -> I (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012463.
FT   VARIANT    2674   2674       P -> S. {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_011045.
FT   VARIANT    2696   2696       L -> R (in PKD1).
FT                                {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012464.
FT   VARIANT    2708   2708       T -> M. {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_011046.
FT   VARIANT    2734   2734       P -> T (in dbSNP:rs150568356).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011047.
FT   VARIANT    2735   2735       Q -> L (in dbSNP:rs141717814).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011048.
FT   VARIANT    2746   2746       R -> P (in dbSNP:rs1800569).
FT                                /FTId=VAR_014918.
FT   VARIANT    2752   2752       A -> D (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011049.
FT   VARIANT    2760   2760       M -> T (associated with PKD1;
FT                                dbSNP:rs1800568).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005533.
FT   VARIANT    2761   2761       R -> P (associated with PKD1).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_058795.
FT   VARIANT    2763   2763       L -> V (in PKD1).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005535.
FT   VARIANT    2764   2764       M -> T (associated with PKD1;
FT                                dbSNP:rs1800570).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005536.
FT   VARIANT    2765   2765       R -> C (in dbSNP:rs144979397).
FT                                {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_011051.
FT   VARIANT    2765   2765       R -> RILMR (in PKD1).
FT                                /FTId=VAR_011050.
FT   VARIANT    2767   2767       R -> C (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068028.
FT   VARIANT    2768   2768       V -> M (in PKD1; associated with S-2858).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011052.
FT   VARIANT    2771   2771       E -> K (in PKD1; does not undergo
FT                                autoproteolytic cleavage).
FT                                {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:12482949,
FT                                ECO:0000269|PubMed:12842373,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_011053.
FT   VARIANT    2782   2782       V -> M. {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011054.
FT   VARIANT    2785   2785       G -> D (in PKD1).
FT                                {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058796.
FT   VARIANT    2791   2791       R -> Q (in a patient with polycystic
FT                                kidney disease; does not affect
FT                                autoproteolytic cleavage at the GPS
FT                                domain). {ECO:0000269|PubMed:12482949,
FT                                ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005537.
FT   VARIANT    2802   2802       P -> L (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058797.
FT   VARIANT    2814   2814       G -> R (in PKD1; unknown pathological
FT                                significance; dbSNP:rs149151043).
FT                                {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12007219,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_011055.
FT   VARIANT    2816   2816       L -> P (in PKD1).
FT                                {ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:12007219}.
FT                                /FTId=VAR_011056.
FT   VARIANT    2826   2826       I -> T (in PKD1).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005538.
FT   VARIANT    2858   2858       G -> S (in PKD1; associated with M-2768).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011057.
FT   VARIANT    2888   2888       R -> G. {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011058.
FT   VARIANT    2889   2889       S -> R (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064390.
FT   VARIANT    2905   2905       V -> I (in dbSNP:rs147788838).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011059.
FT   VARIANT    2921   2921       H -> P (in PKD1; does not undergo
FT                                autoproteolytic cleavage).
FT                                {ECO:0000269|PubMed:10923040,
FT                                ECO:0000269|PubMed:12482949}.
FT                                /FTId=VAR_011060.
FT   VARIANT    2958   2958       S -> L. {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058798.
FT   VARIANT    2966   2966       E -> D (in dbSNP:rs13337123).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011061.
FT   VARIANT    2972   2972       D -> N. {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012465.
FT   VARIANT    2977   2977       T -> N. {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058799.
FT   VARIANT    2978   2978       Missing (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:11571556}.
FT                                /FTId=VAR_012466.
FT   VARIANT    2985   2985       R -> G (in PKD1).
FT                                {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012467.
FT   VARIANT    2993   2993       L -> P (in PKD1; does not undergo
FT                                autoproteolytic cleavage).
FT                                {ECO:0000269|PubMed:12482949,
FT                                ECO:0000269|PubMed:9199561}.
FT                                /FTId=VAR_010089.
FT   VARIANT    2995   2995       L -> R (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068029.
FT   VARIANT    3005   3005       Q -> E (in dbSNP:rs1063401).
FT                                /FTId=VAR_056703.
FT   VARIANT    3008   3008       V -> L (in PKD1).
FT                                {ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_005539.
FT   VARIANT    3008   3008       V -> M (in dbSNP:rs117896488).
FT                                {ECO:0000269|PubMed:11558899}.
FT                                /FTId=VAR_058800.
FT   VARIANT    3012   3017       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:11115377}.
FT                                /FTId=VAR_011062.
FT   VARIANT    3016   3016       Q -> R (in PKD1; does not undergo
FT                                autoproteolytic cleavage).
FT                                {ECO:0000269|PubMed:12482949,
FT                                ECO:0000269|PubMed:9199561}.
FT                                /FTId=VAR_010090.
FT   VARIANT    3023   3023       M -> V (in dbSNP:rs17135779).
FT                                /FTId=VAR_056704.
FT   VARIANT    3027   3039       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:11857740}.
FT                                /FTId=VAR_058801.
FT   VARIANT    3039   3039       R -> C (in PKD1).
FT                                {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012468.
FT   VARIANT    3057   3057       V -> M. {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058802.
FT   VARIANT    3066   3066       F -> L (in PKD1; dbSNP:rs77028972).
FT                                {ECO:0000269|PubMed:10854095,
FT                                ECO:0000269|PubMed:10923040,
FT                                ECO:0000269|PubMed:11115377,
FT                                ECO:0000269|PubMed:11571556,
FT                                ECO:0000269|PubMed:11857740,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007,
FT                                ECO:0000269|PubMed:9285784}.
FT                                /FTId=VAR_011063.
FT   VARIANT    3138   3138       V -> M (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15772804}.
FT                                /FTId=VAR_058803.
FT   VARIANT    3139   3139       G -> V. {ECO:0000269|PubMed:10854095}.
FT                                /FTId=VAR_011064.
FT   VARIANT    3154   3154       L -> P (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064391.
FT   VARIANT    3167   3167       I -> F (in PKD1).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058804.
FT   VARIANT    3188   3188       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058805.
FT   VARIANT    3193   3193       P -> L. {ECO:0000269|PubMed:10854095}.
FT                                /FTId=VAR_011065.
FT   VARIANT    3247   3247       R -> H (in PKD1).
FT                                {ECO:0000269|PubMed:11216660}.
FT                                /FTId=VAR_013838.
FT   VARIANT    3285   3285       V -> I (in PKD1).
FT                                {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012469.
FT   VARIANT    3311   3311       H -> R. {ECO:0000269|PubMed:11316854}.
FT                                /FTId=VAR_012470.
FT   VARIANT    3355   3355       P -> L (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058806.
FT   VARIANT    3375   3375       V -> M (in PKD1).
FT                                {ECO:0000269|PubMed:10923040,
FT                                ECO:0000269|PubMed:9921908}.
FT                                /FTId=VAR_005541.
FT   VARIANT    3382   3382       T -> M (in PKD1).
FT                                {ECO:0000269|PubMed:11216660}.
FT                                /FTId=VAR_013839.
FT   VARIANT    3435   3435       R -> Q (in dbSNP:rs140189010).
FT                                {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058807.
FT   VARIANT    3510   3510       T -> M (in PKD1; dbSNP:rs45478794).
FT                                {ECO:0000269|PubMed:11558899,
FT                                ECO:0000269|PubMed:11691639,
FT                                ECO:0000269|PubMed:12007219,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:9199561}.
FT                                /FTId=VAR_010091.
FT   VARIANT    3511   3511       L -> V (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:9199561}.
FT                                /FTId=VAR_010092.
FT   VARIANT    3512   3512       A -> V (in dbSNP:rs34197769).
FT                                {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_011066.
FT   VARIANT    3560   3560       G -> R (in PKD1; dbSNP:rs79000340).
FT                                {ECO:0000269|PubMed:11691639}.
FT                                /FTId=VAR_012471.
FT   VARIANT    3562   3562       S -> N.
FT                                /FTId=VAR_010093.
FT   VARIANT    3602   3602       G -> S (in PKD1).
FT                                {ECO:0000269|PubMed:12220456}.
FT                                /FTId=VAR_058808.
FT   VARIANT    3603   3603       W -> R (in PKD1).
FT                                {ECO:0000269|PubMed:21115670}.
FT                                /FTId=VAR_064392.
FT   VARIANT    3632   3632       E -> D (in PKD1).
FT                                {ECO:0000269|PubMed:11773467,
FT                                ECO:0000269|PubMed:8554072}.
FT                                /FTId=VAR_005542.
FT   VARIANT    3649   3649       P -> L (in PKD1).
FT                                {ECO:0000269|PubMed:11773467}.
FT                                /FTId=VAR_058809.
FT   VARIANT    3651   3651       G -> S (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068030.
FT   VARIANT    3678   3678       M -> T (in PKD1).
FT                                {ECO:0000269|PubMed:11773467,
FT                                ECO:0000269|PubMed:9259200}.
FT                                /FTId=VAR_005543.
FT   VARIANT    3682   3682       L -> P (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058810.
FT   VARIANT    3719   3719       R -> Q (in PKD1).
FT                                {ECO:0000269|PubMed:11058904,
FT                                ECO:0000269|PubMed:11691639}.
FT                                /FTId=VAR_011067.
FT   VARIANT    3726   3726       W -> S (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058811.
FT   VARIANT    3748   3752       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:10647901,
FT                                ECO:0000269|PubMed:8554072}.
FT                                /FTId=VAR_005544.
FT   VARIANT    3750   3750       R -> Q (in PKD1).
FT                                {ECO:0000269|PubMed:21115670,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_064393.
FT   VARIANT    3751   3751       Q -> R (in PKD1).
FT                                {ECO:0000269|PubMed:12842373}.
FT                                /FTId=VAR_058812.
FT   VARIANT    3753   3753       R -> W (in PKD1).
FT                                {ECO:0000269|PubMed:10729710,
FT                                ECO:0000269|PubMed:11691639,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_011068.
FT   VARIANT    3815   3815       D -> N (in PKD1).
FT                                {ECO:0000269|PubMed:10729710}.
FT                                /FTId=VAR_011069.
FT   VARIANT    3852   3852       L -> P (in PKD1).
FT                                {ECO:0000269|PubMed:11058904,
FT                                ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_011070.
FT   VARIANT    3954   3954       A -> P (in PKD1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15772804}.
FT                                /FTId=VAR_058813.
FT   VARIANT    3996   3996       F -> FLLF (in PKD1).
FT                                /FTId=VAR_010094.
FT   VARIANT    4032   4032       G -> D (in PKD1).
FT                                {ECO:0000269|PubMed:9521593}.
FT                                /FTId=VAR_005545.
FT   VARIANT    4045   4045       I -> V (in dbSNP:rs10960).
FT                                {ECO:0000269|PubMed:10647901,
FT                                ECO:0000269|PubMed:11058904,
FT                                ECO:0000269|PubMed:11773467,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:12070253,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007,
FT                                ECO:0000269|PubMed:9521593}.
FT                                /FTId=VAR_005546.
FT   VARIANT    4058   4058       V -> A. {ECO:0000269|PubMed:9150733}.
FT                                /FTId=VAR_005547.
FT   VARIANT    4059   4059       A -> V (in dbSNP:rs3209986).
FT                                {ECO:0000269|PubMed:11773467,
FT                                ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:15772804,
FT                                ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_010095.
FT   VARIANT    4102   4102       G -> E. {ECO:0000269|PubMed:11773467}.
FT                                /FTId=VAR_058814.
FT   VARIANT    4106   4106       L -> P. {ECO:0000269|PubMed:11773467}.
FT                                /FTId=VAR_058815.
FT   VARIANT    4124   4124       P -> S. {ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058816.
FT   VARIANT    4132   4132       Missing (in PKD1).
FT                                {ECO:0000269|PubMed:10647901}.
FT                                /FTId=VAR_011071.
FT   VARIANT    4136   4136       R -> G (in PKD1).
FT                                {ECO:0000269|PubMed:10987650}.
FT                                /FTId=VAR_010096.
FT   VARIANT    4146   4146       V -> I (in dbSNP:rs148478410).
FT                                {ECO:0000269|PubMed:11773467,
FT                                ECO:0000269|PubMed:11967008}.
FT                                /FTId=VAR_058817.
FT   VARIANT    4150   4150       R -> C (in PKD1).
FT                                {ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_068031.
FT   VARIANT    4154   4154       R -> C (in PKD1; dbSNP:rs115538130).
FT                                {ECO:0000269|PubMed:10987650}.
FT                                /FTId=VAR_010097.
FT   VARIANT    4155   4155       F -> V (in PKD1).
FT                                {ECO:0000269|PubMed:18837007}.
FT                                /FTId=VAR_058818.
FT   VARIANT    4190   4190       S -> F. {ECO:0000269|PubMed:11967008,
FT                                ECO:0000269|PubMed:9199561}.
FT                                /FTId=VAR_010098.
FT   VARIANT    4225   4225       Q -> P (in PKD1).
FT                                {ECO:0000269|PubMed:10200984}.
FT                                /FTId=VAR_010099.
FT   VARIANT    4255   4255       P -> S (in PKD1).
FT                                {ECO:0000269|PubMed:12220456}.
FT                                /FTId=VAR_058819.
FT   VARIANT    4276   4276       R -> W (in PKD1; dbSNP:rs114251396).
FT                                {ECO:0000269|PubMed:10200984,
FT                                ECO:0000269|PubMed:22508176}.
FT                                /FTId=VAR_010100.
FT   MUTAGEN    3049   3049       T->C,S: Does not affect auto-cleavage.
FT                                {ECO:0000269|PubMed:17525154}.
FT   MUTAGEN    3049   3049       T->G,R,V: Does not undergo auto-cleavage.
FT                                {ECO:0000269|PubMed:17525154}.
FT   CONFLICT     71     71       A -> E (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       R -> Q (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    253    253       P -> A (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    302    302       A -> D (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    691    691       P -> A (in Ref. 2; AAC37576/AAC41765).
FT                                {ECO:0000305}.
FT   CONFLICT    763    763       A -> G (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    774    775       AT -> QR (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    792    792       L -> M (in Ref. 2; AAC37576/AAC41765).
FT                                {ECO:0000305}.
FT   CONFLICT    866    866       V -> L (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT    884    884       G -> A (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT   1056   1056       T -> N (in Ref. 2; AAC37576/AAC41765).
FT                                {ECO:0000305}.
FT   CONFLICT   1277   1277       A -> G (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT   1724   1724       A -> T (in Ref. 2; AAC37576/AAC41765).
FT                                {ECO:0000305}.
FT   CONFLICT   1976   1976       V -> M (in Ref. 2; AAC37576/AAC41765).
FT                                {ECO:0000305}.
FT   CONFLICT   3982   3983       QL -> HV (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   CONFLICT   4005   4006       QL -> HV (in Ref. 1; AAC50128).
FT                                {ECO:0000305}.
FT   STRAND      276    278       {ECO:0000244|PDB:1B4R}.
FT   STRAND      285    296       {ECO:0000244|PDB:1B4R}.
FT   STRAND      301    306       {ECO:0000244|PDB:1B4R}.
FT   STRAND      313    317       {ECO:0000244|PDB:1B4R}.
FT   STRAND      320    325       {ECO:0000244|PDB:1B4R}.
FT   STRAND      327    338       {ECO:0000244|PDB:1B4R}.
FT   STRAND      343    353       {ECO:0000244|PDB:1B4R}.
SQ   SEQUENCE   4303 AA;  462529 MW;  AEDAC48F3F0A853C CRC64;
     MPPAAPARLA LALGLGLWLG ALAGGPGRGC GPCEPPCLCG PAPGAACRVN CSGRGLRTLG
     PALRIPADAT ALDVSHNLLR ALDVGLLANL SALAELDISN NKISTLEEGI FANLFNLSEI
     NLSGNPFECD CGLAWLPRWA EEQQVRVVQP EAATCAGPGS LAGQPLLGIP LLDSGCGEEY
     VACLPDNSSG TVAAVSFSAA HEGLLQPEAC SAFCFSTGQG LAALSEQGWC LCGAAQPSSA
     SFACLSLCSG PPPPPAPTCR GPTLLQHVFP ASPGATLVGP HGPLASGQLA AFHIAAPLPV
     TATRWDFGDG SAEVDAAGPA ASHRYVLPGR YHVTAVLALG AGSALLGTDV QVEAAPAALE
     LVCPSSVQSD ESLDLSIQNR GGSGLEAAYS IVALGEEPAR AVHPLCPSDT EIFPGNGHCY
     RLVVEKAAWL QAQEQCQAWA GAALAMVDSP AVQRFLVSRV TRSLDVWIGF STVQGVEVGP
     APQGEAFSLE SCQNWLPGEP HPATAEHCVR LGPTGWCNTD LCSAPHSYVC ELQPGGPVQD
     AENLLVGAPS GDLQGPLTPL AQQDGLSAPH EPVEVMVFPG LRLSREAFLT TAEFGTQELR
     RPAQLRLQVY RLLSTAGTPE NGSEPESRSP DNRTQLAPAC MPGGRWCPGA NICLPLDASC
     HPQACANGCT SGPGLPGAPY ALWREFLFSV PAGPPAQYSV TLHGQDVLML PGDLVGLQHD
     AGPGALLHCS PAPGHPGPRA PYLSANASSW LPHLPAQLEG TWACPACALR LLAATEQLTV
     LLGLRPNPGL RLPGRYEVRA EVGNGVSRHN LSCSFDVVSP VAGLRVIYPA PRDGRLYVPT
     NGSALVLQVD SGANATATAR WPGGSVSARF ENVCPALVAT FVPGCPWETN DTLFSVVALP
     WLSEGEHVVD VVVENSASRA NLSLRVTAEE PICGLRATPS PEARVLQGVL VRYSPVVEAG
     SDMVFRWTIN DKQSLTFQNV VFNVIYQSAA VFKLSLTASN HVSNVTVNYN VTVERMNRMQ
     GLQVSTVPAV LSPNATLALT AGVLVDSAVE VAFLWTFGDG EQALHQFQPP YNESFPVPDP
     SVAQVLVEHN VMHTYAAPGE YLLTVLASNA FENLTQQVPV SVRASLPSVA VGVSDGVLVA
     GRPVTFYPHP LPSPGGVLYT WDFGDGSPVL TQSQPAANHT YASRGTYHVR LEVNNTVSGA
     AAQADVRVFE ELRGLSVDMS LAVEQGAPVV VSAAVQTGDN ITWTFDMGDG TVLSGPEATV
     EHVYLRAQNC TVTVGAASPA GHLARSLHVL VFVLEVLRVE PAACIPTQPD ARLTAYVTGN
     PAHYLFDWTF GDGSSNTTVR GCPTVTHNFT RSGTFPLALV LSSRVNRAHY FTSICVEPEV
     GNVTLQPERQ FVQLGDEAWL VACAWPPFPY RYTWDFGTEE AAPTRARGPE VTFIYRDPGS
     YLVTVTASNN ISAANDSALV EVQEPVLVTS IKVNGSLGLE LQQPYLFSAV GRGRPASYLW
     DLGDGGWLEG PEVTHAYNST GDFTVRVAGW NEVSRSEAWL NVTVKRRVRG LVVNASRTVV
     PLNGSVSFST SLEAGSDVRY SWVLCDRCTP IPGGPTISYT FRSVGTFNII VTAENEVGSA
     QDSIFVYVLQ LIEGLQVVGG GRYFPTNHTV QLQAVVRDGT NVSYSWTAWR DRGPALAGSG
     KGFSLTVLEA GTYHVQLRAT NMLGSAWADC TMDFVEPVGW LMVAASPNPA AVNTSVTLSA
     ELAGGSGVVY TWSLEEGLSW ETSEPFTTHS FPTPGLHLVT MTAGNPLGSA NATVEVDVQV
     PVSGLSIRAS EPGGSFVAAG SSVPFWGQLA TGTNVSWCWA VPGGSSKRGP HVTMVFPDAG
     TFSIRLNASN AVSWVSATYN LTAEEPIVGL VLWASSKVVA PGQLVHFQIL LAAGSAVTFR
     LQVGGANPEV LPGPRFSHSF PRVGDHVVSV RGKNHVSWAQ AQVRIVVLEA VSGLQVPNCC
     EPGIATGTER NFTARVQRGS RVAYAWYFSL QKVQGDSLVI LSGRDVTYTP VAAGLLEIQV
     RAFNALGSEN RTLVLEVQDA VQYVALQSGP CFTNRSAQFE AATSPSPRRV AYHWDFGDGS
     PGQDTDEPRA EHSYLRPGDY RVQVNASNLV SFFVAQATVT VQVLACREPE VDVVLPLQVL
     MRRSQRNYLE AHVDLRDCVT YQTEYRWEVY RTASCQRPGR PARVALPGVD VSRPRLVLPR
     LALPVGHYCF VFVVSFGDTP LTQSIQANVT VAPERLVPII EGGSYRVWSD TRDLVLDGSE
     SYDPNLEDGD QTPLSFHWAC VASTQREAGG CALNFGPRGS STVTIPRERL AAGVEYTFSL
     TVWKAGRKEE ATNQTVLIRS GRVPIVSLEC VSCKAQAVYE VSRSSYVYLE GRCLNCSSGS
     KRGRWAARTF SNKTLVLDET TTSTGSAGMR LVLRRGVLRD GEGYTFTLTV LGRSGEEEGC
     ASIRLSPNRP PLGGSCRLFP LGAVHALTTK VHFECTGWHD AEDAGAPLVY ALLLRRCRQG
     HCEEFCVYKG SLSSYGAVLP PGFRPHFEVG LAVVVQDQLG AAVVALNRSL AITLPEPNGS
     ATGLTVWLHG LTASVLPGLL RQADPQHVIE YSLALVTVLN EYERALDVAA EPKHERQHRA
     QIRKNITETL VSLRVHTVDD IQQIAAALAQ CMGPSRELVC RSCLKQTLHK LEAMMLILQA
     ETTAGTVTPT AIGDSILNIT GDLIHLASSD VRAPQPSELG AESPSRMVAS QAYNLTSALM
     RILMRSRVLN EEPLTLAGEE IVAQGKRSDP RSLLCYGGAP GPGCHFSIPE AFSGALANLS
     DVVQLIFLVD SNPFPFGYIS NYTVSTKVAS MAFQTQAGAQ IPIERLASER AITVKVPNNS
     DWAARGHRSS ANSANSVVVQ PQASVGAVVT LDSSNPAAGL HLQLNYTLLD GHYLSEEPEP
     YLAVYLHSEP RPNEHNCSAS RRIRPESLQG ADHRPYTFFI SPGSRDPAGS YHLNLSSHFR
     WSALQVSVGL YTSLCQYFSE EDMVWRTEGL LPLEETSPRQ AVCLTRHLTA FGASLFVPPS
     HVRFVFPEPT ADVNYIVMLT CAVCLVTYMV MAAILHKLDQ LDASRGRAIP FCGQRGRFKY
     EILVKTGWGR GSGTTAHVGI MLYGVDSRSG HRHLDGDRAF HRNSLDIFRI ATPHSLGSVW
     KIRVWHDNKG LSPAWFLQHV IVRDLQTARS AFFLVNDWLS VETEANGGLV EKEVLAASDA
     ALLRFRRLLV AELQRGFFDK HIWLSIWDRP PRSRFTRIQR ATCCVLLICL FLGANAVWYG
     AVGDSAYSTG HVSRLSPLSV DTVAVGLVSS VVVYPVYLAI LFLFRMSRSK VAGSPSPTPA
     GQQVLDIDSC LDSSVLDSSF LTFSGLHAEQ AFVGQMKSDL FLDDSKSLVC WPSGEGTLSW
     PDLLSDPSIV GSNLRQLARG QAGHGLGPEE DGFSLASPYS PAKSFSASDE DLIQQVLAEG
     VSSPAPTQDT HMETDLLSSL SSTPGEKTET LALQRLGELG PPSPGLNWEQ PQAARLSRTG
     LVEGLRKRLL PAWCASLAHG LSLLLVAVAV AVSGWVGASF PPGVSVAWLL SSSASFLASF
     LGWEPLKVLL EALYFSLVAK RLHPDEDDTL VESPAVTPVS ARVPRVRPPH GFALFLAKEE
     ARKVKRLHGM LRSLLVYMLF LLVTLLASYG DASCHGHAYR LQSAIKQELH SRAFLAITRS
     EELWPWMAHV LLPYVHGNQS SPELGPPRLR QVRLQEALYP DPPGPRVHTC SAAGGFSTSD
     YDVGWESPHN GSGTWAYSAP DLLGAWSWGS CAVYDSGGYV QELGLSLEES RDRLRFLQLH
     NWLDNRSRAV FLELTRYSPA VGLHAAVTLR LEFPAAGRAL AALSVRPFAL RRLSAGLSLP
     LLTSVCLLLF AVHFAVAEAR TWHREGRWRV LRLGAWARWL LVALTAATAL VRLAQLGAAD
     RQWTRFVRGR PRRFTSFDQV AQLSSAARGL AASLLFLLLV KAAQQLRFVR QWSVFGKTLC
     RALPELLGVT LGLVVLGVAY AQLAILLVSS CVDSLWSVAQ ALLVLCPGTG LSTLCPAESW
     HLSPLLCVGL WALRLWGALR LGAVILRWRY HALRGELYRP AWEPQDYEMV ELFLRRLRLW
     MGLSKVKEFR HKVRFEGMEP LPSRSSRGSK VSPDVPPPSA GSDASHPSTS SSQLDGLSVS
     LGRLGTRCEP EPSRLQAVFE ALLTQFDRLN QATEDVYQLE QQLHSLQGRR SSRAPAGSSR
     GPSPGLRPAL PSRLARASRG VDLATGPSRT PLRAKNKVHP SST
//
ID   NPC1_HUMAN              Reviewed;        1278 AA.
AC   O15118; B4DET3; Q9P130;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   17-FEB-2016, entry version 156.
DE   RecName: Full=Niemann-Pick C1 protein;
DE   Flags: Precursor;
GN   Name=NPC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ILE-642, AND VARIANTS
RP   NPC1.
RX   PubMed=9211849; DOI=10.1126/science.277.5323.228;
RA   Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D.,
RA   Cummings C., Gu J., Rosenfeld M.A., Pavan W.J., Krizman D.B.,
RA   Nagle J., Polymeropoulos M.H., Sturley S.L., Ioannou Y.A.,
RA   Higgins M.E., Comly M., Cooney A., Brown A., Kaneski C.R.,
RA   Blanchette-Mackie E.J., Dwyer N.K., Neufeld E.B., Chang T.-Y.,
RA   Liscum L., Strauss J.F. III, Ohno K., Zeigler M., Carmi R., Sokol J.,
RA   Markie D., O'Neill R.R., van Diggelen O.P., Elleder M.,
RA   Patterson M.C., Brady R.O., Vanier M.T., Pentchev P.G., Tagle D.A.;
RT   "Niemann-Pick C1 disease gene: homology to mediators of cholesterol
RT   homeostasis.";
RL   Science 277:228-231(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS.
RX   PubMed=10425213; DOI=10.1006/bbrc.1999.1070;
RA   Morris J.A., Zhang D., Coleman K.G., Nagle J., Pentchev P.G.,
RA   Carstea E.D.;
RT   "The genomic organization and polymorphism analysis of the human
RT   Niemann-Pick C1 gene.";
RL   Biochem. Biophys. Res. Commun. 261:493-498(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS NPC1 ARG-512; TRP-670;
RP   CYS-825; ILE-849; VAL-874; TYR-948; LEU-954; LEU-958; ALA-1007 AND
RP   THR-1061, AND VARIANTS ARG-215; ILE-642; VAL-858; GLY-971 AND
RP   VAL-1049.
RX   PubMed=11754101; DOI=10.1002/humu.10016;
RA   Bauer P., Knoblich R., Bauer C., Finckh U., Hufen A., Kropp J.,
RA   Braun S., Kustermann-Kuhn B., Schmidt D., Harzer K., Rolfs A.;
RT   "NPC1: complete genomic sequence, mutation analysis, and
RT   characterization of haplotypes.";
RL   Hum. Mutat. 19:30-38(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLY-151 AND ILE-642.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION, AND MUTAGENESIS OF CYS-63 AND CYS-97.
RX   PubMed=9927649; DOI=10.1073/pnas.96.3.805;
RA   Watari H., Blanchette-Mackie E.J., Dwyer N.K., Glick J.M., Patel S.,
RA   Neufeld E.B., Brady R.O., Pentchev P.G., Strauss J.F. III;
RT   "Niemann-Pick C1 protein: obligatory roles for N-terminal domains and
RT   lysosomal targeting in cholesterol mobilization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:805-810(1999).
RN   [8]
RP   TOPOLOGY, AND GLYCOSYLATION.
RX   PubMed=10821832; DOI=10.1074/jbc.M002184200;
RA   Davies J.P., Ioannou Y.A.;
RT   "Topological analysis of Niemann-Pick C1 protein reveals that the
RT   membrane orientation of the putative sterol-sensing domain is
RT   identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and
RT   sterol regulatory element binding protein cleavage-activating
RT   protein.";
RL   J. Biol. Chem. 275:24367-24374(2000).
RN   [9]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [10]
RP   FUNCTION.
RX   PubMed=18772377; DOI=10.1073/pnas.0807328105;
RA   Infante R.E., Wang M.L., Radhakrishnan A., Kwon H.J., Brown M.S.,
RA   Goldstein J.L.;
RT   "NPC2 facilitates bidirectional transfer of cholesterol between NPC1
RT   and lipid bilayers, a step in cholesterol egress from lysosomes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:15287-15292(2008).
RN   [11]
RP   INTERACTION WITH TMEM97.
RX   PubMed=19583955; DOI=10.1016/j.cmet.2009.05.009;
RA   Bartz F., Kern L., Erz D., Zhu M., Gilbert D., Meinhof T., Wirkner U.,
RA   Erfle H., Muckenthaler M., Pepperkok R., Runz H.;
RT   "Identification of cholesterol-regulating genes by targeted RNAi
RT   screening.";
RL   Cell Metab. 10:63-75(2009).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-135 AND ASN-524.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [13]
RP   REVIEW ON FUNCTION.
RX   PubMed=18832164; DOI=10.1073/pnas.0808256105;
RA   Subramanian K., Balch W.E.;
RT   "NPC1/NPC2 function as a tag team duo to mobilize cholesterol.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:15223-15224(2008).
RN   [14]
RP   REVIEW ON FUNCTION.
RX   PubMed=20674853; DOI=10.1016/j.cmet.2010.07.004;
RA   Vance J.E.;
RT   "Transfer of cholesterol by the NPC team.";
RL   Cell Metab. 12:105-106(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=21412152; DOI=10.1097/MOL.0b013e3283453e69;
RA   Vance J.E., Peake K.B.;
RT   "Function of the Niemann-Pick type C proteins and their bypass by
RT   cyclodextrin.";
RL   Curr. Opin. Lipidol. 22:204-209(2011).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH EBOLAVIRUS
RP   GLYCOPROTEIN.
RX   PubMed=21866103; DOI=10.1038/nature10348;
RA   Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G.,
RA   Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G.,
RA   Dal Cin P., Dye J.M., Whelan S.P., Chandran K., Brummelkamp T.R.;
RT   "Ebola virus entry requires the cholesterol transporter Niemann-Pick
RT   C1.";
RL   Nature 477:340-343(2011).
RN   [18]
RP   INTERACTION WITH TIM1, AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=25855742; DOI=10.1128/JVI.03156-14;
RA   Kuroda M., Fujikura D., Nanbo A., Marzi A., Noyori O., Kajihara M.,
RA   Maruyama J., Matsuno K., Miyamoto H., Yoshida R., Feldmann H.,
RA   Takada A.;
RT   "Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of
RT   Ebola Virus.";
RL   J. Virol. 89:6481-6493(2015).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 23-252 OF MUTANT GLN-70;
RP   GLN-122 AND GLN-185 IN COMPLEX WITH CHOLESTEROL, FUNCTION, DISULFIDE
RP   BONDS, GLYCOSYLATION AT ASN-158 AND ASN-222, AND MUTAGENESIS OF
RP   26-VAL-TRP-27; 39-ARG--ASN-41; ASN-41; ASN-70; 82-THR-LEU-83;
RP   101-PHE-TYR-102; 106-ASN--PHE-108; 110-GLU--THR-112; ASN-122;
RP   144-LEU-GLN-145; 146-TYR-TYR-147; 175-LEU-LEU-176; 180-ASP--ASP-182;
RP   ASN-185; 187-TYR-ASN-188; 191-GLU-TYR-192; 195-ASN-LYS-196;
RP   197-ASP-ASN-198; 199-GLY-GLN-200; 202-PRO-PHE-203; 204-THR-ILE-205 AND
RP   GLY-660.
RX   PubMed=19563754; DOI=10.1016/j.cell.2009.03.049;
RA   Kwon H.J., Abi-Mosleh L., Wang M.L., Deisenhofer J., Goldstein J.L.,
RA   Brown M.S., Infante R.E.;
RT   "Structure of N-terminal domain of NPC1 reveals distinct subdomains
RT   for binding and transfer of cholesterol.";
RL   Cell 137:1213-1224(2009).
RN   [21]
RP   VARIANT NPC1 TRP-992.
RX   PubMed=9634529; DOI=10.1086/301931;
RA   Greer W.L., Riddell D.C., Gillan T.L., Girouard G.S., Sparrow S.M.,
RA   Byers D.M., Dobson M.J., Neumann P.E.;
RT   "The Nova Scotia (type D) form of Niemann-Pick disease is caused by a
RT   G3097-->T transversion in NPC1.";
RL   Am. J. Hum. Genet. 63:52-54(1998).
RN   [22]
RP   VARIANTS NPC1 GLN-934; LEU-940; ASN-948; LEU-954; TRP-992; ALA-1007;
RP   THR-1061 AND VAL-1213.
RX   PubMed=10521290; DOI=10.1086/302620;
RA   Greer W.L., Dobson M.J., Girouard G.S., Byers D.M., Riddell D.C.,
RA   Neumann P.E.;
RT   "Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich
RT   domain.";
RL   Am. J. Hum. Genet. 65:1252-1260(1999).
RN   [23]
RP   VARIANT NPC1 THR-1061.
RX   PubMed=10521297; DOI=10.1086/302626;
RA   Millat G., Marcais C., Rafi M.A., Yamamoto T., Morris J.A.,
RA   Pentchev P.G., Ohno K., Wenger D.A., Vanier M.T.;
RT   "Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant
RT   allele in patients of Western European descent and correlates with a
RT   classic juvenile phenotype.";
RL   Am. J. Hum. Genet. 65:1321-1329(1999).
RN   [24]
RP   VARIANTS NPC1, AND VARIANTS ARG-215; VAL-858 AND GLN-1266.
RX   PubMed=10480349; DOI=10.1007/s004399900059;
RA   Yamamoto T., Nanba E., Ninomiya H., Higaki K., Taniguchi M., Zhang H.,
RA   Akaboshi S., Watanabe Y., Takeshima T., Inui K., Okada S., Tanaka A.,
RA   Sakuragawa N., Millat G., Vanier M.T., Morris J.A., Pentchev P.G.,
RA   Ohno K.;
RT   "NPC1 gene mutations in Japanese patients with Niemann-Pick disease
RT   type C.";
RL   Hum. Genet. 105:10-16(1999).
RN   [25]
RP   VARIANTS NPC1 GLY-177; SER-237; PRO-473; PRO-510; GLN-518; SER-703;
RP   MET-889; LEU-954; TYR-956; ARG-996; THR-1061; CYS-1088; ARG-1205;
RP   PHE-1213 AND GLU-1236, AND VARIANT ALA-873.
RX   PubMed=11182931; DOI=10.1136/jmg.37.9.707;
RA   Yamamoto T., Ninomiya H., Matsumoto M., Ohta Y., Nanba E.,
RA   Tsutsumi Y., Yamakawa K., Millat G., Vanier M.T., Pentchev P.G.,
RA   Ohno K.;
RT   "Genotype-phenotype relationship of Niemann-Pick disease type C: a
RT   possible correlation between clinical onset and levels of NPC1 protein
RT   in isolated skin fibroblasts.";
RL   J. Med. Genet. 37:707-712(2000).
RN   [26]
RP   VARIANTS NPC1 ARG-92; MET-137; SER-237; ASN-242; VAL-248; THR-401;
RP   GLN-404; ASP-612; TRP-652; CYS-789; CYS-825; VAL-874; SER-888;
RP   PRO-929; LEU-940; ASN-944; ASN-948; GLN-958; ARG-976; CYS-978;
RP   LEU-1004; ALA-1007; GLY-1023; THR-1061; LYS-1089; THR-1142; LYS-1150;
RP   SER-1156; MET-1165; HIS-1186 AND GLY-1189.
RX   PubMed=11349231; DOI=10.1086/320599;
RA   Sun X., Marks D.L., Park W.D., Wheatley C.L., Puri V., O'Brien J.F.,
RA   Kraft D.L., Lundquist P.A., Patterson M.C., Pagano R.E., Snow K.;
RT   "Niemann-Pick C variant detection by altered sphingolipid trafficking
RT   and correlation with mutations within a specific domain of NPC1.";
RL   Am. J. Hum. Genet. 68:1361-1372(2001).
RN   [27]
RP   VARIANTS NPC1 SER-237; HIS-242; ARG-272; ALA-378; GLN-404; GLN-518;
RP   VAL-605; ARG-631; PRO-724; PRO-775; CYS-825; VAL-874; GLN-934;
RP   MET-943; ASN-944; MET-950; SER-986; ARG-992; ALA-1007; THR-1054;
RP   THR-1061; THR-1142; TYR-1168 AND HIS-1186.
RX   PubMed=11333381; DOI=10.1086/320606;
RA   Millat G., Marcais C., Tomasetto C., Chikh K., Fensom A.H., Harzer K.,
RA   Wenger D.A., Ohno K., Vanier M.T.;
RT   "Niemann-Pick C1 disease: correlations between NPC1 mutations, levels
RT   of NPC1 protein, and phenotypes emphasize the functional significance
RT   of the putative sterol-sensing domain and of the cysteine-rich luminal
RT   loop.";
RL   Am. J. Hum. Genet. 68:1373-1385(2001).
RN   [28]
RP   VARIANTS NPC1 ARG-63; GLN-404; VAL-927; TRP-992; ASP-1012 AND
RP   SER-1156.
RX   PubMed=11545687; DOI=10.1097/00125817-200109000-00003;
RA   Meiner V., Shpitzen S., Mandel H., Klar A., Ben-Neriah Z.,
RA   Zlotogora J., Sagi M., Lossos A., Bargal R., Sury V., Carmi R.,
RA   Leitersdorf E., Zeigler M.;
RT   "Clinical-biochemical correlation in molecularly characterized
RT   patients with Niemann-Pick type C.";
RL   Genet. Med. 3:343-348(2001).
RN   [29]
RP   VARIANTS NPC1 ARG-92; TYR-177; TRP-518; CYS-942; CYS-978; ALA-1007
RP   VAL-1035 AND THR-1061, AND VARIANTS ARG-215; ILE-642 AND VAL-858.
RX   PubMed=11479732; DOI=10.1007/s004390100531;
RA   Ribeiro I., Marcao A., Amaral O., Sa Miranda M.C., Vanier M.T.,
RA   Millat G.;
RT   "Niemann-Pick type C disease: NPC1 mutations associated with severe
RT   and mild cellular cholesterol trafficking alterations.";
RL   Hum. Genet. 109:24-32(2001).
RN   [30]
RP   VARIANTS NPC1 GLY-231; SER-237; VAL-874 ASN-948 AND THR-1094, AND
RP   VARIANTS CYS-381 AND ILE-642.
RX   PubMed=12408188; DOI=10.1023/A:1020151801060;
RA   Kaminski W.E., Kluenemann H.H., Ibach B., Aslanidis C., Klein H.E.,
RA   Schmitz G.;
RT   "Identification of novel mutations in the NPC1 gene in German patients
RT   with Niemann-Pick C disease.";
RL   J. Inherit. Metab. Dis. 25:385-389(2002).
RN   [31]
RP   VARIANTS NPC1 LYS-451; LEU-474; CYS-890; ASP-899; SER-910; TRP-992;
RP   ALA-1007; THR-1061 AND SER-1156, AND VARIANTS ARG-215; ILE-642 AND
RP   VAL-858.
RX   PubMed=12401890; DOI=10.1194/jlr.M200203-JLR200;
RA   Tarugi P., Ballarini G., Bembi B., Battisti C., Palmeri S.,
RA   Panzani F., Di Leo E., Martini C., Federico A., Calandra S.;
RT   "Niemann-Pick type C disease: mutations of NPC1 gene and evidence of
RT   abnormal expression of some mutant alleles in fibroblasts.";
RL   J. Lipid Res. 43:1908-1919(2002).
RN   [32]
RP   VARIANT NPC1 ARG-113, VARIANT SER-273, CHARACTERIZATION OF VARIANT
RP   NPC1 ARG-113, AND CHARACTERIZATION OF VARIANT SER-273.
RX   PubMed=12554680; DOI=10.1093/hmg/ddg025;
RA   Blom T.S., Linder M.D., Snow K., Pihko H., Hess M.W., Jokitalo E.,
RA   Veckman V., Syvaenen A.-C., Ikonen E.;
RT   "Defective endocytic trafficking of NPC1 and NPC2 underlying infantile
RT   Niemann-Pick type C disease.";
RL   Hum. Mol. Genet. 12:257-272(2003).
RN   [33]
RP   VARIANTS NPC1 TYR-74; SER-166; SER-222; TYR-247; PHE-380; PRO-388;
RP   CYS-389; TRP-404; LEU-433; SER-509; SER-521; LEU-543; CYS-615;
RP   ARG-640; SER-660; MET-664; VAL-673; PHE-684; LEU-691; VAL-695;
RP   ASN-700; ILE-734; LYS-742; GLU-745; VAL-767; GLY-789; ASN-945;
RP   ARG-1016; GLN-1059; LEU-1087; ILE-1137; VAL-1140; LYS-1205 AND
RP   GLY-1249, AND VARIANTS ARG-215; SER-237; SER-434 AND GLN-1266.
RX   PubMed=12955717; DOI=10.1002/humu.10255;
RA   Park W.D., O'Brien J.F., Lundquist P.A., Kraft D.L., Vockley C.W.,
RA   Karnes P.S., Patterson M.C., Snow K.;
RT   "Identification of 58 novel mutations in Niemann-Pick disease type C:
RT   correlation with biochemical phenotype and importance of PTC1-like
RT   domains in NPC1.";
RL   Hum. Mutat. 22:313-325(2003).
RN   [34]
RP   VARIANTS NPC1 MET-137; TYR-177; TRP-372; LEU-434; LEU-474; TYR-479;
RP   ARG-576; MET-664; PHE-727; LYS-754; PRO-775; LEU-865; THR-926;
RP   CYS-942; ASN-944; HIS-948; GLU-959; 961-ASN--PHE-966 DELINS SER;
RP   ALA-1007; VAL-1035; LYS-1036; THR-1061; ASN-1066; ILE-1156; SER-1156
RP   AND LEU-1224, AND VARIANTS ARG-215; ILE-642; VAL-858 AND GLN-1266.
RX   PubMed=16098014; DOI=10.1111/j.1399-0004.2005.00490.x;
RA   Fernandez-Valero E.M., Ballart A., Iturriaga C., Lluch M., Macias J.,
RA   Vanier M.T., Pineda M., Coll M.J.;
RT   "Identification of 25 new mutations in 40 unrelated Spanish Niemann-
RT   Pick type C patients: genotype-phenotype correlations.";
RL   Clin. Genet. 68:245-254(2005).
RN   [35]
RP   VARIANTS NPC1 SER-968; VAL-1015; ARG-1034 AND LEU-1212, AND VARIANTS
RP   ARG-215; ILE-642; VAL-858 AND GLN-1266.
RX   PubMed=15774455; DOI=10.1136/jnnp.2004.046045;
RA   Yang C.-C., Su Y.-N., Chiou P.-C., Fietz M.J., Yu C.-L., Hwu W.-L.,
RA   Lee M.-J.;
RT   "Six novel NPC1 mutations in Chinese patients with Niemann-Pick
RT   disease type C.";
RL   J. Neurol. Neurosurg. Psych. 76:592-595(2005).
RN   [36]
RP   VARIANTS NPC1 SER-166; TYR-177; PRO-404; LEU-537; LEU-543; LEU-615;
RP   ARG-631; LEU-763; CYS-825; LEU-862; LEU-865; CYS-871; TYR-917;
RP   GLN-934; LEU-940; MET-950; SER-968; ALA-992; ARG-992; TRP-992;
RP   ALA-1007; MET-1036; THR-1061; VAL-1062; ASN-1097; VAL-1174; HIS-1186;
RP   VAL-1216 AND ARG-1240, AND VARIANT MET-511.
RX   PubMed=16126423; DOI=10.1016/j.ymgme.2005.07.007;
RA   Millat G., Baielo N., Molinero S., Rodriguez C., Chikh K.,
RA   Vanier M.T.;
RT   "Niemann-Pick C disease: use of denaturing high performance liquid
RT   chromatography for the detection of NPC1 and NPC2 genetic variations
RT   and impact on management of patients and families.";
RL   Mol. Genet. Metab. 86:220-232(2005).
RN   [37]
RP   VARIANTS NPC1 ASN-666 AND SER-961.
RX   PubMed=16802107; DOI=10.1007/s10545-006-0330-z;
RA   Dvorakova L., Sikora J., Hrebicek M., Hulkova H., Bouckova M.,
RA   Stolnaja L., Elleder M.;
RT   "Subclinical course of adult visceral Niemann-Pick type C1 disease. A
RT   rare or underdiagnosed disorder?";
RL   J. Inherit. Metab. Dis. 29:591-591(2006).
RN   [38]
RP   VARIANT NCP1 MET-137.
RX   PubMed=23453666; DOI=10.1016/j.ajhg.2013.02.004;
RA   Akizu N., Shembesh N.M., Ben-Omran T., Bastaki L., Al-Tawari A.,
RA   Zaki M.S., Koul R., Spencer E., Rosti R.O., Scott E., Nickerson E.,
RA   Gabriel S., da Gente G., Li J., Deardorff M.A., Conlin L.K.,
RA   Horton M.A., Zackai E.H., Sherr E.H., Gleeson J.G.;
RT   "Whole-exome sequencing identifies mutated c12orf57 in recessive
RT   corpus callosum hypoplasia.";
RL   Am. J. Hum. Genet. 92:392-400(2013).
CC   -!- FUNCTION: Intracellular cholesterol transporter which acts in
CC       concert with NPC2 and plays an important role in the egress of
CC       cholesterol from the endosomal/lysosomal compartment. Both NPC1
CC       and NPC2 function as the cellular 'tag team duo' (TTD) to catalyze
CC       the mobilization of cholesterol within the multivesicular
CC       environment of the late endosome (LE) to effect egress through the
CC       limiting bilayer of the LE. NPC2 binds unesterified cholesterol
CC       that has been released from LDLs in the lumen of the late
CC       endosomes/lysosomes and transfers it to the cholesterol-binding
CC       pocket of the N-terminal domain of NPC1. Cholesterol binds to NPC1
CC       with the hydroxyl group buried in the binding pocket and is
CC       exported from the limiting membrane of late endosomes/ lysosomes
CC       to the ER and plasma membrane by an unknown mechanism. Binds
CC       oxysterol with higher affinity than cholesterol. May play a role
CC       in vesicular trafficking in glia, a process that may be crucial
CC       for maintaining the structural and functional integrity of nerve
CC       terminals. {ECO:0000269|PubMed:18772377,
CC       ECO:0000269|PubMed:19563754}.
CC   -!- FUNCTION: (Microbial infection) Acts as an endosomal entry
CC       receptor for ebolavirus. {ECO:0000269|PubMed:21866103,
CC       ECO:0000269|PubMed:25855742}.
CC   -!- SUBUNIT: Interacts with TMEM97. Interacts (via the second lumenal
CC       domain) with NPC2 in a cholestrol-dependent manner (By
CC       similarity). Interacts with TIM1 (PubMed:25855742). (Microbial
CC       infection) Interacts with ebolavirus glycoprotein
CC       (PubMed:21866103). {ECO:0000250, ECO:0000269|PubMed:21866103,
CC       ECO:0000269|PubMed:25855742}.
CC   -!- SUBCELLULAR LOCATION: Late endosome membrane
CC       {ECO:0000269|PubMed:17897319}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:17897319}. Lysosome membrane
CC       {ECO:0000269|PubMed:17897319}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:17897319}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15118-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15118-2; Sequence=VSP_056431, VSP_056432, VSP_056433;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: A cysteine-rich N-terminal domain and a C-terminal domain
CC       containing a di-leucine motif necessary for lysosomal targeting
CC       are critical for mobilization of cholesterol from lysosomes.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:10821832,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19563754}.
CC   -!- DISEASE: Niemann-Pick disease C1 (NPC1) [MIM:257220]: A lysosomal
CC       storage disorder that affects the viscera and the central nervous
CC       system. It is due to defective intracellular processing and
CC       transport of low-density lipoprotein derived cholesterol. It
CC       causes accumulation of cholesterol in lysosomes, with delayed
CC       induction of cholesterol homeostatic reactions. Niemann-Pick
CC       disease type C1 has a highly variable clinical phenotype. Clinical
CC       features include variable hepatosplenomegaly and severe
CC       progressive neurological dysfunction such as ataxia, dystonia and
CC       dementia. The age of onset can vary from infancy to late
CC       adulthood. An allelic variant of Niemann-Pick disease type C1 is
CC       found in people with Nova Scotia ancestry. Patients with the Nova
CC       Scotian clinical variant are less severely affected.
CC       {ECO:0000269|PubMed:10480349, ECO:0000269|PubMed:10521290,
CC       ECO:0000269|PubMed:10521297, ECO:0000269|PubMed:11182931,
CC       ECO:0000269|PubMed:11333381, ECO:0000269|PubMed:11349231,
CC       ECO:0000269|PubMed:11479732, ECO:0000269|PubMed:11545687,
CC       ECO:0000269|PubMed:11754101, ECO:0000269|PubMed:12401890,
CC       ECO:0000269|PubMed:12408188, ECO:0000269|PubMed:12554680,
CC       ECO:0000269|PubMed:12955717, ECO:0000269|PubMed:15774455,
CC       ECO:0000269|PubMed:16098014, ECO:0000269|PubMed:16126423,
CC       ECO:0000269|PubMed:16802107, ECO:0000269|PubMed:9211849,
CC       ECO:0000269|PubMed:9634529}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the patched family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 SSD (sterol-sensing) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00199}.
CC   -!- WEB RESOURCE: Name=Niemann-Pick type C disease gene variation
CC       database;
CC       URL="http://npc.fzk.de";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF002020; AAB63982.1; -; mRNA.
DR   EMBL; AF157379; AAD48006.1; -; Genomic_DNA.
DR   EMBL; AF157365; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157366; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157367; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157368; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157369; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157370; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157371; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157372; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157373; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157374; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157375; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157376; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157377; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF157378; AAD48006.1; JOINED; Genomic_DNA.
DR   EMBL; AF338230; AAK25791.1; -; Genomic_DNA.
DR   EMBL; AH009108; AAF28875.1; -; Genomic_DNA.
DR   EMBL; AK293779; BAG57194.1; -; mRNA.
DR   EMBL; AC010853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026634; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC063302; AAH63302.1; -; mRNA.
DR   CCDS; CCDS11878.1; -. [O15118-1]
DR   RefSeq; NP_000262.2; NM_000271.4. [O15118-1]
DR   UniGene; Hs.464779; -.
DR   UniGene; Hs.715623; -.
DR   PDB; 3GKH; X-ray; 1.81 A; A=23-252.
DR   PDB; 3GKI; X-ray; 1.80 A; A=23-252.
DR   PDB; 3GKJ; X-ray; 1.60 A; A=23-252.
DR   PDBsum; 3GKH; -.
DR   PDBsum; 3GKI; -.
DR   PDBsum; 3GKJ; -.
DR   ProteinModelPortal; O15118; -.
DR   SMR; O15118; 23-247.
DR   BioGrid; 110925; 13.
DR   IntAct; O15118; 4.
DR   STRING; 9606.ENSP00000269228; -.
DR   BindingDB; O15118; -.
DR   ChEMBL; CHEMBL1293277; -.
DR   SwissLipids; SLP:000000478; -.
DR   TCDB; 2.A.6.6.1; the resistance-nodulation-cell division (rnd) superfamily.
DR   iPTMnet; O15118; -.
DR   PhosphoSite; O15118; -.
DR   SwissPalm; O15118; -.
DR   BioMuta; NPC1; -.
DR   MaxQB; O15118; -.
DR   PaxDb; O15118; -.
DR   PeptideAtlas; O15118; -.
DR   PRIDE; O15118; -.
DR   Ensembl; ENST00000269228; ENSP00000269228; ENSG00000141458. [O15118-1]
DR   GeneID; 4864; -.
DR   KEGG; hsa:4864; -.
DR   UCSC; uc002kum.4; human. [O15118-1]
DR   CTD; 4864; -.
DR   GeneCards; NPC1; -.
DR   GeneReviews; NPC1; -.
DR   H-InvDB; HIX0039703; -.
DR   HGNC; HGNC:7897; NPC1.
DR   HPA; CAB070132; -.
DR   HPA; HPA026618; -.
DR   MalaCards; NPC1; -.
DR   MIM; 257220; phenotype.
DR   MIM; 607623; gene.
DR   neXtProt; NX_O15118; -.
DR   Orphanet; 216986; Niemann-Pick disease type C, adult neurologic onset.
DR   Orphanet; 216981; Niemann-Pick disease type C, juvenile neurologic onset.
DR   Orphanet; 216978; Niemann-Pick disease type C, late infantile neurologic onset.
DR   Orphanet; 216975; Niemann-Pick disease type C, severe early infantile neurologic onset.
DR   Orphanet; 216972; Niemann-Pick disease type C, severe perinatal form.
DR   PharmGKB; PA31698; -.
DR   eggNOG; KOG1933; Eukaryota.
DR   eggNOG; ENOG410XR54; LUCA.
DR   GeneTree; ENSGT00800000124043; -.
DR   HOGENOM; HOG000036674; -.
DR   HOVERGEN; HBG003913; -.
DR   InParanoid; O15118; -.
DR   KO; K12385; -.
DR   OMA; ITRAFTM; -.
DR   OrthoDB; EOG7QRQT0; -.
DR   PhylomeDB; O15118; -.
DR   TreeFam; TF300416; -.
DR   ChiTaRS; NPC1; human.
DR   EvolutionaryTrace; O15118; -.
DR   GeneWiki; NPC1; -.
DR   GenomeRNAi; 4864; -.
DR   NextBio; 18738; -.
DR   PRO; PR:O15118; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; O15118; -.
DR   CleanEx; HS_NPC1; -.
DR   ExpressionAtlas; O15118; baseline and differential.
DR   Genevisible; O15118; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; ISS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IDA:UniProtKB.
DR   GO; GO:0008158; F:hedgehog receptor activity; IEA:InterPro.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0015248; F:sterol transporter activity; TAS:ProtInc.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IGI:MGI.
DR   GO; GO:0008206; P:bile acid metabolic process; ISS:UniProtKB.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; IEA:Ensembl.
DR   GO; GO:0071383; P:cellular response to steroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:UniProtKB.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0030301; P:cholesterol transport; IDA:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:Ensembl.
DR   GO; GO:0090150; P:establishment of protein localization to membrane; IDA:UniProtKB.
DR   GO; GO:0007041; P:lysosomal transport; ISS:UniProtKB.
DR   GO; GO:0031579; P:membrane raft organization; IMP:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:2000189; P:positive regulation of cholesterol homeostasis; IMP:CACAO.
DR   GO; GO:0006486; P:protein glycosylation; IDA:UniProtKB.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:GOC.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:CACAO.
DR   InterPro; IPR004765; NP_C_type.
DR   InterPro; IPR032190; NPC1_N.
DR   InterPro; IPR003392; Patched.
DR   InterPro; IPR000731; SSD.
DR   PANTHER; PTHR10796:SF116; PTHR10796:SF116; 1.
DR   Pfam; PF16414; NPC1_N; 1.
DR   Pfam; PF02460; Patched; 1.
DR   Pfam; PF12349; Sterol-sensing; 1.
DR   TIGRFAMs; TIGR00917; 2A060601; 1.
DR   PROSITE; PS50156; SSD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cholesterol metabolism;
KW   Complete proteome; Disease mutation; Disulfide bond; Endosome;
KW   Glycoprotein; Host cell receptor for virus entry;
KW   Host-virus interaction; Lipid metabolism; Lysosome; Membrane;
KW   Niemann-Pick disease; Polymorphism; Receptor; Reference proteome;
KW   Signal; Steroid metabolism; Sterol metabolism; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1278       Niemann-Pick C1 protein.
FT                                /FTId=PRO_0000023261.
FT   TOPO_DOM     23    269       Lumenal. {ECO:0000255}.
FT   TRANSMEM    270    290       Helical. {ECO:0000255}.
FT   TOPO_DOM    291    350       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    351    371       Helical. {ECO:0000255}.
FT   TOPO_DOM    372    620       Lumenal. {ECO:0000255}.
FT   TRANSMEM    621    641       Helical. {ECO:0000255}.
FT   TOPO_DOM    642    654       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    655    675       Helical. {ECO:0000255}.
FT   TOPO_DOM    676    677       Lumenal. {ECO:0000255}.
FT   TRANSMEM    678    698       Helical. {ECO:0000255}.
FT   TOPO_DOM    699    734       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    735    755       Helical. {ECO:0000255}.
FT   TOPO_DOM    756    759       Lumenal. {ECO:0000255}.
FT   TRANSMEM    760    780       Helical. {ECO:0000255}.
FT   TOPO_DOM    781    832       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    833    853       Helical. {ECO:0000255}.
FT   TOPO_DOM    854   1098       Lumenal. {ECO:0000255}.
FT   TRANSMEM   1099   1119       Helical. {ECO:0000255}.
FT   TOPO_DOM   1120   1124       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1125   1145       Helical. {ECO:0000255}.
FT   TOPO_DOM   1146   1146       Lumenal. {ECO:0000255}.
FT   TRANSMEM   1147   1167       Helical. {ECO:0000255}.
FT   TOPO_DOM   1168   1195       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1196   1216       Helical. {ECO:0000255}.
FT   TOPO_DOM   1217   1227       Lumenal. {ECO:0000255}.
FT   TRANSMEM   1228   1248       Helical. {ECO:0000255}.
FT   TOPO_DOM   1249   1278       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      620    785       SSD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00199}.
FT   REGION      175    205       Important for cholesterol binding and
FT                                cholesterol transfer from NPC1 to
FT                                liposomes.
FT   MOTIF      1275   1278       Di-leucine motif.
FT   COMPBIAS    249    259       Poly-Pro.
FT   BINDING      41     41       Cholesterol.
FT                                {ECO:0000269|PubMed:19563754}.
FT   BINDING      79     79       Cholesterol.
FT                                {ECO:0000269|PubMed:19563754}.
FT   SITE        108    108       Important for cholesterol binding.
FT   CARBOHYD     70     70       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:10821832}.
FT   CARBOHYD    122    122       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:10821832}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19563754}.
FT   CARBOHYD    185    185       N-linked (GlcNAc...).
FT                                {ECO:0000305|PubMed:10821832}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19563754}.
FT   CARBOHYD    452    452       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    459    459       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    478    478       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    524    524       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    961    961       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    968    968       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1064   1064       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1072   1072       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     25     74       {ECO:0000269|PubMed:19563754}.
FT   DISULFID     31     42       {ECO:0000269|PubMed:19563754}.
FT   DISULFID     63    109       {ECO:0000269|PubMed:19563754}.
FT   DISULFID     75    113       {ECO:0000269|PubMed:19563754}.
FT   DISULFID     97    238       {ECO:0000269|PubMed:19563754}.
FT   DISULFID    100    160       {ECO:0000269|PubMed:19563754}.
FT   DISULFID    177    184       {ECO:0000269|PubMed:19563754}.
FT   DISULFID    227    243       {ECO:0000269|PubMed:19563754}.
FT   DISULFID    240    247       {ECO:0000269|PubMed:19563754}.
FT   VAR_SEQ       1    267       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056431.
FT   VAR_SEQ     318    318       K -> KGTAWLLTSTFPSSPVLP (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056432.
FT   VAR_SEQ     519    586       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056433.
FT   VARIANT      63     63       C -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11545687}.
FT                                /FTId=VAR_043172.
FT   VARIANT      74     74       C -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043173.
FT   VARIANT      92     92       Q -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11479732}.
FT                                /FTId=VAR_043174.
FT   VARIANT     113    113       C -> R (in NPC1; partially mislocalized
FT                                from late endocytic organelles diffusely
FT                                to the cell periphery; localizes to the
FT                                endoplasmic reticulum Rab7-negative
FT                                endosomes and the cell surface; does not
FT                                clears the lysosomal cholesterol
FT                                accumulation in NPC1-deficient cells).
FT                                {ECO:0000269|PubMed:12554680}.
FT                                /FTId=VAR_043175.
FT   VARIANT     137    137       T -> M (in NPC1).
FT                                {ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:23453666}.
FT                                /FTId=VAR_043176.
FT   VARIANT     151    151       S -> G (in dbSNP:rs17855819).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_043177.
FT   VARIANT     166    166       P -> S (in NPC1).
FT                                {ECO:0000269|PubMed:12955717,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043178.
FT   VARIANT     177    177       C -> G (in NPC1; late infantile form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008815.
FT   VARIANT     177    177       C -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_015561.
FT   VARIANT     215    215       H -> R (common polymorphism in Japanese;
FT                                dbSNP:rs1805081).
FT                                {ECO:0000269|PubMed:10480349,
FT                                ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:12955717,
FT                                ECO:0000269|PubMed:15774455,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_008816.
FT   VARIANT     222    222       N -> S (in NPC1; dbSNP:rs55680026).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043179.
FT   VARIANT     231    231       V -> G (in NPC1).
FT                                {ECO:0000269|PubMed:12408188}.
FT                                /FTId=VAR_043180.
FT   VARIANT     237    237       P -> S (in NPC1; late infantile form;
FT                                dbSNP:rs80358251).
FT                                {ECO:0000269|PubMed:11182931,
FT                                ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:12408188,
FT                                ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_008817.
FT   VARIANT     242    242       D -> H (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043181.
FT   VARIANT     242    242       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043182.
FT   VARIANT     247    247       C -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043183.
FT   VARIANT     248    248       G -> V (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043184.
FT   VARIANT     272    272       M -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043185.
FT   VARIANT     273    273       W -> S (colocalizes with the wild-type
FT                                protein with Rab7-positive late
FT                                endosomes; clears the lysosomal
FT                                cholesterol accumulation in NPC1-
FT                                deficient cells).
FT                                {ECO:0000269|PubMed:12554680}.
FT                                /FTId=VAR_043186.
FT   VARIANT     333    333       G -> D.
FT                                /FTId=VAR_008818.
FT   VARIANT     372    372       R -> W (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043187.
FT   VARIANT     378    378       V -> A (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_015562.
FT   VARIANT     380    380       L -> F (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043188.
FT   VARIANT     381    381       W -> C. {ECO:0000269|PubMed:12408188}.
FT                                /FTId=VAR_043189.
FT   VARIANT     388    388       A -> P (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043190.
FT   VARIANT     389    389       R -> C (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043191.
FT   VARIANT     401    401       P -> T (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043192.
FT   VARIANT     404    404       R -> P (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043193.
FT   VARIANT     404    404       R -> Q (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11545687}.
FT                                /FTId=VAR_043194.
FT   VARIANT     404    404       R -> W (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043195.
FT   VARIANT     433    433       P -> L (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043196.
FT   VARIANT     434    434       P -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043197.
FT   VARIANT     434    434       P -> S (in dbSNP:rs61731962).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043198.
FT   VARIANT     451    451       E -> K (in NPC1).
FT                                {ECO:0000269|PubMed:12401890}.
FT                                /FTId=VAR_043199.
FT   VARIANT     472    472       L -> P.
FT                                /FTId=VAR_008819.
FT   VARIANT     473    473       S -> P (in NPC1; late infantile form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008820.
FT   VARIANT     474    474       P -> L (in NPC1).
FT                                {ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043200.
FT   VARIANT     479    479       C -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043201.
FT   VARIANT     509    509       Y -> S (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043202.
FT   VARIANT     510    510       H -> P (in NPC1; late infantile form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008821.
FT   VARIANT     511    511       T -> M (in dbSNP:rs13381670).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043203.
FT   VARIANT     512    512       H -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043204.
FT   VARIANT     518    518       R -> Q (in NPC1; late infantile form;
FT                                Common in Japanese).
FT                                {ECO:0000269|PubMed:11182931,
FT                                ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_008822.
FT   VARIANT     518    518       R -> W (in NPC1).
FT                                {ECO:0000269|PubMed:11479732}.
FT                                /FTId=VAR_043205.
FT   VARIANT     521    521       A -> S (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043206.
FT   VARIANT     537    537       F -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043207.
FT   VARIANT     543    543       P -> L (in NPC1).
FT                                {ECO:0000269|PubMed:12955717,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043208.
FT   VARIANT     574    574       T -> K (in NPC1).
FT                                /FTId=VAR_043209.
FT   VARIANT     576    576       K -> R (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043210.
FT   VARIANT     605    605       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043211.
FT   VARIANT     612    612       E -> D (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043212.
FT   VARIANT     615    615       R -> C (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043213.
FT   VARIANT     615    615       R -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043214.
FT   VARIANT     631    631       M -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043215.
FT   VARIANT     640    640       G -> R (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043216.
FT   VARIANT     642    642       M -> I (in dbSNP:rs1788799).
FT                                {ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:12408188,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15774455,
FT                                ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:9211849}.
FT                                /FTId=VAR_008823.
FT   VARIANT     652    652       S -> W (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043217.
FT   VARIANT     660    660       G -> S (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043218.
FT   VARIANT     664    664       V -> M (in NPC1).
FT                                {ECO:0000269|PubMed:12955717,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043219.
FT   VARIANT     666    666       S -> N (in NPC1).
FT                                {ECO:0000269|PubMed:16802107}.
FT                                /FTId=VAR_043220.
FT   VARIANT     670    670       C -> W (in NPC1).
FT                                {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043221.
FT   VARIANT     673    673       G -> V (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043222.
FT   VARIANT     684    684       L -> F (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043223.
FT   VARIANT     691    691       P -> L (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043224.
FT   VARIANT     695    695       L -> V (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043225.
FT   VARIANT     700    700       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043226.
FT   VARIANT     703    703       F -> S (in NPC1).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_043227.
FT   VARIANT     724    724       L -> P (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043228.
FT   VARIANT     727    727       V -> F (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043229.
FT   VARIANT     734    734       S -> I (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043230.
FT   VARIANT     742    742       E -> K (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043231.
FT   VARIANT     745    745       A -> E (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043232.
FT   VARIANT     754    754       M -> K (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043233.
FT   VARIANT     757    757       V -> A.
FT                                /FTId=VAR_008824.
FT   VARIANT     763    763       F -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043234.
FT   VARIANT     767    767       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043235.
FT   VARIANT     775    775       Q -> P (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043236.
FT   VARIANT     789    789       R -> C (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043237.
FT   VARIANT     789    789       R -> G (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043238.
FT   VARIANT     825    825       Y -> C (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043239.
FT   VARIANT     849    849       S -> I (in NPC1).
FT                                {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043240.
FT   VARIANT     858    858       I -> V (common polymorphism in Japanese;
FT                                dbSNP:rs1805082).
FT                                {ECO:0000269|PubMed:10480349,
FT                                ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:15774455,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_008825.
FT   VARIANT     862    862       Q -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043241.
FT   VARIANT     865    865       S -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043242.
FT   VARIANT     871    871       Y -> C (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043243.
FT   VARIANT     873    873       V -> A. {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_043244.
FT   VARIANT     874    874       D -> V (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043245.
FT   VARIANT     888    888       P -> S (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043246.
FT   VARIANT     889    889       V -> M (in NPC1; adult form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008826.
FT   VARIANT     890    890       Y -> C (in NPC1).
FT                                {ECO:0000269|PubMed:12401890}.
FT                                /FTId=VAR_043247.
FT   VARIANT     899    899       Y -> D (in NPC1).
FT                                {ECO:0000269|PubMed:12401890}.
FT                                /FTId=VAR_043248.
FT   VARIANT     910    910       G -> S (in NPC1).
FT                                {ECO:0000269|PubMed:12401890}.
FT                                /FTId=VAR_043249.
FT   VARIANT     917    917       D -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043250.
FT   VARIANT     926    926       A -> T (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043251.
FT   VARIANT     927    927       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:11545687}.
FT                                /FTId=VAR_043252.
FT   VARIANT     928    928       Q -> P (in NPC1; dbSNP:rs28940897).
FT                                /FTId=VAR_008827.
FT   VARIANT     929    929       L -> P (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043253.
FT   VARIANT     934    934       R -> Q (in NPC1).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008828.
FT   VARIANT     940    940       S -> L (in NPC1).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008829.
FT   VARIANT     942    942       W -> C (in NPC1).
FT                                {ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043254.
FT   VARIANT     943    943       I -> M (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043255.
FT   VARIANT     944    944       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043256.
FT   VARIANT     945    945       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043257.
FT   VARIANT     948    948       D -> H (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043258.
FT   VARIANT     948    948       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:12408188}.
FT                                /FTId=VAR_008830.
FT   VARIANT     948    948       D -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043259.
FT   VARIANT     950    950       V -> M (in NPC1; adult form).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_015563.
FT   VARIANT     954    954       S -> L (in NPC1).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11182931,
FT                                ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_008831.
FT   VARIANT     956    956       C -> Y (in NPC1; late infantile form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008832.
FT   VARIANT     958    958       R -> L (in NPC1).
FT                                {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043260.
FT   VARIANT     958    958       R -> Q (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_015564.
FT   VARIANT     959    959       V -> E (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043261.
FT   VARIANT     961    966       NITDQF -> S (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043262.
FT   VARIANT     961    961       N -> S (in NPC1; dbSNP:rs34084984).
FT                                {ECO:0000269|PubMed:16802107}.
FT                                /FTId=VAR_043263.
FT   VARIANT     968    968       N -> S (in NPC1).
FT                                {ECO:0000269|PubMed:15774455,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043264.
FT   VARIANT     971    971       V -> G. {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043265.
FT   VARIANT     976    976       C -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043266.
FT   VARIANT     978    978       R -> C (in NPC1; dbSNP:rs28942108).
FT                                {ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11479732}.
FT                                /FTId=VAR_015565.
FT   VARIANT     986    986       G -> S (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043267.
FT   VARIANT     992    992       G -> A (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043268.
FT   VARIANT     992    992       G -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_015566.
FT   VARIANT     992    992       G -> W (in NPC1; found in the Nova
FT                                Scotian clinical variant).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11545687,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:16126423,
FT                                ECO:0000269|PubMed:9634529}.
FT                                /FTId=VAR_008833.
FT   VARIANT     996    996       M -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_043269.
FT   VARIANT    1004   1004       S -> L (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043270.
FT   VARIANT    1007   1007       P -> A (in NPC1).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008834.
FT   VARIANT    1012   1012       G -> D (in NPC1).
FT                                {ECO:0000269|PubMed:11545687}.
FT                                /FTId=VAR_043271.
FT   VARIANT    1015   1015       G -> V (in NPC1).
FT                                {ECO:0000269|PubMed:15774455}.
FT                                /FTId=VAR_043272.
FT   VARIANT    1016   1016       H -> R (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043273.
FT   VARIANT    1023   1023       V -> G (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043274.
FT   VARIANT    1034   1034       G -> R (in NPC1).
FT                                {ECO:0000269|PubMed:15774455}.
FT                                /FTId=VAR_043275.
FT   VARIANT    1035   1035       A -> V (in NPC1; dbSNP:rs28942107).
FT                                {ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_015567.
FT   VARIANT    1036   1036       T -> K (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043276.
FT   VARIANT    1036   1036       T -> M (in NPC1; dbSNP:rs28942104).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008835.
FT   VARIANT    1049   1049       A -> V. {ECO:0000269|PubMed:11754101}.
FT                                /FTId=VAR_043277.
FT   VARIANT    1054   1054       A -> T (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043278.
FT   VARIANT    1059   1059       R -> Q (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043279.
FT   VARIANT    1061   1061       I -> T (in NPC1; late infantile form).
FT                                {ECO:0000269|PubMed:10521290,
FT                                ECO:0000269|PubMed:10521297,
FT                                ECO:0000269|PubMed:11182931,
FT                                ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11479732,
FT                                ECO:0000269|PubMed:11754101,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:16098014,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008836.
FT   VARIANT    1062   1062       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043280.
FT   VARIANT    1066   1066       T -> N (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043281.
FT   VARIANT    1087   1087       F -> L (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043282.
FT   VARIANT    1088   1088       Y -> C (in NPC1; juvenile form;
FT                                dbSNP:rs28942106).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008837.
FT   VARIANT    1089   1089       E -> K (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043283.
FT   VARIANT    1094   1094       I -> T (in NPC1).
FT                                {ECO:0000269|PubMed:12408188}.
FT                                /FTId=VAR_043284.
FT   VARIANT    1097   1097       D -> N (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043285.
FT   VARIANT    1137   1137       N -> I (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043286.
FT   VARIANT    1140   1140       G -> V (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043287.
FT   VARIANT    1142   1142       M -> T (in NPC1).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043288.
FT   VARIANT    1150   1150       N -> K (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043289.
FT   VARIANT    1156   1156       N -> I (in NPC1; dbSNP:rs28942105).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043290.
FT   VARIANT    1156   1156       N -> S (in NPC1; dbSNP:rs28942105).
FT                                {ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:11545687,
FT                                ECO:0000269|PubMed:12401890,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_008838.
FT   VARIANT    1165   1165       V -> M (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043291.
FT   VARIANT    1167   1167       F -> L (in NPC1).
FT                                /FTId=VAR_008839.
FT   VARIANT    1168   1168       C -> Y (in NPC1).
FT                                {ECO:0000269|PubMed:11333381}.
FT                                /FTId=VAR_043292.
FT   VARIANT    1174   1174       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043293.
FT   VARIANT    1186   1186       R -> H (in NPC1; dbSNP:rs200444084).
FT                                {ECO:0000269|PubMed:11333381,
FT                                ECO:0000269|PubMed:11349231,
FT                                ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_008840.
FT   VARIANT    1189   1189       E -> G (in NPC1).
FT                                {ECO:0000269|PubMed:11349231}.
FT                                /FTId=VAR_043294.
FT   VARIANT    1205   1205       T -> K (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043295.
FT   VARIANT    1205   1205       T -> R (in NPC1).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_043296.
FT   VARIANT    1212   1212       V -> L (in NPC1).
FT                                {ECO:0000269|PubMed:15774455}.
FT                                /FTId=VAR_043297.
FT   VARIANT    1213   1213       L -> F (in NPC1; juvenile form).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_008841.
FT   VARIANT    1213   1213       L -> V (in NPC1).
FT                                {ECO:0000269|PubMed:10521290}.
FT                                /FTId=VAR_008842.
FT   VARIANT    1216   1216       A -> V (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043298.
FT   VARIANT    1220   1220       I -> T.
FT                                /FTId=VAR_008843.
FT   VARIANT    1224   1224       F -> L (in NPC1).
FT                                {ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_043299.
FT   VARIANT    1236   1236       G -> E (in NPC1).
FT                                {ECO:0000269|PubMed:11182931}.
FT                                /FTId=VAR_043300.
FT   VARIANT    1240   1240       G -> R (in NPC1).
FT                                {ECO:0000269|PubMed:16126423}.
FT                                /FTId=VAR_043301.
FT   VARIANT    1249   1249       S -> G (in NPC1).
FT                                {ECO:0000269|PubMed:12955717}.
FT                                /FTId=VAR_043302.
FT   VARIANT    1266   1266       R -> Q (common polymorphism in Japanese;
FT                                dbSNP:rs1805084).
FT                                {ECO:0000269|PubMed:10480349,
FT                                ECO:0000269|PubMed:12955717,
FT                                ECO:0000269|PubMed:15774455,
FT                                ECO:0000269|PubMed:16098014}.
FT                                /FTId=VAR_008844.
FT   MUTAGEN      26     27       VW->AA: Nearly abolishes 25-
FT                                hydroxycholesterol binding. Reduces
FT                                cholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN      39     41       RYN->AAA: Strongly reduces cholesterol
FT                                and 25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN      41     41       N->A: Nearly abolishes cholesterol and
FT                                25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN      63     63       C->S: Loss of function.
FT                                {ECO:0000269|PubMed:9927649}.
FT   MUTAGEN      70     70       N->Q: Reduces glycosylation; when
FT                                associated with Q-122 and Q-185. No
FT                                effect on cholesterol and 25-
FT                                hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN      82     83       TL->AA: Strongly reduces cholesterol and
FT                                25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN      97     97       C->S: Loss of function.
FT                                {ECO:0000269|PubMed:9927649}.
FT   MUTAGEN     101    102       FY->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding. No effect on
FT                                cholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     106    108       NLF->AAA: Nearly abolishes cholesterol
FT                                and 25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     110    112       ELT->AAA: No effect on cholesterol and
FT                                25-hydroxycholesterol binding and
FT                                transfer. {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     122    122       N->Q: Reduces glycosylation; when
FT                                associated with Q-70 and Q-185. No effect
FT                                on cholesterol and 25-hydroxycholesterol
FT                                binding. {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     144    145       LQ->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding. No effect on
FT                                cholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     146    147       YY->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding. No effect on
FT                                cholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     175    176       LL->AA: No effect on cholesterol or 25-
FT                                hydroxycholesterol binding. Strongly
FT                                reduces cholesterol transfer to liposomes
FT                                in a NPC2-dependent manner.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     180    182       DAD->AAA: Strongly reduces cholesterol
FT                                transfer to liposomes in a NPC2-dependent
FT                                manner. {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     185    185       N->Q: Reduces glycosylation; when
FT                                associated with Q-70 and Q-122. No effect
FT                                on cholesterol and 25-hydroxycholesterol
FT                                binding. Strongly reduces cholesterol
FT                                transfer to liposomes in a NPC2-dependent
FT                                manner. {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     187    188       TN->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding and
FT                                cholesterol transfer to liposomes in a
FT                                NPC2-dependent manner.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     191    192       EY->AA: No effect on cholesterol or 25-
FT                                hydroxycholesterol binding. Nearly
FT                                abolishes cholesterol transfer to
FT                                liposomes in a NPC2-dependent manner.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     195    196       NK->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding. No effect on
FT                                cholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     197    198       DN->AA: Strongly reduces cholesterol and
FT                                25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     199    200       GQ->AA: Strongly reduces 25-
FT                                hydroxycholesterol binding and
FT                                cholesterol transfer to liposomes in a
FT                                NPC2-dependent manner.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     202    203       PF->AA: Abolishes cholesterol and 25-
FT                                hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     204    205       TI->AA: Strongly reduces cholesterol and
FT                                25-hydroxycholesterol binding.
FT                                {ECO:0000269|PubMed:19563754}.
FT   MUTAGEN     660    660       G->R: Loss of function.
FT                                {ECO:0000269|PubMed:19563754}.
FT   STRAND       26     35       {ECO:0000244|PDB:3GKJ}.
FT   STRAND       38     43       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        53     55       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        56     62       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        64     66       {ECO:0000244|PDB:3GKJ}.
FT   STRAND       72     74       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        77     85       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        88     94       {ECO:0000244|PDB:3GKJ}.
FT   HELIX        98    113       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       117    120       {ECO:0000244|PDB:3GKJ}.
FT   STRAND      121    130       {ECO:0000244|PDB:3GKJ}.
FT   TURN        132    134       {ECO:0000244|PDB:3GKJ}.
FT   STRAND      137    148       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       150    160       {ECO:0000244|PDB:3GKJ}.
FT   STRAND      168    171       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       173    176       {ECO:0000244|PDB:3GKJ}.
FT   STRAND      177    179       {ECO:0000244|PDB:3GKJ}.
FT   TURN        181    183       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       186    193       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       196    198       {ECO:0000244|PDB:3GKJ}.
FT   STRAND      199    209       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       240    242       {ECO:0000244|PDB:3GKJ}.
FT   HELIX       244    246       {ECO:0000244|PDB:3GKJ}.
SQ   SEQUENCE   1278 AA;  142167 MW;  DA1523E09822E5C7 CRC64;
     MTARGLALGL LLLLLCPAQV FSQSCVWYGE CGIAYGDKRY NCEYSGPPKP LPKDGYDLVQ
     ELCPGFFFGN VSLCCDVRQL QTLKDNLQLP LQFLSRCPSC FYNLLNLFCE LTCSPRQSQF
     LNVTATEDYV DPVTNQTKTN VKELQYYVGQ SFANAMYNAC RDVEAPSSND KALGLLCGKD
     ADACNATNWI EYMFNKDNGQ APFTITPVFS DFPVHGMEPM NNATKGCDES VDEVTAPCSC
     QDCSIVCGPK PQPPPPPAPW TILGLDAMYV IMWITYMAFL LVFFGAFFAV WCYRKRYFVS
     EYTPIDSNIA FSVNASDKGE ASCCDPVSAA FEGCLRRLFT RWGSFCVRNP GCVIFFSLVF
     ITACSSGLVF VRVTTNPVDL WSAPSSQARL EKEYFDQHFG PFFRTEQLII RAPLTDKHIY
     QPYPSGADVP FGPPLDIQIL HQVLDLQIAI ENITASYDNE TVTLQDICLA PLSPYNTNCT
     ILSVLNYFQN SHSVLDHKKG DDFFVYADYH THFLYCVRAP ASLNDTSLLH DPCLGTFGGP
     VFPWLVLGGY DDQNYNNATA LVITFPVNNY YNDTEKLQRA QAWEKEFINF VKNYKNPNLT
     ISFTAERSIE DELNRESDSD VFTVVISYAI MFLYISLALG HMKSCRRLLV DSKVSLGIAG
     ILIVLSSVAC SLGVFSYIGL PLTLIVIEVI PFLVLAVGVD NIFILVQAYQ RDERLQGETL
     DQQLGRVLGE VAPSMFLSSF SETVAFFLGA LSVMPAVHTF SLFAGLAVFI DFLLQITCFV
     SLLGLDIKRQ EKNRLDIFCC VRGAEDGTSV QASESCLFRF FKNSYSPLLL KDWMRPIVIA
     IFVGVLSFSI AVLNKVDIGL DQSLSMPDDS YMVDYFKSIS QYLHAGPPVY FVLEEGHDYT
     SSKGQNMVCG GMGCNNDSLV QQIFNAAQLD NYTRIGFAPS SWIDDYFDWV KPQSSCCRVD
     NITDQFCNAS VVDPACVRCR PLTPEGKQRP QGGDFMRFLP MFLSDNPNPK CGKGGHAAYS
     SAVNILLGHG TRVGATYFMT YHTVLQTSAD FIDALKKARL IASNVTETMG INGSAYRVFP
     YSVFYVFYEQ YLTIIDDTIF NLGVSLGAIF LVTMVLLGCE LWSAVIMCAT IAMVLVNMFG
     VMWLWGISLN AVSLVNLVMS CGISVEFCSH ITRAFTVSMK GSRVERAEEA LAHMGSSVFS
     GITLTKFGGI VVLAFAKSQI FQIFYFRMYL AMVLLGATHG LIFLPVLLSY IGPSVNKAKS
     CATEERYKGT ERERLLNF
//
ID   PGFRB_HUMAN             Reviewed;        1106 AA.
AC   P09619; B5A957; Q8N5L4;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   20-JAN-2016, entry version 200.
DE   RecName: Full=Platelet-derived growth factor receptor beta;
DE            Short=PDGF-R-beta;
DE            Short=PDGFR-beta;
DE            EC=2.7.10.1;
DE   AltName: Full=Beta platelet-derived growth factor receptor;
DE   AltName: Full=Beta-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member B;
DE   AltName: Full=Platelet-derived growth factor receptor 1;
DE            Short=PDGFR-1;
DE   AltName: CD_antigen=CD140b;
DE   Flags: Precursor;
GN   Name=PDGFRB; Synonyms=PDGFR, PDGFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB.
RX   PubMed=2835772; DOI=10.1073/pnas.85.10.3435;
RA   Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J.,
RA   Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.;
RT   "Cloning and expression of a cDNA coding for the human platelet-
RT   derived growth factor receptor: evidence for more than one receptor
RT   class.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH PDGFA AND PDGFB.
RX   PubMed=2850496;
RA   Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B.,
RA   Oestman A., Betsholtz C., Heldin C.-H.;
RT   "cDNA cloning and expression of a human platelet-derived growth factor
RT   (PDGF) receptor specific for B-chain-containing PDGF molecules.";
RL   Mol. Cell. Biol. 8:3476-3486(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PHE-180.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569.
RX   PubMed=9285559; DOI=10.1038/sj.onc.1201267;
RA   Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P.,
RA   Goustin A.S.;
RT   "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-
RT   I-infected T-cells results in a novel tyrosine kinase product with
RT   transforming activity.";
RL   Oncogene 15:1051-1057(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CEP85L.
RX   PubMed=21938754; DOI=10.1002/gcc.20930;
RA   Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J.,
RA   Socci N.D., Hollis C.J., Dean R.S., Yenamandra A., Jagasia M.,
RA   Kim A.S., Dave U.P., Thomas R.K., Pao W.;
RT   "Systematic screen for tyrosine kinase rearrangements identifies a
RT   novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an
RT   associated myeloproliferative neoplasm.";
RL   Genes Chromosomes Cancer 51:54-65(2012).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106.
RX   PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3;
RA   Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.;
RT   "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor
RT   genes.";
RL   Cell 55:655-661(1988).
RN   [9]
RP   PROTEIN SEQUENCE OF 33-47.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [10]
RP   PHOSPHORYLATION AT TYR-751 AND TYR-857.
RX   PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2;
RA   Kazlauskas A., Cooper J.A.;
RT   "Autophosphorylation of the PDGF receptor in the kinase insert region
RT   regulates interactions with cell proteins.";
RL   Cell 58:1121-1133(1989).
RN   [11]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=2554309; DOI=10.1073/pnas.86.21.8314;
RA   Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S.,
RA   LaRochelle W.J., Ruggiero M., Aaronson S.A.;
RT   "Independent expression of human alpha or beta platelet-derived growth
RT   factor receptor cDNAs in a naive hematopoietic cell leads to
RT   functional coupling with mitogenic and chemotactic signaling
RT   pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN
RP   PHOSPHORYLATION OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND
RP   TYR-857.
RX   PubMed=1653029;
RA   Kazlauskas A., Durden D.L., Cooper J.A.;
RT   "Functions of the major tyrosine phosphorylation site of the PDGF
RT   receptor beta subunit.";
RL   Cell Regul. 2:413-425(1991).
RN   [13]
RP   INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR
RP   PDGFA AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751.
RX   PubMed=1709159;
RA   Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A.,
RA   Bowen-Pope D.F., Cooper J.A., Kazlauskas A.;
RT   "Platelet-derived growth factor (PDGF) stimulates PDGF receptor
RT   subunit dimerization and intersubunit trans-phosphorylation.";
RL   J. Biol. Chem. 266:8987-8992(1991).
RN   [14]
RP   FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION,
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-634.
RX   PubMed=1846866; DOI=10.1083/jcb.112.3.469;
RA   Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.;
RT   "Effect of receptor kinase inactivation on the rate of internalization
RT   and degradation of PDGF and the PDGF beta-receptor.";
RL   J. Cell Biol. 112:469-478(1991).
RN   [15]
RP   FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY,
RP   INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740;
RP   TYR-751; TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716;
RP   TYR-740; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857.
RX   PubMed=1314164;
RA   Kashishian A., Kazlauskas A., Cooper J.A.;
RT   "Phosphorylation sites in the PDGF receptor with different
RT   specificities for binding GAP and PI3 kinase in vivo.";
RL   EMBO J. 11:1373-1382(1992).
RN   [16]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION
RP   OF PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND
RP   TYR-1021, AND MUTAGENESIS OF TYR-1009 AND TYR-1021.
RX   PubMed=1396585;
RA   Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C.,
RA   Hellman U., Claesson-Welsh L., Heldin C.H.;
RT   "Identification of two C-terminal autophosphorylation sites in the
RT   PDGF beta-receptor: involvement in the interaction with phospholipase
RT   C-gamma.";
RL   EMBO J. 11:3911-3919(1992).
RN   [17]
RP   UBIQUITINATION, AND DEGRADATION.
RX   PubMed=1313434;
RA   Mori S., Heldin C.H., Claesson-Welsh L.;
RT   "Ligand-induced polyubiquitination of the platelet-derived growth
RT   factor beta-receptor.";
RL   J. Biol. Chem. 267:6429-6434(1992).
RN   [18]
RP   INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751
RP   AND TYR-771.
RX   PubMed=1375321;
RA   Kazlauskas A., Kashishian A., Cooper J.A., Valius M.;
RT   "GTPase-activating protein and phosphatidylinositol 3-kinase bind to
RT   distinct regions of the platelet-derived growth factor receptor beta
RT   subunit.";
RL   Mol. Cell. Biol. 12:2534-2544(1992).
RN   [19]
RP   FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT
RP   TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF TYR-579 AND TYR-581.
RX   PubMed=7685273;
RA   Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A.,
RA   Claesson-Welsh L., Heldin C.H.;
RT   "Identification of two juxtamembrane autophosphorylation sites in the
RT   PDGF beta-receptor; involvement in the interaction with Src family
RT   tyrosine kinases.";
RL   EMBO J. 12:2257-2264(1993).
RN   [20]
RP   INTERACTION WITH DGFA AND PDGFB.
RX   PubMed=7679113;
RA   Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L.,
RA   LaRochelle W.J., Giese N.A.;
RT   "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB
RT   binding to alpha and beta PDGF receptor.";
RL   J. Biol. Chem. 268:3625-3631(1993).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH
RP   PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009.
RX   PubMed=7691811;
RA   Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S.,
RA   Cooper J.A., Shoelson S.E., Walsh C.T., Neel B.G.;
RT   "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2
RT   by its binding site, phosphotyrosine 1009, on the human platelet-
RT   derived growth factor receptor.";
RL   J. Biol. Chem. 268:21478-21481(1993).
RN   [22]
RP   INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1,
RP   AND MUTAGENESIS OF TYR-751.
RX   PubMed=7692233;
RA   Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J.,
RA   Schlessinger J.;
RT   "Two signaling molecules share a phosphotyrosine-containing binding
RT   site in the platelet-derived growth factor receptor.";
RL   Mol. Cell. Biol. 13:6889-6896(1993).
RN   [23]
RP   INTERACTION WITH SHB.
RX   PubMed=8302579;
RA   Welsh M., Mares J., Karlsson T., Lavergne C., Breant B.,
RA   Claesson-Welsh L.;
RT   "Shb is a ubiquitously expressed Src homology 2 protein.";
RL   Oncogene 9:19-27(1994).
RN   [24]
RP   INTERACTION WITH GRB7.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth
RT   factor alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [25]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIP11.
RX   PubMed=9373237;
RA   Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.;
RT   "Fusion of the platelet-derived growth factor receptor beta to a novel
RT   gene CEV14 in acute myelogenous leukemia after clonal evolution.";
RL   Blood 90:4271-4277(1997).
RN   [26]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716;
RP   TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [27]
RP   INTERACTION WITH SH2B2/APS.
RX   PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S.,
RA   Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated
RT   with the PDGF receptor and c-Cbl and inhibits PDGF-induced
RT   mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [28]
RP   PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775;
RP   TYR-778; TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT
RP   TYR-751; TYR-857; TYR-1009 AND TYR-1021 BY PTPRJ.
RX   PubMed=10821867; DOI=10.1074/jbc.275.21.16219;
RA   Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E.,
RA   Vilella R., Bohmer F., Ostman A.;
RT   "Site-selective dephosphorylation of the platelet-derived growth
RT   factor beta-receptor by the receptor-like protein-tyrosine phosphatase
RT   DEP-1.";
RL   J. Biol. Chem. 275:16219-16226(2000).
RN   [29]
RP   INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [30]
RP   FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC.
RX   PubMed=11297552; DOI=10.1074/jbc.M101056200;
RA   Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O.,
RA   Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M.,
RA   Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.;
RT   "Platelet-derived growth factor C (PDGF-C), a novel growth factor that
RT   binds to PDGF alpha and beta receptor.";
RL   J. Biol. Chem. 276:27406-27414(2001).
RN   [31]
RP   FUNCTION AS A RECEPTOR FOR PDGFD.
RX   PubMed=11331881; DOI=10.1038/35074588;
RA   Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H.,
RA   Alitalo K., Eriksson U.;
RT   "PDGF-D is a specific, protease-activated ligand for the PDGF beta-
RT   receptor.";
RL   Nat. Cell Biol. 3:512-516(2001).
RN   [32]
RP   CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   PubMed=12181402; DOI=10.1056/NEJMoa020150;
RA   Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J.,
RA   Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E.,
RA   Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E.,
RA   Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.;
RT   "Response to imatinib mesylate in patients with chronic
RT   myeloproliferative diseases with rearrangements of the platelet-
RT   derived growth factor receptor beta.";
RL   N. Engl. J. Med. 347:481-487(2002).
RN   [33]
RP   CHROMOSOMAL TRANSLOCATION WITH PDE4DIP.
RX   PubMed=12907457; DOI=10.1182/blood-2003-04-1150;
RA   Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C.,
RA   Shipp M.A., Aguiar R.C.T.;
RT   "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder
RT   associated with eosinophilia: involvement of PDGFRB and response to
RT   imatinib.";
RL   Blood 102:4187-4190(2003).
RN   [34]
RP   CHROMOSOMAL TRANSLOCATION WITH SPECC1.
RX   PubMed=15087372; DOI=10.1158/0008-5472.CAN-03-4026;
RA   Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C.,
RA   Locatelli F., Maserati E., Pasquali F., Panarello C.;
RT   "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile
RT   myelomonocytic leukemia with t(5;17)(q33;p11.2).";
RL   Cancer Res. 64:2649-2651(2004).
RN   [35]
RP   CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ENZYME REGULATION.
RX   PubMed=15492236; DOI=10.1158/0008-5472.CAN-04-2005;
RA   Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G.,
RA   Thaler J., Chase A.J., Cross N.C.;
RT   "p53-Binding protein 1 is fused to the platelet-derived growth factor
RT   receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-
RT   responsive eosinophilic myeloproliferative disorder.";
RL   Cancer Res. 64:7216-7219(2004).
RN   [36]
RP   PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND
RP   DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2.
RX   PubMed=14966296; DOI=10.1128/MCB.24.5.2190-2201.2004;
RA   Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B.,
RA   Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H.,
RA   Roennstrand L., Ostman A., Hellberg C.;
RT   "Site-selective regulation of platelet-derived growth factor beta
RT   receptor tyrosine phosphorylation by T-cell protein tyrosine
RT   phosphatase.";
RL   Mol. Cell. Biol. 24:2190-2201(2004).
RN   [37]
RP   PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771;
RP   TYR-857; TYR-1009 AND TYR-1021.
RX   PubMed=15902258; DOI=10.1038/nature03587;
RA   Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S.,
RA   Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.;
RT   "Regulation of PDGF signalling and vascular remodelling by
RT   peroxiredoxin II.";
RL   Nature 435:347-353(2005).
RN   [38]
RP   INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021,
RP   AND UBIQUITINATION.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [39]
RP   FUNCTION AS PDGFD RECEPTOR.
RX   PubMed=21098708; DOI=10.1158/0008-5472.CAN-10-0511;
RA   Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M.,
RA   Abrams J., Kim H.R.;
RT   "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human
RT   prostate cancer.";
RL   Cancer Res. 70:9631-9640(2010).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND
RP   PTPN11, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF LYS-634 AND TYR-857.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [41]
RP   FUNCTION.
RX   PubMed=20529858; DOI=10.1074/jbc.M110.102566;
RA   Mendelson K., Swendeman S., Saftig P., Blobel C.P.;
RT   "Stimulation of platelet-derived growth factor receptor beta
RT   (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent
RT   cross-talk between the PDGFRbeta and epidermal growth factor receptor
RT   (EGFR) signaling pathways.";
RL   J. Biol. Chem. 285:25024-25032(2010).
RN   [42]
RP   FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION.
RX   PubMed=21733313; DOI=10.1017/S0007114511002571;
RA   Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.;
RT   "Glyceollins inhibit platelet-derived growth factor-mediated human
RT   arterial smooth muscle cell proliferation and migration.";
RL   Br. J. Nutr. 107:24-35(2012).
RN   [43]
RP   INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF
RP   SHC1.
RX   PubMed=8195171;
RA   Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H.,
RA   Claesson-Welsh L.;
RT   "Direct interaction between Shc and the platelet-derived growth factor
RT   beta-receptor.";
RL   J. Biol. Chem. 269:15337-15343(1994).
RN   [44]
RP   FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER
RP   BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021.
RX   PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037;
RA   Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L.,
RA   Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H.,
RA   Tallquist M.D., Rosenkranz S.;
RT   "Disruption of platelet-derived growth factor-dependent
RT   phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity
RT   abolishes vascular smooth muscle cell proliferation and migration and
RT   attenuates neointima formation in vivo.";
RL   J. Am. Coll. Cardiol. 57:2527-2538(2011).
RN   [45]
RP   REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION.
RX   PubMed=9739761; DOI=10.1016/S0304-419X(98)00015-8;
RA   Heldin C.H., Ostman A., Ronnstrand L.;
RT   "Signal transduction via platelet-derived growth factor receptors.";
RL   Biochim. Biophys. Acta 1378:F79-113(1998).
RN   [46]
RP   REVIEW.
RX   PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002;
RA   Ostman A.;
RT   "PDGF receptors-mediators of autocrine tumor growth and regulators of
RT   tumor vasculature and stroma.";
RL   Cytokine Growth Factor Rev. 15:275-286(2004).
RN   [47]
RP   REVIEW.
RX   PubMed=17419949; DOI=10.1016/S0065-230X(06)97011-0;
RA   Ostman A., Heldin C.H.;
RT   "PDGF receptors as targets in tumor treatment.";
RL   Adv. Cancer Res. 97:247-274(2007).
RN   [48]
RP   REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND
RP   ACTIVATION OF SIGNALING PATHWAYS.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH
RP   PIK3R1, AND COMPARISON WITH NMR ANALYSIS.
RX   PubMed=11567151; DOI=10.1107/S0907444901012434;
RA   Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A.,
RA   Rowsell S., Murshudov G.N.;
RT   "NMR trial models: experiences with the colicin immunity protein Im7
RT   and the p85alpha C-terminal SH2-peptide complex.";
RL   Acta Crystallogr. D 57:1397-1404(2001).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH
RP   SLC9A3R1, AND INTERACTION WITH SLC9A3R1.
RX   PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB,
RP   SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230;
RP   ASN-292 AND ASN-307, AND DISULFIDE BONDS.
RX   PubMed=20534510; DOI=10.1073/pnas.1000806107;
RA   Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.;
RT   "Structures of a platelet-derived growth factor/propeptide complex and
RT   a platelet-derived growth factor/receptor complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010).
RN   [52]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589;
RP   TYR-718 AND ILE-882.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [53]
RP   VARIANT IMF1 THR-660.
RX   PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024;
RA   Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O.,
RA   Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E.,
RA   Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D.,
RA   Fournet J.C., Papp E., McPherson E.W., Zabel C., Vaksmann G.,
RA   Morisot C., Keating B., Sleiman P.M., Cleveland J.A., Everman D.B.,
RA   Zackai E., Hakonarson H.;
RT   "Mutations in PDGFRB cause autosomal-dominant infantile
RT   myofibromatosis.";
RL   Am. J. Hum. Genet. 92:1001-1007(2013).
RN   [54]
RP   VARIANT IMF1 CYS-561.
RX   PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026;
RA   Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D.,
RA   Nguyen V.H., Guo J., Qi M., Guan Y., Albrecht S., Moroz B.,
RA   Eldin K.W., Lu J.T., Schwartzentruber J., Malkin D., Berghuis A.M.,
RA   Emil S., Gibbs R.A., Burk D.L., Vanstone M., Lee B.H., Orchard D.,
RA   Boycott K.M., Chung W.K., Jabado N.;
RT   "A recurrent PDGFRB mutation causes familial infantile
RT   myofibromatosis.";
RL   Am. J. Hum. Genet. 92:996-1000(2013).
RN   [55]
RP   VARIANTS IBGC4 PRO-658 AND TRP-987.
RX   PubMed=23255827; DOI=10.1212/WNL.0b013e31827ccf34;
RA   Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A.,
RA   Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L.,
RA   Augustin J., Martinaud O., Defebvre L., Krystkowiak P., Pariente J.,
RA   Clanet M., Labauge P., Ayrignac X., Lefaucheur R., Le Ber I.,
RA   Frebourg T., Hannequin D., Campion D.;
RT   "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia
RT   calcification.";
RL   Neurology 80:181-187(2013).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for homodimeric PDGFB and PDGFD and for heterodimers
CC       formed by PDGFA and PDGFB, and plays an essential role in the
CC       regulation of embryonic development, cell proliferation, survival,
CC       differentiation, chemotaxis and migration. Plays an essential role
CC       in blood vessel development by promoting proliferation, migration
CC       and recruitment of pericytes and smooth muscle cells to
CC       endothelial cells. Plays a role in the migration of vascular
CC       smooth muscle cells and the formation of neointima at vascular
CC       injury sites. Required for normal development of the
CC       cardiovascular system. Required for normal recruitment of
CC       pericytes (mesangial cells) in the kidney glomerulus, and for
CC       normal formation of a branched network of capillaries in kidney
CC       glomeruli. Promotes rearrangement of the actin cytoskeleton and
CC       the formation of membrane ruffles. Binding of its cognate ligands
CC       - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFD -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL,
CC       SHC1 and NCK1. Activation of PLCG1 leads to the production of the
CC       cellular signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, mobilization of cytosolic Ca(2+) and the activation
CC       of protein kinase C. Phosphorylation of PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, leads to the activation
CC       of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the
CC       C-terminus of PTPN11, creates a binding site for GRB2, resulting
CC       in the activation of HRAS, RAF1 and down-stream MAP kinases,
CC       including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation
CC       and activation of SRC family kinases. Promotes phosphorylation of
CC       PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by
CC       protein phosphatases that dephosphorylate the receptor and its
CC       down-stream effectors, and by rapid internalization of the
CC       activated receptor. {ECO:0000269|PubMed:11297552,
CC       ECO:0000269|PubMed:11331881, ECO:0000269|PubMed:1314164,
CC       ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:1653029,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:1846866,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:20529858,
CC       ECO:0000269|PubMed:21098708, ECO:0000269|PubMed:21679854,
CC       ECO:0000269|PubMed:21733313, ECO:0000269|PubMed:2554309,
CC       ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496,
CC       ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811,
CC       ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1846866,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:7685273}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFB and/or PDGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues. Inhibited by imatinib. {ECO:0000269|PubMed:15492236}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with
CC       heterodimers formed by PDGFA and PDGFB. May also interact with
CC       homodimeric PDGFC. Monomer in the absence of bound ligand.
CC       Interaction with homodimeric PDGFB, heterodimers formed by PDGFA
CC       and PDGFB or homodimeric PDGFD, leads to receptor dimerization,
CC       where both PDGFRA homodimers and heterodimers with PDGFRB are
CC       observed. Interacts with SH2B2/APS. Interacts directly (tyrosine
CC       phosphorylated) with SHB. Interacts (tyrosine phosphorylated) with
CC       PIK3R1 and RASA1. Interacts (tyrosine phosphorylated) with CBL.
CC       Interacts (tyrosine phosphorylated) with SRC and SRC family
CC       kinases. Interacts (tyrosine phosphorylated) with PIK3C2B, maybe
CC       indirectly. Interacts (tyrosine phosphorylated) with SHC1, GRB7,
CC       GRB10 and NCK1. Interaction with GRB2 is mediated by SHC1.
CC       Interacts (via C-terminus) with SLC9A3R1.
CC       {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151,
CC       ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164,
CC       ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338,
CC       ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772,
CC       ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113,
CC       ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233,
CC       ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}.
CC   -!- INTERACTION:
CC       P0CK45:E5 (xeno); NbExp=2; IntAct=EBI-641237, EBI-7015490;
CC       P06241:FYN; NbExp=3; IntAct=EBI-641237, EBI-515315;
CC       Q14451:GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191;
CC       Q53G59:KLHL12; NbExp=3; IntAct=EBI-641237, EBI-740929;
CC       P01127:PDGFB; NbExp=13; IntAct=EBI-641237, EBI-1554925;
CC       P23727:PIK3R1 (xeno); NbExp=6; IntAct=EBI-641237, EBI-520244;
CC       P27986:PIK3R1; NbExp=19; IntAct=EBI-641237, EBI-79464;
CC       P08487:PLCG1 (xeno); NbExp=3; IntAct=EBI-641237, EBI-8013886;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-641237, EBI-79387;
CC       P60484:PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788;
CC       Q06124:PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779;
CC       Q05209:PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035;
CC       Q12913:PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500;
CC       P04049:RAF1; NbExp=2; IntAct=EBI-641237, EBI-365996;
CC       P20936:RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476;
CC       Q13239:SLA; NbExp=4; IntAct=EBI-641237, EBI-726214;
CC       O14745:SLC9A3R1; NbExp=5; IntAct=EBI-641237, EBI-349787;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327;
CC       P25020:V-SRC (xeno); NbExp=4; IntAct=EBI-641237, EBI-8636140;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand
CC       binding, the autophosphorylated receptor is ubiquitinated and
CC       internalized, leading to its degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P09619-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P09619-2; Sequence=VSP_056008, VSP_056009;
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-579, and to a lesser degree, at
CC       Tyr-581, is important for interaction with SRC family kinases.
CC       Phosphorylation at Tyr-740 and Tyr-751 is important for
CC       interaction with PIK3R1. Phosphorylation at Tyr-751 is important
CC       for interaction with NCK1. Phosphorylation at Tyr-771 and Tyr-857
CC       is important for interaction with RASA1/GAP. Phosphorylation at
CC       Tyr-857 is important for efficient phosphorylation of PLCG1 and
CC       PTPN11, resulting in increased phosphorylation of AKT1, MAPK1/ERK2
CC       and/or MAPK3/ERK1, PDCD6IP/ALIX and STAM, and in increased cell
CC       proliferation. Phosphorylation at Tyr-1009 is important for
CC       interaction with PTPN11. Phosphorylation at Tyr-1009 and Tyr-1021
CC       is important for interaction with PLCG1. Phosphorylation at Tyr-
CC       1021 is important for interaction with CBL; PLCG1 and CBL compete
CC       for the same binding site. Dephosphorylated by PTPRJ at Tyr-751,
CC       Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr-
CC       579 and Tyr-1021. {ECO:0000269|PubMed:10821867,
CC       ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585,
CC       ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144,
CC       ECO:0000269|PubMed:7685273}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510,
CC       ECO:0000269|PubMed:2850496}.
CC   -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is
CC       polyubiquitinated, leading to its degradation.
CC       {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found
CC       in a form of chronic myelomonocytic leukemia (CMML). Translocation
CC       t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal
CC       clonal myeloid proliferation and by progression to acute
CC       myelogenous leukemia (AML).
CC   -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia
CC       (MPE) [MIM:131440]: A hematologic disorder characterized by
CC       malignant eosinophils proliferation. Note=The gene represented in
CC       this entry may be involved in disease pathogenesis. Chromosomal
CC       aberrations involving PDGFRB have been found in many instances of
CC       chronic myeloproliferative disorder with eosinophilia.
CC       Translocation t(5;12) with ETV6 on chromosome 12 creating an
CC       PDGFRB-ETV6 fusion protein (PubMed:12181402). Translocation
CC       t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 fusion
CC       protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that
CC       forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457).
CC       Translocation t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end
CC       of CEP85L (isoform 4) to the 3'-end of PDGFRB (PubMed:21938754).
CC       {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457,
CC       ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes. Note=The gene represented in
CC       this entry may be involved in disease pathogenesis. A chromosomal
CC       aberration involving PDGFRB has been found in a patient with AML.
CC       Translocation t(5;14)(q33;q32) with TRIP11 (PubMed:9373237).
CC       {ECO:0000269|PubMed:9373237}.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the
CC       hematopoietic stem cell compartment with proliferation of
CC       differentiated progeny. Patients have splenomegaly, enlarged lymph
CC       nodes, rashes, and hemorrhages. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. A chromosomal
CC       aberration involving PDGFRB has been found in a patient with JMML.
CC       Translocation t(5;17)(q33;p11.2) with SPECC1 (PubMed:15087372).
CC       {ECO:0000269|PubMed:15087372}.
CC   -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4)
CC       [MIM:615007]: A form of basal ganglia calcification, an autosomal
CC       dominant condition characterized by symmetric calcification in the
CC       basal ganglia and other brain regions. Affected individuals can
CC       either be asymptomatic or show a wide spectrum of neuropsychiatric
CC       symptoms, including parkinsonism, dystonia, tremor, ataxia,
CC       dementia, psychosis, seizures, and chronic headache. Serum levels
CC       of calcium, phosphate, alkaline phosphatase and parathyroid
CC       hormone are normal. The neuropathological hallmark of the disease
CC       is vascular and pericapillary calcification, mainly of calcium
CC       phosphate, in the affected brain areas.
CC       {ECO:0000269|PubMed:23255827}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare
CC       mesenchymal disorder characterized by the development of benign
CC       tumors in the skin, striated muscles, bones, and, more rarely,
CC       visceral organs. Subcutaneous or soft tissue nodules commonly
CC       involve the skin of the head, neck, and trunk. Skeletal and
CC       muscular lesions occur in about half of the patients. Lesions may
CC       be solitary or multicentric, and they may be present at birth or
CC       become apparent in early infancy or occasionally in adult life.
CC       Visceral lesions are associated with high morbidity and mortality.
CC       {ECO:0000269|PubMed:23731537, ECO:0000269|PubMed:23731542}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDGFRBID21ch5q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03278; AAA60049.1; -; mRNA.
DR   EMBL; M21616; AAA36427.1; -; mRNA.
DR   EMBL; EU826595; ACF47631.1; -; mRNA.
DR   EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032224; AAH32224.1; -; mRNA.
DR   EMBL; U33172; AAC51675.1; -; Genomic_DNA.
DR   CCDS; CCDS4303.1; -. [P09619-1]
DR   PIR; A28206; PFHUGB.
DR   RefSeq; NP_002600.1; NM_002609.3. [P09619-1]
DR   RefSeq; XP_011535960.1; XM_011537658.1. [P09619-1]
DR   RefSeq; XP_011535961.1; XM_011537659.1. [P09619-1]
DR   UniGene; Hs.509067; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106.
DR   PDB; 1H9O; X-ray; 1.79 A; B=751-755.
DR   PDB; 1LWP; Model; -; A=600-962.
DR   PDB; 1SHA; X-ray; 1.50 A; B=751-755.
DR   PDB; 2L6W; NMR; -; A/B=526-563.
DR   PDB; 2PLD; NMR; -; B=1018-1029.
DR   PDB; 2PLE; NMR; -; B=1018-1029.
DR   PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 1H9O; -.
DR   PDBsum; 1LWP; -.
DR   PDBsum; 1SHA; -.
DR   PDBsum; 2L6W; -.
DR   PDBsum; 2PLD; -.
DR   PDBsum; 2PLE; -.
DR   PDBsum; 3MJG; -.
DR   ProteinModelPortal; P09619; -.
DR   SMR; P09619; 33-312, 526-563, 576-695, 798-959.
DR   BioGrid; 111185; 64.
DR   DIP; DIP-558N; -.
DR   IntAct; P09619; 64.
DR   MINT; MINT-148093; -.
DR   STRING; 9606.ENSP00000261799; -.
DR   BindingDB; P09619; -.
DR   ChEMBL; CHEMBL2095189; -.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1804; -.
DR   iPTMnet; P09619; -.
DR   PhosphoSite; P09619; -.
DR   BioMuta; PDGFRB; -.
DR   DMDM; 129890; -.
DR   MaxQB; P09619; -.
DR   PaxDb; P09619; -.
DR   PRIDE; P09619; -.
DR   DNASU; 5159; -.
DR   Ensembl; ENST00000261799; ENSP00000261799; ENSG00000113721. [P09619-1]
DR   GeneID; 5159; -.
DR   KEGG; hsa:5159; -.
DR   UCSC; uc003lro.3; human. [P09619-1]
DR   CTD; 5159; -.
DR   GeneCards; PDGFRB; -.
DR   GeneReviews; PDGFRB; -.
DR   HGNC; HGNC:8804; PDGFRB.
DR   HPA; CAB003842; -.
DR   HPA; CAB018144; -.
DR   HPA; HPA028499; -.
DR   MalaCards; PDGFRB; -.
DR   MIM; 131440; phenotype.
DR   MIM; 173410; gene.
DR   MIM; 228550; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 607785; phenotype.
DR   MIM; 615007; phenotype.
DR   neXtProt; NX_P09619; -.
DR   Orphanet; 1980; Bilateral striopallidodentate calcinosis.
DR   Orphanet; 98823; Chronic myelomonocytic leukemia.
DR   Orphanet; 2591; Infantile myofibromatosis.
DR   Orphanet; 168950; Myeloid neoplasm associated with PDGFRB rearrangement.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   Orphanet; 86830; Unclassified chronic myeloproliferative disease.
DR   PharmGKB; PA33148; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112009; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P09619; -.
DR   KO; K05089; -.
DR   OMA; APYDNYV; -.
DR   OrthoDB; EOG7GXP9Q; -.
DR   PhylomeDB; P09619; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P09619; -.
DR   ChiTaRS; PDGFRB; human.
DR   EvolutionaryTrace; P09619; -.
DR   GeneWiki; PDGFRB; -.
DR   GenomeRNAi; 5159; -.
DR   NextBio; 19958; -.
DR   PRO; PR:P09619; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P09619; -.
DR   CleanEx; HS_PDGFRB; -.
DR   ExpressionAtlas; P09619; baseline and differential.
DR   Genevisible; P09619; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc.
DR   GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005017; F:platelet-derived growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB.
DR   GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; TAS:GOC.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:GOC.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0072278; P:metanephric comma-shaped body morphogenesis; IEA:Ensembl.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0035789; P:metanephric mesenchymal cell migration; IEA:Ensembl.
DR   GO; GO:0072075; P:metanephric mesenchyme development; IEA:Ensembl.
DR   GO; GO:0072284; P:metanephric S-shaped body morphogenesis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IEA:Ensembl.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0034405; P:response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0048745; P:smooth muscle tissue development; IEA:Ensembl.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027288; PGFRB.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF53; PTHR24416:SF53; 3.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500948; Beta-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chemotaxis; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasmic vesicle; Developmental protein; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Lysosome; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        33   1106       Platelet-derived growth factor receptor
FT                                beta.
FT                                /FTId=PRO_0000016757.
FT   TOPO_DOM     33    532       Extracellular. {ECO:0000255}.
FT   TRANSMEM    533    553       Helical. {ECO:0000255}.
FT   TOPO_DOM    554   1106       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       33    120       Ig-like C2-type 1.
FT   DOMAIN      129    210       Ig-like C2-type 2.
FT   DOMAIN      214    309       Ig-like C2-type 3.
FT   DOMAIN      331    403       Ig-like C2-type 4.
FT   DOMAIN      416    524       Ig-like C2-type 5.
FT   DOMAIN      600    962       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     606    614       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    826    826       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     634    634       ATP. {ECO:0000305}.
FT   SITE        527    528       Breakpoint for insertion to form PDE4DIP-
FT                                PDGFRB fusion protein.
FT   SITE        527    528       Breakpoint for translocation to form
FT                                TRIP11-PDGFRB.
FT   SITE        558    559       Breakpoint for translocation to form the
FT                                CEP85L-PDGFRB fusion protein.
FT   MOD_RES     562    562       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     579    579       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:7685273}.
FT   MOD_RES     581    581       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:7685273}.
FT   MOD_RES     686    686       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES     716    716       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15902258}.
FT   MOD_RES     740    740       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES     751    751       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:1709159,
FT                                ECO:0000269|PubMed:2550144}.
FT   MOD_RES     763    763       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     771    771       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES     775    775       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     778    778       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867}.
FT   MOD_RES     857    857       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:15902258,
FT                                ECO:0000269|PubMed:1709159,
FT                                ECO:0000269|PubMed:2550144}.
FT   MOD_RES     934    934       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES     970    970       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000250}.
FT   MOD_RES    1009   1009       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:15902258}.
FT   MOD_RES    1021   1021       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10821867,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:14966296,
FT                                ECO:0000269|PubMed:15902258}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     89     89       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    103    103       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    215    215       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    292    292       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    307    307       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:20534510}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    479    479       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     54    100       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    149    190       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    235    291       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:20534510}.
FT   DISULFID    436    508       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     311    336       VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERW
FT                                AHYNLLSCIGAGHCR (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056008.
FT   VAR_SEQ     337   1106       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056009.
FT   VARIANT      29     29       I -> F (in dbSNP:rs17110944).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034377.
FT   VARIANT     180    180       S -> F (in dbSNP:rs17853027).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_035125.
FT   VARIANT     282    282       E -> K (in dbSNP:rs34586048).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042027.
FT   VARIANT     345    345       P -> S (in dbSNP:rs2229558).
FT                                /FTId=VAR_049717.
FT   VARIANT     485    485       E -> K (in dbSNP:rs41287110).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042028.
FT   VARIANT     561    561       R -> C (in IMF1).
FT                                {ECO:0000269|PubMed:23731537}.
FT                                /FTId=VAR_069925.
FT   VARIANT     589    589       Y -> H (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042029.
FT   VARIANT     658    658       L -> P (in IBGC4).
FT                                {ECO:0000269|PubMed:23255827}.
FT                                /FTId=VAR_069320.
FT   VARIANT     660    660       P -> T (in IMF1; dbSNP:rs144050370).
FT                                {ECO:0000269|PubMed:23731542}.
FT                                /FTId=VAR_069926.
FT   VARIANT     718    718       N -> Y (in dbSNP:rs35322465).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042030.
FT   VARIANT     882    882       T -> I (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042031.
FT   VARIANT     987    987       R -> W (in IBGC4).
FT                                {ECO:0000269|PubMed:23255827}.
FT                                /FTId=VAR_069321.
FT   MUTAGEN     579    579       Y->F: Loss of kinase activity; when
FT                                associated with F-581. Strongly reduces
FT                                interaction with SRC family kinases. No
FT                                effect on interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7685273}.
FT   MUTAGEN     581    581       Y->F: Loss of kinase activity; when
FT                                associated with F-579. No effect on
FT                                interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7685273}.
FT   MUTAGEN     634    634       K->A,R: Loss of kinase activity.
FT                                Abolishes interaction with RASA1. No
FT                                effect on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1846866,
FT                                ECO:0000269|PubMed:20494825}.
FT   MUTAGEN     716    716       Y->F: No effect neither on interaction
FT                                with GRB10 and RASA1 nor on
FT                                phosphatidylinositol 3-kinase activity.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     740    740       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation; when associated with
FT                                F-751. Strongly decreases
FT                                phosphatidylinositol 3-kinase activity.
FT                                No effect on interaction with GRB10 and
FT                                RASA1. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321,
FT                                ECO:0000269|PubMed:21679854}.
FT   MUTAGEN     751    751       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation; when associated with
FT                                F-740. Abolishes phosphatidylinositol 3-
FT                                kinase activity and interaction with
FT                                NCK1, and slightly reduces interaction
FT                                with RASA1. No effect on interaction with
FT                                GRB10. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321,
FT                                ECO:0000269|PubMed:1653029,
FT                                ECO:0000269|PubMed:21679854,
FT                                ECO:0000269|PubMed:7692233}.
FT   MUTAGEN     763    763       Y->F: No effect on interaction with RASA1
FT                                and on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     771    771       Y->F: Loss of interaction with GRB10.
FT                                Abolishes interaction with RASA1. No
FT                                effect on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1375321}.
FT   MUTAGEN     775    775       Y->F: No effect on interaction with RASA1
FT                                and on phosphatidylinositol 3-kinase
FT                                activity. {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     778    778       Y->F: Strongly reduces expression levels.
FT                                {ECO:0000269|PubMed:1314164}.
FT   MUTAGEN     857    857       Y->F: Reduces kinase activity. No effect
FT                                on interaction with GRB10. Abolishes
FT                                interaction with RASA1. No effect on
FT                                phosphatidylinositol 3-kinase activity.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1314164,
FT                                ECO:0000269|PubMed:1653029,
FT                                ECO:0000269|PubMed:20494825}.
FT   MUTAGEN    1009   1009       Y->F: No effect on interaction with
FT                                GRB10. Abolishes interaction with PLCG1;
FT                                when associated with F-1021.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:7691811}.
FT   MUTAGEN    1021   1021       Y->F: Strongly reduces up-regulation of
FT                                cell proliferation. Abolishes interaction
FT                                with PLCG1; when associated with F-1009.
FT                                No effect on interaction with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:1396585,
FT                                ECO:0000269|PubMed:17620338,
FT                                ECO:0000269|PubMed:21679854}.
FT   CONFLICT    241    241       E -> D (in Ref. 2; AAA36427).
FT                                {ECO:0000305}.
FT   STRAND       40     43       {ECO:0000244|PDB:3MJG}.
FT   STRAND       50     58       {ECO:0000244|PDB:3MJG}.
FT   STRAND       61     64       {ECO:0000244|PDB:3MJG}.
FT   STRAND       70     75       {ECO:0000244|PDB:3MJG}.
FT   STRAND       81     87       {ECO:0000244|PDB:3MJG}.
FT   HELIX        92     94       {ECO:0000244|PDB:3MJG}.
FT   STRAND       96    101       {ECO:0000244|PDB:3MJG}.
FT   STRAND      114    119       {ECO:0000244|PDB:3MJG}.
FT   HELIX       132    135       {ECO:0000244|PDB:3MJG}.
FT   STRAND      136    141       {ECO:0000244|PDB:3MJG}.
FT   STRAND      145    147       {ECO:0000244|PDB:3MJG}.
FT   STRAND      158    164       {ECO:0000244|PDB:3MJG}.
FT   TURN        175    177       {ECO:0000244|PDB:3MJG}.
FT   STRAND      178    181       {ECO:0000244|PDB:3MJG}.
FT   STRAND      185    194       {ECO:0000244|PDB:3MJG}.
FT   STRAND      197    200       {ECO:0000244|PDB:3MJG}.
FT   STRAND      204    208       {ECO:0000244|PDB:3MJG}.
FT   STRAND      217    221       {ECO:0000244|PDB:3MJG}.
FT   STRAND      223    226       {ECO:0000244|PDB:3MJG}.
FT   STRAND      231    239       {ECO:0000244|PDB:3MJG}.
FT   STRAND      241    248       {ECO:0000244|PDB:3MJG}.
FT   STRAND      252    255       {ECO:0000244|PDB:3MJG}.
FT   STRAND      261    265       {ECO:0000244|PDB:3MJG}.
FT   TURN        267    270       {ECO:0000244|PDB:3MJG}.
FT   STRAND      271    280       {ECO:0000244|PDB:3MJG}.
FT   STRAND      287    295       {ECO:0000244|PDB:3MJG}.
FT   TURN        296    299       {ECO:0000244|PDB:3MJG}.
FT   STRAND      300    311       {ECO:0000244|PDB:3MJG}.
FT   HELIX       530    556       {ECO:0000244|PDB:2L6W}.
SQ   SEQUENCE   1106 AA;  123968 MW;  038C15E531D6E89D CRC64;
     MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV
     VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV
     PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS
     GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN
     EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH
     QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS
     SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL
     ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV
     TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA
     LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL
     VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP
     HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL
     PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP
     SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV
     KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG
     GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER
     LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND
     YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV
     EPEPELEQLP DSGCPAPRAE AEDSFL
//
ID   FGFR2_MOUSE             Reviewed;         821 AA.
AC   P21803; O55141; Q00389; Q61342;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 4.
DT   11-NOV-2015, entry version 160.
DE   RecName: Full=Fibroblast growth factor receptor 2;
DE            Short=FGFR-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Keratinocyte growth factor receptor;
DE            Short=KGFR;
DE   AltName: CD_antigen=CD332;
DE   Flags: Precursor;
GN   Name=Fgfr2; Synonyms=Bek, Ect1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=1711190;
RA   Raz V., Kelman Z., Avivi A., Neufeld G., Givol D., Yarden Y.;
RT   "PCR-based identification of new receptors: molecular cloning of a
RT   receptor for fibroblast growth factors.";
RL   Oncogene 6:753-760(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=1846048; DOI=10.1126/science.1846048;
RA   Miki T., Fleming T.P., Bottaro D.P., Rubin J.S., Ron D.,
RA   Aaronson S.A.;
RT   "Expression cDNA cloning of the KGF receptor by creation of a
RT   transforming autocrine loop.";
RL   Science 251:72-75(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Brain, and Liver;
RX   PubMed=1373495; DOI=10.1073/pnas.89.8.3305;
RA   Mansukhani A., Dell'Era P., Moscatelli D., Kornbluth S., Hanafusa H.,
RA   Basilico C.;
RT   "Characterization of the murine BEK fibroblast growth factor (FGF)
RT   receptor: activation by three members of the FGF family and
RT   requirement for heparin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3305-3309(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM LONG).
RX   PubMed=9499422; DOI=10.1093/hmg/7.4.685;
RA   Twigg S.R.F., Burns H.D., Oldridge M., Heath J.K., Wilkie A.O.M.;
RT   "Conserved use of a non-canonical 5' splice site (/GA) in alternative
RT   splicing by fibroblast growth factor receptors 1, 2 and 3.";
RL   Hum. Mol. Genet. 7:685-691(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 477-821.
RC   TISSUE=Liver;
RX   PubMed=2468999;
RA   Kornbluth S., Paulson K.E., Hanafusa H.;
RT   "Novel tyrosine kinase identified by phosphotyrosine antibody
RT   screening of cDNA libraries.";
RL   Mol. Cell. Biol. 8:5541-5544(1988).
RN   [6]
RP   FUNCTION.
RX   PubMed=8393815; DOI=10.1006/dbio.1993.1205;
RA   Orr-Urtreger A., Bedford M.T., Burakova T., Arman E., Zimmer Y.,
RA   Yayon A., Givol D., Lonai P.;
RT   "Developmental localization of the splicing alternatives of fibroblast
RT   growth factor receptor-2 (FGFR2).";
RL   Dev. Biol. 158:475-486(1993).
RN   [7]
RP   INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [8]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=9435295;
RA   Xu X., Weinstein M., Li C., Naski M., Cohen R.I., Ornitz D.M.,
RA   Leder P., Deng C.;
RT   "Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal
RT   regulation loop between FGF8 and FGF10 is essential for limb
RT   induction.";
RL   Development 125:753-765(1998).
RN   [9]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=9560232; DOI=10.1073/pnas.95.9.5082;
RA   Arman E., Haffner-Krausz R., Chen Y., Heath J.K., Lonai P.;
RT   "Targeted disruption of fibroblast growth factor (FGF) receptor 2
RT   suggests a role for FGF signaling in pregastrulation mammalian
RT   development.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5082-5087(1998).
RN   [10]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=10518547; DOI=10.1073/pnas.96.21.11895;
RA   Arman E., Haffner-Krausz R., Gorivodsky M., Lonai P.;
RT   "Fgfr2 is required for limb outgrowth and lung-branching
RT   morphogenesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11895-11899(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=10851026; DOI=10.1083/jcb.149.6.1297;
RA   Mansukhani A., Bellosta P., Sahni M., Basilico C.;
RT   "Signaling by fibroblast growth factors (FGF) and fibroblast growth
RT   factor receptor 2 (FGFR2)-activating mutations blocks mineralization
RT   and induces apoptosis in osteoblasts.";
RL   J. Cell Biol. 149:1297-1308(2000).
RN   [12]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=12135917;
RA   Eswarakumar V.P., Monsonego-Ornan E., Pines M., Antonopoulou I.,
RA   Morriss-Kay G.M., Lonai P.;
RT   "The IIIc alternative of Fgfr2 is a positive regulator of bone
RT   formation.";
RL   Development 129:3783-3793(2002).
RN   [13]
RP   FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS,
RP   MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION
RP   WITH PLCG1.
RX   PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031;
RA   Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.;
RT   "Tyrosine 769 of the keratinocyte growth factor receptor is required
RT   for receptor signaling but not endocytosis.";
RL   Biochem. Biophys. Res. Commun. 327:523-532(2005).
RN   [14]
RP   INTERACTION WITH FLRT2.
RX   PubMed=21765038; DOI=10.1177/0022034511415272;
RA   Wei K., Xu Y., Tse H., Manolson M.F., Gong S.G.;
RT   "Mouse FLRT2 interacts with the extracellular and intracellular
RT   regions of FGFR2.";
RL   J. Dent. Res. 90:1234-1239(2011).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of cell proliferation, differentiation,
CC       migration and apoptosis, and in the regulation of embryonic
CC       development. Required for normal embryonic patterning, trophoblast
CC       function, limb bud development, lung morphogenesis, osteogenesis
CC       and skin development. Plays an essential role in the regulation of
CC       osteoblast differentiation, proliferation and apoptosis, and is
CC       required for normal skeleton development. Promotes cell
CC       proliferation in keratinocytes and immature osteoblasts, but
CC       promotes apoptosis in differentiated osteoblasts. Phosphorylates
CC       PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of
CC       several signaling cascades. Activation of PLCG1 leads to the
CC       production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers
CC       recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates
CC       activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase
CC       signaling pathway, as well as of the AKT1 signaling pathway. FGFR2
CC       signaling is down-regulated by ubiquitination, internalization and
CC       degradation. Mutations that lead to constitutive kinase activation
CC       or impair normal FGFR2 maturation, internalization and degradation
CC       lead to aberrant signaling. Over-expressed FGFR2 promotes
CC       activation of STAT1. {ECO:0000269|PubMed:10851026,
CC       ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:8393815,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts
CC       predominantly with FGF1 and FGF2, but can also interact with FGF3,
CC       FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in
CC       vitro) (PubMed:8663044). Ligand specificity is determined by
CC       tissue-specific expression of isoforms, and differences in the
CC       third Ig-like domain are crucial for ligand specificity. Affinity
CC       for fibroblast growth factors (FGFs) is increased by heparan
CC       sulfate glycosaminoglycans that function as coreceptors. Likewise,
CC       KLB increases the affinity for FGF19 and FGF21. Interacts with
CC       PLCG1 (PubMed:15629145). Interacts with GRB2 and PAK4 (By
CC       similarity). Interacts with FLRT2 (PubMed:21765038).
CC       {ECO:0000250|UniProtKB:P21802, ECO:0000269|PubMed:15629145,
CC       ECO:0000269|PubMed:21765038, ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P13595:Ncam1; NbExp=2; IntAct=EBI-6286942, EBI-774943;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Golgi apparatus {ECO:0000250}. Cytoplasmic vesicle
CC       {ECO:0000250}. Note=Detected on osteoblast plasma membrane lipid
CC       rafts. After ligand binding, the activated receptor is rapidly
CC       internalized and degraded (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P21803-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P21803-2; Sequence=VSP_002985, VSP_002986, VSP_002987;
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. Alternative splicing events affecting the third Ig-
CC       like domain are crucial for ligand selectivity (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer (By similarity). {ECO:0000250}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after
CC       autophosphorylation, leading to internalization and degradation.
CC       Subject to degradation both in lysosomes and by the proteasome (By
CC       similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Embryonic lethality shortly after
CC       implantation, due to trophoblast defects, absence of a functional
CC       placenta, failure of limb bud formation, plus defects in lung
CC       branching and heart development. {ECO:0000269|PubMed:10518547,
CC       ECO:0000269|PubMed:12135917, ECO:0000269|PubMed:9435295,
CC       ECO:0000269|PubMed:9560232}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X55441; CAA39083.1; -; mRNA.
DR   EMBL; M63503; AAA39377.1; -; mRNA.
DR   EMBL; M86441; AAA37286.1; -; mRNA.
DR   EMBL; Y16152; CAA76098.1; -; Genomic_DNA.
DR   EMBL; Y16167; CAA76099.1; -; Genomic_DNA.
DR   EMBL; M23362; AAA37285.1; -; mRNA.
DR   PIR; A38429; A38429.
DR   PIR; A44142; TVMSBK.
DR   PIR; S17295; S17295.
DR   RefSeq; NP_034337.2; NM_010207.2.
DR   RefSeq; NP_963895.2; NM_201601.2.
DR   UniGene; Mm.16340; -.
DR   PDB; 4HWU; X-ray; 2.90 A; A/B=45-127.
DR   PDBsum; 4HWU; -.
DR   ProteinModelPortal; P21803; -.
DR   SMR; P21803; 47-363, 462-801.
DR   BioGrid; 199657; 2.
DR   DIP; DIP-6038N; -.
DR   IntAct; P21803; 2.
DR   STRING; 10090.ENSMUSP00000112430; -.
DR   ChEMBL; CHEMBL2111391; -.
DR   PhosphoSite; P21803; -.
DR   MaxQB; P21803; -.
DR   PaxDb; P21803; -.
DR   PRIDE; P21803; -.
DR   GeneID; 14183; -.
DR   KEGG; mmu:14183; -.
DR   CTD; 2263; -.
DR   MGI; MGI:95523; Fgfr2.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P21803; -.
DR   KO; K05093; -.
DR   PhylomeDB; P21803; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   ChiTaRS; Fgfr2; mouse.
DR   NextBio; 285386; -.
DR   PRO; PR:P21803; -.
DR   Proteomes; UP000000589; Unplaced.
DR   CleanEx; MM_FGFR2; -.
DR   GO; GO:0005938; C:cell cortex; ISO:MGI.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0060076; C:excitatory synapse; IMP:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISO:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:MGI.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0001525; P:angiogenesis; IGI:MGI.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007409; P:axonogenesis; IMP:MGI.
DR   GO; GO:0060348; P:bone development; IMP:MGI.
DR   GO; GO:0030282; P:bone mineralization; IMP:MGI.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:MGI.
DR   GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IMP:MGI.
DR   GO; GO:0060442; P:branching involved in prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0048755; P:branching morphogenesis of a nerve; IMP:MGI.
DR   GO; GO:0060449; P:bud elongation involved in lung branching; IMP:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IDA:MGI.
DR   GO; GO:0007267; P:cell-cell signaling; IMP:MGI.
DR   GO; GO:0060365; P:coronal suture morphogenesis; IMP:MGI.
DR   GO; GO:0048565; P:digestive tract development; IMP:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISO:MGI.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IMP:MGI.
DR   GO; GO:0048562; P:embryonic organ morphogenesis; IMP:MGI.
DR   GO; GO:0009880; P:embryonic pattern specification; IMP:MGI.
DR   GO; GO:0061031; P:endodermal digestive tract morphogenesis; IMP:MGI.
DR   GO; GO:0048730; P:epidermis morphogenesis; IMP:MGI.
DR   GO; GO:0030855; P:epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0050673; P:epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IMP:MGI.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0060595; P:fibroblast growth factor receptor signaling pathway involved in mammary gland specification; IMP:MGI.
DR   GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow; IMP:UniProtKB.
DR   GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; IMP:UniProtKB.
DR   GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; IMP:UniProtKB.
DR   GO; GO:0022612; P:gland morphogenesis; IMP:MGI.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0042472; P:inner ear morphogenesis; IMP:MGI.
DR   GO; GO:0032808; P:lacrimal gland development; IMP:MGI.
DR   GO; GO:0060601; P:lateral sprouting from an epithelium; IMP:MGI.
DR   GO; GO:0070307; P:lens fiber cell development; IMP:MGI.
DR   GO; GO:0060174; P:limb bud formation; IMP:MGI.
DR   GO; GO:0048286; P:lung alveolus development; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IMP:MGI.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IMP:MGI.
DR   GO; GO:0060615; P:mammary gland bud formation; IMP:MGI.
DR   GO; GO:0003149; P:membranous septum morphogenesis; IMP:MGI.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; IGI:MGI.
DR   GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; IGI:MGI.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IMP:MGI.
DR   GO; GO:0030901; P:midbrain development; IGI:MGI.
DR   GO; GO:0016331; P:morphogenesis of embryonic epithelium; IMP:MGI.
DR   GO; GO:0035264; P:multicellular organism growth; IMP:MGI.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IGI:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0007528; P:neuromuscular junction development; IMP:MGI.
DR   GO; GO:0042476; P:odontogenesis; IMP:MGI.
DR   GO; GO:0021769; P:orbitofrontal cortex development; IMP:UniProtKB.
DR   GO; GO:0035265; P:organ growth; IMP:MGI.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0030916; P:otic vesicle formation; IMP:MGI.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; IMP:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IGI:MGI.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IGI:MGI.
DR   GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; IMP:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IGI:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IGI:MGI.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:MGI.
DR   GO; GO:0009791; P:post-embryonic development; IMP:MGI.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IMP:MGI.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IMP:MGI.
DR   GO; GO:0060512; P:prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; ISO:MGI.
DR   GO; GO:0021860; P:pyramidal neuron development; IMP:UniProtKB.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IMP:MGI.
DR   GO; GO:0010453; P:regulation of cell fate commitment; IMP:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:MGI.
DR   GO; GO:0040036; P:regulation of fibroblast growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0060688; P:regulation of morphogenesis of a branching structure; IMP:MGI.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IMP:MGI.
DR   GO; GO:0051150; P:regulation of smooth muscle cell differentiation; IMP:MGI.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; IMP:MGI.
DR   GO; GO:0048608; P:reproductive structure development; IMP:MGI.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IMP:MGI.
DR   GO; GO:0048489; P:synaptic vesicle transport; IMP:MGI.
DR   GO; GO:0001657; P:ureteric bud development; IGI:MGI.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; TAS:DFLAT.
DR   GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; IMP:MGI.
DR   GO; GO:0021847; P:ventricular zone neuroblast division; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 3.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasmic vesicle; Disulfide bond;
KW   Glycoprotein; Golgi apparatus; Heparin-binding; Immunoglobulin domain;
KW   Kinase; Membrane; Nucleotide-binding; Phosphoprotein; Proto-oncogene;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     21
FT   CHAIN        22    821       Fibroblast growth factor receptor 2.
FT                                /FTId=PRO_0000016784.
FT   TOPO_DOM     22    377       Extracellular. {ECO:0000255}.
FT   TRANSMEM    378    398       Helical. {ECO:0000255}.
FT   TOPO_DOM    399    821       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       25    125       Ig-like C2-type 1.
FT   DOMAIN      154    247       Ig-like C2-type 2.
FT   DOMAIN      256    358       Ig-like C2-type 3.
FT   DOMAIN      481    770       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     487    495       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     565    567       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      161    178       Heparin-binding. {ECO:0000250}.
FT   ACT_SITE    626    626       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     517    517       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     571    571       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     466    466       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     586    586       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     588    588       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     656    656       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     657    657       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     769    769       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     780    780       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P21802}.
FT   CARBOHYD     83     83       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    123    123       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    147    147       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    228    228       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    241    241       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    297    297       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    331    331       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     62    107       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    179    231       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    278    342       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ      37     37       E -> G (in isoform Short).
FT                                {ECO:0000303|PubMed:1846048}.
FT                                /FTId=VSP_002985.
FT   VAR_SEQ      38    152       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:1846048}.
FT                                /FTId=VSP_002986.
FT   VAR_SEQ     314    361       AAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHS
FT                                AWLTVLP -> HSGINSSNAEVLALFNVTEMDAGEYICKVS
FT                                NYIGQANQSAWLTVLPKQQ (in isoform Short).
FT                                {ECO:0000303|PubMed:1846048}.
FT                                /FTId=VSP_002987.
FT   MUTAGEN     769    769       Y->F: Abolishes phosphorylation of FRS2
FT                                and activation of MAP kinases.
FT                                {ECO:0000269|PubMed:15629145}.
FT   CONFLICT     53     53       A -> V (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT     55     56       GE -> RG (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT     90     90       E -> R (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       I -> Y (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    142    143       DV -> R (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    169    169       C -> V (in Ref. 1; CAA39083 and 2;
FT                                AAA39377). {ECO:0000305}.
FT   CONFLICT    187    187       S -> P (in Ref. 1; CAA39083 and 2;
FT                                AAA39377). {ECO:0000305}.
FT   CONFLICT    214    214       W -> R (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       Y -> I (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    275    275       E -> R (in Ref. 1; CAA39083).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       N -> Y (in Ref. 1; CAA39083 and 2;
FT                                AAA39377). {ECO:0000305}.
FT   STRAND       48     52       {ECO:0000244|PDB:4HWU}.
FT   STRAND       58     61       {ECO:0000244|PDB:4HWU}.
FT   STRAND       69     74       {ECO:0000244|PDB:4HWU}.
FT   STRAND       77     79       {ECO:0000244|PDB:4HWU}.
FT   STRAND       83     88       {ECO:0000244|PDB:4HWU}.
FT   STRAND       91     94       {ECO:0000244|PDB:4HWU}.
FT   HELIX        99    101       {ECO:0000244|PDB:4HWU}.
FT   STRAND      103    110       {ECO:0000244|PDB:4HWU}.
FT   STRAND      115    124       {ECO:0000244|PDB:4HWU}.
SQ   SEQUENCE   821 AA;  91984 MW;  FCDB28ADD61F4414 CRC64;
     MVSWGRFICL VLVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEAY VVAPGESLEL
     QCMLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAA RTVDSETWIF
     MVNVTDAISS GDDEDDTDSS EDVVSENRSN QRAPYWTNTE KMEKRLHACP AANTVKFRCP
     AGGNPTSTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CLVENEYGSI
     NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK
     NGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL
     PAPVREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVIFCRM KTTTKKPDFS SQPAVHKLTK
     RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK
     LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM
     IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF
     KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT
     TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH
     RMDKPTNCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLTQPLEQYS
     PSYPDTSSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T
//
ID   TGFB1_MOUSE             Reviewed;         390 AA.
AC   P04202;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-1987, sequence version 1.
DT   17-FEB-2016, entry version 177.
DE   RecName: Full=Transforming growth factor beta-1;
DE            Short=TGF-beta-1;
DE   Contains:
DE     RecName: Full=Latency-associated peptide;
DE              Short=LAP;
DE   Flags: Precursor;
GN   Name=Tgfb1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3007454;
RA   Derynck R., Jarrett J.A., Chen E.Y., Goeddel D.V.;
RT   "The murine transforming growth factor-beta precursor.";
RL   J. Biol. Chem. 261:4377-4379(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=BALB/cJ;
RX   PubMed=8522200; DOI=10.1016/0378-1119(95)00460-N;
RA   Guron C., Sudarshan C., Raghow R.;
RT   "Molecular organization of the gene encoding murine transforming
RT   growth factor beta 1.";
RL   Gene 165:325-326(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6J, and NOD/LT; TISSUE=Spleen;
RA   Poirot L., Benoist C., Mathis D.;
RT   "Transforming growth factor-beta 1 sequence and expression: no
RT   difference between NOD/Lt and C57Bl/6 mouse strains.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH NREP.
RX   PubMed=14985127; DOI=10.1016/j.bbrc.2004.01.171;
RA   Paliwal S., Shi J., Dhru U., Zhou Y., Schuger L.;
RT   "P311 binds to the latency associated protein and downregulates the
RT   expression of TGF-beta1 and TGF-beta2.";
RL   Biochem. Biophys. Res. Commun. 315:1104-1109(2004).
RN   [6]
RP   INTERACTION WITH HTRA3.
RX   PubMed=15206957; DOI=10.1111/j.1440-169X.2004.00743.x;
RA   Tocharus J., Tsuchiya A., Kajikawa M., Ueta Y., Oka C., Kawaichi M.;
RT   "Developmentally regulated expression of mouse HtrA3 and its role as
RT   an inhibitor of TGF-beta signaling.";
RL   Dev. Growth Differ. 46:257-274(2004).
RN   [7]
RP   INTERACTION WITH HTRA1.
RX   PubMed=14973287; DOI=10.1242/dev.00999;
RA   Oka C., Tsujimoto R., Kajikawa M., Koshiba-Takeuchi K., Ina J.,
RA   Yano M., Tsuchiya A., Ueta Y., Soma A., Kanda H., Matsumoto M.,
RA   Kawaichi M.;
RT   "HtrA1 serine protease inhibits signaling mediated by Tgfbeta family
RT   proteins.";
RL   Development 131:1041-1053(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=18368049; DOI=10.1038/nature06878;
RA   Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D.,
RA   Shen Y., Du J., Rubtsov Y.P., Rudensky A.Y., Ziegler S.F.,
RA   Littman D.R.;
RT   "TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by
RT   antagonizing RORgammat function.";
RL   Nature 453:236-240(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   INTERACTION WITH THSD4.
RX   PubMed=21880733; DOI=10.1074/jbc.M111.243451;
RA   Saito M., Kurokawa M., Oda M., Oshima M., Tsutsui K., Kosaka K.,
RA   Nakao K., Ogawa M., Manabe R., Suda N., Ganjargal G., Hada Y.,
RA   Noguchi T., Teranaka T., Sekiguchi K., Yoneda T., Tsuji T.;
RT   "ADAMTSL6beta protein rescues fibrillin-1 microfibril disorder in a
RT   Marfan syndrome mouse model through the promotion of fibrillin-1
RT   assembly.";
RL   J. Biol. Chem. 286:38602-38613(2011).
RN   [11]
RP   FUNCTION.
RX   PubMed=22781750; DOI=10.1016/j.cellsig.2012.07.003;
RA   Bruce D.L., Macartney T., Yong W., Shou W., Sapkota G.P.;
RT   "Protein phosphatase 5 modulates SMAD3 function in the transforming
RT   growth factor-beta pathway.";
RL   Cell. Signal. 24:1999-2006(2012).
CC   -!- FUNCTION: Multifunctional protein that controls proliferation,
CC       differentiation and other functions in many cell types. Many cells
CC       synthesize TGFB1 and have specific receptors for it. It positively
CC       and negatively regulates many other growth factors. It plays an
CC       important role in bone remodeling as it is a potent stimulator of
CC       osteoblastic bone formation, causing chemotaxis, proliferation and
CC       differentiation in committed osteoblasts. Can promote either T-
CC       helper 17 cells (Th17) or regulatory T-cells (Treg) lineage
CC       differentiation in a concentration-dependent manner. At high
CC       concentrations, leads to FOXP3-mediated suppression of RORC and
CC       down-regulation of IL-17 expression, favoring Treg cell
CC       development. At low concentrations in concert with IL-6 and IL-21,
CC       leads to expression of the IL-17 and IL-23 receptors, favoring
CC       differentiation to Th17 cells (PubMed:18368049).
CC       {ECO:0000269|PubMed:18368049, ECO:0000269|PubMed:22781750}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked, or heterodimer with TGFB2
CC       (By similarity). Secreted and stored as a biologically inactive
CC       form in the extracellular matrix in a 290 kDa complex (large
CC       latent TGF-beta1 complex) containing the TGFB1 homodimer, the
CC       latency-associated peptide (LAP), and the latent TGFB1 binding
CC       protein-1 (LTBP1). The complex without LTBP1 is known as the'small
CC       latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is
CC       required for growth factor activation and biological activity.
CC       Release of the large latent TGF-beta1 complex from the
CC       extracellular matrix is carried out by the matrix
CC       metalloproteinase MMP3 (By similarity). Interacts with CD109 and
CC       DPT. Interacts with ASPN (By similarity). May interact with THSD4;
CC       this interaction may lead to sequestration by FBN1 microfibril
CC       assembly and attenuation of TGFB signaling. Interacts with the
CC       serine proteases, HTRA1 and HTRA3: the interaction with either
CC       inhibits TGFB1-mediated signaling. The HTRA protease activity is
CC       required for this inhibition. Latency-associated peptide interacts
CC       with NREP; the interaction results in a decrease in TGFB1
CC       autoinduction. {ECO:0000250, ECO:0000269|PubMed:14973287,
CC       ECO:0000269|PubMed:14985127, ECO:0000269|PubMed:15206957,
CC       ECO:0000269|PubMed:21880733}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000250}.
CC   -!- DOMAIN: The 'straitjacket' and 'arm' domains encircle the growth
CC       factor monomers and are fastened together by strong bonding
CC       between Lys-56 and Tyr-103/Tyr-104. Activation of TGF-beta1
CC       requires the binding of integrin alpha-V to an RGD sequence in the
CC       prodomain and exertion of force on this domain, which is held in
CC       the extracellular matrix by latent TGF-beta binding proteins. The
CC       sheer physical force unfastens the straitjacket and releases the
CC       active growth factor dimer (By similarity). {ECO:0000250}.
CC   -!- PTM: Glycosylated. {ECO:0000250}.
CC   -!- PTM: The precursor is cleaved into mature TGF-beta-1 and LAP,
CC       which remains non-covalently linked to mature TGF-beta-1 rendering
CC       it inactive. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13177; AAA40423.1; -; mRNA.
DR   EMBL; L42462; AAB00138.1; -; Genomic_DNA.
DR   EMBL; L42456; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; L42457; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; L42458; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; L42459; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; L42460; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; L42461; AAB00138.1; JOINED; Genomic_DNA.
DR   EMBL; AJ009862; CAA08900.1; -; mRNA.
DR   EMBL; BC013738; AAH13738.1; -; mRNA.
DR   CCDS; CCDS20993.1; -.
DR   PIR; A01396; WFMS2.
DR   RefSeq; NP_035707.1; NM_011577.2.
DR   UniGene; Mm.248380; -.
DR   ProteinModelPortal; P04202; -.
DR   SMR; P04202; 30-390.
DR   BioGrid; 204157; 4.
DR   DIP; DIP-48640N; -.
DR   STRING; 10090.ENSMUSP00000002678; -.
DR   PhosphoSite; P04202; -.
DR   MaxQB; P04202; -.
DR   PaxDb; P04202; -.
DR   PRIDE; P04202; -.
DR   Ensembl; ENSMUST00000002678; ENSMUSP00000002678; ENSMUSG00000002603.
DR   GeneID; 21803; -.
DR   KEGG; mmu:21803; -.
DR   UCSC; uc009ftq.1; mouse.
DR   CTD; 7040; -.
DR   MGI; MGI:98725; Tgfb1.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   HOGENOM; HOG000290198; -.
DR   HOVERGEN; HBG074115; -.
DR   InParanoid; P04202; -.
DR   KO; K13375; -.
DR   OMA; SHSIYMF; -.
DR   OrthoDB; EOG70GMFT; -.
DR   PhylomeDB; P04202; -.
DR   TreeFam; TF318514; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-MMU-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-MMU-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-MMU-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-MMU-3000170; Syndecan interactions.
DR   Reactome; R-MMU-442533; Transcriptional Regulation of Adipocyte Differentiation in 3T3-L1 Pre-adipocytes.
DR   NextBio; 301176; -.
DR   PMAP-CutDB; P04202; -.
DR   PRO; PR:P04202; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   Bgee; P04202; -.
DR   CleanEx; MM_TGFB1; -.
DR   ExpressionAtlas; P04202; baseline and differential.
DR   Genevisible; P04202; MM.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; ISS:AgBase.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005902; C:microvillus; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IDA:MGI.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0003823; F:antigen binding; ISS:AgBase.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0001948; F:glycoprotein binding; ISS:AgBase.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IPI:MGI.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; ISS:UniProtKB.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; ISS:AgBase.
DR   GO; GO:0002460; P:adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains; IDA:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006754; P:ATP biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0060751; P:branch elongation involved in mammary gland duct branching; IMP:MGI.
DR   GO; GO:0002362; P:CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment; TAS:UniProtKB.
DR   GO; GO:0001775; P:cell activation; IDA:MGI.
DR   GO; GO:0007050; P:cell cycle arrest; ISS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; IEA:InterPro.
DR   GO; GO:0008283; P:cell proliferation; IDA:MGI.
DR   GO; GO:0045216; P:cell-cell junction organization; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IMP:MGI.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:MGI.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISS:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:MGI.
DR   GO; GO:0002062; P:chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0006952; P:defense response; TAS:MGI.
DR   GO; GO:0009817; P:defense response to fungus, incompatible interaction; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IDA:MGI.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0019049; P:evasion or tolerance of host defenses by virus; ISS:UniProtKB.
DR   GO; GO:0085029; P:extracellular matrix assembly; IDA:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0060325; P:face morphogenesis; IEP:UniProtKB.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060364; P:frontal suture morphogenesis; IEA:Ensembl.
DR   GO; GO:0008354; P:germ cell migration; IDA:MGI.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030214; P:hyaluronan catabolic process; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:AgBase.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0070306; P:lens fiber cell differentiation; IMP:MGI.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048535; P:lymph node development; IMP:MGI.
DR   GO; GO:0060744; P:mammary gland branching involved in thelarche; IMP:MGI.
DR   GO; GO:0030879; P:mammary gland development; IDA:MGI.
DR   GO; GO:0000165; P:MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; ISS:UniProtKB.
DR   GO; GO:0032943; P:mononuclear cell proliferation; IMP:MGI.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:MGI.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; ISS:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; ISS:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:MGI.
DR   GO; GO:0060965; P:negative regulation of gene silencing by miRNA; ISO:MGI.
DR   GO; GO:1900126; P:negative regulation of hyaluronan biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IDA:UniProtKB.
DR   GO; GO:0010936; P:negative regulation of macrophage cytokine production; ISS:AgBase.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0030279; P:negative regulation of ossification; IDA:MGI.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISO:MGI.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0051280; P:negative regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0048642; P:negative regulation of skeletal muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IMP:MGI.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IMP:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:MGI.
DR   GO; GO:0014003; P:oligodendrocyte development; IMP:CACAO.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:MGI.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0043932; P:ossification involved in bone remodeling; ISS:AgBase.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:AgBase.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; ISS:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:MGI.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IEA:Ensembl.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; ISS:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IDA:MGI.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IDA:MGI.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IDA:BHF-UCL.
DR   GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; ISS:AgBase.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:1901666; P:positive regulation of NAD+ ADP-ribosyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IDA:MGI.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; ISS:UniProtKB.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:AgBase.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IGI:MGI.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050714; P:positive regulation of protein secretion; ISS:UniProtKB.
DR   GO; GO:1903911; P:positive regulation of receptor clustering; IDA:UniProtKB.
DR   GO; GO:0045591; P:positive regulation of regulatory T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; ISS:AgBase.
DR   GO; GO:0051152; P:positive regulation of smooth muscle cell differentiation; ISO:MGI.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; ISO:MGI.
DR   GO; GO:0006611; P:protein export from nucleus; ISS:UniProtKB.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0032801; P:receptor catabolic process; ISS:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IGI:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0051098; P:regulation of binding; IDA:MGI.
DR   GO; GO:0060762; P:regulation of branching involved in mammary gland duct morphogenesis; IGI:MGI.
DR   GO; GO:0061035; P:regulation of cartilage development; IDA:MGI.
DR   GO; GO:0032829; P:regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0051101; P:regulation of DNA binding; IDA:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0032667; P:regulation of interleukin-23 production; IDA:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IDA:MGI.
DR   GO; GO:0045589; P:regulation of regulatory T cell differentiation; IGI:MGI.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IDA:MGI.
DR   GO; GO:0016202; P:regulation of striated muscle tissue development; IDA:MGI.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045066; P:regulatory T cell differentiation; IDA:MGI.
DR   GO; GO:0070723; P:response to cholesterol; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; ISS:UniProtKB.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0034616; P:response to laminar fluid shear stress; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; ISS:UniProtKB.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; ISS:AgBase.
DR   GO; GO:0007435; P:salivary gland morphogenesis; ISS:AgBase.
DR   GO; GO:0007519; P:skeletal muscle tissue development; TAS:MGI.
DR   GO; GO:0001501; P:skeletal system development; TAS:MGI.
DR   GO; GO:0007183; P:SMAD protein complex assembly; ISS:UniProtKB.
DR   GO; GO:0007184; P:SMAD protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0042110; P:T cell activation; IDA:MGI.
DR   GO; GO:0030217; P:T cell differentiation; IMP:MGI.
DR   GO; GO:0043029; P:T cell homeostasis; IMP:MGI.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; TAS:UniProtKB.
DR   GO; GO:0002513; P:tolerance induction to self antigen; IMP:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:MGI.
DR   GO; GO:0001657; P:ureteric bud development; IEP:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR016319; TGF-beta.
DR   InterPro; IPR003939; TGFb1.
DR   InterPro; IPR017948; TGFb_CS.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PIRSF; PIRSF001787; TGF-beta; 1.
DR   PRINTS; PR01423; TGFBETA.
DR   PRINTS; PR01424; TGFBETA1.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Cleavage on pair of basic residues; Complete proteome; Disulfide bond;
KW   Extracellular matrix; Glycoprotein; Growth factor; Mitogen;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     29       {ECO:0000250}.
FT   CHAIN        30    278       Latency-associated peptide.
FT                                /FTId=PRO_0000033766.
FT   CHAIN       279    390       Transforming growth factor beta-1.
FT                                /FTId=PRO_0000033767.
FT   REGION       30     74       Straightjacket domain. {ECO:0000250}.
FT   REGION       75    271       Arm domain. {ECO:0000250}.
FT   MOTIF       244    246       Cell attachment site. {ECO:0000255}.
FT   CARBOHYD     82     82       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    136    136       N-linked (GlcNAc...). {ECO:0000250}.
FT   CARBOHYD    176    176       N-linked (GlcNAc...). {ECO:0000250}.
FT   DISULFID     33     33       Interchain (with C-1350 or C-1375 in
FT                                LTBP1); in inactive form. {ECO:0000250}.
FT   DISULFID    223    223       Interchain (with C-225). {ECO:0000250}.
FT   DISULFID    225    225       Interchain (with C-223). {ECO:0000250}.
FT   DISULFID    285    294       {ECO:0000250}.
FT   DISULFID    293    356       {ECO:0000250}.
FT   DISULFID    322    387       {ECO:0000250}.
FT   DISULFID    326    389       {ECO:0000250}.
FT   DISULFID    355    355       Interchain. {ECO:0000250}.
SQ   SEQUENCE   390 AA;  44310 MW;  4381A51B711D689E CRC64;
     MPPSGLRLLP LLLPLPWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA
     SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESADPEPEPE ADYYAKEVTR VLMVDRNNAI
     YEKTKDISHS IYMFFNTSDI REAVPEPPLL SRAELRLQRL KSSVEQHVEL YQKYSNNSWR
     YLGNRLLTPT DTPEWLSFDV TGVVRQWLNQ GDGIQGFRFS AHCSCDSKDN KLHVEINGIS
     PKRRGDLGTI HDMNRPFLLL MATPLERAQH LHSSRHRRAL DTNYCFSSTE KNCCVRQLYI
     DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SASPCCVPQA
     LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS
//
ID   VEGFA_HUMAN             Reviewed;         232 AA.
AC   P15692; B5BU86; H0Y2S8; H0Y407; H0Y414; H0Y462; H0Y8N2; H3BLW7;
AC   O60720; O75875; Q074Z4; Q16889; Q5UB46; Q6P0P5; Q96KJ0; Q96L82;
AC   Q96NW5; Q9H1W8; Q9H1W9; Q9UH58; Q9UL23;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2001, sequence version 2.
DT   20-JAN-2016, entry version 207.
DE   RecName: Full=Vascular endothelial growth factor A;
DE            Short=VEGF-A;
DE   AltName: Full=Vascular permeability factor;
DE            Short=VPF;
DE   Flags: Precursor;
GN   Name=VEGFA; Synonyms=VEGF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS VEGF189 AND VEGF165).
RX   PubMed=2479986; DOI=10.1126/science.2479986;
RA   Leung D.W., Cachianes G., Kuang W.-J., Goeddel D.V., Ferrara N.;
RT   "Vascular endothelial growth factor is a secreted angiogenic
RT   mitogen.";
RL   Science 246:1306-1309(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF189), AND PARTIAL PROTEIN
RP   SEQUENCE.
RX   PubMed=2479987; DOI=10.1126/science.2479987;
RA   Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J.,
RA   Connolly D.T.;
RT   "Vascular permeability factor, an endothelial cell mitogen related to
RT   PDGF.";
RL   Science 246:1309-1312(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM VEGF189).
RX   PubMed=1711045;
RA   Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D.,
RA   Fiddes J.C., Abraham J.A.;
RT   "The human gene for vascular endothelial growth factor. Multiple
RT   protein forms are encoded through alternative exon splicing.";
RL   J. Biol. Chem. 266:11947-11954(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM VEGF206).
RX   PubMed=1791831; DOI=10.1210/mend-5-12-1806;
RA   Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W.;
RT   "The vascular endothelial growth factor family: identification of a
RT   fourth molecular species and characterization of alternative splicing
RT   of RNA.";
RL   Mol. Endocrinol. 5:1806-1814(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165).
RX   PubMed=1567395; DOI=10.1016/S0006-291X(05)80313-4;
RA   Weindel K., Marme D., Weich H.A.;
RT   "AIDS-associated Kaposi's sarcoma cells in culture express vascular
RT   endothelial growth factor.";
RL   Biochem. Biophys. Res. Commun. 183:1167-1174(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF145).
RX   PubMed=9054410; DOI=10.1074/jbc.272.11.7151;
RA   Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I.,
RA   Keshet E., Neufeld G.;
RT   "VEGF145, a secreted vascular endothelial growth factor isoform that
RT   binds to extracellular matrix.";
RL   J. Biol. Chem. 272:7151-7158(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF183).
RC   TISSUE=Kidney;
RX   PubMed=9878851; DOI=10.1016/S0167-4781(98)00240-1;
RA   Lei J., Jiang A., Pei D.;
RT   "Identification and characterization of a new splicing variant of
RT   vascular endothelial growth factor: VEGF183.";
RL   Biochim. Biophys. Acta 1443:400-406(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-VEGF165).
RC   TISSUE=Mammary gland;
RX   PubMed=9450968; DOI=10.1091/mbc.9.2.469;
RA   Claffey K.P., Shih S.-C., Mullen A., Dziennis S., Cusick J.L.,
RA   Abrams K.R., Lee S.W., Detmar M.;
RT   "Identification of a human VPF/VEGF 3' untranslated region mediating
RT   hypoxia-induced mRNA stability.";
RL   Mol. Biol. Cell 9:469-481(1998).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF148).
RC   TISSUE=Renal glomerulus;
RX   PubMed=10464055; DOI=10.1042/CS19990016;
RA   Whittle C.J., Gillespie K.M., Harrison R., Mathieson P.W.,
RA   Harper S.J.;
RT   "Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA
RT   and receptor mRNA expression in human glomeruli, and the
RT   identification of VEGF148 mRNA, a novel truncated splice variant.";
RL   Clin. Sci. 97:303-312(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165B).
RC   TISSUE=Kidney;
RX   PubMed=12124351;
RA   Bates D.O., Cui T.-G., Doughty J.M., Winkler M., Sugiono M.,
RA   Shields J.D., Peat D., Gillatt D., Harper S.J.;
RT   "VEGF165b, an inhibitory splice variant of vascular endothelial growth
RT   factor, is down-regulated in renal cell carcinoma.";
RL   Cancer Res. 62:4123-4131(2002).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165).
RC   TISSUE=Hemangioendothelioma;
RA   Murata H., Fukushima J., Hattori S., Okuda K., Yanagi H.;
RT   "Human cDNA for the vascular endothelial growth factor isoform
RT   VEGF165.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF121).
RA   Sato J.D., Whitney R.G.;
RT   "Human cDNA for vascular endothelial growth factor isoform VEGF121.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165).
RA   Liu J., Peng X., Yuan J., Qiang B.;
RT   "Cloning of vascular endothelial growth factor (VEGF) cDNA.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165).
RC   TISSUE=Heart;
RA   Shan Z.X., Yu X.Y., Lin Q.X., Fu Y.H., Zheng M., Tan H.H., Lin S.G.;
RT   "Cloning and identification of vascular endothelial growth factor
RT   isoform VEGF165.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165).
RA   Koul S., Johnson T., Meacham R.B., Koul H.K.;
RT   "Cloning and characterization of VEGF from LNCaP cells, a line of
RT   prostate cancer cells.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF111).
RA   Mineur P.J., Colige A.C., Lambert C.A.;
RT   "VEGF111, a new VEGF-A variant lacking exons 5, 6 and 7.";
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM VEGF165).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM L-VEGF121).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 23-232.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   PROTEIN SEQUENCE OF 27-41.
RX   PubMed=7678805; DOI=10.1111/j.1432-1033.1993.tb19865.x;
RA   Fiebich B.L., Jaeger B., Schoellmann C., Weindel K., Wilting J.,
RA   Kochs G., Marme D., Hug H., Weich H.A.;
RT   "Synthesis and assembly of functionally active human vascular
RT   endothelial growth factor homodimers in insect cells.";
RL   Eur. J. Biochem. 211:19-26(1993).
RN   [23]
RP   PROTEIN SEQUENCE OF 27-41.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [24]
RP   PRELIMINARY PROTEIN SEQUENCE OF 27-36; 43-50 AND 59-81.
RX   PubMed=2584205;
RA   Connolly D.T., Olander J.V., Heuvelman D., Nelson R., Monsell R.,
RA   Siegel N., Haymore B.L., Leimgruber R., Feder J.;
RT   "Human vascular permeability factor. Isolation from U937 cells.";
RL   J. Biol. Chem. 264:20017-20024(1989).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 114-209 (ISOFORM VEGF183).
RC   TISSUE=Retina;
RX   PubMed=10067980;
RA   Jingjing L., Xue Y., Agarwal N., Roque R.S.;
RT   "Human Muller cells express VEGF183, a novel spliced variant of
RT   vascular endothelial growth factor.";
RL   Invest. Ophthalmol. Vis. Sci. 40:752-759(1999).
RN   [26]
RP   ALTERNATIVE SPLICING (ISOFORMS L-VEGF121 AND L-VEGF165), PROCESSING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=11563986; DOI=10.1042/0264-6021:3590219;
RA   Tee M.K., Jaffe R.B.;
RT   "A precursor form of vascular endothelial growth factor arises by
RT   initiation from an upstream in-frame CUG codon.";
RL   Biochem. J. 359:219-226(2001).
RN   [27]
RP   FUNCTION.
RX   PubMed=11427521;
RA   Murphy J.F., Fitzgerald D.J.;
RT   "Vascular endothelial growth factor induces cyclooxygenase-dependent
RT   proliferation of endothelial cells via the VEGF-2 receptor.";
RL   FASEB J. 15:1667-1669(2001).
RN   [28]
RP   ALTERNATIVE SPLICING (ISOFORM L-VEGF189), PROCESSING, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11731620; DOI=10.1210/me.15.12.2197;
RA   Huez I., Bornes S., Bresson D., Creancier L., Prats H.;
RT   "New vascular endothelial growth factor isoform generated by internal
RT   ribosome entry site-driven CUG translation initiation.";
RL   Mol. Endocrinol. 15:2197-2210(2001).
RN   [29]
RP   INVOLVEMENT IN MVCD1.
RX   PubMed=11978667; DOI=10.2337/diabetes.51.5.1635;
RA   Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K.,
RA   Inoue I., Katayama S.;
RT   "A common polymorphism in the 5'-untranslated region of the VEGF gene
RT   is associated with diabetic retinopathy in type 2 diabetes.";
RL   Diabetes 51:1635-1639(2002).
RN   [30]
RP   FUNCTION (ISOFORM VEGF165B).
RX   PubMed=15520188; DOI=10.1158/0008-5472.CAN-04-0934;
RA   Woolard J., Wang W.-Y., Bevan H.S., Qiu Y., Morbidelli L.,
RA   Pritchard-Jones R.O., Cui T.-G., Sugiono M., Waine E., Perrin R.,
RA   Foster R., Digby-Bell J., Shields J.D., Whittles C.E., Mushens R.E.,
RA   Gillatt D.A., Ziche M., Harper S.J., Bates D.O.;
RT   "VEGF165b, an inhibitory vascular endothelial growth factor splice
RT   variant: mechanism of action, in vivo effect on angiogenesis and
RT   endogenous protein expression.";
RL   Cancer Res. 64:7822-7835(2004).
RN   [31]
RP   ALTERNATIVE SPLICING (ISOFORMS L-VEGF121; L-VEGF165 AND L-VEGF189).
RX   PubMed=14764596; DOI=10.1074/jbc.M308410200;
RA   Bornes S., Boulard M., Hieblot C., Zanibellato C., Iacovoni J.S.,
RA   Prats H., Touriol C.;
RT   "Control of the vascular endothelial growth factor internal ribosome
RT   entry site (IRES) activity and translation initiation by alternatively
RT   spliced coding sequences.";
RL   J. Biol. Chem. 279:18717-18726(2004).
RN   [32]
RP   ALTERNATIVE SPLICING (ISOFORMS L-VEGF121 AND L-VEGF165), PROCESSING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15896327; DOI=10.1016/j.bbrc.2005.04.123;
RA   Rosenbaum-Dekel Y., Fuchs A., Yakirevich E., Azriel A., Mazareb S.,
RA   Resnick M.B., Levi B.Z.;
RT   "Nuclear localization of long-VEGF is associated with hypoxia and
RT   tumor angiogenesis.";
RL   Biochem. Biophys. Res. Commun. 332:271-278(2005).
RN   [33]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=16489009; DOI=10.1158/0008-5472.CAN-05-2217;
RA   Dixelius J., Olsson A.K., Thulin A., Lee C., Johansson I.,
RA   Claesson-Welsh L.;
RT   "Minimal active domain and mechanism of action of the angiogenesis
RT   inhibitor histidine-rich glycoprotein.";
RL   Cancer Res. 66:2089-2097(2006).
RN   [34]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=22009797; DOI=10.1530/ERC-11-0211;
RA   Shan B., Gerez J., Haedo M., Fuertes M., Theodoropoulou M.,
RA   Buchfelder M., Losa M., Stalla G.K., Arzt E., Renner U.;
RT   "RSUME is implicated in HIF-1-induced VEGF-A production in pituitary
RT   tumour cells.";
RL   Endocr. Relat. Cancer 19:13-27(2012).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 34-135.
RX   PubMed=9207067; DOI=10.1073/pnas.94.14.7192;
RA   Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C.,
RA   de Vos A.M.;
RT   "Vascular endothelial growth factor: crystal structure and functional
RT   mapping of the kinase domain receptor binding site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7192-7197(1997).
RN   [36]
RP   STRUCTURE BY NMR OF 34-135.
RX   PubMed=9336848; DOI=10.1002/pro.5560061020;
RA   Fairbrother W.J., Champe M.A., Christinger H.W., Keyt B.A.,
RA   Starovasnik M.A.;
RT   "1H, 13C, and 15N backbone assignment and secondary structure of the
RT   receptor-binding domain of vascular endothelial growth factor.";
RL   Protein Sci. 6:2250-2260(1997).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 34-135.
RX   PubMed=9351807; DOI=10.1016/S0969-2126(97)00284-0;
RA   Muller Y.A., Christinger H.W., Keyt B.A., de Vos A.M.;
RT   "The crystal structure of vascular endothelial growth factor (VEGF)
RT   refined to 1.93-A resolution: multiple copy flexibility and receptor
RT   binding.";
RL   Structure 5:1325-1338(1997).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 39-134.
RX   PubMed=9922142; DOI=10.1021/bi9819327;
RA   Wiesmann C., Christinger H.W., Cochran A.G., Cunningham B.C.,
RA   Fairbrother W.J., Keenan C.J., Meng G., de Vos A.M.;
RT   "Crystal structure of the complex between VEGF and a receptor-blocking
RT   peptide.";
RL   Biochemistry 37:17765-17772(1998).
RN   [39]
RP   STRUCTURE BY NMR OF 137-215.
RX   PubMed=9634701; DOI=10.1016/S0969-2126(98)00065-3;
RA   Fairbrother W.J., Champe M.A., Christinger H.W., Keyt B.A.,
RA   Starovasnik M.A.;
RT   "Solution structure of the heparin-binding domain of vascular
RT   endothelial growth factor.";
RL   Structure 6:637-648(1998).
CC   -!- FUNCTION: Growth factor active in angiogenesis, vasculogenesis and
CC       endothelial cell growth. Induces endothelial cell proliferation,
CC       promotes cell migration, inhibits apoptosis and induces
CC       permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and
CC       KDR/VEGFR2 receptors, heparan sulfate and heparin.
CC       NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform
CC       VEGF165B binds to KDR but does not activate downstream signaling
CC       pathways, does not activate angiogenesis and inhibits tumor
CC       growth. {ECO:0000269|PubMed:11427521,
CC       ECO:0000269|PubMed:16489009}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Also found as heterodimer
CC       with PGF (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=10; IntAct=EBI-1026643, EBI-1026643;
CC       P17948:FLT1; NbExp=4; IntAct=EBI-1026643, EBI-1026718;
CC       P35968:KDR; NbExp=6; IntAct=EBI-1026691, EBI-1005487;
CC       O14786:NRP1; NbExp=4; IntAct=EBI-1026643, EBI-1187100;
CC       O14786-2:NRP1; NbExp=4; IntAct=EBI-1026691, EBI-6285281;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11563986,
CC       ECO:0000269|PubMed:11731620, ECO:0000269|PubMed:15896327}.
CC       Note=VEGF121 is acidic and freely secreted. VEGF165 is more basic,
CC       has heparin-binding properties and, although a signicant
CC       proportion remains cell-associated, most is freely secreted.
CC       VEGF189 is very basic, it is cell-associated after secretion and
CC       is bound avidly by heparin and the extracellular matrix, although
CC       it may be released as a soluble form by heparin, heparinase or
CC       plasmin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing, Alternative initiation; Named isoforms=17;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=VEGF206;
CC         IsoId=P15692-1; Sequence=Displayed;
CC       Name=VEGF189;
CC         IsoId=P15692-2; Sequence=VSP_004622;
CC       Name=VEGF183;
CC         IsoId=P15692-3; Sequence=VSP_004621;
CC       Name=VEGF165; Synonyms=VEGF;
CC         IsoId=P15692-4; Sequence=VSP_004618, VSP_004619;
CC       Name=VEGF148;
CC         IsoId=P15692-5; Sequence=VSP_004618, VSP_004619, VSP_004624,
CC                                  VSP_004625;
CC       Name=VEGF145;
CC         IsoId=P15692-6; Sequence=VSP_004623;
CC       Name=VEGF165B;
CC         IsoId=P15692-8; Sequence=VSP_004618, VSP_004619, VSP_014783;
CC       Name=VEGF121;
CC         IsoId=P15692-9; Sequence=VSP_004620;
CC         Note=No experimental confirmation available.;
CC       Name=VEGF111;
CC         IsoId=P15692-10; Sequence=VSP_026781;
CC         Note=No experimental confirmation available.;
CC       Name=L-VEGF165;
CC         IsoId=P15692-11; Sequence=VSP_038745, VSP_004618, VSP_004619;
CC         Note=Produced by alternative promoter usage and alternative
CC         initiation. Starts at an alternative upstream CUG codon.
CC         Post-translationally processed to produce the secreted VEGF
CC         peptide and a N-terminal peptide N-VEGF. The unprocessed protein
CC         and the N-VEGF peptide may localize to the nucleus (Ref.32), the
CC         endoplasmic reticulum and the Golgi (Ref.28) or the
CC         extracellular matrix (Ref.26). {ECO:0000305|PubMed:11563986,
CC         ECO:0000305|PubMed:11731620, ECO:0000305|PubMed:15896327};
CC       Name=L-VEGF121;
CC         IsoId=P15692-12; Sequence=VSP_038745, VSP_004620;
CC         Note=Produced by alternative promoter usage and alternative
CC         initiation. Starts at an alternative upstream CUG codon.
CC         Post-translationally processed to produce the secreted VEGF
CC         peptide and a N-terminal peptide N-VEGF. The unprocessed protein
CC         and the N-VEGF peptide may localize to the nucleus (Ref.32), the
CC         endoplasmic reticulum and the Golgi (Ref.28) or the
CC         extracellular matrix (Ref.26). {ECO:0000305|PubMed:11563986,
CC         ECO:0000305|PubMed:11731620, ECO:0000305|PubMed:15896327};
CC       Name=L-VEGF189;
CC         IsoId=P15692-13; Sequence=VSP_038745, VSP_004622;
CC         Note=Produced by alternative promoter usage and alternative
CC         initiation. Starts at an alternative upstream CUG codon.
CC         Post-translationally processed to produce the secreted VEGF
CC         peptide and a N-terminal peptide N-VEGF. The unprocessed protein
CC         and the N-VEGF peptide may localize to the nucleus (Ref.32), the
CC         endoplasmic reticulum and the Golgi (Ref.28) or the
CC         extracellular matrix (Ref.26). {ECO:0000305|PubMed:11563986,
CC         ECO:0000305|PubMed:11731620, ECO:0000305|PubMed:15896327};
CC       Name=L-VEGF206;
CC         IsoId=P15692-14; Sequence=VSP_038745;
CC         Note=Gene prediction based on EST data. Produced by alternative
CC         promoter usage and alternative initiation. Starts at an
CC         alternative upstream CUG codon.;
CC       Name=15;
CC         IsoId=P15692-15; Sequence=VSP_038745, VSP_054111, VSP_014783;
CC         Note=Starts at an alternative upstream CUG codon.;
CC       Name=16;
CC         IsoId=P15692-16; Sequence=VSP_038745, VSP_004621;
CC         Note=Starts at an alternative upstream CUG codon.;
CC       Name=17;
CC         IsoId=P15692-17; Sequence=VSP_038745, VSP_054111, VSP_004624,
CC                                   VSP_004625;
CC         Note=Starts at an alternative upstream CUG codon.;
CC       Name=18;
CC         IsoId=P15692-18; Sequence=VSP_038745, VSP_026781;
CC         Note=Starts at an alternative upstream CUG codon.;
CC   -!- TISSUE SPECIFICITY: Isoform VEGF189, isoform VEGF165 and isoform
CC       VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145
CC       are not widely expressed. A higher level expression seen in
CC       pituitary tumors as compared to the pituitary gland.
CC       {ECO:0000269|PubMed:22009797}.
CC   -!- INDUCTION: By hypoxia. Regulated by growth factors, cytokines,
CC       gonadotropins, nitric oxide, hypoglycemia and oncogenic mutations.
CC       {ECO:0000269|PubMed:22009797}.
CC   -!- DISEASE: Microvascular complications of diabetes 1 (MVCD1)
CC       [MIM:603933]: Pathological conditions that develop in numerous
CC       tissues and organs as a consequence of diabetes mellitus. They
CC       include diabetic retinopathy, diabetic nephropathy leading to end-
CC       stage renal disease, and diabetic neuropathy. Diabetic retinopathy
CC       remains the major cause of new-onset blindness among diabetic
CC       adults. It is characterized by vascular permeability and increased
CC       tissue ischemia and angiogenesis. {ECO:0000269|PubMed:11978667}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC63102.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAC63143.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAC19512.2; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAC19516.2; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine mini-reviews: VEGF;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=2247";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=VEGF entry;
CC       URL="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/vegf/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32977; AAA35789.1; -; mRNA.
DR   EMBL; M27281; AAA36807.1; -; mRNA.
DR   EMBL; M63978; AAA36804.1; -; Genomic_DNA.
DR   EMBL; M63971; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63972; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63973; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63974; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63975; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63976; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; M63977; AAA36804.1; JOINED; Genomic_DNA.
DR   EMBL; S85192; AAC63102.1; ALT_INIT; mRNA.
DR   EMBL; AH006909; AAC63101.1; -; Genomic_DNA.
DR   EMBL; X62568; CAA44447.1; -; mRNA.
DR   EMBL; AJ010438; CAA09179.1; -; mRNA.
DR   EMBL; AF022375; AAC63143.1; ALT_SEQ; mRNA.
DR   EMBL; AF091352; AAD55345.1; -; mRNA.
DR   EMBL; AF430806; AAL27435.1; -; mRNA.
DR   EMBL; AB021221; BAA78418.1; -; mRNA.
DR   EMBL; AF214570; AAF19659.1; -; mRNA.
DR   EMBL; AY047581; AAK95847.1; -; mRNA.
DR   EMBL; AF486837; AAM03108.1; -; mRNA.
DR   EMBL; AY766116; AAV34601.1; -; mRNA.
DR   EMBL; DQ229900; ABB58912.1; -; mRNA.
DR   EMBL; AB451322; BAG70136.1; -; mRNA.
DR   EMBL; AB451451; BAG70265.1; -; mRNA.
DR   EMBL; AL136131; CAC19512.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL136131; CAC19513.2; -; Genomic_DNA.
DR   EMBL; AL136131; CAC19515.2; -; Genomic_DNA.
DR   EMBL; AL136131; CAC19516.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471081; EAX04229.1; -; Genomic_DNA.
DR   EMBL; BC065522; AAH65522.2; -; mRNA.
DR   EMBL; AF437895; AAL27630.1; -; Genomic_DNA.
DR   EMBL; AF062645; AAC16730.1; -; mRNA.
DR   CCDS; CCDS34457.1; -. [P15692-14]
DR   CCDS; CCDS34458.1; -. [P15692-11]
DR   CCDS; CCDS47432.1; -. [P15692-15]
DR   CCDS; CCDS47433.1; -. [P15692-16]
DR   CCDS; CCDS47434.1; -. [P15692-12]
DR   CCDS; CCDS47435.1; -. [P15692-17]
DR   CCDS; CCDS4907.2; -. [P15692-13]
DR   CCDS; CCDS55007.1; -. [P15692-18]
DR   CCDS; CCDS55008.1; -. [P15692-3]
DR   CCDS; CCDS55009.1; -. [P15692-2]
DR   CCDS; CCDS55010.1; -. [P15692-1]
DR   CCDS; CCDS55011.1; -. [P15692-5]
DR   CCDS; CCDS55012.1; -. [P15692-4]
DR   CCDS; CCDS55013.1; -. [P15692-8]
DR   CCDS; CCDS55014.1; -. [P15692-9]
DR   CCDS; CCDS55015.1; -. [P15692-10]
DR   PIR; A41551; A41551.
DR   RefSeq; NP_001020537.2; NM_001025366.2. [P15692-14]
DR   RefSeq; NP_001020538.2; NM_001025367.2. [P15692-16]
DR   RefSeq; NP_001020539.2; NM_001025368.2. [P15692-11]
DR   RefSeq; NP_001020540.2; NM_001025369.2. [P15692-17]
DR   RefSeq; NP_001020541.2; NM_001025370.2. [P15692-12]
DR   RefSeq; NP_001028928.1; NM_001033756.2. [P15692-15]
DR   RefSeq; NP_001165093.1; NM_001171622.1. [P15692-18]
DR   RefSeq; NP_001165094.1; NM_001171623.1. [P15692-1]
DR   RefSeq; NP_001165095.1; NM_001171624.1. [P15692-2]
DR   RefSeq; NP_001165096.1; NM_001171625.1. [P15692-3]
DR   RefSeq; NP_001165097.1; NM_001171626.1. [P15692-4]
DR   RefSeq; NP_001165098.1; NM_001171627.1. [P15692-5]
DR   RefSeq; NP_001165099.1; NM_001171628.1. [P15692-9]
DR   RefSeq; NP_001165100.1; NM_001171629.1. [P15692-8]
DR   RefSeq; NP_001165101.1; NM_001171630.1. [P15692-10]
DR   RefSeq; NP_001191313.1; NM_001204384.1. [P15692-6]
DR   RefSeq; NP_001191314.1; NM_001204385.1.
DR   RefSeq; NP_001273973.1; NM_001287044.1.
DR   RefSeq; NP_003367.4; NM_003376.5. [P15692-13]
DR   UniGene; Hs.73793; -.
DR   PDB; 1BJ1; X-ray; 2.40 A; V/W=34-135.
DR   PDB; 1CZ8; X-ray; 2.40 A; V/W=40-133.
DR   PDB; 1FLT; X-ray; 1.70 A; V/W=38-135.
DR   PDB; 1KAT; NMR; -; V/W=37-135.
DR   PDB; 1KMX; NMR; -; A=183-232.
DR   PDB; 1MJV; X-ray; 2.10 A; A/B=40-134.
DR   PDB; 1MKG; X-ray; 2.50 A; A/B/C/D=40-134.
DR   PDB; 1MKK; X-ray; 1.32 A; A/B=40-134.
DR   PDB; 1QTY; X-ray; 2.70 A; R/S/V/W=34-135.
DR   PDB; 1TZH; X-ray; 2.60 A; V/W=34-135.
DR   PDB; 1TZI; X-ray; 2.80 A; V=34-135.
DR   PDB; 1VGH; NMR; -; A=180-232.
DR   PDB; 1VPF; X-ray; 2.50 A; A/B/C/D=34-135.
DR   PDB; 1VPP; X-ray; 1.90 A; V/W=34-135.
DR   PDB; 2FJG; X-ray; 2.80 A; V/W=34-135.
DR   PDB; 2FJH; X-ray; 3.10 A; V/W=34-135.
DR   PDB; 2QR0; X-ray; 3.50 A; C/D/I/J/O/P/U/V=39-135.
DR   PDB; 2VGH; NMR; -; A=182-232.
DR   PDB; 2VPF; X-ray; 1.93 A; A/B/C/D/E/F/G/H=34-135.
DR   PDB; 3BDY; X-ray; 2.60 A; V=34-135.
DR   PDB; 3P9W; X-ray; 2.41 A; A/C/E/G=35-138.
DR   PDB; 3QTK; X-ray; 1.85 A; A/B/C/D/E/F=34-135.
DR   PDB; 3S1B; X-ray; 2.90 A; V=38-133.
DR   PDB; 3S1K; X-ray; 2.55 A; V/W=34-135.
DR   PDB; 3V2A; X-ray; 3.20 A; A=27-140.
DR   PDB; 4DEQ; X-ray; 2.65 A; A/B=183-232.
DR   PDB; 4GLN; X-ray; 1.60 A; E/F=34-135.
DR   PDB; 4GLS; X-ray; 1.60 A; E/F=34-135.
DR   PDB; 4KZN; X-ray; 1.71 A; A=39-135.
DR   PDB; 4QAF; X-ray; 1.80 A; C/D=34-135.
DR   PDB; 4WPB; X-ray; 3.11 A; A/B=34-135.
DR   PDB; 4ZFF; X-ray; 2.75 A; C/D=37-135.
DR   PDBsum; 1BJ1; -.
DR   PDBsum; 1CZ8; -.
DR   PDBsum; 1FLT; -.
DR   PDBsum; 1KAT; -.
DR   PDBsum; 1KMX; -.
DR   PDBsum; 1MJV; -.
DR   PDBsum; 1MKG; -.
DR   PDBsum; 1MKK; -.
DR   PDBsum; 1QTY; -.
DR   PDBsum; 1TZH; -.
DR   PDBsum; 1TZI; -.
DR   PDBsum; 1VGH; -.
DR   PDBsum; 1VPF; -.
DR   PDBsum; 1VPP; -.
DR   PDBsum; 2FJG; -.
DR   PDBsum; 2FJH; -.
DR   PDBsum; 2QR0; -.
DR   PDBsum; 2VGH; -.
DR   PDBsum; 2VPF; -.
DR   PDBsum; 3BDY; -.
DR   PDBsum; 3P9W; -.
DR   PDBsum; 3QTK; -.
DR   PDBsum; 3S1B; -.
DR   PDBsum; 3S1K; -.
DR   PDBsum; 3V2A; -.
DR   PDBsum; 4DEQ; -.
DR   PDBsum; 4GLN; -.
DR   PDBsum; 4GLS; -.
DR   PDBsum; 4KZN; -.
DR   PDBsum; 4QAF; -.
DR   PDBsum; 4WPB; -.
DR   PDBsum; 4ZFF; -.
DR   ProteinModelPortal; P15692; -.
DR   SMR; P15692; 39-133, 183-232.
DR   BioGrid; 113265; 28.
DR   DIP; DIP-5740N; -.
DR   IntAct; P15692; 16.
DR   MINT; MINT-2834049; -.
DR   STRING; 9606.ENSP00000361125; -.
DR   BindingDB; P15692; -.
DR   ChEMBL; CHEMBL1783; -.
DR   DrugBank; DB08885; Aflibercept.
DR   DrugBank; DB00112; Bevacizumab.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB06779; Dalteparin.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB01270; Ranibizumab.
DR   DrugBank; DB03754; Tris.
DR   DrugBank; DB05294; Vandetanib.
DR   GuidetoPHARMACOLOGY; 2644; -.
DR   PhosphoSite; P15692; -.
DR   BioMuta; VEGFA; -.
DR   DMDM; 17380528; -.
DR   PaxDb; P15692; -.
DR   PRIDE; P15692; -.
DR   DNASU; 7422; -.
DR   Ensembl; ENST00000372077; ENSP00000361148; ENSG00000112715. [P15692-9]
DR   Ensembl; ENST00000457104; ENSP00000409911; ENSG00000112715. [P15692-10]
DR   Ensembl; ENST00000518689; ENSP00000430829; ENSG00000112715. [P15692-3]
DR   Ensembl; ENST00000518824; ENSP00000430002; ENSG00000112715. [P15692-8]
DR   Ensembl; ENST00000520948; ENSP00000428321; ENSG00000112715. [P15692-2]
DR   Ensembl; ENST00000523125; ENSP00000429008; ENSG00000112715. [P15692-5]
DR   Ensembl; ENST00000523873; ENSP00000430479; ENSG00000112715. [P15692-1]
DR   Ensembl; ENST00000523950; ENSP00000429643; ENSG00000112715. [P15692-4]
DR   GeneID; 7422; -.
DR   KEGG; hsa:7422; -.
DR   UCSC; uc003owd.3; human. [P15692-5]
DR   UCSC; uc003owe.3; human. [P15692-4]
DR   UCSC; uc003owf.3; human. [P15692-13]
DR   UCSC; uc003owg.3; human. [P15692-3]
DR   UCSC; uc003owh.3; human. [P15692-1]
DR   UCSC; uc003owi.3; human. [P15692-8]
DR   UCSC; uc003owj.3; human. [P15692-9]
DR   UCSC; uc010jyx.3; human. [P15692-10]
DR   CTD; 7422; -.
DR   GeneCards; VEGFA; -.
DR   HGNC; HGNC:12680; VEGFA.
DR   HPA; CAB005429; -.
DR   MalaCards; VEGFA; -.
DR   MIM; 192240; gene.
DR   MIM; 603933; phenotype.
DR   neXtProt; NX_P15692; -.
DR   PharmGKB; PA37302; -.
DR   eggNOG; ENOG410IGCM; Eukaryota.
DR   eggNOG; ENOG410ZWYU; LUCA.
DR   GeneTree; ENSGT00730000110791; -.
DR   HOVERGEN; HBG000105; -.
DR   InParanoid; P15692; -.
DR   KO; K05448; -.
DR   PhylomeDB; P15692; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-194313; VEGF ligand-receptor interactions.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   ChiTaRS; VEGFA; human.
DR   EvolutionaryTrace; P15692; -.
DR   GeneWiki; Vascular_endothelial_growth_factor_A; -.
DR   GenomeRNAi; 7422; -.
DR   NextBio; 29060; -.
DR   PRO; PR:P15692; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; P15692; -.
DR   ExpressionAtlas; P15692; baseline and differential.
DR   Genevisible; P15692; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:InterPro.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; NAS:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:UniProtKB.
DR   GO; GO:0042056; F:chemoattractant activity; IDA:UniProtKB.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0050840; F:extracellular matrix binding; IC:BHF-UCL.
DR   GO; GO:0001968; F:fibronectin binding; IDA:BHF-UCL.
DR   GO; GO:0008083; F:growth factor activity; IDA:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0038191; F:neuropilin binding; IPI:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0048018; F:receptor agonist activity; IPI:BHF-UCL.
DR   GO; GO:0043183; F:vascular endothelial growth factor receptor 1 binding; IPI:BHF-UCL.
DR   GO; GO:0043184; F:vascular endothelial growth factor receptor 2 binding; IPI:BHF-UCL.
DR   GO; GO:0005172; F:vascular endothelial growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0002575; P:basophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:BHF-UCL.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048739; P:cardiac muscle fiber development; ISS:BHF-UCL.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; ISS:BHF-UCL.
DR   GO; GO:0048469; P:cell maturation; ISS:BHF-UCL.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:MGI.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:BHF-UCL.
DR   GO; GO:0071679; P:commissural neuron axon guidance; ISS:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003169; P:coronary vein morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0071542; P:dopaminergic neuron differentiation; ISS:BHF-UCL.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0042462; P:eye photoreceptor cell development; ISS:BHF-UCL.
DR   GO; GO:0040007; P:growth; ISS:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:BHF-UCL.
DR   GO; GO:0050930; P:induction of positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0007595; P:lactation; ISS:BHF-UCL.
DR   GO; GO:0030324; P:lung development; ISS:BHF-UCL.
DR   GO; GO:0036303; P:lymph vessel morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030225; P:macrophage differentiation; IDA:DFLAT.
DR   GO; GO:0060749; P:mammary gland alveolus development; ISS:BHF-UCL.
DR   GO; GO:0007498; P:mesoderm development; ISS:BHF-UCL.
DR   GO; GO:0030224; P:monocyte differentiation; IDA:DFLAT.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001541; P:ovarian follicle development; ISS:BHF-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; ISS:BHF-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; IDA:BHF-UCL.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:1901727; P:positive regulation of histone deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; TAS:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0060754; P:positive regulation of mast cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:BHF-UCL.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0090037; P:positive regulation of protein kinase C signaling; IDA:BHF-UCL.
DR   GO; GO:1903572; P:positive regulation of protein kinase D signaling; IDA:BHF-UCL.
DR   GO; GO:1902966; P:positive regulation of protein localization to early endosome; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:BHF-UCL.
DR   GO; GO:1902336; P:positive regulation of retinal ganglion cell axon guidance; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IDA:UniProtKB.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; ISS:BHF-UCL.
DR   GO; GO:0060319; P:primitive erythrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   GO; GO:0030823; P:regulation of cGMP metabolic process; IDA:MGI.
DR   GO; GO:0090259; P:regulation of retinal ganglion cell axon guidance; ISS:BHF-UCL.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0001666; P:response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0043129; P:surfactant homeostasis; ISS:BHF-UCL.
DR   GO; GO:0035148; P:tube formation; IDA:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; TAS:UniProtKB.
DR   GO; GO:0038190; P:VEGF-activated neuropilin signaling pathway; ISS:BHF-UCL.
DR   Gene3D; 2.10.160.10; -; 1.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR023581; PD_growth_factor_CS.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR027928; VEGF_C.
DR   Pfam; PF00341; PDGF; 1.
DR   Pfam; PF14554; VEGF_C; 1.
DR   SMART; SM00141; PDGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   SUPFAM; SSF57593; SSF57593; 1.
DR   PROSITE; PS00249; PDGF_1; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative promoter usage;
KW   Alternative splicing; Angiogenesis; Complete proteome;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Growth factor; Heparin-binding; Mitogen;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:15340161,
FT                                ECO:0000269|PubMed:7678805}.
FT   CHAIN        27    232       Vascular endothelial growth factor A.
FT                                /FTId=PRO_0000023386.
FT   CARBOHYD    101    101       N-linked (GlcNAc...).
FT   DISULFID     52     94
FT   DISULFID     77     77       Interchain.
FT   DISULFID     83    128
FT   DISULFID     86     86       Interchain.
FT   DISULFID     87    130
FT   VAR_SEQ       1      1       M -> MTDRQTDTAPSPSYHLLPGRRRTVDAAASRGQGPEP
FT                                APGGGVEGVGARGVALKLFVQLLGCSRFGGAVVRAGEAEPS
FT                                GAARSASSGREEPQPEEGEEEEEKEEERGPQWRLGARKPGS
FT                                WTGEAAVCADSAPAARAPQALARASGRGGRVARRGAEESGP
FT                                PHSPSRRGSASRAGPGRASETM (in isoform L-
FT                                VEGF165, isoform L-VEGF121, isoform L-
FT                                VEGF189, isoform L-VEGF206, isoform 15,
FT                                isoform 16, isoform 17 and isoform 18).
FT                                {ECO:0000303|PubMed:9450968}.
FT                                /FTId=VSP_038745.
FT   VAR_SEQ     132    226       Missing (in isoform VEGF111 and isoform
FT                                18). {ECO:0000303|Ref.16}.
FT                                /FTId=VSP_026781.
FT   VAR_SEQ     141    182       KKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGP
FT                                H -> N (in isoform 15 and isoform 17).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_054111.
FT   VAR_SEQ     141    141       K -> N (in isoform VEGF148, isoform
FT                                VEGF165, isoform VEGF165B and isoform L-
FT                                VEGF165). {ECO:0000303|PubMed:10464055,
FT                                ECO:0000303|PubMed:12124351,
FT                                ECO:0000303|PubMed:1567395,
FT                                ECO:0000303|PubMed:19054851,
FT                                ECO:0000303|PubMed:2479986,
FT                                ECO:0000303|PubMed:9450968,
FT                                ECO:0000303|Ref.11, ECO:0000303|Ref.13,
FT                                ECO:0000303|Ref.14, ECO:0000303|Ref.15}.
FT                                /FTId=VSP_004618.
FT   VAR_SEQ     142    226       Missing (in isoform VEGF121 and isoform
FT                                L-VEGF121). {ECO:0000303|Ref.12}.
FT                                /FTId=VSP_004620.
FT   VAR_SEQ     142    182       Missing (in isoform VEGF148, isoform
FT                                VEGF165, isoform VEGF165B and isoform L-
FT                                VEGF165). {ECO:0000303|PubMed:10464055,
FT                                ECO:0000303|PubMed:12124351,
FT                                ECO:0000303|PubMed:1567395,
FT                                ECO:0000303|PubMed:19054851,
FT                                ECO:0000303|PubMed:2479986,
FT                                ECO:0000303|PubMed:9450968,
FT                                ECO:0000303|Ref.11, ECO:0000303|Ref.13,
FT                                ECO:0000303|Ref.14, ECO:0000303|Ref.15}.
FT                                /FTId=VSP_004619.
FT   VAR_SEQ     160    182       Missing (in isoform VEGF183 and isoform
FT                                16). {ECO:0000303|PubMed:10067980,
FT                                ECO:0000303|PubMed:9878851}.
FT                                /FTId=VSP_004621.
FT   VAR_SEQ     166    226       Missing (in isoform VEGF145).
FT                                {ECO:0000303|PubMed:9054410}.
FT                                /FTId=VSP_004623.
FT   VAR_SEQ     166    182       Missing (in isoform VEGF189 and isoform
FT                                L-VEGF189). {ECO:0000303|PubMed:2479986,
FT                                ECO:0000303|PubMed:2479987}.
FT                                /FTId=VSP_004622.
FT   VAR_SEQ     215    215       A -> M (in isoform VEGF148 and isoform
FT                                17). {ECO:0000303|PubMed:10464055}.
FT                                /FTId=VSP_004624.
FT   VAR_SEQ     216    232       Missing (in isoform VEGF148 and isoform
FT                                17). {ECO:0000303|PubMed:10464055}.
FT                                /FTId=VSP_004625.
FT   VAR_SEQ     227    232       CDKPRR -> SLTRKD (in isoform VEGF165B and
FT                                isoform 15).
FT                                {ECO:0000303|PubMed:12124351}.
FT                                /FTId=VSP_014783.
FT   CONFLICT     87     87       C -> S (in Ref. 8; AAC63143).
FT                                {ECO:0000305}.
FT   CONFLICT    210    210       D -> H (in Ref. 8; AAC63143).
FT                                {ECO:0000305}.
FT   HELIX        43     50       {ECO:0000244|PDB:1MKK}.
FT   STRAND       51     60       {ECO:0000244|PDB:1MKK}.
FT   HELIX        61     64       {ECO:0000244|PDB:1MKK}.
FT   HELIX        66     68       {ECO:0000244|PDB:1MKK}.
FT   STRAND       71     84       {ECO:0000244|PDB:1MKK}.
FT   STRAND       93    109       {ECO:0000244|PDB:1MKK}.
FT   TURN        111    113       {ECO:0000244|PDB:4GLN}.
FT   STRAND      116    131       {ECO:0000244|PDB:1MKK}.
FT   STRAND      189    191       {ECO:0000244|PDB:4DEQ}.
FT   STRAND      194    197       {ECO:0000244|PDB:4DEQ}.
FT   TURN        199    201       {ECO:0000244|PDB:4DEQ}.
FT   STRAND      204    208       {ECO:0000244|PDB:4DEQ}.
FT   HELIX       210    214       {ECO:0000244|PDB:4DEQ}.
FT   TURN        215    217       {ECO:0000244|PDB:4DEQ}.
FT   STRAND      219    221       {ECO:0000244|PDB:1KMX}.
FT   TURN        222    224       {ECO:0000244|PDB:4DEQ}.
FT   STRAND      226    228       {ECO:0000244|PDB:1KMX}.
SQ   SEQUENCE   232 AA;  27042 MW;  FB49F364446F4D01 CRC64;
     MNFLLSWVHW SLALLLYLHH AKWSQAAPMA EGGGQNHHEV VKFMDVYQRS YCHPIETLVD
     IFQEYPDEIE YIFKPSCVPL MRCGGCCNDE GLECVPTEES NITMQIMRIK PHQGQHIGEM
     SFLQHNKCEC RPKKDRARQE KKSVRGKGKG QKRKRKKSRY KSWSVYVGAR CCLMPWSLPG
     PHPCGPCSER RKHLFVQDPQ TCKCSCKNTD SRCKARQLEL NERTCRCDKP RR
//
ID   APOA1_HUMAN             Reviewed;         267 AA.
AC   P02647; A8K866; Q6LDN9; Q6Q785; Q9UCS8; Q9UCT8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   17-FEB-2016, entry version 212.
DE   RecName: Full=Apolipoprotein A-I;
DE            Short=Apo-AI;
DE            Short=ApoA-I;
DE   AltName: Full=Apolipoprotein A1;
DE   Contains:
DE     RecName: Full=Proapolipoprotein A-I;
DE              Short=ProapoA-I;
DE   Contains:
DE     RecName: Full=Truncated apolipoprotein A-I;
DE     AltName: Full=Apolipoprotein A-I(1-242);
DE   Flags: Precursor;
GN   Name=APOA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6406984; DOI=10.1093/nar/11.9.2827;
RA   Shoulders C.C., Kornblihtt A.R., Munro B.S., Baralle F.E.;
RT   "Gene structure of human apolipoprotein A1.";
RL   Nucleic Acids Res. 11:2827-2837(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6304641; DOI=10.1093/nar/11.11.3703;
RA   Cheung P., Chan L.;
RT   "Nucleotide sequence of cloned cDNA of human apolipoprotein A-I.";
RL   Nucleic Acids Res. 11:3703-3715(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6413973; DOI=10.1073/pnas.80.20.6147;
RA   Karathanasis S.K., Zannis V.I., Breslow J.L.;
RT   "Isolation and characterization of the human apolipoprotein A-I
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:6147-6151(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6207999; DOI=10.1089/dna.1.1984.3.309;
RA   Seilhamer J.J., Protter A.A., Frossard P., Levy-Wilson B.;
RT   "Isolation and DNA sequence of full-length cDNA and of the entire gene
RT   for human apolipoprotein AI -- discovery of a new genetic polymorphism
RT   in the apo AI gene.";
RL   DNA 3:309-317(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6328445; DOI=10.1093/nar/12.9.3917;
RA   Sharpe C.R., Sidoli A., Shelley C.S., Lucero M.A., Shoulders C.C.,
RA   Baralle F.E.;
RT   "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA
RT   abundance.";
RL   Nucleic Acids Res. 12:3917-3932(1984).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6198645; DOI=10.1073/pnas.81.1.66;
RA   Law S.W., Brewer H.B. Jr.;
RT   "Nucleotide sequence and the encoded amino acids of human
RT   apolipoprotein A-I mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:66-70(1984).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2995392;
RA   Law S.W., Brewer H.B. Jr.;
RT   "Tangier disease. The complete mRNA sequence encoding for preproapo-A-
RT   I.";
RL   J. Biol. Chem. 260:12810-12814(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT TANGIER).
RX   PubMed=3129297; DOI=10.1111/j.1432-1033.1988.tb14022.x;
RA   Makrides S.C., Ruiz-Opazo N., Hayden M.R., Nussbaum A.L.,
RA   Breslow J.L., Zannis V.I.;
RT   "Sequence and expression of Tangier apoA-I gene.";
RL   Eur. J. Biochem. 173:465-471(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2673706; DOI=10.1089/dna.1.1989.8.429;
RA   Moguilevsky N., Roobol C., Loriau R., Guillaume J.P., Jacobs P.,
RA   Cravador A., Herzog A., Brouwers L., Scarso A., Gilles P.,
RA   Holmquist L., Carlson L.A., Bollen A.;
RT   "Production of human recombinant proapolipoprotein A-I in Escherichia
RT   coli: purification and biochemical characterization.";
RL   DNA 8:429-436(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-61.
RX   PubMed=15108119; DOI=10.1007/s00439-004-1106-x;
RA   Fullerton S.M., Buchanan A.V., Sonpar V.A., Taylor S.L., Smith J.D.,
RA   Carlson C.S., Salomaa V., Stengaard J.H., Boerwinkle E., Clark A.G.,
RA   Nickerson D.A., Weiss K.M.;
RT   "The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.";
RL   Hum. Genet. 115:36-56(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Bollen A., Gobert J., Wuelfert E.;
RT   "Expression of human proapolipoprotein A-1.";
RL   Patent number EP0293357, 30-NOV-1988.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   PROTEIN SEQUENCE OF 19-27.
RX   PubMed=6409108; DOI=10.1016/0006-291X(83)91772-2;
RA   Brewer H.B. Jr., Fairwell T., Kay L., Meng M., Ronan R., Law S.,
RA   Light J.A.;
RT   "Human plasma proapoA-I: isolation and amino-terminal sequence.";
RL   Biochem. Biophys. Res. Commun. 113:626-632(1983).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-267.
RX   PubMed=164450;
RA   Baker H.N., Gotto A.M. Jr., Jackson R.L.;
RT   "The primary structure of human plasma high density apolipoprotein
RT   glutamine I (ApoA-I). II. The amino acid sequence and alignment of
RT   cyanogen bromide fragments IV, III, and I.";
RL   J. Biol. Chem. 250:2725-2738(1975).
RN   [18]
RP   PROTEIN SEQUENCE OF 25-267.
RX   PubMed=204308; DOI=10.1016/0006-291X(78)91614-5;
RA   Brewer H.B. Jr., Fairwell T., Larue A., Ronan R., Houser A.,
RA   Bronzert T.J.;
RT   "The amino acid sequence of human APOA-I, an apolipoprotein isolated
RT   from high density lipoproteins.";
RL   Biochem. Biophys. Res. Commun. 80:623-630(1978).
RN   [19]
RP   PROTEIN SEQUENCE OF 25-56.
RX   PubMed=3047170; DOI=10.1172/JCI113682;
RA   Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., Kawai C.;
RT   "Serum prostacyclin stabilizing factor is identical to apolipoprotein
RT   A-I (Apo A-I). A novel function of Apo A-I.";
RL   J. Clin. Invest. 82:803-807(1988).
RN   [20]
RP   PROTEIN SEQUENCE OF 25-50, FUNCTION, AND IDENTIFICATION IN THE SPAP
RP   COMPLEX.
RC   TISSUE=Serum;
RX   PubMed=1909888; DOI=10.1021/bi00101a011;
RA   Aakerloef E., Joernvall H., Slotte H., Pousette A.;
RT   "Identification of apolipoprotein A1 and immunoglobulin as components
RT   of a serum complex that mediates activation of human sperm motility.";
RL   Biochemistry 30:8986-8990(1991).
RN   [21]
RP   PROTEIN SEQUENCE OF 25-48.
RX   PubMed=2506184;
RA   Manjunath P., Marcel Y.L., Uma J., Seidah N.G., Chretien M.,
RA   Chapdelaine A.;
RT   "Apolipoprotein A-I binds to a family of bovine seminal plasma
RT   proteins.";
RL   J. Biol. Chem. 264:16853-16857(1989).
RN   [22]
RP   PROTEIN SEQUENCE OF 25-43.
RX   PubMed=3120314; DOI=10.1126/science.3120314;
RA   Prioli R.P., Ordovas J.M., Rosenberg I., Schaeffer E.J.,
RA   Pereira M.E.A.;
RT   "Similarity of cruzin, an inhibitor of Trypanosoma cruzi
RT   neuraminidase, to high-density lipoprotein.";
RL   Science 238:1417-1419(1987).
RN   [23]
RP   PROTEIN SEQUENCE OF 25-42.
RC   TISSUE=Heart;
RX   PubMed=7895732; DOI=10.1002/elps.11501501209;
RA   Corbett J.M., Wheeler C.H., Baker C.S., Yacoub M.H., Dunn M.J.;
RT   "The human myocardial two-dimensional gel protein database: update
RT   1994.";
RL   Electrophoresis 15:1459-1465(1994).
RN   [24]
RP   PROTEIN SEQUENCE OF 25-34.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [25]
RP   PROTEIN SEQUENCE OF 25-33, AND INTERACTION WITH APOA1BP AND CLU.
RX   PubMed=1742316; DOI=10.1016/0005-2760(91)90167-G;
RA   Ehnholm C., Bozas S.E., Tenkanen H., Kirszbaum L., Metso J.,
RA   Murphy B., Walker I.D.;
RT   "The apolipoprotein A-I binding protein of placenta and the SP-40,40
RT   protein of human blood are different proteins which both bind to
RT   apolipoprotein A-I.";
RL   Biochim. Biophys. Acta 1086:255-260(1991).
RN   [26]
RP   PROTEIN SEQUENCE OF 35-64; 70-101; 121-140; 165-173; 185-195 AND
RP   240-263, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [27]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 118-267.
RX   PubMed=6294659; DOI=10.1073/pnas.79.22.6861;
RA   Breslow J.L., Ross D., McPherson J., Williams H.W., Kurnit D.,
RA   Nussbaum A.L., Karathanasis S.K., Zannis V.I.;
RT   "Isolation and characterization of cDNA clones for human
RT   apolipoprotein A-I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6861-6865(1982).
RN   [28]
RP   PALMITOYLATION.
RX   PubMed=3005308;
RA   Hoeg J.M., Meng M.S., Ronan R., Fairwell T., Brewer H.B. Jr.;
RT   "Human apolipoprotein A-I. Post-translational modification by fatty
RT   acid acylation.";
RL   J. Biol. Chem. 261:3911-3914(1986).
RN   [29]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=6405383; DOI=10.1073/pnas.80.9.2574;
RA   Zannis V.I., Karathanasis S.K., Keutmann H.T., Goldberger G.,
RA   Breslow J.L.;
RT   "Intracellular and extracellular processing of human apolipoprotein A-
RT   I: secreted apolipoprotein A-I isoprotein 2 is a propeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:2574-2578(1983).
RN   [30]
RP   GLYCATION AT LYS-263.
RX   PubMed=8261628; DOI=10.1016/0009-8981(93)90165-Z;
RA   Calvo C., Ulloa N., Campos M., Verdugo C., Ayrault-Jarrier M.;
RT   "The preferential site of non-enzymatic glycation of human
RT   apolipoprotein A-I in vivo.";
RL   Clin. Chim. Acta 217:193-198(1993).
RN   [31]
RP   INTERACTION WITH APOA1BP.
RX   PubMed=11991719; DOI=10.1006/geno.2002.6761;
RA   Ritter M., Buechler C., Boettcher A., Barlage S., Schmitz-Madry A.,
RA   Orso E., Bared S.M., Schmiedeknecht G., Baehr C.H., Fricker G.,
RA   Schmitz G.;
RT   "Cloning and characterization of a novel apolipoprotein A-I-binding
RT   protein, AI-BP, secreted by cells of the kidney proximal tubules in
RT   response to HDL or ApoA-I.";
RL   Genomics 79:693-702(2002).
RN   [32]
RP   MASS SPECTROMETRY, OXIDATION AT MET-110 AND MET-136, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12576517; DOI=10.1194/jlr.M200256-JLR200;
RA   Pankhurst G., Wang X.L., Wilcken D.E., Baernthaler G., Panzenboeck U.,
RA   Raftery M., Stocker R.;
RT   "Characterization of specifically oxidized apolipoproteins in mildly
RT   oxidized high density lipoprotein.";
RL   J. Lipid Res. 44:349-355(2003).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12562854; DOI=10.1194/jlr.D200034-JLR200;
RA   Niederkofler E.E., Tubbs K.A., Kiernan U.A., Nedelkov D., Nelson R.W.;
RT   "Novel mass spectrometric immunoassays for the rapid structural
RT   characterization of plasma apolipoproteins.";
RL   J. Lipid Res. 44:630-639(2003).
RN   [34]
RP   INTERACTION WITH NDRG1.
RX   PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050;
RA   Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C.,
RA   Watts G.F., Kremensky I., Kalaydjieva L.;
RT   "NDRG1 interacts with APO A-I and A-II and is a functional candidate
RT   for the HDL-C QTL on 8q24.";
RL   Biochem. Biophys. Res. Commun. 332:982-992(2005).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   CHARACTERIZATION OF VARIANT MILANO CYS-197.
RX   PubMed=24755625; DOI=10.1371/journal.pone.0096150;
RA   Petrlova J., Dalla-Riva J., Morgelin M., Lindahl M., Krupinska E.,
RA   Stenkula K.G., Voss J.C., Lagerstedt J.O.;
RT   "Secondary structure changes in ApoA-I Milano (R173C) are not
RT   accompanied by a decrease in protein stability or solubility.";
RL   PLoS ONE 9:E96150-E96150(2014).
RN   [38]
RP   STRUCTURE BY NMR OF 190-209.
RX   PubMed=8664326; DOI=10.1016/0005-2760(96)00037-9;
RA   Wang G., Treleaven W.D., Cushley R.J.;
RT   "Conformation of human serum apolipoprotein A-I(166-185) in the
RT   presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR
RT   and CD. Evidence for specific peptide-SDS interactions.";
RL   Biochim. Biophys. Acta 1301:174-184(1996).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF 67-267.
RX   PubMed=9356442; DOI=10.1073/pnas.94.23.12291;
RA   Borhani D.W., Rogers D.P., Engler J.A., Brouillette C.G.;
RT   "Crystal structure of truncated human apolipoprotein A-I suggests a
RT   lipid-bound conformation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:12291-12296(1997).
RN   [40]
RP   DISEASE.
RX   PubMed=8240372; DOI=10.1006/bbrc.1993.2341;
RA   Nakata K., Kobayashi K., Yanagi H., Shimakura Y., Tsuchiya S.,
RA   Arinami T., Hamaguchi H.;
RT   "Autosomal dominant hypoalphalipoproteinemia due to a completely
RT   defective apolipoprotein A-I gene.";
RL   Biochem. Biophys. Res. Commun. 196:950-955(1993).
RN   [41]
RP   DISEASE.
RX   PubMed=8282791; DOI=10.1172/JCI116949;
RA   Ng D.S., Leiter L.A., Vezina C., Connelly P.W., Hegele R.A.;
RT   "Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I
RT   deficiency in a family with analphalipoproteinemia.";
RL   J. Clin. Invest. 93:223-229(1994).
RN   [42]
RP   VARIANT MILANO CYS-197.
RX   PubMed=6401735;
RA   Weisgraber K.H., Rall S.C. Jr., Bersot T.P., Mahley R.W.,
RA   Franceschini G., Sirtori C.R.;
RT   "Apolipoprotein A-IMilano. Detection of normal A-I in affected
RT   subjects and evidence for a cysteine for arginine substitution in the
RT   variant A-I.";
RL   J. Biol. Chem. 258:2508-2513(1983).
RN   [43]
RP   VARIANT TANGIER.
RX   PubMed=6412234; DOI=10.1073/pnas.80.19.6081;
RA   Schmitz G., Assmann G., Rall S.C. Jr., Mahley R.W.;
RT   "Tangier disease: defective recombination of a specific Tangier
RT   apolipoprotein A-I isoform (pro-apo A-I) with high density
RT   lipoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:6081-6085(1983).
RN   [44]
RP   VARIANT GIESSEN ARG-167.
RX   PubMed=6489332; DOI=10.1111/j.1432-1033.1984.tb08467.x;
RA   Utermann G., Haas J., Steinmetz A., Paetzold R., Rall S.C. Jr.,
RA   Weisgraber K.H., Mahley R.W.;
RT   "Apolipoprotein A-IGiessen (Pro143-->Arg). A mutant that is defective
RT   in activating lecithin:cholesterol acyltransferase.";
RL   Eur. J. Biochem. 144:325-331(1984).
RN   [45]
RP   VARIANT NORWAY LYS-160.
RX   PubMed=6432779;
RA   Rall S.C. Jr., Weisgraber K.H., Mahley R.W., Ogawa Y., Fielding C.J.,
RA   Utermann G., Haas J., Steinmetz A., Menzel H.J., Assmann G.;
RT   "Abnormal lecithin:cholesterol acyltransferase activation by a human
RT   apolipoprotein A-I variant in which a single lysine residue is
RT   deleted.";
RL   J. Biol. Chem. 259:10063-10070(1984).
RN   [46]
RP   PROTEIN SEQUENCE OF 25-107, AND VARIANT AMYL8 ARG-50.
RX   PubMed=3142462; DOI=10.1016/S0006-291X(88)80909-4;
RA   Nichols W.C., Dwulet F.E., Liepnieks J., Benson M.D.;
RT   "Variant apolipoprotein AI as a major constituent of a human
RT   hereditary amyloid.";
RL   Biochem. Biophys. Res. Commun. 156:762-768(1988).
RN   [47]
RP   VARIANT AMYL8 ARG-50.
RX   PubMed=2123470; DOI=10.1016/0888-7543(90)90288-6;
RA   Nichols W.C., Gregg R.E., Brewer H.B. Jr., Benson M.D.;
RT   "A mutation in apolipoprotein A-I in the Iowa type of familial
RT   amyloidotic polyneuropathy.";
RL   Genomics 8:318-323(1990).
RN   [48]
RP   PROTEIN SEQUENCE OF 25-267, AND VARIANT FUKUOKA LYS-134.
RX   PubMed=2107878; DOI=10.1016/0005-2760(90)90292-6;
RA   Takada Y., Sasaki J., Ogata S., Nakanishi T., Ikehara Y., Arakawa K.;
RT   "Isolation and characterization of human apolipoprotein A-I Fukuoka
RT   (110 Glu-->Lys). A novel apolipoprotein variant.";
RL   Biochim. Biophys. Acta 1043:169-176(1990).
RN   [49]
RP   PROTEIN SEQUENCE OF 25-112, AND VARIANT AMYL8 ARG-84.
RX   PubMed=1502149; DOI=10.1073/pnas.89.16.7389;
RA   Soutar A.K., Hawkins P.N., Vigushin D.M., Tennent G.A., Booth S.E.,
RA   Hutton T., Nguyen O., Totty N.F., Feest T.G., Hsuan J.J., Pepys M.B.;
RT   "Apolipoprotein AI mutation Arg-60 causes autosomal dominant
RT   amyloidosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7389-7393(1992).
RN   [50]
RP   VARIANT BALTIMORE LEU-34.
RX   PubMed=2108924; DOI=10.1007/BF00195816;
RA   Ladias J.A.A., Kwiterovich P.O. Jr., Smith H.H., Karathanasis S.K.,
RA   Antonarakis S.E.;
RT   "Apolipoprotein A1 Baltimore (Arg-10-->Leu), a new ApoA1 variant.";
RL   Hum. Genet. 84:439-445(1990).
RN   [51]
RP   VARIANTS ARG-27; ARG-28 AND ARG-189.
RX   PubMed=2512329; DOI=10.1172/JCI114355;
RA   von Eckardstein A., Funke H., Henke A., Altland K., Benninghoven A.,
RA   Assmann G., Welp S., Roetrige A., Kock R.;
RT   "Apolipoprotein A-I variants. Naturally occurring substitutions of
RT   proline residues affect plasma concentration of apolipoprotein A-I.";
RL   J. Clin. Invest. 84:1722-1730(1989).
RN   [52]
RP   VARIANTS GLU-113; MET-131; GLY-163; VAL-171 AND LYS-222.
RX   PubMed=2111322;
RA   von Eckardstein A., Funke H., Walter M., Altland K., Benninghoven A.,
RA   Assmann G.;
RT   "Structural analysis of human apolipoprotein A-I variants. Amino acid
RT   substitutions are nonrandomly distributed throughout the
RT   apolipoprotein A-I primary structure.";
RL   J. Biol. Chem. 265:8610-8617(1990).
RN   [53]
RP   VARIANTS HITA AND TSUSHIMA.
RX   PubMed=7918609;
RA   Araki K., Sasaki J., Matsunaga A., Takada Y., Moriyama K., Hidaka K.,
RA   Arakawa K.;
RT   "Characterization of two new human apolipoprotein A-I variants:
RT   apolipoprotein A-I Tsushima (Trp-108-->Arg) and A-I Hita (Ala-
RT   95-->Asp).";
RL   Biochim. Biophys. Acta 1214:272-278(1994).
RN   [54]
RP   VARIANT AMYL8 ARG-50.
RX   PubMed=8208902;
RA   Vigushin D.M., Gough J., Allan D., Alguacil A., Penner B.,
RA   Pettigrew N.M., Quinonez G., Bernstein K., Booth S.E., Booth D.R.,
RA   Soutar A.K., Hawkins P.N., Pepys M.B.;
RT   "Familial nephropathic systemic amyloidosis caused by apolipoprotein
RT   AI variant Arg26.";
RL   Q. J. Med. 87:149-154(1994).
RN   [55]
RP   VARIANT AOITA GLU-180.
RX   PubMed=9514407; DOI=10.1161/01.ATV.18.3.389;
RA   Huang W., Sasaki J., Matsunaga A., Nanimatsu H., Moriyama K., Han H.,
RA   Kugi M., Koga T., Yamaguchi K., Arakawa K.;
RT   "A novel homozygous missense mutation in the apo A-I gene with apo A-I
RT   deficiency.";
RL   Arterioscler. Thromb. Vasc. Biol. 18:389-396(1998).
RN   [56]
RP   VARIANT ZARAGOZA ARG-168.
RA   Recalde D., Cenarro A., Civeira F., Pocovi M.;
RT   "Apo A-I Zaragoza(L144R): a novel mutation in the apolipoprotein A-I
RT   gene associated with familial hypoalphalipoproteinemia.";
RL   Hum. Mutat. 11:416-416(1998).
RN   [57]
RP   VARIANT ILE-92.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [58]
RP   VARIANT ILE-92, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [59]
RP   VARIANT BOSTON SER-173.
RX   PubMed=26073399; DOI=10.1016/j.jacl.2015.02.005;
RA   Anthanont P., Asztalos B.F., Polisecki E., Zachariah B.,
RA   Schaefer E.J.;
RT   "Case report: A novel apolipoprotein A-I missense mutation apoA-I
RT   (Arg149Ser)Boston associated with decreased lecithin-cholesterol
RT   acyltransferase activation and cellular cholesterol efflux.";
RL   J. Clin. Lipidol. 9:390-395(2015).
CC   -!- FUNCTION: Participates in the reverse transport of cholesterol
CC       from tissues to the liver for excretion by promoting cholesterol
CC       efflux from tissues and by acting as a cofactor for the lecithin
CC       cholesterol acyltransferase (LCAT). As part of the SPAP complex,
CC       activates spermatozoa motility. {ECO:0000269|PubMed:1909888}.
CC   -!- SUBUNIT: Interacts with APOA1BP and CLU. Component of a sperm
CC       activating protein complex (SPAP), consisting of APOA1, an
CC       immunoglobulin heavy chain, an immunoglobulin light chain and
CC       albumin. Interacts with NDRG1. {ECO:0000269|PubMed:11991719,
CC       ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:1742316,
CC       ECO:0000269|PubMed:1909888}.
CC   -!- INTERACTION:
CC       Self; NbExp=14; IntAct=EBI-701692, EBI-701692;
CC       O95477:ABCA1; NbExp=4; IntAct=EBI-701692, EBI-784112;
CC       P05067:APP; NbExp=5; IntAct=EBI-701692, EBI-77613;
CC       Q96DZ9:CMTM5; NbExp=3; IntAct=EBI-701692, EBI-2548702;
CC       P02671:FGA; NbExp=2; IntAct=EBI-701692, EBI-348571;
CC       P00738:HP; NbExp=3; IntAct=EBI-701692, EBI-1220767;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Major protein of plasma HDL, also found in
CC       chylomicrons. Synthesized in the liver and small intestine. The
CC       oxidized form at Met-110 and Met-136 is increased in individuals
CC       with increased risk for coronary artery disease, such as in
CC       carrier of the eNOSa/b genotype and exposure to cigarette smoking.
CC       It is also present in increased levels in aortic lesions relative
CC       to native ApoA-I and increased levels are seen with increasing
CC       severity of disease. {ECO:0000269|PubMed:12576517}.
CC   -!- PTM: Glycosylated. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:3005308}.
CC   -!- PTM: Phosphorylation sites are present in the extracellular
CC       medium.
CC   -!- MASS SPECTROMETRY: Mass=28081; Method=Electrospray; Range=25-267;
CC       Note=Without methionine sulfoxide.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28098; Method=Electrospray; Range=25-267;
CC       Note=With 1 methionine sulfoxide, oxidation at Met-110.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28095; Method=Electrospray; Range=25-267;
CC       Note=With 1 methionine sulfoxide, oxidation at Met-136.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28114; Method=Electrospray; Range=25-267;
CC       Note=With 2 methionine sulfoxides, oxidation at Met-110 and Met-
CC       136.; Evidence={ECO:0000269|PubMed:12576517};
CC   -!- POLYMORPHISM: Genetic variations in APOA1 can result in APOA1
CC       deficiency and are associated with low levels of HDL cholesterol
CC       [MIM:107680]. {ECO:0000305}.
CC   -!- DISEASE: High density lipoprotein deficiency 2 (HDLD2)
CC       [MIM:604091]: Inherited as autosomal dominant trait. It is
CC       characterized by moderately low HDL cholesterol, predilection
CC       toward premature coronary artery disease (CAD) and a reduction in
CC       cellular cholesterol efflux. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: High density lipoprotein deficiency 1 (HDLD1)
CC       [MIM:205400]: Recessive disorder characterized by absence of high
CC       density lipoprotein (HDL) cholesterol from plasma, accumulation of
CC       cholesteryl esters, premature coronary artery disease (CAD),
CC       hepatosplenomegaly, recurrent peripheral neuropathy and
CC       progressive muscle wasting and weakness. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=APOA1 mutations may be involved in the pathogenesis
CC       of amyloid polyneuropathy-nephropathy Iowa type, also known as
CC       amyloidosis van Allen type or familial amyloid polyneuropathy type
CC       III (PubMed:3142462 and PubMed:2123470). The clinical picture is
CC       dominated by neuropathy in the early stages of the disease and
CC       nephropathy late in the course. Death is due in most cases to
CC       renal amyloidosis.
CC   -!- DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A hereditary
CC       generalized amyloidosis due to deposition of apolipoprotein A1,
CC       fibrinogen and lysozyme amyloids. Viscera are particularly
CC       affected. There is no involvement of the nervous system. Clinical
CC       features include renal amyloidosis resulting in nephrotic
CC       syndrome, arterial hypertension, hepatosplenomegaly, cholestasis,
CC       petechial skin rash. {ECO:0000269|PubMed:1502149,
CC       ECO:0000269|PubMed:2123470, ECO:0000269|PubMed:3142462,
CC       ECO:0000269|PubMed:8208902}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOA1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00098; AAB59514.1; -; Genomic_DNA.
DR   EMBL; X01038; CAA25519.1; -; Genomic_DNA.
DR   EMBL; X02162; CAA26097.1; -; mRNA.
DR   EMBL; X00566; CAA25232.1; -; mRNA.
DR   EMBL; M11791; AAA35545.1; -; mRNA.
DR   EMBL; X07496; CAA30377.1; -; Genomic_DNA.
DR   EMBL; M27875; AAA62829.1; -; mRNA.
DR   EMBL; M29068; AAA51747.1; -; mRNA.
DR   EMBL; AY422952; AAQ91811.1; -; Genomic_DNA.
DR   EMBL; AY555191; AAS68227.1; -; Genomic_DNA.
DR   EMBL; A14829; CAA01198.1; -; mRNA.
DR   EMBL; AK292231; BAF84920.1; -; mRNA.
DR   EMBL; EF444948; ACA05932.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05933.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05934.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05935.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05936.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67274.1; -; Genomic_DNA.
DR   EMBL; BC005380; AAH05380.1; -; mRNA.
DR   EMBL; BC110286; AAI10287.1; -; mRNA.
DR   CCDS; CCDS8378.1; -.
DR   PIR; A90947; LPHUA1.
DR   RefSeq; NP_000030.1; NM_000039.1.
DR   RefSeq; XP_005271596.1; XM_005271539.2.
DR   RefSeq; XP_005271597.1; XM_005271540.1.
DR   UniGene; Hs.93194; -.
DR   PDB; 1AV1; X-ray; 4.00 A; A/B/C/D=68-267.
DR   PDB; 1GW3; NMR; -; A=166-211.
DR   PDB; 1GW4; NMR; -; A=166-211.
DR   PDB; 1ODP; NMR; -; A=190-209.
DR   PDB; 1ODQ; NMR; -; A=190-209.
DR   PDB; 1ODR; NMR; -; A=190-209.
DR   PDB; 2A01; X-ray; 2.40 A; A/B/C=25-267.
DR   PDB; 2MSC; NMR; -; A/C=68-265.
DR   PDB; 2MSD; NMR; -; A/C=68-265.
DR   PDB; 2MSE; NMR; -; A/C=68-265.
DR   PDB; 3K2S; X-ray; -; A/B=25-267.
DR   PDB; 3R2P; X-ray; 2.20 A; A=25-208.
DR   PDB; 4V6M; EM; 7.10 A; A0/A1=68-267.
DR   PDBsum; 1AV1; -.
DR   PDBsum; 1GW3; -.
DR   PDBsum; 1GW4; -.
DR   PDBsum; 1ODP; -.
DR   PDBsum; 1ODQ; -.
DR   PDBsum; 1ODR; -.
DR   PDBsum; 2A01; -.
DR   PDBsum; 2MSC; -.
DR   PDBsum; 2MSD; -.
DR   PDBsum; 2MSE; -.
DR   PDBsum; 3K2S; -.
DR   PDBsum; 3R2P; -.
DR   PDBsum; 4V6M; -.
DR   DisProt; DP00386; -.
DR   ProteinModelPortal; P02647; -.
DR   SMR; P02647; 26-267.
DR   BioGrid; 106832; 85.
DR   DIP; DIP-29619N; -.
DR   IntAct; P02647; 69.
DR   MINT; MINT-5000866; -.
DR   STRING; 9606.ENSP00000236850; -.
DR   ChEMBL; CHEMBL5984; -.
DR   iPTMnet; P02647; -.
DR   PhosphoSite; P02647; -.
DR   BioMuta; APOA1; -.
DR   DMDM; 113992; -.
DR   DOSAC-COBS-2DPAGE; P02647; -.
DR   OGP; P02647; -.
DR   REPRODUCTION-2DPAGE; IPI00021841; -.
DR   REPRODUCTION-2DPAGE; P02647; -.
DR   SWISS-2DPAGE; P02647; -.
DR   UCD-2DPAGE; P02647; -.
DR   MaxQB; P02647; -.
DR   PaxDb; P02647; -.
DR   PeptideAtlas; P02647; -.
DR   PRIDE; P02647; -.
DR   DNASU; 335; -.
DR   Ensembl; ENST00000236850; ENSP00000236850; ENSG00000118137.
DR   Ensembl; ENST00000359492; ENSP00000352471; ENSG00000118137.
DR   Ensembl; ENST00000375320; ENSP00000364469; ENSG00000118137.
DR   Ensembl; ENST00000375323; ENSP00000364472; ENSG00000118137.
DR   GeneID; 335; -.
DR   KEGG; hsa:335; -.
DR   UCSC; uc001ppv.1; human.
DR   CTD; 335; -.
DR   GeneCards; APOA1; -.
DR   HGNC; HGNC:600; APOA1.
DR   HPA; CAB016778; -.
DR   HPA; HPA046715; -.
DR   MalaCards; APOA1; -.
DR   MIM; 105200; phenotype.
DR   MIM; 107680; gene+phenotype.
DR   MIM; 205400; phenotype.
DR   MIM; 604091; phenotype.
DR   neXtProt; NX_P02647; -.
DR   Orphanet; 425; Apolipoprotein A-I deficiency.
DR   Orphanet; 93560; Familial renal amyloidosis due to Apolipoprotein AI variant.
DR   Orphanet; 314701; Primary systemic amyloidosis.
DR   PharmGKB; PA49; -.
DR   eggNOG; ENOG410IWKR; Eukaryota.
DR   eggNOG; ENOG410YGQ6; LUCA.
DR   GeneTree; ENSGT00530000063081; -.
DR   HOGENOM; HOG000033998; -.
DR   HOVERGEN; HBG105708; -.
DR   InParanoid; P02647; -.
DR   KO; K08757; -.
DR   OMA; KDFATVY; -.
DR   OrthoDB; EOG7TBC3N; -.
DR   PhylomeDB; P02647; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1369062; ABC transporters in lipid homeostasis.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; APOA1; human.
DR   EvolutionaryTrace; P02647; -.
DR   GeneWiki; Apolipoprotein_A1; -.
DR   GenomeRNAi; 335; -.
DR   NextBio; 1387; -.
DR   PMAP-CutDB; P02647; -.
DR   PRO; PR:P02647; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P02647; -.
DR   CleanEx; HS_APOA1; -.
DR   ExpressionAtlas; P02647; baseline and differential.
DR   Genevisible; P02647; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0042627; C:chylomicron; IBA:GO_Central.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0034365; C:discoidal high-density lipoprotein particle; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034191; F:apolipoprotein A-I receptor binding; IPI:BHF-UCL.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IPI:BHF-UCL.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:BHF-UCL.
DR   GO; GO:0045499; F:chemorepellent activity; IDA:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IDA:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IMP:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0070653; F:high-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0055102; F:lipase inhibitor activity; IEA:Ensembl.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IBA:GO_Central.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0005548; F:phospholipid transporter activity; IEA:Ensembl.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0043534; P:blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0070508; P:cholesterol import; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:BHF-UCL.
DR   GO; GO:0030301; P:cholesterol transport; IDA:MGI.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0008211; P:glucocorticoid metabolic process; IEA:Ensembl.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IC:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0050919; P:negative chemotaxis; IDA:UniProtKB.
DR   GO; GO:0060354; P:negative regulation of cell adhesion molecule production; IDA:BHF-UCL.
DR   GO; GO:0002740; P:negative regulation of cytokine secretion involved in immune response; IDA:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0050713; P:negative regulation of interleukin-1 beta secretion; IDA:BHF-UCL.
DR   GO; GO:0060192; P:negative regulation of lipase activity; IEA:Ensembl.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IDA:BHF-UCL.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010903; P:negative regulation of very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0018206; P:peptidyl-methionine modification; IDA:UniProtKB.
DR   GO; GO:0014012; P:peripheral nervous system axon regeneration; IEA:Ensembl.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0055091; P:phospholipid homeostasis; IDA:BHF-UCL.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IBA:GO_Central.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0018158; P:protein oxidation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IBA:GO_Central.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0070328; P:triglyceride homeostasis; IDA:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IBA:GO_Central.
DR   GO; GO:0051180; P:vitamin transport; IMP:AgBase.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyloid; Amyloidosis; Atherosclerosis;
KW   Cholesterol metabolism; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glycation; Glycoprotein; HDL; Lipid metabolism;
KW   Lipid transport; Lipoprotein; Neuropathy; Oxidation; Palmitate;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Secreted;
KW   Signal; Steroid metabolism; Sterol metabolism; Transport.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:6328445,
FT                                ECO:0000269|PubMed:6409108}.
FT   CHAIN        19    267       Proapolipoprotein A-I.
FT                                /FTId=PRO_0000425323.
FT   CHAIN        25    267       Apolipoprotein A-I.
FT                                /FTId=PRO_0000001939.
FT   CHAIN        25    266       Truncated apolipoprotein A-I.
FT                                /FTId=PRO_0000001940.
FT   REPEAT       68     89       1.
FT   REPEAT       90    111       2.
FT   REPEAT      112    122       3; half-length.
FT   REPEAT      123    144       4.
FT   REPEAT      145    166       5.
FT   REPEAT      167    188       6.
FT   REPEAT      189    210       7.
FT   REPEAT      211    232       8.
FT   REPEAT      233    243       9; half-length.
FT   REPEAT      244    267       10.
FT   REGION       68    267       10 X approximate tandem repeats.
FT   MOD_RES     110    110       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:12576517}.
FT   MOD_RES     136    136       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:12576517}.
FT   CARBOHYD    263    263       N-linked (Glc) (glycation).
FT   VARIANT      27     27       P -> H (in Munster-3C;
FT                                dbSNP:rs121912720).
FT                                /FTId=VAR_000605.
FT   VARIANT      27     27       P -> R (in dbSNP:rs121912720).
FT                                {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000606.
FT   VARIANT      28     28       P -> R (in Munster-3B).
FT                                {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000607.
FT   VARIANT      34     34       R -> L (in Baltimore; dbSNP:rs28929476).
FT                                {ECO:0000269|PubMed:2108924}.
FT                                /FTId=VAR_000608.
FT   VARIANT      50     50       G -> R (in AMYL8; also found in a family
FT                                with amyloid polyneuropathy-nephropathy
FT                                Iowa; dbSNP:rs28931574).
FT                                {ECO:0000269|PubMed:2123470,
FT                                ECO:0000269|PubMed:3142462,
FT                                ECO:0000269|PubMed:8208902}.
FT                                /FTId=VAR_000609.
FT   VARIANT      61     61       A -> T (in dbSNP:rs12718465).
FT                                {ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_025445.
FT   VARIANT      84     84       L -> R (in AMYL8).
FT                                {ECO:0000269|PubMed:1502149}.
FT                                /FTId=VAR_000610.
FT   VARIANT      92     92       T -> I (polymorphism; confirmed at
FT                                protein level).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_017017.
FT   VARIANT     113    113       D -> E. {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000611.
FT   VARIANT     119    119       A -> D (in Hita).
FT                                /FTId=VAR_000612.
FT   VARIANT     126    126       D -> H (in dbSNP:rs5077).
FT                                /FTId=VAR_016189.
FT   VARIANT     127    127       D -> N (in Munster-3A).
FT                                /FTId=VAR_000613.
FT   VARIANT     131    131       K -> M (in dbSNP:rs4882).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000615.
FT   VARIANT     131    131       Missing (in Marburg/Munster-2).
FT                                /FTId=VAR_000614.
FT   VARIANT     132    132       W -> R (in Tsushima).
FT                                /FTId=VAR_000616.
FT   VARIANT     134    134       E -> K (in Fukuoka).
FT                                {ECO:0000269|PubMed:2107878}.
FT                                /FTId=VAR_000617.
FT   VARIANT     160    160       E -> K (in Norway).
FT                                {ECO:0000269|PubMed:6432779}.
FT                                /FTId=VAR_000618.
FT   VARIANT     163    163       E -> G. {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000619.
FT   VARIANT     167    167       P -> R (in Giessen).
FT                                {ECO:0000269|PubMed:6489332}.
FT                                /FTId=VAR_000620.
FT   VARIANT     168    168       L -> R (in Zaragoza).
FT                                {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_000621.
FT   VARIANT     171    171       E -> V. {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000622.
FT   VARIANT     173    173       R -> S (in Boston; no evidence of
FT                                association with premature coronary heart
FT                                disease; associated with decreased levels
FT                                of HDL cholesterol; associated with
FT                                decreased serum cellular cholesterol
FT                                efflux; associated with decreased
FT                                lecithin-cholesterol acyltransferase
FT                                (LCAT) activity).
FT                                {ECO:0000269|PubMed:26073399}.
FT                                /FTId=VAR_074073.
FT   VARIANT     180    180       V -> E (in Oita; 60% of normal apoA-I and
FT                                normal HDL cholesterol levels. Rapidly
FT                                cleared from plasma).
FT                                {ECO:0000269|PubMed:9514407}.
FT                                /FTId=VAR_021362.
FT   VARIANT     184    184       R -> P (in dbSNP:rs5078).
FT                                /FTId=VAR_014609.
FT   VARIANT     189    189       P -> R. {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000623.
FT   VARIANT     197    197       R -> C (in Milano; no evidence of
FT                                association with premature vascular
FT                                disease; associated with decreased HDL
FT                                levels and moderate increase in
FT                                triglycerides; allows the formation of
FT                                disulfide-linked homodimers via the
FT                                introduced cysteine; assembles properly
FT                                in HDL; alters protein structure; has no
FT                                tendency to form fibrils and aggregates;
FT                                dbSNP:rs28931573).
FT                                {ECO:0000269|PubMed:24755625,
FT                                ECO:0000269|PubMed:6401735}.
FT                                /FTId=VAR_000624.
FT   VARIANT     222    222       E -> K (in Munster-4).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000625.
FT   CONFLICT     32     32       W -> P (in Ref. 25; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        33     42       {ECO:0000244|PDB:3R2P}.
FT   HELIX        45     59       {ECO:0000244|PDB:3R2P}.
FT   HELIX        61     65       {ECO:0000244|PDB:3R2P}.
FT   STRAND       69     73       {ECO:0000244|PDB:2A01}.
FT   HELIX        80     88       {ECO:0000244|PDB:3R2P}.
FT   HELIX        93    158       {ECO:0000244|PDB:3R2P}.
FT   TURN        159    164       {ECO:0000244|PDB:3R2P}.
FT   HELIX       166    203       {ECO:0000244|PDB:3R2P}.
FT   TURN        212    214       {ECO:0000244|PDB:2A01}.
FT   STRAND      215    217       {ECO:0000244|PDB:2A01}.
FT   HELIX       220    237       {ECO:0000244|PDB:2A01}.
FT   STRAND      238    240       {ECO:0000244|PDB:2A01}.
FT   HELIX       243    266       {ECO:0000244|PDB:2A01}.
SQ   SEQUENCE   267 AA;  30778 MW;  1A28B8366E620310 CRC64;
     MKAAVLTLAV LFLTGSQARH FWQQDEPPQS PWDRVKDLAT VYVDVLKDSG RDYVSQFEGS
     ALGKQLNLKL LDNWDSVTST FSKLREQLGP VTQEFWDNLE KETEGLRQEM SKDLEEVKAK
     VQPYLDDFQK KWQEEMELYR QKVEPLRAEL QEGARQKLHE LQEKLSPLGE EMRDRARAHV
     DALRTHLAPY SDELRQRLAA RLEALKENGG ARLAEYHAKA TEHLSTLSEK AKPALEDLRQ
     GLLPVLESFK VSFLSALEEY TKKLNTQ
//
ID   GLCM_HUMAN              Reviewed;         536 AA.
AC   P04062; A8K796; B7Z5G2; B7Z6S1; J3KQG4; J3KQK9; Q16545; Q4VX22;
AC   Q6I9R6; Q9UMJ8;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   09-NOV-2004, sequence version 3.
DT   17-FEB-2016, entry version 204.
DE   RecName: Full=Glucosylceramidase;
DE            EC=3.2.1.45;
DE   AltName: Full=Acid beta-glucosidase;
DE   AltName: Full=Alglucerase;
DE   AltName: Full=Beta-glucocerebrosidase;
DE            Short=Beta-GC;
DE   AltName: Full=D-glucosyl-N-acylsphingosine glucohydrolase;
DE   AltName: Full=Imiglucerase;
DE   Flags: Precursor;
GN   Name=GBA; Synonyms=GC, GLUC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Placenta;
RX   PubMed=3864160; DOI=10.1073/pnas.82.21.7289;
RA   Sorge J., West C., Westwood B., Beutler E.;
RT   "Molecular cloning and nucleotide sequence of human glucocerebrosidase
RT   cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7289-7293(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND VARIANT LEU-298.
RC   TISSUE=Hepatoma;
RX   PubMed=3001061;
RA   Tsuji S., Choudary P.V., Martin B.M., Winfield S., Barranger J.A.,
RA   Ginns E.I.;
RT   "Nucleotide sequence of cDNA containing the complete coding sequence
RT   for human lysosomal glucocerebrosidase.";
RL   J. Biol. Chem. 261:50-53(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=2914709; DOI=10.1016/0888-7543(89)90319-4;
RA   Horowitz M., Wilder S., Horowitz Z., Reiner O., Gelbart T.,
RA   Beutler E.;
RT   "The human glucocerebrosidase gene and pseudogene: structure and
RT   evolution.";
RL   Genomics 4:87-96(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=1572652; DOI=10.1016/0888-7543(92)90311-F;
RA   Beutler E., West C., Gelbart T.;
RT   "Polymorphisms in the human glucocerebrosidase gene.";
RL   Genomics 12:795-800(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND 3), VARIANTS GD ARG-223;
RP   GLY-230; PRO-235; ARG-241; ILE-252 AND ARG-364, AND VARIANTS GLY-310
RP   AND HIS-368.
RX   PubMed=8294033; DOI=10.1016/0378-1119(93)90497-Q;
RA   Imai K., Nakamura M., Yamada M., Asano A., Yokoyama S., Tsuji S.,
RA   Ginns E.I.;
RT   "A novel transcript from a pseudogene for human glucocerebrosidase in
RT   non-Gaucher disease cells.";
RL   Gene 136:365-368(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9331372;
RA   Winfield S.L., Tayebi N., Martin B.M., Ginns E.I., Sidransky E.;
RT   "Identification of three additional genes contiguous to the
RT   glucocerebrosidase locus on chromosome 1q21: implications for Gaucher
RT   disease.";
RL   Genome Res. 7:1020-1026(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG; 4 AND 5), AND
RP   VARIANT MET-408.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-11.
RX   PubMed=3359914; DOI=10.1089/dna.1988.7.107;
RA   Reiner O., Wigderson M., Horowitz M.;
RT   "Structural analysis of the human glucocerebrosidase genes.";
RL   DNA 7:107-116(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45.
RX   PubMed=3687939;
RA   Sorge J.A., West C., Kuhl W., Treger L., Beutler E.;
RT   "The human glucocerebrosidase gene has two functional ATG initiator
RT   codons.";
RL   Am. J. Hum. Genet. 41:1016-1024(1987).
RN   [12]
RP   PROTEIN SEQUENCE OF 40-44.
RC   TISSUE=Placenta;
RA   Martin B.M., Murray G.J., Coligan J.E., Raum M., Brady R.O.,
RA   Barranger J.A.;
RT   "Structural studies of human placental glucocerebrosidase.";
RL   Fed. Proc. 43:1869-1869(1984).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 403-416.
RX   PubMed=6091633; DOI=10.1016/0006-291X(84)90268-7;
RA   Ginns E.I., Choudary P.V., Martin B.M., Winfield S., Stubblefield B.,
RA   Mayor J., Merkle-Lehman D., Murray G.J., Bowers L.A., Barranger J.A.;
RT   "Isolation of cDNA clones for human beta-glucocerebrosidase using the
RT   lambda gt11 expression system.";
RL   Biochem. Biophys. Res. Commun. 123:574-580(1984).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 409-462, AND VARIANT GD1 SER-409.
RC   TISSUE=Skin;
RA   Tsuji S., Martin B.M., Barranger J.A., Stubblefield B.K.,
RA   LaMarca M.E., Ginns E.I.;
RT   "Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes
RT   in Ashkenazic and non-Ashkenazic individuals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:2349-2352(1988).
RN   [15]
RP   PROTEIN SEQUENCE OF 469-520.
RC   TISSUE=Placenta;
RX   PubMed=3456607; DOI=10.1073/pnas.83.6.1660;
RA   Dinur T., Osiecki K.M., Legler G., Gatt S., Desnick R.J.,
RA   Grabowski G.A.;
RT   "Human acid beta-glucosidase: isolation and amino acid sequence of a
RT   peptide containing the catalytic site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:1660-1664(1986).
RN   [16]
RP   MUTAGENESIS OF GLU-379, ACTIVE SITE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=7908905;
RA   Miao S., McCarter J.D., Grace M.E., Grabowski G.A., Aebersold R.,
RA   Withers S.G.;
RT   "Identification of Glu340 as the active-site nucleophile in human
RT   glucocerebrosidase by use of electrospray tandem mass spectrometry.";
RL   J. Biol. Chem. 269:10975-10978(1994).
RN   [17]
RP   INTERACTION WITH SAPOSIN-C AND MEMBRANES CONTAINING ANIONIC
RP   PHOSPHOLIPIDS.
RX   PubMed=10781797; DOI=10.1016/S0014-5793(00)01417-4;
RA   Salvioli R., Tatti M., Ciaffoni F., Vaccaro A.M.;
RT   "Further studies on the reconstitution of glucosylceramidase activity
RT   by Sap C and anionic phospholipids.";
RL   FEBS Lett. 472:17-21(2000).
RN   [18]
RP   GLYCOSYLATION AT ASN-98; ASN-185 AND ASN-309.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [19]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SCARB2.
RX   PubMed=18022370; DOI=10.1016/j.cell.2007.10.018;
RA   Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X.,
RA   Brondyk W., Van Patten S., Edmunds T., Saftig P.;
RT   "LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent
RT   targeting of beta-glucocerebrosidase.";
RL   Cell 131:770-783(2007).
RN   [20]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [21]
RP   INVOLVEMENT IN PARKINSON DISEASE, AND VARIANTS GLU-46; CYS-170;
RP   GLU-232; GLN-296; SER-409; ALA-419; HIS-448; ASN-482; PRO-483;
RP   PRO-495; LEU-497 AND CYS-502.
RX   PubMed=19286695; DOI=10.1093/brain/awp044;
RA   Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L.,
RA   Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B.,
RA   Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W.;
RT   "Glucocerebrosidase mutations in clinical and pathologically proven
RT   Parkinson's disease.";
RL   Brain 132:1783-1794(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-98 AND ASN-309.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 40-536, GLYCOSYLATION AT
RP   ASN-58, AND DISULFIDE BONDS.
RX   PubMed=12792654; DOI=10.1038/sj.embor.embor873;
RA   Dvir H., Harel M., McCarthy A.A., Toker L., Silman I., Futerman A.H.,
RA   Sussman J.L.;
RT   "X-ray structure of human acid-beta-glucosidase, the defective enzyme
RT   in Gaucher disease.";
RL   EMBO Rep. 4:704-709(2003).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 40-536 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND ACTIVE SITE.
RX   PubMed=15817452; DOI=10.1074/jbc.M502799200;
RA   Premkumar L., Sawkar A.R., Boldin-Adamsky S., Toker L., Silman I.,
RA   Kelly J.W., Futerman A.H., Sussman J.L.;
RT   "X-ray structure of human acid-beta-glucosidase covalently bound to
RT   conduritol-B-epoxide. Implications for Gaucher disease.";
RL   J. Biol. Chem. 280:23815-23819(2005).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 40-536, CHARACTERIZATION OF
RP   VARIANTS GD SER-55; GLN-87; ASN-118; GLN-159; LEU-161; VAL-162;
RP   VAL-166; ASN-200; PHE-213; PHE-224; GLU-232; GLU-237; LEU-298;
RP   ILE-303; CYS-343; ILE-362; LYS-365; GLY-381; LYS-388; TRP-392;
RP   CYS-402; SER-409; VAL-410; HIS-419; LYS-421; ARG-429; LEU-433;
RP   SER-436; ASN-438; HIS-448; VAL-455; PRO-483; PRO-500 AND PRO-502, AND
RP   MUTAGENESIS OF CYS-43; CYS-57 AND CYS-62.
RX   PubMed=16293621; DOI=10.1074/jbc.M511110200;
RA   Liou B., Kazimierczuk A., Zhang M., Scott C.R., Hegde R.S.,
RA   Grabowski G.A.;
RT   "Analyses of variant acid beta-glucosidases: effects of Gaucher
RT   disease mutations.";
RL   J. Biol. Chem. 281:4242-4253(2006).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 40-536, AND GLYCOSYLATION AT
RP   ASN-58; ASN-98 AND ASN-185.
RX   PubMed=17139081; DOI=10.1107/S0907444906038303;
RA   Brumshtein B., Wormald M.R., Silman I., Futerman A.H., Sussman J.L.;
RT   "Structural comparison of differently glycosylated forms of acid-beta-
RT   glucosidase, the defective enzyme in Gaucher disease.";
RL   Acta Crystallogr. D 62:1458-1465(2006).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 40-536 IN COMPLEXES WITH
RP   ISOFAGOMINE, AND SUBCELLULAR LOCATION.
RX   PubMed=17187079; DOI=10.1038/nchembio850;
RA   Lieberman R.L., Wustman B.A., Huertas P., Powe A.C. Jr., Pine C.W.,
RA   Khanna R., Schlossmacher M.G., Ringe D., Petsko G.A.;
RT   "Structure of acid beta-glucosidase with pharmacological chaperone
RT   provides insight into Gaucher disease.";
RL   Nat. Chem. Biol. 3:101-107(2007).
RN   [29]
RP   REVIEW ON GD VARIANTS.
RX   PubMed=8118460; DOI=10.1002/humu.1380030102;
RA   Horowitz M., Zimran A.;
RT   "Mutations causing Gaucher disease.";
RL   Hum. Mutat. 3:1-11(1994).
RN   [30]
RP   REVIEW ON GD VARIANTS.
RX   PubMed=8889578;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.3.CO;2-5;
RA   Beutler E., Gelbart T.;
RT   "Glucocerebrosidase (Gaucher disease).";
RL   Hum. Mutat. 8:207-213(1996).
RN   [31]
RP   REVIEW ON GD VARIANTS.
RX   PubMed=10527671; DOI=10.1006/mgme.1999.2918;
RA   Tayebi N., Stone D.L., Sidransky E.;
RT   "Type 2 Gaucher disease: an expanding phenotype.";
RL   Mol. Genet. Metab. 68:209-219(1999).
RN   [32]
RP   REVIEW ON GD VARIANTS.
RX   PubMed=10649495;
RX   DOI=10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.3.CO;2-J;
RA   Stone D.L., Tayebi N., Orvisky E., Stubblefield B., Madike V.,
RA   Sidransky E.;
RT   "Glucocerebrosidase gene mutations in patients with type 2 Gaucher
RT   disease.";
RL   Hum. Mutat. 15:181-188(2000).
RN   [33]
RP   VARIANT GD TYR-255.
RX   PubMed=1974409; DOI=10.1111/j.1469-1809.1990.tb00371.x;
RA   Beutler E., Gelbart T.;
RT   "Gaucher disease associated with a unique KpnI restriction site:
RT   identification of the amino-acid substitution.";
RL   Ann. Hum. Genet. 54:149-153(1990).
RN   [34]
RP   VARIANT GD CYS-502, AND CHARACTERIZATION OF VARIANT GD CYS-502.
RX   PubMed=1972019; DOI=10.1089/dna.1990.9.233;
RA   Hong C.M., Ohashi T., Yu X.J., Weiler S., Barranger J.A.;
RT   "Sequence of two alleles responsible for Gaucher disease.";
RL   DNA Cell Biol. 9:233-241(1990).
RN   [35]
RP   VARIANTS GD.
RX   PubMed=8432537; DOI=10.1006/geno.1993.1035;
RA   Beutler E., Gelbart T., West C.;
RT   "Identification of six new Gaucher disease mutations.";
RL   Genomics 15:203-205(1993).
RN   [36]
RP   VARIANT GD HIS-535.
RX   PubMed=7916532; DOI=10.1002/ajmg.1320510216;
RA   Choy F.Y.M., Wei C., Applegarth D.A., McGillivray B.C.;
RT   "DNA analysis of an uncommon missense mutation in a Gaucher disease
RT   patient of Jewish-Polish-Russian descent.";
RL   Am. J. Med. Genet. 51:156-160(1994).
RN   [37]
RP   VARIANT GD ASN-438.
RX   PubMed=8112750; DOI=10.1007/BF00210614;
RA   Beutler E., Gelbart T.;
RT   "Two new Gaucher disease mutations.";
RL   Hum. Genet. 93:209-210(1994).
RN   [38]
RP   VARIANTS GD SER-409 AND CYS-457.
RX   PubMed=8076951; DOI=10.1007/BF00208292;
RA   Tuteja R., Tuteja N., Lilliu F., Bembi B., Galanello R., Cao A.,
RA   Baralle F.E.;
RT   "Y418C: a novel mutation in exon 9 of the glucocerebrosidase gene of a
RT   patient with Gaucher disease creates a new Bgl I site.";
RL   Hum. Genet. 94:314-315(1994).
RN   [39]
RP   VARIANTS GD ASP-215; THR-221; ARG-241; GLN-296; CYS-324; GLY-417 AND
RP   ASN-419.
RX   PubMed=8790604;
RA   Beutler E., Demina A., Gelbart T.;
RT   "Glucocerebrosidase mutations in Gaucher disease.";
RL   Mol. Med. 1:82-92(1994).
RN   [40]
RP   VARIANTS GD SER-409; HIS-448; PRO-483 AND CYS-502.
RX   PubMed=7627184; DOI=10.1002/humu.1380050406;
RA   Cormand B., Vilageliu L., Burguera J.M., Balcells S.,
RA   Gonzalez-Duarte R., Grinberg D., Chabas A.;
RT   "Gaucher disease in Spanish patients: analysis of eight mutations.";
RL   Hum. Mutat. 5:303-309(1995).
RN   [41]
RP   VARIANT GD SER-217.
RX   PubMed=7627192; DOI=10.1002/humu.1380050414;
RA   Choy F.Y.M., Wei C.;
RT   "Identification of a new mutation (P178S) in an African-American
RT   patient with type 2 Gaucher disease.";
RL   Hum. Mutat. 5:345-347(1995).
RN   [42]
RP   VARIANTS GD SER-409; LEU-426; LEU-433 AND PRO-483.
RX   PubMed=8937765;
RA   Morar B., Lane A.B.;
RT   "The molecular characterization of Gaucher disease in South Africa.";
RL   Clin. Genet. 50:78-84(1996).
RN   [43]
RP   VARIANTS GD LEU-54; GLU-85 AND SER-227.
RX   PubMed=8829654;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<214::AID-HUMU5>3.0.CO;2-A;
RA   Kim J.-W., Liou B.B., Lai M.-Y., Ponce E., Grabowski G.A.;
RT   "Gaucher disease: identification of three new mutations in the Korean
RT   and Chinese (Taiwanese) populations.";
RL   Hum. Mutat. 7:214-218(1996).
RN   [44]
RP   VARIANTS GD HIS-352 AND GLN-398.
RX   PubMed=8829663;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<272::AID-HUMU14>3.3.CO;2-7;
RA   Cormand B., Vilageliu L., Balcells S., Gonzalez-Duatre R., Chabas A.,
RA   Grinberg D.;
RT   "Two novel (1098insA and Y313H) and one rare (R359Q) mutations
RT   detected in exon 8 of the beta-glucocerebrosidase gene in Gaucher's
RT   disease patients.";
RL   Hum. Mutat. 7:272-274(1996).
RN   [45]
RP   VARIANT GD1 THR-435.
RX   PubMed=8889591;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<280::AID-HUMU15>3.3.CO;2-6;
RA   Amaral O., Pinto E., Fortuna M., Lacerda L., Sa Miranda M.C.;
RT   "Type 1 Gaucher disease: identification of N396T and prevalence of
RT   glucocerebrosidase mutations in the Portuguese.";
RL   Hum. Mutat. 8:280-281(1996).
RN   [46]
RP   VARIANTS GD3 LEU-437 AND ILE-530.
RX   PubMed=8780099; DOI=10.1212/WNL.46.4.1102;
RA   Seeman P.J.V., Finckh U., Hoeppner J., Lakner V., Liebisch I.,
RA   Grau G., Rolfs A.;
RT   "Two new missense mutations in a non-Jewish Caucasian family with type
RT   3 Gaucher disease.";
RL   Neurology 46:1102-1107(1996).
RN   [47]
RP   VARIANTS GD LEU-414 AND THR-441.
RX   PubMed=9182788;
RX   DOI=10.1002/(SICI)1096-8628(19970627)70:4<437::AID-AJMG19>3.0.CO;2-I;
RA   Cormand B., Grinberg D., Gort L., Fiumara A., Barone R., Vilageliu L.,
RA   Chabas A.;
RT   "Two new mild homozygous mutations in Gaucher disease patients:
RT   clinical signs and biochemical analyses.";
RL   Am. J. Med. Genet. 70:437-443(1997).
RN   [48]
RP   VARIANTS GD VAL-76; GLU-85; TRP-87; TRP-159; SER-227; ILE-252 AND
RP   PRO-483.
RX   PubMed=9217217;
RX   DOI=10.1002/(SICI)1096-8628(19970808)71:2<172::AID-AJMG10>3.0.CO;2-B;
RA   Choy F.Y.M., Humphries M.L., Shi H.;
RT   "Identification of two novel and four uncommon missense mutations
RT   among Chinese Gaucher disease patients.";
RL   Am. J. Med. Genet. 71:172-178(1997).
RN   [49]
RP   VARIANT GD LYS-501.
RX   PubMed=9279145; DOI=10.1136/adc.77.1.17;
RA   Hatton C.E., Cooper A., Whitehouse C., Wraith J.E.;
RT   "Mutation analysis in 46 British and Irish patients with Gaucher's
RT   disease.";
RL   Arch. Dis. Child. 77:17-22(1997).
RN   [50]
RP   VARIANTS GD TRP-87; GLU-234; ARG-241; ILE-252; ASN-310; LEU-391 AND
RP   SER-409.
RX   PubMed=9153297; DOI=10.1172/JCI119437;
RA   Grace M.E., Desnick R.J., Pastores G.M.;
RT   "Identification and expression of acid beta-glucosidase mutations
RT   causing severe type 1 and neurologic type 2 Gaucher disease in non-
RT   Jewish patients.";
RL   J. Clin. Invest. 99:2530-2537(1997).
RN   [51]
RP   VARIANTS GD VAL-228; ILE-252; GLY-405; HIS-448; GLN-452; PRO-483 AND
RP   CYS-535.
RX   PubMed=9061570; DOI=10.1023/A:1005313724361;
RA   Ida H., Rennert O.M., Kawame H., Maekawa K., Eto Y.;
RT   "Mutation prevalence among 47 unrelated Japanese patients with Gaucher
RT   disease: identification of four novel mutations.";
RL   J. Inherit. Metab. Dis. 20:67-73(1997).
RN   [52]
RP   VARIANT PSEUDO-GAUCHER HIS-448.
RX   PubMed=9040001; DOI=10.1136/jmg.34.2.175;
RA   Uyama E., Uchino M., Ida H., Eto Y., Owada M.;
RT   "D409H/D409H genotype in Gaucher-like disease.";
RL   J. Med. Genet. 34:175-175(1997).
RN   [53]
RP   VARIANTS GD LEU-146; LEU-198; THR-380; ASN-405 AND ARG-432.
RX   PubMed=9554454; DOI=10.1159/000040815;
RA   Demina A., Beutler E.;
RT   "Six new Gaucher disease mutations.";
RL   Acta Haematol. 99:80-82(1998).
RN   [54]
RP   VARIANTS GD.
RX   PubMed=9683600; DOI=10.1086/301969;
RA   Germain D.P., Puech J.-P., Caillaud C., Kahn A., Poenaru L.;
RT   "Exhaustive screening of the acid beta-glucosidase gene, by
RT   fluorescence-assisted mismatch analysis using universal primers:
RT   mutation profile and genotype/phenotype correlations in Gaucher
RT   disease.";
RL   Am. J. Hum. Genet. 63:415-427(1998).
RN   [55]
RP   VARIANT GD2 TYR-513.
RX   PubMed=9637431;
RX   DOI=10.1002/(SICI)1096-8628(19980616)78:1<92::AID-AJMG19>3.0.CO;2-J;
RA   Choy F.Y.M., Humphries M.L., Ben-Yoseph Y.;
RT   "Gaucher type 2 disease: identification of a novel transversion
RT   mutation in a French-Irish patient.";
RL   Am. J. Med. Genet. 78:92-93(1998).
RN   [56]
RP   VARIANTS GD.
RX   PubMed=9516376; DOI=10.1006/bcmd.1998.0165;
RA   Beutler E., Gelbart T.;
RT   "Hematologically important mutations: Gaucher disease.";
RL   Blood Cells Mol. Dis. 24:2-8(1998).
RN   [57]
RP   VARIANTS GD2 LYS-80; CYS-170 AND PRO-483.
RX   PubMed=9851895; DOI=10.1006/bcmd.1998.0210;
RA   Sinclair G., Choy F.Y.M., Humphries L.;
RT   "A novel complex allele and two new point mutations in type 2 (acute
RT   neuronopathic) Gaucher disease.";
RL   Blood Cells Mol. Dis. 24:420-427(1998).
RN   [58]
RP   VARIANT GD GLY-392.
RX   PubMed=9650766;
RA   Parenti G., Filocamo M., Titomanlio L., Rizzolo G., Silvestro E.,
RA   Perretti A., Gatti R., Andria G.;
RT   "A novel mutation of the beta-glucocerebrosidase gene associated with
RT   neurologic manifestations in three sibs.";
RL   Clin. Genet. 53:281-285(1998).
RN   [59]
RP   VARIANTS GD GLU-152; PRO-173; GLU-428; LEU-430; ILE-431 AND HIS-451.
RX   PubMed=9554746;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<295::AID-HUMU7>3.0.CO;2-6;
RA   Cormand B., Grinberg D., Gort L., Chabas A., Vilageliu L.;
RT   "Molecular analysis and clinical findings in the Spanish Gaucher
RT   disease population: putative haplotype of the N370S ancestral
RT   chromosome.";
RL   Hum. Mutat. 11:295-305(1998).
RN   [60]
RP   VARIANTS GD1 GLY-230 AND SER-409.
RX   PubMed=10206680;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<411::AID-HUMU13>3.0.CO;2-X;
RA   Choy F.Y.M., Humphries M.L., Ben-Yoseph Y.;
RT   "A novel mutation (V191G) in a German-British type 1 Gaucher disease
RT   patient.";
RL   Hum. Mutat. 11:411-412(1998).
RN   [61]
RP   VARIANTS GD1 SER-409 AND LEU-440.
RX   PubMed=10340647;
RX   DOI=10.1002/(SICI)1096-8628(19990604)84:4<334::AID-AJMG5>3.3.CO;2-G;
RA   Wasserstein M.P., Martignetti J.A., Zeitlin R., Lumerman H.,
RA   Solomon M., Grace M.E., Desnick R.J.;
RT   "Type 1 Gaucher disease presenting with extensive mandibular lytic
RT   lesions: identification and expression of a novel acid beta-
RT   glucosidase mutation.";
RL   Am. J. Med. Genet. 84:334-339(1999).
RN   [62]
RP   VARIANTS GD ARG-241; CYS-244; ILE-252; HIS-448 AND PRO-483.
RX   PubMed=10360404;
RX   DOI=10.1002/(SICI)1096-8628(19990611)84:5<484::AID-AJMG14>3.0.CO;2-W;
RA   Choy F.Y.M., Wong K., Shi H.P.;
RT   "Glucocerebrosidase mutations among Chinese neuronopathic and non-
RT   neuronopathic Gaucher disease patients.";
RL   Am. J. Med. Genet. 84:484-486(1999).
RN   [63]
RP   VARIANTS GD.
RX   PubMed=10744424;
RA   Hodanov K., Hrebicek M., Cervenkov M., Mrzov L., Veprekov L.,
RA   Zemen J.;
RT   "Analysis of the beta-glucocerebrosidase gene in Czech and Slovak
RT   Gaucher patients: mutation profile and description of six novel mutant
RT   alleles.";
RL   Blood Cells Mol. Dis. 25:287-298(1999).
RN   [64]
RP   VARIANTS PERINATAL LETHAL GD ARG-350 AND PHE-437.
RX   PubMed=10352942; DOI=10.1038/sj.ejhg.5200315;
RA   Stone D.L., van Diggelen O.P., de Klerk J.B.C., Gaillard J.L.J.,
RA   Niermeijer M.F., Willemsen R., Tayebi N., Sidransky E.;
RT   "Is the perinatal lethal form of Gaucher disease more common than
RT   classic type 2 Gaucher disease?";
RL   Eur. J. Hum. Genet. 7:505-509(1999).
RN   [65]
RP   VARIANTS GD PRO-173; TRP-234; SER-409; SER-416; HIS-448 AND PRO-483.
RX   PubMed=10447266;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU16>3.0.CO;2-E;
RA   Sarria A.J., Giraldo P., Perez-Calvo J.I., Pocovi M.;
RT   "Detection of three rare (G377S, T134P and 1451delAC), and two novel
RT   mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher
RT   disease patients.";
RL   Hum. Mutat. 14:88-88(1999).
RN   [66]
RP   VARIANTS GD TRP-87; ASN-118; THR-129; ASP-156; GLN-159; TRP-159;
RP   LEU-170; ILE-173; CYS-209; PRO-209; SER-227; THR-229; PRO-235;
RP   ARG-241; ILE-252; GLN-296; CYS-324; THR-380; MET-408; SER-409;
RP   SER-416; LEU-433; TYR-438; HIS-448; PRO-483 AND CYS-502, AND VARIANT
RP   LYS-365.
RX   PubMed=10796875; DOI=10.1086/302925;
RA   Koprivica V., Stone D.L., Park J.K., Callahan M., Frisch A.,
RA   Cohen I.J., Tayebi N., Sidransky E.;
RT   "Analysis and classification of 304 mutant alleles in patients with
RT   type 1 and type 3 Gaucher disease.";
RL   Am. J. Hum. Genet. 66:1777-1786(2000).
RN   [67]
RP   VARIANTS GD SER-55 AND HIS-448.
RX   PubMed=11992489; DOI=10.1002/ajmg.10385;
RA   Bodamer O.A.F., Church H.J., Cooper A., Wraith J.E., Scott C.R.,
RA   Scaglia F.;
RT   "Variant Gaucher disease characterized by dysmorphic features, absence
RT   of cardiovascular involvement, laryngospasm, and compound
RT   heterozygosity for a novel mutation (D409H/C16S).";
RL   Am. J. Med. Genet. 109:328-331(2002).
RN   [68]
RP   VARIANTS GD GLU-175; PRO-201; GLU-237; LEU-290 AND PHE-441.
RX   PubMed=11933202; DOI=10.1002/humu.9024;
RA   Orvisky E., Park J.K., Parker A., Walker J.M., Martin B.M.,
RA   Stubblefield B.K., Uyama E., Tayebi N., Sidransky E.;
RT   "The identification of eight novel glucocerebrosidase (GBA) mutations
RT   in patients with Gaucher disease.";
RL   Hum. Mutat. 19:458-459(2002).
RN   [69]
RP   VARIANTS GD THR-198; ARG-241; ARG-270; ILE-400 AND ARG-490.
RX   PubMed=12204005; DOI=10.1002/humu.9058;
RA   Filocamo M., Mazzotti R., Stroppiano M., Seri M., Giona F.,
RA   Parenti G., Regis S., Corsolini F., Zoboli S., Gatti R.;
RT   "Analysis of the glucocerebrosidase gene and mutation profile in 144
RT   Italian Gaucher patients.";
RL   Hum. Mutat. 20:234-235(2002).
RN   [70]
RP   POSSIBLE INVOLVEMENT IN PARKINSON DISEASE.
RX   PubMed=12847165; DOI=10.1212/01.WNL.0000072482.70963.D7;
RA   Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M.,
RA   Zorzon M., Martini C., Gioulis M., Pittis M.G., Capus L.;
RT   "Gaucher's disease with Parkinson's disease: clinical and pathological
RT   aspects.";
RL   Neurology 61:99-101(2003).
RN   [71]
RP   VARIANT GD SER-55.
RX   PubMed=15292921; DOI=10.1038/sj.ejhg.5201251;
RA   Church H.J., Cooper A., Stewart F., Thornton C.M., Wraith J.E.;
RT   "Homozygous loss of a cysteine residue in the glucocerebrosidase gene
RT   results in Gaucher's disease with a hydropic phenotype.";
RL   Eur. J. Hum. Genet. 12:975-978(2004).
RN   [72]
RP   CHARACTERIZATION OF VARIANT GD SER-409.
RX   PubMed=15826241; DOI=10.1042/BJ20050325;
RA   Salvioli R., Tatti M., Scarpa S., Moavero S.M., Ciaffoni F.,
RA   Felicetti F., Kaneski C.R., Brady R.O., Vaccaro A.M.;
RT   "The N370S (Asn370->Ser) mutation affects the capacity of
RT   glucosylceramidase to interact with anionic phospholipid-containing
RT   membranes and saposin C.";
RL   Biochem. J. 390:95-103(2005).
RN   [73]
RP   VARIANTS GD1 ASN-63; SER-158; TRP-159; CYS-170; LEU-221; GLU-230;
RP   ARG-241; GLN-294; CYS-324; SER-409; ASN-438; LEU-440; HIS-448;
RP   CYS-457; ASP-460; PRO-483 AND ARG-490, AND CHARACTERIZATION OF
RP   VARIANTS GD1 ASN-63; SER-158; LEU-221; GLU-230 AND ASP-460.
RX   PubMed=15605411; DOI=10.1002/humu.9301;
RA   Miocic S., Filocamo M., Dominissini S., Montalvo A.L., Vlahovicek K.,
RA   Deganuto M., Mazzotti R., Cariati R., Bembi B., Pittis M.G.;
RT   "Identification and functional characterization of five novel mutant
RT   alleles in 58 Italian patients with Gaucher disease type 1.";
RL   Hum. Mutat. 25:100-100(2005).
RN   [74]
RP   POSSIBLE INVOLVEMENT IN PARKINSON DISEASE.
RX   PubMed=16148263; DOI=10.1212/01.wnl.0000176987.47875.28;
RA   Aharon-Peretz J., Badarny S., Rosenbaum H., Gershoni-Baruch R.;
RT   "Mutations in the glucocerebrosidase gene and Parkinson disease:
RT   phenotype-genotype correlation.";
RL   Neurology 65:1460-1461(2005).
RN   [75]
RP   INVOLVEMENT OF VARIANT GD PRO-483 IN SUSCEPTIBILITY TO PARKINSON
RP   DISEASE.
RX   PubMed=17620502; DOI=10.1001/archneur.64.7.1056;
RA   Tan E.K., Tong J., Fook-Chong S., Yih Y., Wong M.C., Pavanni R.,
RA   Zhao Y.;
RT   "Glucocerebrosidase mutations and risk of Parkinson disease in Chinese
RT   patients.";
RL   Arch. Neurol. 64:1056-1058(2007).
RN   [76]
RP   INVOLVEMENT OF VARIANTS GD SER-409 AND PRO-483 IN SUSCEPTIBILITY TO
RP   PARKINSON DISEASE.
RX   PubMed=18332251; DOI=10.1001/archneurol.2007.68;
RA   Mata I.F., Samii A., Schneer S.H., Roberts J.W., Griffith A.,
RA   Leis B.C., Schellenberg G.D., Sidransky E., Bird T.D., Leverenz J.B.,
RA   Tsuang D., Zabetian C.P.;
RT   "Glucocerebrosidase gene mutations: a risk factor for Lewy body
RT   disorders.";
RL   Arch. Neurol. 65:379-382(2008).
RN   [77]
RP   INVOLVEMENT OF VARIANTS GD SER-409 AND PRO-483 IN SUSCEPTIBILITY TO
RP   PARKINSON DISEASE.
RX   PubMed=19846850; DOI=10.1056/NEJMoa0901281;
RA   Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G.,
RA   Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M.,
RA   Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S.,
RA   Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R.,
RA   Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E.,
RA   Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A.,
RA   Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R.,
RA   Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A.,
RA   Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C.,
RA   Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T.,
RA   Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R.,
RA   Zabetian C.P., Zhao Y., Ziegler S.G.;
RT   "Multicenter analysis of glucocerebrosidase mutations in Parkinson's
RT   disease.";
RL   N. Engl. J. Med. 361:1651-1661(2009).
CC   -!- CATALYTIC ACTIVITY: D-glucosyl-N-acylsphingosine + H(2)O = D-
CC       glucose + N-acylsphingosine.
CC   -!- ENZYME REGULATION: Requires saposin-C and anionic phospholipids
CC       for activity.
CC   -!- SUBUNIT: Interacts with saposin-C. Interacts with SCARB2.
CC       {ECO:0000269|PubMed:10781797, ECO:0000269|PubMed:15817452,
CC       ECO:0000269|PubMed:18022370}.
CC   -!- INTERACTION:
CC       O35114:Scarb2 (xeno); NbExp=1; IntAct=EBI-1564609, EBI-1564519;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane
CC       {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:18022370}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:18022370}; Lumenal side
CC       {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319,
CC       ECO:0000269|PubMed:18022370}. Note=Interaction with saposin-C
CC       promotes membrane association. Targeting to lysosomes occurs
CC       through an alternative MPR-independent mechanism via SCARB2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=5;
CC       Name=Long;
CC         IsoId=P04062-1; Sequence=Displayed;
CC         Note=Has a 39 residue signal sequence. The upstream initiation
CC         site produces two to three times as much protein as does the
CC         downstream initiation codon.;
CC       Name=Short;
CC         IsoId=P04062-2; Sequence=VSP_018800;
CC         Note=Has a 19 residue signal sequence.;
CC       Name=3;
CC         IsoId=P04062-3; Sequence=VSP_025216, VSP_025217, VSP_025218;
CC         Note=Produced by alternative splicing.;
CC       Name=4;
CC         IsoId=P04062-4; Sequence=VSP_054655;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=P04062-5; Sequence=VSP_054656;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Gaucher disease (GD) [MIM:230800]: A lysosomal storage
CC       disease due to deficient activity of beta-glucocerebrosidase and
CC       characterized by accumulation of glucosylceramide in the reticulo-
CC       endothelial system. Different clinical forms are recognized
CC       depending on the presence (neuronopathic forms) or absence of
CC       central nervous system involvement, severity and age of onset.
CC       {ECO:0000269|PubMed:10352942, ECO:0000269|PubMed:10360404,
CC       ECO:0000269|PubMed:10447266, ECO:0000269|PubMed:10744424,
CC       ECO:0000269|PubMed:10796875, ECO:0000269|PubMed:11933202,
CC       ECO:0000269|PubMed:11992489, ECO:0000269|PubMed:12204005,
CC       ECO:0000269|PubMed:15292921, ECO:0000269|PubMed:1972019,
CC       ECO:0000269|PubMed:1974409, ECO:0000269|PubMed:7627184,
CC       ECO:0000269|PubMed:7627192, ECO:0000269|PubMed:7916532,
CC       ECO:0000269|PubMed:8076951, ECO:0000269|PubMed:8112750,
CC       ECO:0000269|PubMed:8294033, ECO:0000269|PubMed:8432537,
CC       ECO:0000269|PubMed:8790604, ECO:0000269|PubMed:8829654,
CC       ECO:0000269|PubMed:8829663, ECO:0000269|PubMed:8937765,
CC       ECO:0000269|PubMed:9061570, ECO:0000269|PubMed:9153297,
CC       ECO:0000269|PubMed:9182788, ECO:0000269|PubMed:9217217,
CC       ECO:0000269|PubMed:9279145, ECO:0000269|PubMed:9516376,
CC       ECO:0000269|PubMed:9554454, ECO:0000269|PubMed:9554746,
CC       ECO:0000269|PubMed:9650766, ECO:0000269|PubMed:9683600}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Gaucher disease 1 (GD1) [MIM:230800]: A form of Gaucher
CC       disease characterized by hepatosplenomegaly with consequent anemia
CC       and thrombopenia, and bone involvement. The central nervous system
CC       is not involved. {ECO:0000269|PubMed:10206680,
CC       ECO:0000269|PubMed:10340647, ECO:0000269|PubMed:15605411,
CC       ECO:0000269|PubMed:8889591, ECO:0000269|Ref.14}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Gaucher disease 2 (GD2) [MIM:230900]: The most severe
CC       form of Gaucher disease. It manifests soon after birth, with death
CC       generally occurring before patients reach two years of age.
CC       {ECO:0000269|PubMed:9637431, ECO:0000269|PubMed:9851895}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Gaucher disease 3 (GD3) [MIM:231000]: A subacute form of
CC       neuronopathic Gaucher disease. It has later onset and slower
CC       progression compared to the acute form of neuronopathic Gaucher
CC       disease 2. {ECO:0000269|PubMed:8780099}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Gaucher disease 3C (GD3C) [MIM:231005]: A variant of
CC       subacute neuronopathic Gaucher disease 3 associated with
CC       cardiovascular calcifications. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Gaucher disease perinatal lethal (GDPL) [MIM:608013]:
CC       Distinct form of Gaucher disease type 2, characterized by fetal
CC       onset. Hydrops fetalis, in utero fetal death and neonatal distress
CC       are prominent features. When hydrops is absent, neurologic
CC       involvement begins in the first week and leads to death within 3
CC       months. Hepatosplenomegaly is a major sign, and is associated with
CC       ichthyosis, arthrogryposis, and facial dysmorphism. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Perinatal lethal Gaucher disease is associated with
CC       non-immune hydrops fetalis, a generalized edema of the fetus with
CC       fluid accumulation in the body cavities due to non-immune causes.
CC       Non-immune hydrops fetalis is not a diagnosis in itself but a
CC       symptom, a feature of many genetic disorders, and the end-stage of
CC       a wide variety of disorders.
CC   -!- DISEASE: Parkinson disease (PARK) [MIM:168600]: A complex
CC       neurodegenerative disorder characterized by bradykinesia, resting
CC       tremor, muscular rigidity and postural instability. Additional
CC       features are characteristic postural abnormalities, dysautonomia,
CC       dystonic cramps, and dementia. The pathology of Parkinson disease
CC       involves the loss of dopaminergic neurons in the substantia nigra
CC       and the presence of Lewy bodies (intraneuronal accumulations of
CC       aggregated proteins), in surviving neurons in various areas of the
CC       brain. The disease is progressive and usually manifests after the
CC       age of 50 years, although early-onset cases (before 50 years) are
CC       known. The majority of the cases are sporadic suggesting a
CC       multifactorial etiology based on environmental and genetic
CC       factors. However, some patients present with a positive family
CC       history for the disease. Familial forms of the disease usually
CC       begin at earlier ages and are associated with atypical clinical
CC       features. {ECO:0000269|PubMed:12847165,
CC       ECO:0000269|PubMed:16148263, ECO:0000269|PubMed:19286695}.
CC       Note=Disease susceptibility may be associated with variations
CC       affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the names Ceredase and Cerezyme
CC       (Genzyme). Used to treat Gaucher's disease.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 30 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Ceredase; Note=Clinical information on
CC       Ceredase;
CC       URL="http://www.rxlist.com/ceredase-drug.htm";
CC   -!- WEB RESOURCE: Name=Cerezyme; Note=Clinical information on
CC       Cerezyme;
CC       URL="http://www.rxlist.com/cerezyme-drug.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16328; AAA35873.1; -; mRNA.
DR   EMBL; K02920; AAA35877.1; -; mRNA.
DR   EMBL; J03059; AAC63056.1; -; Genomic_DNA.
DR   EMBL; D13286; BAA02545.1; -; mRNA.
DR   EMBL; D13287; BAA02546.1; -; mRNA.
DR   EMBL; AF023268; AAC51820.1; -; Genomic_DNA.
DR   EMBL; AK291911; BAF84600.1; -; mRNA.
DR   EMBL; AK298900; BAH12898.1; -; mRNA.
DR   EMBL; AK300829; BAH13357.1; -; mRNA.
DR   EMBL; AL713999; CAI95090.1; -; Genomic_DNA.
DR   EMBL; BC003356; AAH03356.1; -; mRNA.
DR   EMBL; M19285; AAA35880.1; -; mRNA.
DR   EMBL; M18916; AAA35878.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M18917; AAA35879.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M20248; AAA35874.1; -; Genomic_DNA.
DR   EMBL; M20282; AAA35876.1; -; Genomic_DNA.
DR   CCDS; CCDS1102.1; -. [P04062-1]
DR   CCDS; CCDS53373.1; -. [P04062-4]
DR   CCDS; CCDS53374.1; -. [P04062-5]
DR   PIR; A94068; EUHUGC.
DR   PIR; I52980; I52980.
DR   PIR; I67792; I67792.
DR   RefSeq; NP_000148.2; NM_000157.3. [P04062-1]
DR   RefSeq; NP_001005741.1; NM_001005741.2. [P04062-1]
DR   RefSeq; NP_001005742.1; NM_001005742.2. [P04062-1]
DR   RefSeq; NP_001165282.1; NM_001171811.1. [P04062-4]
DR   RefSeq; NP_001165283.1; NM_001171812.1. [P04062-5]
DR   RefSeq; XP_006711333.1; XM_006711270.1. [P04062-1]
DR   RefSeq; XP_011507709.1; XM_011509407.1. [P04062-1]
DR   UniGene; Hs.282997; -.
DR   PDB; 1OGS; X-ray; 2.00 A; A/B=40-536.
DR   PDB; 1Y7V; X-ray; 2.40 A; A/B=40-536.
DR   PDB; 2F61; X-ray; 2.50 A; A/B=40-536.
DR   PDB; 2J25; X-ray; 2.90 A; A/B=40-536.
DR   PDB; 2NSX; X-ray; 2.11 A; A/B/C/D=40-536.
DR   PDB; 2NT0; X-ray; 1.79 A; A/B/C/D=40-536.
DR   PDB; 2NT1; X-ray; 2.30 A; A/B/C/D=40-536.
DR   PDB; 2V3D; X-ray; 1.96 A; A/B=40-536.
DR   PDB; 2V3E; X-ray; 2.00 A; A/B=40-536.
DR   PDB; 2V3F; X-ray; 1.95 A; A/B=40-536.
DR   PDB; 2VT0; X-ray; 2.15 A; A/B=40-536.
DR   PDB; 2WCG; X-ray; 2.30 A; A/B=40-536.
DR   PDB; 2WKL; X-ray; 2.70 A; A/B=40-536.
DR   PDB; 2XWD; X-ray; 2.66 A; A/B=40-536.
DR   PDB; 2XWE; X-ray; 2.31 A; A/B=40-536.
DR   PDB; 3GXD; X-ray; 2.50 A; A/B/C/D=40-536.
DR   PDB; 3GXF; X-ray; 2.40 A; A/B/C/D=40-536.
DR   PDB; 3GXI; X-ray; 1.84 A; A/B/C/D=40-536.
DR   PDB; 3GXM; X-ray; 2.20 A; A/B/C/D=40-536.
DR   PDB; 3KE0; X-ray; 2.70 A; A/B=40-536.
DR   PDB; 3KEH; X-ray; 2.80 A; A/B=40-536.
DR   PDB; 3RIK; X-ray; 2.48 A; A/B/C/D=40-536.
DR   PDB; 3RIL; X-ray; 2.40 A; A/B/C/D=40-536.
DR   PDBsum; 1OGS; -.
DR   PDBsum; 1Y7V; -.
DR   PDBsum; 2F61; -.
DR   PDBsum; 2J25; -.
DR   PDBsum; 2NSX; -.
DR   PDBsum; 2NT0; -.
DR   PDBsum; 2NT1; -.
DR   PDBsum; 2V3D; -.
DR   PDBsum; 2V3E; -.
DR   PDBsum; 2V3F; -.
DR   PDBsum; 2VT0; -.
DR   PDBsum; 2WCG; -.
DR   PDBsum; 2WKL; -.
DR   PDBsum; 2XWD; -.
DR   PDBsum; 2XWE; -.
DR   PDBsum; 3GXD; -.
DR   PDBsum; 3GXF; -.
DR   PDBsum; 3GXI; -.
DR   PDBsum; 3GXM; -.
DR   PDBsum; 3KE0; -.
DR   PDBsum; 3KEH; -.
DR   PDBsum; 3RIK; -.
DR   PDBsum; 3RIL; -.
DR   ProteinModelPortal; P04062; -.
DR   SMR; P04062; 40-536.
DR   BioGrid; 108899; 14.
DR   DIP; DIP-38645N; -.
DR   IntAct; P04062; 28.
DR   MINT; MINT-3004354; -.
DR   STRING; 9606.ENSP00000314508; -.
DR   BindingDB; P04062; -.
DR   ChEMBL; CHEMBL2179; -.
DR   DrugBank; DB06720; Velaglucerase alfa.
DR   SwissLipids; SLP:000001387; -.
DR   Allergome; 8244; Hom s Glucocerebrosidase.
DR   CAZy; GH30; Glycoside Hydrolase Family 30.
DR   iPTMnet; P04062; -.
DR   PhosphoSite; P04062; -.
DR   SwissPalm; P04062; -.
DR   BioMuta; GBA; -.
DR   DMDM; 55584151; -.
DR   MaxQB; P04062; -.
DR   PaxDb; P04062; -.
DR   PRIDE; P04062; -.
DR   DNASU; 2629; -.
DR   Ensembl; ENST00000327247; ENSP00000314508; ENSG00000177628. [P04062-1]
DR   Ensembl; ENST00000368373; ENSP00000357357; ENSG00000177628. [P04062-1]
DR   Ensembl; ENST00000427500; ENSP00000402577; ENSG00000177628. [P04062-5]
DR   Ensembl; ENST00000428024; ENSP00000397986; ENSG00000177628. [P04062-4]
DR   GeneID; 2629; -.
DR   KEGG; hsa:2629; -.
DR   UCSC; uc001fjh.3; human. [P04062-1]
DR   CTD; 2629; -.
DR   GeneCards; GBA; -.
DR   GeneReviews; GBA; -.
DR   H-InvDB; HIX0001123; -.
DR   HGNC; HGNC:4177; GBA.
DR   HPA; CAB037171; -.
DR   HPA; CAB037289; -.
DR   HPA; HPA006667; -.
DR   MalaCards; GBA; -.
DR   MIM; 168600; phenotype.
DR   MIM; 230800; phenotype.
DR   MIM; 230900; phenotype.
DR   MIM; 231000; phenotype.
DR   MIM; 231005; phenotype.
DR   MIM; 606463; gene.
DR   MIM; 608013; phenotype.
DR   neXtProt; NX_P04062; -.
DR   Orphanet; 1648; Dementia with Lewy body.
DR   Orphanet; 85212; Fetal Gaucher disease.
DR   Orphanet; 2072; Gaucher disease - ophthalmoplegia - cardiovascular calcification.
DR   Orphanet; 77259; Gaucher disease type 1.
DR   Orphanet; 77260; Gaucher disease type 2.
DR   Orphanet; 77261; Gaucher disease type 3.
DR   Orphanet; 319705; Parkinson disease.
DR   Orphanet; 2828; Young adult-onset Parkinsonism.
DR   PharmGKB; PA28591; -.
DR   eggNOG; KOG2566; Eukaryota.
DR   eggNOG; COG5520; LUCA.
DR   GeneTree; ENSGT00390000009464; -.
DR   HOVERGEN; HBG002285; -.
DR   InParanoid; P04062; -.
DR   KO; K01201; -.
DR   OMA; QPDQKFQ; -.
DR   OrthoDB; EOG76DTRZ; -.
DR   PhylomeDB; P04062; -.
DR   TreeFam; TF314254; -.
DR   BRENDA; 3.2.1.45; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   EvolutionaryTrace; P04062; -.
DR   GeneWiki; Glucocerebrosidase; -.
DR   GenomeRNAi; 2629; -.
DR   NextBio; 10357; -.
DR   PRO; PR:P04062; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P04062; -.
DR   CleanEx; HS_GBA; -.
DR   CleanEx; HS_GC; -.
DR   ExpressionAtlas; P04062; baseline and differential.
DR   Genevisible; P04062; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; ISS:BHF-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0004348; F:glucosylceramidase activity; IDA:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; ISS:BHF-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0006680; P:glucosylceramide catabolic process; IMP:BHF-UCL.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:1903052; P:positive regulation of proteolysis involved in cellular protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0033561; P:regulation of water loss via skin; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0009268; P:response to pH; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0097066; P:response to thyroid hormone; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   Gene3D; 2.60.40.1180; -; 1.
DR   Gene3D; 3.20.20.80; -; 1.
DR   InterPro; IPR013780; Glyco_hydro_13_b.
DR   InterPro; IPR001139; Glyco_hydro_30.
DR   InterPro; IPR013781; Glyco_hydro_catalytic_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR11069; PTHR11069; 1.
DR   Pfam; PF02055; Glyco_hydro_30; 1.
DR   PRINTS; PR00843; GLHYDRLASE30.
DR   SUPFAM; SSF51445; SSF51445; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Gaucher disease; Glycoprotein; Glycosidase; Hydrolase;
KW   Ichthyosis; Lipid metabolism; Lysosome; Membrane; Neurodegeneration;
KW   Parkinson disease; Parkinsonism; Pharmaceutical; Polymorphism;
KW   Reference proteome; Signal; Sphingolipid metabolism.
FT   SIGNAL        1     39       In isoform Long. {ECO:0000269|Ref.12}.
FT   SIGNAL       21     39       In isoform Short. {ECO:0000269|Ref.12}.
FT   CHAIN        40    536       Glucosylceramidase.
FT                                /FTId=PRO_0000012177.
FT   ACT_SITE    274    274       Proton donor.
FT                                {ECO:0000269|PubMed:15817452}.
FT   ACT_SITE    379    379       Nucleophile.
FT                                {ECO:0000269|PubMed:15817452}.
FT   CARBOHYD     58     58       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12792654,
FT                                ECO:0000269|PubMed:17139081}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:17139081,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    185    185       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:17139081}.
FT   CARBOHYD    309    309       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    501    501       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     43     55       {ECO:0000269|PubMed:12792654}.
FT   DISULFID     57     62       {ECO:0000269|PubMed:12792654}.
FT   VAR_SEQ       1    161       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8294033}.
FT                                /FTId=VSP_025216.
FT   VAR_SEQ       1     87       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054655.
FT   VAR_SEQ       1     20       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:3001061,
FT                                ECO:0000303|PubMed:3864160}.
FT                                /FTId=VSP_018800.
FT   VAR_SEQ     103    151       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054656.
FT   VAR_SEQ     422    423       LA -> PS (in isoform 3).
FT                                {ECO:0000303|PubMed:8294033}.
FT                                /FTId=VSP_025217.
FT   VAR_SEQ     425    536       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:8294033}.
FT                                /FTId=VSP_025218.
FT   VARIANT      46     46       K -> E (in a patient with Parkinson
FT                                disease). {ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_063066.
FT   VARIANT      54     54       V -> L (in GD).
FT                                {ECO:0000269|PubMed:8829654}.
FT                                /FTId=VAR_003255.
FT   VARIANT      55     55       C -> S (in GD; neuronopathic and
FT                                perinatal lethal forms; loss of
FT                                activity). {ECO:0000269|PubMed:11992489,
FT                                ECO:0000269|PubMed:15292921,
FT                                ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032394.
FT   VARIANT      63     63       D -> N (in GD1; very low activity).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032395.
FT   VARIANT      76     76       F -> V (in GD).
FT                                {ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003256.
FT   VARIANT      80     80       E -> K (in GD2; dbSNP:rs1141808).
FT                                {ECO:0000269|PubMed:9851895}.
FT                                /FTId=VAR_009033.
FT   VARIANT      82     82       T -> I (in GD).
FT                                /FTId=VAR_003257.
FT   VARIANT      85     85       G -> E (in GD).
FT                                {ECO:0000269|PubMed:8829654,
FT                                ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003258.
FT   VARIANT      87     87       R -> Q (in GD; 20% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032197.
FT   VARIANT      87     87       R -> W (in GD; mild; dbSNP:rs1141814).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:9153297,
FT                                ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003259.
FT   VARIANT      92     92       M -> T (in dbSNP:rs3205619).
FT                                /FTId=VAR_032396.
FT   VARIANT     118    118       K -> N (in GD; mild; 8% of normal
FT                                activity; increases susceptibility to
FT                                proteolytic degradation).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_003260.
FT   VARIANT     129    129       A -> T (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032397.
FT   VARIANT     146    146       S -> L (in GD; type 2).
FT                                {ECO:0000269|PubMed:9554454}.
FT                                /FTId=VAR_009034.
FT   VARIANT     152    152       G -> E (in GD).
FT                                {ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003261.
FT   VARIANT     156    156       N -> D (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032398.
FT   VARIANT     158    158       I -> S (in GD1; very low activity).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032399.
FT   VARIANT     158    158       I -> T (in GD).
FT                                /FTId=VAR_003262.
FT   VARIANT     159    159       R -> Q (in GD; type 2; 13% of normal
FT                                activity). {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_003263.
FT   VARIANT     159    159       R -> W (in GD; severe).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003264.
FT   VARIANT     161    161       P -> L (in GD; 16% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032198.
FT   VARIANT     161    161       P -> S (in GD; mild).
FT                                /FTId=VAR_003265.
FT   VARIANT     162    162       M -> V (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032199.
FT   VARIANT     166    166       D -> V (in GD; 9% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032200.
FT   VARIANT     170    170       R -> C (in GD1 and GD2; also found in a
FT                                patient with Parkinson disease).
FT                                {ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:9851895}.
FT                                /FTId=VAR_009035.
FT   VARIANT     170    170       R -> L (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_009036.
FT   VARIANT     173    173       T -> I (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032400.
FT   VARIANT     173    173       T -> P (in GD).
FT                                {ECO:0000269|PubMed:10447266,
FT                                ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003266.
FT   VARIANT     175    175       A -> E (in GD).
FT                                {ECO:0000269|PubMed:11933202}.
FT                                /FTId=VAR_032401.
FT   VARIANT     179    179       D -> H (in GD).
FT                                /FTId=VAR_003267.
FT   VARIANT     196    196       K -> Q (in GD; severe).
FT                                /FTId=VAR_003268.
FT   VARIANT     198    198       P -> L (in GD).
FT                                {ECO:0000269|PubMed:9554454}.
FT                                /FTId=VAR_009037.
FT   VARIANT     198    198       P -> T (in GD).
FT                                {ECO:0000269|PubMed:12204005}.
FT                                /FTId=VAR_032402.
FT   VARIANT     200    200       I -> N (in GD; 5% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032201.
FT   VARIANT     200    200       I -> S (in GD).
FT                                /FTId=VAR_010059.
FT   VARIANT     201    201       H -> P (in GD).
FT                                {ECO:0000269|PubMed:11933202}.
FT                                /FTId=VAR_032403.
FT   VARIANT     209    209       R -> C (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032404.
FT   VARIANT     209    209       R -> P (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_003269.
FT   VARIANT     213    213       L -> F (in GD; 12% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032202.
FT   VARIANT     215    215       A -> D (in GD).
FT                                {ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003270.
FT   VARIANT     217    217       P -> S (in GD; type 2).
FT                                {ECO:0000269|PubMed:7627192}.
FT                                /FTId=VAR_003271.
FT   VARIANT     221    221       P -> L (in GD1; very low activity).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032405.
FT   VARIANT     221    221       P -> T (in GD).
FT                                {ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003272.
FT   VARIANT     223    223       W -> R (in GD; gene conversion).
FT                                {ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_003273.
FT   VARIANT     224    224       L -> F (in GD; 4% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032203.
FT   VARIANT     227    227       N -> K (in GD; gene conversion;
FT                                dbSNP:rs381418).
FT                                /FTId=VAR_003275.
FT   VARIANT     227    227       N -> S (in GD; type 2; dbSNP:rs364897).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:8829654,
FT                                ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003274.
FT   VARIANT     228    228       G -> V (in GD).
FT                                {ECO:0000269|PubMed:9061570}.
FT                                /FTId=VAR_010060.
FT   VARIANT     229    229       A -> E (in GD; type 2).
FT                                /FTId=VAR_009038.
FT   VARIANT     229    229       A -> T (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032406.
FT   VARIANT     230    230       V -> E (in GD1; very low activity).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032407.
FT   VARIANT     230    230       V -> G (in GD1; gene conversion;
FT                                dbSNP:rs381427).
FT                                {ECO:0000269|PubMed:10206680,
FT                                ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_003276.
FT   VARIANT     232    232       G -> E (in GD; also found in a patient
FT                                with Parkinson disease; 7% of normal
FT                                activity). {ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_032204.
FT   VARIANT     234    234       G -> E (in GD; severe).
FT                                {ECO:0000269|PubMed:9153297}.
FT                                /FTId=VAR_003277.
FT   VARIANT     234    234       G -> W (in GD).
FT                                {ECO:0000269|PubMed:10447266}.
FT                                /FTId=VAR_009039.
FT   VARIANT     235    235       S -> P (in GD; type 2; gene conversion;
FT                                dbSNP:rs1064644).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_003278.
FT   VARIANT     237    237       K -> E (in GD; severe; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:11933202,
FT                                ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032205.
FT   VARIANT     241    241       G -> E (in GD).
FT                                /FTId=VAR_010061.
FT   VARIANT     241    241       G -> R (in GD; type 1 and type 2; gene
FT                                conversion).
FT                                {ECO:0000269|PubMed:10360404,
FT                                ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:12204005,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:8294033,
FT                                ECO:0000269|PubMed:8790604,
FT                                ECO:0000269|PubMed:9153297}.
FT                                /FTId=VAR_003279.
FT   VARIANT     244    244       Y -> C (in GD).
FT                                {ECO:0000269|PubMed:10360404}.
FT                                /FTId=VAR_010062.
FT   VARIANT     251    251       Y -> H (in GD).
FT                                /FTId=VAR_003280.
FT   VARIANT     252    252       F -> I (in GD; type 2; gene conversion;
FT                                dbSNP:rs381737).
FT                                {ECO:0000269|PubMed:10360404,
FT                                ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:8294033,
FT                                ECO:0000269|PubMed:9061570,
FT                                ECO:0000269|PubMed:9153297,
FT                                ECO:0000269|PubMed:9217217}.
FT                                /FTId=VAR_003281.
FT   VARIANT     255    255       F -> Y (in GD; mild).
FT                                {ECO:0000269|PubMed:1974409}.
FT                                /FTId=VAR_003282.
FT   VARIANT     270    270       T -> R (in GD).
FT                                {ECO:0000269|PubMed:12204005}.
FT                                /FTId=VAR_032408.
FT   VARIANT     276    276       S -> P (in GD).
FT                                /FTId=VAR_003283.
FT   VARIANT     290    290       F -> L (in GD; perinatal lethal form).
FT                                {ECO:0000269|PubMed:11933202}.
FT                                /FTId=VAR_032409.
FT   VARIANT     294    294       H -> Q (in GD1; also found in Gaucher
FT                                disease type 2).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_009040.
FT   VARIANT     296    296       R -> Q (in GD; type 2; also found in a
FT                                patient with Parkinson disease).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003284.
FT   VARIANT     298    298       F -> L (in GD; type 2; 4% of normal
FT                                activity). {ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:3001061}.
FT                                /FTId=VAR_009041.
FT   VARIANT     303    303       L -> I (in GD; 5% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032206.
FT   VARIANT     304    304       G -> D (in GD).
FT                                /FTId=VAR_010063.
FT   VARIANT     305    305       P -> R (in GD; mild).
FT                                /FTId=VAR_003285.
FT   VARIANT     310    310       S -> G (in dbSNP:rs1057942).
FT                                {ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_032410.
FT   VARIANT     310    310       S -> N (in GD; less than 5% of normal
FT                                activity). {ECO:0000269|PubMed:9153297}.
FT                                /FTId=VAR_010064.
FT   VARIANT     324    324       R -> C (in GD; type 1).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003286.
FT   VARIANT     324    324       R -> H (in GD; type 2).
FT                                /FTId=VAR_009042.
FT   VARIANT     328    328       P -> L (in GD; mild).
FT                                /FTId=VAR_003287.
FT   VARIANT     342    342       K -> I (in GD).
FT                                /FTId=VAR_003288.
FT   VARIANT     343    343       Y -> C (in GD; type 2; 16% of normal
FT                                activity; increases susceptibility to
FT                                proteolytic degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_009043.
FT   VARIANT     348    348       A -> V (in GD).
FT                                /FTId=VAR_003289.
FT   VARIANT     350    350       H -> R (in perinatal lethal GD).
FT                                {ECO:0000269|PubMed:10352942}.
FT                                /FTId=VAR_009044.
FT   VARIANT     351    351       W -> C (in GD; mild).
FT                                /FTId=VAR_003290.
FT   VARIANT     352    352       Y -> H (in GD).
FT                                {ECO:0000269|PubMed:8829663}.
FT                                /FTId=VAR_003291.
FT   VARIANT     354    354       D -> H (in GD).
FT                                /FTId=VAR_003292.
FT   VARIANT     357    357       A -> D (in GD).
FT                                /FTId=VAR_003293.
FT   VARIANT     362    362       T -> I (in GD; 6% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_003294.
FT   VARIANT     363    363       L -> P (in GD).
FT                                /FTId=VAR_003295.
FT   VARIANT     364    364       G -> R (in GD; type 2).
FT                                {ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_003296.
FT   VARIANT     365    365       E -> K (in GD; mild; 42% of normal
FT                                activity; dbSNP:rs2230288).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_003297.
FT   VARIANT     368    368       R -> H (in dbSNP:rs1064648).
FT                                {ECO:0000269|PubMed:8294033}.
FT                                /FTId=VAR_032411.
FT   VARIANT     380    380       A -> T (in GD).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:9554454}.
FT                                /FTId=VAR_009045.
FT   VARIANT     381    381       C -> G (in GD; type 2; loss of activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_003298.
FT   VARIANT     388    388       E -> K (in GD; 12% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032207.
FT   VARIANT     391    391       V -> L (in GD).
FT                                {ECO:0000269|PubMed:9153297}.
FT                                /FTId=VAR_010065.
FT   VARIANT     392    392       R -> G (in GD).
FT                                {ECO:0000269|PubMed:9650766}.
FT                                /FTId=VAR_010066.
FT   VARIANT     392    392       R -> W (in GD; 5% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032208.
FT   VARIANT     398    398       R -> Q (in GD; mild).
FT                                {ECO:0000269|PubMed:8829663}.
FT                                /FTId=VAR_003299.
FT   VARIANT     400    400       M -> I (in GD; dbSNP:rs149487315).
FT                                {ECO:0000269|PubMed:12204005}.
FT                                /FTId=VAR_032412.
FT   VARIANT     402    402       Y -> C (in GD; 8% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032209.
FT   VARIANT     403    403       S -> T (in GD; mild).
FT                                /FTId=VAR_003300.
FT   VARIANT     405    405       S -> G (in GD).
FT                                {ECO:0000269|PubMed:9061570}.
FT                                /FTId=VAR_010067.
FT   VARIANT     405    405       S -> N (in GD).
FT                                {ECO:0000269|PubMed:9554454}.
FT                                /FTId=VAR_009046.
FT   VARIANT     408    408       T -> M (in GD; dbSNP:rs2230289).
FT                                {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_003301.
FT   VARIANT     409    409       N -> S (in GD1; common mutation;
FT                                associated with susceptibility to
FT                                Parkinson disease; alters interaction
FT                                with saposin-C; mild; dbSNP:rs76763715).
FT                                {ECO:0000269|PubMed:10206680,
FT                                ECO:0000269|PubMed:10340647,
FT                                ECO:0000269|PubMed:10447266,
FT                                ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:15826241,
FT                                ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:18332251,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:19846850,
FT                                ECO:0000269|PubMed:7627184,
FT                                ECO:0000269|PubMed:8076951,
FT                                ECO:0000269|PubMed:8937765,
FT                                ECO:0000269|PubMed:9153297,
FT                                ECO:0000269|Ref.14}.
FT                                /FTId=VAR_003302.
FT   VARIANT     410    410       L -> V (in GD; 15% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032210.
FT   VARIANT     414    414       V -> L (in GD; mild).
FT                                {ECO:0000269|PubMed:9182788}.
FT                                /FTId=VAR_010068.
FT   VARIANT     416    416       G -> S (in GD; mild).
FT                                {ECO:0000269|PubMed:10447266,
FT                                ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_003303.
FT   VARIANT     417    417       W -> G (in GD).
FT                                {ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003304.
FT   VARIANT     419    419       D -> A (in GD; type 2; also found in a
FT                                patient with Parkinson disease).
FT                                {ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_003305.
FT   VARIANT     419    419       D -> H (in GD; 4% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032211.
FT   VARIANT     419    419       D -> N (in GD).
FT                                {ECO:0000269|PubMed:8790604}.
FT                                /FTId=VAR_003306.
FT   VARIANT     421    421       N -> K (in GD; 22% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032212.
FT   VARIANT     426    426       P -> L (in GD).
FT                                {ECO:0000269|PubMed:8937765}.
FT                                /FTId=VAR_010069.
FT   VARIANT     428    428       G -> E (in GD; type 2).
FT                                {ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003307.
FT   VARIANT     429    429       G -> R (in GD; 17% of normal activity).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032213.
FT   VARIANT     430    430       P -> L (in GD).
FT                                {ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003308.
FT   VARIANT     431    431       N -> I (in GD; type 2).
FT                                {ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003309.
FT   VARIANT     432    432       W -> R (in GD).
FT                                {ECO:0000269|PubMed:9554454}.
FT                                /FTId=VAR_009047.
FT   VARIANT     433    433       V -> L (in GD; severe; 12% of normal
FT                                activity). {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:8937765}.
FT                                /FTId=VAR_003310.
FT   VARIANT     435    435       N -> T (in GD1; mild).
FT                                {ECO:0000269|PubMed:8889591}.
FT                                /FTId=VAR_003311.
FT   VARIANT     436    436       F -> S (in GD; 6% of normal activity;
FT                                alters protein stability and increases
FT                                susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032214.
FT   VARIANT     437    437       V -> F (in perinatal lethal GD).
FT                                {ECO:0000269|PubMed:10352942}.
FT                                /FTId=VAR_009048.
FT   VARIANT     437    437       V -> L (in GD3).
FT                                {ECO:0000269|PubMed:8780099}.
FT                                /FTId=VAR_010070.
FT   VARIANT     438    438       D -> N (in GD; type 1 and type 2; 14% of
FT                                normal activity; increases susceptibility
FT                                to proteolytic degradation).
FT                                {ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:8112750}.
FT                                /FTId=VAR_003312.
FT   VARIANT     438    438       D -> Y (in GD).
FT                                {ECO:0000269|PubMed:10796875}.
FT                                /FTId=VAR_032413.
FT   VARIANT     440    440       P -> L (in GD1).
FT                                {ECO:0000269|PubMed:10340647,
FT                                ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_010071.
FT   VARIANT     441    441       I -> F (in GD; type 3).
FT                                {ECO:0000269|PubMed:11933202}.
FT                                /FTId=VAR_032414.
FT   VARIANT     441    441       I -> T (in GD; mild).
FT                                {ECO:0000269|PubMed:9182788}.
FT                                /FTId=VAR_010072.
FT   VARIANT     448    448       D -> H (in GD; type 1 and type
FT                                neuronopathic; at homozygosity it causes
FT                                GD3C; also found in a patient with
FT                                Parkinson disease; gene conversion; very
FT                                low activity; alters protein stability;
FT                                dbSNP:rs1064651).
FT                                {ECO:0000269|PubMed:10360404,
FT                                ECO:0000269|PubMed:10447266,
FT                                ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:11992489,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:7627184,
FT                                ECO:0000269|PubMed:9040001,
FT                                ECO:0000269|PubMed:9061570}.
FT                                /FTId=VAR_003313.
FT   VARIANT     448    448       D -> V (in GD; severe; very low activity;
FT                                alters protein stability).
FT                                /FTId=VAR_003314.
FT   VARIANT     450    450       F -> I (in GD).
FT                                /FTId=VAR_010073.
FT   VARIANT     451    451       Y -> H (in GD).
FT                                {ECO:0000269|PubMed:9554746}.
FT                                /FTId=VAR_003315.
FT   VARIANT     452    452       K -> Q (in GD).
FT                                {ECO:0000269|PubMed:9061570}.
FT                                /FTId=VAR_010074.
FT   VARIANT     454    454       P -> R (in GD; type 2).
FT                                /FTId=VAR_003316.
FT   VARIANT     455    455       M -> V (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032215.
FT   VARIANT     456    456       F -> V (in GD).
FT                                /FTId=VAR_003317.
FT   VARIANT     457    457       Y -> C (in GD).
FT                                {ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:8076951}.
FT                                /FTId=VAR_003318.
FT   VARIANT     460    460       G -> D (in GD1; associated with R-490;
FT                                loss of activity).
FT                                {ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032415.
FT   VARIANT     464    464       K -> E (in GD; severe).
FT                                /FTId=VAR_003319.
FT   VARIANT     482    482       D -> N (in a patient with Parkinson
FT                                disease; dbSNP:rs75671029).
FT                                {ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_063067.
FT   VARIANT     483    483       L -> P (in GD1 and GD2; common mutation;
FT                                associated with susceptibility to
FT                                Parkinson disease; gene conversion; very
FT                                low activity; alters protein stability).
FT                                {ECO:0000269|PubMed:10360404,
FT                                ECO:0000269|PubMed:10447266,
FT                                ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:15605411,
FT                                ECO:0000269|PubMed:16293621,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:7627184,
FT                                ECO:0000269|PubMed:8937765,
FT                                ECO:0000269|PubMed:9061570,
FT                                ECO:0000269|PubMed:9217217,
FT                                ECO:0000269|PubMed:9851895}.
FT                                /FTId=VAR_003321.
FT   VARIANT     483    483       L -> R (in GD; severe).
FT                                /FTId=VAR_003320.
FT   VARIANT     485    485       A -> P (in GD).
FT                                /FTId=VAR_003322.
FT   VARIANT     490    490       H -> R (in GD; type 1; associated with D-
FT                                460). {ECO:0000269|PubMed:12204005,
FT                                ECO:0000269|PubMed:15605411}.
FT                                /FTId=VAR_032416.
FT   VARIANT     495    495       A -> P (in GD; gene conversion;
FT                                dbSNP:rs368060).
FT                                {ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_003323.
FT   VARIANT     497    497       V -> L. {ECO:0000269|PubMed:19286695}.
FT                                /FTId=VAR_063068.
FT   VARIANT     500    500       L -> P (in GD; 10% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032216.
FT   VARIANT     501    501       N -> K (in GD; type 2).
FT                                {ECO:0000269|PubMed:9279145}.
FT                                /FTId=VAR_009049.
FT   VARIANT     502    502       R -> C (in GD; 37% of normal activity;
FT                                also found in patients with Parkinson
FT                                disease). {ECO:0000269|PubMed:10796875,
FT                                ECO:0000269|PubMed:19286695,
FT                                ECO:0000269|PubMed:1972019,
FT                                ECO:0000269|PubMed:7627184}.
FT                                /FTId=VAR_003324.
FT   VARIANT     502    502       R -> P (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                {ECO:0000269|PubMed:16293621}.
FT                                /FTId=VAR_032217.
FT   VARIANT     509    509       L -> P.
FT                                /FTId=VAR_003325.
FT   VARIANT     513    513       D -> Y (in GD2).
FT                                {ECO:0000269|PubMed:9637431}.
FT                                /FTId=VAR_009050.
FT   VARIANT     517    517       G -> S (in GD).
FT                                /FTId=VAR_003326.
FT   VARIANT     530    530       T -> I (in GD3).
FT                                {ECO:0000269|PubMed:8780099}.
FT                                /FTId=VAR_010075.
FT   VARIANT     535    535       R -> C (in GD; mild).
FT                                {ECO:0000269|PubMed:9061570}.
FT                                /FTId=VAR_003327.
FT   VARIANT     535    535       R -> H (in GD; mild).
FT                                {ECO:0000269|PubMed:7916532}.
FT                                /FTId=VAR_003328.
FT   MUTAGEN      43     43       C->S: Loss of activity.
FT                                {ECO:0000269|PubMed:16293621}.
FT   MUTAGEN      57     57       C->S: Loss of activity.
FT                                {ECO:0000269|PubMed:16293621}.
FT   MUTAGEN      62     62       C->S: Loss of activity.
FT                                {ECO:0000269|PubMed:16293621}.
FT   MUTAGEN     379    379       E->G: Decreases activity 1000-fold.
FT                                {ECO:0000269|PubMed:7908905}.
FT   CONFLICT    176    176       D -> G (in Ref. 7; BAH13357).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       N -> R (in Ref. 5; BAA02546).
FT                                {ECO:0000305}.
FT   CONFLICT    470    470       S -> I (in Ref. 15; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    534    534       R -> H (in Ref. 1; AAA35873).
FT                                {ECO:0000305}.
FT   STRAND       49     52       {ECO:0000244|PDB:2NT0}.
FT   STRAND       54     57       {ECO:0000244|PDB:2NT0}.
FT   STRAND       75     82       {ECO:0000244|PDB:2NT0}.
FT   STRAND       88     94       {ECO:0000244|PDB:2NT0}.
FT   STRAND       96     98       {ECO:0000244|PDB:2NT0}.
FT   STRAND      103    116       {ECO:0000244|PDB:2NT0}.
FT   STRAND      119    123       {ECO:0000244|PDB:2NT0}.
FT   HELIX       126    133       {ECO:0000244|PDB:2NT0}.
FT   HELIX       137    148       {ECO:0000244|PDB:2NT0}.
FT   TURN        150    153       {ECO:0000244|PDB:2NT0}.
FT   STRAND      157    163       {ECO:0000244|PDB:2NT0}.
FT   STRAND      166    170       {ECO:0000244|PDB:2NT0}.
FT   STRAND      177    179       {ECO:0000244|PDB:1OGS}.
FT   HELIX       190    193       {ECO:0000244|PDB:2NT0}.
FT   HELIX       196    206       {ECO:0000244|PDB:2NT0}.
FT   STRAND      212    218       {ECO:0000244|PDB:2NT0}.
FT   HELIX       222    224       {ECO:0000244|PDB:2NT0}.
FT   STRAND      225    227       {ECO:0000244|PDB:2J25}.
FT   STRAND      229    233       {ECO:0000244|PDB:2NT0}.
FT   STRAND      235    238       {ECO:0000244|PDB:2NT0}.
FT   HELIX       243    261       {ECO:0000244|PDB:2NT0}.
FT   STRAND      267    271       {ECO:0000244|PDB:2NT0}.
FT   HELIX       275    279       {ECO:0000244|PDB:2NT0}.
FT   STRAND      284    286       {ECO:0000244|PDB:3GXF}.
FT   HELIX       292    301       {ECO:0000244|PDB:2NT0}.
FT   HELIX       303    308       {ECO:0000244|PDB:2NT0}.
FT   TURN        311    314       {ECO:0000244|PDB:2NT0}.
FT   STRAND      315    323       {ECO:0000244|PDB:2NT0}.
FT   HELIX       324    326       {ECO:0000244|PDB:2NT0}.
FT   HELIX       329    335       {ECO:0000244|PDB:2NT0}.
FT   HELIX       338    341       {ECO:0000244|PDB:2NT0}.
FT   STRAND      346    352       {ECO:0000244|PDB:2NT0}.
FT   HELIX       354    356       {ECO:0000244|PDB:3GXI}.
FT   HELIX       359    369       {ECO:0000244|PDB:2NT0}.
FT   STRAND      373    381       {ECO:0000244|PDB:2NT0}.
FT   STRAND      386    388       {ECO:0000244|PDB:2J25}.
FT   HELIX       396    411       {ECO:0000244|PDB:2NT0}.
FT   STRAND      414    424       {ECO:0000244|PDB:2NT0}.
FT   STRAND      426    428       {ECO:0000244|PDB:3KEH}.
FT   STRAND      440    444       {ECO:0000244|PDB:2NT0}.
FT   HELIX       445    447       {ECO:0000244|PDB:2NT0}.
FT   STRAND      449    452       {ECO:0000244|PDB:2NT0}.
FT   HELIX       454    463       {ECO:0000244|PDB:2NT0}.
FT   STRAND      471    479       {ECO:0000244|PDB:2NT0}.
FT   STRAND      482    489       {ECO:0000244|PDB:2NT0}.
FT   STRAND      495    501       {ECO:0000244|PDB:2NT0}.
FT   STRAND      503    505       {ECO:0000244|PDB:2NT0}.
FT   STRAND      507    513       {ECO:0000244|PDB:2NT0}.
FT   TURN        514    516       {ECO:0000244|PDB:2NT0}.
FT   STRAND      517    523       {ECO:0000244|PDB:2NT0}.
FT   STRAND      527    533       {ECO:0000244|PDB:2NT0}.
SQ   SEQUENCE   536 AA;  59716 MW;  FA1E15684344A0E6 CRC64;
     MEFSSPSREE CPKPLSRVSI MAGSLTGLLL LQAVSWASGA RPCIPKSFGY SSVVCVCNAT
     YCDSFDPPTF PALGTFSRYE STRSGRRMEL SMGPIQANHT GTGLLLTLQP EQKFQKVKGF
     GGAMTDAAAL NILALSPPAQ NLLLKSYFSE EGIGYNIIRV PMASCDFSIR TYTYADTPDD
     FQLHNFSLPE EDTKLKIPLI HRALQLAQRP VSLLASPWTS PTWLKTNGAV NGKGSLKGQP
     GDIYHQTWAR YFVKFLDAYA EHKLQFWAVT AENEPSAGLL SGYPFQCLGF TPEHQRDFIA
     RDLGPTLANS THHNVRLLML DDQRLLLPHW AKVVLTDPEA AKYVHGIAVH WYLDFLAPAK
     ATLGETHRLF PNTMLFASEA CVGSKFWEQS VRLGSWDRGM QYSHSIITNL LYHVVGWTDW
     NLALNPEGGP NWVRNFVDSP IIVDITKDTF YKQPMFYHLG HFSKFIPEGS QRVGLVASQK
     NDLDAVALMH PDGSAVVVVL NRSSKDVPLT IKDPAVGFLE TISPGYSIHT YLWRRQ
//
ID   FGFR3_HUMAN             Reviewed;         806 AA.
AC   P22607; D3DVP9; D3DVQ0; Q14308; Q16294; Q16608; Q59FL9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   17-FEB-2016, entry version 207.
DE   RecName: Full=Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=FGFR3; Synonyms=JTK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1847508; DOI=10.1073/pnas.88.4.1095;
RA   Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
RT   "Isolation of an additional member of the fibroblast growth factor
RT   receptor family, FGFR-3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND
RP   FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION.
RC   TISSUE=Squamous cell carcinoma;
RX   PubMed=11703096; DOI=10.1006/mcbr.2001.0306;
RA   Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H.,
RA   Kurokawa-Seo M.;
RT   "Fibroblast growth factor receptor 3 lacking the Ig IIIb and
RT   transmembrane domains secreted from human squamous cell carcinoma DJM-
RT   1 binds to FGFs.";
RL   Mol. Cell Biol. Res. Commun. 4:365-373(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384;
RP   THR-441; THR-717 AND PHE-726.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=1664411; DOI=10.1016/0888-7543(91)90041-C;
RA   Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F.,
RA   Housman D.E., Wasmuth J.J.;
RT   "A gene encoding a fibroblast growth factor receptor isolated from the
RT   Huntington disease gene region of human chromosome 4.";
RL   Genomics 11:1133-1142(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Colon tumor;
RX   PubMed=7923141;
RA   Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
RT   "Identification of a novel variant form of fibroblast growth factor
RT   receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
RL   Cancer Res. 54:5206-5211(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Keratinocyte;
RX   PubMed=7495869; DOI=10.1016/0167-4781(95)00156-B;
RA   Scotet E., Houssaint E.;
RT   "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene
RT   is not strictly tissue-specific.";
RL   Biochim. Biophys. Acta 1264:238-242(1995).
RN   [11]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [12]
RP   INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF
RP   VARIANT SADDAN MET-650.
RX   PubMed=10053006; DOI=10.1086/302275;
RA   Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E.,
RA   McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J.,
RA   Donoghue D.J., Thompson L.M., Francomano C.A.;
RT   "A novel skeletal dysplasia with developmental delay and acanthosis
RT   nigricans is caused by a Lys650Met mutation in the fibroblast growth
RT   factor receptor 3 gene.";
RL   Am. J. Hum. Genet. 64:722-731(1999).
RN   [13]
RP   FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF
RP   SIGNALING PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION,
RP   AUTOPHOSPHORYLATION, AND CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=10611230; DOI=10.1128/MCB.20.2.516-522.2000;
RA   Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.;
RT   "The transmembrane mutation G380R in fibroblast growth factor receptor
RT   3 uncouples ligand-mediated receptor activation from down-
RT   regulation.";
RL   Mol. Cell. Biol. 20:516-522(2000).
RN   [14]
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF
RP   PIK3R1; PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT
RP   TYR-724, MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND
RP   CHARACTERIZATION OF VARIANT GLU-650.
RX   PubMed=11294897; DOI=10.1091/mbc.12.4.931;
RA   Hart K.C., Robertson S.C., Donoghue D.J.;
RT   "Identification of tyrosine residues in constitutively activated
RT   fibroblast growth factor receptor 3 involved in mitogenesis, Stat
RT   activation, and phosphatidylinositol 3-kinase activation.";
RL   Mol. Biol. Cell 12:931-942(2001).
RN   [15]
RP   UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION
RP   OF VARIANT TD2 GLU-650.
RX   PubMed=12297284; DOI=10.1016/S0014-5793(02)03255-6;
RA   Monsonego-Ornan E., Adar R., Rom E., Yayon A.;
RT   "FGF receptors ubiquitylation: dependence on tyrosine kinase activity
RT   and role in downregulation.";
RL   FEBS Lett. 528:83-89(2002).
RN   [16]
RP   FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION
RP   OF VARIANT GLU-650, AND AUTOPHOSPHORYLATION.
RX   PubMed=14534538; DOI=10.1038/sj.onc.1206798;
RA   Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.;
RT   "The phosphotyrosine phosphatase SHP2 is a critical mediator of
RT   transformation induced by the oncogenic fibroblast growth factor
RT   receptor 3.";
RL   Oncogene 22:6909-6918(2003).
RN   [17]
RP   INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [18]
RP   INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND
RP   MAP KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16410555; DOI=10.1242/jcs.02740;
RA   Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
RT   "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with
RT   and modulate fibroblast growth factor receptor signaling.";
RL   J. Cell Sci. 119:380-387(2006).
RN   [19]
RP   FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION
RP   OF PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380;
RP   GLU-650 AND MET-650.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of
RT   genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell
RT   line via PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, ENZYME REGULATION, AND CHARACTERIZATION OF
RP   VARIANTS CYS-248; CYS-373 AND MET-650.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia
RT   type I differentially affects phosphorylation, processing and
RT   ubiquitylation of the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT
RP   GLU-650, ENZYME REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=17145761; DOI=10.1074/jbc.M606144200;
RA   Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H.,
RA   Thompson L.M., Wilcox W.R.;
RT   "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated
RT   activation of Erk MAP kinase in chondrocytes by preventing Shp2
RT   association with the Frs2 and Gab1 adaptor proteins.";
RL   J. Biol. Chem. 282:2929-2936(2007).
RN   [22]
RP   INTERACTION WITH FGF19; FGF21 AND KLB.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [23]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [24]
RP   FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE
RP   MAP KINASE SIGNALING PATHWAY.
RX   PubMed=19088846; DOI=10.1371/journal.pone.0003961;
RA   Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A.,
RA   Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.;
RT   "Analysis of STAT1 activation by six FGFR3 mutants associated with
RT   skeletal dysplasia undermines dominant role of STAT1 in FGFR3
RT   signaling in cartilage.";
RL   PLoS ONE 3:E3961-E3961(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT
RP   TYR-760.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and
RT   the p85 subunit of phosphoinositide 3-kinase: activation-dependent
RT   regulation of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [27]
RP   REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN
RP   DISEASE.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [28]
RP   REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN;
RP   ROLE IN DISEASE; UBIQUITINATION AND DEGRADATION.
RX   PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012;
RA   L'Hote C.G., Knowles M.A.;
RT   "Cell responses to FGFR3 signalling: growth, differentiation and
RT   apoptosis.";
RL   Exp. Cell Res. 304:417-431(2005).
RN   [29]
RP   REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE.
RX   PubMed=19066716; DOI=10.1007/s00774-008-0009-7;
RA   Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.;
RT   "FGFR3-related dwarfism and cell signaling.";
RL   J. Bone Miner. Metab. 27:9-15(2009).
RN   [30]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1,
RP   ENZYME REGULATION, AND DOMAIN.
RX   PubMed=14732692; DOI=10.1073/pnas.0307287101;
RA   Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V.,
RA   Yayon A., Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
RT   "Insights into the molecular basis for fibroblast growth factor
RT   receptor autoinhibition and ligand-binding promiscuity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
RN   [32]
RP   VARIANT ACH ARG-380.
RX   PubMed=8078586; DOI=10.1038/371252a0;
RA   Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M.,
RA   Maroteaux P., le Merrer M., Munnich A.;
RT   "Mutations in the gene encoding fibroblast growth factor receptor-3 in
RT   achondroplasia.";
RL   Nature 371:252-254(1994).
RN   [33]
RP   VARIANT ACH ARG-380.
RX   PubMed=7847369;
RA   Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A.,
RA   Machado M., Kaitila I., McIntosh I., Francomano C.A.;
RT   "Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
RL   Am. J. Hum. Genet. 56:368-373(1995).
RN   [34]
RP   VARIANT ACH CYS-375.
RX   PubMed=7758520; DOI=10.1007/BF01954274;
RA   Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A.,
RA   Gitzelmann R., Steinmann B.;
RT   "A glycine 375-to-cysteine substitution in the transmembrane domain of
RT   the fibroblast growth factor receptor-3 in a newborn with
RT   achondroplasia.";
RL   Eur. J. Pediatr. 154:215-219(1995).
RN   [35]
RP   VARIANT TD1 CYS-249.
RX   PubMed=8589699; DOI=10.1093/hmg/4.11.2175;
RA   Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R.,
RA   Wasmuth J.J.;
RT   "Another mutation that results in the substitution of an unpaired
RT   cysteine residue in the extracellular domain of FGFR3 in thanatophoric
RT   dysplasia type I.";
RL   Hum. Mol. Genet. 4:2175-2177(1995).
RN   [36]
RP   VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650.
RX   PubMed=7773297; DOI=10.1038/ng0395-321;
RA   Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J.,
RA   Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
RT   "Thanatophoric dysplasia (types I and II) caused by distinct mutations
RT   in fibroblast growth factor receptor 3.";
RL   Nat. Genet. 9:321-328(1995).
RN   [37]
RP   VARIANT HYPOCHONDROPLASIA LYS-540.
RX   PubMed=7670477; DOI=10.1038/ng0795-357;
RA   Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I.,
RA   Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
RT   "A recurrent mutation in the tyrosine kinase domain of fibroblast
RT   growth factor receptor 3 causes hypochondroplasia.";
RL   Nat. Genet. 10:357-359(1995).
RN   [38]
RP   VARIANT CAN GLU-391.
RX   PubMed=7493034; DOI=10.1038/ng1295-462;
RA   Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
RT   "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in
RT   Crouzon syndrome with acanthosis nigricans.";
RL   Nat. Genet. 11:462-464(1995).
RN   [39]
RP   CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=8599935;
RA   Webster M.K., Donoghue D.J.;
RT   "Constitutive activation of fibroblast growth factor receptor 3 by the
RT   transmembrane domain point mutation found in achondroplasia.";
RL   EMBO J. 15:520-527(1996).
RN   [40]
RP   VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373.
RX   PubMed=8845844; DOI=10.1093/hmg/5.4.509;
RA   Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L.,
RA   le Merrer M., Munnich A., Bonaventure J.;
RT   "Missense FGFR3 mutations create cysteine residues in thanatophoric
RT   dwarfism type I (TD1).";
RL   Hum. Mol. Genet. 5:509-512(1996).
RN   [41]
RP   CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT
RP   GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648.
RX   PubMed=8754806;
RA   Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.;
RT   "Profound ligand-independent kinase activation of fibroblast growth
RT   factor receptor 3 by the activation loop mutation responsible for a
RT   lethal skeletal dysplasia, thanatophoric dysplasia type II.";
RL   Mol. Cell. Biol. 16:4081-4087(1996).
RN   [42]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9042914;
RA   Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K.,
RA   Whitaker L.A., Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N.,
RA   Mulvihill J.J., Losken H.W., Mulliken J.B., Guttmacher A.E.,
RA   Wilroy R.S., Clarke L.A., Hollway G., Ades L.C., Haan E.A.,
RA   Mulley J.C., Cohen M.M. Jr., Bellus G.A., Francomano C.A.,
RA   Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
RT   "A unique point mutation in the fibroblast growth factor receptor 3
RT   gene (FGFR3) defines a new craniosynostosis syndrome.";
RL   Am. J. Hum. Genet. 60:555-564(1997).
RN   [43]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND
RP   MET-650.
RX   PubMed=9207791; DOI=10.1038/ng0797-260;
RA   Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M.,
RA   Bergsagel P.L.;
RT   "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
RT   associated with increased expression and activating mutations of
RT   fibroblast growth factor receptor 3.";
RL   Nat. Genet. 16:260-264(1997).
RN   [44]
RP   VARIANT TD1 CYS-370.
RX   PubMed=9790257;
RA   Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A.,
RA   Nimura A., Horikawa R., Tanaka T.;
RT   "G370C mutation in the FGFR3 gene in a Japanese patient with
RT   thanatophoric dysplasia.";
RL   Endocr. J. 45:S171-S174(1998).
RN   [45]
RP   VARIANT HYPOCHONDROPLASIA VAL-538.
RX   PubMed=10215410;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU17>3.0.CO;2-J;
RA   Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E.,
RA   Anvret M.;
RT   "A novel missense mutation Ile538Val in the fibroblast growth factor
RT   receptor 3 in hypochondroplasia.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [46]
RP   VARIANT HYPOCHONDROPLASIA THR-540.
RX   PubMed=9452043;
RA   Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M.,
RA   Bakker E.;
RT   "Asn540Thr substitution in the fibroblast growth factor receptor 3
RT   tyrosine kinase domain causing hypochondroplasia.";
RL   Hum. Mutat. Suppl. 1:S62-S65(1998).
RN   [47]
RP   VARIANT TD1 MET-650.
RX   PubMed=10671061;
RA   Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
RT   "Lys650Met substitution in the tyrosine kinase domain of the
RT   fibroblast growth factor receptor gene causes thanatophoric dysplasia
RT   type I.";
RL   Hum. Mutat. 12:362-363(1998).
RN   [48]
RP   VARIANT ARG-250.
RX   PubMed=9525367; DOI=10.1016/S0140-6736(98)24012-8;
RA   Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J.,
RA   Mulley J.C.;
RT   "Deafness due to Pro250Arg mutation of FGFR3.";
RL   Lancet 351:877-878(1998).
RN   [49]
RP   VARIANTS TD1 CYS-248; CYS-249 AND CYS-373.
RX   PubMed=10360402;
RX   DOI=10.1002/(SICI)1096-8628(19990611)84:5<476::AID-AJMG12>3.3.CO;2-O;
RA   Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B.,
RA   Wilcox W.R.;
RT   "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused
RT   by FGFR3 mutations.";
RL   Am. J. Med. Genet. 84:476-480(1999).
RN   [50]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9950359;
RA   Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J.,
RA   Renier D.;
RT   "Sex related expressivity of the phenotype in coronal craniosynostosis
RT   caused by the recurrent P250R FGFR3 mutation.";
RL   J. Med. Genet. 36:9-13(1999).
RN   [51]
RP   VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA
RP   CYS-248; CYS-249; CYS-370 AND GLU-650.
RX   PubMed=10471491; DOI=10.1038/12615;
RA   Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S.,
RA   Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
RT   "Frequent activating mutations of FGFR3 in human bladder and cervix
RT   carcinomas.";
RL   Nat. Genet. 23:18-20(1999).
RN   [52]
RP   VARIANT HYPOCHONDROPLASIA GLN-650.
RX   PubMed=11055896; DOI=10.1086/316892;
RA   Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T.,
RA   Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J.,
RA   Francomano C.A.;
RT   "Distinct missense mutations of the FGFR3 Lys650 codon modulate
RT   receptor kinase activation and the severity of the skeletal dysplasia
RT   phenotype.";
RL   Am. J. Hum. Genet. 67:1411-1421(2000).
RN   [53]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=10777366; DOI=10.1136/jmg.37.3.220;
RA   Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G.,
RA   De Paepe A.;
RT   "Clinical and radiographic features of a family with hypochondroplasia
RT   owing to a novel asn540ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   J. Med. Genet. 37:220-224(2000).
RN   [54]
RP   VARIANT MNKS ARG-250.
RX   PubMed=11746040; DOI=10.1002/ajmg.10049;
RA   Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
RT   "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and
RT   sprengel shoulder with and without Pro250Arg mutation in the FGFR3
RT   gene.";
RL   Am. J. Med. Genet. 104:112-119(2001).
RN   [55]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
RX   PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x;
RA   Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T.,
RA   Neri A.;
RT   "Analysis of FGFR3 gene mutations in multiple myeloma patients with
RT   t(4;14).";
RL   Br. J. Haematol. 114:362-364(2001).
RN   [56]
RP   VARIANT COLORECTAL CANCER LYS-322.
RX   PubMed=11325814;
RA   Jang J.-H., Shin K.-H., Park J.-G.;
RT   "Mutations in fibroblast growth factor receptor 2 and fibroblast
RT   growth factor receptor 3 genes associated with human gastric and
RT   colorectal cancers.";
RL   Cancer Res. 61:3541-3543(2001).
RN   [57]
RP   VARIANT BLC CANCER GLN-650.
RX   PubMed=11314002; DOI=10.1038/sj.onc.1204110;
RA   Sibley K., Cuthbert-Heavens D., Knowles M.A.;
RT   "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in
RT   transitional cell carcinoma.";
RL   Oncogene 20:686-691(2001).
RN   [58]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=12707965; DOI=10.1002/ajmg.a.10238;
RA   Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V.,
RA   Francois C., Huet F., Couailler J.-F., Campos-Xavier A.B.,
RA   Bonaventure J., Le Merrer M.;
RT   "Hypochondroplasia and stature within normal limits: another family
RT   with an Asn540-to-Ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   Am. J. Med. Genet. A 119:81-84(2003).
RN   [59]
RP   VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650
RP   AND MET-650.
RX   PubMed=15772091; DOI=10.1093/hmg/ddi127;
RA   Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M.,
RA   Ribeiro A., Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X.,
RA   Thiery J.P., Radvanyi F.;
RT   "Activating mutations of the tyrosine kinase receptor FGFR3 are
RT   associated with benign skin tumors in mice and humans.";
RL   Hum. Mol. Genet. 14:1153-1160(2005).
RN   [60]
RP   VARIANT CATSHL SYNDROME HIS-621.
RX   PubMed=17033969; DOI=10.1086/508433;
RA   Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A.,
RA   Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C.,
RA   Bamshad M.J.;
RT   "A novel mutation in FGFR3 causes camptodactyly, tall stature, and
RT   hearing loss (CATSHL) syndrome.";
RL   Am. J. Hum. Genet. 79:935-941(2006).
RN   [61]
RP   VARIANTS KNEN CYS-248; CYS-370 AND ARG-380.
RX   PubMed=16841094; DOI=10.1172/JCI28163;
RA   Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R.,
RA   Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A.;
RT   "Mosaicism of activating FGFR3 mutations in human skin causes
RT   epidermal nevi.";
RL   J. Clin. Invest. 116:2201-2207(2006).
RN   [62]
RP   VARIANT LADDS ASN-513.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [63]
RP   VARIANT CAN GLU-391.
RX   PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x;
RA   Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
RT   "Crouzon with acanthosis nigricans. Further delineation of the
RT   syndrome.";
RL   Clin. Genet. 72:405-410(2007).
RN   [64]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384;
RP   ASN-646 AND GLU-650.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [65]
RP   VARIANT TGCT GLU-650.
RX   PubMed=19855393; DOI=10.1038/ng.470;
RA   Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K.,
RA   McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E.,
RA   Wilkie A.O.;
RT   "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin
RT   for congenital disorders and testicular tumors.";
RL   Nat. Genet. 41:1247-1252(2009).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of cell proliferation, differentiation and
CC       apoptosis. Plays an essential role in the regulation of
CC       chondrocyte differentiation, proliferation and apoptosis, and is
CC       required for normal skeleton development. Regulates both
CC       osteogenesis and postnatal bone mineralization by osteoblasts.
CC       Promotes apoptosis in chondrocytes, but can also promote cancer
CC       cell proliferation. Required for normal development of the inner
CC       ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Plays a role in the regulation of vitamin D metabolism.
CC       Mutations that lead to constitutive kinase activation or impair
CC       normal FGFR3 maturation, internalization and degradation lead to
CC       aberrant signaling. Over-expressed or constitutively activated
CC       FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and
CC       STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and
CC       FGF2 and hence may interfere with FGF signaling.
CC       {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897,
CC       ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:17145761}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues. Inhibited
CC       by SU5402. {ECO:0000269|PubMed:14732692,
CC       ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17509076}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with
CC       FGF1, FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19,
CC       FGF20 and FGF23 (in vitro). Interacts with KLB. Affinity for
CC       fibroblast growth factors (FGFs) is increased by heparan sulfate
CC       glycosaminoglycans that function as coreceptors. Likewise, KLB
CC       increases the affinity for FGF19 and FGF21. Interacts with PIK3R1,
CC       PLCG1, SOCS1 and SOCS3. Isoform 3 forms disulfide-linked dimers.
CC       {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11703096,
CC       ECO:0000269|PubMed:14732692, ECO:0000269|PubMed:16410555,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P05230:FGF1; NbExp=3; IntAct=EBI-348399, EBI-698068;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-348399, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum.
CC       Note=The activated receptor is rapidly internalized and degraded.
CC       Detected in intracellular vesicles after internalization of the
CC       autophosphorylated receptor.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane {ECO:0000250};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cell membrane {ECO:0000250};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=P22607-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=P22607-2; Sequence=VSP_002988;
CC       Name=3; Synonyms=FGFR3deltaTM;
CC         IsoId=P22607-3; Sequence=VSP_002989;
CC       Name=4;
CC         IsoId=P22607-4; Sequence=VSP_040945;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very
CC       low or no expression in spleen, heart, and muscle. In 20- to 22-
CC       week old fetuses it is expressed at high level in kidney, lung,
CC       small intestine and brain, and to a lower degree in spleen, liver,
CC       and muscle. Isoform 2 is detected in epithelial cells. Isoform 1
CC       is not detected in epithelial cells. Isoform 1 and isoform 2 are
CC       detected in fibroblastic cells. {ECO:0000269|PubMed:1664411}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. {ECO:0000269|PubMed:14732692}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. Phosphorylation at Tyr-724 is essential for
CC       stimulation of cell proliferation and activation of PIK3R1, STAT1
CC       and MAP kinase signaling. Phosphorylation at Tyr-760 is required
CC       for interaction with PIK3R1 and PLCG1.
CC       {ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:19286672}.
CC   -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding
CC       and autophosphorylation, leading to receptor internalization and
CC       degradation. Subject to both proteasomal and lysosomal
CC       degradation. {ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:17509076}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:11703096,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17509076}.
CC   -!- DISEASE: Achondroplasia (ACH) [MIM:100800]: A frequent form of
CC       short-limb dwarfism. It is characterized by a long, narrow trunk,
CC       short extremities, particularly in the proximal (rhizomelic)
CC       segments, a large head with frontal bossing, hypoplasia of the
CC       midface and a trident configuration of the hands.
CC       {ECO:0000269|PubMed:7758520, ECO:0000269|PubMed:7847369,
CC       ECO:0000269|PubMed:8078586}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Crouzon syndrome with acanthosis nigricans (CAN)
CC       [MIM:612247]: Classic Crouzon disease which is caused by mutations
CC       in the FGFR2 gene is characterized by craniosynostosis (premature
CC       fusion of the skull sutures), and facial hypoplasia. Crouzon
CC       syndrome with acanthosis nigricans (a skin disorder characterized
CC       by pigmentation anomalies), CAN, is considered to be an
CC       independent disorder from classic Crouzon syndrome. CAN is
CC       characterized by additional more severe physical manifestation,
CC       such as Chiari malformation, hydrocephalus, and atresia or
CC       stenosis of the choanas, and is caused by a specific mutation
CC       (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is
CC       proposed to have an autosomal dominant mode of inheritance.
CC       {ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Thanatophoric dysplasia 1 (TD1) [MIM:187600]: A neonatal
CC       lethal skeletal dysplasia. Affected individuals manifest severe
CC       shortening of the limbs with macrocephaly, narrow thorax, short
CC       ribs, and curved femurs. {ECO:0000269|PubMed:10360402,
CC       ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:7773297,
CC       ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844,
CC       ECO:0000269|PubMed:9790257}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Thanatophoric dysplasia 2 (TD2) [MIM:187601]: A neonatal
CC       lethal skeletal dysplasia causing severe shortening of the limbs,
CC       narrow thorax and short ribs. Patients with thanatophoric
CC       dysplasia type 2 have straight femurs and cloverleaf skull.
CC       {ECO:0000269|PubMed:7773297}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypochondroplasia (HCH) [MIM:146000]: Autosomal dominant
CC       disease and is characterized by disproportionate short stature. It
CC       resembles achondroplasia, but with a less severe phenotype.
CC       {ECO:0000269|PubMed:10215410, ECO:0000269|PubMed:10777366,
CC       ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:12707965,
CC       ECO:0000269|PubMed:7670477, ECO:0000269|PubMed:9452043}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy
CC       originating in tissues of the urinary bladder. It often presents
CC       with multiple tumors appearing at different times and at different
CC       sites in the bladder. Most bladder cancers are transitional cell
CC       carcinomas that begin in cells that normally make up the inner
CC       lining of the bladder. Other types of bladder cancer include
CC       squamous cell carcinoma (cancer that begins in thin, flat cells)
CC       and adenocarcinoma (cancer that begins in cells that make and
CC       release mucus and other fluids). Bladder cancer is a complex
CC       disorder with both genetic and environmental influences.
CC       {ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11314002}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. Somatic mutations
CC       can constitutively activate FGFR3.
CC   -!- DISEASE: Cervical cancer (CERCA) [MIM:603956]: A malignant
CC       neoplasm of the cervix, typically originating from a dysplastic or
CC       premalignant lesion previously present at the active
CC       squamocolumnar junction. The transformation from mild dysplastic
CC       to invasive carcinoma generally occurs slowly within several
CC       years, although the rate of this process varies widely. Carcinoma
CC       in situ is particularly known to precede invasive cervical cancer
CC       in most cases. Cervical cancer is strongly associated with
CC       infection by oncogenic types of human papillomavirus.
CC       {ECO:0000269|PubMed:10471491}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Camptodactyly tall stature and hearing loss syndrome
CC       (CATSHL syndrome) [MIM:610474]: Autosomal dominant syndrome
CC       characterized by permanent and irreducible flexion of one or more
CC       fingers of the hand and/or feet, tall stature, scoliosis and/or a
CC       pectus excavatum, and hearing loss. Affected individuals have
CC       developmental delay and/or mental retardation, and several of
CC       these have microcephaly. Radiographic findings included tall
CC       vertebral bodies with irregular borders and broad femoral
CC       metaphyses with long tubular shafts. On audiological exam, each
CC       tested member have bilateral sensorineural hearing loss and absent
CC       otoacoustic emissions. The hearing loss was congenital or
CC       developed in early infancy, progressed variably in early
CC       childhood, and range from mild to severe. Computed tomography and
CC       magnetic resonance imaging reveal that the brain, middle ear, and
CC       inner ear are structurally normal. {ECO:0000269|PubMed:17033969}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of
CC       plasma cells usually arising in the bone marrow and characterized
CC       by diffuse involvement of the skeletal system, hyperglobulinemia,
CC       Bence-Jones proteinuria and anemia. Complications of multiple
CC       myeloma are bone pain, hypercalcemia, renal failure and spinal
CC       cord compression. The aberrant antibodies that are produced lead
CC       to impaired humoral immunity and patients have a high prevalence
CC       of infection. Amyloidosis may develop in some patients. Multiple
CC       myeloma is part of a spectrum of diseases ranging from monoclonal
CC       gammopathy of unknown significance (MGUS) to plasma cell leukemia.
CC       {ECO:0000269|PubMed:11529856, ECO:0000269|PubMed:9207791}.
CC       Note=The gene represented in this entry may be involved in disease
CC       pathogenesis. A chromosomal aberration involving FGFR3 is found in
CC       multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH
CC       locus.
CC   -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS)
CC       [MIM:149730]: An autosomal dominant ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. Lacrimo-auriculo-dento-digital
CC       syndrome is characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed. {ECO:0000269|PubMed:16501574}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN)
CC       [MIM:162900]: Epidermal nevi of the common, non-organoid and non-
CC       epidermolytic type are benign skin lesions and may vary in their
CC       extent from a single (usually linear) lesion to widespread and
CC       systematized involvement. They may be present at birth or develop
CC       early during childhood. {ECO:0000269|PubMed:16841094}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Muenke syndrome (MNKS) [MIM:602849]: A condition
CC       characterized by premature closure of coronal suture of skull
CC       during development (coronal craniosynostosis), which affects the
CC       shape of the head and face. It may be uni- or bilateral. When
CC       bilateral, it is characterized by a skull with a small antero-
CC       posterior diameter (brachycephaly), often with a decrease in the
CC       depth of the orbits and hypoplasia of the maxillae. Unilateral
CC       closure of the coronal sutures leads to flattening of the orbit on
CC       the involved side (plagiocephaly). The intellect is normal. In
CC       addition to coronal craniosynostosis some affected individuals
CC       show skeletal abnormalities of hands and feet, sensorineural
CC       hearing loss, mental retardation and respiratory insufficiency.
CC       {ECO:0000269|PubMed:11746040, ECO:0000269|PubMed:9042914,
CC       ECO:0000269|PubMed:9950359}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common
CC       benign skin tumor. Seborrheic keratoses usually begin with the
CC       appearance of one or more sharply defined, light brown, flat
CC       macules. The lesions may be sparse or numerous. As they initially
CC       grow, they develop a velvety to finely verrucous surface, followed
CC       by an uneven warty surface with multiple plugged follicles and a
CC       dull or lackluster appearance. {ECO:0000269|PubMed:15772091}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
CC       {ECO:0000269|PubMed:19855393}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis.
CC   -!- DISEASE: Achondroplasia, severe, with developmental delay and
CC       acanthosis nigricans (SADDAN) [MIM:616482]: A severe form of
CC       achondroplasia associated with developmental delay and acanthosis
CC       nigricans. Patients manifest short-limb dwarfism, with a long,
CC       narrow trunk, short extremities, particularly in the proximal
CC       (rhizomelic) segments, a large head with frontal bossing,
CC       hypoplasia of the midface and a trident configuration of the
CC       hands. Acanthosis nigricans is a skin condition characterized by
CC       brown-pigmented, velvety verrucosities in body folds and creases.
CC       {ECO:0000269|PubMed:10053006}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92678.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFRID99.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58051; AAA52450.1; -; mRNA.
DR   EMBL; AF245114; AAF63380.1; -; mRNA.
DR   EMBL; AB209441; BAD92678.1; ALT_INIT; mRNA.
DR   EMBL; AY768549; AAU89726.1; -; Genomic_DNA.
DR   EMBL; AC016773; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471131; EAW82564.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82565.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82566.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82567.1; -; Genomic_DNA.
DR   EMBL; M64347; AAA58470.1; -; mRNA.
DR   EMBL; M59374; AAA63209.1; -; mRNA.
DR   EMBL; S76733; AAB33323.1; -; Genomic_DNA.
DR   EMBL; X84939; CAA59334.1; -; mRNA.
DR   EMBL; U22410; AAA67781.1; -; Genomic_DNA.
DR   CCDS; CCDS3353.1; -. [P22607-1]
DR   CCDS; CCDS3354.1; -. [P22607-3]
DR   CCDS; CCDS54706.1; -. [P22607-2]
DR   PIR; A38576; TVHUF3.
DR   RefSeq; NP_000133.1; NM_000142.4. [P22607-1]
DR   RefSeq; NP_001156685.1; NM_001163213.1. [P22607-2]
DR   RefSeq; NP_075254.1; NM_022965.3. [P22607-3]
DR   UniGene; Hs.1420; -.
DR   PDB; 1RY7; X-ray; 3.20 A; B=33-365.
DR   PDB; 2LZL; NMR; -; A/B=357-399.
DR   PDB; 4K33; X-ray; 2.34 A; A=449-759.
DR   PDBsum; 1RY7; -.
DR   PDBsum; 2LZL; -.
DR   PDBsum; 4K33; -.
DR   ProteinModelPortal; P22607; -.
DR   SMR; P22607; 53-399, 459-776.
DR   BioGrid; 108552; 41.
DR   DIP; DIP-4016N; -.
DR   IntAct; P22607; 27.
DR   MINT; MINT-1034697; -.
DR   STRING; 9606.ENSP00000339824; -.
DR   BindingDB; P22607; -.
DR   ChEMBL; CHEMBL2742; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   GuidetoPHARMACOLOGY; 1810; -.
DR   iPTMnet; P22607; -.
DR   PhosphoSite; P22607; -.
DR   BioMuta; FGFR3; -.
DR   DMDM; 120050; -.
DR   PaxDb; P22607; -.
DR   PRIDE; P22607; -.
DR   DNASU; 2261; -.
DR   Ensembl; ENST00000260795; ENSP00000260795; ENSG00000068078. [P22607-1]
DR   Ensembl; ENST00000340107; ENSP00000339824; ENSG00000068078. [P22607-2]
DR   Ensembl; ENST00000352904; ENSP00000231803; ENSG00000068078. [P22607-3]
DR   Ensembl; ENST00000412135; ENSP00000412903; ENSG00000068078. [P22607-3]
DR   Ensembl; ENST00000440486; ENSP00000414914; ENSG00000068078. [P22607-1]
DR   GeneID; 2261; -.
DR   KEGG; hsa:2261; -.
DR   UCSC; uc003gdr.3; human. [P22607-1]
DR   UCSC; uc003gds.3; human. [P22607-3]
DR   UCSC; uc003gdu.2; human. [P22607-2]
DR   CTD; 2261; -.
DR   GeneCards; FGFR3; -.
DR   GeneReviews; FGFR3; -.
DR   HGNC; HGNC:3690; FGFR3.
DR   HPA; CAB004231; -.
DR   MalaCards; FGFR3; -.
DR   MIM; 100800; phenotype.
DR   MIM; 109800; phenotype.
DR   MIM; 134934; gene.
DR   MIM; 146000; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 162900; phenotype.
DR   MIM; 182000; phenotype.
DR   MIM; 187600; phenotype.
DR   MIM; 187601; phenotype.
DR   MIM; 254500; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 602849; phenotype.
DR   MIM; 603956; phenotype.
DR   MIM; 610474; phenotype.
DR   MIM; 612247; phenotype.
DR   MIM; 616482; phenotype.
DR   neXtProt; NX_P22607; -.
DR   Orphanet; 15; Achondroplasia.
DR   Orphanet; 85164; Camptodactyly - tall stature - scoliosis - hearing loss.
DR   Orphanet; 93262; Crouzon syndrome - acanthosis nigricans.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 429; Hypochondroplasia.
DR   Orphanet; 35099; Isolated brachycephaly.
DR   Orphanet; 35098; Isolated plagiocephaly.
DR   Orphanet; 2363; Lacrimoauriculodentodigital syndrome.
DR   Orphanet; 53271; Muenke syndrome.
DR   Orphanet; 794; Saethre-Chotzen syndrome.
DR   Orphanet; 85165; Severe achondroplasia - developmental delay - acanthosis nigricans.
DR   Orphanet; 1860; Thanatophoric dysplasia type 1.
DR   Orphanet; 93274; Thanatophoric dysplasia type 2.
DR   PharmGKB; PA28129; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P22607; -.
DR   KO; K05094; -.
DR   OMA; SFDTCKP; -.
DR   PhylomeDB; P22607; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839130; Signaling by activated point mutants of FGFR3.
DR   Reactome; R-HSA-190371; FGFR3b ligand binding and activation.
DR   Reactome; R-HSA-190372; FGFR3c ligand binding and activation.
DR   Reactome; R-HSA-2033514; FGFR3 mutant receptor activation.
DR   Reactome; R-HSA-2033515; t(4;14) translocations of FGFR3.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5655332; Signaling by FGFR3 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P22607; -.
DR   ChiTaRS; FGFR3; human.
DR   EvolutionaryTrace; P22607; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_3; -.
DR   GenomeRNAi; 2261; -.
DR   NextBio; 9179; -.
DR   PRO; PR:P22607; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P22607; -.
DR   CleanEx; HS_FGFR3; -.
DR   ExpressionAtlas; P22607; baseline and differential.
DR   Genevisible; P22607; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IMP:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0061144; P:alveolar secondary septum development; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; IEA:Ensembl.
DR   GO; GO:0070977; P:bone maturation; ISS:BHF-UCL.
DR   GO; GO:0030282; P:bone mineralization; ISS:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; TAS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl.
DR   GO; GO:0022010; P:central nervous system myelination; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0035988; P:chondrocyte proliferation; TAS:UniProtKB.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0003416; P:endochondral bone growth; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; TAS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0072148; P:epithelial cell fate commitment; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0060113; P:inner ear receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0070307; P:lens fiber cell development; IEA:Ensembl.
DR   GO; GO:0002089; P:lens morphogenesis in camera-type eye; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IEA:Ensembl.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0048640; P:negative regulation of developmental growth; ISS:BHF-UCL.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IEA:Ensembl.
DR   GO; GO:0045879; P:negative regulation of smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090080; P:positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0021762; P:substantia nigra development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Craniosynostosis; Cytoplasmic vesicle; Deafness; Disease mutation;
KW   Disulfide bond; Dwarfism; Ectodermal dysplasia; Endoplasmic reticulum;
KW   Glycoprotein; Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     22
FT   CHAIN        23    806       Fibroblast growth factor receptor 3.
FT                                /FTId=PRO_0000016785.
FT   TOPO_DOM     23    375       Extracellular. {ECO:0000255}.
FT   TRANSMEM    376    396       Helical. {ECO:0000255}.
FT   TOPO_DOM    397    806       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    126       Ig-like C2-type 1.
FT   DOMAIN      151    244       Ig-like C2-type 2.
FT   DOMAIN      253    355       Ig-like C2-type 3.
FT   DOMAIN      472    761       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     478    486       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    617    617       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     508    508       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     444    444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61851}.
FT   MOD_RES     445    445       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61851}.
FT   MOD_RES     647    647       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8754806}.
FT   MOD_RES     648    648       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8754806}.
FT   MOD_RES     724    724       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MOD_RES     760    760       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19286672}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    225    225       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    262    262       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    294    294       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    315    315       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    328    328       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     61    109       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    176    228       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    275    339       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     311    422       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11703096}.
FT                                /FTId=VSP_002989.
FT   VAR_SEQ     311    358       TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHS
FT                                AWLVVLP -> SWISESVEADVRLRLANVSERDGGEYLCRA
FT                                TNFIGVAEKAFWLSVHGPRA (in isoform 2).
FT                                {ECO:0000303|PubMed:7495869}.
FT                                /FTId=VSP_002988.
FT   VAR_SEQ     654    806       GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSP
FT                                YPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAP
FT                                SQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQD
FT                                TPSSSSSGDDSVFAHDLLPPAPPSSGGSRT -> LVLWGPA
FT                                LGDLHAGGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVH
FT                                DHAGVLACRALPEAHLQAAGGGPGPCPYRDVHRRVPGPVGA
FT                                FRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADV
FT                                KGHWSPTM (in isoform 4).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_040945.
FT   VARIANT      65     65       G -> R (in dbSNP:rs2305178).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022167.
FT   VARIANT      79     79       T -> S (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042207.
FT   VARIANT     228    228       C -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042208.
FT   VARIANT     248    248       R -> C (in KERSEB, BLC, keratinocytic
FT                                non-epidermolytic nevus and TD1; severe
FT                                and lethal; also found as somatic
FT                                mutation in one patient with multiple
FT                                myeloma; constitutive dimerization and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:11529856,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:7773297,
FT                                ECO:0000269|PubMed:8845844}.
FT                                /FTId=VAR_004148.
FT   VARIANT     249    249       S -> C (in KERSEB, BLC, cervical cancer
FT                                and TD1). {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:8589699,
FT                                ECO:0000269|PubMed:8845844}.
FT                                /FTId=VAR_004149.
FT   VARIANT     250    250       P -> R (in MNKS; also some individuals
FT                                with autosomal dominant congenital
FT                                sensorineural deafness without
FT                                craniosynostosis; dbSNP:rs4647924).
FT                                {ECO:0000269|PubMed:11746040,
FT                                ECO:0000269|PubMed:9042914,
FT                                ECO:0000269|PubMed:9525367,
FT                                ECO:0000269|PubMed:9950359}.
FT                                /FTId=VAR_004150.
FT   VARIANT     322    322       E -> K (in colorectal cancer).
FT                                {ECO:0000269|PubMed:11325814}.
FT                                /FTId=VAR_018388.
FT   VARIANT     338    338       T -> M. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042209.
FT   VARIANT     370    370       G -> C (in KERSEB, BLC, keratinocytic
FT                                non-epidermolytic nevus and TD1).
FT                                {ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:8845844,
FT                                ECO:0000269|PubMed:9790257}.
FT                                /FTId=VAR_004151.
FT   VARIANT     371    371       S -> C (in KERSEB and TD1).
FT                                {ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:7773297}.
FT                                /FTId=VAR_004152.
FT   VARIANT     373    373       Y -> C (in KERSEB and TD1; disulfide-
FT                                linked dimer with constitutive kinase
FT                                activation).
FT                                {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:8845844,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004153.
FT   VARIANT     375    375       G -> C (in ACH).
FT                                {ECO:0000269|PubMed:7758520}.
FT                                /FTId=VAR_004154.
FT   VARIANT     380    380       G -> R (in keratinocytic non-
FT                                epidermolytic nevus and ACH; very common
FT                                mutation; constitutively activated kinase
FT                                with impaired internalization and
FT                                degradation, resulting in prolonged FGFR3
FT                                signaling; dbSNP:rs28931614).
FT                                {ECO:0000269|PubMed:10611230,
FT                                ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:7847369,
FT                                ECO:0000269|PubMed:8078586,
FT                                ECO:0000269|PubMed:8599935}.
FT                                /FTId=VAR_004155.
FT   VARIANT     384    384       F -> L (in dbSNP:rs17881656).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022168.
FT   VARIANT     391    391       A -> E (in CAN; dbSNP:rs28931615).
FT                                {ECO:0000269|PubMed:17935505,
FT                                ECO:0000269|PubMed:7493034}.
FT                                /FTId=VAR_004156.
FT   VARIANT     441    441       A -> T (in dbSNP:rs17884368).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022169.
FT   VARIANT     513    513       D -> N (in LADDS).
FT                                {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029887.
FT   VARIANT     538    538       I -> V (in hypochondroplasia).
FT                                {ECO:0000269|PubMed:10215410}.
FT                                /FTId=VAR_004157.
FT   VARIANT     540    540       N -> K (in hypochondroplasia;
FT                                dbSNP:rs28933068).
FT                                {ECO:0000269|PubMed:7670477}.
FT                                /FTId=VAR_004158.
FT   VARIANT     540    540       N -> S (in hypochondroplasia; mild).
FT                                {ECO:0000269|PubMed:10777366,
FT                                ECO:0000269|PubMed:12707965}.
FT                                /FTId=VAR_018389.
FT   VARIANT     540    540       N -> T (in hypochondroplasia).
FT                                {ECO:0000269|PubMed:9452043}.
FT                                /FTId=VAR_004159.
FT   VARIANT     621    621       R -> H (in CATSHL syndrome).
FT                                {ECO:0000269|PubMed:17033969}.
FT                                /FTId=VAR_029108.
FT   VARIANT     646    646       D -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042210.
FT   VARIANT     650    650       K -> E (in KERSEB, TD2, TGCT and BLC;
FT                                bladder transitional cell carcinoma;
FT                                somatic mutation; constitutively
FT                                activated kinase with impaired
FT                                internalization and degradation,
FT                                resulting in prolonged FGFR3 signaling).
FT                                {ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:11294897,
FT                                ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:14534538,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17145761,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:19855393,
FT                                ECO:0000269|PubMed:7773297,
FT                                ECO:0000269|PubMed:8754806,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004160.
FT   VARIANT     650    650       K -> M (in KERSEB, ACH, TD1 and SADDAN;
FT                                constitutively activated kinase with
FT                                impaired internalization and degradation,
FT                                resulting in prolonged FGFR3 signaling).
FT                                {ECO:0000269|PubMed:10053006,
FT                                ECO:0000269|PubMed:10671061,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004161.
FT   VARIANT     650    650       K -> Q (in hypochondroplasia and BLC; in
FT                                hypochondroplasia the form is milder than
FT                                that seen in individuals with the K-540
FT                                or M-650 mutations; constitutively
FT                                activated kinase).
FT                                {ECO:0000269|PubMed:11055896,
FT                                ECO:0000269|PubMed:11314002,
FT                                ECO:0000269|PubMed:8754806}.
FT                                /FTId=VAR_018390.
FT   VARIANT     717    717       A -> T (in dbSNP:rs17882190).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022170.
FT   VARIANT     726    726       I -> F (in dbSNP:rs17880763).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022171.
FT   MUTAGEN     508    508       K->A: Loss of kinase activity. Abolishes
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:16410555}.
FT   MUTAGEN     577    577       Y->F: Minor effect on kinase activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     650    650       K->D: Constitutively activated kinase.
FT   MUTAGEN     650    650       K->L: Constitutively activated kinase.
FT   MUTAGEN     724    724       Y->F: Strongly reduced kinase activity.
FT                                Strongly reduced mitogen activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     760    760       Y->F: Minor effect on kinase activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     770    770       Y->F: Minor effect on kinase activity.
FT                                Increased mitogen activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   CONFLICT    395    395       L -> V (in Ref. 7; AAA58470).
FT                                {ECO:0000305}.
FT   CONFLICT    421    421       R -> RQ (in Ref. 3; BAD92678).
FT                                {ECO:0000305}.
FT   STRAND      163    167       {ECO:0000244|PDB:1RY7}.
FT   STRAND      172    175       {ECO:0000244|PDB:1RY7}.
FT   STRAND      185    187       {ECO:0000244|PDB:1RY7}.
FT   TURN        208    211       {ECO:0000244|PDB:1RY7}.
FT   STRAND      212    215       {ECO:0000244|PDB:1RY7}.
FT   HELIX       220    222       {ECO:0000244|PDB:1RY7}.
FT   STRAND      226    232       {ECO:0000244|PDB:1RY7}.
FT   STRAND      235    246       {ECO:0000244|PDB:1RY7}.
FT   STRAND      263    268       {ECO:0000244|PDB:1RY7}.
FT   STRAND      271    273       {ECO:0000244|PDB:1RY7}.
FT   STRAND      283    289       {ECO:0000244|PDB:1RY7}.
FT   HELIX       293    295       {ECO:0000244|PDB:1RY7}.
FT   STRAND      302    304       {ECO:0000244|PDB:1RY7}.
FT   STRAND      324    326       {ECO:0000244|PDB:1RY7}.
FT   STRAND      335    345       {ECO:0000244|PDB:1RY7}.
FT   STRAND      348    357       {ECO:0000244|PDB:1RY7}.
FT   STRAND      369    372       {ECO:0000244|PDB:2LZL}.
FT   HELIX       374    398       {ECO:0000244|PDB:2LZL}.
FT   TURN        463    465       {ECO:0000244|PDB:4K33}.
FT   HELIX       469    471       {ECO:0000244|PDB:4K33}.
FT   STRAND      472    480       {ECO:0000244|PDB:4K33}.
FT   STRAND      482    496       {ECO:0000244|PDB:4K33}.
FT   STRAND      503    510       {ECO:0000244|PDB:4K33}.
FT   HELIX       516    532       {ECO:0000244|PDB:4K33}.
FT   STRAND      541    545       {ECO:0000244|PDB:4K33}.
FT   STRAND      547    550       {ECO:0000244|PDB:4K33}.
FT   STRAND      552    556       {ECO:0000244|PDB:4K33}.
FT   HELIX       563    568       {ECO:0000244|PDB:4K33}.
FT   HELIX       591    610       {ECO:0000244|PDB:4K33}.
FT   HELIX       620    622       {ECO:0000244|PDB:4K33}.
FT   STRAND      623    625       {ECO:0000244|PDB:4K33}.
FT   STRAND      631    633       {ECO:0000244|PDB:4K33}.
FT   STRAND      646    649       {ECO:0000244|PDB:4K33}.
FT   HELIX       658    660       {ECO:0000244|PDB:4K33}.
FT   HELIX       663    668       {ECO:0000244|PDB:4K33}.
FT   HELIX       673    688       {ECO:0000244|PDB:4K33}.
FT   HELIX       700    708       {ECO:0000244|PDB:4K33}.
FT   HELIX       721    730       {ECO:0000244|PDB:4K33}.
FT   HELIX       735    737       {ECO:0000244|PDB:4K33}.
FT   HELIX       741    753       {ECO:0000244|PDB:4K33}.
SQ   SEQUENCE   806 AA;  87710 MW;  BC5EA75EA46F447E CRC64;
     MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS
     CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH
     FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG
     NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT
     YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP
     DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE
     EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK
     RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE
     GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN
     LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ
     VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW
     MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT
     HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS
     SSSGDDSVFA HDLLPPAPPS SGGSRT
//